[
    {
        "text": "The failure of the myometrium to respond to [CHEMICAL]ritodrine[\\CHEMICAL] (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and [GENE]beta 2-adrenergic receptor[\\GENE] concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Labetalol and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to labetalol at 10(-6) M was abolished by [CHEMICAL]ICI 118,551[\\CHEMICAL] which illustrates that the labetalol-induced attenuation is [GENE]beta 2-adrenoceptor[\\GENE] mediated.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Labetalol and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to labetalol at 10(-6) M was abolished by ICI 118,551 which illustrates that the [CHEMICAL]labetalol[\\CHEMICAL]-induced attenuation is [GENE]beta 2-adrenoceptor[\\GENE] mediated.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the [CHEMICAL]isoprenaline[\\CHEMICAL] responses of the atria and the pA2 values were 8.60 and 8.98 at the [GENE]beta 1-adrenoceptors[\\GENE] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
        "label": 5,
        "major": 6,
        "len": 60
    },
    {
        "text": "[CHEMICAL]Labetalol[\\CHEMICAL] (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the [GENE]beta 1-adrenoceptors[\\GENE] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 60
    },
    {
        "text": "Labetalol (> or = 3 x 10(-8) M) and [CHEMICAL]dilevalol[\\CHEMICAL] (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the [GENE]beta 1-adrenoceptors[\\GENE] of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 60
    },
    {
        "text": "The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the [CHEMICAL]labetalol[\\CHEMICAL] at [GENE]beta 2-adrenoceptors[\\GENE] was 7.59.",
        "label": 6,
        "major": 4,
        "len": 33
    },
    {
        "text": "It is concluded that [CHEMICAL]labetalol[\\CHEMICAL] and dilevalol are [GENE]beta 1-adrenoceptor[\\GENE] selective antagonists.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "It is concluded that labetalol and [CHEMICAL]dilevalol[\\CHEMICAL] are [GENE]beta 1-adrenoceptor[\\GENE] selective antagonists.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "The inhibitory effects of iloprost on [GENE]tissue factor[\\GENE] expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not [CHEMICAL]dibutyryl cyclic GMP[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 27
    },
    {
        "text": "Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for [CHEMICAL]iloprost[\\CHEMICAL] binding to the platelet [GENE]prostacyclin receptor[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for iloprost binding to the platelet [CHEMICAL]prostacyclin[\\CHEMICAL][GENE]prostacyclin receptor[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "An orally active analogue, [CHEMICAL]cicaprost[\\CHEMICAL], was equally effective against endotoxin-induced [GENE]tissue factor[\\GENE] expression.",
        "label": 2,
        "major": 3,
        "len": 13
    },
    {
        "text": "Prostacyclin analogues inhibit [GENE]tissue factor[\\GENE] expression in the human monocytic cell line THP-1 via a [CHEMICAL]cyclic AMP[\\CHEMICAL]-dependent mechanism.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "These results suggest that prostacyclin may play a role in downregulating [GENE]tissue factor[\\GENE] expression in monocytes, at least in part via elevation of intracellular levels of [CHEMICAL]cyclic AMP[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "These results suggest that [CHEMICAL]prostacyclin[\\CHEMICAL] may play a role in downregulating [GENE]tissue factor[\\GENE] expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The present studies were undertaken to determine whether stable analogues of [CHEMICAL]prostacyclin[\\CHEMICAL], a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit [GENE]tissue factor[\\GENE] expression by human monocytic cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Preincubation for 30 minutes with [CHEMICAL]iloprost[\\CHEMICAL], ciprostene, and carbacyclin led to a dose-dependent inhibition of [GENE]tissue factor[\\GENE] expression induced by all three challenging agents.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Preincubation for 30 minutes with iloprost, [CHEMICAL]ciprostene[\\CHEMICAL], and carbacyclin led to a dose-dependent inhibition of [GENE]tissue factor[\\GENE] expression induced by all three challenging agents.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Preincubation for 30 minutes with iloprost, ciprostene, and [CHEMICAL]carbacyclin[\\CHEMICAL] led to a dose-dependent inhibition of [GENE]tissue factor[\\GENE] expression induced by all three challenging agents.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Prostacyclin[\\CHEMICAL] analogues inhibit [GENE]tissue factor[\\GENE] expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "This effect was potentiated by [CHEMICAL]isobutylmethylxanthine[\\CHEMICAL], an inhibitor of [GENE]phosphodiesterase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "The inhibitory effects of iloprost on [GENE]tissue factor[\\GENE] expression were also potentiated by [CHEMICAL]isobutylmethylxanthine[\\CHEMICAL] and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "The inhibitory effects of iloprost on [GENE]tissue factor[\\GENE] expression were also potentiated by isobutylmethylxanthine and mimicked by [CHEMICAL]forskolin[\\CHEMICAL] and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The inhibitory effects of iloprost on [GENE]tissue factor[\\GENE] expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d[CHEMICAL]ibutyryl cyclic AMP[\\CHEMICAL] but not dibutyryl cyclic GMP.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "On study day 1, [CHEMICAL]candoxatril[\\CHEMICAL] acutely increased plasma [GENE]ANP[\\GENE] levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "On study day 10, the acute effects of [CHEMICAL]candoxatril[\\CHEMICAL] were similar to those on day 1 (i.e., [GENE]ANP[\\GENE] was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased).",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Candoxatril[\\CHEMICAL] is a novel, orally active inhibitor of [GENE]neutral endopeptidase[\\GENE] EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Candoxatril[\\CHEMICAL] is a novel, orally active inhibitor of neutral endopeptidase [GENE]EC 3.4.24.11[\\GENE], the enzyme that degrades atrial natriuretic peptide (ANP).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Effectiveness of [GENE]endopeptidase[\\GENE] inhibition ([CHEMICAL]candoxatril[\\CHEMICAL]) in congestive heart failure.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic [CHEMICAL]amino acid[\\CHEMICAL] residues, an event necessary for the maturation of a variety of important biologically active proteins, such as [GENE]insulin[\\GENE] and nerve growth factor.",
        "label": 1,
        "major": 1,
        "len": 38
    },
    {
        "text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic [CHEMICAL]amino acid[\\CHEMICAL] residues, an event necessary for the maturation of a variety of important biologically active proteins, such as insulin and [GENE]nerve growth factor[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 38
    },
    {
        "text": "Other agents, such as [CHEMICAL]methimazole[\\CHEMICAL] and sodium iodide, which influence thyroid cell function, do not directly interfere with the expression of [GENE]M/TPO-Ag[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "Other agents, such as methimazole and [CHEMICAL]sodium iodide[\\CHEMICAL], which influence thyroid cell function, do not directly interfere with the expression of [GENE]M/TPO-Ag[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "TSH and [CHEMICAL]cAMP[\\CHEMICAL] also increase the levels of the specific mRNA for [GENE]TPO[\\GENE] in thyroid cells from different species.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Evidence has accumulated in the last few years that the expression of the [GENE]microsomal/peroxidase antigen[\\GENE] (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular [CHEMICAL]cAMP[\\CHEMICAL] accumulation and protein synthesis.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen ([GENE]M/TPO-Ag[\\GENE]) in thyroid cells is induced by TSH, through pathways which involve intracellular [CHEMICAL]cAMP[\\CHEMICAL] accumulation and protein synthesis.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Adrenaline[\\CHEMICAL] via [GENE]alpha 2-adrenoceptors[\\GENE] inhibited the Ca2+ currents by about 50%.",
        "label": 2,
        "major": 4,
        "len": 11
    },
    {
        "text": "In membranes of control but not of pertussis toxin-treated cells, [CHEMICAL]adrenaline[\\CHEMICAL] via [GENE]alpha 2-adrenoceptors[\\GENE] stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype.",
        "label": 2,
        "major": 10,
        "len": 41
    },
    {
        "text": "These [GENE]G-proteins[\\GENE] are likely to be involved in the [CHEMICAL]adrenaline[\\CHEMICAL]-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the adrenaline-induced inhibition of insulin secretion.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the [CHEMICAL]adrenaline[\\CHEMICAL]-induced inhibition of [GENE]insulin[\\GENE] secretion.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Somatostatin[\\CHEMICAL] which also inhibits [GENE]insulin[\\GENE] secretion was less efficient (inhibition by 20%).",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Adrenaline[\\CHEMICAL] inhibits [GENE]insulin[\\GENE] secretion via pertussis toxin-sensitive mechanisms.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "In contrast to [CHEMICAL]adrenaline[\\CHEMICAL] and somatostatin, galanin, another inhibitor of [GENE]insulin[\\GENE] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In contrast to adrenaline and [CHEMICAL]somatostatin[\\CHEMICAL], galanin, another inhibitor of [GENE]insulin[\\GENE] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Before the next drug intake, [GENE]MAO-A[\\GENE] inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with [CHEMICAL]moclobemide[\\CHEMICAL] but not with toloxatone.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Before the next drug intake, [GENE]MAO-A[\\GENE] inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with [CHEMICAL]toloxatone[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The effects of two reversible, predominantly [GENE]monoamine oxidase-A[\\GENE] (MAO-A) inhibitors, [CHEMICAL]moclobemide[\\CHEMICAL] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Comparison of the [GENE]monoamine oxidase[\\GENE] inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [CHEMICAL]moclobemide[\\CHEMICAL] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective [GENE]monoamine oxidase-A[\\GENE] inhibitors [CHEMICAL]moclobemide[\\CHEMICAL] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Comparison of the [GENE]monoamine oxidase[\\GENE] inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and [CHEMICAL]toloxatone[\\CHEMICAL], and assessment of their effect on psychometric performance in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective [GENE]monoamine oxidase-A[\\GENE] inhibitors moclobemide and [CHEMICAL]toloxatone[\\CHEMICAL], and assessment of their effect on psychometric performance in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The effects of two reversible, predominantly [GENE]monoamine oxidase-A[\\GENE] (MAO-A) inhibitors, moclobemide (150 mg three times daily) and [CHEMICAL]toloxatone[\\CHEMICAL] (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Clinical pharmacology of [CHEMICAL]enalkiren[\\CHEMICAL], a novel, dipeptide [GENE]renin[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Clinical pharmacology of enalkiren, a novel, [CHEMICAL]dipeptide[\\CHEMICAL] [GENE]renin[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Enalkiren[\\CHEMICAL] (A-64662), a potent, dipeptide [GENE]renin[\\GENE] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Enalkiren[\\CHEMICAL] (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the [GENE]human renin[\\GENE] substrate, angiotensinogen.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Enalkiren ([CHEMICAL]A-64662[\\CHEMICAL]), a potent, dipeptide [GENE]renin[\\GENE] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Enalkiren ([CHEMICAL]A-64662[\\CHEMICAL]), a potent, dipeptide renin inhibitor, mimics the transition state of the [GENE]human renin[\\GENE] substrate, angiotensinogen.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "The results of clinical trials with [CHEMICAL]enalkiren[\\CHEMICAL] are encouraging, and suggest that [GENE]renin[\\GENE] inhibitors may be safe, useful therapeutic agents in the management of hypertension.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Enalkiren[\\CHEMICAL] has been shown to produce dose-related suppression of plasma [GENE]renin[\\GENE] activity (PRA) and angiotensin II when administered intravenously.",
        "label": 4,
        "major": 9,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Enalkiren[\\CHEMICAL] has been shown to produce dose-related suppression of plasma renin activity (PRA) and [GENE]angiotensin II[\\GENE] when administered intravenously.",
        "label": 4,
        "major": 9,
        "len": 19
    },
    {
        "text": "Enalkiren (A-64662), a potent, [CHEMICAL]dipeptide[\\CHEMICAL] [GENE]renin[\\GENE] inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Enalkiren (A-64662), a potent, [CHEMICAL]dipeptide[\\CHEMICAL] renin inhibitor, mimics the transition state of the [GENE]human renin[\\GENE] substrate, angiotensinogen.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "We evaluated the clinical effectiveness of [CHEMICAL]esmolol[\\CHEMICAL], an ultra-short-acting [GENE]beta 1-adrenergic receptor[\\GENE] blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] and asthma: an appraisal based on specific [GENE]H1-receptor[\\GENE] antagonism.",
        "label": 2,
        "major": 6,
        "len": 10
    },
    {
        "text": "[GENE]H1-receptor[\\GENE] antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of [CHEMICAL]histamine[\\CHEMICAL] in disease, through an evaluation of their influence on disease expression.",
        "label": 5,
        "major": 6,
        "len": 48
    },
    {
        "text": "While there is considerable indirect evidence to implicate [CHEMICAL]histamine[\\CHEMICAL] in the pathogenesis of asthma, a critical evaluation of [GENE]H1-receptor[\\GENE] antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
        "label": 5,
        "major": 6,
        "len": 48
    },
    {
        "text": "While there is considerable indirect evidence to implicate [CHEMICAL]histamine[\\CHEMICAL] in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early [GENE]H1-receptor[\\GENE] antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity.",
        "label": 5,
        "major": 6,
        "len": 48
    },
    {
        "text": "[GENE]H1-receptor[\\GENE] antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which [CHEMICAL]histamine[\\CHEMICAL] is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.",
        "label": 5,
        "major": 9,
        "len": 48
    },
    {
        "text": "The recent development of [GENE]H1-receptor[\\GENE] antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of [CHEMICAL]histamine[\\CHEMICAL] in this condition.",
        "label": 5,
        "major": 6,
        "len": 43
    },
    {
        "text": "The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of [GENE]H1-receptor[\\GENE] blockade within the airways, thus permitting a better appraisal of the role of [CHEMICAL]histamine[\\CHEMICAL] in this condition.",
        "label": 5,
        "major": 6,
        "len": 43
    },
    {
        "text": "Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while [CHEMICAL]sodium salicylate[\\CHEMICAL], hardly active on [GENE]COX[\\GENE] by itself, is well tolerated by these patients.",
        "label": 10,
        "major": 4,
        "len": 33
    },
    {
        "text": "However, [CHEMICAL]salicylate[\\CHEMICAL] moiety appears to interfere with aspirin inhibitory action on platelets and vascular [GENE]COX[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "However, salicylate moiety appears to interfere with [CHEMICAL]aspirin[\\CHEMICAL] inhibitory action on platelets and vascular [GENE]COX[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] (ASA) and other non-steroidal anti-inflammatory drugs, which are [GENE]cyclooxygenase[\\GENE] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase ([GENE]COX[\\GENE]) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Aspirin ([CHEMICAL]ASA[\\CHEMICAL]) and other non-steroidal anti-inflammatory drugs, which are [GENE]cyclooxygenase[\\GENE] (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Aspirin ([CHEMICAL]ASA[\\CHEMICAL]) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase ([GENE]COX[\\GENE]) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between [CHEMICAL]salicylate[\\CHEMICAL] and ASA on [GENE]cyclo-oxygenase[\\GENE] locus in the respiratory tract in ASA-intolerant patients.",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and [CHEMICAL]ASA[\\CHEMICAL] on [GENE]cyclo-oxygenase[\\GENE] locus in the respiratory tract in ASA-intolerant patients.",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The high-affinity binding of [CHEMICAL]L-noradrenaline[\\CHEMICAL] to [GENE]phenylalanine hydroxylase[\\GENE], as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "The high-affinity binding of L-noradrenaline to [GENE]phenylalanine hydroxylase[\\GENE], as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol [CHEMICAL]L-noradrenaline[\\CHEMICAL]/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "The high-affinity binding of L-noradrenaline to [GENE]phenylalanine hydroxylase[\\GENE], as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM [CHEMICAL]L-noradrenaline[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "Cooperative homotropic interaction of [CHEMICAL]L-noradrenaline[\\CHEMICAL] with the catalytic site of [GENE]phenylalanine 4-monooxygenase[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "The high-affinity of [CHEMICAL]catecholamines[\\CHEMICAL] to [GENE]phenylalanine hydroxylase[\\GENE] is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "The high-affinity of [CHEMICAL]catecholamines[\\CHEMICAL] to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme [GENE]tyrosine hydroxylase[\\GENE], which is purified as a stable catecholamine-Fe(III) complex.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Catecholamines ([CHEMICAL]adrenaline[\\CHEMICAL], noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([GENE]phenylalanine hydroxylase[\\GENE], EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines ([CHEMICAL]adrenaline[\\CHEMICAL], noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, [GENE]EC 1.14.16.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines ([CHEMICAL]adrenaline[\\CHEMICAL], noradrenaline and dopamine) are potent inhibitors of [GENE]phenylalanine 4-monooxygenase[\\GENE] (phenylalanine hydroxylase, EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, [CHEMICAL]noradrenaline[\\CHEMICAL] and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([GENE]phenylalanine hydroxylase[\\GENE], EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, [CHEMICAL]noradrenaline[\\CHEMICAL] and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, [GENE]EC 1.14.16.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, [CHEMICAL]noradrenaline[\\CHEMICAL] and dopamine) are potent inhibitors of [GENE]phenylalanine 4-monooxygenase[\\GENE] (phenylalanine hydroxylase, EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, noradrenaline and [CHEMICAL]dopamine[\\CHEMICAL]) are potent inhibitors of phenylalanine 4-monooxygenase ([GENE]phenylalanine hydroxylase[\\GENE], EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, noradrenaline and [CHEMICAL]dopamine[\\CHEMICAL]) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, [GENE]EC 1.14.16.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Catecholamines (adrenaline, noradrenaline and [CHEMICAL]dopamine[\\CHEMICAL]) are potent inhibitors of [GENE]phenylalanine 4-monooxygenase[\\GENE] (phenylalanine hydroxylase, EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Catecholamines[\\CHEMICAL] (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ([GENE]phenylalanine hydroxylase[\\GENE], EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Catecholamines[\\CHEMICAL] (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, [GENE]EC 1.14.16.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Catecholamines[\\CHEMICAL] (adrenaline, noradrenaline and dopamine) are potent inhibitors of [GENE]phenylalanine 4-monooxygenase[\\GENE] (phenylalanine hydroxylase, EC 1.14.16.1).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "These results suggest that the beneficial effect of [CHEMICAL]minaprine[\\CHEMICAL] on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems ([GENE]5-HT2 receptors[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "These results suggest that the beneficial effect of minaprine on [CHEMICAL]cycloheximide[\\CHEMICAL]-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems ([GENE]5-HT2 receptors[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a [GENE]5-HT1A[\\GENE]-selective agonist, [CHEMICAL]8-hydroxy-2-(di-n-propylamino)tetralin[\\CHEMICAL], was inactive.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective [GENE]5-HT2[\\GENE] antagonist, [CHEMICAL]ritanserin[\\CHEMICAL].",
        "label": 6,
        "major": 3,
        "len": 16
    },
    {
        "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [GENE]histamine H1-receptor[\\GENE] antagonists [CHEMICAL]terfenadine[\\CHEMICAL], astemizole, loratadine, and acrivastine are reviewed.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [GENE]histamine H1-receptor[\\GENE] antagonists terfenadine, [CHEMICAL]astemizole[\\CHEMICAL], loratadine, and acrivastine are reviewed.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [GENE]histamine H1-receptor[\\GENE] antagonists terfenadine, astemizole, [CHEMICAL]loratadine[\\CHEMICAL], and acrivastine are reviewed.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating [GENE]histamine H1-receptor[\\GENE] antagonists terfenadine, astemizole, loratadine, and [CHEMICAL]acrivastine[\\CHEMICAL] are reviewed.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Terfenadine[\\CHEMICAL] and astemizole are chemically unrelated to [GENE]histamine H1-receptor[\\GENE] antagonists such as diphenhydramine and chlorpheniramine.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Terfenadine and [CHEMICAL]astemizole[\\CHEMICAL] are chemically unrelated to [GENE]histamine H1-receptor[\\GENE] antagonists such as diphenhydramine and chlorpheniramine.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Terfenadine and astemizole are chemically unrelated to [GENE]histamine H1-receptor[\\GENE] antagonists such as [CHEMICAL]diphenhydramine[\\CHEMICAL] and chlorpheniramine.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Terfenadine and astemizole are chemically unrelated to [GENE]histamine H1-receptor[\\GENE] antagonists such as diphenhydramine and [CHEMICAL]chlorpheniramine[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Similarly, felodipine and the p-chloro analogue blocked [GENE]myosin[\\GENE] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and [CHEMICAL]t-butyl[\\CHEMICAL] analogues did not.",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "The oxidized and [CHEMICAL]t-butyl[\\CHEMICAL] analogues were relatively ineffective in inhibiting [GENE]cAMP phosphodiesterase[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 12
    },
    {
        "text": "Felodipine and the p-chloro analogue inhibited Ca2+/calmodulin-dependent [GENE]caldesmon kinase[\\GENE] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and [CHEMICAL]t-butyl[\\CHEMICAL] analogues caused no inhibition.",
        "label": 10,
        "major": 4,
        "len": 25
    },
    {
        "text": "Finally, the effects of [CHEMICAL]felodipine[\\CHEMICAL] and the three analogues on two processes which are dependent on [GENE]myosin[\\GENE] phosphorylation were examined, namely the actin-activated Mg2+-ATPase activity of myosin and the assembly of myosin filaments.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "Finally, the effects of [CHEMICAL]felodipine[\\CHEMICAL] and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated [GENE]Mg2+-ATPase[\\GENE] activity of myosin and the assembly of myosin filaments.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "Finally, the effects of [CHEMICAL]felodipine[\\CHEMICAL] and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated Mg2+-ATPase activity of [GENE]myosin[\\GENE] and the assembly of myosin filaments.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "Finally, the effects of [CHEMICAL]felodipine[\\CHEMICAL] and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated Mg2+-ATPase activity of myosin and the assembly of [GENE]myosin[\\GENE] filaments.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "Felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited the actin-activated [GENE]Mg2+-ATPase[\\GENE] activity of smooth muscle myosin (IC50 = 25.1 microM).",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle [GENE]myosin[\\GENE] (IC50 = 25.1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Similarly, [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue blocked [GENE]myosin[\\GENE] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Similarly, felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue blocked [GENE]myosin[\\GENE] filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not.",
        "label": 4,
        "major": 10,
        "len": 24
    },
    {
        "text": "Again, inhibition of the actin-activated [GENE]myosin[\\GENE] Mg2+-ATPase and myosin filament assembly by [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Again, inhibition of the actin-activated myosin [GENE]Mg2+-ATPase[\\GENE] and myosin filament assembly by [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Again, inhibition of the actin-activated myosin Mg2+-ATPase and [GENE]myosin[\\GENE] filament assembly by [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Again, inhibition of the actin-activated [GENE]myosin[\\GENE] Mg2+-ATPase and myosin filament assembly by felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Again, inhibition of the actin-activated myosin [GENE]Mg2+-ATPase[\\GENE] and myosin filament assembly by felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Again, inhibition of the actin-activated myosin Mg2+-ATPase and [GENE]myosin[\\GENE] filament assembly by felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue could be reversed by raising the calmodulin concentration.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "These observations suggest that some of the pharmacological actions of [CHEMICAL]felodipine[\\CHEMICAL] on smooth muscle may involve inhibition of [GENE]calmodulin-dependent enzymes[\\GENE] which are functionally involved in the regulation of smooth muscle contraction.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The [GENE]cAMP phosphodiesterase[\\GENE] was inhibited completely by [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The [GENE]cAMP phosphodiesterase[\\GENE] was inhibited completely by felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue with IC50 values of 3.7 and 1.5 microM respectively.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of [GENE]cAMP phosphodiesterase[\\GENE] as well as the calmodulin-stimulated activity.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of cAMP phosphodiesterase as well as the [GENE]calmodulin[\\GENE]-stimulated activity.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited the basal (Ca2+/calmodulin-independent) activity of [GENE]cAMP phosphodiesterase[\\GENE] as well as the calmodulin-stimulated activity.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited the basal (Ca2+/calmodulin-independent) activity of cAMP phosphodiesterase as well as the [GENE]calmodulin[\\GENE]-stimulated activity.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Calmodulin was relatively ineffective in preventing inhibition of [GENE]cAMP phosphodiesterase[\\GENE] by [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Calmodulin was relatively ineffective in preventing inhibition of [GENE]cAMP phosphodiesterase[\\GENE] by felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and the p-chloro analogue inhibited Ca2+/calmodulin-dependent [GENE]caldesmon kinase[\\GENE] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited Ca2+/calmodulin-dependent [GENE]caldesmon kinase[\\GENE] with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Similarly, [CHEMICAL]felodipine[\\CHEMICAL] and the p-chloro analogue inhibited [GENE]myosin light chain kinase[\\GENE] activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "Similarly, felodipine and the [CHEMICAL]p-chloro[\\CHEMICAL] analogue inhibited [GENE]myosin light chain kinase[\\GENE] activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and the p-chloro analogue inhibited the actin-activated [GENE]Mg2+-ATPase[\\GENE] activity of smooth muscle myosin (IC50 = 25.1 microM).",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle [GENE]myosin[\\GENE] (IC50 = 25.1 microM).",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "These data demonstrate that [CHEMICAL]loperamide[\\CHEMICAL] differently modifies the stimulatory action of LVP and CRH on [GENE]ACTH[\\GENE] secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Although these findings might be explained by the involvement of different intracellular ACTH-secreting mechanisms, an influence of [CHEMICAL]loperamide[\\CHEMICAL] on some suprapituitary factors modulating the [GENE]ACTH[\\GENE] response is suggested.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "These data demonstrate that [CHEMICAL]loperamide[\\CHEMICAL] differently modifies the stimulatory action of [GENE]LVP[\\GENE] and CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "These data demonstrate that [CHEMICAL]loperamide[\\CHEMICAL] differently modifies the stimulatory action of LVP and [GENE]CRH[\\GENE] on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of [GENE]CRH[\\GENE]-induced ACTH secretion was significantly lower after [CHEMICAL]loperamide[\\CHEMICAL].",
        "label": 4,
        "major": 2,
        "len": 54
    },
    {
        "text": "In all patients [CHEMICAL]loperamide[\\CHEMICAL] induced a significant fall in plasma [GENE]ACTH[\\GENE] levels.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL] is a peripheral opiate agonist able to inhibit [GENE]ACTH[\\GENE] secretion.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "CRH caused a rise in plasma ACTH after both loperamide (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced [GENE]ACTH[\\GENE] secretion was significantly lower after [CHEMICAL]loperamide[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 54
    },
    {
        "text": "The interaction of [CHEMICAL]naloxone estrone azine[\\CHEMICAL] (N-EH) with various [GENE]opioid receptor[\\GENE] types was studied in vitro.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "The interaction of naloxone estrone azine ([CHEMICAL]N-EH[\\CHEMICAL]) with various [GENE]opioid receptor[\\GENE] types was studied in vitro.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "A [CHEMICAL]naloxone-steroid hybrid azine[\\CHEMICAL] with selective and long-acting opioid antagonism at [GENE]delta receptors[\\GENE] in vitro.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Actions of [CHEMICAL]nizatidine[\\CHEMICAL], a selective [GENE]histamine H2-receptor[\\GENE] antagonist, on gastric acid secretion in dogs, rats and frogs.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Nizatidine[\\CHEMICAL] (LY139037), a selective [GENE]histamine H2-receptor[\\GENE] antagonist, is a potent inhibitor of gastric acid secretion.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Nizatidine ([CHEMICAL]LY139037[\\CHEMICAL]), a selective [GENE]histamine H2-receptor[\\GENE] antagonist, is a potent inhibitor of gastric acid secretion.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "[CHEMICAL]ORF 17583[\\CHEMICAL], a [GENE]histamine H2-receptor[\\GENE] antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Effects of [CHEMICAL]ORF 17583[\\CHEMICAL], other [GENE]histamine H2-receptor[\\GENE] antagonists and omeprazole on gastric acid secretory states in rats and dogs.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "[GENE]Acetylcholinesterase[\\GENE] (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [CHEMICAL]oximes[\\CHEMICAL] due to dealkylation of the soman-enzyme complex.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Acetylcholinesterase ([GENE]AChE[\\GENE]) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [CHEMICAL]oximes[\\CHEMICAL] due to dealkylation of the soman-enzyme complex.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of [CHEMICAL]soman[\\CHEMICAL]-inhibited, solubilized [GENE]AChE[\\GENE] from human erythrocytes was investigated in vitro.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]Acetylcholinesterase[\\GENE] (AChE) inhibited by the [CHEMICAL]organophosphate[\\CHEMICAL] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Acetylcholinesterase ([GENE]AChE[\\GENE]) inhibited by the [CHEMICAL]organophosphate[\\CHEMICAL] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]Acetylcholinesterase[\\GENE] (AChE) inhibited by the organophosphate [CHEMICAL]soman[\\CHEMICAL] (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Acetylcholinesterase ([GENE]AChE[\\GENE]) inhibited by the organophosphate [CHEMICAL]soman[\\CHEMICAL] (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]Acetylcholinesterase[\\GENE] (AChE) inhibited by the organophosphate soman ([CHEMICAL]1,2,2-trimethyl-propylmethylphosphonofluoridate[\\CHEMICAL]) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Acetylcholinesterase ([GENE]AChE[\\GENE]) inhibited by the organophosphate soman ([CHEMICAL]1,2,2-trimethyl-propylmethylphosphonofluoridate[\\CHEMICAL]) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of [CHEMICAL]soman[\\CHEMICAL]-inhibited [GENE]human acetylcholinesterase[\\GENE] in vitro.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "If the effectors were added after 5 min of aging they increased the activity of [CHEMICAL]soman[\\CHEMICAL]-inhibited [GENE]AChE[\\GENE], but to a considerably smaller extent than HI 6.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "The most potent compound, [CHEMICAL]D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid[\\CHEMICAL] (lorglumide, CR 1409), has a great affinity for the pancreatic [GENE]CCK receptors[\\GENE] and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 2,
        "major": 2,
        "len": 52
    },
    {
        "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ([CHEMICAL]lorglumide[\\CHEMICAL], CR 1409), has a great affinity for the pancreatic [GENE]CCK receptors[\\GENE] and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 2,
        "major": 2,
        "len": 52
    },
    {
        "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, [CHEMICAL]CR 1409[\\CHEMICAL]), has a great affinity for the pancreatic [GENE]CCK receptors[\\GENE] and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 2,
        "major": 6,
        "len": 52
    },
    {
        "text": "Pharmacological properties of [CHEMICAL]lorglumide[\\CHEMICAL] as a member of a new class of [GENE]cholecystokinin[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "The most potent compound, [CHEMICAL]D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid[\\CHEMICAL] (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [GENE]CCK[\\GENE] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 6,
        "major": 2,
        "len": 52
    },
    {
        "text": "Derivatives of [CHEMICAL]5-(dipentylamino)-5-oxo-pentanoic acid[\\CHEMICAL] are a new class of non-peptide cholecystokinin ([GENE]CCK[\\GENE]) antagonists.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "Derivatives of [CHEMICAL]5-(dipentylamino)-5-oxo-pentanoic acid[\\CHEMICAL] are a new class of non-peptide [GENE]cholecystokinin[\\GENE] (CCK) antagonists.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ([CHEMICAL]lorglumide[\\CHEMICAL], CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [GENE]CCK[\\GENE] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 6,
        "major": 2,
        "len": 52
    },
    {
        "text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, [CHEMICAL]CR 1409[\\CHEMICAL]), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent [GENE]CCK[\\GENE] antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.",
        "label": 6,
        "major": 6,
        "len": 52
    },
    {
        "text": "In vivo [CHEMICAL]lorglumide[\\CHEMICAL] antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. [GENE]CCK-8[\\GENE] or ceruletide (caerulein).",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although [CHEMICAL]oleate[\\CHEMICAL] or benzyl alcohol exhibited procoagulant activity in [GENE]FPA[\\GENE] formation in vitro.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or [CHEMICAL]benzyl alcohol[\\CHEMICAL] exhibited procoagulant activity in [GENE]FPA[\\GENE] formation in vitro.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "The activation may be accelerated by an acute inflammatory process provoked by [CHEMICAL]oleate[\\CHEMICAL], which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma [GENE]fibrinogen[\\GENE] level which was observed in all during the period.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "In vitro studies, however, revealed that [CHEMICAL]EO[\\CHEMICAL] inhibits [GENE]fibrin[\\GENE] clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The efficacy of [CHEMICAL]astemizole[\\CHEMICAL], a new, long acting, oral [GENE]histamine H1-receptor[\\GENE] antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.",
        "label": 6,
        "major": 6,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Astemizole[\\CHEMICAL], a potent [GENE]histamine H1-receptor[\\GENE] antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "However, due to the very high affinity of [GENE]CBG[\\GENE] for [CHEMICAL]corticosterone[\\CHEMICAL] at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for aldosterone-binding sites.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Characterization of [GENE]rat brain aldosterone receptors[\\GENE] reveals high affinity for [CHEMICAL]corticosterone[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of [CHEMICAL]steroid[\\CHEMICAL] binding similar to that of the kidney [GENE]mineralocorticoid receptor[\\GENE] (aldosterone greater than desoxycorticosterone greater than corticosterone).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney [GENE]mineralocorticoid receptor[\\GENE] ([CHEMICAL]aldosterone[\\CHEMICAL] greater than desoxycorticosterone greater than corticosterone).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney [GENE]mineralocorticoid receptor[\\GENE] (aldosterone greater than [CHEMICAL]desoxycorticosterone[\\CHEMICAL] greater than corticosterone).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Selective precipitation of cytosol receptors with 36% [CHEMICAL](NH4)2SO4[\\CHEMICAL] reduced [GENE]CBG[\\GENE] concentrations to negligible levels.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "The nonsteroidal antiandrogen [CHEMICAL]RU 23908[\\CHEMICAL] ( Anandron ) weakly interacts with the prostatic cytosolic [GENE]androgen receptor[\\GENE] and shows a fast dissociation rate.",
        "label": 10,
        "major": 2,
        "len": 22
    },
    {
        "text": "The nonsteroidal antiandrogen RU 23908 ( [CHEMICAL]Anandron[\\CHEMICAL] ) weakly interacts with the prostatic cytosolic [GENE]androgen receptor[\\GENE] and shows a fast dissociation rate.",
        "label": 10,
        "major": 2,
        "len": 22
    },
    {
        "text": "Although inhibition of [GENE]LH[\\GENE] release can be achieved by [CHEMICAL]estrogen[\\CHEMICAL] and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.",
        "label": 4,
        "major": 5,
        "len": 52
    },
    {
        "text": "Although inhibition of [GENE]LH[\\GENE] release can be achieved by estrogen and [CHEMICAL]progestins[\\CHEMICAL], an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "Here we report the [CHEMICAL]amino acid[\\CHEMICAL] sequence of the [GENE]bovine oxytocin-neurophysin I (OT-NpI) precursor[\\GENE] which was derived from sequence analysis of the cloned cDNA.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Deduced [CHEMICAL]amino acid[\\CHEMICAL] sequence from the [GENE]bovine oxytocin-neurophysin I precursor[\\GENE] cDNA.",
        "label": 1,
        "major": 1,
        "len": 11
    },
    {
        "text": "The aim of the study was to determine whether the dihydroxylated antiestrogen [CHEMICAL]LY117018[\\CHEMICAL], with a high affinity for the [GENE]estrogen receptor[\\GENE] and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat.",
        "label": 2,
        "major": 4,
        "len": 63
    },
    {
        "text": "[CHEMICAL]BMY 7378[\\CHEMICAL] displayed high affinity for cloned [GENE]human alpha 1D-adrenoceptors[\\GENE] (pKi = 8.2 +/- 0.10) and was selective over alpha 1A (pKi = 6.2 +/- 0.10) and alpha 1B subtypes (6.7 +/- 0.11).",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "WB 4101, [CHEMICAL]benoxathian[\\CHEMICAL] and phentolamine displayed high affinity for [GENE]alpha 1A and alpha 1D adrenoceptors[\\GENE] compared to the alpha 1B subtype.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "WB 4101, benoxathian and [CHEMICAL]phentolamine[\\CHEMICAL] displayed high affinity for [GENE]alpha 1A and alpha 1D adrenoceptors[\\GENE] compared to the alpha 1B subtype.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Spiperone[\\CHEMICAL] displayed high affinity and selectivity for [GENE]alpha 1B adrenoceptors[\\GENE] (pKi 8.8 +/- 0.16).",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "The affinities of a number of alpha 1-adrenoceptor antagonists were determined by displacement of [CHEMICAL][3H]-prazosin[\\CHEMICAL] binding from cloned [GENE]human alpha 1A-adrenoceptors[\\GENE] (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and rat alpha 1D-adrenoceptors, stably expressed in rat-1 fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "The affinities of a number of alpha 1-adrenoceptor antagonists were determined by displacement of [CHEMICAL][3H]-prazosin[\\CHEMICAL] binding from cloned human alpha 1A-adrenoceptors (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and [GENE]rat alpha 1D-adrenoceptors[\\GENE], stably expressed in rat-1 fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "The affinities of a number of [GENE]alpha 1-adrenoceptor[\\GENE] antagonists were determined by displacement of [CHEMICAL][3H]-prazosin[\\CHEMICAL] binding from cloned human alpha 1A-adrenoceptors (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and rat alpha 1D-adrenoceptors, stably expressed in rat-1 fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "The results of this study suggest that [CHEMICAL]noradrenaline[\\CHEMICAL] predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an [GENE]alphalD-adrenoceptor[\\GENE].",
        "label": 3,
        "major": 10,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Alprenolol[\\CHEMICAL] and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of [GENE]beta-adrenoceptor[\\GENE] blockade.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Alprenolol and [CHEMICAL]BAAM[\\CHEMICAL] at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of [GENE]beta-adrenoceptor[\\GENE] blockade.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Alprenolol and BAAM also caused surmountable antagonism of [CHEMICAL]isoprenaline[\\CHEMICAL] responses, and this [GENE]beta 1-adrenoceptor[\\GENE] antagonism was slowly reversible.",
        "label": 5,
        "major": 6,
        "len": 18
    },
    {
        "text": "We conclude that [CHEMICAL]alprenolol[\\CHEMICAL] and BAAM are competitive slowly reversible [GENE]beta 1-adrenoceptor[\\GENE] antagonists on rat left atria.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "We conclude that alprenolol and [CHEMICAL]BAAM[\\CHEMICAL] are competitive slowly reversible [GENE]beta 1-adrenoceptor[\\GENE] antagonists on rat left atria.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Alprenolol[\\CHEMICAL] and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the [GENE]beta 1-adrenoceptors[\\GENE] of rat left atria.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "Alprenolol and [CHEMICAL]bromoacetylalprenololmenthane[\\CHEMICAL] are competitive slowly reversible antagonists at the [GENE]beta 1-adrenoceptors[\\GENE] of rat left atria.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Alprenolol[\\CHEMICAL] and BAAM also caused surmountable antagonism of isoprenaline responses, and this [GENE]beta 1-adrenoceptor[\\GENE] antagonism was slowly reversible.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Alprenolol and [CHEMICAL]BAAM[\\CHEMICAL] also caused surmountable antagonism of isoprenaline responses, and this [GENE]beta 1-adrenoceptor[\\GENE] antagonism was slowly reversible.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Cloning and expression of a novel [GENE]serotonin receptor[\\GENE] with high affinity for [CHEMICAL]tricyclic[\\CHEMICAL] psychotropic drugs.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "The inhibition of [CHEMICAL][125I]LSD[\\CHEMICAL] binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described [GENE]serotonin receptor[\\GENE] subtype.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In HEK-293 cells stably transfected with this receptor, [CHEMICAL]serotonin[\\CHEMICAL] elicits a potent stimulation of [GENE]adenylyl cyclase[\\GENE] activity, which is blocked by antipsychotic and antidepressant drugs.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Norethisterone[\\CHEMICAL] metabolites modulate the [GENE]uteroglobin[\\GENE] and progesterone receptor gene expression in prepubertal rabbits.",
        "label": 2,
        "major": 7,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Norethisterone[\\CHEMICAL] metabolites modulate the uteroglobin and [GENE]progesterone receptor[\\GENE] gene expression in prepubertal rabbits.",
        "label": 2,
        "major": 7,
        "len": 13
    },
    {
        "text": "Both [CHEMICAL]5 alpha-NET[\\CHEMICAL] and 3 beta,5 alpha-NET blocked the [GENE]PR[\\GENE] down-regulation induced by P4 as assessed by Western and Northern blot methods.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "Both 5 alpha-NET and [CHEMICAL]3 beta,5 alpha-NET[\\CHEMICAL] blocked the [GENE]PR[\\GENE] down-regulation induced by P4 as assessed by Western and Northern blot methods.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "The inhibition of UG synthesis and [GENE]PR[\\GENE] down-regulation by [CHEMICAL]5 alpha-NET[\\CHEMICAL] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "As determined by Western and Northern blot analyses, [CHEMICAL]5 alpha-NET[\\CHEMICAL] inhibited the P4-induced [GENE]UG[\\GENE] gene expression in a dose-dependent manner.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "The estrogenic agent [CHEMICAL]3 beta,5 alpha-NET[\\CHEMICAL] and estradiol at a dose of 1.0 mg also inhibited the [GENE]UG[\\GENE] gene expression induced by P4.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The estrogenic agent 3 beta,5 alpha-NET and [CHEMICAL]estradiol[\\CHEMICAL] at a dose of 1.0 mg also inhibited the [GENE]UG[\\GENE] gene expression induced by P4.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The inhibition of [GENE]UG[\\GENE] synthesis and PR down-regulation by [CHEMICAL]5 alpha-NET[\\CHEMICAL] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The inhibition of [GENE]UG[\\GENE] synthesis and PR down-regulation by 5 alpha-NET and [CHEMICAL]3 beta,5 alpha-NET[\\CHEMICAL] indicates that these NET metabolites possess antiprogestational properties.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The inhibition of UG synthesis and [GENE]PR[\\GENE] down-regulation by 5 alpha-NET and [CHEMICAL]3 beta,5 alpha-NET[\\CHEMICAL] indicates that these NET metabolites possess antiprogestational properties.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The inhibition of [GENE]UG[\\GENE] synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these [CHEMICAL]NET[\\CHEMICAL] metabolites possess antiprogestational properties.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The inhibition of UG synthesis and [GENE]PR[\\GENE] down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these [CHEMICAL]NET[\\CHEMICAL] metabolites possess antiprogestational properties.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [GENE]dopamine D1 receptor[\\GENE] antagonist [CHEMICAL]SCH 39166[\\CHEMICAL] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 9,
        "len": 43
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [GENE]dopamine D1 receptor[\\GENE] antagonist SCH 39166 ([CHEMICAL](-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine[\\CHEMICAL]) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 9,
        "len": 43
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the [GENE]dopamine D2 receptor[\\GENE] antagonist [CHEMICAL]raclopride[\\CHEMICAL] (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "In all cases at both the [GENE]5-HT2A[\\GENE] and 5-HT2C receptors, the affinities of the isomers of [CHEMICAL]MDMA[\\CHEMICAL] and MDA were at least 2-3 orders of magnitude less than 5-HT.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In all cases at both the 5-HT2A and [GENE]5-HT2C[\\GENE] receptors, the affinities of the isomers of [CHEMICAL]MDMA[\\CHEMICAL] and MDA were at least 2-3 orders of magnitude less than 5-HT.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In all cases at both the [GENE]5-HT2A[\\GENE] and 5-HT2C receptors, the affinities of the isomers of MDMA and [CHEMICAL]MDA[\\CHEMICAL] were at least 2-3 orders of magnitude less than 5-HT.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In all cases at both the 5-HT2A and [GENE]5-HT2C[\\GENE] receptors, the affinities of the isomers of MDMA and [CHEMICAL]MDA[\\CHEMICAL] were at least 2-3 orders of magnitude less than 5-HT.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In all cases at both the [GENE]5-HT2A[\\GENE] and 5-HT2C receptors, the affinities of the isomers of MDMA and MDA were at least 2-3 orders of magnitude less than [CHEMICAL]5-HT[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In all cases at both the 5-HT2A and [GENE]5-HT2C[\\GENE] receptors, the affinities of the isomers of MDMA and MDA were at least 2-3 orders of magnitude less than [CHEMICAL]5-HT[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "At the [GENE]5-HT2C[\\GENE] receptor, both [CHEMICAL]R(-) and S(+)MDA[\\CHEMICAL] were equipotent at stimulating PI hydrolysis, with the S(+) isomer of MDMA being more efficacious at the 5-HT2C receptor compared with the R(-) isomer.",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "At the 5-HT2C receptor, both R(-) and S(+)MDA were equipotent at stimulating PI hydrolysis, with the [CHEMICAL]S(+) isomer of MDMA[\\CHEMICAL] being more efficacious at the [GENE]5-HT2C[\\GENE] receptor compared with the R(-) isomer.",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "The isomers of [CHEMICAL]MDA[\\CHEMICAL] produced a concentration dependent increase in phosphatidyl inositol (PI) hydrolysis at the [GENE]5-HT2A[\\GENE] receptors, with the R(-) isomer of MDA being more potent than the S(+) at the 5-HT2A receptor.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "The isomers of MDA produced a concentration dependent increase in phosphatidyl inositol (PI) hydrolysis at the 5-HT2A receptors, with the [CHEMICAL]R(-) isomer of MDA[\\CHEMICAL] being more potent than the S(+) at the [GENE]5-HT2A[\\GENE] receptor.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] inhibited both [GENE]hCOX-1[\\GENE] and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] inhibited both hCOX-1 and [GENE]hCOX-2[\\GENE], whereas NS-398 and Dup-697 selectively inhibited hCOX-2.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Indomethacin inhibited both hCOX-1 and hCOX-2, whereas [CHEMICAL]NS-398[\\CHEMICAL] and Dup-697 selectively inhibited [GENE]hCOX-2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and [CHEMICAL]Dup-697[\\CHEMICAL] selectively inhibited [GENE]hCOX-2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Both [CHEMICAL]NS-398[\\CHEMICAL] and Dup-697 exhibited time-dependent inactivation of [GENE]hCOX-2[\\GENE], as did indomethacin on both enzymes.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Both NS-398 and [CHEMICAL]Dup-697[\\CHEMICAL] exhibited time-dependent inactivation of [GENE]hCOX-2[\\GENE], as did indomethacin on both enzymes.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Both NS-398 and Dup-697 exhibited time-dependent inactivation of [GENE]hCOX-2[\\GENE], as did [CHEMICAL]indomethacin[\\CHEMICAL] on both enzymes.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "The competitive inhibitor of [GENE]hCOX-1[\\GENE], [CHEMICAL]mefenamic acid[\\CHEMICAL], also displayed competitive inhibition of hCOX-2.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The competitive inhibitor of hCOX-1, [CHEMICAL]mefenamic acid[\\CHEMICAL], also displayed competitive inhibition of [GENE]hCOX-2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The enzyme [GENE]cyclo-oxygenase[\\GENE] catalyses the oxygenation of arachidonic acid, leading to the formation of [CHEMICAL]prostaglandins[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "The enzyme [GENE]cyclo-oxygenase[\\GENE] catalyses the oxygenation of [CHEMICAL]arachidonic acid[\\CHEMICAL], leading to the formation of prostaglandins.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, [CHEMICAL]p-aminobenzamidine[\\CHEMICAL] (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of [GENE]alpha-thrombin[\\GENE], i.e.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine ([CHEMICAL]p-ABZ[\\CHEMICAL]) and proflavin binding to the catalytic site of two proteolyzed forms of [GENE]alpha-thrombin[\\GENE], i.e.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (p-ABZ) and [CHEMICAL]proflavin[\\CHEMICAL] binding to the catalytic site of two proteolyzed forms of [GENE]alpha-thrombin[\\GENE], i.e.",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "In conclusion, these data demonstrate that: (1) the Leu144-Gly150 loop and the FRS are both involved in the conformational transition linked to the binding of [CHEMICAL]p-aminobenzamidine[\\CHEMICAL] to the [GENE]thrombin[\\GENE] active site; (2) the extent of thrombin's capacity to undergo conformational transitions in alpha-, zeta- and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the FRS.",
        "label": 2,
        "major": 2,
        "len": 71
    },
    {
        "text": "A phenomenological analysis of thermodynamic data showed that the amide substrates and [CHEMICAL]p-ABZ[\\CHEMICAL] interactions with [GENE]zeta-thrombin[\\GENE] were respectively, associated with a chemical compensation (i.e.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "In contrast, the [CHEMICAL]Ala[\\CHEMICAL]-->Gly replacement has less impact in protecting the [GENE]chloride channel[\\GENE] from the action of insecticidal blockers.",
        "label": 1,
        "major": 1,
        "len": 19
    },
    {
        "text": "In contrast, the Ala-->[CHEMICAL]Gly[\\CHEMICAL] replacement has less impact in protecting the [GENE]chloride channel[\\GENE] from the action of insecticidal blockers.",
        "label": 1,
        "major": 1,
        "len": 19
    },
    {
        "text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->[CHEMICAL]Ser[\\CHEMICAL] replacement in the [GENE]Rdl GABA receptor[\\GENE] subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the [GENE]Rdl GABA receptor[\\GENE] subunit and in D. simulans to an homologous [CHEMICAL]Ala[\\CHEMICAL]-->Ser or Gly replacement.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the [GENE]Rdl GABA receptor[\\GENE] subunit and in D. simulans to an homologous Ala-->[CHEMICAL]Ser[\\CHEMICAL] or Gly replacement.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the [GENE]Rdl GABA receptor[\\GENE] subunit and in D. simulans to an homologous Ala-->Ser or [CHEMICAL]Gly[\\CHEMICAL] replacement.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala-->Ser or [CHEMICAL]Gly[\\CHEMICAL] mutants of [GENE]Rdl[\\GENE] subunit.",
        "label": 1,
        "major": 2,
        "len": 17
    },
    {
        "text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with [CHEMICAL]Ala[\\CHEMICAL]-->Ser or Gly mutants of [GENE]Rdl[\\GENE] subunit.",
        "label": 1,
        "major": 2,
        "len": 17
    },
    {
        "text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala-->[CHEMICAL]Ser[\\CHEMICAL] or Gly mutants of [GENE]Rdl[\\GENE] subunit.",
        "label": 1,
        "major": 1,
        "len": 17
    },
    {
        "text": "The non-competitive blocker site of the [GENE]GABA-gated chloride ion channel[\\GENE] in normal susceptible strains of Drosophila melanogaster and simulans binds [CHEMICAL]4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate[\\CHEMICAL] ([3H]EBOB) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "The non-competitive blocker site of the [GENE]GABA-gated chloride ion channel[\\GENE] in normal susceptible strains of Drosophila melanogaster and simulans binds 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate ([CHEMICAL][3H]EBOB[\\CHEMICAL]) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "[GENE]Drosophila GABA-gated chloride channel[\\GENE]: modified [CHEMICAL][3H]EBOB[\\CHEMICAL] binding site associated with Ala-->Ser or Gly mutants of Rdl subunit.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The channel activators [CHEMICAL]avermectin[\\CHEMICAL] and moxidectin usually retain their inhibitory potency in the [GENE]Rdl[\\GENE] subunit mutants.",
        "label": 4,
        "major": 1,
        "len": 16
    },
    {
        "text": "The channel activators avermectin and [CHEMICAL]moxidectin[\\CHEMICAL] usually retain their inhibitory potency in the [GENE]Rdl[\\GENE] subunit mutants.",
        "label": 4,
        "major": 1,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Agmatine[\\CHEMICAL], locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at [GENE]alpha 2-adrenergic receptors[\\GENE] and may act as a neurotransmitter.",
        "label": 2,
        "major": 5,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Clonidine[\\CHEMICAL], an antihypertensive drug, binds to [GENE]alpha 2-adrenergic and imidazoline receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Agmatine[\\CHEMICAL] binds to [GENE]alpha 2-adrenergic and imidazoline receptors[\\GENE] and stimulates release of catecholamines from adrenal chromaffin cells.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Agmatine[\\CHEMICAL], locally synthesized, is an endogenous agonist at [GENE]imidazoline receptors[\\GENE], a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "Both [CHEMICAL]BRL[\\CHEMICAL] and SAL produced a significant increase in postural finger tremor in keeping with [GENE]beta 2-adrenoceptor[\\GENE] stimulation, and this response was totally abolished by pretreatment with N20.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Both BRL and [CHEMICAL]SAL[\\CHEMICAL] produced a significant increase in postural finger tremor in keeping with [GENE]beta 2-adrenoceptor[\\GENE] stimulation, and this response was totally abolished by pretreatment with N20.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Cardiac effects of the [GENE]beta 3-adrenoceptor[\\GENE] agonist [CHEMICAL]BRL35135[\\CHEMICAL] in man.",
        "label": 5,
        "major": 5,
        "len": 10
    },
    {
        "text": "The aim of the present study was to evaluate the cardiac effects of the [GENE]beta 3-adrenoceptor[\\GENE] agonist [CHEMICAL]BRL35135[\\CHEMICAL], and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.",
        "label": 5,
        "major": 10,
        "len": 33
    },
    {
        "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective [GENE]beta 2-adrenoceptor[\\GENE] agonist [CHEMICAL]salbutamol[\\CHEMICAL] 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
        "label": 5,
        "major": 5,
        "len": 54
    },
    {
        "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective [GENE]beta 2-adrenoceptor[\\GENE] agonist salbutamol 8 mg ([CHEMICAL]SAL[\\CHEMICAL]), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
        "label": 5,
        "major": 5,
        "len": 54
    },
    {
        "text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), [CHEMICAL]bisoprolol[\\CHEMICAL] 5 mg (B5) as a selective [GENE]beta 1-adrenoceptor[\\GENE] antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.",
        "label": 6,
        "major": 6,
        "len": 54
    },
    {
        "text": "The two [CHEMICAL]NH2[\\CHEMICAL]-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a [GENE]carbonic anhydrase (CA) V[\\GENE] isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.",
        "label": 1,
        "major": 9,
        "len": 41
    },
    {
        "text": "The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-[CHEMICAL]amino acid[\\CHEMICAL] putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a [GENE]carbonic anhydrase (CA) V[\\GENE] isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 [CHEMICAL]amino acids[\\CHEMICAL], yielding a protein equivalent to a [GENE]carbonic anhydrase (CA) V[\\GENE] isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.",
        "label": 1,
        "major": 9,
        "len": 41
    },
    {
        "text": "Investigation of a site-specific mutant of [GENE]CA V[\\GENE] containing the replacement Tyr64-->[CHEMICAL]His[\\CHEMICAL] showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.",
        "label": 1,
        "major": 1,
        "len": 32
    },
    {
        "text": "Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of [GENE]CA V[\\GENE] are not due to the presence of [CHEMICAL]tyrosine[\\CHEMICAL] at position 64.",
        "label": 1,
        "major": 1,
        "len": 32
    },
    {
        "text": "[GENE]The carbonic anhydrase V[\\GENE] produced by a vector containing the full coding sequence, which includes a possible [CHEMICAL]NH2[\\CHEMICAL]-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends.",
        "label": 1,
        "major": 9,
        "len": 32
    },
    {
        "text": "[GENE]The carbonic anhydrase V[\\GENE] produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several [CHEMICAL]amino[\\CHEMICAL]-terminal ends.",
        "label": 1,
        "major": 9,
        "len": 32
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by [CHEMICAL]acetazolamide[\\CHEMICAL], ethoxzolamide, and cyanate, [GENE]CA V[\\GENE] is very similar to CA II.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by [CHEMICAL]acetazolamide[\\CHEMICAL], ethoxzolamide, and cyanate, CA V is very similar to [GENE]CA II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, [CHEMICAL]ethoxzolamide[\\CHEMICAL], and cyanate, [GENE]CA V[\\GENE] is very similar to CA II.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, [CHEMICAL]ethoxzolamide[\\CHEMICAL], and cyanate, CA V is very similar to [GENE]CA II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and [CHEMICAL]cyanate[\\CHEMICAL], [GENE]CA V[\\GENE] is very similar to CA II.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and [CHEMICAL]cyanate[\\CHEMICAL], CA V is very similar to [GENE]CA II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for [GENE]5-HT1A[\\GENE] and 5-HT1B binding sites [CHEMICAL](+/-)-pindolol[\\CHEMICAL] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and [GENE]5-HT1B[\\GENE] binding sites [CHEMICAL](+/-)-pindolol[\\CHEMICAL] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "It is concluded that [CHEMICAL]D-1997[\\CHEMICAL] contracts the canine basilar artery by stimulating [GENE]5-HT1-like receptors[\\GENE] unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "It is concluded that [CHEMICAL]D-1997[\\CHEMICAL] contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the [GENE]5-HT1A[\\GENE] or 5-HT1B receptor subtypes.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "It is concluded that [CHEMICAL]D-1997[\\CHEMICAL] contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or [GENE]5-HT1B[\\GENE] receptor subtypes.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the [GENE]beta-adrenoceptor[\\GENE] blocker with high affinity for 5-HT1A and 5-HT1B binding sites [CHEMICAL](+/-)-pindolol[\\CHEMICAL] (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 4,
        "major": 2,
        "len": 62
    },
    {
        "text": "[CHEMICAL]2-(2-Aminoethyl)-quinoline[\\CHEMICAL] (D-1997): a novel agonist at [GENE]5-hydroxytryptamine1-like receptors[\\GENE] in the canine basilar artery.",
        "label": 5,
        "major": 5,
        "len": 13
    },
    {
        "text": "2-(2-Aminoethyl)-quinoline ([CHEMICAL]D-1997[\\CHEMICAL]): a novel agonist at [GENE]5-hydroxytryptamine1-like receptors[\\GENE] in the canine basilar artery.",
        "label": 5,
        "major": 5,
        "len": 13
    },
    {
        "text": "In contrast, the [CHEMICAL]D-1997[\\CHEMICAL]-induced responses were potently and concentration-dependently antagonized by the mixed [GENE]5-HT1-like[\\GENE] and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "In contrast, the [CHEMICAL]D-1997[\\CHEMICAL]-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and [GENE]5-HT2 receptor[\\GENE] antagonist methiothepin (0.01-1 microM).",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed [GENE]5-HT1-like[\\GENE] and 5-HT2 receptor antagonist [CHEMICAL]methiothepin[\\CHEMICAL] (0.01-1 microM).",
        "label": 6,
        "major": 3,
        "len": 21
    },
    {
        "text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and [GENE]5-HT2 receptor[\\GENE] antagonist [CHEMICAL]methiothepin[\\CHEMICAL] (0.01-1 microM).",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the [GENE]5-HT2 receptor[\\GENE] antagonist [CHEMICAL]ketanserin[\\CHEMICAL] (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 6,
        "major": 2,
        "len": 62
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the [GENE]5-HT3[\\GENE] and 5-HT4 receptor antagonist ICS205930 ([CHEMICAL]tropisetron[\\CHEMICAL]; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 6,
        "major": 2,
        "len": 62
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and [GENE]5-HT4[\\GENE] receptor antagonist ICS205930 ([CHEMICAL]tropisetron[\\CHEMICAL]; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 6,
        "major": 2,
        "len": 62
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the [GENE]5-HT1A[\\GENE] receptor antagonist [CHEMICAL]spiroxatrine[\\CHEMICAL] (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).",
        "label": 6,
        "major": 2,
        "len": 62
    },
    {
        "text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the [GENE]alpha 1-adrenoceptor[\\GENE] antagonist [CHEMICAL]prazosin[\\CHEMICAL] (0.01-1 microM).",
        "label": 6,
        "major": 2,
        "len": 62
    },
    {
        "text": "Recent studies highlight the capacity of [CHEMICAL]sucralfate[\\CHEMICAL] to bind [GENE]basic fibroblast growth factor[\\GENE] (bFGF) and deliver it in high concentration to the ulcer.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Recent studies highlight the capacity of [CHEMICAL]sucralfate[\\CHEMICAL] to bind basic fibroblast growth factor ([GENE]bFGF[\\GENE]) and deliver it in high concentration to the ulcer.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact [GENE]bovine pancreatic ribonuclease A[\\GENE] (RNase A) and its [CHEMICAL]proline[\\CHEMICAL]-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ([GENE]RNase A[\\GENE]) and its [CHEMICAL]proline[\\CHEMICAL]-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact [GENE]bovine pancreatic ribonuclease A[\\GENE] (RNase A) and its proline-42-to-[CHEMICAL]alanine[\\CHEMICAL] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ([GENE]RNase A[\\GENE]) and its proline-42-to-[CHEMICAL]alanine[\\CHEMICAL] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 1,
        "major": 2,
        "len": 30
    },
    {
        "text": "The folding rate monitored by [CHEMICAL]2'CMP[\\CHEMICAL] binding to the major slow-folding species of [GENE]Pro42Ala[\\GENE] RNase A is faster than the folding rate monitored by tyrosine burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.",
        "label": 2,
        "major": 4,
        "len": 73
    },
    {
        "text": "The folding rate monitored by [CHEMICAL]2'CMP[\\CHEMICAL] binding to the major slow-folding species of Pro42Ala [GENE]RNase A[\\GENE] is faster than the folding rate monitored by tyrosine burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.",
        "label": 2,
        "major": 4,
        "len": 73
    },
    {
        "text": "The folding rate monitored by 2'CMP binding to the major slow-folding species of [GENE]Pro42Ala[\\GENE] RNase A is faster than the folding rate monitored by [CHEMICAL]tyrosine[\\CHEMICAL] burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.",
        "label": 2,
        "major": 4,
        "len": 73
    },
    {
        "text": "The folding rate monitored by 2'CMP binding to the major slow-folding species of Pro42Ala [GENE]RNase A[\\GENE] is faster than the folding rate monitored by [CHEMICAL]tyrosine[\\CHEMICAL] burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.",
        "label": 2,
        "major": 4,
        "len": 73
    },
    {
        "text": "Folding pathway of guanidine-denatured [CHEMICAL]disulfide[\\CHEMICAL]-intact wild-type and mutant [GENE]bovine pancreatic ribonuclease A[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 12
    },
    {
        "text": "The refolding kinetics of guanidine-denatured [CHEMICAL]disulfide[\\CHEMICAL]-intact [GENE]bovine pancreatic ribonuclease A[\\GENE] (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured [CHEMICAL]disulfide[\\CHEMICAL]-intact bovine pancreatic ribonuclease A ([GENE]RNase A[\\GENE]) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "The folding rate monitored by 2'CMP binding to the major slow-folding species of Pro42Ala [GENE]RNase A[\\GENE] is faster than the folding rate monitored by tyrosine burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by [CHEMICAL]tyrosine[\\CHEMICAL] burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.",
        "label": 2,
        "major": 4,
        "len": 73
    },
    {
        "text": "The folding rate for wild-type [GENE]RNase A[\\GENE] is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by [CHEMICAL]2'CMP[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its [GENE]proline-42-to-alanine[\\GENE] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [CHEMICAL]2'-cytidine monophosphate[\\CHEMICAL] (2'CMP) inhibitor binding.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ([GENE]Pro42Ala[\\GENE]) have been studied by monitoring tyrosine burial and [CHEMICAL]2'-cytidine monophosphate[\\CHEMICAL] (2'CMP) inhibitor binding.",
        "label": 4,
        "major": 1,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact [GENE]bovine pancreatic ribonuclease A[\\GENE] (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [CHEMICAL]2'-cytidine monophosphate[\\CHEMICAL] (2'CMP) inhibitor binding.",
        "label": 4,
        "major": 1,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ([GENE]RNase A[\\GENE]) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [CHEMICAL]2'-cytidine monophosphate[\\CHEMICAL] (2'CMP) inhibitor binding.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its [GENE]proline-42-to-alanine[\\GENE] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([CHEMICAL]2'CMP[\\CHEMICAL]) inhibitor binding.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ([GENE]Pro42Ala[\\GENE]) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([CHEMICAL]2'CMP[\\CHEMICAL]) inhibitor binding.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact [GENE]bovine pancreatic ribonuclease A[\\GENE] (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([CHEMICAL]2'CMP[\\CHEMICAL]) inhibitor binding.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ([GENE]RNase A[\\GENE]) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([CHEMICAL]2'CMP[\\CHEMICAL]) inhibitor binding.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The folding rate for wild-type [GENE]RNase A[\\GENE] is faster in the presence of the inhibitor [CHEMICAL]2'CMP[\\CHEMICAL] than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The anti-inflammatory drugs [CHEMICAL]sodium salicylate[\\CHEMICAL] and aspirin inhibited the activation of [GENE]NF-kappa B[\\GENE], which further explains the mechanism of action of these drugs.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The anti-inflammatory drugs sodium salicylate and [CHEMICAL]aspirin[\\CHEMICAL] inhibited the activation of [GENE]NF-kappa B[\\GENE], which further explains the mechanism of action of these drugs.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Sodium salicylate[\\CHEMICAL] and aspirin also inhibited [GENE]NF-kappa B[\\GENE]-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sodium salicylate[\\CHEMICAL] and aspirin also inhibited NF-kappa B-dependent transcription from the [GENE]Ig kappa[\\GENE] enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Sodium salicylate and [CHEMICAL]aspirin[\\CHEMICAL] also inhibited [GENE]NF-kappa B[\\GENE]-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Sodium salicylate and [CHEMICAL]aspirin[\\CHEMICAL] also inhibited NF-kappa B-dependent transcription from the [GENE]Ig kappa[\\GENE] enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In animals, the [CHEMICAL]R-enantiomer of timolol[\\CHEMICAL] causes a significant reduction in intraocular pressure but had only 1/80 the activity of the S-enantiomer at [GENE]extraocular receptors[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Preliminary evidence suggests that [CHEMICAL]ergotamine[\\CHEMICAL] may not occupy striatal [GENE]dopamine D2-receptors[\\GENE] to a large extent and thus may not cross the blood brain barrier in large quantities.",
        "label": 10,
        "major": 10,
        "len": 27
    },
    {
        "text": "Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to [GENE]human subtype-I1 imidazol(in)e receptor[\\GENE] sites in the brain stem (rank order: [CHEMICAL]moxonidine[\\CHEMICAL] > clonidine > cirazoline > IDX > amiloride).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to [GENE]human subtype-I1 imidazol(in)e receptor[\\GENE] sites in the brain stem (rank order: moxonidine > [CHEMICAL]clonidine[\\CHEMICAL] > cirazoline > IDX > amiloride).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to [GENE]human subtype-I1 imidazol(in)e receptor[\\GENE] sites in the brain stem (rank order: moxonidine > clonidine > [CHEMICAL]cirazoline[\\CHEMICAL] > IDX > amiloride).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to [GENE]human subtype-I1 imidazol(in)e receptor[\\GENE] sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > [CHEMICAL]IDX[\\CHEMICAL] > amiloride).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to [GENE]human subtype-I1 imidazol(in)e receptor[\\GENE] sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > IDX > [CHEMICAL]amiloride[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to clonidine and endogenous [CHEMICAL]clonidine[\\CHEMICAL]-displacing substance(s), and may serve as markers of [GENE]imidazoline receptors[\\GENE] in humans.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to [CHEMICAL]clonidine[\\CHEMICAL] and endogenous clonidine-displacing substance(s), and may serve as markers of [GENE]imidazoline receptors[\\GENE] in humans.",
        "label": 3,
        "major": 2,
        "len": 29
    },
    {
        "text": "[GENE]dSERT1[\\GENE] shows little transport of other [CHEMICAL]monoamines[\\CHEMICAL] and is Na+ and Cl- dependent.",
        "label": 10,
        "major": 9,
        "len": 13
    },
    {
        "text": "A [CHEMICAL]cocaine[\\CHEMICAL]-sensitive [GENE]Drosophila serotonin transporter[\\GENE]: cloning, expression, and electrophysiological characterization.",
        "label": 2,
        "major": 9,
        "len": 10
    },
    {
        "text": "[GENE]dSERT1[\\GENE] shows little transport of other monoamines and is [CHEMICAL]Na+[\\CHEMICAL] and Cl- dependent.",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[GENE]dSERT1[\\GENE] shows little transport of other monoamines and is Na+ and [CHEMICAL]Cl-[\\CHEMICAL] dependent.",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "A [CHEMICAL]cocaine[\\CHEMICAL]-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted [GENE]dSERT1[\\GENE], was isolated and characterized in oocytes.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "A [CHEMICAL]cocaine[\\CHEMICAL]-sensitive, high-affinity [GENE]Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter[\\GENE] cDNA, denoted dSERT1, was isolated and characterized in oocytes.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "[CHEMICAL]GCS[\\CHEMICAL] therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of [GENE]IFN-gamma[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 22
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of [CHEMICAL]GCS[\\CHEMICAL] on [GENE]IL-2[\\GENE] production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",
        "label": 2,
        "major": 4,
        "len": 55
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of [CHEMICAL]GCS[\\CHEMICAL] on IL-2 production and [GENE]IL-2R alpha[\\GENE] expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",
        "label": 2,
        "major": 4,
        "len": 55
    },
    {
        "text": "The differential effects of [CHEMICAL]DEX[\\CHEMICAL] on the proliferation of high and low [GENE]IL-2[\\GENE] producers in vitro may implicate a selective outgrowth of Th1-like T cells in vivo in patients treated with steroids.",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers [CHEMICAL]DEX[\\CHEMICAL] inhibited IL-2 production partially and enhanced [GENE]IL-2R alpha[\\GENE] expression and proliferation.",
        "label": 3,
        "major": 4,
        "len": 55
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DEX[\\CHEMICAL]) inhibited the anti-CD3-induced production of [GENE]IL-4[\\GENE], IL-5 and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DEX[\\CHEMICAL]) inhibited the anti-CD3-induced production of IL-4, [GENE]IL-5[\\GENE] and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DEX[\\CHEMICAL]) inhibited the anti-CD3-induced production of IL-4, IL-5 and [GENE]IFN-gamma[\\GENE] in all 20 clones tested.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]GCS[\\CHEMICAL] therapy results in reduced mRNA expression of [GENE]interleukin-4[\\GENE] (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GCS[\\CHEMICAL] therapy results in reduced mRNA expression of interleukin-4 ([GENE]IL-4[\\GENE]) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GCS[\\CHEMICAL] therapy results in reduced mRNA expression of interleukin-4 (IL-4) and [GENE]IL-5[\\GENE] in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers [CHEMICAL]DEX[\\CHEMICAL] blocked [GENE]IL-2[\\GENE] production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",
        "label": 4,
        "major": 4,
        "len": 55
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers [CHEMICAL]DEX[\\CHEMICAL] blocked IL-2 production and decreased [GENE]IL-2R alpha[\\GENE] expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.",
        "label": 4,
        "major": 4,
        "len": 55
    },
    {
        "text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers [CHEMICAL]DEX[\\CHEMICAL] inhibited [GENE]IL-2[\\GENE] production partially and enhanced IL-2R alpha expression and proliferation.",
        "label": 4,
        "major": 4,
        "len": 55
    },
    {
        "text": "In conclusion, the production of [GENE]IL-4[\\GENE] and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [CHEMICAL]DEX[\\CHEMICAL] than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "In conclusion, the production of IL-4 and [GENE]IL-5[\\GENE] by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [CHEMICAL]DEX[\\CHEMICAL] than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by [CHEMICAL]DEX[\\CHEMICAL] than that of [GENE]IFN-gamma[\\GENE], which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DEX) inhibited the anti-CD3-induced production of [GENE]IL-4[\\GENE], IL-5 and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DEX) inhibited the anti-CD3-induced production of IL-4, [GENE]IL-5[\\GENE] and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and [GENE]IFN-gamma[\\GENE] in all 20 clones tested.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DEX[\\CHEMICAL]) inhibited the anti-[GENE]CD3[\\GENE]-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "In vitro studies with blood-derived T cells, however, show inhibition of all three [GENE]cytokines[\\GENE] by [CHEMICAL]GCS[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DEX) inhibited the anti-[GENE]CD3[\\GENE]-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the [GENE]CB1[\\GENE] variant but that eliminated [CHEMICAL]CP 55,940[\\CHEMICAL] binding in both mutants.",
        "label": 10,
        "major": 1,
        "len": 32
    },
    {
        "text": "The replacement of the conserved cysteine residues in e2 of [GENE]CB2[\\GENE] by serine also eliminated [CHEMICAL]CP 55,940[\\CHEMICAL] binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.",
        "label": 10,
        "major": 1,
        "len": 36
    },
    {
        "text": "The antagonist [CHEMICAL]SR 141716A[\\CHEMICAL] has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral [GENE]CB2[\\GENE] receptor, making it an excellent tool for probing receptor structure-activity relationships.",
        "label": 10,
        "major": 6,
        "len": 32
    },
    {
        "text": "The replacement of the conserved [CHEMICAL]cysteine[\\CHEMICAL] residues in e2 of [GENE]CB2[\\GENE] by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "The replacement of the conserved cysteine residues in e2 of [GENE]CB2[\\GENE] by [CHEMICAL]serine[\\CHEMICAL] also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on [CHEMICAL]SR 141716A[\\CHEMICAL] binding in the [GENE]CB1[\\GENE] variant but that eliminated CP 55,940 binding in both mutants.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Structural features of the central cannabinoid [GENE]CB1[\\GENE] receptor involved in the binding of the specific CB1 antagonist [CHEMICAL]SR 141716A[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 19
    },
    {
        "text": "The [GENE]e2 domain[\\GENE] thus plays some role in [CHEMICAL]CP 55,940[\\CHEMICAL] binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]e2 domain[\\GENE] thus plays some role in CP 55,940 binding but none in [CHEMICAL]SR 141716A[\\CHEMICAL] recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The antagonist [CHEMICAL]SR 141716A[\\CHEMICAL] has a high specificity for the central [GENE]CB1[\\GENE] cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships.",
        "label": 2,
        "major": 6,
        "len": 32
    },
    {
        "text": "The antagonist [CHEMICAL]SR 141716A[\\CHEMICAL] has a high specificity for the central CB1 [GENE]cannabinoid receptor[\\GENE] and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The region delineated by the fourth and fifth transmembrane helices of [GENE]CB1[\\GENE] proved to be crucial for high affinity binding of [CHEMICAL]SR 141716A[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific [GENE]CB1[\\GENE] antagonist [CHEMICAL]SR 141716A[\\CHEMICAL].",
        "label": 6,
        "major": 2,
        "len": 19
    },
    {
        "text": "The pharmacologic properties of [CHEMICAL]fluticasone propionate[\\CHEMICAL]-including high lipophilicity, high selectivity and affinity for the [GENE]glucocorticoid receptor[\\GENE], low systemic absorption, and rapid metabolism and clearance-combine to give fluticasone propionate a high therapeutic index.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] abolished the inhibitory effect of acetazolamide on [GENE]CA I[\\GENE] and CA II.",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] abolished the inhibitory effect of acetazolamide on CA I and [GENE]CA II[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "Histamine and [CHEMICAL]Ca[\\CHEMICAL] added to NSAIDs amplified the activating effect of the latter on [GENE]CA II[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Association of PGE2 or [CHEMICAL]acetazolamide[\\CHEMICAL] to NSAIDs reduced NSAID-induced activation of [GENE]CA I[\\GENE] and CA II.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Association of PGE2 or [CHEMICAL]acetazolamide[\\CHEMICAL] to NSAIDs reduced NSAID-induced activation of CA I and [GENE]CA II[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Indomethacin abolished the inhibitory effect of [CHEMICAL]acetazolamide[\\CHEMICAL] on [GENE]CA I[\\GENE] and CA II.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Indomethacin abolished the inhibitory effect of [CHEMICAL]acetazolamide[\\CHEMICAL] on CA I and [GENE]CA II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Previous studies by this research team proved that vasodilating [CHEMICAL]prostaglandins[\\CHEMICAL] (PGs) E1, E2 and I2 inhibit [GENE]carbonic anhydrase[\\GENE] (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",
        "label": 4,
        "major": 9,
        "len": 48
    },
    {
        "text": "Previous studies by this research team proved that vasodilating [CHEMICAL]prostaglandins[\\CHEMICAL] (PGs) E1, E2 and I2 inhibit carbonic anhydrase ([GENE]CA[\\GENE]) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",
        "label": 4,
        "major": 9,
        "len": 48
    },
    {
        "text": "Previous studies by this research team proved that vasodilating prostaglandins ([CHEMICAL]PGs[\\CHEMICAL]) E1, E2 and I2 inhibit [GENE]carbonic anhydrase[\\GENE] (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",
        "label": 4,
        "major": 9,
        "len": 48
    },
    {
        "text": "Previous studies by this research team proved that vasodilating prostaglandins ([CHEMICAL]PGs[\\CHEMICAL]) E1, E2 and I2 inhibit carbonic anhydrase ([GENE]CA[\\GENE]) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.",
        "label": 4,
        "major": 9,
        "len": 48
    },
    {
        "text": "The affinity estimate for [CHEMICAL]prazosin[\\CHEMICAL] on human prostate was lower than the corresponding binding affinity determined at [GENE]alpha 1A adrenoceptors[\\GENE] and RS 17053 was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned human alpha 1A adrenoceptors.",
        "label": 2,
        "major": 2,
        "len": 49
    },
    {
        "text": "[CHEMICAL](+)-Tamsulosin[\\CHEMICAL], (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "The affinity estimate for prazosin on human prostate was lower than the corresponding binding affinity determined at alpha 1A adrenoceptors and [CHEMICAL]RS 17053[\\CHEMICAL] was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned [GENE]human alpha 1A adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 49
    },
    {
        "text": "The [CHEMICAL]quinazoline[\\CHEMICAL] antagonists, prazosin, doxazosin and alfuzosin displayed high affinity but were non selective for the three cloned [GENE]human alpha 1 adrenoceptors[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "(+)-Tamsulosin, [CHEMICAL](-)-tamsulosin[\\CHEMICAL], SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "The quinazoline antagonists, [CHEMICAL]prazosin[\\CHEMICAL], doxazosin and alfuzosin displayed high affinity but were non selective for the three cloned [GENE]human alpha 1 adrenoceptors[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "The quinazoline antagonists, prazosin, [CHEMICAL]doxazosin[\\CHEMICAL] and alfuzosin displayed high affinity but were non selective for the three cloned [GENE]human alpha 1 adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "The quinazoline antagonists, prazosin, doxazosin and [CHEMICAL]alfuzosin[\\CHEMICAL] displayed high affinity but were non selective for the three cloned [GENE]human alpha 1 adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "[CHEMICAL]RS 17053[\\CHEMICAL] showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and [GENE]alpha 1D[\\GENE] (pKi = 7.1) subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]RS 17053[\\CHEMICAL] showed high affinity and selectivity for [GENE]alpha 1A adrenoceptors[\\GENE] (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]RS 17053[\\CHEMICAL] showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to [GENE]alpha 1B[\\GENE] (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, [CHEMICAL]SL 89,0591[\\CHEMICAL], Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, [CHEMICAL]Rec 15/2739[\\CHEMICAL], SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, [CHEMICAL]SNAP 1069[\\CHEMICAL] and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and [CHEMICAL]RS 17053[\\CHEMICAL] appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "Data in this study suggest that the [GENE]alpha 1 adrenoceptor[\\GENE] mediating [CHEMICAL]noradrenaline[\\CHEMICAL]-induced contractions of human prostate, whilst having some of the characteristics of an alpha 1A adrenoceptor, cannot be satisfactorily aligned with cloned alpha 1A, alpha 1B or alpha 1D adrenoceptors.",
        "label": 2,
        "major": 10,
        "len": 41
    },
    {
        "text": "[CHEMICAL](+)-Tamsulosin[\\CHEMICAL], (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, [CHEMICAL](-)-tamsulosin[\\CHEMICAL], SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, [CHEMICAL]SL 89,0591[\\CHEMICAL], Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, [CHEMICAL]Rec 15/2739[\\CHEMICAL], SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, [CHEMICAL]SNAP 1069[\\CHEMICAL] and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and [CHEMICAL]RS 17053[\\CHEMICAL] appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned [GENE]human alpha 1D adrenoceptors[\\GENE].",
        "label": 6,
        "major": 2,
        "len": 39
    },
    {
        "text": "Forskolin did not affect the relaxant response to UK14,304, suggesting that [CHEMICAL]cAMP[\\CHEMICAL] is not involved in the coupling of [GENE]alpha-2 adrenoceptors[\\GENE] to nitric oxide-induced vascular relaxation.",
        "label": 10,
        "major": 10,
        "len": 26
    },
    {
        "text": "Ka values in nM for [CHEMICAL]rauwolscine[\\CHEMICAL] (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [GENE]alpha-2D adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Ka values in nM for rauwolscine (19), [CHEMICAL]WB-4101[\\CHEMICAL] (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [GENE]alpha-2D adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Ka values in nM for rauwolscine (19), WB-4101 (265), [CHEMICAL]SKF-104078[\\CHEMICAL] (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [GENE]alpha-2D adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), [CHEMICAL]spiroxatrine[\\CHEMICAL] (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [GENE]alpha-2D adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and [CHEMICAL]prazosin[\\CHEMICAL] (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [GENE]alpha-2D adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Ka values for [CHEMICAL]rauwolscine[\\CHEMICAL] and WB-4101, drugs distinguishing the alpha-2D from the [GENE]alpha-2A adrenoceptor[\\GENE] subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries.",
        "label": 2,
        "major": 3,
        "len": 39
    },
    {
        "text": "Ka values for rauwolscine and [CHEMICAL]WB-4101[\\CHEMICAL], drugs distinguishing the alpha-2D from the [GENE]alpha-2A adrenoceptor[\\GENE] subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries.",
        "label": 2,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Chlorpheniramine[\\CHEMICAL] (10 microM), another histamine H1 receptor antagonist without significant [GENE]5-HT receptor[\\GENE] binding affinity, did not produce any inhibition of the eNANC contraction.",
        "label": 10,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Epinastine[\\CHEMICAL] (100 microM) did not displace the dose-response curve to exogenously applied [GENE]substance P[\\GENE] (0.01-10 microM).",
        "label": 10,
        "major": 10,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Epinastine[\\CHEMICAL] (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including [GENE]alpha-adrenergic receptors[\\GENE] and various serotonin (5-HT) receptor subtypes.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Epinastine[\\CHEMICAL] (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various [GENE]serotonin (5-HT) receptor[\\GENE] subtypes.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Epinastine ([CHEMICAL]WAL 801CL[\\CHEMICAL]) is an antihistaminic drug with binding affinity at certain other receptors, including [GENE]alpha-adrenergic receptors[\\GENE] and various serotonin (5-HT) receptor subtypes.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Epinastine ([CHEMICAL]WAL 801CL[\\CHEMICAL]) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various [GENE]serotonin (5-HT) receptor[\\GENE] subtypes.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Epinastine[\\CHEMICAL] (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional [GENE]5-HT1-like receptor[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "Epinastine ([CHEMICAL]WAL 801CL[\\CHEMICAL]) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional [GENE]5-HT1-like receptor[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "These results suggest that [CHEMICAL]epinastine[\\CHEMICAL], although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional [GENE]5-HT1-like receptor[\\GENE], located to sensory nerves.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "These results suggest that [CHEMICAL]epinastine[\\CHEMICAL], although identified as a 5-HT antagonist, acts as a [GENE]5-HT1[\\GENE] agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.",
        "label": 5,
        "major": 3,
        "len": 37
    },
    {
        "text": "Pretreatment of the tissues with combined [GENE]5-HT1[\\GENE]/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of [CHEMICAL]epinastine[\\CHEMICAL] on the noncholinergic contraction.",
        "label": 5,
        "major": 6,
        "len": 26
    },
    {
        "text": "Pretreatment of the tissues with combined 5-HT1/[GENE]5-HT2[\\GENE] antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of [CHEMICAL]epinastine[\\CHEMICAL] on the noncholinergic contraction.",
        "label": 5,
        "major": 4,
        "len": 26
    },
    {
        "text": "Pretreatment of the tissues with combined [GENE]5-HT1[\\GENE]/5-HT2 antagonists, [CHEMICAL]methysergide[\\CHEMICAL] (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
        "label": 6,
        "major": 4,
        "len": 26
    },
    {
        "text": "Pretreatment of the tissues with combined 5-HT1/[GENE]5-HT2[\\GENE] antagonists, [CHEMICAL]methysergide[\\CHEMICAL] (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
        "label": 6,
        "major": 4,
        "len": 26
    },
    {
        "text": "Pretreatment of the tissues with combined [GENE]5-HT1[\\GENE]/5-HT2 antagonists, methysergide (1 microM) or [CHEMICAL]methiothepin[\\CHEMICAL] (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
        "label": 6,
        "major": 4,
        "len": 26
    },
    {
        "text": "Pretreatment of the tissues with combined 5-HT1/[GENE]5-HT2[\\GENE] antagonists, methysergide (1 microM) or [CHEMICAL]methiothepin[\\CHEMICAL] (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "Pretreatment with [CHEMICAL]tropisetron[\\CHEMICAL] (1 microM), a [GENE]5-HT3[\\GENE] antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, [CHEMICAL]ketanserin[\\CHEMICAL] (10 microM), a [GENE]5-HT2[\\GENE] antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, [CHEMICAL]thioperamide[\\CHEMICAL] (10 microM), a [GENE]histamine H3[\\GENE] antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Chlorpheniramine[\\CHEMICAL] (10 microM), another [GENE]histamine H1 receptor[\\GENE] antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.",
        "label": 6,
        "major": 2,
        "len": 23
    },
    {
        "text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and oxymetazoline-sensitive subtype of [GENE]alpha 1-adrenoceptors[\\GENE], is exerted by a subcellular mechanism that is independent of the accumulation of [CHEMICAL]inositol phosphates[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 32
    },
    {
        "text": "The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another [GENE]alpha 1A-adrenoceptor[\\GENE] ligand [CHEMICAL]oxymetazoline[\\CHEMICAL] in the rabbit ventricular myocardium.",
        "label": 2,
        "major": 10,
        "len": 43
    },
    {
        "text": "Phenylephrine elicited a concentration-dependent positive inotropic effect via [GENE]alpha 1-adrenoceptors[\\GENE] in the presence of either [CHEMICAL](+/-)-bupranolol[\\CHEMICAL] or S(-)-timolol.",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "Phenylephrine elicited a concentration-dependent positive inotropic effect via [GENE]alpha 1-adrenoceptors[\\GENE] in the presence of either (+/-)-bupranolol or [CHEMICAL]S(-)-timolol[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [GENE]alpha 1B-adrenoceptors[\\GENE] by treatment with [CHEMICAL]chlorethylclonidine[\\CHEMICAL], which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
        "label": 4,
        "major": 6,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Phenylephrine[\\CHEMICAL] elicited a concentration-dependent positive inotropic effect via [GENE]alpha 1-adrenoceptors[\\GENE] in the presence of either (+/-)-bupranolol or S(-)-timolol.",
        "label": 5,
        "major": 10,
        "len": 18
    },
    {
        "text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and [CHEMICAL]oxymetazoline[\\CHEMICAL]-sensitive subtype of [GENE]alpha 1-adrenoceptors[\\GENE], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
        "label": 5,
        "major": 10,
        "len": 32
    },
    {
        "text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of [CHEMICAL]phenylephrine[\\CHEMICAL] even after inactivation of [GENE]alpha 1B-adrenoceptors[\\GENE] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
        "label": 5,
        "major": 6,
        "len": 34
    },
    {
        "text": "The influence of [CHEMICAL](+/-)-tamsulosin[\\CHEMICAL], a selective [GENE]alpha 1A-adrenoceptor[\\GENE] antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "These results indicate that the positive inotropic effect, mediated via [CHEMICAL](+/-)-tamsulosin[\\CHEMICAL]- and oxymetazoline-sensitive subtype of [GENE]alpha 1-adrenoceptors[\\GENE], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
        "label": 6,
        "major": 10,
        "len": 32
    },
    {
        "text": "[CHEMICAL](+/-)-Tamsulosin[\\CHEMICAL] effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [GENE]alpha 1B-adrenoceptors[\\GENE] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.",
        "label": 6,
        "major": 10,
        "len": 34
    },
    {
        "text": "[CHEMICAL](+/-)-tamsulosin[\\CHEMICAL], an [GENE]alpha 1A-adrenoceptor[\\GENE] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.",
        "label": 6,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL](+/-)-Tamsulosin[\\CHEMICAL], over the range of concentrations at which it antagonized the positive inotropic effect mediated by [GENE]alpha 1-adrenoceptors[\\GENE], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.",
        "label": 6,
        "major": 10,
        "len": 33
    },
    {
        "text": "Thus, in functional experiments the presumed high selectivity of [CHEMICAL]risperidone[\\CHEMICAL] for the B subtype of [GENE]alpha 1-adrenoceptors[\\GENE] could not be confirmed, the drug instead appears to be moderately selective (10-fold) for the A subtype.",
        "label": 10,
        "major": 10,
        "len": 34
    },
    {
        "text": "However, at [GENE]guinea-pig and mouse splenic alpha 1B-adrenoceptors[\\GENE], the affinity values of [CHEMICAL]risperidone[\\CHEMICAL] were 10-fold lower than those of prazosin.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "However, at [GENE]guinea-pig and mouse splenic alpha 1B-adrenoceptors[\\GENE], the affinity values of risperidone were 10-fold lower than those of [CHEMICAL]prazosin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "In functional experiments, [CHEMICAL]risperidone[\\CHEMICAL] is selective, not for the B, but for the A subtype of [GENE]alpha 1-adrenoceptors[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "The potency of the antipsychotic drug, [CHEMICAL]risperidone[\\CHEMICAL], to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and [GENE]alpha 1B-adrenoceptor[\\GENE]-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "The potency of the antipsychotic drug, [CHEMICAL]risperidone[\\CHEMICAL], to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of [GENE]alpha 1-adrenoceptor[\\GENE] subtype-discriminating antagonists.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "The potency of the antipsychotic drug, [CHEMICAL]risperidone[\\CHEMICAL], to antagonize [GENE]alpha 1A-adrenoceptor[\\GENE]-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "Despite a low [CHEMICAL]amino acid[\\CHEMICAL] identity between [GENE]TWIK-1[\\GENE] and TREK-1 (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "Despite a low [CHEMICAL]amino acid[\\CHEMICAL] identity between TWIK-1 and [GENE]TREK-1[\\GENE] (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C. [GENE]TREK-1[\\GENE] currents are sensitive to extracellular [CHEMICAL]K+[\\CHEMICAL] and Na+.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C. [GENE]TREK-1[\\GENE] currents are sensitive to extracellular K+ and [CHEMICAL]Na+[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The atypical neuroleptics [CHEMICAL]remoxipride[\\CHEMICAL], clozapine, perlapine, seroquel, and melperone had low affinity for the dopamine [GENE]D2 receptor[\\GENE] (radioligand-independent dissociation constants of 30 to 90 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The atypical neuroleptics remoxipride, [CHEMICAL]clozapine[\\CHEMICAL], perlapine, seroquel, and melperone had low affinity for the dopamine [GENE]D2 receptor[\\GENE] (radioligand-independent dissociation constants of 30 to 90 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The atypical neuroleptics remoxipride, clozapine, [CHEMICAL]perlapine[\\CHEMICAL], seroquel, and melperone had low affinity for the dopamine [GENE]D2 receptor[\\GENE] (radioligand-independent dissociation constants of 30 to 90 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The atypical neuroleptics remoxipride, clozapine, perlapine, [CHEMICAL]seroquel[\\CHEMICAL], and melperone had low affinity for the dopamine [GENE]D2 receptor[\\GENE] (radioligand-independent dissociation constants of 30 to 90 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and [CHEMICAL]melperone[\\CHEMICAL] had low affinity for the dopamine [GENE]D2 receptor[\\GENE] (radioligand-independent dissociation constants of 30 to 90 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Conversely, opioid antagonists such as [CHEMICAL]naloxone[\\CHEMICAL] and naltrexone (which bind to non-selectively [GENE]opioid receptors[\\GENE]) have been shown to decrease alcohol consumption under various experimental conditions.",
        "label": 2,
        "major": 9,
        "len": 25
    },
    {
        "text": "Conversely, opioid antagonists such as naloxone and [CHEMICAL]naltrexone[\\CHEMICAL] (which bind to non-selectively [GENE]opioid receptors[\\GENE]) have been shown to decrease alcohol consumption under various experimental conditions.",
        "label": 2,
        "major": 6,
        "len": 25
    },
    {
        "text": "There is, however, much information on the direct (acute and chronic) effects of [CHEMICAL]alcohol[\\CHEMICAL] on the binding properties of [GENE]opioid receptors[\\GENE], as well as modulation of opioid peptide synthesis and secretion (e.g.",
        "label": 2,
        "major": 7,
        "len": 32
    },
    {
        "text": "There is, however, much information on the direct (acute and chronic) effects of [CHEMICAL]alcohol[\\CHEMICAL] on the binding properties of opioid receptors, as well as modulation of [GENE]opioid peptide[\\GENE] synthesis and secretion (e.g.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Conversely, opioid antagonists such as naloxone and [CHEMICAL]naltrexone[\\CHEMICAL] (which bind to non-selectively [GENE]opioid receptors[\\GENE]) have been shown to decrease alcohol consumption under various experimental conditions.",
        "label": 3,
        "major": 2,
        "len": 25
    },
    {
        "text": "There is, however, much information on the direct (acute and chronic) effects of [CHEMICAL]alcohol[\\CHEMICAL] on the binding properties of opioid receptors, as well as modulation of opioid peptide synthesis and secretion (e.g. a suggested increase in [GENE]beta-endorphin[\\GENE] release).",
        "label": 3,
        "major": 2,
        "len": 38
    },
    {
        "text": "Conversely, opioid antagonists such as [CHEMICAL]naloxone[\\CHEMICAL] and naltrexone (which bind to non-selectively [GENE]opioid receptors[\\GENE]) have been shown to decrease alcohol consumption under various experimental conditions.",
        "label": 6,
        "major": 9,
        "len": 25
    },
    {
        "text": "Factor Xa or catalytically inactive [CHEMICAL]5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone[\\CHEMICAL]-[GENE]factor Xa[\\GENE] bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells.",
        "label": 1,
        "major": 4,
        "len": 28
    },
    {
        "text": "A [GENE]factor X[\\GENE] peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- ([CHEMICAL]Gly[\\CHEMICAL]) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM).",
        "label": 1,
        "major": 4,
        "len": 34
    },
    {
        "text": "Although FGF-2 strongly binds to basement membrane heparan sulfate in skin and most other tissue sites examined, [GENE]FGF-7[\\GENE] fails to bind to basement membrane heparan [CHEMICAL]sulfate[\\CHEMICAL] in most locations.",
        "label": 10,
        "major": 2,
        "len": 29
    },
    {
        "text": "In summary, distinct and specific affinities of heparan [CHEMICAL]sulfates[\\CHEMICAL] for different [GENE]FGFs[\\GENE] were identified that may affect growth factor activation and local distribution.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between [GENE]FGFs[\\GENE] and heparan [CHEMICAL]sulfates[\\CHEMICAL] in human tissues.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Although [GENE]FGF-2[\\GENE] strongly binds to basement membrane heparan [CHEMICAL]sulfate[\\CHEMICAL] in skin and most other tissue sites examined, FGF-7 fails to bind to basement membrane heparan sulfate in most locations.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Felodipine[\\CHEMICAL] and nicardipine have similar affinities for 60-kDa [GENE]CaMPDE[\\GENE] isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Felodipine and [CHEMICAL]nicardipine[\\CHEMICAL] have similar affinities for 60-kDa [GENE]CaMPDE[\\GENE] isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers.",
        "label": 2,
        "major": 4,
        "len": 36
    },
    {
        "text": "The results suggest that the 63-kDa ([GENE]PDE 1B1[\\GENE]) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by [CHEMICAL]felodipine[\\CHEMICAL] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa ([GENE]PDE 1A2[\\GENE]) CaMPDE isozymes are inhibited by [CHEMICAL]felodipine[\\CHEMICAL] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) [GENE]CaMPDE[\\GENE] isozymes are inhibited by [CHEMICAL]felodipine[\\CHEMICAL] and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "The results suggest that the 63-kDa ([GENE]PDE 1B1[\\GENE]) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and [CHEMICAL]nicardipine[\\CHEMICAL] by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa ([GENE]PDE 1A2[\\GENE]) CaMPDE isozymes are inhibited by felodipine and [CHEMICAL]nicardipine[\\CHEMICAL] by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) [GENE]CaMPDE[\\GENE] isozymes are inhibited by felodipine and [CHEMICAL]nicardipine[\\CHEMICAL] by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "Felodipine and nicardipine have similar affinities for 60-kDa [GENE]CaMPDE[\\GENE] isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by [CHEMICAL]dihydropyridine[\\CHEMICAL] Ca2+-channel blockers.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by [CHEMICAL]dihydropyridine[\\CHEMICAL] [GENE]Ca2+-channel[\\GENE] blockers.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Consistent with its selectivity for [GENE]5HT1B/1D[\\GENE] receptors, [CHEMICAL]zolmitriptan[\\CHEMICAL] produces constriction of various isolated blood vessels, most notably cranial arteries.",
        "label": 2,
        "major": 9,
        "len": 19
    },
    {
        "text": "These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that [CHEMICAL]zolmitriptan[\\CHEMICAL] blocks elevations of [GENE]calcitonin-gene-related peptide[\\GENE] in jugular venous blood during electrical stimulation of the trigeminal ganglion.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Zolmitriptan (Zomig; formerly [CHEMICAL]311C90[\\CHEMICAL]) is a novel [GENE]5-hydroxytryptamine (5HT)1B/1D[\\GENE] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "Pre-clinical pharmacology of [CHEMICAL]zolmitriptan[\\CHEMICAL] (Zomig; formerly 311C90), a centrally and peripherally acting [GENE]5HT1B/1D[\\GENE] agonist for migraine.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Zolmitriptan[\\CHEMICAL] (Zomig; formerly 311C90) is a novel [GENE]5-hydroxytryptamine (5HT)1B/1D[\\GENE] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "Pre-clinical pharmacology of zolmitriptan ([CHEMICAL]Zomig[\\CHEMICAL]; formerly 311C90), a centrally and peripherally acting [GENE]5HT1B/1D[\\GENE] agonist for migraine.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly [CHEMICAL]311C90[\\CHEMICAL]), a centrally and peripherally acting [GENE]5HT1B/1D[\\GENE] agonist for migraine.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "Zolmitriptan ([CHEMICAL]Zomig[\\CHEMICAL]; formerly 311C90) is a novel [GENE]5-hydroxytryptamine (5HT)1B/1D[\\GENE] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide-induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that [GENE]Rac[\\GENE] activity is essential for the signalling cascade of [CHEMICAL]ceramide[\\CHEMICAL] to the nucleus.",
        "label": 2,
        "major": 3,
        "len": 54
    },
    {
        "text": "Exogenous [CHEMICAL]C2-ceramide[\\CHEMICAL] activates c-fos serum response element via [GENE]Rac[\\GENE]-dependent signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of [GENE]cPLA2[\\GENE] in [CHEMICAL]C2-ceramide[\\CHEMICAL]-induced signalling to nucleus.",
        "label": 2,
        "major": 3,
        "len": 56
    },
    {
        "text": "Consistent with these results, the translocation of [GENE]cPLA2[\\GENE] protein as well as the release of arachidonic acid, a principal product of phospholipase A2, was rapidly induced by the addition of [CHEMICAL]C2-ceramide[\\CHEMICAL] in a Rac-dependent manner.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Consistent with these results, the translocation of cPLA2 protein as well as the release of arachidonic acid, a principal product of phospholipase A2, was rapidly induced by the addition of [CHEMICAL]C2-ceramide[\\CHEMICAL] in a [GENE]Rac[\\GENE]-dependent manner.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Together, our findings suggest the critical role of '[GENE]Rac[\\GENE] and subsequent activation of phospholipase A2' in [CHEMICAL]ceramide[\\CHEMICAL]-signalling to nucleus.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "Treatment of Rat-2 fibroblast cells with [CHEMICAL]C2-ceramide[\\CHEMICAL] caused the stimulation of [GENE]c-fos SRE[\\GENE]-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Next, we examined the role of Rho family GTPases in the [CHEMICAL]ceramide[\\CHEMICAL]-induced signalling to [GENE]SRE[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, [CHEMICAL]C2-ceramide[\\CHEMICAL]-induced [GENE]SRE[\\GENE] activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus.",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "Exogenous [CHEMICAL]C2-ceramide[\\CHEMICAL] activates [GENE]c-fos serum response element[\\GENE] via Rac-dependent signalling pathway.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the [CHEMICAL]C2-ceramide[\\CHEMICAL]-induced [GENE]SRE[\\GENE] activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.",
        "label": 3,
        "major": 3,
        "len": 56
    },
    {
        "text": "Together, our findings suggest the critical role of 'Rac and subsequent activation of [GENE]phospholipase A2[\\GENE]' in [CHEMICAL]ceramide[\\CHEMICAL]-signalling to nucleus.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Consistent with these results, the translocation of cPLA2 protein as well as the release of [CHEMICAL]arachidonic acid[\\CHEMICAL], a principal product of [GENE]phospholipase A2[\\GENE], was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Mutation of a single [CHEMICAL]amino acid[\\CHEMICAL] residue in the potential [GENE]BiP binding site[\\GENE] increased the secretion efficiency of factor VIII by threefold.",
        "label": 1,
        "major": 1,
        "len": 22
    },
    {
        "text": "We propose that [CHEMICAL]Cu(I)[\\CHEMICAL] binds the [GENE]type-1 copper ion-binding site[\\GENE] in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "We propose that [CHEMICAL]Cu(I)[\\CHEMICAL] binds the type-1 copper ion-binding site in the [GENE]A1 domain[\\GENE] and provides the essential requirement for a stable interaction between the heavy and light chains.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of [GENE]AADC[\\GENE] (carbidopa or [CHEMICAL]benserazide[\\CHEMICAL]), and inhibitors of COMT will also enter clinical use.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of [GENE]AADC[\\GENE] ([CHEMICAL]carbidopa[\\CHEMICAL] or benserazide), and inhibitors of COMT will also enter clinical use.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Because gastric [GENE]AADC[\\GENE] and COMT degrade [CHEMICAL]levodopa[\\CHEMICAL], the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Because gastric AADC and [GENE]COMT[\\GENE] degrade [CHEMICAL]levodopa[\\CHEMICAL], the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Two mechanisms of action have been identified for [CHEMICAL]A77 1726[\\CHEMICAL]: inhibition of [GENE]dihydroorotate dehydrogenase[\\GENE] (DHODH) and inhibition of tyrosine kinases.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Two mechanisms of action have been identified for [CHEMICAL]A77 1726[\\CHEMICAL]: inhibition of dihydroorotate dehydrogenase ([GENE]DHODH[\\GENE]) and inhibition of tyrosine kinases.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Two mechanisms of action have been identified for [CHEMICAL]A77 1726[\\CHEMICAL]: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of [GENE]tyrosine kinases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[GENE]DHODH[\\GENE] inhibition occurs at lower concentrations of [CHEMICAL]A77 1726[\\CHEMICAL] than that of tyrosine kinases and is currently considered the major mode of action.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "DHODH inhibition occurs at lower concentrations of [CHEMICAL]A77 1726[\\CHEMICAL] than that of [GENE]tyrosine kinases[\\GENE] and is currently considered the major mode of action.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Interestingly, [CHEMICAL]venlafaxine[\\CHEMICAL], a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the [GENE]norepinephrine transporter[\\GENE] (Ki = 1.26 microM).",
        "label": 10,
        "major": 9,
        "len": 35
    },
    {
        "text": "The selective 5-HT reuptake inhibitors [CHEMICAL]paroxetine[\\CHEMICAL], indalpine and fluvoxamine displayed a high affinity for the [GENE]5-HT transporter[\\GENE], whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The selective 5-HT reuptake inhibitors paroxetine, [CHEMICAL]indalpine[\\CHEMICAL] and fluvoxamine displayed a high affinity for the [GENE]5-HT transporter[\\GENE], whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "The selective 5-HT reuptake inhibitors paroxetine, indalpine and [CHEMICAL]fluvoxamine[\\CHEMICAL] displayed a high affinity for the [GENE]5-HT transporter[\\GENE], whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor [CHEMICAL]desipramine[\\CHEMICAL] had a high affinity for the [GENE]norepinephrine transporter[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "Interestingly, [CHEMICAL]venlafaxine[\\CHEMICAL], a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the [GENE]5-HT transporter[\\GENE] (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM).",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "[GENE]N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase[\\GENE] (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [CHEMICAL]mannose 6-phosphate[\\CHEMICAL] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase ([GENE]EC 3.1.4.45[\\GENE]; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the [CHEMICAL]mannose 6-phosphate[\\CHEMICAL] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; [GENE]phosphodiester alpha-GlcNAcase[\\GENE]) catalyzes the second step in the synthesis of the [CHEMICAL]mannose 6-phosphate[\\CHEMICAL] determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "The purified [GENE]phosphodiester alpha-GlcNAcase[\\GENE] has a specific activity of 498 micromol of [CHEMICAL][3H]GlcNAc-alpha-phosphomannose-alpha-methyl[\\CHEMICAL] cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "The purified [GENE]phosphodiester alpha-GlcNAcase[\\GENE] has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [CHEMICAL][3H]GlcNAc-alpha-phosphomannose-alpha-methyl[\\CHEMICAL] as substrate.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "Both the [GENE]5 alpha-reductase[\\GENE] inhibitor [CHEMICAL]finasteride[\\CHEMICAL] and alpha 1-adrenoceptor antagonists (e.g.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Both the 5 alpha-reductase inhibitor finasteride and [GENE]alpha 1-adrenoceptor[\\GENE] antagonists (e.g. [CHEMICAL]alfuzosin[\\CHEMICAL], doxazosin, prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
        "label": 6,
        "major": 4,
        "len": 48
    },
    {
        "text": "Both the 5 alpha-reductase inhibitor finasteride and [GENE]alpha 1-adrenoceptor[\\GENE] antagonists (e.g. alfuzosin, [CHEMICAL]doxazosin[\\CHEMICAL], prazosin, tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
        "label": 6,
        "major": 4,
        "len": 48
    },
    {
        "text": "Both the 5 alpha-reductase inhibitor finasteride and [GENE]alpha 1-adrenoceptor[\\GENE] antagonists (e.g. alfuzosin, doxazosin, [CHEMICAL]prazosin[\\CHEMICAL], tamsulosin and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
        "label": 6,
        "major": 4,
        "len": 48
    },
    {
        "text": "Both the 5 alpha-reductase inhibitor finasteride and [GENE]alpha 1-adrenoceptor[\\GENE] antagonists (e.g. alfuzosin, doxazosin, prazosin, [CHEMICAL]tamsulosin[\\CHEMICAL] and terazosin) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
        "label": 6,
        "major": 4,
        "len": 48
    },
    {
        "text": "Both the 5 alpha-reductase inhibitor finasteride and [GENE]alpha 1-adrenoceptor[\\GENE] antagonists (e.g. alfuzosin, doxazosin, prazosin, tamsulosin and [CHEMICAL]terazosin[\\CHEMICAL]) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO), and their efficacy has been proven in several placebo-controlled trials.",
        "label": 6,
        "major": 4,
        "len": 48
    },
    {
        "text": "Addition of a specific number of FGFR sequences to the [CHEMICAL]C[\\CHEMICAL]-terminus of [GENE]Ig module II[\\GENE] resulted in a gain in affinity for FGF-7.",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "Several site-specific alterations in the [CHEMICAL]C[\\CHEMICAL]-terminus of full-length [GENE]FGFR1IIIc[\\GENE], an isoform that otherwise absolutely rejects FGF-7, resulted in gain of FGF-7 binding.",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "Ig module I and the [CHEMICAL]C[\\CHEMICAL]-terminus of [GENE]Ig module III[\\GENE] are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7.",
        "label": 1,
        "major": 2,
        "len": 20
    },
    {
        "text": "These results suggest that a complex of [GENE]Ig module II[\\GENE] and heparan [CHEMICAL]sulfate[\\CHEMICAL] is the base common active core of the FGFR ectodomain and that flanking structural domains modify FGF affinity and determine specificity.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Previously, we reported that a primary heparin or heparan [CHEMICAL]sulfate[\\CHEMICAL] binding site resides in a distinct sequence in [GENE]immunoglobulin (Ig)-like module II[\\GENE] of the three modules of FGFR.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Previously, we reported that a primary heparin or heparan [CHEMICAL]sulfate[\\CHEMICAL] binding site resides in a distinct sequence in immunoglobulin (Ig)-like module II of the three modules of [GENE]FGFR[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "In another experiment, [CHEMICAL]cyanopindolol[\\CHEMICAL], an antagonist of the [GENE]serotonin terminal autoreceptor[\\GENE], also prolonged the clearance of 5-HT from the CA3 region.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of [CHEMICAL]5-HT[\\CHEMICAL] uptake through an effect on the [GENE]serotonin transporter[\\GENE].",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "These and other data have generated a working hypothesis that activation of the terminal [GENE]serotonin autoreceptor[\\GENE] enhances the kinetics of [CHEMICAL]5-HT[\\CHEMICAL] uptake through an effect on the serotonin transporter.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Tomudex[\\CHEMICAL] treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and [GENE]kinase[\\GENE] activities 24 h after a 2-h exposure.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [CHEMICAL]Tomudex[\\CHEMICAL] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in [GENE]cyclin E[\\GENE] and cdk2 kinase activities.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [CHEMICAL]Tomudex[\\CHEMICAL] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and [GENE]cdk2[\\GENE] kinase activities.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [CHEMICAL]Tomudex[\\CHEMICAL] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 [GENE]kinase[\\GENE] activities.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Tomudex[\\CHEMICAL] treatment resulted in the decrease in p27(kip1) expression, with an increase in [GENE]cyclin E[\\GENE] and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Tomudex[\\CHEMICAL] treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and [GENE]cdk2[\\GENE] protein expression and kinase activities 24 h after a 2-h exposure.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The studies with dThyd rescue from [GENE]cyclin E[\\GENE]-cdk2 protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "The studies with dThyd rescue from cyclin E-[GENE]cdk2[\\GENE] protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased [GENE]cyclin E[\\GENE]-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-[GENE]cdk2[\\GENE] protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Tomudex[\\CHEMICAL] treatment resulted in the decrease in [GENE]p27(kip1)[\\GENE] expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by [CHEMICAL]Tomudex[\\CHEMICAL] and kilobase DNA fragmentation may correlate with the reduction of [GENE]p27(kip1)[\\GENE] expression and the increase in cyclin E and cdk2 kinase activities.",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of [GENE]thymidylate synthase[\\GENE] by [CHEMICAL]Tomudex[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the [GENE]thymidylate synthase[\\GENE] inhibitor [CHEMICAL]Tomudex[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Tomudex[\\CHEMICAL] (ZD1694) is a specific antifolate-based [GENE]thymidylate synthase[\\GENE] inhibitor active in a variety of solid tumor malignancies.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The studies with dThyd rescue from [GENE]cyclin E[\\GENE]-cdk2 protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The studies with dThyd rescue from cyclin E-[GENE]cdk2[\\GENE] protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by [CHEMICAL]Tomudex[\\CHEMICAL] indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of [GENE]thymidylate synthase[\\GENE] and resultant dNTP pool imbalance.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of [GENE]thymidylate synthase[\\GENE] by [CHEMICAL]Tomudex[\\CHEMICAL] and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In the long term, [CHEMICAL]orlistat[\\CHEMICAL] has been shown to be more effective than placebo in reducing body weight and serum total and [GENE]low-density lipoprotein[\\GENE] cholesterol levels.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Orlistat[\\CHEMICAL] is a new inhibitor of [GENE]pancreatic lipase[\\GENE] enzyme.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "The action of [CHEMICAL]15d-PGJ2[\\CHEMICAL] does not appear to involve its nuclear receptor [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] (PPARgamma) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 10,
        "major": 3,
        "len": 49
    },
    {
        "text": "The action of [CHEMICAL]15d-PGJ2[\\CHEMICAL] does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma ([GENE]PPARgamma[\\GENE]) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 10,
        "major": 3,
        "len": 49
    },
    {
        "text": "The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) because [CHEMICAL]troglitazone[\\CHEMICAL], a specific ligand of PPARgamma, was unable to inhibit [GENE]iNOS[\\GENE] induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 10,
        "major": 3,
        "len": 49
    },
    {
        "text": "The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither [CHEMICAL]troglitazone[\\CHEMICAL] nor 15d-PGJ2 could stimulate the activity of a [GENE]PPAR[\\GENE]-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 10,
        "major": 3,
        "len": 49
    },
    {
        "text": "The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor [CHEMICAL]15d-PGJ2[\\CHEMICAL] could stimulate the activity of a [GENE]PPAR[\\GENE]-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 10,
        "major": 3,
        "len": 49
    },
    {
        "text": "[CHEMICAL]15d-PGJ2[\\CHEMICAL] did not block nuclear translocation or DNA-binding activity of the transcription factor [GENE]NFkappaB[\\GENE], but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.",
        "label": 10,
        "major": 4,
        "len": 46
    },
    {
        "text": "The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) because [CHEMICAL]troglitazone[\\CHEMICAL], a specific ligand of [GENE]PPARgamma[\\GENE], was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.",
        "label": 2,
        "major": 3,
        "len": 49
    },
    {
        "text": "15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by [CHEMICAL]15d-PGJ2[\\CHEMICAL] may involve interference with [GENE]NFkappaB[\\GENE] transcriptional activity in the nucleus.",
        "label": 2,
        "major": 10,
        "len": 46
    },
    {
        "text": "Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of [GENE]inducible nitric-oxide synthase[\\GENE] by [CHEMICAL]15-deoxy-Delta12,14-prostaglandin J2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "In activated microglia, [CHEMICAL]15d-PGJ2[\\CHEMICAL] suppressed iNOS promoter activity, [GENE]iNOS[\\GENE] mRNA, and protein levels.",
        "label": 4,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Cyclopentenone prostaglandins[\\CHEMICAL] suppress activation of microglia: down-regulation of [GENE]inducible nitric-oxide synthase[\\GENE] by 15-deoxy-Delta12,14-prostaglandin J2.",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Cyclopentenone prostaglandins[\\CHEMICAL] were potent inhibitors of [GENE]iNOS[\\GENE] induction and were more effective than their precursors, prostaglandins E2 and D2.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Cyclopentenone prostaglandins were potent inhibitors of [GENE]iNOS[\\GENE] induction and were more effective than their precursors, [CHEMICAL]prostaglandins E2 and D2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "In activated microglia, [CHEMICAL]15d-PGJ2[\\CHEMICAL] suppressed [GENE]iNOS promoter[\\GENE] activity, iNOS mRNA, and protein levels.",
        "label": 4,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]15d-PGJ2[\\CHEMICAL] did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an [GENE]NFkappaB[\\GENE] reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial [GENE]iNOS[\\GENE] by [CHEMICAL]15d-PGJ2[\\CHEMICAL] may involve interference with NFkappaB transcriptional activity in the nucleus.",
        "label": 4,
        "major": 2,
        "len": 46
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide ([CHEMICAL]BPB[\\CHEMICAL]) and arachidonyl trifluoromethyl ketone (AACOCF3) on [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide ([CHEMICAL]BPB[\\CHEMICAL]) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] (AACOCF3) on [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] (AACOCF3) on interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone ([CHEMICAL]AACOCF3[\\CHEMICAL]) on [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone ([CHEMICAL]AACOCF3[\\CHEMICAL]) on interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "[GENE]Phospholipase A2[\\GENE] inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 3,
        "major": 4,
        "len": 17
    },
    {
        "text": "Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] plus ionomycin-induced [GENE]IL-2[\\GENE] secretion in a concentration-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Likewise, [GENE]IL-2[\\GENE] steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM [CHEMICAL]BPB[\\CHEMICAL] and 20 microM AACOCF3.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Likewise, [GENE]IL-2[\\GENE] steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM [CHEMICAL]AACOCF3[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Taken together, these data demonstrated that PLA2 inhibitors [CHEMICAL]BPB[\\CHEMICAL] and AACOCF3 are robust inhibitors of [GENE]IL-2[\\GENE] expression at both the mRNA and protein levels in murine splenocytes.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Taken together, these data demonstrated that PLA2 inhibitors BPB and [CHEMICAL]AACOCF3[\\CHEMICAL] are robust inhibitors of [GENE]IL-2[\\GENE] expression at both the mRNA and protein levels in murine splenocytes.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Phospholipase A2 inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] and arachidonyl trifluoromethyl ketone suppressed [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Phospholipase A2 inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] and arachidonyl trifluoromethyl ketone suppressed interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Phospholipase A2 inhibitors p-bromophenacyl bromide and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] suppressed [GENE]interleukin-2[\\GENE] (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Phospholipase A2 inhibitors p-bromophenacyl bromide and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] suppressed interleukin-2 ([GENE]IL-2[\\GENE]) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Pretreatment of the splenocytes with both [CHEMICAL]BPB[\\CHEMICAL] and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced [GENE]IL-2[\\GENE] secretion in a concentration-dependent manner.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Pretreatment of the splenocytes with both BPB and [CHEMICAL]AACOCF3[\\CHEMICAL] suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced [GENE]IL-2[\\GENE] secretion in a concentration-dependent manner.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Inhibition > 90% of [GENE]IL-2[\\GENE] secretion was observed at 1 microM [CHEMICAL]BPB[\\CHEMICAL] and 10 microM AACOCF3 compared to the respective vehicle control.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Inhibition > 90% of [GENE]IL-2[\\GENE] secretion was observed at 1 microM BPB and 10 microM [CHEMICAL]AACOCF3[\\CHEMICAL] compared to the respective vehicle control.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Likewise, IL-2 steady-state mRNA expression was inhibited by both [GENE]PLA2[\\GENE] inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM [CHEMICAL]BPB[\\CHEMICAL] and 20 microM AACOCF3.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Likewise, IL-2 steady-state mRNA expression was inhibited by both [GENE]PLA2[\\GENE] inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM [CHEMICAL]AACOCF3[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Taken together, these data demonstrated that [GENE]PLA2[\\GENE] inhibitors [CHEMICAL]BPB[\\CHEMICAL] and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Taken together, these data demonstrated that [GENE]PLA2[\\GENE] inhibitors BPB and [CHEMICAL]AACOCF3[\\CHEMICAL] are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[GENE]Phospholipase A2[\\GENE] inhibitors p-bromophenacyl bromide and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of [GENE]PLA2[\\GENE] inhibitors [CHEMICAL]p-bromophenacyl bromide[\\CHEMICAL] (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of [GENE]PLA2[\\GENE] inhibitors p-bromophenacyl bromide ([CHEMICAL]BPB[\\CHEMICAL]) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of [GENE]PLA2[\\GENE] inhibitors p-bromophenacyl bromide (BPB) and [CHEMICAL]arachidonyl trifluoromethyl ketone[\\CHEMICAL] (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Therefore, the objective of the present study was to investigate the effects of [GENE]PLA2[\\GENE] inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone ([CHEMICAL]AACOCF3[\\CHEMICAL]) on interleukin-2 (IL-2) expression in murine primary splenocytes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The effect of sumatriptan, but not of [CHEMICAL]LY 344864[\\CHEMICAL], was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for [GENE]rat 5-HT1B[\\GENE] receptors.",
        "label": 10,
        "major": 10,
        "len": 26
    },
    {
        "text": "To establish the relative importance of these subtypes, we compared the effects of [CHEMICAL]sumatriptan[\\CHEMICAL] with those of a selective 5-HT1F receptor agonist (LY 344864) on [GENE]c-fos[\\GENE] protein expression in the trigeminal nucleus caudalis.",
        "label": 2,
        "major": 5,
        "len": 33
    },
    {
        "text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist ([CHEMICAL]LY 344864[\\CHEMICAL]) on [GENE]c-fos[\\GENE] protein expression in the trigeminal nucleus caudalis.",
        "label": 2,
        "major": 5,
        "len": 33
    },
    {
        "text": "The effect of [CHEMICAL]sumatriptan[\\CHEMICAL], but not of LY 344864, was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for [GENE]rat 5-HT1B[\\GENE] receptors.",
        "label": 2,
        "major": 6,
        "len": 26
    },
    {
        "text": "[GENE]c-fos[\\GENE] expression was induced in urethane-anaesthetized rats by intracisternal [CHEMICAL]capsaicin[\\CHEMICAL] administration.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Sumatriptan and LY 344864 decreased the number of [CHEMICAL]capsaicin[\\CHEMICAL]-induced [GENE]c-fos[\\GENE]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Sumatriptan[\\CHEMICAL] and LY 344864 decreased the number of capsaicin-induced [GENE]c-fos[\\GENE]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Sumatriptan and [CHEMICAL]LY 344864[\\CHEMICAL] decreased the number of capsaicin-induced [GENE]c-fos[\\GENE]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective [GENE]5-HT1F[\\GENE] receptor agonist ([CHEMICAL]LY 344864[\\CHEMICAL]) on c-fos protein expression in the trigeminal nucleus caudalis.",
        "label": 5,
        "major": 5,
        "len": 33
    },
    {
        "text": "The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist [CHEMICAL]SDZ 21-009[\\CHEMICAL], which displays high affinity for [GENE]rat 5-HT1B[\\GENE] receptors.",
        "label": 6,
        "major": 10,
        "len": 26
    },
    {
        "text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, [CHEMICAL]batimastat[\\CHEMICAL] (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on [GENE]metalloproteinase[\\GENE] activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 2,
        "major": 9,
        "len": 46
    },
    {
        "text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat ([CHEMICAL]BB-94[\\CHEMICAL]) and the angiotensin-converting enzyme inhibitor, captopril, on [GENE]metalloproteinase[\\GENE] activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 2,
        "major": 9,
        "len": 46
    },
    {
        "text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, [CHEMICAL]captopril[\\CHEMICAL], on [GENE]metalloproteinase[\\GENE] activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 2,
        "major": 4,
        "len": 46
    },
    {
        "text": "Both [CHEMICAL]BB-94[\\CHEMICAL] and captopril also prevented substrate degradation by [GENE]gelatinase A and B[\\GENE] released in conditioned medium by cultured cells.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "Here we report that [CHEMICAL]captopril[\\CHEMICAL] treatment resulted in decreased transcription and protein levels of [GENE]gelatinase A[\\GENE] by 3LL cells.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "We have examined the effects of the synthetic [GENE]matrix metalloproteinase[\\GENE] inhibitor, [CHEMICAL]batimastat[\\CHEMICAL] (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 4,
        "major": 9,
        "len": 46
    },
    {
        "text": "We have examined the effects of the synthetic [GENE]matrix metalloproteinase[\\GENE] inhibitor, batimastat ([CHEMICAL]BB-94[\\CHEMICAL]) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "Inhibition of [GENE]gelatinase A[\\GENE] (MMP-2) by [CHEMICAL]batimastat[\\CHEMICAL] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of gelatinase A ([GENE]MMP-2[\\GENE]) by [CHEMICAL]batimastat[\\CHEMICAL] and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of [GENE]gelatinase A[\\GENE] (MMP-2) by batimastat and [CHEMICAL]captopril[\\CHEMICAL] reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of gelatinase A ([GENE]MMP-2[\\GENE]) by batimastat and [CHEMICAL]captopril[\\CHEMICAL] reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the [GENE]angiotensin-converting enzyme[\\GENE] inhibitor, [CHEMICAL]captopril[\\CHEMICAL], on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "Thus our data suggest that the [GENE]COX-2[\\GENE] preference of [CHEMICAL]meloxicam[\\CHEMICAL] observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "The effects of [CHEMICAL]meloxicam[\\CHEMICAL] were compared with those of diclofenac, a nonselective [GENE]COX[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "The effects of meloxicam were compared with those of [CHEMICAL]diclofenac[\\CHEMICAL], a nonselective [GENE]COX[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "METHODS: [GENE]COX-1[\\GENE] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg [CHEMICAL]meloxicam[\\CHEMICAL] and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "METHODS: [GENE]COX-1[\\GENE] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg [CHEMICAL]diclofenac[\\CHEMICAL] and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "METHODS: [GENE]COX-1[\\GENE] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg [CHEMICAL]meloxicam[\\CHEMICAL] daily and 150 mg diclofenac daily).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "METHODS: [GENE]COX-1[\\GENE] inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg [CHEMICAL]diclofenac[\\CHEMICAL] daily).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by [CHEMICAL]meloxicam[\\CHEMICAL], which has been reported to preferentially inhibit [GENE]cyclooxygenase-2[\\GENE] (COX-2).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by [CHEMICAL]meloxicam[\\CHEMICAL], which has been reported to preferentially inhibit cyclooxygenase-2 ([GENE]COX-2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "OBJECTIVE: To evaluate the extent of [GENE]human cyclooxygenase-1[\\GENE] (COX-1) inhibition by [CHEMICAL]meloxicam[\\CHEMICAL], which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 ([GENE]COX-1[\\GENE]) inhibition by [CHEMICAL]meloxicam[\\CHEMICAL], which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The deduced [CHEMICAL]amino acid[\\CHEMICAL] sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other [GENE]PDE[\\GENE] families.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "The deduced amino acid sequence contains 779 [CHEMICAL]amino acids[\\CHEMICAL], including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other [GENE]PDE[\\GENE] families.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the [CHEMICAL]amino[\\CHEMICAL]-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other [GENE]PDE[\\GENE] families.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in [CHEMICAL]amino acid[\\CHEMICAL] sequence to those of other [GENE]PDE[\\GENE] families.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "Of the [GENE]PDE[\\GENE] inhibitors tested, [CHEMICAL]dipyridamole[\\CHEMICAL] was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Of the [GENE]PDE[\\GENE] inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of [CHEMICAL]cAMP[\\CHEMICAL] and cGMP hydrolysis, respectively.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "Of the [GENE]PDE[\\GENE] inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and [CHEMICAL]cGMP[\\CHEMICAL] hydrolysis, respectively.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH4), the obligate cofactor for [GENE]TPH[\\GENE].",
        "label": 8,
        "major": 8,
        "len": 29
    },
    {
        "text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin ([CHEMICAL]BH4[\\CHEMICAL]), the obligate cofactor for [GENE]TPH[\\GENE].",
        "label": 8,
        "major": 8,
        "len": 29
    },
    {
        "text": "In contrast, there was little change in mRNA levels for [GENE]GTP cyclohydrolase I[\\GENE] (GTPCH), the rate limiting enzyme in synthesis of the [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH4), the obligate cofactor for TPH.",
        "label": 9,
        "major": 8,
        "len": 29
    },
    {
        "text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I ([GENE]GTPCH[\\GENE]), the rate limiting enzyme in synthesis of the [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH4), the obligate cofactor for TPH.",
        "label": 9,
        "major": 8,
        "len": 29
    },
    {
        "text": "In contrast, there was little change in mRNA levels for [GENE]GTP cyclohydrolase I[\\GENE] (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin ([CHEMICAL]BH4[\\CHEMICAL]), the obligate cofactor for TPH.",
        "label": 9,
        "major": 8,
        "len": 29
    },
    {
        "text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I ([GENE]GTPCH[\\GENE]), the rate limiting enzyme in synthesis of the tetrahydrobiopterin ([CHEMICAL]BH4[\\CHEMICAL]), the obligate cofactor for TPH.",
        "label": 9,
        "major": 8,
        "len": 29
    },
    {
        "text": "We topically applied the [GENE]nitric oxide synthase[\\GENE] (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a [CHEMICAL]cilazapril[\\CHEMICAL] diet.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "We evaluated the effects of [GENE]angiotensin II[\\GENE] and an angiotensin-converting enzyme inhibitor ([CHEMICAL]cilazapril[\\CHEMICAL]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "We evaluated the effects of angiotensin II and an [GENE]angiotensin-converting enzyme[\\GENE] inhibitor ([CHEMICAL]cilazapril[\\CHEMICAL]) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "We topically applied the nitric oxide synthase ([GENE]NOS[\\GENE]) inhibitor, [CHEMICAL]NG-nitro-L-arginine[\\CHEMICAL], on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "We topically applied the [GENE]nitric oxide synthase[\\GENE] (NOS) inhibitor, [CHEMICAL]NG-nitro-L-arginine[\\CHEMICAL], on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Combined concentration-ratio analysis demonstrated that [CHEMICAL]tamsulosin[\\CHEMICAL], which does not discriminate between [GENE]alpha 1A[\\GENE]- and alpha 1L-adrenoceptors, and RS-17053 competed for binding at the same site in the SMA.",
        "label": 2,
        "major": 10,
        "len": 28
    },
    {
        "text": "Combined concentration-ratio analysis demonstrated that [CHEMICAL]tamsulosin[\\CHEMICAL], which does not discriminate between alpha 1A- and [GENE]alpha 1L-adrenoceptors[\\GENE], and RS-17053 competed for binding at the same site in the SMA.",
        "label": 2,
        "major": 10,
        "len": 28
    },
    {
        "text": "Combined concentration-ratio analysis demonstrated that tamsulosin, which does not discriminate between [GENE]alpha 1A[\\GENE]- and alpha 1L-adrenoceptors, and [CHEMICAL]RS-17053[\\CHEMICAL] competed for binding at the same site in the SMA.",
        "label": 2,
        "major": 10,
        "len": 28
    },
    {
        "text": "Combined concentration-ratio analysis demonstrated that tamsulosin, which does not discriminate between alpha 1A- and [GENE]alpha 1L-adrenoceptors[\\GENE], and [CHEMICAL]RS-17053[\\CHEMICAL] competed for binding at the same site in the SMA.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Prazosin[\\CHEMICAL] antagonized all agonists with a low potency (pA2: 8.29-8.80) indicating the involvement of [GENE]alpha 1L[\\GENE]-rather than alpha 1A-adrenoceptors.",
        "label": 2,
        "major": 6,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Prazosin[\\CHEMICAL] antagonized all agonists with a low potency (pA2: 8.29-8.80) indicating the involvement of alpha 1L-rather than [GENE]alpha 1A-adrenoceptors[\\GENE].",
        "label": 2,
        "major": 5,
        "len": 19
    },
    {
        "text": "To illuminate the controversy on [GENE]alpha 1A[\\GENE]- or alpha 1L-adrenoceptor involvement in [CHEMICAL]noradrenaline[\\CHEMICAL]-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective alpha 1-adrenoceptor agonists and antagonists under different experimental conditions.",
        "label": 2,
        "major": 5,
        "len": 36
    },
    {
        "text": "To illuminate the controversy on alpha 1A- or [GENE]alpha 1L-adrenoceptor[\\GENE] involvement in [CHEMICAL]noradrenaline[\\CHEMICAL]-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective alpha 1-adrenoceptor agonists and antagonists under different experimental conditions.",
        "label": 2,
        "major": 5,
        "len": 36
    },
    {
        "text": "Selective protection of a putative [GENE]alpha 1A-adrenoceptor[\\GENE] population against the irreversible action of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] also failed to increase the potency of RS-17053 (pA2 = 8.25 +/- 0.06 against A61603).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "In summary, data obtained in our experiments in rat SMA indicate that the [GENE]alpha 1-adrenoceptor[\\GENE] mediating [CHEMICAL]noradrenaline[\\CHEMICAL]-induced contraction displays a distinct alpha 1L-adrenoceptor pharmacology.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "In summary, data obtained in our experiments in rat SMA indicate that the alpha 1-adrenoceptor mediating [CHEMICAL]noradrenaline[\\CHEMICAL]-induced contraction displays a distinct [GENE]alpha 1L-adrenoceptor[\\GENE] pharmacology.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective [GENE]alpha 1A-adrenoceptor[\\GENE] agonist [CHEMICAL]A-61603[\\CHEMICAL] (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
        "label": 5,
        "major": 6,
        "len": 57
    },
    {
        "text": "The putative [GENE]alpha 1L-adrenoceptor[\\GENE] antagonist [CHEMICAL]JTH-601[\\CHEMICAL], but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the [GENE]alpha 1B-adrenoceptor[\\GENE] antagonist [CHEMICAL]chloroethylclonidine[\\CHEMICAL] (10 microM) antagonized noradrenaline-induced contractions of SMA.",
        "label": 6,
        "major": 3,
        "len": 20
    },
    {
        "text": "The potency of the selective [GENE]alpha 1D-adrenoceptor[\\GENE] antagonist [CHEMICAL]BMY 7378[\\CHEMICAL] against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
        "label": 6,
        "major": 5,
        "len": 57
    },
    {
        "text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective [GENE]alpha 1A-adrenoceptor[\\GENE] antagonist [CHEMICAL]RS-17053[\\CHEMICAL] against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.",
        "label": 6,
        "major": 6,
        "len": 57
    },
    {
        "text": "In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher [CHEMICAL]sarin[\\CHEMICAL] dose, respectively, was needed to cause a 50% inhibition of brain [GENE]AChE[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The acute toxicity of [CHEMICAL]organophosphorus[\\CHEMICAL] (OP) compounds in mammals is due to their irreversible inhibition of [GENE]acetylcholinesterase[\\GENE] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The acute toxicity of [CHEMICAL]organophosphorus[\\CHEMICAL] (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([GENE]AChE[\\GENE]) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of [GENE]acetylcholinesterase[\\GENE] (AChE) in the nervous system, which leads to increased synaptic [CHEMICAL]acetylcholine[\\CHEMICAL] levels.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([GENE]AChE[\\GENE]) in the nervous system, which leads to increased synaptic [CHEMICAL]acetylcholine[\\CHEMICAL] levels.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "In the present study, the ability of different concentrations of [CHEMICAL]torasemide[\\CHEMICAL] to modify [GENE]angiotensin II[\\GENE] (Ang II)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "In the present study, the ability of different concentrations of [CHEMICAL]torasemide[\\CHEMICAL] to modify angiotensin II ([GENE]Ang II[\\GENE])-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Torasemide[\\CHEMICAL] inhibits [GENE]angiotensin II[\\GENE]-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Isometric contraction induced by a submaximal concentration of [GENE]Ang II[\\GENE] (10(-7) mol/L) was reduced in a dose-dependent way by [CHEMICAL]torasemide[\\CHEMICAL] (IC(50)=0.5+/-0.04 micromol/L).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of [GENE]Ang II[\\GENE] (10(-7) mol/L) was blocked by [CHEMICAL]torasemide[\\CHEMICAL] (IC(50)=0.5+/-0.3 nmol/L).",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "This action can be related to the ability of [CHEMICAL]torasemide[\\CHEMICAL] to block the increase of [Ca(2+)](i) induced by [GENE]Ang II[\\GENE] in VSMCs.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "The dimeric [CHEMICAL]C[\\CHEMICAL]-terminal deletion mutant (Delta473-528) of [GENE]hTH1[\\GENE] also showed negative cooperativity of H4biopterin binding (h = 0.4).",
        "label": 1,
        "major": 2,
        "len": 18
    },
    {
        "text": "On phosphorylation of Ser40 by [GENE]protein kinase A[\\GENE], the affinity for [CHEMICAL]H4biopterin[\\CHEMICAL] increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]Tyrosine hydroxylase[\\GENE] binds [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection.",
        "label": 2,
        "major": 8,
        "len": 18
    },
    {
        "text": "Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-[GENE]hTH1[\\GENE] on binding of [CHEMICAL]H4biopterin[\\CHEMICAL] and Lerythro-dihydrobiopterin (H2biopterin).",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-[GENE]hTH1[\\GENE] on binding of H4biopterin and [CHEMICAL]Lerythro-dihydrobiopterin[\\CHEMICAL] (H2biopterin).",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-[GENE]hTH1[\\GENE] on binding of H4biopterin and Lerythro-dihydrobiopterin ([CHEMICAL]H2biopterin[\\CHEMICAL]).",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "The dimeric C-terminal deletion mutant (Delta473-528) of [GENE]hTH1[\\GENE] also showed negative cooperativity of [CHEMICAL]H4biopterin[\\CHEMICAL] binding (h = 0.4).",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "On phosphorylation of [CHEMICAL]Ser40[\\CHEMICAL] by [GENE]protein kinase A[\\GENE], the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).",
        "label": 9,
        "major": 2,
        "len": 30
    },
    {
        "text": "[GENE]Ribonucleotide reductase[\\GENE] activity was found to be strongly increased in the [CHEMICAL]gemcitabine[\\CHEMICAL]-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and [GENE]purine nucleoside phosphorylase[\\GENE] was increased in the [CHEMICAL]2-chlorodeoxyadenosine[\\CHEMICAL]-selected line.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "[GENE]Endothelial NO synthase[\\GENE] expression was increased by cilazapril but not by [CHEMICAL]losartan[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 12
    },
    {
        "text": "Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by [CHEMICAL]losartan[\\CHEMICAL] and cilazapril treatments, whereas no changes in the expression of [GENE]rat ACE[\\GENE] and AT1A receptor genes were observed.",
        "label": 10,
        "major": 3,
        "len": 34
    },
    {
        "text": "Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by [CHEMICAL]losartan[\\CHEMICAL] and cilazapril treatments, whereas no changes in the expression of rat ACE and [GENE]AT1A[\\GENE] receptor genes were observed.",
        "label": 10,
        "major": 4,
        "len": 34
    },
    {
        "text": "Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and [CHEMICAL]cilazapril[\\CHEMICAL] treatments, whereas no changes in the expression of [GENE]rat ACE[\\GENE] and AT1A receptor genes were observed.",
        "label": 10,
        "major": 4,
        "len": 34
    },
    {
        "text": "Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and [CHEMICAL]cilazapril[\\CHEMICAL] treatments, whereas no changes in the expression of rat ACE and [GENE]AT1A[\\GENE] receptor genes were observed.",
        "label": 10,
        "major": 3,
        "len": 34
    },
    {
        "text": "[GENE]Endothelial NO synthase[\\GENE] expression was increased by [CHEMICAL]cilazapril[\\CHEMICAL] but not by losartan.",
        "label": 3,
        "major": 10,
        "len": 12
    },
    {
        "text": "[GENE]Human and rat renin[\\GENE] and angiotensinogen genes were downregulated in dTGR and were increased by [CHEMICAL]losartan[\\CHEMICAL] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "Human and rat renin and [GENE]angiotensinogen[\\GENE] genes were downregulated in dTGR and were increased by [CHEMICAL]losartan[\\CHEMICAL] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",
        "label": 3,
        "major": 4,
        "len": 34
    },
    {
        "text": "[GENE]Human and rat renin[\\GENE] and angiotensinogen genes were downregulated in dTGR and were increased by losartan and [CHEMICAL]cilazapril[\\CHEMICAL] treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",
        "label": 3,
        "major": 4,
        "len": 34
    },
    {
        "text": "Human and rat renin and [GENE]angiotensinogen[\\GENE] genes were downregulated in dTGR and were increased by losartan and [CHEMICAL]cilazapril[\\CHEMICAL] treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Angiotensin[\\CHEMICAL]-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with [GENE]human renin[\\GENE] and angiotensinogen genes.",
        "label": 8,
        "major": 9,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Angiotensin[\\CHEMICAL]-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and [GENE]angiotensinogen[\\GENE] genes.",
        "label": 8,
        "major": 9,
        "len": 22
    },
    {
        "text": "Using the alpha1 and alpha2-adrenoceptor antagonists, prazosin and idazoxane, we also demonstrate the role of the [GENE]alpha-adrenoceptors[\\GENE] in the augmentation of [CHEMICAL]venlafaxine[\\CHEMICAL]-induced changes.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Preclinically, [CHEMICAL]venlafaxine[\\CHEMICAL] has been shown to potently inhibit dorsal raphe neuronal (DRN) firing through a [GENE]5-HT1A[\\GENE] mediated mechanism, in a similar manner to SSRIs.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "Combination treatment with the selective [GENE]5-HT1A[\\GENE] antagonist [CHEMICAL]WAY100635[\\CHEMICAL] produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "The beta-adrenergic/[GENE]5-HT1A[\\GENE] receptor antagonist [CHEMICAL](+/-)pindolol[\\CHEMICAL] and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.",
        "label": 6,
        "major": 3,
        "len": 23
    },
    {
        "text": "The [GENE]kinase[\\GENE] activity of EGFR was little inhibited by [CHEMICAL]TT-B[\\CHEMICAL] in a cell-free system.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "The kinase activity of [GENE]EGFR[\\GENE] was little inhibited by [CHEMICAL]TT-B[\\CHEMICAL] in a cell-free system.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Structural basis for LFA-1 inhibition upon [CHEMICAL]lovastatin[\\CHEMICAL] binding to the [GENE]CD11a I-domain[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "We report here that [CHEMICAL]lovastatin[\\CHEMICAL], a drug clinically used for lowering cholesterol levels, inhibits the interaction of [GENE]human LFA-1[\\GENE] with its counter-receptor intercellular adhesion molecule-1.",
        "label": 4,
        "major": 2,
        "len": 25
    },
    {
        "text": "We report here that [CHEMICAL]lovastatin[\\CHEMICAL], a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor [GENE]intercellular adhesion molecule-1[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 25
    },
    {
        "text": "Structural basis for [GENE]LFA-1[\\GENE] inhibition upon [CHEMICAL]lovastatin[\\CHEMICAL] binding to the CD11a I-domain.",
        "label": 4,
        "major": 2,
        "len": 12
    },
    {
        "text": "The inhibitory effect of [GENE]endothelin-1[\\GENE] on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist [CHEMICAL]RES 701-1[\\CHEMICAL], by indomethacin, or by glibenclamide.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "The inhibitory effect of [GENE]endothelin-1[\\GENE] on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by [CHEMICAL]indomethacin[\\CHEMICAL], or by glibenclamide.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "The inhibitory effect of [GENE]endothelin-1[\\GENE] on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by indomethacin, or by [CHEMICAL]glibenclamide[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 28
    },
    {
        "text": "The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the [GENE]endothelin ET(B) receptor[\\GENE] antagonist [CHEMICAL]RES 701-1[\\CHEMICAL], by indomethacin, or by glibenclamide.",
        "label": 6,
        "major": 4,
        "len": 28
    },
    {
        "text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the [GENE]thromboxane A2 receptor[\\GENE] antagonists [CHEMICAL]GR32191[\\CHEMICAL] and ridogrel.",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the [GENE]thromboxane A2 receptor[\\GENE] antagonists GR32191 and [CHEMICAL]ridogrel[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "This work showed that appropriate structural modification of [CHEMICAL]diphenidol[\\CHEMICAL] can lead to [GENE]M2[\\GENE]-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "A series of 2-carbonyl analogues of the muscarinic antagonist [CHEMICAL]diphenidol[\\CHEMICAL] bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the [GENE]M2 and M3 muscarinic receptor[\\GENE] subtypes was evaluated by functional tests.",
        "label": 6,
        "major": 2,
        "len": 37
    },
    {
        "text": "Synthesis and antagonistic activity at [GENE]muscarinic receptor[\\GENE] subtypes of some 2-carbonyl derivatives of [CHEMICAL]diphenidol[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and antagonistic activity at [GENE]muscarinic receptor[\\GENE] subtypes of some [CHEMICAL]2-carbonyl[\\CHEMICAL] derivatives of diphenidol.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the [CHEMICAL]bumetanide[\\CHEMICAL][GENE]bumetanide-sensitive sodium-potassium-chloride cotransporter[\\GENE] (NKCC2) and the potassium channel, ROMK.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "Finally, mutations of the [CHEMICAL]thiazide[\\CHEMICAL][GENE]thiazide-sensitive sodium-chloride cotransporter[\\GENE] (NCCT) are associated with Gitelman's syndrome.",
        "label": 2,
        "major": 1,
        "len": 13
    },
    {
        "text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific [GENE]renin[\\GENE]-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [CHEMICAL]remikiren[\\CHEMICAL] could be predicted from pretreatment renal vascular tone.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-[GENE]angiotensin[\\GENE]-aldosterone system (RAAS) blockade by renin-inhibitor [CHEMICAL]remikiren[\\CHEMICAL] could be predicted from pretreatment renal vascular tone.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by [GENE]renin[\\GENE]-inhibitor [CHEMICAL]remikiren[\\CHEMICAL] could be predicted from pretreatment renal vascular tone.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of [GENE]TcAChE[\\GENE], interacting with both the choline-binding site ([CHEMICAL]Trp[\\CHEMICAL]-84) and the acyl-binding pocket (Phe-288, Phe-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the [GENE]choline-binding site[\\GENE] ([CHEMICAL]Trp[\\CHEMICAL]-84) and the acyl-binding pocket (Phe-288, Phe-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of [GENE]TcAChE[\\GENE], interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket ([CHEMICAL]Phe[\\CHEMICAL]-288, Phe-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the [GENE]acyl-binding pocket[\\GENE] ([CHEMICAL]Phe[\\CHEMICAL]-288, Phe-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of [GENE]TcAChE[\\GENE], interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (Phe-288, [CHEMICAL]Phe[\\CHEMICAL]-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the [GENE]acyl-binding pocket[\\GENE] (Phe-288, [CHEMICAL]Phe[\\CHEMICAL]-290).",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "Compared with WT, [GENE]DeltaKPQ[\\GENE] I([CHEMICAL]Na[\\CHEMICAL]) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).",
        "label": 10,
        "major": 4,
        "len": 29
    },
    {
        "text": "Preferential block of late [CHEMICAL]sodium[\\CHEMICAL] current in the [GENE]LQT3 DeltaKPQ mutant[\\GENE] by the class I(C) antiarrhythmic flecainide.",
        "label": 10,
        "major": 1,
        "len": 17
    },
    {
        "text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three [CHEMICAL]amino acids[\\CHEMICAL] deleted ([GENE]DeltaKPQ[\\GENE]) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the [GENE]long QT syndrome 3 (LQT3) sodium channel alpha[\\GENE] subunit mutation with three [CHEMICAL]amino acids[\\CHEMICAL] deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Flecainide[\\CHEMICAL] block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ([GENE]DeltaKPQ[\\GENE]) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
        "label": 4,
        "major": 1,
        "len": 41
    },
    {
        "text": "Compared with WT, [GENE]DeltaKPQ[\\GENE] I(Na) was more sensitive to [CHEMICAL]flecainide[\\CHEMICAL], and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Compared with WT, [GENE]DeltaKPQ[\\GENE] I(Na) was more sensitive to flecainide, and [CHEMICAL]flecainide[\\CHEMICAL] preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Flecainide[\\CHEMICAL] block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the [GENE]long QT syndrome 3 (LQT3) sodium channel alpha[\\GENE] subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
        "label": 4,
        "major": 1,
        "len": 41
    },
    {
        "text": "Preferential block of late sodium current in the [GENE]LQT3 DeltaKPQ mutant[\\GENE] by the class I(C) antiarrhythmic [CHEMICAL]flecainide[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 17
    },
    {
        "text": "We conclude that [GENE]DeltaKPQ[\\GENE] interacts differently with [CHEMICAL]flecainide[\\CHEMICAL] than with WT, leading to increased block and slowed recovery, especially for late I(Na).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the [GENE]long QT syndrome 3 (LQT3) sodium channel alpha[\\GENE][CHEMICAL]sodium[\\CHEMICAL] channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.",
        "label": 9,
        "major": 1,
        "len": 43
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; [CHEMICAL]exisulind[\\CHEMICAL] (sulindac sulfone), a novel proapoptotic agent that does not inhibit [GENE]COX[\\GENE] enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",
        "label": 10,
        "major": 10,
        "len": 42
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind ([CHEMICAL]sulindac sulfone[\\CHEMICAL]), a novel proapoptotic agent that does not inhibit [GENE]COX[\\GENE] enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",
        "label": 10,
        "major": 10,
        "len": 42
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of [CHEMICAL]sulindac sulfide[\\CHEMICAL], a [GENE]COX-1[\\GENE] and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of [CHEMICAL]sulindac sulfide[\\CHEMICAL], a COX-1 and [GENE]COX-2[\\GENE] inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and [CHEMICAL]nordihydroguaiaretic acid[\\CHEMICAL] (NDGA), a [GENE]lipoxygenase[\\GENE] inhibitor on human lung cancer cell lines.",
        "label": 4,
        "major": 10,
        "len": 42
    },
    {
        "text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid ([CHEMICAL]NDGA[\\CHEMICAL]), a [GENE]lipoxygenase[\\GENE] inhibitor on human lung cancer cell lines.",
        "label": 4,
        "major": 10,
        "len": 42
    },
    {
        "text": "Specifically, [CHEMICAL]aniracetam[\\CHEMICAL], which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing [GENE]GluR3[\\GENE](L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.",
        "label": 10,
        "major": 1,
        "len": 23
    },
    {
        "text": "Specifically, [CHEMICAL]aniracetam[\\CHEMICAL], which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3([GENE]L507Y[\\GENE]) mutant, but has synergistic effects with lithium on wild-type receptors.",
        "label": 10,
        "major": 1,
        "len": 23
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on [CHEMICAL]glutamate[\\CHEMICAL][GENE]glutamate receptor[\\GENE] function.",
        "label": 2,
        "major": 9,
        "len": 57
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the [CHEMICAL]AMPA[\\CHEMICAL][GENE]AMPA receptor[\\GENE] GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.",
        "label": 2,
        "major": 1,
        "len": 57
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the [CHEMICAL]AMPA[\\CHEMICAL] receptor [GENE]GluR3[\\GENE] expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.",
        "label": 2,
        "major": 9,
        "len": 57
    },
    {
        "text": "We now show that mutation of the 769R/ G desensitization site (Lomeli, H.M.J., Melcher, T., Hoger, T., Geiger, J.R., Kuner, T., Monyer, H., Higuchi, M.B.A. and Seeburg, P.H, Control of kinetic properties of [CHEMICAL]AMPA[\\CHEMICAL][GENE]AMPA receptor[\\GENE] channels by nuclear RNA editing.",
        "label": 2,
        "major": 1,
        "len": 40
    },
    {
        "text": "Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the [CHEMICAL]glutamate[\\CHEMICAL] binding site blocks desensitization of [GENE]AMPA receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "Lithium modulates desensitization of the [CHEMICAL]glutamate[\\CHEMICAL][GENE]glutamate receptor[\\GENE] subtype gluR3 in Xenopus oocytes.",
        "label": 2,
        "major": 7,
        "len": 12
    },
    {
        "text": "Lithium modulates desensitization of the [CHEMICAL]glutamate[\\CHEMICAL] receptor subtype [GENE]gluR3[\\GENE] in Xenopus oocytes.",
        "label": 2,
        "major": 7,
        "len": 12
    },
    {
        "text": "Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of [CHEMICAL]AMPA[\\CHEMICAL][GENE]AMPA receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "Specifically, aniracetam, which potentiates wild-type [CHEMICAL]AMPA[\\CHEMICAL][GENE]AMPA receptors[\\GENE], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Lithium[\\CHEMICAL] modulates desensitization of the [GENE]glutamate receptor[\\GENE] subtype gluR3 in Xenopus oocytes.",
        "label": 2,
        "major": 7,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Lithium[\\CHEMICAL] modulates desensitization of the glutamate receptor subtype [GENE]gluR3[\\GENE] in Xenopus oocytes.",
        "label": 2,
        "major": 7,
        "len": 12
    },
    {
        "text": "Specifically, aniracetam, which potentiates wild-type [GENE]AMPA receptors[\\GENE], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with [CHEMICAL]lithium[\\CHEMICAL] on wild-type receptors.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of [CHEMICAL]lithium[\\CHEMICAL] on [GENE]glutamate receptor[\\GENE] function.",
        "label": 2,
        "major": 9,
        "len": 57
    },
    {
        "text": "Science, 9(266) (1994) 1709-1713) greatly attenuates the [CHEMICAL]lithium[\\CHEMICAL]-induced potentiation of [GENE]GluR3[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Neuron, 21 (1998) 907-918) further confirms that [CHEMICAL]lithium[\\CHEMICAL] enhances [GENE]GluR3[\\GENE] responses by reducing desensitization, since lithium's effects are reversed in this mutant.",
        "label": 3,
        "major": 1,
        "len": 22
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that [CHEMICAL]lithium[\\CHEMICAL] produces a large potentiation of the [GENE]GluR3 flop[\\GENE] splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.",
        "label": 3,
        "major": 9,
        "len": 57
    },
    {
        "text": "Specifically, [CHEMICAL]aniracetam[\\CHEMICAL], which potentiates wild-type [GENE]AMPA receptors[\\GENE], is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.",
        "label": 3,
        "major": 1,
        "len": 23
    },
    {
        "text": "Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing [GENE]GluR3[\\GENE](L507Y) mutant, but has synergistic effects with [CHEMICAL]lithium[\\CHEMICAL] on wild-type receptors.",
        "label": 3,
        "major": 1,
        "len": 23
    },
    {
        "text": "Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3([GENE]L507Y[\\GENE]) mutant, but has synergistic effects with [CHEMICAL]lithium[\\CHEMICAL] on wild-type receptors.",
        "label": 3,
        "major": 1,
        "len": 23
    },
    {
        "text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the [GENE]GluR3 flop[\\GENE] splice variant and suggested that [CHEMICAL]lithium[\\CHEMICAL] might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.",
        "label": 3,
        "major": 4,
        "len": 57
    },
    {
        "text": "The modulation of [GENE]high-voltage-activated (HVA) Ca2+ channels[\\GENE] by the prostaglandin E series (PGE1 and [CHEMICAL]PGE2[\\CHEMICAL]) was studied in the paratracheal ganglion cells.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "The modulation of [GENE]high-voltage-activated (HVA) Ca2+ channels[\\GENE] by the [CHEMICAL]prostaglandin E[\\CHEMICAL] series (PGE1 and PGE2) was studied in the paratracheal ganglion cells.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "[CHEMICAL]PGE1[\\CHEMICAL] and PGE2 also inhibited the remaining ICa in a saturating concentration of nifedipine, omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that [GENE]R-type Ca2+ channels[\\GENE] are involved.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "PGE1 and [CHEMICAL]PGE2[\\CHEMICAL] also inhibited the remaining ICa in a saturating concentration of nifedipine, omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that [GENE]R-type Ca2+ channels[\\GENE] are involved.",
        "label": 2,
        "major": 10,
        "len": 24
    },
    {
        "text": "The modulation of [GENE]high-voltage-activated (HVA) Ca2+ channels[\\GENE] by the prostaglandin E series ([CHEMICAL]PGE1[\\CHEMICAL] and PGE2) was studied in the paratracheal ganglion cells.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "The [CHEMICAL]prostaglandin E[\\CHEMICAL] series modulates [GENE]high-voltage-activated calcium channels[\\GENE] probably through the EP3 receptor in rat paratracheal ganglia.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that [CHEMICAL]PGE1[\\CHEMICAL]- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the [GENE]EP3 receptor[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 39
    },
    {
        "text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and [CHEMICAL]PGE2[\\CHEMICAL]-induced inhibition of the HVA Ca2+ channels is possibly mediated by the [GENE]EP3 receptor[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 39
    },
    {
        "text": "The [CHEMICAL]prostaglandin E[\\CHEMICAL] series modulates high-voltage-activated calcium channels probably through the [GENE]EP3 receptor[\\GENE] in rat paratracheal ganglia.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "It was concluded that [CHEMICAL]PGE1[\\CHEMICAL] selectively reduces both N- and R-type Ca2+ currents by activating a G-protein probably through the [GENE]EP3 receptor[\\GENE] in paratracheal ganglion cells.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "It was concluded that [CHEMICAL]PGE1[\\CHEMICAL] selectively reduces both N- and R-type Ca2+ currents by activating a [GENE]G-protein[\\GENE] probably through the EP3 receptor in paratracheal ganglion cells.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [CHEMICAL]17-phenyl-trinor-PGE2[\\CHEMICAL] (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 5,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, [CHEMICAL]STA2[\\CHEMICAL] (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of [CHEMICAL]thromboxane A2[\\CHEMICAL]), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and [CHEMICAL]sulprostone[\\CHEMICAL] (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was [CHEMICAL]sulprostone[\\CHEMICAL]>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 5,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>[CHEMICAL]PGE2[\\CHEMICAL], PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, [CHEMICAL]PGE1[\\CHEMICAL]>STA2>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 5,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>[CHEMICAL]STA2[\\CHEMICAL]>>17-phenyl-trinor-PGE2.",
        "label": 4,
        "major": 5,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit [GENE]HVA Ca2+ channels[\\GENE] was sulprostone>PGE2, PGE1>STA2>>[CHEMICAL]17-phenyl-trinor-PGE2[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that [CHEMICAL]PGE1[\\CHEMICAL]- and PGE2-induced inhibition of the [GENE]HVA Ca2+ channels[\\GENE] is possibly mediated by the EP3 receptor.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and [CHEMICAL]PGE2[\\CHEMICAL]-induced inhibition of the [GENE]HVA Ca2+ channels[\\GENE] is possibly mediated by the EP3 receptor.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the [GENE]protein kinase C[\\GENE] (PKC) inhibitor [CHEMICAL]chelerythrine[\\CHEMICAL] blocked the action of PMA.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C ([GENE]PKC[\\GENE]) inhibitor [CHEMICAL]chelerythrine[\\CHEMICAL] blocked the action of PMA.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), [CHEMICAL]17-phenyl-trinor-PGE2[\\CHEMICAL] (an [GENE]EP1[\\GENE]-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 5,
        "major": 4,
        "len": 41
    },
    {
        "text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and [CHEMICAL]sulprostone[\\CHEMICAL] (an [GENE]EP3[\\GENE]-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.",
        "label": 5,
        "major": 5,
        "len": 41
    },
    {
        "text": "[CHEMICAL]SC-51089[\\CHEMICAL] (10(-5) M), a selective [GENE]EP1-receptor[\\GENE] antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.",
        "label": 6,
        "major": 4,
        "len": 39
    },
    {
        "text": "[GENE]PR mRNA[\\GENE] abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing [CHEMICAL]mifepristone[\\CHEMICAL] treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation.",
        "label": 4,
        "major": 10,
        "len": 37
    },
    {
        "text": "One of the mechanism of [CHEMICAL]mifepristone[\\CHEMICAL] action on decreasing leiomyomata volume may be related to suppression on expression of [GENE]PR gene[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Felbamate[\\CHEMICAL] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the [GENE]rat NR1a[\\GENE] subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "[CHEMICAL]Felbamate[\\CHEMICAL] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the [GENE]NR2A[\\GENE], NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "[CHEMICAL]Felbamate[\\CHEMICAL] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, [GENE]NR2B[\\GENE] or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "[CHEMICAL]Felbamate[\\CHEMICAL] produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or [GENE]NR2C[\\GENE] subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "The higher affinity of [CHEMICAL]felbamate[\\CHEMICAL] block of [GENE]NMDA receptors[\\GENE] containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.",
        "label": 4,
        "major": 2,
        "len": 27
    },
    {
        "text": "The higher affinity of [CHEMICAL]felbamate[\\CHEMICAL] block of NMDA receptors containing the [GENE]NR2B[\\GENE] subunit could be accounted for by more rapid association and slower dissociation from these sites.",
        "label": 4,
        "major": 2,
        "len": 27
    },
    {
        "text": "The anticonvulsant [CHEMICAL]felbamate[\\CHEMICAL] blocks [GENE]N-methyl-D-asparate (NMDA) receptors[\\GENE] but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.",
        "label": 4,
        "major": 6,
        "len": 20
    },
    {
        "text": "This selectivity could, in part, account for the more favorable clinical profile of [CHEMICAL]felbamate[\\CHEMICAL] in comparison with [GENE]NMDA receptor[\\GENE] antagonists that do not show subunit selectivity.",
        "label": 6,
        "major": 10,
        "len": 26
    },
    {
        "text": "The anticonvulsant [CHEMICAL]felbamate[\\CHEMICAL] blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other [GENE]NMDA receptor[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "Comparison of the effect of [CHEMICAL]rofecoxib[\\CHEMICAL] (a [GENE]cyclooxygenase 2[\\GENE] inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "OBJECTIVE: This randomized, double-blind study tested the hypothesis that [CHEMICAL]rofecoxib[\\CHEMICAL], a drug that specifically inhibits [GENE]cyclooxygenase 2[\\GENE], would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "The effect of [CHEMICAL]troglitazone[\\CHEMICAL], an anti-diabetic drug with [GENE]insulin[\\GENE]-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin.",
        "label": 2,
        "major": 3,
        "len": 44
    },
    {
        "text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of [CHEMICAL]zileuton[\\CHEMICAL], a specific inhibitor of [GENE]5-lipoxygenase[\\GENE] (5-LOX) and a clinically used anti-asthmatic drug.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of [CHEMICAL]zileuton[\\CHEMICAL], a specific inhibitor of 5-lipoxygenase ([GENE]5-LOX[\\GENE]) and a clinically used anti-asthmatic drug.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to [CHEMICAL]zileuton[\\CHEMICAL], suggesting that troglitazone inhibits LT production by direct inhibition of [GENE]5-LOX[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that [CHEMICAL]troglitazone[\\CHEMICAL] inhibits LT production by direct inhibition of [GENE]5-LOX[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "These findings suggest that [CHEMICAL]troglitazone[\\CHEMICAL] inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of [GENE]5-LOX[\\GENE] activity.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "The functional protein contains 1160 amino acids with a large central [GENE]mucin domain[\\GENE], three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the [CHEMICAL]C[\\CHEMICAL]-terminal.",
        "label": 1,
        "major": 2,
        "len": 36
    },
    {
        "text": "The functional protein contains 1160 amino acids with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative [GENE]hyaluronan-binding motif[\\GENE], and a potential transmembrane domain near the [CHEMICAL]C[\\CHEMICAL]-terminal.",
        "label": 1,
        "major": 2,
        "len": 36
    },
    {
        "text": "Removal of [CHEMICAL]N[\\CHEMICAL]- and O-linked oligosaccharides reduces the M(r) to approximately 160,000, suggesting that approximately 60% of the mass of [GENE]SPACRCAN[\\GENE] is carbohydrate.",
        "label": 1,
        "major": 4,
        "len": 23
    },
    {
        "text": "Removal of N- and [CHEMICAL]O[\\CHEMICAL]-linked oligosaccharides reduces the M(r) to approximately 160,000, suggesting that approximately 60% of the mass of [GENE]SPACRCAN[\\GENE] is carbohydrate.",
        "label": 1,
        "major": 4,
        "len": 23
    },
    {
        "text": "The functional protein contains 1160 [CHEMICAL]amino acids[\\CHEMICAL] with a large central [GENE]mucin domain[\\GENE], three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the C-terminal.",
        "label": 1,
        "major": 2,
        "len": 36
    },
    {
        "text": "The functional protein contains 1160 [CHEMICAL]amino acids[\\CHEMICAL] with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative [GENE]hyaluronan-binding motif[\\GENE], and a potential transmembrane domain near the C-terminal.",
        "label": 1,
        "major": 2,
        "len": 36
    },
    {
        "text": "Addition of [CHEMICAL]putrescine[\\CHEMICAL] to DFMO-treated cell extracts did not increase [GENE]caspase 3[\\GENE] activity.",
        "label": 10,
        "major": 3,
        "len": 13
    },
    {
        "text": "The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that [CHEMICAL]polyamines[\\CHEMICAL] might be involved in the [GENE]caspase[\\GENE] activating signal cascade.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "Addition of [CHEMICAL]putrescine[\\CHEMICAL] restored the induction of apoptosis as indicated by an increase in the number of detached cells and [GENE]caspase 3[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Depletion of putrescine, spermidine, and spermine by [CHEMICAL]DL-alpha-difluoromethylornithine[\\CHEMICAL] (DFMO), a specific inhibitor of [GENE]ornithine decarboxylase[\\GENE] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, spermidine, and spermine by [CHEMICAL]DL-alpha-difluoromethylornithine[\\CHEMICAL] (DFMO), a specific inhibitor of ornithine decarboxylase ([GENE]ODC[\\GENE]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine ([CHEMICAL]DFMO[\\CHEMICAL]), a specific inhibitor of [GENE]ornithine decarboxylase[\\GENE] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine ([CHEMICAL]DFMO[\\CHEMICAL]), a specific inhibitor of ornithine decarboxylase ([GENE]ODC[\\GENE]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Inhibition of [GENE]S-adenosylmethionine decarboxylase[\\GENE] by a specific inhibitor [[CHEMICAL]diethylglyoxal bis-(guanylhydrazone)[\\CHEMICAL]; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Inhibition of [GENE]S-adenosylmethionine decarboxylase[\\GENE] by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); [CHEMICAL]DEGBG[\\CHEMICAL]] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Depletion of [CHEMICAL]putrescine[\\CHEMICAL], spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [GENE]ornithine decarboxylase[\\GENE] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of [CHEMICAL]putrescine[\\CHEMICAL], spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([GENE]ODC[\\GENE]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, [CHEMICAL]spermidine[\\CHEMICAL], and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [GENE]ornithine decarboxylase[\\GENE] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, [CHEMICAL]spermidine[\\CHEMICAL], and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([GENE]ODC[\\GENE]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, spermidine, and [CHEMICAL]spermine[\\CHEMICAL] by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [GENE]ornithine decarboxylase[\\GENE] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Depletion of putrescine, spermidine, and [CHEMICAL]spermine[\\CHEMICAL] by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([GENE]ODC[\\GENE]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Inhibition of [GENE]S-adenosylmethionine decarboxylase[\\GENE] by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of [CHEMICAL]spermidine[\\CHEMICAL] and spermine with a significant accumulation of putrescine and induction of ODC.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Inhibition of [GENE]S-adenosylmethionine decarboxylase[\\GENE] by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and [CHEMICAL]spermine[\\CHEMICAL] with a significant accumulation of putrescine and induction of ODC.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that (+/-)pindolol produces much of its acute potentiation of [CHEMICAL]fluoxetine[\\CHEMICAL]-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [GENE]5-HT(1A)[\\GENE] receptor.",
        "label": 2,
        "major": 3,
        "len": 51
    },
    {
        "text": "In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that [CHEMICAL](+/-)pindolol[\\CHEMICAL] produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [GENE]5-HT(1A)[\\GENE] receptor.",
        "label": 6,
        "major": 3,
        "len": 51
    },
    {
        "text": "This effect has been attributed to the antagonist effects of [CHEMICAL]pindolol[\\CHEMICAL] at the [GENE]5-HT(1A)[\\GENE] receptor.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "In the present study, we compared the pharmacology of [CHEMICAL](+/-)pindolol[\\CHEMICAL], WAY-100635 (a [GENE]5-HT(1A)[\\GENE] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "In the present study, we compared the pharmacology of (+/-)pindolol, [CHEMICAL]WAY-100635[\\CHEMICAL] (a [GENE]5-HT(1A)[\\GENE] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and [CHEMICAL]isamoltane[\\CHEMICAL] (a [GENE]5-HT(1B)[\\GENE] antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "[CHEMICAL]Orlistat[\\CHEMICAL], a new [GENE]lipase[\\GENE] inhibitor for the management of obesity.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Flutamide[\\CHEMICAL], an effective competitive inhibitor of the [GENE]androgen receptor[\\GENE] used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited [GENE]phenylalanine hydroxylase[\\GENE], whereas [CHEMICAL]N(5)-formyl[\\CHEMICAL]- and N(5)-acetyl H(4)biopterin had no effect.",
        "label": 10,
        "major": 9,
        "len": 39
    },
    {
        "text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited [GENE]phenylalanine hydroxylase[\\GENE], whereas N(5)-formyl- and [CHEMICAL]N(5)-acetyl H(4)biopterin[\\CHEMICAL] had no effect.",
        "label": 10,
        "major": 9,
        "len": 39
    },
    {
        "text": "As compared with [CHEMICAL]N(5)-methyl H(4)biopterin[\\CHEMICAL], N(5)-formyl H(4)biopterin bound with twice the capacity but stimulated [GENE]nitric oxide synthase[\\GENE] to a lesser extent.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "As compared with N(5)-methyl H(4)biopterin, [CHEMICAL]N(5)-formyl H(4)biopterin[\\CHEMICAL] bound with twice the capacity but stimulated [GENE]nitric oxide synthase[\\GENE] to a lesser extent.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Here we compared the action of [CHEMICAL]N(5)[\\CHEMICAL]-substituted derivatives on recombinant [GENE]rat neuronal nitric oxide synthase[\\GENE] with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Here we compared the action of [CHEMICAL]N(5)[\\CHEMICAL]-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on [GENE]dihydropteridine reductase[\\GENE] (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Here we compared the action of [CHEMICAL]N(5)[\\CHEMICAL]-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase ([GENE]EC 1.6.99.7[\\GENE]) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Here we compared the action of [CHEMICAL]N(5)[\\CHEMICAL]-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and [GENE]phenylalanine hydroxylase[\\GENE] (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Here we compared the action of [CHEMICAL]N(5)[\\CHEMICAL]-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase ([GENE]EC 1.14.16.1[\\GENE]),the well-studied classical H(4)biopterin-dependent reactions.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Contrasting effects of [CHEMICAL]N5-substituted tetrahydrobiopterin[\\CHEMICAL] derivatives on phenylalanine hydroxylase, [GENE]dihydropteridine reductase[\\GENE] and nitric oxide synthase.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "Contrasting effects of [CHEMICAL]N5-substituted tetrahydrobiopterin[\\CHEMICAL] derivatives on phenylalanine hydroxylase, dihydropteridine reductase and [GENE]nitric oxide synthase[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "Contrasting effects of [CHEMICAL]N5-substituted tetrahydrobiopterin[\\CHEMICAL] derivatives on [GENE]phenylalanine hydroxylase[\\GENE], dihydropteridine reductase and nitric oxide synthase.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: [CHEMICAL]N(5)-methyl[\\CHEMICAL]- and N(5)-hydroxymethyl H(4)biopterin inhibited [GENE]phenylalanine hydroxylase[\\GENE], whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",
        "label": 4,
        "major": 9,
        "len": 39
    },
    {
        "text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and [CHEMICAL]N(5)-hydroxymethyl H(4)biopterin[\\CHEMICAL] inhibited [GENE]phenylalanine hydroxylase[\\GENE], whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Our data demonstrate differences in the mechanism of stimulation of [GENE]phenylalanine hydroxylase[\\GENE] and nitric oxide synthase by [CHEMICAL]H(4)biopterin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Our data demonstrate differences in the mechanism of stimulation of phenylalanine hydroxylase and [GENE]nitric oxide synthase[\\GENE] by [CHEMICAL]H(4)biopterin[\\CHEMICAL].",
        "label": 8,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Tetrahydrobiopterin[\\CHEMICAL] [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of [GENE]nitric oxide synthases[\\GENE] (EC 1.14.13.39).",
        "label": 8,
        "major": 8,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Tetrahydrobiopterin[\\CHEMICAL] [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of nitric oxide synthases ([GENE]EC 1.14.13.39[\\GENE]).",
        "label": 8,
        "major": 8,
        "len": 14
    },
    {
        "text": "They are compatible with a novel, non-classical, redox-active contribution of [CHEMICAL]H(4)biopterin[\\CHEMICAL] to the catalysis of the [GENE]nitric oxide synthase[\\GENE] reaction.",
        "label": 8,
        "major": 9,
        "len": 20
    },
    {
        "text": "Tetrahydrobiopterin [[CHEMICAL](6R)-5,6,7,8-tetrahydro-L-biopterin[\\CHEMICAL], H(4)biopterin] is one of several cofactors of [GENE]nitric oxide synthases[\\GENE] (EC 1.14.13.39).",
        "label": 8,
        "major": 8,
        "len": 14
    },
    {
        "text": "Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, [CHEMICAL]H(4)biopterin[\\CHEMICAL]] is one of several cofactors of [GENE]nitric oxide synthases[\\GENE] (EC 1.14.13.39).",
        "label": 8,
        "major": 8,
        "len": 14
    },
    {
        "text": "[CHEMICAL]N(5)-Substituted H(4)biopterin[\\CHEMICAL] derivatives were not oxidized to products serving as substrates for [GENE]dihydropteridine reductase[\\GENE] and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "The ability of [CHEMICAL]betaxolol[\\CHEMICAL] to interact with neurotoxin site 2 of the [GENE]Na(+) channel[\\GENE] and inhibit Na(+) influx may have a role in its neuroprotective action in paradigms of excitotoxicity/ischaemia and in its therapeutic effect in glaucoma.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "In this study, we examined whether [CHEMICAL]betaxolol[\\CHEMICAL] and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the [GENE]voltage-sensitive sodium channel[\\GENE] (Na(+) channel) in rat cerebrocortical synaptosomes.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "In this study, we examined whether [CHEMICAL]betaxolol[\\CHEMICAL] and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel ([GENE]Na(+) channel[\\GENE]) in rat cerebrocortical synaptosomes.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Betaxolol[\\CHEMICAL] inhibited specific [(3)H]-batrachotoxinin-A 20-alpha-benzoate ([(3)H]-BTX-B) binding to [GENE]neurotoxin site 2[\\GENE] in a concentration-dependent manner with an IC(50) value of 9.8 microM.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "Betaxolol inhibited specific [CHEMICAL][(3)H]-batrachotoxinin-A 20-alpha-benzoate[\\CHEMICAL] ([(3)H]-BTX-B) binding to [GENE]neurotoxin site 2[\\GENE] in a concentration-dependent manner with an IC(50) value of 9.8 microM.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "Betaxolol inhibited specific [(3)H]-batrachotoxinin-A 20-alpha-benzoate ([CHEMICAL][(3)H]-BTX-B[\\CHEMICAL]) binding to [GENE]neurotoxin site 2[\\GENE] in a concentration-dependent manner with an IC(50) value of 9.8 microM.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "None of the drugs caused a significant inhibition of [CHEMICAL][(3)H]-saxitoxin[\\CHEMICAL] binding to [GENE]neurotoxin receptor site 1[\\GENE], even at concentrations as high as 250 microM.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Betaxolol[\\CHEMICAL], a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with [GENE]Na(+) channels[\\GENE]: comparison with other beta-adrenoceptor antagonists.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "In this study, we examined whether [CHEMICAL]betaxolol[\\CHEMICAL] and other [GENE]beta-adrenoceptor[\\GENE] antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.",
        "label": 6,
        "major": 2,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Betaxolol[\\CHEMICAL], a [GENE]beta(1)-adrenoceptor[\\GENE] antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of [CHEMICAL]propranolol[\\CHEMICAL]>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>[CHEMICAL]betaxolol[\\CHEMICAL] approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>betaxolol approximately [CHEMICAL]levobetaxolol[\\CHEMICAL]>levobunolol approximately carteolol>/=timolol>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>[CHEMICAL]levobunolol[\\CHEMICAL] approximately carteolol>/=timolol>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately [CHEMICAL]carteolol[\\CHEMICAL]>/=timolol>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=[CHEMICAL]timolol[\\CHEMICAL]>atenolol.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Comparison of all the [GENE]beta-adrenoceptor[\\GENE] antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>[CHEMICAL]atenolol[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Betaxolol[\\CHEMICAL], a [GENE]beta(1)-adrenoceptor[\\GENE] antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Betaxolol[\\CHEMICAL], a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other [GENE]beta-adrenoceptor[\\GENE] antagonists.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "5-Fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]5-Fluorouracil[\\CHEMICAL] (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]5-Fluorouracil[\\CHEMICAL] (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to [CHEMICAL]F3(d)Thd[\\CHEMICAL] is due to a mechanism other than [GENE]TS[\\GENE] inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure.",
        "label": 4,
        "major": 4,
        "len": 68
    },
    {
        "text": "In conclusion, [CHEMICAL]F3(d)Thd[\\CHEMICAL], an antimetabolite that inhibits [GENE]TS[\\GENE] activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "5-Fluorouracil (5-FU), [CHEMICAL]5-fluoro-2'-deoxyuridine[\\CHEMICAL] (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), [CHEMICAL]5-fluoro-2'-deoxyuridine[\\CHEMICAL] (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine ([CHEMICAL]FdUrd[\\CHEMICAL]) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine ([CHEMICAL]FdUrd[\\CHEMICAL]) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and [CHEMICAL]5-trifluorothymidine[\\CHEMICAL] (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and [CHEMICAL]5-trifluorothymidine[\\CHEMICAL] (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine ([CHEMICAL]F3(d)Thd[\\CHEMICAL]) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine ([CHEMICAL]F3(d)Thd[\\CHEMICAL]) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In contrast, [CHEMICAL]2, 4-dioxo-5-acetamido-6-phenylhexanoic acid[\\CHEMICAL], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both [GENE]PAM[\\GENE] and dopamine-beta-hydroxylase.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "In contrast, [CHEMICAL]2, 4-dioxo-5-acetamido-6-phenylhexanoic acid[\\CHEMICAL], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and [GENE]dopamine-beta-hydroxylase[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Stereochemical studies established that [GENE]PAM[\\GENE] inactivation by [CHEMICAL]4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid[\\CHEMICAL] is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.",
        "label": 4,
        "major": 9,
        "len": 31
    },
    {
        "text": "In contrast, [CHEMICAL]2, 4-dioxo-5-acetamido-6-phenylhexanoic acid[\\CHEMICAL], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both [GENE]PAM[\\GENE] and dopamine-beta-hydroxylase.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "In contrast, [CHEMICAL]2, 4-dioxo-5-acetamido-6-phenylhexanoic acid[\\CHEMICAL], which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and [GENE]dopamine-beta-hydroxylase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Kinetic parameters for [GENE]PAM[\\GENE] inactivation by [CHEMICAL]4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid[\\CHEMICAL] were obtained by using both the conventional dilution assay method and the more complex progress curve method.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Endogenously produced asymmetrically methylated [CHEMICAL]arginine[\\CHEMICAL] residues are competitive inhibitors of all three isoforms of [GENE]nitric oxide synthase[\\GENE] (NOS).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Endogenously produced asymmetrically methylated [CHEMICAL]arginine[\\CHEMICAL] residues are competitive inhibitors of all three isoforms of nitric oxide synthase ([GENE]NOS[\\GENE]).",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "Experimental cystathioninuria was induced in rats by administration of the [GENE]cystathionine gamma-lyase[\\GENE] inhibitor, [CHEMICAL]D,L-propargylglycine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "The antagonistic property of [CHEMICAL]rilmenidine[\\CHEMICAL] at human alpha(2A)-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of [GENE]alpha(2A)-adrenoceptors[\\GENE] but other, presumably I(1)-imidazoline receptors, are probably involved.",
        "label": 10,
        "major": 6,
        "len": 42
    },
    {
        "text": "In addition, a partial nucleotide and [CHEMICAL]amino acid[\\CHEMICAL] sequence of the [GENE]rabbit alpha(2A)-adrenoceptor[\\GENE] (a region known to substantially influence the pharmacological characteristics of the alpha(2)-adrenoceptor) revealed marked differences between the rabbit and the human alpha(2A)-adrenoceptor.",
        "label": 1,
        "major": 1,
        "len": 35
    },
    {
        "text": "On the basis of data obtained in rabbits, the [GENE]imidazoline receptor[\\GENE] ligand [CHEMICAL]rilmenidine[\\CHEMICAL] has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "The antagonistic property of [CHEMICAL]rilmenidine[\\CHEMICAL] at human alpha(2A)-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably [GENE]I(1)-imidazoline receptors[\\GENE], are probably involved.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "A prerequisite for this hypothesis was the unproved assumption that rabbit and human [GENE]alpha(2A)-adrenoceptors[\\GENE] are equally activated by [CHEMICAL]rilmenidine[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "On the basis of data obtained in rabbits, the imidazoline receptor ligand [CHEMICAL]rilmenidine[\\CHEMICAL] has been suggested to decrease blood pressure in humans by activating central [GENE]alpha(2A)-adrenoceptors[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 26
    },
    {
        "text": "Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the [GENE]alpha(2)-adrenoceptor[\\GENE]-mediated inhibition induced by [CHEMICAL]moxonidine[\\CHEMICAL].",
        "label": 4,
        "major": 5,
        "len": 36
    },
    {
        "text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [GENE]alpha(2A)-autoreceptors[\\GENE], at which, however, both rilmenidine and [CHEMICAL]oxymetazoline[\\CHEMICAL] exhibit different properties (antagonism and agonism, respectively).",
        "label": 5,
        "major": 6,
        "len": 31
    },
    {
        "text": "In the rabbit pulmonary artery, [CHEMICAL]rilmenidine[\\CHEMICAL] and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [GENE]alpha(2)-autoreceptors[\\GENE], sharing this property with rauwolscine, phentolamine, and idazoxan.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "In the rabbit pulmonary artery, rilmenidine and [CHEMICAL]oxymetazoline[\\CHEMICAL] are potent full agonists, whereas in the human atrial appendages they are antagonists at the [GENE]alpha(2)-autoreceptors[\\GENE], sharing this property with rauwolscine, phentolamine, and idazoxan.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [GENE]alpha(2)-autoreceptors[\\GENE], sharing this property with [CHEMICAL]rauwolscine[\\CHEMICAL], phentolamine, and idazoxan.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [GENE]alpha(2)-autoreceptors[\\GENE], sharing this property with rauwolscine, [CHEMICAL]phentolamine[\\CHEMICAL], and idazoxan.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [GENE]alpha(2)-autoreceptors[\\GENE], sharing this property with rauwolscine, phentolamine, and [CHEMICAL]idazoxan[\\CHEMICAL].",
        "label": 6,
        "major": 5,
        "len": 32
    },
    {
        "text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with [GENE]alpha(2A)-autoreceptors[\\GENE], at which, however, both [CHEMICAL]rilmenidine[\\CHEMICAL] and oxymetazoline exhibit different properties (antagonism and agonism, respectively).",
        "label": 6,
        "major": 6,
        "len": 31
    },
    {
        "text": "The antagonistic property of [CHEMICAL]rilmenidine[\\CHEMICAL] at [GENE]human alpha(2A)-adrenoceptors[\\GENE] indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.",
        "label": 6,
        "major": 10,
        "len": 42
    },
    {
        "text": "U50, 488H caused a significant down-regulation of the [GENE]hkor[\\GENE], although [CHEMICAL]etorphine[\\CHEMICAL] did not.",
        "label": 10,
        "major": 10,
        "len": 13
    },
    {
        "text": "Neither [CHEMICAL]U50,488H[\\CHEMICAL] nor etorphine caused down-regulation of the [GENE]rat kappa-opioid receptor[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 11
    },
    {
        "text": "Neither U50,488H nor [CHEMICAL]etorphine[\\CHEMICAL] caused down-regulation of the [GENE]rat kappa-opioid receptor[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]U50, 488H[\\CHEMICAL] caused a significant down-regulation of the [GENE]hkor[\\GENE], although etorphine did not.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation of the [GENE]hkor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Coexpression of GRK2 or GRK2 and arrestin-2 permitted [CHEMICAL]etorphine[\\CHEMICAL] to induce down-regulation of the [GENE]hkor[\\GENE], although expression of arrestin-2 or dynamin I alone did not.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Expression of the dominant negative mutants [GENE]rab5A[\\GENE]-N133I or rab7-N125I blunted [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation.",
        "label": 4,
        "major": 1,
        "len": 12
    },
    {
        "text": "Expression of the dominant negative mutants rab5A-[GENE]N133I[\\GENE] or rab7-N125I blunted [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation.",
        "label": 4,
        "major": 1,
        "len": 12
    },
    {
        "text": "Expression of the dominant negative mutants rab5A-N133I or [GENE]rab7[\\GENE]-N125I blunted [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "Expression of the dominant negative mutants rab5A-N133I or rab7-[GENE]N125I[\\GENE] blunted [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation.",
        "label": 4,
        "major": 1,
        "len": 12
    },
    {
        "text": "These results indicate that [CHEMICAL]U50,488H[\\CHEMICAL]-induced down-regulation of the [GENE]hkor[\\GENE] involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Thus, [CHEMICAL]U50,488H[\\CHEMICAL]-induced internalization and down-regulation of the [GENE]hkor[\\GENE] share initial common mechanisms.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Previously, we showed that the [GENE]human kappa-opioid receptor[\\GENE] (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged [CHEMICAL]U50,488H[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Previously, we showed that the human kappa-opioid receptor ([GENE]hkor[\\GENE]) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged [CHEMICAL]U50,488H[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors ([GENE]proteasome[\\GENE] inhibitor I, [CHEMICAL]MG-132[\\CHEMICAL], or lactacystin) decreased the extent of U50,488H-induced down-regulation.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors ([GENE]proteasome[\\GENE] inhibitor I, MG-132, or [CHEMICAL]lactacystin[\\CHEMICAL]) decreased the extent of U50,488H-induced down-regulation.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "These results indicate that [CHEMICAL]BH(4)[\\CHEMICAL] augmentation is essential for the restoration of [GENE]eNOS[\\GENE] function and the reduction of vascular oxidative stress in insulin-resistant rats.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "The [CHEMICAL]BH(4)[\\CHEMICAL] treatment was associated with a 2-fold increase in [GENE]eNOS[\\GENE] activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Moreover, BH(4) treatment of the [CHEMICAL]fructose[\\CHEMICAL]-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [GENE]nuclear factor-kappaB[\\GENE] and activating protein-1, which were increased in fructose-fed rats.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Moreover, BH(4) treatment of the [CHEMICAL]fructose[\\CHEMICAL]-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and [GENE]activating protein-1[\\GENE], which were increased in fructose-fed rats.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [GENE]nuclear factor-kappaB[\\GENE] and activating protein-1, which were increased in [CHEMICAL]fructose[\\CHEMICAL]-fed rats.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and [GENE]activating protein-1[\\GENE], which were increased in [CHEMICAL]fructose[\\CHEMICAL]-fed rats.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Moreover, [CHEMICAL]BH(4)[\\CHEMICAL] treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, [GENE]nuclear factor-kappaB[\\GENE] and activating protein-1, which were increased in fructose-fed rats.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Moreover, [CHEMICAL]BH(4)[\\CHEMICAL] treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and [GENE]activating protein-1[\\GENE], which were increased in fructose-fed rats.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "We have reported that a deficiency of [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH(4)), an active cofactor of endothelial NO synthase ([GENE]eNOS[\\GENE]), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 8,
        "len": 36
    },
    {
        "text": "We have reported that a deficiency of [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH(4)), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced [GENE]eNOS[\\GENE] activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 8,
        "len": 36
    },
    {
        "text": "We have reported that a deficiency of [CHEMICAL]tetrahydrobiopterin[\\CHEMICAL] (BH(4)), an active cofactor of [GENE]endothelial NO synthase[\\GENE] (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 3,
        "len": 36
    },
    {
        "text": "We have reported that a deficiency of tetrahydrobiopterin ([CHEMICAL]BH(4)[\\CHEMICAL]), an active cofactor of endothelial NO synthase ([GENE]eNOS[\\GENE]), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 3,
        "len": 36
    },
    {
        "text": "We have reported that a deficiency of tetrahydrobiopterin ([CHEMICAL]BH(4)[\\CHEMICAL]), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced [GENE]eNOS[\\GENE] activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 3,
        "len": 36
    },
    {
        "text": "We have reported that a deficiency of tetrahydrobiopterin ([CHEMICAL]BH(4)[\\CHEMICAL]), an active cofactor of [GENE]endothelial NO synthase[\\GENE] (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.",
        "label": 8,
        "major": 8,
        "len": 36
    },
    {
        "text": "Given that [GENE]FRD[\\GENE], present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ([CHEMICAL]morantel[\\CHEMICAL], oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.",
        "label": 4,
        "major": 4,
        "len": 58
    },
    {
        "text": "Given that [GENE]FRD[\\GENE], present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, [CHEMICAL]oxantel[\\CHEMICAL] and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.",
        "label": 4,
        "major": 4,
        "len": 58
    },
    {
        "text": "Given that [GENE]FRD[\\GENE], present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and [CHEMICAL]thiabendazole[\\CHEMICAL]), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.",
        "label": 4,
        "major": 4,
        "len": 58
    },
    {
        "text": "Fumarate reductase ([GENE]FRD[\\GENE]) is the key enzyme in [CHEMICAL]fumarate[\\CHEMICAL] respiration induced by anaerobic growth of bacteria.",
        "label": 9,
        "major": 4,
        "len": 16
    },
    {
        "text": "[GENE]Fumarate reductase[\\GENE] (FRD) is the key enzyme in [CHEMICAL]fumarate[\\CHEMICAL] respiration induced by anaerobic growth of bacteria.",
        "label": 9,
        "major": 4,
        "len": 16
    },
    {
        "text": "The frdA gene coding for subunit A of FRD, and two control genes, [GENE]copA[\\GENE] and copP associated with the export of [CHEMICAL]copper[\\CHEMICAL] out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
        "label": 9,
        "major": 3,
        "len": 39
    },
    {
        "text": "The frdA gene coding for subunit A of FRD, and two control genes, copA and [GENE]copP[\\GENE] associated with the export of [CHEMICAL]copper[\\CHEMICAL] out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.",
        "label": 9,
        "major": 3,
        "len": 39
    },
    {
        "text": "For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the [CHEMICAL]C[\\CHEMICAL] terminus of [GENE]GAD65[\\GENE] that has previously been identified as critical for MICA3 binding.",
        "label": 1,
        "major": 2,
        "len": 42
    },
    {
        "text": "Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing [CHEMICAL]amino acids[\\CHEMICAL], and the surface of the [GENE]GAD65 PLP-binding domain[\\GENE] surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids.",
        "label": 1,
        "major": 1,
        "len": 39
    },
    {
        "text": "Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing amino acids, and the surface of the [GENE]GAD65 PLP-binding domain[\\GENE] surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these [CHEMICAL]amino acids[\\CHEMICAL].",
        "label": 1,
        "major": 2,
        "len": 39
    },
    {
        "text": "Effects of a [CHEMICAL]serotonin[\\CHEMICAL][GENE]serotonin 5-HT(4) receptor[\\GENE] antagonist SB-207266 on gastrointestinal motor and sensory function in humans.",
        "label": 2,
        "major": 6,
        "len": 16
    },
    {
        "text": "CONCLUSION: [GENE]5-HT(4)[\\GENE] receptors are involved in the regulation of [CHEMICAL]cisapride[\\CHEMICAL] stimulated orocaecal transit; SB 207266 tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "METHODS: Part A compared the effects of placebo to four doses of a [GENE]5-HT(4)[\\GENE] receptor antagonist (SB-207266) on the [CHEMICAL]cisapride[\\CHEMICAL] mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
        "label": 5,
        "major": 3,
        "len": 35
    },
    {
        "text": "Effects of a [GENE]serotonin 5-HT(4) receptor[\\GENE] antagonist [CHEMICAL]SB-207266[\\CHEMICAL] on gastrointestinal motor and sensory function in humans.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "METHODS: Part A compared the effects of placebo to four doses of a [GENE]5-HT(4)[\\GENE] receptor antagonist ([CHEMICAL]SB-207266[\\CHEMICAL]) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist ([CHEMICAL]SB-207266[\\CHEMICAL]) on the cisapride mediated increase in plasma aldosterone (a [GENE]5-HT(4)[\\GENE] mediated response) and orocaecal transit in 18 subjects.",
        "label": 6,
        "major": 3,
        "len": 35
    },
    {
        "text": "Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins ([GENE]IGFBP-rPs[\\GENE]) are newly described [CHEMICAL]cysteine[\\CHEMICAL]-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.",
        "label": 1,
        "major": 2,
        "len": 35
    },
    {
        "text": "[GENE]Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins[\\GENE] (IGFBP-rPs) are newly described [CHEMICAL]cysteine[\\CHEMICAL]-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.",
        "label": 1,
        "major": 10,
        "len": 35
    },
    {
        "text": "Moreover, [GENE]IGFBP-rP2[\\GENE] noticeably increased in response to TGF-beta1 and [CHEMICAL]all-trans retinoic acid[\\CHEMICAL] (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.",
        "label": 3,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, [GENE]IGFBP-rP2[\\GENE] noticeably increased in response to TGF-beta1 and all-trans retinoic acid ([CHEMICAL]atRA[\\CHEMICAL]) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Although the data collected on [GENE]IGFBP-rP3[\\GENE] in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [CHEMICAL]atRA[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. [CHEMICAL][(3)H]-prazosin[\\CHEMICAL] binds to [GENE]alpha(1) adrenoceptors[\\GENE] on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.",
        "label": 2,
        "major": 2,
        "len": 74
    },
    {
        "text": "In COS cells transfected with [GENE]alpha(1b) adrenoceptor[\\GENE] cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, [CHEMICAL][(3)H]-prazosin[\\CHEMICAL] was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.",
        "label": 2,
        "major": 5,
        "len": 62
    },
    {
        "text": "In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native [GENE]alpha(1B) adrenoceptors[\\GENE], [CHEMICAL][(3)H]-prazosin[\\CHEMICAL] was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.",
        "label": 2,
        "major": 3,
        "len": 62
    },
    {
        "text": "In COS cells transfected with [GENE]alpha(1b) adrenoceptor[\\GENE] cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, [(3)H]-prazosin was displaced by unlabelled [CHEMICAL]prazosin[\\CHEMICAL] in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native [GENE]alpha(1B) adrenoceptors[\\GENE], [(3)H]-prazosin was displaced by unlabelled [CHEMICAL]prazosin[\\CHEMICAL] in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, [(3)H]-prazosin was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [CHEMICAL][(3)H]-prazosin[\\CHEMICAL] was displaced likewise by a series of [GENE]alpha(1)[\\GENE] adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, [(3)H]-prazosin was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of [GENE]alpha(1)[\\GENE] adrenergic agonists, none of which increased the binding of [CHEMICAL][(3)H]-prazosin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 62
    },
    {
        "text": "Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. [(3)H]-prazosin binds to [GENE]alpha(1) adrenoceptors[\\GENE] on these cells and is displaceable by unlabelled [CHEMICAL]prazosin[\\CHEMICAL] in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.",
        "label": 2,
        "major": 2,
        "len": 74
    },
    {
        "text": "Activation of endogenous [GENE]somatostatin receptor subtype 2[\\GENE] (sst2) by [CHEMICAL]somatostatin-14[\\CHEMICAL] or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Activation of endogenous somatostatin receptor subtype 2 ([GENE]sst2[\\GENE]) by [CHEMICAL]somatostatin-14[\\CHEMICAL] or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected [GENE]rat D2 dopamine receptors[\\GENE] (rD2(long)) by [CHEMICAL]quinpirole[\\CHEMICAL] had no effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors ([GENE]rD2[\\GENE](long)) by [CHEMICAL]quinpirole[\\CHEMICAL] had no effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In contrast, in the same system, [CHEMICAL]N[\\CHEMICAL]-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong [GENE]G-protein[\\GENE]-mediated inhibition.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "High p53 protein levels, but not genetic or functional [GENE]p53[\\GENE] status, were associated with increased [CHEMICAL]topotecan[\\CHEMICAL]-induced DNA/topoisomerase I complex formation.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "We thus confirm a possible role for [GENE]p53[\\GENE] protein in modulating topoisomerase I activity but conclude that the major molecular determinants of [CHEMICAL]topotecan[\\CHEMICAL] sensitivity in glioma cells await identification.",
        "label": 2,
        "major": 7,
        "len": 29
    },
    {
        "text": "High p53 protein levels, but not genetic or functional p53 status, were associated with increased [CHEMICAL]topotecan[\\CHEMICAL]-induced DNA/[GENE]topoisomerase I[\\GENE] complex formation.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "We thus confirm a possible role for p53 protein in modulating [GENE]topoisomerase I[\\GENE] activity but conclude that the major molecular determinants of [CHEMICAL]topotecan[\\CHEMICAL] sensitivity in glioma cells await identification.",
        "label": 2,
        "major": 7,
        "len": 29
    },
    {
        "text": "High [GENE]p53[\\GENE] protein levels, but not genetic or functional p53 status, were associated with increased [CHEMICAL]topotecan[\\CHEMICAL]-induced DNA/topoisomerase I complex formation.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Topotecan[\\CHEMICAL] is a [GENE]topoisomerase I[\\GENE] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Clinical effects of pranlukast, an oral [CHEMICAL]leukotriene[\\CHEMICAL][GENE]leukotriene receptor[\\GENE] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",
        "label": 2,
        "major": 6,
        "len": 19
    },
    {
        "text": "Pranlukast is a new, orally active, selective inhibitor of [GENE]CysLt1[\\GENE] [CHEMICAL]leukotriene[\\CHEMICAL] receptor.",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "Pranlukast is a new, orally active, selective inhibitor of CysLt1 [CHEMICAL]leukotriene[\\CHEMICAL][GENE]leukotriene receptor[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL] is a new, orally active, selective inhibitor of [GENE]CysLt1[\\GENE] leukotriene receptor.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL] is a new, orally active, selective inhibitor of CysLt1 [GENE]leukotriene receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Clinical effects of [CHEMICAL]pranlukast[\\CHEMICAL], an oral [GENE]leukotriene receptor[\\GENE] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "Third, using [CHEMICAL]ciprofloxacin[\\CHEMICAL] competition assay, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by ciprofloxacin.",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "Third, using ciprofloxacin competition assay, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by [CHEMICAL]ciprofloxacin[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "In addition, [CHEMICAL]ADP[\\CHEMICAL] was shown to strongly antagonize [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive TOP2 poisons.",
        "label": 2,
        "major": 6,
        "len": 19
    },
    {
        "text": "In addition, ADP was shown to strongly antagonize [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by [CHEMICAL]ATP[\\CHEMICAL]-sensitive but not ATP-insensitive TOP2 poisons.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Second, C427A mutant human TOP2alpha, which exhibits reduced [GENE]ATPase[\\GENE] activity, was shown to exhibit cross-resistance to all ATP-sensitive but not [CHEMICAL]ATP[\\CHEMICAL]-insensitive TOP2 poisons.",
        "label": 4,
        "major": 1,
        "len": 23
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. [CHEMICAL]doxorubicin[\\CHEMICAL], etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive [GENE]TOP2[\\GENE] poisons (e.g. [CHEMICAL]doxorubicin[\\CHEMICAL], etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, [CHEMICAL]etoposide[\\CHEMICAL], mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive [GENE]TOP2[\\GENE] poisons (e.g. doxorubicin, [CHEMICAL]etoposide[\\CHEMICAL], mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, [CHEMICAL]mitoxantrone[\\CHEMICAL], and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive [GENE]TOP2[\\GENE] poisons (e.g. doxorubicin, etoposide, [CHEMICAL]mitoxantrone[\\CHEMICAL], and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, [GENE]TOP2[\\GENE]-mediated DNA cleavage induced by ATP-sensitive TOP2 poisons (e.g. doxorubicin, etoposide, mitoxantrone, and [CHEMICAL]4'-(9-acridinylamino)methanesulfon-m-anisidide[\\CHEMICAL]) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "First, in the presence of 1 mm ATP or the nonhydrolyzable analog adenosine 5'-(beta,gamma-imino)triphosphate, TOP2-mediated DNA cleavage induced by ATP-sensitive [GENE]TOP2[\\GENE] poisons (e.g. doxorubicin, etoposide, mitoxantrone, and [CHEMICAL]4'-(9-acridinylamino)methanesulfon-m-anisidide[\\CHEMICAL]) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive TOP2 poisons (e.g.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive [GENE]TOP2[\\GENE] poisons (e.g. [CHEMICAL]amonafide[\\CHEMICAL], batracylin, and menadione) was only slightly (less than 3-fold) affected.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive [GENE]TOP2[\\GENE] poisons (e.g. amonafide, [CHEMICAL]batracylin[\\CHEMICAL], and menadione) was only slightly (less than 3-fold) affected.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "doxorubicin, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive [GENE]TOP2[\\GENE] poisons (e.g. amonafide, batracylin, and [CHEMICAL]menadione[\\CHEMICAL]) was only slightly (less than 3-fold) affected.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "In contrast, in the presence of [CHEMICAL]Ca[\\CHEMICAL] UFH accelerated the inhibition of [GENE]factor Xa[\\GENE] by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "In contrast, in the presence of [CHEMICAL]Ca[\\CHEMICAL] UFH accelerated the inhibition of factor Xa by [GENE]antithrombin[\\GENE] 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "[GENE]Follicle-stimulating hormone[\\GENE] (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex [CHEMICAL]steroids[\\CHEMICAL] and gametes.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Follicle-stimulating hormone ([GENE]FSH[\\GENE]), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex [CHEMICAL]steroids[\\CHEMICAL] and gametes.",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "Humans with [GENE]FSH beta[\\GENE] gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex [CHEMICAL]steroid[\\CHEMICAL] production occur in both types of mutations.",
        "label": 9,
        "major": 1,
        "len": 35
    },
    {
        "text": "Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified [CHEMICAL]triacsin[\\CHEMICAL]-sensitive [GENE]ACS[\\GENE] is present in mitochondria.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Re-feeding normal chow or a high [CHEMICAL]sucrose[\\CHEMICAL] diet for 24 h after a 48-h fast increased both [GENE]ACS1[\\GENE] and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.",
        "label": 3,
        "major": 4,
        "len": 27
    },
    {
        "text": "Re-feeding normal chow or a high [CHEMICAL]sucrose[\\CHEMICAL] diet for 24 h after a 48-h fast increased both ACS1 and [GENE]ACS4[\\GENE] protein expression 1.5-2.0-fold, consistent with inhibition studies.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Consistent with these locations, [CHEMICAL]N-ethylmaleimide[\\CHEMICAL], an inhibitor of [GENE]ACS4[\\GENE], inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Consistent with these locations, [CHEMICAL]N-ethylmaleimide[\\CHEMICAL], an inhibitor of ACS4, inhibited [GENE]ACS[\\GENE] activity 47% in MAM and 28% in endoplasmic reticulum.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Troglitazone[\\CHEMICAL], a second [GENE]ACS4[\\GENE] inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Troglitazone[\\CHEMICAL], a second ACS4 inhibitor, inhibited [GENE]ACS[\\GENE] activity <10% in microsomes and mitochondria and 45% in MAM.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Triacsin C[\\CHEMICAL], a competitive inhibitor of both [GENE]ACS1[\\GENE] and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Triacsin C[\\CHEMICAL], a competitive inhibitor of both ACS1 and [GENE]ACS4[\\GENE], inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Triacsin C[\\CHEMICAL], a competitive inhibitor of both ACS1 and ACS4, inhibited [GENE]ACS[\\GENE] activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The capacity of these inhibitors to displace [3H]-oxotremorine-M binding preclude their utilisation for the prevention of acetylcholine catabolism in rat brain membranes, the latter being required to estimate the binding of acetylcholine to [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL]-labelled [GENE]muscarinic receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, fasciculin-2, a potent peptide inhibitor of acetylcholinesterase (IC50 24 nM), did prevent catabolism of acetylcholine in rat brain membranes with an atypical inhibition isotherm of [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL] binding, thus permitting an estimation of the \"global affinity\" of acetylcholine (Ki 85 nM) for [3H]-oxotremorine-M-labelled [GENE]muscarinic receptors[\\GENE] in rat brain.",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "However, fasciculin-2, a potent peptide inhibitor of acetylcholinesterase (IC50 24 nM), did prevent catabolism of acetylcholine in rat brain membranes with an atypical inhibition isotherm of [3H]-oxotremorine-M binding, thus permitting an estimation of the \"global affinity\" of acetylcholine (Ki 85 nM) for [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL]-labelled [GENE]muscarinic receptors[\\GENE] in rat brain.",
        "label": 2,
        "major": 2,
        "len": 48
    },
    {
        "text": "In the present study, the capacity of acetylcholinesterase inhibitors to interact with [GENE]muscarinic receptors[\\GENE] was assessed by their ability to displace both [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL] and [3H]-quinuclinidyl benzilate binding in rat brain membranes.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "In the present study, the capacity of acetylcholinesterase inhibitors to interact with [GENE]muscarinic receptors[\\GENE] was assessed by their ability to displace both [3H]-oxotremorine-M and [CHEMICAL][3H]-quinuclinidyl benzilate[\\CHEMICAL] binding in rat brain membranes.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Differential inhibition of [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL] and [3H]-quinuclinidyl benzilate binding to [GENE]muscarinic receptors[\\GENE] in rat brain membranes with acetylcholinesterase inhibitors.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "Differential inhibition of [3H]-oxotremorine-M and [CHEMICAL][3H]-quinuclinidyl benzilate[\\CHEMICAL] binding to [GENE]muscarinic receptors[\\GENE] in rat brain membranes with acetylcholinesterase inhibitors.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [CHEMICAL][3H]-oxotremorine-M[\\CHEMICAL] in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at [GENE]muscarinic receptors[\\GENE].",
        "label": 2,
        "major": 5,
        "len": 34
    },
    {
        "text": "The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [CHEMICAL][3H]quinuclinidyl benzilate[\\CHEMICAL] predicts that the former compounds could act as potential agonists at [GENE]muscarinic receptors[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>[CHEMICAL]pyridostigmine[\\CHEMICAL]=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>[CHEMICAL]pyridostigmine[\\CHEMICAL]=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=[CHEMICAL]edrophonium[\\CHEMICAL]=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=[CHEMICAL]edrophonium[\\CHEMICAL]=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=[CHEMICAL]galanthamine[\\CHEMICAL] >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=[CHEMICAL]galanthamine[\\CHEMICAL] >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >[CHEMICAL]desoxypeganine[\\CHEMICAL]>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >[CHEMICAL]desoxypeganine[\\CHEMICAL]>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>[CHEMICAL]parathion[\\CHEMICAL]>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>[CHEMICAL]parathion[\\CHEMICAL]>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>[CHEMICAL]gramine[\\CHEMICAL]) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>[CHEMICAL]gramine[\\CHEMICAL]) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The capacity of [GENE]acetylcholinesterase[\\GENE] inhibitors, with the exception of [CHEMICAL]tacrine[\\CHEMICAL] and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors.",
        "label": 4,
        "major": 5,
        "len": 34
    },
    {
        "text": "The capacity of [GENE]acetylcholinesterase[\\GENE] inhibitors, with the exception of tacrine and [CHEMICAL]ambenonium[\\CHEMICAL], to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] ([CHEMICAL]ambenonium[\\CHEMICAL]>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase ([CHEMICAL]ambenonium[\\CHEMICAL]>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>[CHEMICAL]neostigmine[\\CHEMICAL]=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>[CHEMICAL]neostigmine[\\CHEMICAL]=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=[CHEMICAL]physostigmine[\\CHEMICAL] =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=[CHEMICAL]physostigmine[\\CHEMICAL] =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting [GENE]acetylcholinesterase[\\GENE] (ambenonium>neostigmine=physostigmine =[CHEMICAL]tacrine[\\CHEMICAL]>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =[CHEMICAL]tacrine[\\CHEMICAL]>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of [GENE]acetylcholinesterase[\\GENE] also displaced [3H]-oxotremorine-M to the greatest extent.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] reduced the risk of death or heart failure in patients with above-median levels of [GENE]N-BNP[\\GENE] or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] reduced the risk of death or heart failure in patients with above-median levels of N-BNP or [GENE]adrenomedullin[\\GENE], or both, to rates not significantly different from those observed in patients with levels below the median value.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] reduced mortality and heart failure in patients with higher pre-treatment plasma [GENE]N-BNP[\\GENE] and adrenomedullin.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and [GENE]adrenomedullin[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by [CHEMICAL]indomethacin[\\CHEMICAL] might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in [GENE]COX[\\GENE] activity, a hypothesis that requires further study.",
        "label": 2,
        "major": 3,
        "len": 70
    },
    {
        "text": "In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by [CHEMICAL]indomethacin[\\CHEMICAL] might cause changes in [GENE]COX[\\GENE] activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.",
        "label": 2,
        "major": 3,
        "len": 70
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] completely antagonizes [GENE]CA[\\GENE] activity, i.e.",
        "label": 3,
        "major": 6,
        "len": 6
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on [GENE]CA[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] activates [GENE]carbonic anhydrase[\\GENE] and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.",
        "label": 3,
        "major": 6,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] activates carbonic anhydrase and antagonizes the effect of the specific [GENE]carbonic anhydrase[\\GENE] inhibitor acetazolamide, by a direct mechanism of action.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "CONCLUSIONS: Our results show that [CHEMICAL]indomethacin[\\CHEMICAL], a known cyclooxygenase (COX) inhibitor, is also an activator of [GENE]CA[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 17
    },
    {
        "text": "Our data also prove that [CHEMICAL]indomethacin[\\CHEMICAL] is not only an activator of [GENE]CA[\\GENE] but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.",
        "label": 3,
        "major": 4,
        "len": 26
    },
    {
        "text": "In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, [GENE]CA[\\GENE] activation induced by [CHEMICAL]indomethacin[\\CHEMICAL] might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.",
        "label": 3,
        "major": 3,
        "len": 70
    },
    {
        "text": "RESULTS: [CHEMICAL]Indomethacin[\\CHEMICAL], in vitro and in vivo. induces an increase in erythorcyte [GENE]CA I[\\GENE] and CA II activity.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "RESULTS: [CHEMICAL]Indomethacin[\\CHEMICAL], in vitro and in vivo. induces an increase in erythorcyte CA I and [GENE]CA II[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Acetazolamide[\\CHEMICAL], a specific inhibitor of [GENE]CA[\\GENE], reduces the activity of CA I and CA II from red cells.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Acetazolamide[\\CHEMICAL], a specific inhibitor of CA, reduces the activity of [GENE]CA I[\\GENE] and CA II from red cells.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Acetazolamide[\\CHEMICAL], a specific inhibitor of CA, reduces the activity of CA I and [GENE]CA II[\\GENE] from red cells.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Indomethacin completely antagonizes [GENE]CA[\\GENE] activity, i.e. abolishes the inhibitory effect of [CHEMICAL]acetazolamide[\\CHEMICAL] on CA.",
        "label": 4,
        "major": 6,
        "len": 14
    },
    {
        "text": "abolishes the inhibitory effect of [CHEMICAL]acetazolamide[\\CHEMICAL] on [GENE]CA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "Indomethacin activates [GENE]carbonic anhydrase[\\GENE] and antagonizes the effect of the specific carbonic anhydrase inhibitor [CHEMICAL]acetazolamide[\\CHEMICAL], by a direct mechanism of action.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific [GENE]carbonic anhydrase[\\GENE] inhibitor [CHEMICAL]acetazolamide[\\CHEMICAL], by a direct mechanism of action.",
        "label": 4,
        "major": 6,
        "len": 21
    },
    {
        "text": "CONCLUSIONS: Our results show that [CHEMICAL]indomethacin[\\CHEMICAL], a known [GENE]cyclooxygenase[\\GENE] (COX) inhibitor, is also an activator of CA.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "CONCLUSIONS: Our results show that [CHEMICAL]indomethacin[\\CHEMICAL], a known cyclooxygenase ([GENE]COX[\\GENE]) inhibitor, is also an activator of CA.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Our data also prove that indomethacin is not only an activator of [GENE]CA[\\GENE] but also antagonizes the effect of [CHEMICAL]acetazolamide[\\CHEMICAL], a specific inhibitor of this enzyme.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Pimozide[\\CHEMICAL] blocked [GENE]erg3[\\GENE] channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The antipsychotic drugs [CHEMICAL]sertindole[\\CHEMICAL] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the [GENE]cardiac K(+) channel[\\GENE] known as HERG (human ether-a-go-go-related gene; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs [CHEMICAL]sertindole[\\CHEMICAL] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as [GENE]HERG[\\GENE] (human ether-a-go-go-related gene; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs [CHEMICAL]sertindole[\\CHEMICAL] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG ([GENE]human ether-a-go-go-related gene[\\GENE]; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs [CHEMICAL]sertindole[\\CHEMICAL] and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; [GENE]erg1[\\GENE]).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs sertindole and [CHEMICAL]pimozide[\\CHEMICAL] are known to prolong the QT interval on the electrocardiogram via a high affinity block of the [GENE]cardiac K(+) channel[\\GENE] known as HERG (human ether-a-go-go-related gene; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs sertindole and [CHEMICAL]pimozide[\\CHEMICAL] are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as [GENE]HERG[\\GENE] (human ether-a-go-go-related gene; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs sertindole and [CHEMICAL]pimozide[\\CHEMICAL] are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG ([GENE]human ether-a-go-go-related gene[\\GENE]; erg1).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "The antipsychotic drugs sertindole and [CHEMICAL]pimozide[\\CHEMICAL] are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; [GENE]erg1[\\GENE]).",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "A great deal of information has now accumulated pertaining to the mechanisms by which [GENE]nuclear receptors[\\GENE], such as the [CHEMICAL]androgen[\\CHEMICAL] receptor, modulate the activity of responsive genes.",
        "label": 7,
        "major": 7,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Amiloride[\\CHEMICAL] is a specific inhibitor of uPA but does not inhibit [GENE]tPA[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 12
    },
    {
        "text": "Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of [CHEMICAL]amiloride[\\CHEMICAL] to the [GENE]tissue plasminogen activator[\\GENE] (tPA).",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of [CHEMICAL]amiloride[\\CHEMICAL] to the tissue plasminogen activator ([GENE]tPA[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Binding site of [CHEMICAL]amiloride[\\CHEMICAL] to [GENE]urokinase plasminogen activator[\\GENE] depends on species.",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Amiloride[\\CHEMICAL] is a specific inhibitor of [GENE]uPA[\\GENE] but does not inhibit tPA.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]ZD1839[\\CHEMICAL] (\"Iressa\"), a quinazoline [GENE]tyrosine kinase[\\GENE] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]ZD1839[\\CHEMICAL] (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the [GENE]EGFR[\\GENE], has shown good activity in preclinical studies and in the early phase of clinical trials.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "ZD1839 (\"[CHEMICAL]Iressa[\\CHEMICAL]\"), a quinazoline [GENE]tyrosine kinase[\\GENE] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "ZD1839 (\"[CHEMICAL]Iressa[\\CHEMICAL]\"), a quinazoline tyrosine kinase inhibitor selective for the [GENE]EGFR[\\GENE], has shown good activity in preclinical studies and in the early phase of clinical trials.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "The [GENE]tyrosine kinase[\\GENE] inhibitor [CHEMICAL]ZD1839[\\CHEMICAL] (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The tyrosine kinase inhibitor [CHEMICAL]ZD1839[\\CHEMICAL] (\"Iressa\") inhibits [GENE]HER2[\\GENE]-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The tyrosine kinase inhibitor ZD1839 (\"[CHEMICAL]Iressa[\\CHEMICAL]\") inhibits HER2-driven signaling and suppresses the growth of [GENE]HER2[\\GENE]-overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The [GENE]tyrosine kinase[\\GENE] inhibitor ZD1839 (\"[CHEMICAL]Iressa[\\CHEMICAL]\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The tyrosine kinase inhibitor ZD1839 (\"[CHEMICAL]Iressa[\\CHEMICAL]\") inhibits [GENE]HER2[\\GENE]-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]tyrosine[\\CHEMICAL][GENE]tyrosine kinase[\\GENE] inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
        "label": 9,
        "major": 4,
        "len": 17
    },
    {
        "text": "These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family [CHEMICAL]tyrosine[\\CHEMICAL][GENE]tyrosine kinase[\\GENE] signaling and suggest novel strategies to treat these particularly aggressive tumors.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "ZD1839 (\"Iressa\"), a [CHEMICAL]quinazoline tyrosine[\\CHEMICAL][GENE]tyrosine kinase[\\GENE] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with [CHEMICAL]phosphatidylinositol[\\CHEMICAL][GENE]phosphatidylinositol 3-kinase[\\GENE], and down-regulation of Akt activity.",
        "label": 9,
        "major": 4,
        "len": 33
    },
    {
        "text": "In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the [GENE]dopamine D2[\\GENE] agonist [CHEMICAL]apomorphine[\\CHEMICAL]; however, it is not clear whether both findings share the same biological basis.",
        "label": 5,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either [GENE]Kir6.2[\\GENE]/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/[GENE]SUR2A[\\GENE] or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",
        "label": 10,
        "major": 4,
        "len": 41
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or [GENE]Kir6.2[\\GENE]/SUR2B channel currents even at high doses (more than 10 microM).",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/[GENE]SUR2B[\\GENE] channel currents even at high doses (more than 10 microM).",
        "label": 10,
        "major": 4,
        "len": 41
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [CHEMICAL][3H]glibenclamide[\\CHEMICAL] to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on [CHEMICAL]mitiglinide[\\CHEMICAL], nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on [CHEMICAL]mitiglinide[\\CHEMICAL], nateglinide, and repaglinide to [GENE]SUR1[\\GENE] expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, [CHEMICAL]nateglinide[\\CHEMICAL], and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, [CHEMICAL]nateglinide[\\CHEMICAL], and repaglinide to [GENE]SUR1[\\GENE] expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and [CHEMICAL]repaglinide[\\CHEMICAL] to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and [CHEMICAL]repaglinide[\\CHEMICAL] to [GENE]SUR1[\\GENE] expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: [CHEMICAL]mitiglinide[\\CHEMICAL], 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; [CHEMICAL]nateglinide[\\CHEMICAL], 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; [CHEMICAL]repaglinide[\\CHEMICAL], 1.6 microM), suggesting that they all share a glibenclamide binding site.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to [GENE]SUR1[\\GENE] (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a [CHEMICAL]glibenclamide[\\CHEMICAL] binding site.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Mitiglinide ([CHEMICAL]KAD-1229[\\CHEMICAL]), a new anti-diabetic drug, is thought to stimulate [GENE]insulin[\\GENE] secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Mitiglinide[\\CHEMICAL] (KAD-1229), a new anti-diabetic drug, is thought to stimulate [GENE]insulin[\\GENE] secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Mitiglinide ([CHEMICAL]KAD-1229[\\CHEMICAL]), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the [GENE]ATP-sensitive K+ (K(ATP)) channels[\\GENE] in pancreatic beta-cells.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Mitiglinide[\\CHEMICAL] (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the [GENE]ATP-sensitive K+ (K(ATP)) channels[\\GENE] in pancreatic beta-cells.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the [GENE]Kir6.2[\\GENE]/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Patch-clamp analysis using inside-out recording configuration showed that [CHEMICAL]mitiglinide[\\CHEMICAL] inhibits the Kir6.2/[GENE]SUR1[\\GENE] channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM).",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits [GENE]Kir6.2[\\GENE]/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits Kir6.2/[GENE]SUR1[\\GENE] and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits Kir6.2/SUR1 and [GENE]Kir6.2[\\GENE]/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits Kir6.2/SUR1 and Kir6.2/[GENE]SUR2B[\\GENE] channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits [GENE]Kir6.2[\\GENE]/SUR2A channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nateglinide[\\CHEMICAL] inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/[GENE]SUR2A[\\GENE] channels at high concentrations (1 microM).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "In the present study, we investigated the effect of [CHEMICAL]fenoterol[\\CHEMICAL]-induced constitutive [GENE]beta(2)-adrenoceptor[\\GENE] activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Effect of [CHEMICAL]fenoterol[\\CHEMICAL]-induced constitutive [GENE]beta(2)-adrenoceptor[\\GENE] activity on contractile receptor function in airway smooth muscle.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "In conclusion, [CHEMICAL]fenoterol[\\CHEMICAL]-induced constitutive [GENE]beta(2)-adrenoceptor[\\GENE] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial [GENE]muscarinic receptor[\\GENE] agonist [CHEMICAL]4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium[\\CHEMICAL] (McN-A-343) and histamine.",
        "label": 5,
        "major": 5,
        "len": 55
    },
    {
        "text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial [GENE]muscarinic receptor[\\GENE] agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and [CHEMICAL]histamine[\\CHEMICAL].",
        "label": 5,
        "major": 10,
        "len": 55
    },
    {
        "text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full [GENE]muscarinic receptor[\\GENE] agonist [CHEMICAL]methacholine[\\CHEMICAL], the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine.",
        "label": 5,
        "major": 10,
        "len": 55
    },
    {
        "text": "In conclusion, fenoterol-induced constitutive [GENE]beta(2)-adrenoceptor[\\GENE] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [CHEMICAL]timolol[\\CHEMICAL].",
        "label": 5,
        "major": 3,
        "len": 27
    },
    {
        "text": "The inhibition of [GENE]aminopeptidase[\\GENE] activity in the presence of [CHEMICAL]bestatin[\\CHEMICAL] and puromycin inhibitors was also investigated.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The inhibition of [GENE]aminopeptidase[\\GENE] activity in the presence of bestatin and [CHEMICAL]puromycin[\\CHEMICAL] inhibitors was also investigated.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of [CHEMICAL]L-arginine[\\CHEMICAL] for [GENE]aminopeptidase B[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: [CHEMICAL]4-methoxy-2-naphthylamide[\\CHEMICAL] of L-alanine for [GENE]aminopeptidase N[\\GENE], 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of [CHEMICAL]L-alanine[\\CHEMICAL] for [GENE]aminopeptidase N[\\GENE], 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, [CHEMICAL]4-methoxy-2-naphthylamide[\\CHEMICAL] of L-leucine for [GENE]leucine aminopeptidase[\\GENE], 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of [CHEMICAL]L-leucine[\\CHEMICAL] for [GENE]leucine aminopeptidase[\\GENE], 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, [CHEMICAL]4-methoxy-2-naphthylamide[\\CHEMICAL] of L-glutamic acid for [GENE]aminopeptidase A[\\GENE] and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of [CHEMICAL]L-glutamic acid[\\CHEMICAL] for [GENE]aminopeptidase A[\\GENE] and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and [CHEMICAL]4-methoxy-2-naphthylamide[\\CHEMICAL] of L-arginine for [GENE]aminopeptidase B[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 42
    },
    {
        "text": "PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the [GENE]aromatase[\\GENE] inhibitor, [CHEMICAL]testolactone[\\CHEMICAL], and resulting changes in semen parameters.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "We evaluated the effect of [CHEMICAL]anastrozole[\\CHEMICAL], a more selective [GENE]aromatase[\\GENE] inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Also in contrast to effects of multiple METH injections, 1) [CHEMICAL]MDMA[\\CHEMICAL] caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",
        "label": 10,
        "major": 4,
        "len": 42
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and [GENE]vesicular monoamine transporter-2[\\GENE][CHEMICAL]monoamine[\\CHEMICAL] transporter-2 (VMAT-2) were assessed.",
        "label": 1,
        "major": 9,
        "len": 30
    },
    {
        "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand [CHEMICAL]WIN35428[\\CHEMICAL], and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "To determine whether these responses were common to other [CHEMICAL]amphetamines[\\CHEMICAL] of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal [GENE]DA transporter[\\GENE] (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other [CHEMICAL]amphetamines[\\CHEMICAL] of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter ([GENE]DAT[\\GENE]) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other [CHEMICAL]amphetamines[\\CHEMICAL] of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and [GENE]vesicular monoamine transporter-2[\\GENE] (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other [CHEMICAL]amphetamines[\\CHEMICAL] of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 ([GENE]VMAT-2[\\GENE]) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of [CHEMICAL]methylenedioxymethamphetamine[\\CHEMICAL] (MDMA) on the plasmalemmal [GENE]DA transporter[\\GENE] (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of [CHEMICAL]methylenedioxymethamphetamine[\\CHEMICAL] (MDMA) on the plasmalemmal DA transporter ([GENE]DAT[\\GENE]) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of [CHEMICAL]methylenedioxymethamphetamine[\\CHEMICAL] (MDMA) on the plasmalemmal DA transporter (DAT) and [GENE]vesicular monoamine transporter-2[\\GENE] (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of [CHEMICAL]methylenedioxymethamphetamine[\\CHEMICAL] (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 ([GENE]VMAT-2[\\GENE]) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]) on the plasmalemmal [GENE]DA transporter[\\GENE] (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]) on the plasmalemmal DA transporter ([GENE]DAT[\\GENE]) and vesicular monoamine transporter-2 (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]) on the plasmalemmal DA transporter (DAT) and [GENE]vesicular monoamine transporter-2[\\GENE] (VMAT-2) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 ([GENE]VMAT-2[\\GENE]) were assessed.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "In addition to affecting [GENE]DAT[\\GENE] function, [CHEMICAL]MDMA[\\CHEMICAL] rapidly decreased vesicular DA transport as assessed in striatal vesicles prepared from treated rats.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "Also in contrast to effects of multiple [CHEMICAL]METH[\\CHEMICAL] injections, 1) MDMA caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the [CHEMICAL]MDMA[\\CHEMICAL]-induced reduction in plasmalemmal DA transport.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal [CHEMICAL]DA[\\CHEMICAL] transport.",
        "label": 9,
        "major": 4,
        "len": 42
    },
    {
        "text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the [GENE]DAT[\\GENE] ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of [CHEMICAL]DA[\\CHEMICAL] prevented the MDMA-induced reduction in plasmalemmal DA transport.",
        "label": 9,
        "major": 4,
        "len": 42
    },
    {
        "text": "In addition to affecting [GENE]DAT[\\GENE] function, MDMA rapidly decreased vesicular [CHEMICAL]DA[\\CHEMICAL] transport as assessed in striatal vesicles prepared from treated rats.",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Tamoxifen[\\CHEMICAL] does not reduce the incidence of [GENE]ER[\\GENE]-negative cancers, nor does it appear to be effective in preventing the appearance of one third of ER-positive cancers.",
        "label": 10,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Tamoxifen[\\CHEMICAL] does not reduce the incidence of ER-negative cancers, nor does it appear to be effective in preventing the appearance of one third of [GENE]ER[\\GENE]-positive cancers.",
        "label": 10,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Raloxifene[\\CHEMICAL] is a selective [GENE]ER[\\GENE] modulator with less uterine estrogen agonist activity than tamoxifen, and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer.",
        "label": 2,
        "major": 7,
        "len": 38
    },
    {
        "text": "It is not yet clear whether [CHEMICAL]tamoxifen[\\CHEMICAL] can reduce breast cancer incidence in women with BRCA1 and [GENE]BRCA2[\\GENE] mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.",
        "label": 4,
        "major": 1,
        "len": 32
    },
    {
        "text": "It is not yet clear whether [CHEMICAL]tamoxifen[\\CHEMICAL] can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a [GENE]BRCA2[\\GENE] mutation.",
        "label": 4,
        "major": 10,
        "len": 32
    },
    {
        "text": "In addition, we found that [GENE]MCP-1[\\GENE] transcription and translation was completely inhibited by [CHEMICAL]mimosine[\\CHEMICAL], while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "In addition, we found that MCP-1 transcription and translation was completely inhibited by [CHEMICAL]mimosine[\\CHEMICAL], while [GENE]MIP-2[\\GENE] transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Inhibition of [GENE]MCP-1[\\GENE] and MIP-2 transcription and translation by [CHEMICAL]mimosine[\\CHEMICAL] in muscle tissue infected with the parasite Trichinella spiralis.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Inhibition of MCP-1 and [GENE]MIP-2[\\GENE] transcription and translation by [CHEMICAL]mimosine[\\CHEMICAL] in muscle tissue infected with the parasite Trichinella spiralis.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Radiosequence analysis of [(14)C]halothane-labeled [GENE]rhodopsin[\\GENE] revealed that halothane contacts an [CHEMICAL]amino acid[\\CHEMICAL] residue (Trp265) lining the ligand binding cavity in the transmembrane core of the receptor.",
        "label": 1,
        "major": 1,
        "len": 26
    },
    {
        "text": "We report herein the location of the binding site for the inhaled anesthetic halothane at the [CHEMICAL]amino acid[\\CHEMICAL] residue level of resolution in the ligand binding cavity in a prototypical [GENE]G protein-coupled receptor[\\GENE], bovine rhodopsin.",
        "label": 1,
        "major": 1,
        "len": 35
    },
    {
        "text": "We report herein the location of the binding site for the inhaled anesthetic halothane at the [CHEMICAL]amino acid[\\CHEMICAL] residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, [GENE]bovine rhodopsin[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 35
    },
    {
        "text": "We report herein the location of the binding site for the inhaled anesthetic [CHEMICAL]halothane[\\CHEMICAL] at the amino acid residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, [GENE]bovine rhodopsin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Radiosequence analysis of [CHEMICAL][(14)C]halothane[\\CHEMICAL]-labeled [GENE]rhodopsin[\\GENE] revealed that halothane contacts an amino acid residue (Trp265) lining the ligand binding cavity in the transmembrane core of the receptor.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "We report herein the location of the binding site for the inhaled anesthetic [CHEMICAL]halothane[\\CHEMICAL] at the amino acid residue level of resolution in the ligand binding cavity in a prototypical [GENE]G protein-coupled receptor[\\GENE], bovine rhodopsin.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced [GENE]TNF[\\GENE] release, with the exception of [CHEMICAL]dexamethasone[\\CHEMICAL], was much less pronounced.",
        "label": 2,
        "major": 4,
        "len": 48
    },
    {
        "text": "The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and [CHEMICAL]milrinone[\\CHEMICAL], reduced the [GENE]GM-CSF[\\GENE] release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Amrinone[\\CHEMICAL] and milrinone, selective PDE3 inhibitors, suppressed [GENE]TNF[\\GENE] secretion to a lesser extent.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Amrinone and [CHEMICAL]milrinone[\\CHEMICAL], selective PDE3 inhibitors, suppressed [GENE]TNF[\\GENE] secretion to a lesser extent.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "In human blood, the tested glucocorticoids [CHEMICAL]beclomethasone[\\CHEMICAL], dexamethasone and fluticasone inhibited the LPS induced [GENE]TNF[\\GENE] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "In human blood, the tested glucocorticoids beclomethasone, [CHEMICAL]dexamethasone[\\CHEMICAL] and fluticasone inhibited the LPS induced [GENE]TNF[\\GENE] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 3,
        "len": 48
    },
    {
        "text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and [CHEMICAL]fluticasone[\\CHEMICAL] inhibited the LPS induced [GENE]TNF[\\GENE] release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 3,
        "len": 48
    },
    {
        "text": "The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors [CHEMICAL]amrinone[\\CHEMICAL] and milrinone, reduced the [GENE]GM-CSF[\\GENE] release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The selective [GENE]PDE 4[\\GENE] inhibitors, and to a certain extent the PDE3 inhibitors amrinone and [CHEMICAL]milrinone[\\CHEMICAL], reduced the GM-CSF release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The selective PDE 4 inhibitors, and to a certain extent the [GENE]PDE3[\\GENE] inhibitors amrinone and [CHEMICAL]milrinone[\\CHEMICAL], reduced the GM-CSF release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Amrinone[\\CHEMICAL] and milrinone, selective [GENE]PDE3[\\GENE] inhibitors, suppressed TNF secretion to a lesser extent.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Amrinone and [CHEMICAL]milrinone[\\CHEMICAL], selective [GENE]PDE3[\\GENE] inhibitors, suppressed TNF secretion to a lesser extent.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The effects of [CHEMICAL]theophylline[\\CHEMICAL] (unspecific [GENE]PDE[\\GENE] inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The effects of theophylline (unspecific PDE inhibitor), [CHEMICAL]vinpocetine[\\CHEMICAL] ([GENE]PDE1[\\GENE] inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the [GENE]PDE5[\\GENE] inhibitors [CHEMICAL]zaprinast[\\CHEMICAL] and E 4021 were weak.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the [GENE]PDE5[\\GENE] inhibitors zaprinast and [CHEMICAL]E 4021[\\CHEMICAL] were weak.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In human blood, the tested glucocorticoids [CHEMICAL]beclomethasone[\\CHEMICAL], dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced [GENE]TNF[\\GENE] release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 3,
        "len": 48
    },
    {
        "text": "In human blood, the tested glucocorticoids beclomethasone, [CHEMICAL]dexamethasone[\\CHEMICAL] and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced [GENE]TNF[\\GENE] release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 3,
        "len": 48
    },
    {
        "text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and [CHEMICAL]fluticasone[\\CHEMICAL] inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced [GENE]TNF[\\GENE] release, with the exception of dexamethasone, was much less pronounced.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "The selective [GENE]PDE 4[\\GENE] inhibitors, and to a certain extent the PDE3 inhibitors [CHEMICAL]amrinone[\\CHEMICAL] and milrinone, reduced the GM-CSF release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The selective PDE 4 inhibitors, and to a certain extent the [GENE]PDE3[\\GENE] inhibitors [CHEMICAL]amrinone[\\CHEMICAL] and milrinone, reduced the GM-CSF release in a concentration dependent manner.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with [CHEMICAL]m-CPBG[\\CHEMICAL] were a result of its interaction with [GENE]5-HT3[\\GENE] receptors.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Central [GENE]5-HT3[\\GENE] receptor stimulation by [CHEMICAL]m-CPBG[\\CHEMICAL] increases blood glucose in rats.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Injections of [CHEMICAL]m-CPBG[\\CHEMICAL], a selective [GENE]5-HT3[\\GENE] receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states.",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "The hyperglycemic effect of [CHEMICAL]m-CPBG[\\CHEMICAL] central administration was blocked by pretreatment with ondansetron, a specific [GENE]5-HT3[\\GENE] receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors.",
        "label": 5,
        "major": 2,
        "len": 35
    },
    {
        "text": "OBJECTIVE: We examined the effect of CysLT antagonists ([CHEMICAL]pranlukast[\\CHEMICAL] and MCI-826) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on [GENE]IL-5[\\GENE] activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.",
        "label": 2,
        "major": 3,
        "len": 39
    },
    {
        "text": "OBJECTIVE: We examined the effect of CysLT antagonists (pranlukast and [CHEMICAL]MCI-826[\\CHEMICAL]) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on [GENE]IL-5[\\GENE] activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.",
        "label": 2,
        "major": 3,
        "len": 39
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]CysLTs[\\CHEMICAL] produced after antigen provocation sequentially induced IL-5 production from some immune component cells via [GENE]CysLT1[\\GENE] receptor activation.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Increased [GENE]IL-5[\\GENE] activity in the serum was inhibited by both [CHEMICAL]pranlukast[\\CHEMICAL] and MCI-826 by over 90%.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Increased [GENE]IL-5[\\GENE] activity in the serum was inhibited by both pranlukast and [CHEMICAL]MCI-826[\\CHEMICAL] by over 90%.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Minocycline[\\CHEMICAL] inhibits [GENE]cytochrome c[\\GENE] release and delays progression of amyotrophic lateral sclerosis in mice.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "We find that [CHEMICAL]minocycline[\\CHEMICAL] inhibits mitochondrial permeability-transition-mediated [GENE]cytochrome c[\\GENE] release.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Minocycline[\\CHEMICAL]-mediated inhibition of [GENE]cytochrome c[\\GENE] release is demonstrated in vivo, in cells, and in isolated mitochondria.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "the [GENE]NOS[\\GENE]-catalyzed oxidation of NADPH in the absence of substrate or pterin that does not result in [CHEMICAL]NO[\\CHEMICAL] production.",
        "label": 10,
        "major": 9,
        "len": 19
    },
    {
        "text": "the [GENE]NOS[\\GENE]-catalyzed oxidation of [CHEMICAL]NADPH[\\CHEMICAL] in the absence of substrate or pterin that does not result in NO production.",
        "label": 2,
        "major": 9,
        "len": 19
    },
    {
        "text": "We describe the function of BH4 in aromatic amino acid hydroxylation, and discuss the allosteric and structural effects that [CHEMICAL]BH4[\\CHEMICAL] exerts on [GENE]NOS[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "Ever since the discovery that [CHEMICAL](6R)-5,6,7,8-tetrahydro-L-biopterin[\\CHEMICAL] (BH4) is a cofactor of [GENE]NOS[\\GENE], its function has been the object of intense research and occasional controversy.",
        "label": 8,
        "major": 8,
        "len": 24
    },
    {
        "text": "In this review we aim to provide an outline of the various ways in which [CHEMICAL]BH4[\\CHEMICAL] affects [GENE]NOS[\\GENE] catalysis.",
        "label": 8,
        "major": 9,
        "len": 19
    },
    {
        "text": "Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin ([CHEMICAL]BH4[\\CHEMICAL]) is a cofactor of [GENE]NOS[\\GENE], its function has been the object of intense research and occasional controversy.",
        "label": 8,
        "major": 8,
        "len": 24
    },
    {
        "text": "We also shortly discuss the ongoing debate on whether [CHEMICAL]NO[\\CHEMICAL] is the actual reaction product of [GENE]NOS[\\GENE] catalysis, as well as the phenomenon of NO-mediated autoinhibition.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "CONCLUSIONS: In the maximum registered dosage, [CHEMICAL]nabumetone[\\CHEMICAL] inhibits thromboxane production much more than meloxicam, signifying less [GENE]COX-2[\\GENE] selectivity of the former.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[GENE]COX-1[\\GENE] inhibition was measured as percentage inhibition of serum [CHEMICAL]TXB2[\\CHEMICAL] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Rheumatoid synovial cells expressed [GENE]PPARgamma[\\GENE] mRNA, and the PPARgamma ligands [CHEMICAL]15-deoxy-Delta(12,14)-prostaglandin J(2)[\\CHEMICAL] and troglitazone reduced the proliferation and induced apoptosis in synovial cells.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Rheumatoid synovial cells expressed PPARgamma mRNA, and the [GENE]PPARgamma[\\GENE] ligands [CHEMICAL]15-deoxy-Delta(12,14)-prostaglandin J(2)[\\CHEMICAL] and troglitazone reduced the proliferation and induced apoptosis in synovial cells.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Rheumatoid synovial cells expressed [GENE]PPARgamma[\\GENE] mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and [CHEMICAL]troglitazone[\\CHEMICAL] reduced the proliferation and induced apoptosis in synovial cells.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Rheumatoid synovial cells expressed PPARgamma mRNA, and the [GENE]PPARgamma[\\GENE] ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and [CHEMICAL]troglitazone[\\CHEMICAL] reduced the proliferation and induced apoptosis in synovial cells.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide[\\CHEMICAL] (NS-398), a selective [GENE]cyclooxygenase-2[\\GENE] inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide ([CHEMICAL]NS-398[\\CHEMICAL]), a selective [GENE]cyclooxygenase-2[\\GENE] inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.",
        "label": 4,
        "major": 10,
        "len": 16
    },
    {
        "text": "A hybrid cDNA was created by fusing a human cDNA for [CHEMICAL]amino acids[\\CHEMICAL] 1-101 of [GENE]GAD67[\\GENE] to a human cDNA for amino acids 96-585 of GAD65; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera.",
        "label": 1,
        "major": 1,
        "len": 48
    },
    {
        "text": "A hybrid cDNA was created by fusing a human cDNA for amino acids 1-101 of GAD67 to a human cDNA for [CHEMICAL]amino acids[\\CHEMICAL] 96-585 of [GENE]GAD65[\\GENE]; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera.",
        "label": 1,
        "major": 1,
        "len": 48
    },
    {
        "text": "BACKGROUND AND AIMS: [GENE]Glutamic acid decarboxylase[\\GENE] (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ([GENE]GAD[\\GENE], EC 4.1.1.15) catalyses the conversion of glutamate to [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, [GENE]EC 4.1.1.15[\\GENE]) catalyses the conversion of glutamate to [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: [GENE]Glutamic acid decarboxylase[\\GENE] (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid ([CHEMICAL]GABA[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ([GENE]GAD[\\GENE], EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid ([CHEMICAL]GABA[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, [GENE]EC 4.1.1.15[\\GENE]) catalyses the conversion of glutamate to gamma-aminobutyric acid ([CHEMICAL]GABA[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: [GENE]Glutamic acid decarboxylase[\\GENE] (GAD, EC 4.1.1.15) catalyses the conversion of [CHEMICAL]glutamate[\\CHEMICAL] to gamma-aminobutyric acid (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ([GENE]GAD[\\GENE], EC 4.1.1.15) catalyses the conversion of [CHEMICAL]glutamate[\\CHEMICAL] to gamma-aminobutyric acid (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, [GENE]EC 4.1.1.15[\\GENE]) catalyses the conversion of [CHEMICAL]glutamate[\\CHEMICAL] to gamma-aminobutyric acid (GABA).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "OBJECTIVE: Celecoxib and [CHEMICAL]rofecoxib[\\CHEMICAL] are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [GENE]cyclo-oxygenase-2[\\GENE] (COX-2) isoenzyme at therapeutic concentrations.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "OBJECTIVE: Celecoxib and [CHEMICAL]rofecoxib[\\CHEMICAL] are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ([GENE]COX-2[\\GENE]) isoenzyme at therapeutic concentrations.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "This study was conducted in order to understand the association between acute renal failure and the two [GENE]COX-2[\\GENE] inhibitors [CHEMICAL]celecoxib[\\CHEMICAL] and rofecoxib.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "This study was conducted in order to understand the association between acute renal failure and the two [GENE]COX-2[\\GENE] inhibitors celecoxib and [CHEMICAL]rofecoxib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Celecoxib[\\CHEMICAL] and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [GENE]cyclo-oxygenase-2[\\GENE] (COX-2) isoenzyme at therapeutic concentrations.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Celecoxib[\\CHEMICAL] and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ([GENE]COX-2[\\GENE]) isoenzyme at therapeutic concentrations.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The results reinforce previous assumptions that [CHEMICAL]dopamine[\\CHEMICAL] may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of [GENE]cPLA(2)[\\GENE] and COX-2 in this effect.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The results reinforce previous assumptions that [CHEMICAL]dopamine[\\CHEMICAL] may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of cPLA(2) and [GENE]COX-2[\\GENE] in this effect.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The results reinforce previous assumptions that [CHEMICAL]dopamine[\\CHEMICAL] may interact with eicosanoid metabolism by means of [GENE]D(2) receptor[\\GENE] activation, and implicate an involvement of cPLA(2) and COX-2 in this effect.",
        "label": 3,
        "major": 2,
        "len": 29
    },
    {
        "text": "It was also antagonized by the non-specific [GENE]cyclooxygenase[\\GENE] (COX) inhibitor, [CHEMICAL]indomethacin[\\CHEMICAL], and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "It was also antagonized by the non-specific cyclooxygenase ([GENE]COX[\\GENE]) inhibitor, [CHEMICAL]indomethacin[\\CHEMICAL], and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective [GENE]COX-2[\\GENE] inhibitor, [CHEMICAL]NS-398[\\CHEMICAL], but not by the specific COX-1 inhibitor, valeryl salicylate.",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific [GENE]COX-1[\\GENE] inhibitor, [CHEMICAL]valeryl salicylate[\\CHEMICAL].",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "Both the non-specific [GENE]phospholipase A(2)[\\GENE] inhibitor, [CHEMICAL]quinacrine[\\CHEMICAL], and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The effect was counteracted by the [GENE]D(2)[\\GENE] antagonist [CHEMICAL]eticlopride[\\CHEMICAL], pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.",
        "label": 6,
        "major": 4,
        "len": 35
    },
    {
        "text": "Dopamine D(2) receptor-induced [GENE]COX-2[\\GENE]-mediated production of [CHEMICAL]prostaglandin E(2)[\\CHEMICAL] in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Minocycline[\\CHEMICAL] treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a [GENE]calpain[\\GENE] cleaved substrate, a marker of excitotoxic/necrotic cell death.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Minocycline[\\CHEMICAL] treatment prevents the formation of activated [GENE]caspase-3[\\GENE], a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "A novel SCN5A arrhythmia mutation, [GENE]M1766L[\\GENE], with expression defect rescued by [CHEMICAL]mexiletine[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 12
    },
    {
        "text": "A novel [GENE]SCN5A[\\GENE] arrhythmia mutation, M1766L, with expression defect rescued by [CHEMICAL]mexiletine[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 12
    },
    {
        "text": "In addition to this pronounced loss of function, [GENE]M1766L[\\GENE] also showed a 10-fold increase in the persistent late [CHEMICAL]sodium[\\CHEMICAL] current.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Valdecoxib[\\CHEMICAL] is a potent and specific inhibitor of [GENE]cyclooxygenase-2[\\GENE], which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Disposition of a specific [GENE]cyclooxygenase-2[\\GENE] inhibitor, [CHEMICAL]valdecoxib[\\CHEMICAL], in human.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Thus, [CHEMICAL]bupropion[\\CHEMICAL] acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits [GENE]DAT[\\GENE] and NET function.",
        "label": 4,
        "major": 6,
        "len": 28
    },
    {
        "text": "Thus, [CHEMICAL]bupropion[\\CHEMICAL] acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and [GENE]NET[\\GENE] function.",
        "label": 4,
        "major": 6,
        "len": 28
    },
    {
        "text": "The combination of [GENE]nAChR[\\GENE] and transporter inhibition produced by [CHEMICAL]bupropion[\\CHEMICAL] may contribute to its clinical efficacy as a smoking cessation agent.",
        "label": 4,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Bupropion[\\CHEMICAL], an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters ([GENE]DAT[\\GENE] and NET, respectively).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Bupropion[\\CHEMICAL], an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and [GENE]NET[\\GENE], respectively).",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "To eliminate the interaction of [CHEMICAL]bupropion[\\CHEMICAL] with [GENE]DAT[\\GENE] or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.",
        "label": 4,
        "major": 2,
        "len": 20
    },
    {
        "text": "To eliminate the interaction of [CHEMICAL]bupropion[\\CHEMICAL] with DAT or [GENE]NET[\\GENE], nomifensine or desipramine, respectively, was included in the superfusion buffer.",
        "label": 4,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] is not metabolized by [GENE]cytochrome P450[\\GENE] enzymes and therefore has a low potential for metabolic drug interactions, which may be of importance when treating the elderly and patients on multiple drugs.",
        "label": 10,
        "major": 10,
        "len": 32
    },
    {
        "text": "Angiotensin II receptor antagonists block [GENE]angiotensin II type 1 (AT1) receptors[\\GENE] and reduce the pressor effects of [CHEMICAL]angiotensin[\\CHEMICAL] in the vasculature.",
        "label": 2,
        "major": 6,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts not only at vascular [GENE]AT1[\\GENE] receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts not only at vascular AT1 receptors but also at presynaptic [GENE]AT1[\\GENE] receptors, causing inhibition of sympathetically stimulated noradrenaline release.",
        "label": 2,
        "major": 10,
        "len": 21
    },
    {
        "text": "In clinical trials [CHEMICAL]eprosartan[\\CHEMICAL] has proven to be at least as effective as the [GENE]ACE[\\GENE] inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Moreover, in rat hepatoma H4-II-E cells, the esterified-[CHEMICAL]BM[\\CHEMICAL] failed to induce [GENE]tyrosine aminotransferase[\\GENE], which is regulated by GR-mediated transactivation activity.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "Species-specific differences in the [GENE]glucocorticoid receptor[\\GENE] transactivation function upon binding with [CHEMICAL]betamethasone-esters[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with [GENE]rat GR[\\GENE], whereas [CHEMICAL]BM[\\CHEMICAL] and esterified-DEX had full transactivation agonistic activity.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with [GENE]rat GR[\\GENE], whereas BM and esterified-[CHEMICAL]DEX[\\CHEMICAL] had full transactivation agonistic activity.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "Moreover, in rat hepatoma H4-II-E cells, the esterified-[CHEMICAL]BM[\\CHEMICAL] failed to induce tyrosine aminotransferase, which is regulated by [GENE]GR[\\GENE]-mediated transactivation activity.",
        "label": 5,
        "major": 3,
        "len": 20
    },
    {
        "text": "Consistent with the weak transactivation activity of esterified-[CHEMICAL]BM[\\CHEMICAL] mediated by [GENE]rat GR[\\GENE], there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats.",
        "label": 5,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [GENE]human or rat GR[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DEX[\\CHEMICAL]), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [GENE]human or rat GR[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Dexamethasone (DEX), [CHEMICAL]betamethasone[\\CHEMICAL] (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [GENE]human or rat GR[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Dexamethasone (DEX), betamethasone ([CHEMICAL]BM[\\CHEMICAL]), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either [GENE]human or rat GR[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "The esterified-[CHEMICAL]BM[\\CHEMICAL], however, had only partial transactivation agonistic activity in cells transfected with [GENE]rat GR[\\GENE], whereas BM and esterified-DEX had full transactivation agonistic activity.",
        "label": 5,
        "major": 3,
        "len": 24
    },
    {
        "text": "Among the [Fe-S] cluster biosynthetic proteins are included a [CHEMICAL]pyridoxal phosphate[\\CHEMICAL]-dependent enzyme ([GENE]NifS[\\GENE]) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",
        "label": 8,
        "major": 3,
        "len": 36
    },
    {
        "text": "Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ([GENE]NifS[\\GENE]) that is involved in the activation of sulphur from [CHEMICAL]l-cysteine[\\CHEMICAL], and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [CHEMICAL][(125)I] RTI-55[\\CHEMICAL] at HEK-[GENE]hDAT[\\GENE], HEK-hSERT, and HEK-hNET cells.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [CHEMICAL][(125)I] RTI-55[\\CHEMICAL] at HEK-hDAT, HEK-[GENE]hSERT[\\GENE], and HEK-hNET cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [CHEMICAL][(125)I] RTI-55[\\CHEMICAL] at HEK-hDAT, HEK-hSERT, and HEK-[GENE]hNET[\\GENE] cells.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "A series of [CHEMICAL]mazindol[\\CHEMICAL] (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of [CHEMICAL]mazindol[\\CHEMICAL] (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant [CHEMICAL]aryl[\\CHEMICAL] group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant [CHEMICAL]aryl[\\CHEMICAL] group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the [CHEMICAL]benzo[\\CHEMICAL] ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the [CHEMICAL]benzo[\\CHEMICAL] ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, [CHEMICAL]methoxy[\\CHEMICAL], and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, [CHEMICAL]methoxy[\\CHEMICAL], and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and [CHEMICAL]alkyl[\\CHEMICAL] groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and [CHEMICAL]alkyl[\\CHEMICAL] groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the [CHEMICAL]hydroxyl[\\CHEMICAL] group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the [CHEMICAL]hydroxyl[\\CHEMICAL] group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and [CHEMICAL]homomazindol[\\CHEMICAL] (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the [GENE]dopamine transporter[\\GENE] (DAT) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "A series of mazindol (2) and [CHEMICAL]homomazindol[\\CHEMICAL] (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter ([GENE]DAT[\\GENE]) on rat or guinea pig striatal membranes were determined.",
        "label": 2,
        "major": 2,
        "len": 59
    },
    {
        "text": "[CHEMICAL]Mazindol[\\CHEMICAL] analogues as potential inhibitors of the [GENE]cocaine binding site[\\GENE] at the dopamine transporter.",
        "label": 4,
        "major": 2,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Mazindol[\\CHEMICAL] analogues as potential inhibitors of the cocaine binding site at the [GENE]dopamine transporter[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of DA, [CHEMICAL]5-HT[\\CHEMICAL], and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-[GENE]hSERT[\\GENE], and HEK-hNET cells.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and [CHEMICAL]NE[\\CHEMICAL] and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-[GENE]hNET[\\GENE] cells.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Mazindol analogues as potential inhibitors of the cocaine binding site at the [CHEMICAL]dopamine[\\CHEMICAL][GENE]dopamine transporter[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 14
    },
    {
        "text": "Several active analogues were also evaluated for their ability to block uptake of [CHEMICAL]DA[\\CHEMICAL], 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-[GENE]hDAT[\\GENE], HEK-hSERT, and HEK-hNET cells.",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the [GENE]K(IR)[\\GENE] [CHEMICAL]N[\\CHEMICAL] terminus and L0 of SUR1 are in proximity.",
        "label": 1,
        "major": 4,
        "len": 35
    },
    {
        "text": "We hypothesize that L0 interacts with the [GENE]K(IR)[\\GENE] [CHEMICAL]N[\\CHEMICAL] terminus in ligand-inhibited K(ATP) channels and put forward a model, based on the architecture of BtuCD, MsbA, and the KcsA channel, in which TMD0-L0 links the MDR-like core of SUR with the K(IR) pore.",
        "label": 1,
        "major": 2,
        "len": 43
    },
    {
        "text": "These effects resemble those seen with [CHEMICAL]N[\\CHEMICAL]-terminal deletions (DeltaN) of [GENE]K(IR)6.0[\\GENE], and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+).",
        "label": 1,
        "major": 4,
        "len": 31
    },
    {
        "text": "SUR-dependent modulation of KATP channels by an [CHEMICAL]N[\\CHEMICAL]-terminal [GENE]KIR6.2[\\GENE] peptide.",
        "label": 1,
        "major": 7,
        "len": 10
    },
    {
        "text": "The L0 linker has been reported to be required for glibenclamide binding, and [GENE]DeltaNK(IR)6.2[\\GENE]/SUR1 channels exhibit reduced labeling of K(IR) with [CHEMICAL](125)I-azidoglibenclamide[\\CHEMICAL], implying that the K(IR) N terminus and L0 of SUR1 are in proximity.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/[GENE]SUR1[\\GENE] channels exhibit reduced labeling of K(IR) with [CHEMICAL](125)I-azidoglibenclamide[\\CHEMICAL], implying that the K(IR) N terminus and L0 of SUR1 are in proximity.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of [GENE]K(IR)[\\GENE] with [CHEMICAL](125)I-azidoglibenclamide[\\CHEMICAL], implying that the K(IR) N terminus and L0 of SUR1 are in proximity.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity [CHEMICAL]sulfonylurea[\\CHEMICAL] binding with [GENE]K(ATP)[\\GENE] pore closure.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the [CHEMICAL]ATP[\\CHEMICAL] inhibition of [GENE]K(IR)6.2[\\GENE]/SUR1, but had no effect on homomeric K(IR)6.2 channels.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the [CHEMICAL]ATP[\\CHEMICAL] inhibition of K(IR)6.2/[GENE]SUR1[\\GENE], but had no effect on homomeric K(IR)6.2 channels.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to [GENE]DeltaNK(ATP) channels[\\GENE] decreased their P(O(max)) and apparent IC(50) for [CHEMICAL]ATP[\\CHEMICAL] in the absence of Mg(2+).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits iNOS independent of [GENE]PPAR-alpha[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Interestingly, [CHEMICAL]gemfibrozil[\\CHEMICAL] strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in [GENE]cytokine[\\GENE]-stimulated astroglial cells.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "Since [CHEMICAL]gemfibrozil[\\CHEMICAL] is known to activate [GENE]peroxisome proliferator-activated receptor-alpha[\\GENE] (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Since [CHEMICAL]gemfibrozil[\\CHEMICAL] is known to activate peroxisome proliferator-activated receptor-alpha ([GENE]PPAR-alpha[\\GENE]), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of [GENE]PPAR-alpha[\\GENE] in [CHEMICAL]gemfibrozil[\\CHEMICAL]-mediated inhibition of iNOS.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL] induced [GENE]peroxisome proliferator-responsive element[\\GENE] (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.",
        "label": 3,
        "major": 1,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL] induced peroxisome proliferator-responsive element ([GENE]PPRE[\\GENE])-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.",
        "label": 3,
        "major": 1,
        "len": 22
    },
    {
        "text": "Inhibition of human iNOS promoter-driven luciferase activity by [CHEMICAL]gemfibrozil[\\CHEMICAL] in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL], a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [GENE]inducible nitric-oxide synthase[\\GENE] (iNOS) in human U373MG astroglial cells and primary astrocytes.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL], a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase ([GENE]iNOS[\\GENE]) in human U373MG astroglial cells and primary astrocytes.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Similar to [CHEMICAL]gemfibrozil[\\CHEMICAL], clofibrate, another fibrate drug, also inhibited the expression of [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 10,
        "len": 13
    },
    {
        "text": "Similar to gemfibrozil, [CHEMICAL]clofibrate[\\CHEMICAL], another fibrate drug, also inhibited the expression of [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Similar to gemfibrozil, clofibrate, another [CHEMICAL]fibrate[\\CHEMICAL] drug, also inhibited the expression of [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Inhibition of [GENE]human iNOS promoter[\\GENE]-driven luciferase activity by [CHEMICAL]gemfibrozil[\\CHEMICAL] in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in [CHEMICAL]gemfibrozil[\\CHEMICAL]-mediated inhibition of [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "However, DeltahPPAR-alpha was unable to abrogate [CHEMICAL]gemfibrozil[\\CHEMICAL]-mediated inhibition of [GENE]iNOS[\\GENE] suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits [GENE]iNOS[\\GENE] independent of PPAR-alpha.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL], a lipid-lowering drug, inhibits the induction of [GENE]nitric-oxide synthase[\\GENE] in human astrocytes.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Gemfibrozil[\\CHEMICAL], a lipid-lowering drug, inhibited [GENE]cytokine[\\GENE]-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "Interestingly, [CHEMICAL]gemfibrozil[\\CHEMICAL] strongly inhibited the activation of [GENE]NF-kappaB[\\GENE], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Interestingly, [CHEMICAL]gemfibrozil[\\CHEMICAL] strongly inhibited the activation of NF-kappaB, [GENE]AP-1[\\GENE], and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Interestingly, [CHEMICAL]gemfibrozil[\\CHEMICAL] strongly inhibited the activation of NF-kappaB, AP-1, and [GENE]C/EBPbeta[\\GENE] but not that of GAS in cytokine-stimulated astroglial cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "These results suggest that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits the induction of [GENE]iNOS[\\GENE] probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "These results suggest that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits the induction of iNOS probably by inhibiting the activation of [GENE]NF-kappaB[\\GENE], AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "These results suggest that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, [GENE]AP-1[\\GENE], and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "These results suggest that [CHEMICAL]gemfibrozil[\\CHEMICAL] inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and [GENE]C/EBPbeta[\\GENE] and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of [CHEMICAL]NO[\\CHEMICAL] and the expression of [GENE]inducible nitric-oxide synthase[\\GENE] (iNOS) in human U373MG astroglial cells and primary astrocytes.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of [CHEMICAL]NO[\\CHEMICAL] and the expression of inducible nitric-oxide synthase ([GENE]iNOS[\\GENE]) in human U373MG astroglial cells and primary astrocytes.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "Gemfibrozil, a lipid-lowering drug, inhibits the induction of [CHEMICAL]nitric-oxide[\\CHEMICAL][GENE]nitric-oxide synthase[\\GENE] in human astrocytes.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [GENE]inducible nitric-oxide synthase[\\GENE][CHEMICAL]nitric-oxide[\\CHEMICAL] synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible [CHEMICAL]nitric-oxide[\\CHEMICAL] synthase ([GENE]iNOS[\\GENE]) in human U373MG astroglial cells and primary astrocytes.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "These conclusions are surprising when one considers that the potent interaction of [CHEMICAL]lisuride[\\CHEMICAL] with [GENE]5-HT(1A)[\\GENE] receptors has been demonstrated in several different laboratories and that activation of 5-HT(1A) and 5-HT(1B) receptors can modulate dopaminergically mediated responses.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "RATIONALE: There is substantial evidence that [CHEMICAL]lisuride[\\CHEMICAL] can produce effects linked to [GENE]5-HT(1A)[\\GENE] receptor occupancy.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "Nevertheless, this action has generally been ignored in the mechanism of action of [CHEMICAL]lisuride[\\CHEMICAL], in favor of an exclusive role for [GENE]dopamine receptors[\\GENE] in considering its antiparkinsonian effects, or an exclusive role of 5-HT(2A/2C) receptor activation in hallucinogenesis.",
        "label": 2,
        "major": 3,
        "len": 38
    },
    {
        "text": "CONCLUSION: We have demonstrated that the behavioral effects of low doses of [CHEMICAL]lisuride[\\CHEMICAL] are clearly mediated by stimulation of [GENE]5-HT(1A)[\\GENE] receptors.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Lisuride[\\CHEMICAL] produced a significant dose-related increase in flat body posture, forepaw treading, and lower-lip retraction which reflect a modulation of behavior by action at central [GENE]5-HT(1A)[\\GENE] receptors.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective [GENE]5-HT(1A)[\\GENE] agonist [CHEMICAL]LY 293284[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 21
    },
    {
        "text": "RESULTS: In drug discrimination studies, [CHEMICAL]lisuride[\\CHEMICAL] fully mimicked the [GENE]5-HT(1A)[\\GENE] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "RESULTS: In drug discrimination studies, lisuride fully mimicked the [GENE]5-HT(1A)[\\GENE] agonist [CHEMICAL]LY 293284[\\CHEMICAL], only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Only pMPPI [[CHEMICAL]4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride[\\CHEMICAL]], a selective [GENE]5-HT(1A)[\\GENE] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.",
        "label": 6,
        "major": 3,
        "len": 30
    },
    {
        "text": "We hypothesized that the [CHEMICAL]HED[\\CHEMICAL] compounds would be most potent at the [GENE]norepinephrine transporter[\\GENE] (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "We hypothesized that the [CHEMICAL]HED[\\CHEMICAL] compounds would be most potent at the norepinephrine transporter ([GENE]NET[\\GENE]) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "Stereospecific inhibition of [GENE]monoamine uptake transporters[\\GENE] by [CHEMICAL]meta-hydroxyephedrine[\\CHEMICAL] isomers.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "To extend structure-activity analyses of binding sites within [GENE]monoamine transporters[\\GENE] and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the [CHEMICAL]HED[\\CHEMICAL] compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In addition, [CHEMICAL]escitalopram[\\CHEMICAL] has negligible effects on [GENE]cytochrome P450[\\GENE] drug-metabolising enzymes in vitro, suggesting a low potential for drug-drug interactions.",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that [CHEMICAL]escitalopram[\\CHEMICAL] binds with high affinity to the [GENE]human serotonin transporter[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "In contrast, an [CHEMICAL]NH(2)[\\CHEMICAL]-terminal deletion mutant of [GENE]K8[\\GENE] promoted the formation of intracellular aggregates even in the absence of K18 overexpression.",
        "label": 1,
        "major": 1,
        "len": 21
    },
    {
        "text": "Culture of HepG2 cells with [CHEMICAL]griseofulvin[\\CHEMICAL] has now been shown to induce both the formation of intracellular aggregates containing [GENE]K18[\\GENE] as well as an increase in the abundance of K18 mRNA.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Culture of HepG2 cells with [CHEMICAL]griseofulvin[\\CHEMICAL] has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of [GENE]K18[\\GENE] mRNA.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the [GENE]5-LOX[\\GENE] inhibitor [CHEMICAL]REV 5901[\\CHEMICAL]; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the [GENE]5-LOX activating protein[\\GENE] (FLAP) inhibitor [CHEMICAL]MK-886[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ([GENE]FLAP[\\GENE]) inhibitor [CHEMICAL]MK-886[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the [GENE]COX-2[\\GENE] inhibitor [CHEMICAL]NS-398[\\CHEMICAL]; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed [GENE]COX-1[\\GENE]/COX-2 inhibitor [CHEMICAL]ibuprofen[\\CHEMICAL]; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/[GENE]COX-2[\\GENE] inhibitor [CHEMICAL]ibuprofen[\\CHEMICAL]; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, [CHEMICAL]p-chlorophenylalanine[\\CHEMICAL] or MDMA was administered to rats, and brain serotonin and [GENE]SERT[\\GENE] density were measured.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or [CHEMICAL]MDMA[\\CHEMICAL] was administered to rats, and brain serotonin and [GENE]SERT[\\GENE] density were measured.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "This observation suggests that [CHEMICAL]MDMA[\\CHEMICAL]-induced reductions in [GENE]SERT[\\GENE] density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Low levels of [CHEMICAL]serotonin[\\CHEMICAL] may reduce the density of the [GENE]serotonin transporter[\\GENE] (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Low levels of [CHEMICAL]serotonin[\\CHEMICAL] may reduce the density of the serotonin transporter ([GENE]SERT[\\GENE]) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\".",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "To determine whether [CHEMICAL]3,4-methylenedioxymethamphetamine[\\CHEMICAL] (MDMA)-induced reductions in [GENE]SERT[\\GENE] density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To determine whether 3,4-methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL])-induced reductions in [GENE]SERT[\\GENE] density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "However, only [CHEMICAL]MDMA[\\CHEMICAL] reduced [GENE]SERT[\\GENE] density.",
        "label": 4,
        "major": 4,
        "len": 6
    },
    {
        "text": "We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of [CHEMICAL]atomoxetine[\\CHEMICAL] with [GENE]monoamine transporters[\\GENE], the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Atomoxetine[\\CHEMICAL] inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for [GENE]NE transporters[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of [CHEMICAL]atomoxetine[\\CHEMICAL] with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker [GENE]Fos[\\GENE] in brain regions.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "The expression of the neuronal activity marker [GENE]Fos[\\GENE] was increased 3.7-fold in PFC by [CHEMICAL]atomoxetine[\\CHEMICAL] administration, but was not increased in the striatum or nucleus accumbens, consistent with the regional distribution of increased DA(EX).",
        "label": 2,
        "major": 10,
        "len": 34
    },
    {
        "text": "The selective [GENE]norepinephrine (NE) transporter[\\GENE] inhibitor [CHEMICAL]atomoxetine[\\CHEMICAL] (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).",
        "label": 4,
        "major": 9,
        "len": 23
    },
    {
        "text": "The selective [GENE]norepinephrine (NE) transporter[\\GENE] inhibitor atomoxetine (formerly called [CHEMICAL]tomoxetine[\\CHEMICAL] or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).",
        "label": 4,
        "major": 9,
        "len": 23
    },
    {
        "text": "The selective [GENE]norepinephrine (NE) transporter[\\GENE] inhibitor atomoxetine (formerly called tomoxetine or [CHEMICAL]LY139603[\\CHEMICAL]) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).",
        "label": 4,
        "major": 9,
        "len": 23
    },
    {
        "text": "Reserpine-induced ptosis was reversed by [CHEMICAL]rasagiline[\\CHEMICAL] at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at [GENE]MAO-B[\\GENE]-selective doses.",
        "label": 10,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit [GENE]MAO-B[\\GENE] but not MAO-A.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not [GENE]MAO-A[\\GENE].",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible [GENE]monoamine oxidase[\\GENE] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase ([GENE]MAO[\\GENE]) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Rasagiline [N-propargyl-1R(+)-aminoindan; [CHEMICAL]TVP1012[\\CHEMICAL]] is a potent irreversible [GENE]monoamine oxidase[\\GENE] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Rasagiline [N-propargyl-1R(+)-aminoindan; [CHEMICAL]TVP1012[\\CHEMICAL]] is a potent irreversible monoamine oxidase ([GENE]MAO[\\GENE]) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Reserpine-induced ptosis was reversed by [CHEMICAL]rasagiline[\\CHEMICAL] at doses above 2 mg x kg(-1) i.p., which inhibit [GENE]MAO-A[\\GENE] as well as MAO-B, but not at MAO-B-selective doses.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Reserpine-induced ptosis was reversed by [CHEMICAL]rasagiline[\\CHEMICAL] at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as [GENE]MAO-B[\\GENE], but not at MAO-B-selective doses.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both [GENE]MAO-A[\\GENE] and MAO-B by [CHEMICAL]tranylcypromine[\\CHEMICAL] together with the monoamine precursors.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and [GENE]MAO-B[\\GENE] by [CHEMICAL]tranylcypromine[\\CHEMICAL] together with the monoamine precursors.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both [GENE]MAO-A[\\GENE] and MAO-B by tranylcypromine together with the [CHEMICAL]monoamine[\\CHEMICAL] precursors.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and [GENE]MAO-B[\\GENE] by tranylcypromine together with the [CHEMICAL]monoamine[\\CHEMICAL] precursors.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Rasagiline [[CHEMICAL]N-propargyl-1R(+)-aminoindan[\\CHEMICAL]; TVP1012] is a potent irreversible [GENE]monoamine oxidase[\\GENE] (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Rasagiline [[CHEMICAL]N-propargyl-1R(+)-aminoindan[\\CHEMICAL]; TVP1012] is a potent irreversible monoamine oxidase ([GENE]MAO[\\GENE]) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding [GENE]gamma-glutamyl kinase[\\GENE], which resulted in a single [CHEMICAL]amino acid[\\CHEMICAL] replacement; Asp (GAC) at position 154 was replaced by Asn (AAC).",
        "label": 1,
        "major": 1,
        "len": 44
    },
    {
        "text": "By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding [GENE]gamma-glutamyl kinase[\\GENE], which resulted in a single amino acid replacement; [CHEMICAL]Asp[\\CHEMICAL] (GAC) at position 154 was replaced by Asn (AAC).",
        "label": 1,
        "major": 1,
        "len": 44
    },
    {
        "text": "By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding [GENE]gamma-glutamyl kinase[\\GENE], which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by [CHEMICAL]Asn[\\CHEMICAL] (AAC).",
        "label": 1,
        "major": 1,
        "len": 44
    },
    {
        "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of [GENE]gamma-glutamyl kinase[\\GENE] and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of [CHEMICAL]L-proline[\\CHEMICAL] synthesis from L-glutamate and which together may form a complex in vivo.",
        "label": 9,
        "major": 4,
        "len": 40
    },
    {
        "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and [GENE]gamma-glutamyl phosphate reductase[\\GENE], both of which catalyze the first two steps of [CHEMICAL]L-proline[\\CHEMICAL] synthesis from L-glutamate and which together may form a complex in vivo.",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "[CHEMICAL]L-proline[\\CHEMICAL] accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding [GENE]gamma-glutamyl kinase[\\GENE].",
        "label": 9,
        "major": 1,
        "len": 20
    },
    {
        "text": "When cultured in liquid minimal medium, yeast cells expressing the mutated [GENE]gamma-glutamyl kinase[\\GENE] were found to accumulate intracellular [CHEMICAL]L-proline[\\CHEMICAL] and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene.",
        "label": 9,
        "major": 1,
        "len": 44
    },
    {
        "text": "These results suggest that the altered [GENE]gamma-glutamyl kinase[\\GENE] results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in [CHEMICAL]L-proline[\\CHEMICAL] production in Saccharomyces cerevisiae.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on [GENE]gamma-glutamyl phosphate reductase[\\GENE] activity, which leads to an increase in [CHEMICAL]L-proline[\\CHEMICAL] production in Saccharomyces cerevisiae.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of [GENE]gamma-glutamyl kinase[\\GENE] and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from [CHEMICAL]L-glutamate[\\CHEMICAL] and which together may form a complex in vivo.",
        "label": 9,
        "major": 4,
        "len": 40
    },
    {
        "text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and [GENE]gamma-glutamyl phosphate reductase[\\GENE], both of which catalyze the first two steps of L-proline synthesis from [CHEMICAL]L-glutamate[\\CHEMICAL] and which together may form a complex in vivo.",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts at vascular [GENE]AT(1) receptors[\\GENE] (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated noradrenaline release.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts at vascular AT(1) receptors (postsynaptically) and at presynaptic [GENE]AT(1) receptors[\\GENE], where it inhibits sympathetically stimulated noradrenaline release.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of [GENE]AII[\\GENE] blockers, [CHEMICAL]eprosartan[\\CHEMICAL] differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.",
        "label": 4,
        "major": 6,
        "len": 66
    },
    {
        "text": "In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the [GENE]ACE[\\GENE] inhibitor [CHEMICAL]enalapril[\\CHEMICAL], and has significantly lower side effects.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Racemization of serine is catalyzed by [GENE]serine racemase[\\GENE], a [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL]-dependent enzyme expressed mainly in brain and liver.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Mouse brain serine racemase[\\GENE] catalyzes specific elimination of L-serine to [CHEMICAL]pyruvate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "[GENE]Mouse brain serine racemase[\\GENE] catalyzes specific elimination of [CHEMICAL]L-serine[\\CHEMICAL] to pyruvate.",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "Racemization of [CHEMICAL]serine[\\CHEMICAL] is catalyzed by [GENE]serine racemase[\\GENE], a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce [GENE]ERK1/2[\\GENE] and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.",
        "label": 10,
        "major": 4,
        "len": 26
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not [GENE]ERK1/2[\\GENE] protein levels.",
        "label": 10,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibits epidermal growth factor-induced phosphorylation of [GENE]extracellular-regulated kinase 1/2[\\GENE] and Bad in human colon cancer cells.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce [GENE]ERK1/2[\\GENE] and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not [GENE]ERK1/2[\\GENE] protein levels.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit [GENE]ERK1/2[\\GENE] phosphorylation in human colon cancer cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total [GENE]Bad[\\GENE] but not ERK1/2 protein levels.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "The ability of [CHEMICAL]sulindac[\\CHEMICAL] to block [GENE]ERK1/2[\\GENE] signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with [CHEMICAL]U0126[\\CHEMICAL], a selective [GENE]MAP kinase kinase (MKK)1/2[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[GENE]EGF[\\GENE]-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with [CHEMICAL]U0126[\\CHEMICAL], a selective MAP kinase kinase (MKK)1/2 inhibitor.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "EGF-stimulated phosphorylation of [GENE]ERK[\\GENE] and Bad is blocked by pretreatment with [CHEMICAL]U0126[\\CHEMICAL], a selective MAP kinase kinase (MKK)1/2 inhibitor.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "EGF-stimulated phosphorylation of ERK and [GENE]Bad[\\GENE] is blocked by pretreatment with [CHEMICAL]U0126[\\CHEMICAL], a selective MAP kinase kinase (MKK)1/2 inhibitor.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of [GENE]EGF[\\GENE] to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "Similarly, pretreatment with [CHEMICAL]sulindac sulfide[\\CHEMICAL] blocks the ability of EGF to induce ERK1/2 and [GENE]Bad[\\GENE] phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "The ability of [CHEMICAL]sulindac[\\CHEMICAL] to block ERK1/2 signaling by the [GENE]EGF receptor[\\GENE] may account for at least part of its potent growth-inhibitory effects against cancer cells.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] and selective [GENE]cyclooxygenase (COX)-2[\\GENE] inhibitors cause regression of colonic polyps in familial polyposis patients.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and [GENE]Bad[\\GENE] in human colon cancer cells.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibits [GENE]epidermal growth factor[\\GENE]-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "db/db mice treated with [CHEMICAL]DRF 2655[\\CHEMICAL] showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes [GENE]carnitine palmitoyltransferase[\\GENE] and carnitine acetyltransferase, respectively.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "db/db mice treated with [CHEMICAL]DRF 2655[\\CHEMICAL] showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and [GENE]carnitine acetyltransferase[\\GENE], respectively.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "db/db mice treated with [CHEMICAL]DRF 2655[\\CHEMICAL] showed 5- and 3.6-fold inhibition in [GENE]phosphoenolpyruvate carboxykinase[\\GENE] and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "db/db mice treated with [CHEMICAL]DRF 2655[\\CHEMICAL] showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and [GENE]glucose 6-phosphatase[\\GENE] activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "RESULTS: [CHEMICAL]DRF 2655[\\CHEMICAL] showed concentration-dependent transactivation of [GENE]PPARalpha[\\GENE] and PPARgamma.",
        "label": 5,
        "major": 3,
        "len": 10
    },
    {
        "text": "RESULTS: [CHEMICAL]DRF 2655[\\CHEMICAL] showed concentration-dependent transactivation of PPARalpha and [GENE]PPARgamma[\\GENE].",
        "label": 5,
        "major": 3,
        "len": 10
    },
    {
        "text": "OBJECTIVE: Preclinical evaluation of [CHEMICAL]DRF 2655[\\CHEMICAL], a peroxisome proliferator-activated receptor alpha (PPARalpha) and [GENE]PPARgamma[\\GENE] agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
        "label": 5,
        "major": 3,
        "len": 23
    },
    {
        "text": "OBJECTIVE: Preclinical evaluation of [CHEMICAL]DRF 2655[\\CHEMICAL], a [GENE]peroxisome proliferator-activated receptor alpha[\\GENE] (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
        "label": 5,
        "major": 3,
        "len": 23
    },
    {
        "text": "OBJECTIVE: Preclinical evaluation of [CHEMICAL]DRF 2655[\\CHEMICAL], a peroxisome proliferator-activated receptor alpha ([GENE]PPARalpha[\\GENE]) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "With the use of [CHEMICAL]sildenafil[\\CHEMICAL], it has been clearly, clinically demonstrated that the selective inhibition of [GENE]PDE5[\\GENE] is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of [CHEMICAL]sildenafil[\\CHEMICAL] (Viagra, Pfizer) - the first approved selective [GENE]PDE[\\GENE] inhibitor for the treatment of ED.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil ([CHEMICAL]Viagra[\\CHEMICAL], Pfizer) - the first approved selective [GENE]PDE[\\GENE] inhibitor for the treatment of ED.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] is inhibitory of [GENE]PDE5[\\GENE] at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] is inhibitory of PDE5 at a rate tenfold higher than for the next [GENE]PDE[\\GENE] (PDE6), which produces visual changes through the retinal rods.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] is inhibitory of PDE5 at a rate tenfold higher than for the next PDE ([GENE]PDE6[\\GENE]), which produces visual changes through the retinal rods.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of [GENE]PDE5[\\GENE] that breaks down [CHEMICAL]cGMP[\\CHEMICAL], the key pathway for the production of erectile function in humans.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL]L-nor-okadaone[\\CHEMICAL] (0.001 pg/mouse-1 ng/mouse, i.c.v. ), an analogue of okadaic acid lacking activity against [GENE]protein phosphatases[\\GENE], did not affect the antinociceptive effect of morphine.",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "), an analogue of [CHEMICAL]okadaic acid[\\CHEMICAL] lacking activity against [GENE]protein phosphatases[\\GENE], did not affect the antinociceptive effect of morphine.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Neither [CHEMICAL]okadaic acid[\\CHEMICAL] nor cantharidin (1-10000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the [GENE]opioid receptor[\\GENE] level.",
        "label": 10,
        "major": 2,
        "len": 26
    },
    {
        "text": "Neither okadaic acid nor [CHEMICAL]cantharidin[\\CHEMICAL] (1-10000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the [GENE]opioid receptor[\\GENE] level.",
        "label": 10,
        "major": 2,
        "len": 26
    },
    {
        "text": "Neither okadaic acid nor cantharidin (1-10000 nM) displaced [CHEMICAL][3H]naloxone[\\CHEMICAL] from its specific binding sites, which indicates that they do not interact at the [GENE]opioid receptor[\\GENE] level.",
        "label": 10,
        "major": 2,
        "len": 26
    },
    {
        "text": "These results suggest that the activation of [GENE]type 2A serine/threonine protein phosphatases[\\GENE] may play a role in the antinociceptive effect of [CHEMICAL]morphine[\\CHEMICAL], and that PP1 might counterbalace this activity.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "administration of very low doses of [CHEMICAL]okadaic acid[\\CHEMICAL] (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit [GENE]PP2A[\\GENE], produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "administration of very low doses of okadaic acid (0.001-1 pg/mouse) and [CHEMICAL]cantharidin[\\CHEMICAL] (0.001-1 ng/mouse), which inhibit [GENE]PP2A[\\GENE], produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).",
        "label": 4,
        "major": 6,
        "len": 28
    },
    {
        "text": "), which also block PP1, and [CHEMICAL]calyculin-A[\\CHEMICAL] (0.1 fg/mouse-1 ng/mouse, i.c.v. ), which inhibits equally both [GENE]PP1[\\GENE] and PP2A, did not modify the morphine-induced antinociception.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "), which also block PP1, and [CHEMICAL]calyculin-A[\\CHEMICAL] (0.1 fg/mouse-1 ng/mouse, i.c.v. ), which inhibits equally both PP1 and [GENE]PP2A[\\GENE], did not modify the morphine-induced antinociception.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Their deduced amino acid sequences show a high degree of conservation compared with orthologues from other mammalian species, with the notable exception of the [CHEMICAL]N[\\CHEMICAL]-terminus of [GENE]ovine M-CPT 1[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 29
    },
    {
        "text": "Expression in yeast allowed kinetic characterization of the two native enzymes, and of a chimaera in which the distinctive [CHEMICAL]N[\\CHEMICAL]-terminal segment of [GENE]ovine M-CPT 1[\\GENE] was replaced with that from rat M-CPT 1.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "The beta subunit has been cloned and shown to lower the K(m) of [GENE]methionine adenosyltransferase II alpha2[\\GENE] (the MAT2A product) for methionine and to render the enzyme more susceptible to [CHEMICAL]S-adenosylmethionine[\\CHEMICAL] inhibition.",
        "label": 4,
        "major": 9,
        "len": 32
    },
    {
        "text": "The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the [GENE]MAT2A[\\GENE] product) for methionine and to render the enzyme more susceptible to [CHEMICAL]S-adenosylmethionine[\\CHEMICAL] inhibition.",
        "label": 4,
        "major": 9,
        "len": 32
    },
    {
        "text": "The beta subunit has been cloned and shown to lower the K(m) of [GENE]methionine adenosyltransferase II alpha2[\\GENE] (the MAT2A product) for [CHEMICAL]methionine[\\CHEMICAL] and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the [GENE]MAT2A[\\GENE] product) for [CHEMICAL]methionine[\\CHEMICAL] and to render the enzyme more susceptible to S-adenosylmethionine inhibition.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "However, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations causes slow inhibition of [GENE]GluR5[\\GENE] kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations causes slow inhibition of GluR5 [GENE]kainate receptor[\\GENE]-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of [GENE]GluR5[\\GENE] kainate receptor responses.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 [GENE]kainate receptor[\\GENE] responses.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the [GENE]GluR5[\\GENE] kainate receptor antagonist [CHEMICAL]LY293558[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 [GENE]kainate receptor[\\GENE] antagonist [CHEMICAL]LY293558[\\CHEMICAL].",
        "label": 6,
        "major": 5,
        "len": 21
    },
    {
        "text": "Purified [GENE]PAOh1[\\GENE]/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize [CHEMICAL]spermidine[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 16
    },
    {
        "text": "Purified PAOh1/[GENE]SMO[\\GENE] oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize [CHEMICAL]spermidine[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 16
    },
    {
        "text": "The purified human enzyme also does not oxidize eight representative antitumor [CHEMICAL]polyamine[\\CHEMICAL] analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by [GENE]PAOh1[\\GENE]/SMO.",
        "label": 10,
        "major": 4,
        "len": 30
    },
    {
        "text": "The purified human enzyme also does not oxidize eight representative antitumor [CHEMICAL]polyamine[\\CHEMICAL] analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1/[GENE]SMO[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "Purified [GENE]PAOh1[\\GENE]/SMO oxidizes both [CHEMICAL]spermine[\\CHEMICAL] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
        "label": 9,
        "major": 10,
        "len": 16
    },
    {
        "text": "Purified PAOh1/[GENE]SMO[\\GENE] oxidizes both [CHEMICAL]spermine[\\CHEMICAL] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.",
        "label": 9,
        "major": 10,
        "len": 16
    },
    {
        "text": "Purified [GENE]PAOh1[\\GENE]/SMO oxidizes both spermine (K(m)=1.6 microM) and [CHEMICAL]N(1)-acetylspermine[\\CHEMICAL] (K(m)=51 microM), but does not oxidize spermidine.",
        "label": 9,
        "major": 10,
        "len": 16
    },
    {
        "text": "Purified PAOh1/[GENE]SMO[\\GENE] oxidizes both spermine (K(m)=1.6 microM) and [CHEMICAL]N(1)-acetylspermine[\\CHEMICAL] (K(m)=51 microM), but does not oxidize spermidine.",
        "label": 9,
        "major": 10,
        "len": 16
    },
    {
        "text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of [CHEMICAL]spermine[\\CHEMICAL] by [GENE]PAOh1[\\GENE]/SMO.",
        "label": 9,
        "major": 10,
        "len": 30
    },
    {
        "text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of [CHEMICAL]spermine[\\CHEMICAL] by PAOh1/[GENE]SMO[\\GENE].",
        "label": 9,
        "major": 10,
        "len": 30
    },
    {
        "text": "The discovery of an inducible [GENE]oxidase[\\GENE] whose apparent substrate preference is [CHEMICAL]spermine[\\CHEMICAL] indicates that polyamine catabolism is more complex than that originally proposed.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Even though the activities of [GENE]MAT[\\GENE] and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [CHEMICAL]S-adenosylhomocysteine[\\CHEMICAL] increased (113%, p<0.001) in the dwarf mice.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Even though the activities of MAT and [GENE]GNMT[\\GENE] were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and [CHEMICAL]S-adenosylhomocysteine[\\CHEMICAL] increased (113%, p<0.001) in the dwarf mice.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "Even though the activities of [GENE]MAT[\\GENE] and GNMT were elevated, the concentration of liver [CHEMICAL]S-adenosylmethionine[\\CHEMICAL] was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Even though the activities of MAT and [GENE]GNMT[\\GENE] were elevated, the concentration of liver [CHEMICAL]S-adenosylmethionine[\\CHEMICAL] was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "Treatment with [CHEMICAL]diclofenac[\\CHEMICAL] resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated [GENE]caspase-3[\\GENE] after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that [CHEMICAL]diclofenac[\\CHEMICAL] may cause apoptosis of neuronal cells via activation of the [GENE]caspase[\\GENE] cascade.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Kynurenic acid[\\CHEMICAL] (KA) is an endogenous [GENE]glutamate receptor[\\GENE] antagonist at the level of the different ionotropic glutamate receptors.",
        "label": 6,
        "major": 10,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Kynurenic acid[\\CHEMICAL] (KA) is an endogenous glutamate receptor antagonist at the level of the different [GENE]ionotropic glutamate receptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Kynurenic acid ([CHEMICAL]KA[\\CHEMICAL]) is an endogenous [GENE]glutamate receptor[\\GENE] antagonist at the level of the different ionotropic glutamate receptors.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Kynurenic acid ([CHEMICAL]KA[\\CHEMICAL]) is an endogenous glutamate receptor antagonist at the level of the different [GENE]ionotropic glutamate receptors[\\GENE].",
        "label": 6,
        "major": 10,
        "len": 18
    },
    {
        "text": "One of the enzymes responsible for the production of [CHEMICAL]KA[\\CHEMICAL], [GENE]kynurenine aminotransferase I[\\GENE] (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of [CHEMICAL]KA[\\CHEMICAL], kynurenine aminotransferase I ([GENE]KATI[\\GENE]), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, [GENE]kynurenine aminotransferase I[\\GENE] (KATI), also catalyses the reversible transamination of [CHEMICAL]glutamine[\\CHEMICAL] to oxoglutaramic acid (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I ([GENE]KATI[\\GENE]), also catalyses the reversible transamination of [CHEMICAL]glutamine[\\CHEMICAL] to oxoglutaramic acid (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of [CHEMICAL]glutamine[\\CHEMICAL] to oxoglutaramic acid ([GENE]GTK[\\GENE], EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, [GENE]kynurenine aminotransferase I[\\GENE] (KATI), also catalyses the reversible transamination of glutamine to [CHEMICAL]oxoglutaramic acid[\\CHEMICAL] (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I ([GENE]KATI[\\GENE]), also catalyses the reversible transamination of glutamine to [CHEMICAL]oxoglutaramic acid[\\CHEMICAL] (GTK, EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to [CHEMICAL]oxoglutaramic acid[\\CHEMICAL] ([GENE]GTK[\\GENE], EC 2.6.1.15).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to [CHEMICAL]oxoglutaramic acid[\\CHEMICAL] (GTK, [GENE]EC 2.6.1.15[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "These compounds are competitive and, in a few cases, non-competitive inhibitors for [GENE]AChE[\\GENE], the most potent being compound (14), though three-fold less active than [CHEMICAL]tacrine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of [CHEMICAL]pyrano[2,3-b]quinolines[\\CHEMICAL] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of [CHEMICAL]pyrano[2,3-b]quinolines[\\CHEMICAL] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of [CHEMICAL]pyrano[2,3-b]quinolines[\\CHEMICAL] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of [CHEMICAL]pyrano[2,3-b]quinolines[\\CHEMICAL] (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]BuChE[\\GENE] inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than [CHEMICAL]tacrine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [CHEMICAL][1,8]naphthyridines[\\CHEMICAL] (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [CHEMICAL][1,8]naphthyridines[\\CHEMICAL] (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [CHEMICAL][1,8]naphthyridines[\\CHEMICAL] (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [CHEMICAL][1,8]naphthyridines[\\CHEMICAL] (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), [CHEMICAL]4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines[\\CHEMICAL] (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), [CHEMICAL]4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines[\\CHEMICAL] (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), [CHEMICAL]4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines[\\CHEMICAL] (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), [CHEMICAL]4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines[\\CHEMICAL] (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine[\\CHEMICAL] (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine[\\CHEMICAL] (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine[\\CHEMICAL] (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine[\\CHEMICAL] (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), [CHEMICAL]4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline[\\CHEMICAL] (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), [CHEMICAL]4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline[\\CHEMICAL] (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), [CHEMICAL]4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline[\\CHEMICAL] (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), [CHEMICAL]4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline[\\CHEMICAL] (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase ([GENE]AChE[\\GENE]) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine[\\CHEMICAL] (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine[\\CHEMICAL] (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The [GENE]acetylcholinesterase[\\GENE] (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine[\\CHEMICAL] (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ [CHEMICAL]4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine[\\CHEMICAL] (16) are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Nevertheless, 3 mM [CHEMICAL]DMA[\\CHEMICAL], a higher concentration that inhibits [GENE]NHE1[\\GENE], NHE2, and NHE3, significantly increased DBS.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Nevertheless, 3 mM [CHEMICAL]DMA[\\CHEMICAL], a higher concentration that inhibits NHE1, [GENE]NHE2[\\GENE], and NHE3, significantly increased DBS.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Nevertheless, 3 mM [CHEMICAL]DMA[\\CHEMICAL], a higher concentration that inhibits NHE1, NHE2, and [GENE]NHE3[\\GENE], significantly increased DBS.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Moreover, [CHEMICAL]S1611[\\CHEMICAL] and S3226, both specific inhibitors of [GENE]NHE3[\\GENE] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Moreover, S1611 and [CHEMICAL]S3226[\\CHEMICAL], both specific inhibitors of [GENE]NHE3[\\GENE] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Nevertheless, coperfusion with 0.1 and 0.3 mM [CHEMICAL]5-nitro-2-(3-phenylpropylamino) benzoic acid[\\CHEMICAL], which inhibits the [GENE]cystic fibrosis transmembrane conductor regulator[\\GENE] (CFTR), dose dependently inhibited S3226-induced DBS.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Nevertheless, coperfusion with 0.1 and 0.3 mM [CHEMICAL]5-nitro-2-(3-phenylpropylamino) benzoic acid[\\CHEMICAL], which inhibits the cystic fibrosis transmembrane conductor regulator ([GENE]CFTR[\\GENE]), dose dependently inhibited S3226-induced DBS.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]5-(N,N-dimethyl)-amiloride[\\CHEMICAL] (50 microM; DMA), a concentration that selectively inhibits the [GENE]NHE[\\GENE] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]5-(N,N-dimethyl)-amiloride[\\CHEMICAL] (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms [GENE]NHE1[\\GENE] and NHE2, but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]5-(N,N-dimethyl)-amiloride[\\CHEMICAL] (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and [GENE]NHE2[\\GENE], but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "[CHEMICAL]5-(N,N-dimethyl)-amiloride[\\CHEMICAL] (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not [GENE]NHE3[\\GENE], did not affect DBS.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "5-(N,N-dimethyl)-amiloride (50 microM; [CHEMICAL]DMA[\\CHEMICAL]), a concentration that selectively inhibits the [GENE]NHE[\\GENE] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "5-(N,N-dimethyl)-amiloride (50 microM; [CHEMICAL]DMA[\\CHEMICAL]), a concentration that selectively inhibits the NHE isoforms [GENE]NHE1[\\GENE] and NHE2, but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "5-(N,N-dimethyl)-amiloride (50 microM; [CHEMICAL]DMA[\\CHEMICAL]), a concentration that selectively inhibits the NHE isoforms NHE1 and [GENE]NHE2[\\GENE], but not NHE3, did not affect DBS.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "5-(N,N-dimethyl)-amiloride (50 microM; [CHEMICAL]DMA[\\CHEMICAL]), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not [GENE]NHE3[\\GENE], did not affect DBS.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular [CHEMICAL]HCO3[\\CHEMICAL]- formation by [GENE]carbonic anhydrase[\\GENE] was not involved.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by [GENE]kainate receptors[\\GENE] containing the GluR5 subunit.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, [CHEMICAL]topiramate[\\CHEMICAL] at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the [GENE]GluR5[\\GENE] subunit.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Inhibition of [GENE]GluR5[\\GENE] kainate receptors could represent a key mechanism underlying the anticonvulsant activity of [CHEMICAL]topiramate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Inhibition of GluR5 [GENE]kainate receptors[\\GENE] could represent a key mechanism underlying the anticonvulsant activity of [CHEMICAL]topiramate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Selective antagonism of [GENE]GluR5[\\GENE] kainate-receptor-mediated synaptic currents by [CHEMICAL]topiramate[\\CHEMICAL] in rat basolateral amygdala neurons.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Selective antagonism of GluR5 [GENE]kainate-receptor[\\GENE]-mediated synaptic currents by [CHEMICAL]topiramate[\\CHEMICAL] in rat basolateral amygdala neurons.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Weekly subcutaneous [CHEMICAL]decitabine[\\CHEMICAL] produces cumulative increases in [GENE]HbF[\\GENE] and total hemoglobin through a noncytotoxic mechanism of action.",
        "label": 3,
        "major": 9,
        "len": 17
    },
    {
        "text": "Weekly subcutaneous [CHEMICAL]decitabine[\\CHEMICAL] produces cumulative increases in HbF and total [GENE]hemoglobin[\\GENE] through a noncytotoxic mechanism of action.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "We examined if subcutaneous [CHEMICAL]decitabine[\\CHEMICAL] could increase [GENE]HbF[\\GENE] levels and improve SSD pathophysiology without cytotoxicity.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The [CHEMICAL]cytosine[\\CHEMICAL] analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting [GENE]DNA methyltransferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The cytosine analog [CHEMICAL]5-aza-2'-deoxycytidine[\\CHEMICAL] (decitabine) hypomethylates DNA by inhibiting [GENE]DNA methyltransferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The cytosine analog 5-aza-2'-deoxycytidine ([CHEMICAL]decitabine[\\CHEMICAL]) hypomethylates DNA by inhibiting [GENE]DNA methyltransferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Aliskiren[\\CHEMICAL] represents the first in a novel class of [GENE]renin[\\GENE] inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "This led to the discovery of [CHEMICAL]aliskiren[\\CHEMICAL], a highly potent and selective inhibitor of [GENE]human renin[\\GENE] in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of [CHEMICAL]aliskiren[\\CHEMICAL] inhibit [GENE]renin[\\GENE] and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Structure-based design of [CHEMICAL]aliskiren[\\CHEMICAL], a novel orally effective [GENE]renin[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "However, chronic [CHEMICAL]ethanol[\\CHEMICAL], as well as ethanol withdrawal failed to produce any significant alteration in the level of [GENE]CREB[\\GENE] protein in the nucleus accumbens.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "However, chronic ethanol, as well as [CHEMICAL]ethanol[\\CHEMICAL] withdrawal failed to produce any significant alteration in the level of [GENE]CREB[\\GENE] protein in the nucleus accumbens.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "AIM: To study the changes in the expression and phosphorylation of cAMP response element binding protein ([GENE]CREB[\\GENE]) in the rat nucleus accumbens after chronic [CHEMICAL]ethanol[\\CHEMICAL] intake and its withdrawal.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "AIM: To study the changes in the expression and phosphorylation of [GENE]cAMP response element binding protein[\\GENE] (CREB) in the rat nucleus accumbens after chronic [CHEMICAL]ethanol[\\CHEMICAL] intake and its withdrawal.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Changes of phosphorylation of [GENE]cAMP response element binding protein[\\GENE] in rat nucleus accumbens after chronic [CHEMICAL]ethanol[\\CHEMICAL] intake: naloxone reversal.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Changes of phosphorylation of [GENE]cAMP response element binding protein[\\GENE] in rat nucleus accumbens after chronic ethanol intake: [CHEMICAL]naloxone[\\CHEMICAL] reversal.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "AIM: To study the changes in the expression and phosphorylation of [GENE]cAMP response element binding protein[\\GENE] (CREB) in the rat nucleus accumbens after chronic [CHEMICAL]ethanol[\\CHEMICAL] intake and its withdrawal.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of [GENE]CREB[\\GENE] in the nucleus accumbens, and those changes can be reversed by [CHEMICAL]naloxone[\\CHEMICAL], which may be one kind of the molecular mechanisms associated with ethanol dependence.",
        "label": 3,
        "major": 4,
        "len": 37
    },
    {
        "text": "CONCLUSION: A long-term intake of [CHEMICAL]ethanol[\\CHEMICAL] solution down-regulates the phosphorylation of [GENE]CREB[\\GENE] in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "However, when naloxone was administered concurrently with [CHEMICAL]ethanol[\\CHEMICAL] treatment, it antagonized the down-regulation of [GENE]p-CREB[\\GENE] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of [GENE]p-CREB[\\GENE] protein in the nucleus accumbens (142 %) of rats exposed to [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "RESULTS: [CHEMICAL]Ethanol[\\CHEMICAL] given to rats in drinking water decreased the level of [GENE]p-CREB[\\GENE] protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid[\\CHEMICAL] (1) is a potent AMPA receptor agonist with moderate affinity for native [GENE]kainic acid (KA) receptors[\\GENE], whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas [CHEMICAL](S)-E-4-(2,2-dimethylpropylidene)glutamic acid[\\CHEMICAL] (3) show high affinity for the [GENE]GluR5[\\GENE] subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas [CHEMICAL](S)-E-4-(2,2-dimethylpropylidene)glutamic acid[\\CHEMICAL] (3) show high affinity for the GluR5 subtype of [GENE]KA receptors[\\GENE] and much lower affinity for the GluR2 subtype of AMPA receptors.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas [CHEMICAL](S)-E-4-(2,2-dimethylpropylidene)glutamic acid[\\CHEMICAL] (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the [GENE]GluR2[\\GENE] subtype of AMPA receptors.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas [CHEMICAL](S)-E-4-(2,2-dimethylpropylidene)glutamic acid[\\CHEMICAL] (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of [GENE]AMPA receptors[\\GENE].",
        "label": 2,
        "major": 5,
        "len": 43
    },
    {
        "text": "Compounds 4b-h were either inactive (4e,f) or weaker than 4a as affinity ligands for GluR1-4 and [GENE]GluR5[\\GENE] with relative potencies comparable with those of the corresponding [CHEMICAL]AMPA[\\CHEMICAL] analogues as AMPA receptor agonists.",
        "label": 2,
        "major": 5,
        "len": 32
    },
    {
        "text": "Compounds 4b-h were either inactive (4e,f) or weaker than 4a as affinity ligands for [GENE]GluR1-4[\\GENE] and GluR5 with relative potencies comparable with those of the corresponding [CHEMICAL]AMPA[\\CHEMICAL] analogues as AMPA receptor agonists.",
        "label": 2,
        "major": 5,
        "len": 32
    },
    {
        "text": "[CHEMICAL]2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid[\\CHEMICAL] (1) is a potent [GENE]AMPA receptor[\\GENE] agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "These results suggest that [CHEMICAL]clomipramine[\\CHEMICAL] induces hyperglycemia in mice by blocking the [GENE]5-HT(2B )[\\GENE]and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "These results suggest that [CHEMICAL]clomipramine[\\CHEMICAL] induces hyperglycemia in mice by blocking the 5-HT(2B )and/or [GENE]5-HT(2C)[\\GENE] receptors, which results in facilitation of adrenaline release.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the [GENE]5-HT(1A/1B)-receptor[\\GENE] antagonist [CHEMICAL](-)-propranolol[\\CHEMICAL] and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
        "label": 6,
        "major": 3,
        "len": 27
    },
    {
        "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the [GENE]5-HT(3/4)-receptor[\\GENE] antagonist [CHEMICAL]tropisetron[\\CHEMICAL] did not affect it.",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "The [GENE]5-HT(2B/2C)-receptor[\\GENE] antagonist [CHEMICAL]SB 206553[\\CHEMICAL] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the [GENE]5-HT(2A)[\\GENE]-receptor antagonist [CHEMICAL]ketanserin[\\CHEMICAL] was without effect.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the [GENE]5-HT(2A/2B/2C)-receptor[\\GENE] antagonist [CHEMICAL]LY 53857[\\CHEMICAL] enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "The potent [GENE]histamine H(1)-receptor[\\GENE] antagonist [CHEMICAL]cetirizine[\\CHEMICAL] (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The potent [GENE]histamine H(1)-receptor[\\GENE] antagonist cetirizine ([CHEMICAL]Zyrtec[\\CHEMICAL]) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The potent [GENE]histamine H(1)-receptor[\\GENE] antagonist cetirizine (Zyrtec) is a racemic mixture of [CHEMICAL]levocetirizine[\\CHEMICAL] (now available under the trademark Xyzal and dextrocetirizine.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Compared pharmacological characteristics in humans of racemic [CHEMICAL]cetirizine[\\CHEMICAL] and levocetirizine, two [GENE]histamine H1-receptor[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Compared pharmacological characteristics in humans of racemic cetirizine and [CHEMICAL]levocetirizine[\\CHEMICAL], two [GENE]histamine H1-receptor[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "The potent [GENE]histamine H(1)-receptor[\\GENE] antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark [CHEMICAL]Xyzal[\\CHEMICAL] and dextrocetirizine.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The potent [GENE]histamine H(1)-receptor[\\GENE] antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and [CHEMICAL]dextrocetirizine[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "[GENE]P2Y(2) receptor[\\GENE] agonist [CHEMICAL]INS37217[\\CHEMICAL] enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "RESULTS: In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of etomidate in wild-type and in alpha2A-receptor-deficient mice, indicating that the hypnotic effect of [CHEMICAL]etomidate[\\CHEMICAL] in mice does not require the [GENE]alpha2A-receptor[\\GENE] subtype.",
        "label": 10,
        "major": 10,
        "len": 39
    },
    {
        "text": "Inhibition of binding of the [GENE]alpha2-receptor[\\GENE] antagonist [3H]RX821002 to recombinant alpha2-receptors by [CHEMICAL]etomidate[\\CHEMICAL] was tested in human embryonic kidney (HEK293) cells in vitro.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant [GENE]alpha2-receptors[\\GENE] by [CHEMICAL]etomidate[\\CHEMICAL] was tested in human embryonic kidney (HEK293) cells in vitro.",
        "label": 2,
        "major": 6,
        "len": 23
    },
    {
        "text": "In membranes from HEK293 cells transfected with alpha2-receptors, [CHEMICAL]etomidate[\\CHEMICAL] inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from alpha2B- and alpha2C-receptors than from [GENE]alpha2A-receptors[\\GENE] (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "RESULTS: In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of [CHEMICAL]etomidate[\\CHEMICAL] in wild-type and in [GENE]alpha2A-receptor[\\GENE]-deficient mice, indicating that the hypnotic effect of etomidate in mice does not require the alpha2A-receptor subtype.",
        "label": 2,
        "major": 10,
        "len": 39
    },
    {
        "text": "In membranes from HEK293 cells transfected with [GENE]alpha2-receptors[\\GENE], [CHEMICAL]etomidate[\\CHEMICAL] inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
        "label": 2,
        "major": 6,
        "len": 35
    },
    {
        "text": "In membranes from HEK293 cells transfected with alpha2-receptors, [CHEMICAL]etomidate[\\CHEMICAL] inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from [GENE]alpha2B- and alpha2C-receptors[\\GENE] than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "In [GENE]alpha2B-receptor[\\GENE]-expressing HEK293 cells, [CHEMICAL]etomidate[\\CHEMICAL] rapidly increased phosphorylation of the extracellular signal-related kinases ERK1/2.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "CONCLUSIONS: These results indicate that [CHEMICAL]etomidate[\\CHEMICAL] acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an [GENE]alpha2B-receptor[\\GENE]-mediated increase in blood pressure.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The current study was performed to elucidate the possible interaction of [CHEMICAL]etomidate[\\CHEMICAL] with [GENE]alpha2-adrenoceptors[\\GENE] in mice lacking individual alpha2-adrenoceptor subtypes (alpha2-KO).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "The current study was performed to elucidate the possible interaction of [CHEMICAL]etomidate[\\CHEMICAL] with alpha2-adrenoceptors in mice lacking individual [GENE]alpha2-adrenoceptor[\\GENE] subtypes (alpha2-KO).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Activation of [GENE]alpha 2B-adrenoceptors[\\GENE] mediates the cardiovascular effects of [CHEMICAL]etomidate[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "In alpha2B-receptor-expressing HEK293 cells, [CHEMICAL]etomidate[\\CHEMICAL] rapidly increased phosphorylation of the [GENE]extracellular signal-related kinases[\\GENE] ERK1/2.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "In alpha2B-receptor-expressing HEK293 cells, [CHEMICAL]etomidate[\\CHEMICAL] rapidly increased phosphorylation of the extracellular signal-related kinases [GENE]ERK1/2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific [GENE]alpha2-adrenoceptor[\\GENE] agonists of the type such as [CHEMICAL]dexmedetomidine[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "CONCLUSIONS: These results indicate that [CHEMICAL]etomidate[\\CHEMICAL] acts as an agonist at [GENE]alpha2-adrenoceptors[\\GENE], which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "Inhibition of binding of the [GENE]alpha2-receptor[\\GENE] antagonist [CHEMICAL][3H]RX821002[\\CHEMICAL] to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Inhibition of binding of the alpha2-receptor antagonist [CHEMICAL][3H]RX821002[\\CHEMICAL] to recombinant [GENE]alpha2-receptors[\\GENE] by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "In membranes from HEK293 cells transfected with [GENE]alpha2-receptors[\\GENE], etomidate inhibited binding of the alpha2-antagonist, [CHEMICAL][3H]RX821002[\\CHEMICAL], with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, [CHEMICAL][3H]RX821002[\\CHEMICAL], with higher potency from alpha2B- and alpha2C-receptors than from [GENE]alpha2A-receptors[\\GENE] (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "[GENE]Cat-1[\\GENE], the transporter for the essential [CHEMICAL]amino acids[\\CHEMICAL], arginine and lysine, is one of the up-regulated genes.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Cat-1[\\GENE], the transporter for the essential amino acids, [CHEMICAL]arginine[\\CHEMICAL] and lysine, is one of the up-regulated genes.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Cat-1[\\GENE], the transporter for the essential amino acids, arginine and [CHEMICAL]lysine[\\CHEMICAL], is one of the up-regulated genes.",
        "label": 9,
        "major": 1,
        "len": 17
    },
    {
        "text": "While the neurobiological basis for the therapeutic activity of [CHEMICAL]memantine[\\CHEMICAL] is not fully understood, the drug is not a [GENE]cholinesterase[\\GENE] inhibitor and, therefore, acts differently from current AD therapies.",
        "label": 10,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Memantine[\\CHEMICAL] can interact with a variety of [GENE]ligand-gated ion channels[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 10
    },
    {
        "text": "Moreover, recent in vitro studies suggest that [CHEMICAL]memantine[\\CHEMICAL] abrogates [GENE]beta-amyloid[\\GENE] (Abeta) toxicity and possibly inhibits Abeta production.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Moreover, recent in vitro studies suggest that [CHEMICAL]memantine[\\CHEMICAL] abrogates beta-amyloid ([GENE]Abeta[\\GENE]) toxicity and possibly inhibits Abeta production.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Moreover, recent in vitro studies suggest that [CHEMICAL]memantine[\\CHEMICAL] abrogates beta-amyloid (Abeta) toxicity and possibly inhibits [GENE]Abeta[\\GENE] production.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Blockade of [GENE]NMDA receptors[\\GENE] by [CHEMICAL]memantine[\\CHEMICAL] could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Blockade of NMDA receptors by [CHEMICAL]memantine[\\CHEMICAL] could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" [GENE]NMDA receptor[\\GENE]-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Memantine[\\CHEMICAL] is an uncompetitive (channel blocking) [GENE]NMDA receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "Like other [GENE]NMDA receptor[\\GENE] antagonists, [CHEMICAL]memantine[\\CHEMICAL] at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.",
        "label": 6,
        "major": 4,
        "len": 23
    },
    {
        "text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of [CHEMICAL]memantine[\\CHEMICAL] over other [GENE]NMDA receptor[\\GENE] antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Rivastigmine[\\CHEMICAL] is a carbamate drug designed to inhibit both [GENE]acetylcholinesterase[\\GENE] and butyrylcholinesterase by reversibly covalently bonding to these enzymes.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Rivastigmine[\\CHEMICAL] is a carbamate drug designed to inhibit both acetylcholinesterase and [GENE]butyrylcholinesterase[\\GENE] by reversibly covalently bonding to these enzymes.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "BACKGROUND: Rivastigmine is a [CHEMICAL]carbamate[\\CHEMICAL] drug designed to inhibit both [GENE]acetylcholinesterase[\\GENE] and butyrylcholinesterase by reversibly covalently bonding to these enzymes.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "BACKGROUND: Rivastigmine is a [CHEMICAL]carbamate[\\CHEMICAL] drug designed to inhibit both acetylcholinesterase and [GENE]butyrylcholinesterase[\\GENE] by reversibly covalently bonding to these enzymes.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Glycylsarcosine[\\CHEMICAL] coadministration could inhibit the uptake of cefadroxil in PEPT2(+/+) mice (p < 0.01) but not [GENE]PEPT2[\\GENE](-/-) mice.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Glycylsarcosine[\\CHEMICAL] coadministration could inhibit the uptake of cefadroxil in [GENE]PEPT2[\\GENE](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "Glycylsarcosine coadministration could inhibit the uptake of [CHEMICAL]cefadroxil[\\CHEMICAL] in [GENE]PEPT2[\\GENE](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.",
        "label": 9,
        "major": 10,
        "len": 18
    },
    {
        "text": "Glycylsarcosine coadministration could inhibit the uptake of [CHEMICAL]cefadroxil[\\CHEMICAL] in PEPT2(+/+) mice (p < 0.01) but not [GENE]PEPT2[\\GENE](-/-) mice.",
        "label": 9,
        "major": 10,
        "len": 18
    },
    {
        "text": "Although a proton-stimulated uptake of [CHEMICAL]cefadroxil[\\CHEMICAL] was demonstrated in [GENE]PEPT2[\\GENE](+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Although a proton-stimulated uptake of [CHEMICAL]cefadroxil[\\CHEMICAL] was demonstrated in PEPT2(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in [GENE]PEPT2[\\GENE](-/-) mice.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "These findings demonstrate that [GENE]PEPT2[\\GENE] is the primary transporter responsible for [CHEMICAL]cefadroxil[\\CHEMICAL] uptake in the choroid plexus.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM [CHEMICAL]cefadroxil[\\CHEMICAL] was reduced by 83% in [GENE]PEPT2[\\GENE](-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM [CHEMICAL]cefadroxil[\\CHEMICAL] was reduced by 83% in PEPT2(-/-) mice as compared with [GENE]PEPT2[\\GENE](+/+) mice (p < 0.001).",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "The choroid plexus uptake of [CHEMICAL][(3)H]cefadroxil[\\CHEMICAL] was studied in [GENE]peptide transporter 2[\\GENE] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "The choroid plexus uptake of [CHEMICAL][(3)H]cefadroxil[\\CHEMICAL] was studied in peptide transporter 2 ([GENE]PEPT2[\\GENE]) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Two mutations that were generated by PCR mutagenesis of the [GENE]ERG1[\\GENE] gene and that conferred [CHEMICAL]terbinafine[\\CHEMICAL] resistance mapped in the same regions of the Erg1 protein, with one resulting in an L251F exchange and the other resulting in an F433S exchange.",
        "label": 10,
        "major": 1,
        "len": 41
    },
    {
        "text": "Two mutations that were generated by PCR mutagenesis of the ERG1 gene and that conferred [CHEMICAL]terbinafine[\\CHEMICAL] resistance mapped in the same regions of the [GENE]Erg1[\\GENE] protein, with one resulting in an L251F exchange and the other resulting in an F433S exchange.",
        "label": 10,
        "major": 1,
        "len": 41
    },
    {
        "text": "The [CHEMICAL]amino acid[\\CHEMICAL] changes caused by the point mutations were clustered in two regions of the [GENE]Erg1[\\GENE] protein.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "Interestingly, all exchanges identified involved [CHEMICAL]amino acids[\\CHEMICAL] which are conserved in the [GENE]squalene epoxidases[\\GENE] of yeasts and mammals.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "Terbinafine resistance was transmitted with the mutated alleles in gene replacement experiments, proving that single [CHEMICAL]amino acid[\\CHEMICAL] substitutions in the [GENE]Erg1[\\GENE] protein were sufficient to confer the resistance phenotype.",
        "label": 1,
        "major": 1,
        "len": 29
    },
    {
        "text": "Molecular analysis of these mutants revealed single base pair exchanges in the [GENE]ERG1[\\GENE] gene coding for squalene epoxidase, the target of [CHEMICAL]terbinafine[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 22
    },
    {
        "text": "The results strongly indicate that these regions are responsible for the interaction of [GENE]yeast squalene epoxidase[\\GENE] with [CHEMICAL]terbinafine[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Molecular analysis of these mutants revealed single base pair exchanges in the ERG1 gene coding for [GENE]squalene epoxidase[\\GENE], the target of [CHEMICAL]terbinafine[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 22
    },
    {
        "text": "But, intracerebroventricular injection of each [CHEMICAL]ginsenoside[\\CHEMICAL] did not affect plasma [GENE]IL-6[\\GENE] level induced by immobilization stress.",
        "label": 10,
        "major": 10,
        "len": 16
    },
    {
        "text": "Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or [CHEMICAL]epinephrine[\\CHEMICAL]-induced increase of [GENE]IL-6[\\GENE] level in macrophage rather than in the brain.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Ginsenosides Rb2, Rd and Rg1 significantly decreased [CHEMICAL]norepinephrine[\\CHEMICAL] and/or epinephrine-induced increase of [GENE]IL-6[\\GENE] level in macrophage cell line (RAW 264.7).",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and/or [CHEMICAL]epinephrine[\\CHEMICAL]-induced increase of [GENE]IL-6[\\GENE] level in macrophage cell line (RAW 264.7).",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking [CHEMICAL]norepinephrine[\\CHEMICAL]- and/or epinephrine-induced increase of [GENE]IL-6[\\GENE] level in macrophage rather than in the brain.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "The inhibitory effect of [CHEMICAL]ginseng saponins[\\CHEMICAL] on the stress-induced plasma [GENE]interleukin-6[\\GENE] level in mice.",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "Ginseng total [CHEMICAL]saponins[\\CHEMICAL], ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma [GENE]IL-6[\\GENE] level.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Ginseng total saponins, [CHEMICAL]ginsenosides Rb2, Rg1 and Rd[\\CHEMICAL] administered intraperitoneally attenuated the immobilization stress-induced increase in plasma [GENE]IL-6[\\GENE] level.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Ginsenosides Rb2, Rd and Rg1[\\CHEMICAL] significantly decreased norepinephrine and/or epinephrine-induced increase of [GENE]IL-6[\\GENE] level in macrophage cell line (RAW 264.7).",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Thus, it can be suggested that the inhibitory action of [CHEMICAL]ginseng saponins[\\CHEMICAL] against the immobilization stress-induced increase of plasma [GENE]IL-6[\\GENE] level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain.",
        "label": 4,
        "major": 3,
        "len": 46
    },
    {
        "text": "Thus, it can be suggested that the inhibitory action of [CHEMICAL]ginseng saponins[\\CHEMICAL] against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of [GENE]IL-6[\\GENE] level in macrophage rather than in the brain.",
        "label": 4,
        "major": 3,
        "len": 46
    },
    {
        "text": "The [CHEMICAL][3H]DHA[\\CHEMICAL] binding was to a single receptor population with a dissociation constant of 0.42 nM, as would be expected for wild-type [GENE]beta2AR[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Agonist competition assays with [CHEMICAL][3H]DHA[\\CHEMICAL] showed the following rank order of potency: isoproterenol>epinephrine> norepinephrine, consistent with [GENE]beta2AR[\\GENE] interaction.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: [CHEMICAL]isoproterenol[\\CHEMICAL]>epinephrine> norepinephrine, consistent with [GENE]beta2AR[\\GENE] interaction.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol>[CHEMICAL]epinephrine[\\CHEMICAL]> norepinephrine, consistent with [GENE]beta2AR[\\GENE] interaction.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol>epinephrine> [CHEMICAL]norepinephrine[\\CHEMICAL], consistent with [GENE]beta2AR[\\GENE] interaction.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "[GENE]beta2AR[\\GENE] density measured with [CHEMICAL][3H]dihydroalprenolol[\\CHEMICAL] ([3H]DHA) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "[GENE]beta2AR[\\GENE] density measured with [3H]dihydroalprenolol ([CHEMICAL][3H]DHA[\\CHEMICAL]) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "The [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist, [CHEMICAL]tamsulosin[\\CHEMICAL], is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "The alpha(1)-adrenoceptor antagonist, [CHEMICAL]tamsulosin[\\CHEMICAL], is selective for [GENE]alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "On the other hand, in patients with a mean serum [CHEMICAL]carvedilol[\\CHEMICAL] level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the [GENE]BNP[\\GENE] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start of[CHEMICAL]carvedilol[\\CHEMICAL] therapy, the degree of reduction in the [GENE]BNP[\\GENE] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "The model includes 607 of the 773 [CHEMICAL]amino acids[\\CHEMICAL] of [GENE]L-CPT I[\\GENE], and the positions of carnitine, CoA and the palmitoyl group were assigned by superposition and docking analysis.",
        "label": 1,
        "major": 1,
        "len": 29
    },
    {
        "text": "[GENE]CPT I[\\GENE] (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into [CHEMICAL]palmitoylcarnitine[\\CHEMICAL] in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "CPT I ([GENE]carnitine palmitoyltransferase I[\\GENE]) catalyses the conversion of palmitoyl-CoA into [CHEMICAL]palmitoylcarnitine[\\CHEMICAL] in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[GENE]CPT I[\\GENE] (carnitine palmitoyltransferase I) catalyses the conversion of [CHEMICAL]palmitoyl-CoA[\\CHEMICAL] into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "CPT I ([GENE]carnitine palmitoyltransferase I[\\GENE]) catalyses the conversion of [CHEMICAL]palmitoyl-CoA[\\CHEMICAL] into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[CHEMICAL]TAS-102[\\CHEMICAL] currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of [GENE]TS[\\GENE] and incorporation into DNA.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the [GENE]beta(2)-adrenoceptor[\\GENE] agonist [CHEMICAL]formoterol[\\CHEMICAL] [eformoterol].",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the [GENE]beta(2)-adrenoceptor[\\GENE] agonist formoterol [[CHEMICAL]eformoterol[\\CHEMICAL]].",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with [GENE]ErbB3[\\GENE] yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-[GENE]Erk1/2[\\GENE], phospho-AKT, and cyclin D steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-Erk1/2, phospho-[GENE]AKT[\\GENE], and cyclin D steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and [GENE]cyclin D[\\GENE] steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Increased phosphorylation of [GENE]p95ErbB2[\\GENE] and AKT in response to HRG was abrogated to varying degrees by [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Increased phosphorylation of p95ErbB2 and [GENE]AKT[\\GENE] in response to HRG was abrogated to varying degrees by [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]GW572016[\\CHEMICAL], a reversible small molecule inhibitor of [GENE]EGFR[\\GENE] and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GW572016[\\CHEMICAL], a reversible small molecule inhibitor of EGFR and [GENE]ErbB2[\\GENE] tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GW572016[\\CHEMICAL], a reversible small molecule inhibitor of EGFR and ErbB2 [GENE]tyrosine kinases[\\GENE], inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GW572016[\\CHEMICAL], a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline [GENE]p95ErbB2[\\GENE] phosphorylation in BT474 cells and tumor xenografts.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Inhibition of [GENE]p95ErbB2[\\GENE], p185ErbB2, and EGFR phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of p95ErbB2, [GENE]p185ErbB2[\\GENE], and EGFR phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of p95ErbB2, p185ErbB2, and [GENE]EGFR[\\GENE] phosphorylation by [CHEMICAL]GW572016[\\CHEMICAL] resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/[GENE]ErbB2[\\GENE] kinase inhibitor [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "CGP 12177A but not [CHEMICAL]isoprenaline[\\CHEMICAL] initiated arrhythmias at lower concentrations following [GENE]beta(1)-adrenoceptor[\\GENE] overexpression.",
        "label": 10,
        "major": 10,
        "len": 13
    },
    {
        "text": "This study demonstrates enhanced cardiostimulation by [CHEMICAL]CGP 12177A[\\CHEMICAL] (in the presence of propranolol) in rat ventricular myocytes overexpressing [GENE]beta(1)-adrenoceptors[\\GENE], mediated by a Gs/cAMP signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of [CHEMICAL]propranolol[\\CHEMICAL]) in rat ventricular myocytes overexpressing [GENE]beta(1)-adrenoceptors[\\GENE], mediated by a Gs/cAMP signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "[GENE]beta(1)-adrenoceptor[\\GENE] overexpression enhanced the inotropic potency of [CHEMICAL]isoprenaline[\\CHEMICAL] by 11.7-fold (pD(2) 8.76+/-0.14) and CGP 12177A by 5.9-fold (7.11+/-0.10), respectively.",
        "label": 2,
        "major": 10,
        "len": 19
    },
    {
        "text": "Overexpression of [GENE]beta 1-adrenoceptors[\\GENE] in adult rat ventricular myocytes enhances [CHEMICAL]CGP 12177A[\\CHEMICAL] cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "This study demonstrates enhanced cardiostimulation by [CHEMICAL]CGP 12177A[\\CHEMICAL] (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a [GENE]Gs[\\GENE]/cAMP signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of [CHEMICAL]propranolol[\\CHEMICAL]) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a [GENE]Gs[\\GENE]/cAMP signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a [GENE]Gs[\\GENE]/[CHEMICAL]cAMP[\\CHEMICAL] signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "We have adenovirally overexpressed [GENE]beta(1)-adrenoceptors[\\GENE] in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of [CHEMICAL]isoprenaline[\\CHEMICAL] and CGP 12177A (in the presence of 1 microm propranolol).",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "We have adenovirally overexpressed [GENE]beta(1)-adrenoceptors[\\GENE] in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and [CHEMICAL]CGP 12177A[\\CHEMICAL] (in the presence of 1 microm propranolol).",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "We have adenovirally overexpressed [GENE]beta(1)-adrenoceptors[\\GENE] in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and CGP 12177A (in the presence of 1 microm [CHEMICAL]propranolol[\\CHEMICAL]).",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances [CHEMICAL]CGP 12177A[\\CHEMICAL] cardiostimulation: implications for 'putative' [GENE]beta 4-adrenoceptor[\\GENE] pharmacology.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]CGP 12177A[\\CHEMICAL] mediates cardiostimulation by activation of the 'putative' [GENE]beta(4)-adrenoceptor[\\GENE]; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "(3)H-CGP 12177A saturation binding, in the presence of [CHEMICAL]propranolol[\\CHEMICAL], increased approximately 5-fold following overexpression of [GENE]beta(1)-adrenoceptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]CGP 12177A[\\CHEMICAL] but not isoprenaline initiated arrhythmias at lower concentrations following [GENE]beta(1)-adrenoceptor[\\GENE] overexpression.",
        "label": 3,
        "major": 10,
        "len": 13
    },
    {
        "text": "[CHEMICAL](125)I-Cyanopindolol[\\CHEMICAL] saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [GENE]beta(1)-adrenoceptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL](3)H-CGP 12177A[\\CHEMICAL] saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of [GENE]beta(1)-adrenoceptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]CGP 12177A[\\CHEMICAL] mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the [GENE]beta(1)-adrenoceptor[\\GENE] gene abolishes this effect.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Tamsulosin[\\CHEMICAL], which has high affinity for alpha1aAR and alpha1dAR subtypes but not for [GENE]alpha1bAR[\\GENE], shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Tamsulosin[\\CHEMICAL], which has high affinity for [GENE]alpha1aAR[\\GENE] and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Tamsulosin[\\CHEMICAL], which has high affinity for alpha1aAR and [GENE]alpha1dAR[\\GENE] subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for [GENE]alpha1aAR[\\GENE] and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and [CHEMICAL]doxazosin[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for alpha1aAR and [GENE]alpha1dAR[\\GENE] subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and [CHEMICAL]doxazosin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for [GENE]alpha1aAR[\\GENE] and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents [CHEMICAL]terazosin[\\CHEMICAL] and doxazosin.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for alpha1aAR and [GENE]alpha1dAR[\\GENE] subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents [CHEMICAL]terazosin[\\CHEMICAL] and doxazosin.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for alpha1aAR and alpha1dAR subtypes but not for [GENE]alpha1bAR[\\GENE], shows efficacy similar to the nonsubtype selective agents [CHEMICAL]terazosin[\\CHEMICAL] and doxazosin.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Tamsulosin, which has high affinity for alpha1aAR and alpha1dAR subtypes but not for [GENE]alpha1bAR[\\GENE], shows efficacy similar to the nonsubtype selective agents terazosin and [CHEMICAL]doxazosin[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include [CHEMICAL]CI-1033[\\CHEMICAL], an irreversible pan-[GENE]erbB[\\GENE] tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include [CHEMICAL]CI-1033[\\CHEMICAL], an irreversible pan-erbB [GENE]tyrosine kinase[\\GENE] inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and [CHEMICAL]PKI166[\\CHEMICAL] and GW572016, both examples of dual [GENE]kinase[\\GENE] inhibitors (inhibiting epidermal growth factor receptor and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and [CHEMICAL]PKI166[\\CHEMICAL] and GW572016, both examples of dual kinase inhibitors (inhibiting [GENE]epidermal growth factor receptor[\\GENE] and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and [CHEMICAL]PKI166[\\CHEMICAL] and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and [GENE]Her2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and [CHEMICAL]GW572016[\\CHEMICAL], both examples of dual [GENE]kinase[\\GENE] inhibitors (inhibiting epidermal growth factor receptor and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and [CHEMICAL]GW572016[\\CHEMICAL], both examples of dual kinase inhibitors (inhibiting [GENE]epidermal growth factor receptor[\\GENE] and Her2).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and [CHEMICAL]GW572016[\\CHEMICAL], both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and [GENE]Her2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules [CHEMICAL]gefitinib[\\CHEMICAL] (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib ([CHEMICAL]Iressa[\\CHEMICAL], ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, [CHEMICAL]ZD1839[\\CHEMICAL]) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and [CHEMICAL]erlotinib[\\CHEMICAL] (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib ([CHEMICAL]Tarceva[\\CHEMICAL], OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, [CHEMICAL]OSI-774[\\CHEMICAL]), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as [CHEMICAL]cetuximab[\\CHEMICAL] (IMC-225, Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab ([CHEMICAL]IMC-225[\\CHEMICAL], Erbitux).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Epidermal growth factor receptor[\\GENE] inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, [CHEMICAL]Erbitux[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Moreover, a normal level of expression of [GENE]PSS1[\\GENE] and/or PSS2 is not required for generating the pool of [CHEMICAL]PtdSer[\\CHEMICAL] externalized during apoptosis.",
        "label": 9,
        "major": 10,
        "len": 22
    },
    {
        "text": "Moreover, a normal level of expression of PSS1 and/or [GENE]PSS2[\\GENE] is not required for generating the pool of [CHEMICAL]PtdSer[\\CHEMICAL] externalized during apoptosis.",
        "label": 9,
        "major": 10,
        "len": 22
    },
    {
        "text": "In this study, we have synthesized novel [CHEMICAL]alpha-hydroxyphenylamide[\\CHEMICAL] analogues of diphenylhydantoin and examined their ability to inhibit [GENE]human Na(V)1.5[\\GENE] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In this study, we have synthesized novel [CHEMICAL]alpha-hydroxyphenylamide[\\CHEMICAL] analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 [GENE]sodium channels[\\GENE] expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of [CHEMICAL]diphenylhydantoin[\\CHEMICAL] and examined their ability to inhibit [GENE]human Na(V)1.5[\\GENE] sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of [CHEMICAL]diphenylhydantoin[\\CHEMICAL] and examined their ability to inhibit human Na(V)1.5 [GENE]sodium channels[\\GENE] expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In comparison to [CHEMICAL]diphenylhydantoin[\\CHEMICAL], the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [GENE]Na(V)1.5[\\GENE] channels with an IC(50) value of 14.5 microM.",
        "label": 4,
        "major": 9,
        "len": 30
    },
    {
        "text": "In comparison to diphenylhydantoin, the novel [CHEMICAL]chloro[\\CHEMICAL]-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [GENE]Na(V)1.5[\\GENE] channels with an IC(50) value of 14.5 microM.",
        "label": 4,
        "major": 9,
        "len": 30
    },
    {
        "text": "In comparison to diphenylhydantoin, the novel chloro-substituted [CHEMICAL]alpha-hydroxyphenylamide[\\CHEMICAL] compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of [GENE]Na(V)1.5[\\GENE] channels with an IC(50) value of 14.5 microM.",
        "label": 4,
        "major": 9,
        "len": 30
    },
    {
        "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit [GENE]human Na(V)1.5[\\GENE] [CHEMICAL]sodium[\\CHEMICAL] channels expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 [CHEMICAL]sodium[\\CHEMICAL][GENE]sodium channels[\\GENE] expressed in Chinese Hamster Ovary (CHO-K1) cells.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Our results indicate that Salix extract 1520L inhibits [GENE]COX-2[\\GENE]-mediated [CHEMICAL]PGE2[\\CHEMICAL] release through compounds other than salicin or salicylate.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting [GENE]cyclooxygenase (COX)-2[\\GENE]-mediated [CHEMICAL]PGE2[\\CHEMICAL] release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "[GENE]Quinone oxidoreductase 2[\\GENE] (QR2) purified from human red blood cells was recently shown to be a potential target of the [CHEMICAL]quinoline[\\CHEMICAL] antimalarial compounds [Graves et al., (2002) Mol.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Quinone oxidoreductase 2 ([GENE]QR2[\\GENE]) purified from human red blood cells was recently shown to be a potential target of the [CHEMICAL]quinoline[\\CHEMICAL] antimalarial compounds [Graves et al., (2002) Mol.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "To investigate the mechanism and consequences of inhibition of [GENE]QR2[\\GENE] by the [CHEMICAL]quinolines[\\CHEMICAL] further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "To investigate the mechanism and consequences of inhibition of QR2 by the [CHEMICAL]quinolines[\\CHEMICAL] further, we have used steady-state and transient-state kinetics to define the mechanism of [GENE]QR2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Kinetic mechanism of [GENE]quinone oxidoreductase 2[\\GENE] and its inhibition by the antimalarial [CHEMICAL]quinolines[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Our studies shed light on the possible in vivo potency of the [CHEMICAL]quinolines[\\CHEMICAL] and provide a foundation for future studies aimed at creating more potent [GENE]QR2[\\GENE] inhibitors and at understanding the physiological significance of QR2.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[GENE]QR2[\\GENE] catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or [CHEMICAL]N-ribosylated nicotinamides[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "[GENE]QR2[\\GENE] catalyzes the two-electron reduction of [CHEMICAL]menadione[\\CHEMICAL] via the oxidation of N-alkylated or N-ribosylated nicotinamides.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "[GENE]QR2[\\GENE] catalyzes the two-electron reduction of menadione via the oxidation of [CHEMICAL]N-alkylated[\\CHEMICAL] or N-ribosylated nicotinamides.",
        "label": 9,
        "major": 4,
        "len": 15
    },
    {
        "text": "As is the case with BLTs, [CHEMICAL]glyburide[\\CHEMICAL] increased the apparent affinity of [GENE]HDL[\\GENE] binding to SR-BI.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "As is the case with BLTs, [CHEMICAL]glyburide[\\CHEMICAL] increased the apparent affinity of HDL binding to [GENE]SR-BI[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ([CHEMICAL]BLT-4[\\CHEMICAL]), blocked [GENE]ABCA1[\\GENE]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ([CHEMICAL]BLT-4[\\CHEMICAL]), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of [GENE]SR-BI[\\GENE] (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Reciprocally, [CHEMICAL]glyburide[\\CHEMICAL] blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of [GENE]ABCA1[\\GENE] (IC(50) approximately 275-300 microM).",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Reciprocally, [CHEMICAL]glyburide[\\CHEMICAL] blocked [GENE]SR-BI[\\GENE]-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM).",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Cross-inhibition of [GENE]SR-BI[\\GENE]- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and [CHEMICAL]glyburide[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "Cross-inhibition of SR-BI- and [GENE]ABCA1[\\GENE]-mediated cholesterol transport by the small molecules BLT-4 and [CHEMICAL]glyburide[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "The reciprocal inhibition of [GENE]SR-BI[\\GENE] and ABCA1 by BLT-4 and [CHEMICAL]glyburide[\\CHEMICAL] raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The reciprocal inhibition of SR-BI and [GENE]ABCA1[\\GENE] by BLT-4 and [CHEMICAL]glyburide[\\CHEMICAL] raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The activities of [GENE]ABCA1[\\GENE] and other ATP binding cassette superfamily members are inhibited by the drug [CHEMICAL]glyburide[\\CHEMICAL], and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The activities of ABCA1 and other [GENE]ATP binding cassette superfamily[\\GENE] members are inhibited by the drug [CHEMICAL]glyburide[\\CHEMICAL], and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "Here, we show that one [CHEMICAL]BLT[\\CHEMICAL], [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked [GENE]ABCA1[\\GENE]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here, we show that one [CHEMICAL]BLT[\\CHEMICAL], [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of [GENE]SR-BI[\\GENE] (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here, we show that one BLT, [[CHEMICAL]1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea[\\CHEMICAL]] (BLT-4), blocked [GENE]ABCA1[\\GENE]-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here, we show that one BLT, [[CHEMICAL]1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea[\\CHEMICAL]] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of [GENE]SR-BI[\\GENE] (IC(50) approximately 55-60 microM).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked [GENE]ABCA1[\\GENE]-mediated [CHEMICAL]cholesterol[\\CHEMICAL] efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Cross-inhibition of [GENE]SR-BI[\\GENE]- and ABCA1-mediated [CHEMICAL]cholesterol[\\CHEMICAL] transport by the small molecules BLT-4 and glyburide.",
        "label": 9,
        "major": 9,
        "len": 14
    },
    {
        "text": "Cross-inhibition of SR-BI- and [GENE]ABCA1[\\GENE]-mediated [CHEMICAL]cholesterol[\\CHEMICAL] transport by the small molecules BLT-4 and glyburide.",
        "label": 9,
        "major": 9,
        "len": 14
    },
    {
        "text": "[GENE]SR-BI[\\GENE] is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of [CHEMICAL]cholesteryl esters[\\CHEMICAL] from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.",
        "label": 9,
        "major": 2,
        "len": 35
    },
    {
        "text": "[GENE]SR-BI[\\GENE] is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified [CHEMICAL]cholesterol[\\CHEMICAL] from cells to HDL.",
        "label": 9,
        "major": 2,
        "len": 35
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two [GENE]human CA[\\GENE] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, [GENE]CA I[\\GENE], and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and [GENE]CA II[\\GENE], of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[GENE]Carbonic anhydrase[\\GENE] inhibitors: [CHEMICAL]aromatic and heterocyclic sulfonamides[\\CHEMICAL] incorporating adamantyl moieties with strong anticonvulsant activity.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[GENE]Carbonic anhydrase[\\GENE] inhibitors: aromatic and heterocyclic sulfonamides incorporating [CHEMICAL]adamantyl[\\CHEMICAL] moieties with strong anticonvulsant activity.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two [GENE]human CA[\\GENE] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, [GENE]CA I[\\GENE], and CA II, of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and [GENE]CA II[\\GENE], of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, [CHEMICAL]kuraridin[\\CHEMICAL] ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, [CHEMICAL]kuraridin[\\CHEMICAL] ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), [CHEMICAL]kurarinol[\\CHEMICAL] ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), [CHEMICAL]kurarinol[\\CHEMICAL] ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "These data suggest that the [CHEMICAL]lavandulyl[\\CHEMICAL] side chain and the position of the hydroxy group are important for high [GENE]DGAT[\\GENE] inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These data suggest that the lavandulyl side chain and the position of the [CHEMICAL]hydroxy[\\CHEMICAL] group are important for high [GENE]DGAT[\\GENE] inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), [CHEMICAL]kushenol H[\\CHEMICAL] ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), [CHEMICAL]kushenol H[\\CHEMICAL] ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and [CHEMICAL]kushenol K[\\CHEMICAL] ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and [CHEMICAL]kushenol K[\\CHEMICAL] ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "In vitro inhibition of [GENE]diacylglycerol acyltransferase[\\GENE] by [CHEMICAL]prenylflavonoids[\\CHEMICAL] from Sophora flavescens.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Four prenylflavonoids, [CHEMICAL]kurarinone[\\CHEMICAL] ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, [CHEMICAL]kurarinone[\\CHEMICAL] ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The [CHEMICAL]flavonoids[\\CHEMICAL] inhibited [GENE]DGAT[\\GENE] activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a [CHEMICAL]chalcone[\\CHEMICAL] of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four prenylflavonoids, kurarinone ( 1), a [CHEMICAL]chalcone[\\CHEMICAL] of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four [CHEMICAL]prenylflavonoids[\\CHEMICAL], kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on [GENE]diacylglycerol acyltransferase[\\GENE] (DGAT).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Four [CHEMICAL]prenylflavonoids[\\CHEMICAL], kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ([GENE]DGAT[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Monodemethylated [CHEMICAL]mifepristone[\\CHEMICAL] bound to [GENE]rabbit thymic GR[\\GENE] with higher affinity than monodemethylated CDB-2914 or CDB-4124.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "Monodemethylated mifepristone bound to [GENE]rabbit thymic GR[\\GENE] with higher affinity than monodemethylated [CHEMICAL]CDB-2914[\\CHEMICAL] or CDB-4124.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "In vitro antiprogestational/antiglucocorticoid activity and progestin and [GENE]glucocorticoid receptor[\\GENE] binding of the putative metabolites and synthetic derivatives of [CHEMICAL]CDB-2914[\\CHEMICAL], CDB-4124, and mifepristone.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "In vitro antiprogestational/antiglucocorticoid activity and progestin and [GENE]glucocorticoid receptor[\\GENE] binding of the putative metabolites and synthetic derivatives of CDB-2914, [CHEMICAL]CDB-4124[\\CHEMICAL], and mifepristone.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "In vitro antiprogestational/antiglucocorticoid activity and progestin and [GENE]glucocorticoid receptor[\\GENE] binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and [CHEMICAL]mifepristone[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Monodemethylated mifepristone bound to [GENE]rabbit thymic GR[\\GENE] with higher affinity than monodemethylated CDB-2914 or [CHEMICAL]CDB-4124[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas [CHEMICAL]mifepristone[\\CHEMICAL] and its monodemethylated metabolite manifested slight [GENE]glucocorticoid[\\GENE] agonist activity.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Ziprasidone[\\CHEMICAL] is an atypical antipsychotic drug that shows a higher affinity for serotonin [GENE]5-HT(2) receptors[\\GENE] compared with dopamine D(2) receptors in vitro.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Ziprasidone[\\CHEMICAL] is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with [GENE]dopamine D(2) receptors[\\GENE] in vitro.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] was unable to cause the same extent of association of the [GENE]C1b domain[\\GENE] of PKC-delta with lipids, compared with PMA or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 10,
        "major": 3,
        "len": 43
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] was unable to cause the same extent of association of the C1b domain of [GENE]PKC-delta[\\GENE] with lipids, compared with PMA or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 10,
        "major": 3,
        "len": 43
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] bound to [GENE]PKC-alpha[\\GENE] in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] bound to PKC-alpha in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little [GENE]PKC[\\GENE] isoform selectivity was observed.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "I3A bound to [GENE]PKC-alpha[\\GENE] in the presence of [CHEMICAL]phosphatidylserine[\\CHEMICAL] with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "I3A was unable to cause the same extent of association of the [GENE]C1b domain[\\GENE] of PKC-delta with lipids, compared with [CHEMICAL]PMA[\\CHEMICAL] or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "I3A was unable to cause the same extent of association of the C1b domain of [GENE]PKC-delta[\\GENE] with lipids, compared with [CHEMICAL]PMA[\\CHEMICAL] or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "I3A was unable to cause the same extent of association of the [GENE]C1b domain[\\GENE] of PKC-delta with lipids, compared with PMA or the physiological regulator [CHEMICAL]diacylglycerol[\\CHEMICAL], and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "I3A was unable to cause the same extent of association of the C1b domain of [GENE]PKC-delta[\\GENE] with lipids, compared with PMA or the physiological regulator [CHEMICAL]diacylglycerol[\\CHEMICAL], and was able to partially block the association induced by these agents, measured by surface plasmon resonance.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Characterization of the interaction of [CHEMICAL]ingenol 3-angelate[\\CHEMICAL] with [GENE]protein kinase C[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "The in vitro kinase activity of [GENE]PKC-alpha[\\GENE] induced by [CHEMICAL]I3A[\\CHEMICAL] was lower than that induced by PMA.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "The in vitro kinase activity of [GENE]PKC-alpha[\\GENE] induced by I3A was lower than that induced by [CHEMICAL]PMA[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] induced a higher level of secretion of the inflammatory cytokine [GENE]interleukin 6[\\GENE] compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]I3A[\\CHEMICAL] induced a higher level of secretion of the inflammatory [GENE]cytokine[\\GENE] interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "I3A induced a higher level of secretion of the inflammatory cytokine [GENE]interleukin 6[\\GENE] compared with [CHEMICAL]PMA[\\CHEMICAL] in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "I3A induced a higher level of secretion of the inflammatory [GENE]cytokine[\\GENE] interleukin 6 compared with [CHEMICAL]PMA[\\CHEMICAL] in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]PKC[\\GENE] isoforms did show different sensitivity and selectivity for down-regulation by [CHEMICAL]I3A[\\CHEMICAL] and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[GENE]PKC[\\GENE] isoforms did show different sensitivity and selectivity for down-regulation by I3A and [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] (PMA) in WEHI-231, HOP-92, and Colo-205 cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[GENE]PKC[\\GENE] isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate ([CHEMICAL]PMA[\\CHEMICAL]) in WEHI-231, HOP-92, and Colo-205 cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking [GENE]thymidylate synthase[\\GENE] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking thymidylate synthase ([GENE]TS[\\GENE]) but is inactivated by dihydropyrimidine dehydrogenase (DPD).",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [CHEMICAL]5-fluorouracil[\\CHEMICAL] (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [CHEMICAL]5-fluorouracil[\\CHEMICAL] (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The [CHEMICAL]fluoropyrimidine carbamate[\\CHEMICAL] (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The [CHEMICAL]fluoropyrimidine carbamate[\\CHEMICAL] (capecitabine) is converted to 5-fluorouracil (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate ([CHEMICAL]capecitabine[\\CHEMICAL]) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate ([CHEMICAL]capecitabine[\\CHEMICAL]) is converted to 5-fluorouracil (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "SL-11158 inhibited [GENE]SSAT[\\GENE] activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, [CHEMICAL]spermine[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "[CHEMICAL]SL-11158[\\CHEMICAL] inhibited [GENE]SSAT[\\GENE] activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of [CHEMICAL]BW-1[\\CHEMICAL], acted as substrate for [GENE]PAO[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "We show for the first time that a single [CHEMICAL]amino acid[\\CHEMICAL] is able to determine the substrate specificity of [GENE]CrAT[\\GENE] and COT.",
        "label": 1,
        "major": 9,
        "len": 22
    },
    {
        "text": "We show for the first time that a single [CHEMICAL]amino acid[\\CHEMICAL] is able to determine the substrate specificity of CrAT and [GENE]COT[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 22
    },
    {
        "text": "Carnitine acetyltransferases ([GENE]CrAT[\\GENE]) catalyze the reversible conversion of acetyl-CoA and carnitine to [CHEMICAL]acetylcarnitine[\\CHEMICAL] and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "The [GENE]M564G[\\GENE] mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, [CHEMICAL]acetyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "The M564G mutated [GENE]CrAT[\\GENE] showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, [CHEMICAL]acetyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type [GENE]CrAT[\\GENE], and lower activity toward its natural substrate, [CHEMICAL]acetyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "Kinetic constants of the mutant [GENE]CrAT[\\GENE] showed modification in favor of longer [CHEMICAL]acyl-CoAs[\\CHEMICAL] as substrates.",
        "label": 9,
        "major": 1,
        "len": 15
    },
    {
        "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in [GENE]carnitine octanoyltransferase[\\GENE] (COT) decreased activity toward its natural substrates, medium- and long-chain [CHEMICAL]acyl-CoAs[\\CHEMICAL], and increased activity toward short-chain acyl-CoAs.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ([GENE]COT[\\GENE]) decreased activity toward its natural substrates, medium- and long-chain [CHEMICAL]acyl-CoAs[\\CHEMICAL], and increased activity toward short-chain acyl-CoAs.",
        "label": 9,
        "major": 3,
        "len": 32
    },
    {
        "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in [GENE]carnitine octanoyltransferase[\\GENE] (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain [CHEMICAL]acyl-CoAs[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 32
    },
    {
        "text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ([GENE]COT[\\GENE]) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain [CHEMICAL]acyl-CoAs[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "Carnitine acetyltransferases ([GENE]CrAT[\\GENE]) catalyze the reversible conversion of [CHEMICAL]acetyl-CoA[\\CHEMICAL] and carnitine to acetylcarnitine and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "Carnitine acetyltransferases ([GENE]CrAT[\\GENE]) catalyze the reversible conversion of acetyl-CoA and [CHEMICAL]carnitine[\\CHEMICAL] to acetylcarnitine and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "The [GENE]M564G[\\GENE] mutated CrAT showed higher activity toward longer chain [CHEMICAL]acyl-CoAs[\\CHEMICAL]: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "The M564G mutated [GENE]CrAT[\\GENE] showed higher activity toward longer chain [CHEMICAL]acyl-CoAs[\\CHEMICAL]: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "The M564G mutated CrAT showed higher activity toward longer chain [CHEMICAL]acyl-CoAs[\\CHEMICAL]: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type [GENE]CrAT[\\GENE], and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "The [GENE]M564G[\\GENE] mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward [CHEMICAL]myristoyl-CoA[\\CHEMICAL] was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "The M564G mutated [GENE]CrAT[\\GENE] showed higher activity toward longer chain acyl-CoAs: activity toward [CHEMICAL]myristoyl-CoA[\\CHEMICAL] was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward [CHEMICAL]myristoyl-CoA[\\CHEMICAL] was 1250-fold higher than that of the wild-type [GENE]CrAT[\\GENE], and lower activity toward its natural substrate, acetyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "[GENE]Carnitine acetyltransferases[\\GENE] (CrAT) catalyze the reversible conversion of [CHEMICAL]acetyl-CoA[\\CHEMICAL] and carnitine to acetylcarnitine and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "[GENE]Carnitine acetyltransferases[\\GENE] (CrAT) catalyze the reversible conversion of acetyl-CoA and [CHEMICAL]carnitine[\\CHEMICAL] to acetylcarnitine and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "[GENE]Carnitine acetyltransferases[\\GENE] (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to [CHEMICAL]acetylcarnitine[\\CHEMICAL] and free CoA.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "No influence of moderate hepatic impairment on the pharmacokinetics of [CHEMICAL]lumiracoxib[\\CHEMICAL], an oral [GENE]COX-2[\\GENE] selective inhibitor.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel [GENE]cyclooxygenase-2[\\GENE] (COX-2) selective inhibitor [CHEMICAL]lumiracoxib[\\CHEMICAL] (Prexige), so that dose recommendations for clinical use can be provided.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 ([GENE]COX-2[\\GENE]) selective inhibitor [CHEMICAL]lumiracoxib[\\CHEMICAL] (Prexige), so that dose recommendations for clinical use can be provided.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel [GENE]cyclooxygenase-2[\\GENE] (COX-2) selective inhibitor lumiracoxib ([CHEMICAL]Prexige[\\CHEMICAL]), so that dose recommendations for clinical use can be provided.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 ([GENE]COX-2[\\GENE]) selective inhibitor lumiracoxib ([CHEMICAL]Prexige[\\CHEMICAL]), so that dose recommendations for clinical use can be provided.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Several [GENE]purinergic receptors[\\GENE] have been described on platelets; P2X (1), a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by [CHEMICAL]clopidogrel[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 29
    },
    {
        "text": "Several purinergic receptors have been described on platelets; [GENE]P2X (1)[\\GENE], a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by [CHEMICAL]clopidogrel[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 29
    },
    {
        "text": "Several purinergic receptors have been described on platelets; P2X (1), a [GENE]calcium channel[\\GENE], and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by [CHEMICAL]clopidogrel[\\CHEMICAL].",
        "label": 10,
        "major": 6,
        "len": 29
    },
    {
        "text": "Several purinergic receptors have been described on platelets; P2X (1), a calcium channel, and [GENE]P2Y1[\\GENE] a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by [CHEMICAL]clopidogrel[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 29
    },
    {
        "text": "Several purinergic receptors have been described on platelets; P2X (1), a calcium channel, and P2Y1 a [GENE]Gq-coupled seven-transmembrane domain receptor[\\GENE], have been found not to be antagonized by [CHEMICAL]clopidogrel[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 29
    },
    {
        "text": "These results demonstrate that this receptor corresponds to the previously called \"[GENE]P2t[\\GENE]\" platelet receptor and show that the active metabolite of [CHEMICAL]clopidogrel[\\CHEMICAL] binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "These results demonstrate that this receptor corresponds to the previously called \"P2t\" [GENE]platelet receptor[\\GENE] and show that the active metabolite of [CHEMICAL]clopidogrel[\\CHEMICAL] binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "These results demonstrate that this receptor corresponds to the previously called \"[GENE]P2t[\\GENE]\" platelet receptor and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of [CHEMICAL]ADP[\\CHEMICAL] on platelets.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "These results demonstrate that this receptor corresponds to the previously called \"P2t\" [GENE]platelet receptor[\\GENE] and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of [CHEMICAL]ADP[\\CHEMICAL] on platelets.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "The antiaggregating effect of [CHEMICAL]clopidogrel[\\CHEMICAL] is attributed to an irreversible inhibition of ADP binding to a [GENE]purinergic receptor[\\GENE] present at the platelet surface.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The antiaggregating effect of clopidogrel is attributed to an irreversible inhibition of [CHEMICAL]ADP[\\CHEMICAL] binding to a [GENE]purinergic receptor[\\GENE] present at the platelet surface.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "It has previously been suggested that [CHEMICAL]ergotamine[\\CHEMICAL] produces external carotid vasoconstriction in vagosympathectomised dogs via [GENE]5-HT1B/1D[\\GENE] receptors and alpha2-adrenoceptors.",
        "label": 2,
        "major": 9,
        "len": 19
    },
    {
        "text": "It has previously been suggested that [CHEMICAL]ergotamine[\\CHEMICAL] produces external carotid vasoconstriction in vagosympathectomised dogs via 5-HT1B/1D receptors and [GENE]alpha2-adrenoceptors[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 19
    },
    {
        "text": "bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists [CHEMICAL]SB224289[\\CHEMICAL] (300 microg/kg; [GENE]5-HT1B[\\GENE]), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
        "label": 6,
        "major": 6,
        "len": 104
    },
    {
        "text": "bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), [CHEMICAL]BRL15572[\\CHEMICAL] (300 microg/kg; [GENE]5-HT1D[\\GENE]), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).",
        "label": 6,
        "major": 6,
        "len": 104
    },
    {
        "text": "In competition experiments with [GENE]human lung glucocorticoid receptors[\\GENE] we have determined the relative receptor affinities (RRA) of these substances with reference to [CHEMICAL]dexamethasone[\\CHEMICAL] (RRA = 100).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Probing for a hydrophobic a binding register in [GENE]prostate-specific membrane antigen[\\GENE] with [CHEMICAL]phenylalkylphosphonamidates[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of [CHEMICAL]phenylalkylphosphonamidate[\\CHEMICAL] derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against [GENE]PSMA[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of [CHEMICAL]glutamic acid[\\CHEMICAL] were synthesized and evaluated for their inhibitory potencies against [GENE]PSMA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that [CHEMICAL][3H]CP-101,606[\\CHEMICAL] bound to the brain [GENE]NR2B[\\GENE] receptor with a greater extent compared to the spinal cord one.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "These findings suggest that the anti-allodynia effect of [CHEMICAL]CP-101,606[\\CHEMICAL] is ascribable to blockade of [GENE]NR2B[\\GENE] receptors at the brain, but not at the spinal cord.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "In order to examine the site of action of an [GENE]NR2B[\\GENE] subtype-selective NMDA antagonist [CHEMICAL]CP-101,606[\\CHEMICAL], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "In order to examine the site of action of an NR2B subtype-selective [GENE]NMDA[\\GENE] antagonist [CHEMICAL]CP-101,606[\\CHEMICAL], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "Brain but not spinal [GENE]NR2B[\\GENE] receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist [CHEMICAL]CP-101,606[\\CHEMICAL] in a rat chronic constriction injury model.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an [GENE]NR2B[\\GENE] subunit-selective antagonist [CHEMICAL]CP-101,606[\\CHEMICAL] in a rat chronic constriction injury model.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "In contrast, intrathecal injection of a non-selective [GENE]NMDA[\\GENE] antagonist, [CHEMICAL]memantine[\\CHEMICAL], significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.",
        "label": 6,
        "major": 4,
        "len": 39
    },
    {
        "text": "In contrast, [CHEMICAL]NTG[\\CHEMICAL] or ISDN does not affect [GENE]HIF-1[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 10
    },
    {
        "text": "In contrast, NTG or [CHEMICAL]ISDN[\\CHEMICAL] does not affect [GENE]HIF-1[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 10
    },
    {
        "text": "[CHEMICAL]SNP[\\CHEMICAL] inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or [GENE]soluble guanylate cyclase[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effect of [CHEMICAL]sodium nitroprusside[\\CHEMICAL] on HIF-1 activation is not dependent on nitric oxide-[GENE]soluble guanylyl cyclase[\\GENE] pathway.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]SNP[\\CHEMICAL] inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of [GENE]HIF-1alpha[\\GENE] via a mechanism that is not dependent on either NO or soluble guanylate cyclase.",
        "label": 4,
        "major": 10,
        "len": 31
    },
    {
        "text": "We demonstrate that among the three nitrates, only [CHEMICAL]SNP[\\CHEMICAL] inhibits [GENE]HIF-1[\\GENE] activation in response to hypoxia.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]SNP[\\CHEMICAL] inhibits the accumulation of [GENE]HIF-1alpha[\\GENE], the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]SNP[\\CHEMICAL] inhibits the accumulation of HIF-1alpha, the regulatory subunit of [GENE]HIF-1[\\GENE], and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "The inhibitory effect of [CHEMICAL]sodium nitroprusside[\\CHEMICAL] on [GENE]HIF-1[\\GENE] activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.",
        "label": 4,
        "major": 10,
        "len": 18
    },
    {
        "text": "Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the [CHEMICAL]amiloride[\\CHEMICAL][GENE]amiloride-sensitive epithelial sodium channel[\\GENE] (ENaC).",
        "label": 2,
        "major": 1,
        "len": 25
    },
    {
        "text": "Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the [CHEMICAL]amiloride[\\CHEMICAL]-sensitive epithelial sodium channel ([GENE]ENaC[\\GENE]).",
        "label": 2,
        "major": 1,
        "len": 25
    },
    {
        "text": "The narrow substrate specificity prevents interaction of drugs with dicarboxylate-like structure with hNaDC-3 and ensures sufficient support of the proximal tubule cells with [CHEMICAL]alpha-ketoglutarate[\\CHEMICAL] for anion secretion via [GENE]organic anion transporter 1 or 3[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "As opposed to the rat and flounder orthologs, [GENE]hNaDC-3[\\GENE] was hardly inhibited by [CHEMICAL]lithium[\\CHEMICAL] concentrations up to 5 mM.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "We further probed the interaction of [CHEMICAL]mibefradil[\\CHEMICAL] with inactivated [GENE]Nav1.5[\\GENE] channels.",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] blocked [GENE]Nav1.5[\\GENE] in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.",
        "label": 4,
        "major": 2,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] blocked currents of all [GENE]Na+ channel[\\GENE] isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5).",
        "label": 4,
        "major": 2,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for [GENE]Nav1.5[\\GENE]).",
        "label": 4,
        "major": 2,
        "len": 38
    },
    {
        "text": "In addition, inhibiting the binding of the fast inactivation lid ([GENE]Nav1.5[\\GENE] ICM + MTSET) did not alter [CHEMICAL]mibefradil[\\CHEMICAL] block, confirming that the drug does not preferentially interact with the fast-inactivated state.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, [CHEMICAL]mibefradil[\\CHEMICAL] (1 microM) produced 45% fractional block in [GENE]Nav1.5[\\GENE] and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, [CHEMICAL]mibefradil[\\CHEMICAL] (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform ([GENE]Nav1.4[\\GENE]) that slow-inactivates more completely.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "Our results suggest that [CHEMICAL]mibefradil[\\CHEMICAL] blocks [GENE]Na+ channels[\\GENE] in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).",
        "label": 4,
        "major": 10,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] is a [GENE]T-type Ca2+ channel[\\GENE] antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "Extracellular application of meclofenamate (EC(50) = 25 microM) and [CHEMICAL]diclofenac[\\CHEMICAL] (EC(50) = 2.6 microM) resulted in the activation of [GENE]KCNQ2/Q3[\\GENE] K(+) currents, heterologously expressed in Chinese hamster ovary cells.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Extracellular application of [CHEMICAL]meclofenamate[\\CHEMICAL] (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of [GENE]KCNQ2/Q3[\\GENE] K(+) currents, heterologously expressed in Chinese hamster ovary cells.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/[CHEMICAL]Cys[\\CHEMICAL](7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Furthermore, a combinatory mutation ([CHEMICAL]Pro[\\CHEMICAL](7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in [GENE]EL3[\\GENE] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 1,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-[CHEMICAL]Pro[\\CHEMICAL](7.32)-Ser(7.33) motif to Ser-Glu-Pro in [GENE]EL3[\\GENE] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 1,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-[CHEMICAL]Ser[\\CHEMICAL](7.33) motif to Ser-Glu-Pro in [GENE]EL3[\\GENE] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 3,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to [CHEMICAL]Ser-Glu-Pro[\\CHEMICAL] in [GENE]EL3[\\GENE] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 1,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and [CHEMICAL]Leu[\\CHEMICAL](7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of [GENE]rat GnRHR[\\GENE]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 3,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), [CHEMICAL]Leu[\\CHEMICAL](7.43), Ala(7.46), and Pro(7.47) to those of [GENE]rat GnRHR[\\GENE]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 3,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), [CHEMICAL]Ala[\\CHEMICAL](7.46), and Pro(7.47) to those of [GENE]rat GnRHR[\\GENE]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 1,
        "len": 42
    },
    {
        "text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), Ala(7.46), and [CHEMICAL]Pro[\\CHEMICAL](7.47) to those of [GENE]rat GnRHR[\\GENE]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.",
        "label": 1,
        "major": 3,
        "len": 42
    },
    {
        "text": "[Trp(7)]GnRH-I and [Trp(8)]GnRH-I but not [His(5)]GnRH-I exhibit a higher potency in activating wild-type gmGnRHR-2 than native GnRH-I, indicating that [CHEMICAL]amino acids[\\CHEMICAL] at positions 7 and 8 of [GENE]GnRHs[\\GENE] are more important than position 5 for differential recognition by type I and type II GnRHRs.",
        "label": 1,
        "major": 10,
        "len": 44
    },
    {
        "text": "Point-mutation studies indicate that four [CHEMICAL]amino acids[\\CHEMICAL], Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, [CHEMICAL]Leu[\\CHEMICAL]/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/[CHEMICAL]Phe[\\CHEMICAL](7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), [CHEMICAL]Leu[\\CHEMICAL]/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/[CHEMICAL]Phe[\\CHEMICAL](7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), [CHEMICAL]Ala[\\CHEMICAL]/Pro(7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/[CHEMICAL]Pro[\\CHEMICAL](7.46), and Pro/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and [CHEMICAL]Pro[\\CHEMICAL]/Cys(7.47) in [GENE]TMH7[\\GENE] are critical for ligand selectivity as well as receptor conformation.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "In addition, [CHEMICAL]cysteinyl leukotrienes[\\CHEMICAL] per se failed to upregulate the [GENE]IL-5[\\GENE] production.",
        "label": 10,
        "major": 9,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL]-induced inhibition of IL-5 mRNA expression was noted in various cells, irrespective of their [GENE]CysLTR1[\\GENE] mRNA expression status.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL]-induced inhibition of [GENE]IL-5[\\GENE] mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "RESULTS: Pretreatment of lung tissues with [CHEMICAL]pranlukast[\\CHEMICAL] alone significantly decreased the amount of [GENE]IL-5[\\GENE] protein in the culture medium by 40%.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL], a leukotriene receptor antagonist, inhibits [GENE]interleukin-5[\\GENE] production via a mechanism distinct from leukotriene receptor antagonism.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "CONCLUSION: Our results indicate that [CHEMICAL]pranlukast[\\CHEMICAL] inhibits [GENE]IL-5[\\GENE] synthesis via a mechanism distinct from CysLTR1 antagonism.",
        "label": 4,
        "major": 6,
        "len": 16
    },
    {
        "text": "The aim of this study was to determine the mechanism of [CHEMICAL]pranlukast[\\CHEMICAL]-induced [GENE]interleukin-5[\\GENE] (IL-5) inhibition in allergic inflammation.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The aim of this study was to determine the mechanism of [CHEMICAL]pranlukast[\\CHEMICAL]-induced interleukin-5 ([GENE]IL-5[\\GENE]) inhibition in allergic inflammation.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL], a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from [GENE]leukotriene receptor[\\GENE] antagonism.",
        "label": 6,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Pranlukast[\\CHEMICAL], a [GENE]leukotriene receptor[\\GENE] antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.",
        "label": 6,
        "major": 4,
        "len": 16
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Pranlukast[\\CHEMICAL], a [GENE]cysteinyl leukotriene receptor 1[\\GENE] (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
        "label": 6,
        "major": 10,
        "len": 20
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Pranlukast[\\CHEMICAL], a cysteinyl leukotriene receptor 1 ([GENE]CysLTR1[\\GENE]) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.",
        "label": 6,
        "major": 10,
        "len": 20
    },
    {
        "text": "CONCLUSION: Our results indicate that [CHEMICAL]pranlukast[\\CHEMICAL] inhibits IL-5 synthesis via a mechanism distinct from [GENE]CysLTR1[\\GENE] antagonism.",
        "label": 6,
        "major": 4,
        "len": 16
    },
    {
        "text": "Data from heterologous expression of wild-type and mutant [GENE]HERG[\\GENE] genes indicate the mutation causes a 20-fold increase in IC50 of d-sotalol but only a 5.8-fold increase in IC50 of [CHEMICAL]quinidine[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "CONCLUSION: Oral [CHEMICAL]quinidine[\\CHEMICAL] is effective in suppressing the gain of function in IKr responsible for some cases of short QT syndrome with a mutation in [GENE]HERG[\\GENE] and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.",
        "label": 2,
        "major": 1,
        "len": 42
    },
    {
        "text": "CONCLUSION: Oral [CHEMICAL]quinidine[\\CHEMICAL] is effective in suppressing the gain of function in [GENE]IKr[\\GENE] responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "INTRODUCTION: The principal aim of this study was to assess the efficacy of [CHEMICAL]quinidine[\\CHEMICAL] in suppressing [GENE]IKr[\\GENE] in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome.",
        "label": 4,
        "major": 7,
        "len": 38
    },
    {
        "text": "Hence, it is proposed that a conformational change is induced when ApoCaM interacts with GAD65 or tGAD67, resulting in an increase of [GENE]GAD[\\GENE] affinity for [CHEMICAL]PLP[\\CHEMICAL] and the activation of GAD.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The activation appears to be due to an increase of [GENE]GAD[\\GENE] affinity for its cofactor, [CHEMICAL]pyridoxal phosphate[\\CHEMICAL] (PLP).",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "The activation appears to be due to an increase of [GENE]GAD[\\GENE] affinity for its cofactor, pyridoxal phosphate ([CHEMICAL]PLP[\\CHEMICAL]).",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Secondly, the affinity of [GENE]GAD[\\GENE] for [CHEMICAL]PLP[\\CHEMICAL] was increased in the presence of ApoCaM.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "The activation appears to be due to an increase of [GENE]GAD[\\GENE] affinity for its cofactor, [CHEMICAL]pyridoxal phosphate[\\CHEMICAL] (PLP).",
        "label": 8,
        "major": 3,
        "len": 18
    },
    {
        "text": "The activation appears to be due to an increase of [GENE]GAD[\\GENE] affinity for its cofactor, pyridoxal phosphate ([CHEMICAL]PLP[\\CHEMICAL]).",
        "label": 8,
        "major": 3,
        "len": 18
    },
    {
        "text": "Firstly, the V(max) of [GENE]GAD[\\GENE] was increased when ApoCaM was present whereas the affinity for the substrate, [CHEMICAL]glutamate[\\CHEMICAL], was not affected.",
        "label": 9,
        "major": 2,
        "len": 21
    },
    {
        "text": "[GENE]L-serine dehydratase[\\GENE] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield [CHEMICAL]pyruvate[\\CHEMICAL] or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "L-serine dehydratase ([GENE]SDH[\\GENE]), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield [CHEMICAL]pyruvate[\\CHEMICAL] or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[GENE]L-serine dehydratase[\\GENE] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or [CHEMICAL]2-oxobutyrate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "L-serine dehydratase ([GENE]SDH[\\GENE]), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or [CHEMICAL]2-oxobutyrate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[GENE]L-serine dehydratase[\\GENE] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of [CHEMICAL]L-serine[\\CHEMICAL] and L-threonine to yield pyruvate or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "L-serine dehydratase ([GENE]SDH[\\GENE]), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of [CHEMICAL]L-serine[\\CHEMICAL] and L-threonine to yield pyruvate or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[GENE]L-serine dehydratase[\\GENE] (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and [CHEMICAL]L-threonine[\\CHEMICAL] to yield pyruvate or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "L-serine dehydratase ([GENE]SDH[\\GENE]), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and [CHEMICAL]L-threonine[\\CHEMICAL] to yield pyruvate or 2-oxobutyrate.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Docetaxel[\\CHEMICAL] is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of [GENE]bcl-2[\\GENE] inactivation, which induce apoptosis.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Docetaxel is a semisynthetic [CHEMICAL]taxane[\\CHEMICAL] that inhibit tumor growth by induction of microtubule stabilization and promotion of [GENE]bcl-2[\\GENE] inactivation, which induce apoptosis.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] modulates the expression of [GENE]hypoxia-inducible factor-1alpha[\\GENE] and vascular endothelial growth factor in a rat model of volume-overload heart failure.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] modulates the expression of hypoxia-inducible factor-1alpha and [GENE]vascular endothelial growth factor[\\GENE] in a rat model of volume-overload heart failure.",
        "label": 2,
        "major": 7,
        "len": 20
    },
    {
        "text": "Increased immunohistochemical labeling of [GENE]HIF-1alpha[\\GENE], VEGF, and BNP in the ventricular myocardium was observed in the shunt group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Increased immunohistochemical labeling of HIF-1alpha, [GENE]VEGF[\\GENE], and BNP in the ventricular myocardium was observed in the shunt group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Increased immunohistochemical labeling of HIF-1alpha, VEGF, and [GENE]BNP[\\GENE] in the ventricular myocardium was observed in the shunt group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "The kinetic parameters indicate that the main effect of the mutation of Arg228 to [CHEMICAL]lysine[\\CHEMICAL] is on the k(cat) of [GENE]Glc-T[\\GENE], which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold.",
        "label": 1,
        "major": 1,
        "len": 44
    },
    {
        "text": "In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to [CHEMICAL]lysine[\\CHEMICAL] (R228K-[GENE]Gal-T1[\\GENE]) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type.",
        "label": 1,
        "major": 1,
        "len": 43
    },
    {
        "text": "In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to [CHEMICAL]lysine[\\CHEMICAL] (R228K-Gal-T1) results in a 15-fold higher [GENE]Glc-T[\\GENE] activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type.",
        "label": 1,
        "major": 1,
        "len": 43
    },
    {
        "text": "In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to [CHEMICAL]lysine[\\CHEMICAL] (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the [GENE]Gal-T[\\GENE] activity of the wild type.",
        "label": 1,
        "major": 1,
        "len": 43
    },
    {
        "text": "Mutation of [CHEMICAL]arginine[\\CHEMICAL] 228 to lysine enhances the glucosyltransferase activity of [GENE]bovine beta-1,4-galactosyltransferase I[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 14
    },
    {
        "text": "Mutation of arginine 228 to [CHEMICAL]lysine[\\CHEMICAL] enhances the glucosyltransferase activity of [GENE]bovine beta-1,4-galactosyltransferase I[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 14
    },
    {
        "text": "This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the [CHEMICAL]Gal[\\CHEMICAL] moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the [GENE]Gal-T[\\GENE] reaction.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of [CHEMICAL]UDP-Gal[\\CHEMICAL], probably causing the dissociation of UDP-Gal and the reduced k(cat) of the [GENE]Gal-T[\\GENE] reaction.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "This alternate conformation now causes a steric hindrance to the [CHEMICAL]O4 hydroxyl[\\CHEMICAL] group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the [GENE]Gal-T[\\GENE] reaction.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of [CHEMICAL]UDP-Gal[\\CHEMICAL] and the reduced k(cat) of the [GENE]Gal-T[\\GENE] reaction.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "Mutation of arginine 228 to [CHEMICAL]lysine[\\CHEMICAL] enhances the [GENE]glucosyltransferase[\\GENE] activity of bovine beta-1,4-galactosyltransferase I.\tBeta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
        "label": 3,
        "major": 1,
        "len": 46
    },
    {
        "text": "Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.\tBeta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from [CHEMICAL]UDP-Glc[\\CHEMICAL] to GlcNAc ([GENE]Glc-T[\\GENE] activity), albeit at only 0.3% efficiency.",
        "label": 9,
        "major": 1,
        "len": 46
    },
    {
        "text": "Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.\tBeta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from [CHEMICAL]UDP-Gal[\\CHEMICAL] to GlcNAc in the presence of Mn(2+) ion ([GENE]Gal-T[\\GENE] activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
        "label": 9,
        "major": 1,
        "len": 46
    },
    {
        "text": "Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.\tBeta-1,4-galactosyltransferase I ([GENE]beta4Gal-T1[\\GENE]) normally transfers Gal from [CHEMICAL]UDP-Gal[\\CHEMICAL] to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.",
        "label": 9,
        "major": 1,
        "len": 46
    },
    {
        "text": "As a result, we demonstrated that the apoE3 significantly protects these cells from [CHEMICAL]GMC[\\CHEMICAL]-induced reduction in AMG uptake, but neither [GENE]lactoferrin[\\GENE] nor albumin does.",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "As a result, we demonstrated that the apoE3 significantly protects these cells from [CHEMICAL]GMC[\\CHEMICAL]-induced reduction in AMG uptake, but neither lactoferrin nor [GENE]albumin[\\GENE] does.",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "We previously reported that [CHEMICAL]aminoglycoside[\\CHEMICAL] antibiotics reduce [GENE]SGLT1[\\GENE]-dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In this study, using a model of [CHEMICAL]gentamicin C[\\CHEMICAL] (GMC)-induced reduction in [GENE]SGLT1[\\GENE] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In this study, using a model of gentamicin C ([CHEMICAL]GMC[\\CHEMICAL])-induced reduction in [GENE]SGLT1[\\GENE] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the [CHEMICAL]GMC[\\CHEMICAL]-induced reduction in [GENE]SGLT1[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in [GENE]SGLT1[\\GENE] activity induced by [CHEMICAL]gentamicin C[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C.\tMegalin, a family of [GENE]endocytic receptors[\\GENE] related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [CHEMICAL]aminoglycoside[\\CHEMICAL] accumulation.",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C.\tMegalin, a family of endocytic receptors related to the [GENE]low-density lipoprotein (LDL) receptor[\\GENE], is a major pathway for proximal tubular [CHEMICAL]aminoglycoside[\\CHEMICAL] accumulation.",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "The effect of [CHEMICAL]gemcitabine[\\CHEMICAL] and pemetrexed on [GENE]Akt[\\GENE] phosphorylation was investigated with enzyme-linked immunosorbent assay, whereas quantitative polymerase chain reaction (PCR) was used to study target gene-expression profiles and its modulation by each drug.",
        "label": 2,
        "major": 7,
        "len": 34
    },
    {
        "text": "Synergistic cytotoxicity was demonstrated, and [CHEMICAL]pemetrexed[\\CHEMICAL] significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of [GENE]dCK[\\GENE] in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",
        "label": 3,
        "major": 3,
        "len": 43
    },
    {
        "text": "Synergistic cytotoxicity was demonstrated, and [CHEMICAL]pemetrexed[\\CHEMICAL] significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the [GENE]human nucleoside equilibrative transporter 1[\\GENE] (hENT1) in all cell lines.",
        "label": 3,
        "major": 9,
        "len": 43
    },
    {
        "text": "Synergistic cytotoxicity was demonstrated, and [CHEMICAL]pemetrexed[\\CHEMICAL] significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 ([GENE]hENT1[\\GENE]) in all cell lines.",
        "label": 3,
        "major": 4,
        "len": 43
    },
    {
        "text": "These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) [CHEMICAL]pemetrexed[\\CHEMICAL] enhances [GENE]dCK[\\GENE] and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",
        "label": 3,
        "major": 7,
        "len": 57
    },
    {
        "text": "These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) [CHEMICAL]pemetrexed[\\CHEMICAL] enhances dCK and [GENE]hENT1[\\GENE] expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",
        "label": 3,
        "major": 2,
        "len": 57
    },
    {
        "text": "Synergistic cytotoxicity was demonstrated, and [CHEMICAL]pemetrexed[\\CHEMICAL] significantly decreased the amount of [GENE]phosphorylated Akt[\\GENE], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "These data demonstrated that 1) [CHEMICAL]gemcitabine[\\CHEMICAL] and pemetrexed synergistically interact against NSCLC cells through the suppression of [GENE]Akt[\\GENE] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",
        "label": 4,
        "major": 3,
        "len": 57
    },
    {
        "text": "These data demonstrated that 1) gemcitabine and [CHEMICAL]pemetrexed[\\CHEMICAL] synergistically interact against NSCLC cells through the suppression of [GENE]Akt[\\GENE] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.",
        "label": 4,
        "major": 3,
        "len": 57
    },
    {
        "text": "[CHEMICAL]Phenytoin[\\CHEMICAL] is principally metabolized by [GENE]CYP2C9[\\GENE], and both are probable substrates of the drug transporter P-glycoprotein.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Phenytoin[\\CHEMICAL] is principally metabolized by CYP2C9, and both are probable substrates of the [GENE]drug transporter[\\GENE] P-glycoprotein.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Phenytoin[\\CHEMICAL] is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter [GENE]P-glycoprotein[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Am80[\\CHEMICAL] inhibited VEGF-induced phosphorylation of [GENE]VEGF receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "[CHEMICAL]Am80[\\CHEMICAL] inhibited [GENE]VEGF[\\GENE]-induced phosphorylation of VEGF receptor.",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "In addition, [GENE]VEGF[\\GENE]-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by [CHEMICAL]Am80[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Am80[\\CHEMICAL] slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by [GENE]VEGF[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "When [CHEMICAL]amiloride[\\CHEMICAL] was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, [GENE]u-PA[\\GENE] activity in both cornea and tear fluid was strongly inhibited.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "In conclusion, early application of [CHEMICAL]amiloride[\\CHEMICAL] inhibited [GENE]u-PA[\\GENE] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The purpose of the present study was to test our hypothesis that [CHEMICAL]amiloride[\\CHEMICAL], a specific [GENE]u-PA[\\GENE] inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The purpose of the present study was to test our hypothesis that [CHEMICAL]amiloride[\\CHEMICAL], a specific u-PA inhibitor, effectively decreases [GENE]u-PA[\\GENE] activity in cornea as well as in tear fluid and favourably affects corneal healing.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Effects of inhibition of [GENE]urokinase-type plasminogen activator[\\GENE] (u-PA) by [CHEMICAL]amiloride[\\CHEMICAL] in the cornea and tear fluid of eyes irradiated with UVB.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Effects of inhibition of urokinase-type plasminogen activator ([GENE]u-PA[\\GENE]) by [CHEMICAL]amiloride[\\CHEMICAL] in the cornea and tear fluid of eyes irradiated with UVB.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Therefore, comparative histochemical and biochemical studies of [GENE]u-PA[\\GENE] and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [CHEMICAL]Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "This 40 kDa [CHEMICAL]PEG[\\CHEMICAL]-conjugated [GENE]IFNalpha(2a)[\\GENE] ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a).",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a [CHEMICAL]lysine[\\CHEMICAL] side-chain of [GENE]IFNalpha(2a)[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "In higher cortical structures such as the hippocampus, [CHEMICAL]norepinephrine[\\CHEMICAL], via [GENE]beta adrenergic receptor[\\GENE] (AR) activation, has been shown to reinforce the cognitive processes of attention and memory.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In higher cortical structures such as the hippocampus, [CHEMICAL]norepinephrine[\\CHEMICAL], via beta adrenergic receptor ([GENE]AR[\\GENE]) activation, has been shown to reinforce the cognitive processes of attention and memory.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In contrast, the selective [GENE]beta2AR[\\GENE] antagonists ICI-118,551 and butoxamine inhibited [CHEMICAL]isoproterenol[\\CHEMICAL]-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
        "label": 5,
        "major": 2,
        "len": 27
    },
    {
        "text": "Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, [GENE]beta1AR[\\GENE] activation is responsible for the enhanced hippocampal CA3 network activity initiated by [CHEMICAL]isoproterenol[\\CHEMICAL].",
        "label": 5,
        "major": 6,
        "len": 27
    },
    {
        "text": "The selective [GENE]betaAR[\\GENE] agonist [CHEMICAL]isoproterenol[\\CHEMICAL] caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",
        "label": 5,
        "major": 5,
        "len": 29
    },
    {
        "text": "The selective [GENE]beta1AR[\\GENE] antagonists atenolol and metoprolol blocked [CHEMICAL]isoproterenol[\\CHEMICAL]-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "In contrast, the selective [GENE]beta2AR[\\GENE] antagonists ICI-118,551 and [CHEMICAL]butoxamine[\\CHEMICAL] inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
        "label": 6,
        "major": 4,
        "len": 27
    },
    {
        "text": "The selective [GENE]beta1AR[\\GENE] antagonists [CHEMICAL]atenolol[\\CHEMICAL] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
        "label": 6,
        "major": 3,
        "len": 24
    },
    {
        "text": "The selective [GENE]beta1AR[\\GENE] antagonists atenolol and [CHEMICAL]metoprolol[\\CHEMICAL] blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.",
        "label": 6,
        "major": 3,
        "len": 24
    },
    {
        "text": "In contrast, the selective [GENE]beta2AR[\\GENE] antagonists [CHEMICAL]ICI-118,551[\\CHEMICAL] and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).",
        "label": 6,
        "major": 4,
        "len": 27
    },
    {
        "text": "On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the [GENE]FIP1L1[\\GENE]-PDGFRa positive cases the tyrosine kinase inhibitor [CHEMICAL]imatinib mesylate[\\CHEMICAL] (Glivec) would be effective.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-[GENE]PDGFRa[\\GENE] positive cases the tyrosine kinase inhibitor [CHEMICAL]imatinib mesylate[\\CHEMICAL] (Glivec) would be effective.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the [GENE]tyrosine kinase[\\GENE] inhibitor [CHEMICAL]imatinib mesylate[\\CHEMICAL] (Glivec) would be effective.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Western blot analysis was used to determine any effect of [CHEMICAL]DEC[\\CHEMICAL] on the production of [GENE]COX[\\GENE] and inducible nitric-oxide synthase (iNOS) proteins.",
        "label": 2,
        "major": 9,
        "len": 22
    },
    {
        "text": "Western blot analysis was used to determine any effect of [CHEMICAL]DEC[\\CHEMICAL] on the production of COX and inducible [GENE]nitric-oxide synthase[\\GENE] (iNOS) proteins.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Western blot analysis was used to determine any effect of [CHEMICAL]DEC[\\CHEMICAL] on the production of COX and inducible nitric-oxide synthase ([GENE]iNOS[\\GENE]) proteins.",
        "label": 2,
        "major": 9,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Diethylcarbamazine[\\CHEMICAL] activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the [GENE]cyclooxygenase[\\GENE] pathway.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Diethylcarbamazine[\\CHEMICAL] activity against Brugia malayi microfilariae is dependent on [GENE]inducible nitric-oxide synthase[\\GENE] and the cyclooxygenase pathway.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Pre-treatment of animals with [CHEMICAL]dexamethasone[\\CHEMICAL] or indomethacin reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and [GENE]cyclooxygenase[\\GENE] pathways in vivo.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pre-treatment of animals with dexamethasone or [CHEMICAL]indomethacin[\\CHEMICAL] reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and [GENE]cyclooxygenase[\\GENE] pathways in vivo.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Furthermore, experiments showed that treatment with [CHEMICAL]DEC[\\CHEMICAL] results in a reduction in the amount of [GENE]COX-1[\\GENE] protein in peritoneal exudate cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, [CHEMICAL]veratridine[\\CHEMICAL] (0.1 microM), an inhibitor of [GENE]sodium channel[\\GENE] inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "The positive correlation between [CHEMICAL]vitamin A[\\CHEMICAL] and [GENE]immunoglobulin A[\\GENE] concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "The positive correlation between [CHEMICAL]vitamin A[\\CHEMICAL] and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during [GENE]immunoglobulins A[\\GENE] synthesis.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "The positive correlation between vitamin A and [GENE]immunoglobulin A[\\GENE] concentrations might be the result of the [CHEMICAL]vitamin A[\\CHEMICAL] inductive effect during immunoglobulins A synthesis.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the [CHEMICAL]vitamin A[\\CHEMICAL] inductive effect during [GENE]immunoglobulins A[\\GENE] synthesis.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[GENE]Monocarboxylate transporters[\\GENE] (MCTs) are proton-linked membrane carriers involved in the transport of [CHEMICAL]monocarboxylates[\\CHEMICAL] such as lactate, pyruvate, as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Monocarboxylate transporters ([GENE]MCTs[\\GENE]) are proton-linked membrane carriers involved in the transport of [CHEMICAL]monocarboxylates[\\CHEMICAL] such as lactate, pyruvate, as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Monocarboxylate transporters[\\GENE] (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as [CHEMICAL]lactate[\\CHEMICAL], pyruvate, as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Monocarboxylate transporters ([GENE]MCTs[\\GENE]) are proton-linked membrane carriers involved in the transport of monocarboxylates such as [CHEMICAL]lactate[\\CHEMICAL], pyruvate, as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Monocarboxylate transporters[\\GENE] (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, [CHEMICAL]pyruvate[\\CHEMICAL], as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Monocarboxylate transporters ([GENE]MCTs[\\GENE]) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, [CHEMICAL]pyruvate[\\CHEMICAL], as well as ketone bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Monocarboxylate transporters[\\GENE] (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as [CHEMICAL]ketone[\\CHEMICAL] bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Monocarboxylate transporters ([GENE]MCTs[\\GENE]) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as [CHEMICAL]ketone[\\CHEMICAL] bodies.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Interestingly, part of [GENE]MCT2[\\GENE] immunoreactivity is located at postsynaptic sites, suggesting a particular role of [CHEMICAL]monocarboxylates[\\CHEMICAL] and their transporters in synaptic transmission.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that [CHEMICAL]troglitazone[\\CHEMICAL] inhibited ENT1 but had no effect on [GENE]ENT2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 25
    },
    {
        "text": "Although incubating HASMCs for 48h with [CHEMICAL]thiazolidinediones[\\CHEMICAL] had no effect on [GENE]ENT1[\\GENE] mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.",
        "label": 10,
        "major": 2,
        "len": 34
    },
    {
        "text": "The effect of [CHEMICAL]troglitazone[\\CHEMICAL] on ENT1 was [GENE]PPAR(gamma)[\\GENE]-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.",
        "label": 10,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Thiazolidinediones[\\CHEMICAL] are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Thiazolidinediones[\\CHEMICAL] are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma ([GENE]PPAR(gamma)[\\GENE]) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "Although incubating HASMCs for 48h with thiazolidinediones had no effect on [GENE]ENT1[\\GENE] mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and [CHEMICAL][3H]NBMPR[\\CHEMICAL] binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Although incubating HASMCs for 48h with thiazolidinediones had no effect on [GENE]ENT1[\\GENE] mRNA and protein levels, [CHEMICAL]troglitazone[\\CHEMICAL] acutely inhibited [3H]adenosine uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "Although incubating HASMCs for 48h with thiazolidinediones had no effect on [GENE]ENT1[\\GENE] mRNA and protein levels, troglitazone acutely inhibited [CHEMICAL][3H]adenosine[\\CHEMICAL] uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "The effect of [CHEMICAL]troglitazone[\\CHEMICAL] on [GENE]ENT1[\\GENE] was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Effect of [CHEMICAL]thiazolidinediones[\\CHEMICAL] on [GENE]equilibrative nucleoside transporter-1[\\GENE] in human aortic smooth muscle cells.",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Thiazolidinediones[\\CHEMICAL] are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of [GENE]insulin[\\GENE]-responsive genes involved in glucose and lipid metabolism.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Thiazolidinediones[\\CHEMICAL] are a new class of anti-diabetic agents which increase [GENE]insulin[\\GENE] sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "The difference in structure of [CHEMICAL]troglitazone[\\CHEMICAL] did not account for its inhibitory effect on [GENE]ENT1[\\GENE] because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that [CHEMICAL]troglitazone[\\CHEMICAL] inhibited [GENE]ENT1[\\GENE] but had no effect on ENT2.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "From these results, it is suggested that [CHEMICAL]troglitazone[\\CHEMICAL] may enhance the vasodilatory effect of adenosine by inhibiting [GENE]ENT1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Pharmacologically, [CHEMICAL]troglitazone[\\CHEMICAL] is a novel inhibitor of [GENE]ENT1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that [CHEMICAL]troglitazone[\\CHEMICAL] was a competitive inhibitor of [GENE]ENT1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]2-Arylpropionic[\\CHEMICAL] [GENE]CXC chemokine receptor 1[\\GENE] (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]2-Arylpropionic[\\CHEMICAL] CXC chemokine receptor 1 ([GENE]CXCR1[\\GENE]) ligands as novel noncompetitive CXCL8 inhibitors.",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL](R)-Ketoprofen[\\CHEMICAL] (1) was previously reported to be a potent and specific noncompetitive inhibitor of [GENE]CXCL8[\\GENE]-induced human PMNs chemotaxis.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]2-Arylpropionic[\\CHEMICAL] CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive [GENE]CXCL8[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of [GENE]COX-1[\\GENE], in MCF-7 and HL-60.",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased [GENE]cytochrome c[\\GENE], but had no effect on that of COX-1, in MCF-7 and HL-60.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced [GENE]COX-2[\\GENE] expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced COX-2 expression accompanied by a decrease of [GENE]bcl-2[\\GENE] protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, [GENE]TNFalpha[\\GENE], VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, [GENE]VEGF[\\GENE], GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] inhibits growth of tumors through [GENE]COX-2[\\GENE] degradation independent of antiangiogenesis.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "These results demonstrated that [CHEMICAL]thalidomide[\\CHEMICAL] might inhibit growth of tumors through [GENE]COX-2[\\GENE] degradation independent of antiangiogenesis.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Similar to [CHEMICAL]cocaine[\\CHEMICAL], other local anesthetics bind to the [GENE]dopamine transporter[\\GENE] (DAT) and inhibit DA uptake in rodent and monkey brain.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Similar to [CHEMICAL]cocaine[\\CHEMICAL], other local anesthetics bind to the dopamine transporter ([GENE]DAT[\\GENE]) and inhibit DA uptake in rodent and monkey brain.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "There was close correspondence between peak increases in [CHEMICAL]DA[\\CHEMICAL] and [GENE]DAT[\\GENE] occupancy.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "In conclusion, of the seven NSAIDs investigated, [CHEMICAL]niflumic acid[\\CHEMICAL] was the most potent inhibitor of recombinant [GENE]UGT1A9[\\GENE] via 4-MUG in a competitive manner.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant [GENE]human UDP-glucuronosyltransferase 1A9[\\GENE]--potent inhibition by [CHEMICAL]niflumic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Binding sites for [GENE]hERG[\\GENE] blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, [CHEMICAL]Ser[\\CHEMICAL]-624, Val-625).",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "Binding sites for [GENE]hERG[\\GENE] blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, [CHEMICAL]Val[\\CHEMICAL]-625).",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "Binding sites for [GENE]hERG[\\GENE] blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ([CHEMICAL]Tyr[\\CHEMICAL]-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, Val-625).",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "Binding sites for [GENE]hERG[\\GENE] blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, [CHEMICAL]Phe[\\CHEMICAL]-656) and residues in the pore helix (Thr-623, Ser-624, Val-625).",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "Binding sites for [GENE]hERG[\\GENE] blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix ([CHEMICAL]Thr[\\CHEMICAL]-623, Ser-624, Val-625).",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "Drug binding interactions in the inner cavity of [GENE]HERG[\\GENE] channels: molecular insights from structure-activity relationships of [CHEMICAL]clofilium[\\CHEMICAL] and ibutilide analogs.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Drug binding interactions in the inner cavity of [GENE]HERG[\\GENE] channels: molecular insights from structure-activity relationships of clofilium and [CHEMICAL]ibutilide[\\CHEMICAL] analogs.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "We used mutagenesis of these residues, combined with an investigation of [GENE]hERG[\\GENE] block by close analogs of [CHEMICAL]clofilium[\\CHEMICAL] and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "We used mutagenesis of these residues, combined with an investigation of [GENE]hERG[\\GENE] block by close analogs of clofilium and [CHEMICAL]ibutilide[\\CHEMICAL], to assess how specific alterations in drug structure affected potency and binding interactions.",
        "label": 4,
        "major": 2,
        "len": 33
    },
    {
        "text": "[CHEMICAL]MELANOTAN[\\CHEMICAL] (NDP-MSH) binds the [GENE]MC1 receptor[\\GENE] to significantly increase the eumelanin content of human skin cells.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "MELANOTAN ([CHEMICAL]NDP-MSH[\\CHEMICAL]) binds the [GENE]MC1 receptor[\\GENE] to significantly increase the eumelanin content of human skin cells.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor [GENE]LRP-1[\\GENE], induces its [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.",
        "label": 1,
        "major": 3,
        "len": 41
    },
    {
        "text": "Furthermore, tPA induced rapid [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation on the beta subunit of [GENE]LRP-1[\\GENE], which was followed by the activation of Mek1 and its downstream Erk-1 and -2.",
        "label": 1,
        "major": 3,
        "len": 26
    },
    {
        "text": "Tissue-type plasminogen activator (tPA), a [CHEMICAL]serine[\\CHEMICAL] protease well known for generating plasmin, has been demonstrated to induce [GENE]matrix metalloproteinase-9[\\GENE] (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Tissue-type plasminogen activator (tPA), a [CHEMICAL]serine[\\CHEMICAL] protease well known for generating [GENE]plasmin[\\GENE], has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Furthermore, tPA induced rapid [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation on the beta subunit of LRP-1, which was followed by the activation of [GENE]Mek1[\\GENE] and its downstream Erk-1 and -2.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Furthermore, tPA induced rapid [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream [GENE]Erk-1 and -2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Co-C[\\CHEMICAL] bond activation in [GENE]methylmalonyl-CoA mutase[\\GENE] by stabilization of the post-homolysis product Co2+ cobalamin.",
        "label": 1,
        "major": 3,
        "len": 14
    },
    {
        "text": "showed that when [CHEMICAL]AdoCbl[\\CHEMICAL] is bound to the [GENE]MMCM[\\GENE] active site, no enzymatic perturbation of the Co3+ Cbl electronic structure occurs, even in the presence of substrate (analogues).",
        "label": 2,
        "major": 9,
        "len": 28
    },
    {
        "text": "Co-C bond activation in [GENE]methylmalonyl-CoA mutase[\\GENE] by stabilization of the post-homolysis product Co2+ [CHEMICAL]cobalamin[\\CHEMICAL].",
        "label": 8,
        "major": 3,
        "len": 14
    },
    {
        "text": "Co-C bond activation in [GENE]methylmalonyl-CoA mutase[\\GENE] by stabilization of the post-homolysis product [CHEMICAL]Co2+[\\CHEMICAL] cobalamin.",
        "label": 8,
        "major": 9,
        "len": 14
    },
    {
        "text": "In this work, we utilized magnetic circular dichroism spectroscopy to explore how the electronic structure of the reduced B12 cofactor (i.e., the post-homolysis product [CHEMICAL]Co2+ Cbl[\\CHEMICAL]) is modulated by the enzyme [GENE]methylmalonyl-CoA mutase[\\GENE].",
        "label": 8,
        "major": 8,
        "len": 33
    },
    {
        "text": "Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which microcystins but not [CHEMICAL]nodularins[\\CHEMICAL] permanently modify their [GENE]protein phosphatase[\\GENE] targets by covalent addition to an active site cysteine residue.",
        "label": 10,
        "major": 10,
        "len": 34
    },
    {
        "text": "Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which microcystins but not nodularins permanently modify their [GENE]protein phosphatase[\\GENE] targets by covalent addition to an active site [CHEMICAL]cysteine[\\CHEMICAL] residue.",
        "label": 1,
        "major": 10,
        "len": 34
    },
    {
        "text": "We have elucidated the crystal structures of the cyanotoxins, motuporin ([CHEMICAL]nodularin-V[\\CHEMICAL]) and dihydromicrocystin-LA bound to [GENE]human protein phosphatase-1c (gamma isoform)[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "We have elucidated the crystal structures of the cyanotoxins, motuporin (nodularin-V) and [CHEMICAL]dihydromicrocystin-LA[\\CHEMICAL] bound to [GENE]human protein phosphatase-1c (gamma isoform)[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Crystal structures of [GENE]protein phosphatase-1[\\GENE] bound to [CHEMICAL]motuporin[\\CHEMICAL] and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Crystal structures of [GENE]protein phosphatase-1[\\GENE] bound to motuporin and [CHEMICAL]dihydromicrocystin-LA[\\CHEMICAL]: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which [CHEMICAL]microcystins[\\CHEMICAL] but not nodularins permanently modify their [GENE]protein phosphatase[\\GENE] targets by covalent addition to an active site cysteine residue.",
        "label": 2,
        "major": 10,
        "len": 34
    },
    {
        "text": "We have elucidated the crystal structures of the cyanotoxins, [CHEMICAL]motuporin[\\CHEMICAL] (nodularin-V) and dihydromicrocystin-LA bound to [GENE]human protein phosphatase-1c (gamma isoform)[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Expression of L-type pyruvate kinase ([GENE]L-PK[\\GENE]) is upregulated in the liver by dietary [CHEMICAL]carbohydrate[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Expression of [GENE]L-type pyruvate kinase[\\GENE] (L-PK) is upregulated in the liver by dietary [CHEMICAL]carbohydrate[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Our results have shown that [GENE]MMP-9[\\GENE] messenger ribonucleic acid (mRNA) expression was inhibited by [CHEMICAL]doxycycline[\\CHEMICAL] starting at 10 mg/kg/day (P<0.02).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Minocycline[\\CHEMICAL] showed more potent inhibition on [GENE]MMP-9[\\GENE] mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the [GENE]MMP-9[\\GENE] inhibition by [CHEMICAL]tetracyclines[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In vitro, [CHEMICAL]minocycline[\\CHEMICAL], but not doxycycline, inhibits [GENE]MMP-9[\\GENE], at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.",
        "label": 4,
        "major": 10,
        "len": 20
    },
    {
        "text": "In vitro, minocycline, but not [CHEMICAL]doxycycline[\\CHEMICAL], inhibits [GENE]MMP-9[\\GENE], at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "This study provided the evidence that the [CHEMICAL]tetracyclines[\\CHEMICAL] inhibit stimulated cerebral [GENE]MMP-9[\\GENE] at multiple levels and are effective at very low doses, offering great potential for therapeutic use.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Doxycycline[\\CHEMICAL] was shown to decrease cerebral [GENE]MMP-9[\\GENE] activities and angiogenesis induced by vascular endothelial growth factor (VEGF).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Doxycycline[\\CHEMICAL] was shown to decrease cerebral MMP-9 activities and angiogenesis induced by [GENE]vascular endothelial growth factor[\\GENE] (VEGF).",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Doxycycline[\\CHEMICAL] was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor ([GENE]VEGF[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[GENE]Omega class GSTs[\\GENE] have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of [CHEMICAL]monomethylarsonate[\\CHEMICAL], an intermediate in the pathway of arsenic biotransformation.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "Galanin attenuates [GENE]cyclic AMP regulatory element-binding protein[\\GENE] (CREB) phosphorylation induced by chronic [CHEMICAL]morphine[\\CHEMICAL] and naloxone challenge in Cath.a cells and primary striatal cultures.",
        "label": 3,
        "major": 2,
        "len": 23
    },
    {
        "text": "Galanin attenuates cyclic AMP regulatory element-binding protein ([GENE]CREB[\\GENE]) phosphorylation induced by chronic [CHEMICAL]morphine[\\CHEMICAL] and naloxone challenge in Cath.a cells and primary striatal cultures.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Galanin attenuates [GENE]cyclic AMP regulatory element-binding protein[\\GENE] (CREB) phosphorylation induced by chronic morphine and [CHEMICAL]naloxone[\\CHEMICAL] challenge in Cath.a cells and primary striatal cultures.",
        "label": 3,
        "major": 2,
        "len": 23
    },
    {
        "text": "Galanin attenuates cyclic AMP regulatory element-binding protein ([GENE]CREB[\\GENE]) phosphorylation induced by chronic morphine and [CHEMICAL]naloxone[\\CHEMICAL] challenge in Cath.a cells and primary striatal cultures.",
        "label": 3,
        "major": 2,
        "len": 23
    },
    {
        "text": "Two beta(2)-agonists, [CHEMICAL]formoterol[\\CHEMICAL] and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [GENE]beta(2)-adrenoceptor[\\GENE] selectivity.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two beta(2)-agonists, formoterol and [CHEMICAL]salmeterol[\\CHEMICAL], are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [GENE]beta(2)-adrenoceptor[\\GENE] selectivity.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "A dose of 25 microg kg(-1) day(-1) of [CHEMICAL]formoterol[\\CHEMICAL] elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar [GENE]beta-adrenoceptor[\\GENE] downregulation.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than [CHEMICAL]salmeterol[\\CHEMICAL], but resulted in similar [GENE]beta-adrenoceptor[\\GENE] downregulation.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Two beta(2)-agonists, [CHEMICAL]formoterol[\\CHEMICAL] and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [GENE]beta(2)-adrenoceptor[\\GENE] selectivity.",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "Two beta(2)-agonists, formoterol and [CHEMICAL]salmeterol[\\CHEMICAL], are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [GENE]beta(2)-adrenoceptor[\\GENE] selectivity.",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "Systemic administration of [GENE]beta2-adrenoceptor[\\GENE] agonists, [CHEMICAL]formoterol[\\CHEMICAL] and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Systemic administration of [GENE]beta2-adrenoceptor[\\GENE] agonists, formoterol and [CHEMICAL]salmeterol[\\CHEMICAL], elicit skeletal muscle hypertrophy in rats at micromolar doses.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Dasatinib (BMS-354825) inhibits [GENE]KIT[\\GENE]D816V, an [CHEMICAL]imatinib[\\CHEMICAL]-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "Dasatinib (BMS-354825) inhibits KIT[GENE]D816V[\\GENE], an [CHEMICAL]imatinib[\\CHEMICAL]-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "This mutation is inherently resistant to [CHEMICAL]imatinib[\\CHEMICAL] and, to date, there remains no effective curative therapy for systemic mastocytosis associated with [GENE]KIT[\\GENE]D816V.",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "This mutation is inherently resistant to [CHEMICAL]imatinib[\\CHEMICAL] and, to date, there remains no effective curative therapy for systemic mastocytosis associated with KIT[GENE]D816V[\\GENE].",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple [CHEMICAL]imatinib[\\CHEMICAL]-resistant [GENE]BCR[\\GENE]-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 10,
        "major": 4,
        "len": 34
    },
    {
        "text": "Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple [CHEMICAL]imatinib[\\CHEMICAL]-resistant BCR-[GENE]ABL[\\GENE] isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 10,
        "major": 4,
        "len": 34
    },
    {
        "text": "Computer modeling suggests that the [GENE]KIT[\\GENE]D816V mutation destabilizes the inactive conformation of the KIT activation loop to which [CHEMICAL]imatinib[\\CHEMICAL] binds, but it is not predicted to impair binding of KIT by dasatinib.",
        "label": 2,
        "major": 10,
        "len": 32
    },
    {
        "text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the [GENE]KIT activation loop[\\GENE] to which [CHEMICAL]imatinib[\\CHEMICAL] binds, but it is not predicted to impair binding of KIT by dasatinib.",
        "label": 2,
        "major": 10,
        "len": 32
    },
    {
        "text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which [CHEMICAL]imatinib[\\CHEMICAL] binds, but it is not predicted to impair binding of [GENE]KIT[\\GENE] by dasatinib.",
        "label": 2,
        "major": 10,
        "len": 32
    },
    {
        "text": "Computer modeling suggests that the [GENE]KIT[\\GENE]D816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by [CHEMICAL]dasatinib[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 32
    },
    {
        "text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of [GENE]KIT[\\GENE] by [CHEMICAL]dasatinib[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "In this study, we demonstrate significant inhibitory activity of [CHEMICAL]dasatinib[\\CHEMICAL] against both wild-type [GENE]KIT[\\GENE] and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.",
        "label": 4,
        "major": 1,
        "len": 29
    },
    {
        "text": "In this study, we demonstrate significant inhibitory activity of [CHEMICAL]dasatinib[\\CHEMICAL] against both wild-type KIT and the [GENE]KIT[\\GENE]D816V mutation in the nanomolar range in in vitro and cell-based kinase assays.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In this study, we demonstrate significant inhibitory activity of [CHEMICAL]dasatinib[\\CHEMICAL] against both wild-type KIT and the KIT[GENE]D816V[\\GENE] mutation in the nanomolar range in in vitro and cell-based kinase assays.",
        "label": 4,
        "major": 1,
        "len": 29
    },
    {
        "text": "Additionally, [CHEMICAL]dasatinib[\\CHEMICAL] leads to growth inhibition of a [GENE]KIT[\\GENE]D816V-harboring human masto-cytosis cell line.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Additionally, [CHEMICAL]dasatinib[\\CHEMICAL] leads to growth inhibition of a KIT[GENE]D816V[\\GENE]-harboring human masto-cytosis cell line.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) inhibits [GENE]KIT[\\GENE]D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
        "label": 4,
        "major": 1,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) inhibits KIT[GENE]D816V[\\GENE], an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
        "label": 4,
        "major": 1,
        "len": 18
    },
    {
        "text": "Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]) inhibits KIT[GENE]D816V[\\GENE], an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
        "label": 4,
        "major": 1,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) is a novel orally bioavailable [GENE]SRC[\\GENE]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825) is a novel orally bioavailable SRC/[GENE]ABL[\\GENE] inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]) is a novel orally bioavailable [GENE]SRC[\\GENE]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]) is a novel orally bioavailable SRC/[GENE]ABL[\\GENE] inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BACKGROUND: Since the introduction of the first [GENE]cholinesterase[\\GENE] inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, [CHEMICAL]donepezil[\\CHEMICAL], galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, [CHEMICAL]donepezil[\\CHEMICAL], galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme [GENE]acetylcholinesterase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first [GENE]cholinesterase[\\GENE] inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, [CHEMICAL]galantamine[\\CHEMICAL] and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, [CHEMICAL]galantamine[\\CHEMICAL] and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme [GENE]acetylcholinesterase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first [GENE]cholinesterase[\\GENE] inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and [CHEMICAL]rivastigmine[\\CHEMICAL], to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and [CHEMICAL]rivastigmine[\\CHEMICAL], to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme [GENE]acetylcholinesterase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of [CHEMICAL]acetylcholine[\\CHEMICAL], an important neurotransmitter associated with memory, by blocking the enzyme [GENE]acetylcholinesterase[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 66
    },
    {
        "text": "[GENE]SSAT[\\GENE] was found to self-acetylate [CHEMICAL]lysine[\\CHEMICAL]-26 in the presence of AcCoA and absence of substrate, a reaction apparently catalzyed by AcCoA bound in the second channel of the asymmetric dimer.",
        "label": 1,
        "major": 9,
        "len": 30
    },
    {
        "text": "In general, [CHEMICAL]rifampicin[\\CHEMICAL] can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects [GENE]cytochromes P450[\\GENE], glucuronosyltransferases and p-glycoprotein activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, rifampicin can act on a pattern: [CHEMICAL]rifampicin[\\CHEMICAL] activates the nuclear pregnane X receptor that in turn affects cytochromes P450, [GENE]glucuronosyltransferases[\\GENE] and p-glycoprotein activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, rifampicin can act on a pattern: [CHEMICAL]rifampicin[\\CHEMICAL] activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and [GENE]p-glycoprotein[\\GENE] activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, [CHEMICAL]rifampicin[\\CHEMICAL] can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, [GENE]glucuronosyltransferases[\\GENE] and p-glycoprotein activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, [CHEMICAL]rifampicin[\\CHEMICAL] can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and [GENE]p-glycoprotein[\\GENE] activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, rifampicin can act on a pattern: [CHEMICAL]rifampicin[\\CHEMICAL] activates the nuclear pregnane X receptor that in turn affects [GENE]cytochromes P450[\\GENE], glucuronosyltransferases and p-glycoprotein activities.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Roles of [CHEMICAL]rifampicin[\\CHEMICAL] in drug-drug interactions: underlying molecular mechanisms involving the [GENE]nuclear pregnane X receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "In general, rifampicin can act on a pattern: [CHEMICAL]rifampicin[\\CHEMICAL] activates the [GENE]nuclear pregnane X receptor[\\GENE] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In general, [CHEMICAL]rifampicin[\\CHEMICAL] can act on a pattern: rifampicin activates the [GENE]nuclear pregnane X receptor[\\GENE] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "The concomitantly administered effects of [CHEMICAL]rifampicin[\\CHEMICAL] on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by [GENE]p-glycoprotein[\\GENE] in the gastrointestinal tract and liver.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "The concomitantly administered effects of [CHEMICAL]rifampicin[\\CHEMICAL] on other drugs can result in their altered metabolism or transportation that are metabolised by [GENE]cytochromes P450[\\GENE] or transported by p-glycoprotein in the gastrointestinal tract and liver.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Ethanol[\\CHEMICAL] withdrawal significantly increased the packing density of [GENE]GS[\\GENE]- and GFAP-IR astrocytes in the PLC of P rats as compared with P rats with continuous access to ethanol.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Ethanol[\\CHEMICAL] withdrawal significantly increased the packing density of GS- and [GENE]GFAP[\\GENE]-IR astrocytes in the PLC of P rats as compared with P rats with continuous access to ethanol.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free-choice [CHEMICAL]ethanol[\\CHEMICAL] consumption and point to differential adaptations of [GENE]GS[\\GENE] and GFAP to prolonged alcohol drinking in the PLC of P rats.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free-choice [CHEMICAL]ethanol[\\CHEMICAL] consumption and point to differential adaptations of GS and [GENE]GFAP[\\GENE] to prolonged alcohol drinking in the PLC of P rats.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "Withdrawal from free-choice [CHEMICAL]ethanol[\\CHEMICAL] consumption results in increased packing density of [GENE]glutamine synthetase[\\GENE]-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to [CHEMICAL]glutamine[\\CHEMICAL] through the enzyme [GENE]glutamine synthetase[\\GENE] (GS).",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to [CHEMICAL]glutamine[\\CHEMICAL] through the enzyme glutamine synthetase ([GENE]GS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released [CHEMICAL]glutamate[\\CHEMICAL] and its conversion to glutamine through the enzyme [GENE]glutamine synthetase[\\GENE] (GS).",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released [CHEMICAL]glutamate[\\CHEMICAL] and its conversion to glutamine through the enzyme glutamine synthetase ([GENE]GS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired [GENE]pyridoxal kinase[\\GENE] for the conversion of pyridoxine and pyridoxal to [CHEMICAL]PLP[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired [GENE]pyridoxal kinase[\\GENE] for the conversion of [CHEMICAL]pyridoxine[\\CHEMICAL] and pyridoxal to PLP.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired [GENE]pyridoxal kinase[\\GENE] for the conversion of pyridoxine and [CHEMICAL]pyridoxal[\\CHEMICAL] to PLP.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "In this article, the action of [CHEMICAL]dasatinib[\\CHEMICAL] (BMS-354825) is contrasted with that of imatinib, a [GENE]kinase[\\GENE] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In this article, the action of dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]) is contrasted with that of imatinib, a [GENE]kinase[\\GENE] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In this article, the action of dasatinib (BMS-354825) is contrasted with that of [CHEMICAL]imatinib[\\CHEMICAL], a [GENE]kinase[\\GENE] inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The work of Chen and colleagues shows that [CHEMICAL]dasatinib[\\CHEMICAL] is a particularly potent inhibitor of [GENE]PDGFR[\\GENE] and that the compound also targets Src kinase.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The work of Chen and colleagues shows that [CHEMICAL]dasatinib[\\CHEMICAL] is a particularly potent inhibitor of PDGFR and that the compound also targets [GENE]Src kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of [GENE]EP1 receptors[\\GENE] in the [CHEMICAL]PGE1[\\CHEMICAL] mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.",
        "label": 2,
        "major": 3,
        "len": 45
    },
    {
        "text": "Also consistent with the involvement of Gq coupled [GENE]EP1 receptors[\\GENE], the [CHEMICAL]PGE1[\\CHEMICAL] stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.",
        "label": 2,
        "major": 6,
        "len": 39
    },
    {
        "text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the [CHEMICAL]PGE1[\\CHEMICAL] mediated stimulation of [GENE]Na,K-ATPase beta[\\GENE] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.",
        "label": 3,
        "major": 4,
        "len": 45
    },
    {
        "text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of [GENE]Na,K-ATPase beta[\\GENE] subunit gene transcription includes the stimulatory effect of [CHEMICAL]17-phenyl trinor PGE2[\\CHEMICAL], as well as the inhibitory effects of SC-51089.",
        "label": 3,
        "major": 4,
        "len": 45
    },
    {
        "text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of [GENE]Na,K-ATPase beta[\\GENE] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [CHEMICAL]SC-51089[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 45
    },
    {
        "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the [GENE]PKC[\\GENE] inhibitor Go 6976, [CHEMICAL]thapsigargin[\\CHEMICAL], as well as the calmodulin antagonists W7 and W13.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the [GENE]PKC[\\GENE] inhibitor [CHEMICAL]Go 6976[\\CHEMICAL], thapsigargin, as well as the calmodulin antagonists W7 and W13.",
        "label": 4,
        "major": 6,
        "len": 39
    },
    {
        "text": "The involvement of [GENE]EP1[\\GENE] and EP2 receptors is indicated by studies with the EP1 selective agonist [CHEMICAL]17-phenyl trinor PGE2[\\CHEMICAL], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the [GENE]EP1[\\GENE] selective agonist [CHEMICAL]17-phenyl trinor PGE2[\\CHEMICAL], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and [GENE]EP2 receptors[\\GENE] is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist [CHEMICAL]butaprost[\\CHEMICAL] (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the [GENE]EP2[\\GENE] selective agonist [CHEMICAL]butaprost[\\CHEMICAL] (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 6,
        "len": 45
    },
    {
        "text": "The involvement of [GENE]EP1[\\GENE] and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists [CHEMICAL]SC-51089[\\CHEMICAL] (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 3,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the [GENE]EP1[\\GENE] selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists [CHEMICAL]SC-51089[\\CHEMICAL] (EP1 specific) and AH 6809 (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists [CHEMICAL]SC-51089[\\CHEMICAL] (EP1 specific) and AH 6809 ([GENE]EP1[\\GENE] and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of [GENE]EP1[\\GENE] and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and [GENE]EP2 receptors[\\GENE] is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] (EP1 and EP2 specific).",
        "label": 5,
        "major": 3,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the [GENE]EP1[\\GENE] selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] (EP1 and EP2 specific).",
        "label": 5,
        "major": 3,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the [GENE]EP2[\\GENE] selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] (EP1 and EP2 specific).",
        "label": 5,
        "major": 5,
        "len": 45
    },
    {
        "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the [GENE]calmodulin[\\GENE] antagonists [CHEMICAL]W7[\\CHEMICAL] and W13.",
        "label": 6,
        "major": 4,
        "len": 39
    },
    {
        "text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the [GENE]calmodulin[\\GENE] antagonists W7 and [CHEMICAL]W13[\\CHEMICAL].",
        "label": 6,
        "major": 4,
        "len": 39
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] ([GENE]EP1[\\GENE] and EP2 specific).",
        "label": 6,
        "major": 5,
        "len": 45
    },
    {
        "text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [CHEMICAL]AH 6809[\\CHEMICAL] (EP1 and [GENE]EP2[\\GENE] specific).",
        "label": 6,
        "major": 3,
        "len": 45
    },
    {
        "text": "Inhibition of ERK1/2 with [CHEMICAL]U0126[\\CHEMICAL] induces apoptosis but fails to activate [GENE]JNK[\\GENE] phosphorylation or down-regulate beta-catenin protein expression.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Inhibition of ERK1/2 with [CHEMICAL]U0126[\\CHEMICAL] induces apoptosis but fails to activate JNK phosphorylation or down-regulate [GENE]beta-catenin[\\GENE] protein expression.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] independently modulates extracellular signal-regulated kinase 1/2 and [GENE]cyclic GMP-dependent protein kinase[\\GENE] signaling pathways.",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "These results indicate that [CHEMICAL]sulindac[\\CHEMICAL] metabolites modulate ERK1/2 and [GENE]PKG[\\GENE] pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway.",
        "label": 2,
        "major": 7,
        "len": 32
    },
    {
        "text": "Cotreatment with [CHEMICAL]U0126[\\CHEMICAL] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [GENE]JNK[\\GENE], and beta-catenin.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Cotreatment with U0126 and [CHEMICAL]YC-1[\\CHEMICAL] synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, [GENE]JNK[\\GENE], and beta-catenin.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of [CHEMICAL]sulindac[\\CHEMICAL] treatment on ERK1/2, [GENE]JNK[\\GENE], and beta-catenin.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate [GENE]cyclic GMP-dependent protein kinase[\\GENE] (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase ([GENE]PKG[\\GENE]); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "Cotreatment with [CHEMICAL]U0126[\\CHEMICAL] and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and [GENE]beta-catenin[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Cotreatment with U0126 and [CHEMICAL]YC-1[\\CHEMICAL] synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and [GENE]beta-catenin[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of [CHEMICAL]sulindac[\\CHEMICAL] treatment on ERK1/2, JNK, and [GENE]beta-catenin[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease [GENE]beta-catenin[\\GENE] protein expression at times and doses consistent with apoptosis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate [GENE]c-jun NH2-terminal kinase[\\GENE] (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Sulindac[\\CHEMICAL] metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase ([GENE]JNK[\\GENE]); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Glyphosate[\\CHEMICAL] affects aromatic amino acid biosynthesis by inhibiting [GENE]5-enolpyruvylshikimate-3-phosphate synthase[\\GENE] (EPSPS).",
        "label": 4,
        "major": 1,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Glyphosate[\\CHEMICAL] affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase ([GENE]EPSPS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Glufosinate[\\CHEMICAL] inhibits [GENE]glutamine synthetase[\\GENE] and blocks biosynthesis of glutamine.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Glufosinate inhibits [GENE]glutamine synthetase[\\GENE] and blocks biosynthesis of [CHEMICAL]glutamine[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Citalopram[\\CHEMICAL], which is devoid of affinity for the [GENE]NET[\\GENE], exerted a significant reduction of immobility time in the NET-/- mice.",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "Autoradiographic studies showed decreased binding of the beta-adrenergic ligand [CHEMICAL][3H]CGP12177[\\CHEMICAL] in the cerebral cortex of NET-/- mice, indicating the changes at the level of [GENE]beta-adrenergic receptors[\\GENE] similar to those obtained with ADs treatment.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The binding of [CHEMICAL][3H]prazosin[\\CHEMICAL] to [GENE]alpha1-adrenergic receptors[\\GENE] in the cerebral cortex of NET-/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular NE levels observed in these mice.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by [GENE]NET[\\GENE]-inhibiting ADs such as [CHEMICAL]reboxetine[\\CHEMICAL], desipramine, and imipramine.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by [GENE]NET[\\GENE]-inhibiting ADs such as reboxetine, [CHEMICAL]desipramine[\\CHEMICAL], and imipramine.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by [GENE]NET[\\GENE]-inhibiting ADs such as reboxetine, desipramine, and [CHEMICAL]imipramine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Reboxetine[\\CHEMICAL], a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [GENE]human norepinephrine transporter[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Reboxetine[\\CHEMICAL], a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [GENE]human norepinephrine transporter[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Theophylline[\\CHEMICAL] exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A, but [GENE]PDE4D[\\GENE] gene expression was unchanged.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Theophylline[\\CHEMICAL] exposure resulted in a sustained increase in mRNA expression for [GENE]CysS[\\GENE] and PDE3A, but PDE4D gene expression was unchanged.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Theophylline[\\CHEMICAL] exposure resulted in a sustained increase in mRNA expression for CysS and [GENE]PDE3A[\\GENE], but PDE4D gene expression was unchanged.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Multiple exposure to [CHEMICAL]theophylline[\\CHEMICAL], a phosphodiesterase ([GENE]PDE[\\GENE]) inhibitor, induces acinar hypertrophy in the salivary gland.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Multiple exposure to [CHEMICAL]theophylline[\\CHEMICAL], a [GENE]phosphodiesterase[\\GENE] (PDE) inhibitor, induces acinar hypertrophy in the salivary gland.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and [CHEMICAL]RSD1235[\\CHEMICAL], a novel mixed [GENE]ion channel[\\GENE] blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.",
        "label": 4,
        "major": 3,
        "len": 56
    },
    {
        "text": "The [GENE]Na channel[\\GENE] block caused by [CHEMICAL]lidocaine[\\CHEMICAL] and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "The [GENE]Na channel[\\GENE] block caused by lidocaine and [CHEMICAL]RSD1235[\\CHEMICAL] can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]NO[\\CHEMICAL] rebinding in [GENE]HNS[\\GENE] from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "[CHEMICAL]NO[\\CHEMICAL] rebinding in HNS from Staphylococcus aureus ([GENE]SA-HNS[\\GENE]) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]NO[\\CHEMICAL] rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis ([GENE]BA-HNS[\\GENE]) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]NO[\\CHEMICAL] rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for [GENE]eNOS(HD)[\\GENE] in both oxidized and reduced forms in the presence of arginine.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Dynamics of [CHEMICAL]NO[\\CHEMICAL] rebinding to the [GENE]heme domain of NO synthase-like proteins[\\GENE] from bacterial pathogens.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "We conclude that lutein and [CHEMICAL]EPA[\\CHEMICAL] interact through the [GENE]PPARgamma[\\GENE] and RXR pathways to modulate iNOS mRNA.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "We conclude that lutein and [CHEMICAL]EPA[\\CHEMICAL] interact through the PPARgamma and [GENE]RXR[\\GENE] pathways to modulate iNOS mRNA.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "Lutein and [CHEMICAL]eicosapentaenoic acid[\\CHEMICAL] interact to modify iNOS mRNA levels through the [GENE]PPARgamma[\\GENE]/RXR pathway in chickens and HD11 cell lines.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Lutein and [CHEMICAL]eicosapentaenoic acid[\\CHEMICAL] interact to modify iNOS mRNA levels through the PPARgamma/[GENE]RXR[\\GENE] pathway in chickens and HD11 cell lines.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "We conclude that lutein and [CHEMICAL]EPA[\\CHEMICAL] interact through the PPARgamma and RXR pathways to modulate [GENE]iNOS[\\GENE] mRNA.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Lutein and [CHEMICAL]eicosapentaenoic acid[\\CHEMICAL] interact to modify [GENE]iNOS[\\GENE] mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]GW9662[\\CHEMICAL], a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced [GENE]iNOS[\\GENE] mRNA downregulation in HD11 cells.",
        "label": 3,
        "major": 6,
        "len": 16
    },
    {
        "text": "[CHEMICAL]GW9662[\\CHEMICAL], a [GENE]PPARgamma[\\GENE] antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.",
        "label": 6,
        "major": 3,
        "len": 16
    },
    {
        "text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide ([CHEMICAL]ramelteon[\\CHEMICAL], TAK-375), a selective [GENE]MT1/MT2 receptor[\\GENE] agonist, on motor coordination was studied using rota-rod performance in mice.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, [CHEMICAL]TAK-375[\\CHEMICAL]), a selective [GENE]MT1/MT2 receptor[\\GENE] agonist, on motor coordination was studied using rota-rod performance in mice.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Effect of [CHEMICAL]ramelteon[\\CHEMICAL] (TAK-375), a selective [GENE]MT1/MT2 receptor[\\GENE] agonist, on motor performance in mice.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "Effect of ramelteon ([CHEMICAL]TAK-375[\\CHEMICAL]), a selective [GENE]MT1/MT2 receptor[\\GENE] agonist, on motor performance in mice.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "Effect of [CHEMICAL](S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide[\\CHEMICAL] (ramelteon, TAK-375), a selective [GENE]MT1/MT2 receptor[\\GENE] agonist, on motor coordination was studied using rota-rod performance in mice.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Thus, [CHEMICAL]sorafenib[\\CHEMICAL] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of [GENE]Raf[\\GENE] and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Thus, [CHEMICAL]sorafenib[\\CHEMICAL] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and [GENE]Kit[\\GENE] signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Thus, [CHEMICAL]sorafenib[\\CHEMICAL] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of [GENE]VEGFR[\\GENE] and PDGFR signaling).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Thus, [CHEMICAL]sorafenib[\\CHEMICAL] may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and [GENE]PDGFR[\\GENE] signaling).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [GENE]tyrosine kinases[\\GENE] VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases [GENE]VEGFR[\\GENE]/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/[GENE]PDGFR[\\GENE] in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets [GENE]RAF[\\GENE]/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/[GENE]MEK[\\GENE]/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/[GENE]ERK[\\GENE] pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [GENE]tyrosine kinases[\\GENE] VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases [GENE]VEGFR[\\GENE]/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/[GENE]PDGFR[\\GENE] in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets [GENE]RAF[\\GENE]/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets RAF/[GENE]MEK[\\GENE]/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar), a dual-action inhibitor that targets RAF/MEK/[GENE]ERK[\\GENE] pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and [GENE]tyrosine kinases[\\GENE] VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases [GENE]VEGFR[\\GENE]/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/[GENE]PDGFR[\\GENE] in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets [GENE]RAF[\\GENE]/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets RAF/[GENE]MEK[\\GENE]/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]), a dual-action inhibitor that targets RAF/MEK/[GENE]ERK[\\GENE] pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the [GENE]vascular endothelial growth factor receptor[\\GENE] family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family ([GENE]VEGFR-2[\\GENE] and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and [GENE]VEGFR-3[\\GENE]) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and [GENE]platelet-derived growth factor receptor[\\GENE] family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family ([GENE]PDGFR-beta[\\GENE] and Kit), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Further characterization of [CHEMICAL]sorafenib[\\CHEMICAL] revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and [GENE]Kit[\\GENE]), which play key roles in tumor progression and angiogenesis.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "A novel class of [CHEMICAL]biaryl urea[\\CHEMICAL] that inhibits [GENE]C-RAF[\\GENE] kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "A novel class of [CHEMICAL]biaryl urea[\\CHEMICAL] that inhibits C-RAF [GENE]kinase[\\GENE] was discovered using a combination of medicinal and combinatorial chemistry approaches.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] inhibited the [GENE]kinase[\\GENE] activity of both C-RAF and B-RAF (wild type and V600E mutant).",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] inhibited the kinase activity of both [GENE]C-RAF[\\GENE] and B-RAF (wild type and V600E mutant).",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] inhibited the kinase activity of both C-RAF and [GENE]B-RAF[\\GENE] (wild type and V600E mutant).",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] inhibited the kinase activity of both C-RAF and B-RAF (wild type and [GENE]V600E[\\GENE] mutant).",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "In the present study, we have evaluated possible participation of [GENE]monocarboxylate transporters[\\GENE] (MCTs) responsible for the bidirectional membrane transport of [CHEMICAL]pyruvate[\\CHEMICAL] in the cytoprotective property in osteoblasts.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "In the present study, we have evaluated possible participation of monocarboxylate transporters ([GENE]MCTs[\\GENE]) responsible for the bidirectional membrane transport of [CHEMICAL]pyruvate[\\CHEMICAL] in the cytoprotective property in osteoblasts.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "The x-ray co-crystal structure of LeuRS showed that a [CHEMICAL]C[\\CHEMICAL]-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the [GENE]LeuRSs[\\GENE] and interacts with the corner of the L-shaped tRNALeu.",
        "label": 1,
        "major": 2,
        "len": 35
    },
    {
        "text": "The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60 [CHEMICAL]amino acids[\\CHEMICAL] forms a discrete domain, which is unique among the [GENE]LeuRSs[\\GENE] and interacts with the corner of the L-shaped tRNALeu.",
        "label": 1,
        "major": 1,
        "len": 35
    },
    {
        "text": "Interestingly, deletion of the entire [GENE]yeast mitochondrial LeuRS[\\GENE] [CHEMICAL]C[\\CHEMICAL]-terminal domain enhanced its aminoacylation and amino acid editing activities.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "Interestingly, deletion of the entire [GENE]yeast mitochondrial LeuRS[\\GENE] C-terminal domain enhanced its aminoacylation and [CHEMICAL]amino acid[\\CHEMICAL] editing activities.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "In striking contrast, deletion of the corresponding [CHEMICAL]C[\\CHEMICAL]-terminal domain of [GENE]Escherichia coli LeuRS[\\GENE] abolished aminoacylation of tRNALeu and also amino acid editing of mischarged tRNA molecules.",
        "label": 1,
        "major": 1,
        "len": 26
    },
    {
        "text": "In striking contrast, deletion of the corresponding C-terminal domain of [GENE]Escherichia coli LeuRS[\\GENE] abolished aminoacylation of tRNALeu and also [CHEMICAL]amino acid[\\CHEMICAL] editing of mischarged tRNA molecules.",
        "label": 1,
        "major": 1,
        "len": 26
    },
    {
        "text": "Herein, we determined that a fiveamino acid [CHEMICAL]C[\\CHEMICAL]-terminal deletion of [GENE]LeuRS[\\GENE], which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner.",
        "label": 1,
        "major": 1,
        "len": 32
    },
    {
        "text": "As part of an effort to discover orally active reversible inhibitors of [GENE]MetAP2[\\GENE], a series of [CHEMICAL]anthranilic acid sulfonamides[\\CHEMICAL] with micromolar affinities for human MetAP2 were identified using affinity selection by mass spectrometry (ASMS) screening.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "As part of an effort to discover orally active reversible inhibitors of MetAP2, a series of [CHEMICAL]anthranilic acid sulfonamides[\\CHEMICAL] with micromolar affinities for [GENE]human MetAP2[\\GENE] were identified using affinity selection by mass spectrometry (ASMS) screening.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Discovery and optimization of [CHEMICAL]anthranilic acid sulfonamides[\\CHEMICAL] as inhibitors of [GENE]methionine aminopeptidase-2[\\GENE]: a structural basis for the reduction of albumin binding.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "Discovery and optimization of [CHEMICAL]anthranilic acid sulfonamides[\\CHEMICAL] as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of [GENE]albumin[\\GENE] binding.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "When HUVECs were stimulated by thrombin in the presence of 100 microM L-arginine, [GENE]NOS[\\GENE] activity and NO release were similar in untreated and [CHEMICAL]Nor-NOHA[\\CHEMICAL]-treated cells.",
        "label": 10,
        "major": 3,
        "len": 25
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor [CHEMICAL]N(omega)-hydroxy-nor-L-arginine[\\CHEMICAL] (Nor-NOHA) on the activity of [GENE]NOS[\\GENE], arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 9,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor [CHEMICAL]N(omega)-hydroxy-nor-L-arginine[\\CHEMICAL] (Nor-NOHA) on the activity of NOS, [GENE]arginases[\\GENE], and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor [CHEMICAL]N(omega)-hydroxy-nor-L-arginine[\\CHEMICAL] (Nor-NOHA) on the activity of NOS, arginases, and [GENE]L-arginine transporter[\\GENE] and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine ([CHEMICAL]Nor-NOHA[\\CHEMICAL]) on the activity of [GENE]NOS[\\GENE], arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 9,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine ([CHEMICAL]Nor-NOHA[\\CHEMICAL]) on the activity of NOS, [GENE]arginases[\\GENE], and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine ([CHEMICAL]Nor-NOHA[\\CHEMICAL]) on the activity of NOS, arginases, and [GENE]L-arginine transporter[\\GENE] and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "When HUVECs were stimulated by thrombin without extracellular L-arginine, [CHEMICAL]Nor-NOHA[\\CHEMICAL] dose-dependently increased the [GENE]NOS[\\GENE] activity and the NO release with maximal effects at 20 microM.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Extracellular [CHEMICAL]L-arginine[\\CHEMICAL] also dose-dependently increased NO release and [GENE]arginase[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive [GENE]arginase[\\GENE] inhibitor [CHEMICAL]N(omega)-hydroxy-nor-L-arginine[\\CHEMICAL] (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 4,
        "major": 9,
        "len": 42
    },
    {
        "text": "To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive [GENE]arginase[\\GENE] inhibitor N(omega)-hydroxy-nor-L-arginine ([CHEMICAL]Nor-NOHA[\\CHEMICAL]) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 4,
        "major": 9,
        "len": 42
    },
    {
        "text": "In unstimulated cells, [CHEMICAL]Nor-NOHA[\\CHEMICAL] dose-dependently reduced the [GENE]arginase[\\GENE] activity with maximal inhibition at 20 microM.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "However, despite activation of L-arginine uptake, the inhibition of [GENE]arginase[\\GENE] activity by [CHEMICAL]Nor-NOHA[\\CHEMICAL] was still significant.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Reduced synthesis of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of [GENE]constitutive nitric-oxide synthase[\\GENE] (NOS) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ([GENE]NOS[\\GENE]) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Reduced synthesis of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic [GENE]arginase I[\\GENE] and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and [GENE]mitochondrial arginase II[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "To determine whether [GENE]arginases[\\GENE] modulate the endothelial [CHEMICAL]NO[\\CHEMICAL] synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).",
        "label": 9,
        "major": 7,
        "len": 42
    },
    {
        "text": "Reduced synthesis of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of [GENE]constitutive nitric-oxide synthase[\\GENE] (NOS) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ([GENE]NOS[\\GENE]) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic [GENE]arginase I[\\GENE] and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and [GENE]mitochondrial arginase II[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "[GENE]Mitochondrial arginase II[\\GENE] modulates [CHEMICAL]nitric-oxide[\\CHEMICAL] synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.",
        "label": 9,
        "major": 7,
        "len": 15
    },
    {
        "text": "[GENE]Mitochondrial arginase II[\\GENE] modulates nitric-oxide synthesis through nonfreely exchangeable [CHEMICAL]L-arginine[\\CHEMICAL] pools in human endothelial cells.",
        "label": 9,
        "major": 7,
        "len": 15
    },
    {
        "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of [CHEMICAL]L-arginine[\\CHEMICAL], the common substrate of [GENE]constitutive nitric-oxide synthase[\\GENE] (NOS) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of [CHEMICAL]L-arginine[\\CHEMICAL], the common substrate of constitutive nitric-oxide synthase ([GENE]NOS[\\GENE]) and cytosolic arginase I and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of [CHEMICAL]L-arginine[\\CHEMICAL], the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic [GENE]arginase I[\\GENE] and mitochondrial arginase II.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of [CHEMICAL]L-arginine[\\CHEMICAL], the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and [GENE]mitochondrial arginase II[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both [CHEMICAL]octreotide[\\CHEMICAL] and lanreotide bind preferentially to [GENE]SSTR2[\\GENE] and, to a lesser extent, to SSTR5.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both [CHEMICAL]octreotide[\\CHEMICAL] and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to [GENE]SSTR5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and [CHEMICAL]lanreotide[\\CHEMICAL] bind preferentially to [GENE]SSTR2[\\GENE] and, to a lesser extent, to SSTR5.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and [CHEMICAL]lanreotide[\\CHEMICAL] bind preferentially to SSTR2 and, to a lesser extent, to [GENE]SSTR5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Qualitatively similar but significantly attenuated responses to the [CHEMICAL]catecholamines[\\CHEMICAL] were observed in tissue from ANXA1-null mice, an effect that was not associated with changes in [GENE]beta-adrenoceptor[\\GENE] mRNA expression.",
        "label": 10,
        "major": 10,
        "len": 28
    },
    {
        "text": "Epididymal tissue from wild-type mice responded in vitro to [CHEMICAL]noradrenaline[\\CHEMICAL] and isoprenaline with increased glycerol release, reduced [GENE]IL-6[\\GENE] release, and increased cAMP accumulation.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Epididymal tissue from wild-type mice responded in vitro to noradrenaline and [CHEMICAL]isoprenaline[\\CHEMICAL] with increased glycerol release, reduced [GENE]IL-6[\\GENE] release, and increased cAMP accumulation.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of [GENE]MEN1[\\GENE] that results in a replacement of [CHEMICAL]lysine[\\CHEMICAL] by glutamic acid.",
        "label": 1,
        "major": 1,
        "len": 34
    },
    {
        "text": "The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of [GENE]MEN1[\\GENE] that results in a replacement of lysine by [CHEMICAL]glutamic acid[\\CHEMICAL].",
        "label": 1,
        "major": 1,
        "len": 34
    },
    {
        "text": "Comparison of [GENE]cyclooxygenase[\\GENE] inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and [CHEMICAL]bromfenac sodium[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Comparison of [GENE]cyclooxygenase[\\GENE] inhibitory activity and ocular anti-inflammatory effects of [CHEMICAL]ketorolac tromethamine[\\CHEMICAL] and bromfenac sodium.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "METHODS: [GENE]Cyclooxygenase[\\GENE] activity and selectivity was determined in vitro by measuring [CHEMICAL]prostaglandin E(2)[\\CHEMICAL] (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "METHODS: [GENE]Cyclooxygenase[\\GENE] activity and selectivity was determined in vitro by measuring prostaglandin E(2) ([CHEMICAL]PGE(2)[\\CHEMICAL]) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [GENE]c-FOS[\\GENE] mRNA, whereas [CHEMICAL]mesalamine[\\CHEMICAL] had no effect.",
        "label": 10,
        "major": 4,
        "len": 28
    },
    {
        "text": "Colonic [GENE]cyclooxygenase-2[\\GENE] and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by [CHEMICAL]mesalamine[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 19
    },
    {
        "text": "Colonic cyclooxygenase-2 and [GENE]interkeukin-1beta[\\GENE] mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by [CHEMICAL]mesalamine[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal [GENE]c-FOS[\\GENE] mRNA expression were significantly down-regulated by ATB-429, but not by [CHEMICAL]mesalamine[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Taken together, these data suggest that [CHEMICAL]ATB-429[\\CHEMICAL] inhibits hypersensitivity induced by CRD in both healthy and postcolitic, allodynic rats by a [GENE]K(ATP) channel[\\GENE]-mediated mechanism.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "In healthy rats, [CHEMICAL]ATB-429[\\CHEMICAL] dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal [GENE]c-FOS[\\GENE] mRNA, whereas mesalamine had no effect.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Colonic [GENE]cyclooxygenase-2[\\GENE] and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [CHEMICAL]ATB-429[\\CHEMICAL], but not by mesalamine.",
        "label": 4,
        "major": 10,
        "len": 19
    },
    {
        "text": "Colonic cyclooxygenase-2 and [GENE]interkeukin-1beta[\\GENE] mRNA and spinal c-FOS mRNA expression were significantly down-regulated by [CHEMICAL]ATB-429[\\CHEMICAL], but not by mesalamine.",
        "label": 4,
        "major": 10,
        "len": 19
    },
    {
        "text": "Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal [GENE]c-FOS[\\GENE] mRNA expression were significantly down-regulated by [CHEMICAL]ATB-429[\\CHEMICAL], but not by mesalamine.",
        "label": 4,
        "major": 10,
        "len": 19
    },
    {
        "text": "ATB-429-induced antinociception was reversed by [CHEMICAL]glibenclamide[\\CHEMICAL], a [GENE]ATP-sensitive K(+) (K(ATP)) channel[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "CONCLUSION: The peptide sequences containing [CHEMICAL]Tyr[\\CHEMICAL], Phe conservative residues identified in this study can bind to cell surface [GENE]IL-2Ralpha[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "CONCLUSION: The peptide sequences containing Tyr, [CHEMICAL]Phe[\\CHEMICAL] conservative residues identified in this study can bind to cell surface [GENE]IL-2Ralpha[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "The [GENE]adenosine triphosphate binding cassette (ABC)-transporter[\\GENE] ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs [CHEMICAL]cisplatin[\\CHEMICAL] and paclitaxel.",
        "label": 10,
        "major": 9,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter [GENE]ABCC2[\\GENE] (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs [CHEMICAL]cisplatin[\\CHEMICAL] and paclitaxel.",
        "label": 10,
        "major": 9,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 ([GENE]MRP2[\\GENE]/cMOAT) can mediate resistance against the commonly used anticancer drugs [CHEMICAL]cisplatin[\\CHEMICAL] and paclitaxel.",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/[GENE]cMOAT[\\GENE]) can mediate resistance against the commonly used anticancer drugs [CHEMICAL]cisplatin[\\CHEMICAL] and paclitaxel.",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "The [GENE]adenosine triphosphate binding cassette (ABC)-transporter[\\GENE] ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 10,
        "major": 9,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter [GENE]ABCC2[\\GENE] (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 ([GENE]MRP2[\\GENE]/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/[GENE]cMOAT[\\GENE]) can mediate resistance against the commonly used anticancer drugs cisplatin and [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 10,
        "major": 2,
        "len": 20
    },
    {
        "text": "A premature stop codon (TGA) replaces the expected [CHEMICAL]tryptophan[\\CHEMICAL] codon at position seven of [GENE]GnRH-II[\\GENE] in sheep DNA.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The updated [GENE]bovine type II GnRH receptor[\\GENE] gene sequence revealed inactivation by frame shifts, premature stop codons, and [CHEMICAL]nucleotide[\\CHEMICAL] changes specifying nonconservative replacement of amino acid residues, similar to inactivation of sheep type II GnRH receptor.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "The updated [GENE]bovine type II GnRH receptor[\\GENE] gene sequence revealed inactivation by frame shifts, premature stop codons, and nucleotide changes specifying nonconservative replacement of [CHEMICAL]amino acid[\\CHEMICAL] residues, similar to inactivation of sheep type II GnRH receptor.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "Liver choline dehydrogenase and kidney [GENE]betaine-homocysteine methyltransferase[\\GENE] expression are not affected by [CHEMICAL]methionine[\\CHEMICAL] or choline intake in growing rats.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Liver [GENE]choline dehydrogenase[\\GENE] and kidney betaine-homocysteine methyltransferase expression are not affected by [CHEMICAL]methionine[\\CHEMICAL] or choline intake in growing rats.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Liver choline dehydrogenase and kidney [GENE]betaine-homocysteine methyltransferase[\\GENE] expression are not affected by methionine or [CHEMICAL]choline[\\CHEMICAL] intake in growing rats.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Liver [GENE]choline dehydrogenase[\\GENE] and kidney betaine-homocysteine methyltransferase expression are not affected by methionine or [CHEMICAL]choline[\\CHEMICAL] intake in growing rats.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Liver [GENE]BHMT[\\GENE] activity was 1.3-fold higher in rats fed the Met deficient diet containing [CHEMICAL]choline[\\CHEMICAL], which was reflected in corresponding increases in mRNA content and immunodetectable protein.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Independent of dietary [CHEMICAL]choline[\\CHEMICAL], supplemental Met increased hepatic [GENE]BHMT[\\GENE] activity approximately 30%.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Independent of dietary choline, supplemental [CHEMICAL]Met[\\CHEMICAL] increased hepatic [GENE]BHMT[\\GENE] activity approximately 30%.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Liver [GENE]BHMT[\\GENE] activity was 1.3-fold higher in rats fed the Met deficient diet containing [CHEMICAL]choline[\\CHEMICAL], which was reflected in corresponding increases in mRNA content and immunodetectable protein.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "The beta(2)-adrenoceptor ([GENE]beta(2)-AR[\\GENE]) agonists [CHEMICAL]clenbuterol[\\CHEMICAL] and fenoterol have similar beneficial effects in animal models of heart failure.",
        "label": 5,
        "major": 10,
        "len": 17
    },
    {
        "text": "The [GENE]beta(2)-adrenoceptor[\\GENE] (beta(2)-AR) agonists [CHEMICAL]clenbuterol[\\CHEMICAL] and fenoterol have similar beneficial effects in animal models of heart failure.",
        "label": 5,
        "major": 10,
        "len": 17
    },
    {
        "text": "The beta(2)-adrenoceptor ([GENE]beta(2)-AR[\\GENE]) agonists clenbuterol and [CHEMICAL]fenoterol[\\CHEMICAL] have similar beneficial effects in animal models of heart failure.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "The [GENE]beta(2)-adrenoceptor[\\GENE] (beta(2)-AR) agonists clenbuterol and [CHEMICAL]fenoterol[\\CHEMICAL] have similar beneficial effects in animal models of heart failure.",
        "label": 5,
        "major": 10,
        "len": 17
    },
    {
        "text": "[GENE]beta(1)-Adrenoceptor[\\GENE] antagonism (10 mg kg(-1) [CHEMICAL]bisoprolol[\\CHEMICAL]) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Fingolimod[\\CHEMICAL] (FTY720), a synthetic [GENE]sphingosine phosphate receptor[\\GENE] modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Fingolimod ([CHEMICAL]FTY720[\\CHEMICAL]), a synthetic [GENE]sphingosine phosphate receptor[\\GENE] modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.",
        "label": 2,
        "major": 7,
        "len": 30
    },
    {
        "text": "CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic [CHEMICAL]malononitrilamide[\\CHEMICAL] that targets the critical enzyme of the de novo pyrimidine synthesis, [GENE]dihydroorotic acid dehydrogenase[\\GENE], and receptor-associated tyrosine kinases has completed phase II trials.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic [CHEMICAL]malononitrilamide[\\CHEMICAL] that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and [GENE]receptor-associated tyrosine kinases[\\GENE] has completed phase II trials.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "[CHEMICAL]CP-690550[\\CHEMICAL], a [GENE]JAK3[\\GENE] inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "To address this issue and taking into account that effects of synthetic [CHEMICAL]progestins[\\CHEMICAL] are not only referable to action through the [GENE]progesterone receptor[\\GENE] but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity.",
        "label": 10,
        "major": 10,
        "len": 59
    },
    {
        "text": "To address this issue and taking into account that effects of synthetic [CHEMICAL]progestins[\\CHEMICAL] are not only referable to action through the progesterone receptor but may also be mediated by other [GENE]steroid receptors[\\GENE], we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity.",
        "label": 2,
        "major": 10,
        "len": 59
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL] reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [GENE]monocyte chemoattractant protein-1[\\GENE] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL] reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 ([GENE]MCP-1[\\GENE]) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL] reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of [GENE]nuclear factor-kappaB[\\GENE] in rabbit atheroma.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Moreover, [CHEMICAL]licofelone[\\CHEMICAL] inhibited [GENE]COX-2[\\GENE] and 5-LOX protein expression in vascular lesions.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Moreover, [CHEMICAL]licofelone[\\CHEMICAL] inhibited COX-2 and [GENE]5-LOX[\\GENE] protein expression in vascular lesions.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of [GENE]COX-2[\\GENE], [CHEMICAL]rofecoxib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a balanced inhibitor of [GENE]cyclooxygenase[\\GENE] and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a balanced inhibitor of cyclooxygenase and [GENE]5-lipoxygenase[\\GENE], reduces inflammation in a rabbit model of atherosclerosis.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to [GENE]cycloxygenase-1[\\GENE] blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a dual anti-inflammatory drug that inhibits [GENE]5-lipoxygenase[\\GENE] (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a dual anti-inflammatory drug that inhibits 5-lipoxygenase ([GENE]LOX[\\GENE]) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and [GENE]cyclooxygenase[\\GENE] (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL], a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase ([GENE]COX[\\GENE]) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Licofelone[\\CHEMICAL] almost abolished [GENE]5-LOX[\\GENE] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Licofelone almost abolished [GENE]5-LOX[\\GENE] activity by inhibiting [CHEMICAL]leukotriene B4[\\CHEMICAL] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Licofelone almost abolished [GENE]5-LOX[\\GENE] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet [CHEMICAL]thromboxane B2[\\CHEMICAL] production from whole blood.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Chronic insulin (24 h) activates NHE3 through the classic [GENE]phosphatidylinositol 3-kinase[\\GENE]-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [CHEMICAL]wortmannin[\\CHEMICAL] or a dominant-negative SGK1.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 ([GENE]PI3K[\\GENE]-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [CHEMICAL]wortmannin[\\CHEMICAL] or a dominant-negative SGK1.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the [GENE]PI3K[\\GENE] inhibitor [CHEMICAL]wortmannin[\\CHEMICAL] or a dominant-negative SGK1.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "The potent and selective third-generation [GENE]aromatase[\\GENE] inhibitors anastrozole, [CHEMICAL]letrozole[\\CHEMICAL] and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Anastrozole[\\CHEMICAL] and letrozole are both non-steroidal [GENE]aromatase[\\GENE] inhibitors that compete with the substrate for binding to the enzyme active site.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Anastrozole and [CHEMICAL]letrozole[\\CHEMICAL] are both non-steroidal [GENE]aromatase[\\GENE] inhibitors that compete with the substrate for binding to the enzyme active site.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The potent and selective third-generation [GENE]aromatase[\\GENE] inhibitors [CHEMICAL]anastrozole[\\CHEMICAL], letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In breast cancer, intratumoural [GENE]aromatase[\\GENE] is the source for local [CHEMICAL]estrogen[\\CHEMICAL] production in the tissue.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "[GENE]IRF3[\\GENE] activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by [CHEMICAL]auranofin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "IRF3 activation induced by MyD88-independent signaling components, [GENE]TRIF[\\GENE] and TBK1, was also downregulated by [CHEMICAL]auranofin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "IRF3 activation induced by MyD88-independent signaling components, TRIF and [GENE]TBK1[\\GENE], was also downregulated by [CHEMICAL]auranofin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Our results demonstrated that [CHEMICAL]auranofin[\\CHEMICAL] suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of [GENE]COX-2[\\GENE], a pro-inflammatory enzyme.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, [CHEMICAL]auranofin[\\CHEMICAL] inhibited [GENE]NF-kappaB[\\GENE] activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Auranofin[\\CHEMICAL], as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of [GENE]TLR4[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "Our results demonstrated that [CHEMICAL]auranofin[\\CHEMICAL] suppressed [GENE]TLR4[\\GENE]-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our results demonstrated that [CHEMICAL]auranofin[\\CHEMICAL] suppressed TLR4-mediated activation of transcription factors, [GENE]NF-kappaB[\\GENE] and IRF3, and expression of COX-2, a pro-inflammatory enzyme.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our results demonstrated that [CHEMICAL]auranofin[\\CHEMICAL] suppressed TLR4-mediated activation of transcription factors, NF-kappaB and [GENE]IRF3[\\GENE], and expression of COX-2, a pro-inflammatory enzyme.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "This suppression was well correlated with the inhibitory effect of [CHEMICAL]auranofin[\\CHEMICAL] on the homodimerization of [GENE]TLR4[\\GENE] induced by an agonist.",
        "label": 4,
        "major": 5,
        "len": 20
    },
    {
        "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens was catalyzed by [GENE]NADH cytochrome b5 reductase[\\GENE] (b5R) and cytochrome b5 (cyt b5).",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens was catalyzed by NADH cytochrome b5 reductase ([GENE]b5R[\\GENE]) and cytochrome b5 (cyt b5).",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and [GENE]cytochrome b5[\\GENE] (cyt b5).",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 ([GENE]cyt b5[\\GENE]).",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found that reduction of the carcinogenic [CHEMICAL]hydroxylamines[\\CHEMICAL] of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic [CHEMICAL]hydroxylamines[\\CHEMICAL] of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the [CHEMICAL]aromatic amine[\\CHEMICAL] 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the [CHEMICAL]aromatic amine[\\CHEMICAL] 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine [CHEMICAL]4-aminobiphenyl[\\CHEMICAL] (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine [CHEMICAL]4-aminobiphenyl[\\CHEMICAL] (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ([CHEMICAL]4-ABP[\\CHEMICAL]; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ([CHEMICAL]4-ABP[\\CHEMICAL]; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the [CHEMICAL]heterocyclic amine[\\CHEMICAL] 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the [CHEMICAL]heterocyclic amine[\\CHEMICAL] 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine [CHEMICAL]2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine[\\CHEMICAL] (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine [CHEMICAL]2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine[\\CHEMICAL] (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "Reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens by human NADH cytochrome b5 reductase and [GENE]cytochrome b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 14
    },
    {
        "text": "Reductive detoxification of [CHEMICAL]arylhydroxylamine[\\CHEMICAL] carcinogens by [GENE]human NADH cytochrome b5 reductase[\\GENE] and cytochrome b5.",
        "label": 9,
        "major": 4,
        "len": 14
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ([CHEMICAL]PhIP[\\CHEMICAL]; found in grilled meats) was indeed catalyzed by a purified system containing only [GENE]human b5R[\\GENE] and cyt b5.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ([CHEMICAL]PhIP[\\CHEMICAL]; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [GENE]cyt b5[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 44
    },
    {
        "text": "Polyclonal antisera to either [GENE]b5R[\\GENE] or cyt b5 significantly inhibited [CHEMICAL]N-hydroxy-4-aminobiphenyl[\\CHEMICAL] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "Polyclonal antisera to either b5R or [GENE]cyt b5[\\GENE] significantly inhibited [CHEMICAL]N-hydroxy-4-aminobiphenyl[\\CHEMICAL] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "Polyclonal antisera to either [GENE]b5R[\\GENE] or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl ([CHEMICAL]NHOH-4-ABP[\\CHEMICAL]) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "Polyclonal antisera to either b5R or [GENE]cyt b5[\\GENE] significantly inhibited N-hydroxy-4-aminobiphenyl ([CHEMICAL]NHOH-4-ABP[\\CHEMICAL]) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on [GENE]interleukin 1alpha[\\GENE] (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 10,
        "major": 3,
        "len": 54
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha ([GENE]IL-1alpha[\\GENE]) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 10,
        "major": 3,
        "len": 54
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and [GENE]receptor activator of nuclear factor kappa B ligand[\\GENE] (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 10,
        "major": 3,
        "len": 54
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand ([GENE]RANKL[\\GENE])-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 10,
        "major": 3,
        "len": 54
    },
    {
        "text": "Given that [GENE]M-CSF[\\GENE] signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with [CHEMICAL]imatinib[\\CHEMICAL] may modulate osteoclast activity.",
        "label": 4,
        "major": 7,
        "len": 26
    },
    {
        "text": "Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that [CHEMICAL]imatinib[\\CHEMICAL] may affect mature osteoclasts through the inhibition of [GENE]c-FMS[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 54
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular [GENE]tyrosine kinase[\\GENE] BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular tyrosine kinase [GENE]BCR[\\GENE]-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular tyrosine kinase BCR-[GENE]ABL[\\GENE] and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the [GENE]platelet derived growth factor (PDGF) receptor[\\GENE], is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the [GENE]macrophage colony stimulating factor (M-CSF) receptor[\\GENE], c-FMS.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, [GENE]c-FMS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Recent studies have reported that [CHEMICAL]imatinib mesylate[\\CHEMICAL], a [GENE]kinase[\\GENE] inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Given that M-CSF signalling through [GENE]c-FMS[\\GENE] plays an important role in osteoclast biology, we speculated that blocking such a pathway with [CHEMICAL]imatinib[\\CHEMICAL] may modulate osteoclast activity.",
        "label": 4,
        "major": 7,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit [GENE]M-CSF[\\GENE]-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 4,
        "major": 3,
        "len": 54
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] was also found to inhibit M-CSF-induced osteoclast survival as well as [GENE]M-CSF[\\GENE]-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.",
        "label": 4,
        "major": 3,
        "len": 54
    },
    {
        "text": "In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective [GENE]estrogen receptor[\\GENE] modulators (raloxifene and [CHEMICAL]toremifene[\\CHEMICAL]) increased bone mineral density in GnRH agonist-treated men.",
        "label": 2,
        "major": 7,
        "len": 25
    },
    {
        "text": "In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective [GENE]estrogen receptor[\\GENE] modulators ([CHEMICAL]raloxifene[\\CHEMICAL] and toremifene) increased bone mineral density in GnRH agonist-treated men.",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "Neonatal quinpirole treatment produced a significant decrease in [GENE]BDNF[\\GENE] and ChAT in the frontal cortex that was unaffected by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 10,
        "major": 9,
        "len": 21
    },
    {
        "text": "Neonatal quinpirole treatment produced a significant decrease in BDNF and [GENE]ChAT[\\GENE] in the frontal cortex that was unaffected by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 10,
        "major": 4,
        "len": 21
    },
    {
        "text": "Results showed that neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment induced [GENE]D2[\\GENE] priming that was eliminated by olanzapine treatment.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal [GENE]NGF[\\GENE], BDNF and ChAT that was eliminated by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, [GENE]BDNF[\\GENE] and ChAT that was eliminated by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and [GENE]ChAT[\\GENE] that was eliminated by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "Results showed that neonatal quinpirole treatment induced [GENE]D2[\\GENE] priming that was eliminated by [CHEMICAL]olanzapine[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Brain tissue analyses revealed that neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment produced a significant decrease in hippocampal [GENE]NGF[\\GENE], BDNF and ChAT that was eliminated by olanzapine treatment.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Brain tissue analyses revealed that neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment produced a significant decrease in hippocampal NGF, [GENE]BDNF[\\GENE] and ChAT that was eliminated by olanzapine treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Brain tissue analyses revealed that neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment produced a significant decrease in hippocampal NGF, BDNF and [GENE]ChAT[\\GENE] that was eliminated by olanzapine treatment.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment produced a significant decrease in [GENE]BDNF[\\GENE] and ChAT in the frontal cortex that was unaffected by olanzapine treatment.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Neonatal [CHEMICAL]quinpirole[\\CHEMICAL] treatment produced a significant decrease in BDNF and [GENE]ChAT[\\GENE] in the frontal cortex that was unaffected by olanzapine treatment.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "These results show that [CHEMICAL]olanzapine[\\CHEMICAL] eliminates [GENE]D2 receptor[\\GENE] priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "Histamine content, [GENE]HDC[\\GENE] activity and HDC mRNA expression in nasal mucosa were also significantly increased after [CHEMICAL]TDI[\\CHEMICAL] provocation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, [GENE]HDC[\\GENE] activity and HDC mRNA induced by [CHEMICAL]TDI[\\CHEMICAL] in TDI-sensitized rats.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Histamine content, HDC activity and [GENE]HDC[\\GENE] mRNA expression in nasal mucosa were also significantly increased after [CHEMICAL]TDI[\\CHEMICAL] provocation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [GENE]HDC[\\GENE] mRNA induced by [CHEMICAL]TDI[\\CHEMICAL] in TDI-sensitized rats.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [GENE]HDC[\\GENE] mRNA induced by TDI in [CHEMICAL]TDI[\\CHEMICAL]-sensitized rats.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Pretreatment with [CHEMICAL]dexamethasone[\\CHEMICAL] significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and [GENE]HDC[\\GENE] mRNA induced by TDI in TDI-sensitized rats.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Pretreatment with [CHEMICAL]dexamethasone[\\CHEMICAL] significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, [GENE]HDC[\\GENE] activity and HDC mRNA induced by TDI in TDI-sensitized rats.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "CONCLUSIONS: These findings indicate that increased synthesis of [CHEMICAL]histamine[\\CHEMICAL] through up-regulation of [GENE]HDC[\\GENE] gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "CONCLUSIONS: These findings indicate that increased synthesis of [CHEMICAL]histamine[\\CHEMICAL] through up-regulation of HDC gene expression and [GENE]HDC[\\GENE] activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Methionine synthase reductase ([GENE]MTRR[\\GENE]) is an enzyme involved in the conversion of Hcy to [CHEMICAL]methionine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "[GENE]Methionine synthase reductase[\\GENE] (MTRR) is an enzyme involved in the conversion of Hcy to [CHEMICAL]methionine[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 15
    },
    {
        "text": "Methionine synthase reductase ([GENE]MTRR[\\GENE]) is an enzyme involved in the conversion of [CHEMICAL]Hcy[\\CHEMICAL] to methionine.",
        "label": 9,
        "major": 4,
        "len": 15
    },
    {
        "text": "[GENE]Methionine synthase reductase[\\GENE] (MTRR) is an enzyme involved in the conversion of [CHEMICAL]Hcy[\\CHEMICAL] to methionine.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "[GENE]GPxs[\\GENE] reduce hydroperoxides to the corresponding [CHEMICAL]alcohols[\\CHEMICAL] by means of glutathione (GSH).",
        "label": 9,
        "major": 4,
        "len": 12
    },
    {
        "text": "The non-selective [GENE]adenosine receptor[\\GENE] antagonist ([CHEMICAL]caffeine[\\CHEMICAL]), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "The non-selective adenosine receptor antagonist (caffeine), and the selective [GENE]adenosine A1 receptor[\\GENE] antagonist ([CHEMICAL]DPCPX[\\CHEMICAL]), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of [CHEMICAL]flumazenil[\\CHEMICAL] (5.0 mg/kg) - a [GENE]BDZ receptor[\\GENE] antagonist, immediately induced BDZ withdrawal signs in these animals.",
        "label": 6,
        "major": 3,
        "len": 30
    },
    {
        "text": "In vitro data show comparable affinity to [GENE]dopamine D(2)[\\GENE], D(1) and 5-HT(2A) receptors and recently, [CHEMICAL]FLX[\\CHEMICAL] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), [GENE]D(1)[\\GENE] and 5-HT(2A) receptors and recently, [CHEMICAL]FLX[\\CHEMICAL] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and [GENE]5-HT(2A) receptors[\\GENE] and recently, [CHEMICAL]FLX[\\CHEMICAL] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, [CHEMICAL]FLX[\\CHEMICAL] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with [GENE]5-HT(2A)[\\GENE] and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, [CHEMICAL]FLX[\\CHEMICAL] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or [GENE]D(1) receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to [GENE]dopamine D(2)[\\GENE], D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [CHEMICAL]risperidone[\\CHEMICAL] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), [GENE]D(1)[\\GENE] and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [CHEMICAL]risperidone[\\CHEMICAL] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and [GENE]5-HT(2A) receptors[\\GENE] and recently, FLX showed to be not inferior to [CHEMICAL]risperidone[\\CHEMICAL] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [CHEMICAL]risperidone[\\CHEMICAL] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with [GENE]5-HT(2A)[\\GENE] and/or D(1) receptors.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [CHEMICAL]risperidone[\\CHEMICAL] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or [GENE]D(1) receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In addition to the [CHEMICAL]N[\\CHEMICAL]-terminal and [GENE]Src homology 2 domains[\\GENE] that mediate these interactions, SOCS proteins contain a C-terminal SOCS box.",
        "label": 1,
        "major": 2,
        "len": 21
    },
    {
        "text": "In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a [CHEMICAL]C[\\CHEMICAL]-terminal [GENE]SOCS box[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 21
    },
    {
        "text": "In the interaction of [CHEMICAL]GAL[\\CHEMICAL] and CAR, [GENE]AChE[\\GENE] inhibition was stronger but without any statistical significance.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "OBJECTIVES: The alkaloid [CHEMICAL]galantamine[\\CHEMICAL] (GAL), which exhibits a combined [GENE]anticholinesterase[\\GENE] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "OBJECTIVES: The alkaloid galantamine ([CHEMICAL]GAL[\\CHEMICAL]), which exhibits a combined [GENE]anticholinesterase[\\GENE] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "RESULTS: Following administration of the highest of the [CHEMICAL]GAL[\\CHEMICAL] doses used (2.5; 5; 10 mg/kg i.m. ), [GENE]AChE[\\GENE] activity decreased mainly in the frontal cortex, hippocampus and hypophysis.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and [CHEMICAL]warfarin[\\CHEMICAL] target enzyme, [GENE]vitamin K epoxide reductase complex 1[\\GENE] VKORC1, confirmed their influence on warfarin maintenance dose.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and [CHEMICAL]warfarin[\\CHEMICAL] target enzyme, vitamin K epoxide reductase complex 1 [GENE]VKORC1[\\GENE], confirmed their influence on warfarin maintenance dose.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pharmacogenetic analysis of two genes, the [CHEMICAL]warfarin[\\CHEMICAL] metabolic enzyme [GENE]CYP2C9[\\GENE] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Possession of [GENE]CYP2C9[\\GENE]*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [CHEMICAL]warfarin[\\CHEMICAL] dose.",
        "label": 9,
        "major": 4,
        "len": 24
    },
    {
        "text": "Possession of CYP2C9*2 or [GENE]CYP2C9[\\GENE]*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [CHEMICAL]warfarin[\\CHEMICAL] dose.",
        "label": 9,
        "major": 4,
        "len": 24
    },
    {
        "text": "The identification of the [GENE]succinate receptor[\\GENE] SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of [CHEMICAL]succinate[\\CHEMICAL] were shown to potentiate the effect of low doses of a variety of platelet agonists.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "The identification of the succinate receptor [GENE]SUCNR1[\\GENE] in platelets is of particular interest, because physiologically relevant concentrations of [CHEMICAL]succinate[\\CHEMICAL] were shown to potentiate the effect of low doses of a variety of platelet agonists.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to [CHEMICAL]foscarnet[\\CHEMICAL] ([GENE]V715M[\\GENE], T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 10,
        "major": 1,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to [CHEMICAL]foscarnet[\\CHEMICAL] (V715M, [GENE]T700A[\\GENE] and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 10,
        "major": 1,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to [CHEMICAL]foscarnet[\\CHEMICAL] (V715M, T700A and [GENE]N495K[\\GENE]) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 10,
        "major": 1,
        "len": 34
    },
    {
        "text": "The activity of [GENE]polymerases[\\GENE] containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of [CHEMICAL]foscarnet[\\CHEMICAL] eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to foscarnet ([GENE]V715M[\\GENE], T700A and N495K) was inhibited by concentrations of [CHEMICAL]foscarnet[\\CHEMICAL] eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, [GENE]T700A[\\GENE] and N495K) was inhibited by concentrations of [CHEMICAL]foscarnet[\\CHEMICAL] eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and [GENE]N495K[\\GENE]) was inhibited by concentrations of [CHEMICAL]foscarnet[\\CHEMICAL] eight to 14 times higher than those required to inhibit wild-type polymerases.",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of [CHEMICAL]foscarnet[\\CHEMICAL] eight to 14 times higher than those required to inhibit wild-type [GENE]polymerases[\\GENE].",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "[GENE]Adenine phosphoribosyltransferase[\\GENE] plays a role in purine salvage by catalyzing the direct conversion of adenine to [CHEMICAL]adenosine monophosphate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Adenine phosphoribosyltransferase[\\GENE] plays a role in purine salvage by catalyzing the direct conversion of [CHEMICAL]adenine[\\CHEMICAL] to adenosine monophosphate.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "The demonstration that [CHEMICAL]sorafenib[\\CHEMICAL] exhibits potent target inhibition and efficacy in [GENE]FLT3[\\GENE]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The demonstration that [CHEMICAL]sorafenib[\\CHEMICAL] exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with [GENE]FLT3[\\GENE]-driven leukemias.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We show that [CHEMICAL]sorafenib[\\CHEMICAL] (BAY 43-9006, Nexavar) potently inhibits [GENE]FLT3[\\GENE] enzymatic and signaling activities.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "We show that sorafenib ([CHEMICAL]BAY 43-9006[\\CHEMICAL], Nexavar) potently inhibits [GENE]FLT3[\\GENE] enzymatic and signaling activities.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "We show that sorafenib (BAY 43-9006, [CHEMICAL]Nexavar[\\CHEMICAL]) potently inhibits [GENE]FLT3[\\GENE] enzymatic and signaling activities.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "In leukemia cell lines MV4-11 and EOL-1, [CHEMICAL]sorafenib[\\CHEMICAL] treatment resulted in decreased cell proliferation and inhibition of [GENE]FLT3[\\GENE] signaling.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The growth of the [GENE]FLT3[\\GENE]-independent RS4-11 cell line was only weakly inhibited by [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with [GENE]rhArg[\\GENE], to [CHEMICAL]citrulline[\\CHEMICAL], which is converted back to arginine via ASS.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "They all expressed ASS, but not [GENE]ornithine transcarbamylase[\\GENE] (OTC), the enzyme that converts [CHEMICAL]ornithine[\\CHEMICAL], the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "They all expressed ASS, but not ornithine transcarbamylase ([GENE]OTC[\\GENE]), the enzyme that converts [CHEMICAL]ornithine[\\CHEMICAL], the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of [CHEMICAL]arginine[\\CHEMICAL] with [GENE]rhArg[\\GENE], to citrulline, which is converted back to arginine via ASS.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to [CHEMICAL]arginine[\\CHEMICAL] via [GENE]ASS[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "Exogenous [CHEMICAL]all-trans-retinol[\\CHEMICAL], all-trans-13,14-dihydroretinol, or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, [GENE]Cyp26A1[\\GENE], arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Exogenous all-trans-retinol, [CHEMICAL]all-trans-13,14-dihydroretinol[\\CHEMICAL], or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, [GENE]Cyp26A1[\\GENE], arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Exogenous all-trans-retinol, all-trans-13,14-dihydroretinol, or [CHEMICAL]all-trans-7,8-dihydroretinol[\\CHEMICAL] led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, [GENE]Cyp26A1[\\GENE], arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Unlike mouse RetSat (mRetSat), [GENE]zRetSat A[\\GENE] had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either [CHEMICAL]all-trans-13,14-dihydroretinol[\\CHEMICAL] or all-trans-7,8-dihydroretinol, respectively.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Unlike mouse RetSat (mRetSat), [GENE]zRetSat A[\\GENE] had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or [CHEMICAL]all-trans-7,8-dihydroretinol[\\CHEMICAL], respectively.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Unlike mouse RetSat (mRetSat), [GENE]zRetSat A[\\GENE] had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of [CHEMICAL]all-trans-retinol[\\CHEMICAL] to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "The latter reaction, catalyzed by [GENE]aspartoacylase[\\GENE] (ASPA), produces [CHEMICAL]acetyl[\\CHEMICAL] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "The latter reaction, catalyzed by aspartoacylase ([GENE]ASPA[\\GENE]), produces [CHEMICAL]acetyl[\\CHEMICAL] groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "The latter reaction, catalyzed by [GENE]aspartoacylase[\\GENE] (ASPA), produces acetyl groups plus [CHEMICAL]aspartate[\\CHEMICAL] and has been proposed to occur in both soluble and membranous subfractions of white matter.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "The latter reaction, catalyzed by aspartoacylase ([GENE]ASPA[\\GENE]), produces acetyl groups plus [CHEMICAL]aspartate[\\CHEMICAL] and has been proposed to occur in both soluble and membranous subfractions of white matter.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "[GENE]LDH[\\GENE] is responsible for pyruvate conversion to [CHEMICAL]lactate[\\CHEMICAL] through glycolysis.",
        "label": 9,
        "major": 9,
        "len": 10
    },
    {
        "text": "[GENE]LDH[\\GENE] is responsible for [CHEMICAL]pyruvate[\\CHEMICAL] conversion to lactate through glycolysis.",
        "label": 9,
        "major": 9,
        "len": 10
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 ([CHEMICAL]milrinone[\\CHEMICAL], 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 ([CHEMICAL]8-methoxymethyl-3-isobutyl-1-methylxanthine[\\CHEMICAL], 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [[CHEMICAL]erythro-9-(2-hydroxy-3-nonyl)adenine[\\CHEMICAL], 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [[CHEMICAL]4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one[\\CHEMICAL]], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 ([CHEMICAL]zaprinast[\\CHEMICAL], 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [[CHEMICAL]BRL-50481[\\CHEMICAL] (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 ([CHEMICAL]5-nitro-2,N,N-trimethylbenzenesulfonamide[\\CHEMICAL]), 10 microM] did not alter renal ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 41
    },
    {
        "text": "However, a lower concentration of [CHEMICAL]dipyridamole[\\CHEMICAL] (3 microM) that blocks PDE9, PDE10, and PDE11, but not [GENE]PDE8[\\GENE], did not inhibit ecto-phosphodiesterase activity.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "However, a lower concentration of [CHEMICAL]dipyridamole[\\CHEMICAL] (3 microM) that blocks PDE9, PDE10, and PDE11, but not PDE8, did not inhibit ecto-[GENE]phosphodiesterase[\\GENE] activity.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "These data support the conclusion that renal ecto-[GENE]phosphodiesterase[\\GENE] activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of [CHEMICAL]dipyridamole[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "A broad-spectrum [GENE]phosphodiesterase[\\GENE] (PDE) inhibitor ([CHEMICAL]1,3-isobutyl-1-methylxanthine[\\CHEMICAL], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "A broad-spectrum phosphodiesterase ([GENE]PDE[\\GENE]) inhibitor ([CHEMICAL]1,3-isobutyl-1-methylxanthine[\\CHEMICAL], 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], [GENE]PDE3[\\GENE] ([CHEMICAL]milrinone[\\CHEMICAL], 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of [GENE]PDE1[\\GENE] ([CHEMICAL]8-methoxymethyl-3-isobutyl-1-methylxanthine[\\CHEMICAL], 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), [GENE]PDE2[\\GENE] [[CHEMICAL]erythro-9-(2-hydroxy-3-nonyl)adenine[\\CHEMICAL], 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), [GENE]PDE4[\\GENE] (Ro 20-1724 [[CHEMICAL]4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one[\\CHEMICAL]], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), [GENE]PDE5[\\GENE] and PDE6 ([CHEMICAL]zaprinast[\\CHEMICAL], 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and [GENE]PDE6[\\GENE] ([CHEMICAL]zaprinast[\\CHEMICAL], 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and [GENE]PDE7[\\GENE] [[CHEMICAL]BRL-50481[\\CHEMICAL] (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and [GENE]PDE7[\\GENE] [BRL-50481 ([CHEMICAL]5-nitro-2,N,N-trimethylbenzenesulfonamide[\\CHEMICAL]), 10 microM] did not alter renal ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 41
    },
    {
        "text": "Administration of a concentration (100 microM) of [CHEMICAL]dipyridamole[\\CHEMICAL] that blocks [GENE]PDE8[\\GENE] inhibited ecto-phosphodiesterase activity (by 44%).",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Administration of a concentration (100 microM) of [CHEMICAL]dipyridamole[\\CHEMICAL] that blocks PDE8 inhibited ecto-[GENE]phosphodiesterase[\\GENE] activity (by 44%).",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "However, a lower concentration of [CHEMICAL]dipyridamole[\\CHEMICAL] (3 microM) that blocks [GENE]PDE9[\\GENE], PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "However, a lower concentration of [CHEMICAL]dipyridamole[\\CHEMICAL] (3 microM) that blocks PDE9, [GENE]PDE10[\\GENE], and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 10,
        "len": 22
    },
    {
        "text": "However, a lower concentration of [CHEMICAL]dipyridamole[\\CHEMICAL] (3 microM) that blocks PDE9, PDE10, and [GENE]PDE11[\\GENE], but not PDE8, did not inhibit ecto-phosphodiesterase activity.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to [CHEMICAL]AMP[\\CHEMICAL] by ecto-[GENE]phosphodiesterase[\\GENE], and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to [CHEMICAL]adenosine[\\CHEMICAL] by [GENE]ecto-5'-nucleotidase[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of [CHEMICAL]cAMP[\\CHEMICAL] to AMP by ecto-[GENE]phosphodiesterase[\\GENE], and metabolism of AMP to adenosine by ecto-5'-nucleotidase.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of [CHEMICAL]AMP[\\CHEMICAL] to adenosine by [GENE]ecto-5'-nucleotidase[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "Molecular modeling of the [GENE]kinase domain[\\GENE] of mutant c-Kit (V654A) and AXL showed no binding to [CHEMICAL]IM[\\CHEMICAL] but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant [GENE]c-Kit[\\GENE] (V654A) and AXL showed no binding to [CHEMICAL]IM[\\CHEMICAL] but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit ([GENE]V654A[\\GENE]) and AXL showed no binding to [CHEMICAL]IM[\\CHEMICAL] but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.",
        "label": 10,
        "major": 4,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and [GENE]AXL[\\GENE] showed no binding to [CHEMICAL]IM[\\CHEMICAL] but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.",
        "label": 10,
        "major": 4,
        "len": 27
    },
    {
        "text": "In GIST-R, [GENE]AXL[\\GENE] is [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylated and its ligand growth-arrest-specific gene 6 is overexpressed implying autocrine activation.",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "Molecular modeling of the [GENE]kinase domain[\\GENE] of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/AXL kinase inhibitor.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant [GENE]c-Kit[\\GENE] (V654A) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/AXL kinase inhibitor.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit ([GENE]V654A[\\GENE]) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/AXL kinase inhibitor.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and [GENE]AXL[\\GENE] showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/AXL kinase inhibitor.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Gene expression profiling (GEP) of GIST-S, GIST-R cells and two [CHEMICAL]IM[\\CHEMICAL] resistant GIST patients demonstrated that [GENE]KIT[\\GENE] is downregulated implying a major role in IM resistance.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that [GENE]KIT[\\GENE] is downregulated implying a major role in [CHEMICAL]IM[\\CHEMICAL] resistance.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel [GENE]c-Kit[\\GENE]/AXL kinase inhibitor.",
        "label": 4,
        "major": 1,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/[GENE]AXL[\\GENE] kinase inhibitor.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to [CHEMICAL]MP470[\\CHEMICAL], a novel c-Kit/AXL [GENE]kinase[\\GENE] inhibitor.",
        "label": 4,
        "major": 2,
        "len": 27
    },
    {
        "text": "Combining in vivo and in vitro findings, we identified nine [GENE]AhR[\\GENE] agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including [CHEMICAL]leflunomide[\\CHEMICAL], flutamide, and nimodipine.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "Combining in vivo and in vitro findings, we identified nine [GENE]AhR[\\GENE] agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, [CHEMICAL]flutamide[\\CHEMICAL], and nimodipine.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "Combining in vivo and in vitro findings, we identified nine [GENE]AhR[\\GENE] agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and [CHEMICAL]nimodipine[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "In PDE4B wild-type mice, rolipram dose-dependently suppressed CAR (ED(50) = 2.4 mg/kg); however, in knockout mice, their sensitivity to rolipram at the higher doses (1.0 and 3.2 mg/kg) was reduced, resulting in a threefold shift in the ED(50) (7.3 mg/kg), suggesting [GENE]PDE4B[\\GENE] is involved, at least in part, with the activity of [CHEMICAL]rolipram[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 53
    },
    {
        "text": "OBJECTIVES: The aim of the current study was to assess the activity of [CHEMICAL]rolipram[\\CHEMICAL], a nonsubtype-selective [GENE]PDE4[\\GENE] inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram.",
        "label": 4,
        "major": 4,
        "len": 49
    },
    {
        "text": "Mutation analysis of KYNU encoding [GENE]kynureninase[\\GENE] of the index case revealed homozygosity for a c.593 A > G substitution leading to a [CHEMICAL]threonine[\\CHEMICAL]-to-alanine (T198A) shift.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "Mutation analysis of KYNU encoding [GENE]kynureninase[\\GENE] of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to-[CHEMICAL]alanine[\\CHEMICAL] (T198A) shift.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "Improvements from baseline in mean [GENE]glycosylated haemoglobin[\\GENE] (HbA(1c)) were significantly greater with [CHEMICAL]sitagliptin[\\CHEMICAL] monotherapy than with placebo in patients with type 2 diabetes.",
        "label": 3,
        "major": 10,
        "len": 23
    },
    {
        "text": "Improvements from baseline in mean glycosylated haemoglobin ([GENE]HbA(1c)[\\GENE]) were significantly greater with [CHEMICAL]sitagliptin[\\CHEMICAL] monotherapy than with placebo in patients with type 2 diabetes.",
        "label": 3,
        "major": 10,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the [GENE]incretin hormones[\\GENE] glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones [GENE]glucagon-like peptide-1[\\GENE] and glucose-dependent insulinotropic polypeptide.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and [GENE]glucose-dependent insulinotropic polypeptide[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting [GENE]DPP-4[\\GENE] inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral [GENE]dipeptidyl peptidase-4[\\GENE] (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Sitagliptin[\\CHEMICAL], an oral dipeptidyl peptidase-4 ([GENE]DPP-4[\\GENE]) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "There was also an increase in [GENE]c-kit[\\GENE], Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, [GENE]Trio[\\GENE], Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, [GENE]Rho-A[\\GENE], Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, [GENE]Rac-3[\\GENE], EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, [GENE]Notch-4[\\GENE], Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, [GENE]Dvl-2[\\GENE], Ezrin, beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, [GENE]Ezrin[\\GENE], beta catenin and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, [GENE]beta catenin[\\GENE] and mutant p53 protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant [GENE]p53[\\GENE] protein expression in the [CHEMICAL]parathion[\\CHEMICAL]-treated cells.",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Parathion[\\CHEMICAL] is a [GENE]cholinesterase[\\GENE] inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and [GENE]COX-2[\\GENE] selective ([CHEMICAL]celecoxib[\\CHEMICAL]) NSAIDs.",
        "label": 2,
        "major": 4,
        "len": 58
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] treatment led to an increase in lipid peroxidation, [GENE]glutathione peroxidase[\\GENE] and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] treatment led to an increase in lipid peroxidation, glutathione peroxidase and [GENE]glucose-6-phosphate dehydrogenase[\\GENE] activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in [GENE]catalase[\\GENE] activity and glutathione levels in gastric mucosa.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Cisapride[\\CHEMICAL] was found to bind the [GENE]human ether-a-go-go-related gene (HERG) potassium channel[\\GENE], which provides a plausible mechanism for QTc interval prolongation/arrhythmia.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Other QTc interval-prolonging/arrhythmic drugs that also bind to [GENE]HERG[\\GENE] provided an analogy for [CHEMICAL]cisapride[\\CHEMICAL] causing QTc interval prolongation/arrhythmia via this mechanism.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of [CHEMICAL]sulindac[\\CHEMICAL] on [GENE]14-3-3epsilon protein[\\GENE] expression in colorectal cancer cells.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibited [GENE]PPARdelta[\\GENE] protein expression and PPARdelta transcriptional activity.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibited PPARdelta protein expression and [GENE]PPARdelta[\\GENE] transcriptional activity.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Sulindac sulfide[\\CHEMICAL] inhibited [GENE]14-3-3epsilon proteins[\\GENE] in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] and SC-236, a selective [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor, exerted a similar effect as sulindac.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL] and SC-236, a selective cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor, exerted a similar effect as sulindac.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Indomethacin and [CHEMICAL]SC-236[\\CHEMICAL], a selective [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor, exerted a similar effect as sulindac.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Indomethacin and [CHEMICAL]SC-236[\\CHEMICAL], a selective cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor, exerted a similar effect as sulindac.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Under isotonic conditions, [CHEMICAL]N-ethylmaleimide[\\CHEMICAL] (NEM) produced [GENE]KCC[\\GENE] activation and transient cell shrinkage.",
        "label": 3,
        "major": 9,
        "len": 12
    },
    {
        "text": "Under isotonic conditions, N-ethylmaleimide ([CHEMICAL]NEM[\\CHEMICAL]) produced [GENE]KCC[\\GENE] activation and transient cell shrinkage.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "A [GENE]KCC[\\GENE] inhibitor-[CHEMICAL][(dihydroindenyl)oxy] alkanoic acid[\\CHEMICAL] (DIOA)-blocked RVD more in HCEC than RCEC.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "A [GENE]KCC[\\GENE] inhibitor-[(dihydroindenyl)oxy] alkanoic acid ([CHEMICAL]DIOA[\\CHEMICAL])-blocked RVD more in HCEC than RCEC.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "PURPOSE: [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825), a potent oral multi-targeted [GENE]kinase[\\GENE] inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825), a potent oral multi-targeted kinase inhibitor against [GENE]SRC[\\GENE] and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and [GENE]BCR[\\GENE]-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: [CHEMICAL]Dasatinib[\\CHEMICAL] (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-[GENE]ABL[\\GENE], has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of [CHEMICAL]dasatinib[\\CHEMICAL] (BMS-354825): a potent oral multi-targeted [GENE]kinase[\\GENE] inhibitor against SRC and BCR-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of [CHEMICAL]dasatinib[\\CHEMICAL] (BMS-354825): a potent oral multi-targeted kinase inhibitor against [GENE]SRC[\\GENE] and BCR-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of [CHEMICAL]dasatinib[\\CHEMICAL] (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and [GENE]BCR[\\GENE]-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of [CHEMICAL]dasatinib[\\CHEMICAL] (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-[GENE]ABL[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]): a potent oral multi-targeted [GENE]kinase[\\GENE] inhibitor against SRC and BCR-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]): a potent oral multi-targeted kinase inhibitor against [GENE]SRC[\\GENE] and BCR-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]): a potent oral multi-targeted kinase inhibitor against SRC and [GENE]BCR[\\GENE]-ABL.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]): a potent oral multi-targeted kinase inhibitor against SRC and BCR-[GENE]ABL[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "PURPOSE: Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]), a potent oral multi-targeted [GENE]kinase[\\GENE] inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]), a potent oral multi-targeted kinase inhibitor against [GENE]SRC[\\GENE] and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]), a potent oral multi-targeted kinase inhibitor against SRC and [GENE]BCR[\\GENE]-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "PURPOSE: Dasatinib ([CHEMICAL]BMS-354825[\\CHEMICAL]), a potent oral multi-targeted kinase inhibitor against SRC and BCR-[GENE]ABL[\\GENE], has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Mutation of [GENE]Ser-530 to Ala[\\GENE] or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key [CHEMICAL]lumiracoxib[\\CHEMICAL] analogs.",
        "label": 10,
        "major": 4,
        "len": 24
    },
    {
        "text": "Mutation of Ser-530 to Ala or [GENE]Val-349 to Ala or Leu[\\GENE] abolished the potent inhibition observed with wild-type human COX-2 and key [CHEMICAL]lumiracoxib[\\CHEMICAL] analogs.",
        "label": 10,
        "major": 4,
        "len": 24
    },
    {
        "text": "Taken together with a recent crystal structure of a [CHEMICAL]lumiracoxib[\\CHEMICAL]-[GENE]COX-2[\\GENE] complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "The chemical identity and position of the substituents on the lower [CHEMICAL]aniline[\\CHEMICAL] ring were important in determining the potency and extent of COX inhibition as well as [GENE]COX-2[\\GENE] selectivity.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Interestingly, a [GENE]Val-349 to Ile[\\GENE] mutant was inhibited with equal potency to human COX-2 with [CHEMICAL]2,6-dichloro[\\CHEMICAL]-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 1,
        "len": 32
    },
    {
        "text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to [GENE]human COX-2[\\GENE] with [CHEMICAL]2,6-dichloro[\\CHEMICAL]-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Interestingly, a [GENE]Val-349 to Ile[\\GENE] mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, [CHEMICAL]2,6-dimethyl[\\CHEMICAL]-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to [GENE]human COX-2[\\GENE] with 2,6-dichloro-, [CHEMICAL]2,6-dimethyl[\\CHEMICAL]-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Interestingly, a [GENE]Val-349 to Ile[\\GENE] mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or [CHEMICAL]2-chloro-6-methyl[\\CHEMICAL]-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 1,
        "len": 32
    },
    {
        "text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to [GENE]human COX-2[\\GENE] with 2,6-dichloro-, 2,6-dimethyl-, or [CHEMICAL]2-chloro-6-methyl[\\CHEMICAL]-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Interestingly, a [GENE]Val-349 to Ile[\\GENE] mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of [CHEMICAL]lumiracoxib[\\CHEMICAL], actually showed an increase in potency.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to [GENE]human COX-2[\\GENE] with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of [CHEMICAL]lumiracoxib[\\CHEMICAL], actually showed an increase in potency.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant [GENE]COX-2s[\\GENE] by [CHEMICAL]lumiracoxib[\\CHEMICAL] allows the definition of the molecular basis of COX-2 inhibition.",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "Using standard assays, [CHEMICAL]lumiracoxib[\\CHEMICAL] was found to be a poor inhibitor of purified [GENE]ovine COX-1[\\GENE] and a relatively weak inhibitor of purified human COX-2.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Using standard assays, [CHEMICAL]lumiracoxib[\\CHEMICAL] was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified [GENE]human COX-2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Kinetic studies with [CHEMICAL]lumiracoxib[\\CHEMICAL] demonstrated that it was a time-dependent and slowly reversible inhibitor of [GENE]human COX-2[\\GENE] that exhibited at least two binding steps during inhibition.",
        "label": 4,
        "major": 2,
        "len": 26
    },
    {
        "text": "Lumiracoxib is the first example of a marketed [GENE]COX-2[\\GENE] inhibitor of the [CHEMICAL]arylacetic acid[\\CHEMICAL] class, and it is reported to be the most selective COXIB in vivo.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Lumiracoxib[\\CHEMICAL] is the first example of a marketed [GENE]COX-2[\\GENE] inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Inhibition studies demonstrated that the [CHEMICAL]methyl[\\CHEMICAL] group on the phenylacetic acid ring is required for [GENE]COX-2[\\GENE] selectivity.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Inhibition studies demonstrated that the methyl group on the [CHEMICAL]phenylacetic acid[\\CHEMICAL] ring is required for [GENE]COX-2[\\GENE] selectivity.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Molecular determinants for the selective inhibition of [GENE]cyclooxygenase-2[\\GENE] by [CHEMICAL]lumiracoxib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "The chemical identity and position of the substituents on the lower [CHEMICAL]aniline[\\CHEMICAL] ring were important in determining the potency and extent of [GENE]COX[\\GENE] inhibition as well as COX-2 selectivity.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type [GENE]human COX-2[\\GENE] and key [CHEMICAL]lumiracoxib[\\CHEMICAL] analogs.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity [CHEMICAL]Na(+)[\\CHEMICAL]-dependent amino acid transporter, with functional features of [GENE]ASCT2[\\GENE] transport.",
        "label": 3,
        "major": 9,
        "len": 25
    },
    {
        "text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent [CHEMICAL]amino acid[\\CHEMICAL] transporter, with functional features of [GENE]ASCT2[\\GENE] transport.",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by [CHEMICAL]alanine[\\CHEMICAL], serine, and cysteine, which is consistent with amino acid transport through [GENE]ASCT2[\\GENE].",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, [CHEMICAL]serine[\\CHEMICAL], and cysteine, which is consistent with amino acid transport through [GENE]ASCT2[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and [CHEMICAL]cysteine[\\CHEMICAL], which is consistent with amino acid transport through [GENE]ASCT2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent [CHEMICAL]l-alanine[\\CHEMICAL] uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through [GENE]ASCT2[\\GENE].",
        "label": 9,
        "major": 1,
        "len": 34
    },
    {
        "text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with [CHEMICAL]amino acid[\\CHEMICAL] transport through [GENE]ASCT2[\\GENE].",
        "label": 9,
        "major": 1,
        "len": 34
    },
    {
        "text": "In conclusion, immortalized SHR and WKY PTE cells take up [CHEMICAL]l-alanine[\\CHEMICAL] mainly through a high-affinity [GENE]Na(+)-dependent amino acid transporter[\\GENE], with functional features of ASCT2 transport.",
        "label": 9,
        "major": 2,
        "len": 25
    },
    {
        "text": "In conclusion, immortalized SHR and WKY PTE cells take up [CHEMICAL]l-alanine[\\CHEMICAL] mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of [GENE]ASCT2[\\GENE] transport.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "This study examined the inward transport of [CHEMICAL]l-[(14)C]alanine[\\CHEMICAL], an [GENE]ASCT2[\\GENE] preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "The early [GENE]insulin[\\GENE] response to oral [CHEMICAL]glucose[\\CHEMICAL] was reduced in mice on HFD + GRA (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but glucose excursions were improved.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Intravenous [CHEMICAL]arginine[\\CHEMICAL] significantly increased the acute [GENE]glucagon[\\GENE] response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Isolated islets displayed improved [CHEMICAL]glucose[\\CHEMICAL]-stimulated [GENE]insulin[\\GENE] secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, [CHEMICAL]sodium hydrosulphide[\\CHEMICAL] (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [GENE]SP[\\GENE] concentration and expression of PPT-A and NK1-R in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, [CHEMICAL]sodium hydrosulphide[\\CHEMICAL] (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of [GENE]PPT-A[\\GENE] and NK1-R in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, [CHEMICAL]sodium hydrosulphide[\\CHEMICAL] (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and [GENE]NK1-R[\\GENE] in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ([CHEMICAL]NaHS[\\CHEMICAL]), (10, 50 and 100 muM), that resulted in a significant increase in [GENE]SP[\\GENE] concentration and expression of PPT-A and NK1-R in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ([CHEMICAL]NaHS[\\CHEMICAL]), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of [GENE]PPT-A[\\GENE] and NK1-R in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ([CHEMICAL]NaHS[\\CHEMICAL]), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and [GENE]NK1-R[\\GENE] in acinar cells.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Caerulein[\\CHEMICAL] increased the levels of H(2)S and [GENE]CSE[\\GENE] mRNA expression while CBS mRNA expression was decreased.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Furthermore, [GENE]substance P[\\GENE] (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P ([GENE]SP[\\GENE]) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P (SP) concentration in the acini and expression of [GENE]SP[\\GENE] gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene ([GENE]preprotachykinin-A[\\GENE], PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, [GENE]PPT-A[\\GENE]) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and [GENE]neurokinin-1 receptor[\\GENE] (NK-1R), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor ([GENE]NK-1R[\\GENE]), the primary receptor for SP, are increased in secretagogue [CHEMICAL]caerulein[\\CHEMICAL]-treated acinar cells.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Caerulein[\\CHEMICAL] increased the levels of H(2)S and CSE mRNA expression while [GENE]CBS[\\GENE] mRNA expression was decreased.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Inhibition of endogenous production of [CHEMICAL]H(2)S[\\CHEMICAL] by PAG significantly suppressed [GENE]SP[\\GENE] concentration, PPT-A expression and NK1-R expression in the acini.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "Inhibition of endogenous production of [CHEMICAL]H(2)S[\\CHEMICAL] by PAG significantly suppressed SP concentration, [GENE]PPT-A[\\GENE] expression and NK1-R expression in the acini.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "Inhibition of endogenous production of [CHEMICAL]H(2)S[\\CHEMICAL] by PAG significantly suppressed SP concentration, PPT-A expression and [GENE]NK1-R[\\GENE] expression in the acini.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "In addition, cells pre-treated with [CHEMICAL]DL-propargylglycine[\\CHEMICAL] (PAG, 3 mM), a [GENE]CSE[\\GENE] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "In addition, cells pre-treated with DL-propargylglycine ([CHEMICAL]PAG[\\CHEMICAL], 3 mM), a [GENE]CSE[\\GENE] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that [GENE]CSE[\\GENE] may be the main enzyme involved in [CHEMICAL]H(2)S[\\CHEMICAL] formation in mouse acinar cells.",
        "label": 9,
        "major": 4,
        "len": 37
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [CHEMICAL]1400W dihydrochloride[\\CHEMICAL] (1400W), a selective inhibitor of iNOS, decreased the expression of [GENE]E-selectin[\\GENE], VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [CHEMICAL]1400W dihydrochloride[\\CHEMICAL] (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, [GENE]VEGF[\\GENE], and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [CHEMICAL]1400W dihydrochloride[\\CHEMICAL] (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ([CHEMICAL]1400W[\\CHEMICAL]), a selective inhibitor of iNOS, decreased the expression of [GENE]E-selectin[\\GENE], VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ([CHEMICAL]1400W[\\CHEMICAL]), a selective inhibitor of iNOS, decreased the expression of E-selectin, [GENE]VEGF[\\GENE], and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ([CHEMICAL]1400W[\\CHEMICAL]), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and [GENE]iNOS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]DXM[\\CHEMICAL] and 1400W attenuated the mRNA expression of [GENE]E-selectin[\\GENE] and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]DXM[\\CHEMICAL] and 1400W attenuated the mRNA expression of E-selectin and [GENE]iNOS[\\GENE] induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "DXM and [CHEMICAL]1400W[\\CHEMICAL] attenuated the mRNA expression of [GENE]E-selectin[\\GENE] and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "DXM and [CHEMICAL]1400W[\\CHEMICAL] attenuated the mRNA expression of E-selectin and [GENE]iNOS[\\GENE] induced by the costimulation of reIL-4, reTNF-alpha, and LPS.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DXM) decreased the expression of [GENE]CXCL-8[\\GENE], VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DXM) decreased the expression of CXCL-8, [GENE]VEGF[\\GENE], and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Dexamethasone[\\CHEMICAL] (DXM) decreased the expression of CXCL-8, VEGF, and [GENE]iNOS[\\GENE] induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DXM[\\CHEMICAL]) decreased the expression of [GENE]CXCL-8[\\GENE], VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DXM[\\CHEMICAL]) decreased the expression of CXCL-8, [GENE]VEGF[\\GENE], and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone ([CHEMICAL]DXM[\\CHEMICAL]) decreased the expression of CXCL-8, VEGF, and [GENE]iNOS[\\GENE] induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while [CHEMICAL]1400W dihydrochloride[\\CHEMICAL] (1400W), a selective inhibitor of [GENE]iNOS[\\GENE], decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride ([CHEMICAL]1400W[\\CHEMICAL]), a selective inhibitor of [GENE]iNOS[\\GENE], decreased the expression of E-selectin, VEGF, and iNOS.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., [CHEMICAL]sotalol[\\CHEMICAL] or ibutilide in patients with a mutation in the [GENE]IKr[\\GENE]-coding gene KCNH2 (HERG).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., [CHEMICAL]sotalol[\\CHEMICAL] or ibutilide in patients with a mutation in the IKr-coding gene [GENE]KCNH2[\\GENE] (HERG).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., [CHEMICAL]sotalol[\\CHEMICAL] or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 ([GENE]HERG[\\GENE]).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or [CHEMICAL]ibutilide[\\CHEMICAL] in patients with a mutation in the [GENE]IKr[\\GENE]-coding gene KCNH2 (HERG).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or [CHEMICAL]ibutilide[\\CHEMICAL] in patients with a mutation in the IKr-coding gene [GENE]KCNH2[\\GENE] (HERG).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or [CHEMICAL]ibutilide[\\CHEMICAL] in patients with a mutation in the IKr-coding gene KCNH2 ([GENE]HERG[\\GENE]).",
        "label": 4,
        "major": 1,
        "len": 43
    },
    {
        "text": "The deduced amino acid sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and [CHEMICAL]PLP[\\CHEMICAL]-interacting amino acid residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The deduced amino acid sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting [CHEMICAL]amino acid[\\CHEMICAL] residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In this study, we cloned and sequenced a cDNA encoding a [GENE]serine racemase[\\GENE] from barley which contained an open reading frame encoding 337 [CHEMICAL]amino acid[\\CHEMICAL] residues.",
        "label": 1,
        "major": 1,
        "len": 26
    },
    {
        "text": "The deduced [CHEMICAL]amino acid[\\CHEMICAL] sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting amino acid residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The deduced amino acid sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved [CHEMICAL]pyridoxal 5-phosphate[\\CHEMICAL] (PLP)-binding lysine and PLP-interacting amino acid residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The deduced amino acid sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved pyridoxal 5-phosphate ([CHEMICAL]PLP[\\CHEMICAL])-binding lysine and PLP-interacting amino acid residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The deduced amino acid sequence showed significant identity to plant and mammalian [GENE]serine racemases[\\GENE] and contained conserved pyridoxal 5-phosphate (PLP)-binding [CHEMICAL]lysine[\\CHEMICAL] and PLP-interacting amino acid residues.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian [GENE]serine racemase[\\GENE] activity is increased by [CHEMICAL]ATP[\\CHEMICAL].",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "The enzyme requires [CHEMICAL]PLP[\\CHEMICAL] and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian [GENE]serine racemase[\\GENE] activity is increased by ATP.",
        "label": 8,
        "major": 3,
        "len": 25
    },
    {
        "text": "The enzyme requires PLP and divalent cations such as [CHEMICAL]Ca(2+)[\\CHEMICAL], Mg(2+), or Mn(2+), but not ATP, whereas mammalian [GENE]serine racemase[\\GENE] activity is increased by ATP.",
        "label": 8,
        "major": 3,
        "len": 25
    },
    {
        "text": "The enzyme requires PLP and divalent cations such as Ca(2+), [CHEMICAL]Mg(2+)[\\CHEMICAL], or Mn(2+), but not ATP, whereas mammalian [GENE]serine racemase[\\GENE] activity is increased by ATP.",
        "label": 8,
        "major": 3,
        "len": 25
    },
    {
        "text": "The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or [CHEMICAL]Mn(2+)[\\CHEMICAL], but not ATP, whereas mammalian [GENE]serine racemase[\\GENE] activity is increased by ATP.",
        "label": 8,
        "major": 10,
        "len": 25
    },
    {
        "text": "Decreased expression of [GENE]VKORC1[\\GENE] resulting from the -1639G>A substitution has also been implicated in lower [CHEMICAL]warfarin[\\CHEMICAL] dose requirements.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "BACKGROUND: [GENE]CYP2C9[\\GENE] polymorphisms are associated with decreased [CHEMICAL]S-warfarin[\\CHEMICAL] clearance and lower maintenance dosage.",
        "label": 2,
        "major": 4,
        "len": 13
    },
    {
        "text": "The [GENE]cAspAT[\\GENE] TZD-responsive site was restricted to a single [CHEMICAL]AGGACA[\\CHEMICAL] hexanucleotide located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "The [GENE]cAspAT[\\GENE] TZD-responsive site was restricted to a single AGGACA [CHEMICAL]hexanucleotide[\\CHEMICAL] located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "The [GENE]cAspAT[\\GENE] [CHEMICAL]TZD[\\CHEMICAL]-responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.",
        "label": 2,
        "major": 1,
        "len": 24
    },
    {
        "text": "[GENE]Cytosolic aspartate aminotransferase[\\GENE], a new partner in adipocyte glyceroneogenesis and an atypical target of [CHEMICAL]thiazolidinedione[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 15
    },
    {
        "text": "[GENE]cAspAT[\\GENE] activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the [CHEMICAL]thiazolidinedione[\\CHEMICAL] (TZD) rosiglitazone.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[GENE]cAspAT[\\GENE] activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione ([CHEMICAL]TZD[\\CHEMICAL]) rosiglitazone.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[GENE]cAspAT[\\GENE] activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) [CHEMICAL]rosiglitazone[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[GENE]RORalpha[\\GENE] ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by [CHEMICAL]rosiglitazone[\\CHEMICAL] treatment of adipocytes.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "RORalpha ectopic expression activated the [GENE]cAspAT[\\GENE] gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by [CHEMICAL]rosiglitazone[\\CHEMICAL] treatment of adipocytes.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Finally, the amounts of [GENE]RORalpha[\\GENE] and cAspAT mRNAs were similarly increased by [CHEMICAL]TZD[\\CHEMICAL] treatment of human adipose tissue explants, confirming coordinated regulation.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Finally, the amounts of RORalpha and [GENE]cAspAT[\\GENE] mRNAs were similarly increased by [CHEMICAL]TZD[\\CHEMICAL] treatment of human adipose tissue explants, confirming coordinated regulation.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "As expected, the [GENE]hGSTA4[\\GENE] cells showed resistance to [CHEMICAL]4-HNE[\\CHEMICAL] stimulated lipid peroxidation at all 4-HNE doses.",
        "label": 10,
        "major": 3,
        "len": 16
    },
    {
        "text": "As expected, the [GENE]hGSTA4[\\GENE] cells showed resistance to 4-HNE stimulated lipid peroxidation at all [CHEMICAL]4-HNE[\\CHEMICAL] doses.",
        "label": 10,
        "major": 3,
        "len": 16
    },
    {
        "text": "4-Hydroxynonenal ([CHEMICAL]4-HNE[\\CHEMICAL]) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several [GENE]glutathione S-transferase[\\GENE] (GST) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "4-Hydroxynonenal ([CHEMICAL]4-HNE[\\CHEMICAL]) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ([GENE]GST[\\GENE]) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "However, the loss of proliferative capacity of [GENE]hGSTA4[\\GENE] cells challenged with levels of [CHEMICAL]4-HNE[\\CHEMICAL] associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "[CHEMICAL]4-Hydroxynonenal[\\CHEMICAL] (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several [GENE]glutathione S-transferase[\\GENE] (GST) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "[CHEMICAL]4-Hydroxynonenal[\\CHEMICAL] (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ([GENE]GST[\\GENE]) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "4-Hydroxynonenal (4-HNE) is a mutagenic [CHEMICAL]alpha,beta-unsaturated aldehyde[\\CHEMICAL] produced during oxidative injury that is conjugated by several [GENE]glutathione S-transferase[\\GENE] (GST) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "4-Hydroxynonenal (4-HNE) is a mutagenic [CHEMICAL]alpha,beta-unsaturated aldehyde[\\CHEMICAL] produced during oxidative injury that is conjugated by several glutathione S-transferase ([GENE]GST[\\GENE]) isoforms.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "Specifically, [GENE]hGSTA4[\\GENE] cells had significantly higher GSH concentrations when exposed to 5-15 microM [CHEMICAL]4-HNE[\\CHEMICAL], but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE.",
        "label": 9,
        "major": 10,
        "len": 29
    },
    {
        "text": "Specifically, [GENE]hGSTA4[\\GENE] cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM [CHEMICAL]4-HNE[\\CHEMICAL], suggesting extensive GSH utilization at high concentrations of 4-HNE.",
        "label": 9,
        "major": 10,
        "len": 29
    },
    {
        "text": "Recently, it has been shown that the activation of particular [GENE]T2R[\\GENE] bitter taste receptors is partially involved with the bitter aftertaste sensation of [CHEMICAL]saccharin[\\CHEMICAL] and acesulfame-K. To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals.",
        "label": 3,
        "major": 3,
        "len": 64
    },
    {
        "text": "Recently, it has been shown that the activation of particular [GENE]T2R[\\GENE] bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and [CHEMICAL]acesulfame-K[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "We also found that [GENE]TRPV1[\\GENE] receptors are activated by [CHEMICAL]CuSO(4)[\\CHEMICAL], ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.",
        "label": 3,
        "major": 9,
        "len": 22
    },
    {
        "text": "We also found that [GENE]TRPV1[\\GENE] receptors are activated by CuSO(4), [CHEMICAL]ZnSO(4)[\\CHEMICAL], and FeSO(4), three salts known to produce a metallic taste sensation.",
        "label": 3,
        "major": 9,
        "len": 22
    },
    {
        "text": "We also found that [GENE]TRPV1[\\GENE] receptors are activated by CuSO(4), ZnSO(4), and [CHEMICAL]FeSO(4)[\\CHEMICAL], three salts known to produce a metallic taste sensation.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "FINDINGS: Compared with other ARBs, [CHEMICAL]candesartan[\\CHEMICAL] demonstrates the strongest binding affinity to the [GENE]angiotensin II type 1 receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Clinical trials have demonstrated that [CHEMICAL]candesartan[\\CHEMICAL] is well tolerated in combination with diuretics or [GENE]calcium channel[\\GENE] blockers (CCBs), making it a suitable treatment option for patients whose hypertension is not adequately controlled by monotherapy.",
        "label": 8,
        "major": 10,
        "len": 34
    },
    {
        "text": "These effects were fully counteracted by dietary [CHEMICAL]phenolics[\\CHEMICAL] which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of [GENE]p66Shc[\\GENE] signalling molecule.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "AIM: To assess the efficacy and safety of a 24-week treatment with [CHEMICAL]sitagliptin[\\CHEMICAL], a highly selective once-daily oral [GENE]dipeptidyl peptidase-4[\\GENE] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "AIM: To assess the efficacy and safety of a 24-week treatment with [CHEMICAL]sitagliptin[\\CHEMICAL], a highly selective once-daily oral dipeptidyl peptidase-4 ([GENE]DPP-4[\\GENE]) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "Efficacy and safety of the [GENE]dipeptidyl peptidase-4[\\GENE] inhibitor, [CHEMICAL]sitagliptin[\\CHEMICAL], in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Miglustat[\\CHEMICAL], a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits [GENE]glucosylceramide synthase[\\GENE], which catalyses the first committed step in glycosphingolipid synthesis.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "At PND35, the medial prefrontal cortex (mPFC) of rats given [CHEMICAL]MPH[\\CHEMICAL] showed 55% greater immunoreactivity (-ir) for the catecholamine marker [GENE]tyrosine hydroxylase[\\GENE] (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.",
        "label": 3,
        "major": 9,
        "len": 34
    },
    {
        "text": "At PND35, the medial prefrontal cortex (mPFC) of rats given [CHEMICAL]MPH[\\CHEMICAL] showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase ([GENE]TH[\\GENE]), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.",
        "label": 3,
        "major": 9,
        "len": 34
    },
    {
        "text": "In hippocampal dentate gyrus, [CHEMICAL]MPH[\\CHEMICAL]-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of [GENE]neural cell adhesion molecule[\\GENE]).",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "In hippocampal dentate gyrus, [CHEMICAL]MPH[\\CHEMICAL]-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-[GENE]NCAM[\\GENE] (polysialylated form of neural cell adhesion molecule).",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "In medial striatum, TH-ir decreased by 21%, and in hypothalamus [GENE]neuropeptide Y[\\GENE]-ir increased by 10% in [CHEMICAL]MPH[\\CHEMICAL]-exposed rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "At PND35, the medial prefrontal cortex (mPFC) of rats given [CHEMICAL]MPH[\\CHEMICAL] showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less [GENE]norepinephrine transporter[\\GENE] (NET)-ir density.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "At PND35, the medial prefrontal cortex (mPFC) of rats given [CHEMICAL]MPH[\\CHEMICAL] showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter ([GENE]NET[\\GENE])-ir density.",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "In hippocampal dentate gyrus, [CHEMICAL]MPH[\\CHEMICAL]-receiving rats showed a 51% decrease in [GENE]NET[\\GENE]-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In medial striatum, [GENE]TH[\\GENE]-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in [CHEMICAL]MPH[\\CHEMICAL]-exposed rats.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Noradrenaline and [CHEMICAL]phenylephrine[\\CHEMICAL] ([GENE]alpha(1)-adrenoceptor[\\GENE] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "Prazosin (nonselective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [CHEMICAL]phenylephrine[\\CHEMICAL]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 5,
        "major": 3,
        "len": 27
    },
    {
        "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective [GENE]alpha(1A)-adrenoceptor[\\GENE] antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [CHEMICAL]phenylephrine[\\CHEMICAL]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 5,
        "major": 3,
        "len": 27
    },
    {
        "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective [GENE]alpha(1D)-adrenoceptor[\\GENE] antagonist) competitively antagonized the [CHEMICAL]phenylephrine[\\CHEMICAL]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 5,
        "major": 3,
        "len": 27
    },
    {
        "text": "alpha(1)-Adrenoceptor antagonists were tested against the [CHEMICAL]phenylephrine[\\CHEMICAL] ([GENE]alpha(1)-adrenoceptor[\\GENE] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Noradrenaline[\\CHEMICAL] and phenylephrine ([GENE]alpha(1)-adrenoceptor[\\GENE] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Prazosin[\\CHEMICAL] (nonselective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 6,
        "major": 3,
        "len": 27
    },
    {
        "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), [CHEMICAL]silodosin[\\CHEMICAL] (selective [GENE]alpha(1A)-adrenoceptor[\\GENE] antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and [CHEMICAL]BMY-7378[\\CHEMICAL] (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective [GENE]alpha(1D)-adrenoceptor[\\GENE] antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 ([CHEMICAL]8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride[\\CHEMICAL]) (selective [GENE]alpha(1D)-adrenoceptor[\\GENE] antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Dexmedetomidine[\\CHEMICAL] was effective in blocking these sympathomimetic actions of cocaine even in all 7 subjects who were homozygous for the Del322-325 polymorphism in the [GENE]alpha2C AR[\\GENE], a loss-of-function mutation that is highly enriched in blacks.",
        "label": 2,
        "major": 1,
        "len": 35
    },
    {
        "text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting [GENE]alpha2 adrenergic receptor[\\GENE] (AR) agonist ([CHEMICAL]dexmedetomidine[\\CHEMICAL]).",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor ([GENE]AR[\\GENE]) agonist ([CHEMICAL]dexmedetomidine[\\CHEMICAL]).",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "In vitro, [CHEMICAL]acetaminophen[\\CHEMICAL] elicited a 4.4-fold selectivity toward [GENE]COX-2[\\GENE] inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "In vitro, [CHEMICAL]acetaminophen[\\CHEMICAL] elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for [GENE]COX-1[\\GENE]; IC(50)=25.8 micromol/L for COX-2).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "In vitro, [CHEMICAL]acetaminophen[\\CHEMICAL] elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for [GENE]COX-2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Acetaminophen[\\CHEMICAL] (paracetamol) is a selective [GENE]cyclooxygenase-2[\\GENE] inhibitor in man.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Acetaminophen ([CHEMICAL]paracetamol[\\CHEMICAL]) is a selective [GENE]cyclooxygenase-2[\\GENE] inhibitor in man.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "In contrast to previous concepts, [CHEMICAL]acetaminophen[\\CHEMICAL] inhibited [GENE]COX-2[\\GENE] by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In view of its substantial [GENE]COX-2[\\GENE] inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for [CHEMICAL]acetaminophen[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The fact that [CHEMICAL]acetaminophen[\\CHEMICAL] acts functionally as a selective [GENE]COX-2[\\GENE] inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Ex vivo [GENE]COX[\\GENE] inhibition and pharmacokinetics of [CHEMICAL]acetaminophen[\\CHEMICAL] were assessed in 5 volunteers receiving single 1000 mg doses orally.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Coagulation-induced [CHEMICAL]thromboxane B(2)[\\CHEMICAL] and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of [GENE]COX-1[\\GENE] and COX-2 activity.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced [CHEMICAL]prostaglandin E(2)[\\CHEMICAL] were measured ex vivo and in vitro in human whole blood as indices of COX-1 and [GENE]COX-2[\\GENE] activity.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "Existing [GENE]ion channel[\\GENE] blockers, such as amiodarone, dronedarone, bepridil, aprindine, and [CHEMICAL]cibenzoline[\\CHEMICAL], have been found to have an NCX inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and [CHEMICAL]cibenzoline[\\CHEMICAL], have been found to have an [GENE]NCX[\\GENE] inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The pharmacology of NCX inhibitors has been studied extensively since the development of [CHEMICAL]KB-R7943[\\CHEMICAL], a prototype benzyloxyphenyl [GENE]NCX[\\GENE] inhibitor, in 1996.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype [CHEMICAL]benzyloxyphenyl[\\CHEMICAL] [GENE]NCX[\\GENE] inhibitor, in 1996.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Intriguingly, the inhibitory potency of [CHEMICAL]benzyloxyphenyl[\\CHEMICAL] [GENE]NCX[\\GENE] inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Existing [GENE]ion channel[\\GENE] blockers, such as [CHEMICAL]amiodarone[\\CHEMICAL], dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing ion channel blockers, such as [CHEMICAL]amiodarone[\\CHEMICAL], dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an [GENE]NCX[\\GENE] inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing [GENE]ion channel[\\GENE] blockers, such as amiodarone, [CHEMICAL]dronedarone[\\CHEMICAL], bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing ion channel blockers, such as amiodarone, [CHEMICAL]dronedarone[\\CHEMICAL], bepridil, aprindine, and cibenzoline, have been found to have an [GENE]NCX[\\GENE] inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing [GENE]ion channel[\\GENE] blockers, such as amiodarone, dronedarone, [CHEMICAL]bepridil[\\CHEMICAL], aprindine, and cibenzoline, have been found to have an NCX inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing ion channel blockers, such as amiodarone, dronedarone, [CHEMICAL]bepridil[\\CHEMICAL], aprindine, and cibenzoline, have been found to have an [GENE]NCX[\\GENE] inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing [GENE]ion channel[\\GENE] blockers, such as amiodarone, dronedarone, bepridil, [CHEMICAL]aprindine[\\CHEMICAL], and cibenzoline, have been found to have an NCX inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, [CHEMICAL]aprindine[\\CHEMICAL], and cibenzoline, have been found to have an [GENE]NCX[\\GENE] inhibitory action.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The [GENE]Na(+)/Ca(2+) exchanger[\\GENE] (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings [CHEMICAL]Ca(2+)[\\CHEMICAL] into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
        "label": 9,
        "major": 9,
        "len": 38
    },
    {
        "text": "The [GENE]Na(+)/Ca(2+) exchanger[\\GENE] (NCX) is a bidirectional transporter that normally extrudes [CHEMICAL]Ca(2+)[\\CHEMICAL] from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.",
        "label": 9,
        "major": 9,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Conivaptan[\\CHEMICAL] is a nonpeptide dual [GENE]V1a/V2 AVP receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Conivaptan[\\CHEMICAL]: a dual [GENE]vasopressin receptor v1a/v2[\\GENE] antagonist [corrected].",
        "label": 6,
        "major": 6,
        "len": 8
    },
    {
        "text": "[GENE]AdSS[\\GENE] from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 [CHEMICAL]amino acids[\\CHEMICAL] long against an average length of 430-457 amino acids for most mesophilic AdSS.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "AdSS from the thermophilic archaea, Methanocaldococcus jannaschii ([GENE]MjAdSS[\\GENE]) is 345 [CHEMICAL]amino acids[\\CHEMICAL] long against an average length of 430-457 amino acids for most mesophilic AdSS.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "AdSS from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 amino acids long against an average length of 430-457 [CHEMICAL]amino acids[\\CHEMICAL] for most mesophilic [GENE]AdSS[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Phosphate[\\CHEMICAL], a product of the reaction, was found to be a potent inhibitor of [GENE]MjAdSS[\\GENE] showing biphasic inhibition of enzyme activity.",
        "label": 4,
        "major": 9,
        "len": 21
    },
    {
        "text": "[GENE]Adenylosuccinate synthetase[\\GENE] (AdSS) catalyzes the [CHEMICAL]Mg2+[\\CHEMICAL] dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.",
        "label": 8,
        "major": 9,
        "len": 29
    },
    {
        "text": "[GENE]Adenylosuccinate synthetase[\\GENE] (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form [CHEMICAL]adenylosuccinate[\\CHEMICAL], in a reaction driven by the hydrolysis of GTP to GDP.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Adenylosuccinate synthetase ([GENE]AdSS[\\GENE]) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form [CHEMICAL]adenylosuccinate[\\CHEMICAL], in a reaction driven by the hydrolysis of GTP to GDP.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Adenylosuccinate synthetase ([GENE]AdSS[\\GENE]) catalyzes the [CHEMICAL]Mg2+[\\CHEMICAL] dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Vardenafil[\\CHEMICAL] has higher affinity to [GENE]phosphodiesterase-5[\\GENE] (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Vardenafil[\\CHEMICAL] has higher affinity to phosphodiesterase-5 ([GENE]PDE5[\\GENE]) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Reported here is a crystal structure of the fully active and nonmutated [GENE]PDE5A1 catalytic domain[\\GENE] in complex with [CHEMICAL]vardenafil[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "The structure shows that the conformation of the H-loop in the [GENE]PDE5A1[\\GENE]-[CHEMICAL]vardenafil[\\CHEMICAL] complex is different from those of any known structures of the unliganded PDE5 and its complexes with the inhibitors.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Vardenafil has higher affinity to [GENE]phosphodiesterase-5[\\GENE] (PDE5) than [CHEMICAL]sildenafil[\\CHEMICAL] and lower administered dosage for the treatment of erectile dysfunction.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Vardenafil has higher affinity to phosphodiesterase-5 ([GENE]PDE5[\\GENE]) than [CHEMICAL]sildenafil[\\CHEMICAL] and lower administered dosage for the treatment of erectile dysfunction.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "It is noteworthy that the binding of [CHEMICAL]vardenafil[\\CHEMICAL] causes loss of the divalent metal ions that have been observed in all the previously published [GENE]PDE[\\GENE] structures.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "Conformational variations of both [GENE]phosphodiesterase-5[\\GENE] and inhibitors provide the structural basis for the physiological effects of [CHEMICAL]vardenafil[\\CHEMICAL] and sildenafil.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Conformational variations of both [GENE]phosphodiesterase-5[\\GENE] and inhibitors provide the structural basis for the physiological effects of vardenafil and [CHEMICAL]sildenafil[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results quantify the role of [GENE]PDE5[\\GENE] catalytic-site residues for cGMP and inhibitors, indicate that [CHEMICAL]Tyr[\\CHEMICAL]-612, Gln-817, and Phe-820 are the most important cGMP or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.",
        "label": 1,
        "major": 4,
        "len": 40
    },
    {
        "text": "The results quantify the role of [GENE]PDE5[\\GENE] catalytic-site residues for cGMP and inhibitors, indicate that Tyr-612, [CHEMICAL]Gln[\\CHEMICAL]-817, and Phe-820 are the most important cGMP or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.",
        "label": 1,
        "major": 4,
        "len": 40
    },
    {
        "text": "The results quantify the role of [GENE]PDE5[\\GENE] catalytic-site residues for cGMP and inhibitors, indicate that Tyr-612, Gln-817, and [CHEMICAL]Phe[\\CHEMICAL]-820 are the most important cGMP or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.",
        "label": 1,
        "major": 4,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with [CHEMICAL]Tyr[\\CHEMICAL]-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with [CHEMICAL]Gln[\\CHEMICAL]-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by [CHEMICAL]Phe[\\CHEMICAL]-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and [CHEMICAL]Val[\\CHEMICAL]-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with [CHEMICAL]His[\\CHEMICAL]-613, Leu-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 4,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, [CHEMICAL]Leu[\\CHEMICAL]-765, and Phe-786 [Sung et al.",
        "label": 1,
        "major": 4,
        "len": 40
    },
    {
        "text": "Cocrystal structures of [GENE]PDE5 catalytic (C) domain[\\GENE] with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and [CHEMICAL]Phe[\\CHEMICAL]-786 [Sung et al.",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Critical [CHEMICAL]amino acids[\\CHEMICAL] in [GENE]phosphodiesterase-5[\\GENE] catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.",
        "label": 1,
        "major": 2,
        "len": 18
    },
    {
        "text": "Affinity of [GENE]V782A[\\GENE] for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Affinity of [GENE]V782A[\\GENE] for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Affinity of [GENE]V782A[\\GENE] for cGMP, vardenafil, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Affinity of [GENE]V782A[\\GENE] for cGMP, vardenafil, sildenafil, tadalafil, or [CHEMICAL]IBMX[\\CHEMICAL] was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Change in affinity for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, or IBMX in [GENE]Y612F[\\GENE], H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, or IBMX in Y612F, [GENE]H613A[\\GENE], L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, or IBMX in Y612F, H613A, [GENE]L765A[\\GENE], or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or [GENE]F786A[\\GENE] was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, or IBMX in [GENE]Y612F[\\GENE], H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, or IBMX in Y612F, [GENE]H613A[\\GENE], L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, or IBMX in Y612F, H613A, [GENE]L765A[\\GENE], or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, or IBMX in Y612F, H613A, L765A, or [GENE]F786A[\\GENE] was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], or IBMX in [GENE]Y612F[\\GENE], H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], or IBMX in Y612F, [GENE]H613A[\\GENE], L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], or IBMX in Y612F, H613A, [GENE]L765A[\\GENE], or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], or IBMX in Y612F, H613A, L765A, or [GENE]F786A[\\GENE] was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or [CHEMICAL]IBMX[\\CHEMICAL] in [GENE]Y612F[\\GENE], H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or [CHEMICAL]IBMX[\\CHEMICAL] in Y612F, [GENE]H613A[\\GENE], L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or [CHEMICAL]IBMX[\\CHEMICAL] in Y612F, H613A, [GENE]L765A[\\GENE], or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or [CHEMICAL]IBMX[\\CHEMICAL] in Y612F, H613A, L765A, or [GENE]F786A[\\GENE] was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or F786A was less, but affinity of [GENE]H613A[\\GENE] or F786A for [CHEMICAL]tadalafil[\\CHEMICAL] was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or F786A was less, but affinity of H613A or [GENE]F786A[\\GENE] for [CHEMICAL]tadalafil[\\CHEMICAL] was weakened 37- and 17-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The results quantify the role of [GENE]PDE5[\\GENE] catalytic-site residues for [CHEMICAL]cGMP[\\CHEMICAL] and inhibitors, indicate that Tyr-612, Gln-817, and Phe-820 are the most important cGMP or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "The results quantify the role of [GENE]PDE5[\\GENE] catalytic-site residues for cGMP and inhibitors, indicate that Tyr-612, Gln-817, and Phe-820 are the most important [CHEMICAL]cGMP[\\CHEMICAL] or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "Catalytic-site affinities for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, [CHEMICAL]vardenafil[\\CHEMICAL], sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or [CHEMICAL]3-isobutyl-1-methylxanthine[\\CHEMICAL] (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or [CHEMICAL]3-isobutyl-1-methylxanthine[\\CHEMICAL] (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or [CHEMICAL]3-isobutyl-1-methylxanthine[\\CHEMICAL] (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine ([CHEMICAL]IBMX[\\CHEMICAL]) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for [GENE]Y612A[\\GENE]; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine ([CHEMICAL]IBMX[\\CHEMICAL]) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine ([CHEMICAL]IBMX[\\CHEMICAL]) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for [GENE]F820A[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "The molecular bases for [GENE]phosphodiesterase 5[\\GENE] (PDE5) catalytic-site affinity for [CHEMICAL]cyclic guanosine monophosphate[\\CHEMICAL] (cGMP) and potency of inhibitors are poorly understood.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "The molecular bases for phosphodiesterase 5 ([GENE]PDE5[\\GENE]) catalytic-site affinity for [CHEMICAL]cyclic guanosine monophosphate[\\CHEMICAL] (cGMP) and potency of inhibitors are poorly understood.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "The molecular bases for [GENE]phosphodiesterase 5[\\GENE] (PDE5) catalytic-site affinity for cyclic guanosine monophosphate ([CHEMICAL]cGMP[\\CHEMICAL]) and potency of inhibitors are poorly understood.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "The molecular bases for phosphodiesterase 5 ([GENE]PDE5[\\GENE]) catalytic-site affinity for cyclic guanosine monophosphate ([CHEMICAL]cGMP[\\CHEMICAL]) and potency of inhibitors are poorly understood.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "Critical amino acids in [GENE]phosphodiesterase-5[\\GENE] catalytic site that provide for high-affinity interaction with [CHEMICAL]cyclic guanosine monophosphate[\\CHEMICAL] and inhibitors.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Affinity of [GENE]V782A[\\GENE] for [CHEMICAL]cGMP[\\CHEMICAL], vardenafil, sildenafil, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for [GENE]Q817A[\\GENE]; and 59-, 448-, 71-, 137-, and 93-fold for F820A.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "In this report, we show that the hypolipidemic agent [CHEMICAL]atorvastatin[\\CHEMICAL] is a competitive inhibitor of [GENE]porcine DPP-IV[\\GENE] in vitro, with K(i)=57.8+/-2.3 microM.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These results may have implications in the development of novel [GENE]DPP-IV[\\GENE] inhibitors based on the use of [CHEMICAL]atorvastatin[\\CHEMICAL] as a lead compound for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Inhibition of [GENE]dipeptidyl peptidase-IV[\\GENE] (DPP-IV) by [CHEMICAL]atorvastatin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "Inhibition of dipeptidyl peptidase-IV ([GENE]DPP-IV[\\GENE]) by [CHEMICAL]atorvastatin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts at vascular AT1 receptors (postsynaptically) and at presynaptic [GENE]AT1 receptors[\\GENE], where it inhibits noradrenaline release.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Eprosartan[\\CHEMICAL] acts at vascular [GENE]AT1 receptors[\\GENE] (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "The ARB [CHEMICAL]eprosartan[\\CHEMICAL] is a nonbiphenyl nontetrazole [GENE]angiotensin II type 1 receptor[\\GENE] (AT1) antagonist, which acts to decrease total peripheral resistance.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The ARB [CHEMICAL]eprosartan[\\CHEMICAL] is a nonbiphenyl nontetrazole angiotensin II type 1 receptor ([GENE]AT1[\\GENE]) antagonist, which acts to decrease total peripheral resistance.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibitors of [GENE]PDE4[\\GENE] ([CHEMICAL]rolipram[\\CHEMICAL]; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibitors of PDE4 (rolipram; 0.1-10 microM) and [GENE]PDE3[\\GENE] ([CHEMICAL]cilostazol[\\CHEMICAL]; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibitor of [GENE]cGMP-specific PDE5[\\GENE] ([CHEMICAL]zaprinast[\\CHEMICAL]; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.",
        "label": 4,
        "major": 10,
        "len": 19
    },
    {
        "text": "Computational modeling showed the direct interaction of the [CHEMICAL]carboxylic acid[\\CHEMICAL] moiety of statins with the catalytic site of [GENE]HDAC2[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Statins[\\CHEMICAL] increase [GENE]p21[\\GENE] through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.",
        "label": 3,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Statins[\\CHEMICAL] increase p21 through inhibition of histone deacetylase activity and release of promoter-associated [GENE]HDAC1/2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Statins[\\CHEMICAL] are [GENE]3-hydroxy-3-methylglutaryl-CoA reductase[\\GENE] inhibitors broadly used for the control of hypercholesterolemia.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "In the subsequent enzymatic assay, it was shown that [CHEMICAL]lovastatin[\\CHEMICAL] inhibited [GENE]HDAC2[\\GENE] activity competitively with a K(i) value of 31.6 micromol/L.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Statins[\\CHEMICAL] increase p21 through inhibition of [GENE]histone deacetylase[\\GENE] activity and release of promoter-associated HDAC1/2.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Flavopiridol[\\CHEMICAL], a [GENE]cyclin-dependent kinase[\\GENE] inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent [GENE]CDK2[\\GENE] inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of [CHEMICAL]flavopiridol[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Flavopiridol[\\CHEMICAL] inhibits [GENE]CDK[\\GENE] with an IC50 value of 0.4 mM [285707].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The [GENE]microtubule[\\GENE] binding affinities of a series of synthetic [CHEMICAL]taxanes[\\CHEMICAL] have been measured with the aims of dissecting individual group contributions and obtaining a rationale for the design of novel compounds with the ability to overcome drug resistance.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Taxanes[\\CHEMICAL] with affinities for [GENE]microtubules[\\GENE] well above their affinities for P-glycoprotein are shown not to be affected by multidrug resistance.",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Taxanes[\\CHEMICAL] with affinities for microtubules well above their affinities for [GENE]P-glycoprotein[\\GENE] are shown not to be affected by multidrug resistance.",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Optimization of taxane binding to [GENE]microtubules[\\GENE]: binding affinity dissection and incremental construction of a high-affinity analog of [CHEMICAL]paclitaxel[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Optimization of [CHEMICAL]taxane[\\CHEMICAL] binding to [GENE]microtubules[\\GENE]: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Both [CHEMICAL]risperidone[\\CHEMICAL] and 9-hydroxyrisperidone are substrates of [GENE]P-glycoprotein[\\GENE] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Both [CHEMICAL]risperidone[\\CHEMICAL] and 9-hydroxyrisperidone are substrates of P-glycoprotein ([GENE]P-gp[\\GENE]), a transport protein involved in drug absorption, distribution, and elimination.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Both risperidone and [CHEMICAL]9-hydroxyrisperidone[\\CHEMICAL] are substrates of [GENE]P-glycoprotein[\\GENE] (P-gp), a transport protein involved in drug absorption, distribution, and elimination.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "Both risperidone and [CHEMICAL]9-hydroxyrisperidone[\\CHEMICAL] are substrates of P-glycoprotein ([GENE]P-gp[\\GENE]), a transport protein involved in drug absorption, distribution, and elimination.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four [GENE]prostanoid receptors EP(1)[\\GENE] through EP(4).",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through [GENE]EP(4)[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[GENE]EP(1)[\\GENE] and EP(3) receptor antagonists [CHEMICAL]ONO-8713[\\CHEMICAL] and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 4,
        "len": 34
    },
    {
        "text": "EP(1) and [GENE]EP(3) receptor[\\GENE] antagonists [CHEMICAL]ONO-8713[\\CHEMICAL] and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 4,
        "len": 34
    },
    {
        "text": "[GENE]EP(1)[\\GENE] and EP(3) receptor antagonists ONO-8713 and [CHEMICAL]ONO-AE3-240[\\CHEMICAL], but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "EP(1) and [GENE]EP(3) receptor[\\GENE] antagonists ONO-8713 and [CHEMICAL]ONO-AE3-240[\\CHEMICAL], but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the [GENE]EP(4)[\\GENE] antagonists [CHEMICAL]ONO-AE3-208[\\CHEMICAL] and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the [GENE]EP(4)[\\GENE] antagonists ONO-AE3-208 and [CHEMICAL]AH 23848[\\CHEMICAL], inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by [GENE]cyclooxygenases[\\GENE] (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by cyclooxygenases ([GENE]COX[\\GENE]) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by cyclooxygenases (COX) and [GENE]prostaglandin E synthases[\\GENE] (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]PGE(2)[\\CHEMICAL] is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases ([GENE]PGES[\\GENE]) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "PGE(2) is synthesized from [CHEMICAL]arachidonic acid[\\CHEMICAL] by [GENE]cyclooxygenases[\\GENE] (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "PGE(2) is synthesized from [CHEMICAL]arachidonic acid[\\CHEMICAL] by cyclooxygenases ([GENE]COX[\\GENE]) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "PGE(2) is synthesized from [CHEMICAL]arachidonic acid[\\CHEMICAL] by cyclooxygenases (COX) and [GENE]prostaglandin E synthases[\\GENE] (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "PGE(2) is synthesized from [CHEMICAL]arachidonic acid[\\CHEMICAL] by cyclooxygenases (COX) and prostaglandin E synthases ([GENE]PGES[\\GENE]) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Plerixafor[\\CHEMICAL] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [GENE]stromal cell-derived factor-1[\\GENE] (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Plerixafor[\\CHEMICAL] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ([GENE]SDF-1[\\GENE]) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Plerixafor[\\CHEMICAL] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor [GENE]CXCR4[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Plerixafor[\\CHEMICAL] (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the [GENE]chemokine[\\GENE] stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "Plerixafor ([CHEMICAL]AMD3100[\\CHEMICAL], Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine [GENE]stromal cell-derived factor-1[\\GENE] (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "Plerixafor ([CHEMICAL]AMD3100[\\CHEMICAL], Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ([GENE]SDF-1[\\GENE]) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Plerixafor ([CHEMICAL]AMD3100[\\CHEMICAL], Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor [GENE]CXCR4[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "Plerixafor ([CHEMICAL]AMD3100[\\CHEMICAL], Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the [GENE]chemokine[\\GENE] stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "Plerixafor (AMD3100, Genzyme Corporation) is a [CHEMICAL]bicyclam[\\CHEMICAL] molecule that antagonizes the binding of the chemokine [GENE]stromal cell-derived factor-1[\\GENE] (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Plerixafor (AMD3100, Genzyme Corporation) is a [CHEMICAL]bicyclam[\\CHEMICAL] molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ([GENE]SDF-1[\\GENE]) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Plerixafor (AMD3100, Genzyme Corporation) is a [CHEMICAL]bicyclam[\\CHEMICAL] molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor [GENE]CXCR4[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Plerixafor (AMD3100, Genzyme Corporation) is a [CHEMICAL]bicyclam[\\CHEMICAL] molecule that antagonizes the binding of the [GENE]chemokine[\\GENE] stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Plerixafor[\\CHEMICAL], a [GENE]CXCR4[\\GENE] antagonist for the mobilization of hematopoietic stem cells.",
        "label": 6,
        "major": 6,
        "len": 11
    },
    {
        "text": "[Pharmacological effects of a [GENE]mu-opioid receptor[\\GENE] antagonist [CHEMICAL]naltrexone[\\CHEMICAL] on alcohol dependence].",
        "label": 6,
        "major": 6,
        "len": 11
    },
    {
        "text": "In many countries, a [GENE]mu-opioid receptor[\\GENE] antagonist [CHEMICAL]naltrexone[\\CHEMICAL] has been used in the treatment of alcohol dependence.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "The effects of [CHEMICAL]PLZ[\\CHEMICAL] on both amino acids and their [GENE]transaminases[\\GENE] were blocked by pre-treatment with the MAO inhibitor tranylcypromine.",
        "label": 2,
        "major": 1,
        "len": 20
    },
    {
        "text": "Pretreatment of rats with the [GENE]MAO[\\GENE] inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the [GENE]MAO[\\GENE] inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 20
    },
    {
        "text": "The effects of PLZ on both amino acids and their [GENE]transaminases[\\GENE] were blocked by pre-treatment with the MAO inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "PURPOSE: To compare [CHEMICAL]phenelzine[\\CHEMICAL] (PLZ), an antidepressant drug with anxiolytic properties which inhibits [GENE]monoamine oxidase[\\GENE] (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 4,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare [CHEMICAL]phenelzine[\\CHEMICAL] (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase ([GENE]MAO[\\GENE]) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 1,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with [CHEMICAL]vigabatrin[\\CHEMICAL] (VIG), an anticonvulsant which elevates brain GABA by inhibition of [GENE]GABA transaminase[\\GENE] (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 4,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with [CHEMICAL]vigabatrin[\\CHEMICAL] (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase ([GENE]GABA-T[\\GENE]), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 1,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin ([CHEMICAL]VIG[\\CHEMICAL]), an anticonvulsant which elevates brain GABA by inhibition of [GENE]GABA transaminase[\\GENE] (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 4,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin ([CHEMICAL]VIG[\\CHEMICAL]), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase ([GENE]GABA-T[\\GENE]), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 1,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), an antidepressant drug with anxiolytic properties which inhibits [GENE]monoamine oxidase[\\GENE] (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 4,
        "len": 69
    },
    {
        "text": "PURPOSE: To compare phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase ([GENE]MAO[\\GENE]) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).",
        "label": 4,
        "major": 1,
        "len": 69
    },
    {
        "text": "RESULTS: Both [CHEMICAL]PLZ[\\CHEMICAL] and VIG inhibited [GENE]GABA-T[\\GENE] and elevated GABA levels.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "RESULTS: Both PLZ and [CHEMICAL]VIG[\\CHEMICAL] inhibited [GENE]GABA-T[\\GENE] and elevated GABA levels.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Only [CHEMICAL]PLZ[\\CHEMICAL] inhibited [GENE]MAO[\\GENE] and ALA-T and elevated ALA levels.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Only [CHEMICAL]PLZ[\\CHEMICAL] inhibited MAO and [GENE]ALA-T[\\GENE] and elevated ALA levels.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Neurochemical effects of the [GENE]monoamine oxidase[\\GENE] inhibitor [CHEMICAL]phenelzine[\\CHEMICAL] on brain GABA and alanine: A comparison with vigabatrin.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "This pretreament had no effect on the inhibition of [GENE]GABA-T[\\GENE] or the elevation of brain GABA levels produced by [CHEMICAL]VIG[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike [CHEMICAL]VIG[\\CHEMICAL], also inhibited [GENE]MAO[\\GENE] and ALA-T (and increased brain ALA levels).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike [CHEMICAL]VIG[\\CHEMICAL], also inhibited MAO and [GENE]ALA-T[\\GENE] (and increased brain ALA levels).",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Ramelteon[\\CHEMICAL] (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin [GENE]MT(1)[\\GENE]/MT(2) receptor agonist.",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Ramelteon[\\CHEMICAL] (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/[GENE]MT(2)[\\GENE] receptor agonist.",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes, [CHEMICAL]ramelteon[\\CHEMICAL] is a chronohypnotic that acts on the melatonin [GENE]MT(1)[\\GENE] and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\"",
        "label": 5,
        "major": 10,
        "len": 34
    },
    {
        "text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes, [CHEMICAL]ramelteon[\\CHEMICAL] is a chronohypnotic that acts on the melatonin MT(1) and [GENE]MT(2)[\\GENE] receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\"",
        "label": 5,
        "major": 10,
        "len": 34
    },
    {
        "text": "Pharmacology of [CHEMICAL]ramelteon[\\CHEMICAL], a selective [GENE]MT1[\\GENE]/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "Pharmacology of [CHEMICAL]ramelteon[\\CHEMICAL], a selective MT1/[GENE]MT2[\\GENE] receptor agonist: a novel therapeutic drug for sleep disorders.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine ([CHEMICAL]SoRI-9804[\\CHEMICAL]), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), [CHEMICAL]N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine[\\CHEMICAL] (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine ([CHEMICAL]SoRI-20040[\\CHEMICAL]), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and [CHEMICAL]N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine[\\CHEMICAL] (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine ([CHEMICAL]SoRI-20041[\\CHEMICAL]) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [CHEMICAL][(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester[\\CHEMICAL] (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester ([CHEMICAL]RTI-55[\\CHEMICAL]) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [CHEMICAL][(125)I]RTI-55[\\CHEMICAL] from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [CHEMICAL][(3)H]dopamine[\\CHEMICAL] uptake.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine[\\CHEMICAL] (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [GENE]DAT[\\GENE], and partially inhibited [(3)H]dopamine uptake.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]SoRI-20041[\\CHEMICAL], which does not alter [GENE]DAT[\\GENE]-mediated DA release measured with [(3)H]DA, reversed the effect of SoRI-20040.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Acarbose[\\CHEMICAL], an [GENE]alpha-glucosidase[\\GENE] inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Clinical utility of [CHEMICAL]acarbose[\\CHEMICAL], an [GENE]alpha-glucosidase[\\GENE] inhibitor in cardiometabolic disorders.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Prolonged use of [CHEMICAL]tolvaptan[\\CHEMICAL] leads to increased endogenous levels of AVP and perhaps over-stimulation of [GENE]V(1A) receptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Prolonged use of [CHEMICAL]tolvaptan[\\CHEMICAL] leads to increased endogenous levels of [GENE]AVP[\\GENE] and perhaps over-stimulation of V(1A) receptors.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Tolvaptan[\\CHEMICAL] is a selective [GENE]arginine vasopressin (AVP) V(2) receptor[\\GENE] blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "In addition, [CHEMICAL]tolvaptan[\\CHEMICAL] is metabolized by the [GENE]CYP3A4[\\GENE] system; thus physicians should be aware of the potential for increased interactions with other medications.",
        "label": 9,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Tacrine[\\CHEMICAL], the first of the [GENE]cholinesterase[\\GENE] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Other [GENE]cholinesterase[\\GENE] inhibitors, including [CHEMICAL]rivastigmine[\\CHEMICAL], with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In summary, [CHEMICAL]ketoconazole[\\CHEMICAL] had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [GENE]CYP3A4[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The potential for [CHEMICAL]ketoconazole[\\CHEMICAL], the archetypal strong inhibitor of [GENE]CYP3A4[\\GENE], to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Ambrisentan[\\CHEMICAL] is an [GENE]endothelin type A (ET(A))-selective receptor[\\GENE] antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ambrisentan[\\CHEMICAL] is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by [GENE]CYP3A4[\\GENE].",
        "label": 9,
        "major": 6,
        "len": 22
    },
    {
        "text": "Second, [CHEMICAL]probucol[\\CHEMICAL], an antiatherogenic compound reported to be an inactivator of [GENE]ABCA1[\\GENE] reduced hepatic alpha-tocopherol secretion.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "First, addition of [GENE]apolipoprotein A-I[\\GENE] (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [CHEMICAL]alpha-tocopherol[\\CHEMICAL] secretion in a dose-dependent manner.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "First, addition of apolipoprotein A-I ([GENE]apoA-I[\\GENE]), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased [CHEMICAL]alpha-tocopherol[\\CHEMICAL] secretion in a dose-dependent manner.",
        "label": 9,
        "major": 2,
        "len": 24
    },
    {
        "text": "First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the [GENE]ATP-binding cassette transporter A1[\\GENE] (ABCA1)-secreted lipids, increased [CHEMICAL]alpha-tocopherol[\\CHEMICAL] secretion in a dose-dependent manner.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 ([GENE]ABCA1[\\GENE])-secreted lipids, increased [CHEMICAL]alpha-tocopherol[\\CHEMICAL] secretion in a dose-dependent manner.",
        "label": 9,
        "major": 2,
        "len": 24
    },
    {
        "text": "[GENE]ATP-binding cassette transporter A1[\\GENE] is involved in hepatic [CHEMICAL]alpha-tocopherol[\\CHEMICAL] secretion.",
        "label": 9,
        "major": 2,
        "len": 10
    },
    {
        "text": "alpha-Tocopherol transfer protein ([GENE]alpha-TTP[\\GENE]), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [CHEMICAL]alpha-tocopherol[\\CHEMICAL] level by mediating the secretion of alpha-tocopherol by the liver.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "[GENE]alpha-Tocopherol transfer protein[\\GENE] (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma [CHEMICAL]alpha-tocopherol[\\CHEMICAL] level by mediating the secretion of alpha-tocopherol by the liver.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "alpha-Tocopherol transfer protein ([GENE]alpha-TTP[\\GENE]), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of [CHEMICAL]alpha-tocopherol[\\CHEMICAL] by the liver.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "[GENE]alpha-Tocopherol transfer protein[\\GENE] (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of [CHEMICAL]alpha-tocopherol[\\CHEMICAL] by the liver.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "[GENE]AMPK[\\GENE] activators [CHEMICAL]metformin[\\CHEMICAL] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[GENE]AMPK[\\GENE] activators metformin and [CHEMICAL]AICAR[\\CHEMICAL] partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "The [GENE]neuronal vesicular monoamine transporter[\\GENE] (VMAT2) is the target molecule of action of some psychostimulants, such as [CHEMICAL]methamphetamine[\\CHEMICAL] and 3,4-methylenedioxymethamphetamine (MDMA).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The neuronal vesicular monoamine transporter ([GENE]VMAT2[\\GENE]) is the target molecule of action of some psychostimulants, such as [CHEMICAL]methamphetamine[\\CHEMICAL] and 3,4-methylenedioxymethamphetamine (MDMA).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The [GENE]neuronal vesicular monoamine transporter[\\GENE] (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and [CHEMICAL]3,4-methylenedioxymethamphetamine[\\CHEMICAL] (MDMA).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The neuronal vesicular monoamine transporter ([GENE]VMAT2[\\GENE]) is the target molecule of action of some psychostimulants, such as methamphetamine and [CHEMICAL]3,4-methylenedioxymethamphetamine[\\CHEMICAL] (MDMA).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The [GENE]neuronal vesicular monoamine transporter[\\GENE] (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The neuronal vesicular monoamine transporter ([GENE]VMAT2[\\GENE]) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine ([CHEMICAL]MDMA[\\CHEMICAL]).",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "Moreover, kinetic analysis revealed that inhibition by [CHEMICAL]reserpine[\\CHEMICAL], a typical [GENE]VMAT2[\\GENE] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "These results suggest that fluoxetine inhibited the activity of [GENE]VMAT2[\\GENE] by a mechanism different from that of [CHEMICAL]reserpine[\\CHEMICAL] and did not directly interact with the active site of VMAT2.",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "These results suggest that [CHEMICAL]fluoxetine[\\CHEMICAL] inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of [GENE]VMAT2[\\GENE].",
        "label": 4,
        "major": 10,
        "len": 29
    },
    {
        "text": "These results suggest that [CHEMICAL]fluoxetine[\\CHEMICAL] inhibited the activity of [GENE]VMAT2[\\GENE] by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.",
        "label": 4,
        "major": 10,
        "len": 29
    },
    {
        "text": "Moreover, kinetic analysis revealed that inhibition by reserpine, a typical [GENE]VMAT2[\\GENE] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for [CHEMICAL]dopamine[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on [GENE]VMAT2[\\GENE] activity by measuring adenosine triphosphate-dependent [CHEMICAL][(3)H]dopamine[\\CHEMICAL] uptake into synaptic vesicles prepared from rat striatum.",
        "label": 9,
        "major": 4,
        "len": 31
    },
    {
        "text": "Amitriptyline, but not any other [CHEMICAL]tricyclic[\\CHEMICAL] or selective serotonin reuptake inhibitor antidepressants, promotes [GENE]TrkA[\\GENE] autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.",
        "label": 10,
        "major": 4,
        "len": 25
    },
    {
        "text": "We report here that [CHEMICAL]amitriptyline[\\CHEMICAL], an antidepressant drug, directly binds [GENE]TrkA[\\GENE] and TrkB and triggers their dimerization and activation.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "We report here that [CHEMICAL]amitriptyline[\\CHEMICAL], an antidepressant drug, directly binds TrkA and [GENE]TrkB[\\GENE] and triggers their dimerization and activation.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] binds the extracellular domain of both [GENE]TrkA[\\GENE] and TrkB and promotes TrkA-TrkB receptor heterodimerization.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] binds the extracellular domain of both TrkA and [GENE]TrkB[\\GENE] and promotes TrkA-TrkB receptor heterodimerization.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "Truncation of [CHEMICAL]amitriptyline[\\CHEMICAL] binding motif on [GENE]TrkA[\\GENE] abrogates the receptor dimerization by amitriptyline.",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] is a TrkA and TrkB receptor agonist that promotes [GENE]TrkA[\\GENE]/TrkB heterodimerization and has potent neurotrophic activity.",
        "label": 2,
        "major": 5,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] is a TrkA and TrkB receptor agonist that promotes TrkA/[GENE]TrkB[\\GENE] heterodimerization and has potent neurotrophic activity.",
        "label": 2,
        "major": 5,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] binds the extracellular domain of both TrkA and TrkB and promotes [GENE]TrkA[\\GENE]-TrkB receptor heterodimerization.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] binds the extracellular domain of both TrkA and TrkB and promotes TrkA-[GENE]TrkB[\\GENE] receptor heterodimerization.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "Truncation of amitriptyline binding motif on [GENE]TrkA[\\GENE] abrogates the receptor dimerization by [CHEMICAL]amitriptyline[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL], but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes [GENE]TrkA[\\GENE] autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.",
        "label": 3,
        "major": 10,
        "len": 25
    },
    {
        "text": "Thus, [CHEMICAL]amitriptyline[\\CHEMICAL] acts as a TrkA and [GENE]TrkB[\\GENE] agonist and possesses marked neurotrophic activity.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "Thus, [CHEMICAL]amitriptyline[\\CHEMICAL] acts as a [GENE]TrkA[\\GENE] and TrkB agonist and possesses marked neurotrophic activity.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] is a [GENE]TrkA[\\GENE] and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Amitriptyline[\\CHEMICAL] is a TrkA and [GENE]TrkB[\\GENE] receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "INTRODUCTION: In this study, we examined the effects of the [GENE]alpha-glucosidase[\\GENE] inhibitors acarbose and [CHEMICAL]voglibose[\\CHEMICAL] on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "INTRODUCTION: In this study, we examined the effects of the [GENE]alpha-glucosidase[\\GENE] inhibitors [CHEMICAL]acarbose[\\CHEMICAL] and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "INTRODUCTION: In this study, we examined the effects of the [GENE]alpha-glucosidase[\\GENE] inhibitors acarbose and voglibose on postprandial plasma [CHEMICAL]glucose[\\CHEMICAL] and serum triglyceride levels in patients with type 2 diabetes mellitus.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Insulin receptor substrates ([GENE]IRS[\\GENE]) [CHEMICAL]serine[\\CHEMICAL] phosphorylation is a time-controlled physiological feedback mechanism in insulin signaling that is hijacked by metabolic and inflammatory stresses to promote insulin resistance.",
        "label": 1,
        "major": 9,
        "len": 27
    },
    {
        "text": "[GENE]Insulin receptor substrates[\\GENE] (IRS) [CHEMICAL]serine[\\CHEMICAL] phosphorylation is a time-controlled physiological feedback mechanism in insulin signaling that is hijacked by metabolic and inflammatory stresses to promote insulin resistance.",
        "label": 1,
        "major": 9,
        "len": 27
    },
    {
        "text": "Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled [GENE]IRS[\\GENE] [CHEMICAL]serine[\\CHEMICAL] phosphorylation.",
        "label": 1,
        "major": 3,
        "len": 20
    },
    {
        "text": "Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates ([GENE]IRS[\\GENE]) [CHEMICAL]serine[\\CHEMICAL] phosphorylation.",
        "label": 1,
        "major": 9,
        "len": 17
    },
    {
        "text": "Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and [GENE]insulin receptor substrates[\\GENE] (IRS) [CHEMICAL]serine[\\CHEMICAL] phosphorylation.",
        "label": 1,
        "major": 9,
        "len": 17
    },
    {
        "text": "Furthermore, the [GENE]Panx1[\\GENE] channel blockers [CHEMICAL]carbenoxolone[\\CHEMICAL] and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Furthermore, the [GENE]Panx1[\\GENE] channel blockers carbenoxolone and [CHEMICAL]Probenecid[\\CHEMICAL] were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "A few compounds, [CHEMICAL]17alpha-methyltestosterone[\\CHEMICAL] (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the [GENE]AR[\\GENE] was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "A few compounds, 17alpha-methyltestosterone ([CHEMICAL]17alpha-MT[\\CHEMICAL]), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the [GENE]AR[\\GENE] was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "A few compounds, 17alpha-methyltestosterone (17alpha-MT), [CHEMICAL]vinclozolin[\\CHEMICAL] and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the [GENE]AR[\\GENE] was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and [CHEMICAL]linuron[\\CHEMICAL], were studied using a real world scenario, i.e., assuming that their interaction with the [GENE]AR[\\GENE] was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "A [GENE]VLA-4[\\GENE] containing membrane preparation of MV3 cells was immobilised at the sensors to allow for detection of kinetic binding constants of [CHEMICAL]tinzaparin[\\CHEMICAL] compared to VCAM-1.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Tinzaparin[\\CHEMICAL] binds to [GENE]VLA-4[\\GENE] with affinity in the low micromolar range (4.61 x 10(-6) M), which clearly indicates specific molecular recognition.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Terbutaline (Bricanyl) and its prodrug [CHEMICAL]Bambuterol[\\CHEMICAL] (Bambec) are highly potent [GENE]beta(2)-adrenoceptor[\\GENE] agonists often used in asthma patients.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Terbutaline (Bricanyl) and its prodrug Bambuterol ([CHEMICAL]Bambec[\\CHEMICAL]) are highly potent [GENE]beta(2)-adrenoceptor[\\GENE] agonists often used in asthma patients.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Terbutaline[\\CHEMICAL] (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent [GENE]beta(2)-adrenoceptor[\\GENE] agonists often used in asthma patients.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Terbutaline ([CHEMICAL]Bricanyl[\\CHEMICAL]) and its prodrug Bambuterol (Bambec) are highly potent [GENE]beta(2)-adrenoceptor[\\GENE] agonists often used in asthma patients.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "Polymorphisms in dopamine transporter ([GENE]SLC6A3[\\GENE]) are associated with stimulant effects of [CHEMICAL]D-amphetamine[\\CHEMICAL]: an exploratory pharmacogenetic study using healthy volunteers.",
        "label": 3,
        "major": 9,
        "len": 19
    },
    {
        "text": "Polymorphisms in [GENE]dopamine transporter[\\GENE] (SLC6A3) are associated with stimulant effects of [CHEMICAL]D-amphetamine[\\CHEMICAL]: an exploratory pharmacogenetic study using healthy volunteers.",
        "label": 3,
        "major": 9,
        "len": 19
    },
    {
        "text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the [CHEMICAL]chenodeoxycholic acid[\\CHEMICAL] (CDCA)-induced expression of [GENE]Cdx2[\\GENE] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the [CHEMICAL]chenodeoxycholic acid[\\CHEMICAL] (CDCA)-induced expression of Cdx2 and [GENE]MUC2[\\GENE] in normal rat gastric epithelial cells (RGM-1 cells).",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ([CHEMICAL]CDCA[\\CHEMICAL])-induced expression of [GENE]Cdx2[\\GENE] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ([CHEMICAL]CDCA[\\CHEMICAL])-induced expression of Cdx2 and [GENE]MUC2[\\GENE] in normal rat gastric epithelial cells (RGM-1 cells).",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]CDCA[\\CHEMICAL] induced dose-dependent expression of [GENE]Cdx2[\\GENE] and MUC2 at both the mRNA and protein levels.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]CDCA[\\CHEMICAL] induced dose-dependent expression of Cdx2 and [GENE]MUC2[\\GENE] at both the mRNA and protein levels.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The maximum stimulation of [GENE]Cdx2[\\GENE] and MUC2 mRNA induced by [CHEMICAL]CDCA[\\CHEMICAL] was observed at 3 h and by 6 h, respectively.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The maximum stimulation of Cdx2 and [GENE]MUC2[\\GENE] mRNA induced by [CHEMICAL]CDCA[\\CHEMICAL] was observed at 3 h and by 6 h, respectively.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "RGM-1 cells were treated with [CHEMICAL]CDCA[\\CHEMICAL] or GW4064, an [GENE]FXR[\\GENE] agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
        "label": 5,
        "major": 5,
        "len": 21
    },
    {
        "text": "RGM-1 cells were treated with CDCA or [CHEMICAL]GW4064[\\CHEMICAL], an [GENE]FXR[\\GENE] agonist, in the presence or absence of guggulsterone, an FXR antagonist.",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of [CHEMICAL]guggulsterone[\\CHEMICAL], an [GENE]FXR[\\GENE] antagonist.",
        "label": 6,
        "major": 5,
        "len": 21
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as [CHEMICAL]p-hydroxybenzoic acid[\\CHEMICAL], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as [CHEMICAL]p-hydroxybenzoic acid[\\CHEMICAL], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as [CHEMICAL]p-hydroxybenzoic acid[\\CHEMICAL], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as [CHEMICAL]p-hydroxybenzoic acid[\\CHEMICAL], p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Phenols[\\CHEMICAL] like the ones investigated here possess a [GENE]CA[\\GENE] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Phenols like the ones investigated here possess a [GENE]CA[\\GENE] inhibition mechanism distinct of that of the [CHEMICAL]sulfonamides[\\CHEMICAL]/sulfamates used clinically or the coumarins.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Phenols like the ones investigated here possess a [GENE]CA[\\GENE] inhibition mechanism distinct of that of the sulfonamides/[CHEMICAL]sulfamates[\\CHEMICAL] used clinically or the coumarins.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Phenols like the ones investigated here possess a [GENE]CA[\\GENE] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the [CHEMICAL]coumarins[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, [CHEMICAL]p-coumaric acid[\\CHEMICAL], caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, [CHEMICAL]p-coumaric acid[\\CHEMICAL], caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, [CHEMICAL]p-coumaric acid[\\CHEMICAL], caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, [CHEMICAL]p-coumaric acid[\\CHEMICAL], caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, [CHEMICAL]caffeic acid[\\CHEMICAL], ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, [CHEMICAL]caffeic acid[\\CHEMICAL], ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, [CHEMICAL]caffeic acid[\\CHEMICAL], ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, [CHEMICAL]caffeic acid[\\CHEMICAL], ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "Inhibition of [GENE]mammalian isoforms I-XIV[\\GENE] with a series of natural product [CHEMICAL]polyphenols[\\CHEMICAL] and phenolic acids.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Inhibition of [GENE]mammalian isoforms I-XIV[\\GENE] with a series of natural product polyphenols and [CHEMICAL]phenolic acids[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, [CHEMICAL]ferulic acid[\\CHEMICAL], gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, [CHEMICAL]ferulic acid[\\CHEMICAL], gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, [CHEMICAL]ferulic acid[\\CHEMICAL], gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, [CHEMICAL]ferulic acid[\\CHEMICAL], gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of [CHEMICAL]phenolic acids[\\CHEMICAL] and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of [CHEMICAL]phenolic acids[\\CHEMICAL] and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of [CHEMICAL]phenolic acids[\\CHEMICAL] and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of [CHEMICAL]phenolic acids[\\CHEMICAL] and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, [CHEMICAL]gallic acid[\\CHEMICAL], syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, [CHEMICAL]gallic acid[\\CHEMICAL], syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, [CHEMICAL]gallic acid[\\CHEMICAL], syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, [CHEMICAL]gallic acid[\\CHEMICAL], syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, [CHEMICAL]syringic acid[\\CHEMICAL], quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, [CHEMICAL]syringic acid[\\CHEMICAL], quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, [CHEMICAL]syringic acid[\\CHEMICAL], quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, [CHEMICAL]syringic acid[\\CHEMICAL], quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, [CHEMICAL]quercetin[\\CHEMICAL], and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, [CHEMICAL]quercetin[\\CHEMICAL], and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, [CHEMICAL]quercetin[\\CHEMICAL], and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, [CHEMICAL]quercetin[\\CHEMICAL], and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and [CHEMICAL]ellagic acid[\\CHEMICAL], were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and [CHEMICAL]ellagic acid[\\CHEMICAL], were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and [CHEMICAL]ellagic acid[\\CHEMICAL], were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and [CHEMICAL]ellagic acid[\\CHEMICAL], were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and [CHEMICAL]phenol[\\CHEMICAL] natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [GENE]metalloenzyme[\\GENE] carbonic anhydrase (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and [CHEMICAL]phenol[\\CHEMICAL] natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and [CHEMICAL]phenol[\\CHEMICAL] natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1).",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "A series of phenolic acids and [CHEMICAL]phenol[\\CHEMICAL] natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "In untrained and trained treated animals with the amnesic dose (1.0mg/kg) of [CHEMICAL]METH[\\CHEMICAL] [GENE]SERT[\\GENE] binding in several areas including hippocampus and cortex decreased, more remarkably in the trained animals.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[GENE]Serotonin transporter[\\GENE] (SERT) has been associated with drugs of abuse like [CHEMICAL]d-methamphetamine[\\CHEMICAL] (METH).",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "Serotonin transporter ([GENE]SERT[\\GENE]) has been associated with drugs of abuse like [CHEMICAL]d-methamphetamine[\\CHEMICAL] (METH).",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "A comparative autoradiography study of the relationship between the binding pattern of [GENE]SERT[\\GENE] in autoshaping new untrained vs. trained treated ([CHEMICAL]METH[\\CHEMICAL], FLX, or both) animals was made.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "A comparative autoradiography study of the relationship between the binding pattern of [GENE]SERT[\\GENE] in autoshaping new untrained vs. trained treated (METH, [CHEMICAL]FLX[\\CHEMICAL], or both) animals was made.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[GENE]Serotonin transporter[\\GENE] (SERT) has been associated with drugs of abuse like d-methamphetamine ([CHEMICAL]METH[\\CHEMICAL]).",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "Serotonin transporter ([GENE]SERT[\\GENE]) has been associated with drugs of abuse like d-methamphetamine ([CHEMICAL]METH[\\CHEMICAL]).",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "METH is well known to produce effects on the monoamine systems but it is unclear how [CHEMICAL]METH[\\CHEMICAL] affects [GENE]SERT[\\GENE] and memory.",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone ([CHEMICAL]NAN[\\CHEMICAL]), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and [CHEMICAL]oxandrolone[\\CHEMICAL] (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone ([CHEMICAL]OXA[\\CHEMICAL]) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of [CHEMICAL]testosterone[\\CHEMICAL] and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous [CHEMICAL]steroids[\\CHEMICAL] ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids [CHEMICAL]ANE[\\CHEMICAL] and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and [CHEMICAL]DHT[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic [CHEMICAL]steroids[\\CHEMICAL] (AAS) were activating hAR and potentially interacting with [GENE]hGR[\\GENE] and how glucocorticoid ligands were interacting with the hGR and hAR.",
        "label": 2,
        "major": 2,
        "len": 47
    },
    {
        "text": "The other endogenous [CHEMICAL]steroids[\\CHEMICAL], androstenedione (ANE) and dihydrotestosterone (DHT), had considerably lower [GENE]hAR[\\GENE] transport rates.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The other endogenous steroids, [CHEMICAL]androstenedione[\\CHEMICAL] (ANE) and dihydrotestosterone (DHT), had considerably lower [GENE]hAR[\\GENE] transport rates.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The other endogenous steroids, androstenedione ([CHEMICAL]ANE[\\CHEMICAL]) and dihydrotestosterone (DHT), had considerably lower [GENE]hAR[\\GENE] transport rates.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The other endogenous steroids, androstenedione (ANE) and [CHEMICAL]dihydrotestosterone[\\CHEMICAL] (DHT), had considerably lower [GENE]hAR[\\GENE] transport rates.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The other endogenous steroids, androstenedione (ANE) and dihydrotestosterone ([CHEMICAL]DHT[\\CHEMICAL]), had considerably lower [GENE]hAR[\\GENE] transport rates.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous [CHEMICAL]steroids[\\CHEMICAL] methyltrienelone (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids [CHEMICAL]methyltrienelone[\\CHEMICAL] (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone ([CHEMICAL]MET[\\CHEMICAL]), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The rates of [GENE]hAR[\\GENE] transport for the exogenous steroids methyltrienelone (MET), [CHEMICAL]nandrolone[\\CHEMICAL] (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic [CHEMICAL]steroids[\\CHEMICAL] (AAS) were activating [GENE]hAR[\\GENE] and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR.",
        "label": 3,
        "major": 2,
        "len": 47
    },
    {
        "text": "The contractions to 5-HT were inhibited by [CHEMICAL]ketanserin[\\CHEMICAL] and alosetron indicating involvement of [GENE]5-HT(2A)[\\GENE] and 5-HT(3) receptors, respectively.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The contractions to 5-HT were inhibited by ketanserin and [CHEMICAL]alosetron[\\CHEMICAL] indicating involvement of 5-HT(2A) and [GENE]5-HT(3)[\\GENE] receptors, respectively.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Numerous studies have suggested that increased [GENE]TS[\\GENE] levels are associated closely with resistance to [CHEMICAL]fluoropyrimidine[\\CHEMICAL]-based chemotherapy.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]TAS-102[\\CHEMICAL] is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit [GENE]TS[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high [GENE]TS[\\GENE] expression, indicating activation of [CHEMICAL]pyrimidine[\\CHEMICAL] synthesis through both the salvage and de novo pathways.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]TAS-102[\\CHEMICAL] is a novel drug containing trifluorothymidine, which is phosphorylated by [GENE]TK-1[\\GENE] to its active monophosphated form, that in turn can inhibit TS.",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "TAS-102 is a novel drug containing [CHEMICAL]trifluorothymidine[\\CHEMICAL], which is phosphorylated by [GENE]TK-1[\\GENE] to its active monophosphated form, that in turn can inhibit TS.",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "To examine the interaction of S100A4 with TFP, we determined the 2.3 A crystal structure of human Ca(2+)-[GENE]S100A4[\\GENE] bound to [CHEMICAL]TFP[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Two [CHEMICAL]TFP[\\CHEMICAL] molecules bind within the hydrophobic target binding pocket of Ca(2+)-[GENE]S100A4[\\GENE] with no significant conformational changes observed in the protein upon complex formation.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "NMR chemical shift perturbations are consistent with the crystal structure and demonstrate that [CHEMICAL]TFP[\\CHEMICAL] binds to the target binding cleft of [GENE]S100A4[\\GENE] in solution.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Remarkably, [CHEMICAL]TFP[\\CHEMICAL] binding results in the assembly of five Ca(2+)-[GENE]S100A4[\\GENE]/TFP dimers into a tightly packed pentameric ring.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "To examine the interaction of [GENE]S100A4[\\GENE] with [CHEMICAL]TFP[\\CHEMICAL], we determined the 2.3 A crystal structure of human Ca(2+)-S100A4 bound to TFP.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Together these studies support a unique mode of inhibition in which [CHEMICAL]phenothiazines[\\CHEMICAL] disrupt the S100A4/myosin-IIA interaction by sequestering [GENE]S100A4[\\GENE] via small molecule-induced oligomerization.",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at [CHEMICAL]TFP[\\CHEMICAL] concentrations that promote [GENE]S100A4[\\GENE] oligomerization.",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "Using a unique biosensor-based assay, [CHEMICAL]trifluoperazine[\\CHEMICAL] (TFP) was identified as an inhibitor that disrupts the [GENE]S100A4[\\GENE]/myosin-IIA interaction.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Using a unique biosensor-based assay, [CHEMICAL]trifluoperazine[\\CHEMICAL] (TFP) was identified as an inhibitor that disrupts the S100A4/[GENE]myosin-IIA[\\GENE] interaction.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Using a unique biosensor-based assay, trifluoperazine ([CHEMICAL]TFP[\\CHEMICAL]) was identified as an inhibitor that disrupts the [GENE]S100A4[\\GENE]/myosin-IIA interaction.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Using a unique biosensor-based assay, trifluoperazine ([CHEMICAL]TFP[\\CHEMICAL]) was identified as an inhibitor that disrupts the S100A4/[GENE]myosin-IIA[\\GENE] interaction.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Phenothiazines[\\CHEMICAL] inhibit [GENE]S100A4[\\GENE] function by inducing protein oligomerization.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "Assays examining the ability of [CHEMICAL]TFP[\\CHEMICAL] to block [GENE]S100A4[\\GENE]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Assays examining the ability of [CHEMICAL]TFP[\\CHEMICAL] to block S100A4-mediated disassembly of [GENE]myosin-IIA[\\GENE] filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of [GENE]S100A4[\\GENE] function occurs only at [CHEMICAL]TFP[\\CHEMICAL] concentrations that promote S100A4 oligomerization.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Together these studies support a unique mode of inhibition in which [CHEMICAL]phenothiazines[\\CHEMICAL] disrupt the [GENE]S100A4[\\GENE]/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.",
        "label": 4,
        "major": 10,
        "len": 23
    },
    {
        "text": "Together these studies support a unique mode of inhibition in which [CHEMICAL]phenothiazines[\\CHEMICAL] disrupt the S100A4/[GENE]myosin-IIA[\\GENE] interaction by sequestering S100A4 via small molecule-induced oligomerization.",
        "label": 4,
        "major": 2,
        "len": 23
    },
    {
        "text": "Circulating [GENE]POMC[\\GENE] peptide concentrations were unaffected, suggesting that the rapid [CHEMICAL]corticosteroid[\\CHEMICAL] inhibitory effect specifically targeted ACTH secretion from pituitary corticotrophs.",
        "label": 10,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Prednisolone[\\CHEMICAL] fast feedback was only reduced by glucocorticoid receptor antagonist pretreatment and not by [GENE]mineralocorticoid receptor[\\GENE] antagonism, suggesting a glucocorticoid receptor-mediated pathway.",
        "label": 10,
        "major": 6,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Prednisolone[\\CHEMICAL] fast feedback was only reduced by [GENE]glucocorticoid receptor[\\GENE] antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway.",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Prednisolone[\\CHEMICAL] fast feedback was only reduced by glucocorticoid receptor antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a [GENE]glucocorticoid receptor[\\GENE]-mediated pathway.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal [CHEMICAL]corticosteroid[\\CHEMICAL] feedback and its interaction with [GENE]corticotrophin releasing hormone[\\GENE] (CRH) drive.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal [CHEMICAL]corticosteroid[\\CHEMICAL] feedback and its interaction with corticotrophin releasing hormone ([GENE]CRH[\\GENE]) drive.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Prednisolone[\\CHEMICAL] also inhibited ACTH and cortisol secretion in response to exogenous [GENE]CRH[\\GENE] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Prednisolone also inhibited ACTH and [CHEMICAL]cortisol[\\CHEMICAL] secretion in response to exogenous [GENE]CRH[\\GENE] stimulation, inferring rapid feedback inhibition at the anterior pituitary.",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] is a novel, potent, and irreversible [GENE]monoamine oxidase type B[\\GENE] (MAO-B) inhibitor which has been approved for treatment of PD.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] is a novel, potent, and irreversible monoamine oxidase type B ([GENE]MAO-B[\\GENE]) inhibitor which has been approved for treatment of PD.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] inhibits [GENE]MAO-B[\\GENE] more potently than selegiline and has the advantage of once-daily dosing.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the [GENE]VEGFR[\\GENE] tyrosine kinase inhibitors sunitinib and/or [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR [GENE]tyrosine kinase[\\GENE] inhibitors sunitinib and/or [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Everolimus[\\CHEMICAL] (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of [GENE]mTOR[\\GENE] (mammalian target of rapamycin) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Everolimus[\\CHEMICAL] (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ([GENE]mammalian target of rapamycin[\\GENE]) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Everolimus ([CHEMICAL]RAD001[\\CHEMICAL], Afinitor((R)) Novartis) is the first oral inhibitor of [GENE]mTOR[\\GENE] (mammalian target of rapamycin) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Everolimus ([CHEMICAL]RAD001[\\CHEMICAL], Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ([GENE]mammalian target of rapamycin[\\GENE]) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Everolimus (RAD001, [CHEMICAL]Afinitor((R)) Novartis[\\CHEMICAL]) is the first oral inhibitor of [GENE]mTOR[\\GENE] (mammalian target of rapamycin) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Everolimus (RAD001, [CHEMICAL]Afinitor((R)) Novartis[\\CHEMICAL]) is the first oral inhibitor of mTOR ([GENE]mammalian target of rapamycin[\\GENE]) to reach the oncology clinic.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the [GENE]VEGFR[\\GENE] tyrosine kinase inhibitors [CHEMICAL]sunitinib[\\CHEMICAL] and/or sorafenib.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR [GENE]tyrosine kinase[\\GENE] inhibitors [CHEMICAL]sunitinib[\\CHEMICAL] and/or sorafenib.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Predicting cardiomyopathic phenotypes by altering [CHEMICAL]Ca2+[\\CHEMICAL] affinity of [GENE]cardiac troponin C[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 11
    },
    {
        "text": "Steady-state fluorescence was utilized to assess [CHEMICAL]Ca(2+)[\\CHEMICAL] affinity in isolated [GENE]cardiac (c)TnCs[\\GENE] containing F27W and did not necessarily mirror the fiber Ca(2+) sensitivity.",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "Steady-state fluorescence was utilized to assess [CHEMICAL]Ca(2+)[\\CHEMICAL] affinity in isolated cardiac (c)TnCs containing [GENE]F27W[\\GENE] and did not necessarily mirror the fiber Ca(2+) sensitivity.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Steady-state fluorescence was utilized to assess Ca(2+) affinity in isolated [GENE]cardiac (c)TnCs[\\GENE] containing F27W and did not necessarily mirror the fiber [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Circular dichroism of mutant [GENE]cTnCs[\\GENE] revealed a trend where increased alpha-helical content correlated with increased [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity in skinned fibers and vice versa.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "The main findings from this study were as follows: 1) [GENE]cTnC[\\GENE] mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM, RCM, and DCM mutations; 2) a region in cTnC associated with increased [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity in skinned fibers was identified; and 3) the F27W reporter mutation affected Ca(2+) sensitivity, maximal force, and ATPase activation of some mutants.",
        "label": 2,
        "major": 3,
        "len": 57
    },
    {
        "text": "The main findings from this study were as follows: 1) cTnC mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM, RCM, and DCM mutations; 2) a region in [GENE]cTnC[\\GENE] associated with increased [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity in skinned fibers was identified; and 3) the F27W reporter mutation affected Ca(2+) sensitivity, maximal force, and ATPase activation of some mutants.",
        "label": 2,
        "major": 3,
        "len": 57
    },
    {
        "text": "The main findings from this study were as follows: 1) [GENE]cTnC[\\GENE] mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM, RCM, and DCM mutations; 2) a region in cTnC associated with increased Ca(2+) sensitivity in skinned fibers was identified; and 3) the F27W reporter mutation affected [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity, maximal force, and ATPase activation of some mutants.",
        "label": 2,
        "major": 3,
        "len": 57
    },
    {
        "text": "The main findings from this study were as follows: 1) cTnC mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM, RCM, and DCM mutations; 2) a region in [GENE]cTnC[\\GENE] associated with increased Ca(2+) sensitivity in skinned fibers was identified; and 3) the F27W reporter mutation affected [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity, maximal force, and ATPase activation of some mutants.",
        "label": 2,
        "major": 3,
        "len": 57
    },
    {
        "text": "Mutations in the [CHEMICAL]Ca(2+)[\\CHEMICAL] sensor, [GENE]troponin C[\\GENE] (TnC), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Mutations in the [CHEMICAL]Ca(2+)[\\CHEMICAL] sensor, troponin C ([GENE]TnC[\\GENE]), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Mutations in the Ca(2+) sensor, [GENE]troponin C[\\GENE] (TnC), were generated to increase/decrease the [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Mutations in the Ca(2+) sensor, troponin C ([GENE]TnC[\\GENE]), were generated to increase/decrease the [CHEMICAL]Ca(2+)[\\CHEMICAL] sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.",
        "label": 2,
        "major": 1,
        "len": 29
    },
    {
        "text": "After inflammation was established mice were dosed with the [GENE]H4R[\\GENE] antagonist, [CHEMICAL]JNJ 7777120[\\CHEMICAL], or anti-IL-13 antibody for comparison.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]VP-16[\\CHEMICAL] induced the release of [GENE]IL-8[\\GENE], and addition of MXF reduced enhanced release and the spontaneous release of VEGF from the cells.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "VP-16 induced the release of [GENE]IL-8[\\GENE], and addition of [CHEMICAL]MXF[\\CHEMICAL] reduced enhanced release and the spontaneous release of VEGF from the cells.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "VP-16 induced the release of IL-8, and addition of [CHEMICAL]MXF[\\CHEMICAL] reduced enhanced release and the spontaneous release of [GENE]VEGF[\\GENE] from the cells.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]MXF[\\CHEMICAL] or VP-16 slightly affected cellular [GENE]topo II[\\GENE] activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "MXF or [CHEMICAL]VP-16[\\CHEMICAL] slightly affected cellular [GENE]topo II[\\GENE] activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Apoptosis studies (DAPI staining and [GENE]caspase 3[\\GENE] activity) showed a marked increase in the presence of [CHEMICAL]MXF[\\CHEMICAL] and VP-16 compared to VP-16 alone.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Apoptosis studies (DAPI staining and [GENE]caspase 3[\\GENE] activity) showed a marked increase in the presence of MXF and [CHEMICAL]VP-16[\\CHEMICAL] compared to VP-16 alone.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Apoptosis studies (DAPI staining and [GENE]caspase 3[\\GENE] activity) showed a marked increase in the presence of MXF and VP-16 compared to [CHEMICAL]VP-16[\\CHEMICAL] alone.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "In conclusion, the results suggest that the enhancement in the reduction of [GENE]topo II[\\GENE] activity by the combined [CHEMICAL]MXF[\\CHEMICAL]/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "In conclusion, the results suggest that the enhancement in the reduction of [GENE]topo II[\\GENE] activity by the combined MXF/[CHEMICAL]VP-16[\\CHEMICAL] treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Etoposide[\\CHEMICAL] (VP-16) is a [GENE]topoisomerase-II[\\GENE] (topo II) inhibitor chemotherapeutic agent.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Etoposide[\\CHEMICAL] (VP-16) is a topoisomerase-II ([GENE]topo II[\\GENE]) inhibitor chemotherapeutic agent.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]MXF[\\CHEMICAL] or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [GENE]topo II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "MXF or [CHEMICAL]VP-16[\\CHEMICAL] slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [GENE]topo II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Etoposide ([CHEMICAL]VP-16[\\CHEMICAL]) is a [GENE]topoisomerase-II[\\GENE] (topo II) inhibitor chemotherapeutic agent.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Etoposide ([CHEMICAL]VP-16[\\CHEMICAL]) is a topoisomerase-II ([GENE]topo II[\\GENE]) inhibitor chemotherapeutic agent.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "We demonstrate that [CHEMICAL]rasagiline[\\CHEMICAL] protects against cell death induced by the combination of free radicals generated by paraquat and either wild-type or [GENE]A53T[\\GENE] mutant alpha-synuclein over-expression.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "We demonstrate that [CHEMICAL]rasagiline[\\CHEMICAL] protects against cell death induced by the combination of free radicals generated by paraquat and either wild-type or A53T mutant [GENE]alpha-synuclein[\\GENE] over-expression.",
        "label": 2,
        "major": 1,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] protects against [GENE]alpha-synuclein[\\GENE] induced sensitivity to oxidative stress in dopaminergic cells.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] is a propargylamine and irreversible [GENE]monoamine oxidase (MAO) B[\\GENE] inhibitor used for the treatment of Parkinson's disease (PD).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Rasagiline is a [CHEMICAL]propargylamine[\\CHEMICAL] and irreversible [GENE]monoamine oxidase (MAO) B[\\GENE] inhibitor used for the treatment of Parkinson's disease (PD).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The affinities of [CHEMICAL]dfbp[\\CHEMICAL] and dfbp-o for the regulatory domain of [GENE]cTnC[\\GENE] were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The affinities of dfbp and [CHEMICAL]dfbp-o[\\CHEMICAL] for the regulatory domain of [GENE]cTnC[\\GENE] were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The affinities of dfbp and dfbp-o for the regulatory domain of [GENE]cTnC[\\GENE] were measured in the absence and presence of cTnI by NMR spectroscopy, and [CHEMICAL]dfbp-o[\\CHEMICAL] was found to bind more strongly than dfbp.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The affinities of dfbp and dfbp-o for the regulatory domain of [GENE]cTnC[\\GENE] were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than [CHEMICAL]dfbp[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Dfbp-o[\\CHEMICAL] also increased the affinity of [GENE]cTnI[\\GENE] for cTnC.",
        "label": 2,
        "major": 3,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Dfbp-o[\\CHEMICAL] also increased the affinity of cTnI for [GENE]cTnC[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 9
    },
    {
        "text": "The high resolution NMR solution structure of the [GENE]cTnC[\\GENE]-cTnI-[CHEMICAL]dfbp-o[\\CHEMICAL] ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The high resolution NMR solution structure of the cTnC-[GENE]cTnI[\\GENE]-[CHEMICAL]dfbp-o[\\CHEMICAL] ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that [CHEMICAL]dfbp-o[\\CHEMICAL] bound at the hydrophobic interface formed by [GENE]cTnC[\\GENE] and cTnI making critical interactions with residues such as Arg147 of cTnI.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that [CHEMICAL]dfbp-o[\\CHEMICAL] bound at the hydrophobic interface formed by cTnC and [GENE]cTnI[\\GENE] making critical interactions with residues such as Arg147 of cTnI.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that [CHEMICAL]dfbp-o[\\CHEMICAL] bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of [GENE]cTnI[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "The structural and functional data reveal that the [CHEMICAL]levosimendan[\\CHEMICAL] class of Ca(2+)-sensitizers work by binding to the regulatory domain of [GENE]cTnC[\\GENE] and stabilizing the pivotal cTnC-cTnI regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.",
        "label": 2,
        "major": 2,
        "len": 51
    },
    {
        "text": "The [CHEMICAL]Ca(2+)[\\CHEMICAL] dependent interaction between [GENE]troponin I[\\GENE] (cTnI) and troponin C (cTnC) triggers contraction in heart muscle.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]Ca(2+)[\\CHEMICAL] dependent interaction between troponin I ([GENE]cTnI[\\GENE]) and troponin C (cTnC) triggers contraction in heart muscle.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]Ca(2+)[\\CHEMICAL] dependent interaction between troponin I (cTnI) and [GENE]troponin C[\\GENE] (cTnC) triggers contraction in heart muscle.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]Ca(2+)[\\CHEMICAL] dependent interaction between troponin I (cTnI) and troponin C ([GENE]cTnC[\\GENE]) triggers contraction in heart muscle.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The structural and functional data reveal that the [CHEMICAL]levosimendan[\\CHEMICAL] class of Ca(2+)-sensitizers work by binding to the regulatory domain of cTnC and stabilizing the pivotal [GENE]cTnC[\\GENE]-cTnI regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.",
        "label": 2,
        "major": 2,
        "len": 51
    },
    {
        "text": "The structural and functional data reveal that the [CHEMICAL]levosimendan[\\CHEMICAL] class of Ca(2+)-sensitizers work by binding to the regulatory domain of cTnC and stabilizing the pivotal cTnC-[GENE]cTnI[\\GENE] regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.",
        "label": 2,
        "major": 2,
        "len": 51
    },
    {
        "text": "Although L-VGCC inhibition by [CHEMICAL]BDZs[\\CHEMICAL] occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of [GENE]L-VGCCs[\\GENE] during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.",
        "label": 10,
        "major": 10,
        "len": 42
    },
    {
        "text": "Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency ([GENE]I1150A[\\GENE]) did not affect [CHEMICAL]diazepam[\\CHEMICAL] potency.",
        "label": 4,
        "major": 1,
        "len": 23
    },
    {
        "text": "Although [GENE]L-VGCC[\\GENE] inhibition by [CHEMICAL]BDZs[\\CHEMICAL] occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, [CHEMICAL]pentobarbital[\\CHEMICAL] and ethanol inhibited [GENE]L-VGCCs[\\GENE] at clinically relevant concentrations.",
        "label": 4,
        "major": 10,
        "len": 42
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including [CHEMICAL]barbiturates[\\CHEMICAL], ethanol, and neurosteroids, can also inhibit [GENE]L-type voltage-gated calcium channels[\\GENE] (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including [CHEMICAL]barbiturates[\\CHEMICAL], ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels ([GENE]L-VGCCs[\\GENE]), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including barbiturates, [CHEMICAL]ethanol[\\CHEMICAL], and neurosteroids, can also inhibit [GENE]L-type voltage-gated calcium channels[\\GENE] (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including barbiturates, [CHEMICAL]ethanol[\\CHEMICAL], and neurosteroids, can also inhibit L-type voltage-gated calcium channels ([GENE]L-VGCCs[\\GENE]), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and [CHEMICAL]neurosteroids[\\CHEMICAL], can also inhibit [GENE]L-type voltage-gated calcium channels[\\GENE] (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and [CHEMICAL]neurosteroids[\\CHEMICAL], can also inhibit L-type voltage-gated calcium channels ([GENE]L-VGCCs[\\GENE]), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[GENE]Ca(v)1.3[\\GENE] channels were less sensitive to [CHEMICAL]pentobarbital[\\CHEMICAL] inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists.",
        "label": 4,
        "major": 6,
        "len": 17
    },
    {
        "text": "Ca(v)1.3 channels were less sensitive to [CHEMICAL]pentobarbital[\\CHEMICAL] inhibition than [GENE]Ca(v)1.2[\\GENE] channels, similar to dihydropyridine (DHP) L-VGCC antagonists.",
        "label": 4,
        "major": 6,
        "len": 17
    },
    {
        "text": "[GENE]Ca(v)1.3[\\GENE] channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to [CHEMICAL]dihydropyridine[\\CHEMICAL] (DHP) L-VGCC antagonists.",
        "label": 4,
        "major": 6,
        "len": 17
    },
    {
        "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than [GENE]Ca(v)1.2[\\GENE] channels, similar to [CHEMICAL]dihydropyridine[\\CHEMICAL] (DHP) L-VGCC antagonists.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[GENE]Ca(v)1.3[\\GENE] channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) L-VGCC antagonists.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than [GENE]Ca(v)1.2[\\GENE] channels, similar to dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) L-VGCC antagonists.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only [CHEMICAL]BDZs[\\CHEMICAL] and pentobarbital induced a negative shift in [GENE]Ca(v)1.2[\\GENE] channel inactivation.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and [CHEMICAL]pentobarbital[\\CHEMICAL] induced a negative shift in [GENE]Ca(v)1.2[\\GENE] channel inactivation.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]BDZs[\\CHEMICAL] and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit [GENE]L-type voltage-gated calcium channels[\\GENE] (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]BDZs[\\CHEMICAL] and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels ([GENE]L-VGCCs[\\GENE]), which could contribute to reduced neuronal excitability.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to [CHEMICAL]dihydropyridine[\\CHEMICAL] (DHP) [GENE]L-VGCC[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine ([CHEMICAL]DHP[\\CHEMICAL]) [GENE]L-VGCC[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Benzodiazepines ([CHEMICAL]BDZs[\\CHEMICAL]) depress neuronal excitability via positive allosteric modulation of inhibitory [GENE]GABA(A) receptors[\\GENE] (GABA(A)R).",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "Benzodiazepines ([CHEMICAL]BDZs[\\CHEMICAL]) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors ([GENE]GABA(A)R[\\GENE]).",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Benzodiazepines[\\CHEMICAL] (BDZs) depress neuronal excitability via positive allosteric modulation of inhibitory [GENE]GABA(A) receptors[\\GENE] (GABA(A)R).",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Benzodiazepines[\\CHEMICAL] (BDZs) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors ([GENE]GABA(A)R[\\GENE]).",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "BDZs and other positive [GENE]GABA(A)R[\\GENE] modulators, including [CHEMICAL]barbiturates[\\CHEMICAL], ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 7,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive [GENE]GABA(A)R[\\GENE] modulators, including barbiturates, [CHEMICAL]ethanol[\\CHEMICAL], and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 7,
        "major": 4,
        "len": 26
    },
    {
        "text": "BDZs and other positive [GENE]GABA(A)R[\\GENE] modulators, including barbiturates, ethanol, and [CHEMICAL]neurosteroids[\\CHEMICAL], can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 7,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]BDZs[\\CHEMICAL] and other positive [GENE]GABA(A)R[\\GENE] modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.",
        "label": 7,
        "major": 4,
        "len": 26
    },
    {
        "text": "The effects of [CHEMICAL]amphetamine[\\CHEMICAL] (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter [GENE]DAT[\\GENE] or the vesicular transporter for monoamine storage, VMAT2.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The effects of [CHEMICAL]amphetamine[\\CHEMICAL] (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, [GENE]VMAT2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The effects of amphetamine ([CHEMICAL]AMPH[\\CHEMICAL]) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter [GENE]DAT[\\GENE] or the vesicular transporter for monoamine storage, VMAT2.",
        "label": 2,
        "major": 9,
        "len": 37
    },
    {
        "text": "The effects of amphetamine ([CHEMICAL]AMPH[\\CHEMICAL]) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, [GENE]VMAT2[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 37
    },
    {
        "text": "The effects of amphetamine (AMPH) and [CHEMICAL]cocaine[\\CHEMICAL] (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter [GENE]DAT[\\GENE] or the vesicular transporter for monoamine storage, VMAT2.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The effects of amphetamine (AMPH) and [CHEMICAL]cocaine[\\CHEMICAL] (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, [GENE]VMAT2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The effects of amphetamine (AMPH) and cocaine ([CHEMICAL]COC[\\CHEMICAL]), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter [GENE]DAT[\\GENE] or the vesicular transporter for monoamine storage, VMAT2.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "The effects of amphetamine (AMPH) and cocaine ([CHEMICAL]COC[\\CHEMICAL]), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, [GENE]VMAT2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Although the inhibition of [GENE]cyclooxygenases[\\GENE] by [CHEMICAL]aspirin[\\CHEMICAL], which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that [CHEMICAL]PSE[\\CHEMICAL] inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic [GENE]NF-kappaB inhibitory protein[\\GENE], IkappaBalpha or the DNA-binding activity.",
        "label": 10,
        "major": 4,
        "len": 62
    },
    {
        "text": "To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that [CHEMICAL]PSE[\\CHEMICAL] inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, [GENE]IkappaBalpha[\\GENE] or the DNA-binding activity.",
        "label": 10,
        "major": 4,
        "len": 62
    },
    {
        "text": "In addition, [CHEMICAL]PSE[\\CHEMICAL] inhibited the transcriptional activity of NFAT without interfering with the calcium-induced [GENE]NFAT[\\GENE] dephosphorylation event, which represents the major signaling pathway for its activation.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the [CHEMICAL]calcium[\\CHEMICAL]-induced [GENE]NFAT[\\GENE] dephosphorylation event, which represents the major signaling pathway for its activation.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "We found that [CHEMICAL]PSE[\\CHEMICAL] inhibits interleukin-2 (IL-2) and [GENE]tumor necrosis factor (TNF) alpha[\\GENE]-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "We found that [CHEMICAL]PSE[\\CHEMICAL] inhibits [GENE]interleukin-2[\\GENE] (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "We found that [CHEMICAL]PSE[\\CHEMICAL] inhibits interleukin-2 ([GENE]IL-2[\\GENE]) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that [CHEMICAL]PSE[\\CHEMICAL] inhibited [GENE]NF-kappaB[\\GENE]-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "[CHEMICAL]Pseudoephedrine[\\CHEMICAL] inhibits T-cell activation by targeting [GENE]NF-kappaB[\\GENE], NFAT and AP-1 signaling pathways.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Pseudoephedrine[\\CHEMICAL] inhibits T-cell activation by targeting NF-kappaB, [GENE]NFAT[\\GENE] and AP-1 signaling pathways.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Pseudoephedrine[\\CHEMICAL] inhibits T-cell activation by targeting NF-kappaB, NFAT and [GENE]AP-1[\\GENE] signaling pathways.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "However, phosphorylation of the [GENE]p65[\\GENE]/RelA subunit was clearly inhibited by [CHEMICAL]PSE[\\CHEMICAL] in stimulated cells.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "However, phosphorylation of the p65/[GENE]RelA[\\GENE] subunit was clearly inhibited by [CHEMICAL]PSE[\\CHEMICAL] in stimulated cells.",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "In addition, [CHEMICAL]PSE[\\CHEMICAL] inhibited the transcriptional activity of [GENE]NFAT[\\GENE] without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that [CHEMICAL]PSE[\\CHEMICAL] inhibited both [GENE]JNK[\\GENE] activation and AP-1 transcriptional activity.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that [CHEMICAL]PSE[\\CHEMICAL] inhibited both JNK activation and [GENE]AP-1[\\GENE] transcriptional activity.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by [CHEMICAL]tetrabenazine[\\CHEMICAL], which has a high affinity for [GENE]VMAT-2[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 35
    },
    {
        "text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the [GENE]VMAT[\\GENE] inhibitor [CHEMICAL]reserpine[\\CHEMICAL] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.",
        "label": 4,
        "major": 2,
        "len": 35
    },
    {
        "text": "Because clinical studies investigating interactions between garlic and [GENE]human immunodeficiency virus protease[\\GENE] inhibitors [CHEMICAL]saquinavir[\\CHEMICAL] and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "Because clinical studies investigating interactions between garlic and [GENE]human immunodeficiency virus protease[\\GENE] inhibitors saquinavir and [CHEMICAL]ritonavir[\\CHEMICAL] have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "The treatment with [CHEMICAL]arsenic[\\CHEMICAL] exhibited a significant increase in some serum hepatic and renal biochemical parameters ([GENE]alanine aminotransferase[\\GENE], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The treatment with [CHEMICAL]arsenic[\\CHEMICAL] exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, [GENE]aspartate aminotransferase[\\GENE], alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The treatment with [CHEMICAL]arsenic[\\CHEMICAL] exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, [GENE]alkaline phosphatase[\\GENE], total protein, albumin, bilirubin, cholesterol, urea and creatinine).",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The treatment with [CHEMICAL]arsenic[\\CHEMICAL] exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, [GENE]albumin[\\GENE], bilirubin, cholesterol, urea and creatinine).",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Notably, the introduction of the F723A mutation greatly enhanced the [CHEMICAL]gefitinib[\\CHEMICAL] sensitivity of the wild-type [GENE]EGFR[\\GENE] in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.",
        "label": 0,
        "major": 10,
        "len": 33
    },
    {
        "text": "In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers [CHEMICAL]gefitinib[\\CHEMICAL] resistance on the [GENE]G719S[\\GENE] mutant.",
        "label": 10,
        "major": 1,
        "len": 21
    },
    {
        "text": "The [CHEMICAL]Met[\\CHEMICAL]790 side chain of the [GENE]G719S[\\GENE]/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.",
        "label": 1,
        "major": 1,
        "len": 28
    },
    {
        "text": "The [CHEMICAL]Met[\\CHEMICAL]790 side chain of the G719S/[GENE]T790M[\\GENE] double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.",
        "label": 1,
        "major": 1,
        "len": 28
    },
    {
        "text": "In the [GENE]L858R[\\GENE] mutant structure, the active-site cleft is expanded by the repositioning of [CHEMICAL]Phe[\\CHEMICAL]723 within the P-loop.",
        "label": 1,
        "major": 1,
        "len": 18
    },
    {
        "text": "The [GENE]G719S[\\GENE]/T790M double mutant has enhanced activity and retains high [CHEMICAL]gefitinib[\\CHEMICAL]-binding affinity.",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "The G719S/[GENE]T790M[\\GENE] double mutant has enhanced activity and retains high [CHEMICAL]gefitinib[\\CHEMICAL]-binding affinity.",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "The T790M mutation increases the [CHEMICAL]ATP[\\CHEMICAL] affinity of the [GENE]G719S[\\GENE] mutant, explaining the acquired drug resistance of the double mutant.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Notably, the introduction of the [GENE]F723A[\\GENE] mutation greatly enhanced the [CHEMICAL]gefitinib[\\CHEMICAL] sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.",
        "label": 2,
        "major": 10,
        "len": 33
    },
    {
        "text": "They display sensitivity to [GENE]TK[\\GENE] inhibitors, including [CHEMICAL]gefitinib[\\CHEMICAL] and erlotinib.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "They display sensitivity to [GENE]TK[\\GENE] inhibitors, including gefitinib and [CHEMICAL]erlotinib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased the activity of the human WNT6 promoter through [GENE]Cav1[\\GENE]-dependent binding of \u03b2-catenin to the proximal WNT6 promoter.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased the activity of the human WNT6 promoter through Cav1-dependent binding of [GENE]\u03b2-catenin[\\GENE] to the proximal WNT6 promoter.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased the activity of the [GENE]human WNT6 promoter[\\GENE] through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased the activity of the human WNT6 promoter through Cav1-dependent binding of \u03b2-catenin to the proximal [GENE]WNT6 promoter[\\GENE].",
        "label": 3,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased both [GENE]WNT6[\\GENE]/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased both WNT6/[GENE]Wnt6[\\GENE] and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Epi[\\CHEMICAL] increased both WNT6/Wnt6 and [GENE]Cav1[\\GENE] expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "These results showed that [GENE]WNT6[\\GENE] and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to [CHEMICAL]anthracycline[\\CHEMICAL] drugs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "These results showed that WNT6 and [GENE]Cav1[\\GENE] are upregulated by chemotherapeutics and enhance the resistance of GC cells to [CHEMICAL]anthracycline[\\CHEMICAL] drugs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY541850[\\CHEMICAL] was claimed from [GENE]human mGlu receptors[\\GENE] expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist.",
        "label": 2,
        "major": 6,
        "len": 21
    },
    {
        "text": "Differentiating the roles of mGlu2 and mGlu3 receptors using [CHEMICAL]LY541850[\\CHEMICAL], an [GENE]mGlu2[\\GENE] agonist/mGlu3 antagonist.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "These results confirm the selective [GENE]mGlu2[\\GENE] agonist and mGlu3 antagonist actions of [CHEMICAL]LY541850[\\CHEMICAL].",
        "label": 5,
        "major": 6,
        "len": 13
    },
    {
        "text": "[CHEMICAL]LY541850[\\CHEMICAL] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric [GENE]mGlu2[\\GENE] agonist and mGlu3 antagonist.",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "Differentiating the roles of mGlu2 and mGlu3 receptors using [CHEMICAL]LY541850[\\CHEMICAL], an mGlu2 agonist/[GENE]mGlu3[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "These results confirm the selective mGlu2 agonist and [GENE]mGlu3[\\GENE] antagonist actions of [CHEMICAL]LY541850[\\CHEMICAL].",
        "label": 6,
        "major": 5,
        "len": 13
    },
    {
        "text": "[CHEMICAL]LY541850[\\CHEMICAL] was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and [GENE]mGlu3[\\GENE] antagonist.",
        "label": 6,
        "major": 5,
        "len": 21
    },
    {
        "text": "METHODS: [CHEMICAL](+/-)-Modafinil[\\CHEMICAL] and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in [GENE]human dopamine transporter[\\GENE] (DAT) wild-type and mutants with altered conformational equilibria.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "METHODS: [CHEMICAL](+/-)-Modafinil[\\CHEMICAL] and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ([GENE]DAT[\\GENE]) wild-type and mutants with altered conformational equilibria.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [CHEMICAL][(3)H]WIN 35428[\\CHEMICAL] binding in [GENE]human dopamine transporter[\\GENE] (DAT) wild-type and mutants with altered conformational equilibria.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [CHEMICAL][(3)H]WIN 35428[\\CHEMICAL] binding in human dopamine transporter ([GENE]DAT[\\GENE]) wild-type and mutants with altered conformational equilibria.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]R-modafinil[\\CHEMICAL] was significantly less potent in the [GENE]DAT[\\GENE] Y156F mutant compared with wild-type DAT, whereas S-modafinil was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]R-modafinil[\\CHEMICAL] was significantly less potent in the DAT [GENE]Y156F[\\GENE] mutant compared with wild-type DAT, whereas S-modafinil was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "[CHEMICAL]R-modafinil[\\CHEMICAL] was significantly less potent in the DAT Y156F mutant compared with wild-type [GENE]DAT[\\GENE], whereas S-modafinil was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "RESULTS: [CHEMICAL](+/-)-, R-, and S-modafinil[\\CHEMICAL] bind to the [GENE]DAT[\\GENE] and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the [GENE]DAT[\\GENE] and inhibit DA uptake less potently than [CHEMICAL]cocaine[\\CHEMICAL], with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the [GENE]DAT[\\GENE] and inhibit DA uptake less potently than cocaine, with [CHEMICAL]R-modafinil[\\CHEMICAL] having approximately threefold higher affinity than its S-enantiomer.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "R-modafinil was significantly less potent in the [GENE]DAT[\\GENE] Y156F mutant compared with wild-type DAT, whereas [CHEMICAL]S-modafinil[\\CHEMICAL] was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "R-modafinil was significantly less potent in the DAT [GENE]Y156F[\\GENE] mutant compared with wild-type DAT, whereas [CHEMICAL]S-modafinil[\\CHEMICAL] was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "R-modafinil was significantly less potent in the DAT Y156F mutant compared with wild-type [GENE]DAT[\\GENE], whereas [CHEMICAL]S-modafinil[\\CHEMICAL] was affected less.",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "Studies with the [GENE]Y335A[\\GENE] DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than [CHEMICAL]cocaine[\\CHEMICAL], which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "Studies with the Y335A [GENE]DAT[\\GENE] mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than [CHEMICAL]cocaine[\\CHEMICAL], which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [CHEMICAL][2-(trimethylammonium)ethyl]-methanethiosulfonate[\\CHEMICAL] reactivity on the [GENE]DAT[\\GENE] E2C I159C.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [CHEMICAL][2-(trimethylammonium)ethyl]-methanethiosulfonate[\\CHEMICAL] reactivity on the DAT [GENE]E2C[\\GENE] I159C.",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by [CHEMICAL][2-(trimethylammonium)ethyl]-methanethiosulfonate[\\CHEMICAL] reactivity on the DAT E2C [GENE]I159C[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 31
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [CHEMICAL][(3)H] dopamine[\\CHEMICAL] (DA) uptake and [(3)H]WIN 35428 binding in [GENE]human dopamine transporter[\\GENE] (DAT) wild-type and mutants with altered conformational equilibria.",
        "label": 9,
        "major": 2,
        "len": 34
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [CHEMICAL][(3)H] dopamine[\\CHEMICAL] (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ([GENE]DAT[\\GENE]) wild-type and mutants with altered conformational equilibria.",
        "label": 9,
        "major": 2,
        "len": 34
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ([CHEMICAL]DA[\\CHEMICAL]) uptake and [(3)H]WIN 35428 binding in [GENE]human dopamine transporter[\\GENE] (DAT) wild-type and mutants with altered conformational equilibria.",
        "label": 9,
        "major": 2,
        "len": 34
    },
    {
        "text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ([CHEMICAL]DA[\\CHEMICAL]) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ([GENE]DAT[\\GENE]) wild-type and mutants with altered conformational equilibria.",
        "label": 9,
        "major": 1,
        "len": 34
    },
    {
        "text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the [GENE]DAT[\\GENE] and inhibit [CHEMICAL]DA[\\CHEMICAL] uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.",
        "label": 9,
        "major": 2,
        "len": 27
    },
    {
        "text": "In addition, [CHEMICAL]Silibinin[\\CHEMICAL] caused an increase in [GENE]p53[\\GENE] and p21 protein level as well as mRNA levels.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "In addition, [CHEMICAL]Silibinin[\\CHEMICAL] caused an increase in p53 and [GENE]p21[\\GENE] protein level as well as mRNA levels.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "In mechanistic studies, [CHEMICAL]Silibinin[\\CHEMICAL] decreased the protein level of [GENE]p34cdc2[\\GENE], which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either [GENE]5-HT(1A)[\\GENE] receptors by [CHEMICAL]WAY100635[\\CHEMICAL], or 5-HT(2A/2C) receptors by ritanserin.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or [GENE]5-HT(2A/2C)[\\GENE] receptors by [CHEMICAL]ritanserin[\\CHEMICAL].",
        "label": 4,
        "major": 6,
        "len": 46
    },
    {
        "text": "Previous studies demonstrated that the [GENE]Group III mGlu receptor[\\GENE]-selective orthosteric agonist, [CHEMICAL]LSP1-2111[\\CHEMICAL] produced anxiolytic- but not antidepressant-like effects upon peripheral administration.",
        "label": 5,
        "major": 5,
        "len": 21
    },
    {
        "text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the [GENE]benzodiazepine receptor[\\GENE] antagonist [CHEMICAL]flumazenil[\\CHEMICAL] (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.",
        "label": 6,
        "major": 6,
        "len": 46
    },
    {
        "text": "Anxiolytic- but not antidepressant-like activity of [CHEMICAL]Lu AF21934[\\CHEMICAL], a novel, selective positive allosteric modulator of the [GENE]mGlu\u2084[\\GENE] receptor.",
        "label": 7,
        "major": 7,
        "len": 18
    },
    {
        "text": "Herein, we report the pharmacological actions of [CHEMICAL]Lu AF21934[\\CHEMICAL], a novel, selective, and brain-penetrant positive allosteric modulator (PAM) of the [GENE]mGlu(4)[\\GENE] receptor in the stress-induced hyperthermia (SIH), four-plate, marble-burying and Vogel's conflict tests.",
        "label": 7,
        "major": 7,
        "len": 33
    },
    {
        "text": "Uncoupling from this channel was achieved by co-expression of an [GENE]mGluR1[\\GENE] [CHEMICAL]C[\\CHEMICAL]-terminal protein designed to disrupt a previously described direct interaction between these two proteins, suggesting that this interaction allows incorporation of Ca(V2.1) into the mGluR1/Homer signaling complex, thereby preserving modulation in the presence of scaffolding Homer proteins.",
        "label": 1,
        "major": 2,
        "len": 48
    },
    {
        "text": "This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal [CHEMICAL]C[\\CHEMICAL]-termini of [GENE]mGluR1 and 5[\\GENE], localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the mGluRs from extra-synaptic effectors such as voltage dependent ion channels.",
        "label": 1,
        "major": 2,
        "len": 52
    },
    {
        "text": "[CHEMICAL]Swertiamarin[\\CHEMICAL] treatment had no significant effect on adipogenesis, or the mRNA expression of [GENE]PPAR-\u03b3[\\GENE] and GLUT-4; however, there was a significant increase in the mRNA expression of adiponectin.",
        "label": 10,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Swertiamarin[\\CHEMICAL] treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and [GENE]GLUT-4[\\GENE]; however, there was a significant increase in the mRNA expression of adiponectin.",
        "label": 10,
        "major": 3,
        "len": 28
    },
    {
        "text": "Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, [CHEMICAL]Gentianine[\\CHEMICAL], that Upregulates [GENE]PPAR-\u03b3[\\GENE] Gene Expression in 3T3-L1 cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Swertiamarin[\\CHEMICAL] treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and GLUT-4; however, there was a significant increase in the mRNA expression of [GENE]adiponectin[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "On the other hand, treatment with [CHEMICAL]gentianine[\\CHEMICAL] significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of [GENE]PPAR-\u03b3[\\GENE], GLUT-4 and adiponectin.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "On the other hand, treatment with [CHEMICAL]gentianine[\\CHEMICAL] significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, [GENE]GLUT-4[\\GENE] and adiponectin.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "On the other hand, treatment with [CHEMICAL]gentianine[\\CHEMICAL] significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and [GENE]adiponectin[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or [CHEMICAL]silymarin[\\CHEMICAL] resulted in significantly increased activities of [GENE]ethylmorphine-N-demethylase[\\GENE] and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or [CHEMICAL]silymarin[\\CHEMICAL] resulted in significantly increased activities of ethylmorphine-N-demethylase and [GENE]aniline 4-hydroxylase[\\GENE] activity and cytochrome P450, compared to the CCl4 only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or [CHEMICAL]silymarin[\\CHEMICAL] resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and [GENE]cytochrome P450[\\GENE], compared to the CCl4 only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of [GENE]ethylmorphine-N-demethylase[\\GENE] and aniline 4-hydroxylase activity and cytochrome P450, compared to the [CHEMICAL]CCl4[\\CHEMICAL] only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and [GENE]aniline 4-hydroxylase[\\GENE] activity and cytochrome P450, compared to the [CHEMICAL]CCl4[\\CHEMICAL] only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and [GENE]cytochrome P450[\\GENE], compared to the [CHEMICAL]CCl4[\\CHEMICAL] only group.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "A significant decrease of [GENE]aspartate aminotransferase[\\GENE], alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [CHEMICAL]CCl4[\\CHEMICAL] and PC administration alone.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "A significant decrease of aspartate aminotransferase, [GENE]alanine aminotransferase[\\GENE], lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [CHEMICAL]CCl4[\\CHEMICAL] and PC administration alone.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "A significant decrease of aspartate aminotransferase, alanine aminotransferase, [GENE]lactate dehydrogenase[\\GENE] (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [CHEMICAL]CCl4[\\CHEMICAL] and PC administration alone.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase ([GENE]LDH[\\GENE]) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after [CHEMICAL]CCl4[\\CHEMICAL] and PC administration alone.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The study showed that [CHEMICAL]fenofibrate[\\CHEMICAL] did not attenuate increased blood pressure induced by PE, [GENE]AII[\\GENE] and ET1 but caused enhanced vasodilation by Ach, SNP and ISO.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "The study showed that [CHEMICAL]fenofibrate[\\CHEMICAL] did not attenuate increased blood pressure induced by PE, AII and [GENE]ET1[\\GENE] but caused enhanced vasodilation by Ach, SNP and ISO.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "Effects of [CHEMICAL]fenofibrate[\\CHEMICAL], a [GENE]PPAR-\u03b1[\\GENE] ligand, on the haemodynamics of glycerol-induced renal failure in rats.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "For [GENE]AII[\\GENE] and ET1, MAP was also increased for the [CHEMICAL]fenofibrate[\\CHEMICAL] group but not in a dose-dependent fashion.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "For AII and [GENE]ET1[\\GENE], MAP was also increased for the [CHEMICAL]fenofibrate[\\CHEMICAL] group but not in a dose-dependent fashion.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "The lysosomal inhibitor [CHEMICAL]chloroquine[\\CHEMICAL] significantly increased [GENE]RCAN1[\\GENE] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "These results suggest that [GENE]AKRs[\\GENE] induction by [CHEMICAL]PAHs[\\CHEMICAL] in smokers' PBLs is associated with BMI; therefore, the role of adipose tissue accumulation in PAHs' effects needs further investigation.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Exposure to [CHEMICAL]PAHs[\\CHEMICAL], their metabolites, and ROS further increase [GENE]AKRs[\\GENE] isoform expression that may amplify oxidative damage.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[GENE]Aldo-keto reductases[\\GENE] (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [CHEMICAL]oxygen[\\CHEMICAL] species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Aldo-keto reductases ([GENE]AKRs[\\GENE]) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [CHEMICAL]oxygen[\\CHEMICAL] species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "[GENE]Aldo-keto reductases[\\GENE] (AKRs) metabolize a wide range of substrates, including [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL] (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Aldo-keto reductases ([GENE]AKRs[\\GENE]) metabolize a wide range of substrates, including [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL] (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "[GENE]Aldo-keto reductases[\\GENE] (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ([CHEMICAL]PAHs[\\CHEMICAL]), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Aldo-keto reductases ([GENE]AKRs[\\GENE]) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ([CHEMICAL]PAHs[\\CHEMICAL]), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "[GENE]Aldo-keto reductases[\\GENE] (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ([CHEMICAL]o-quinones[\\CHEMICAL]) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Aldo-keto reductases ([GENE]AKRs[\\GENE]) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ([CHEMICAL]o-quinones[\\CHEMICAL]) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]TZD[\\CHEMICAL] effects on osteoblast viability, oleic acid uptake, [GENE]alkaline phosphatase[\\GENE] and osteocalcin production are independent of their effects on aromatase.",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "[CHEMICAL]TZD[\\CHEMICAL] effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and [GENE]osteocalcin[\\GENE] production are independent of their effects on aromatase.",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "[CHEMICAL]TZDs[\\CHEMICAL] also inhibited [GENE]alkaline phosphatase[\\GENE] activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).",
        "label": 4,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]TZDs[\\CHEMICAL] also inhibited alkaline phosphatase activity (58-75%, p<0.046) and [GENE]osteocalcin[\\GENE] production (52-75%, p<0.031).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]TZD[\\CHEMICAL] effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on [GENE]aromatase[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "We have previously reported that [CHEMICAL]TZDs[\\CHEMICAL] reduce estrogen synthesis by inhibiting [GENE]aromatase[\\GENE] activity in human granulosa cells (HGC).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether [CHEMICAL]TZD[\\CHEMICAL] inhibition of [GENE]aromatase[\\GENE] plays a role in their effects on bone metabolism.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We have previously reported that TZDs reduce [CHEMICAL]estrogen[\\CHEMICAL] synthesis by inhibiting [GENE]aromatase[\\GENE] activity in human granulosa cells (HGC).",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by [CHEMICAL]glutathione[\\CHEMICAL] conjugate formation catalyzed by [GENE]glutathione S-transferases[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "[GENE]Multidrug resistance-associated proteins[\\GENE] are involved in the transport of the [CHEMICAL]glutathione[\\CHEMICAL] conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Inhibition studies revealed that the [GENE]multidrug resistance-associated proteins[\\GENE] (ABCCs) are involved in the transport of [CHEMICAL]BPDE glutathione[\\CHEMICAL] conjugates.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Inhibition studies revealed that the multidrug resistance-associated proteins ([GENE]ABCCs[\\GENE]) are involved in the transport of [CHEMICAL]BPDE glutathione[\\CHEMICAL] conjugates.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]\u03b1-Amino-\u03b1\u00b4-Halomethylketones[\\CHEMICAL]: Synthetic Methodologies and Pharmaceutical Applications as [GENE]Serine and Cysteine Protease[\\GENE] Inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of [GENE]AKT-1[\\GENE], it increased phosphorylation at [CHEMICAL]Ser[\\CHEMICAL]517/Ser473.",
        "label": 1,
        "major": 3,
        "len": 19
    },
    {
        "text": "While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of [GENE]AKT-1[\\GENE], it increased phosphorylation at Ser517/[CHEMICAL]Ser[\\CHEMICAL]473.",
        "label": 1,
        "major": 10,
        "len": 19
    },
    {
        "text": "[CHEMICAL]2-Deoxyglucose[\\CHEMICAL] increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of [GENE]TSC1[\\GENE] bound to TSC2.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "Phosphorylation of [GENE]AMPK[\\GENE] at [CHEMICAL]Thr[\\CHEMICAL]172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to 2-deoxyglucose.",
        "label": 1,
        "major": 3,
        "len": 23
    },
    {
        "text": "Phosphorylation of [GENE]AMPK[\\GENE] at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to [CHEMICAL]2-deoxyglucose[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Phosphorylation of ER-stress marker [GENE]eIF2\u03b1[\\GENE] was also increased but only at 30 min of [CHEMICAL]2-deoxyglucose[\\CHEMICAL] exposure.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]2-Deoxyglucose[\\CHEMICAL] increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to [GENE]TSC2[\\GENE].",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "[CHEMICAL]2-Deoxyglucose[\\CHEMICAL] increased phosphorylation of [GENE]tuberous sclerosis complex 2[\\GENE] (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "[CHEMICAL]2-Deoxyglucose[\\CHEMICAL] increased phosphorylation of tuberous sclerosis complex 2 ([GENE]TSC2[\\GENE]) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]2-Deoxyglucose[\\CHEMICAL] increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on [GENE]AMPK[\\GENE] consensus sites but did not change the amount of TSC1 bound to TSC2.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Exposure to [CHEMICAL]Cu[\\CHEMICAL] NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [GENE]interleukin-8[\\GENE] that mirrored our findings from subacute in vivo inhalation studies in mice.",
        "label": 3,
        "major": 4,
        "len": 36
    },
    {
        "text": "Exposure to [CHEMICAL]Cu[\\CHEMICAL] NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of [GENE]lactate dehydrogenase[\\GENE], intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice.",
        "label": 3,
        "major": 4,
        "len": 36
    },
    {
        "text": "These results suggest that [CHEMICAL]LTD4[\\CHEMICAL] increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects [GENE]APP[\\GENE] levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Pretreatment with pranlukast (1.5 ng/mouse, intracerebroventricularly), a [GENE]CysLT(1)R[\\GENE] antagonist, blocked [CHEMICAL]LTD4[\\CHEMICAL]-induced amyloidogenesis, memory deficits.",
        "label": 2,
        "major": 6,
        "len": 14
    },
    {
        "text": "These results suggest that [CHEMICAL]LTD4[\\CHEMICAL] increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the [GENE]NF-\u03baB[\\GENE] pathway.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Leukotriene D4[\\CHEMICAL] induces cognitive impairment through enhancement of [GENE]CysLT\u2081 R[\\GENE]-mediated amyloid-\u03b2 generation in mice.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "These results suggest that [CHEMICAL]LTD4[\\CHEMICAL] increases A\u03b2 peptide burden via activation of [GENE]CysLT(1)R[\\GENE], which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Leukotriene D4[\\CHEMICAL] induces cognitive impairment through enhancement of CysLT\u2081 R-mediated [GENE]amyloid-\u03b2[\\GENE] generation in mice.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Moreover, [CHEMICAL]LTD4[\\CHEMICAL]-induced increases in [GENE]CysLT(1)R[\\GENE] and NF-\u03baB p65 in the brain were also attenuated by pranlukast.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Moreover, [CHEMICAL]LTD4[\\CHEMICAL]-induced increases in CysLT(1)R and [GENE]NF-\u03baB[\\GENE] p65 in the brain were also attenuated by pranlukast.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Moreover, [CHEMICAL]LTD4[\\CHEMICAL]-induced increases in CysLT(1)R and NF-\u03baB [GENE]p65[\\GENE] in the brain were also attenuated by pranlukast.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "These results suggest that [CHEMICAL]LTD4[\\CHEMICAL] increases [GENE]A\u03b2 peptide[\\GENE] burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The results demonstrated that intracerebral infusions of [CHEMICAL]LTD4[\\CHEMICAL] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of [GENE]A\u03b21-40[\\GENE] and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP).",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "The results demonstrated that intracerebral infusions of [CHEMICAL]LTD4[\\CHEMICAL] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and [GENE]A\u03b21-42[\\GENE] in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP).",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "The results demonstrated that intracerebral infusions of [CHEMICAL]LTD4[\\CHEMICAL] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of [GENE]amyloid precursor protein[\\GENE] (APP).",
        "label": 3,
        "major": 9,
        "len": 54
    },
    {
        "text": "The results demonstrated that intracerebral infusions of [CHEMICAL]LTD4[\\CHEMICAL] (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein ([GENE]APP[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "[CHEMICAL]LTD4[\\CHEMICAL] also induced expression of [GENE]cysteinyl leukotriene receptor 1[\\GENE] (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]LTD4[\\CHEMICAL] also induced expression of cysteinyl leukotriene receptor 1 ([GENE]CysLT(1)R[\\GENE]) and NF-\u03baB p65 in the hippocampus and cortex.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]LTD4[\\CHEMICAL] also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and [GENE]NF-\u03baB[\\GENE] p65 in the hippocampus and cortex.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]LTD4[\\CHEMICAL] also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB [GENE]p65[\\GENE] in the hippocampus and cortex.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Moreover, LTD4-induced increases in [GENE]CysLT(1)R[\\GENE] and NF-\u03baB p65 in the brain were also attenuated by [CHEMICAL]pranlukast[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Moreover, LTD4-induced increases in CysLT(1)R and [GENE]NF-\u03baB[\\GENE] p65 in the brain were also attenuated by [CHEMICAL]pranlukast[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB [GENE]p65[\\GENE] in the brain were also attenuated by [CHEMICAL]pranlukast[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Pretreatment with [CHEMICAL]pranlukast[\\CHEMICAL] (1.5 ng/mouse, intracerebroventricularly), a [GENE]CysLT(1)R[\\GENE] antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.",
        "label": 6,
        "major": 3,
        "len": 14
    },
    {
        "text": "Although the treatment with MSG increased [GENE]IRS-1[\\GENE] [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation (pIRS-1) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.",
        "label": 1,
        "major": 3,
        "len": 16
    },
    {
        "text": "Current research shows that the practice of swim training increases the [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation of [GENE]IRS-1[\\GENE] which can modulate the effect caused by obesity in insulin receptors.",
        "label": 1,
        "major": 3,
        "len": 26
    },
    {
        "text": "The results showed that [GENE]IR[\\GENE] [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.",
        "label": 1,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results showed that [GENE]IR[\\GENE] tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice ([CHEMICAL]MSG[\\CHEMICAL], 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "Although the treatment with [CHEMICAL]MSG[\\CHEMICAL] increased [GENE]IRS-1[\\GENE] tyrosine phosphorylation (pIRS-1) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Although the treatment with MSG increased [GENE]IRS-1[\\GENE] tyrosine phosphorylation (pIRS-1) by 96\u00a0% ([CHEMICAL]MSG[\\CHEMICAL], 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Although the treatment with MSG increased [GENE]IRS-1[\\GENE] tyrosine phosphorylation (pIRS-1) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u. ), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; [CHEMICAL]MSG[\\CHEMICAL], 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The results showed that [GENE]IR[\\GENE] tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in [CHEMICAL]MSG[\\CHEMICAL]-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results showed that [GENE]IR[\\GENE] tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice ([CHEMICAL]MSG[\\CHEMICAL], 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results showed that [GENE]IR[\\GENE] tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased pIR by 76\u00a0% in [CHEMICAL]MSG[\\CHEMICAL] mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 2,
        "major": 4,
        "len": 41
    },
    {
        "text": "Although the treatment with [CHEMICAL]MSG[\\CHEMICAL] increased IRS-1 tyrosine phosphorylation ([GENE]pIRS-1[\\GENE]) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation ([GENE]pIRS-1[\\GENE]) by 96\u00a0% ([CHEMICAL]MSG[\\CHEMICAL], 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Although the treatment with MSG increased IRS-1 tyrosine phosphorylation ([GENE]pIRS-1[\\GENE]) by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u. ), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; [CHEMICAL]MSG[\\CHEMICAL], 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.).",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation ([GENE]pIR[\\GENE]) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice ([CHEMICAL]MSG[\\CHEMICAL], 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "); on the other hand, exercise training increased [GENE]pIR[\\GENE] by 76\u00a0% in MSG mice without affecting control mice ([CHEMICAL]MSG[\\CHEMICAL], 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation ([GENE]pIR[\\GENE]) was reduced by 42\u00a0% in [CHEMICAL]MSG[\\CHEMICAL]-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in [CHEMICAL]MSG[\\CHEMICAL]-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased [GENE]pIR[\\GENE] by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation ([GENE]pIR[\\GENE]) was reduced by 42\u00a0% in MSG-obese mice ([CHEMICAL]MSG[\\CHEMICAL], 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice ([CHEMICAL]MSG[\\CHEMICAL], 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased [GENE]pIR[\\GENE] by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "The results showed that IR tyrosine phosphorylation ([GENE]pIR[\\GENE]) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u. ); on the other hand, exercise training increased pIR by 76\u00a0% in [CHEMICAL]MSG[\\CHEMICAL] mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "); on the other hand, exercise training increased [GENE]pIR[\\GENE] by 76\u00a0% in [CHEMICAL]MSG[\\CHEMICAL] mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In conclusion, these results suggested that [CHEMICAL]pioglitazone[\\CHEMICAL] protected against cisplatin- induced nephrotoxicity through its interaction with [GENE]PPAR-\u03b3[\\GENE] receptors and antioxidant effects.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the [GENE]extracellular signal-regulated kinase[\\GENE] (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and [GENE]p38[\\GENE] involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase ([GENE]ERK1/2[\\GENE]) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved [GENE]mitogen-activated protein kinase[\\GENE] (MAPK) signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase ([GENE]MAPK[\\GENE]) signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] induces autophagy in MDA-MB-231 cells by regulating [GENE]MAPK[\\GENE]-mTOR pathway.",
        "label": 2,
        "major": 3,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] induces autophagy in MDA-MB-231 cells by regulating MAPK-[GENE]mTOR[\\GENE] pathway.",
        "label": 2,
        "major": 3,
        "len": 10
    },
    {
        "text": "Taken together, these results suggest that [CHEMICAL]wogonoside[\\CHEMICAL] partially inhibits MDA-MB-231 cell growth by inducing autophagy through the [GENE]MAPK[\\GENE]-mTOR pathway and may be a promising anti-tumor agent.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "Taken together, these results suggest that [CHEMICAL]wogonoside[\\CHEMICAL] partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-[GENE]mTOR[\\GENE] pathway and may be a promising anti-tumor agent.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and [GENE]p70-S6 kinase[\\GENE] (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase ([GENE]p70S6K)[\\GENE] by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of [GENE]mammalian target of rapamycin[\\GENE] (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Wogonoside[\\CHEMICAL] also suppressed the activation of mammalian target of rapamycin ([GENE]mTOR[\\GENE]) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the [GENE]GluN1[\\GENE]/GluN2B [CHEMICAL]amino[\\CHEMICAL] terminal domain dimer by an induced-fit mechanism.",
        "label": 1,
        "major": 3,
        "len": 24
    },
    {
        "text": "Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/[GENE]GluN2B[\\GENE] [CHEMICAL]amino[\\CHEMICAL] terminal domain dimer by an induced-fit mechanism.",
        "label": 1,
        "major": 3,
        "len": 24
    },
    {
        "text": "Interestingly, recent crystallographic evidence identified that [CHEMICAL]ifenprodil,[\\CHEMICAL] unlike zinc, binds at the interface of the [GENE]GluN1[\\GENE]/GluN2B amino terminal domain dimer by an induced-fit mechanism.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Interestingly, recent crystallographic evidence identified that [CHEMICAL]ifenprodil,[\\CHEMICAL] unlike zinc, binds at the interface of the GluN1/[GENE]GluN2B[\\GENE] amino terminal domain dimer by an induced-fit mechanism.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "We found distinct differences in the action of [CHEMICAL]ifenprodil[\\CHEMICAL] at [GENE]GluN1[\\GENE]/GluN2B in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "We found distinct differences in the action of [CHEMICAL]ifenprodil[\\CHEMICAL] at GluN1/[GENE]GluN2B[\\GENE] in comparison with previous studies on the effect of zinc on GluN1/GluN2A gating, which may arise due to their unique binding sites.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of [CHEMICAL]zinc[\\CHEMICAL] on [GENE]GluN1[\\GENE]/GluN2A gating, which may arise due to their unique binding sites.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of [CHEMICAL]zinc[\\CHEMICAL] on GluN1/[GENE]GluN2A[\\GENE] gating, which may arise due to their unique binding sites.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "At a low pH (pH 7.4), but not pH 7.9, [CHEMICAL]ifenprodil[\\CHEMICAL] reduces the mean open time of [GENE]GluN1[\\GENE]/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "At a low pH (pH 7.4), but not pH 7.9, [CHEMICAL]ifenprodil[\\CHEMICAL] reduces the mean open time of GluN1/[GENE]GluN2B[\\GENE] receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Ifenprodil[\\CHEMICAL] is an allosteric inhibitor of [GENE]GluN1[\\GENE]/GluN2B N-methyl-D-aspartate receptors.",
        "label": 7,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Ifenprodil[\\CHEMICAL] is an allosteric inhibitor of GluN1/[GENE]GluN2B[\\GENE] N-methyl-D-aspartate receptors.",
        "label": 7,
        "major": 7,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Ifenprodil[\\CHEMICAL] is an allosteric inhibitor of GluN1/GluN2B [GENE]N-methyl-D-aspartate receptors[\\GENE].",
        "label": 7,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]SB365[\\CHEMICAL], Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the [GENE]AKT[\\GENE]/mTOR signalling pathway.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]SB365[\\CHEMICAL], Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/[GENE]mTOR[\\GENE] signalling pathway.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "SB365, [CHEMICAL]Pulsatilla saponin D[\\CHEMICAL] suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the [GENE]AKT[\\GENE]/mTOR signalling pathway.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "SB365, [CHEMICAL]Pulsatilla saponin D[\\CHEMICAL] suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/[GENE]mTOR[\\GENE] signalling pathway.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "Also, [CHEMICAL]SB365[\\CHEMICAL] showed anti-angiogenic activity by decreasing the expression of [GENE]HIF-1\u03b1[\\GENE] and VEGF.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Also, [CHEMICAL]SB365[\\CHEMICAL] showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and [GENE]VEGF[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Taken together, our study demonstrated that [CHEMICAL]SB365[\\CHEMICAL] inhibits the [GENE]AKT[\\GENE]/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Taken together, our study demonstrated that [CHEMICAL]SB365[\\CHEMICAL] inhibits the AKT/[GENE]mTOR[\\GENE] pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "In further studies, the diuretic effects of the [GENE]CB1[\\GENE] agonist [CHEMICAL]AM4054[\\CHEMICAL] were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
        "label": 5,
        "major": 5,
        "len": 60
    },
    {
        "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of [CHEMICAL]WIN 55,212[\\CHEMICAL] antagonized by the [GENE]CB2[\\GENE] antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
        "label": 5,
        "major": 5,
        "len": 60
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including [CHEMICAL]\u0394(9)-tetrahydrocannabinol[\\CHEMICAL], WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 3,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, [CHEMICAL]WIN 55,212[\\CHEMICAL] [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 4,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [[CHEMICAL]R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate[\\CHEMICAL]], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 3,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], [CHEMICAL]AM2389[\\CHEMICAL] [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 3,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [[CHEMICAL]9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol[\\CHEMICAL]], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 9,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and [CHEMICAL]AM4054[\\CHEMICAL] [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "Direct-acting [GENE]CB1[\\GENE] agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [[CHEMICAL]9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol[\\CHEMICAL]], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.",
        "label": 5,
        "major": 3,
        "len": 34
    },
    {
        "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the [GENE]CB2[\\GENE] agonist [CHEMICAL]AM1241[\\CHEMICAL] [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
        "label": 5,
        "major": 10,
        "len": 31
    },
    {
        "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the [GENE]CB2[\\GENE] agonist AM1241 [[CHEMICAL]1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole[\\CHEMICAL]], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.",
        "label": 5,
        "major": 6,
        "len": 31
    },
    {
        "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the [GENE]CB2[\\GENE] agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor [CHEMICAL]AM404[\\CHEMICAL], and the CB antagonist rimonabant did not have diuretic effects.",
        "label": 5,
        "major": 4,
        "len": 31
    },
    {
        "text": "In further studies, the diuretic effects of the [GENE]CB1[\\GENE] agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with [CHEMICAL]rimonabant[\\CHEMICAL], but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
        "label": 6,
        "major": 6,
        "len": 60
    },
    {
        "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the [GENE]vanilloid receptor type I[\\GENE] antagonist [CHEMICAL]capsazepine[\\CHEMICAL], nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
        "label": 6,
        "major": 5,
        "len": 60
    },
    {
        "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the [GENE]CB2[\\GENE] antagonist [CHEMICAL]AM630[\\CHEMICAL] [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].",
        "label": 6,
        "major": 10,
        "len": 60
    },
    {
        "text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the [GENE]CB2[\\GENE] antagonist AM630 [[CHEMICAL](6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)[\\CHEMICAL]].",
        "label": 6,
        "major": 10,
        "len": 60
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the [GENE]heavy subunit of neurofilament[\\GENE], microtubule-associated protein 2, or actin.",
        "label": 10,
        "major": 4,
        "len": 46
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, [GENE]microtubule-associated protein 2[\\GENE], or actin.",
        "label": 10,
        "major": 3,
        "len": 46
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or [GENE]actin[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 46
    },
    {
        "text": "We observed that the area ratio of neurite to cell body in SCAT3-expressing cells was significantly reduced by 5 and 10 \u03bcM [CHEMICAL]NaAsO(2)[\\CHEMICAL], but not by 1 \u03bcM, although the emission ratio of ECFP to Venus, an endpoint of [GENE]caspase-3[\\GENE] activity, was not changed.",
        "label": 10,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the [GENE]light and medium subunits of neurofilament[\\GENE] and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of [GENE]tau[\\GENE] and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",
        "label": 4,
        "major": 3,
        "len": 46
    },
    {
        "text": "[CHEMICAL]NaAsO(2)[\\CHEMICAL] increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and [GENE]tubulin[\\GENE] in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "In the [CHEMICAL]resveratrol[\\CHEMICAL]+As(2)O(3) group, activities of [GENE]superoxide dismutase[\\GENE], catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "In the [CHEMICAL]resveratrol[\\CHEMICAL]+As(2)O(3) group, activities of superoxide dismutase, [GENE]catalase[\\GENE] in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "In the resveratrol+[CHEMICAL]As(2)O(3)[\\CHEMICAL] group, activities of [GENE]superoxide dismutase[\\GENE], catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "In the resveratrol+[CHEMICAL]As(2)O(3)[\\CHEMICAL] group, activities of superoxide dismutase, [GENE]catalase[\\GENE] in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]DBDCT[\\CHEMICAL] induced the release of [GENE]cytochrome c[\\GENE] from the mitochondria to the cytosol and the generation of reactive oxygen species.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "In rats exposed to [CHEMICAL]DBDCT[\\CHEMICAL], apoptosis was also observed in brain, as shown by the detection of cleaved [GENE]caspase-9[\\GENE] and caspase-3 proteins and increased TUNEL positive staining.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In rats exposed to [CHEMICAL]DBDCT[\\CHEMICAL], apoptosis was also observed in brain, as shown by the detection of cleaved caspase-9 and [GENE]caspase-3[\\GENE] proteins and increased TUNEL positive staining.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "PC12 cell apoptosis induced by [CHEMICAL]DBDCT[\\CHEMICAL] was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of [GENE]caspase-9[\\GENE] and caspase-3 proteins.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "PC12 cell apoptosis induced by [CHEMICAL]DBDCT[\\CHEMICAL] was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of caspase-9 and [GENE]caspase-3[\\GENE] proteins.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]DBDCT[\\CHEMICAL] up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [GENE]Bax[\\GENE]/Bcl-2.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]DBDCT[\\CHEMICAL] up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/[GENE]Bcl-2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]DBDCT[\\CHEMICAL] up-regulated the expression of [GENE]Bax[\\GENE], down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2.",
        "label": 3,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]DBDCT[\\CHEMICAL] up-regulated the expression of Bax, down-regulated the expression of [GENE]Bcl-2[\\GENE], and significantly increased the ratio of Bax/Bcl-2.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Additionally, CYP2E1 increased the apparent K(M) of [GENE]CYP2B4[\\GENE] for [CHEMICAL]BNZ[\\CHEMICAL] by 8-fold and the apparent K(M) did not decrease to its original value when saturating concentrations of CPR were used.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "The results show that CYP2E1 inhibits [GENE]CYP2B4[\\GENE]-mediated metabolism of [CHEMICAL]benzphetamine[\\CHEMICAL] (BNZ) with a K(i) of 0.04 \u00b5M.",
        "label": 9,
        "major": 4,
        "len": 17
    },
    {
        "text": "The results show that CYP2E1 inhibits [GENE]CYP2B4[\\GENE]-mediated metabolism of benzphetamine ([CHEMICAL]BNZ[\\CHEMICAL]) with a K(i) of 0.04 \u00b5M.",
        "label": 9,
        "major": 4,
        "len": 17
    },
    {
        "text": "However, CYP2B4 is not an inhibitor of [GENE]CYP2E1[\\GENE]-mediated [CHEMICAL]p-nitrophenol[\\CHEMICAL] hydroxylation.",
        "label": 9,
        "major": 4,
        "len": 10
    },
    {
        "text": "Overall, our data suggest that (1) normal AChE activity is not required for secondary motoneuron development and (2) spontaneous tail contractions at 26 hpf are sensitive to [CHEMICAL]paraoxon[\\CHEMICAL] exposure, an effect that may be independent of [GENE]AChE[\\GENE] inhibition.",
        "label": 10,
        "major": 4,
        "len": 38
    },
    {
        "text": "However, even in the presence of significant [GENE]AChE[\\GENE] inhibition, exposure to non-teratogenic [CHEMICAL]paraoxon[\\CHEMICAL] concentrations (\u2264250 nM) did not adversely impact secondary motoneuron development at 96 hpf.",
        "label": 10,
        "major": 4,
        "len": 26
    },
    {
        "text": "We then showed that static exposure of embryos to [CHEMICAL]paraoxon[\\CHEMICAL] (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent [GENE]AChE[\\GENE] inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Using [CHEMICAL]paraoxon[\\CHEMICAL] as a reference [GENE]acetylcholinesterase[\\GENE] (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Using [CHEMICAL]paraoxon[\\CHEMICAL] as a reference acetylcholinesterase ([GENE]AChE[\\GENE]) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The mRNA levels of [GENE]microphthalmia-associated transcription factor[\\GENE] (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [CHEMICAL]artemisinic acid[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The mRNA levels of microphthalmia-associated transcription factor ([GENE]MITF[\\GENE]) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [CHEMICAL]artemisinic acid[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes [GENE]tyrosinase[\\GENE], tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by [CHEMICAL]artemisinic acid[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, [GENE]tyrosinase-related protein (TRP)-1[\\GENE], and TRP-2 were reduced by [CHEMICAL]artemisinic acid[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and [GENE]TRP-2[\\GENE] were reduced by [CHEMICAL]artemisinic acid[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Additionally, the mRNA levels of melanogenesis-related genes ([GENE]c-KIT[\\GENE], stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, [GENE]stem cell factor[\\GENE] (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor ([GENE]SCF[\\GENE]), and macrophage migration inhibitory factor (MIF)) were down-regulated by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and [GENE]macrophage migration inhibitory factor[\\GENE] (MIF)) were down-regulated by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor ([GENE]MIF[\\GENE])) were down-regulated by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that [CHEMICAL]artemisinic acid[\\CHEMICAL] regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the [GENE]hydroxymethylglutaryl CoA (HMG CoA) reductase[\\GENE] gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) \u03b1 gene.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that [CHEMICAL]artemisinic acid[\\CHEMICAL] regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the [GENE]CCAAT/enhancer-binding protein (C/EBP) \u03b1[\\GENE] gene.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Artemisinic acid[\\CHEMICAL] inhibits melanogenesis through downregulation of C/EBP \u03b1-dependent expression of [GENE]HMG-CoA reductase[\\GENE] gene.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Taken together, these findings indicate that the inhibition of melanogenesis by [CHEMICAL]artemisinic acid[\\CHEMICAL] occurs through reduced expression of the [GENE]HMG CoA reductase[\\GENE] gene, which is mediated by C/EBP \u03b1 inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Furthermore, cAMP production and [GENE]protein kinase A[\\GENE] (PKA) activity were suppressed by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "Furthermore, cAMP production and protein kinase A ([GENE]PKA[\\GENE]) activity were suppressed by [CHEMICAL]artemisinic acid[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Artemisinic acid[\\CHEMICAL] inhibits melanogenesis through downregulation of [GENE]C/EBP \u03b1[\\GENE]-dependent expression of HMG-CoA reductase gene.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Taken together, these findings indicate that the inhibition of melanogenesis by [CHEMICAL]artemisinic acid[\\CHEMICAL] occurs through reduced expression of the HMG CoA reductase gene, which is mediated by [GENE]C/EBP \u03b1[\\GENE] inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]8-pCPT-2'-O-Me-cAMP-AM[\\CHEMICAL] alone (5 \u03bcM) did not stimulate [GENE]insulin[\\GENE] secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 \u03bcM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+).",
        "label": 10,
        "major": 3,
        "len": 32
    },
    {
        "text": "Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that [CHEMICAL]gliclazide[\\CHEMICAL] can stimulate [GENE]phospholipase C[\\GENE] activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "Both [CHEMICAL]tolbutamide[\\CHEMICAL] and gliclazide stimulated [GENE]phospholipase C[\\GENE] activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "Both tolbutamide and [CHEMICAL]gliclazide[\\CHEMICAL] stimulated [GENE]phospholipase C[\\GENE] activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only [CHEMICAL]gliclazide[\\CHEMICAL] did so independently of its activity at [GENE]K(ATP) channels[\\GENE], and this activity was partially inhibited by pertussis toxin.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of [GENE]insulin[\\GENE] secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor [CHEMICAL]bisindolylmaleimide I[\\CHEMICAL] (1 \u03bcM).",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Tolbutamide[\\CHEMICAL] and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating [GENE]insulin[\\GENE] secretion in pancreatic beta cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[GENE]Insulin[\\GENE] secretion stimulated by both 200 \u03bcM [CHEMICAL]tolbutamide[\\CHEMICAL] and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[GENE]Insulin[\\GENE] secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM [CHEMICAL]gliclazide[\\CHEMICAL], concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 3,
        "major": 4,
        "len": 47
    },
    {
        "text": "[GENE]Insulin[\\GENE] secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by [CHEMICAL]8-pCPT-2'-O-Me-cAMP-AM[\\CHEMICAL] at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]8-pCPT-2'-O-Me-cAMP-AM[\\CHEMICAL] potentiation of [GENE]insulin[\\GENE] secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM).",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of [GENE]insulin[\\GENE] secretion stimulated by [CHEMICAL]tolbutamide[\\CHEMICAL] was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM).",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "[GENE]Insulin[\\GENE] secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by [CHEMICAL]thapsigargin[\\CHEMICAL] (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[GENE]Insulin[\\GENE] secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker [CHEMICAL]nicardipine[\\CHEMICAL] (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of [GENE]insulin[\\GENE] secretion stimulated by tolbutamide was markedly inhibited by [CHEMICAL]2-APB[\\CHEMICAL] (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM).",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the [GENE]PKC[\\GENE] inhibitor [CHEMICAL]bisindolylmaleimide I[\\CHEMICAL] (1 \u03bcM).",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Tolbutamide[\\CHEMICAL] and gliclazide block the [GENE]K(ATP) channel[\\GENE] K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Tolbutamide[\\CHEMICAL] and gliclazide block the K(ATP) channel [GENE]K(ir)6.2[\\GENE]/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Tolbutamide[\\CHEMICAL] and gliclazide block the K(ATP) channel K(ir)6.2/[GENE]Sur1[\\GENE], causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the [GENE]L-type Ca(2+) channel[\\GENE] blocker [CHEMICAL]nicardipine[\\CHEMICAL] (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "In vivo genotoxicity of [CHEMICAL]methyleugenol[\\CHEMICAL] in [GENE]gpt[\\GENE] delta transgenic rats following medium-term exposure.",
        "label": 2,
        "major": 10,
        "len": 13
    },
    {
        "text": "In addition, the number and area of [GENE]glutathione S-transferase placental form[\\GENE] (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [CHEMICAL]MEG[\\CHEMICAL] compared with the control animals.",
        "label": 3,
        "major": 3,
        "len": 45
    },
    {
        "text": "In addition, the number and area of glutathione S-transferase placental form ([GENE]GST-P[\\GENE]) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [CHEMICAL]MEG[\\CHEMICAL] compared with the control animals.",
        "label": 3,
        "major": 3,
        "len": 45
    },
    {
        "text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and [GENE]proliferating cell nuclear antigen[\\GENE] (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [CHEMICAL]MEG[\\CHEMICAL] compared with the control animals.",
        "label": 3,
        "major": 3,
        "len": 45
    },
    {
        "text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen ([GENE]PCNA[\\GENE]) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg [CHEMICAL]MEG[\\CHEMICAL] compared with the control animals.",
        "label": 3,
        "major": 3,
        "len": 45
    },
    {
        "text": "The exposure of highly toxic [CHEMICAL]aconitine[\\CHEMICAL] does not significantly impact the activity and expression of [GENE]cytochrome P450 3A[\\GENE] in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone.",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of [GENE]caspase-9[\\GENE] and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and [GENE]caspase-3[\\GENE], and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of [GENE]caspase-9[\\GENE] and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and [GENE]caspase-3[\\GENE], and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Nitrogen[\\CHEMICAL]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and [GENE]Bim[\\GENE]-mediated activation of the intrinsic apoptotic pathway.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Nitrogen-containing [CHEMICAL]bisphosphonates[\\CHEMICAL] induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and [GENE]Bim[\\GENE]-mediated activation of the intrinsic apoptotic pathway.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]N[\\CHEMICAL]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced [GENE]Bim[\\GENE] expression.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, N-[CHEMICAL]BPs[\\CHEMICAL] decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced [GENE]Bim[\\GENE] expression.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing [GENE]Bim[\\GENE] expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing [GENE]Bim[\\GENE] expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Furthermore, [CHEMICAL]N[\\CHEMICAL]-BPs decreased the levels of [GENE]phosphorylated extracellular signal-regulated kinase[\\GENE] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]N[\\CHEMICAL]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]N[\\CHEMICAL]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and [GENE]mTOR[\\GENE] via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, N-[CHEMICAL]BPs[\\CHEMICAL] decreased the levels of [GENE]phosphorylated extracellular signal-regulated kinase[\\GENE] (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, N-[CHEMICAL]BPs[\\CHEMICAL] decreased the levels of phosphorylated extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) and mTOR via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, N-[CHEMICAL]BPs[\\CHEMICAL] decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and [GENE]mTOR[\\GENE] via suppression of Ras prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]N[\\CHEMICAL]-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of [GENE]Ras[\\GENE] prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, N-[CHEMICAL]BPs[\\CHEMICAL] decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of [GENE]Ras[\\GENE] prenylation and enhanced Bim expression.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the [GENE]Ras[\\GENE]/MEK/ERK and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/[GENE]MEK[\\GENE]/ERK and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/[GENE]ERK[\\GENE] and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and [GENE]Ras[\\GENE]/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that [CHEMICAL]N[\\CHEMICAL]-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/[GENE]mTOR[\\GENE] pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the [GENE]Ras[\\GENE]/MEK/ERK and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/[GENE]MEK[\\GENE]/ERK and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/[GENE]ERK[\\GENE] and Ras/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and [GENE]Ras[\\GENE]/mTOR pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The present results indicated that N-[CHEMICAL]BPs[\\CHEMICAL] induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/[GENE]mTOR[\\GENE] pathways.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Nitrogen[\\CHEMICAL]-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of [GENE]Ras[\\GENE] signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Nitrogen-containing [CHEMICAL]bisphosphonates[\\CHEMICAL] induce apoptosis of hematopoietic tumor cells via inhibition of [GENE]Ras[\\GENE] signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Nitrogen[\\CHEMICAL]-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [GENE]G-proteins[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Nitrogen-containing [CHEMICAL]bisphosphonates[\\CHEMICAL] (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [GENE]G-proteins[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Nitrogen-containing bisphosphonates ([CHEMICAL]N[\\CHEMICAL]-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small [GENE]G-proteins[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Nitrogen-containing bisphosphonates (N-[CHEMICAL]BPs[\\CHEMICAL]) induce apoptosis in tumor cells by inhibiting the prenylation of small [GENE]G-proteins[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic [GENE]AhR[\\GENE] ligands [CHEMICAL]2,3,7,8-tetrachlorodibenzo-p-dioxin[\\CHEMICAL] (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands [CHEMICAL]2,3,7,8-tetrachlorodibenzo-p-dioxin[\\CHEMICAL] (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an [GENE]AhR[\\GENE]-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic [GENE]AhR[\\GENE] ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin ([CHEMICAL]TCDD[\\CHEMICAL]) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin ([CHEMICAL]TCDD[\\CHEMICAL]) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an [GENE]AhR[\\GENE]-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic [GENE]AhR[\\GENE] ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL] in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL] in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an [GENE]AhR[\\GENE]-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 45
    },
    {
        "text": "Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by [CHEMICAL]TCDD[\\CHEMICAL], siRNA-mediated [GENE]Cx43[\\GENE] knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands [CHEMICAL]2,3,7,8-tetrachlorodibenzo-p-dioxin[\\CHEMICAL] (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced [GENE]Cx43[\\GENE] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin ([CHEMICAL]TCDD[\\CHEMICAL]) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced [GENE]Cx43[\\GENE] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL] in epithelial WB-F344 cells, reduced [GENE]Cx43[\\GENE] protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "Although both intracellular and membrane [GENE]Cx43[\\GENE] pools were markedly reduced in cells released from contact inhibition by [CHEMICAL]TCDD[\\CHEMICAL], siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The pretreatment with 20\u00a0mg\u2009L(-1) [CHEMICAL]La(III)[\\CHEMICAL] could alleviate the effects of UV-B radiation on the activities of [GENE]nitrate reductase[\\GENE], glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
        "label": 4,
        "major": 1,
        "len": 35
    },
    {
        "text": "The pretreatment with 20\u00a0mg\u2009L(-1) [CHEMICAL]La(III)[\\CHEMICAL] could alleviate the effects of UV-B radiation on the activities of nitrate reductase, [GENE]glutamine synthetase[\\GENE], glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
        "label": 4,
        "major": 1,
        "len": 35
    },
    {
        "text": "The pretreatment with 20\u00a0mg\u2009L(-1) [CHEMICAL]La(III)[\\CHEMICAL] could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, [GENE]glutamate synthase[\\GENE], and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.",
        "label": 4,
        "major": 1,
        "len": 35
    },
    {
        "text": "The pretreatment with 20\u00a0mg\u2009L(-1) [CHEMICAL]La(III)[\\CHEMICAL] could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and [GENE]glutamate dehydrogenase[\\GENE], promoting amino acid conversion and protein synthesis in soybean seedlings.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thus, the apoptosis induction in SGC-7901 cells by [CHEMICAL]\u03b2-ionone[\\CHEMICAL] may be regulated through a [GENE]PI3K[\\GENE]-AKT pathway.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Thus, the apoptosis induction in SGC-7901 cells by [CHEMICAL]\u03b2-ionone[\\CHEMICAL] may be regulated through a PI3K-[GENE]AKT[\\GENE] pathway.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "The results demonstrated that \u03b2-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with \u03b2-ionone (25, 50, 100 and 200\u00a0\u03bcmol/L) for 24\u00a0h. [CHEMICAL]\u03b2-ionone[\\CHEMICAL] was also shown to induce the expression of cleaved-[GENE]caspase-3[\\GENE] and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "The results demonstrated that \u03b2-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with \u03b2-ionone (25, 50, 100 and 200\u00a0\u03bcmol/L) for 24\u00a0h. [CHEMICAL]\u03b2-ionone[\\CHEMICAL] was also shown to induce the expression of cleaved-caspase-3 and inhibit [GENE]bcl-2[\\GENE] expression in SGC-7901 cells in a dose-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "The significantly decreased levels of [GENE]p-PI3K[\\GENE] and p-AKT expression were observed in SGC-7901 cells after [CHEMICAL]\u03b2-ionone[\\CHEMICAL] treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01).",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The significantly decreased levels of p-PI3K and [GENE]p-AKT[\\GENE] expression were observed in SGC-7901 cells after [CHEMICAL]\u03b2-ionone[\\CHEMICAL] treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01).",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Sulfhydration of [GENE]sulfonylurea receptor 2B[\\GENE] (SUR2B) was induced by [CHEMICAL]NaHS[\\CHEMICAL] and colonic inflammation.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Sulfhydration of sulfonylurea receptor 2B ([GENE]SUR2B[\\GENE]) was induced by [CHEMICAL]NaHS[\\CHEMICAL] and colonic inflammation.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Hydrogen sulfide[\\CHEMICAL] as an allosteric modulator of [GENE]ATP-sensitive potassium channels[\\GENE] in colonic inflammation.",
        "label": 7,
        "major": 7,
        "len": 13
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating [GENE]nuclear factor-kappaB[\\GENE] (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB ([GENE]NF-\u03baB[\\GENE]), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of [GENE]tumor necrosis factor-alpha[\\GENE] (TNF-\u03b1) and cyclooxygenase-2 (COX-2).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha ([GENE]TNF-\u03b1[\\GENE]) and cyclooxygenase-2 (COX-2).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and [GENE]cyclooxygenase-2[\\GENE] (COX-2).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 ([GENE]COX-2[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]CCl(4)[\\CHEMICAL] intoxication caused hepatic necrosis and increased serum [GENE]ALT[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "Furthermore, RA significantly inhibited the [CHEMICAL]CCl(4)[\\CHEMICAL]-induced apoptosis, which was evident from decreased cleavage of [GENE]caspase-3[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Antiarrhythmic effects of [CHEMICAL](-)-epicatechin-3-gallate[\\CHEMICAL], a novel [GENE]sodium channel[\\GENE] agonist in cultured neonatal rat ventricular myocytes.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "[GENE]Opioid receptor[\\GENE] binding affinity and activity were assessed using [CHEMICAL][(3)H]-diprenorphine[\\CHEMICAL] binding, guanosine-5'-O-(3-[35S]-thio) triphosphate ([(35)S]-GTP\u03b3S) binding and isolated guinea-pig ileum.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[GENE]Opioid receptor[\\GENE] binding affinity and activity were assessed using [(3)H]-diprenorphine binding, [CHEMICAL]guanosine-5'-O-(3-[35S]-thio) triphosphate[\\CHEMICAL] ([(35)S]-GTP\u03b3S) binding and isolated guinea-pig ileum.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[GENE]Opioid receptor[\\GENE] binding affinity and activity were assessed using [(3)H]-diprenorphine binding, guanosine-5'-O-(3-[35S]-thio) triphosphate ([CHEMICAL][(35)S]-GTP\u03b3S[\\CHEMICAL]) binding and isolated guinea-pig ileum.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Both [CHEMICAL]5'-AMN[\\CHEMICAL] and 5'-MABN had high affinity for [GENE]\u03ba-receptors[\\GENE] (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and \u03bc-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
        "label": 2,
        "major": 6,
        "len": 41
    },
    {
        "text": "Both 5'-AMN and [CHEMICAL]5'-MABN[\\CHEMICAL] had high affinity for [GENE]\u03ba-receptors[\\GENE] (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and \u03bc-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
        "label": 2,
        "major": 6,
        "len": 41
    },
    {
        "text": "Both [CHEMICAL]5'-AMN[\\CHEMICAL] and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and [GENE]\u03bc-receptor[\\GENE] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "Both 5'-AMN and [CHEMICAL]5'-MABN[\\CHEMICAL] had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and [GENE]\u03bc-receptor[\\GENE] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.",
        "label": 6,
        "major": 2,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating [GENE]sterol regulatory element-binding protein-1c[\\GENE] (SREBP-1c) activation.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c ([GENE]SREBP-1c[\\GENE]) activation.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the [CHEMICAL]phillyrin[\\CHEMICAL]-enhanced activation of [GENE]AMPK[\\GENE] in HepG2 hepatocytes.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "These results indicate that [CHEMICAL]phillyrin[\\CHEMICAL] prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through [GENE]LKB1[\\GENE]/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "These results indicate that [CHEMICAL]phillyrin[\\CHEMICAL] prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/[GENE]AMPK[\\GENE] activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of [GENE]LKB1[\\GENE]/AMP-activated protein kinase-dependent signalling.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/[GENE]AMP-activated protein kinase[\\GENE]-dependent signalling.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/AMPK activation, suggesting that [CHEMICAL]phillyrin[\\CHEMICAL] is a novel [GENE]AMPK[\\GENE] activator with a role in the prevention and treatment of obesity.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "Phillyrin strongly inhibited high [CHEMICAL]glucose[\\CHEMICAL]-induced [GENE]fatty acid synthase[\\GENE] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Phillyrin strongly inhibited high [CHEMICAL]glucose[\\CHEMICAL]-induced fatty acid synthase ([GENE]FAS[\\GENE]) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These results indicate that [CHEMICAL]phillyrin[\\CHEMICAL] prevents lipid accumulation in HepG2 cells by blocking the expression of [GENE]SREBP-1c[\\GENE] and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "These results indicate that [CHEMICAL]phillyrin[\\CHEMICAL] prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and [GENE]FAS[\\GENE] through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] strongly inhibited high glucose-induced [GENE]fatty acid synthase[\\GENE] (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Phillyrin[\\CHEMICAL] strongly inhibited high glucose-induced fatty acid synthase ([GENE]FAS[\\GENE]) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Moreover, use of the pharmacological [GENE]AMP-activated protein kinase[\\GENE] (AMPK) inhibitor [CHEMICAL]compound C[\\CHEMICAL] revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Moreover, use of the pharmacological AMP-activated protein kinase ([GENE]AMPK[\\GENE]) inhibitor [CHEMICAL]compound C[\\CHEMICAL] revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor [CHEMICAL]compound C[\\CHEMICAL] revealed that [GENE]AMPK[\\GENE] is essential for suppressing SREBP-1c expression in phillyrin-treated cells.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL][-]-Huperzine A[\\CHEMICAL] ([-]-Hup A), is a naturally occurring potent reversible [GENE]AChE[\\GENE] inhibitor that penetrates the blood-brain barrier.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[-]-Huperzine A ([CHEMICAL][-]-Hup A[\\CHEMICAL]), is a naturally occurring potent reversible [GENE]AChE[\\GENE] inhibitor that penetrates the blood-brain barrier.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The synthetic stereoisomer, [CHEMICAL][+]-Hup A[\\CHEMICAL], is less toxic due to poor [GENE]AChE[\\GENE] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "An increase in the [CHEMICAL]ADP[\\CHEMICAL]/ATP ratio opens [GENE]K(ATP) channels[\\GENE], leading to membrane hyperpolarization.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "An increase in the ADP/[CHEMICAL]ATP[\\CHEMICAL] ratio opens [GENE]K(ATP) channels[\\GENE], leading to membrane hyperpolarization.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both [CHEMICAL]dimethyldiguanide[\\CHEMICAL] (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and [GENE]insulin[\\GENE] levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "These findings demonstrate that cinnamon [CHEMICAL]polyphenols[\\CHEMICAL] can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [GENE]iNOS[\\GENE], NF-\u03baB activation.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "These findings demonstrate that cinnamon [CHEMICAL]polyphenols[\\CHEMICAL] can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, [GENE]NF-\u03baB[\\GENE] activation.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and [CHEMICAL]imatinib[\\CHEMICAL], a selective [GENE]tyrosine kinase[\\GENE] inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "One of the [GENE]CB2[\\GENE] agonists, [CHEMICAL]N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine[\\CHEMICAL] (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "As far as we are aware, the compound's [CHEMICAL]1,3,5-triazine[\\CHEMICAL] scaffold represents a new core structure for [GENE]CB2[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of [CHEMICAL]2,4,6-trisubstituted 1,3,5-triazines[\\CHEMICAL] as [GENE]CB2[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "However, a lid conformation was induced by [[CHEMICAL]Sar[\\CHEMICAL](1),Gln(2),Ile(8)] [GENE]AngII[\\GENE], a specific analog that binds to the D281A mutant with better affinity than AngII.",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [[CHEMICAL]Sar[\\CHEMICAL](1),Gln(2),Ile(8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [GENE]AngII[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),[CHEMICAL]Gln[\\CHEMICAL](2),Ile(8)] [GENE]AngII[\\GENE], a specific analog that binds to the D281A mutant with better affinity than AngII.",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),[CHEMICAL]Gln[\\CHEMICAL](2),Ile(8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [GENE]AngII[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),Gln(2),[CHEMICAL]Ile[\\CHEMICAL](8)] [GENE]AngII[\\GENE], a specific analog that binds to the D281A mutant with better affinity than AngII.",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),Gln(2),[CHEMICAL]Ile[\\CHEMICAL](8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [GENE]AngII[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 23
    },
    {
        "text": "Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type [GENE]AT1R[\\GENE] changed the accessibility of reporter [CHEMICAL]cysteines[\\CHEMICAL], and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2.",
        "label": 1,
        "major": 2,
        "len": 31
    },
    {
        "text": "However, a lid conformation was induced by [[CHEMICAL]Sar[\\CHEMICAL](1),Gln(2),Ile(8)] AngII, a specific analog that binds to the [GENE]D281A[\\GENE] mutant with better affinity than AngII.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),[CHEMICAL]Gln[\\CHEMICAL](2),Ile(8)] AngII, a specific analog that binds to the [GENE]D281A[\\GENE] mutant with better affinity than AngII.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "However, a lid conformation was induced by [Sar(1),Gln(2),[CHEMICAL]Ile[\\CHEMICAL](8)] AngII, a specific analog that binds to the [GENE]D281A[\\GENE] mutant with better affinity than AngII.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Binding of the agonist angiotensin II (AngII) and inverse agonist [CHEMICAL]losartan[\\CHEMICAL] in wild-type [GENE]AT1R[\\GENE] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2.",
        "label": 5,
        "major": 5,
        "len": 31
    },
    {
        "text": "The [CHEMICAL]nucleotide[\\CHEMICAL] sequence of [GENE]HmTx[\\GENE] contains 649 bp, and the mature protein is predicted to have 131 amino acid residues-104 of which make up the large subunit, and 27 of which make up the small subunit.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "The nucleotide sequence of [GENE]HmTx[\\GENE] contains 649 bp, and the mature protein is predicted to have 131 [CHEMICAL]amino acid[\\CHEMICAL] residues-104 of which make up the large subunit, and 27 of which make up the small subunit.",
        "label": 1,
        "major": 1,
        "len": 36
    },
    {
        "text": "In muscle and liver, [CHEMICAL]TCDD[\\CHEMICAL] (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of [GENE]Igf2r[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "While none of the [CHEMICAL]phenethylamides[\\CHEMICAL] (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit [GENE]17\u03b2-HSD2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 25
    },
    {
        "text": "We report here the optimization of [GENE]human 17\u03b2-HSD2[\\GENE] inhibitors in the [CHEMICAL]2,5-thiophene amide[\\CHEMICAL] class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "While none of the phenethylamides (n = 2) were active, most of the [CHEMICAL]anilides[\\CHEMICAL] (n = 0) turned out to moderately or strongly inhibit [GENE]17\u03b2-HSD2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Structural optimization of [CHEMICAL]2,5-thiophene amides[\\CHEMICAL] as highly potent and selective [GENE]17\u03b2-hydroxysteroid dehydrogenase type 2[\\GENE] inhibitors for the treatment of osteoporosis.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The inhibition of phosphoinositide 3-kinase using [CHEMICAL]Ly294002[\\CHEMICAL] augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of [GENE]Sp1[\\GENE] and cyclin D1.",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "The inhibition of phosphoinositide 3-kinase using [CHEMICAL]Ly294002[\\CHEMICAL] augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and [GENE]cyclin D1[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "In combination with [CHEMICAL]clofarabine[\\CHEMICAL], the ability of resveratrol to reduce the contents of [GENE]Sp1[\\GENE] and its target gene products was also evident in a time- and dose-dependent experiment.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "In combination with clofarabine, the ability of [CHEMICAL]resveratrol[\\CHEMICAL] to reduce the contents of [GENE]Sp1[\\GENE] and its target gene products was also evident in a time- and dose-dependent experiment.",
        "label": 4,
        "major": 9,
        "len": 28
    },
    {
        "text": "In combination with [CHEMICAL]clofarabine[\\CHEMICAL], the ability of resveratrol to reduce the contents of [GENE]Sp1[\\GENE] and its target gene products was also evident in a time- and dose-dependent experiment.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In combination with clofarabine, the ability of [CHEMICAL]resveratrol[\\CHEMICAL] to reduce the contents of [GENE]Sp1[\\GENE] and its target gene products was also evident in a time- and dose-dependent experiment.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The inhibition of phosphoinositide 3-kinase using [CHEMICAL]Ly294002[\\CHEMICAL] augmented a decrease in the [GENE]p21[\\GENE] level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of [CHEMICAL]resveratrol[\\CHEMICAL] and clofarabine is linked to the inhibition of [GENE]Akt[\\GENE] and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of [CHEMICAL]resveratrol[\\CHEMICAL] and clofarabine is linked to the inhibition of Akt and [GENE]Sp1[\\GENE] activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and [CHEMICAL]clofarabine[\\CHEMICAL] is linked to the inhibition of [GENE]Akt[\\GENE] and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and [CHEMICAL]clofarabine[\\CHEMICAL] is linked to the inhibition of Akt and [GENE]Sp1[\\GENE] activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "The inhibition of [GENE]phosphoinositide 3-kinase[\\GENE] using [CHEMICAL]Ly294002[\\CHEMICAL] augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Emodin-6-O-\u03b2-D-glucoside[\\CHEMICAL] inhibits [GENE]HMGB1[\\GENE]-induced inflammatory responses in vitro and in vivo.",
        "label": 4,
        "major": 3,
        "len": 10
    },
    {
        "text": "Linking [GENE]GABA(A) receptor[\\GENE] subunits to [CHEMICAL]alcohol[\\CHEMICAL]-induced conditioned taste aversion and recovery from acute alcohol intoxication.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Arsenic[\\CHEMICAL] activates [GENE]endothelin-1[\\GENE] Gi protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "These studies suggest a majority of arsenic-inhibited adipocyte differentiation, and metabolism requires endothelin-1 GPCRs and that [CHEMICAL]As(III)[\\CHEMICAL] effects on [GENE]GPCR[\\GENE] signaling are tissue and context specific.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] decreased the expression of the [GENE]glucose transporter[\\GENE], SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] decreased the expression of the glucose transporter, [GENE]SLC2A1[\\GENE], and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Mitochondrial [GENE]glutathione (GSH) reductase[\\GENE] activity and the GSH/glutathione disulfide ratio were decreased by [CHEMICAL]TCDD[\\CHEMICAL], ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Using the viral mimic [CHEMICAL]polyinosinic:polycytidylic acid[\\CHEMICAL] and the IFN\u03b1/\u03b2 antagonist B18R we furthermore demonstrate the capability of endogenous [GENE]IFN[\\GENE] to promote IL-22-induced STAT1 activation and expression of CXCL10.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Using the viral mimic [CHEMICAL]polyinosinic:polycytidylic acid[\\CHEMICAL] and the IFN\u03b1/\u03b2 antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote [GENE]IL-22[\\GENE]-induced STAT1 activation and expression of CXCL10.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Using the viral mimic [CHEMICAL]polyinosinic:polycytidylic acid[\\CHEMICAL] and the IFN\u03b1/\u03b2 antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced [GENE]STAT1[\\GENE] activation and expression of CXCL10.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Using the viral mimic [CHEMICAL]polyinosinic:polycytidylic acid[\\CHEMICAL] and the IFN\u03b1/\u03b2 antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of [GENE]CXCL10[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Using the viral mimic [CHEMICAL]polyinosinic:polycytidylic acid[\\CHEMICAL] and the [GENE]IFN\u03b1/\u03b2[\\GENE] antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of CXCL10.",
        "label": 8,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Glutaraldehyde[\\CHEMICAL] crosslinked [GENE]albumin[\\GENE] nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.",
        "label": 1,
        "major": 4,
        "len": 35
    },
    {
        "text": "Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to [CHEMICAL]methionine[\\CHEMICAL] residues of [GENE]albumin[\\GENE] and is released in a reductive environment.",
        "label": 1,
        "major": 4,
        "len": 35
    },
    {
        "text": "Nanobody-albumin nanoparticles (NANAPs) for the delivery of a [GENE]multikinase[\\GENE] inhibitor [CHEMICAL]17864[\\CHEMICAL] to EGFR overexpressing tumor cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the [GENE]multikinase[\\GENE] inhibitor [CHEMICAL]17864[\\CHEMICAL]-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The cDNAs of the full-length version of [GENE]Ves a 1s[\\GENE] revealed that the Ves a 1 gene consists of a 1005-bp ORF, which encodes 334 [CHEMICAL]amino acid[\\CHEMICAL] residues, and 67- and 227-bp 5' and 3' UTRs, respectively.",
        "label": 1,
        "major": 1,
        "len": 37
    },
    {
        "text": "The cDNAs of the full-length version of Ves a 1s revealed that the [GENE]Ves a 1[\\GENE] gene consists of a 1005-bp ORF, which encodes 334 [CHEMICAL]amino acid[\\CHEMICAL] residues, and 67- and 227-bp 5' and 3' UTRs, respectively.",
        "label": 1,
        "major": 1,
        "len": 37
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased [GENE]NF-\u03baB[\\GENE] p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased NF-\u03baB [GENE]p65[\\GENE] nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of TLR-4, [GENE]Myd88[\\GENE], ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of TLR-4, Myd88, [GENE]ICAM-1[\\GENE], TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of TLR-4, Myd88, ICAM-1, [GENE]TNF\u03b1[\\GENE], IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, [GENE]IL-1\u03b2[\\GENE] and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and [GENE]IL-6[\\GENE] at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] suppressed the expression of [GENE]TLR-4[\\GENE], Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of [GENE]p38[\\GENE] mitogen-activated protein kinase (p38 MAPK).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 [GENE]mitogen-activated protein kinase[\\GENE] (p38 MAPK).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase ([GENE]p38[\\GENE] MAPK).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]HSYA[\\CHEMICAL] treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 [GENE]MAPK[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "First, we showed that intracerebroventricular administration of [CHEMICAL]glucose[\\CHEMICAL] in rats increases [GENE]DBI[\\GENE] expression in hypothalamic glial-like tanycytes.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "The glycogen synthase kinase-3\u03b2/[GENE]nuclear factor-kappa B[\\GENE] pathway is involved in [CHEMICAL]cinobufagin[\\CHEMICAL]-induced apoptosis in cultured osteosarcoma cells.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "The [GENE]glycogen synthase kinase-3\u03b2[\\GENE]/nuclear factor-kappa B pathway is involved in [CHEMICAL]cinobufagin[\\CHEMICAL]-induced apoptosis in cultured osteosarcoma cells.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "These studies are the first to reveal the involvement of the [GENE]GSK-3\u03b2[\\GENE]/NF-\u03baB pathway in [CHEMICAL]cinobufagin[\\CHEMICAL]-induced apoptosis.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "These studies are the first to reveal the involvement of the GSK-3\u03b2/[GENE]NF-\u03baB[\\GENE] pathway in [CHEMICAL]cinobufagin[\\CHEMICAL]-induced apoptosis.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of [CHEMICAL]cinobufagin[\\CHEMICAL], while the phosphorylation of [GENE]GSK-3\u03b2[\\GENE] was simultaneously increased.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved-[GENE]PARP[\\GENE] that are induced by [CHEMICAL]cinobufagin[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "However, combined treatment with [CHEMICAL]cinobufagin[\\CHEMICAL] and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-[GENE]PARP[\\GENE] in U2OS cells.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "However, combined treatment with cinobufagin and [CHEMICAL]SB216367[\\CHEMICAL] resulted in a significant reduction in p65 and an increase in cleaved-[GENE]PARP[\\GENE] in U2OS cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, we validated the inhibition of [GENE]GSK-3\u03b2[\\GENE]/NF-\u03baB signaling following [CHEMICAL]cinobufagin[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Furthermore, we validated the inhibition of GSK-3\u03b2/[GENE]NF-\u03baB[\\GENE] signaling following [CHEMICAL]cinobufagin[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Western blots showed a decrease in nuclear [GENE]p65[\\GENE] protein expression after exposure to different concentrations of [CHEMICAL]cinobufagin[\\CHEMICAL], while the phosphorylation of GSK-3\u03b2 was simultaneously increased.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of [GENE]p65[\\GENE] and upregulation of cleaved-PARP that are induced by [CHEMICAL]cinobufagin[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "However, combined treatment with [CHEMICAL]cinobufagin[\\CHEMICAL] and SB216367 resulted in a significant reduction in [GENE]p65[\\GENE] and an increase in cleaved-PARP in U2OS cells.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "However, combined treatment with cinobufagin and [CHEMICAL]SB216367[\\CHEMICAL] resulted in a significant reduction in [GENE]p65[\\GENE] and an increase in cleaved-PARP in U2OS cells.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "3D-QSAR-assisted drug design: identification of a potent [CHEMICAL]quinazoline[\\CHEMICAL]-based [GENE]Aurora kinase[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the [GENE]Myc[\\GENE] oncoprotein that is flanked by [CHEMICAL]arginine[\\CHEMICAL] residues - was executed in order to determine its pharmacophore.",
        "label": 1,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the [GENE]c-Myc[\\GENE] (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by [CHEMICAL]arginine[\\CHEMICAL] residues - was executed in order to determine its pharmacophore.",
        "label": 1,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc ([GENE]Myc[\\GENE]) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by [CHEMICAL]arginine[\\CHEMICAL] residues - was executed in order to determine its pharmacophore.",
        "label": 1,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor [CHEMICAL]10074-G5[\\CHEMICAL] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the [GENE]Myc[\\GENE] oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 ([CHEMICAL]N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine[\\CHEMICAL], 1) - which targets a hydrophobic domain of the [GENE]Myc[\\GENE] oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "Pharmacophore identification of [GENE]c-Myc[\\GENE] inhibitor [CHEMICAL]10074-G5[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 6
    },
    {
        "text": "Importantly, the carboxylic acid of [CHEMICAL]JY-3-094[\\CHEMICAL] improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance [GENE]Myc[\\GENE] inhibitory activity further still.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "A structure-activity relationship (SAR) study of the [GENE]c-Myc[\\GENE] (Myc) inhibitor [CHEMICAL]10074-G5[\\CHEMICAL] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc ([GENE]Myc[\\GENE]) inhibitor [CHEMICAL]10074-G5[\\CHEMICAL] (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the [GENE]c-Myc[\\GENE] (Myc) inhibitor 10074-G5 ([CHEMICAL]N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine[\\CHEMICAL], 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "A structure-activity relationship (SAR) study of the c-Myc ([GENE]Myc[\\GENE]) inhibitor 10074-G5 ([CHEMICAL]N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine[\\CHEMICAL], 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-[CHEMICAL]paraoxon[\\CHEMICAL] (Px) was able to prevent inhibition of circulating [GENE]cholinesterase[\\GENE] in a dose-dependent manner.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Ozone[\\CHEMICAL] plus PM(2.5) exposure, however, induced [GENE]CRP[\\GENE], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ozone[\\CHEMICAL] plus PM(2.5) exposure, however, induced CRP, [GENE]IL-6[\\GENE], CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ozone[\\CHEMICAL] plus PM(2.5) exposure, however, induced CRP, IL-6, [GENE]CK[\\GENE], LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ozone[\\CHEMICAL] plus PM(2.5) exposure, however, induced CRP, IL-6, CK, [GENE]LDH[\\GENE] and MDA increase, SOD and HRV decrease significantly in a dose-response way.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ozone[\\CHEMICAL] plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, [GENE]SOD[\\GENE] and HRV decrease significantly in a dose-response way.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished [GENE]\u03b2-cat[\\GENE] [CHEMICAL]Ser[\\CHEMICAL]675 phosphorylation in brain neurons after insulin treatment.",
        "label": 1,
        "major": 4,
        "len": 20
    },
    {
        "text": "Insulin stimulated [GENE]Pak1[\\GENE] activation through increasing its [CHEMICAL]Thr[\\CHEMICAL]423 phosphorylation in gut gcg-expressing cell lines, associated with increased gcg mRNA levels.",
        "label": 1,
        "major": 3,
        "len": 20
    },
    {
        "text": "This stimulation was attenuated by the [GENE]Pak[\\GENE] inhibitor [CHEMICAL]2,2'-dihydroxy-1,1'-dinaphthyldisulfide[\\CHEMICAL] (IPA3) or dominant-negative Pak1.",
        "label": 4,
        "major": 3,
        "len": 13
    },
    {
        "text": "This stimulation was attenuated by the [GENE]Pak[\\GENE] inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide ([CHEMICAL]IPA3[\\CHEMICAL]) or dominant-negative Pak1.",
        "label": 4,
        "major": 3,
        "len": 13
    },
    {
        "text": "Cells exposed to [CHEMICAL]\u03b1-MeDA[\\CHEMICAL] showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of [GENE]\u03b3-glutamylcysteine synthetase[\\GENE] (\u03b3-GCS), revealing a possible transient effect.",
        "label": 10,
        "major": 10,
        "len": 34
    },
    {
        "text": "Cells exposed to [CHEMICAL]\u03b1-MeDA[\\CHEMICAL] showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of \u03b3-glutamylcysteine synthetase ([GENE]\u03b3-GCS[\\GENE]), revealing a possible transient effect.",
        "label": 10,
        "major": 3,
        "len": 34
    },
    {
        "text": "Importantly, pre-treatment with buthionine sulfoximine ([CHEMICAL]BSO[\\CHEMICAL]), an inhibitor of [GENE]\u03b3-GCS[\\GENE], prevented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Neither the superoxide radical scavenger, tiron, nor the inhibitor of the [GENE]dopamine (DA) transporter[\\GENE], [CHEMICAL]GBR 12909[\\CHEMICAL], prevented the metabolites' toxicity.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Importantly, pre-treatment with [CHEMICAL]buthionine sulfoximine[\\CHEMICAL] (BSO), an inhibitor of [GENE]\u03b3-GCS[\\GENE], prevented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of GPx1, [GENE]MsrA[\\GENE] and MsrB1, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by [CHEMICAL]sodium selenite[\\CHEMICAL] and barricade function of blood-retinal barrier (BRB) were investigated.",
        "label": 2,
        "major": 3,
        "len": 55
    },
    {
        "text": "To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of GPx1, MsrA and [GENE]MsrB1[\\GENE], as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by [CHEMICAL]sodium selenite[\\CHEMICAL] and barricade function of blood-retinal barrier (BRB) were investigated.",
        "label": 2,
        "major": 3,
        "len": 55
    },
    {
        "text": "To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of [GENE]GPx1[\\GENE], MsrA and MsrB1, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by [CHEMICAL]sodium selenite[\\CHEMICAL] and barricade function of blood-retinal barrier (BRB) were investigated.",
        "label": 2,
        "major": 3,
        "len": 55
    },
    {
        "text": "To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of GPx1, MsrA and MsrB1, as well as [GENE]GPx[\\GENE] activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by [CHEMICAL]sodium selenite[\\CHEMICAL] and barricade function of blood-retinal barrier (BRB) were investigated.",
        "label": 2,
        "major": 3,
        "len": 55
    },
    {
        "text": "[CHEMICAL](-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one[\\CHEMICAL] (KCA-1490) exhibits moderate dual [GENE]PDE3/4[\\GENE]-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one ([CHEMICAL]KCA-1490[\\CHEMICAL]) exhibits moderate dual [GENE]PDE3/4[\\GENE]-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]N[\\CHEMICAL]-alkylation of the pyridazinone ring markedly enhances potency against [GENE]PDE4[\\GENE] but suppresses PDE3 inhibition.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]N[\\CHEMICAL]-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses [GENE]PDE3[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "N-alkylation of the [CHEMICAL]pyridazinone[\\CHEMICAL] ring markedly enhances potency against [GENE]PDE4[\\GENE] but suppresses PDE3 inhibition.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "N-alkylation of the [CHEMICAL]pyridazinone[\\CHEMICAL] ring markedly enhances potency against PDE4 but suppresses [GENE]PDE3[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Addition of a [CHEMICAL]6-aryl-4,5-dihydropyridazin-3(2H)-one[\\CHEMICAL] extension to the N-alkyl group facilitates both enhancement of [GENE]PDE4[\\GENE]-inhibitory activity and restoration of potent PDE3 inhibition.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Addition of a [CHEMICAL]6-aryl-4,5-dihydropyridazin-3(2H)-one[\\CHEMICAL] extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent [GENE]PDE3[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the [CHEMICAL]N[\\CHEMICAL]-alkyl group facilitates both enhancement of [GENE]PDE4[\\GENE]-inhibitory activity and restoration of potent PDE3 inhibition.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the [CHEMICAL]N[\\CHEMICAL]-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent [GENE]PDE3[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "We have identified >50 potential IAP substrates of both cytosolic and mitochondrial origin that bear hallmark [CHEMICAL]N[\\CHEMICAL]-terminal [GENE]IAP[\\GENE] binding motifs.",
        "label": 1,
        "major": 2,
        "len": 20
    },
    {
        "text": "Identification of a novel [CHEMICAL]benzimidazole[\\CHEMICAL] derivative as a highly potent [GENE]NPY Y5 receptor[\\GENE] antagonist with an anti-obesity profile.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]OMT[\\CHEMICAL] showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of [GENE]Bcl-2[\\GENE] family.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]OMT[\\CHEMICAL] showed partial protection in the cortical neurons via down-regulation of NR2B containing [GENE]NMDA receptors[\\GENE] and up-regulation of Bcl-2 family.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Western blot analysis revealed that [CHEMICAL]OMT[\\CHEMICAL] decreased the expression of [GENE]Bax[\\GENE] and repaired the balance of pro- and anti-apoptotic proteins.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Furthermore, [CHEMICAL]OMT[\\CHEMICAL] significantly reversed the up-regulation of [GENE]NR2B[\\GENE] and inhibited the calcium overload in the cultured neurons after challenging the NMDA.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]OMT[\\CHEMICAL] showed partial protection in the cortical neurons via down-regulation of [GENE]NR2B[\\GENE] containing NMDA receptors and up-regulation of Bcl-2 family.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound [CHEMICAL]BT-07-4M[\\CHEMICAL], TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound BT-07-4M, [CHEMICAL]TMB-4[\\CHEMICAL] and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and [CHEMICAL]obidoxime[\\CHEMICAL] from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric [CHEMICAL]oximes[\\CHEMICAL], and BT-05 and BT-03 possessing asymmetric structure.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and [CHEMICAL]BT-05[\\CHEMICAL] and BT-03 possessing asymmetric structure.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The reactivation of brain [GENE]AChE[\\GENE] inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and [CHEMICAL]BT-03[\\CHEMICAL] possessing asymmetric structure.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[GENE]AChE[\\GENE] was easier reactivated after [CHEMICAL]paraoxon[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 7
    },
    {
        "text": "All compounds showed low activity toward inhibition of [GENE]AChE[\\GENE] caused by [CHEMICAL]dichlorvos[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Reactivators showed different activity in the reactivation of [GENE]rat brain AChE[\\GENE] after [CHEMICAL]dichlorvos[\\CHEMICAL], paraoxon and tabun inhibition.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Reactivators showed different activity in the reactivation of [GENE]rat brain AChE[\\GENE] after dichlorvos, [CHEMICAL]paraoxon[\\CHEMICAL] and tabun inhibition.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Reactivators showed different activity in the reactivation of [GENE]rat brain AChE[\\GENE] after dichlorvos, paraoxon and [CHEMICAL]tabun[\\CHEMICAL] inhibition.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Inhibition by [CHEMICAL]phenformin[\\CHEMICAL] of oxygen consumption via [GENE]complex I[\\GENE] respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Role of organic cation/carnitine transporter 1 in uptake of [CHEMICAL]phenformin[\\CHEMICAL] and inhibitory effect on [GENE]complex I[\\GENE] respiration in mitochondria.",
        "label": 4,
        "major": 9,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Phenformin[\\CHEMICAL] causes lactic acidosis in clinical situations due to inhibition of [GENE]mitochondrial respiratory chain complex I[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of [CHEMICAL]phenformin[\\CHEMICAL] on [GENE]complex I[\\GENE] respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "These observations suggest that uptake of [CHEMICAL]phenformin[\\CHEMICAL] into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of [GENE]complex I[\\GENE] respiration.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and [GENE]complex I[\\GENE] inhibition by [CHEMICAL]phenformin[\\CHEMICAL] were examined in isolated liver and heart mitochondria.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Role of [GENE]organic cation/carnitine transporter 1[\\GENE] in uptake of [CHEMICAL]phenformin[\\CHEMICAL] and inhibitory effect on complex I respiration in mitochondria.",
        "label": 9,
        "major": 9,
        "len": 19
    },
    {
        "text": "These observations suggest that uptake of [CHEMICAL]phenformin[\\CHEMICAL] into liver mitochondria is at least partly mediated by [GENE]OCTN1[\\GENE] and functionally relevant to its inhibition potential of complex I respiration.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Rufinamide[\\CHEMICAL] attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes [GENE]voltage-gated sodium channel[\\GENE] inactivated state.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "CONCLUSIONS A diet that partially replaces [CHEMICAL]carbohydrate[\\CHEMICAL] with unsaturated fat may improve [GENE]insulin[\\GENE] sensitivity in a population at risk for cardiovascular disease.",
        "label": 3,
        "major": 1,
        "len": 22
    },
    {
        "text": "Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the [CHEMICAL]cysteine[\\CHEMICAL]-166 residue of [GENE]Bak[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Vitamin K2[\\CHEMICAL] covalently binds to [GENE]Bak[\\GENE] and induces Bak-mediated apoptosis.",
        "label": 2,
        "major": 2,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Vitamin K2[\\CHEMICAL] covalently binds to Bak and induces [GENE]Bak[\\GENE]-mediated apoptosis.",
        "label": 2,
        "major": 2,
        "len": 10
    },
    {
        "text": "[CHEMICAL]VK2[\\CHEMICAL] directly interacts with [GENE]Bak[\\GENE] and induces mitochondrial-mediated apoptosis.",
        "label": 2,
        "major": 2,
        "len": 9
    },
    {
        "text": "Moreover, [CHEMICAL]VK2-2,3 epoxide[\\CHEMICAL], an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of [GENE]Bak[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Moreover, VK2-2,3 epoxide, an intracellular metabolite of [CHEMICAL]VK2[\\CHEMICAL], was shown to covalently bind to the cysteine-166 residue of [GENE]Bak[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Here, we identified Bcl-2 antagonist killer 1 ([GENE]Bak[\\GENE]) as a molecular target of [CHEMICAL]VK2[\\CHEMICAL]-induced apoptosis.",
        "label": 2,
        "major": 6,
        "len": 15
    },
    {
        "text": "Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for [CHEMICAL]VK2[\\CHEMICAL]-induced [GENE]cytochrome c[\\GENE] (cyt c) release and cell death.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for [CHEMICAL]VK2[\\CHEMICAL]-induced cytochrome c ([GENE]cyt c[\\GENE]) release and cell death.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Here, we demonstrate that [GENE]peptidyl-prolyl cis/trans-isomerase A1[\\GENE] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to [CHEMICAL]HNE[\\CHEMICAL] modification.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ([GENE]Pin1[\\GENE]), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to [CHEMICAL]HNE[\\CHEMICAL] modification.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that [GENE]peptidyl-prolyl cis/trans-isomerase A1[\\GENE] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of [CHEMICAL]pSer[\\CHEMICAL]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ([GENE]Pin1[\\GENE]), an enzyme that catalyzes the conversion of the peptide bond of [CHEMICAL]pSer[\\CHEMICAL]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that [GENE]peptidyl-prolyl cis/trans-isomerase A1[\\GENE] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/[CHEMICAL]pThr[\\CHEMICAL]-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ([GENE]Pin1[\\GENE]), an enzyme that catalyzes the conversion of the peptide bond of pSer/[CHEMICAL]pThr[\\CHEMICAL]-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that [GENE]peptidyl-prolyl cis/trans-isomerase A1[\\GENE] (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-[CHEMICAL]Pro[\\CHEMICAL] moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ([GENE]Pin1[\\GENE]), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-[CHEMICAL]Pro[\\CHEMICAL] moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), [CHEMICAL]corticosterone[\\CHEMICAL]-binding [GENE]glucocorticoid receptors[\\GENE] (GR) and mineralocorticoid receptors (MR) were also measured.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), [CHEMICAL]corticosterone[\\CHEMICAL]-binding glucocorticoid receptors ([GENE]GR[\\GENE]) and mineralocorticoid receptors (MR) were also measured.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), [CHEMICAL]corticosterone[\\CHEMICAL]-binding glucocorticoid receptors (GR) and [GENE]mineralocorticoid receptors[\\GENE] (MR) were also measured.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), [CHEMICAL]corticosterone[\\CHEMICAL]-binding glucocorticoid receptors (GR) and mineralocorticoid receptors ([GENE]MR[\\GENE]) were also measured.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "These results suggest that [GENE]CYP2B6[\\GENE] genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of [CHEMICAL]bupropion[\\CHEMICAL].",
        "label": 9,
        "major": 10,
        "len": 28
    },
    {
        "text": "These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of [GENE]CYP2B6[\\GENE] activity in women, when measured by the metabolism of [CHEMICAL]bupropion[\\CHEMICAL].",
        "label": 9,
        "major": 10,
        "len": 28
    },
    {
        "text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using [CHEMICAL]bupropion[\\CHEMICAL] (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a [GENE]CYP2B6[\\GENE] probe substrate.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion ([CHEMICAL]Wellbutrin SR[\\CHEMICAL] GlaxoSmithKline, Research Triangle Park, NC) as a [GENE]CYP2B6[\\GENE] probe substrate.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "The influence of sex, ethnicity, and [GENE]CYP2B6[\\GENE] genotype on [CHEMICAL]bupropion[\\CHEMICAL] metabolism as an index of hepatic CYP2B6 activity in humans.",
        "label": 9,
        "major": 10,
        "len": 20
    },
    {
        "text": "The [GENE]CYP3A4[\\GENE] activity could be induced 2-fold by [CHEMICAL]rifampicin[\\CHEMICAL], whereas CYP2C9 activity remained equally high.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The CYP3A4 activity could be induced 2-fold by [CHEMICAL]rifampicin[\\CHEMICAL], whereas [GENE]CYP2C9[\\GENE] activity remained equally high.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Since DNA methylation is regulated by [GENE]DNA methyltransferases[\\GENE] and methyl cytosine-binding proteins, this study assessed the extent to which developmental [CHEMICAL]Pb[\\CHEMICAL] exposure might affect expression of these proteins in the hippocampus.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Since DNA methylation is regulated by DNA methyltransferases and [GENE]methyl cytosine-binding proteins[\\GENE], this study assessed the extent to which developmental [CHEMICAL]Pb[\\CHEMICAL] exposure might affect expression of these proteins in the hippocampus.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Bioinformatic analyses of several vertebrate genomes were undertaken using known [GENE]ALDH2[\\GENE] and ALDH1B1 [CHEMICAL]amino acid[\\CHEMICAL] sequences.",
        "label": 1,
        "major": 1,
        "len": 16
    },
    {
        "text": "Bioinformatic analyses of several vertebrate genomes were undertaken using known ALDH2 and [GENE]ALDH1B1[\\GENE] [CHEMICAL]amino acid[\\CHEMICAL] sequences.",
        "label": 1,
        "major": 1,
        "len": 16
    },
    {
        "text": "[GENE]Mammalian ALDH1B1[\\GENE], another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing [CHEMICAL]acetaldehyde[\\CHEMICAL] but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
        "label": 9,
        "major": 10,
        "len": 30
    },
    {
        "text": "Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with [GENE]ALDH2[\\GENE], is also capable of metabolizing [CHEMICAL]acetaldehyde[\\CHEMICAL] but has a tissue distribution and pattern of activity distinct from that of ALDH2.",
        "label": 9,
        "major": 10,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]BGG[\\CHEMICAL]-mediated inhibition of AR prevented LPS-induced activation of [GENE]JNK[\\GENE] and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In addition, [CHEMICAL]BGG[\\CHEMICAL]-mediated inhibition of AR prevented LPS-induced activation of JNK and [GENE]p38[\\GENE] and lowered ROS levels, which could inhibit LPS-induced apoptosis.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Beta-glucogallin[\\CHEMICAL] reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of [GENE]aldose reductase[\\GENE] in murine macrophages and ocular tissues.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Beta-glucogallin[\\CHEMICAL] (BGG), a recently described [GENE]AR[\\GENE] inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Beta-glucogallin ([CHEMICAL]BGG[\\CHEMICAL]), a recently described [GENE]AR[\\GENE] inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "In this study, we found that [CHEMICAL]BGG[\\CHEMICAL] showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited [GENE]AR[\\GENE] activity as measured by a decrease in sorbitol accumulation.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In addition, [CHEMICAL]BGG[\\CHEMICAL]-mediated inhibition of [GENE]AR[\\GENE] prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]Aldose reductase[\\GENE] (AR) catalyzes the reduction of toxic lipid aldehydes to their [CHEMICAL]alcohol[\\CHEMICAL] products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Aldose reductase ([GENE]AR[\\GENE]) catalyzes the reduction of toxic lipid aldehydes to their [CHEMICAL]alcohol[\\CHEMICAL] products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Aldose reductase[\\GENE] (AR) catalyzes the reduction of toxic lipid [CHEMICAL]aldehydes[\\CHEMICAL] to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Aldose reductase ([GENE]AR[\\GENE]) catalyzes the reduction of toxic lipid [CHEMICAL]aldehydes[\\CHEMICAL] to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the [CHEMICAL]valine[\\CHEMICAL] 600 to glutamic acid substitution ([GENE]BRAF[\\GENE](V600E)), which is commonly found in metastatic melanoma.",
        "label": 1,
        "major": 4,
        "len": 32
    },
    {
        "text": "Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to [CHEMICAL]glutamic acid[\\CHEMICAL] substitution ([GENE]BRAF[\\GENE](V600E)), which is commonly found in metastatic melanoma.",
        "label": 1,
        "major": 4,
        "len": 32
    },
    {
        "text": "Mechanisms limiting distribution of the [GENE]threonine-protein kinase B-RaF[\\GENE](V600E) inhibitor [CHEMICAL]dabrafenib[\\CHEMICAL] to the brain: implications for the treatment of melanoma brain metastases.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Mechanisms limiting distribution of the threonine-protein kinase B-RaF([GENE]V600E[\\GENE]) inhibitor [CHEMICAL]dabrafenib[\\CHEMICAL] to the brain: implications for the treatment of melanoma brain metastases.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Further, compared with [CHEMICAL]vemurafenib[\\CHEMICAL], another [GENE]BRAF[\\GENE](V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.",
        "label": 4,
        "major": 10,
        "len": 16
    },
    {
        "text": "Further, compared with [CHEMICAL]vemurafenib[\\CHEMICAL], another BRAF([GENE]V600E[\\GENE]) inhibitor, dabrafenib showed greater brain penetration with a similar dose.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that [CHEMICAL]dabrafenib[\\CHEMICAL] is an avid substrate for both [GENE]P-gp[\\GENE] and BCRP.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that [CHEMICAL]dabrafenib[\\CHEMICAL] is an avid substrate for both P-gp and [GENE]BCRP[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Here, we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing FST315 to a murine IgG(1) Fc and removing the intrinsic heparan [CHEMICAL]sulfate[\\CHEMICAL]-binding activity of [GENE]follistatin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "This study explored whether [CHEMICAL]curcumin[\\CHEMICAL] improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-\u03baB signaling pathway and [GENE]IL-27[\\GENE] expression.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of [GENE]NF-\u03baB[\\GENE] mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, [GENE]IL-27[\\GENE] mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, [GENE]TLR4[\\GENE] protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, [GENE]NF-\u03baB[\\GENE] p65 protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB [GENE]p65[\\GENE] protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and [GENE]IL-27[\\GENE] p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 [GENE]p28[\\GENE] protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Curcumin[\\CHEMICAL] improves TNBS-induced colitis in rats by inhibiting [GENE]IL-27[\\GENE] expression via the TLR4/NF-\u03baB signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "The anti-inflammatory actions of [CHEMICAL]curcumin[\\CHEMICAL] on colitis may involve inhibition of the TLR4/NF-\u03baB signaling pathway and of [GENE]IL-27[\\GENE] expression.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "This study explored whether [CHEMICAL]curcumin[\\CHEMICAL] improves colonic inflammation in a rat colitis model through inhibition of the [GENE]TLR4[\\GENE]/NF-\u03baB signaling pathway and IL-27 expression.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "This study explored whether [CHEMICAL]curcumin[\\CHEMICAL] improves colonic inflammation in a rat colitis model through inhibition of the TLR4/[GENE]NF-\u03baB[\\GENE] signaling pathway and IL-27 expression.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Compared with the untreated colitis group, the [CHEMICAL]curcumin[\\CHEMICAL]-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, [GENE]myeloperoxidase[\\GENE] activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Curcumin[\\CHEMICAL] improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the [GENE]TLR4[\\GENE]/NF-\u03baB signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Curcumin[\\CHEMICAL] improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/[GENE]NF-\u03baB[\\GENE] signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "The anti-inflammatory actions of [CHEMICAL]curcumin[\\CHEMICAL] on colitis may involve inhibition of the [GENE]TLR4[\\GENE]/NF-\u03baB signaling pathway and of IL-27 expression.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The anti-inflammatory actions of [CHEMICAL]curcumin[\\CHEMICAL] on colitis may involve inhibition of the TLR4/[GENE]NF-\u03baB[\\GENE] signaling pathway and of IL-27 expression.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "RESULTS: In an animal study with [CHEMICAL](129)I[\\CHEMICAL]-labeled [GENE]EPO[\\GENE] in Han-Wistar rats, an increase of (129)I-EPO is observed after dose administration.",
        "label": 1,
        "major": 3,
        "len": 20
    },
    {
        "text": "[GENE]Kisspeptin[\\GENE] is a 54-[CHEMICAL]amino acid[\\CHEMICAL] peptide which is encoded by the KiSS-1 gene and activates the G protein-coupled receptor GPR54.",
        "label": 1,
        "major": 3,
        "len": 20
    },
    {
        "text": "Central and peripheral administration of [GENE]kisspeptin[\\GENE] stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a [CHEMICAL]gonadotrophin releasing hormone[\\CHEMICAL] (GnRH) antagonist abolishes this effect.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Central and peripheral administration of [GENE]kisspeptin[\\GENE] stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone ([CHEMICAL]GnRH[\\CHEMICAL]) antagonist abolishes this effect.",
        "label": 4,
        "major": 6,
        "len": 23
    },
    {
        "text": "Several inhibitors of [GENE]Lp-PLA(2)[\\GENE] have been described, including [CHEMICAL]darapladib[\\CHEMICAL], which is currently in phase 3 clinical development for the treatment of atherosclerosis.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "We show that both [CHEMICAL]darapladib[\\CHEMICAL] and a novel class of structurally distinct carbamate inhibitors inactivate [GENE]Lp-PLA(2)[\\GENE] in mouse tissues and human cell lines with high selectivity.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "We show that both darapladib and a novel class of structurally distinct [CHEMICAL]carbamate[\\CHEMICAL] inhibitors inactivate [GENE]Lp-PLA(2)[\\GENE] in mouse tissues and human cell lines with high selectivity.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Identification of [CHEMICAL]benzofuran[\\CHEMICAL] central cores for the inhibition of [GENE]leukotriene A(4) hydrolase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "This paper describes the identification and synthesis of substituted [CHEMICAL]benzofurans[\\CHEMICAL] as [GENE]LTH(4)H[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Benzofuran[\\CHEMICAL] 28 showed dose responsive target engagement and provides a useful tool to explore a [GENE]LTA(4)H[\\GENE] inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Leukotriene A(4) hydrolase ([GENE]LTA(4)H[\\GENE]) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to [CHEMICAL]LTB(4)[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Leukotriene A(4) hydrolase[\\GENE] (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to [CHEMICAL]LTB(4)[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Leukotriene A(4) hydrolase ([GENE]LTA(4)H[\\GENE]) is a cystolic enzyme that stereospecifically catalyzes the transformation of [CHEMICAL]LTA(4)[\\CHEMICAL] to LTB(4).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Leukotriene A(4) hydrolase[\\GENE] (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of [CHEMICAL]LTA(4)[\\CHEMICAL] to LTB(4).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator [GENE]tumour necrosis factor-\u03b1[\\GENE] (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 ([GENE]TNF-\u03b1[\\GENE]), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 9,
        "len": 31
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), [GENE]interleukin-1\u03b2[\\GENE] (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 ([GENE]IL-1\u03b2[\\GENE]), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 9,
        "len": 31
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), [GENE]interleukin-6[\\GENE] (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "In addition, we found that [CHEMICAL]neoechinulin A[\\CHEMICAL] significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 ([GENE]IL-6[\\GENE]), and prostaglandin E2 (PGE2) in activated BV-2 cells.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of [GENE]nuclear factor-\u03baB[\\GENE] (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB ([GENE]NF-\u03baB[\\GENE]) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) [GENE]p65[\\GENE] and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and [GENE]p50[\\GENE] subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Neoechinulin A[\\CHEMICAL] suppresses [GENE]amyloid-\u03b2[\\GENE] oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of [GENE]mitogen-activated protein kinase[\\GENE] (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase ([GENE]MAPK[\\GENE]) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule [GENE]p38[\\GENE], apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, [GENE]apoptosis signal-regulating kinase 1[\\GENE] (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The molecular mechanism studies suggested that [CHEMICAL]neoechinulin A[\\CHEMICAL] may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 ([GENE]ASK-1[\\GENE]) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In this study, focus was given to evaluate the ability of [CHEMICAL]neoechinulin A[\\CHEMICAL], an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [GENE]amyloid-\u03b2 1-42[\\GENE] (A\u03b242).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In this study, focus was given to evaluate the ability of [CHEMICAL]neoechinulin A[\\CHEMICAL], an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 ([GENE]A\u03b242[\\GENE]).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In this study, focus was given to evaluate the ability of neoechinulin A, an [CHEMICAL]indole[\\CHEMICAL] alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [GENE]amyloid-\u03b2 1-42[\\GENE] (A\u03b242).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In this study, focus was given to evaluate the ability of neoechinulin A, an [CHEMICAL]indole[\\CHEMICAL] alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 ([GENE]A\u03b242[\\GENE]).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Neoechinulin A[\\CHEMICAL] treatment significantly inhibited the generation of reactive oxygen and nitrogen species in [GENE]A\u03b242[\\GENE]-activated BV-2 microglia cells.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Jaspamide[\\CHEMICAL] also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the [GENE]Kv11.1[\\GENE] (hERG) channel was minimally affected.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Jaspamide[\\CHEMICAL] also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 ([GENE]hERG[\\GENE]) channel was minimally affected.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Jaspamide[\\CHEMICAL] also inhibited other channels including [GENE]Cav1.2[\\GENE], Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Jaspamide[\\CHEMICAL] also inhibited other channels including Cav1.2, [GENE]Cav3.2[\\GENE], and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Jaspamide[\\CHEMICAL] also inhibited other channels including Cav1.2, Cav3.2, and [GENE]HCN2[\\GENE]; however, the Kv11.1 (hERG) channel was minimally affected.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Among the isolated compounds, [CHEMICAL]trans-dihydromorin[\\CHEMICAL] (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [GENE]tyrosinase[\\GENE] inhibition activities.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Among the isolated compounds, trans-dihydromorin (8), [CHEMICAL]oxyresveratrol[\\CHEMICAL] (9), and steppogenin (12) were found to exhibit significant [GENE]tyrosinase[\\GENE] inhibition activities.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and [CHEMICAL]steppogenin[\\CHEMICAL] (12) were found to exhibit significant [GENE]tyrosinase[\\GENE] inhibition activities.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Cortisol[\\CHEMICAL] and IFNT stimulated endometrial [GENE]HSD11B1[\\GENE] expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Cortisol[\\CHEMICAL] and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial [GENE]PTGS2[\\GENE] activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Cortisol[\\CHEMICAL] and IFNT stimulated endometrial [GENE]HSD11B1[\\GENE] expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In study 1, cyclic ewes received vehicle, cortisol, [CHEMICAL]PF 915275[\\CHEMICAL] (PF; a selective inhibitor of [GENE]HSD11B1[\\GENE]), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, [CHEMICAL]meloxicam[\\CHEMICAL] (a selective inhibitor of [GENE]PTGS2[\\GENE]), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce [CHEMICAL]prostaglandins[\\CHEMICAL] (PG) via [GENE]PG synthase 2[\\GENE] (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1).",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce [CHEMICAL]prostaglandins[\\CHEMICAL] (PG) via PG synthase 2 ([GENE]PTGS2[\\GENE]) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1).",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and [CHEMICAL]cortisol[\\CHEMICAL] via [GENE]hydroxysteroid (11-\u03b2) dehydrogenase 1[\\GENE] (HSD11B1).",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and [CHEMICAL]cortisol[\\CHEMICAL] via hydroxysteroid (11-\u03b2) dehydrogenase 1 ([GENE]HSD11B1[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean [CHEMICAL]isoflavone[\\CHEMICAL] increased gene expression of [GENE]heme oxygenase-1[\\GENE] (HO-1), a major antioxidative stress enzyme.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean [CHEMICAL]isoflavone[\\CHEMICAL] increased gene expression of heme oxygenase-1 ([GENE]HO-1[\\GENE]), a major antioxidative stress enzyme.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Overall, higher alcohol production was reduced by [CHEMICAL]ammonium[\\CHEMICAL] supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the [GENE]Ehrlich pathway[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Overall, higher alcohol production was reduced by [CHEMICAL]ammonium[\\CHEMICAL] supplementation, and this can be correlated with a general downregulation of genes encoding [GENE]decarboxylases[\\GENE] and dehydrogenases of the Ehrlich pathway.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Overall, higher alcohol production was reduced by [CHEMICAL]ammonium[\\CHEMICAL] supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and [GENE]dehydrogenases[\\GENE] of the Ehrlich pathway.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ([CHEMICAL]SCH 900229[\\CHEMICAL]), a potent, [GENE]PS1[\\GENE]-selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ([CHEMICAL]SCH 900229[\\CHEMICAL]), a potent, PS1-selective [GENE]\u03b3-secretase[\\GENE] inhibitor and clinical candidate for the treatment of Alzheimer's disease.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Structure activity relationship studies of [CHEMICAL]tricyclic bispyran sulfone[\\CHEMICAL] [GENE]\u03b3-secretase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Additionally, [GENE]AIF[\\GENE] levels in the cytosol decreased due to EGTA but not due to [CHEMICAL]calpeptin[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 15
    },
    {
        "text": "[CHEMICAL]ALD[\\CHEMICAL] increased calpain expression and [GENE]caspase-3[\\GENE] activity and promoted Bid cleavage.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "The upregulation of calpain, tBid and [GENE]caspase-3[\\GENE] activity were further inhibited by treatment with EGTA in the presence of [CHEMICAL]ALD[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "In this study, aldosterone ([CHEMICAL]ALD[\\CHEMICAL])-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [GENE]calpain[\\GENE] signaling were clarified.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]ALD[\\CHEMICAL] increased [GENE]calpain[\\GENE] expression and caspase-3 activity and promoted Bid cleavage.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of [GENE]calpain[\\GENE] and apoptosis-inducing factor in [CHEMICAL]aldosterone[\\CHEMICAL]-induced primary cultured cardiomyocytes.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and [GENE]apoptosis-inducing factor[\\GENE] in [CHEMICAL]aldosterone[\\CHEMICAL]-induced primary cultured cardiomyocytes.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The upregulation of [GENE]calpain[\\GENE], tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of [CHEMICAL]ALD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "The upregulation of calpain, [GENE]tBid[\\GENE] and caspase-3 activity were further inhibited by treatment with EGTA in the presence of [CHEMICAL]ALD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the [CHEMICAL]ALD[\\CHEMICAL]-induced increase of [GENE]calpain[\\GENE] and AIF levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the [CHEMICAL]ALD[\\CHEMICAL]-induced increase of calpain and [GENE]AIF[\\GENE] levels.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "In this study, [CHEMICAL]aldosterone[\\CHEMICAL] (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [GENE]calpain[\\GENE] signaling were clarified.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The upregulation of [GENE]calpain[\\GENE], tBid and caspase-3 activity were further inhibited by treatment with [CHEMICAL]EGTA[\\CHEMICAL] in the presence of ALD.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "The upregulation of calpain, [GENE]tBid[\\GENE] and caspase-3 activity were further inhibited by treatment with [CHEMICAL]EGTA[\\CHEMICAL] in the presence of ALD.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Additionally, [GENE]AIF[\\GENE] levels in the cytosol decreased due to [CHEMICAL]EGTA[\\CHEMICAL] but not due to calpeptin.",
        "label": 4,
        "major": 10,
        "len": 15
    },
    {
        "text": "Furthermore, treatment with [CHEMICAL]spironoclactone[\\CHEMICAL] not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [GENE]calpain[\\GENE] and AIF levels.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, treatment with [CHEMICAL]spironoclactone[\\CHEMICAL] not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and [GENE]AIF[\\GENE] levels.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "The upregulation of calpain, tBid and [GENE]caspase-3[\\GENE] activity were further inhibited by treatment with [CHEMICAL]EGTA[\\CHEMICAL] in the presence of ALD.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Safrole-2',3'-oxide[\\CHEMICAL] induces atherosclerotic plaque vulnerability in [GENE]apolipoprotein E[\\GENE]-knockout mice.",
        "label": 2,
        "major": 3,
        "len": 9
    },
    {
        "text": "Thus, [CHEMICAL]SFO[\\CHEMICAL] contributes to the instability of atherosclerotic plaque in [GENE]apoE[\\GENE](-/-) mice through activating p75(NTR) and IL-8 and cell apoptosis in plaque.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "In this study, we investigated [CHEMICAL]SFO[\\CHEMICAL]-induced atherosclerotic plaque vulnerability (possibility of rupture) in [GENE]apolipoprotein E[\\GENE]-knockout (apoE(-/-)) mice.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "In this study, we investigated [CHEMICAL]SFO[\\CHEMICAL]-induced atherosclerotic plaque vulnerability (possibility of rupture) in apolipoprotein E-knockout ([GENE]apoE[\\GENE](-/-)) mice.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Thus, [CHEMICAL]SFO[\\CHEMICAL] contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating [GENE]p75(NTR)[\\GENE] and IL-8 and cell apoptosis in plaque.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Thus, [CHEMICAL]SFO[\\CHEMICAL] contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating p75(NTR) and [GENE]IL-8[\\GENE] and cell apoptosis in plaque.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, compared with control groups, the plaque endothelium level of [GENE]p75(NTR)[\\GENE] was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by [CHEMICAL]SFO[\\CHEMICAL]-HD.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Furthermore, compared with control groups, the plaque endothelium level of p75(NTR) was 3-fold increased and the liver level of [GENE]p75(NTR)[\\GENE] was 17.4-fold increased by [CHEMICAL]SFO[\\CHEMICAL]-HD.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "\u03b2-Amyloid aggregation results showed that all compounds exhibited remarkable [GENE]A\u03b2[\\GENE] fibril aggregation inhibition activity with a nearly similar potential as the reference compound [CHEMICAL]rifampicin[\\CHEMICAL], which makes them promising anti-Alzheimer drug candidates.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To develop new drugs for treatment of Alzheimer's disease, a group of [CHEMICAL]N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones[\\CHEMICAL] was designed, synthesized and tested for their ability to inhibit [GENE]acetylcholinesterase[\\GENE], butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "To develop new drugs for treatment of Alzheimer's disease, a group of [CHEMICAL]N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones[\\CHEMICAL] was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, [GENE]butyrylcholinesterase[\\GENE] and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Synthesis, molecular modeling and evaluation of novel [CHEMICAL]N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone[\\CHEMICAL] derivatives as dual inhibitors for [GENE]cholinesterases[\\GENE] and A\u03b2 aggregation.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Synthesis, molecular modeling and evaluation of novel [CHEMICAL]N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone[\\CHEMICAL] derivatives as dual inhibitors for cholinesterases and [GENE]A\u03b2[\\GENE] aggregation.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Furthermore, [CHEMICAL]DOX[\\CHEMICAL]-treated WT and p65(-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of [GENE]p65[\\GENE]-positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of I\u03baB\u03b1-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter.",
        "label": 4,
        "major": 4,
        "len": 58
    },
    {
        "text": "G6PC2: A Negative Regulator of Basal [CHEMICAL]Glucose[\\CHEMICAL]-Stimulated [GENE]Insulin[\\GENE] Secretion.",
        "label": 3,
        "major": 3,
        "len": 9
    },
    {
        "text": "G6pc2 deletion resulted in a leftward shift in the dose-response curve for [CHEMICAL]glucose[\\CHEMICAL]-stimulated [GENE]insulin[\\GENE] secretion (GSIS).",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "These data suggest that [GENE]G6pc2[\\GENE] represents a novel, negative regulator of basal GSIS that acts by hydrolyzing [CHEMICAL]glucose-6-phosphate[\\CHEMICAL], thereby reducing glycolytic flux.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Key marker of diabetes in cells is the [GENE]insulin dependent glucose transporter-4[\\GENE] (Glut-4) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and [CHEMICAL]palmatine[\\CHEMICAL], respectively.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Key marker of diabetes in cells is the insulin dependent glucose transporter-4 ([GENE]Glut-4[\\GENE]) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and [CHEMICAL]palmatine[\\CHEMICAL], respectively.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Further, the inhibitors of insulin pathway prevented glucose uptake mediated by Tinospora cordifolia and [CHEMICAL]palmatine[\\CHEMICAL] which shows that the activity is majorly mediated through [GENE]insulin[\\GENE] pathway.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Next to [GENE]Glut-4[\\GENE], the predominant protein influencing [CHEMICAL]glucose[\\CHEMICAL] metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated.",
        "label": 9,
        "major": 7,
        "len": 19
    },
    {
        "text": "The cellular [GENE]prion protein PrP(C)[\\GENE] consists of two domains--a flexible N-terminal domain, which participates in copper and zinc regulation, and a largely helical [CHEMICAL]C[\\CHEMICAL]-terminal domain that converts to \u03b2 sheet in the course of prion disease.",
        "label": 1,
        "major": 9,
        "len": 36
    },
    {
        "text": "Here, we identify a Zn\u00b2\u207a-driven [CHEMICAL]N[\\CHEMICAL]-terminal to C-terminal tertiary interaction in [GENE]PrP(C)[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 12
    },
    {
        "text": "Here, we identify a Zn\u00b2\u207a-driven N-terminal to [CHEMICAL]C[\\CHEMICAL]-terminal tertiary interaction in [GENE]PrP(C)[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 12
    },
    {
        "text": "The cellular [GENE]prion protein PrP(C)[\\GENE] consists of two domains--a flexible [CHEMICAL]N[\\CHEMICAL]-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to \u03b2 sheet in the course of prion disease.",
        "label": 1,
        "major": 9,
        "len": 36
    },
    {
        "text": "The cellular [GENE]prion protein PrP(C)[\\GENE] consists of two domains--a flexible N-terminal domain, which participates in [CHEMICAL]copper[\\CHEMICAL] and zinc regulation, and a largely helical C-terminal domain that converts to \u03b2 sheet in the course of prion disease.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "The cellular [GENE]prion protein PrP(C)[\\GENE] consists of two domains--a flexible N-terminal domain, which participates in copper and [CHEMICAL]zinc[\\CHEMICAL] regulation, and a largely helical C-terminal domain that converts to \u03b2 sheet in the course of prion disease.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "Here, we identify a [CHEMICAL]Zn\u00b2\u207a[\\CHEMICAL]-driven N-terminal to C-terminal tertiary interaction in [GENE]PrP(C)[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Zinc[\\CHEMICAL] drives a tertiary fold in the [GENE]prion protein[\\GENE] with familial disease mutation sites at the interface.",
        "label": 2,
        "major": 1,
        "len": 17
    },
    {
        "text": "Absorption and secretion of [CHEMICAL]fluoride[\\CHEMICAL] increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a [GENE]F(-)/OH(-) antiporter[\\GENE].",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "Absorption and secretion of [CHEMICAL]fluoride[\\CHEMICAL] increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a [GENE]F(-)/H(+) cotransporter[\\GENE] or a F(-)/OH(-) antiporter.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "[GENE]KCNK1[\\GENE], a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after [CHEMICAL]phenobarbital[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "KCNK1, a member of the family of two-pore [GENE]K(+) ion channels[\\GENE], is specifically induced in the livers of male mice after [CHEMICAL]phenobarbital[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized [GENE]KCNK1[\\GENE] as a [CHEMICAL]phenobarbital[\\CHEMICAL]-inducible antihyperplasia factor.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Upon activation by [CHEMICAL]phenobarbital[\\CHEMICAL], [GENE]nuclear receptor[\\GENE] CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.",
        "label": 3,
        "major": 2,
        "len": 17
    },
    {
        "text": "Upon activation by [CHEMICAL]phenobarbital[\\CHEMICAL], nuclear receptor [GENE]CAR[\\GENE] binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.",
        "label": 3,
        "major": 2,
        "len": 17
    },
    {
        "text": "These results indicate that [CHEMICAL]phenobarbital[\\CHEMICAL] treatment induces [GENE]KCNK1[\\GENE] to elicit a male-specific and growth-suppressing signal.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Here, we have determined the molecular mechanism of this male-specific activation of the [GENE]Kcnk1[\\GENE] gene and characterized KCNK1 as a [CHEMICAL]phenobarbital[\\CHEMICAL]-inducible antihyperplasia factor.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of [CHEMICAL]navitoclax[\\CHEMICAL], a selective inhibitor of both [GENE]BCL-2[\\GENE] and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of [CHEMICAL]navitoclax[\\CHEMICAL], a selective inhibitor of both BCL-2 and [GENE]BCL-2-like 1[\\GENE] (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of [CHEMICAL]navitoclax[\\CHEMICAL], a selective inhibitor of both BCL-2 and BCL-2-like 1 ([GENE]BCL-X(L)[\\GENE]), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Here we report the re-engineering of [CHEMICAL]navitoclax[\\CHEMICAL] to create a highly potent, orally bioavailable and [GENE]BCL-2[\\GENE]-selective inhibitor, ABT-199.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and [GENE]BCL-2[\\GENE]-selective inhibitor, [CHEMICAL]ABT-199[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]ABT-199[\\CHEMICAL], a potent and selective [GENE]BCL-2[\\GENE] inhibitor, achieves antitumor activity while sparing platelets.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Cotreatments of 5, 10 and 20 \u00b5g/mL concentrations of MEP with [CHEMICAL]aflatoxin B(1)[\\CHEMICAL] decreased the frequencies of SCE and the malondialdehyde level and increased amount of [GENE]superoxide dismutase[\\GENE], glutathione and glutathione peroxidase which were decreased by aflatoxin.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Cotreatments of 5, 10 and 20 \u00b5g/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and [GENE]glutathione peroxidase[\\GENE] which were decreased by [CHEMICAL]aflatoxin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[CHEMICAL]All-trans retinoic acid[\\CHEMICAL] protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating [GENE]collagen 8A2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Local [CHEMICAL]PGE2[\\CHEMICAL] administration prevented the increase of airway [GENE]IL-13[\\GENE] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Local [CHEMICAL]PGE2[\\CHEMICAL] administration prevented the increase of airway IL-13 and [GENE]osteopontin[\\GENE] and kept lung plasmacytoid dendritic cell counts close to baseline.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Lung inflammation, [GENE]IL-4[\\GENE] production, and airway mast cell activity were also prevented under this early short-term treatment with [CHEMICAL]PGE2[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 19
    },
    {
        "text": "6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ([CHEMICAL]TAK-441[\\CHEMICAL]) is a potent, selective hedgehog signaling pathway inhibitor that binds to [GENE]Smo[\\GENE] and is being developed for the treatment of cancer.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "To this end, we built pharmacokinetic and pharmacodynamic models that describe the relationship of the concentrations of [CHEMICAL]TAK-441[\\CHEMICAL] plasma to the responses of [GENE]Gli1[\\GENE] mRNA in the tumor (target) and skin (surrogate) and to tumor growth inhibition in mice bearing xenografts of human pancreatic tumors (PAN-04).",
        "label": 2,
        "major": 4,
        "len": 46
    },
    {
        "text": "The IC50 values for [GENE]Gli1[\\GENE] mRNA inhibition in the tumor and skin by [CHEMICAL]TAK-441[\\CHEMICAL] were estimated to be 0.0457 and 0.113 \u03bcg/ml, respectively.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor [CHEMICAL]TAK-441[\\CHEMICAL] for the inhibition of [GENE]Gli1[\\GENE] messenger RNA expression and antitumor efficacy in xenografted tumor model mice.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ([CHEMICAL]TAK-441[\\CHEMICAL]) is a potent, selective [GENE]hedgehog[\\GENE] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Pharmacokinetic and pharmacodynamic modeling of [GENE]hedgehog[\\GENE] inhibitor [CHEMICAL]TAK-441[\\CHEMICAL] for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "CNTs with linear [CHEMICAL]poly(ethylene glycol)[\\CHEMICAL] amphiphiles trigger the lectin pathway of the complement through both L-ficolin and mannan-binding [GENE]lectin[\\GENE] recognition.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "CNTs with linear [CHEMICAL]poly(ethylene glycol)[\\CHEMICAL] amphiphiles trigger the [GENE]lectin[\\GENE] pathway of the complement through both L-ficolin and mannan-binding lectin recognition.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "An amphiphile with branched [CHEMICAL]poly(ethylene glycol)[\\CHEMICAL] architecture also activated the [GENE]lectin[\\GENE] pathway but only through L-ficolin recognition.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "In addition, the new compound [CHEMICAL]perviridicin B[\\CHEMICAL] (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant [GENE]NF-\u03baB[\\GENE] (p65) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound [CHEMICAL]perviridicin B[\\CHEMICAL] (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ([GENE]p65[\\GENE]) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known [CHEMICAL]rocaglate[\\CHEMICAL] derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant [GENE]NF-\u03baB[\\GENE] (p65) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known [CHEMICAL]rocaglate[\\CHEMICAL] derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ([GENE]p65[\\GENE]) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known [CHEMICAL]sesquiterpene[\\CHEMICAL], 2-oxaisodauc-5-en-12-al (17), showed significant [GENE]NF-\u03baB[\\GENE] (p65) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known [CHEMICAL]sesquiterpene[\\CHEMICAL], 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ([GENE]p65[\\GENE]) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, [CHEMICAL]2-oxaisodauc-5-en-12-al[\\CHEMICAL] (17), showed significant [GENE]NF-\u03baB[\\GENE] (p65) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, [CHEMICAL]2-oxaisodauc-5-en-12-al[\\CHEMICAL] (17), showed significant NF-\u03baB ([GENE]p65[\\GENE]) inhibitory activity in an ELISA assay.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Whereas, the levels of both the basal and [CHEMICAL]sulforaphane[\\CHEMICAL]-inducible expression of AKR1C1 were significantly reduced in [GENE]NRF2[\\GENE]-silenced stable U937 cells compared to the control cells.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [GENE]NRF2[\\GENE] target genes in response to NRF2 inducers ([CHEMICAL]sulforaphane[\\CHEMICAL], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to [GENE]NRF2[\\GENE] inducers ([CHEMICAL]sulforaphane[\\CHEMICAL], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [GENE]NRF2[\\GENE] target genes in response to NRF2 inducers (sulforaphane, [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL], cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to [GENE]NRF2[\\GENE] inducers (sulforaphane, [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL], cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [GENE]NRF2[\\GENE] target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, [CHEMICAL]cinnamic aldehyde[\\CHEMICAL], and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to [GENE]NRF2[\\GENE] inducers (sulforaphane, tert-butylhydroquinone, [CHEMICAL]cinnamic aldehyde[\\CHEMICAL], and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported [GENE]NRF2[\\GENE] target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and [CHEMICAL]hydrogen peroxide[\\CHEMICAL]) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to [GENE]NRF2[\\GENE] inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and [CHEMICAL]hydrogen peroxide[\\CHEMICAL]) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "The treatment of U937 cells with [GENE]NRF2[\\GENE] inducers including [CHEMICAL]sulforaphane[\\CHEMICAL] effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers ([CHEMICAL]sulforaphane[\\CHEMICAL], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the [GENE]aldo-keto reductase (AKR) 1C1[\\GENE] is highly inducible by all treatments.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL], cinnamic aldehyde, and hydrogen peroxide) showed that the [GENE]aldo-keto reductase (AKR) 1C1[\\GENE] is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, [CHEMICAL]cinnamic aldehyde[\\CHEMICAL], and hydrogen peroxide) showed that the [GENE]aldo-keto reductase (AKR) 1C1[\\GENE] is highly inducible by all treatments.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and [CHEMICAL]hydrogen peroxide[\\CHEMICAL]) showed that the [GENE]aldo-keto reductase (AKR) 1C1[\\GENE] is highly inducible by all treatments.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "The treatment of U937 cells with NRF2 inducers including [CHEMICAL]sulforaphane[\\CHEMICAL] effectively elevated the expression of [GENE]AKR1B1, 1B10, 1C1, 1C2, and 1C3[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Whereas, the levels of both the basal and [CHEMICAL]sulforaphane[\\CHEMICAL]-inducible expression of [GENE]AKR1C1[\\GENE] were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the [CHEMICAL]lysine[\\CHEMICAL] residue at position 293 of [GENE]TRF2[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "Furthermore, PTE treatment directly inhibited the phosphorylation of [GENE]JAK2[\\GENE] at [CHEMICAL]Tyr[\\CHEMICAL] 1007 and the downstream activation of STAT3.",
        "label": 1,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL], used in combination with a known [GENE]JAK2[\\GENE]/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL], used in combination with a known JAK2/[GENE]STAT3[\\GENE] inhibitor, AG490, further decreased the viability of osteosarcoma cells.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins ([GENE]Bax[\\GENE], Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, [GENE]Bak[\\GENE], cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic [GENE]Cytochrome c[\\GENE], and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved [GENE]Caspase3[\\GENE]) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as [GENE]p21[\\GENE] and p27.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and [GENE]p27[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "Furthermore, [CHEMICAL]PTE[\\CHEMICAL] treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of [GENE]STAT3[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of [GENE]STAT3[\\GENE] target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins [GENE]Bcl-xL[\\GENE] and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]PTE[\\CHEMICAL] also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and [GENE]Mcl-1[\\GENE], leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Pterostilbene[\\CHEMICAL] exerts antitumor activity against human osteosarcoma cells by inhibiting the [GENE]JAK2[\\GENE]/STAT3 signaling pathway.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Pterostilbene[\\CHEMICAL] exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/[GENE]STAT3[\\GENE] signaling pathway.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Furthermore, [CHEMICAL]PTE[\\CHEMICAL] treatment directly inhibited the phosphorylation of [GENE]JAK2[\\GENE] at Tyr 1007 and the downstream activation of STAT3.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "PTE, used in combination with a known [GENE]JAK2[\\GENE]/STAT3 inhibitor, [CHEMICAL]AG490[\\CHEMICAL], further decreased the viability of osteosarcoma cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "PTE, used in combination with a known JAK2/[GENE]STAT3[\\GENE] inhibitor, [CHEMICAL]AG490[\\CHEMICAL], further decreased the viability of osteosarcoma cells.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Taken together, [CHEMICAL]PTE[\\CHEMICAL] is a potent inhibitor of osteosarcoma cell growth that targets the [GENE]JAK2[\\GENE]/STAT3 signaling pathway.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Taken together, [CHEMICAL]PTE[\\CHEMICAL] is a potent inhibitor of osteosarcoma cell growth that targets the JAK2/[GENE]STAT3[\\GENE] signaling pathway.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "These data suggest that inhibition of [GENE]JAK2[\\GENE]/STAT3 signaling is a novel mechanism of action for [CHEMICAL]PTE[\\CHEMICAL] during therapeutic intervention in osteosarcoma cancers.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These data suggest that inhibition of JAK2/[GENE]STAT3[\\GENE] signaling is a novel mechanism of action for [CHEMICAL]PTE[\\CHEMICAL] during therapeutic intervention in osteosarcoma cancers.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In HepG2 cells, GCs induced a decreased expression of FXR and SHP, and inhibited the regulatory effect of [CHEMICAL]GW4064[\\CHEMICAL] on [GENE]FXR[\\GENE]-target genes.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "Moreover, GCs have a synergistic effect on [CHEMICAL]GW4064[\\CHEMICAL]-induced [GENE]FXR[\\GENE] activation, whereas chenodeoxycholate and GW4064 have an additive effect.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "In Alexander cells, only when they were transfected with FXR+RXR, [CHEMICAL]GW4064[\\CHEMICAL] caused up-regulation of [GENE]SHP[\\GENE] and OST\u03b2, and a down-regulation of CYP27A1.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "In Alexander cells, only when they were transfected with FXR+RXR, [CHEMICAL]GW4064[\\CHEMICAL] caused up-regulation of SHP and [GENE]OST\u03b2[\\GENE], and a down-regulation of CYP27A1.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "In Alexander cells, only when they were transfected with FXR+RXR, [CHEMICAL]GW4064[\\CHEMICAL] caused up-regulation of SHP and OST\u03b2, and a down-regulation of [GENE]CYP27A1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Mn[\\CHEMICAL] was also shown to decrease DA uptake and amphetamine-induced DA efflux in [GENE]DAT[\\GENE] containing cells.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "Time-lapsed confocal microscopy indicates that [CHEMICAL]Mn[\\CHEMICAL] can promote trafficking of cell surface [GENE]DAT[\\GENE] into intracellular compartments which may account for the decrease in DA uptake and DA efflux in these cells.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Mn[\\CHEMICAL]-induced internalization of [GENE]DAT[\\GENE] may provide an explanation for disruption in DA transmission previously reported in the striatum.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Although dopaminergic neurons within the nigrostriatal pathway appear intact, [CHEMICAL]Mn[\\CHEMICAL]-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the [GENE]dopamine transporter[\\GENE] (DAT).",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Although dopaminergic neurons within the nigrostriatal pathway appear intact, [CHEMICAL]Mn[\\CHEMICAL]-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter ([GENE]DAT[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "The data indicated that [CHEMICAL]PhIP[\\CHEMICAL] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of [GENE]c-fos[\\GENE] and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "The data indicated that [CHEMICAL]PhIP[\\CHEMICAL] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and [GENE]c-jun[\\GENE] and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [CHEMICAL]PhIP[\\CHEMICAL] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and [GENE]c-jun[\\GENE] expression relative to control.",
        "label": 3,
        "major": 4,
        "len": 50
    },
    {
        "text": "With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [CHEMICAL]PhIP[\\CHEMICAL] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced [GENE]c-fos[\\GENE] and c-jun expression relative to control.",
        "label": 3,
        "major": 4,
        "len": 50
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased [GENE]catalase[\\GENE] (CAT) activity compared with the control.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase ([GENE]CAT[\\GENE]) activity compared with the control.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased [GENE]superoxide dismutase[\\GENE] (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased superoxide dismutase ([GENE]SOD[\\GENE]) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and [GENE]glutathioneperoxidase[\\GENE] (GPx) activities, while increased catalase (CAT) activity compared with the control.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) [CHEMICAL]PhIP[\\CHEMICAL] (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase ([GENE]GPx[\\GENE]) activities, while increased catalase (CAT) activity compared with the control.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) [CHEMICAL]PhIP[\\CHEMICAL] at the doses of 10mg/kg and/or 15mg/kg significantly inhibited [GENE]p16[\\GENE] mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.",
        "label": 4,
        "major": 4,
        "len": 50
    },
    {
        "text": "The data indicated that [CHEMICAL]PhIP[\\CHEMICAL] could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of [GENE]p16[\\GENE], which may play a role in the pathogenesis of PhIP-associated stomach cancer.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective [GENE]acetylcholinesterase[\\GENE] reactivator, [CHEMICAL]1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate[\\CHEMICAL] (MMB-4).",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective [GENE]acetylcholinesterase[\\GENE] reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate ([CHEMICAL]MMB-4[\\CHEMICAL]).",
        "label": 3,
        "major": 1,
        "len": 25
    },
    {
        "text": "Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to [CHEMICAL]SiO(2)[\\CHEMICAL] NPs, the messenger RNA level of apoptotic genes ([GENE]caspase-3[\\GENE] and caspase-9) were upregulated in a dose-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to [CHEMICAL]SiO(2)[\\CHEMICAL] NPs, the messenger RNA level of apoptotic genes (caspase-3 and [GENE]caspase-9[\\GENE]) were upregulated in a dose-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Particularly, the effects of [CHEMICAL]doxycycline[\\CHEMICAL] used as a non selective [GENE]MMP[\\GENE] inhibitor in experimental and clinical studies will be discussed.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Functional and biochemical studies indicated that [CHEMICAL]TES[\\CHEMICAL] signaling involved activity of the [GENE]phosphoinositide 3 (PI3) kinase[\\GENE]-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.",
        "label": 2,
        "major": 9,
        "len": 37
    },
    {
        "text": "Functional and biochemical studies indicated that [CHEMICAL]TES[\\CHEMICAL] signaling involved activity of the phosphoinositide 3 (PI3) kinase-[GENE]protein kinase B[\\GENE] (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Functional and biochemical studies indicated that [CHEMICAL]TES[\\CHEMICAL] signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B ([GENE]Akt[\\GENE]) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Functional and biochemical studies indicated that [CHEMICAL]TES[\\CHEMICAL] signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the [GENE]androgen receptor[\\GENE] and culminated in enhanced production of cGMP and microvascular vasodilation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by [CHEMICAL]peroxynitrite[\\CHEMICAL] formed from [GENE]xanthine oxidase[\\GENE]-generated superoxide and NO.",
        "label": 9,
        "major": 3,
        "len": 38
    },
    {
        "text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from [GENE]xanthine oxidase[\\GENE]-generated [CHEMICAL]superoxide[\\CHEMICAL] and NO.",
        "label": 9,
        "major": 3,
        "len": 38
    },
    {
        "text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from [GENE]xanthine oxidase[\\GENE]-generated superoxide and [CHEMICAL]NO[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 38
    },
    {
        "text": "As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and [GENE]xanthine oxidase[\\GENE] was identified as the likely source of [CHEMICAL]TES[\\CHEMICAL]-stimulated superoxide production.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and [GENE]xanthine oxidase[\\GENE] was identified as the likely source of TES-stimulated [CHEMICAL]superoxide[\\CHEMICAL] production.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "In addition, [CHEMICAL]butein[\\CHEMICAL]-dependent [GENE]HO-1[\\GENE] expression was required for the inhibition of H2O2-induced cell death and ROS generation.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Butein[\\CHEMICAL] protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via Nrf2 pathway-dependent [GENE]heme oxygenase-1[\\GENE] expressions.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Butein[\\CHEMICAL] protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via [GENE]Nrf2[\\GENE] pathway-dependent heme oxygenase-1 expressions.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and [CHEMICAL]butein[\\CHEMICAL] treatment led to increased [GENE]JNK[\\GENE] phosphorylation.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Butein[\\CHEMICAL] also increased [GENE]heme oxygenase-1[\\GENE] (HO-1) protein expression and HO activity.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Butein[\\CHEMICAL] also increased heme oxygenase-1 ([GENE]HO-1[\\GENE]) protein expression and HO activity.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Furthermore, [CHEMICAL]butein[\\CHEMICAL] treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of [GENE]antioxidant response elements[\\GENE] (AREs).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]butein[\\CHEMICAL] treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements ([GENE]AREs[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]butein[\\CHEMICAL] treatment caused nuclear accumulation of [GENE]nuclear factor-E2-related factor 2[\\GENE] (Nrf2) and increased the promoter activity of antioxidant response elements (AREs).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, [CHEMICAL]butein[\\CHEMICAL] treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 ([GENE]Nrf2[\\GENE]) and increased the promoter activity of antioxidant response elements (AREs).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced [CHEMICAL]butein[\\CHEMICAL]-induced [GENE]HO-1[\\GENE] expression, and butein treatment led to increased JNK phosphorylation.",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Butein[\\CHEMICAL] also increased heme oxygenase-1 (HO-1) protein expression and [GENE]HO[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor [CHEMICAL]manumycin A[\\CHEMICAL] caused elevation of [GENE]ApoA-I[\\GENE] secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor [CHEMICAL]manumycin A[\\CHEMICAL] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing [GENE]hApoA-I[\\GENE] and cholesterol ester transfer protein transgenes.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Repression of [GENE]farnesyltransferase[\\GENE] (FNTA) by siRNA and the enzyme inhibitor [CHEMICAL]manumycin A[\\CHEMICAL] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Repression of farnesyltransferase ([GENE]FNTA[\\GENE]) by siRNA and the enzyme inhibitor [CHEMICAL]manumycin A[\\CHEMICAL] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of [GENE]GSK3\u03b2[\\GENE] at inactive form [CHEMICAL]serine[\\CHEMICAL] 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",
        "label": 1,
        "major": 3,
        "len": 36
    },
    {
        "text": "Conversely, AMPK inhibitor [CHEMICAL]compound C[\\CHEMICAL] or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of [GENE]PARP[\\GENE] and caspase 3 induced by ursolic acid in HepG2 cells.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor [CHEMICAL]SB216763[\\CHEMICAL] blocked the cleavages of [GENE]PARP[\\GENE] and caspase 3 induced by ursolic acid in HepG2 cells.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "Furthermore, proteosomal inhibitor [CHEMICAL]MG132[\\CHEMICAL] suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved [GENE]PARP[\\GENE] and deceased AEG-1 induced by ursolic acid in HepG2 cells.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved [GENE]PARP[\\GENE] and deceased AEG-1 induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Interestingly, [CHEMICAL]ursolic acid[\\CHEMICAL] increased the phosphorylation of [GENE]AMPK[\\GENE] and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Interestingly, [CHEMICAL]ursolic acid[\\CHEMICAL] increased the phosphorylation of AMPK and [GENE]coenzyme A carboxylase[\\GENE] and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Interestingly, [CHEMICAL]ursolic acid[\\CHEMICAL] increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of [GENE]GSK3\u03b2[\\GENE] at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Activation of [GENE]AMP-activated Protein Kinase[\\GENE] and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate [CHEMICAL]Ursolic Acid[\\CHEMICAL] Induced Apoptosis in HepG2 Liver Cancer Cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Activation of AMP-activated Protein Kinase and Phosphorylation of [GENE]Glycogen Synthase Kinase3 \u03b2[\\GENE] Mediate [CHEMICAL]Ursolic Acid[\\CHEMICAL] Induced Apoptosis in HepG2 Liver Cancer Cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, proteosomal inhibitor MG132 suppressed [GENE]AMPK[\\GENE] activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, [GENE]GSK3\u03b2[\\GENE] phosphorylation, cleaved PARP and deceased AEG-1 induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Overall, our findings suggest that [CHEMICAL]ursolic acid[\\CHEMICAL] induced apoptosis in HepG2 cells via [GENE]AMPK[\\GENE] activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Overall, our findings suggest that [CHEMICAL]ursolic acid[\\CHEMICAL] induced apoptosis in HepG2 cells via AMPK activation and [GENE]GSK3\u03b2[\\GENE] phosphorylation as a potent chemopreventive agent.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of [GENE]PARP[\\GENE] and caspase 3 induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and [GENE]caspase 3[\\GENE] induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "Furthermore, proteosomal inhibitor [CHEMICAL]MG132[\\CHEMICAL] suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased [GENE]AEG-1[\\GENE] induced by ursolic acid in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased [GENE]AEG-1[\\GENE] induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Conversely, AMPK inhibitor [CHEMICAL]compound C[\\CHEMICAL] or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and [GENE]caspase 3[\\GENE] induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor [CHEMICAL]SB216763[\\CHEMICAL] blocked the cleavages of PARP and [GENE]caspase 3[\\GENE] induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased [GENE]AEG-1[\\GENE] induced by [CHEMICAL]ursolic acid[\\CHEMICAL] in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas [CHEMICAL]ursolic acid[\\CHEMICAL] attenuated the phosphorylation of [GENE]AKT[\\GENE] and mTOR in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas [CHEMICAL]ursolic acid[\\CHEMICAL] attenuated the phosphorylation of AKT and [GENE]mTOR[\\GENE] in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "Conversely, [GENE]AMPK[\\GENE] inhibitor [CHEMICAL]compound C[\\CHEMICAL] or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Conversely, AMPK inhibitor compound C or [GENE]GSK3\u03b2[\\GENE] inhibitor [CHEMICAL]SB216763[\\CHEMICAL] blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Furthermore, proteosomal inhibitor [CHEMICAL]MG132[\\CHEMICAL] suppressed [GENE]AMPK[\\GENE] activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, proteosomal inhibitor [CHEMICAL]MG132[\\CHEMICAL] suppressed AMPK activation, [GENE]GSK3\u03b2[\\GENE] phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Flavonoids[\\CHEMICAL] such as green tea catechins and quercetin glycosides have been shown to modulate the function of some [GENE]OATPs[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "Flavonoids such as green tea [CHEMICAL]catechins[\\CHEMICAL] and quercetin glycosides have been shown to modulate the function of some [GENE]OATPs[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "Flavonoids such as green tea catechins and [CHEMICAL]quercetin glycosides[\\CHEMICAL] have been shown to modulate the function of some [GENE]OATPs[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 19
    },
    {
        "text": "Uptake of the radiolabeled model substrates [CHEMICAL]estradiol 17\u03b2-glucuronide[\\CHEMICAL], estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [GENE]OATP1B1[\\GENE] or OATP1B3.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates [CHEMICAL]estradiol 17\u03b2-glucuronide[\\CHEMICAL], estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or [GENE]OATP1B3[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, [CHEMICAL]estrone 3-sulfate[\\CHEMICAL], and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [GENE]OATP1B1[\\GENE] or OATP1B3.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, [CHEMICAL]estrone 3-sulfate[\\CHEMICAL], and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or [GENE]OATP1B3[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and [CHEMICAL]dehydroepiandrosterone sulfate[\\CHEMICAL] (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [GENE]OATP1B1[\\GENE] or OATP1B3.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and [CHEMICAL]dehydroepiandrosterone sulfate[\\CHEMICAL] (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or [GENE]OATP1B3[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ([CHEMICAL]DHEAS[\\CHEMICAL]) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either [GENE]OATP1B1[\\GENE] or OATP1B3.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ([CHEMICAL]DHEAS[\\CHEMICAL]) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or [GENE]OATP1B3[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Compound 6 stimulated OATP1B3-mediated [CHEMICAL]estradiol 17\u03b2-glucuronide[\\CHEMICAL] uptake by increasing the apparent affinity of [GENE]OATP1B3[\\GENE] for its substrate.",
        "label": 9,
        "major": 3,
        "len": 17
    },
    {
        "text": "Compound 6 stimulated [GENE]OATP1B3[\\GENE]-mediated [CHEMICAL]estradiol 17\u03b2-glucuronide[\\CHEMICAL] uptake by increasing the apparent affinity of OATP1B3 for its substrate.",
        "label": 9,
        "major": 3,
        "len": 17
    },
    {
        "text": "Transport by [GENE]OATP1B1[\\GENE] and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several [CHEMICAL]quercetin[\\CHEMICAL] derivatives.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Transport by OATP1B1 and [GENE]OATP1B3[\\GENE] enhances the cytotoxicity of epigallocatechin 3-O-gallate and several [CHEMICAL]quercetin[\\CHEMICAL] derivatives.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Transport by [GENE]OATP1B1[\\GENE] and OATP1B3 enhances the cytotoxicity of [CHEMICAL]epigallocatechin 3-O-gallate[\\CHEMICAL] and several quercetin derivatives.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Transport by OATP1B1 and [GENE]OATP1B3[\\GENE] enhances the cytotoxicity of [CHEMICAL]epigallocatechin 3-O-gallate[\\CHEMICAL] and several quercetin derivatives.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Unable to reverse ERK1/2 phosphorylation, TXM-CB3 ([CHEMICAL]NAc-Cys-Pro-Cys amide[\\CHEMICAL]) appeared to function in part, through inhibiting [GENE]ASK1[\\GENE]-Trx dissociation.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Unable to reverse ERK1/2 phosphorylation, TXM-CB3 ([CHEMICAL]NAc-Cys-Pro-Cys amide[\\CHEMICAL]) appeared to function in part, through inhibiting ASK1-[GENE]Trx[\\GENE] dissociation.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing [GENE]caspase-3[\\GENE] cleavage and thereby PARP-1 dissociation.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby [GENE]PARP-1[\\GENE] dissociation.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced [GENE]MAPK[\\GENE], JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced MAPK, [GENE]JNK[\\GENE] and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced MAPK, JNK and [GENE]p38[\\GENE](MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "The TXM peptides were effective in inhibiting [CHEMICAL]AuF[\\CHEMICAL]-induced MAPK, JNK and p38([GENE]MAPK[\\GENE]) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting [GENE]TrxR[\\GENE] with [CHEMICAL]auranofin[\\CHEMICAL] (AuF).",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting [GENE]TrxR[\\GENE] with auranofin ([CHEMICAL]AuF[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Since the original discovery of [CHEMICAL]azoles[\\CHEMICAL] analogs as [GENE]PXR[\\GENE] antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Since the original discovery of [CHEMICAL]azoles[\\CHEMICAL] analogs as PXR antagonists, we have preliminarily defined an important [GENE]PXR[\\GENE] antagonist pharmacophore and developed less-toxic PXR antagonists.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Since the original discovery of [CHEMICAL]azoles[\\CHEMICAL] analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic [GENE]PXR[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "It was found that expression of [GENE]Sim2[\\GENE] protein in cortical neurons was increased in [CHEMICAL]streptozotocin[\\CHEMICAL]-induced diabetes mellitus rat model.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of [GENE]p21[\\GENE](WAF1/CIP1) and p53.",
        "label": 3,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21([GENE]WAF1[\\GENE]/CIP1) and p53.",
        "label": 3,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/[GENE]CIP1[\\GENE]) and p53.",
        "label": 3,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and [GENE]p53[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of [GENE]cyclin D1[\\GENE], cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, [GENE]cyclin E[\\GENE], cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, [GENE]cyclin A[\\GENE], cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, [GENE]cyclin dependent kinase 2[\\GENE] (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 ([GENE]CDK2[\\GENE]), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), [GENE]CDK4[\\GENE], c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, [GENE]c-Myc[\\GENE], and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and [GENE]retinoblastoma protein[\\GENE] (pRb), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein ([GENE]pRb[\\GENE]), and the upregulation of p21(WAF1/CIP1) and p53.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "Suppression of [GENE]Src[\\GENE]/ERK and GSK-3/\u03b2-catenin signaling by [CHEMICAL]pinosylvin[\\CHEMICAL] inhibits the growth of human colorectal cancer cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Suppression of Src/[GENE]ERK[\\GENE] and GSK-3/\u03b2-catenin signaling by [CHEMICAL]pinosylvin[\\CHEMICAL] inhibits the growth of human colorectal cancer cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Suppression of Src/ERK and [GENE]GSK-3[\\GENE]/\u03b2-catenin signaling by [CHEMICAL]pinosylvin[\\CHEMICAL] inhibits the growth of human colorectal cancer cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Suppression of Src/ERK and GSK-3/[GENE]\u03b2-catenin[\\GENE] signaling by [CHEMICAL]pinosylvin[\\CHEMICAL] inhibits the growth of human colorectal cancer cells.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in f[GENE]ocal adhesion kinase[\\GENE] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase ([GENE]FAK[\\GENE])/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/[GENE]c-Src[\\GENE]/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/[GENE]extracellular signal-regulated kinase[\\GENE] (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and [GENE]phosphoinositide 3-kinase[\\GENE] (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase ([GENE]PI3K[\\GENE])/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/[GENE]Akt[\\GENE]/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ [GENE]glycogen synthase kinase 3\u03b2[\\GENE] (GSK-3\u03b2) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pinosylvin[\\CHEMICAL] was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 ([GENE]GSK-3\u03b2[\\GENE]) signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of [GENE]\u03b2-catenin[\\GENE], one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of [GENE]PI3K[\\GENE]/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/[GENE]Akt[\\GENE]/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/[GENE]GSK-3\u03b2[\\GENE] signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of [GENE]\u03b2-catenin[\\GENE]-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including [GENE]BMP4[\\GENE], ID2, survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, [GENE]ID2[\\GENE], survivin, cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, [GENE]survivin[\\GENE], cyclin D1, MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, [GENE]cyclin D1[\\GENE], MMP7, and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, [GENE]MMP7[\\GENE], and c-Myc.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Subsequently, [CHEMICAL]pinosylvin[\\CHEMICAL] suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and [GENE]c-Myc[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "[CHEMICAL]\u03b2-Lapachone[\\CHEMICAL] (\u03b2-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through [GENE]NAD(P)H:quinone oxidoreductase-1[\\GENE] (NQO1).",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]\u03b2-Lapachone[\\CHEMICAL] (\u03b2-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 ([GENE]NQO1[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "\u03b2-Lapachone ([CHEMICAL]\u03b2-Lap[\\CHEMICAL]) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through [GENE]NAD(P)H:quinone oxidoreductase-1[\\GENE] (NQO1).",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "\u03b2-Lapachone ([CHEMICAL]\u03b2-Lap[\\CHEMICAL]) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 ([GENE]NQO1[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "\u03b2-Lapachone (\u03b2-Lap) is a [CHEMICAL]1,2-orthonaphthoquinone[\\CHEMICAL] that selectively induces cell death in human cancer cells through [GENE]NAD(P)H:quinone oxidoreductase-1[\\GENE] (NQO1).",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "\u03b2-Lapachone (\u03b2-Lap) is a [CHEMICAL]1,2-orthonaphthoquinone[\\CHEMICAL] that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 ([GENE]NQO1[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "However, recent clinical studies have shown that a single low-dose injection of [CHEMICAL]ketamine[\\CHEMICAL], an [GENE]N-methyl d-aspartate receptor[\\GENE] (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "However, recent clinical studies have shown that a single low-dose injection of [CHEMICAL]ketamine[\\CHEMICAL], an N-methyl d-aspartate receptor ([GENE]NMDAR[\\GENE]) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "Administration of a single dose of [CHEMICAL]DEX-P[\\CHEMICAL] showed a temporal increase in [GENE]CYP3A[\\GENE] activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Administration of a single dose of DEX-P showed a temporal increase in [GENE]CYP3A[\\GENE] activity in both tissues and the induction ratios reached maximum values at 12\u2009h after [CHEMICAL]DEX-P[\\CHEMICAL] administration.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Time-dependent changes in hepatic and intestinal induction of [GENE]cytochrome P450 3A[\\GENE] after administration of [CHEMICAL]dexamethasone[\\CHEMICAL] to rats.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal [GENE]cytochrome P450 3A[\\GENE] (CYP3A) in rats using [CHEMICAL]dexamethasone 21-phosphate[\\CHEMICAL] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 3,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ([GENE]CYP3A[\\GENE]) in rats using [CHEMICAL]dexamethasone 21-phosphate[\\CHEMICAL] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 3,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using [CHEMICAL]dexamethasone 21-phosphate[\\CHEMICAL] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 3,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal [GENE]cytochrome P450 3A[\\GENE] (CYP3A) in rats using dexamethasone 21-phosphate ([CHEMICAL]DEX-P[\\CHEMICAL]) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ([GENE]CYP3A[\\GENE]) in rats using dexamethasone 21-phosphate ([CHEMICAL]DEX-P[\\CHEMICAL]) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 3,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ([CHEMICAL]DEX-P[\\CHEMICAL]) and midazolam (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 3,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and [CHEMICAL]midazolam[\\CHEMICAL] (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ([CHEMICAL]MDZ[\\CHEMICAL]) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "[GENE]CYP3A[\\GENE] induction in the liver increased depending on the dose of [CHEMICAL]DEX-P[\\CHEMICAL], whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P. 4.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[GENE]CYP3A[\\GENE] induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of [CHEMICAL]DEX-P[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using [CHEMICAL]dexamethasone 21-phosphate[\\CHEMICAL] (DEX-P) and midazolam (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 9,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate ([CHEMICAL]DEX-P[\\CHEMICAL]) and midazolam (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 9,
        "major": 3,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal [GENE]cytochrome P450 3A[\\GENE] (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and [CHEMICAL]midazolam[\\CHEMICAL] (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 9,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ([GENE]CYP3A[\\GENE]) in rats using dexamethasone 21-phosphate (DEX-P) and [CHEMICAL]midazolam[\\CHEMICAL] (MDZ) as an inducer and a substrate to CYP3A, respectively.",
        "label": 9,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and [CHEMICAL]midazolam[\\CHEMICAL] (MDZ) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 9,
        "major": 3,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ([GENE]CYP3A[\\GENE]) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ([CHEMICAL]MDZ[\\CHEMICAL]) as an inducer and a substrate to CYP3A, respectively.",
        "label": 9,
        "major": 9,
        "len": 48
    },
    {
        "text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ([CHEMICAL]MDZ[\\CHEMICAL]) as an inducer and a substrate to [GENE]CYP3A[\\GENE], respectively.",
        "label": 9,
        "major": 3,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Camptothecin[\\CHEMICAL] (CPT), a [GENE]topoisomerase (Top) I[\\GENE]-targeting drug that stabilizes Top1-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Camptothecin[\\CHEMICAL] (CPT), a topoisomerase (Top) I-targeting drug that stabilizes [GENE]Top1[\\GENE]-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Camptothecin ([CHEMICAL]CPT[\\CHEMICAL]), a [GENE]topoisomerase (Top) I[\\GENE]-targeting drug that stabilizes Top1-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Camptothecin ([CHEMICAL]CPT[\\CHEMICAL]), a topoisomerase (Top) I-targeting drug that stabilizes [GENE]Top1[\\GENE]-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "In this study, we have identified [GENE]topoisomerase II\u03b2[\\GENE] (Top2\u03b2) as a specific determinant for [CHEMICAL]CPT[\\CHEMICAL] sensitivity, but not for many other cytotoxic agents, in non-S-phase cells.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "In this study, we have identified topoisomerase II\u03b2 ([GENE]Top2\u03b2[\\GENE]) as a specific determinant for [CHEMICAL]CPT[\\CHEMICAL] sensitivity, but not for many other cytotoxic agents, in non-S-phase cells.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "Altogether, our findings support a model in which Top2\u03b2 deficiency promotes [CHEMICAL]CPT[\\CHEMICAL]-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and [GENE]p53[\\GENE] accumulation.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Altogether, our findings support a model in which Top2\u03b2 deficiency promotes [CHEMICAL]CPT[\\CHEMICAL]-induced apoptosis in quiescent non-S-phase cells, possibly due to [GENE]RNAP LS[\\GENE] depletion and p53 accumulation.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Second, [CHEMICAL]ICRF-187[\\CHEMICAL], a [GENE]Top2[\\GENE] catalytic inhibitor known to deplete Top2\u03b2, specifically sensitized MEFs to CPT.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Second, [CHEMICAL]ICRF-187[\\CHEMICAL], a Top2 catalytic inhibitor known to deplete [GENE]Top2\u03b2[\\GENE], specifically sensitized MEFs to CPT.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a [CHEMICAL]phenylalanine[\\CHEMICAL] from the conserved [GENE]FxxA interaction motif[\\GENE] found in BRCA2.",
        "label": 1,
        "major": 2,
        "len": 51
    },
    {
        "text": "The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a [CHEMICAL]phenylalanine[\\CHEMICAL] from the conserved FxxA interaction motif found in [GENE]BRCA2[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 51
    },
    {
        "text": "The M6P ([CHEMICAL]mannose 6-phosphate[\\CHEMICAL])/[GENE]IGF2R[\\GENE] (insulin-like growth factor II receptor) interacts with a variety of factors that impinge on tumour invasion and metastasis.",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "The M6P ([CHEMICAL]mannose 6-phosphate[\\CHEMICAL])/IGF2R ([GENE]insulin-like growth factor II receptor[\\GENE]) interacts with a variety of factors that impinge on tumour invasion and metastasis.",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "The [CHEMICAL]M6P[\\CHEMICAL] (mannose 6-phosphate)/[GENE]IGF2R[\\GENE] (insulin-like growth factor II receptor) interacts with a variety of factors that impinge on tumour invasion and metastasis.",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "The [CHEMICAL]M6P[\\CHEMICAL] (mannose 6-phosphate)/IGF2R ([GENE]insulin-like growth factor II receptor[\\GENE]) interacts with a variety of factors that impinge on tumour invasion and metastasis.",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "These findings highlight that the interaction between M6P/[GENE]IGF2R[\\GENE] and [CHEMICAL]M6P[\\CHEMICAL]-modified ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes, but is also crucial for the ability of the receptor to suppress SCC-VII growth and invasion.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "The [CHEMICAL]mannose 6-phosphate[\\CHEMICAL]-binding sites of M6P/[GENE]IGF2R[\\GENE] determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "The present study also shows that some of the biological activities of M6P/[GENE]IGF2R[\\GENE] in SCC-VII cells strongly depend on a functional [CHEMICAL]M6P[\\CHEMICAL]-binding site within domain 3, thus providing further evidence for the non-redundant cellular functions of the individual carbohydrate-binding domains of the receptor.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Previous work has extensively characterized a common allosteric site on [GENE]mGlu5[\\GENE], termed the [CHEMICAL]MPEP[\\CHEMICAL] (2-Methyl-6-(phenylethynyl)pyridine) binding site.",
        "label": 1,
        "major": 2,
        "len": 17
    },
    {
        "text": "Previous work has extensively characterized a common allosteric site on [GENE]mGlu5[\\GENE], termed the MPEP ([CHEMICAL]2-Methyl-6-(phenylethynyl)pyridine[\\CHEMICAL]) binding site.",
        "label": 1,
        "major": 7,
        "len": 17
    },
    {
        "text": "However, one mGlu5 PAM, [CHEMICAL]CPPHA[\\CHEMICAL] (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on [GENE]mGlu5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "However, one mGlu5 PAM, CPPHA ([CHEMICAL]N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide[\\CHEMICAL]), interacts with a separate allosteric site on [GENE]mGlu5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "[CHEMICAL]NCFP[\\CHEMICAL] binds to the CPPHA site on [GENE]mGlu5[\\GENE] and potentiates mGlu5-mediated responses in both recombinant and native systems.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "[CHEMICAL]NCFP[\\CHEMICAL] binds to the CPPHA site on mGlu5 and potentiates [GENE]mGlu5[\\GENE]-mediated responses in both recombinant and native systems.",
        "label": 3,
        "major": 2,
        "len": 18
    },
    {
        "text": "However, one [GENE]mGlu5[\\GENE] PAM, [CHEMICAL]CPPHA[\\CHEMICAL] (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "However, one [GENE]mGlu5[\\GENE] PAM, CPPHA ([CHEMICAL]N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide[\\CHEMICAL]), interacts with a separate allosteric site on mGlu5.",
        "label": 7,
        "major": 2,
        "len": 14
    },
    {
        "text": "Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious [GENE]mGlu5[\\GENE] PAM from the [CHEMICAL]CPPHA[\\CHEMICAL] series termed NCFP (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).",
        "label": 7,
        "major": 2,
        "len": 25
    },
    {
        "text": "Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious [GENE]mGlu5[\\GENE] PAM from the CPPHA series termed [CHEMICAL]NCFP[\\CHEMICAL] (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).",
        "label": 7,
        "major": 2,
        "len": 25
    },
    {
        "text": "Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious [GENE]mGlu5[\\GENE] PAM from the CPPHA series termed NCFP ([CHEMICAL]N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide[\\CHEMICAL]).",
        "label": 7,
        "major": 2,
        "len": 25
    },
    {
        "text": "NCFP binds to the [CHEMICAL]CPPHA[\\CHEMICAL] site on [GENE]mGlu5[\\GENE] and potentiates mGlu5-mediated responses in both recombinant and native systems.",
        "label": 7,
        "major": 2,
        "len": 18
    },
    {
        "text": "Notably, [CHEMICAL]17-HDHA[\\CHEMICAL] treatment reduced adipose tissue expression of inflammatory cytokines, increased [GENE]adiponectin[\\GENE] expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Notably, [CHEMICAL]17-HDHA[\\CHEMICAL] treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to [GENE]insulin[\\GENE] sensitivity in obese mice.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Notably, [CHEMICAL]17-HDHA[\\CHEMICAL] treatment reduced adipose tissue expression of inflammatory [GENE]cytokines[\\GENE], increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "We describe the discovery of several [CHEMICAL]pyrrolopyrazines[\\CHEMICAL] as potent and selective [GENE]Syk[\\GENE] inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pyrrolopyrazines[\\CHEMICAL] as Selective [GENE]Spleen Tyrosine Kinase[\\GENE] Inhibitors.",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "Experimental studies performed for characterizing the inhibitory mechanism indicate that [GENE]GSK-3\u03b2[\\GENE] inhibition by palinurin cannot be competed out by [CHEMICAL]ATP[\\CHEMICAL] nor peptide substrate.",
        "label": 10,
        "major": 4,
        "len": 23
    },
    {
        "text": "We describe here the isolation and biochemical characterization of the marine natural [CHEMICAL]sesquiterpene[\\CHEMICAL] palinurin as a [GENE]GSK-3\u03b2[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "We describe here the isolation and biochemical characterization of the marine natural sesquiterpene [CHEMICAL]palinurin[\\CHEMICAL] as a [GENE]GSK-3\u03b2[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Experimental studies performed for characterizing the inhibitory mechanism indicate that [GENE]GSK-3\u03b2[\\GENE] inhibition by [CHEMICAL]palinurin[\\CHEMICAL] cannot be competed out by ATP nor peptide substrate.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of [CHEMICAL]palinurin[\\CHEMICAL] leads to [GENE]GSK-3\u03b2[\\GENE] inhibition.",
        "label": 4,
        "major": 7,
        "len": 18
    },
    {
        "text": "Evidence for a new binding mode to [GENE]GSK-3[\\GENE]: allosteric regulation by the marine compound [CHEMICAL]palinurin[\\CHEMICAL].",
        "label": 7,
        "major": 2,
        "len": 15
    },
    {
        "text": "The [CHEMICAL]keto[\\CHEMICAL] and phenolic -OH are major factors that are prominently involved in interaction with [GENE]COX-2[\\GENE] active site.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "The keto and [CHEMICAL]phenolic[\\CHEMICAL] -OH are major factors that are prominently involved in interaction with [GENE]COX-2[\\GENE] active site.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "The keto and phenolic -[CHEMICAL]OH[\\CHEMICAL] are major factors that are prominently involved in interaction with [GENE]COX-2[\\GENE] active site.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "[GENE]Type 2 11\u03b2-hydroxysteroid dehydrogenase[\\GENE] encoded by the HSD11B2 gene converts [CHEMICAL]cortisol[\\CHEMICAL] to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the [GENE]HSD11B2[\\GENE] gene converts [CHEMICAL]cortisol[\\CHEMICAL] to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "[GENE]Type 2 11\u03b2-hydroxysteroid dehydrogenase[\\GENE] encoded by the HSD11B2 gene converts cortisol to inactive [CHEMICAL]cortisone[\\CHEMICAL], and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the [GENE]HSD11B2[\\GENE] gene converts cortisol to inactive [CHEMICAL]cortisone[\\CHEMICAL], and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "A series of [CHEMICAL]xanthine[\\CHEMICAL] derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of [GENE]dipeptidyl peptidase 4[\\GENE] (DPP-4) for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "A series of [CHEMICAL]xanthine[\\CHEMICAL] derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ([GENE]DPP-4[\\GENE]) for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "A series of xanthine derivatives in which a methylene was inserted at position 8 of [CHEMICAL]xanthine[\\CHEMICAL] scaffold was synthesized and evaluated as inhibitors of [GENE]dipeptidyl peptidase 4[\\GENE] (DPP-4) for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "A series of xanthine derivatives in which a methylene was inserted at position 8 of [CHEMICAL]xanthine[\\CHEMICAL] scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ([GENE]DPP-4[\\GENE]) for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The activity of the human nasal mucosa microsomes was inhibited by [CHEMICAL]8-methoxypsoralen[\\CHEMICAL], a known [GENE]CYP2A[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]PP242[\\CHEMICAL]-induced reversal of [GENE]deptor[\\GENE] suppression by TGF\u03b2 was associated with a significant inhibition of TGF\u03b2-stimulated protein synthesis and hypertrophy.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Using the [GENE]mTOR[\\GENE] inhibitor [CHEMICAL]PP242,[\\CHEMICAL] we found that TGF\u03b2-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Based on recent reports that the small molecules, [CHEMICAL]isatin[\\CHEMICAL] and phthalimide, are suitable scaffolds for the design of high potency [GENE]monoamine oxidase[\\GENE] (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Based on recent reports that the small molecules, [CHEMICAL]isatin[\\CHEMICAL] and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase ([GENE]MAO[\\GENE]) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Based on recent reports that the small molecules, isatin and [CHEMICAL]phthalimide[\\CHEMICAL], are suitable scaffolds for the design of high potency [GENE]monoamine oxidase[\\GENE] (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Based on recent reports that the small molecules, isatin and [CHEMICAL]phthalimide[\\CHEMICAL], are suitable scaffolds for the design of high potency monoamine oxidase ([GENE]MAO[\\GENE]) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "In most instances, C6-substituted [CHEMICAL]phthalides[\\CHEMICAL] exhibit [GENE]MAO-B[\\GENE] specific inhibition.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Among a series of 6-benzyloxyphthalides bearing substituents on the para position of the phenyl ring the general order of potency was CF(3) > I > Br > Cl > F > CH(3) > H. The results also show that the binding modes of representative [CHEMICAL]phthalides[\\CHEMICAL] are reversible and competitive at both [GENE]MAO[\\GENE] isoforms.",
        "label": 4,
        "major": 2,
        "len": 53
    },
    {
        "text": "Inhibition of [GENE]monoamine oxidase[\\GENE] by [CHEMICAL]phthalide[\\CHEMICAL] analogues.",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the [GENE]MAO[\\GENE] inhibitory properties of a series of [CHEMICAL]phthalide[\\CHEMICAL] [2-benzofuran-1(3H)-one] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the [GENE]MAO[\\GENE] inhibitory properties of a series of phthalide [[CHEMICAL]2-benzofuran-1(3H)-one[\\CHEMICAL]] analogues.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "A novel class of [CHEMICAL]quinoxalines[\\CHEMICAL] has been discovered as antagonists of the [GENE]IgG[\\GENE]:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "A novel class of [CHEMICAL]quinoxalines[\\CHEMICAL] has been discovered as antagonists of the IgG:[GENE]FcRn[\\GENE] protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.",
        "label": 6,
        "major": 2,
        "len": 26
    },
    {
        "text": "Guided by the [GENE]acetylcholinesterase[\\GENE] inhibiting activity, the [CHEMICAL]bisindole alkaloid[\\CHEMICAL] 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Guided by the [GENE]acetylcholinesterase[\\GENE] inhibiting activity, the bisindole alkaloid [CHEMICAL]3'-R/S-hydroxyvoacamine[\\CHEMICAL] was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]3'-R/S-Hydroxyvoacamine[\\CHEMICAL], a potent [GENE]acetylcholinesterase[\\GENE] inhibitor from Tabernaemontana divaricata.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates [GENE]Stat3[\\GENE] in [CHEMICAL]tyrosine[\\CHEMICAL], allowing its dimerization.",
        "label": 1,
        "major": 3,
        "len": 21
    },
    {
        "text": "Also, ROS from NADPH oxidase favors ERK1/2 activation that phosphorylates [GENE]Stat3[\\GENE] in [CHEMICAL]serine[\\CHEMICAL], resulting in a compensatory or adaptive survival response such as production of metallothionein-II in short Cd exposure times.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "Also, ROS from NADPH oxidase favors ERK1/2 activation that phosphorylates Stat3 in serine, resulting in a compensatory or adaptive survival response such as production of [GENE]metallothionein-II[\\GENE] in short [CHEMICAL]Cd[\\CHEMICAL] exposure times.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Cadmium[\\CHEMICAL] activates [GENE]NADPH oxidase[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 4
    },
    {
        "text": "However, after 12h [CHEMICAL]CdCl2[\\CHEMICAL] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in [GENE]p53[\\GENE] activation and the pro-apoptotic protein Bax.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "However, after 12h [CHEMICAL]CdCl2[\\CHEMICAL] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein [GENE]Bax[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "However, after 12h [CHEMICAL]CdCl2[\\CHEMICAL] treatment, cell viability diminished in 50%, accompanied by a drastic decrease of [GENE]metallothionein-II[\\GENE] production, and an increase in p53 activation and the pro-apoptotic protein Bax.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Promoter and electromobility shift assays showed that transcriptional activation of NF-\u03baB was significantly reduced by [CHEMICAL]catalpol[\\CHEMICAL] treatment, while [GENE]AP-1[\\GENE] was not.",
        "label": 10,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of [GENE]NF-\u03baB[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of [GENE]I\u03baB\u03b1[\\GENE] and the nuclear localization of NF-\u03baB.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as [GENE]monocyte chemotactic protein-1[\\GENE] (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 ([GENE]MCP-1[\\GENE]), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), [GENE]tumor necrosis factor-\u03b1[\\GENE] (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 ([GENE]TNF-\u03b1[\\GENE]), inducible NO synthase (iNOS), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), [GENE]inducible NO synthase[\\GENE] (iNOS), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase ([GENE]iNOS[\\GENE]), and receptor for AGE (RAGE).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and [GENE]receptor for AGE[\\GENE] (RAGE).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE ([GENE]RAGE[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Promoter and electromobility shift assays showed that transcriptional activation of [GENE]NF-\u03baB[\\GENE] was significantly reduced by [CHEMICAL]catalpol[\\CHEMICAL] treatment, while AP-1 was not.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Catalpol[\\CHEMICAL] also suppressed AGE-induced phosphorylation of [GENE]mitogen activated protein (MAP) kinases[\\GENE], degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by [CHEMICAL]catalpol[\\CHEMICAL] treatment, through dual action of reducing ROS itself and inhibiting [GENE]NADPH oxidase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Our findings indicate that [CHEMICAL]catalpol[\\CHEMICAL] suppresses AGE-mediated inflammation by inhibiting ROS production and [GENE]NF-\u03baB[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Exposure to [CHEMICAL]sibutramine[\\CHEMICAL] was higher in subjects with the [GENE]CYP2B6[\\GENE]*6/*6 genotype, but no statistical difference was observed among the CYP2B6 genotypes.",
        "label": 2,
        "major": 10,
        "len": 21
    },
    {
        "text": "In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of [CHEMICAL]racemic sibutramine[\\CHEMICAL] in conjunction with [GENE]CYP2B6[\\GENE] polymorphisms in humans.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, we assessed the effects of [CHEMICAL]clopidogrel[\\CHEMICAL] and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with [GENE]CYP2B6[\\GENE] polymorphisms in humans.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, we assessed the effects of [CHEMICAL]clopidogrel[\\CHEMICAL] and clarithromycin, known [GENE]CYP2B6[\\GENE] and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, we assessed the effects of [CHEMICAL]clopidogrel[\\CHEMICAL] and clarithromycin, known CYP2B6 and [GENE]CYP3A[\\GENE] inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, we assessed the effects of clopidogrel and [CHEMICAL]clarithromycin[\\CHEMICAL], known [GENE]CYP2B6[\\GENE] and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, we assessed the effects of clopidogrel and [CHEMICAL]clarithromycin[\\CHEMICAL], known CYP2B6 and [GENE]CYP3A[\\GENE] inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The activation of the complement cascade, a cornerstone of the innate immune response, produces a number of small (74-77 [CHEMICAL]amino acid[\\CHEMICAL]) fragments, originally termed [GENE]anaphylatoxins[\\GENE], that are potent chemoattractants and secretagogues that act on a wide variety of cell types.",
        "label": 1,
        "major": 3,
        "len": 40
    },
    {
        "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by [CHEMICAL]cyclopiazonic acid[\\CHEMICAL] (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial [GENE]SERCA[\\GENE] pump.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid ([CHEMICAL]CPA[\\CHEMICAL]), which promotes store-operated Ca(2+) entry by inhibiting the endothelial [GENE]SERCA[\\GENE] pump.",
        "label": 4,
        "major": 5,
        "len": 44
    },
    {
        "text": "Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the [GENE]NADPH oxidase[\\GENE] inhibitor [CHEMICAL]apocynin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the [GENE]G protein-coupled receptor[\\GENE] agonist [CHEMICAL]acetylcholine[\\CHEMICAL] (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
        "label": 5,
        "major": 5,
        "len": 44
    },
    {
        "text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the [GENE]G protein-coupled receptor[\\GENE] agonist acetylcholine ([CHEMICAL]ACh[\\CHEMICAL]) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.",
        "label": 5,
        "major": 5,
        "len": 44
    },
    {
        "text": "Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the [CHEMICAL]superoxide[\\CHEMICAL] anion generated by [GENE]NADPH oxidase[\\GENE] can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity.",
        "label": 9,
        "major": 1,
        "len": 43
    },
    {
        "text": "The [GENE]hemoglobin A1c[\\GENE] (HbA1c) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with [CHEMICAL]sitagliptin[\\CHEMICAL] (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U/day to 24.5\u00b116.5 U/day (p<0.001).",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "The hemoglobin A1c ([GENE]HbA1c[\\GENE]) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with [CHEMICAL]sitagliptin[\\CHEMICAL] (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U/day to 24.5\u00b116.5 U/day (p<0.001).",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "Add-on therapy with the [GENE]DPP-4[\\GENE] inhibitor [CHEMICAL]sitagliptin[\\CHEMICAL] improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, [CHEMICAL]clopidogrel-\u03b2-d-glucuronide[\\CHEMICAL], ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit [GENE]hCES2[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, [CHEMICAL]ibuprofen-\u03b2-d-glucuronide[\\CHEMICAL], (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit [GENE]hCES2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, [CHEMICAL](R)-naproxen-\u03b2-d-glucuronide[\\CHEMICAL], and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit [GENE]hCES2[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and [CHEMICAL](S)-naproxen-\u03b2-d-glucuronide[\\CHEMICAL] selectively inhibited hCES1, with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit [GENE]hCES2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Valproate-\u03b2-d-glucuronide[\\CHEMICAL] and CGP 47292-\u03b2-d-glucuronide did not inhibit either [GENE]hCES[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 9
    },
    {
        "text": "Valproate-\u03b2-d-glucuronide and [CHEMICAL]CGP 47292-\u03b2-d-glucuronide[\\CHEMICAL] did not inhibit either [GENE]hCES[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 9
    },
    {
        "text": "Time-dependent inactivation of [GENE]hCES1[\\GENE] by [CHEMICAL]diclofenac-\u03b2-d-glucuronide[\\CHEMICAL] was not observed.",
        "label": 10,
        "major": 10,
        "len": 9
    },
    {
        "text": "Lastly, both [GENE]hCES1[\\GENE] and hCES2 were shown not to catalyze the hydrolysis of the [CHEMICAL]acyl glucuronides[\\CHEMICAL] studied.",
        "label": 10,
        "major": 9,
        "len": 17
    },
    {
        "text": "Lastly, both hCES1 and [GENE]hCES2[\\GENE] were shown not to catalyze the hydrolysis of the [CHEMICAL]acyl glucuronides[\\CHEMICAL] studied.",
        "label": 10,
        "major": 9,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Diclofenac-\u03b2-d-glucuronide[\\CHEMICAL], clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit [GENE]hCES2[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, [CHEMICAL]clopidogrel-\u03b2-d-glucuronide[\\CHEMICAL], ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited [GENE]hCES1[\\GENE], with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, [CHEMICAL]ibuprofen-\u03b2-d-glucuronide[\\CHEMICAL], (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited [GENE]hCES1[\\GENE], with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, [CHEMICAL](R)-naproxen-\u03b2-d-glucuronide[\\CHEMICAL], and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited [GENE]hCES1[\\GENE], with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and [CHEMICAL](S)-naproxen-\u03b2-d-glucuronide[\\CHEMICAL] selectively inhibited [GENE]hCES1[\\GENE], with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to [CHEMICAL]acyl glucuronides[\\CHEMICAL] due to the potential inhibition of [GENE]hCESs[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 21
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of [GENE]human carboxylesterases 1[\\GENE] (hCES1) and 2 (hCES2).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of human carboxylesterases 1 ([GENE]hCES1[\\GENE]) and 2 (hCES2).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 ([GENE]hCES2[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Reversible inhibition of [GENE]human carboxylesterases[\\GENE] by [CHEMICAL]acyl glucuronides[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Diclofenac-\u03b2-d-glucuronide[\\CHEMICAL], clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited [GENE]hCES1[\\GENE], with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting [CHEMICAL]alcohols[\\CHEMICAL], amines, and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Uridine 5'-diphosphate- glucuronosyltransferases[\\GENE] are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to [CHEMICAL]acyl glucuronides[\\CHEMICAL], but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with [GENE]carboxylesterases[\\GENE] and have the potential to further metabolize carboxylic acids to [CHEMICAL]acyl glucuronides[\\CHEMICAL], but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "[GENE]Uridine 5'-diphosphate- glucuronosyltransferases[\\GENE] are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if [CHEMICAL]acyl glucuronides[\\CHEMICAL], being esters, also interact with carboxylesterases.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, amides, and thioesters to produce [CHEMICAL]carboxylic acids[\\CHEMICAL] and resulting alcohols, amines, and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, [CHEMICAL]amines[\\CHEMICAL], and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and [CHEMICAL]thiols[\\CHEMICAL], respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Uridine 5'-diphosphate- glucuronosyltransferases[\\GENE] are colocalized with carboxylesterases and have the potential to further metabolize [CHEMICAL]carboxylic acids[\\CHEMICAL] to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with [GENE]carboxylesterases[\\GENE] and have the potential to further metabolize [CHEMICAL]carboxylic acids[\\CHEMICAL] to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze [CHEMICAL]esters[\\CHEMICAL], amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, [CHEMICAL]amides[\\CHEMICAL], and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of [GENE]human carboxylesterases 1[\\GENE] (hCES1) and 2 (hCES2).",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of human carboxylesterases 1 ([GENE]hCES1[\\GENE]) and 2 (hCES2).",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "Objective: This study explores the ability of [CHEMICAL]acyl glucuronides[\\CHEMICAL] to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 ([GENE]hCES2[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "[GENE]Carboxylesterases[\\GENE] hydrolyze esters, amides, and [CHEMICAL]thioesters[\\CHEMICAL] to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Our results showed that low dose [CHEMICAL]BPA[\\CHEMICAL] and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of [GENE]Oct4[\\GENE] and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our results showed that low dose [CHEMICAL]BPA[\\CHEMICAL] and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and [GENE]Nanog[\\GENE] proteins, while only BPA could downregulate the expression of E-cadherin protein.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only [CHEMICAL]BPA[\\CHEMICAL] could downregulate the expression of [GENE]E-cadherin[\\GENE] protein.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "The in vivo inhibitory effect of [CHEMICAL]harmaline[\\CHEMICAL] on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified [GENE]CYP2D6[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of [GENE]MAO-A[\\GENE]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [CHEMICAL]harmaline[\\CHEMICAL], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and [GENE]CYP2D6[\\GENE]-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [CHEMICAL]harmaline[\\CHEMICAL], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 4,
        "major": 9,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood [CHEMICAL]harmaline[\\CHEMICAL], 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-[GENE]CYP2D6[\\GENE] mouse models.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Our recent study has demonstrated that coadministration of [GENE]monoamine oxidase A[\\GENE] (MAO-A) inhibitor [CHEMICAL]harmaline[\\CHEMICAL] (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Our recent study has demonstrated that coadministration of monoamine oxidase A ([GENE]MAO-A[\\GENE]) inhibitor [CHEMICAL]harmaline[\\CHEMICAL] (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Our data revealed that inhibition of [GENE]MAO-A[\\GENE]-mediated metabolic elimination by [CHEMICAL]harmaline[\\CHEMICAL] (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "Pharmacokinetic Interactions between [GENE]Monoamine Oxidase A[\\GENE] Inhibitor [CHEMICAL]Harmaline[\\CHEMICAL] and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The in vivo inhibitory effect of [CHEMICAL]harmaline[\\CHEMICAL] on [GENE]CYP2D6[\\GENE]-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of [GENE]MAO-A[\\GENE]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by [CHEMICAL]harmaline[\\CHEMICAL] was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 4,
        "major": 9,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and [GENE]CYP2D6[\\GENE]-catalyzed 5-MeO-DMT metabolism by [CHEMICAL]harmaline[\\CHEMICAL] was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 4,
        "major": 9,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by [CHEMICAL]harmaline[\\CHEMICAL] was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-[GENE]CYP2D6[\\GENE] mouse models.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed [CHEMICAL]bufotenine[\\CHEMICAL] formation was confirmed by in vitro study using purified [GENE]CYP2D6[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of [GENE]MAO-A[\\GENE]- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [CHEMICAL]5-MeO-DMT[\\CHEMICAL], and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and [GENE]CYP2D6[\\GENE]-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [CHEMICAL]5-MeO-DMT[\\CHEMICAL], and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, [CHEMICAL]5-MeO-DMT[\\CHEMICAL], and bufotenine PK profiles in both wild-type and Tg-[GENE]CYP2D6[\\GENE] mouse models.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "The in vivo inhibitory effect of harmaline on [GENE]CYP2D6[\\GENE]-catalyzed [CHEMICAL]bufotenine[\\CHEMICAL] formation was confirmed by in vitro study using purified CYP2D6.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of [GENE]MAO-A[\\GENE]- and CYP2D6-catalyzed [CHEMICAL]5-MeO-DMT[\\CHEMICAL] metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and [GENE]CYP2D6[\\GENE]-catalyzed [CHEMICAL]5-MeO-DMT[\\CHEMICAL] metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.",
        "label": 9,
        "major": 4,
        "len": 36
    },
    {
        "text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed [CHEMICAL]5-MeO-DMT[\\CHEMICAL] metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-[GENE]CYP2D6[\\GENE] mouse models.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "The present study was designed to test the hypothesis that [CHEMICAL]alcohol[\\CHEMICAL] alters global DNA methylation, and modulates expression of the [GENE]DNA methyltransferases[\\GENE] (DNMTs) and various methyl CpG-binding proteins.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "The present study was designed to test the hypothesis that [CHEMICAL]alcohol[\\CHEMICAL] alters global DNA methylation, and modulates expression of the DNA methyltransferases ([GENE]DNMTs[\\GENE]) and various methyl CpG-binding proteins.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "The present study was designed to test the hypothesis that [CHEMICAL]alcohol[\\CHEMICAL] alters global DNA methylation, and modulates expression of the DNA methyltransferases (DNMTs) and various methyl [GENE]CpG-binding proteins[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Alcohol[\\CHEMICAL] modulates expression of [GENE]DNA methyltranferases[\\GENE] and methyl CpG-/CpG domain-binding proteins in murine embryonic fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Alcohol[\\CHEMICAL] modulates expression of DNA methyltranferases and [GENE]methyl CpG-/CpG domain-binding proteins[\\GENE] in murine embryonic fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of [GENE]DNA methyltransferases[\\GENE] (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases ([GENE]DNMT-[\\GENE]1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, [GENE]DNMT-3a[\\GENE], and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and [GENE]DNMT-3b[\\GENE]), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the [GENE]methyl CpG-binding proteins[\\GENE] (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins ([GENE]MeCP-2[\\GENE], MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, [GENE]MBD-2[\\GENE] and MBD-3), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "In addition, [CHEMICAL]ethanol[\\CHEMICAL] induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and [GENE]MBD-3[\\GENE]), in MEF cells by the proteasomal pathway.",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Adenosine[\\CHEMICAL], an enzymatic ATP degradation product, acts at prejunctional [GENE]A1 adenosine receptors[\\GENE] (A1Rs) to inhibit NE release.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "The [GENE]A2A adenosine receptor[\\GENE] agonist CGS21680 ([CHEMICAL]C23H29N7O6.HCl.xH2O[\\CHEMICAL]) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
        "label": 5,
        "major": 10,
        "len": 15
    },
    {
        "text": "Adenosine and N(6)-cyclopentyl-adenosine ([CHEMICAL]CPA[\\CHEMICAL], [GENE]A1R[\\GENE] agonist) constricted MVs but not MAs.",
        "label": 5,
        "major": 5,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Adenosine[\\CHEMICAL] and N(6)-cyclopentyl-adenosine (CPA, [GENE]A1R[\\GENE] agonist) constricted MVs but not MAs.",
        "label": 5,
        "major": 5,
        "len": 11
    },
    {
        "text": "Adenosine and [CHEMICAL]N(6)-cyclopentyl-adenosine[\\CHEMICAL] (CPA, [GENE]A1R[\\GENE] agonist) constricted MVs but not MAs.",
        "label": 5,
        "major": 5,
        "len": 11
    },
    {
        "text": "The [GENE]A2A adenosine receptor[\\GENE] agonist [CHEMICAL]CGS21680[\\CHEMICAL] (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "Nitric oxide products of [CHEMICAL]VP-16[\\CHEMICAL] displayed significantly diminished [GENE]topoisomerase II[\\GENE]-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.",
        "label": 4,
        "major": 9,
        "len": 20
    },
    {
        "text": "The values of mean corpuscular hemoglobin concentration and mean corpuscular [GENE]hemoglobin[\\GENE] increased in the [CHEMICAL]STX[\\CHEMICAL] group.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "The values of mean corpuscular [GENE]hemoglobin[\\GENE] concentration and mean corpuscular hemoglobin increased in the [CHEMICAL]STX[\\CHEMICAL] group.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Inhibition of lysosomes or proteasomes by co-treatment with antofine and their respective specific inhibitors, [CHEMICAL]NH4Cl[\\CHEMICAL] or MG132, partially inhibited the antofine-induced decrease in [GENE]Cx43[\\GENE] protein levels, but did not inhibit the antofine-induced inhibition of GJIC.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "Inhibition of lysosomes or proteasomes by co-treatment with antofine and their respective specific inhibitors, NH4Cl or [CHEMICAL]MG132[\\CHEMICAL], partially inhibited the antofine-induced decrease in [GENE]Cx43[\\GENE] protein levels, but did not inhibit the antofine-induced inhibition of GJIC.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Antofine[\\CHEMICAL]-induced [GENE]connexin43[\\GENE] gap junction disassembly in rat astrocytes involves protein kinase C\u03b2.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Antofine[\\CHEMICAL]-induced connexin43 gap junction disassembly in rat astrocytes involves [GENE]protein kinase C\u03b2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "Taken together, these findings indicate that [CHEMICAL]antofine[\\CHEMICAL] induces [GENE]Cx43[\\GENE] gap junction disassembly by the PKC\u03b2 signaling pathway.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Taken together, these findings indicate that [CHEMICAL]antofine[\\CHEMICAL] induces Cx43 gap junction disassembly by the [GENE]PKC\u03b2[\\GENE] signaling pathway.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator [CHEMICAL]BAPTA-AM[\\CHEMICAL] prevented downregulation of [GENE]Cx43[\\GENE] and inhibition of GJIC.",
        "label": 3,
        "major": 4,
        "len": 19
    },
    {
        "text": "Levels of [GENE]Cx43[\\GENE] protein were also decreased in a dose- and time-dependent manner following [CHEMICAL]antofine[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Co-treatment of astrocytes with [CHEMICAL]antofine[\\CHEMICAL] and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of [GENE]Cx43[\\GENE] and inhibition of GJIC.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Moreover, co-treatment with [CHEMICAL]antofine[\\CHEMICAL] and a specific PKC\u03b2 inhibitor prevented endocytosis of gap junctions, downregulation of [GENE]Cx43[\\GENE], and inhibition of GJIC.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the center of a laminar-flow microfluidic channel, where they are exposed to overlapping, opposed gradients of inducers of the [CHEMICAL]N[\\CHEMICAL]- and C-terminal [GENE]MetRS[\\GENE] fragments.",
        "label": 1,
        "major": 3,
        "len": 38
    },
    {
        "text": "The approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the center of a laminar-flow microfluidic channel, where they are exposed to overlapping, opposed gradients of inducers of the N- and [CHEMICAL]C[\\CHEMICAL]-terminal [GENE]MetRS[\\GENE] fragments.",
        "label": 1,
        "major": 3,
        "len": 38
    },
    {
        "text": "Cellular protein labeling occurs only upon activation of two different promoters that drive expression of the [CHEMICAL]N[\\CHEMICAL]- and C-terminal fragments of the bisected [GENE]MetRS[\\GENE].",
        "label": 1,
        "major": 3,
        "len": 24
    },
    {
        "text": "Cellular protein labeling occurs only upon activation of two different promoters that drive expression of the N- and [CHEMICAL]C[\\CHEMICAL]-terminal fragments of the bisected [GENE]MetRS[\\GENE].",
        "label": 1,
        "major": 3,
        "len": 24
    },
    {
        "text": "The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free [CHEMICAL]fatty acid[\\CHEMICAL] sensitive [GENE]GPCRs[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 37
    },
    {
        "text": "The therapeutic potential of allosteric ligands for free [CHEMICAL]fatty acid[\\CHEMICAL] sensitive [GENE]GPCRs[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 12
    },
    {
        "text": "Our previous work, built on the early pioneering multikinase inhibitor [CHEMICAL]LY294002[\\CHEMICAL], resulted in the only [GENE]PI3K[\\GENE] vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Our previous work, built on the early pioneering multikinase inhibitor [CHEMICAL]LY294002[\\CHEMICAL], resulted in the only PI3K vascular-targeted [GENE]PI3K[\\GENE] inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only [GENE]PI3K[\\GENE] vascular-targeted PI3K inhibitor prodrug, [CHEMICAL]SF1126[\\CHEMICAL], which has now completed Phase I clinical trials.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted [GENE]PI3K[\\GENE] inhibitor prodrug, [CHEMICAL]SF1126[\\CHEMICAL], which has now completed Phase I clinical trials.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "This work resulted in the discovery of the [CHEMICAL]5-morpholino-7H-thieno[3,2-b]pyran-7-one[\\CHEMICAL] system as the foundation of a new compound class of potential [GENE]PI3K[\\GENE] inhibitors having improved potency toward PI3K.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "This work resulted in the discovery of the [CHEMICAL]5-morpholino-7H-thieno[3,2-b]pyran-7-one[\\CHEMICAL] system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward [GENE]PI3K[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Synthesis and cancer stem cell-based activity of substituted [CHEMICAL]5-morpholino-7H-thieno[3,2-b]pyran-7-ones[\\CHEMICAL] designed as next generation [GENE]PI3K[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Spiro heterocycles as potential inhibitors of [GENE]SIRT1[\\GENE]: Pd/C-mediated synthesis of novel [CHEMICAL]N-indolylmethyl spiroindoline-3,2'-quinazolines[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Novel [CHEMICAL]N-indolylmethyl substituted spiroindoline-3,2'-quinazolines[\\CHEMICAL] were designed as potential inhibitiors of [GENE]SIRT1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "A significant decrease in HLA-DR expression was observed in the AP and fractionated [CHEMICAL]procyanidin[\\CHEMICAL]-treated cells in the presence of ovalbumin (OVA), but no effect on [GENE]CD86[\\GENE] expression was observed.",
        "label": 10,
        "major": 4,
        "len": 29
    },
    {
        "text": "A significant decrease in [GENE]HLA-DR[\\GENE] expression was observed in the AP and fractionated [CHEMICAL]procyanidin[\\CHEMICAL]-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In relation to zinc bioavailability, [GENE]\u03b1-CPPs[\\GENE], \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased [CHEMICAL]zinc[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "In relation to zinc bioavailability, \u03b1-CPPs, [GENE]\u03b2-CPPs[\\GENE], \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased [CHEMICAL]zinc[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, [GENE]\u03b1(s1)-CN[\\GENE](64-74)4P and \u03b2-CN(1-25)4P increased [CHEMICAL]zinc[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and [GENE]\u03b2-CN[\\GENE](1-25)4P increased [CHEMICAL]zinc[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "A new inhibitor of [GENE]VEGF receptor tyrosine kinases[\\GENE], [CHEMICAL]vegfrecine[\\CHEMICAL] (1), was isolated from the culture broth of Streptomyces sp.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Vegfrecine[\\CHEMICAL], an Inhibitor of [GENE]VEGF Receptor Tyrosine Kinases[\\GENE] Isolated from the Culture Broth of Streptomyces sp.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Although [GENE]thioredoxin reductase[\\GENE] (TRR) inhibitors ([CHEMICAL]aurothioglucose[\\CHEMICAL] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Although thioredoxin reductase ([GENE]TRR[\\GENE]) inhibitors ([CHEMICAL]aurothioglucose[\\CHEMICAL] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Although [GENE]thioredoxin reductase[\\GENE] (TRR) inhibitors (aurothioglucose and [CHEMICAL]Sb(III)[\\CHEMICAL]) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Although thioredoxin reductase ([GENE]TRR[\\GENE]) inhibitors (aurothioglucose and [CHEMICAL]Sb(III)[\\CHEMICAL]) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect [GENE]methyltransferase[\\GENE] inhibitor periodate-oxidized [CHEMICAL]adenosine[\\CHEMICAL] was without effect.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Although [GENE]glutathione S-transferase omega 1[\\GENE] (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze [CHEMICAL]DMAs(V)[\\CHEMICAL] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "Although glutathione S-transferase omega 1 (GSTO1) and [GENE]arsenic methyltransferase[\\GENE] have been shown or thought to catalyze [CHEMICAL]DMAs(V)[\\CHEMICAL] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.",
        "label": 9,
        "major": 4,
        "len": 31
    },
    {
        "text": "In this study, a novel series of [CHEMICAL]2-hydroxydiarylamide[\\CHEMICAL] derivatives were synthesized and evaluated for inhibiting [GENE]TMPRSS4[\\GENE] serine protease activity and suppressing cancer cell invasion.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In this study, a novel series of [CHEMICAL]2-hydroxydiarylamide[\\CHEMICAL] derivatives were synthesized and evaluated for inhibiting TMPRSS4 [GENE]serine protease[\\GENE] activity and suppressing cancer cell invasion.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Discovery of novel [CHEMICAL]2-hydroxydiarylamide[\\CHEMICAL] derivatives as [GENE]TMPRSS4[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "This effect requires cold-induced, TRPA-1-mediated calcium influx and a [CHEMICAL]calcium[\\CHEMICAL]-sensitive [GENE]PKC[\\GENE] that signals to the transcription factor DAF-16/FOXO.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Chronic consumption of [CHEMICAL]alcohol[\\CHEMICAL] also stimulated abrupt increases in pro-inflammatory cytokines such as [GENE]nuclear factor (NF)-\u03baB[\\GENE], tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Chronic consumption of [CHEMICAL]alcohol[\\CHEMICAL] also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, [GENE]tumor necrosis factor (TNF)-\u03b1[\\GENE] and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Chronic consumption of [CHEMICAL]alcohol[\\CHEMICAL] also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and [GENE]interleukin (IL)-1\u03b2[\\GENE] in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Consumption of [CHEMICAL]alcohol[\\CHEMICAL] for 8weeks induced severe liver damage with increases in prognostic indicators such as [GENE]aspartate transaminase[\\GENE], alanine transaminase in serum whereas co-administration of CNF suppressed their increases.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Consumption of [CHEMICAL]alcohol[\\CHEMICAL] for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, [GENE]alanine transaminase[\\GENE] in serum whereas co-administration of CNF suppressed their increases.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]BPA[\\CHEMICAL] induced sex-specific altered DNA methylation in specific CpG pairs in the [GENE]calsequestrin 2[\\GENE] CpG island.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "[GENE]DNA methyltransferase 3a[\\GENE] expression was increased in all [CHEMICAL]BPA[\\CHEMICAL] males and BPA 0.5 females and reduced in BPA 200 females.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[GENE]DNA methyltransferase 3a[\\GENE] expression was increased in all BPA males and [CHEMICAL]BPA[\\CHEMICAL] 0.5 females and reduced in BPA 200 females.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "[GENE]DNA methyltransferase 3a[\\GENE] expression was increased in all BPA males and BPA 0.5 females and reduced in [CHEMICAL]BPA[\\CHEMICAL] 200 females.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The results suggested that both the [CHEMICAL]EtOAc[\\CHEMICAL] extract and berberine were able to activate [GENE]PPAR\u03b1/\u03b2/\u03b3[\\GENE], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.",
        "label": 5,
        "major": 3,
        "len": 26
    },
    {
        "text": "The results suggested that both the EtOAc extract and [CHEMICAL]berberine[\\CHEMICAL] were able to activate [GENE]PPAR\u03b1/\u03b2/\u03b3[\\GENE], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.",
        "label": 5,
        "major": 3,
        "len": 26
    },
    {
        "text": "The results suggested that both the EtOAc extract and berberine were able to activate [GENE]PPAR\u03b1/\u03b2/\u03b3[\\GENE], and Rhizoma Coptis contains potential natural agonists of PPARs besides [CHEMICAL]berberine[\\CHEMICAL].",
        "label": 5,
        "major": 3,
        "len": 26
    },
    {
        "text": "The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1/\u03b2/\u03b3, and Rhizoma Coptis contains potential natural agonists of [GENE]PPARs[\\GENE] besides [CHEMICAL]berberine[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Overall, although most [CHEMICAL]anthocyanidins[\\CHEMICAL] had no effects on [GENE]AhR[\\GENE]-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "Overall, although most [CHEMICAL]anthocyanidins[\\CHEMICAL] had no effects on AhR-[GENE]CYP1A1[\\GENE] signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",
        "label": 10,
        "major": 4,
        "len": 31
    },
    {
        "text": "Ligand binding analysis demonstrated that [CHEMICAL]pelargonidin[\\CHEMICAL] was a weak ligand of [GENE]AhR[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, [CHEMICAL]pelargonidin[\\CHEMICAL] can bind to and activate the [GENE]AhR[\\GENE] and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, [CHEMICAL]pelargonidin[\\CHEMICAL] can bind to and activate the AhR and [GENE]AhR[\\GENE]-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pelargonidin[\\CHEMICAL] activates the AhR and induces [GENE]CYP1A1[\\GENE] in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM [CHEMICAL]2,3,7,8-tetrachlorodibenzodioxin[\\CHEMICAL] (TCDD), the most potent activator of [GENE]AhR[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin ([CHEMICAL]TCDD[\\CHEMICAL]), the most potent activator of [GENE]AhR[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Pelargonidin[\\CHEMICAL] activates the [GENE]AhR[\\GENE] and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, [CHEMICAL]pelargonidin[\\CHEMICAL] can bind to and activate the [GENE]AhR[\\GENE] and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.",
        "label": 3,
        "major": 2,
        "len": 31
    },
    {
        "text": "Similarly, [CHEMICAL]pelargonidin[\\CHEMICAL] induced the expression of [GENE]CYP1A1[\\GENE] mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Similarly, pelargonidin induced the expression of [GENE]CYP1A1[\\GENE] mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM [CHEMICAL]2,3,7,8-tetrachlorodibenzodioxin[\\CHEMICAL] (TCDD), the most potent activator of AhR.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[GENE]CYP1A1[\\GENE] and CYP1A2 mRNAs were also increased by [CHEMICAL]pelargonidin[\\CHEMICAL] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "CYP1A1 and [GENE]CYP1A2[\\GENE] mRNAs were also increased by [CHEMICAL]pelargonidin[\\CHEMICAL] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "[GENE]AhR[\\GENE]-dependent reporter gene expression in transfected HepG2 cells was increased by [CHEMICAL]pelargonidin[\\CHEMICAL] in a concentration-dependent manner at 24h.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Similarly, pelargonidin induced the expression of [GENE]CYP1A1[\\GENE] mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin ([CHEMICAL]TCDD[\\CHEMICAL]), the most potent activator of AhR.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "CYP1A1 and CYP1A2 mRNAs were also increased by [CHEMICAL]pelargonidin[\\CHEMICAL] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in [GENE]CYP1A1[\\GENE] protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "CYP1A1 and CYP1A2 mRNAs were also increased by [CHEMICAL]pelargonidin[\\CHEMICAL] in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of [GENE]CYP1A1[\\GENE] enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "[GENE]CYP1A1[\\GENE] and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of [CHEMICAL]TCDD[\\CHEMICAL] potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "CYP1A1 and [GENE]CYP1A2[\\GENE] mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of [CHEMICAL]TCDD[\\CHEMICAL] potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of [CHEMICAL]TCDD[\\CHEMICAL] potency) and the increase in [GENE]CYP1A1[\\GENE] protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of [CHEMICAL]TCDD[\\CHEMICAL] potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of [GENE]CYP1A1[\\GENE] enzyme.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "Enzyme kinetic analyses using human liver microsomes revealed inhibition of [GENE]CYP1A1[\\GENE] activity by [CHEMICAL]delphinidin[\\CHEMICAL] (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM).",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Enzyme kinetic analyses using human liver microsomes revealed inhibition of [GENE]CYP1A1[\\GENE] activity by delphinidin (IC50 78 \u03bcM) and [CHEMICAL]pelargonidin[\\CHEMICAL] (IC50 33 \u03bcM).",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and [CHEMICAL]pelargonidin[\\CHEMICAL] and delphinidin inhibit the [GENE]CYP1A1[\\GENE] catalytic activity.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and [CHEMICAL]delphinidin[\\CHEMICAL] inhibit the [GENE]CYP1A1[\\GENE] catalytic activity.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "Endothelial dysfunction induced by [GENE]SIRT1[\\GENE] inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor [CHEMICAL]apocynin[\\CHEMICAL] or superoxide dismutase.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Inhibition of [GENE]SIRT1[\\GENE] significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of [CHEMICAL]resveratrol[\\CHEMICAL] while PPAR\u03b1 inhibition prevented the effects of this [GENE]SIRT1[\\GENE] activator.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "SIRT1 co-precipitated with PPAR\u03b1 and [CHEMICAL]nicotinamide[\\CHEMICAL] increased the acetylation of the PPAR\u03b1 coactivator [GENE]PGC-1\u03b1[\\GENE], which was suppressed by resveratrol.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced [GENE]NADPH oxidase[\\GENE] activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits [GENE]p22(phox)[\\GENE] and NOX4, which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and [GENE]NOX4[\\GENE], which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced [GENE]NADPH oxidase[\\GENE] activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits [GENE]p22(phox)[\\GENE] and NOX4, which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and [GENE]NOX4[\\GENE], which were prevented by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 26
    },
    {
        "text": "To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of [GENE]SIRT1[\\GENE] ([CHEMICAL]nicotinamide[\\CHEMICAL], sirtinol, EX527) in aorta segments isolated from young Wistar rats.",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of [GENE]SIRT1[\\GENE] (nicotinamide, [CHEMICAL]sirtinol[\\CHEMICAL], EX527) in aorta segments isolated from young Wistar rats.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of [GENE]SIRT1[\\GENE] (nicotinamide, sirtinol, [CHEMICAL]EX527[\\CHEMICAL]) in aorta segments isolated from young Wistar rats.",
        "label": 4,
        "major": 9,
        "len": 41
    },
    {
        "text": "Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the [GENE]NADPH oxidase[\\GENE] inhibitor [CHEMICAL]apocynin[\\CHEMICAL] or superoxide dismutase.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator [GENE]PGC-1\u03b1[\\GENE], which was suppressed by [CHEMICAL]resveratrol[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "To determine whether dysregulation of SIRT1 promotes [GENE]NADPH oxidase[\\GENE]-dependent production of reactive [CHEMICAL]oxygen[\\CHEMICAL] species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "Inhibition of [GENE]SIRT1[\\GENE] significantly increased vascular [CHEMICAL]superoxide[\\CHEMICAL] production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "This is described in a case study of the expedited review and approval of [CHEMICAL]peramivir[\\CHEMICAL], a novel [GENE]neuraminidase[\\GENE] inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -[GENE]extracelluar signal-regulated kinase[\\GENE] (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",
        "label": 2,
        "major": 9,
        "len": 38
    },
    {
        "text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase ([GENE]ERK[\\GENE]) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",
        "label": 2,
        "major": 9,
        "len": 38
    },
    {
        "text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced IL-8 production via [GENE]epidermal growth factor receptor[\\GENE] (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",
        "label": 2,
        "major": 9,
        "len": 38
    },
    {
        "text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced IL-8 production via epidermal growth factor receptor ([GENE]EGFR[\\GENE]) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",
        "label": 2,
        "major": 9,
        "len": 38
    },
    {
        "text": "In conclusion, [GENE]IL-8[\\GENE] production and neutrophil infiltration are increased in high-[CHEMICAL]glucose[\\CHEMICAL] environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced [GENE]IL-8[\\GENE] production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.",
        "label": 3,
        "major": 9,
        "len": 38
    },
    {
        "text": "High-[CHEMICAL]glucose[\\CHEMICAL] environment enhanced oxidative stress and increased [GENE]interleukin-8[\\GENE] secretion from keratinocytes: New insights on impaired diabetic wound healing.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5\u00a0mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15\u00a0\u03bcg/kg) for 6 and 24\u00a0h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20\u00a0\u03bcM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24\u00a0h. In vivo, [CHEMICAL]V(5+)[\\CHEMICAL] alone did not significantly alter [GENE]Cyp1a1[\\GENE], Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.",
        "label": 2,
        "major": 10,
        "len": 71
    },
    {
        "text": "For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5\u00a0mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15\u00a0\u03bcg/kg) for 6 and 24\u00a0h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20\u00a0\u03bcM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24\u00a0h. In vivo, [CHEMICAL]V(5+)[\\CHEMICAL] alone did not significantly alter Cyp1a1, [GENE]Cyp1a2[\\GENE], or Cyp1b1 mRNA, protein, or catalytic activity levels.",
        "label": 2,
        "major": 10,
        "len": 71
    },
    {
        "text": "For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5\u00a0mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15\u00a0\u03bcg/kg) for 6 and 24\u00a0h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20\u00a0\u03bcM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24\u00a0h. In vivo, [CHEMICAL]V(5+)[\\CHEMICAL] alone did not significantly alter Cyp1a1, Cyp1a2, or [GENE]Cyp1b1[\\GENE] mRNA, protein, or catalytic activity levels.",
        "label": 2,
        "major": 10,
        "len": 71
    },
    {
        "text": "Modulation of [GENE]cytochrome P450 1[\\GENE] (Cyp1) by [CHEMICAL]vanadium[\\CHEMICAL] in hepatic tissue and isolated hepatocyte of C57BL/6 mice.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "Modulation of cytochrome P450 1 ([GENE]Cyp1[\\GENE]) by [CHEMICAL]vanadium[\\CHEMICAL] in hepatic tissue and isolated hepatocyte of C57BL/6 mice.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "The present study demonstrates that there is a differential modulation of [GENE]Cyp1a1[\\GENE] by [CHEMICAL]V(5+)[\\CHEMICAL] in C57BL/6 mice livers and isolated hepatocytes and demonstrates Hb as an in vivo specific modulator.",
        "label": 2,
        "major": 7,
        "len": 30
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the [GENE]Cyp1a1[\\GENE], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, [GENE]Cyp1a2[\\GENE], and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and [GENE]Cyp1b1[\\GENE] mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to [CHEMICAL]V(5+)[\\CHEMICAL] and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the [GENE]Cyp1a1[\\GENE], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to [CHEMICAL]V(5+)[\\CHEMICAL] and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, [GENE]Cyp1a2[\\GENE], and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to [CHEMICAL]V(5+)[\\CHEMICAL] and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and [GENE]Cyp1b1[\\GENE] mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, [CHEMICAL]V(5+)[\\CHEMICAL] significantly potentiated the TCDD-mediated induction of the [GENE]Cyp1a1[\\GENE], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, [CHEMICAL]V(5+)[\\CHEMICAL] significantly potentiated the TCDD-mediated induction of the Cyp1a1, [GENE]Cyp1a2[\\GENE], and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, [CHEMICAL]V(5+)[\\CHEMICAL] significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and [GENE]Cyp1b1[\\GENE] mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the [CHEMICAL]TCDD[\\CHEMICAL]-mediated induction of the [GENE]Cyp1a1[\\GENE], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the [CHEMICAL]TCDD[\\CHEMICAL]-mediated induction of the Cyp1a1, [GENE]Cyp1a2[\\GENE], and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the [CHEMICAL]TCDD[\\CHEMICAL]-mediated induction of the Cyp1a1, Cyp1a2, and [GENE]Cyp1b1[\\GENE] mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "[CHEMICAL]V(5+)[\\CHEMICAL] also increased [GENE]serum hemoglobin[\\GENE] (Hb) levels in animals treated for 24\u00a0h. Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]V(5+)[\\CHEMICAL] also increased serum hemoglobin ([GENE]Hb[\\GENE]) levels in animals treated for 24\u00a0h. Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the [CHEMICAL]TCDD[\\CHEMICAL]-mediated induction of [GENE]Cyp1a1[\\GENE] mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Furthermore, V(5+) significantly inhibited the [CHEMICAL]TCDD[\\CHEMICAL]-induced [GENE]AhR[\\GENE]-dependent luciferase activity.",
        "label": 3,
        "major": 4,
        "len": 9
    },
    {
        "text": "V(5+) also increased serum hemoglobin (Hb) levels in animals treated for 24\u00a0h. Upon treatment of isolated hepatocytes with Hb alone or in the presence of [CHEMICAL]TCDD[\\CHEMICAL], there was an increase in the [GENE]AhR[\\GENE]-dependent luciferase activity.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the [GENE]Cyp1a1[\\GENE], Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, [GENE]Cyp1a2[\\GENE], and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and [CHEMICAL]TCDD[\\CHEMICAL], V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and [GENE]Cyp1b1[\\GENE] mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h. In vitro, [CHEMICAL]V(5+)[\\CHEMICAL] decreased the TCDD-mediated induction of [GENE]Cyp1a1[\\GENE] mRNA, protein, and catalytic activity levels.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "Furthermore, [CHEMICAL]V(5+)[\\CHEMICAL] significantly inhibited the TCDD-induced [GENE]AhR[\\GENE]-dependent luciferase activity.",
        "label": 4,
        "major": 3,
        "len": 9
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of [GENE]Dickkopfs[\\GENE] (Dkks), inhibitors of canonical Wnt signaling, is not increased by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs ([GENE]Dkks[\\GENE]), inhibitors of canonical Wnt signaling, is not increased by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 100
    },
    {
        "text": "Thus, the [CHEMICAL]TCDD[\\CHEMICAL]-induced reduction in canonical Wnt signaling is associated with a decrease in activators ([GENE]Rspo2[\\GENE] and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Thus, the [CHEMICAL]TCDD[\\CHEMICAL]-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and [GENE]Rspo3[\\GENE]) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Thus, the [CHEMICAL]TCDD[\\CHEMICAL]-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors ([GENE]Dkk1[\\GENE] and Dkk2) of the pathway.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Thus, the [CHEMICAL]TCDD[\\CHEMICAL]-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and [GENE]Dkk2[\\GENE]) of the pathway.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of [GENE]Lgr5[\\GENE], a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a [GENE]RSPO receptor[\\GENE] that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of [GENE]R-spondins[\\GENE] (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins ([GENE]Rspo2[\\GENE] and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and [GENE]Rspo3[\\GENE]) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of [GENE]Lef1[\\GENE], Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, [GENE]Tcf1[\\GENE], and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of [CHEMICAL]TCDD[\\CHEMICAL] on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and [GENE]Wif1[\\GENE], established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] inhibition of canonical [GENE]wnt[\\GENE] signaling disrupts prostatic bud formation in mouse urogenital sinus.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Thus, the [CHEMICAL]TCDD[\\CHEMICAL]-induced reduction in canonical [GENE]Wnt[\\GENE] signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of [CHEMICAL]TCDD[\\CHEMICAL] on canonical [GENE]Wnt[\\GENE] signaling and prostatic bud formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "We discovered that each RSPO alone or in combination partially rescues [CHEMICAL]TCDD[\\CHEMICAL] inhibition of both canonical [GENE]Wnt[\\GENE] signaling and prostatic bud formation.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In support of the hypothesis that [CHEMICAL]TCDD[\\CHEMICAL] decreases canonical [GENE]Wnt[\\GENE] signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.",
        "label": 4,
        "major": 4,
        "len": 100
    },
    {
        "text": "In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of [CHEMICAL]tunicamycin[\\CHEMICAL], higher fold change of [GENE]TCF7L2[\\GENE] and VEGFA mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for TCF7L2; P = 0.004 for VEGFA), suggesting ER stress plays a role in PDR pathogenesis.",
        "label": 2,
        "major": 3,
        "len": 52
    },
    {
        "text": "In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of [CHEMICAL]tunicamycin[\\CHEMICAL], higher fold change of TCF7L2 and [GENE]VEGFA[\\GENE] mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for TCF7L2; P = 0.004 for VEGFA), suggesting ER stress plays a role in PDR pathogenesis.",
        "label": 2,
        "major": 3,
        "len": 52
    },
    {
        "text": "Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and [CHEMICAL]8Br-cAMP[\\CHEMICAL] treatment through two [GENE]SF-1[\\GENE] binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Luciferase reporter assays showed that transcription of [GENE]FDX1[\\GENE] was synergistically activated by the NR5A family and [CHEMICAL]8Br-cAMP[\\CHEMICAL] treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.",
        "label": 3,
        "major": 2,
        "len": 35
    },
    {
        "text": "These results indicate transcription of [GENE]FDX1[\\GENE] is regulated by the NR5A family and [CHEMICAL]cAMP[\\CHEMICAL] signaling, and participates in steroid hormone production in ovarian granulosa cells.",
        "label": 3,
        "major": 9,
        "len": 25
    },
    {
        "text": "These results indicate transcription of [GENE]FDX1[\\GENE] is regulated by the NR5A family and cAMP signaling, and participates in [CHEMICAL]steroid[\\CHEMICAL] hormone production in ovarian granulosa cells.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "Furthermore, [CHEMICAL]sinapic acid[\\CHEMICAL] reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of type I collagen mRNA and histological analysis of [GENE]collagen[\\GENE] in liver tissue.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Furthermore, [CHEMICAL]sinapic acid[\\CHEMICAL] reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of [GENE]type I collagen[\\GENE] mRNA and histological analysis of collagen in liver tissue.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Additionally, the expression of hepatic fibrosis-related factors such as [GENE]\u03b1-smooth muscle actin[\\GENE] and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with [CHEMICAL]sinapic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and [GENE]transforming growth factor-\u03b21[\\GENE] (TGF-\u03b21), were reduced in rats treated with [CHEMICAL]sinapic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 ([GENE]TGF-\u03b21[\\GENE]), were reduced in rats treated with [CHEMICAL]sinapic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In conclusion, we find that [CHEMICAL]sinapic acid[\\CHEMICAL] exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress [GENE]TGF-\u03b21[\\GENE] and its ability to attenuate activation of hepatic stellate cells.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Genistin[\\CHEMICAL] decreased [GENE]myosin light chain kinase[\\GENE] (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Genistin[\\CHEMICAL] decreased myosin light chain kinase ([GENE]MLCK[\\GENE]) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Genistin[\\CHEMICAL] decreased myosin light chain kinase (MLCK) protein contents and [GENE]MLCK[\\GENE] mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of [GENE]MLCK[\\GENE] contents and inhibition of MLCK activity are involved in the [CHEMICAL]genistin[\\CHEMICAL]-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Genistin[\\CHEMICAL] decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-[GENE]ATPase[\\GENE] activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of [GENE]MLCK[\\GENE] activity are involved in the [CHEMICAL]genistin[\\CHEMICAL]-induced inhibitory effects.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "We conclude that [GENE]mPGES1[\\GENE] mediates acid-induced increase in [CHEMICAL]PGE2[\\CHEMICAL] production and cell proliferation.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "We have shown that [GENE]COX-2[\\GENE] mediates acid-induced [CHEMICAL]PGE2[\\CHEMICAL] production.",
        "label": 9,
        "major": 9,
        "len": 9
    },
    {
        "text": "(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole ([CHEMICAL]GSK2251052[\\CHEMICAL]) is a novel boron-containing antibiotic that inhibits [GENE]bacterial leucyl tRNA synthetase[\\GENE], and that has been in development for the treatment of serious Gram-negative infections.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL](S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole[\\CHEMICAL] (GSK2251052) is a novel boron-containing antibiotic that inhibits [GENE]bacterial leucyl tRNA synthetase[\\GENE], and that has been in development for the treatment of serious Gram-negative infections.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor [CHEMICAL]4-methylpyrazole[\\CHEMICAL] provided strong evidence that [GENE]alcohol dehydrogenase[\\GENE], potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The treatment of mice with [CHEMICAL]Fe-NTA[\\CHEMICAL] alone enhances [GENE]ornithine decarboxylase[\\GENE] activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.",
        "label": 3,
        "major": 4,
        "len": 51
    },
    {
        "text": "In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and [CHEMICAL]EETs[\\CHEMICAL] markedly suppressed Ang II-induced inflammatory [GENE]cytokine[\\GENE] expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Moreover, overexpressed CYP2J2 and [CHEMICAL]EETs[\\CHEMICAL] inhibited [GENE]Ang II[\\GENE]-induced macrophage migration in a VSMC-macrophage coculture system.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and [CHEMICAL]EETs[\\CHEMICAL] markedly suppressed [GENE]Ang II[\\GENE]-induced inflammatory cytokine expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "However, whether increasing [CHEMICAL]EETs[\\CHEMICAL] production by [GENE]CYP2J2[\\GENE] overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.",
        "label": 9,
        "major": 3,
        "len": 18
    },
    {
        "text": "[GENE]Regucalcin[\\GENE] (RGN/SMP30) was originally discovered in 1978 as a unique [CHEMICAL]calcium[\\CHEMICAL]-binding protein that does not contain the EF-hand motif of calcium-binding domain.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "Regucalcin ([GENE]RGN[\\GENE]/SMP30) was originally discovered in 1978 as a unique [CHEMICAL]calcium[\\CHEMICAL]-binding protein that does not contain the EF-hand motif of calcium-binding domain.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "Regucalcin (RGN/[GENE]SMP30[\\GENE]) was originally discovered in 1978 as a unique [CHEMICAL]calcium[\\CHEMICAL]-binding protein that does not contain the EF-hand motif of calcium-binding domain.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "The expression of [GENE]regucalcin[\\GENE] is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by [CHEMICAL]streptozotocin[\\CHEMICAL] administration in vivo.",
        "label": 4,
        "major": 3,
        "len": 38
    },
    {
        "text": "Previously, we have found that [CHEMICAL]BRN-103[\\CHEMICAL], a nicotinamide derivative, inhibits vascular endothelial growth factor ([GENE]VEGF[\\GENE])-mediated angiogenesis signaling in human endothelial cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Previously, we have found that [CHEMICAL]BRN-103[\\CHEMICAL], a nicotinamide derivative, inhibits [GENE]vascular endothelial growth factor[\\GENE] (VEGF)-mediated angiogenesis signaling in human endothelial cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Previously, we have found that BRN-103, a [CHEMICAL]nicotinamide[\\CHEMICAL] derivative, inhibits vascular endothelial growth factor ([GENE]VEGF[\\GENE])-mediated angiogenesis signaling in human endothelial cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Previously, we have found that BRN-103, a [CHEMICAL]nicotinamide[\\CHEMICAL] derivative, inhibits [GENE]vascular endothelial growth factor[\\GENE] (VEGF)-mediated angiogenesis signaling in human endothelial cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Furthermore, [CHEMICAL]BRN-250[\\CHEMICAL] inhibited the [GENE]VEGF[\\GENE]-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]BRN-250[\\CHEMICAL] inhibited the VEGF-induced phosphorylation and intracellular [GENE]tyrosine kinase[\\GENE] activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]BRN-250[\\CHEMICAL] inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of [GENE]VEGF receptor 2[\\GENE] (VEGFR2) and the activation of its downstream AKT pathway.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]BRN-250[\\CHEMICAL] inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 ([GENE]VEGFR2[\\GENE]) and the activation of its downstream AKT pathway.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]BRN-250[\\CHEMICAL] inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream [GENE]AKT[\\GENE] pathway.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Inhibition of angiogenesis and invasion by [CHEMICAL]DMBT[\\CHEMICAL] is mediated by downregulation of [GENE]VEGF[\\GENE] and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of angiogenesis and invasion by [CHEMICAL]DMBT[\\CHEMICAL] is mediated by downregulation of VEGF and [GENE]MMP-9[\\GENE] through Akt pathway in MDA-MB-231 breast cancer cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These results suggested that [CHEMICAL]DMBT[\\CHEMICAL] could inhibit invasion and angiogenesis by downregulation of [GENE]VEGF[\\GENE]and MMP-9, resulting from the inhibition of Akt pathway.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These results suggested that [CHEMICAL]DMBT[\\CHEMICAL] could inhibit invasion and angiogenesis by downregulation of VEGFand [GENE]MMP-9[\\GENE], resulting from the inhibition of Akt pathway.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Gelatin zymography showed that [CHEMICAL]DMBT[\\CHEMICAL] inhibited secretion and activity of [GENE]MMP-9[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Inhibition of angiogenesis and invasion by [CHEMICAL]DMBT[\\CHEMICAL] is mediated by downregulation of VEGF and MMP-9 through [GENE]Akt[\\GENE] pathway in MDA-MB-231 breast cancer cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These results suggested that [CHEMICAL]DMBT[\\CHEMICAL] could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of [GENE]Akt[\\GENE] pathway.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]AOH[\\CHEMICAL] treatment also induced abnormal [GENE]Aurora B[\\GENE] bridges, suggesting that cytokinesis was interfered within cells undergoing karyokinesis.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "We show that [CHEMICAL]CIQ[\\CHEMICAL] does not bind to the amino-terminal domain of the [GENE]NMDA receptor[\\GENE] and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or ion channel pore.",
        "label": 10,
        "major": 7,
        "len": 34
    },
    {
        "text": "We show that [CHEMICAL]CIQ[\\CHEMICAL] does not bind to the amino-terminal domain of the NMDA receptor and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or [GENE]ion channel[\\GENE] pore.",
        "label": 10,
        "major": 2,
        "len": 34
    },
    {
        "text": "We show that CIQ does not bind to the [CHEMICAL]amino[\\CHEMICAL]-terminal domain of the [GENE]NMDA receptor[\\GENE] and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or ion channel pore.",
        "label": 1,
        "major": 2,
        "len": 34
    },
    {
        "text": "The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of [CHEMICAL]baicalin[\\CHEMICAL] had no obvious effect on the activity of [GENE]CYP2D[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 39
    },
    {
        "text": "Concentration-dependent inhibitory effects of [CHEMICAL]baicalin[\\CHEMICAL] on the metabolism of dextromethorphan, a dual probe of [GENE]CYP2D[\\GENE] and CYP3A, in rats.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Concentration-dependent inhibitory effects of [CHEMICAL]baicalin[\\CHEMICAL] on the metabolism of dextromethorphan, a dual probe of CYP2D and [GENE]CYP3A[\\GENE], in rats.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The activity of [GENE]CYP3A[\\GENE] in excised liver samples from rats following multiple [CHEMICAL]baicalin[\\CHEMICAL] treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Taken together, these data demonstrate that [CHEMICAL]baicalin[\\CHEMICAL] inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic [GENE]CYP2D[\\GENE] and CYP3A activities.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Taken together, these data demonstrate that [CHEMICAL]baicalin[\\CHEMICAL] inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and [GENE]CYP3A[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of [CHEMICAL]baicalin[\\CHEMICAL] on the metabolism of dextromethorphan (DXM), a dual probe substrate of [GENE]CYP2D[\\GENE] and CYP3A, in rats.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of [CHEMICAL]baicalin[\\CHEMICAL] on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and [GENE]CYP3A[\\GENE], in rats.",
        "label": 4,
        "major": 9,
        "len": 27
    },
    {
        "text": "Lineweaver-Burk plots demonstrated that [CHEMICAL]baicalin[\\CHEMICAL] inhibited the activities of [GENE]CYP2D[\\GENE] and CYP3A in a non-competitive manner in rat liver microsomes (RLMs).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Lineweaver-Burk plots demonstrated that [CHEMICAL]baicalin[\\CHEMICAL] inhibited the activities of CYP2D and [GENE]CYP3A[\\GENE] in a non-competitive manner in rat liver microsomes (RLMs).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of [CHEMICAL]dextromethorphan[\\CHEMICAL], a dual probe of [GENE]CYP2D[\\GENE] and CYP3A, in rats.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of [CHEMICAL]dextromethorphan[\\CHEMICAL], a dual probe of CYP2D and [GENE]CYP3A[\\GENE], in rats.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of [CHEMICAL]DXM[\\CHEMICAL] in a concentration-dependent manner in rats, possibly through inhibiting hepatic [GENE]CYP2D[\\GENE] and CYP3A activities.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of [CHEMICAL]DXM[\\CHEMICAL] in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and [GENE]CYP3A[\\GENE] activities.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of [CHEMICAL]dextromethorphan[\\CHEMICAL] (DXM), a dual probe substrate of [GENE]CYP2D[\\GENE] and CYP3A, in rats.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of [CHEMICAL]dextromethorphan[\\CHEMICAL] (DXM), a dual probe substrate of CYP2D and [GENE]CYP3A[\\GENE], in rats.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ([CHEMICAL]DXM[\\CHEMICAL]), a dual probe substrate of [GENE]CYP2D[\\GENE] and CYP3A, in rats.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ([CHEMICAL]DXM[\\CHEMICAL]), a dual probe substrate of CYP2D and [GENE]CYP3A[\\GENE], in rats.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "The neurotrophic factors [GENE]pleiotrophin[\\GENE] (PTN) and midkine (MK) have been shown to modulate [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "The neurotrophic factors pleiotrophin ([GENE]PTN[\\GENE]) and midkine (MK) have been shown to modulate [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "The neurotrophic factors pleiotrophin (PTN) and [GENE]midkine[\\GENE] (MK) have been shown to modulate [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "The neurotrophic factors pleiotrophin (PTN) and midkine ([GENE]MK[\\GENE]) have been shown to modulate [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "We identified 13 differentially expressed phosphoproteins that are judged to be relevant in the neuroprotective roles of [GENE]PTN[\\GENE] and MK against [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "We identified 13 differentially expressed phosphoproteins that are judged to be relevant in the neuroprotective roles of PTN and [GENE]MK[\\GENE] against [CHEMICAL]amphetamine[\\CHEMICAL]-induced neurotoxicity.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "The structure-activity relationship of a series of [CHEMICAL]dihydroisoquinoline[\\CHEMICAL] [GENE]BACE-1[\\GENE] inhibitors is described.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Structure-based design of novel [CHEMICAL]dihydroisoquinoline[\\CHEMICAL] [GENE]BACE-1[\\GENE] inhibitors that do not engage the catalytic aspartates.",
        "label": 4,
        "major": 10,
        "len": 14
    },
    {
        "text": "The modification of the inhibitor scaffold of 1 and 2 from a [CHEMICAL]dihydroquinolinone[\\CHEMICAL] core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent [GENE]KAT II[\\GENE] inhibitors with excellent physicochemical properties.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a [CHEMICAL]tetrahydropyrazolopyridinone[\\CHEMICAL] core led to discovery of a new series of potent [GENE]KAT II[\\GENE] inhibitors with excellent physicochemical properties.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "The structure-based design, synthesis, and biological evaluation of a new [CHEMICAL]pyrazole[\\CHEMICAL] series of irreversible [GENE]KAT II[\\GENE] inhibitors are described herein.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]PF-04859989[\\CHEMICAL] as a template for structure-based drug design: identification of new pyrazole series of irreversible [GENE]KAT II[\\GENE] inhibitors with improved lipophilic efficiency.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "PF-04859989 as a template for structure-based drug design: identification of new [CHEMICAL]pyrazole[\\CHEMICAL] series of irreversible [GENE]KAT II[\\GENE] inhibitors with improved lipophilic efficiency.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Structure-activity relationship studies indicated that [CHEMICAL]5-(p-toluenesulfonylamino)phthalimide[\\CHEMICAL] moiety is a favorable scaffold to exert the [GENE]\u03b1-glucosidase[\\GENE] inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Several members of a new family of non-sugar-type [GENE]\u03b1-glycosidase[\\GENE] inhibitors, bearing a [CHEMICAL]5-(p-toluenesulfonylamino)phthalimide[\\CHEMICAL] moiety and various substituent at the N2 position, were synthesized and their activities were investigated.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "A new series of [CHEMICAL]N2-substituted-5-(p-toluenesulfonylamino)phthalimide[\\CHEMICAL] analogues as [GENE]\u03b1-glucosidase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "In vivo [GENE]HIF[\\GENE]-mediated reductive carboxylation is regulated by [CHEMICAL]citrate[\\CHEMICAL] levels and sensitizes VHL-deficient cells to glutamine deprivation.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Taken together, we conclude that the [CHEMICAL]thiourea[\\CHEMICAL] series of compounds share a similar cellular mechanism that includes interaction with [GENE]LolA[\\GENE] in addition to the well-characterized target MreB.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Taken together, we conclude that the [CHEMICAL]thiourea[\\CHEMICAL] series of compounds share a similar cellular mechanism that includes interaction with LolA in addition to the well-characterized target [GENE]MreB[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "We provide STD NMR data which confirms a physical interaction between [GENE]LolA[\\GENE] and the [CHEMICAL]thiourea[\\CHEMICAL] degradation product of MAC13243, with a Kd of ~150 \u03bcM.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "We provide STD NMR data which confirms a physical interaction between [GENE]LolA[\\GENE] and the thiourea degradation product of [CHEMICAL]MAC13243[\\CHEMICAL], with a Kd of ~150 \u03bcM.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Degradation of MAC13243 and studies of the interaction of resulting [CHEMICAL]thiourea[\\CHEMICAL] compounds with the lipoprotein targeting [GENE]chaperone[\\GENE] LolA.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Degradation of MAC13243 and studies of the interaction of resulting [CHEMICAL]thiourea[\\CHEMICAL] compounds with the lipoprotein targeting chaperone [GENE]LolA[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Degradation of MAC13243 and studies of the interaction of resulting [CHEMICAL]thiourea[\\CHEMICAL] compounds with the [GENE]lipoprotein[\\GENE] targeting chaperone LolA.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "We previously employed a chemical genomic strategy to identify a novel small molecule, [CHEMICAL]MAC13243[\\CHEMICAL], as a likely inhibitor of the [GENE]bacterial lipoprotein[\\GENE] targeting chaperone, LolA.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We previously employed a chemical genomic strategy to identify a novel small molecule, [CHEMICAL]MAC13243[\\CHEMICAL], as a likely inhibitor of the bacterial lipoprotein targeting [GENE]chaperone[\\GENE], LolA.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We previously employed a chemical genomic strategy to identify a novel small molecule, [CHEMICAL]MAC13243[\\CHEMICAL], as a likely inhibitor of the bacterial lipoprotein targeting chaperone, [GENE]LolA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with [CHEMICAL]7KC[\\CHEMICAL] or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of [GENE]Akt[\\GENE] and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with [CHEMICAL]7KC[\\CHEMICAL] or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and [GENE]GSK3[\\GENE], mitochondrial depolarization involving Mcl-1, and caspase-3 activation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with 7KC or [CHEMICAL]7\u03b2OHC[\\CHEMICAL] inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of [GENE]Akt[\\GENE] and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with 7KC or [CHEMICAL]7\u03b2OHC[\\CHEMICAL] inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and [GENE]GSK3[\\GENE], mitochondrial depolarization involving Mcl-1, and caspase-3 activation.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Thus, in 158N cells, the ability of [CHEMICAL]oxysterols[\\CHEMICAL] to trigger a mode of cell death by apoptosis involving [GENE]GSK-3[\\GENE] and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Thus, in 158N cells, the ability of [CHEMICAL]oxysterols[\\CHEMICAL] to trigger a mode of cell death by apoptosis involving GSK-3 and [GENE]caspase-3[\\GENE] activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with [CHEMICAL]7KC[\\CHEMICAL] or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [GENE]Mcl-1[\\GENE], and caspase-3 activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with [CHEMICAL]7KC[\\CHEMICAL] or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and [GENE]caspase-3[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with 7KC or [CHEMICAL]7\u03b2OHC[\\CHEMICAL] inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving [GENE]Mcl-1[\\GENE], and caspase-3 activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "To this end, 158N murine oligodendrocytes were treated with 7KC or [CHEMICAL]7\u03b2OHC[\\CHEMICAL] inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and [GENE]caspase-3[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Lastly, the results add to the growing literature on [GENE]H3R[\\GENE] modulation in the pharmacotherapy of [CHEMICAL]EtOH[\\CHEMICAL] addiction.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "This inhibition was blocked when mice were pretreated with the selective [GENE]H3R[\\GENE] agonist [CHEMICAL]R-(alpha)-methyl-histamine[\\CHEMICAL] (10\u00a0mg/kg).",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "However, Rac1 activation was not affected by Jak2 or Stat3 RNA interference, suggesting that the effect of [CHEMICAL]cucurbitacin I[\\CHEMICAL] occurs through a [GENE]Jak2[\\GENE]-independent mechanism.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Cucurbitacin I[\\CHEMICAL] also failed to affect the activation of [GENE]P-Rex1[\\GENE] by heregulin.",
        "label": 10,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Cucurbitacin I[\\CHEMICAL] also failed to affect the activation of P-Rex1 by [GENE]heregulin[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Cucurbitacin I[\\CHEMICAL] inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of [GENE]janus tyrosine kinase 2[\\GENE] and p-rex1.",
        "label": 10,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Cucurbitacin I[\\CHEMICAL] inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and [GENE]p-rex1[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "Subsequent analysis revealed that [CHEMICAL]cucurbitacin I[\\CHEMICAL] strongly activates [GENE]RhoA[\\GENE] and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Subsequent analysis revealed that [CHEMICAL]cucurbitacin I[\\CHEMICAL] strongly activates RhoA and the [GENE]Rho[\\GENE] effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Subsequent analysis revealed that [CHEMICAL]cucurbitacin I[\\CHEMICAL] strongly activates RhoA and the Rho effector [GENE]Rho kinase[\\GENE] (ROCK) in breast cancer cells and induces the formation of stress fibers.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Subsequent analysis revealed that [CHEMICAL]cucurbitacin I[\\CHEMICAL] strongly activates RhoA and the Rho effector Rho kinase ([GENE]ROCK[\\GENE]) in breast cancer cells and induces the formation of stress fibers.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Lastly, we found that [GENE]RhoA[\\GENE] activation by [CHEMICAL]cucurbitacin I[\\CHEMICAL] is mediated by reactive oxygen species (ROS).",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "The ROS scavenger [CHEMICAL]N-acetyl l-cysteine[\\CHEMICAL] and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on [GENE]Rac1[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Cucurbitacin I[\\CHEMICAL] inhibits [GENE]rac1[\\GENE] activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of [CHEMICAL]cucurbitacin I[\\CHEMICAL] on [GENE]Rac1[\\GENE] activation by heregulin.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of [CHEMICAL]cucurbitacin I[\\CHEMICAL] on [GENE]Rac1[\\GENE] activation.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Moreover, they established that the inhibitory effect of [CHEMICAL]cucurbitacin I[\\CHEMICAL] on [GENE]Rac1[\\GENE] activity involves the alteration of the balance between Rho and Rac.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Here we found that the anticancer agent [CHEMICAL]cucurbitacin I[\\CHEMICAL], a [GENE]Jak2[\\GENE] inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Here we found that the anticancer agent [CHEMICAL]cucurbitacin I[\\CHEMICAL], a Jak2 inhibitor, reduced the activation of [GENE]Rac1[\\GENE] and motility in response to the ErbB3 ligand heregulin in breast cancer cells.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The major ingredient of ginger, [CHEMICAL][6]-gingerol[\\CHEMICAL], could inhibit [GENE]angiotensin II type 1 receptor[\\GENE] activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL][6]-Gingerol[\\CHEMICAL] derived from Zingiber officinale Roscoe (ginger) was identified as a novel [GENE]angiotensin II type 1 receptor[\\GENE] antagonist, with an IC50 value of 8.173 \u00b5M.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "[CHEMICAL][6]-gingerol[\\CHEMICAL]: a novel [GENE]AT\u2081[\\GENE] antagonist for the treatment of cardiovascular disease.",
        "label": 6,
        "major": 6,
        "len": 11
    },
    {
        "text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and [GENE]PTP1B[\\GENE] phosphorylation at serine (Ser) 50, Ser 398 and [CHEMICAL]tyrosine[\\CHEMICAL] 152.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and [GENE]PTP1B[\\GENE] phosphorylation at [CHEMICAL]serine[\\CHEMICAL] (Ser) 50, Ser 398 and tyrosine 152.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and [GENE]PTP1B[\\GENE] phosphorylation at serine ([CHEMICAL]Ser[\\CHEMICAL]) 50, Ser 398 and tyrosine 152.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and [GENE]PTP1B[\\GENE] phosphorylation at serine (Ser) 50, [CHEMICAL]Ser[\\CHEMICAL] 398 and tyrosine 152.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and [GENE]PTP1B[\\GENE] phosphorylation at [CHEMICAL]Ser[\\CHEMICAL] 50 impaired.",
        "label": 1,
        "major": 3,
        "len": 19
    },
    {
        "text": "Only FFAs that increased ceramides caused impairment of AKt and [GENE]PTP1B[\\GENE] phosphorylation at [CHEMICAL]Ser[\\CHEMICAL] 50.",
        "label": 1,
        "major": 3,
        "len": 15
    },
    {
        "text": "Saturated [CHEMICAL]palmitic and stearic acids[\\CHEMICAL] increased ceramides, up-regulated PTP1B, and had AKt and [GENE]PTP1B[\\GENE] phosphorylation at Ser 50 impaired.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Saturated [CHEMICAL]palmitic and stearic acids[\\CHEMICAL] increased ceramides, up-regulated PTP1B, and had [GENE]AKt[\\GENE] and PTP1B phosphorylation at Ser 50 impaired.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Saturated [CHEMICAL]palmitic and stearic acids[\\CHEMICAL] increased ceramides, up-regulated [GENE]PTP1B[\\GENE], and had AKt and PTP1B phosphorylation at Ser 50 impaired.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Cells were also evaluated in the presence of [CHEMICAL]wortmannin[\\CHEMICAL], an inhibitor of phosphatidylinositol 3-kinases and thus [GENE]AKt[\\GENE] (0-100 nM).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Only FFAs that increased [CHEMICAL]ceramides[\\CHEMICAL] caused impairment of [GENE]AKt[\\GENE] and PTP1B phosphorylation at Ser 50.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Cells were also evaluated in the presence of [CHEMICAL]wortmannin[\\CHEMICAL], an inhibitor of [GENE]phosphatidylinositol 3-kinases[\\GENE] and thus AKt (0-100 nM).",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Only FFAs that increased [CHEMICAL]ceramides[\\CHEMICAL] caused impairment of AKt and [GENE]PTP1B[\\GENE] phosphorylation at Ser 50.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly [CHEMICAL]telmisartan[\\CHEMICAL], are partial agonists at [GENE]peroxisome proliferator-activated receptor-\u03b3[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 21
    },
    {
        "text": "Although generally highly specific for [GENE]angiotensin II type 1 receptors[\\GENE], some ARBs, particularly [CHEMICAL]telmisartan[\\CHEMICAL], are partial agonists at peroxisome proliferator-activated receptor-\u03b3.",
        "label": 6,
        "major": 5,
        "len": 21
    },
    {
        "text": "A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma [CHEMICAL]glucose[\\CHEMICAL] improved with [GENE]insulin[\\GENE] detemir without an increased incidence of hypoglycaemia.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "In this study, we employed virtual screening and chemical synthesis to identify a series of [CHEMICAL]N-(thiophen-2-yl) benzamide[\\CHEMICAL] derivatives as potent [GENE]BRAF[\\GENE](V600E) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In this study, we employed virtual screening and chemical synthesis to identify a series of [CHEMICAL]N-(thiophen-2-yl) benzamide[\\CHEMICAL] derivatives as potent BRAF([GENE]V600E[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Identification and synthesis of [CHEMICAL]N-(thiophen-2-yl) benzamide[\\CHEMICAL] derivatives as [GENE]BRAF[\\GENE](V600E) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Identification and synthesis of [CHEMICAL]N-(thiophen-2-yl) benzamide[\\CHEMICAL] derivatives as BRAF([GENE]V600E[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Chromatin immunoprecipitation (IP) revealed that methyl-CpG binding protein 2 (Mecp2) bound the [GENE]glut3[\\GENE]-[CHEMICAL](m)CpGs[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "Sequential chromatin IP uncovered the [GENE]glut3[\\GENE]-[CHEMICAL](m)CpGs[\\CHEMICAL] to bind Mecp2 exponentially upon recruitment of Creb1 rather than histone deacetylase 1.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Recruitment of Creb1-Mecp2 by [GENE]glut3[\\GENE]-[CHEMICAL](m)CpG[\\CHEMICAL] contributes towards transactivation, formulating an escape from (m)CpG-induced gene suppression, and thereby promoting developmental neuronal glut3 gene transcription and expression.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this [CHEMICAL]CpG[\\CHEMICAL] ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in [GENE]DNA methyl transferase 3a[\\GENE] concentrations noted with advancing postnatal age (PN14 vs PN3).",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ([CHEMICAL](m)CpG[\\CHEMICAL]) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in [GENE]DNA methyl transferase 3a[\\GENE] concentrations noted with advancing postnatal age (PN14 vs PN3).",
        "label": 3,
        "major": 10,
        "len": 39
    },
    {
        "text": "5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that [CHEMICAL](m)CpGs[\\CHEMICAL] inhibit [GENE]glut3[\\GENE] transcription.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Separate [CHEMICAL]5-aza-2'-deoxycytidine[\\CHEMICAL] pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting [GENE]Mecp2[\\GENE] and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Separate [CHEMICAL]5-aza-2'-deoxycytidine[\\CHEMICAL] pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and [GENE]Creb1[\\GENE] separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with [CHEMICAL]trichostatin A[\\CHEMICAL] reduced (m)CpG and specific small interference RNAs targeting [GENE]Mecp2[\\GENE] and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with [CHEMICAL]trichostatin A[\\CHEMICAL] reduced (m)CpG and specific small interference RNAs targeting Mecp2 and [GENE]Creb1[\\GENE] separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. [CHEMICAL]ezetimibe[\\CHEMICAL], bile acid sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. ezetimibe, [CHEMICAL]bile acid[\\CHEMICAL] sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or [CHEMICAL]fibrates[\\CHEMICAL]) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "The parent [CHEMICAL]phenol[\\CHEMICAL] of this compound inhibits [GENE]aromatase[\\GENE] with an IC50 value of 0.028\u2005nM in the same assay.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ([CHEMICAL]F[\\CHEMICAL], Cl, Br) derivatives are first-generation dual [GENE]aromatase[\\GENE] and sulfatase inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ([CHEMICAL]F[\\CHEMICAL], Cl, Br) derivatives are first-generation dual aromatase and [GENE]sulfatase[\\GENE] inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual [GENE]Aromatase[\\GENE]-Sulfatase Inhibitor [CHEMICAL]4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-[GENE]Sulfatase[\\GENE] Inhibitor [CHEMICAL]4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate[\\CHEMICAL] and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual [GENE]aromatase[\\GENE] and sulfatase inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate[\\CHEMICAL] and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and [GENE]sulfatase[\\GENE] inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, [CHEMICAL]Cl[\\CHEMICAL], Br) derivatives are first-generation dual [GENE]aromatase[\\GENE] and sulfatase inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, [CHEMICAL]Cl[\\CHEMICAL], Br) derivatives are first-generation dual aromatase and [GENE]sulfatase[\\GENE] inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, [CHEMICAL]Br[\\CHEMICAL]) derivatives are first-generation dual [GENE]aromatase[\\GENE] and sulfatase inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, [CHEMICAL]Br[\\CHEMICAL]) derivatives are first-generation dual aromatase and [GENE]sulfatase[\\GENE] inhibitors (DASIs).",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "A series of [CHEMICAL]pyrido-quinazolines[\\CHEMICAL] have been synthesised, characterised and tested for their in vitro [GENE]EGFR[\\GENE] tyrosine kinase inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "A series of [CHEMICAL]pyrido-quinazolines[\\CHEMICAL] have been synthesised, characterised and tested for their in vitro EGFR [GENE]tyrosine kinase[\\GENE] inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Synthesis and in vitro evaluation of [CHEMICAL]N-Aryl pyrido-quinazolines[\\CHEMICAL] derivatives as potent [GENE]EGFR[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the [GENE]matrix metalloproteinases[\\GENE]-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the [GENE]tissue inhibitors of matrix metalloproteinases[\\GENE] (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases ([GENE]MMP[\\GENE]-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-[GENE]TIM[\\GENE]P) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [GENE]lactic dehydrogenase[\\GENE] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase ([GENE]LDH[\\GENE]), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), [GENE]superoxide dismutase[\\GENE] (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase ([GENE]SOD[\\GENE]), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and [GENE]catalase[\\GENE] (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, kinsenoside (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ([GENE]CAT[\\GENE])) in human umbilical vein endothelial cells (HUVECs) damaged by high [CHEMICAL]glucose[\\CHEMICAL] (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 2,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), [GENE]lactic dehydrogenase[\\GENE] (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase ([GENE]LDH[\\GENE]), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), [GENE]superoxide dismutase[\\GENE] (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase ([GENE]SOD[\\GENE]), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and [GENE]catalase[\\GENE] (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "In the in vitro assay, [CHEMICAL]kinsenoside[\\CHEMICAL] (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ([GENE]CAT[\\GENE])) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.",
        "label": 4,
        "major": 4,
        "len": 57
    },
    {
        "text": "The vascular protective effects of [CHEMICAL]kinsenoside[\\CHEMICAL] were speculated to be attributed to oxidative stress inhibition and the reduction of [GENE]nuclear factor kappa B[\\GENE] (NF-\u03baB) mRNA expression levels in high glucose conditions.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The vascular protective effects of [CHEMICAL]kinsenoside[\\CHEMICAL] were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B ([GENE]NF-\u03baB[\\GENE]) mRNA expression levels in high glucose conditions.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Cholesterol uptake from [GENE]lipoproteins[\\GENE], intracellular vesicle transport and lipid transfer are also modified by [CHEMICAL]oxysterols[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Cholesterol[\\CHEMICAL] uptake from [GENE]lipoproteins[\\GENE], intracellular vesicle transport and lipid transfer are also modified by oxysterols.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Activation of [GENE]ALDH2[\\GENE] with [CHEMICAL]ethanol[\\CHEMICAL] attenuates diabetes induced myocardial injury in rats.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with [GENE]ALDH2[\\GENE] activator [CHEMICAL]ethanol[\\CHEMICAL] (EtOH).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with [GENE]ALDH2[\\GENE] activator ethanol ([CHEMICAL]EtOH[\\CHEMICAL]).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Compared with DM8W group, [GENE]SOD[\\GENE] and ALDH2 in [CHEMICAL]EtOH[\\CHEMICAL]+DM8W group was increased, MDA was decreased.",
        "label": 3,
        "major": 4,
        "len": 15
    },
    {
        "text": "Compared with DM8W group, SOD and [GENE]ALDH2[\\GENE] in [CHEMICAL]EtOH[\\CHEMICAL]+DM8W group was increased, MDA was decreased.",
        "label": 3,
        "major": 4,
        "len": 15
    },
    {
        "text": "Correlations between matrices made it possible to conclude that EROD activity in PBL should be considered as a sensitive, convenient and non-destructive approach for (i) evaluating EROD activity in liver, which was found to represent 98% of the observed EROD activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race, diet) to [GENE]CYP[\\GENE] inducing PAH and [CHEMICAL]PHH[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 65
    },
    {
        "text": "[GENE]EROD[\\GENE] activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to [CHEMICAL]polycyclic aromatic hydrocarbons[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Little is known in terms of multi-matrix [GENE]cytochrome P450[\\GENE] activity induction under repeated oral exposure to planar [CHEMICAL]halogenated and polycyclic aromatic hydrocarbons[\\CHEMICAL] (PHH, PAH).",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Little is known in terms of multi-matrix [GENE]cytochrome P450[\\GENE] activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, [CHEMICAL]PAH[\\CHEMICAL]).",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "In the present study, we aimed at examining the effect of [CHEMICAL]1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole[\\CHEMICAL], a synthetic small molecular compound also named Fc11a-2, for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting [GENE]NLRP3[\\GENE] inflammasome.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named [CHEMICAL]Fc11a-2[\\CHEMICAL], for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting [GENE]NLRP3[\\GENE] inflammasome.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "The mechanism of action of [CHEMICAL]Fc11a-2[\\CHEMICAL] was related to the inhibition of the cleavage of [GENE]pro-caspase-1[\\GENE], pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The mechanism of action of [CHEMICAL]Fc11a-2[\\CHEMICAL] was related to the inhibition of the cleavage of pro-caspase-1, [GENE]pro-IL-1\u03b2[\\GENE] and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The mechanism of action of [CHEMICAL]Fc11a-2[\\CHEMICAL] was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and [GENE]pro-IL-18[\\GENE] which in turn suppressed the activation of NLRP3 inflammasome.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory [GENE]cytokines[\\GENE] in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including [GENE]TNF-\u03b1[\\GENE], IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, [GENE]IL-1\u03b2[\\GENE], IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, [GENE]IL-18[\\GENE], IL-17A and IFN-\u03b3, were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, [GENE]IL-17A[\\GENE] and IFN-\u03b3, were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and [GENE]IFN-\u03b3[\\GENE], were markedly suppressed by [CHEMICAL]Fc11a-2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "A novel [CHEMICAL]benzo[d]imidazole[\\CHEMICAL] derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of [GENE]NLRP3[\\GENE] inflammasome.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of [GENE]caspase-1[\\GENE] in peritoneal macrophages were detected in [CHEMICAL]Fc11a[\\CHEMICAL]-2-treated mice.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "The mechanism of action of [CHEMICAL]Fc11a-2[\\CHEMICAL] was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of [GENE]NLRP3[\\GENE] inflammasome.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Taken together, our results demonstrate the ability of [CHEMICAL]Fc11a-2[\\CHEMICAL] to inhibit [GENE]NLRP3[\\GENE] inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In addition, the disease activity index, histopathologic scores and [GENE]myeloperoxidase[\\GENE] activity were also significantly reduced by [CHEMICAL]Fc11a-2[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The inhibitory effect of [CHEMICAL]fisetin[\\CHEMICAL] on adipogenesis is dependent of [GENE]mTOR[\\GENE] activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting mTORC1 signaling.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that [CHEMICAL]fisetin[\\CHEMICAL] inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting [GENE]mTORC1[\\GENE] signaling.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "In this study, we have demonstrated that [CHEMICAL]fisetin[\\CHEMICAL] prevents diet-induced obesity through regulation of the signaling of [GENE]mammalian target of rapamycin complex 1[\\GENE] (mTORC1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "In this study, we have demonstrated that [CHEMICAL]fisetin[\\CHEMICAL] prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 ([GENE]mTORC1[\\GENE]), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of [CHEMICAL]fisetin[\\CHEMICAL] on [GENE]mTOR[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Collectively, these results suggest that inhibition of [GENE]mTORC1[\\GENE] signaling by [CHEMICAL]fisetin[\\CHEMICAL] prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Fisetin[\\CHEMICAL] treatment of preadipocytes reduced the phosphorylation of [GENE]S6K1[\\GENE] and mTORC1 in a time- and concentration-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Fisetin[\\CHEMICAL] treatment of preadipocytes reduced the phosphorylation of S6K1 and [GENE]mTORC1[\\GENE] in a time- and concentration-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The results suggested that [CHEMICAL]fisetin[\\CHEMICAL] treatment inhibits [GENE]mTORC1[\\GENE] activity in an Akt-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The results suggested that [CHEMICAL]fisetin[\\CHEMICAL] treatment inhibits mTORC1 activity in an [GENE]Akt[\\GENE]-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Short-term exposure to [CHEMICAL]amprenavir[\\CHEMICAL] significantly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels in wild-type mice, but not in [GENE]PXR[\\GENE]-deficient mice.",
        "label": 10,
        "major": 10,
        "len": 23
    },
    {
        "text": "Computational docking studies combined with site-direct mutagenesis identified several key residues within the ligand binding pocket of [GENE]PXR[\\GENE] that constitute points of interaction with [CHEMICAL]amprenavir[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Amprenavir[\\CHEMICAL]-mediated [GENE]PXR[\\GENE] activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Amprenavir[\\CHEMICAL] efficiently activated [GENE]PXR[\\GENE] and induced PXR target gene expression in vitro and in vivo.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Amprenavir[\\CHEMICAL] efficiently activated PXR and induced [GENE]PXR[\\GENE] target gene expression in vitro and in vivo.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Pregnane X Receptor Mediates Dyslipidemia Induced by the [GENE]HIV Protease[\\GENE] Inhibitor [CHEMICAL]Amprenavir[\\CHEMICAL] in Mice.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "In the present study, we identified [CHEMICAL]amprenavir[\\CHEMICAL], a widely used HIV PI, as a potent [GENE]PXR[\\GENE]-selective agonist.",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "One exception is [CHEMICAL]tranexamic acid[\\CHEMICAL] (TXA), which, as a lysine mimetic, inhibits binding of [GENE]plasminogen[\\GENE] to fibrin.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "One exception is [CHEMICAL]tranexamic acid[\\CHEMICAL] (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to [GENE]fibrin[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 17
    },
    {
        "text": "One exception is tranexamic acid ([CHEMICAL]TXA[\\CHEMICAL]), which, as a lysine mimetic, inhibits binding of [GENE]plasminogen[\\GENE] to fibrin.",
        "label": 4,
        "major": 2,
        "len": 17
    },
    {
        "text": "One exception is tranexamic acid ([CHEMICAL]TXA[\\CHEMICAL]), which, as a lysine mimetic, inhibits binding of plasminogen to [GENE]fibrin[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 17
    },
    {
        "text": "One exception is tranexamic acid (TXA), which, as a [CHEMICAL]lysine[\\CHEMICAL] mimetic, inhibits binding of [GENE]plasminogen[\\GENE] to fibrin.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "One exception is tranexamic acid (TXA), which, as a [CHEMICAL]lysine[\\CHEMICAL] mimetic, inhibits binding of plasminogen to [GENE]fibrin[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 17
    },
    {
        "text": "Coupling this computational technique with a high-quality low-throughput screen identified [CHEMICAL]5-(4-piperidyl)-3-isoxazolol[\\CHEMICAL] (4-PIOL) as a potent [GENE]plasminogen[\\GENE] binding inhibitor with the potential for the treatment of various bleeding disorders.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol ([CHEMICAL]4-PIOL[\\CHEMICAL]) as a potent [GENE]plasminogen[\\GENE] binding inhibitor with the potential for the treatment of various bleeding disorders.",
        "label": 4,
        "major": 2,
        "len": 28
    },
    {
        "text": "Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of [CHEMICAL]dihydropteridinone[\\CHEMICAL] based [GENE]Plk-2[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [GENE]caspase 3[\\GENE] and release of cytochrome c to the cytosol induced by [CHEMICAL]DZN[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Crocin[\\CHEMICAL] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [GENE]caspase 3[\\GENE] and release of cytochrome c to the cytosol induced by DZN.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "RESULTS: [CHEMICAL]DZN[\\CHEMICAL] induced histophatological damages and elevated the level of cardiac marker [GENE]CK-MB[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Crocin (25 and 50mg/kg) or [CHEMICAL]vitamin E[\\CHEMICAL] improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [GENE]caspase 3[\\GENE] and release of cytochrome c to the cytosol induced by DZN.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [GENE]cytochrome c[\\GENE] to the cytosol induced by [CHEMICAL]DZN[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of [GENE]Bax[\\GENE]/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by [CHEMICAL]DZN[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Crocin[\\CHEMICAL] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of [GENE]cytochrome c[\\GENE] to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/[GENE]Bcl2[\\GENE] ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by [CHEMICAL]DZN[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Crocin[\\CHEMICAL] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and [GENE]CK-MB[\\GENE], increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Crocin[\\CHEMICAL] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of [GENE]Bax[\\GENE]/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Crocin[\\CHEMICAL] (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/[GENE]Bcl2[\\GENE] ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or [CHEMICAL]vitamin E[\\CHEMICAL] improved histopathological damages, decreased MDA and [GENE]CK-MB[\\GENE], increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or [CHEMICAL]vitamin E[\\CHEMICAL] improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of [GENE]Bax[\\GENE]/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Crocin (25 and 50mg/kg) or [CHEMICAL]vitamin E[\\CHEMICAL] improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/[GENE]Bcl2[\\GENE] ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear [GENE]CAR[\\GENE] and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Phenobarbital[\\CHEMICAL] (PB), a typical CAR activator, increased the gene expression of [GENE]HIF[\\GENE]-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical HIF activator, induced the gene expression of [GENE]CAR[\\GENE]-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the [GENE]PB-responsive enhancer module[\\GENE]-mediated transactivation in the mouse liver.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Phenobarbital[\\CHEMICAL] (PB), a typical [GENE]CAR[\\GENE] activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical [GENE]HIF[\\GENE] activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Phenobarbital[\\CHEMICAL] (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including [GENE]erythropoietin[\\GENE], heme oxygenase-1 and vascular endothelial growth factor-a.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Phenobarbital[\\CHEMICAL] (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, [GENE]heme oxygenase-1[\\GENE] and vascular endothelial growth factor-a.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Phenobarbital[\\CHEMICAL] (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and [GENE]vascular endothelial growth factor-a[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical HIF activator, induced the gene expression of CAR-target genes, including [GENE]cyp2b9[\\GENE] and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Cobalt chloride[\\CHEMICAL], a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and [GENE]cyp2b10[\\GENE], an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "In contrast, their effects on [GENE]MRP2[\\GENE] varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while [CHEMICAL]CGP[\\CHEMICAL] I-5 had no effect.",
        "label": 10,
        "major": 4,
        "len": 30
    },
    {
        "text": "Five classes of chalcogenopyrylium dyes ([CHEMICAL]CGPs[\\CHEMICAL]) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217\u03b2G) (a prototypical [GENE]MRP[\\GENE] substrate) into MRP-enriched inside-out membrane vesicles.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Chalcogenopyrylium[\\CHEMICAL] Dyes as Differential Modulators of Organic Anion Transport by [GENE]MRP1[\\GENE], MRP2 and MRP4.",
        "label": 2,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Chalcogenopyrylium[\\CHEMICAL] Dyes as Differential Modulators of Organic Anion Transport by MRP1, [GENE]MRP2[\\GENE] and MRP4.",
        "label": 2,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Chalcogenopyrylium[\\CHEMICAL] Dyes as Differential Modulators of Organic Anion Transport by MRP1, MRP2 and [GENE]MRP4[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 14
    },
    {
        "text": "This study is the first to identify Class V CGPs with their distinctive [CHEMICAL]methine[\\CHEMICAL] or trimethine linkage between two disubstituted pyrylium moieties as a particularly potent class of [GENE]MRP[\\GENE] modulators and also show that within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.",
        "label": 2,
        "major": 4,
        "len": 61
    },
    {
        "text": "This study is the first to identify Class V CGPs with their distinctive methine or [CHEMICAL]trimethine[\\CHEMICAL] linkage between two disubstituted pyrylium moieties as a particularly potent class of [GENE]MRP[\\GENE] modulators and also show that within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.",
        "label": 2,
        "major": 4,
        "len": 61
    },
    {
        "text": "This study is the first to identify Class V CGPs with their distinctive methine or trimethine linkage between two disubstituted [CHEMICAL]pyrylium[\\CHEMICAL] moieties as a particularly potent class of [GENE]MRP[\\GENE] modulators and also show that within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.",
        "label": 2,
        "major": 3,
        "len": 61
    },
    {
        "text": "Five classes of [CHEMICAL]chalcogenopyrylium[\\CHEMICAL] dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217\u03b2G) (a prototypical [GENE]MRP[\\GENE] substrate) into MRP-enriched inside-out membrane vesicles.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "Sixteen of 34 [CHEMICAL]CGPs[\\CHEMICAL] inhibited [GENE]MRP1[\\GENE]-mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Of 9 CGPs with IC50's \u22642 \u03bcM, two belonged to Class I, two to Class III and five to Class V. When tested in the intact cells, only 4 of 16 [CHEMICAL]CGPs[\\CHEMICAL] (at 10 \u03bcM) inhibited [GENE]MRP1[\\GENE]-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",
        "label": 4,
        "major": 4,
        "len": 54
    },
    {
        "text": "These five [CHEMICAL]CGPs[\\CHEMICAL] also inhibited [(3)H]E217\u03b2G uptake by [GENE]MRP4[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [CHEMICAL][(3)H]estradiol glucuronide[\\CHEMICAL] (E217\u03b2G) (a prototypical [GENE]MRP[\\GENE] substrate) into MRP-enriched inside-out membrane vesicles.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide ([CHEMICAL]E217\u03b2G[\\CHEMICAL]) (a prototypical [GENE]MRP[\\GENE] substrate) into MRP-enriched inside-out membrane vesicles.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "Sixteen of 34 CGPs inhibited [GENE]MRP1[\\GENE]-mediated [CHEMICAL]E217\u03b2G[\\CHEMICAL] uptake by >50% (IC50's 0.7-7.6 \u03bcM).",
        "label": 9,
        "major": 4,
        "len": 13
    },
    {
        "text": "Of 9 CGPs with IC50's \u22642 \u03bcM, two belonged to Class I, two to Class III and five to Class V. When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited [GENE]MRP1[\\GENE]-mediated [CHEMICAL]calcein[\\CHEMICAL] efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.",
        "label": 9,
        "major": 4,
        "len": 54
    },
    {
        "text": "These five CGPs also inhibited [CHEMICAL][(3)H]E217\u03b2G[\\CHEMICAL] uptake by [GENE]MRP4[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 9
    },
    {
        "text": "Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the [GENE]histone deacetylase[\\GENE] inhibitor [CHEMICAL]LBH589[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "These variants are expected to encode either a full length ([GENE]OATP2B1-FL[\\GENE]) or shortened protein lacking 22 [CHEMICAL]N[\\CHEMICAL]-terminus amino acids (OATP2B-Short).",
        "label": 1,
        "major": 1,
        "len": 20
    },
    {
        "text": "These variants are expected to encode either a full length (OATP2B1-FL) or shortened protein lacking 22 [CHEMICAL]N[\\CHEMICAL]-terminus amino acids ([GENE]OATP2B-Short[\\GENE]).",
        "label": 1,
        "major": 1,
        "len": 20
    },
    {
        "text": "These variants are expected to encode either a full length ([GENE]OATP2B1-FL[\\GENE]) or shortened protein lacking 22 N-terminus [CHEMICAL]amino acids[\\CHEMICAL] (OATP2B-Short).",
        "label": 1,
        "major": 1,
        "len": 20
    },
    {
        "text": "Little is known regarding the transport activity and regulation of [GENE]OATP2B1[\\GENE] variants with [CHEMICAL]N[\\CHEMICAL]-terminus truncation.",
        "label": 1,
        "major": 9,
        "len": 15
    },
    {
        "text": "Using a transient heterologous cell expression system, we find that the transport activities of the [GENE]short OATP2B1[\\GENE] variant towards substrates [CHEMICAL]estrone sulfate[\\CHEMICAL] and rosuvastatin are similar to the well-characterized full length variant.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "Using a transient heterologous cell expression system, we find that the transport activities of the [GENE]short OATP2B1[\\GENE] variant towards substrates estrone sulfate and [CHEMICAL]rosuvastatin[\\CHEMICAL] are similar to the well-characterized full length variant.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "In four (10\u00a0%) patients the peak [GENE]ACTH[\\GENE]-stimulated [CHEMICAL]cortisol[\\CHEMICAL] values were lower than 18\u00a0\u03bcg/dL.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "[GENE]ACTH[\\GENE]-stimulated peak [CHEMICAL]cortisol[\\CHEMICAL], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.",
        "label": 9,
        "major": 3,
        "len": 18
    },
    {
        "text": "[GENE]ACTH[\\GENE]-stimulated peak cortisol, [CHEMICAL]delta cortisol[\\CHEMICAL], and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.",
        "label": 9,
        "major": 3,
        "len": 18
    },
    {
        "text": "[GENE]ACTH[\\GENE]-stimulated peak cortisol, delta cortisol, and [CHEMICAL]delta DHEA[\\CHEMICAL]-S levels are decreased during hyperthyroidism, probably due to increased turnover.",
        "label": 9,
        "major": 3,
        "len": 18
    },
    {
        "text": "We had previously reported a [CHEMICAL]fluorescein[\\CHEMICAL] conjugate that was shown (by confocal microscopy imaging of DS-red-labelled cortical neurons) to bind specifically to [GENE]GluN2B[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Synthesis and in Vitro Characterisation of [CHEMICAL]Ifenprodil[\\CHEMICAL]-Based Fluorescein Conjugates as [GENE]GluN1[\\GENE]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and in Vitro Characterisation of [CHEMICAL]Ifenprodil[\\CHEMICAL]-Based Fluorescein Conjugates as GluN1/[GENE]GluN2B[\\GENE] N-Methyl-D-aspartate Receptor Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and in Vitro Characterisation of [CHEMICAL]Ifenprodil[\\CHEMICAL]-Based Fluorescein Conjugates as GluN1/GluN2B [GENE]N-Methyl-D-aspartate Receptor[\\GENE] Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based [CHEMICAL]Fluorescein[\\CHEMICAL] Conjugates as [GENE]GluN1[\\GENE]/GluN2B N-Methyl-D-aspartate Receptor Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based [CHEMICAL]Fluorescein[\\CHEMICAL] Conjugates as GluN1/[GENE]GluN2B[\\GENE] N-Methyl-D-aspartate Receptor Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based [CHEMICAL]Fluorescein[\\CHEMICAL] Conjugates as GluN1/GluN2B [GENE]N-Methyl-D-aspartate Receptor[\\GENE] Antagonists.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Ifenprodil[\\CHEMICAL], known as the [GENE]GluNR2B[\\GENE] antagonist of reference, was chosen as the template for the elaboration of probes.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Nitrooxy[\\CHEMICAL] derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [GENE]COX-2[\\GENE] inhibitors in in vitro experimental models.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as [GENE]cyclooxygenase-2[\\GENE] inhibiting [CHEMICAL]nitric oxide[\\CHEMICAL] donors.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Novel analgesic/anti-inflammatory agents: [CHEMICAL]1,5-diarylpyrrole nitrooxyalkyl ethers[\\CHEMICAL] and related compounds as [GENE]cyclooxygenase-2[\\GENE] inhibiting nitric oxide donors.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "New classes of [CHEMICAL]pyrrole[\\CHEMICAL]-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as [GENE]COX-2[\\GENE] selective inhibitors and NO donors were synthesized and are herein reported.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "New classes of pyrrole-derived [CHEMICAL]nitrooxyalkyl[\\CHEMICAL] inverse esters, carbonates, and ethers (7-10) as [GENE]COX-2[\\GENE] selective inhibitors and NO donors were synthesized and are herein reported.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "New classes of pyrrole-derived nitrooxyalkyl inverse [CHEMICAL]esters[\\CHEMICAL], carbonates, and ethers (7-10) as [GENE]COX-2[\\GENE] selective inhibitors and NO donors were synthesized and are herein reported.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters, [CHEMICAL]carbonates[\\CHEMICAL], and ethers (7-10) as [GENE]COX-2[\\GENE] selective inhibitors and NO donors were synthesized and are herein reported.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and [CHEMICAL]ethers[\\CHEMICAL] (7-10) as [GENE]COX-2[\\GENE] selective inhibitors and NO donors were synthesized and are herein reported.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Synthesis and structure-activity relationship of [CHEMICAL]pyripyropene A[\\CHEMICAL] derivatives as potent and selective [GENE]acyl-CoA:cholesterol acyltransferase 2[\\GENE] (ACAT2) inhibitors: Part 2.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Synthesis and structure-activity relationship of [CHEMICAL]pyripyropene A[\\CHEMICAL] derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 ([GENE]ACAT2[\\GENE]) inhibitors: Part 2.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "These illnesses are a result of [CHEMICAL]saxitoxin[\\CHEMICAL]'s ability to bind to the [GENE]voltage-gated sodium channel[\\GENE], blocking the passage of nerve impulses and leading to death via respiratory paralysis.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Recent advances in [CHEMICAL]saxitoxin[\\CHEMICAL] research are discussed, including the molecular biology of toxin synthesis, new protein targets, association with [GENE]metal-binding motifs[\\GENE] and methods of detection.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [[CHEMICAL]Nle[\\CHEMICAL](4), D-Phe(7)][GENE]\u03b1-melanocyte-stimulating hormone[\\GENE] (NDP-\u03b1-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-\u03b1 levels; these effects of NDP-\u03b1-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.",
        "label": 1,
        "major": 3,
        "len": 63
    },
    {
        "text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [[CHEMICAL]Nle[\\CHEMICAL](4), D-Phe(7)]\u03b1-melanocyte-stimulating hormone (NDP-[GENE]\u03b1-MSH[\\GENE]) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-\u03b1 levels; these effects of NDP-\u03b1-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.",
        "label": 1,
        "major": 4,
        "len": 63
    },
    {
        "text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), [CHEMICAL]D-Phe[\\CHEMICAL](7)][GENE]\u03b1-melanocyte-stimulating hormone[\\GENE] (NDP-\u03b1-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-\u03b1 levels; these effects of NDP-\u03b1-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.",
        "label": 1,
        "major": 4,
        "len": 63
    },
    {
        "text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), [CHEMICAL]D-Phe[\\CHEMICAL](7)]\u03b1-melanocyte-stimulating hormone (NDP-[GENE]\u03b1-MSH[\\GENE]) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-\u03b1 levels; these effects of NDP-\u03b1-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.",
        "label": 1,
        "major": 3,
        "len": 63
    },
    {
        "text": "Blockade of [GENE]JAK[\\GENE] and ERK pathways with [CHEMICAL]AG490[\\CHEMICAL] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Blockade of JAK and [GENE]ERK[\\GENE] pathways with AG490 and [CHEMICAL]U0126[\\CHEMICAL], respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "A decrease in [GENE]ADA[\\GENE] activity was observed when the slices were exposed to [CHEMICAL]organoselenium[\\CHEMICAL] at the concentrations of 1, 10 and 30 \u00b5M.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary [GENE]GR[\\GENE]-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "These data provided a novel insight to the mechanisms of [CHEMICAL]Rg1[\\CHEMICAL]protective effects on A\u03b225-35-induced endothelial cells apoptosis, suggesting that [GENE]GR[\\GENE]-ERK signaling pathway might play an important role in it.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "These data provided a novel insight to the mechanisms of [CHEMICAL]Rg1[\\CHEMICAL]protective effects on A\u03b225-35-induced endothelial cells apoptosis, suggesting that GR-[GENE]ERK[\\GENE] signaling pathway might play an important role in it.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent [GENE]ERK[\\GENE] phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 3,
        "major": 4,
        "len": 34
    },
    {
        "text": "Activating [GENE]glucocorticoid receptor[\\GENE]-ERK signaling pathway contributes to [CHEMICAL]ginsenoside Rg1[\\CHEMICAL] protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Activating glucocorticoid receptor-[GENE]ERK[\\GENE] signaling pathway contributes to [CHEMICAL]ginsenoside Rg1[\\CHEMICAL] protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [GENE]HIF-1\u03b1[\\GENE] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Rg1[\\CHEMICAL] attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting [GENE]HIF-1\u03b1[\\GENE] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against [GENE]A\u03b225-35[\\GENE]-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Activating glucocorticoid receptor-ERK signaling pathway contributes to [CHEMICAL]ginsenoside Rg1[\\CHEMICAL] protection against [GENE]\u03b2-amyloid peptide[\\GENE]-induced human endothelial cells apoptosis.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "These data provided a novel insight to the mechanisms of [CHEMICAL]Rg1[\\CHEMICAL]protective effects on [GENE]A\u03b225-35[\\GENE]-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Rg1[\\CHEMICAL] attenuated the [GENE]A\u03b225-35[\\GENE]-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or [GENE]p-ERK[\\GENE] inhibitor [CHEMICAL]U0126[\\CHEMICAL] rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than [GENE]estrogen receptor \u03b1[\\GENE] antagonist [CHEMICAL]ICI 82,780[\\CHEMICAL].",
        "label": 6,
        "major": 4,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by [GENE]glucocorticoid receptor[\\GENE] (GR) antagonist [CHEMICAL]RU486[\\CHEMICAL] or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor ([GENE]GR[\\GENE]) antagonist [CHEMICAL]RU486[\\CHEMICAL] or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 6,
        "major": 4,
        "len": 23
    },
    {
        "text": "In addition to CYP2B6, [CHEMICAL]anisomycin[\\CHEMICAL] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not [GENE]CYP3A4[\\GENE] or UDP-glucuronosyltransferase 1A1 mRNAs.",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "In addition to CYP2B6, [CHEMICAL]anisomycin[\\CHEMICAL] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or [GENE]UDP-glucuronosyltransferase 1A1[\\GENE] mRNAs.",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "Here, we have now found that activation of p38 MAPK by [CHEMICAL]anisomycin[\\CHEMICAL] potentiated induction of CYP2B6 mRNA by [GENE]CAR[\\GENE] ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here, we have now found that activation of [GENE]p38[\\GENE] MAPK by [CHEMICAL]anisomycin[\\CHEMICAL] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here, we have now found that activation of p38 [GENE]MAPK[\\GENE] by [CHEMICAL]anisomycin[\\CHEMICAL] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Here, we have now found that activation of p38 MAPK by [CHEMICAL]anisomycin[\\CHEMICAL] potentiated induction of [GENE]CYP2B6[\\GENE] mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "siRNA knockdown of p38 MAPK abrogated the ability of [CHEMICAL]anisomycin[\\CHEMICAL] to synergistically induce [GENE]CYP2B6[\\GENE] mRNA.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "In addition to [GENE]CYP2B6[\\GENE], [CHEMICAL]anisomycin[\\CHEMICAL] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "In addition to CYP2B6, [CHEMICAL]anisomycin[\\CHEMICAL] co-treatment potentiated an increase in [GENE]CYP2A7[\\GENE] and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "In addition to CYP2B6, [CHEMICAL]anisomycin[\\CHEMICAL] co-treatment potentiated an increase in CYP2A7 and [GENE]CYP2C9[\\GENE] mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "FCEO significantly inhibited [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of [GENE]inducible nitric oxide synthase[\\GENE] (iNOS) and cyclooxygenase (COX)-2, respectively.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "FCEO significantly inhibited [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase ([GENE]iNOS[\\GENE]) and cyclooxygenase (COX)-2, respectively.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "FCEO significantly inhibited nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) and prostaglandin E2 (PGE2) by suppressing the protein expression of [GENE]inducible nitric oxide synthase[\\GENE] (iNOS) and cyclooxygenase (COX)-2, respectively.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "FCEO significantly inhibited nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase ([GENE]iNOS[\\GENE]) and cyclooxygenase (COX)-2, respectively.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "FCEO significantly inhibited nitric oxide (NO) and [CHEMICAL]prostaglandin E2[\\CHEMICAL] (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and [GENE]cyclooxygenase (COX)-2[\\GENE], respectively.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 ([CHEMICAL]PGE2[\\CHEMICAL]) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and [GENE]cyclooxygenase (COX)-2[\\GENE], respectively.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "PKD1 and PI4KIII\u03b2 localize to the TGN, and [CHEMICAL]aldosterone[\\CHEMICAL] induced an interaction between [GENE]PKD1[\\GENE] and PI4KIII\u03b2 following aldosterone treatment.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "PKD1 and PI4KIII\u03b2 localize to the TGN, and [CHEMICAL]aldosterone[\\CHEMICAL] induced an interaction between PKD1 and [GENE]PI4KIII\u03b2[\\GENE] following aldosterone treatment.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL]-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via [GENE]protein kinase D1[\\GENE]-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL]-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-[GENE]phosphatidylinositol 4-kinaseIII\u03b2[\\GENE] trans Golgi signalling in M1 cortical collecting duct cells.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL] regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial [GENE]sodium channel[\\GENE] (ENaC) and Na(+)/K(+)-ATPase subunits.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL] regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel ([GENE]ENaC[\\GENE]) and Na(+)/K(+)-ATPase subunits.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL] regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial sodium channel (ENaC) and [GENE]Na(+)/K(+)-ATPase[\\GENE] subunits.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL] also induces the rapid phosphorylation of [GENE]Protein Kinase D1[\\GENE] (PKD1).",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL] also induces the rapid phosphorylation of Protein Kinase D1 ([GENE]PKD1[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL]-induced [GENE]ENaC[\\GENE] and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Aldosterone[\\CHEMICAL]-induced ENaC and basal [GENE]Na(+)/K(+)-ATPase[\\GENE] trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-\u03baB complex containing a form of [GENE]p65[\\GENE] phosphorylated on [CHEMICAL]Ser[\\CHEMICAL]536, did not change.",
        "label": 1,
        "major": 10,
        "len": 38
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of [GENE]iNOS[\\GENE] expression.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Taken together, our findings indicate that [CHEMICAL]5HHMF[\\CHEMICAL] suppresses NO production through modulation of [GENE]iNOS[\\GENE], consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent HO-1 activity.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "Thus, we found that [CHEMICAL]5HHMF[\\CHEMICAL] enhances heme oxygenase-1 (HO-1) expression via [GENE]nuclear factor-erythroid 2-related factor 2[\\GENE] (Nrf2) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Thus, we found that [CHEMICAL]5HHMF[\\CHEMICAL] enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 ([GENE]Nrf2[\\GENE]) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "In addition, [CHEMICAL]cobalt protoporphyrin[\\CHEMICAL] (CoPP), a specific [GENE]HO-1[\\GENE] inducer, predominantly suppressed LPS-induced NO production.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "In addition, cobalt protoporphyrin ([CHEMICAL]CoPP[\\CHEMICAL]), a specific [GENE]HO-1[\\GENE] inducer, predominantly suppressed LPS-induced NO production.",
        "label": 3,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone[\\CHEMICAL] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and [GENE]Nrf-2[\\GENE]-dependent heme oxygenase-1 induction.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone[\\CHEMICAL] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent [GENE]heme oxygenase-1[\\GENE] induction.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Further, [CHEMICAL]5HHMF[\\CHEMICAL] increased specific DNA-binding activity of [GENE]Nrf2[\\GENE], and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Taken together, our findings indicate that [CHEMICAL]5HHMF[\\CHEMICAL] suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of [GENE]Nrf2[\\GENE]-dependent HO-1 activity.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "Taken together, our findings indicate that [CHEMICAL]5HHMF[\\CHEMICAL] suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent [GENE]HO-1[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Thus, we found that [CHEMICAL]5HHMF[\\CHEMICAL] enhances [GENE]heme oxygenase-1[\\GENE] (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Thus, we found that [CHEMICAL]5HHMF[\\CHEMICAL] enhances heme oxygenase-1 ([GENE]HO-1[\\GENE]) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Further, [CHEMICAL]5HHMF[\\CHEMICAL] increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of [GENE]HO-1[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Further, [CHEMICAL]5HHMF[\\CHEMICAL] increased specific DNA-binding activity of Nrf2, and transient knockdown with [GENE]Nrf2[\\GENE] siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Further, 5HHMF increased specific DNA-binding activity of [GENE]Nrf2[\\GENE], and transient knockdown with Nrf2 siRNA subsequently reversed [CHEMICAL]5HHMF[\\CHEMICAL]-induced NO inhibition, which was followed by suppression of HO-1 activity.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with [GENE]Nrf2[\\GENE] siRNA subsequently reversed [CHEMICAL]5HHMF[\\CHEMICAL]-induced NO inhibition, which was followed by suppression of HO-1 activity.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Taken together, our findings indicate that 5HHMF suppresses [CHEMICAL]NO[\\CHEMICAL] production through modulation of iNOS, consequently suppressing [GENE]NF-\u03baB[\\GENE] activity and induction of Nrf2-dependent HO-1 activity.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Taken together, our findings indicate that 5HHMF suppresses [CHEMICAL]NO[\\CHEMICAL] production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of [GENE]Nrf2[\\GENE]-dependent HO-1 activity.",
        "label": 4,
        "major": 7,
        "len": 24
    },
    {
        "text": "Taken together, our findings indicate that 5HHMF suppresses [CHEMICAL]NO[\\CHEMICAL] production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent [GENE]HO-1[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced [CHEMICAL]NO[\\CHEMICAL] inhibition, which was followed by suppression of [GENE]HO-1[\\GENE] activity.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of [GENE]nuclear factor-\u03baB[\\GENE] (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB ([GENE]NF-\u03baB[\\GENE]) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely [GENE]p65[\\GENE] and p50, which are important molecules involved in the regulation of iNOS expression.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and [GENE]p50[\\GENE], which are important molecules involved in the regulation of iNOS expression.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "In this study, we found that [CHEMICAL]5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone[\\CHEMICAL] (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of [GENE]inducible NO synthase[\\GENE] (iNOS) in BV2 microglia.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "In this study, we found that [CHEMICAL]5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone[\\CHEMICAL] (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase ([GENE]iNOS[\\GENE]) in BV2 microglia.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Pyrrolidine dithiocarbamate[\\CHEMICAL] (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced [GENE]iNOS[\\GENE] expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Pyrrolidine dithiocarbamate ([CHEMICAL]PDTC[\\CHEMICAL]), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced [GENE]iNOS[\\GENE] expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that [CHEMICAL]5HHMF[\\CHEMICAL] downregulated [GENE]iNOS[\\GENE] expression by suppressing NF-\u03baB activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone ([CHEMICAL]5HHMF[\\CHEMICAL]) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of [GENE]inducible NO synthase[\\GENE] (iNOS) in BV2 microglia.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone ([CHEMICAL]5HHMF[\\CHEMICAL]) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase ([GENE]iNOS[\\GENE]) in BV2 microglia.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "In addition, [CHEMICAL]5HHMF[\\CHEMICAL] blocked LPS-induced phosphorylation of [GENE]I\u03baB[\\GENE], resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Pyrrolidine dithiocarbamate[\\CHEMICAL] (PDTC), a specific [GENE]NF-\u03baB[\\GENE] inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Pyrrolidine dithiocarbamate ([CHEMICAL]PDTC[\\CHEMICAL]), a specific [GENE]NF-\u03baB[\\GENE] inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that [CHEMICAL]5HHMF[\\CHEMICAL] downregulated iNOS expression by suppressing [GENE]NF-\u03baB[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone[\\CHEMICAL] inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via [GENE]NF-\u03baB[\\GENE] suppression and Nrf-2-dependent heme oxygenase-1 induction.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "In contrast, [CHEMICAL]zinc protoporphyrin[\\CHEMICAL] (ZnPP), a specific [GENE]HO-1[\\GENE] inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "In contrast, zinc protoporphyrin ([CHEMICAL]ZnPP[\\CHEMICAL]), a specific [GENE]HO-1[\\GENE] inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed [CHEMICAL]5HHMF[\\CHEMICAL]-induced NO inhibition, which was followed by suppression of [GENE]HO-1[\\GENE] activity.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Taken together, our findings indicate that [CHEMICAL]5HHMF[\\CHEMICAL] suppresses NO production through modulation of iNOS, consequently suppressing [GENE]NF-\u03baB[\\GENE] activity and induction of Nrf2-dependent HO-1 activity.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens [CHEMICAL]GTX2,3-aldehyde[\\CHEMICAL]-[GENE]bovine serum albumin[\\GENE] (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.",
        "label": 2,
        "major": 1,
        "len": 49
    },
    {
        "text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens [CHEMICAL]GTX2,3-aldehyde[\\CHEMICAL]-bovine serum albumin ([GENE]BSA[\\GENE]) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.",
        "label": 2,
        "major": 3,
        "len": 49
    },
    {
        "text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and [CHEMICAL]GTX2,3-aldehyde[\\CHEMICAL]- [GENE]keyhole limpet hemocyanin[\\GENE] (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.",
        "label": 2,
        "major": 3,
        "len": 49
    },
    {
        "text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and [CHEMICAL]GTX2,3-aldehyde[\\CHEMICAL]- keyhole limpet hemocyanin ([GENE]KLH[\\GENE]) were then prepared by cross-linking the intermediate with BSA or KLH.",
        "label": 2,
        "major": 3,
        "len": 49
    },
    {
        "text": "However, we show that [GENE]hCTR1[\\GENE] is not the major entry route of [CHEMICAL]platinum[\\CHEMICAL]-drugs and that the copper transporter is not internalized in response to extracellular drug.",
        "label": 10,
        "major": 9,
        "len": 26
    },
    {
        "text": "It has been claimed that [GENE]hCTR1[\\GENE], the human high affinity copper transporter, is the major entry pathway for [CHEMICAL]cDDP[\\CHEMICAL] and related drugs via a mechanism that mimics copper.",
        "label": 9,
        "major": 2,
        "len": 28
    },
    {
        "text": "It has been claimed that hCTR1, the [GENE]human high affinity copper transporter[\\GENE], is the major entry pathway for [CHEMICAL]cDDP[\\CHEMICAL] and related drugs via a mechanism that mimics copper.",
        "label": 9,
        "major": 2,
        "len": 28
    },
    {
        "text": "Here we report the solution structure of the SH2 domain of [CHEMICAL]C[\\CHEMICAL][GENE]C-terminal Src kinase[\\GENE] (Csk) in complex with a longer phosphopeptide from Csk-binding protein (Cbp).",
        "label": 1,
        "major": 2,
        "len": 25
    },
    {
        "text": "Here we report the solution structure of the SH2 domain of [CHEMICAL]C[\\CHEMICAL]-terminal Src kinase ([GENE]Csk[\\GENE]) in complex with a longer phosphopeptide from Csk-binding protein (Cbp).",
        "label": 1,
        "major": 2,
        "len": 25
    },
    {
        "text": "This structure, together with biochemical experiments, revealed the existence of a novel binding region in addition to the canonical [CHEMICAL]phosphotyrosine[\\CHEMICAL]-314 binding site of [GENE]Cbp[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "Identification of a new interaction mode between the Src homology 2 (SH2) domain of [CHEMICAL]C[\\CHEMICAL][GENE]C-terminal Src kinase[\\GENE] (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG).",
        "label": 1,
        "major": 2,
        "len": 27
    },
    {
        "text": "Our results showed that [CHEMICAL]2-hydroxy-3-methylanthraquinone[\\CHEMICAL] decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of [GENE]p-JNK1/2[\\GENE] in U937 cells.",
        "label": 10,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]2-Hydroxy-3-methylanthraquinone[\\CHEMICAL] from Hedyotis diffusa Willd induces apoptosis in human leukemic U937 cells through modulation of [GENE]MAPK[\\GENE] pathways.",
        "label": 2,
        "major": 7,
        "len": 17
    },
    {
        "text": "Taken together, our study for the first time suggests that [CHEMICAL]2-hydroxy-3-methylanthraquinone[\\CHEMICAL] is able to enhance apoptosis of U937 cells, at least in part, through activation of [GENE]p-p38MAPK[\\GENE] and downregulation of p-ERK1/2.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Our results showed that [CHEMICAL]2-hydroxy-3-methylanthraquinone[\\CHEMICAL] decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased [GENE]p-p38MAPK[\\GENE], but did not affect expressions of p-JNK1/2 in U937 cells.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Moreover, treatment of U937 cells with [CHEMICAL]2-hydroxy-3-methylanthraquinone[\\CHEMICAL] resulted in activation of [GENE]caspase-3[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or [CHEMICAL]SB203580[\\CHEMICAL] ([GENE]p-p38MAPK[\\GENE] inhibitor), decreased apoptosis in U937 cells.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]ThioTEPA[\\CHEMICAL] ([GENE]CYP2B6[\\GENE] inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not [CHEMICAL]troleandomycin[\\CHEMICAL] ([GENE]CYP3A4[\\GENE] inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The intrinsic clearance for both [CHEMICAL]ketamine[\\CHEMICAL] enantiomers by the high affinity enzyme in HLMs with [GENE]CYP2B6*1[\\GENE]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.",
        "label": 9,
        "major": 10,
        "len": 33
    },
    {
        "text": "These results indicate a major role of [GENE]CYP2B6[\\GENE] in [CHEMICAL]ketamine[\\CHEMICAL] N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.",
        "label": 9,
        "major": 2,
        "len": 27
    },
    {
        "text": "These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the [GENE]CYP2B6*6[\\GENE] allele on enzyme-[CHEMICAL]ketamine[\\CHEMICAL] binding and catalytic activity.",
        "label": 9,
        "major": 2,
        "len": 27
    },
    {
        "text": "The [GENE]CYP2B6*6[\\GENE] allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in [CHEMICAL]ketamine[\\CHEMICAL] metabolism.",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "We examined the N-demethylation of individual [CHEMICAL]ketamine[\\CHEMICAL] enantiomers using human liver microsomes (HLMs) genotyped for the [GENE]CYP2B6*6[\\GENE] allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",
        "label": 9,
        "major": 10,
        "len": 36
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were [GENE]UGT1A10[\\GENE] followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were UGT1A10 followed by [GENE]UGT1A6[\\GENE] >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were UGT1A10 followed by UGT1A6 >[GENE]UGT1A7[\\GENE] >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >[GENE]UGT2A1[\\GENE], whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M [GENE]UGT1A6[\\GENE] was about 10 times better catalyst than the other recombinant UGTs.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "At a substrate concentration of 20\u2009\u00b5M, the most active [CHEMICAL]HFC[\\CHEMICAL] glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant [GENE]UGTs[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Results of RT-PCR analysis showed decrease of p53 mRNA level and no significant difference in [GENE]Bcl-2[\\GENE] and Bax mRNA expressions in [CHEMICAL]DEX[\\CHEMICAL]-treated rats.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "Results of RT-PCR analysis showed decrease of p53 mRNA level and no significant difference in Bcl-2 and [GENE]Bax[\\GENE] mRNA expressions in [CHEMICAL]DEX[\\CHEMICAL]-treated rats.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "In PFC, [CHEMICAL]DEX[\\CHEMICAL] caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well [GENE]Bcl-2[\\GENE] translocation to mitochondria.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "In PFC, [CHEMICAL]DEX[\\CHEMICAL] caused activation of [GENE]AKT[\\GENE], augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "In PFC, [CHEMICAL]DEX[\\CHEMICAL] caused activation of AKT, augmentation of pro-survival [GENE]Bcl-2[\\GENE] protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "In PFC, [CHEMICAL]DEX[\\CHEMICAL] caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced [GENE]Bcl-2[\\GENE]/Bax protein ratio, as well Bcl-2 translocation to mitochondria.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "In PFC, [CHEMICAL]DEX[\\CHEMICAL] caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/[GENE]Bax[\\GENE] protein ratio, as well Bcl-2 translocation to mitochondria.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Results of RT-PCR analysis showed decrease of [GENE]p53[\\GENE] mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in [CHEMICAL]DEX[\\CHEMICAL]-treated rats.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Accordingly, loss of [GENE]pip5k1\u03b2[\\GENE] function in FRDA cells was accompanied by decreased [CHEMICAL]PI(4,5)P2[\\CHEMICAL] levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Regarding [GENE]urease[\\GENE] inhibition, [CHEMICAL]n-butanol[\\CHEMICAL] was the most potent fraction (IC50: 97 \u00b5g/mL).",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy mitigates cell apoptosis through modulation of [GENE]PI3K[\\GENE]/Akt and ERK and JNK signaling pathways in human lung cancer cell lines.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy mitigates cell apoptosis through modulation of PI3K/[GENE]Akt[\\GENE] and ERK and JNK signaling pathways in human lung cancer cell lines.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and [GENE]ERK[\\GENE] and JNK signaling pathways in human lung cancer cell lines.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and [GENE]JNK[\\GENE] signaling pathways in human lung cancer cell lines.",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy via [GENE]ERK1/2[\\GENE] and JNK1/2 pathways may provide a protective mechanism for cell survival against dioscin-induced apoptosis to act as a cytoprotective reaction.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Dioscin[\\CHEMICAL]-induced autophagy via ERK1/2 and [GENE]JNK1/2[\\GENE] pathways may provide a protective mechanism for cell survival against dioscin-induced apoptosis to act as a cytoprotective reaction.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Dioscin-induced autophagy via [GENE]ERK1/2[\\GENE] and JNK1/2 pathways may provide a protective mechanism for cell survival against [CHEMICAL]dioscin[\\CHEMICAL]-induced apoptosis to act as a cytoprotective reaction.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Dioscin-induced autophagy via ERK1/2 and [GENE]JNK1/2[\\GENE] pathways may provide a protective mechanism for cell survival against [CHEMICAL]dioscin[\\CHEMICAL]-induced apoptosis to act as a cytoprotective reaction.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Treatment of A549 and H1299 cells with [CHEMICAL]dioscin[\\CHEMICAL] caused a dose-dependent increase in ERK1/2 and [GENE]JNK1/2[\\GENE] activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Treatment of A549 and H1299 cells with [CHEMICAL]dioscin[\\CHEMICAL] caused a dose-dependent increase in [GENE]ERK1/2[\\GENE] and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Treatment of A549 and H1299 cells with [CHEMICAL]dioscin[\\CHEMICAL] caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased [GENE]PI3K[\\GENE] expression and decreased phosphorylation of Akt and mTOR.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Treatment of A549 and H1299 cells with [CHEMICAL]dioscin[\\CHEMICAL] caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of [GENE]Akt[\\GENE] and mTOR.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Treatment of A549 and H1299 cells with [CHEMICAL]dioscin[\\CHEMICAL] caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and [GENE]mTOR[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Though FUR alone obviously induced endoplasmic reticulum stress, this signaling pathway may not contribute to the synergetic anti-proliferative effect as the protein expression of [GENE]CHOP[\\GENE] and BIP was similar in [CHEMICAL]FUR[\\CHEMICAL] alone and combined treatment group.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Though FUR alone obviously induced endoplasmic reticulum stress, this signaling pathway may not contribute to the synergetic anti-proliferative effect as the protein expression of CHOP and [GENE]BIP[\\GENE] was similar in [CHEMICAL]FUR[\\CHEMICAL] alone and combined treatment group.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "High [CHEMICAL]glucose[\\CHEMICAL] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates [GENE]mTOR[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "High [CHEMICAL]glucose[\\CHEMICAL] (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates [GENE]tuberin[\\GENE] and activates mTOR.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Inhibition of mTOR by low dose [CHEMICAL]rapamycin[\\CHEMICAL] decreases HG-induced [GENE]Nox4[\\GENE] and Nox1, NADPH oxidase activity and podocyte apoptosis.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Inhibition of mTOR by low dose [CHEMICAL]rapamycin[\\CHEMICAL] decreases HG-induced Nox4 and [GENE]Nox1[\\GENE], NADPH oxidase activity and podocyte apoptosis.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Pharmacological doses of the [GENE]mTOR[\\GENE] inhibitor [CHEMICAL]rapamycin[\\CHEMICAL] reduce albuminura in diabetes.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "High [CHEMICAL]glucose[\\CHEMICAL] (HG) induces apoptosis of podocytes, inhibits [GENE]AMPK[\\GENE] activation, inactivates tuberin and activates mTOR.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Inhibition of [GENE]mTOR[\\GENE] by low dose [CHEMICAL]rapamycin[\\CHEMICAL] decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Inhibition of mTOR by low dose [CHEMICAL]rapamycin[\\CHEMICAL] decreases HG-induced Nox4 and Nox1, [GENE]NADPH oxidase[\\GENE] activity and podocyte apoptosis.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Inhibition of [GENE]mTOR[\\GENE] by small dose of [CHEMICAL]rapamycin[\\CHEMICAL] reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "We analysed the role of the MBD in [GENE]MeCP2[\\GENE]-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model (Mecp2(tm)(1)(. )(1)(Jae)) in which exon 3 deletion results in an [CHEMICAL]N[\\CHEMICAL]-terminal truncation of the protein, including most of the MBD.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "We analysed the role of the MBD in MeCP2-chromatin associations in vivo using an [GENE]MeCP2[\\GENE] mutant Rett syndrome mouse model (Mecp2(tm)(1)(. )(1)(Jae)) in which exon 3 deletion results in an [CHEMICAL]N[\\CHEMICAL]-terminal truncation of the protein, including most of the MBD.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "We analysed the role of the MBD in MeCP2-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model ([GENE]Mecp2[\\GENE](tm)(1)(. )(1)(Jae)) in which exon 3 deletion results in an [CHEMICAL]N[\\CHEMICAL]-terminal truncation of the protein, including most of the MBD.",
        "label": 1,
        "major": 1,
        "len": 40
    },
    {
        "text": "Correlation between activation of [GENE]PPAR\u03b3[\\GENE] and resistin downregulation in a mouse adipocyte cell line by a series of [CHEMICAL]thiazolidinediones[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 19
    },
    {
        "text": "Correlation between activation of PPAR\u03b3 and [GENE]resistin[\\GENE] downregulation in a mouse adipocyte cell line by a series of [CHEMICAL]thiazolidinediones[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "No mutations in the [CHEMICAL]serotonin[\\CHEMICAL] related [GENE]TPH1[\\GENE] and HTR1B genes in patients with monogenic sclerosing bone disorders.",
        "label": 2,
        "major": 1,
        "len": 17
    },
    {
        "text": "In the present study, the exposure of melanoma cells to [CHEMICAL]vinblastine[\\CHEMICAL] was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both [GENE]cytochrome c[\\GENE] and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase.",
        "label": 2,
        "major": 3,
        "len": 45
    },
    {
        "text": "In the present study, the exposure of melanoma cells to [CHEMICAL]vinblastine[\\CHEMICAL] was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and [GENE]apoptosis inducing factor[\\GENE], activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase.",
        "label": 2,
        "major": 3,
        "len": 45
    },
    {
        "text": "In the present study, the exposure of melanoma cells to [CHEMICAL]vinblastine[\\CHEMICAL] was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of [GENE]Poly (ADP-ribose)-Polymerase[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Vinblastine[\\CHEMICAL]-induced apoptosis of melanoma cells is mediated by [GENE]Ras homologous A protein[\\GENE] (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Vinblastine[\\CHEMICAL]-induced apoptosis of melanoma cells is mediated by Ras homologous A protein ([GENE]Rho A[\\GENE]) via mitochondrial and non-mitochondrial-dependent mechanisms.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor [GENE]NF-\u03baB[\\GENE], HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.",
        "label": 3,
        "major": 2,
        "len": 25
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor NF-\u03baB, [GENE]HSF1[\\GENE], AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, [GENE]AP-1[\\GENE], and ATF-2, together with the expression of HSP70 and Bax proteins.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and [GENE]ATF-2[\\GENE], together with the expression of HSP70 and Bax proteins.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of [GENE]Ras homologous protein A[\\GENE], the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of [GENE]apoptosis signal-regulating kinase 1[\\GENE], c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, [GENE]c-jun-N-terminal kinase[\\GENE], p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, [GENE]p38[\\GENE], inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, [GENE]inhibitor of kappaB\u03b1[\\GENE] (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 ([GENE]I\u03baB\u03b1[\\GENE]) kinase, and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) [GENE]kinase[\\GENE], and inositol requiring enzyme 1\u03b1.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Also, [CHEMICAL]vinblastine[\\CHEMICAL] enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and [GENE]inositol requiring enzyme 1\u03b1[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of [GENE]HSP70[\\GENE] and Bax proteins.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In addition, [CHEMICAL]vinblastine[\\CHEMICAL] induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and [GENE]Bax[\\GENE] proteins.",
        "label": 3,
        "major": 2,
        "len": 25
    },
    {
        "text": "OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in [GENE]insulin[\\GENE] sensitivity with [CHEMICAL]thiazolidinediones[\\CHEMICAL] and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.",
        "label": 2,
        "major": 9,
        "len": 89
    },
    {
        "text": "OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with [CHEMICAL]thiazolidinediones[\\CHEMICAL] and changes in renal threshold with [GENE]sodium glucose transporter[\\GENE] (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.",
        "label": 2,
        "major": 9,
        "len": 89
    },
    {
        "text": "OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with [CHEMICAL]thiazolidinediones[\\CHEMICAL] and changes in renal threshold with sodium glucose transporter ([GENE]SGLT2[\\GENE]) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.",
        "label": 2,
        "major": 9,
        "len": 89
    },
    {
        "text": "In further evaluation, the representative compound [CHEMICAL]N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide[\\CHEMICAL] (3b) exhibited potent pro-apoptotic activity, through [GENE]RhoB[\\GENE] activation, in HeLa cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Treatment of C57 BL/6 mice with [CHEMICAL]bleomycin[\\CHEMICAL] increased fibroblast viability and [GENE]collagen[\\GENE] production and significantly downregulated Nrf2.",
        "label": 2,
        "major": 9,
        "len": 17
    },
    {
        "text": "To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative [GENE]Nrf2[\\GENE] activator, [CHEMICAL]caffeic acid phenethyl ester[\\CHEMICAL], and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "In a cell-based model, [CHEMICAL]bleomycin[\\CHEMICAL] suppressed Nrf2 activation via [GENE]extracellular signal-related kinase[\\GENE] phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "To confirm this novel mechanism of [CHEMICAL]bleomycin[\\CHEMICAL]-induced fibrogenesis, we attempted to upregulate [GENE]Nrf2[\\GENE] and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Treatment of C57 BL/6 mice with [CHEMICAL]bleomycin[\\CHEMICAL] increased fibroblast viability and collagen production and significantly downregulated [GENE]Nrf2[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "In a cell-based model, [CHEMICAL]bleomycin[\\CHEMICAL] suppressed [GENE]Nrf2[\\GENE] activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic [GENE]CYP3A[\\GENE] subfamily-mediated metabolism (21.9% decrease) of [CHEMICAL]doxorubicin[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Fluoride[\\CHEMICAL] treatment also increased phosphorylation of JNK and ERK, but not [GENE]p38[\\GENE], and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.",
        "label": 10,
        "major": 3,
        "len": 30
    },
    {
        "text": "Exposure of cells to 4mM [CHEMICAL]NaF[\\CHEMICAL] for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of [GENE]Bax[\\GENE] to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Exposure of cells to 4mM [CHEMICAL]NaF[\\CHEMICAL] for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of [GENE]cytochrome c[\\GENE] from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "[CHEMICAL]Sodium fluoride[\\CHEMICAL] induces apoptosis in odontoblasts via a [GENE]JNK[\\GENE]-dependent mechanism.",
        "label": 2,
        "major": 3,
        "len": 10
    },
    {
        "text": "Taken together, these findings suggest that [CHEMICAL]NaF[\\CHEMICAL] induces apoptosis in OLC odontoblasts through a [GENE]JNK[\\GENE]-dependent mitochondrial pathway.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Exposure of cells to 4mM [CHEMICAL]NaF[\\CHEMICAL] for 24h induced [GENE]caspase-3[\\GENE] activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.",
        "label": 3,
        "major": 3,
        "len": 43
    },
    {
        "text": "[CHEMICAL]Fluoride[\\CHEMICAL] treatment also increased phosphorylation of [GENE]JNK[\\GENE] and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Fluoride[\\CHEMICAL] treatment also increased phosphorylation of JNK and [GENE]ERK[\\GENE], but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "A series of [CHEMICAL]carbamoylmethylene[\\CHEMICAL] linked prodrugs of 1 (BMS-582949), a clinical [GENE]p38\u03b1[\\GENE] inhibitor, were synthesized and evaluated.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "A series of carbamoylmethylene linked prodrugs of 1 ([CHEMICAL]BMS-582949[\\CHEMICAL]), a clinical [GENE]p38\u03b1[\\GENE] inhibitor, were synthesized and evaluated.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Synthesis and evaluation of [CHEMICAL]carbamoylmethylene[\\CHEMICAL] linked prodrugs of BMS-582949, a clinical [GENE]p38\u03b1[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Synthesis and evaluation of carbamoylmethylene linked prodrugs of [CHEMICAL]BMS-582949[\\CHEMICAL], a clinical [GENE]p38\u03b1[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Here we studied the effects of the recently developed [GENE]monoacylglycerol lipase[\\GENE] inhibitor [CHEMICAL]JZL184[\\CHEMICAL] on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "Fasting plasma glucose (FPG), fasting plasma insulin, [CHEMICAL]C[\\CHEMICAL][GENE]C-peptide[\\GENE] (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 \u00b1 4 to M, 150 \u00b1 4; S, 154 \u00b1 4; and M+S, 125 \u00b1 3 mg/dL.",
        "label": 1,
        "major": 4,
        "len": 48
    },
    {
        "text": "Mechanisms of Glucose Lowering of [GENE]Dipeptidyl Peptidase-4[\\GENE] Inhibitor [CHEMICAL]Sitagliptin[\\CHEMICAL] When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of [GENE]p21[\\GENE](WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by [CHEMICAL]rofecoxib[\\CHEMICAL](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",
        "label": 3,
        "major": 4,
        "len": 32
    },
    {
        "text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21([GENE]WAF1[\\GENE]/CIP1) and upregulation of cyclinB1, since these effects were prevented by [CHEMICAL]rofecoxib[\\CHEMICAL](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/[GENE]CIP1[\\GENE]) and upregulation of cyclinB1, since these effects were prevented by [CHEMICAL]rofecoxib[\\CHEMICAL](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of [GENE]cyclinB1[\\GENE], since these effects were prevented by [CHEMICAL]rofecoxib[\\CHEMICAL](a selective COX-2 inhibitor) and rescued by exogenous PGE2.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by [CHEMICAL]rofecoxib[\\CHEMICAL](a selective [GENE]COX-2[\\GENE] inhibitor) and rescued by exogenous PGE2.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Platelet-induced [GENE]COX-2[\\GENE]-dependent [CHEMICAL]PGE2[\\CHEMICAL] synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.",
        "label": 9,
        "major": 3,
        "len": 32
    },
    {
        "text": "Synthesis and antitumor activity of [CHEMICAL]1,3,4-oxadiazole[\\CHEMICAL] possessing 1,4-benzodioxan moiety as a novel class of potent [GENE]methionine aminopeptidase type II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Synthesis and antitumor activity of 1,3,4-oxadiazole possessing [CHEMICAL]1,4-benzodioxan[\\CHEMICAL] moiety as a novel class of potent [GENE]methionine aminopeptidase type II[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Interestingly, Nox4 activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge ([CHEMICAL]Cys[\\CHEMICAL]226, Cys270) located in the extracellular E-loop of [GENE]Nox4[\\GENE].",
        "label": 1,
        "major": 4,
        "len": 26
    },
    {
        "text": "Interestingly, Nox4 activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (Cys226, [CHEMICAL]Cys[\\CHEMICAL]270) located in the extracellular E-loop of [GENE]Nox4[\\GENE].",
        "label": 1,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Quinone[\\CHEMICAL] compounds regulate the level of ROS production by the [GENE]NADPH oxidase[\\GENE] Nox4.",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Quinone[\\CHEMICAL] compounds regulate the level of ROS production by the NADPH oxidase [GENE]Nox4[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[GENE]Nox4[\\GENE] oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [CHEMICAL]quinone[\\CHEMICAL] derivatives could modulate this activity.",
        "label": 3,
        "major": 7,
        "len": 31
    },
    {
        "text": "Nox4 [GENE]oxidase[\\GENE] activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [CHEMICAL]quinone[\\CHEMICAL] derivatives could modulate this activity.",
        "label": 3,
        "major": 7,
        "len": 31
    },
    {
        "text": "In fact, we demonstrated a significant stimulation of [GENE]Nox4[\\GENE] activity by 4 [CHEMICAL]quinone[\\CHEMICAL] derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In fact, we demonstrated a significant stimulation of [GENE]Nox4[\\GENE] activity by 4 quinone derivatives ([CHEMICAL]AA-861[\\CHEMICAL], tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In fact, we demonstrated a significant stimulation of [GENE]Nox4[\\GENE] activity by 4 quinone derivatives (AA-861, [CHEMICAL]tBuBHQ[\\CHEMICAL], tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In fact, we demonstrated a significant stimulation of [GENE]Nox4[\\GENE] activity by 4 quinone derivatives (AA-861, tBuBHQ, [CHEMICAL]tBuBQ[\\CHEMICAL], and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In fact, we demonstrated a significant stimulation of [GENE]Nox4[\\GENE] activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and [CHEMICAL]duroquinone[\\CHEMICAL]) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[GENE]Nox4[\\GENE] oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [CHEMICAL]quinone[\\CHEMICAL] derivatives could modulate this activity.",
        "label": 3,
        "major": 7,
        "len": 31
    },
    {
        "text": "Nox4 [GENE]oxidase[\\GENE] activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [CHEMICAL]quinone[\\CHEMICAL] derivatives could modulate this activity.",
        "label": 3,
        "major": 7,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Allicin[\\CHEMICAL] treatment showed reduced production of pro-inflammatory cytokines and NO and increased [GENE]HO-1[\\GENE] activity.",
        "label": 3,
        "major": 9,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Allicin[\\CHEMICAL] treatment showed reduced production of pro-inflammatory [GENE]cytokines[\\GENE] and NO and increased HO-1 activity.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "In concert with these results, we highlighted that the secretion of pro-inflammatory [GENE]cytokine[\\GENE] and NF-\u03baB activation induced by TCDD can be mediated by elevation of [[CHEMICAL]Ca(2+)[\\CHEMICAL]]i in HAPI microglial cells.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and [GENE]NF-\u03baB[\\GENE] activation induced by TCDD can be mediated by elevation of [[CHEMICAL]Ca(2+)[\\CHEMICAL]]i in HAPI microglial cells.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Further, [CHEMICAL]TCDD[\\CHEMICAL] exposure could induce phosphorylation- and ubiquitination-dependent degradation of [GENE]I\u043aB\u03b1[\\GENE], and the translocation of NF-\u03baB p65 from the cytosol to the nucleus in this microglial cell line.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Thus, the [GENE]NF-\u03baB[\\GENE] signaling pathway can be activated after [CHEMICAL]TCDD[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "However, Ca(2+) blockers also obviously attenuated [GENE]NF-\u03baB[\\GENE] activation and transnuclear transport induced by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "In concert with these results, we highlighted that the secretion of pro-inflammatory [GENE]cytokine[\\GENE] and NF-\u03baB activation induced by [CHEMICAL]TCDD[\\CHEMICAL] can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and [GENE]NF-\u03baB[\\GENE] activation induced by [CHEMICAL]TCDD[\\CHEMICAL] can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] also caused a fast (within 30min as judged by the increase in its mRNA level) activation of [GENE]cytosolic phospholipase A2[\\GENE] (cPLA2).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 ([GENE]cPLA2[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "However, Ca(2+) blockers also obviously attenuated [GENE]NF-\u03baB[\\GENE] activation and transnuclear transport induced by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Vandetanib[\\CHEMICAL] (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and [GENE]epidermal growth-factor receptors[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Vandetanib[\\CHEMICAL] (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral [GENE]tyrosine kinase[\\GENE] inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Vandetanib[\\CHEMICAL] (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by [GENE]growth-factor receptor tyrosine kinase[\\GENE] RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Vandetanib[\\CHEMICAL] (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase [GENE]RET[\\GENE] (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "Vandetanib ([CHEMICAL]Caprelsa[\\CHEMICAL](\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and [GENE]epidermal growth-factor receptors[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Vandetanib ([CHEMICAL]Caprelsa[\\CHEMICAL](\u00ae), AstraZeneca) is a once-daily oral [GENE]tyrosine kinase[\\GENE] inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "Thus prolonged activation of NMDA receptors in hippocampal neurons reduced [GENE]GABAR \u03b4 subunit[\\GENE] expression through [CHEMICAL]Ca2+[\\CHEMICAL] entry and at least in part by ERK1/2 activation.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Chelation of calcium ions by BAPTA-AM or blockade of [GENE]ERK1/2[\\GENE] activation by [CHEMICAL]UO126[\\CHEMICAL] also prevented the NMDA effects.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "These results support the hypothesis that apoplastic [CHEMICAL]amino acids[\\CHEMICAL] acting through heteromeric [GENE]GLR3.2[\\GENE]/GLR3.4 channels affect lateral root development via Ca(2+) signaling in the phloem.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "These results support the hypothesis that apoplastic [CHEMICAL]amino acids[\\CHEMICAL] acting through heteromeric GLR3.2/[GENE]GLR3.4[\\GENE] channels affect lateral root development via Ca(2+) signaling in the phloem.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits NF-\u03baB-dependent inflammatory responses by modulating [GENE]I\u03baB kinase[\\GENE] (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-NF-\u03baB signaling.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits NF-\u03baB-dependent inflammatory responses by modulating I\u03baB kinase ([GENE]IKK[\\GENE])-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-NF-\u03baB signaling.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits NF-\u03baB-dependent inflammatory responses by modulating I\u03baB kinase (IKK)-[GENE]inhibitor \u03baB\u03b1[\\GENE] (I\u03baB\u03b1)-NF-\u03baB signaling.",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits NF-\u03baB-dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 ([GENE]I\u03baB\u03b1[\\GENE])-NF-\u03baB signaling.",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits NF-\u03baB-dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-[GENE]NF-\u03baB[\\GENE] signaling.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "Promoter assay revealed that [CHEMICAL]prunetin[\\CHEMICAL] inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of [GENE]iNOS[\\GENE] and COX-2 at the transcriptional level.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Promoter assay revealed that [CHEMICAL]prunetin[\\CHEMICAL] inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and [GENE]COX-2[\\GENE] at the transcriptional level.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Consistent with these results, [CHEMICAL]prunetin[\\CHEMICAL] significantly reduced serum levels of inflammatory [GENE]cytokines[\\GENE] and mortality in mice challenged with lipopolysaccharide.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In addition, [CHEMICAL]prunetin[\\CHEMICAL] inhibits [GENE]NF-\u03baB[\\GENE]-dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-NF-\u03baB signaling.",
        "label": 4,
        "major": 7,
        "len": 15
    },
    {
        "text": "Introduction: 5-Lipoxygenase ([GENE]5-LO[\\GENE]) is a crucial enzyme of the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "Introduction: [GENE]5-Lipoxygenase[\\GENE] (5-LO) is a crucial enzyme of the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.",
        "label": 9,
        "major": 3,
        "len": 29
    },
    {
        "text": "Recombinant P2X3/CASK expression in HEK cells increased [CHEMICAL]serine[\\CHEMICAL] phosphorylation of [GENE]P2X3[\\GENE] receptors, typically associated with receptor upregulation.",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "The reduction of [GENE]P2X3[\\GENE] expression levels was reversed by the proteasomal inhibitor [CHEMICAL]MG-132[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "Despite normal binding, autoactivation of mutants [GENE]D22G[\\GENE] and K23_I24insIDK was not stimulated by [CHEMICAL]calcium[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 14
    },
    {
        "text": "Despite normal binding, autoactivation of mutants D22G and [GENE]K23_I24insIDK[\\GENE] was not stimulated by [CHEMICAL]calcium[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 14
    },
    {
        "text": "The [GENE]tetra-aspartate motif[\\GENE] in the trypsinogen activation peptide binds [CHEMICAL]calcium[\\CHEMICAL] (KD ~1.6 mM), which stimulates autoactivation.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "A series of [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic [GENE]cholesterol esterase[\\GENE] (CEase) and acetylcholinesterase (AChE).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "A series of [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase ([GENE]CEase[\\GENE]) and acetylcholinesterase (AChE).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "A series of [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and [GENE]acetylcholinesterase[\\GENE] (AChE).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "A series of [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase ([GENE]AChE[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Furthermore, these [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] demonstrated good to high selectivity for [GENE]CEase[\\GENE] over AChE, which only showed micromolar potency inhibition of AChE.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Furthermore, these [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] demonstrated good to high selectivity for CEase over [GENE]AChE[\\GENE], which only showed micromolar potency inhibition of AChE.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Furthermore, these [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of [GENE]AChE[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The structure-activity relationships revealed that the free [CHEMICAL]hydroxyl[\\CHEMICAL] group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of [GENE]CEase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The structure-activity relationships revealed that the free hydroxyl group at position 5 and [CHEMICAL]phosphate[\\CHEMICAL] group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of [GENE]CEase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] are favorable to the inhibition of [GENE]CEase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Synthesis and biological evaluation of [CHEMICAL]phosphorylated flavonoids[\\CHEMICAL] as potent and selective inhibitors of [GENE]cholesterol esterase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Pasireotide[\\CHEMICAL] (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via [GENE]somatostatin receptors[\\GENE] to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pasireotide ([CHEMICAL]Signifor[\\CHEMICAL](\u00ae)) is a new subcutaneous somatostatin analogue that acts via [GENE]somatostatin receptors[\\GENE] to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Pasireotide[\\CHEMICAL] has a receptor binding profile that is distinct from that of other somatostatin analogues, binding with high affinity to [GENE]somatostatin receptor subtype 5[\\GENE], which is strongly over expressed in corticotroph adenoma cells.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Pasireotide[\\CHEMICAL] (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [GENE]corticotropin[\\GENE] from the pituitary adenoma in patients with Cushing's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pasireotide ([CHEMICAL]Signifor[\\CHEMICAL](\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of [GENE]corticotropin[\\GENE] from the pituitary adenoma in patients with Cushing's disease.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Few targets like epidermal growth factor receptor (EGFR) mutations and [GENE]anaplastic lymphoma kinase[\\GENE] (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and [CHEMICAL]crizotinib[\\CHEMICAL], respectively.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase ([GENE]ALK[\\GENE]) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and [CHEMICAL]crizotinib[\\CHEMICAL], respectively.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for [GENE]P450[\\GENE]-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 10,
        "major": 9,
        "len": 44
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for P450-dependent and [GENE]P450[\\GENE]-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 10,
        "major": 4,
        "len": 44
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [GENE]human cytochrome P450[\\GENE] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary [GENE]efflux transporters[\\GENE] BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters [GENE]BSEP[\\GENE] and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 4,
        "major": 9,
        "len": 44
    },
    {
        "text": "No effects were observed when [CHEMICAL]fenclozic acid[\\CHEMICAL] was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and [GENE]MRP2[\\GENE] or mitochondrial toxicity to THLE or HepG2 cells.",
        "label": 4,
        "major": 9,
        "len": 44
    },
    {
        "text": "The inhibitors of PI3K and Akt suppressed [CHEMICAL]S1P[\\CHEMICAL]-induced nuclear localization of [GENE]\u03b2-catenin[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Sphingosine-1-phosphate[\\CHEMICAL] promotes the nuclear translocation of [GENE]\u03b2-catenin[\\GENE] and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of [GENE]\u03b2-catenin[\\GENE], followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by [GENE]\u03b2-catenin[\\GENE]/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/[GENE]T-cell factor[\\GENE] complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "These findings suggest that [CHEMICAL]S1P[\\CHEMICAL] activates the [GENE]PI3K[\\GENE]/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "These findings suggest that [CHEMICAL]S1P[\\CHEMICAL] activates the PI3K/[GENE]Akt[\\GENE] signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Sphingosine-1-phosphate[\\CHEMICAL] promotes the nuclear translocation of \u03b2-catenin and thereby induces [GENE]osteoprotegerin[\\GENE] gene expression in osteoblast-like cell lines.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] increased the amount of [GENE]osteoprotegerin[\\GENE] at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "These findings suggest that [CHEMICAL]S1P[\\CHEMICAL] activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of [GENE]\u03b2-catenin[\\GENE] in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "These findings suggest that [CHEMICAL]S1P[\\CHEMICAL] activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of [GENE]osteoptotegerin[\\GENE] and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "These findings suggest that [CHEMICAL]S1P[\\CHEMICAL] activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including [GENE]alkaline phosphatase[\\GENE], probably relating to the inhibition of osteoclast formation and the mineralization, respectively.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated [GENE]phosphatidylinositol 3-kinase[\\GENE] (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase ([GENE]PI3K[\\GENE])/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase (PI3K)/[GENE]Akt[\\GENE] signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]S1P[\\CHEMICAL] activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of [GENE]glycogen synthase kinase-3\u03b2[\\GENE] and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "Results: The administration of [CHEMICAL]prallethrin[\\CHEMICAL] 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [GENE]hemoglobin[\\GENE], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h. Significant increases in the levels of CK, \u03b3-GT, SOD, NO, MDA, AFP, IL-2, and TNF\u03b1 were recorded.",
        "label": 3,
        "major": 4,
        "len": 82
    },
    {
        "text": "Results: The administration of [CHEMICAL]prallethrin[\\CHEMICAL] 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular [GENE]hemoglobin[\\GENE] in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h. Significant increases in the levels of CK, \u03b3-GT, SOD, NO, MDA, AFP, IL-2, and TNF\u03b1 were recorded.",
        "label": 3,
        "major": 3,
        "len": 82
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, [GENE]NF-\u03baB[\\GENE] DNA binding, I-\u03baB\u03b5 degradation and c-Rel nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of [GENE]c-Rel[\\GENE]/p50 in alveolar epithelial cells.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel/[GENE]p50[\\GENE] in alveolar epithelial cells.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, I-\u03baB\u03b5 degradation and [GENE]c-Rel[\\GENE] nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of [GENE]I-\u03baB\u03b5[\\GENE] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, [GENE]I-\u03baB\u03b5[\\GENE] degradation and c-Rel nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, I-\u03baB\u03b5 degradation and c-Rel nuclear translocation in cells pretreated with vitamin C. To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with vitamin C. Result showed that [CHEMICAL]vitamin C[\\CHEMICAL] treatment resulted in markedly reduced [GENE]c-Rel[\\GENE] nuclear translocation.",
        "label": 4,
        "major": 3,
        "len": 61
    },
    {
        "text": "All these results demonstrate that [CHEMICAL]vitamin C[\\CHEMICAL] prevents CS(E)-induced [GENE]NF-\u03baB[\\GENE] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced [GENE]NF-\u03baB[\\GENE] activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Vitamin C[\\CHEMICAL] forestalls cigarette smoke induced [GENE]NF-\u03baB[\\GENE] activation in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "Potent and selective: The unique nature of the [CHEMICAL]ATP[\\CHEMICAL] binding pocket structure of [GENE]Pim[\\GENE] family protein kinases (PKs) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Potent and selective: The unique nature of the [CHEMICAL]ATP[\\CHEMICAL] binding pocket structure of Pim family [GENE]protein kinases[\\GENE] (PKs) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Potent and selective: The unique nature of the [CHEMICAL]ATP[\\CHEMICAL] binding pocket structure of Pim family protein kinases ([GENE]PKs[\\GENE]) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Nicotine[\\CHEMICAL] does not account for the CSE stimulation of [GENE]VEGF[\\GENE] in HFL-1.",
        "label": 10,
        "major": 10,
        "len": 12
    },
    {
        "text": "Suppression of T\u03b2R1 by the pharmacological inhibitor ([CHEMICAL]SB431542[\\CHEMICAL]) markedly reduced [GENE]VEGF[\\GENE] release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Suppression of [GENE]T\u03b2R1[\\GENE] by the pharmacological inhibitor ([CHEMICAL]SB431542[\\CHEMICAL]) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "The latter is the first in vivo open-ring metabolite of [CHEMICAL]rapamycin[\\CHEMICAL] that does not affect [GENE]mTOR[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "Interestingly, we showed that [CHEMICAL]rapamycin[\\CHEMICAL] shares all the [GENE]proteasome[\\GENE] targeting properties not only with other two-domain, closed-ring analogs (rapalogs), but also with its single domain mimics, and with seco-rapamycin.",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] inhibits [GENE]proteinase[\\GENE] and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] inhibits proteinase and selected [GENE]peptidase[\\GENE] activities of the catalytic core proteasome at low micromolar concentrations.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] inhibits proteinase and selected peptidase activities of the catalytic core [GENE]proteasome[\\GENE] at low micromolar concentrations.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "We hypothesize that the [CHEMICAL]rapamycin[\\CHEMICAL] and related compounds bind to the \u03b1 face and allosterically impact the [GENE]proteasome[\\GENE] function.",
        "label": 7,
        "major": 7,
        "len": 19
    },
    {
        "text": "The implications of our finding for mechanism of in vivo actions of [CHEMICAL]rapamycin[\\CHEMICAL] and for design of novel allosteric drugs targeting the [GENE]proteasome[\\GENE] are discussed.",
        "label": 7,
        "major": 7,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] allosterically inhibits the [GENE]proteasome[\\GENE].",
        "label": 7,
        "major": 4,
        "len": 5
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] is a canonical allosteric inhibitor of the [GENE]mTOR[\\GENE] kinase with immunosuppressive and pro-apoptotic activities.",
        "label": 7,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Rapamycin[\\CHEMICAL] is a canonical allosteric inhibitor of the mTOR [GENE]kinase[\\GENE] with immunosuppressive and pro-apoptotic activities.",
        "label": 7,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]MNU[\\CHEMICAL]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [GENE]MGMT[\\GENE] staining.",
        "label": 3,
        "major": 10,
        "len": 27
    },
    {
        "text": "[CHEMICAL]MNU[\\CHEMICAL]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [GENE]E-cadherin[\\GENE], and high MGMT staining.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "Further, [CHEMICAL]methylphenidate[\\CHEMICAL] did not alter [GENE]DAT[\\GENE] cellular localization, indicating that methylphenidate treatment during adolescence regulated DAT function in SHR mPFC in a trafficking-independent manner.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "Further, methylphenidate did not alter DAT cellular localization, indicating that [CHEMICAL]methylphenidate[\\CHEMICAL] treatment during adolescence regulated [GENE]DAT[\\GENE] function in SHR mPFC in a trafficking-independent manner.",
        "label": 2,
        "major": 10,
        "len": 24
    },
    {
        "text": "In both OFC and mPFC, no strain differences in Vmax or Km for dopamine uptake into synaptosomes were found between vehicle-treated SHR, WKY and WIS. [CHEMICAL]Methylphenidate[\\CHEMICAL] increased [GENE]DAT[\\GENE] Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Thus, the increase in mPFC [GENE]DAT[\\GENE] function was an SHR-specific long term consequence of [CHEMICAL]methylphenidate[\\CHEMICAL] treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Methylphenidate[\\CHEMICAL], an inhibitor of [GENE]dopamine and norepinephrine transporters[\\GENE] (DAT and NET, respectively), is a standard treatment for ADHD.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Methylphenidate[\\CHEMICAL], an inhibitor of dopamine and norepinephrine transporters ([GENE]DAT[\\GENE] and NET, respectively), is a standard treatment for ADHD.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Methylphenidate[\\CHEMICAL], an inhibitor of dopamine and norepinephrine transporters (DAT and [GENE]NET[\\GENE], respectively), is a standard treatment for ADHD.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "In both OFC and mPFC, no strain differences in Vmax or Km for dopamine uptake into synaptosomes were found between vehicle-treated SHR, WKY and WIS. [CHEMICAL]Methylphenidate[\\CHEMICAL] increased DAT Vmax in SHR mPFC and decreased [GENE]DAT[\\GENE] Vmax in WKY OFC.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Also, [CHEMICAL]methylphenidate[\\CHEMICAL] decreased [GENE]DAT[\\GENE] Km in WIS OFC.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "In the [CHEMICAL]IB-MECA[\\CHEMICAL] group, [GENE]\u03b1-amylase[\\GENE] activity was decreased with statistically high significance compared to group I.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the [GENE]adenosine A3 receptor[\\GENE] agonist [CHEMICAL]IB-MECA[\\CHEMICAL] (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg/kg b.w.",
        "label": 5,
        "major": 5,
        "len": 40
    },
    {
        "text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the [GENE]adenosine A3 receptor[\\GENE] agonist IB-MECA [CHEMICAL](1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide[\\CHEMICAL] at a dose of 0.75\u00a0mg/kg b.w.",
        "label": 5,
        "major": 5,
        "len": 40
    },
    {
        "text": "The effects of the [GENE]adenosine A3 receptor[\\GENE] agonist [CHEMICAL]IB-MECA[\\CHEMICAL] on sodium taurocholate-induced experimental acute pancreatitis.",
        "label": 5,
        "major": 3,
        "len": 15
    },
    {
        "text": "The use of [GENE]A3 receptor[\\GENE] agonist [CHEMICAL]IB-MECA[\\CHEMICAL] attenuates EAP.",
        "label": 5,
        "major": 5,
        "len": 9
    },
    {
        "text": "Furthermore, estrogen responsive genes in fish liver, [GENE]ER\u03b1[\\GENE] and VTG, are not induced by [CHEMICAL]CP[c]Ph[\\CHEMICAL], suggesting that the compound has no endocrine disrupting potential.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "Furthermore, estrogen responsive genes in fish liver, ER\u03b1 and [GENE]VTG[\\GENE], are not induced by [CHEMICAL]CP[c]Ph[\\CHEMICAL], suggesting that the compound has no endocrine disrupting potential.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]estrogen[\\CHEMICAL] responsive genes in fish liver, [GENE]ER\u03b1[\\GENE] and VTG, are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential.",
        "label": 2,
        "major": 10,
        "len": 24
    },
    {
        "text": "Furthermore, [CHEMICAL]estrogen[\\CHEMICAL] responsive genes in fish liver, ER\u03b1 and [GENE]VTG[\\GENE], are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential.",
        "label": 2,
        "major": 10,
        "len": 24
    },
    {
        "text": "The data show that [CHEMICAL]CP[c]Ph[\\CHEMICAL] is less potent at inducing [GENE]CYP1A[\\GENE] gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The data show that CP[c]Ph is less potent at inducing [GENE]CYP1A[\\GENE] gene expression in rainbow trout than [CHEMICAL]benzo[a]pyrene[\\CHEMICAL] (B[a]P), a well-known Ah-receptor agonist.",
        "label": 3,
        "major": 5,
        "len": 23
    },
    {
        "text": "The data show that CP[c]Ph is less potent at inducing [GENE]CYP1A[\\GENE] gene expression in rainbow trout than benzo[a]pyrene ([CHEMICAL]B[a]P[\\CHEMICAL]), a well-known Ah-receptor agonist.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Results demonstrate that LRRK2 down-regulation potentiates [CHEMICAL]Mn[\\CHEMICAL] toxicity in both control and [GENE]DAT[\\GENE]-transfected cell as well as potentiates DA toxicity.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Combined treatment of [CHEMICAL]Mn[\\CHEMICAL] and DA further augments cell toxicity, ROS production and [GENE]JNK[\\GENE] phosphorylation in LRRK2 deficient cells compared to controls.",
        "label": 3,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Type I deiodinase[\\GENE], liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by [CHEMICAL]TCPP[\\CHEMICAL], while TDCPP induced CYP3A37 and CYP2H1.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Type I deiodinase, [GENE]liver fatty-acid binding protein[\\GENE] and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by [CHEMICAL]TCPP[\\CHEMICAL], while TDCPP induced CYP3A37 and CYP2H1.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Type I deiodinase, liver fatty-acid binding protein and [GENE]cytochrome P450 (CYP) 3A37[\\GENE] mRNA levels were significantly induced by [CHEMICAL]TCPP[\\CHEMICAL], while TDCPP induced CYP3A37 and CYP2H1.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while [CHEMICAL]TDCPP[\\CHEMICAL] induced [GENE]CYP3A37[\\GENE] and CYP2H1.",
        "label": 3,
        "major": 2,
        "len": 25
    },
    {
        "text": "Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while [CHEMICAL]TDCPP[\\CHEMICAL] induced CYP3A37 and [GENE]CYP2H1[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "In addition, ATM7 potentiates [CHEMICAL]3,4-methylenedioxy-N-methylamphetamine[\\CHEMICAL] (MDMA, \"Ecstasy\")-induced reversed transport by [GENE]SERT[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "In addition, ATM7 potentiates 3,4-methylenedioxy-N-methylamphetamine ([CHEMICAL]MDMA[\\CHEMICAL], \"Ecstasy\")-induced reversed transport by [GENE]SERT[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 11
    },
    {
        "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of [CHEMICAL]serotonin[\\CHEMICAL], possibly by facilitating the interaction of serotonin with transport-ready conformations of [GENE]SERT[\\GENE] when concentrations of serotonin were low and rate limiting.",
        "label": 9,
        "major": 2,
        "len": 39
    },
    {
        "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of [CHEMICAL]serotonin[\\CHEMICAL] with transport-ready conformations of [GENE]SERT[\\GENE] when concentrations of serotonin were low and rate limiting.",
        "label": 9,
        "major": 3,
        "len": 39
    },
    {
        "text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of [GENE]SERT[\\GENE] when concentrations of [CHEMICAL]serotonin[\\CHEMICAL] were low and rate limiting.",
        "label": 9,
        "major": 2,
        "len": 39
    },
    {
        "text": "[GENE]Clock[\\GENE] Gene Expression in the Liver of [CHEMICAL]Streptozotocin[\\CHEMICAL]-induced and Spontaneous Type 1 Diabetic Rats.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "Local LC [CHEMICAL]citalopram[\\CHEMICAL] effect was abolished by LC presence of the [GENE]5-HT3[\\GENE] receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the 5-HT1/2 receptor antagonist methiothepin (1\u00a0\u03bcM).",
        "label": 2,
        "major": 10,
        "len": 24
    },
    {
        "text": "CONCLUSIONS: The SSRI [CHEMICAL]citalopram[\\CHEMICAL] modulates central noradrenergic neurotransmission by activation, through endogenous serotonin, of [GENE]5-HT3[\\GENE] receptors expressed in the somatodendritic (LC) and terminal (PFC) areas, which subsequently promote an enhancement of local NA.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "In the local presence into the LC of the [GENE]\u03b12-adrenoceptor[\\GENE] antagonist [CHEMICAL]RS79948[\\CHEMICAL] (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Local LC citalopram effect was abolished by LC presence of the [GENE]5-HT3[\\GENE] receptor antagonist [CHEMICAL]MDL72222[\\CHEMICAL] (1\u00a0\u03bcM) but not the 5-HT1/2 receptor antagonist methiothepin (1\u00a0\u03bcM).",
        "label": 6,
        "major": 10,
        "len": 24
    },
    {
        "text": "Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the [GENE]5-HT1/2[\\GENE] receptor antagonist [CHEMICAL]methiothepin[\\CHEMICAL] (1\u00a0\u03bcM).",
        "label": 6,
        "major": 10,
        "len": 24
    },
    {
        "text": "Additionally, [CHEMICAL]MPTP[\\CHEMICAL] significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, [GENE]cytochrome C[\\GENE] translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",
        "label": 2,
        "major": 4,
        "len": 39
    },
    {
        "text": "Additionally, [CHEMICAL]MPTP[\\CHEMICAL] significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in [GENE]Bax[\\GENE] expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Additionally, [CHEMICAL]MPTP[\\CHEMICAL] significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-[GENE]caspase-3[\\GENE] expression, whereas these were inhibited by CRE or EB treatment.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "Additionally, [CHEMICAL]MPTP[\\CHEMICAL] significantly down-regulated [GENE]Bcl-2[\\GENE] expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "[GENE]Cholesterol esterase[\\GENE] (CE) induced surface erosion of poly(ethylene carbonate) ([CHEMICAL]PEC[\\CHEMICAL]) and drug release from PEC under mild physiological environment was investigated.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "Cholesterol esterase ([GENE]CE[\\GENE]) induced surface erosion of poly(ethylene carbonate) ([CHEMICAL]PEC[\\CHEMICAL]) and drug release from PEC under mild physiological environment was investigated.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "[GENE]Cholesterol esterase[\\GENE] (CE) induced surface erosion of [CHEMICAL]poly(ethylene carbonate)[\\CHEMICAL] (PEC) and drug release from PEC under mild physiological environment was investigated.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "Cholesterol esterase ([GENE]CE[\\GENE]) induced surface erosion of [CHEMICAL]poly(ethylene carbonate)[\\CHEMICAL] (PEC) and drug release from PEC under mild physiological environment was investigated.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "A series of [CHEMICAL]benzenesulfonamides[\\CHEMICAL] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of [CHEMICAL]benzenesulfonamides[\\CHEMICAL] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, [GENE]ScCA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of [CHEMICAL]benzenesulfonamides[\\CHEMICAL] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the [GENE]\u03b2-carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of [CHEMICAL]benzenesulfonamides[\\CHEMICAL] incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating [CHEMICAL]cyanoacrylamide[\\CHEMICAL] moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating [CHEMICAL]cyanoacrylamide[\\CHEMICAL] moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, [GENE]ScCA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating [CHEMICAL]cyanoacrylamide[\\CHEMICAL] moieties (tyrphostine analogs) were assayed as inhibitors of the [GENE]\u03b2-carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating [CHEMICAL]cyanoacrylamide[\\CHEMICAL] moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ([CHEMICAL]tyrphostine[\\CHEMICAL] analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ([CHEMICAL]tyrphostine[\\CHEMICAL] analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, [GENE]ScCA[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ([CHEMICAL]tyrphostine[\\CHEMICAL] analogs) were assayed as inhibitors of the [GENE]\u03b2-carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ([CHEMICAL]tyrphostine[\\CHEMICAL] analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Benzenesulfonamides[\\CHEMICAL] incorporating cyanoacrylamide moieties strongly inhibit [GENE]Saccharomyces cerevisiae \u03b2-carbonic anhydrase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Benzenesulfonamides incorporating [CHEMICAL]cyanoacrylamide[\\CHEMICAL] moieties strongly inhibit [GENE]Saccharomyces cerevisiae \u03b2-carbonic anhydrase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Juglone[\\CHEMICAL], isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of [GENE]AR[\\GENE] expression in human prostate cancer LNCaP cells.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of [GENE]androgen receptor[\\GENE] (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of androgen receptor ([GENE]AR[\\GENE]) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of androgen receptor (AR) and [GENE]prostate-specific antigen[\\GENE] (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen ([GENE]PSA[\\GENE]) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of [GENE]AR[\\GENE] and PSA genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Moreover, we found that [CHEMICAL]juglone[\\CHEMICAL] significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and [GENE]PSA[\\GENE] genes with and/or without dihydrotestosterone (DHT).",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Take together, our results demonstrated that [CHEMICAL]juglone[\\CHEMICAL] might induce the apoptosis in LNCaP cell via down-regulation of [GENE]AR[\\GENE] expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "In addition, pretreatment with [CHEMICAL]Z-Val-Ala-Asp-fluoromethylketone[\\CHEMICAL] (Z-VAD-fmk), a broad spectrum of [GENE]caspase[\\GENE] inhibitor, could not rescue apoptotic cells from ClpP toxicity.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone ([CHEMICAL]Z-VAD-fmk[\\CHEMICAL]), a broad spectrum of [GENE]caspase[\\GENE] inhibitor, could not rescue apoptotic cells from ClpP toxicity.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Therefore, [CHEMICAL]TSA[\\CHEMICAL]-induced apoptosis of HCC cells is [GENE]uc002mbe.2[\\GENE] dependent and reduced expression of uc002mbe.2 may be associated with liver carcinogenesis.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Among these differentially expressed lncRNAs, the greatest change was noted for [GENE]uc002mbe.2[\\GENE], which had more than 300 folds induction upon [CHEMICAL]TSA[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]TSA[\\CHEMICAL] selectively induced [GENE]uc002mbe.2[\\GENE] in four studied HCC cell lines.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "The [CHEMICAL]TSA[\\CHEMICAL]-induced [GENE]uc002mbe.2[\\GENE] expression was positively correlated with the apoptotic effect of TSA in HCC cells.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Considerable attention has focused on the antitumor effect of [GENE]histone deacetylase[\\GENE] inhibitor ([CHEMICAL]Trichostatin A[\\CHEMICAL], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Considerable attention has focused on the antitumor effect of [GENE]histone deacetylase[\\GENE] inhibitor (Trichostatin A, [CHEMICAL]TSA[\\CHEMICAL]) as well as the coding gene expression-induced apoptosis of cancer cells.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "RESULTS: Fractionated bulb extracts and the two isolated [CHEMICAL]steroidal glycoalkaloids[\\CHEMICAL] (1) and (2) induced NO production and [GENE]TGF-\u03b2 receptor I[\\GENE] mRNA expression in fibroblast cell culture.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, [CHEMICAL]brexpiprazole[\\CHEMICAL] displayed less efficacy at [GENE]D2 receptors[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In the hippocampus, [CHEMICAL]brexpiprazole[\\CHEMICAL] acted as a full agonist at [GENE]5-HT1A[\\GENE] receptors on pyramidal neurons.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "In the DRN, [CHEMICAL]brexpiprazole[\\CHEMICAL] completely inhibited the firing of 5-HT neurons via [GENE]5-HT1A[\\GENE] agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).",
        "label": 5,
        "major": 4,
        "len": 27
    },
    {
        "text": "In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via [GENE]5-HT1A[\\GENE] agonism and was more potent than [CHEMICAL]aripiprazole[\\CHEMICAL] (ED50 = 230 and 700 mug/kg, respectively).",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential [GENE]5-HT2A[\\GENE] receptor agonist [CHEMICAL]DOI[\\CHEMICAL] (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
        "label": 5,
        "major": 4,
        "len": 29
    },
    {
        "text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential [GENE]5-HT2A[\\GENE] receptor agonist DOI ([CHEMICAL]2,5-dimethoxy-4-iodoamphetamine[\\CHEMICAL]) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.",
        "label": 5,
        "major": 6,
        "len": 29
    },
    {
        "text": "Brexpiprazole reversed the inhibitory effect of the DA agonist [CHEMICAL]apomorphine[\\CHEMICAL] on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on [GENE]D2 receptors[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "In the lateral geniculate nucleus, [CHEMICAL]brexpiprazole[\\CHEMICAL] displayed [GENE]alpha1B-adrenoceptor[\\GENE] antagonistic action.",
        "label": 6,
        "major": 6,
        "len": 10
    },
    {
        "text": "At 37 degrees C the relative affinity of [CHEMICAL]3-keto-desogestrel[\\CHEMICAL], the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of [CHEMICAL]levonorgestrel[\\CHEMICAL] and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and [CHEMICAL]Org 2058[\\CHEMICAL], three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of [CHEMICAL]medroxy-progesterone acetate[\\CHEMICAL] (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of [CHEMICAL]norethisterone[\\CHEMICAL] and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of [CHEMICAL]progesterone[\\CHEMICAL] and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and [CHEMICAL]cyproterone acetate[\\CHEMICAL] whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) [CHEMICAL]3-keto-desogestrel[\\CHEMICAL] and Org 2058 displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel, the major metabolite of desogestrel, for the [GENE]progesterone receptor[\\GENE] in intact MCF-7 cells was twice that of levonorgestrel and Org 2058, three times that of medroxy-progesterone acetate (MPA), 4.5 times that of norethisterone and 5 times that of progesterone and cyproterone acetate whereas at 4 degrees C in the cytosol fraction of MCF-7 cells exposed to molybdate (nontransformed receptor complexes) 3-keto-desogestrel and [CHEMICAL]Org 2058[\\CHEMICAL] displayed similar affinity.",
        "label": 2,
        "major": 2,
        "len": 76
    },
    {
        "text": "The stronger binding of [CHEMICAL]3-keto-desogestrel[\\CHEMICAL] in intact cells was due to the higher stability of its complex with the [GENE]progesterone receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "At 37 degrees C the relative affinity of [CHEMICAL]3-keto-desogestrel[\\CHEMICAL] for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of [CHEMICAL]levonorgestrel[\\CHEMICAL], similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of [CHEMICAL]norethisterone[\\CHEMICAL] and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and [CHEMICAL]medroxyprogesterone acetate[\\CHEMICAL] (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate ([CHEMICAL]MPA[\\CHEMICAL]) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of [CHEMICAL]progestagens[\\CHEMICAL] with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of progestagens with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "At 37 degrees C the relative affinity of 3-keto-desogestrel for the [GENE]androgen receptor[\\GENE] in intact MCF-7 cells was half that of levonorgestrel, similar to that of norethisterone and medroxyprogesterone acetate (MPA) and at least three times higher than that of progestagens with anti-androgenic activity whereas at 4 degrees C in the cytosol fraction exposed to molybdate there was no clear difference between the relative affinities of [CHEMICAL]progestagens[\\CHEMICAL] with androgenic and anti-androgenic properties.",
        "label": 2,
        "major": 2,
        "len": 72
    },
    {
        "text": "Of the progestagens tested in this study, only [CHEMICAL]norethinodrel[\\CHEMICAL] displayed measurable but very low relative affinity for the [GENE]oestrogen receptor[\\GENE] in MCF-7 cells.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Of the [CHEMICAL]progestagens[\\CHEMICAL] tested in this study, only norethinodrel displayed measurable but very low relative affinity for the [GENE]oestrogen receptor[\\GENE] in MCF-7 cells.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Mechanisms that have been proposed for [GENE]peroxidase[\\GENE]-catalyzed iodination require the utilization of 1 mol of [CHEMICAL]H2O2[\\CHEMICAL] for organic binding of 1 mol of iodide.",
        "label": 8,
        "major": 2,
        "len": 24
    },
    {
        "text": "Mechanisms that have been proposed for [GENE]peroxidase[\\GENE]-catalyzed iodination require the utilization of 1 mol of H2O2 for organic binding of 1 mol of [CHEMICAL]iodide[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "This was shown to be attributable to [GENE]catalase[\\GENE]-like activity of these enzymes, resulting in unproductive cleavage of [CHEMICAL]H2O2[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "3) The inhibitory effects of the [CHEMICAL]thioureylene[\\CHEMICAL] drugs, methimazole and carbimazole, on the iodide-dependent catalatic activity were very similar to those reported previously for [GENE]thyroid peroxidase[\\GENE]-catalyzed iodination.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "3) The inhibitory effects of the thioureylene drugs, [CHEMICAL]methimazole[\\CHEMICAL] and carbimazole, on the iodide-dependent catalatic activity were very similar to those reported previously for [GENE]thyroid peroxidase[\\GENE]-catalyzed iodination.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "3) The inhibitory effects of the thioureylene drugs, methimazole and [CHEMICAL]carbimazole[\\CHEMICAL], on the iodide-dependent catalatic activity were very similar to those reported previously for [GENE]thyroid peroxidase[\\GENE]-catalyzed iodination.",
        "label": 4,
        "major": 9,
        "len": 27
    },
    {
        "text": "4) High concentrations of [CHEMICAL]I-[\\CHEMICAL] inhibited the catalatic activity of [GENE]thyroid peroxidase[\\GENE] and lactoperoxidase in a manner similar to that described previously for peroxidase-catalyzed iodination.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "4) High concentrations of [CHEMICAL]I-[\\CHEMICAL] inhibited the catalatic activity of thyroid peroxidase and [GENE]lactoperoxidase[\\GENE] in a manner similar to that described previously for peroxidase-catalyzed iodination.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "4) High concentrations of [CHEMICAL]I-[\\CHEMICAL] inhibited the catalatic activity of thyroid peroxidase and lactoperoxidase in a manner similar to that described previously for [GENE]peroxidase[\\GENE]-catalyzed iodination.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [GENE]dopamine D1 receptor[\\GENE] antagonist [CHEMICAL]SCH 39166[\\CHEMICAL] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the [GENE]dopamine D1 receptor[\\GENE] antagonist SCH 39166 ([CHEMICAL](-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine[\\CHEMICAL]) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 9,
        "len": 43
    },
    {
        "text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the [GENE]dopamine D2 receptor[\\GENE] antagonist [CHEMICAL]raclopride[\\CHEMICAL] (both at 0.003-0.03 mg/kg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg [CHEMICAL]dezocine[\\CHEMICAL] from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 2,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the [CHEMICAL]dezocine[\\CHEMICAL] stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 2,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., [CHEMICAL]fentanyl[\\CHEMICAL] >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[CHEMICAL][-]-cyclazocine[\\CHEMICAL] >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >[CHEMICAL]buprenorphine[\\CHEMICAL] = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = [CHEMICAL]butorphanol[\\CHEMICAL] >l-methadone >nalbuphine >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >[CHEMICAL]l-methadone[\\CHEMICAL] >nalbuphine >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >[CHEMICAL]nalbuphine[\\CHEMICAL] >[-]-metazocine >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[CHEMICAL][-]-metazocine[\\CHEMICAL] >morphine).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the [GENE]mu opioid receptor[\\GENE] substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >[CHEMICAL]morphine[\\CHEMICAL]).",
        "label": 5,
        "major": 5,
        "len": 57
    },
    {
        "text": "Discriminative stimulus effects of the mixed-opioid agonist/antagonist [CHEMICAL]dezocine[\\CHEMICAL]: cross-substitution by [GENE]mu and delta opioid[\\GENE] agonists.",
        "label": 2,
        "major": 5,
        "len": 15
    },
    {
        "text": "The present findings indicate that [CHEMICAL]dezocine[\\CHEMICAL] shares similar stimulus effects with both mu and delta agonists, its stimulus effects are reversed by mu-selective antagonists, and its rate-decreasing effects are not mediated by activity at [GENE]mu, kappa or delta opioid receptors[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 40
    },
    {
        "text": "The present findings indicate that [CHEMICAL]dezocine[\\CHEMICAL] shares similar stimulus effects with both [GENE]mu and delta[\\GENE] agonists, its stimulus effects are reversed by mu-selective antagonists, and its rate-decreasing effects are not mediated by activity at mu, kappa or delta opioid receptors.",
        "label": 5,
        "major": 6,
        "len": 40
    },
    {
        "text": "In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher [CHEMICAL]sarin[\\CHEMICAL] dose, respectively, was needed to cause a 50% inhibition of brain [GENE]AChE[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In phosphotriesterase and [CHEMICAL]physostigmine[\\CHEMICAL]-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain [GENE]AChE[\\GENE] activity.",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "The acute toxicity of organophosphorus ([CHEMICAL]OP[\\CHEMICAL]) compounds in mammals is due to their irreversible inhibition of [GENE]acetylcholinesterase[\\GENE] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The acute toxicity of organophosphorus ([CHEMICAL]OP[\\CHEMICAL]) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([GENE]AChE[\\GENE]) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The acute toxicity of [CHEMICAL]organophosphorus[\\CHEMICAL] (OP) compounds in mammals is due to their irreversible inhibition of [GENE]acetylcholinesterase[\\GENE] (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The acute toxicity of [CHEMICAL]organophosphorus[\\CHEMICAL] (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ([GENE]AChE[\\GENE]) in the nervous system, which leads to increased synaptic acetylcholine levels.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Probing the salmeterol binding site on the [GENE]beta 2-adrenergic receptor[\\GENE] using a novel photoaffinity ligand, [CHEMICAL][(125)I]iodoazidosalmeterol[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Probing the [CHEMICAL]salmeterol[\\CHEMICAL] binding site on the [GENE]beta 2-adrenergic receptor[\\GENE] using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Salmeterol[\\CHEMICAL] is a long-acting [GENE]beta2-adrenergic receptor[\\GENE] (beta 2AR) agonist used clinically to treat asthma.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Salmeterol[\\CHEMICAL] is a long-acting beta2-adrenergic receptor ([GENE]beta 2AR[\\GENE]) agonist used clinically to treat asthma.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of [CHEMICAL]salmeterol[\\CHEMICAL] in the [GENE]beta 2AR[\\GENE] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "To determine the position of the phenyl ring of the [CHEMICAL]aralkyloxyalkyl[\\CHEMICAL] side chain of salmeterol in the [GENE]beta 2AR[\\GENE] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "To determine the position of the [CHEMICAL]phenyl[\\CHEMICAL] ring of the aralkyloxyalkyl side chain of salmeterol in the [GENE]beta 2AR[\\GENE] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS).",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the [GENE]beta 2AR[\\GENE] binding site, we designed and synthesized the agonist photoaffinity label [CHEMICAL][(125)I]iodoazidosalmeterol[\\CHEMICAL] ([125I]IAS).",
        "label": 5,
        "major": 2,
        "len": 31
    },
    {
        "text": "To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the [GENE]beta 2AR[\\GENE] binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([CHEMICAL][125I]IAS[\\CHEMICAL]).",
        "label": 5,
        "major": 2,
        "len": 31
    },
    {
        "text": "In direct [GENE]adenylyl cyclase[\\GENE] activation, in effects on adenylyl cyclase after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, [CHEMICAL]IAS[\\CHEMICAL] and the parent drug salmeterol behave essentially the same.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In direct [GENE]adenylyl cyclase[\\GENE] activation, in effects on adenylyl cyclase after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, IAS and the parent drug [CHEMICAL]salmeterol[\\CHEMICAL] behave essentially the same.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In direct adenylyl cyclase activation, in effects on [GENE]adenylyl cyclase[\\GENE] after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, [CHEMICAL]IAS[\\CHEMICAL] and the parent drug salmeterol behave essentially the same.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In direct adenylyl cyclase activation, in effects on [GENE]adenylyl cyclase[\\GENE] after pretreatment of intact cells, and in guinea pig tracheal relaxation assays, IAS and the parent drug [CHEMICAL]salmeterol[\\CHEMICAL] behave essentially the same.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [GENE]beta 2AR[\\GENE] labeled by the antagonist photoaffinity label [CHEMICAL][125I]iodoazidobenzylpindolol[\\CHEMICAL] ([125I]IABP).",
        "label": 6,
        "major": 2,
        "len": 40
    },
    {
        "text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [GENE]beta 2AR[\\GENE] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([CHEMICAL][125I]IABP[\\CHEMICAL]).",
        "label": 6,
        "major": 6,
        "len": 40
    },
    {
        "text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [CHEMICAL][125I]IAS[\\CHEMICAL] migrated at the same position on an SDS-PAGE gel as the [GENE]beta 2AR[\\GENE] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "Labeling with [CHEMICAL][(125)I]IAS[\\CHEMICAL] was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [GENE]beta 2AR[\\GENE] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).",
        "label": 2,
        "major": 6,
        "len": 40
    },
    {
        "text": "A model of [CHEMICAL]IAS[\\CHEMICAL] binding to the [GENE]beta 2AR[\\GENE] is proposed.",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "Labeling with [(125)I]IAS was blocked by 10 microM [CHEMICAL](-)-alprenolol[\\CHEMICAL] and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the [GENE]beta 2AR[\\GENE] labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "RESULTS: After treatment with [CHEMICAL]triflusal[\\CHEMICAL], there was an increase in NO production by neutrophils and an increase in [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS) protein expression in neutrophils.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "RESULTS: After treatment with [CHEMICAL]triflusal[\\CHEMICAL], there was an increase in NO production by neutrophils and an increase in endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]) protein expression in neutrophils.",
        "label": 3,
        "major": 9,
        "len": 27
    },
    {
        "text": "A slight decrease in [GENE]P-selectin[\\GENE] surface expression on platelets was found which was not modified by the presence of neutrophils and therefore by the neutrophil-derived [CHEMICAL]NO[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 26
    },
    {
        "text": "CONCLUSION: Oral treatment of healthy volunteers with [CHEMICAL]triflusal[\\CHEMICAL] stimulated NO production and [GENE]eNOS[\\GENE] protein expression in their neutrophils.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "However, the neutrophils and the endogenous [CHEMICAL]NO[\\CHEMICAL] generated by them failed to modify [GENE]P-selectin[\\GENE] expression in ADP-activated platelets.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Methamphetamine[\\CHEMICAL] increases the hippocampal [GENE]alpha(2A)-adrenergic receptor[\\GENE] and Galpha(o) in mice.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Methamphetamine[\\CHEMICAL] increases the hippocampal alpha(2A)-adrenergic receptor and [GENE]Galpha(o)[\\GENE] in mice.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "This study investigates the involvement of [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR) in mouse brain induced by a low dose of [CHEMICAL]methamphetamine[\\CHEMICAL] (METH, 2 mg/kg).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "This study investigates the involvement of alpha(2)-adrenergic receptors ([GENE]AR[\\GENE]) in mouse brain induced by a low dose of [CHEMICAL]methamphetamine[\\CHEMICAL] (METH, 2 mg/kg).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "This study investigates the involvement of [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR) in mouse brain induced by a low dose of methamphetamine ([CHEMICAL]METH[\\CHEMICAL], 2 mg/kg).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "This study investigates the involvement of alpha(2)-adrenergic receptors ([GENE]AR[\\GENE]) in mouse brain induced by a low dose of methamphetamine ([CHEMICAL]METH[\\CHEMICAL], 2 mg/kg).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Immunohistochemical studies show that [GENE]alpha(2A)-AR[\\GENE] increased in the dentate gyrus area of the hippocampus 24 h after five repeated administrations of [CHEMICAL]METH[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Accumulation of [CHEMICAL]glutathione disulfide[\\CHEMICAL] mediates [GENE]NF-kappaB[\\GENE] activation during immune stimulation with CpG DNA.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Treatment of cells with [CHEMICAL]BCNU[\\CHEMICAL] to inhibit [GENE]glutathione reductase[\\GENE] (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Treatment of cells with [CHEMICAL]BCNU[\\CHEMICAL] to inhibit glutathione reductase ([GENE]GR[\\GENE]) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Treatment of cells with [CHEMICAL]BCNU[\\CHEMICAL] to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of [GENE]NF-kappaB[\\GENE] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Treatment of cells with [CHEMICAL]BCNU[\\CHEMICAL] to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of [GENE]IL-6[\\GENE] and TNF-alpha.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Treatment of cells with [CHEMICAL]BCNU[\\CHEMICAL] to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [GENE]TNF-alpha[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "Experimental manipulation of the intracellular GSSG concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular [CHEMICAL]GSSG[\\CHEMICAL] is a primary signal that is directly or indirectly required for CpG-induced [GENE]NF-kappaB[\\GENE] activation but is not in itself sufficient to trigger this in the absence of CpG ODN.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "Experimental manipulation of the intracellular [CHEMICAL]GSSG[\\CHEMICAL] concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular GSSG is a primary signal that is directly or indirectly required for CpG-induced [GENE]NF-kappaB[\\GENE] activation but is not in itself sufficient to trigger this in the absence of CpG ODN.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the [CHEMICAL]GSH[\\CHEMICAL]/GSSG, with increased activation of [GENE]NF-kappaB[\\GENE] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the [CHEMICAL]GSH[\\CHEMICAL]/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of [GENE]IL-6[\\GENE] and TNF-alpha.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the [CHEMICAL]GSH[\\CHEMICAL]/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [GENE]TNF-alpha[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/[CHEMICAL]GSSG[\\CHEMICAL], with increased activation of [GENE]NF-kappaB[\\GENE] and a doubling in the CpG-induced production of IL-6 and TNF-alpha.",
        "label": 3,
        "major": 4,
        "len": 35
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/[CHEMICAL]GSSG[\\CHEMICAL], with increased activation of NF-kappaB and a doubling in the CpG-induced production of [GENE]IL-6[\\GENE] and TNF-alpha.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/[CHEMICAL]GSSG[\\CHEMICAL], with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and [GENE]TNF-alpha[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[GENE]Dimethylarginine dimethylaminohydrolase 1[\\GENE] (DDAH1) is an enzyme that metabolizes [CHEMICAL]methylated arginine[\\CHEMICAL] to citrulline and methylamine, thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Dimethylarginine dimethylaminohydrolase 1 ([GENE]DDAH1[\\GENE]) is an enzyme that metabolizes [CHEMICAL]methylated arginine[\\CHEMICAL] to citrulline and methylamine, thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Dimethylarginine dimethylaminohydrolase 1 ([GENE]DDAH1[\\GENE]) is an enzyme that metabolizes methylated arginine to [CHEMICAL]citrulline[\\CHEMICAL] and methylamine, thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Dimethylarginine dimethylaminohydrolase 1[\\GENE] (DDAH1) is an enzyme that metabolizes methylated arginine to [CHEMICAL]citrulline[\\CHEMICAL] and methylamine, thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Dimethylarginine dimethylaminohydrolase 1[\\GENE] (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and [CHEMICAL]methylamine[\\CHEMICAL], thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Dimethylarginine dimethylaminohydrolase 1 ([GENE]DDAH1[\\GENE]) is an enzyme that metabolizes methylated arginine to citrulline and [CHEMICAL]methylamine[\\CHEMICAL], thus working to produce nitric oxide (NO).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[GENE]Carbonic anhydrase[\\GENE] inhibitors: [CHEMICAL]aromatic and heterocyclic sulfonamides[\\CHEMICAL] incorporating adamantyl moieties with strong anticonvulsant activity.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[GENE]Carbonic anhydrase[\\GENE] inhibitors: aromatic and heterocyclic sulfonamides incorporating [CHEMICAL]adamantyl[\\CHEMICAL] moieties with strong anticonvulsant activity.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two [GENE]human CA[\\GENE] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, [GENE]CA I[\\GENE], and CA II, of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and [GENE]CA II[\\GENE], of the same order of magnitude as the clinically used drugs [CHEMICAL]acetazolamide[\\CHEMICAL] and methazolamide.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two [GENE]human CA[\\GENE] isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, [GENE]CA I[\\GENE], and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and [GENE]CA II[\\GENE], of the same order of magnitude as the clinically used drugs acetazolamide and [CHEMICAL]methazolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "PURPOSE: The [CHEMICAL]fluoropyrimidine carbamate[\\CHEMICAL] (capecitabine) is converted to 5-fluorouracil (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate ([CHEMICAL]capecitabine[\\CHEMICAL]) is converted to 5-fluorouracil (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The [CHEMICAL]fluoropyrimidine carbamate[\\CHEMICAL] (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate ([CHEMICAL]capecitabine[\\CHEMICAL]) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [CHEMICAL]5-fluorouracil[\\CHEMICAL] (5-FU) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]) by [GENE]thymidine phosphorylase[\\GENE] (TP) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to [CHEMICAL]5-fluorouracil[\\CHEMICAL] (5-FU) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ([CHEMICAL]5-FU[\\CHEMICAL]) by thymidine phosphorylase ([GENE]TP[\\GENE]) inside target tissues.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking [GENE]thymidylate synthase[\\GENE] (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking thymidylate synthase ([GENE]TS[\\GENE]) but is inactivated by dihydropyrimidine dehydrogenase (DPD).",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by [GENE]dihydropyrimidine dehydrogenase[\\GENE] (DPD).",
        "label": 9,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]5-FU[\\CHEMICAL] interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase ([GENE]DPD[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 17
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high [GENE]5HT-2A[\\GENE] affinity--[CHEMICAL]clozapine[\\CHEMICAL], olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high [GENE]5HT-2A[\\GENE] affinity--clozapine, [CHEMICAL]olanzapine[\\CHEMICAL], risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high [GENE]5HT-2A[\\GENE] affinity--clozapine, olanzapine, [CHEMICAL]risperidone[\\CHEMICAL] vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low [GENE]5HT-2A[\\GENE] affinity--[CHEMICAL]quetiapine[\\CHEMICAL], amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low [GENE]5HT-2A[\\GENE] affinity--quetiapine, [CHEMICAL]amisulpride[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--[CHEMICAL]clozapine[\\CHEMICAL], olanzapine, risperidone vs. low [GENE]5HT-2A[\\GENE] affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, [CHEMICAL]olanzapine[\\CHEMICAL], risperidone vs. low [GENE]5HT-2A[\\GENE] affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, [CHEMICAL]risperidone[\\CHEMICAL] vs. low [GENE]5HT-2A[\\GENE] affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high [GENE]5HT-2A[\\GENE] affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--[CHEMICAL]quetiapine[\\CHEMICAL], amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high [GENE]5HT-2A[\\GENE] affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, [CHEMICAL]amisulpride[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the [GENE]5HT-2A[\\GENE] affinity of the individual medications (high 5HT-2A affinity--[CHEMICAL]clozapine[\\CHEMICAL], olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the [GENE]5HT-2A[\\GENE] affinity of the individual medications (high 5HT-2A affinity--clozapine, [CHEMICAL]olanzapine[\\CHEMICAL], risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the [GENE]5HT-2A[\\GENE] affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, [CHEMICAL]risperidone[\\CHEMICAL] vs. low 5HT-2A affinity--quetiapine, amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the [GENE]5HT-2A[\\GENE] affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--[CHEMICAL]quetiapine[\\CHEMICAL], amisulpride).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The patients were divided into two groups according to the [GENE]5HT-2A[\\GENE] affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, [CHEMICAL]amisulpride[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Intracellular K+ is required for the inactivation-induced high-affinity binding of [CHEMICAL]cisapride[\\CHEMICAL] to [GENE]HERG[\\GENE] channels.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Intracellular [CHEMICAL]K+[\\CHEMICAL] is required for the inactivation-induced high-affinity binding of cisapride to [GENE]HERG[\\GENE] channels.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "In the present study, we examined the effect of inactivation gating on [CHEMICAL]cisapride[\\CHEMICAL] block of [GENE]HERG[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Modulation of [GENE]HERG[\\GENE] inactivation was achieved by either changing extracellular [CHEMICAL]K+[\\CHEMICAL] or Cs+ concentrations or by mutations of the channel.",
        "label": 2,
        "major": 1,
        "len": 20
    },
    {
        "text": "Modulation of [GENE]HERG[\\GENE] inactivation was achieved by either changing extracellular K+ or [CHEMICAL]Cs+[\\CHEMICAL] concentrations or by mutations of the channel.",
        "label": 2,
        "major": 7,
        "len": 20
    },
    {
        "text": "We found that although inactivation facilitated [CHEMICAL]cisapride[\\CHEMICAL] block of the [GENE]HERG[\\GENE] K+ current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated [CHEMICAL]cisapride[\\CHEMICAL] block of the HERG K+ current, it was not coupled with cisapride block of [GENE]HERG[\\GENE] when the Cs+ current was recorded.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with [CHEMICAL]cisapride[\\CHEMICAL] block of [GENE]HERG[\\GENE] when the Cs+ current was recorded.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the [GENE]HERG[\\GENE] K+ current, it was not coupled with [CHEMICAL]cisapride[\\CHEMICAL] block of HERG when the Cs+ current was recorded.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the [GENE]HERG[\\GENE] [CHEMICAL]K+[\\CHEMICAL] current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with cisapride block of [GENE]HERG[\\GENE] when the [CHEMICAL]Cs+[\\CHEMICAL] current was recorded.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the HERG [CHEMICAL]K+[\\CHEMICAL] current, it was not coupled with cisapride block of [GENE]HERG[\\GENE] when the Cs+ current was recorded.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that although inactivation facilitated cisapride block of the [GENE]HERG[\\GENE] K+ current, it was not coupled with cisapride block of HERG when the [CHEMICAL]Cs+[\\CHEMICAL] current was recorded.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "Furthermore, [CHEMICAL]cisapride[\\CHEMICAL] block of the [GENE]HERG[\\GENE] K+ current was not linked with inactivation in the mutant HERG channels F656V and F656M.",
        "label": 4,
        "major": 1,
        "len": 21
    },
    {
        "text": "Furthermore, cisapride block of the [GENE]HERG[\\GENE] [CHEMICAL]K+[\\CHEMICAL] current was not linked with inactivation in the mutant HERG channels F656V and F656M.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, [CHEMICAL]cisapride[\\CHEMICAL] block of the HERG K+ current was not linked with inactivation in the mutant [GENE]HERG[\\GENE] channels F656V and F656M.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, cisapride block of the HERG [CHEMICAL]K+[\\CHEMICAL] current was not linked with inactivation in the mutant [GENE]HERG[\\GENE] channels F656V and F656M.",
        "label": 9,
        "major": 1,
        "len": 21
    },
    {
        "text": "Our results suggest that inactivation facilitates [CHEMICAL]cisapride[\\CHEMICAL] block of [GENE]HERG[\\GENE] channels through affecting the positioning of Phe-656.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Our results suggest that inactivation facilitates cisapride block of [GENE]HERG[\\GENE] channels through affecting the positioning of [CHEMICAL]Phe[\\CHEMICAL]-656.",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "BACKGROUND: [GENE]Norepinephrine transporter[\\GENE] (NET) is involved in the regulation of [CHEMICAL]norepinephrine[\\CHEMICAL] (NE) turnover and metabolism.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "BACKGROUND: Norepinephrine transporter ([GENE]NET[\\GENE]) is involved in the regulation of [CHEMICAL]norepinephrine[\\CHEMICAL] (NE) turnover and metabolism.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "BACKGROUND: Norepinephrine transporter ([GENE]NET[\\GENE]) is involved in the regulation of norepinephrine ([CHEMICAL]NE[\\CHEMICAL]) turnover and metabolism.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "BACKGROUND: [GENE]Norepinephrine transporter[\\GENE] (NET) is involved in the regulation of norepinephrine ([CHEMICAL]NE[\\CHEMICAL]) turnover and metabolism.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Neuronal [CHEMICAL]NE[\\CHEMICAL] reuptake may be impaired in individuals with renal disease and/or hypertension due to dysfunction of the [GENE]NE transporter[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "[GENE]AMP-activated protein kinase[\\GENE]-dependent and -independent mechanisms underlying in vitro antiglioma action of [CHEMICAL]compound C[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C.\tWe investigated the effect of [CHEMICAL]compound C[\\CHEMICAL], a well-known inhibitor of the intracellular energy sensor [GENE]AMP-activated protein kinase[\\GENE] (AMPK), on proliferation and viability of human U251 and rat C6 glioma cell lines.",
        "label": 4,
        "major": 3,
        "len": 45
    },
    {
        "text": "AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C.\tWe investigated the effect of [CHEMICAL]compound C[\\CHEMICAL], a well-known inhibitor of the intracellular energy sensor AMP-activated protein kinase ([GENE]AMPK[\\GENE]), on proliferation and viability of human U251 and rat C6 glioma cell lines.",
        "label": 4,
        "major": 3,
        "len": 45
    },
    {
        "text": "[CHEMICAL]Compound C[\\CHEMICAL] caused G(2)/M cell cycle block, accompanied by apoptotic glioma cell death characterized by [GENE]caspase[\\GENE] activation, phosphatidylserine exposure and DNA fragmentation.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "The mechanisms underlying the pro-apoptotic action of [CHEMICAL]compound C[\\CHEMICAL] involved induction of oxidative stress and downregulation of antiapoptotic molecule [GENE]Bcl-2[\\GENE], while no alteration of pro-apoptotic Bax was observed.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The mechanisms underlying the pro-apoptotic action of [CHEMICAL]compound C[\\CHEMICAL] involved induction of oxidative stress and downregulation of antiapoptotic molecule Bcl-2, while no alteration of pro-apoptotic [GENE]Bax[\\GENE] was observed.",
        "label": 10,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Compound C[\\CHEMICAL] diminished AMPK phosphorylation and enzymatic activity, resulting in reduced phosphorylation of its target [GENE]acetyl CoA carboxylase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[GENE]AMPK[\\GENE] activators [CHEMICAL]metformin[\\CHEMICAL] and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "[GENE]AMPK[\\GENE] activators metformin and [CHEMICAL]AICAR[\\CHEMICAL] partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.",
        "label": 3,
        "major": 3,
        "len": 47
    },
    {
        "text": "In conclusion, our data indicate that [GENE]AMPK[\\GENE] inhibition is required, but not sufficient for [CHEMICAL]compound C[\\CHEMICAL]-mediated apoptotic death of glioma cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Compound C[\\CHEMICAL] diminished [GENE]AMPK[\\GENE] phosphorylation and enzymatic activity, resulting in reduced phosphorylation of its target acetyl CoA carboxylase.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by [CHEMICAL]matrine[\\CHEMICAL] and oxymatrine through up-regulating [GENE]transcription factor Sp1[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and [CHEMICAL]oxymatrine[\\CHEMICAL] through up-regulating [GENE]transcription factor Sp1[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Arsenic trioxide[\\CHEMICAL]-induced [GENE]hERG[\\GENE] K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Arsenic trioxide[\\CHEMICAL]-induced hERG [GENE]K(+) channel[\\GENE] deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Arsenic trioxide-induced [GENE]hERG[\\GENE] K(+) channel deficiency can be rescued by [CHEMICAL]matrine[\\CHEMICAL] and oxymatrine through up-regulating transcription factor Sp1 expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Arsenic trioxide-induced hERG [GENE]K(+) channel[\\GENE] deficiency can be rescued by [CHEMICAL]matrine[\\CHEMICAL] and oxymatrine through up-regulating transcription factor Sp1 expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Arsenic trioxide-induced [GENE]hERG[\\GENE] K(+) channel deficiency can be rescued by matrine and [CHEMICAL]oxymatrine[\\CHEMICAL] through up-regulating transcription factor Sp1 expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Arsenic trioxide-induced hERG [GENE]K(+) channel[\\GENE] deficiency can be rescued by matrine and [CHEMICAL]oxymatrine[\\CHEMICAL] through up-regulating transcription factor Sp1 expression.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Arsenic trioxide[\\CHEMICAL] (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the [GENE]hERG[\\GENE] current through the diversion of hERG trafficking to the cytoplasmic membrane.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Arsenic trioxide[\\CHEMICAL] (As(2)O(3)), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the hERG current through the diversion of [GENE]hERG[\\GENE] trafficking to the cytoplasmic membrane.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Arsenic trioxide ([CHEMICAL]As(2)O(3)[\\CHEMICAL]), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the [GENE]hERG[\\GENE] current through the diversion of hERG trafficking to the cytoplasmic membrane.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Arsenic trioxide ([CHEMICAL]As(2)O(3)[\\CHEMICAL]), which is used to treat acute promyelocytic leukemia, can cause LQTS type 2 (LQT2) by reducing the hERG current through the diversion of [GENE]hERG[\\GENE] trafficking to the cytoplasmic membrane.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "We reported that superfusion of [GENE]hERG[\\GENE]-expressing HEK293 (hERG-HEK) cells with [CHEMICAL]matrine[\\CHEMICAL] (1, 10 \u03bcM) increased the hERG current by promoting hERG channel activation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "We reported that superfusion of hERG-expressing HEK293 ([GENE]hERG[\\GENE]-HEK) cells with [CHEMICAL]matrine[\\CHEMICAL] (1, 10 \u03bcM) increased the hERG current by promoting hERG channel activation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "We reported that superfusion of hERG-expressing HEK293 (hERG-HEK) cells with [CHEMICAL]matrine[\\CHEMICAL] (1, 10 \u03bcM) increased the [GENE]hERG[\\GENE] current by promoting hERG channel activation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "We reported that superfusion of hERG-expressing HEK293 (hERG-HEK) cells with [CHEMICAL]matrine[\\CHEMICAL] (1, 10 \u03bcM) increased the hERG current by promoting [GENE]hERG[\\GENE] channel activation.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM [CHEMICAL]matrine[\\CHEMICAL] or oxymatrine increased expression of the [GENE]hERG[\\GENE] protein and rescued the hERG surface expression disrupted by As(2)O(3).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM matrine or [CHEMICAL]oxymatrine[\\CHEMICAL] increased expression of the [GENE]hERG[\\GENE] protein and rescued the hERG surface expression disrupted by As(2)O(3).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM [CHEMICAL]matrine[\\CHEMICAL] or oxymatrine increased expression of the hERG protein and rescued the [GENE]hERG[\\GENE] surface expression disrupted by As(2)O(3).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM matrine or [CHEMICAL]oxymatrine[\\CHEMICAL] increased expression of the hERG protein and rescued the [GENE]hERG[\\GENE] surface expression disrupted by As(2)O(3).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM matrine or oxymatrine increased expression of the hERG protein and rescued the [GENE]hERG[\\GENE] surface expression disrupted by [CHEMICAL]As(2)O(3)[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Long-term treatment with 1 \u03bcM matrine or oxymatrine increased expression of the [GENE]hERG[\\GENE] protein and rescued the hERG surface expression disrupted by [CHEMICAL]As(2)O(3)[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Therefore, matrine and [CHEMICAL]oxymatrine[\\CHEMICAL] may have the potential to cure LQT2 as a potassium channel activator by promoting [GENE]hERG[\\GENE] channel activation and increasing hERG channel expression.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Therefore, [CHEMICAL]matrine[\\CHEMICAL] and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting [GENE]hERG[\\GENE] channel activation and increasing hERG channel expression.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Therefore, [CHEMICAL]matrine[\\CHEMICAL] and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing [GENE]hERG[\\GENE] channel expression.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Therefore, matrine and [CHEMICAL]oxymatrine[\\CHEMICAL] may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing [GENE]hERG[\\GENE] channel expression.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Ibandronate[\\CHEMICAL] increases the expression of the pro-apoptotic gene [GENE]FAS[\\GENE] by epigenetic mechanisms in tumor cells.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Further we found stimulation of [GENE]FAS[\\GENE]-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both [CHEMICAL]geranylgeranyl-pyrophosphate[\\CHEMICAL] and farnesylpyrophosphate.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [GENE]DNMT1[\\GENE], which was rescued by re-isoprenylation by both [CHEMICAL]geranylgeranyl-pyrophosphate[\\CHEMICAL] and farnesylpyrophosphate.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Further we found stimulation of [GENE]FAS[\\GENE]-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [CHEMICAL]farnesylpyrophosphate[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [GENE]DNMT1[\\GENE], which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [CHEMICAL]farnesylpyrophosphate[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "In contrast, [CHEMICAL]ibandronate[\\CHEMICAL] did not affect [GENE]FAS[\\GENE] and DNMT1 expression in MC3T3-E1 non-neoplastic cells.",
        "label": 10,
        "major": 10,
        "len": 14
    },
    {
        "text": "In contrast, [CHEMICAL]ibandronate[\\CHEMICAL] did not affect FAS and [GENE]DNMT1[\\GENE] expression in MC3T3-E1 non-neoplastic cells.",
        "label": 10,
        "major": 10,
        "len": 14
    },
    {
        "text": "Data suggest that [CHEMICAL]bisphosphonates[\\CHEMICAL] via modulation of the activity of small-[GENE]GTPases[\\GENE] induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Data suggest that [CHEMICAL]bisphosphonates[\\CHEMICAL] via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [GENE]FAS[\\GENE]-expression.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "In comparison to homozygous, wild type (WT) mice, HZ mice show a 40% reduction of AChE activity in the brain, while their hippocampal ACh levels are increased by 56% as measured by microdialysis; [GENE]choline acetyltransferase[\\GENE] levels remain unaltered, and [CHEMICAL]choline[\\CHEMICAL] uptake increases 2-fold.",
        "label": 9,
        "major": 3,
        "len": 43
    },
    {
        "text": "We demonstrate that HZ mice are significantly more sensitive to local [GENE]AChE[\\GENE] inhibition ([CHEMICAL]BW284c51[\\CHEMICAL]), but remain insensitive to butyrylcholinesterase (BuChE) inhibition (bambuterol).",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "We demonstrate that HZ mice are significantly more sensitive to local AChE inhibition (BW284c51), but remain insensitive to [GENE]butyrylcholinesterase[\\GENE] (BuChE) inhibition ([CHEMICAL]bambuterol[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "We demonstrate that HZ mice are significantly more sensitive to local AChE inhibition (BW284c51), but remain insensitive to butyrylcholinesterase ([GENE]BuChE[\\GENE]) inhibition ([CHEMICAL]bambuterol[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "HZ mice are also more sensitive to the peripheral application of the selective [GENE]AChE[\\GENE] inhibitor [CHEMICAL]donepezil[\\CHEMICAL] or the mixed inhibitor physostigmine; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "HZ mice are also more sensitive to the peripheral application of the selective [GENE]AChE[\\GENE] inhibitor donepezil or the mixed inhibitor physostigmine; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of [CHEMICAL]donepezil[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "HZ mice are also more sensitive to the peripheral application of the selective [GENE]AChE[\\GENE] inhibitor donepezil or the mixed inhibitor [CHEMICAL]physostigmine[\\CHEMICAL]; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "HZ mice are also more sensitive to the peripheral application of the selective [GENE]AChE[\\GENE] inhibitor donepezil or the mixed inhibitor physostigmine; extracellular [CHEMICAL]ACh[\\CHEMICAL] levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.",
        "label": 9,
        "major": 3,
        "len": 43
    },
    {
        "text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist ([CHEMICAL]CP55940[\\CHEMICAL], 50\u03bcg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of [GENE]\u03b2-Arrestin 2[\\GENE] and ERK1/2, enhanced pERK protein levels, and enhanced expression of \u03b2-Arrestin 2 mRNA and protein levels in PFCx.",
        "label": 3,
        "major": 5,
        "len": 37
    },
    {
        "text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist ([CHEMICAL]CP55940[\\CHEMICAL], 50\u03bcg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of \u03b2-Arrestin 2 and [GENE]ERK1/2[\\GENE], enhanced pERK protein levels, and enhanced expression of \u03b2-Arrestin 2 mRNA and protein levels in PFCx.",
        "label": 3,
        "major": 5,
        "len": 37
    },
    {
        "text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist ([CHEMICAL]CP55940[\\CHEMICAL], 50\u03bcg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of \u03b2-Arrestin 2 and ERK1/2, enhanced [GENE]pERK[\\GENE] protein levels, and enhanced expression of \u03b2-Arrestin 2 mRNA and protein levels in PFCx.",
        "label": 3,
        "major": 5,
        "len": 37
    },
    {
        "text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist ([CHEMICAL]CP55940[\\CHEMICAL], 50\u03bcg/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of \u03b2-Arrestin 2 and ERK1/2, enhanced pERK protein levels, and enhanced expression of [GENE]\u03b2-Arrestin 2[\\GENE] mRNA and protein levels in PFCx.",
        "label": 3,
        "major": 5,
        "len": 37
    },
    {
        "text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate \u03b2-Arrestin 2, an effect that was prevented by selective [GENE]CB(2)[\\GENE] receptor antagonist [CHEMICAL]JTE-907[\\CHEMICAL] and CB(2) shRNA lentiviral particles.",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "In a neuronal cell line, we found that selective [GENE]CB(2)[\\GENE] receptor agonists upregulate \u03b2-Arrestin 2, an effect that was prevented by selective CB(2) receptor antagonist [CHEMICAL]JTE-907[\\CHEMICAL] and CB(2) shRNA lentiviral particles.",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate \u03b2-Arrestin 2, an effect that was prevented by selective CB(2) receptor antagonist [CHEMICAL]JTE-907[\\CHEMICAL] and [GENE]CB(2)[\\GENE] shRNA lentiviral particles.",
        "label": 6,
        "major": 5,
        "len": 31
    },
    {
        "text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate [GENE]\u03b2-Arrestin 2[\\GENE], an effect that was prevented by selective CB(2) receptor antagonist [CHEMICAL]JTE-907[\\CHEMICAL] and CB(2) shRNA lentiviral particles.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment [CHEMICAL]glucose[\\CHEMICAL]-induced [GENE]insulin[\\GENE] secretion in response to food ingestion in a glucose-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced [GENE]insulin[\\GENE] secretion in response to food ingestion in a [CHEMICAL]glucose[\\CHEMICAL]-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Apomorphine[\\CHEMICAL] is a bimodal modulator of [GENE]TRPA1[\\GENE] channels.",
        "label": 2,
        "major": 7,
        "len": 8
    },
    {
        "text": "On the contrary, [GENE]human TRPA1[\\GENE] could be concentration-dependently modulated by [CHEMICAL]apomorphine[\\CHEMICAL].",
        "label": 2,
        "major": 7,
        "len": 11
    },
    {
        "text": "Whereas the addition of [CHEMICAL]apomorphine[\\CHEMICAL] in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [GENE]TRPA1[\\GENE] channels, resulting from a reduction of single-channel open times.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "In addition, we provide evidence that [CHEMICAL]apomorphine[\\CHEMICAL] also acts on endogenous [GENE]TRPA1[\\GENE] in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "In addition, we provide evidence that [CHEMICAL]apomorphine[\\CHEMICAL] also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [GENE]TRPA1[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Our study shows that [GENE]human TRPA1[\\GENE] is a target for [CHEMICAL]apomorphine[\\CHEMICAL], suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our study shows that human TRPA1 is a target for [CHEMICAL]apomorphine[\\CHEMICAL], suggesting that an activation of [GENE]TRPA1[\\GENE] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our study shows that [GENE]human TRPA1[\\GENE] is a target for apomorphine, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [CHEMICAL]apomorphine[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of [GENE]TRPA1[\\GENE] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [CHEMICAL]apomorphine[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Whereas the addition of [CHEMICAL]apomorphine[\\CHEMICAL] in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [GENE]TRPA1[\\GENE] channels, resulting from a reduction of single-channel open times.",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "We previously demonstrated that developmental exposure to a mixture of [CHEMICAL]polychlorinated biphenyls[\\CHEMICAL] (PCBs) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in [GENE]aromatase[\\GENE] activity in the brain of newborn male pups.",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "We previously demonstrated that developmental exposure to a mixture of polychlorinated biphenyls ([CHEMICAL]PCBs[\\CHEMICAL]) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in [GENE]aromatase[\\GENE] activity in the brain of newborn male pups.",
        "label": 4,
        "major": 4,
        "len": 52
    },
    {
        "text": "[CHEMICAL]As(III)[\\CHEMICAL] also increased total [GENE]epoxygenases[\\GENE] activity in the lung while it decreased its levels in the kidney and had no effect on the liver.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Lastly, [CHEMICAL]As(III)[\\CHEMICAL] increased [GENE]soluble epoxide hydrolase[\\GENE] activity in the lung, while it decreased its levels in the kidney and had no effect on the liver.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "Development of potent and selective [CHEMICAL]indomethacin[\\CHEMICAL] analogues for the inhibition of [GENE]AKR1C3[\\GENE] (Type 5 17\u03b2-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Development of potent and selective [CHEMICAL]indomethacin[\\CHEMICAL] analogues for the inhibition of AKR1C3 ([GENE]Type 5 17\u03b2-hydroxysteroid dehydrogenase[\\GENE]/prostaglandin F synthase) in castrate-resistant prostate cancer.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Development of potent and selective [CHEMICAL]indomethacin[\\CHEMICAL] analogues for the inhibition of AKR1C3 (Type 5 17\u03b2-hydroxysteroid dehydrogenase/[GENE]prostaglandin F synthase[\\GENE]) in castrate-resistant prostate cancer.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[GENE]AKR1C3[\\GENE] is upregulated in CRPC where it catalyzes the formation of potent [CHEMICAL]androgens[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL], used to inhibit [GENE]cyclooxygenase[\\GENE], also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL], used to inhibit cyclooxygenase, also inhibits [GENE]AKR1C3[\\GENE] and displays selectivity over AKR1C1/AKR1C2.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Parallel synthetic strategies were used to generate libraries of [CHEMICAL]indomethacin[\\CHEMICAL] analogues, which exhibit reduced [GENE]cyclooxygenase[\\GENE] inhibitory activity but retain AKR1C3 inhibitory potency and selectivity.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Parallel synthetic strategies were used to generate libraries of [CHEMICAL]indomethacin[\\CHEMICAL] analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain [GENE]AKR1C3[\\GENE] inhibitory potency and selectivity.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The [GENE]AKR1C3[\\GENE]\u00b7[CHEMICAL]NADP(+)[\\CHEMICAL]\u00b72'-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "The [GENE]AKR1C3[\\GENE]\u00b7NADP(+)\u00b7[CHEMICAL]2'-des-methyl-indomethacin[\\CHEMICAL] crystal structure was determined, and it revealed a unique inhibitor binding mode.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "CRPC is characterized by reactivation of the [CHEMICAL]androgen[\\CHEMICAL] axis due to changes in [GENE]androgen receptor[\\GENE] signaling and/or adaptive intratumoral androgen biosynthesis.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "CRPC is characterized by reactivation of the androgen axis due to changes in [GENE]androgen receptor[\\GENE] signaling and/or adaptive intratumoral [CHEMICAL]androgen[\\CHEMICAL] biosynthesis.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL], used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over [GENE]AKR1C1[\\GENE]/AKR1C2.",
        "label": 10,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL], used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/[GENE]AKR1C2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 13
    },
    {
        "text": "In patients who do not reach the [GENE]LDL[\\GENE]-C target, combination therapy with additional LDL-C lowering drugs (e.g. [CHEMICAL]ezetimibe[\\CHEMICAL], bile acid sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the [GENE]LDL[\\GENE]-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, [CHEMICAL]bile acid[\\CHEMICAL] sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the [GENE]LDL[\\GENE]-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or [CHEMICAL]fibrates[\\CHEMICAL]) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. [CHEMICAL]ezetimibe[\\CHEMICAL], bile acid sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. ezetimibe, [CHEMICAL]bile acid[\\CHEMICAL] sequestrants or fibrates) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "In patients who do not reach the LDL-C target, combination therapy with additional [GENE]LDL[\\GENE]-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or [CHEMICAL]fibrates[\\CHEMICAL]) should be considered.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Rg1[\\CHEMICAL] attenuated the [GENE]A\u03b225-35[\\GENE]-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Rg1[\\CHEMICAL] attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting [GENE]HIF-1\u03b1[\\GENE] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "These protective effects were abolished by [GENE]glucocorticoid receptor[\\GENE] (GR) antagonist [CHEMICAL]RU486[\\CHEMICAL] or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor ([GENE]GR[\\GENE]) antagonist [CHEMICAL]RU486[\\CHEMICAL] or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or [GENE]p-ERK[\\GENE] inhibitor [CHEMICAL]U0126[\\CHEMICAL] rather than estrogen receptor \u03b1 antagonist ICI 82,780.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than [GENE]estrogen receptor \u03b1[\\GENE] antagonist [CHEMICAL]ICI 82,780[\\CHEMICAL].",
        "label": 6,
        "major": 4,
        "len": 23
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary [GENE]GR[\\GENE]-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent [GENE]ERK[\\GENE] phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "Taken together, our results suggested that [CHEMICAL]Rg1[\\CHEMICAL] protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [GENE]HIF-1\u03b1[\\GENE] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "These data provided a novel insight to the mechanisms of [CHEMICAL]Rg1[\\CHEMICAL]protective effects on A\u03b225-35-induced endothelial cells apoptosis, suggesting that [GENE]GR[\\GENE]-ERK signaling pathway might play an important role in it.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "These data provided a novel insight to the mechanisms of [CHEMICAL]Rg1[\\CHEMICAL]protective effects on A\u03b225-35-induced endothelial cells apoptosis, suggesting that GR-[GENE]ERK[\\GENE] signaling pathway might play an important role in it.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Perinatal exposure to [CHEMICAL]BDE-99[\\CHEMICAL] causes learning disorders and decreases serum thyroid hormone levels and [GENE]BDNF[\\GENE] gene expression in hippocampus in rat offspring.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an [GENE]IL-8 receptor B[\\GENE] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an IL-8 receptor B ([GENE]IL-8RB[\\GENE]) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 6,
        "major": 4,
        "len": 29
    },
    {
        "text": "Molecular docking studies suggested that SB has a good affinity towards [CHEMICAL]vinblastine[\\CHEMICAL]-binding site on [GENE]\u03b2-tubulin[\\GENE] subunit.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Of note, [CHEMICAL]SB265610[\\CHEMICAL] which is a close structural analogue of SB225002 with a potent [GENE]IL-8RB[\\GENE] antagonistic activity did not exhibit a similar antimitotic activity.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [GENE]IL-8[\\GENE]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Vitamin C[\\CHEMICAL] forestalls cigarette smoke induced [GENE]NF-\u03baB[\\GENE] activation in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced [GENE]NF-\u03baB[\\GENE] activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of [GENE]I-\u03baB\u03b5[\\GENE] and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of [GENE]c-Rel[\\GENE]/p50 in alveolar epithelial cells.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "It is possible that [CHEMICAL]vitamin C[\\CHEMICAL], an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel/[GENE]p50[\\GENE] in alveolar epithelial cells.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, [GENE]NF-\u03baB[\\GENE] DNA binding, I-\u03baB\u03b5 degradation and c-Rel nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, [GENE]I-\u03baB\u03b5[\\GENE] degradation and c-Rel nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 4,
        "major": 2,
        "len": 25
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, I-\u03baB\u03b5 degradation and [GENE]c-Rel[\\GENE] nuclear translocation in cells pretreated with [CHEMICAL]vitamin C[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, I-\u03baB\u03b5 degradation and c-Rel nuclear translocation in cells pretreated with vitamin C. To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with vitamin C. Result showed that [CHEMICAL]vitamin C[\\CHEMICAL] treatment resulted in markedly reduced [GENE]c-Rel[\\GENE] nuclear translocation.",
        "label": 4,
        "major": 4,
        "len": 61
    },
    {
        "text": "All these results demonstrate that [CHEMICAL]vitamin C[\\CHEMICAL] prevents CS(E)-induced [GENE]NF-\u03baB[\\GENE] activation and thus it could be used for the prevention of CS-induced inflammatory diseases.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]MNU[\\CHEMICAL]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of [GENE]E-cadherin[\\GENE], and high MGMT staining.",
        "label": 4,
        "major": 10,
        "len": 27
    },
    {
        "text": "[CHEMICAL]MNU[\\CHEMICAL]-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high [GENE]MGMT[\\GENE] staining.",
        "label": 3,
        "major": 10,
        "len": 27
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant [CHEMICAL]1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[\\CHEMICAL] (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of [GENE]parkin[\\GENE] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ([CHEMICAL]MPTP[\\CHEMICAL]), and the resistance of TIDA neurons to MPTP is associated with increased expression of [GENE]parkin[\\GENE] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to [CHEMICAL]MPTP[\\CHEMICAL] is associated with increased expression of [GENE]parkin[\\GENE] and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant [CHEMICAL]1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[\\CHEMICAL] (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and [GENE]ubiquitin carboxy-terminal hydrolase L-1[\\GENE] (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ([CHEMICAL]MPTP[\\CHEMICAL]), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and [GENE]ubiquitin carboxy-terminal hydrolase L-1[\\GENE] (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to [CHEMICAL]MPTP[\\CHEMICAL] is associated with increased expression of parkin and [GENE]ubiquitin carboxy-terminal hydrolase L-1[\\GENE] (UCHL- 1).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant [CHEMICAL]1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[\\CHEMICAL] (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([GENE]UCHL- 1[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ([CHEMICAL]MPTP[\\CHEMICAL]), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([GENE]UCHL- 1[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to [CHEMICAL]MPTP[\\CHEMICAL] is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 ([GENE]UCHL- 1[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, [GENE]tyrosine hydroxylase[\\GENE] (TH) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [CHEMICAL]MPTP[\\CHEMICAL], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.",
        "label": 4,
        "major": 4,
        "len": 53
    },
    {
        "text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase ([GENE]TH[\\GENE]) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [CHEMICAL]MPTP[\\CHEMICAL], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and [GENE]DA transporter[\\GENE] concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [CHEMICAL]MPTP[\\CHEMICAL], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.",
        "label": 4,
        "major": 4,
        "len": 53
    },
    {
        "text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and DA transporter concentrations in the striatum) as well as loss of [GENE]TH[\\GENE]-immunoreactive (IR) neurons in the substantia nigra (SN) following [CHEMICAL]MPTP[\\CHEMICAL], whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.",
        "label": 4,
        "major": 9,
        "len": 53
    },
    {
        "text": "Resistance of TIDA neurons to [CHEMICAL]MPTP[\\CHEMICAL] toxicity was correlated with a transient increase in [GENE]UCHL-1[\\GENE] and a sustained elevation in parkin in the arcuate nucleus.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Resistance of TIDA neurons to [CHEMICAL]MPTP[\\CHEMICAL] toxicity was correlated with a transient increase in UCHL-1 and a sustained elevation in [GENE]parkin[\\GENE] in the arcuate nucleus.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following [CHEMICAL]MPTP[\\CHEMICAL], whereas TIDA neurons revealed no overt axon terminal pathology or loss of [GENE]TH[\\GENE]-IR cell bodies.",
        "label": 10,
        "major": 9,
        "len": 53
    },
    {
        "text": "This binding was not significantly inhibited by the [CHEMICAL]lysine[\\CHEMICAL] analogue epsilon-amino caproic acid (EACA), indicating that [GENE]plasminogen[\\GENE] binding was not just through lysine binding sites as suggested for other plasminogen binding sites.",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "This binding was not significantly inhibited by the lysine analogue [CHEMICAL]epsilon-amino caproic acid[\\CHEMICAL] (EACA), indicating that [GENE]plasminogen[\\GENE] binding was not just through lysine binding sites as suggested for other plasminogen binding sites.",
        "label": 10,
        "major": 4,
        "len": 32
    },
    {
        "text": "This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid ([CHEMICAL]EACA[\\CHEMICAL]), indicating that [GENE]plasminogen[\\GENE] binding was not just through lysine binding sites as suggested for other plasminogen binding sites.",
        "label": 10,
        "major": 10,
        "len": 32
    },
    {
        "text": "This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (EACA), indicating that [GENE]plasminogen[\\GENE] binding was not just through [CHEMICAL]lysine[\\CHEMICAL] binding sites as suggested for other plasminogen binding sites.",
        "label": 10,
        "major": 10,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and plasmin to [GENE]gp330[\\GENE] by [CHEMICAL]benzamidine[\\CHEMICAL] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although [CHEMICAL]EACA[\\CHEMICAL] inhibited the binding of plasmin to [GENE]gp330[\\GENE] slightly more than the binding of plasminogen to gp330.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although [CHEMICAL]EACA[\\CHEMICAL] inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to [GENE]gp330[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both [GENE]plasminogen[\\GENE] and plasmin to gp330 by [CHEMICAL]benzamidine[\\CHEMICAL] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and [GENE]plasmin[\\GENE] to gp330 by [CHEMICAL]benzamidine[\\CHEMICAL] was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although [CHEMICAL]EACA[\\CHEMICAL] inhibited the binding of [GENE]plasmin[\\GENE] to gp330 slightly more than the binding of plasminogen to gp330.",
        "label": 4,
        "major": 2,
        "len": 32
    },
    {
        "text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although [CHEMICAL]EACA[\\CHEMICAL] inhibited the binding of plasmin to gp330 slightly more than the binding of [GENE]plasminogen[\\GENE] to gp330.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, [GENE]ACY-1[\\GENE]) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except [CHEMICAL]L-aspartic acid[\\CHEMICAL], has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 10,
        "major": 9,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [[GENE]EC 3.5.1.14[\\GENE]], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except [CHEMICAL]L-aspartic acid[\\CHEMICAL], has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 10,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric [GENE]metalloprotein[\\GENE] having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except [CHEMICAL]L-aspartic acid[\\CHEMICAL], has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 10,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of [GENE]aminoacylase 1[\\GENE] (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except [CHEMICAL]L-aspartic acid[\\CHEMICAL], has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 10,
        "major": 9,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 ([GENE]N-acylamino acid aminohydrolase[\\GENE], ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except [CHEMICAL]L-aspartic acid[\\CHEMICAL], has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 10,
        "major": 1,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with [CHEMICAL]acetylalanine[\\CHEMICAL] at the N-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the [CHEMICAL]N[\\CHEMICAL]-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "The [CHEMICAL]amino acid[\\CHEMICAL] sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for [GENE]porcine kidney ACY-1[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "The amino acid sequence deduced from the [CHEMICAL]nucleotide[\\CHEMICAL] sequence of the cDNA from porcine liver was identical to that deduced for [GENE]porcine kidney ACY-1[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "Comparison of the [CHEMICAL]amino acid[\\CHEMICAL] sequence of porcine ACY-1 with those of other [GENE]Zn2+-binding metalloenzymes[\\GENE] showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.",
        "label": 1,
        "major": 2,
        "len": 33
    },
    {
        "text": "Comparison of the [CHEMICAL]amino acid[\\CHEMICAL] sequence of [GENE]porcine ACY-1[\\GENE] with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "A cDNA encoding the complete [CHEMICAL]amino acid[\\CHEMICAL] sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, [GENE]ACY-1[\\GENE]) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete [CHEMICAL]amino acid[\\CHEMICAL] sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [[GENE]EC 3.5.1.14[\\GENE]], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete [CHEMICAL]amino acid[\\CHEMICAL] sequence of [GENE]aminoacylase 1[\\GENE] (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 1,
        "major": 9,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete [CHEMICAL]amino acid[\\CHEMICAL] sequence of aminoacylase 1 ([GENE]N-acylamino acid aminohydrolase[\\GENE], ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 1,
        "major": 9,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the [CHEMICAL]N[\\CHEMICAL]- and C-terminal amino acid analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the N- and [CHEMICAL]C[\\CHEMICAL]-terminal amino acid analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the N- and C-terminal [CHEMICAL]amino acid[\\CHEMICAL] analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the N-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that [GENE]porcine kidney ACY-1[\\GENE] consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 [CHEMICAL]amino acids[\\CHEMICAL] with acetylalanine at the N-terminus.",
        "label": 1,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, [GENE]ACY-1[\\GENE]) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [CHEMICAL]N-acylated L-amino acids[\\CHEMICAL] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 9,
        "major": 9,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [[GENE]EC 3.5.1.14[\\GENE]], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [CHEMICAL]N-acylated L-amino acids[\\CHEMICAL] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 9,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric [GENE]metalloprotein[\\GENE] having two Zn2+ in the molecule, which catalyzes the deacylation of [CHEMICAL]N-acylated L-amino acids[\\CHEMICAL] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 9,
        "major": 1,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of [GENE]aminoacylase 1[\\GENE] (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [CHEMICAL]N-acylated L-amino acids[\\CHEMICAL] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 9,
        "major": 9,
        "len": 49
    },
    {
        "text": "A cDNA encoding the complete amino acid sequence of aminoacylase 1 ([GENE]N-acylamino acid aminohydrolase[\\GENE], ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of [CHEMICAL]N-acylated L-amino acids[\\CHEMICAL] except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.",
        "label": 9,
        "major": 1,
        "len": 49
    },
    {
        "text": "The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or [CHEMICAL]N-ethylmaleimide[\\CHEMICAL], agents known to impair the function of [GENE]Gi[\\GENE]/Go transducer proteins.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or [CHEMICAL]N-ethylmaleimide[\\CHEMICAL], agents known to impair the function of Gi/[GENE]Go[\\GENE] transducer proteins.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "The antinociceptive activity of the [GENE]alpha 2-adrenoceptor[\\GENE] agonist [CHEMICAL]clonidine[\\CHEMICAL] was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL], an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven [GENE]ACTH[\\GENE]-dependent Cushing's disease.",
        "label": 10,
        "major": 5,
        "len": 30
    },
    {
        "text": "In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal [GENE]ACTH[\\GENE] and cortisol levels nor CRH-stimulated levels were influenced by [CHEMICAL]loperamide[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 30
    },
    {
        "text": "In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and cortisol levels nor [GENE]CRH[\\GENE]-stimulated levels were influenced by [CHEMICAL]loperamide[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 30
    },
    {
        "text": "In four cultured human corticotropic adenomas, [CHEMICAL]loperamide[\\CHEMICAL] was not able to reduce basal and [GENE]CRH[\\GENE]-induced ACTH secretion.",
        "label": 10,
        "major": 4,
        "len": 17
    },
    {
        "text": "In four cultured human corticotropic adenomas, [CHEMICAL]loperamide[\\CHEMICAL] was not able to reduce basal and CRH-induced [GENE]ACTH[\\GENE] secretion.",
        "label": 10,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL] has no significant effect on [GENE]insulin[\\GENE]-hypoglycemia-induced ACTH and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.",
        "label": 10,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL] has no significant effect on insulin-hypoglycemia-induced [GENE]ACTH[\\GENE] and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.",
        "label": 10,
        "major": 3,
        "len": 21
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms [GENE]human CRH[\\GENE], 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms [GENE]GnRH[\\GENE], 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms [GENE]GH-releasing hormone[\\GENE], and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms [GENE]TRH[\\GENE]), the ACTH peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the [GENE]ACTH[\\GENE] peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by [CHEMICAL]loperamide[\\CHEMICAL] from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of [GENE]ACTH[\\GENE] from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).",
        "label": 4,
        "major": 3,
        "len": 74
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL], an opiate agonist of high specificity for mu-receptors, was recently reported to suppress [GENE]ACTH[\\GENE] and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.",
        "label": 4,
        "major": 5,
        "len": 30
    },
    {
        "text": "In summary, [CHEMICAL]loperamide[\\CHEMICAL] is able to reduce basal and [GENE]CRH[\\GENE]-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In summary, [CHEMICAL]loperamide[\\CHEMICAL] is able to reduce basal and CRH-induced [GENE]ACTH[\\GENE] and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "We also examined the effects of [CHEMICAL]WEB 2086[\\CHEMICAL], a [GENE]platelet-activating factor (PAF) receptor[\\GENE] antagonist, in parallel.",
        "label": 6,
        "major": 3,
        "len": 16
    },
    {
        "text": "The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where [CHEMICAL]hydroxamic acids[\\CHEMICAL] are potent and more selective inhibitors of [GENE]5-LO[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The [CHEMICAL]benzothiophene hydroxyurea[\\CHEMICAL], zileuton, is the first selective [GENE]5-LO[\\GENE] inhibitor evaluated for the treatment of patients with IBD.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The benzothiophene hydroxyurea, [CHEMICAL]zileuton[\\CHEMICAL], is the first selective [GENE]5-LO[\\GENE] inhibitor evaluated for the treatment of patients with IBD.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The unique role of the enzyme [GENE]5-lipoxygenase[\\GENE] (5-LO) in the production of [CHEMICAL]leukotrienes[\\CHEMICAL] (LTs) makes it a likely target for biochemical manipulation.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "The unique role of the enzyme 5-lipoxygenase ([GENE]5-LO[\\GENE]) in the production of [CHEMICAL]leukotrienes[\\CHEMICAL] (LTs) makes it a likely target for biochemical manipulation.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "The unique role of the enzyme [GENE]5-lipoxygenase[\\GENE] (5-LO) in the production of leukotrienes ([CHEMICAL]LTs[\\CHEMICAL]) makes it a likely target for biochemical manipulation.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "The unique role of the enzyme 5-lipoxygenase ([GENE]5-LO[\\GENE]) in the production of leukotrienes ([CHEMICAL]LTs[\\CHEMICAL]) makes it a likely target for biochemical manipulation.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Terbinafine[\\CHEMICAL] is a potent non-competitive inhibitor of [GENE]squalene epoxidase[\\GENE] from Candida (Ki = 30 nM).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Terbinafine[\\CHEMICAL]: mode of action and properties of the [GENE]squalene epoxidase[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Terbinafine[\\CHEMICAL] (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of [GENE]squalene epoxidase[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In contrast, inhibition of [GENE]rat liver squalene epoxidase[\\GENE] only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with [CHEMICAL]squalene[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Terbinafine ([CHEMICAL]Lamisil[\\CHEMICAL]) has primarily fungicidal action against many fungi as a result of its specific mechanism of [GENE]squalene epoxidase[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Some [GENE]5-HT3[\\GENE] antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, [CHEMICAL]ondansetron[\\CHEMICAL], granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 10,
        "major": 5,
        "len": 28
    },
    {
        "text": "Some 5-HT3 antagonists have [GENE]5-HT4[\\GENE] agonist activity (for example, renzapride, zacopride) and others do not (for example, [CHEMICAL]ondansetron[\\CHEMICAL], granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 10,
        "major": 10,
        "len": 28
    },
    {
        "text": "Some [GENE]5-HT3[\\GENE] antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, [CHEMICAL]granisetron[\\CHEMICAL]), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 10,
        "major": 5,
        "len": 28
    },
    {
        "text": "Some 5-HT3 antagonists have [GENE]5-HT4[\\GENE] agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, [CHEMICAL]granisetron[\\CHEMICAL]), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 10,
        "major": 6,
        "len": 28
    },
    {
        "text": "While the substituted [CHEMICAL]benzamide[\\CHEMICAL] prokinetics (for example, metoclopramide, cisapride) also block [GENE]5-HT3[\\GENE] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.",
        "label": 4,
        "major": 5,
        "len": 35
    },
    {
        "text": "While the substituted benzamide prokinetics (for example, [CHEMICAL]metoclopramide[\\CHEMICAL], cisapride) also block [GENE]5-HT3[\\GENE] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.",
        "label": 4,
        "major": 5,
        "len": 35
    },
    {
        "text": "While the substituted benzamide prokinetics (for example, metoclopramide, [CHEMICAL]cisapride[\\CHEMICAL]) also block [GENE]5-HT3[\\GENE] receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.",
        "label": 4,
        "major": 5,
        "len": 35
    },
    {
        "text": "While the substituted [CHEMICAL]benzamide[\\CHEMICAL] prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [GENE]5-HT4[\\GENE] receptor.",
        "label": 5,
        "major": 5,
        "len": 35
    },
    {
        "text": "While the substituted benzamide prokinetics (for example, [CHEMICAL]metoclopramide[\\CHEMICAL], cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [GENE]5-HT4[\\GENE] receptor.",
        "label": 5,
        "major": 5,
        "len": 35
    },
    {
        "text": "While the substituted benzamide prokinetics (for example, metoclopramide, [CHEMICAL]cisapride[\\CHEMICAL]) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative [GENE]5-HT4[\\GENE] receptor.",
        "label": 5,
        "major": 5,
        "len": 35
    },
    {
        "text": "Some 5-HT3 antagonists have [GENE]5-HT4[\\GENE] agonist activity (for example, [CHEMICAL]renzapride[\\CHEMICAL], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 5,
        "major": 6,
        "len": 28
    },
    {
        "text": "Some 5-HT3 antagonists have [GENE]5-HT4[\\GENE] agonist activity (for example, renzapride, [CHEMICAL]zacopride[\\CHEMICAL]) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 5,
        "major": 6,
        "len": 28
    },
    {
        "text": "A number of selective [GENE]5-HT3[\\GENE] antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and [CHEMICAL]zacopride[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "Some [GENE]5-HT3[\\GENE] antagonists have 5-HT4 agonist activity (for example, [CHEMICAL]renzapride[\\CHEMICAL], zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Some [GENE]5-HT3[\\GENE] antagonists have 5-HT4 agonist activity (for example, renzapride, [CHEMICAL]zacopride[\\CHEMICAL]) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.",
        "label": 6,
        "major": 10,
        "len": 28
    },
    {
        "text": "Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while [CHEMICAL]tropisetron[\\CHEMICAL] in high concentrations is a [GENE]5-HT4[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "A number of selective [GENE]5-HT3[\\GENE] antagonists have been developed including [CHEMICAL]ondansetron[\\CHEMICAL], granisetron, tropisetron renzapride and zacopride.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "A number of selective [GENE]5-HT3[\\GENE] antagonists have been developed including ondansetron, [CHEMICAL]granisetron[\\CHEMICAL], tropisetron renzapride and zacopride.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "A number of selective [GENE]5-HT3[\\GENE] antagonists have been developed including ondansetron, granisetron, [CHEMICAL]tropisetron[\\CHEMICAL] renzapride and zacopride.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "A number of selective [GENE]5-HT3[\\GENE] antagonists have been developed including ondansetron, granisetron, tropisetron [CHEMICAL]renzapride[\\CHEMICAL] and zacopride.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "When [GENE]delta-receptor[\\GENE] binding was determined by using [CHEMICAL][3H]DPDPE[\\CHEMICAL], a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.",
        "label": 2,
        "major": 4,
        "len": 36
    },
    {
        "text": "When [GENE]delta-receptor[\\GENE] binding was determined by using [3H]DPDPE, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of [CHEMICAL]DPDPE[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 4,
        "len": 36
    },
    {
        "text": "To our surprise, when [GENE]mu-receptor[\\GENE] binding was determined by using [CHEMICAL][3H]Tyr-D-Ala-Gly-MePhe-Gly-ol[\\CHEMICAL] (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "To our surprise, when [GENE]mu-receptor[\\GENE] binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol ([CHEMICAL]DAMGO[\\CHEMICAL]), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "To our surprise, when [GENE]mu-receptor[\\GENE] binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of [CHEMICAL]DPDPE[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Our conclusion is that chronic [CHEMICAL]DPDPE[\\CHEMICAL] treatment preferentially reduces [GENE]delta-opioid receptor[\\GENE] binding activity.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Therefore, in the present studies, animals were rendered tolerant to the [GENE]delta-opioid receptor[\\GENE]-selective agonist [D-Pen2,D-Pen5]enkephalin ([CHEMICAL]DPDPE[\\CHEMICAL]), and receptor binding activities were measured.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "Therefore, in the present studies, animals were rendered tolerant to the [GENE]delta-opioid receptor[\\GENE]-selective agonist [CHEMICAL][D-Pen2,D-Pen5]enkephalin[\\CHEMICAL] (DPDPE), and receptor binding activities were measured.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "By contrast, neither amoxapine nor [CHEMICAL]amitriptyline[\\CHEMICAL] can be considered as possible ligands of [GENE]5-HT1A[\\GENE] and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).",
        "label": 10,
        "major": 2,
        "len": 31
    },
    {
        "text": "By contrast, neither amoxapine nor [CHEMICAL]amitriptyline[\\CHEMICAL] can be considered as possible ligands of 5-HT1A and [GENE]5-HT1B[\\GENE] receptors because their affinities for these sites are in the micromolar range (or even worse).",
        "label": 10,
        "major": 2,
        "len": 31
    },
    {
        "text": "By contrast, neither [CHEMICAL]amoxapine[\\CHEMICAL] nor amitriptyline can be considered as possible ligands of [GENE]5-HT1A[\\GENE] and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).",
        "label": 10,
        "major": 2,
        "len": 31
    },
    {
        "text": "By contrast, neither [CHEMICAL]amoxapine[\\CHEMICAL] nor amitriptyline can be considered as possible ligands of 5-HT1A and [GENE]5-HT1B[\\GENE] receptors because their affinities for these sites are in the micromolar range (or even worse).",
        "label": 10,
        "major": 2,
        "len": 31
    },
    {
        "text": "Interestingly, [CHEMICAL]amoxapine[\\CHEMICAL] binds with a good affinity (IC50 = 0.30 microM) to [GENE]5-HT3[\\GENE] receptors labelled by [3H]zacopride in cortical membranes.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to [GENE]5-HT3[\\GENE] receptors labelled by [CHEMICAL][3H]zacopride[\\CHEMICAL] in cortical membranes.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "In vitro binding studies showed that both [CHEMICAL]amoxapine[\\CHEMICAL] and amitriptyline interact in the nanomolar range with [GENE]5-HT2[\\GENE] receptors labelled by [3H]ketanserin in cortical membranes.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "In vitro binding studies showed that both amoxapine and [CHEMICAL]amitriptyline[\\CHEMICAL] interact in the nanomolar range with [GENE]5-HT2[\\GENE] receptors labelled by [3H]ketanserin in cortical membranes.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with [GENE]5-HT2[\\GENE] receptors labelled by [CHEMICAL][3H]ketanserin[\\CHEMICAL] in cortical membranes.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that [CHEMICAL]amoxapine[\\CHEMICAL] really acts in vivo as a [GENE]5-HT3[\\GENE] antagonist (IC50 = 50 micrograms/kg i.v.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Labetalol[\\CHEMICAL] and the enantiomers lacked affinity at [GENE]alpha 2-adrenoceptors[\\GENE] while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.",
        "label": 10,
        "major": 2,
        "len": 26
    },
    {
        "text": "Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at [GENE]alpha 1-adrenoceptors[\\GENE] the order of potency was [CHEMICAL]prazosin[\\CHEMICAL] much greater than RR-SR greater than labetalol.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at [GENE]alpha 1-adrenoceptors[\\GENE] the order of potency was prazosin much greater than RR-SR greater than [CHEMICAL]labetalol[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "At [GENE]beta 1-adrenoceptors[\\GENE], the affinity of the compound RR-SR was about 3 times that of [CHEMICAL]labetalol[\\CHEMICAL].5.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "The pyridoxal 5'-phosphate binding [CHEMICAL]lysine[\\CHEMICAL] in [GENE]mouse ODC[\\GENE] was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.",
        "label": 1,
        "major": 4,
        "len": 49
    },
    {
        "text": "The pyridoxal 5'-phosphate binding lysine in [GENE]mouse ODC[\\GENE] was identified as [CHEMICAL]lysine[\\CHEMICAL] 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.",
        "label": 1,
        "major": 2,
        "len": 49
    },
    {
        "text": "Using a similar procedure to analyze [GENE]ODC[\\GENE] labeled by reaction with [5-14C]DFMO, it was found that [CHEMICAL]lysine[\\CHEMICAL] 69 and cysteine 360 formed covalent adducts with the inhibitor.",
        "label": 1,
        "major": 4,
        "len": 27
    },
    {
        "text": "Using a similar procedure to analyze [GENE]ODC[\\GENE] labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and [CHEMICAL]cysteine[\\CHEMICAL] 360 formed covalent adducts with the inhibitor.",
        "label": 1,
        "major": 4,
        "len": 27
    },
    {
        "text": "The [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] binding lysine in [GENE]mouse ODC[\\GENE] was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.",
        "label": 2,
        "major": 2,
        "len": 49
    },
    {
        "text": "Using a similar procedure to analyze [GENE]ODC[\\GENE] labeled by reaction with [CHEMICAL][5-14C]DFMO[\\CHEMICAL], it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "[GENE]Mouse ornithine decarboxylase[\\GENE] (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "Mouse ornithine decarboxylase ([GENE]ODC[\\GENE]) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).",
        "label": 2,
        "major": 3,
        "len": 42
    },
    {
        "text": "[GENE]Mouse ornithine decarboxylase[\\GENE] (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [CHEMICAL]alpha-difluoromethylornithine[\\CHEMICAL] (DFMO).",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Mouse ornithine decarboxylase ([GENE]ODC[\\GENE]) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [CHEMICAL]alpha-difluoromethylornithine[\\CHEMICAL] (DFMO).",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "[GENE]Mouse ornithine decarboxylase[\\GENE] (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ([CHEMICAL]DFMO[\\CHEMICAL]).",
        "label": 4,
        "major": 2,
        "len": 42
    },
    {
        "text": "Mouse ornithine decarboxylase ([GENE]ODC[\\GENE]) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ([CHEMICAL]DFMO[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Mechanism of the irreversible inactivation of [GENE]mouse ornithine decarboxylase[\\GENE] by [CHEMICAL]alpha-difluoromethylornithine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Fibric acids[\\CHEMICAL], in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving [GENE]LDL[\\GENE] delipidation, thus favoring receptor uptake.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Probucol[\\CHEMICAL] acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from [GENE]high-density lipoproteins[\\GENE] to lower-density lipoproteins.",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Probucol[\\CHEMICAL] acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to [GENE]lower-density lipoproteins[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 20
    },
    {
        "text": "Absorbable drugs ([CHEMICAL]fibric acids[\\CHEMICAL], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce [GENE]plasma very-low-density lipoproteins[\\GENE] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs ([CHEMICAL]fibric acids[\\CHEMICAL], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ([GENE]VLDL[\\GENE]) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs ([CHEMICAL]fibric acids[\\CHEMICAL], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or [GENE]low-density lipoproteins[\\GENE] (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs ([CHEMICAL]fibric acids[\\CHEMICAL], nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins ([GENE]LDL[\\GENE]) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, [CHEMICAL]nicotinic acid[\\CHEMICAL], probucol, HMG-CoA reductase inhibitors) reduce [GENE]plasma very-low-density lipoproteins[\\GENE] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, [CHEMICAL]nicotinic acid[\\CHEMICAL], probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ([GENE]VLDL[\\GENE]) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, [CHEMICAL]nicotinic acid[\\CHEMICAL], probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or [GENE]low-density lipoproteins[\\GENE] (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, [CHEMICAL]nicotinic acid[\\CHEMICAL], probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins ([GENE]LDL[\\GENE]) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, nicotinic acid, [CHEMICAL]probucol[\\CHEMICAL], HMG-CoA reductase inhibitors) reduce [GENE]plasma very-low-density lipoproteins[\\GENE] (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, nicotinic acid, [CHEMICAL]probucol[\\CHEMICAL], HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins ([GENE]VLDL[\\GENE]) and/or low-density lipoproteins (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, nicotinic acid, [CHEMICAL]probucol[\\CHEMICAL], HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or [GENE]low-density lipoproteins[\\GENE] (LDL) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Absorbable drugs (fibric acids, nicotinic acid, [CHEMICAL]probucol[\\CHEMICAL], HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins ([GENE]LDL[\\GENE]) by a variety of mechanisms.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Fibric acids[\\CHEMICAL], in particular, act by stimulating the catabolism of [GENE]VLDL[\\GENE] and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "accelerating reverse transport of [CHEMICAL]cholesteryl esters[\\CHEMICAL] from [GENE]high-density lipoproteins[\\GENE] to lower-density lipoproteins.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "accelerating reverse transport of [CHEMICAL]cholesteryl esters[\\CHEMICAL] from high-density lipoproteins to [GENE]lower-density lipoproteins[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Phenelzine is a more potent [GENE]monoamine oxidase[\\GENE] inhibitor than is [CHEMICAL]N2-acetylphenelzine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Acetylation of [CHEMICAL]phenelzine[\\CHEMICAL] at the N2 position presumably interferes with the inhibition of the [GENE]transaminase[\\GENE] enzymes for gamma-aminobutyric acid and alanine.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Acetylation of phenelzine at the [CHEMICAL]N2[\\CHEMICAL] position presumably interferes with the inhibition of the [GENE]transaminase[\\GENE] enzymes for gamma-aminobutyric acid and alanine.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the [GENE]transaminase[\\GENE] enzymes for [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] and alanine.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the [GENE]transaminase[\\GENE] enzymes for gamma-aminobutyric acid and [CHEMICAL]alanine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] is a more potent [GENE]monoamine oxidase[\\GENE] inhibitor than is N2-acetylphenelzine.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Analysis of this relationship shows that [CHEMICAL]estramustine phosphate[\\CHEMICAL] and tubulin compete for common [GENE]MAP2[\\GENE] sites, that MAP2 can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM estramustine phosphate.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that [GENE]MAP2[\\GENE] can bind 5-6 moles.mole-1 [CHEMICAL]estramustine phosphate[\\CHEMICAL], and that the Kd of these sites is congruent to 20 microM estramustine phosphate.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Analysis of this relationship shows that estramustine phosphate and tubulin compete for common MAP2 sites, that [GENE]MAP2[\\GENE] can bind 5-6 moles.mole-1 estramustine phosphate, and that the Kd of these sites is congruent to 20 microM [CHEMICAL]estramustine phosphate[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "It is proposed that two molecules of [CHEMICAL]estramustine phosphate[\\CHEMICAL] interact with each of the three tubulin-binding sites of [GENE]MAP2[\\GENE] and inhibit the MAP2:tubulin interaction by neutralising two highly conserved basic residues.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Stoichiometry of [CHEMICAL]estramustine phosphate[\\CHEMICAL] binding to [GENE]MAP2[\\GENE] measured by the disassembly of chick brain MAP2:tubulin microtubules.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "The concentration of [CHEMICAL]estramustine phosphate[\\CHEMICAL] required to inhibit the assembly or to induce the disassembly of [GENE]chick brain MAP2[\\GENE]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The concentration of [CHEMICAL]estramustine phosphate[\\CHEMICAL] required to inhibit the assembly or to induce the disassembly of chick brain MAP2:[GENE]tubulin[\\GENE] microtubules is markedly dependent upon the microtubule protein concentration.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The concentration of [CHEMICAL]estramustine phosphate[\\CHEMICAL] required to inhibit the assembly or to induce the disassembly of [GENE]chick brain MAP2[\\GENE]:tubulin microtubules is markedly dependent upon the microtubule protein concentration.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The concentration of [CHEMICAL]estramustine phosphate[\\CHEMICAL] required to inhibit the assembly or to induce the disassembly of chick brain MAP2:[GENE]tubulin[\\GENE] microtubules is markedly dependent upon the microtubule protein concentration.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "It is proposed that two molecules of [CHEMICAL]estramustine phosphate[\\CHEMICAL] interact with each of the three tubulin-binding sites of MAP2 and inhibit the [GENE]MAP2[\\GENE]:tubulin interaction by neutralising two highly conserved basic residues.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "It is proposed that two molecules of [CHEMICAL]estramustine phosphate[\\CHEMICAL] interact with each of the three tubulin-binding sites of MAP2 and inhibit the MAP2:[GENE]tubulin[\\GENE] interaction by neutralising two highly conserved basic residues.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "[CHEMICAL]4-MA[\\CHEMICAL], a well known [GENE]5 alpha-reductase[\\GENE] inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]4-MA[\\CHEMICAL], a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of [GENE]3 beta-HSD[\\GENE] with a Ki value of 56 nM.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Cyproterone acetate[\\CHEMICAL], a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [GENE]3 beta-HSD[\\GENE] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Cyproterone acetate, a [CHEMICAL]progestin[\\CHEMICAL] used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit [GENE]3 beta-HSD[\\GENE] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as [CHEMICAL]norgestrel[\\CHEMICAL] and norethindrone that are widely used as oral contraceptives also inhibit [GENE]3 beta-HSD[\\GENE] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and [CHEMICAL]norethindrone[\\CHEMICAL] that are widely used as oral contraceptives also inhibit [GENE]3 beta-HSD[\\GENE] activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "Inhibitory effect of synthetic [CHEMICAL]progestins[\\CHEMICAL], 4-MA and cyanoketone on [GENE]human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Inhibitory effect of synthetic progestins, [CHEMICAL]4-MA[\\CHEMICAL] and cyanoketone on [GENE]human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Inhibitory effect of synthetic progestins, 4-MA and [CHEMICAL]cyanoketone[\\CHEMICAL] on [GENE]human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Trilostane[\\CHEMICAL], epostane and cyanoketone are potent inhibitors of [GENE]3 beta-HSD[\\GENE] with Ki values of approximately 50 nM.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Trilostane, [CHEMICAL]epostane[\\CHEMICAL] and cyanoketone are potent inhibitors of [GENE]3 beta-HSD[\\GENE] with Ki values of approximately 50 nM.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Trilostane, epostane and [CHEMICAL]cyanoketone[\\CHEMICAL] are potent inhibitors of [GENE]3 beta-HSD[\\GENE] with Ki values of approximately 50 nM.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Pimozide[\\CHEMICAL] and thioridazine had no effect on the estradiol binding properties of the MCF-7 [GENE]ER[\\GENE], nor did pimozide interfere with the induction of progesterone receptors by estradiol.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Pimozide and [CHEMICAL]thioridazine[\\CHEMICAL] had no effect on the estradiol binding properties of the MCF-7 [GENE]ER[\\GENE], nor did pimozide interfere with the induction of progesterone receptors by estradiol.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did [CHEMICAL]pimozide[\\CHEMICAL] interfere with the induction of [GENE]progesterone receptors[\\GENE] by estradiol.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Pimozide and thioridazine had no effect on the [CHEMICAL]estradiol[\\CHEMICAL] binding properties of the MCF-7 [GENE]ER[\\GENE], nor did pimozide interfere with the induction of progesterone receptors by estradiol.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "We conclude that [CHEMICAL]pimozide[\\CHEMICAL] and thioridazine may be useful in the control of estradiol- and [GENE]polypeptide hormone[\\GENE]-induced growth of ER-positive and ER-negative human breast tumors.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "We conclude that pimozide and [CHEMICAL]thioridazine[\\CHEMICAL] may be useful in the control of estradiol- and [GENE]polypeptide hormone[\\GENE]-induced growth of ER-positive and ER-negative human breast tumors.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of [GENE]progesterone receptors[\\GENE] by [CHEMICAL]estradiol[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Inhibition of MCF-7 cell growth by the selective calmodulin antagonists W-13 and W-12 is consistent with a role for [GENE]calmodulin[\\GENE] antagonism in the broad growth-inhibitory properties of [CHEMICAL]pimozide[\\CHEMICAL].",
        "label": 4,
        "major": 6,
        "len": 28
    },
    {
        "text": "Inhibition of MCF-7 cell growth by the selective [GENE]calmodulin[\\GENE] antagonists [CHEMICAL]W-13[\\CHEMICAL] and W-12 is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Inhibition of MCF-7 cell growth by the selective [GENE]calmodulin[\\GENE] antagonists W-13 and [CHEMICAL]W-12[\\CHEMICAL] is consistent with a role for calmodulin antagonism in the broad growth-inhibitory properties of pimozide.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Although numerous mechanisms of action of [CHEMICAL]pimozide[\\CHEMICAL] and thioridazine have been identified, both drugs are [GENE]calmodulin[\\GENE] antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Although numerous mechanisms of action of pimozide and [CHEMICAL]thioridazine[\\CHEMICAL] have been identified, both drugs are [GENE]calmodulin[\\GENE] antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of [GENE]monoamine oxidase type A[\\GENE] (MAO-A) by [CHEMICAL]clorgyline[\\CHEMICAL] (4 mg/kg i.p.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A ([GENE]MAO-A[\\GENE]) by [CHEMICAL]clorgyline[\\CHEMICAL] (4 mg/kg i.p.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL] modifies but does not block the [GENE]corticotropin-releasing hormone[\\GENE]-induced ACTH response in patients with Addison's disease.",
        "label": 10,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Loperamide[\\CHEMICAL] modifies but does not block the corticotropin-releasing hormone-induced [GENE]ACTH[\\GENE] response in patients with Addison's disease.",
        "label": 10,
        "major": 3,
        "len": 16
    },
    {
        "text": "After [CHEMICAL]loperamide[\\CHEMICAL] administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then [GENE]CRH[\\GENE] was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "After [CHEMICAL]loperamide[\\CHEMICAL] administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an [GENE]ACTH[\\GENE] increase; the pattern of ACTH response to CRH was slightly delayed.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "After [CHEMICAL]loperamide[\\CHEMICAL] administration [GENE]ACTH[\\GENE] levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an ACTH increase; the pattern of ACTH response to CRH was slightly delayed.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the [GENE]acetylcholinesterase[\\GENE] inhibitor [CHEMICAL]neostigmine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "These data suggested that [CHEMICAL]ambenonium[\\CHEMICAL] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of [GENE]acetylcholinesterase[\\GENE] and concomitant antagonism by blockade of muscarinic receptors.",
        "label": 4,
        "major": 9,
        "len": 27
    },
    {
        "text": "These data suggested that [CHEMICAL]ambenonium[\\CHEMICAL] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [GENE]muscarinic receptors[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Ambenonium[\\CHEMICAL] is known to be an inhibitor of [GENE]acetylcholinesterase[\\GENE], and recent data have shown this drug to antagonize muscarinic receptors as well.",
        "label": 4,
        "major": 6,
        "len": 22
    },
    {
        "text": "These data suggested that ambenonium had a dual effect on tissue responses to [CHEMICAL]acetylcholine[\\CHEMICAL]-producing potentiation by blockade of [GENE]acetylcholinesterase[\\GENE] and concomitant antagonism by blockade of muscarinic receptors.",
        "label": 5,
        "major": 6,
        "len": 27
    },
    {
        "text": "These data suggested that [CHEMICAL]ambenonium[\\CHEMICAL] had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of [GENE]muscarinic receptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Ambenonium[\\CHEMICAL] is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize [GENE]muscarinic receptors[\\GENE] as well.",
        "label": 6,
        "major": 4,
        "len": 22
    },
    {
        "text": "However, [CHEMICAL]betaxolol[\\CHEMICAL] produces less systemic beta 2- and possibly [GENE]beta 1-adrenergic receptor[\\GENE] blockade than either timolol or levobunolol.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "However, betaxolol produces less systemic beta 2- and possibly [GENE]beta 1-adrenergic receptor[\\GENE] blockade than either [CHEMICAL]timolol[\\CHEMICAL] or levobunolol.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "However, betaxolol produces less systemic beta 2- and possibly [GENE]beta 1-adrenergic receptor[\\GENE] blockade than either timolol or [CHEMICAL]levobunolol[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Phenol oxidase[\\GENE] inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site [CHEMICAL]copper[\\CHEMICAL] of the enzyme in the catalysis.",
        "label": 1,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Phenol oxidase[\\GENE] inhibitors such as [CHEMICAL]phenylthiourea[\\CHEMICAL], potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Phenol oxidase[\\GENE] inhibitors such as phenylthiourea, [CHEMICAL]potassium cyanide[\\CHEMICAL], and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Phenol oxidase[\\GENE] inhibitors such as phenylthiourea, potassium cyanide, and [CHEMICAL]sodium azide[\\CHEMICAL] inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Mimosine[\\CHEMICAL], a well-known competitive inhibitor of [GENE]tyrosinase[\\GENE], competitively inhibited the new reaction also.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Present studies demonstrate that [GENE]mushroom tyrosinase[\\GENE] will also catalyze [CHEMICAL]quinone methide[\\CHEMICAL] production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Present studies demonstrate that [GENE]mushroom tyrosinase[\\GENE] will also catalyze quinone methide production with the same active site copper if a suitable substrate such as [CHEMICAL]3,4-dihydroxymandelic acid[\\CHEMICAL] is provided.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "[GENE]Tyrosinase[\\GENE] usually catalyzes the conversion of [CHEMICAL]monophenols[\\CHEMICAL] to o-diphenols and oxidation of diphenols to the corresponding quinones.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Tyrosinase[\\GENE] usually catalyzes the conversion of monophenols to o-diphenols and oxidation of [CHEMICAL]diphenols[\\CHEMICAL] to the corresponding quinones.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Tyrosinase[\\GENE] catalyzes an unusual oxidative decarboxylation of [CHEMICAL]3,4-dihydroxymandelate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Chloride[\\CHEMICAL] functions as a result of its binding to [GENE][Glu1]Pg[\\GENE], with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-t-PA. EACA stimulates the activation in Cl-(-)containing solutions, with a Ka of approximately 4.0 mM, primarily by reversal of the Cl-(-)inhibitory effect.",
        "label": 2,
        "major": 3,
        "len": 48
    },
    {
        "text": "Analysis of the results of this paper reveals that normal plasma components, [CHEMICAL]Cl-[\\CHEMICAL] and fibrinogen, exert major regulatory roles on the ability of [GENE][Glu1]Pg[\\GENE] to be activated by two-chain rec-t-PA, in in vitro systems.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "Analysis of the results of this paper reveals that normal plasma components, [CHEMICAL]Cl-[\\CHEMICAL] and fibrinogen, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-[GENE]t-PA[\\GENE], in in vitro systems.",
        "label": 2,
        "major": 3,
        "len": 34
    },
    {
        "text": "Fibrinogen appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-[GENE]t-PA[\\GENE], with a Ka of approximately 3.7 microM in activation systems containing physiological levels of [CHEMICAL]Cl-[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([GENE]t-PA[\\GENE]) is inhibited by Cl-, at physiological concentrations, and stimulated by [CHEMICAL]epsilon-aminocaproic acid[\\CHEMICAL] (EACA), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of [GENE]human [Glu1]plasminogen[\\GENE] [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by [CHEMICAL]epsilon-aminocaproic acid[\\CHEMICAL] (EACA), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [[GENE]( Glu1]Pg[\\GENE]) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by [CHEMICAL]epsilon-aminocaproic acid[\\CHEMICAL] (EACA), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain [GENE]tissue plasminogen activator[\\GENE] (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by [CHEMICAL]epsilon-aminocaproic acid[\\CHEMICAL] (EACA), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([GENE]t-PA[\\GENE]) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ([CHEMICAL]EACA[\\CHEMICAL]), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of [GENE]human [Glu1]plasminogen[\\GENE] [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ([CHEMICAL]EACA[\\CHEMICAL]), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [[GENE]( Glu1]Pg[\\GENE]) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ([CHEMICAL]EACA[\\CHEMICAL]), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain [GENE]tissue plasminogen activator[\\GENE] (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid ([CHEMICAL]EACA[\\CHEMICAL]), as well as fibrin(ogen).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "The presence of [CHEMICAL]Cl-[\\CHEMICAL] inhibits the stimulation of [GENE][Glu1]Pg[\\GENE] activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator ([GENE]t-PA[\\GENE]) is inhibited by [CHEMICAL]Cl-[\\CHEMICAL], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of [GENE]human [Glu1]plasminogen[\\GENE] [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by [CHEMICAL]Cl-[\\CHEMICAL], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [[GENE]( Glu1]Pg[\\GENE]) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by [CHEMICAL]Cl-[\\CHEMICAL], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain [GENE]tissue plasminogen activator[\\GENE] (t-PA) is inhibited by [CHEMICAL]Cl-[\\CHEMICAL], at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Whole-cell voltage-clamp of [GENE]hNET[\\GENE]-293 cells reveals [CHEMICAL]NE[\\CHEMICAL]-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Sodium-dependent [CHEMICAL]norepinephrine[\\CHEMICAL]-induced currents in [GENE]norepinephrine-transporter[\\GENE]-transfected HEK-293 cells blocked by cocaine and antidepressants.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "Whole-cell voltage-clamp of [GENE]hNET[\\GENE]-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and [CHEMICAL]cocaine[\\CHEMICAL] that are absent in parental cells.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Sodium-dependent norepinephrine-induced currents in [GENE]norepinephrine-transporter[\\GENE]-transfected HEK-293 cells blocked by [CHEMICAL]cocaine[\\CHEMICAL] and antidepressants.",
        "label": 4,
        "major": 9,
        "len": 12
    },
    {
        "text": "To explain our observations, we propose that [GENE]hNETs[\\GENE] function as ion-gated ligand channels with an indefinite stoichiometry relating ion flux to [CHEMICAL]NE[\\CHEMICAL] transport.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "The [CHEMICAL]N[\\CHEMICAL]-terminal portion of [GENE]TSG-6[\\GENE] shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.",
        "label": 1,
        "major": 2,
        "len": 20
    },
    {
        "text": "The protein that binds TSG-6 was purified from human serum and identified as [GENE]inter-alpha-inhibitor[\\GENE] (I alpha I) by [CHEMICAL]N[\\CHEMICAL]-terminal microsequencing.",
        "label": 1,
        "major": 4,
        "len": 20
    },
    {
        "text": "The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor ([GENE]I alpha I[\\GENE]) by [CHEMICAL]N[\\CHEMICAL]-terminal microsequencing.",
        "label": 1,
        "major": 2,
        "len": 20
    },
    {
        "text": "BACKGROUND: The active metabolite of the anti-inflammatory drug [CHEMICAL]nabumetone[\\CHEMICAL] has been characterized as a selective inhibitor of the inducible [GENE]prostaglandin H synthase[\\GENE] (PGHS).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "BACKGROUND: The active metabolite of the anti-inflammatory drug [CHEMICAL]nabumetone[\\CHEMICAL] has been characterized as a selective inhibitor of the inducible prostaglandin H synthase ([GENE]PGHS[\\GENE]).",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The daily administration of low-dose [CHEMICAL]aspirin[\\CHEMICAL] (40 mg), a selective inhibitor of platelet [GENE]PGHS-1[\\GENE], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Nabumetone[\\CHEMICAL] does dose-dependently inhibit the [GENE]cyclooxygenase[\\GENE] activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Nabumetone[\\CHEMICAL] does dose-dependently inhibit the cyclooxygenase activity of platelet [GENE]PGHS-1[\\GENE] of healthy subjects both in vivo and ex vivo.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Moreover, the production of [CHEMICAL]TXB2[\\CHEMICAL] during whole blood clotting was assessed as an index of the [GENE]cyclooxygenase[\\GENE] activity of platelet PGHS-1 ex vivo.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Moreover, the production of [CHEMICAL]TXB2[\\CHEMICAL] during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet [GENE]PGHS-1[\\GENE] ex vivo.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet [GENE]PGHS-1[\\GENE], caused a cumulative inhibition of urinary [CHEMICAL]11-dehydro-TXB2[\\CHEMICAL] and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet [GENE]PGHS-1[\\GENE], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood [CHEMICAL]TXB2[\\CHEMICAL] production that recovered with a timecourse consistent with platelet turnover.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Emedastine[\\CHEMICAL] (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the [GENE]histamine H1 receptor[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Preclinical efficacy of [CHEMICAL]emedastine[\\CHEMICAL], a potent, selective [GENE]histamine H1[\\GENE] antagonist for topical ocular use.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "(2) Exposure histories vary in secondary 11q23 leukemia, as the only [GENE]topoisomerase II[\\GENE] inhibitor was [CHEMICAL]dactinomycin[\\CHEMICAL] in one case, and, in another case, no topoisomerase II inhibitor was administered.",
        "label": 4,
        "major": 10,
        "len": 29
    },
    {
        "text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, [CHEMICAL]aspirin[\\CHEMICAL] treatment of [GENE]PGHS-2[\\GENE] causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Indomethacin[\\CHEMICAL], piroxicam, and sulindac sulfide were found to preferentially inhibit [GENE]PGHS-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Indomethacin, [CHEMICAL]piroxicam[\\CHEMICAL], and sulindac sulfide were found to preferentially inhibit [GENE]PGHS-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Indomethacin, piroxicam, and [CHEMICAL]sulindac sulfide[\\CHEMICAL] were found to preferentially inhibit [GENE]PGHS-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]6-Methoxy-2-naphthylacetic acid[\\CHEMICAL], the active metabolite of Relafen, inhibits murine [GENE]PGHS-2[\\GENE] preferentially.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "6-Methoxy-2-naphthylacetic acid, the active metabolite of [CHEMICAL]Relafen[\\CHEMICAL], inhibits murine [GENE]PGHS-2[\\GENE] preferentially.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] irreversibly inhibits [GENE]PGHS-1[\\GENE], preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of [GENE]PGHS-2[\\GENE] causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ([CHEMICAL]15-HETE[\\CHEMICAL]) instead of PGH2.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of [GENE]PGHS-2[\\GENE] causes this enzyme to form [CHEMICAL]15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid[\\CHEMICAL] (15-HETE) instead of PGH2.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of [CHEMICAL]phenylpropanolamine[\\CHEMICAL], to stimulate directly [GENE]alpha 1-adrenoceptors[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst [CHEMICAL]sumatriptan[\\CHEMICAL], renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, [CHEMICAL]renzapride[\\CHEMICAL] and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, [CHEMICAL]renzapride[\\CHEMICAL] and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and [CHEMICAL]8-hydroxy-2-(di-n-propylamino) tetralin[\\CHEMICAL] (8-OH-DPAT) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and [CHEMICAL]8-hydroxy-2-(di-n-propylamino) tetralin[\\CHEMICAL] (8-OH-DPAT) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin ([CHEMICAL]8-OH-DPAT[\\CHEMICAL]) were very weak or inactive.",
        "label": 10,
        "major": 5,
        "len": 43
    },
    {
        "text": "We conclude that despite small differences concerning the enantiomeric selectivity and affinity of [CHEMICAL]rauwolscine[\\CHEMICAL] and yohimbine, the close pharmacological identity of [GENE]5-HT receptors[\\GENE] in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "We conclude that despite small differences concerning the enantiomeric selectivity and affinity of [CHEMICAL]rauwolscine[\\CHEMICAL] and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned [GENE]5-HT2B[\\GENE] receptor is maintained.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and [CHEMICAL]yohimbine[\\CHEMICAL], the close pharmacological identity of [GENE]5-HT receptors[\\GENE] in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and [CHEMICAL]yohimbine[\\CHEMICAL], the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned [GENE]5-HT2B[\\GENE] receptor is maintained.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), [CHEMICAL]Ru 24969[\\CHEMICAL], MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine (m-CPP), [CHEMICAL]Ru 24969[\\CHEMICAL], MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, [CHEMICAL]MK 212[\\CHEMICAL] and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, [CHEMICAL]MK 212[\\CHEMICAL] and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and [CHEMICAL]SCH 23390[\\CHEMICAL] were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and [CHEMICAL]SCH 23390[\\CHEMICAL] were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including [CHEMICAL]1-m-chlorophenylpiperazine[\\CHEMICAL] (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including [CHEMICAL]1-m-chlorophenylpiperazine[\\CHEMICAL] (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either [GENE]5-HT2A[\\GENE] or 5-HT2C receptors including 1-m-chlorophenylpiperazine ([CHEMICAL]m-CPP[\\CHEMICAL]), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition several ligands known to act as agonists at either 5-HT2A or [GENE]5-HT2C[\\GENE] receptors including 1-m-chlorophenylpiperazine ([CHEMICAL]m-CPP[\\CHEMICAL]), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "Only strains of P. aeruginosa producing large amounts of [GENE]beta-lactamase[\\GENE] may be resistant to both [CHEMICAL]ceftazidime[\\CHEMICAL] and cefepime.",
        "label": 10,
        "major": 9,
        "len": 18
    },
    {
        "text": "Only strains of P. aeruginosa producing large amounts of [GENE]beta-lactamase[\\GENE] may be resistant to both ceftazidime and [CHEMICAL]cefepime[\\CHEMICAL].",
        "label": 10,
        "major": 9,
        "len": 18
    },
    {
        "text": "Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of [CHEMICAL]H-7[\\CHEMICAL] to decrease basal [GENE]alpha-AR[\\GENE] mRNA level.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Neither ryanodine nor [CHEMICAL]EGTA[\\CHEMICAL] inhibited down-regulation of [GENE]alpha-AR[\\GENE] mRNA by NE.",
        "label": 3,
        "major": 4,
        "len": 11
    },
    {
        "text": "Neither [CHEMICAL]ryanodine[\\CHEMICAL] nor EGTA inhibited down-regulation of [GENE]alpha-AR[\\GENE] mRNA by NE.",
        "label": 3,
        "major": 4,
        "len": 11
    },
    {
        "text": "Neither ryanodine nor EGTA inhibited down-regulation of [GENE]alpha-AR[\\GENE] mRNA by [CHEMICAL]NE[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Actinomycin D[\\CHEMICAL] caused [GENE]alpha-AR[\\GENE] mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Actinomycin D[\\CHEMICAL] caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal [GENE]alpha-AR[\\GENE] mRNA level.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Both [CHEMICAL]NE[\\CHEMICAL] and phorbol esters increased the rate of [GENE]alpha-AR[\\GENE] mRNA degradation.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "Both NE and [CHEMICAL]phorbol esters[\\CHEMICAL] increased the rate of [GENE]alpha-AR[\\GENE] mRNA degradation.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "In [CHEMICAL]NE[\\CHEMICAL]-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [GENE]alpha-AR[\\GENE] mRNA.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "In NE-desensitized cells, [CHEMICAL]phorbol esters[\\CHEMICAL] and bradykinin each caused the expected down-regulation of [GENE]alpha-AR[\\GENE] mRNA.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]NE[\\CHEMICAL], phorbol esters, and bradykinin each decreased [GENE]alpha-AR[\\GENE] mRNA levels by 70-80%.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "NE, [CHEMICAL]phorbol esters[\\CHEMICAL], and bradykinin each decreased [GENE]alpha-AR[\\GENE] mRNA levels by 70-80%.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "The mechanism by which [CHEMICAL]norepinephrine[\\CHEMICAL] (NE) down-regulates [GENE]alpha 1B-adrenergic receptor[\\GENE] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The mechanism by which [CHEMICAL]norepinephrine[\\CHEMICAL] (NE) down-regulates alpha 1B-adrenergic receptor ([GENE]alpha-AR[\\GENE]) mRNA was studied in rabbit aortic smooth muscle cells.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The mechanism by which norepinephrine ([CHEMICAL]NE[\\CHEMICAL]) down-regulates [GENE]alpha 1B-adrenergic receptor[\\GENE] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The mechanism by which norepinephrine ([CHEMICAL]NE[\\CHEMICAL]) down-regulates alpha 1B-adrenergic receptor ([GENE]alpha-AR[\\GENE]) mRNA was studied in rabbit aortic smooth muscle cells.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The [GENE]protein phosphatase[\\GENE] inhibitor [CHEMICAL]okadaic acid[\\CHEMICAL] prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.",
        "label": 4,
        "major": 4,
        "len": 61
    },
    {
        "text": "The [GENE]protein kinase C[\\GENE] inhibitor [CHEMICAL](+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride[\\CHEMICAL] (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The [GENE]protein kinase C[\\GENE] inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride ([CHEMICAL]H-7[\\CHEMICAL]) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Degenerate oligonucleotides corresponding to conserved [CHEMICAL]amino acids[\\CHEMICAL] from transmembrane domains III, V, and VI of known receptors [[GENE]5-HT1A[\\GENE], 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Degenerate oligonucleotides corresponding to conserved [CHEMICAL]amino acids[\\CHEMICAL] from transmembrane domains III, V, and VI of known receptors [5-HT1A, [GENE]5-HT1C[\\GENE], and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Degenerate oligonucleotides corresponding to conserved [CHEMICAL]amino acids[\\CHEMICAL] from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and [GENE]5-HT2[\\GENE]; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.",
        "label": 1,
        "major": 1,
        "len": 33
    },
    {
        "text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% [CHEMICAL]amino acid[\\CHEMICAL] identity with the known [GENE]rat 5-HT1A[\\GENE], rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% [CHEMICAL]amino acid[\\CHEMICAL] identity with the known rat 5-HT1A, [GENE]rat 5-HT1B[\\GENE], rat 5-HT1D, and human 5-HT1E receptors, respectively.",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% [CHEMICAL]amino acid[\\CHEMICAL] identity with the known rat 5-HT1A, rat 5-HT1B, [GENE]rat 5-HT1D[\\GENE], and human 5-HT1E receptors, respectively.",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% [CHEMICAL]amino acid[\\CHEMICAL] identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and [GENE]human 5-HT1E[\\GENE] receptors, respectively.",
        "label": 1,
        "major": 1,
        "len": 31
    },
    {
        "text": "HeLa cells transfected with the MR77 gene exhibited inhibition of [GENE]adenylate cyclase[\\GENE] in response to [CHEMICAL]serotonin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The specific binding is displaced by the selective [GENE]5-HT1D[\\GENE] agonist [CHEMICAL]sumatriptan[\\CHEMICAL] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "), a cholinesterase inhibitor that potentiates the effects of [CHEMICAL]acetylcholine[\\CHEMICAL] at the [GENE]muscarinic cholinergic receptor[\\GENE], terminated VT in four of four patients, an effect that was reversed by atropine.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous [CHEMICAL]adenosine[\\CHEMICAL] may modulate VT through alterations in autonomic tone by activation of arterial [GENE]chemoreceptors[\\GENE], and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.",
        "label": 3,
        "major": 4,
        "len": 62
    },
    {
        "text": "), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the [GENE]muscarinic cholinergic receptor[\\GENE], terminated VT in four of four patients, an effect that was reversed by [CHEMICAL]atropine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Edrophonium[\\CHEMICAL] (10 mg i.v. ), a [GENE]cholinesterase[\\GENE] inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "VT recurred with the addition of [CHEMICAL]aminophylline[\\CHEMICAL], a competitive [GENE]adenosine A1-receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "However, amantadine induction of [GENE]Fos[\\GENE] in the striatum was unaffected by the dopamine D2 receptor antagonist, [CHEMICAL]sulpiride[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 17
    },
    {
        "text": "These results suggest that [CHEMICAL]amantadine[\\CHEMICAL] induction of Fos in the rat striatum is related to dopamine D1 and [GENE]NMDA receptors[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked [CHEMICAL]amantadine[\\CHEMICAL] induction of [GENE]Fos[\\GENE] in the striatum.",
        "label": 3,
        "major": 6,
        "len": 22
    },
    {
        "text": "However, [CHEMICAL]amantadine[\\CHEMICAL] induction of [GENE]Fos[\\GENE] in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "These results suggest that [CHEMICAL]amantadine[\\CHEMICAL] induction of [GENE]Fos[\\GENE] in the rat striatum is related to dopamine D1 and NMDA receptors.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Amantadine[\\CHEMICAL] induces [GENE]c-fos[\\GENE] in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.",
        "label": 3,
        "major": 6,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Amantadine[\\CHEMICAL] (1-aminoadamantane) induced [GENE]Fos[\\GENE] expression in the central, dorsal-medial and ventral-medial part of the striatum.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Amantadine ([CHEMICAL]1-aminoadamantane[\\CHEMICAL]) induced [GENE]Fos[\\GENE] expression in the central, dorsal-medial and ventral-medial part of the striatum.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The distribution pattern of [GENE]Fos[\\GENE] induced by [CHEMICAL]amantadine[\\CHEMICAL] was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.",
        "label": 3,
        "major": 6,
        "len": 22
    },
    {
        "text": "Pretreatment with the dopamine D1 receptor antagonist, [CHEMICAL]SCH23390[\\CHEMICAL], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of [GENE]Fos[\\GENE] in the striatum.",
        "label": 4,
        "major": 6,
        "len": 22
    },
    {
        "text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, [CHEMICAL]MK-801[\\CHEMICAL], blocked amantadine induction of [GENE]Fos[\\GENE] in the striatum.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "However, amantadine induction of Fos in the striatum was unaffected by the [GENE]dopamine D2 receptor[\\GENE] antagonist, [CHEMICAL]sulpiride[\\CHEMICAL].",
        "label": 6,
        "major": 3,
        "len": 17
    },
    {
        "text": "Pretreatment with the [GENE]dopamine D1 receptor[\\GENE] antagonist, [CHEMICAL]SCH23390[\\CHEMICAL], and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.",
        "label": 6,
        "major": 3,
        "len": 22
    },
    {
        "text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the [GENE]NMDA receptor[\\GENE] antagonist, [CHEMICAL]MK-801[\\CHEMICAL], blocked amantadine induction of Fos in the striatum.",
        "label": 6,
        "major": 3,
        "len": 22
    },
    {
        "text": "bolus); finally, 8 rabbits received [CHEMICAL]aurintrycarboxilic acid[\\CHEMICAL] (ATA), an inhibitor of platelet [GENE]glycoprotein Ib[\\GENE]/von Willebrand factor interaction (10 mg/kg i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "bolus); finally, 8 rabbits received [CHEMICAL]aurintrycarboxilic acid[\\CHEMICAL] (ATA), an inhibitor of platelet glycoprotein Ib/[GENE]von Willebrand factor[\\GENE] interaction (10 mg/kg i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "bolus); finally, 8 rabbits received aurintrycarboxilic acid ([CHEMICAL]ATA[\\CHEMICAL]), an inhibitor of platelet [GENE]glycoprotein Ib[\\GENE]/von Willebrand factor interaction (10 mg/kg i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "bolus); finally, 8 rabbits received aurintrycarboxilic acid ([CHEMICAL]ATA[\\CHEMICAL]), an inhibitor of platelet glycoprotein Ib/[GENE]von Willebrand factor[\\GENE] interaction (10 mg/kg i.v.",
        "label": 4,
        "major": 2,
        "len": 20
    },
    {
        "text": "These events are stimulated by NE and by guanethidine, an [GENE]hNET[\\GENE] substrate, and they are blocked by [CHEMICAL]cocaine[\\CHEMICAL] and the antidepressant desipramine.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "These events are stimulated by NE and by guanethidine, an [GENE]hNET[\\GENE] substrate, and they are blocked by cocaine and the antidepressant [CHEMICAL]desipramine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Voltage-clamp data combined with [CHEMICAL]NE[\\CHEMICAL] uptake data from these same cells indicate that [GENE]hNETs[\\GENE] have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "These events are stimulated by [CHEMICAL]NE[\\CHEMICAL] and by guanethidine, an [GENE]hNET[\\GENE] substrate, and they are blocked by cocaine and the antidepressant desipramine.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "These events are stimulated by NE and by [CHEMICAL]guanethidine[\\CHEMICAL], an [GENE]hNET[\\GENE] substrate, and they are blocked by cocaine and the antidepressant desipramine.",
        "label": 9,
        "major": 3,
        "len": 22
    },
    {
        "text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the [GENE]mineralocorticoid receptor[\\GENE] (MR) antagonist [CHEMICAL]RU28318[\\CHEMICAL]; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",
        "label": 6,
        "major": 6,
        "len": 147
    },
    {
        "text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor ([GENE]MR[\\GENE]) antagonist [CHEMICAL]RU28318[\\CHEMICAL]; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",
        "label": 6,
        "major": 3,
        "len": 147
    },
    {
        "text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical [GENE]MR[\\GENE], in that it is blocked by concurrent administration of the MR antagonist [CHEMICAL]potassium canrenoate[\\CHEMICAL]; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",
        "label": 6,
        "major": 10,
        "len": 147
    },
    {
        "text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the [GENE]MR[\\GENE] antagonist [CHEMICAL]potassium canrenoate[\\CHEMICAL]; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.",
        "label": 6,
        "major": 6,
        "len": 147
    },
    {
        "text": "When [GENE]MAO-B[\\GENE] was also inhibited, 10 nmol/l [CHEMICAL]amezinium[\\CHEMICAL] caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.",
        "label": 0,
        "major": 4,
        "len": 21
    },
    {
        "text": "The results when considered with previous reports in the literature show that [CHEMICAL]amezinium[\\CHEMICAL] is about 1000 times more potent and debrisoquine is about 20 times more potent for [GENE]MAO[\\GENE] inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and [CHEMICAL]debrisoquine[\\CHEMICAL] is about 20 times more potent for [GENE]MAO[\\GENE] inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "[CHEMICAL]Amezinium[\\CHEMICAL] is much less potent as a [GENE]MAO[\\GENE] inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Previous studies have resulted in the classification of [CHEMICAL]amezinium[\\CHEMICAL] as a selective inhibitor of neuronal [GENE]monoamine oxidase[\\GENE] (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Previous studies have resulted in the classification of [CHEMICAL]amezinium[\\CHEMICAL] as a selective inhibitor of neuronal monoamine oxidase ([GENE]MAO[\\GENE]), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Previous studies have resulted in the classification of [CHEMICAL]amezinium[\\CHEMICAL] as a selective inhibitor of neuronal monoamine oxidase (MAO), because it is a much more potent [GENE]MAO[\\GENE] inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "In addition, another drug that is both a substrate of uptake1 and a [GENE]MAO[\\GENE] inhibitor, [CHEMICAL]debrisoquine[\\CHEMICAL], was investigated in the study.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Amezinium[\\CHEMICAL] and debrisoquine are substrates of uptake1 and potent inhibitors of [GENE]monoamine oxidase[\\GENE] in perfused lungs of rats.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "Amezinium and [CHEMICAL]debrisoquine[\\CHEMICAL] are substrates of uptake1 and potent inhibitors of [GENE]monoamine oxidase[\\GENE] in perfused lungs of rats.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "When MAO-B was also inhibited, 10 nmol/l [CHEMICAL]amezinium[\\CHEMICAL] caused 84% inhibition of the deamination of noradrenaline by [GENE]MAO-A[\\GENE] in the lungs.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The results when considered with previous reports in the literature show that [CHEMICAL]amezinium[\\CHEMICAL] is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by [GENE]uptake1[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 62
    },
    {
        "text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and [CHEMICAL]debrisoquine[\\CHEMICAL] is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by [GENE]uptake1[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 62
    },
    {
        "text": "[CHEMICAL]Amezinium[\\CHEMICAL] is much less potent as a MAO inhibitor in cells with the [GENE]uptake2 transporter[\\GENE], such as the myocardial cells of the heart.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "In addition, another drug that is both a substrate of [GENE]uptake1[\\GENE] and a MAO inhibitor, [CHEMICAL]debrisoquine[\\CHEMICAL], was investigated in the study.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Amezinium[\\CHEMICAL] and debrisoquine are substrates of [GENE]uptake1[\\GENE] and potent inhibitors of monoamine oxidase in perfused lungs of rats.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "Amezinium and [CHEMICAL]debrisoquine[\\CHEMICAL] are substrates of [GENE]uptake1[\\GENE] and potent inhibitors of monoamine oxidase in perfused lungs of rats.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Role of [GENE]tachykinin and bradykinin receptors[\\GENE] and mast cells in gaseous [CHEMICAL]formaldehyde[\\CHEMICAL]-induced airway microvascular leakage in rats.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "The increase in vascular permeability induced by [CHEMICAL]formaldehyde[\\CHEMICAL] in the rat airway was mediated predominantly by [GENE]NK1 receptor[\\GENE] stimulation.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "We have investigated the effects of [CHEMICAL]CP-99,994[\\CHEMICAL] [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a [GENE]tachykinin NK1 receptor[\\GENE] antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 3,
        "len": 43
    },
    {
        "text": "We have investigated the effects of CP-99,994 [CHEMICAL][(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine][\\CHEMICAL], a [GENE]tachykinin NK1 receptor[\\GENE] antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 3,
        "len": 43
    },
    {
        "text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, [CHEMICAL]HOE 140[\\CHEMICAL] (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a [GENE]bradykinin B2 receptor[\\GENE] antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 [CHEMICAL](D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)[\\CHEMICAL], a [GENE]bradykinin B2 receptor[\\GENE] antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 3,
        "len": 43
    },
    {
        "text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and [CHEMICAL]ketotifen[\\CHEMICAL] (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a [GENE]histamine H1 receptor[\\GENE] antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 3,
        "len": 43
    },
    {
        "text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen [CHEMICAL](4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)[\\CHEMICAL], a [GENE]histamine H1 receptor[\\GENE] antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.",
        "label": 6,
        "major": 3,
        "len": 43
    },
    {
        "text": "To identify the molecular determinants for dofetilide block, we first engineered chimeras between [GENE]HERG[\\GENE] and BEAG and then used site-directed mutagenesis to localize single [CHEMICAL]amino acid[\\CHEMICAL] residues responsible for block.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and [GENE]BEAG[\\GENE] and then used site-directed mutagenesis to localize single [CHEMICAL]amino acid[\\CHEMICAL] residues responsible for block.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "Thus, the [CHEMICAL]serine[\\CHEMICAL] in position [GENE]HERG[\\GENE] 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.",
        "label": 1,
        "major": 2,
        "len": 27
    },
    {
        "text": "Thus, our results indicate that important determinants of [CHEMICAL]dofetilide[\\CHEMICAL] binding are localized to the pore region of [GENE]HERG[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Moreover, the reverse mutation [GENE]BEAG[\\GENE] T432S increased the affinity of BEAG K+ channels for [CHEMICAL]dofetilide[\\CHEMICAL], whereas C-type inactivation could not be recovered.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Moreover, the reverse mutation BEAG [GENE]T432S[\\GENE] increased the affinity of BEAG K+ channels for [CHEMICAL]dofetilide[\\CHEMICAL], whereas C-type inactivation could not be recovered.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Moreover, the reverse mutation BEAG T432S increased the affinity of [GENE]BEAG[\\GENE] K+ channels for [CHEMICAL]dofetilide[\\CHEMICAL], whereas C-type inactivation could not be recovered.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG [GENE]K+ channels[\\GENE] for [CHEMICAL]dofetilide[\\CHEMICAL], whereas C-type inactivation could not be recovered.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Thus, the serine in position [GENE]HERG[\\GENE] 620 may participate directly in [CHEMICAL]dofetilide[\\CHEMICAL] binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Treatment using a combination of [CHEMICAL]testosterone[\\CHEMICAL] and the [GENE]aromatase[\\GENE] inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than testosterone alone.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Treatment using a combination of testosterone and the [GENE]aromatase[\\GENE] inhibitor [CHEMICAL]testolactone[\\CHEMICAL] may have significantly better effects on sexual function and also seizure frequency than testosterone alone.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "There are 3-4 drug binding sites in the [CHEMICAL]N[\\CHEMICAL]- and C-terminal domains of intact [GENE]cTnC[\\GENE] that exhibit fast exchange on the NMR time scale.",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "There are 3-4 drug binding sites in the N- and [CHEMICAL]C[\\CHEMICAL]-terminal domains of intact [GENE]cTnC[\\GENE] that exhibit fast exchange on the NMR time scale.",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "For example, it is clear that the closed conformation of the regulatory [CHEMICAL]N[\\CHEMICAL]-terminal domain in Ca2+-bound [GENE]cardiac troponin C[\\GENE] (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.",
        "label": 1,
        "major": 2,
        "len": 32
    },
    {
        "text": "For example, it is clear that the closed conformation of the regulatory [CHEMICAL]N[\\CHEMICAL]-terminal domain in Ca2+-bound cardiac troponin C ([GENE]cTnC[\\GENE]) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.",
        "label": 1,
        "major": 2,
        "len": 32
    },
    {
        "text": "Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [[CHEMICAL]methyl-13C[\\CHEMICAL]]Met-labeled [GENE]cTnC[\\GENE] indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled [GENE]cTnC[\\GENE] indicate that [CHEMICAL]bepridil[\\CHEMICAL] and trifluoperazine bind to similar sites but only in the presence of Ca2+.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled [GENE]cTnC[\\GENE] indicate that bepridil and [CHEMICAL]trifluoperazine[\\CHEMICAL] bind to similar sites but only in the presence of Ca2+.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Identification of binding sites for [CHEMICAL]bepridil[\\CHEMICAL] and trifluoperazine on [GENE]cardiac troponin C[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "Identification of binding sites for bepridil and [CHEMICAL]trifluoperazine[\\CHEMICAL] on [GENE]cardiac troponin C[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "For example, it is clear that the closed conformation of the regulatory N-terminal domain in [CHEMICAL]Ca2+[\\CHEMICAL]-bound [GENE]cardiac troponin C[\\GENE] (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "For example, it is clear that the closed conformation of the regulatory N-terminal domain in [CHEMICAL]Ca2+[\\CHEMICAL]-bound cardiac troponin C ([GENE]cTnC[\\GENE]) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for [CHEMICAL]trifluoperazine[\\CHEMICAL] and bepridil on [GENE]cTnC[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and [CHEMICAL]bepridil[\\CHEMICAL] on [GENE]cTnC[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled [GENE]cTnC[\\GENE] indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of [CHEMICAL]Ca2+[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, etoposide and mitoxantrone, and an alkylating agent, [CHEMICAL]cyclophosphamide[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, etoposide and mitoxantrone, and the alkylating agent, [CHEMICAL]cyclophosphamide[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, [CHEMICAL]etoposide[\\CHEMICAL] and mitoxantrone, and an alkylating agent, cyclophosphamide.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, etoposide and [CHEMICAL]mitoxantrone[\\CHEMICAL], and an alkylating agent, cyclophosphamide.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, [CHEMICAL]etoposide[\\CHEMICAL] and mitoxantrone, and the alkylating agent, cyclophosphamide.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with [GENE]DNA-topoisomerase II[\\GENE] inhibitors, etoposide and [CHEMICAL]mitoxantrone[\\CHEMICAL], and the alkylating agent, cyclophosphamide.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "A low tyramine diet is recommended if [CHEMICAL]selegiline[\\CHEMICAL] is used together with nonselective [GENE]MAO[\\GENE] inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible [GENE]MAO-A[\\GENE] inhibitor, [CHEMICAL]moclobemide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Selegiline[\\CHEMICAL] (deprenyl), a selective, irreversible inhibitor of [GENE]monoamine oxidase type B[\\GENE] (MAO-B) is widely used in the treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Selegiline[\\CHEMICAL] (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B ([GENE]MAO-B[\\GENE]) is widely used in the treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Unlike the nonselective [GENE]MAO[\\GENE] inhibitors, [CHEMICAL]selegiline[\\CHEMICAL] does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Selegiline ([CHEMICAL]deprenyl[\\CHEMICAL]), a selective, irreversible inhibitor of [GENE]monoamine oxidase type B[\\GENE] (MAO-B) is widely used in the treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Selegiline ([CHEMICAL]deprenyl[\\CHEMICAL]), a selective, irreversible inhibitor of monoamine oxidase type B ([GENE]MAO-B[\\GENE]) is widely used in the treatment of Parkinson's disease.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit [CHEMICAL]cAMP[\\CHEMICAL]-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [GENE]CFTR[\\GENE] Cl- channels as well as basolateral membrane K+ channels.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit [CHEMICAL]cAMP[\\CHEMICAL]-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR [GENE]Cl- channels[\\GENE] as well as basolateral membrane K+ channels.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Ibuprofen[\\CHEMICAL] inhibits [GENE]cystic fibrosis transmembrane conductance regulator[\\GENE]-mediated Cl- secretion.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Ibuprofen[\\CHEMICAL] (300 microM) reduced [GENE]CFTR[\\GENE] Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Similarly, [CHEMICAL]salicylic acid[\\CHEMICAL] (3 mM) reduced [GENE]CFTR[\\GENE] Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs [CHEMICAL]ibuprofen[\\CHEMICAL] and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [GENE]CFTR[\\GENE] Cl- channels as well as basolateral membrane K+ channels.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs [CHEMICAL]ibuprofen[\\CHEMICAL] and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR [GENE]Cl- channels[\\GENE] as well as basolateral membrane K+ channels.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs [CHEMICAL]ibuprofen[\\CHEMICAL] and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane [GENE]K+ channels[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs ibuprofen and [CHEMICAL]salicylic acid[\\CHEMICAL] inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of [GENE]CFTR[\\GENE] Cl- channels as well as basolateral membrane K+ channels.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs ibuprofen and [CHEMICAL]salicylic acid[\\CHEMICAL] inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR [GENE]Cl- channels[\\GENE] as well as basolateral membrane K+ channels.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Based on these results, we conclude that the NSAIDs ibuprofen and [CHEMICAL]salicylic acid[\\CHEMICAL] inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane [GENE]K+ channels[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in [GENE]plasma prolactin[\\GENE] and ACTH levels after i.v. [CHEMICAL]mCPP[\\CHEMICAL], pointing to a general state of arousal in these mCPP-treated animals.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and [GENE]ACTH[\\GENE] levels after i.v. [CHEMICAL]mCPP[\\CHEMICAL], pointing to a general state of arousal in these mCPP-treated animals.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective [GENE]5-HT2A[\\GENE]/5-HT2C antagonist [CHEMICAL]ritanserin[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/[GENE]5-HT2C[\\GENE] antagonist [CHEMICAL]ritanserin[\\CHEMICAL].",
        "label": 6,
        "major": 3,
        "len": 41
    },
    {
        "text": "These data indicate that mixed [GENE]5-HT1[\\GENE]/5-HT2 receptor antagonists such as [CHEMICAL]pizotifen[\\CHEMICAL] and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.",
        "label": 6,
        "major": 3,
        "len": 41
    },
    {
        "text": "These data indicate that mixed 5-HT1/[GENE]5-HT2[\\GENE] receptor antagonists such as [CHEMICAL]pizotifen[\\CHEMICAL] and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "These data indicate that mixed [GENE]5-HT1[\\GENE]/5-HT2 receptor antagonists such as pizotifen and [CHEMICAL]methysergide[\\CHEMICAL], and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.",
        "label": 6,
        "major": 3,
        "len": 41
    },
    {
        "text": "These data indicate that mixed 5-HT1/[GENE]5-HT2[\\GENE] receptor antagonists such as pizotifen and [CHEMICAL]methysergide[\\CHEMICAL], and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.",
        "label": 6,
        "major": 4,
        "len": 41
    },
    {
        "text": "[CHEMICAL]Tacrine[\\CHEMICAL] was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. [GENE]cholinesterase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The cardiovascular effects of three different [GENE]acetylcholinesterase[\\GENE] inhibitors: [CHEMICAL]physostigmine[\\CHEMICAL], tacrine and rivastigmine injected by intravenous (i.v.)",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The cardiovascular effects of three different [GENE]acetylcholinesterase[\\GENE] inhibitors: physostigmine, [CHEMICAL]tacrine[\\CHEMICAL] and rivastigmine injected by intravenous (i.v.)",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The cardiovascular effects of three different [GENE]acetylcholinesterase[\\GENE] inhibitors: physostigmine, tacrine and [CHEMICAL]rivastigmine[\\CHEMICAL] injected by intravenous (i.v.)",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The [GENE]alpha1-adrenoceptor[\\GENE] antagonist [CHEMICAL]prazosin[\\CHEMICAL] or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.",
        "label": 6,
        "major": 4,
        "len": 28
    },
    {
        "text": "The alpha1-adrenoceptor antagonist prazosin or the [GENE]vasopressin V1 receptor[\\GENE] antagonist, [CHEMICAL][beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin[\\CHEMICAL] partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "administration of the non-selective [GENE]muscarinic receptor[\\GENE] antagonist [CHEMICAL]atropine[\\CHEMICAL] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the [GENE]muscarinic M1 receptor[\\GENE] antagonist [CHEMICAL]pirenzepine[\\CHEMICAL] (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the [GENE]muscarinic M2 receptor[\\GENE] antagonist [CHEMICAL]methoctramine[\\CHEMICAL] (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the [GENE]muscarinic M3 receptor[\\GENE] antagonist [CHEMICAL]para-fluoro-hexahydro-sila-difenidol[\\CHEMICAL] (ID50 = 31.19 microg).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "[CHEMICAL]Cocaine[\\CHEMICAL] block of [GENE]hH1 channels[\\GENE] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Cocaine[\\CHEMICAL] block of hH1 channels was greater than block of [GENE]mu1 channels[\\GENE] at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Cocaine[\\CHEMICAL] block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of [GENE]hH1 channels[\\GENE] in this voltage range makes them more susceptible to cocaine block.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of [GENE]hH1 channels[\\GENE] in this voltage range makes them more susceptible to [CHEMICAL]cocaine[\\CHEMICAL] block.",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to [GENE]sigma-1 receptors[\\GENE], the very low affinity of [CHEMICAL]DF[\\CHEMICAL] at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.",
        "label": 2,
        "major": 2,
        "len": 45
    },
    {
        "text": "Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to [GENE]sigma-1 receptors[\\GENE], the very low affinity of DF at [CHEMICAL]PCP[\\CHEMICAL] sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.",
        "label": 2,
        "major": 2,
        "len": 45
    },
    {
        "text": "This study therefore characterized the binding of [CHEMICAL]DF[\\CHEMICAL] to the [GENE]sigma receptors[\\GENE] and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that [CHEMICAL]DF[\\CHEMICAL], DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [GENE]sigma-2 receptors[\\GENE] (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that [CHEMICAL]DF[\\CHEMICAL], DM, and DR were relative high-affinity ligands at [GENE]sigma-1 receptors[\\GENE] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, [CHEMICAL]DM[\\CHEMICAL], and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [GENE]sigma-2 receptors[\\GENE] (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, [CHEMICAL]DM[\\CHEMICAL], and DR were relative high-affinity ligands at [GENE]sigma-1 receptors[\\GENE] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and [CHEMICAL]DR[\\CHEMICAL] were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [GENE]sigma-2 receptors[\\GENE] (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and [CHEMICAL]DR[\\CHEMICAL] were relative high-affinity ligands at [GENE]sigma-1 receptors[\\GENE] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).",
        "label": 2,
        "major": 2,
        "len": 69
    },
    {
        "text": "Binding of [CHEMICAL]dimemorfan[\\CHEMICAL] to [GENE]sigma-1 receptor[\\GENE] and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "At 4 hours, losartan blocked 43% of the [GENE]Ang II[\\GENE]-induced systolic blood pressure increase; [CHEMICAL]valsartan[\\CHEMICAL], 51%; and irbesartan, 88% (P<0.01 between drugs).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "At 4 hours, losartan blocked 43% of the [GENE]Ang II[\\GENE]-induced systolic blood pressure increase; valsartan, 51%; and [CHEMICAL]irbesartan[\\CHEMICAL], 88% (P<0.01 between drugs).",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "This study thus demonstrates that the first administration of the recommended starting dose of [CHEMICAL]irbesartan[\\CHEMICAL] induces a greater and longer lasting [GENE]Ang II receptor[\\GENE] blockade than that of valsartan and losartan in normotensive subjects.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting [GENE]Ang II receptor[\\GENE] blockade than that of [CHEMICAL]valsartan[\\CHEMICAL] and losartan in normotensive subjects.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting [GENE]Ang II receptor[\\GENE] blockade than that of valsartan and [CHEMICAL]losartan[\\CHEMICAL] in normotensive subjects.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, [CHEMICAL]naratriptan[\\CHEMICAL] and rizatriptan had highest affinity for the [GENE]human 5-HT1B[\\GENE], 5-HT1D and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, [CHEMICAL]naratriptan[\\CHEMICAL] and rizatriptan had highest affinity for the human 5-HT1B, [GENE]5-HT1D[\\GENE] and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, [CHEMICAL]naratriptan[\\CHEMICAL] and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative [GENE]5-ht1f[\\GENE] receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, naratriptan and [CHEMICAL]rizatriptan[\\CHEMICAL] had highest affinity for the [GENE]human 5-HT1B[\\GENE], 5-HT1D and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, naratriptan and [CHEMICAL]rizatriptan[\\CHEMICAL] had highest affinity for the human 5-HT1B, [GENE]5-HT1D[\\GENE] and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, zolmitriptan, naratriptan and [CHEMICAL]rizatriptan[\\CHEMICAL] had highest affinity for the human 5-HT1B, 5-HT1D and putative [GENE]5-ht1f[\\GENE] receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Kinetic studies comparing the binding of [CHEMICAL][3H]eletriptan[\\CHEMICAL] and [3H]sumatriptan to the [GENE]human recombinant 5-HT1B[\\GENE] and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Kinetic studies comparing the binding of [CHEMICAL][3H]eletriptan[\\CHEMICAL] and [3H]sumatriptan to the human recombinant 5-HT1B and [GENE]5-HT1D[\\GENE] receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Kinetic studies comparing the binding of [3H]eletriptan and [CHEMICAL][3H]sumatriptan[\\CHEMICAL] to the [GENE]human recombinant 5-HT1B[\\GENE] and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Kinetic studies comparing the binding of [3H]eletriptan and [CHEMICAL][3H]sumatriptan[\\CHEMICAL] to the human recombinant 5-HT1B and [GENE]5-HT1D[\\GENE] receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL][3H]eletriptan[\\CHEMICAL] had over 6-fold higher affinity than [3H]sumatriptan at the [GENE]5-HT1D[\\GENE] receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, [CHEMICAL][3H]eletriptan[\\CHEMICAL] had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the [GENE]5-HT1B[\\GENE] receptor (K(D): 3.14 and 11.07 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, [3H]eletriptan had over 6-fold higher affinity than [CHEMICAL][3H]sumatriptan[\\CHEMICAL] at the [GENE]5-HT1D[\\GENE] receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, [3H]eletriptan had over 6-fold higher affinity than [CHEMICAL][3H]sumatriptan[\\CHEMICAL] at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the [GENE]5-HT1B[\\GENE] receptor (K(D): 3.14 and 11.07 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [CHEMICAL][3H]sumatriptan[\\CHEMICAL] at the [GENE]5-HT1B[\\GENE] receptor (K(D): 3.14 and 11.07 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Characterisation of the [GENE]5-HT receptor[\\GENE] binding profile of [CHEMICAL]eletriptan[\\CHEMICAL] and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [CHEMICAL][3H]eletriptan[\\CHEMICAL] binding at [GENE]human 5-HT1B[\\GENE] and 5-HT1D receptors.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [CHEMICAL][3H]eletriptan[\\CHEMICAL] binding at human 5-HT1B and [GENE]5-HT1D[\\GENE] receptors.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "The affinity of [CHEMICAL]eletriptan[\\CHEMICAL] ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of [GENE]5-HT receptors[\\GENE] was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.",
        "label": 2,
        "major": 5,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Eletriptan[\\CHEMICAL], like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the [GENE]human 5-HT1B[\\GENE], 5-HT1D and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Eletriptan[\\CHEMICAL], like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, [GENE]5-HT1D[\\GENE] and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Eletriptan[\\CHEMICAL], like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative [GENE]5-ht1f[\\GENE] receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like [CHEMICAL]sumatriptan[\\CHEMICAL], zolmitriptan, naratriptan and rizatriptan had highest affinity for the [GENE]human 5-HT1B[\\GENE], 5-HT1D and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like [CHEMICAL]sumatriptan[\\CHEMICAL], zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, [GENE]5-HT1D[\\GENE] and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like [CHEMICAL]sumatriptan[\\CHEMICAL], zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative [GENE]5-ht1f[\\GENE] receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "The affinity of eletriptan ([CHEMICAL](R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole[\\CHEMICAL]) for a range of [GENE]5-HT receptors[\\GENE] was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.",
        "label": 2,
        "major": 5,
        "len": 31
    },
    {
        "text": "Eletriptan, like sumatriptan, [CHEMICAL]zolmitriptan[\\CHEMICAL], naratriptan and rizatriptan had highest affinity for the [GENE]human 5-HT1B[\\GENE], 5-HT1D and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, [CHEMICAL]zolmitriptan[\\CHEMICAL], naratriptan and rizatriptan had highest affinity for the human 5-HT1B, [GENE]5-HT1D[\\GENE] and putative 5-ht1f receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Eletriptan, like sumatriptan, [CHEMICAL]zolmitriptan[\\CHEMICAL], naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative [GENE]5-ht1f[\\GENE] receptor.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the [GENE]human serotonin transporter[\\GENE] were [CHEMICAL]triflupromazine[\\CHEMICAL], fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the [GENE]human serotonin transporter[\\GENE] were triflupromazine, [CHEMICAL]fluperlapine[\\CHEMICAL], chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the [GENE]human serotonin transporter[\\GENE] were triflupromazine, fluperlapine, [CHEMICAL]chlorpromazine[\\CHEMICAL], and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the [GENE]human serotonin transporter[\\GENE] were triflupromazine, fluperlapine, chlorpromazine, and [CHEMICAL]ziprasidone[\\CHEMICAL] (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the [GENE]norepinephrine transporter[\\GENE], [CHEMICAL]chlorpromazine[\\CHEMICAL], zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the [GENE]norepinephrine transporter[\\GENE], chlorpromazine, [CHEMICAL]zotepine[\\CHEMICAL], chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the [GENE]norepinephrine transporter[\\GENE], chlorpromazine, zotepine, [CHEMICAL]chlorprothixene[\\CHEMICAL], and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the [GENE]norepinephrine transporter[\\GENE], chlorpromazine, zotepine, chlorprothixene, and [CHEMICAL]promazine[\\CHEMICAL] (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "At the [GENE]human dopamine transporter[\\GENE], only [CHEMICAL]pimozide[\\CHEMICAL] (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.",
        "label": 2,
        "major": 9,
        "len": 17
    },
    {
        "text": "At the [GENE]human dopamine transporter[\\GENE], only pimozide (K(D) = 69+/-3) [CHEMICAL]ziprasidone[\\CHEMICAL] (K(D) = 76+/-5) had notable potency.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "Among [CHEMICAL]neuroleptics[\\CHEMICAL], the four most potent compounds at the [GENE]human serotonin transporter[\\GENE] were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Pharmacological profile of [CHEMICAL]neuroleptics[\\CHEMICAL] at [GENE]human monoamine transporters[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 8
    },
    {
        "text": "In humans, prolonged administration of the [GENE]beta 2-adrenoceptor[\\GENE] agonist [CHEMICAL]terbutaline[\\CHEMICAL] leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.",
        "label": 5,
        "major": 5,
        "len": 31
    },
    {
        "text": "beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective [GENE]beta-adrenoceptor[\\GENE] agonist [CHEMICAL]isoprenaline[\\CHEMICAL]; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.",
        "label": 5,
        "major": 3,
        "len": 39
    },
    {
        "text": "A multicenter, randomized study of [CHEMICAL]argatroban[\\CHEMICAL] versus heparin as adjunct to tissue plasminogen activator ([GENE]TPA[\\GENE]) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "A multicenter, randomized study of [CHEMICAL]argatroban[\\CHEMICAL] versus heparin as adjunct to [GENE]tissue plasminogen activator[\\GENE] (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In vitro and in vivo studies have shown that [CHEMICAL]argatroban[\\CHEMICAL] has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with [GENE]TPA[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "OBJECTIVES: This study examined the effect of a small-molecule, direct [GENE]thrombin[\\GENE] inhibitor, [CHEMICAL]argatroban[\\CHEMICAL], on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "In vitro and in vivo studies have shown that [CHEMICAL]argatroban[\\CHEMICAL] has advantages over heparin for the inhibition of clot-bound [GENE]thrombin[\\GENE] and for the enhancement of thrombolysis with TPA.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "At clinically relevant concentrations, [CHEMICAL]candesartan[\\CHEMICAL] is an insurmountable and long-lasting antagonist of the vascular contractile responses to [GENE]Ang II[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 19
    },
    {
        "text": "In both vascular preparations, [CHEMICAL]candesartan[\\CHEMICAL] caused a marked decrease in the maximal contractile response of the [GENE]angiotensin II[\\GENE] (Ang II) concentration-response curve.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In both vascular preparations, [CHEMICAL]candesartan[\\CHEMICAL] caused a marked decrease in the maximal contractile response of the angiotensin II ([GENE]Ang II[\\GENE]) concentration-response curve.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "In addition, when [CHEMICAL]candesartan[\\CHEMICAL] was given to conscious rats, the inhibitory effect on [GENE]Ang II[\\GENE]-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of candesartan at 24 hours.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "The functional inhibitory characteristics of the [GENE]angiotensin II type 1 receptor[\\GENE] blockers (ARB) candesartan; [CHEMICAL]irbesartan[\\CHEMICAL]; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "The functional inhibitory characteristics of the [GENE]angiotensin II type 1 receptor[\\GENE] blockers (ARB) [CHEMICAL]candesartan[\\CHEMICAL]; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "The functional inhibitory characteristics of the [GENE]angiotensin II type 1 receptor[\\GENE] blockers (ARB) candesartan; irbesartan; and [CHEMICAL]losartan[\\CHEMICAL] and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "The functional inhibitory characteristics of the [GENE]angiotensin II type 1 receptor[\\GENE] blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite [CHEMICAL]EXP 3174[\\CHEMICAL] (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "The functional inhibitory characteristics of the [GENE]angiotensin II type 1 receptor[\\GENE] blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite EXP 3174 ([CHEMICAL]EXP[\\CHEMICAL]) were studied in rabbit aortic strips and rat portal vein preparations in vitro.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Dose-dependent inhibition of platelet [GENE]cyclooxygenase-1[\\GENE] and monocyte cyclooxygenase-2 by [CHEMICAL]meloxicam[\\CHEMICAL] in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte [GENE]cyclooxygenase-2[\\GENE] by [CHEMICAL]meloxicam[\\CHEMICAL] in healthy subjects.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "In contrast, the administration of 7.5 and 15 mg of [CHEMICAL]meloxicam[\\CHEMICAL] caused dose-dependent reductions in monocyte [GENE]COX-2[\\GENE] activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "In contrast, the administration of 7.5 and 15 mg of [CHEMICAL]meloxicam[\\CHEMICAL] caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet [GENE]COX-1[\\GENE] activity by 25% and 35%, respectively.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Although the IC50 value of [CHEMICAL]meloxicam[\\CHEMICAL] for inhibition of [GENE]COX-1[\\GENE] was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.",
        "label": 4,
        "major": 4,
        "len": 54
    },
    {
        "text": "Although the IC50 value of [CHEMICAL]meloxicam[\\CHEMICAL] for inhibition of COX-1 was 10-fold higher than the IC50 value of [GENE]COX-2[\\GENE] in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.",
        "label": 4,
        "major": 4,
        "len": 54
    },
    {
        "text": "Concentration-response curves for the inhibition of monocyte [GENE]COX-2[\\GENE] and platelet COX-1 were obtained in vitro after the incubation of [CHEMICAL]meloxicam[\\CHEMICAL] with whole blood samples.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Concentration-response curves for the inhibition of monocyte COX-2 and platelet [GENE]COX-1[\\GENE] were obtained in vitro after the incubation of [CHEMICAL]meloxicam[\\CHEMICAL] with whole blood samples.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The production of [CHEMICAL]thromboxane B2[\\CHEMICAL] in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet [GENE]COX-1[\\GENE] activity.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "In conclusion, [CHEMICAL](-)-pindolol[\\CHEMICAL] modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, [GENE]5-HT1A[\\GENE], and 5-HT1B receptors.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "In conclusion, [CHEMICAL](-)-pindolol[\\CHEMICAL] modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and [GENE]5-HT1B[\\GENE] receptors.",
        "label": 2,
        "major": 7,
        "len": 33
    },
    {
        "text": "[CHEMICAL](-)-Pindolol[\\CHEMICAL], which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors [GENE](AR)s[\\GENE], dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL](-)-Pindolol[\\CHEMICAL], which possesses significant affinity for [GENE]5-HT1A[\\GENE], 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL](-)-Pindolol[\\CHEMICAL], which possesses significant affinity for 5-HT1A, [GENE]5-HT1B[\\GENE], and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.",
        "label": 2,
        "major": 2,
        "len": 40
    },
    {
        "text": "In distinction, the preferential [GENE]beta 1-AR[\\GENE] antagonist, [CHEMICAL]betaxolol[\\CHEMICAL], and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.",
        "label": 6,
        "major": 3,
        "len": 25
    },
    {
        "text": "In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential [GENE]beta 2-AR[\\GENE] antagonist, [CHEMICAL]ICI118,551[\\CHEMICAL], did not increase basal levels of DA, NAD, or 5-HT.",
        "label": 6,
        "major": 10,
        "len": 25
    },
    {
        "text": "The selective [GENE]5-HT1A[\\GENE] receptor antagonist, [CHEMICAL]WAY100,635[\\CHEMICAL], slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.",
        "label": 6,
        "major": 3,
        "len": 24
    },
    {
        "text": "The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective [GENE]5-HT1B[\\GENE] antagonist, [CHEMICAL]SB224,289[\\CHEMICAL], was ineffective.",
        "label": 6,
        "major": 3,
        "len": 24
    },
    {
        "text": "UNLABELLED: [CHEMICAL]Entacapone[\\CHEMICAL] is a potent and specific peripheral [GENE]catechol-O-methyltransferase[\\GENE] (COMT) inhibitor.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "UNLABELLED: [CHEMICAL]Entacapone[\\CHEMICAL] is a potent and specific peripheral catechol-O-methyltransferase ([GENE]COMT[\\GENE]) inhibitor.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "We found that [CHEMICAL]5-HT[\\CHEMICAL] stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating [GENE]eNOS[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]5-hydroxytryptamine[\\CHEMICAL] evokes [GENE]endothelial nitric oxide synthase[\\GENE] activation in bovine aortic endothelial cell cultures.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of [GENE]eNOS[\\GENE] by [CHEMICAL]5-HT[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The high affinity [GENE]5-HT1B[\\GENE] receptor agonist, [CHEMICAL]5-nonyloxytryptamine[\\CHEMICAL] (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.",
        "label": 5,
        "major": 2,
        "len": 19
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [GENE]eNOS[\\GENE] selective antagonists (0.01-10 microM): [CHEMICAL]L-Nomega -monomethyl-L-arginine[\\CHEMICAL] (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the [GENE]5-HT1B[\\GENE]/5-HT2 receptor antagonist, [CHEMICAL]methiothepin[\\CHEMICAL], and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/[GENE]5-HT2 receptor[\\GENE] antagonist, [CHEMICAL]methiothepin[\\CHEMICAL], and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [GENE]eNOS[\\GENE] selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine ([CHEMICAL]L-NMMA[\\CHEMICAL]) and L-N omega-iminoethyl-L-ornithine (L-NIO).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [GENE]eNOS[\\GENE] selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and [CHEMICAL]L-N omega-iminoethyl-L-ornithine[\\CHEMICAL] (L-NIO).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the [GENE]eNOS[\\GENE] selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine ([CHEMICAL]L-NIO[\\CHEMICAL]).",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "Here, we tested the hypothesis that 5-HT receptors mediate [GENE]eNOS[\\GENE] activation by measuring agonist-stimulated [CHEMICAL][3H]L-citrulline[\\CHEMICAL] ([3H]L-Cit) formation in BAEC cultures.",
        "label": 9,
        "major": 3,
        "len": 20
    },
    {
        "text": "Here, we tested the hypothesis that 5-HT receptors mediate [GENE]eNOS[\\GENE] activation by measuring agonist-stimulated [3H]L-citrulline ([CHEMICAL][3H]L-Cit[\\CHEMICAL]) formation in BAEC cultures.",
        "label": 9,
        "major": 3,
        "len": 20
    },
    {
        "text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [CHEMICAL][3H]L-Cit[\\CHEMICAL], indicating [GENE]eNOS[\\GENE] activation.",
        "label": 9,
        "major": 3,
        "len": 15
    },
    {
        "text": "Activation of [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS) results in the production of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) that mediates the vasorelaxing properties of endothelial cells.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Activation of endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]) results in the production of [CHEMICAL]nitric oxide[\\CHEMICAL] (NO) that mediates the vasorelaxing properties of endothelial cells.",
        "label": 9,
        "major": 3,
        "len": 23
    },
    {
        "text": "Activation of [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS) results in the production of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) that mediates the vasorelaxing properties of endothelial cells.",
        "label": 9,
        "major": 3,
        "len": 23
    },
    {
        "text": "Activation of endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]) results in the production of nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) that mediates the vasorelaxing properties of endothelial cells.",
        "label": 9,
        "major": 3,
        "len": 23
    },
    {
        "text": "We found that 5-HT stimulated the conversion of [CHEMICAL][3H]L-arginine[\\CHEMICAL] ([3H]L-Arg) to [3H]L-Cit, indicating [GENE]eNOS[\\GENE] activation.",
        "label": 9,
        "major": 3,
        "len": 15
    },
    {
        "text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ([CHEMICAL][3H]L-Arg[\\CHEMICAL]) to [3H]L-Cit, indicating [GENE]eNOS[\\GENE] activation.",
        "label": 9,
        "major": 3,
        "len": 15
    },
    {
        "text": "We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that [GENE]ATM[\\GENE] kinase activity is directly inhibited by [CHEMICAL]caffeine[\\CHEMICAL] in vitro.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by caffeine in vivo and that ATM [GENE]kinase[\\GENE] activity is directly inhibited by [CHEMICAL]caffeine[\\CHEMICAL] in vitro.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Inhibition of [GENE]ATM[\\GENE] provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of [CHEMICAL]caffeine[\\CHEMICAL]-treated cells [6] [7] [8].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We report that the radiation-induced activation of the [GENE]kinase[\\GENE] Cds1 [4] (also known as Chk2 [5]) is inhibited by [CHEMICAL]caffeine[\\CHEMICAL] in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "We report that the radiation-induced activation of the kinase [GENE]Cds1[\\GENE] [4] (also known as Chk2 [5]) is inhibited by [CHEMICAL]caffeine[\\CHEMICAL] in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "We report that the radiation-induced activation of the kinase Cds1 [4] (also known as [GENE]Chk2[\\GENE] [5]) is inhibited by [CHEMICAL]caffeine[\\CHEMICAL] in vivo and that ATM kinase activity is directly inhibited by caffeine in vitro.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Caffeine[\\CHEMICAL] inhibits the checkpoint [GENE]kinase[\\GENE] ATM.",
        "label": 4,
        "major": 4,
        "len": 6
    },
    {
        "text": "[CHEMICAL]Caffeine[\\CHEMICAL] inhibits the checkpoint kinase [GENE]ATM[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 6
    },
    {
        "text": "[CHEMICAL]Citalopram[\\CHEMICAL] protected against the RTI-76-induced inhibition of [GENE]SERT[\\GENE] binding.",
        "label": 2,
        "major": 2,
        "len": 9
    },
    {
        "text": "Following 6 h of in vivo intracerebroventricular injections of 100 nmol of [CHEMICAL]RTI-76[\\CHEMICAL], there was a dose- and time-dependent reduction (- 60%) of [GENE]SERT[\\GENE] binding in hippocampus and striatum, without a change in the Kd.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "The turnover of [GENE]SERT[\\GENE] was determined from the rate of recovery of binding after administration of [CHEMICAL]RTI-76[\\CHEMICAL], an irreversible inhibitor of ligand binding.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In preliminary studies, in vitro incubation of rat cerebral cortex with [CHEMICAL]RTI-76[\\CHEMICAL] produced a wash and temperature resistant inhibition of [GENE]SERT[\\GENE] binding densities (Bmax).",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Citalopram protected against the [CHEMICAL]RTI-76[\\CHEMICAL]-induced inhibition of [GENE]SERT[\\GENE] binding.",
        "label": 4,
        "major": 2,
        "len": 9
    },
    {
        "text": "The decrease and recovery of [CHEMICAL][3H]-5-HT[\\CHEMICAL] uptake correlated highly (r = 0.93) with the recovery of [GENE]SERT[\\GENE] binding.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [CHEMICAL]losartan[\\CHEMICAL]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, [CHEMICAL]tasosartan[\\CHEMICAL] 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: [CHEMICAL]candesartan[\\CHEMICAL] 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, [CHEMICAL]telmisartan[\\CHEMICAL] 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, [CHEMICAL]E3174[\\CHEMICAL] (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, [CHEMICAL]losartan[\\CHEMICAL] 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, [CHEMICAL]eprosartan[\\CHEMICAL] 100 and the prodrug candesartan cilexetil 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug [CHEMICAL]candesartan cilexetil[\\CHEMICAL] 280.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, [CHEMICAL]saprisartan[\\CHEMICAL], zolasartan, irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, [CHEMICAL]zolasartan[\\CHEMICAL], irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, [CHEMICAL]irbesartan[\\CHEMICAL], valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, [CHEMICAL]valsartan[\\CHEMICAL], telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, [CHEMICAL]telmisartan[\\CHEMICAL], E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, [CHEMICAL]E3174[\\CHEMICAL]).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of [CHEMICAL]losartan[\\CHEMICAL]) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL] was the first, but by no means remained the only, [GENE]AT1[\\GENE] receptor antagonist.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, [CHEMICAL]tasosartan[\\CHEMICAL] 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: [CHEMICAL]candesartan[\\CHEMICAL] 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, [CHEMICAL]telmisartan[\\CHEMICAL] 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, [CHEMICAL]E3174[\\CHEMICAL] (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, [CHEMICAL]losartan[\\CHEMICAL] 50, eprosartan 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, [CHEMICAL]eprosartan[\\CHEMICAL] 100 and the prodrug candesartan cilexetil 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "Among the current [GENE]AT1[\\GENE] receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug [CHEMICAL]candesartan cilexetil[\\CHEMICAL] 280.",
        "label": 6,
        "major": 2,
        "len": 42
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive ([CHEMICAL]losartan[\\CHEMICAL], tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, [CHEMICAL]tasosartan[\\CHEMICAL], eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, [CHEMICAL]eprosartan[\\CHEMICAL]) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The mode of (functional) [GENE]AT1[\\GENE] receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive ([CHEMICAL]candesartan[\\CHEMICAL], saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The [GENE]mNQO[\\GENE] activity was insensitive to [CHEMICAL]dicoumarol[\\CHEMICAL], a potent inhibitor of cytosolic NQO1.",
        "label": 10,
        "major": 4,
        "len": 13
    },
    {
        "text": "The mNQO activity was insensitive to [CHEMICAL]dicoumarol[\\CHEMICAL], a potent inhibitor of cytosolic [GENE]NQO1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The [GENE]mNQO[\\GENE] activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of [CHEMICAL]2,6-dichlorophenolindophenol[\\CHEMICAL] and menadione.",
        "label": 9,
        "major": 2,
        "len": 21
    },
    {
        "text": "The [GENE]mNQO[\\GENE] activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and [CHEMICAL]menadione[\\CHEMICAL].",
        "label": 9,
        "major": 2,
        "len": 21
    },
    {
        "text": "[GENE]Quinone oxidoreductases[\\GENE] are flavoproteins that catalyze two-electron reduction and detoxification of [CHEMICAL]quinones[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "The affinity and functional profile of opioids possessing activity at the [GENE]nociceptin receptor[\\GENE] was determined using [3H]nociceptin and nociceptin-stimulated [CHEMICAL][35S]GTPgammaS[\\CHEMICAL] binding.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Lofentanil exhibited full agonism for enhancement of [CHEMICAL][35S]GTPgammaS[\\CHEMICAL] binding to human recombinant [GENE]ORL1[\\GENE] receptors (EC(50) 50 nM).",
        "label": 2,
        "major": 5,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Lofentanil[\\CHEMICAL] exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant [GENE]ORL1[\\GENE] receptors (EC(50) 50 nM).",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "The related piperidines ohmefentanyl and [CHEMICAL]sufentanil[\\CHEMICAL] and the nonselective opioid receptor agonist etorphine were less potent [GENE]nociceptin receptor[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The related piperidines ohmefentanyl and sufentanil and the nonselective [GENE]opioid receptor[\\GENE] agonist [CHEMICAL]etorphine[\\CHEMICAL] were less potent nociceptin receptor agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist [CHEMICAL]etorphine[\\CHEMICAL] were less potent [GENE]nociceptin receptor[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The nonselective [GENE]opioid receptor[\\GENE] partial agonist [CHEMICAL]buprenorphine[\\CHEMICAL] and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",
        "label": 5,
        "major": 5,
        "len": 29
    },
    {
        "text": "The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist [CHEMICAL](-)-quadazocine[\\CHEMICAL] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at [GENE]human ORL1[\\GENE] receptors.",
        "label": 5,
        "major": 6,
        "len": 29
    },
    {
        "text": "The [GENE]mu-opioid receptor[\\GENE]-selective agonist [CHEMICAL]lofentanil[\\CHEMICAL] potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).",
        "label": 5,
        "major": 5,
        "len": 17
    },
    {
        "text": "The related [CHEMICAL]piperidines[\\CHEMICAL] ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent [GENE]nociceptin receptor[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The related piperidines [CHEMICAL]ohmefentanyl[\\CHEMICAL] and sufentanil and the nonselective opioid receptor agonist etorphine were less potent [GENE]nociceptin receptor[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist [CHEMICAL]naloxone benzoylhydrazone[\\CHEMICAL] was a pure antagonist at both rat brain and human [GENE]ORL1[\\GENE] receptors.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "The kappa(1)+kappa(3)-opioid receptor agonist/[GENE]mu-opioid receptor[\\GENE] antagonist [CHEMICAL]naloxone benzoylhydrazone[\\CHEMICAL] was a pure antagonist at both rat brain and human ORL1 receptors.",
        "label": 6,
        "major": 5,
        "len": 20
    },
    {
        "text": "The nonselective opioid receptor partial agonist buprenorphine and the nonselective [GENE]opioid receptor[\\GENE] antagonist [CHEMICAL](-)-quadazocine[\\CHEMICAL] exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "Thirty-week administration of [CHEMICAL]UFT[\\CHEMICAL] with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of [GENE]thymidylate synthase[\\GENE] inhibition and the decrease of thymidine kinase activity in the tumor cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thirty-week administration of [CHEMICAL]UFT[\\CHEMICAL] with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of [GENE]thymidine kinase[\\GENE] activity in the tumor cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thirty-week administration of UFT with or without [CHEMICAL]leucovorin[\\CHEMICAL] markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of [GENE]thymidylate synthase[\\GENE] inhibition and the decrease of thymidine kinase activity in the tumor cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thirty-week administration of UFT with or without [CHEMICAL]leucovorin[\\CHEMICAL] markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of [GENE]thymidine kinase[\\GENE] activity in the tumor cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[GENE]Thymidylate synthase[\\GENE] is inhibited by [CHEMICAL]5-fluorodeoxyuridine monophosphate[\\CHEMICAL], forming an inactive ternary complex with intracellular folate.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Ornithine decarboxylase ([GENE]ODC[\\GENE]) catalyses the first step in the synthesis of the polyamines putrescine, [CHEMICAL]spermidine[\\CHEMICAL] and spermine.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Ornithine decarboxylase[\\GENE] (ODC) catalyses the first step in the synthesis of the polyamines putrescine, [CHEMICAL]spermidine[\\CHEMICAL] and spermine.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Ornithine decarboxylase ([GENE]ODC[\\GENE]) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and [CHEMICAL]spermine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Ornithine decarboxylase[\\GENE] (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and [CHEMICAL]spermine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Ornithine decarboxylase ([GENE]ODC[\\GENE]) catalyses the first step in the synthesis of the polyamines [CHEMICAL]putrescine[\\CHEMICAL], spermidine and spermine.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Ornithine decarboxylase[\\GENE] (ODC) catalyses the first step in the synthesis of the polyamines [CHEMICAL]putrescine[\\CHEMICAL], spermidine and spermine.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "The selective [GENE]alpha(2)-adrenoceptor[\\GENE] ligand [CHEMICAL]rauwolscine[\\CHEMICAL] antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.",
        "label": 2,
        "major": 6,
        "len": 25
    },
    {
        "text": "The selective [GENE]alpha(2)-adrenoceptor[\\GENE] ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against [CHEMICAL]noradrenaline[\\CHEMICAL] was 8.43.",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "In [GENE]alpha(2A)-adrenoceptor[\\GENE] transfected cells the rank order of agonist potency was [CHEMICAL]A-54741[\\CHEMICAL] (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "In [GENE]alpha(2A)-adrenoceptor[\\GENE] transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>[CHEMICAL]dexmedetomidine[\\CHEMICAL] (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "In [GENE]alpha(2A)-adrenoceptor[\\GENE] transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>[CHEMICAL]UK-14304[\\CHEMICAL] (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "In [GENE]alpha(2A)-adrenoceptor[\\GENE] transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>[CHEMICAL]B-HT 920[\\CHEMICAL] (7.05)>noradrenaline (6.92).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "In [GENE]alpha(2A)-adrenoceptor[\\GENE] transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>[CHEMICAL]noradrenaline[\\CHEMICAL] (6.92).",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "[GENE]Glucocorticoid receptors[\\GENE] were activated by [CHEMICAL]dexamethasone[\\CHEMICAL] as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "The [GENE]glucocorticoid receptor[\\GENE] antagonist [CHEMICAL]RU-486[\\CHEMICAL] (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.",
        "label": 6,
        "major": 3,
        "len": 30
    },
    {
        "text": "The [GENE]glucocorticoid receptor[\\GENE] antagonist RU-486 ([CHEMICAL]mifepristone[\\CHEMICAL]) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.",
        "label": 6,
        "major": 3,
        "len": 30
    },
    {
        "text": "Study of the additional subjects revealed that [CHEMICAL]quetiapine[\\CHEMICAL] does give rise to transiently high (58%-64%) [GENE]D2[\\GENE] occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.",
        "label": 2,
        "major": 4,
        "len": 34
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Quetiapine[\\CHEMICAL] shows a transiently high [GENE]D2[\\GENE] occupancy, which decreases to very low levels by the end of the dosing interval.",
        "label": 2,
        "major": 4,
        "len": 21
    },
    {
        "text": "RESULTS: [CHEMICAL]Quetiapine[\\CHEMICAL] was an effective antipsychotic and improved the extrapyramidal symptoms and [GENE]prolactin[\\GENE] level elevation noted at baseline.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "The attachment of a [CHEMICAL]fatty acid[\\CHEMICAL] chain to LysB29 provided [GENE]insulin[\\GENE] detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.",
        "label": 1,
        "major": 4,
        "len": 32
    },
    {
        "text": "Finally, [CHEMICAL]cysteine[\\CHEMICAL] 53 in the [GENE]M1P1 external loop[\\GENE] is required for functional expression of TWIK-2 but is not critical for subunit self-assembly.",
        "label": 1,
        "major": 10,
        "len": 22
    },
    {
        "text": "Finally, [CHEMICAL]cysteine[\\CHEMICAL] 53 in the M1P1 external loop is required for functional expression of [GENE]TWIK-2[\\GENE] but is not critical for subunit self-assembly.",
        "label": 1,
        "major": 10,
        "len": 22
    },
    {
        "text": "In a physiological K(+) gradient, [GENE]TWIK-2[\\GENE] is half inhibited by 0.1 mm [CHEMICAL]Ba(2+)[\\CHEMICAL], quinine, and quinidine.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "In a physiological K(+) gradient, [GENE]TWIK-2[\\GENE] is half inhibited by 0.1 mm Ba(2+), [CHEMICAL]quinine[\\CHEMICAL], and quinidine.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "In a physiological K(+) gradient, [GENE]TWIK-2[\\GENE] is half inhibited by 0.1 mm Ba(2+), quinine, and [CHEMICAL]quinidine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "BACKGROUND: This study examines the effects of [CHEMICAL]nicorandil[\\CHEMICAL], a [GENE]K(+) channel[\\GENE] opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, [CHEMICAL]d-sotalol[\\CHEMICAL] (100 micromol/L) to block [GENE]I(Kr)[\\GENE] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, [CHEMICAL]d-sotalol[\\CHEMICAL] (100 micromol/L) to block I(Kr) (LQT2 model), and [GENE]ATX-II[\\GENE] (20 nmol/L) to augment late I(Na) (LQT3 model).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block [GENE]I(Kr)[\\GENE] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and [GENE]ATX-II[\\GENE] (20 nmol/L) to augment late I(Na) (LQT3 model).",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "[GENE]Peroxisome proliferator-activated receptor alpha[\\GENE] (PPARalpha) activators, [CHEMICAL]bezafibrate[\\CHEMICAL] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Peroxisome proliferator-activated receptor alpha ([GENE]PPARalpha[\\GENE]) activators, [CHEMICAL]bezafibrate[\\CHEMICAL] and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[GENE]Peroxisome proliferator-activated receptor alpha[\\GENE] (PPARalpha) activators, bezafibrate and [CHEMICAL]Wy-14,643[\\CHEMICAL], increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Peroxisome proliferator-activated receptor alpha ([GENE]PPARalpha[\\GENE]) activators, bezafibrate and [CHEMICAL]Wy-14,643[\\CHEMICAL], increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, [CHEMICAL]bezafibrate[\\CHEMICAL] and Wy-14,643, increase [GENE]uncoupling protein-3[\\GENE] mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and [CHEMICAL]Wy-14,643[\\CHEMICAL], increase [GENE]uncoupling protein-3[\\GENE] mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "The induction in [GENE]UCP-3[\\GENE] expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after [CHEMICAL]bezafibrate[\\CHEMICAL] or Wy-14,643 treatment.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "The induction in [GENE]UCP-3[\\GENE] expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or [CHEMICAL]Wy-14,643[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the [GENE]UCP-3[\\GENE] induction achieved after [CHEMICAL]bezafibrate[\\CHEMICAL] and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "Since it has been proposed that UCP-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the [GENE]UCP-3[\\GENE] induction achieved after bezafibrate and [CHEMICAL]Wy-14, 643[\\CHEMICAL] treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.",
        "label": 3,
        "major": 3,
        "len": 48
    },
    {
        "text": "Thus, [CHEMICAL]bezafibrate[\\CHEMICAL] treatment resulted in an 8-fold induction in [GENE]UCP-3[\\GENE] mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[GENE]Uncoupling proteins[\\GENE] (UCPs) are inner mitochondrial membrane transporters which act as pores for [CHEMICAL]H(+)[\\CHEMICAL] ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Uncoupling proteins ([GENE]UCPs[\\GENE]) are inner mitochondrial membrane transporters which act as pores for [CHEMICAL]H(+)[\\CHEMICAL] ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Schisandrin B[\\CHEMICAL] protects against menadione-induced hepatotoxicity by enhancing [GENE]DT-diaphorase[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "Hepatocytes isolated from [CHEMICAL]Sch B[\\CHEMICAL] pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in [GENE]DTD[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against [CHEMICAL]menadione[\\CHEMICAL]-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma [GENE]alanine aminotransferase[\\GENE] activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.",
        "label": 4,
        "major": 3,
        "len": 57
    },
    {
        "text": "[GENE]Creatine phosphokinase[\\GENE] activity in plasma increased slightly (compared to control, [CHEMICAL]pyridostigmine[\\CHEMICAL] or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "[GENE]Creatine phosphokinase[\\GENE] activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with [CHEMICAL]pyridostigmine[\\CHEMICAL] plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "The group treated with [CHEMICAL]pyridostigmine[\\CHEMICAL] alone showed decreased plasma [GENE]butyrylcholinesterase[\\GENE] (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.",
        "label": 4,
        "major": 2,
        "len": 34
    },
    {
        "text": "The group treated with [CHEMICAL]pyridostigmine[\\CHEMICAL] alone showed decreased plasma butyrylcholinesterase ([GENE]BChE[\\GENE]) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.",
        "label": 4,
        "major": 2,
        "len": 34
    },
    {
        "text": "The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas [CHEMICAL]pyridostigmine[\\CHEMICAL] plus exercise significantly decreased the [GENE]BChE[\\GENE] activity (79% of control), indicating an interactive effect of the combination.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "However, [GENE]AChE[\\GENE] activity in triceps muscle decreased significantly (78% of control) in the group treated with [CHEMICAL]pyridostigmine[\\CHEMICAL] plus exercise.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "RESULT(S): [CHEMICAL]Buserelin acetate[\\CHEMICAL], a GnRH agonist (0.1-10 ng/mL), had no significant effect on [GENE]MCP-1[\\GENE] expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.",
        "label": 10,
        "major": 5,
        "len": 40
    },
    {
        "text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas [CHEMICAL]danazol[\\CHEMICAL] (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [GENE]MCP-1[\\GENE] expression.",
        "label": 4,
        "major": 5,
        "len": 40
    },
    {
        "text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a [CHEMICAL]testosterone[\\CHEMICAL] analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [GENE]MCP-1[\\GENE] expression.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and [CHEMICAL]dexamethasone[\\CHEMICAL], an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on [GENE]MCP-1[\\GENE] expression.",
        "label": 4,
        "major": 5,
        "len": 40
    },
    {
        "text": "RESULT(S): [CHEMICAL]Buserelin acetate[\\CHEMICAL], a [GENE]GnRH[\\GENE] agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.",
        "label": 5,
        "major": 5,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Clenbuterol[\\CHEMICAL] was without effect on [GENE]NGF[\\GENE] mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.",
        "label": 10,
        "major": 3,
        "len": 29
    },
    {
        "text": "Mobility shift assays on whole cell extracts showed that [CHEMICAL]clenbuterol[\\CHEMICAL] increased AP1 binding in 3T3 cells prior to increasing [GENE]NGF[\\GENE] synthesis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas [CHEMICAL]CB1093[\\CHEMICAL] caused significant increases in both [GENE]NGF[\\GENE] mRNA and protein levels in both 3T3 and L929 cells.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "This study demonstrates that [CHEMICAL]CB1093[\\CHEMICAL] and clenbuterol stimulate [GENE]NGF[\\GENE] levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "This study demonstrates that [CHEMICAL]CB1093[\\CHEMICAL] and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of [GENE]NGF[\\GENE] induction of these two compounds.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "This study demonstrates that CB1093 and [CHEMICAL]clenbuterol[\\CHEMICAL] stimulate [GENE]NGF[\\GENE] levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "This study demonstrates that CB1093 and [CHEMICAL]clenbuterol[\\CHEMICAL] stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of [GENE]NGF[\\GENE] induction of these two compounds.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue ([CHEMICAL]CB1093[\\CHEMICAL]) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [GENE]NGF[\\GENE] synthesis in vivo.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and [CHEMICAL]clenbuterol[\\CHEMICAL], a long-acting beta(2)-adrenoceptor agonist, both of which induce [GENE]NGF[\\GENE] synthesis in vivo.",
        "label": 3,
        "major": 5,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Clenbuterol[\\CHEMICAL] caused significant increases in both [GENE]NGF[\\GENE] mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The present studies were undertaken to compare two compounds, a [CHEMICAL]vitamin D(3)[\\CHEMICAL] analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce [GENE]NGF[\\GENE] synthesis in vivo.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and [CHEMICAL]clenbuterol[\\CHEMICAL], a long-acting [GENE]beta(2)-adrenoceptor[\\GENE] agonist, both of which induce NGF synthesis in vivo.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "CONCLUSIONS: After the initial bleach, [CHEMICAL]halothane[\\CHEMICAL] impeded photon absorption by [GENE]rhodopsin[\\GENE] by inhibiting metabolic rhodopsin regeneration.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "Consequently, [GENE]photoreceptors[\\GENE] of mice and rats anesthetized with [CHEMICAL]halothane[\\CHEMICAL] were completely protected against degeneration induced by white light.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "CONCLUSIONS: After the initial bleach, [CHEMICAL]halothane[\\CHEMICAL] impeded photon absorption by rhodopsin by inhibiting metabolic [GENE]rhodopsin[\\GENE] regeneration.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "RESULTS: [CHEMICAL]Halothane[\\CHEMICAL] anesthesia reversibly inhibited metabolic [GENE]rhodopsin[\\GENE] regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "RESULTS: [CHEMICAL]Halothane[\\CHEMICAL] anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented [GENE]rhodopsin[\\GENE] from absorbing high numbers of photons during light exposure.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Protective effect of [CHEMICAL]halothane[\\CHEMICAL] anesthesia on retinal light damage: inhibition of metabolic [GENE]rhodopsin[\\GENE] regeneration.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [[CHEMICAL]buspirone[\\CHEMICAL] (partial [GENE]5-HT1A[\\GENE] agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.",
        "label": 5,
        "major": 5,
        "len": 56
    },
    {
        "text": "METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and 5-HT1B receptor agonists [buspirone (partial 5-HT1A agonist), [CHEMICAL]anpirtoline[\\CHEMICAL] ([GENE]5-HT1B[\\GENE] agonist)] in the mouse forced swimming test.",
        "label": 5,
        "major": 5,
        "len": 56
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [GENE]dihydrofolate reductase[\\GENE], and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and [GENE]glycinamide ribonucleotide formyl transferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits [GENE]thymidylate synthase[\\GENE], dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]Alimta[\\CHEMICAL], LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [GENE]dihydrofolate reductase[\\GENE], and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]Alimta[\\CHEMICAL], LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and [GENE]glycinamide ribonucleotide formyl transferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]Alimta[\\CHEMICAL], LY231514) is a novel, multitargeted antifolate that inhibits [GENE]thymidylate synthase[\\GENE], dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium (Alimta, [CHEMICAL]LY231514[\\CHEMICAL]) is a novel, multitargeted antifolate that inhibits thymidylate synthase, [GENE]dihydrofolate reductase[\\GENE], and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium (Alimta, [CHEMICAL]LY231514[\\CHEMICAL]) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and [GENE]glycinamide ribonucleotide formyl transferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Pemetrexed disodium (Alimta, [CHEMICAL]LY231514[\\CHEMICAL]) is a novel, multitargeted antifolate that inhibits [GENE]thymidylate synthase[\\GENE], dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "We took advantage of the previous observations that [CHEMICAL]phosphatidylserine[\\CHEMICAL] inhibits [GENE]DGK-delta[\\GENE] (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[GENE]Diacylglycerol kinase[\\GENE] (DGK) catalyzes the conversion of diacylglycerol to [CHEMICAL]phosphatidic acid[\\CHEMICAL], making it an attractive candidate for a signal transduction component.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Diacylglycerol kinase ([GENE]DGK[\\GENE]) catalyzes the conversion of diacylglycerol to [CHEMICAL]phosphatidic acid[\\CHEMICAL], making it an attractive candidate for a signal transduction component.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[GENE]Diacylglycerol kinase[\\GENE] (DGK) catalyzes the conversion of [CHEMICAL]diacylglycerol[\\CHEMICAL] to phosphatidic acid, making it an attractive candidate for a signal transduction component.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Diacylglycerol kinase ([GENE]DGK[\\GENE]) catalyzes the conversion of [CHEMICAL]diacylglycerol[\\CHEMICAL] to phosphatidic acid, making it an attractive candidate for a signal transduction component.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Nordihydroguaiaretic acid[\\CHEMICAL] (NDGA) has been shown to inhibit both 5-lipoxygenase and [GENE]ornithine decarboxylase[\\GENE] and is active against several cancer cell lines and at least one mouse tumor model.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Nordihydroguaiaretic acid[\\CHEMICAL] (NDGA) has been shown to inhibit both [GENE]5-lipoxygenase[\\GENE] and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Nordihydroguaiaretic acid ([CHEMICAL]NDGA[\\CHEMICAL]) has been shown to inhibit both 5-lipoxygenase and [GENE]ornithine decarboxylase[\\GENE] and is active against several cancer cell lines and at least one mouse tumor model.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Nordihydroguaiaretic acid ([CHEMICAL]NDGA[\\CHEMICAL]) has been shown to inhibit both [GENE]5-lipoxygenase[\\GENE] and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[GENE]Carbonic anhydrase[\\GENE] (CA) is a zinc enzyme that catalyses the reversible hydration reaction of [CHEMICAL]CO2[\\CHEMICAL] and plays a major role in the acid-base balance.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "Carbonic anhydrase ([GENE]CA[\\GENE]) is a zinc enzyme that catalyses the reversible hydration reaction of [CHEMICAL]CO2[\\CHEMICAL] and plays a major role in the acid-base balance.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "The temporal profile of butyrylcholinesterase (BuChE) and in vitro [CHEMICAL]pralidoxime[\\CHEMICAL]-reactivated [GENE]BuChE[\\GENE] was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Reactivation potentials of [GENE]BuChE[\\GENE] (the difference between [CHEMICAL]oxime[\\CHEMICAL]-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Reactivation potentials of [GENE]BuChE[\\GENE] (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after [CHEMICAL]organophosphate[\\CHEMICAL] ingestion.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Patients who received [CHEMICAL]oxime[\\CHEMICAL] prior to hospitalization had a higher rate of intermediate syndrome and lower levels of [GENE]BuChE[\\GENE] at admission than those who had not.",
        "label": 4,
        "major": 10,
        "len": 26
    },
    {
        "text": "CONCLUSIONS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists [CHEMICAL]brimonidine[\\CHEMICAL], apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "CONCLUSIONS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists brimonidine, [CHEMICAL]apraclonidine[\\CHEMICAL], and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "CONCLUSIONS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists brimonidine, apraclonidine, and [CHEMICAL]oxymetazoline[\\CHEMICAL] are potent vasoconstrictors in the porcine ciliary artery.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "The segments were contracted with the [GENE]alpha(2)-adrenoceptor[\\GENE] agonists [CHEMICAL]brimonidine[\\CHEMICAL], apraclonidine, and oxymetazoline.",
        "label": 5,
        "major": 5,
        "len": 12
    },
    {
        "text": "The segments were contracted with the [GENE]alpha(2)-adrenoceptor[\\GENE] agonists brimonidine, [CHEMICAL]apraclonidine[\\CHEMICAL], and oxymetazoline.",
        "label": 5,
        "major": 5,
        "len": 12
    },
    {
        "text": "The segments were contracted with the [GENE]alpha(2)-adrenoceptor[\\GENE] agonists brimonidine, apraclonidine, and [CHEMICAL]oxymetazoline[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 12
    },
    {
        "text": "RESULTS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: [CHEMICAL]brimonidine[\\CHEMICAL] 2.11, oxymetazoline 5.26, and apraclonidine 13.0.",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "RESULTS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, [CHEMICAL]oxymetazoline[\\CHEMICAL] 5.26, and apraclonidine 13.0.",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "RESULTS: The [GENE]alpha(2)-adrenoceptor[\\GENE] agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and [CHEMICAL]apraclonidine[\\CHEMICAL] 13.0.",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for [CHEMICAL]BRL44408[\\CHEMICAL] (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional [GENE]alpha(2A)-adrenoceptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), [CHEMICAL]ARC 239[\\CHEMICAL] (5.8) and for prazosin (6.0) suggesting the presence of functional [GENE]alpha(2A)-adrenoceptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for [CHEMICAL]prazosin[\\CHEMICAL] (6.0) suggesting the presence of functional [GENE]alpha(2A)-adrenoceptors[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "The following alpha(2)-adrenoceptor antagonists were applied: [CHEMICAL]BRL44408[\\CHEMICAL] ([GENE]alpha(2A)[\\GENE]-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), [CHEMICAL]ARC239[\\CHEMICAL] ([GENE]alpha(2B)[\\GENE]- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), [CHEMICAL]ARC239[\\CHEMICAL] (alpha(2B)- and [GENE]alpha(2C)[\\GENE]-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and [CHEMICAL]prazosin[\\CHEMICAL] ([GENE]alpha(2B)[\\GENE]- and alpha(2C)-selective).",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and [CHEMICAL]prazosin[\\CHEMICAL] (alpha(2B)- and [GENE]alpha(2C)[\\GENE]-selective).",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [GENE]thymidylate synthase[\\GENE], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, [GENE]dihydrofolate reductase[\\GENE], and glycinamide ribonucleotide formyltransferase.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Pemetrexed disodium[\\CHEMICAL] (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and [GENE]glycinamide ribonucleotide formyltransferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]ALIMTA[\\CHEMICAL]) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [GENE]thymidylate synthase[\\GENE], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]ALIMTA[\\CHEMICAL]) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, [GENE]dihydrofolate reductase[\\GENE], and glycinamide ribonucleotide formyltransferase.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Pemetrexed disodium ([CHEMICAL]ALIMTA[\\CHEMICAL]) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and [GENE]glycinamide ribonucleotide formyltransferase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "CONCLUSION: [CHEMICAL]Rabeprazole[\\CHEMICAL] is a well tolerated [GENE]proton pump[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "UNLABELLED: [CHEMICAL]Rabeprazole[\\CHEMICAL] is an inhibitor of the [GENE]gastric proton pump[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "At the same time, mean plasma active [GENE]renin[\\GENE] was increased 16- and 34-fold at the highest dose of [CHEMICAL]Aliskiren[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "In conclusion, the renin inhibitor [CHEMICAL]Aliskiren[\\CHEMICAL] dose-dependently decreases [GENE]Ang II[\\GENE] levels in humans following oral administration.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "There was a dose-dependent decrease in plasma renin activity, [GENE]Ang I[\\GENE], and Ang II following single doses of [CHEMICAL]Aliskiren[\\CHEMICAL] starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.",
        "label": 4,
        "major": 4,
        "len": 59
    },
    {
        "text": "There was a dose-dependent decrease in plasma renin activity, Ang I, and [GENE]Ang II[\\GENE] following single doses of [CHEMICAL]Aliskiren[\\CHEMICAL] starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.",
        "label": 4,
        "major": 4,
        "len": 59
    },
    {
        "text": "[GENE]Angiotensin II[\\GENE] suppression in humans by the orally active renin inhibitor [CHEMICAL]Aliskiren[\\CHEMICAL] (SPP100): comparison with enalapril.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[GENE]Angiotensin II[\\GENE] suppression in humans by the orally active renin inhibitor Aliskiren ([CHEMICAL]SPP100[\\CHEMICAL]): comparison with enalapril.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in [GENE]Ang II[\\GENE] levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of [CHEMICAL]Aliskiren[\\CHEMICAL] was compared with placebo.",
        "label": 4,
        "major": 4,
        "len": 59
    },
    {
        "text": "In conclusion, the [GENE]renin[\\GENE] inhibitor [CHEMICAL]Aliskiren[\\CHEMICAL] dose-dependently decreases Ang II levels in humans following oral administration.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Aliskiren[\\CHEMICAL] has the potential to become the first orally active [GENE]renin[\\GENE] inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Aliskiren[\\CHEMICAL] has the potential to become the first orally active renin inhibitor that provides a true alternative to [GENE]ACE[\\GENE]-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "We tested the new orally active nonpeptidic [GENE]renin[\\GENE] inhibitor [CHEMICAL]SPP100[\\CHEMICAL] (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "We tested the new orally active nonpeptidic [GENE]renin[\\GENE] inhibitor SPP100 ([CHEMICAL]Aliskiren[\\CHEMICAL], an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "We tested the new orally active nonpeptidic [GENE]renin[\\GENE] inhibitor SPP100 (Aliskiren, an [CHEMICAL]octanamide[\\CHEMICAL] with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "There was a dose-dependent decrease in plasma [GENE]renin[\\GENE] activity, Ang I, and Ang II following single doses of [CHEMICAL]Aliskiren[\\CHEMICAL] starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.",
        "label": 4,
        "major": 4,
        "len": 59
    },
    {
        "text": "Angiotensin II suppression in humans by the orally active [GENE]renin[\\GENE] inhibitor [CHEMICAL]Aliskiren[\\CHEMICAL] (SPP100): comparison with enalapril.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Angiotensin II suppression in humans by the orally active [GENE]renin[\\GENE] inhibitor Aliskiren ([CHEMICAL]SPP100[\\CHEMICAL]): comparison with enalapril.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Aliskiren[\\CHEMICAL] has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and [GENE]Ang II receptor[\\GENE] antagonists in therapy for hypertension and other cardiovascular and renal diseases.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "Almost all patients with [GENE]SUR1[\\GENE] (38/41) or KIR6.2 (5/7) mutations were resistant to [CHEMICAL]diazoxide[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 14
    },
    {
        "text": "Almost all patients with SUR1 (38/41) or [GENE]KIR6.2[\\GENE] (5/7) mutations were resistant to [CHEMICAL]diazoxide[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 14
    },
    {
        "text": "The earliest known [GENE]AChE[\\GENE] inhibitors, namely, [CHEMICAL]physostigmine[\\CHEMICAL] and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The earliest known [GENE]AChE[\\GENE] inhibitors, namely, physostigmine and [CHEMICAL]tacrine[\\CHEMICAL], performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Donepezil hydrochloride[\\CHEMICAL] inaugurates a new class of [GENE]AChE[\\GENE] inhibitors with longer and more selective action and with manageable adverse effects.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Experimentation using isoforms of [GENE]alefacept[\\GENE] engineered to have [CHEMICAL]amino acid[\\CHEMICAL] substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.",
        "label": 1,
        "major": 3,
        "len": 59
    },
    {
        "text": "Experimentation using isoforms of alefacept engineered to have [CHEMICAL]amino acid[\\CHEMICAL] substitutions in the [GENE]IgG1 C(H)2 domain[\\GENE] that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.",
        "label": 1,
        "major": 3,
        "len": 59
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL]--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of [GENE]TNF alpha[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "As a prodrug [CHEMICAL]leflunomide[\\CHEMICAL] is completely converted to its active metabolite A 77 1726 (M1) which blocks the [GENE]dihydroorotate dehydrogenase[\\GENE], a key enzyme of the pyrimidine de novo synthesis.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "As a prodrug leflunomide is completely converted to its active metabolite [CHEMICAL]A 77 1726[\\CHEMICAL] (M1) which blocks the [GENE]dihydroorotate dehydrogenase[\\GENE], a key enzyme of the pyrimidine de novo synthesis.",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Fulvestrant[\\CHEMICAL], the first agent in this new class, not only induces the degradation of the [GENE]estrogen receptor[\\GENE] but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "A recent study showed that [CHEMICAL]anastrozole[\\CHEMICAL], an [GENE]aromatase[\\GENE] inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Lovastatin[\\CHEMICAL], a specific inhibitor of [GENE]HMG-CoA reductase[\\GENE], induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Regulation of [GENE]norepinephrine transporter[\\GENE] abundance by [CHEMICAL]catecholamines[\\CHEMICAL] and desipramine in vivo.",
        "label": 2,
        "major": 9,
        "len": 11
    },
    {
        "text": "Regulation of [GENE]norepinephrine transporter[\\GENE] abundance by catecholamines and [CHEMICAL]desipramine[\\CHEMICAL] in vivo.",
        "label": 2,
        "major": 9,
        "len": 11
    },
    {
        "text": "Chronic treatment with the NET inhibitor, [CHEMICAL]desipramine[\\CHEMICAL] (DMI), reduced [GENE]NET[\\GENE] levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Chronic treatment with the [GENE]NET[\\GENE] inhibitor, [CHEMICAL]desipramine[\\CHEMICAL] (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific [GENE]alpha(4)beta(2*) nAChR[\\GENE] agonist [CHEMICAL]metanicotine[\\CHEMICAL], or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific [GENE]alpha(4)beta(2*) nAChR[\\GENE] agonist metanicotine, or [CHEMICAL]nicotine[\\CHEMICAL] plus nAChR antagonists and norepinephrine measured in the microdialysates.",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Cilostazol[\\CHEMICAL] decreases levels of serum triglycerides and causes some increase in [GENE]HDL[\\GENE]-cholesterol levels.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Mutants [GENE]Y751A[\\GENE], D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to [CHEMICAL]cilostazol[\\CHEMICAL] (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 10,
        "major": 1,
        "len": 47
    },
    {
        "text": "Mutants Y751A, [GENE]D950A[\\GENE], and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to [CHEMICAL]cilostazol[\\CHEMICAL] (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 10,
        "major": 4,
        "len": 47
    },
    {
        "text": "Mutants Y751A, D950A, and [GENE]F1004A[\\GENE] had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to [CHEMICAL]cilostazol[\\CHEMICAL] (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 10,
        "major": 4,
        "len": 47
    },
    {
        "text": "To identify [CHEMICAL]amino acid[\\CHEMICAL] residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of [GENE]PDE3A[\\GENE] using a model created on basis of homology to the PDE4B crystal structure.",
        "label": 1,
        "major": 2,
        "len": 35
    },
    {
        "text": "To identify [CHEMICAL]amino acid[\\CHEMICAL] residues involved in [GENE]PDE3[\\GENE]-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.",
        "label": 1,
        "major": 2,
        "len": 35
    },
    {
        "text": "We changed the residues to [CHEMICAL]alanine[\\CHEMICAL] using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of [GENE]PDE3[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 37
    },
    {
        "text": "Identification of interaction sites of cyclic nucleotide [GENE]phosphodiesterase type 3A[\\GENE] with milrinone and [CHEMICAL]cilostazol[\\CHEMICAL] using molecular modeling and site-directed mutagenesis.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Identification of interaction sites of cyclic nucleotide [GENE]phosphodiesterase type 3A[\\GENE] with [CHEMICAL]milrinone[\\CHEMICAL] and cilostazol using molecular modeling and site-directed mutagenesis.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for [CHEMICAL]cilostazol[\\CHEMICAL] but no difference for milrinone from the recombinant [GENE]PDE3A[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In contrast, the mutants [GENE]T844A[\\GENE], F972A and Q975A showed increased K(i) for [CHEMICAL]cilostazol[\\CHEMICAL] but no difference for milrinone from the recombinant PDE3A.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In contrast, the mutants T844A, [GENE]F972A[\\GENE] and Q975A showed increased K(i) for [CHEMICAL]cilostazol[\\CHEMICAL] but no difference for milrinone from the recombinant PDE3A.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In contrast, the mutants T844A, F972A and [GENE]Q975A[\\GENE] showed increased K(i) for [CHEMICAL]cilostazol[\\CHEMICAL] but no difference for milrinone from the recombinant PDE3A.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for [CHEMICAL]milrinone[\\CHEMICAL] from the recombinant [GENE]PDE3A[\\GENE].",
        "label": 4,
        "major": 1,
        "len": 22
    },
    {
        "text": "In contrast, the mutants [GENE]T844A[\\GENE], F972A and Q975A showed increased K(i) for cilostazol but no difference for [CHEMICAL]milrinone[\\CHEMICAL] from the recombinant PDE3A.",
        "label": 4,
        "major": 1,
        "len": 22
    },
    {
        "text": "In contrast, the mutants T844A, [GENE]F972A[\\GENE] and Q975A showed increased K(i) for cilostazol but no difference for [CHEMICAL]milrinone[\\CHEMICAL] from the recombinant PDE3A.",
        "label": 4,
        "major": 1,
        "len": 22
    },
    {
        "text": "In contrast, the mutants T844A, F972A and [GENE]Q975A[\\GENE] showed increased K(i) for cilostazol but no difference for [CHEMICAL]milrinone[\\CHEMICAL] from the recombinant PDE3A.",
        "label": 4,
        "major": 1,
        "len": 22
    },
    {
        "text": "Molecular models show that the [GENE]PDE3[\\GENE] inhibitors [CHEMICAL]cilostazol[\\CHEMICAL] and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Molecular models show that the [GENE]PDE3[\\GENE] inhibitors cilostazol and [CHEMICAL]milrinone[\\CHEMICAL] share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Our study implies that highly conserved residuals Y751, D950 and F1004 in the [GENE]PDE[\\GENE] families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the [CHEMICAL]cilostazol[\\CHEMICAL] selectivity of PDE3A.",
        "label": 4,
        "major": 9,
        "len": 37
    },
    {
        "text": "Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the [CHEMICAL]cilostazol[\\CHEMICAL] selectivity of [GENE]PDE3A[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 37
    },
    {
        "text": "We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by [CHEMICAL]milrinone[\\CHEMICAL] and cilostazol, specific inhibitors of [GENE]PDE3[\\GENE].",
        "label": 4,
        "major": 1,
        "len": 37
    },
    {
        "text": "We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and [CHEMICAL]cilostazol[\\CHEMICAL], specific inhibitors of [GENE]PDE3[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Mutants [GENE]Y751A[\\GENE], D950A, and F1004A had reduced sensitivity to [CHEMICAL]milrinone[\\CHEMICAL] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 4,
        "major": 1,
        "len": 47
    },
    {
        "text": "Mutants Y751A, [GENE]D950A[\\GENE], and F1004A had reduced sensitivity to [CHEMICAL]milrinone[\\CHEMICAL] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Mutants Y751A, D950A, and [GENE]F1004A[\\GENE] had reduced sensitivity to [CHEMICAL]milrinone[\\CHEMICAL] (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to [CHEMICAL]milrinone[\\CHEMICAL] (K(i) changed from 0.66 microM for the recombinant [GENE]PDE3A[\\GENE] to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).",
        "label": 4,
        "major": 1,
        "len": 47
    },
    {
        "text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to [CHEMICAL]cilostazol[\\CHEMICAL] (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant [GENE]PDE3A[\\GENE]).",
        "label": 4,
        "major": 1,
        "len": 47
    },
    {
        "text": "The comparison between [GENE]MalP[\\GENE] structures shows that His377, through a hydrogen bond with the [CHEMICAL]6-hydroxyl[\\CHEMICAL] group of Glc1P substrate, triggers a conformational change of the 380s loop.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "In the active [GENE]MalP[\\GENE] enzyme, the residue Arg569 stabilizes the negative-charged [CHEMICAL]Glc1P[\\CHEMICAL], whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.",
        "label": 2,
        "major": 3,
        "len": 44
    },
    {
        "text": "The comparison between [GENE]MalP[\\GENE] structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of [CHEMICAL]Glc1P[\\CHEMICAL] substrate, triggers a conformational change of the 380s loop.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "The 2.0A crystal structure of the [GENE]MalP[\\GENE]/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential [CHEMICAL]pyridoxal phosphate[\\CHEMICAL] (PLP) cofactor.",
        "label": 8,
        "major": 8,
        "len": 47
    },
    {
        "text": "The 2.0A crystal structure of the [GENE]MalP[\\GENE]/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate ([CHEMICAL]PLP[\\CHEMICAL]) cofactor.",
        "label": 8,
        "major": 10,
        "len": 47
    },
    {
        "text": "The bacterial enzyme [GENE]maltodextrin phosphorylase[\\GENE] (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [CHEMICAL]glucose-1-phosphate[\\CHEMICAL] (Glc1P).",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "The bacterial enzyme maltodextrin phosphorylase ([GENE]MalP[\\GENE]) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [CHEMICAL]glucose-1-phosphate[\\CHEMICAL] (Glc1P).",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "The bacterial enzyme [GENE]maltodextrin phosphorylase[\\GENE] (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ([CHEMICAL]Glc1P[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "The bacterial enzyme maltodextrin phosphorylase ([GENE]MalP[\\GENE]) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ([CHEMICAL]Glc1P[\\CHEMICAL]).",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Fondaparinux sodium[\\CHEMICAL] is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to [GENE]antithrombin III[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Fondaparinux sodium[\\CHEMICAL] is the first in a new class of synthetic [GENE]factor Xa[\\GENE] inhibitors that binds reversibly with high affinity to antithrombin III.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "It is caused by a deficiency of [GENE]propionyl-CoA carboxylase[\\GENE] (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of [CHEMICAL]propionyl-CoA[\\CHEMICAL] to D-methylmalonyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is caused by a deficiency of propionyl-CoA carboxylase ([GENE]PCC[\\GENE], EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of [CHEMICAL]propionyl-CoA[\\CHEMICAL] to D-methylmalonyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is caused by a deficiency of propionyl-CoA carboxylase (PCC, [GENE]EC 6.4.1.3[\\GENE]), a biotin-dependent enzyme that catalyzes the carboxylation of [CHEMICAL]propionyl-CoA[\\CHEMICAL] to D-methylmalonyl-CoA.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is caused by a deficiency of [GENE]propionyl-CoA carboxylase[\\GENE] (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to [CHEMICAL]D-methylmalonyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is caused by a deficiency of propionyl-CoA carboxylase ([GENE]PCC[\\GENE], EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to [CHEMICAL]D-methylmalonyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is caused by a deficiency of propionyl-CoA carboxylase (PCC, [GENE]EC 6.4.1.3[\\GENE]), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to [CHEMICAL]D-methylmalonyl-CoA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "These results indicate that [CHEMICAL]quetiapine[\\CHEMICAL], iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a [GENE]5-HT(1A)[\\GENE]-related mechanism.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "These results indicate that quetiapine, [CHEMICAL]iloperidone[\\CHEMICAL] and melperone preferentially increase DA release in the mPFC, compared to the NAC via a [GENE]5-HT(1A)[\\GENE]-related mechanism.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "These results indicate that quetiapine, iloperidone and [CHEMICAL]melperone[\\CHEMICAL] preferentially increase DA release in the mPFC, compared to the NAC via a [GENE]5-HT(1A)[\\GENE]-related mechanism.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Although only [CHEMICAL]clozapine[\\CHEMICAL] and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [GENE]5-HT(2A)[\\GENE] and D(2) blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only [CHEMICAL]clozapine[\\CHEMICAL] and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and [GENE]D(2)[\\GENE] blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and [CHEMICAL]ziprasidone[\\CHEMICAL] are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [GENE]5-HT(2A)[\\GENE] and D(2) blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and [CHEMICAL]ziprasidone[\\CHEMICAL] are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and [GENE]D(2)[\\GENE] blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, [CHEMICAL]WAY100635[\\CHEMICAL], a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined [GENE]5-HT(2A)[\\GENE] and D(2) blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, [CHEMICAL]WAY100635[\\CHEMICAL], a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and [GENE]D(2)[\\GENE] blockade.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "However, [GENE]5-HT(1A)[\\GENE] agonism may be important only for [CHEMICAL]quetiapine[\\CHEMICAL]-induced ACh release.",
        "label": 5,
        "major": 5,
        "len": 11
    },
    {
        "text": "Although only [CHEMICAL]clozapine[\\CHEMICAL] and ziprasidone are directly acting [GENE]5-HT(1A)[\\GENE] agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",
        "label": 5,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and [CHEMICAL]ziprasidone[\\CHEMICAL] are directly acting [GENE]5-HT(1A)[\\GENE] agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",
        "label": 5,
        "major": 3,
        "len": 35
    },
    {
        "text": "Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, [CHEMICAL]WAY100635[\\CHEMICAL], a selective [GENE]5-HT(1A)[\\GENE] antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.",
        "label": 6,
        "major": 3,
        "len": 35
    },
    {
        "text": "OBJECTIVE: Because of these physiological effects and the widespread use of the selective [GENE]COX-2[\\GENE] inhibitor, [CHEMICAL]celecoxib[\\CHEMICAL], we wanted to determine if inhibition of COX-2 would affect incisional skin wound healing.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of COX-2 in the wound healing process by comparing the effects of a nonselective [GENE]COX[\\GENE] inhibitor, [CHEMICAL]diclofenac[\\CHEMICAL], with a selective COX-2 inhibitor, SC-791.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "In vitro autoradiography studies (rat brain slices) with [CHEMICAL](S,S)-[(11)C]-MeNER[\\CHEMICAL] produced a regional distribution pattern that was consistent with the reported distribution of [GENE]NET[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 23
    },
    {
        "text": "These radiotracers are close analogues of [CHEMICAL]reboxetine[\\CHEMICAL], a potent and selective ligand for the [GENE]norepinephrine transporter[\\GENE] (NET).",
        "label": 2,
        "major": 9,
        "len": 17
    },
    {
        "text": "These radiotracers are close analogues of [CHEMICAL]reboxetine[\\CHEMICAL], a potent and selective ligand for the norepinephrine transporter ([GENE]NET[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 17
    },
    {
        "text": "The effects of histamine H1-receptor antagonists, [CHEMICAL]promethazine[\\CHEMICAL] and homochlorcyclizine, both of which are inhibitors of [GENE]CYP2D6[\\GENE], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "The effects of histamine H1-receptor antagonists, promethazine and [CHEMICAL]homochlorcyclizine[\\CHEMICAL], both of which are inhibitors of [GENE]CYP2D6[\\GENE], on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Thus, the current study suggests that coadministration of clinical doses of [CHEMICAL]promethazine[\\CHEMICAL] and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [GENE]CYP2D6[\\GENE]-catalyzed metabolism of haloperidol and reduced haloperidol.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and [CHEMICAL]homochlorcyclizine[\\CHEMICAL] increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [GENE]CYP2D6[\\GENE]-catalyzed metabolism of haloperidol and reduced haloperidol.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The effects of [GENE]histamine H1-receptor[\\GENE] antagonists, [CHEMICAL]promethazine[\\CHEMICAL] and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",
        "label": 6,
        "major": 4,
        "len": 44
    },
    {
        "text": "The effects of [GENE]histamine H1-receptor[\\GENE] antagonists, promethazine and [CHEMICAL]homochlorcyclizine[\\CHEMICAL], both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.",
        "label": 6,
        "major": 4,
        "len": 44
    },
    {
        "text": "[GENE]Histamine H1-receptor[\\GENE] antagonists, [CHEMICAL]promethazine[\\CHEMICAL] and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.",
        "label": 6,
        "major": 3,
        "len": 16
    },
    {
        "text": "[GENE]Histamine H1-receptor[\\GENE] antagonists, promethazine and [CHEMICAL]homochlorcyclizine[\\CHEMICAL], increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.",
        "label": 6,
        "major": 3,
        "len": 16
    },
    {
        "text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [GENE]CYP2D6[\\GENE]-catalyzed metabolism of haloperidol and reduced [CHEMICAL]haloperidol[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the [GENE]CYP2D6[\\GENE]-catalyzed metabolism of [CHEMICAL]haloperidol[\\CHEMICAL] and reduced haloperidol.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for [CHEMICAL]ornithine[\\CHEMICAL] and impaired the interaction with [GENE]arginase[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, Asp-182, [CHEMICAL]Asn[\\CHEMICAL]-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, Asp-182, Asn-184, [CHEMICAL]Asn[\\CHEMICAL]-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, [CHEMICAL]Cys[\\CHEMICAL]-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and [CHEMICAL]Glu[\\CHEMICAL]-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]arginase[\\GENE], two [CHEMICAL]cysteines[\\CHEMICAL] at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.",
        "label": 1,
        "major": 10,
        "len": 26
    },
    {
        "text": "In [GENE]arginase[\\GENE], two cysteines at the [CHEMICAL]C[\\CHEMICAL] terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.",
        "label": 1,
        "major": 10,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, [CHEMICAL]Asp[\\CHEMICAL]-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 1,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for [CHEMICAL]ornithine[\\CHEMICAL] and impaired the interaction with arginase.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "In [GENE]OTCase[\\GENE], mutations of putative [CHEMICAL]ornithine[\\CHEMICAL] binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "On the other hand, [CHEMICAL]pranlukast[\\CHEMICAL] did not modify the eosinophil spontaneous adhesion to the resting or [GENE]IL-4[\\GENE] plus TNF-alpha-stimulated pulmonary endothelial cells.",
        "label": 10,
        "major": 3,
        "len": 22
    },
    {
        "text": "On the other hand, [CHEMICAL]pranlukast[\\CHEMICAL] did not modify the eosinophil spontaneous adhesion to the resting or IL-4 plus [GENE]TNF-alpha[\\GENE]-stimulated pulmonary endothelial cells.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "Similarly, [CHEMICAL]pranlukast[\\CHEMICAL] did not modulate [GENE]IL-5[\\GENE]- or FMLP-activated eosinophil adhesion to the resting endothelial cells.",
        "label": 10,
        "major": 10,
        "len": 15
    },
    {
        "text": "[CHEMICAL]5TFI[\\CHEMICAL] was incorporated into a model target protein, [GENE]murine dihydrofolate reductase[\\GENE] (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]5TFI[\\CHEMICAL] was incorporated into a model target protein, murine dihydrofolate reductase ([GENE]mDHFR[\\GENE]), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective [GENE]alpha-adrenoceptor[\\GENE] antagonists, [CHEMICAL]phentolamine[\\CHEMICAL] (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective [GENE]alpha-adrenoceptor[\\GENE] antagonists, phentolamine (0.3-3 mg/kg) and [CHEMICAL]phenoxybenzamine[\\CHEMICAL] (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).",
        "label": 6,
        "major": 6,
        "len": 35
    },
    {
        "text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist, [CHEMICAL]prazosin[\\CHEMICAL] (0.3 mg/kg).",
        "label": 6,
        "major": 4,
        "len": 35
    },
    {
        "text": "The [GENE]alpha(2)-adrenoceptor[\\GENE] antagonist, [CHEMICAL]rauwolscine[\\CHEMICAL] (0.5 mg/kg), was without antagonistic effects.",
        "label": 6,
        "major": 6,
        "len": 10
    },
    {
        "text": "[GENE]alpha(1A)-Adrenoceptor[\\GENE] selective antagonists, [CHEMICAL]2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane[\\CHEMICAL] (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "[GENE]alpha(1A)-Adrenoceptor[\\GENE] selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane ([CHEMICAL]WB-4101[\\CHEMICAL]; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "[GENE]alpha(1A)-Adrenoceptor[\\GENE] selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and [CHEMICAL]5-methylurapidil[\\CHEMICAL] (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the [GENE]alpha(1B)-adrenoceptor[\\GENE] selective antagonist, [CHEMICAL]4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline[\\CHEMICAL] (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the [GENE]alpha(1B)-adrenoceptor[\\GENE] selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline ([CHEMICAL]L-765314[\\CHEMICAL]; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the [GENE]alpha(1D)-adrenoceptor[\\GENE] selective antagonist, [CHEMICAL]8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione[\\CHEMICAL] (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the [GENE]alpha(1D)-adrenoceptor[\\GENE] selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione ([CHEMICAL]BMY-7378[\\CHEMICAL]; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "To further investigate this positive correlation and its possible therapeutic implications, a selective [GENE]COX-2[\\GENE] inhibitor, [CHEMICAL]etodolac[\\CHEMICAL], was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "On the other hand, ligands for the renal [GENE]Na(+)-transporter[\\GENE] ([CHEMICAL]amiloride[\\CHEMICAL] and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "On the other hand, ligands for the renal [GENE]Na(+)-transporter[\\GENE] (amiloride and [CHEMICAL]triamterene[\\CHEMICAL]) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "However, other [GENE]alpha(1)-adrenoceptor[\\GENE] antagonists ([CHEMICAL]tamsulosin[\\CHEMICAL], WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.",
        "label": 6,
        "major": 4,
        "len": 35
    },
    {
        "text": "However, other [GENE]alpha(1)-adrenoceptor[\\GENE] antagonists (tamsulosin, [CHEMICAL]WB4101[\\CHEMICAL] and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.",
        "label": 6,
        "major": 10,
        "len": 35
    },
    {
        "text": "However, other [GENE]alpha(1)-adrenoceptor[\\GENE] antagonists (tamsulosin, WB4101 and [CHEMICAL]corynanthine[\\CHEMICAL]) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.",
        "label": 6,
        "major": 2,
        "len": 35
    },
    {
        "text": "Of 18 mutations where [GENE]hNET[\\GENE] [CHEMICAL]amino acid[\\CHEMICAL] residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).",
        "label": 1,
        "major": 1,
        "len": 54
    },
    {
        "text": "A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to [GENE]hNET[\\GENE] occurs at a site that is distinct from but overlaps with the binding sites for [CHEMICAL]tricyclic[\\CHEMICAL] antidepressants and cocaine.",
        "label": 2,
        "major": 2,
        "len": 45
    },
    {
        "text": "A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to [GENE]hNET[\\GENE] occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and [CHEMICAL]cocaine[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 45
    },
    {
        "text": "A comparison of the results with previous data for desipramine and cocaine inhibition of [CHEMICAL]norepinephrine[\\CHEMICAL] uptake by the mutant [GENE]hNETs[\\GENE] reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.",
        "label": 9,
        "major": 4,
        "len": 45
    },
    {
        "text": "The potency of MrIA was greater for inhibition of uptake by [GENE]hNET[\\GENE] of [CHEMICAL][3H]norepinephrine[\\CHEMICAL] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).",
        "label": 9,
        "major": 4,
        "len": 38
    },
    {
        "text": "The potency of MrIA was greater for inhibition of uptake by [GENE]hNET[\\GENE] of [3H]norepinephrine (Ki 1.89 microM) than [CHEMICAL][3H]dopamine[\\CHEMICAL] (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).",
        "label": 9,
        "major": 10,
        "len": 38
    },
    {
        "text": "In the future, codon 49 and 389 genotypes or [GENE]beta(1)-adrenergic receptor[\\GENE] haplotypes might be used to predict the diastolic blood pressure response to [CHEMICAL]metoprolol[\\CHEMICAL] in patients with hypertension.",
        "label": 2,
        "major": 10,
        "len": 28
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [CHEMICAL]salsalate[\\CHEMICAL], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [CHEMICAL]salsalate[\\CHEMICAL], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or [CHEMICAL]acetaminophen[\\CHEMICAL]) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or [CHEMICAL]acetaminophen[\\CHEMICAL]) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received [CHEMICAL]celecoxib[\\CHEMICAL] 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received [CHEMICAL]celecoxib[\\CHEMICAL] 200 mg/day or rofecoxib 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or [CHEMICAL]rofecoxib[\\CHEMICAL] 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or [CHEMICAL]rofecoxib[\\CHEMICAL] 25 mg/day for three weeks.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "RESULTS: [CHEMICAL]Eprosartan[\\CHEMICAL] tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating [GENE]Ang-II[\\GENE] levels (p<0.01).",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[GENE]AT1[\\GENE] antagonism by [CHEMICAL]eprosartan[\\CHEMICAL] lowers heart rate variability and baroreflex gain.",
        "label": 6,
        "major": 6,
        "len": 11
    },
    {
        "text": "CONCLUSIONS: [GENE]AT1[\\GENE] antagonism by [CHEMICAL]eprosartan[\\CHEMICAL] lowers heart rate variability and baroreflex gain.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant [GENE]p53[\\GENE] with a truncated [CHEMICAL]COOH[\\CHEMICAL]-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "In PC3 cells, [CHEMICAL]hydroxyurea[\\CHEMICAL] inhibited [GENE]hRRM2[\\GENE] and resulted in increased sensitivity to UV irradiation.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Ribonucleotide reductase ([GENE]RR[\\GENE]) is responsible for the de novo conversion of the ribonucleoside diphosphates to [CHEMICAL]deoxyribonucleoside diphosphates[\\CHEMICAL], which are essential for DNA synthesis and repair.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "[GENE]Ribonucleotide reductase[\\GENE] (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to [CHEMICAL]deoxyribonucleoside diphosphates[\\CHEMICAL], which are essential for DNA synthesis and repair.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "Ribonucleotide reductase ([GENE]RR[\\GENE]) is responsible for the de novo conversion of the [CHEMICAL]ribonucleoside diphosphates[\\CHEMICAL] to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "[GENE]Ribonucleotide reductase[\\GENE] (RR) is responsible for the de novo conversion of the [CHEMICAL]ribonucleoside diphosphates[\\CHEMICAL] to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.",
        "label": 9,
        "major": 4,
        "len": 25
    },
    {
        "text": "These data suggest that, after SCI, [CHEMICAL]minocycline[\\CHEMICAL] treatment modulated expression of [GENE]cytokines[\\GENE], attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Furthermore, RT-PCR analyses revealed that [CHEMICAL]minocycline[\\CHEMICAL] treatment increased expression of [GENE]interleukin-10[\\GENE] mRNA but decreased tumor necrosis factor-alpha expression.",
        "label": 3,
        "major": 4,
        "len": 18
    },
    {
        "text": "Furthermore, RT-PCR analyses revealed that [CHEMICAL]minocycline[\\CHEMICAL] treatment increased expression of interleukin-10 mRNA but decreased [GENE]tumor necrosis factor-alpha[\\GENE] expression.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "In addition, [CHEMICAL]minocycline[\\CHEMICAL] treatment significantly reduced the specific [GENE]caspase-3[\\GENE] activity after SCI as compared to that of vehicle control.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, [CHEMICAL]bisoprolol[\\CHEMICAL] (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce [GENE]beta(2)-adrenoceptor[\\GENE] desensitization.",
        "label": 2,
        "major": 6,
        "len": 33
    },
    {
        "text": "or were chronically pretreated with the selective beta(2)-adrenoceptor agonist [CHEMICAL]salbutamol[\\CHEMICAL] (40 microg/kg/h) for 1 week to induce [GENE]beta(2)-adrenoceptor[\\GENE] desensitization.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "The pretreatment with [CHEMICAL]salbutamol[\\CHEMICAL] induced a 59% down-regulation of left ventricular [GENE]beta(2)-adrenoceptors[\\GENE] compared to control.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "or were chronically pretreated with the selective [GENE]beta(2)-adrenoceptor[\\GENE] agonist [CHEMICAL]salbutamol[\\CHEMICAL] (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "Rats received a concomitant treatment with the selective [GENE]beta(1)-adrenoceptor[\\GENE] antagonist, [CHEMICAL]bisoprolol[\\CHEMICAL] (50 mg/kg/day p.o.)",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of [GENE]TRPM8[\\GENE] to [CHEMICAL]menthol[\\CHEMICAL] (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 3,
        "major": 6,
        "len": 25
    },
    {
        "text": "The Ca(2+) response of [GENE]hVR1[\\GENE]-transfected HEK293 cells to the endogenous VR1 agonist [CHEMICAL]N-arachidonoyl-dopamine[\\CHEMICAL] was potentiated by low pH.",
        "label": 3,
        "major": 5,
        "len": 18
    },
    {
        "text": "In contrast, [CHEMICAL]menthol[\\CHEMICAL]- and icilin-activated [GENE]TRPM8[\\GENE] currents were suppressed by low pH.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "In contrast, menthol- and [CHEMICAL]icilin[\\CHEMICAL]-activated [GENE]TRPM8[\\GENE] currents were suppressed by low pH.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "TRPM8 ([GENE]CMR1[\\GENE]) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [CHEMICAL]eucalyptol[\\CHEMICAL] and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "TRPM8 (CMR1) is a [GENE]Ca(2+)-permeable channel[\\GENE], which can be activated by low temperatures, menthol, [CHEMICAL]eucalyptol[\\CHEMICAL] and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[GENE]TRPM8[\\GENE] (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, [CHEMICAL]eucalyptol[\\CHEMICAL] and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "TRPM8 ([GENE]CMR1[\\GENE]) is a Ca(2+)-permeable channel, which can be activated by low temperatures, [CHEMICAL]menthol[\\CHEMICAL], eucalyptol and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "TRPM8 (CMR1) is a [GENE]Ca(2+)-permeable channel[\\GENE], which can be activated by low temperatures, [CHEMICAL]menthol[\\CHEMICAL], eucalyptol and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[GENE]TRPM8[\\GENE] (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, [CHEMICAL]menthol[\\CHEMICAL], eucalyptol and icilin.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "TRPM8 ([GENE]CMR1[\\GENE]) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and [CHEMICAL]icilin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "TRPM8 (CMR1) is a [GENE]Ca(2+)-permeable channel[\\GENE], which can be activated by low temperatures, menthol, eucalyptol and [CHEMICAL]icilin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[GENE]TRPM8[\\GENE] (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and [CHEMICAL]icilin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Known VR1 antagonists ([CHEMICAL]BCTC[\\CHEMICAL], thio-BCTC and capsazepine) were also able to block the response of [GENE]TRPM8[\\GENE] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 4,
        "major": 6,
        "len": 25
    },
    {
        "text": "Known VR1 antagonists (BCTC, [CHEMICAL]thio-BCTC[\\CHEMICAL] and capsazepine) were also able to block the response of [GENE]TRPM8[\\GENE] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 4,
        "major": 6,
        "len": 25
    },
    {
        "text": "Known VR1 antagonists (BCTC, thio-BCTC and [CHEMICAL]capsazepine[\\CHEMICAL]) were also able to block the response of [GENE]TRPM8[\\GENE] to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 4,
        "major": 6,
        "len": 25
    },
    {
        "text": "The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous [GENE]VR1[\\GENE] agonist [CHEMICAL]N-arachidonoyl-dopamine[\\CHEMICAL] was potentiated by low pH.",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Known [GENE]VR1[\\GENE] antagonists ([CHEMICAL]BCTC[\\CHEMICAL], thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Known [GENE]VR1[\\GENE] antagonists (BCTC, [CHEMICAL]thio-BCTC[\\CHEMICAL] and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Known [GENE]VR1[\\GENE] antagonists (BCTC, thio-BCTC and [CHEMICAL]capsazepine[\\CHEMICAL]) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Inhibitory effects of the monoamine oxidase inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] on the cytochrome P450 enzymes [GENE]CYP2C19[\\GENE], CYP2C9, and CYP2D6.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Inhibitory effects of the monoamine oxidase inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] on the cytochrome P450 enzymes CYP2C19, [GENE]CYP2C9[\\GENE], and CYP2D6.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Inhibitory effects of the monoamine oxidase inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and [GENE]CYP2D6[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Inhibitory effects of the monoamine oxidase inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] on the [GENE]cytochrome P450[\\GENE] enzymes CYP2C19, CYP2C9, and CYP2D6.",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]tranylcypromine[\\CHEMICAL], a nonselective irreversible inhibitor of [GENE]monoamine oxidase[\\GENE] (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]tranylcypromine[\\CHEMICAL], a nonselective irreversible inhibitor of monoamine oxidase ([GENE]MAO[\\GENE]), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The results demonstrated that [CHEMICAL]tranylcypromine[\\CHEMICAL] is a competitive inhibitor of [GENE]CYP2C19[\\GENE] (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The results demonstrated that [CHEMICAL]tranylcypromine[\\CHEMICAL] is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and [GENE]CYP2D6[\\GENE] (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The results demonstrated that [CHEMICAL]tranylcypromine[\\CHEMICAL] is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of [GENE]CYP2C9[\\GENE] (Ki = 56 microM).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Inhibitory effects of the [GENE]monoamine oxidase[\\GENE] inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than [CHEMICAL]atorvastatin[\\CHEMICAL], a compound that blocks [GENE]HMG-CoA reductase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, [GENE]Flt3[\\GENE] is resistant to the [CHEMICAL]phenylaminopyrimidine[\\CHEMICAL] STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 10,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, [GENE]Flt3[\\GENE] is resistant to the phenylaminopyrimidine [CHEMICAL]STI571[\\CHEMICAL] (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 10,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, [GENE]Flt3[\\GENE] is resistant to the phenylaminopyrimidine STI571 ([CHEMICAL]Gleevec[\\CHEMICAL], Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 10,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, [GENE]Flt3[\\GENE] is resistant to the phenylaminopyrimidine STI571 (Gleevec, [CHEMICAL]Imatinib[\\CHEMICAL]), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 10,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]STI571[\\CHEMICAL] binding to [GENE]Flt3[\\GENE] is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "Compounds of several other structural families, including the [CHEMICAL]quinoxaline[\\CHEMICAL] AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the [CHEMICAL]quinoxaline[\\CHEMICAL] AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline [CHEMICAL]AG1296[\\CHEMICAL], the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline [CHEMICAL]AG1296[\\CHEMICAL], the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the [CHEMICAL]bis(1H-2-indolyl)-1-methanone[\\CHEMICAL] D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the [CHEMICAL]bis(1H-2-indolyl)-1-methanone[\\CHEMICAL] D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone [CHEMICAL]D-65476[\\CHEMICAL], the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone [CHEMICAL]D-65476[\\CHEMICAL], the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the [CHEMICAL]indolinones[\\CHEMICAL] SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the [CHEMICAL]indolinones[\\CHEMICAL] SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones [CHEMICAL]SU5416[\\CHEMICAL] and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones [CHEMICAL]SU5416[\\CHEMICAL] and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and [CHEMICAL]SU11248[\\CHEMICAL], the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and [CHEMICAL]SU11248[\\CHEMICAL], the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the [CHEMICAL]indolocarbazoles[\\CHEMICAL] PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the [CHEMICAL]indolocarbazoles[\\CHEMICAL] PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles [CHEMICAL]PKC412[\\CHEMICAL] and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles [CHEMICAL]PKC412[\\CHEMICAL] and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and [CHEMICAL]CEP-701[\\CHEMICAL], and the piperazonyl quinazoline CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and [CHEMICAL]CEP-701[\\CHEMICAL], and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the [CHEMICAL]phenylaminopyrimidine[\\CHEMICAL] STI571 (Gleevec, Imatinib), a potent inhibitor of other [GENE]RTKs[\\GENE] in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the [CHEMICAL]phenylaminopyrimidine[\\CHEMICAL] STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the [GENE]PDGFbeta-receptor[\\GENE] or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the [CHEMICAL]phenylaminopyrimidine[\\CHEMICAL] STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [GENE]c-Kit[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the [CHEMICAL]piperazonyl quinazoline[\\CHEMICAL] CT53518, are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the [CHEMICAL]piperazonyl quinazoline[\\CHEMICAL] CT53518, are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline [CHEMICAL]CT53518[\\CHEMICAL], are potent inhibitors of [GENE]Flt3[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline [CHEMICAL]CT53518[\\CHEMICAL], are potent inhibitors of Flt3 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine [CHEMICAL]STI571[\\CHEMICAL] (Gleevec, Imatinib), a potent inhibitor of other [GENE]RTKs[\\GENE] in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine [CHEMICAL]STI571[\\CHEMICAL] (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the [GENE]PDGFbeta-receptor[\\GENE] or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine [CHEMICAL]STI571[\\CHEMICAL] (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [GENE]c-Kit[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 ([CHEMICAL]Gleevec[\\CHEMICAL], Imatinib), a potent inhibitor of other [GENE]RTKs[\\GENE] in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 ([CHEMICAL]Gleevec[\\CHEMICAL], Imatinib), a potent inhibitor of other RTKs in the family, such as the [GENE]PDGFbeta-receptor[\\GENE] or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 ([CHEMICAL]Gleevec[\\CHEMICAL], Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [GENE]c-Kit[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, [CHEMICAL]Imatinib[\\CHEMICAL]), a potent inhibitor of other [GENE]RTKs[\\GENE] in the family, such as the PDGFbeta-receptor or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, [CHEMICAL]Imatinib[\\CHEMICAL]), a potent inhibitor of other RTKs in the family, such as the [GENE]PDGFbeta-receptor[\\GENE] or c-Kit.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, [CHEMICAL]Imatinib[\\CHEMICAL]), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [GENE]c-Kit[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding [GENE]Flt3[\\GENE] mutant sensitive to [CHEMICAL]STI571[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for [GENE]HIF[\\GENE] stabilization specifically by inhibition of PHD enzyme activity.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Thus, [CHEMICAL]hydralazine[\\CHEMICAL] activates the [GENE]HIF[\\GENE] pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF ([GENE]endothelin-1[\\GENE], adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, [GENE]adrenomedullin[\\GENE], haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, [GENE]haem oxygenase 1[\\GENE], and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and [GENE]vascular endothelial growth factor[\\GENE] [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [[GENE]VEGF[\\GENE]]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "In vivo, [CHEMICAL]hydralazine[\\CHEMICAL] induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma [GENE]VEGF[\\GENE] levels.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "In vivo, [CHEMICAL]hydralazine[\\CHEMICAL] induced HIF-1alpha and [GENE]VEGF[\\GENE] protein in tissue extracts and elevated plasma VEGF levels.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Novel mechanism of action for [CHEMICAL]hydralazine[\\CHEMICAL]: induction of hypoxia-inducible factor-1alpha, [GENE]vascular endothelial growth factor[\\GENE], and angiogenesis by inhibition of prolyl hydroxylases.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of [GENE]HIF-1alpha[\\GENE] and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] induced rapid and transient expression of HIF-1alpha and downstream targets of [GENE]HIF[\\GENE] (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] dose-dependently inhibited PHD activity and induced nonhydroxylated [GENE]HIF-1alpha[\\GENE], evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "In vivo, [CHEMICAL]hydralazine[\\CHEMICAL] induced [GENE]HIF-1alpha[\\GENE] and VEGF protein in tissue extracts and elevated plasma VEGF levels.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Novel mechanism of action for [CHEMICAL]hydralazine[\\CHEMICAL]: induction of [GENE]hypoxia-inducible factor-1alpha[\\GENE], vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] dose-dependently inhibited [GENE]PHD[\\GENE] activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Hydralazine[\\CHEMICAL] dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of [GENE]PHD[\\GENE] enzyme activity.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Novel mechanism of action for [CHEMICAL]hydralazine[\\CHEMICAL]: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of [GENE]prolyl hydroxylases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Thus, [CHEMICAL]hydralazine[\\CHEMICAL] activates the HIF pathway through inhibition of [GENE]PHD[\\GENE] activity and initiates a pro-angiogenic phenotype.",
        "label": 4,
        "major": 10,
        "len": 16
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, [CHEMICAL]ketoprofen[\\CHEMICAL], meclofenamic acid, and piroxicam had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, [CHEMICAL]meclofenamic acid[\\CHEMICAL], and piroxicam had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and [CHEMICAL]piroxicam[\\CHEMICAL] had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: [CHEMICAL]Aspirin[\\CHEMICAL], diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, [CHEMICAL]diclofenac[\\CHEMICAL], indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, [CHEMICAL]indomethacin[\\CHEMICAL], ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward [GENE]COX[\\GENE] isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than COX-1.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas [CHEMICAL]NS398[\\CHEMICAL], carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [GENE]COX-2[\\GENE] than COX-1.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas [CHEMICAL]NS398[\\CHEMICAL], carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [GENE]COX-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, [CHEMICAL]carprofen[\\CHEMICAL], tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [GENE]COX-2[\\GENE] than COX-1.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, [CHEMICAL]carprofen[\\CHEMICAL], tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [GENE]COX-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, [CHEMICAL]tolfenamic acid[\\CHEMICAL], nimesulide, and etodolac had more than 5 times greater preference for inhibiting [GENE]COX-2[\\GENE] than COX-1.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, [CHEMICAL]tolfenamic acid[\\CHEMICAL], nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [GENE]COX-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, [CHEMICAL]nimesulide[\\CHEMICAL], and etodolac had more than 5 times greater preference for inhibiting [GENE]COX-2[\\GENE] than COX-1.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, [CHEMICAL]nimesulide[\\CHEMICAL], and etodolac had more than 5 times greater preference for inhibiting COX-2 than [GENE]COX-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and [CHEMICAL]etodolac[\\CHEMICAL] had more than 5 times greater preference for inhibiting [GENE]COX-2[\\GENE] than COX-1.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and [CHEMICAL]etodolac[\\CHEMICAL] had more than 5 times greater preference for inhibiting COX-2 than [GENE]COX-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "CONCLUSIONS AND CLINICAL RELEVANCE: [GENE]Canine COX-2[\\GENE] was selectively inhibited by [CHEMICAL]etodolac[\\CHEMICAL], nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "CONCLUSIONS AND CLINICAL RELEVANCE: [GENE]Canine COX-2[\\GENE] was selectively inhibited by etodolac, [CHEMICAL]nimesulide[\\CHEMICAL], and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "CONCLUSIONS AND CLINICAL RELEVANCE: [GENE]Canine COX-2[\\GENE] was selectively inhibited by etodolac, nimesulide, and [CHEMICAL]NS398[\\CHEMICAL]; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; [CHEMICAL]tolfenamic acid[\\CHEMICAL] and carprofen also appeared to be preferential [GENE]COX-2[\\GENE] inhibitors in dogs.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and [CHEMICAL]carprofen[\\CHEMICAL] also appeared to be preferential [GENE]COX-2[\\GENE] inhibitors in dogs.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Acarbose[\\CHEMICAL] served as inhibitor of an interfering [GENE]acid alpha-glucosidase[\\GENE] present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-[CHEMICAL]amino acid[\\CHEMICAL] span in the substrate access channel in [GENE]retinaldehyde dehydrogenase II[\\GENE] is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.",
        "label": 1,
        "major": 9,
        "len": 55
    },
    {
        "text": "Univariate regression analyses showed that only the use of [CHEMICAL]carvedilol[\\CHEMICAL] was correlated with the decrease in [GENE]plasma BNP[\\GENE] concentration (p <0.03).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "After 12 months of treatment, [CHEMICAL]carvedilol[\\CHEMICAL] significantly improved all end points (plasma concentration of [GENE]B-type natriuretic peptide[\\GENE] [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).",
        "label": 4,
        "major": 10,
        "len": 122
    },
    {
        "text": "After 12 months of treatment, [CHEMICAL]carvedilol[\\CHEMICAL] significantly improved all end points (plasma concentration of B-type natriuretic peptide [[GENE]BNP[\\GENE]] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).",
        "label": 4,
        "major": 10,
        "len": 122
    },
    {
        "text": "[CHEMICAL]Levetiracetam[\\CHEMICAL] binds selectively and with high affinity to a [GENE]synaptic vesicle protein[\\GENE] known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Levetiracetam[\\CHEMICAL] binds selectively and with high affinity to a synaptic vesicle protein known as [GENE]SV2A[\\GENE], thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Psychopharmacology of anticonvulsants: [CHEMICAL]levetiracetam[\\CHEMICAL] as a [GENE]synaptic vesicle protein[\\GENE] modulator.",
        "label": 2,
        "major": 7,
        "len": 10
    },
    {
        "text": "Although [CHEMICAL]celecoxib[\\CHEMICAL] inhibits PG biosynthesis, most do not affect the [GENE]peroxidase[\\GENE] activity of COX, which can generate proximate carcinogens.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Although [CHEMICAL]celecoxib[\\CHEMICAL] inhibits PG biosynthesis, most do not affect the peroxidase activity of [GENE]COX[\\GENE], which can generate proximate carcinogens.",
        "label": 10,
        "major": 4,
        "len": 19
    },
    {
        "text": "Because [CHEMICAL]thalidomide[\\CHEMICAL] does not completely inhibit [GENE]COX-2[\\GENE] expression or PG biosynthesis, a therapeutic strategy combining celecoxib with thalidomide might be more effective than using either agent alone.",
        "label": 10,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] decreased the stability of [GENE]TNF[\\GENE]-mRNA and COX-2 mRNA.",
        "label": 2,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] decreased the stability of TNF-mRNA and [GENE]COX-2[\\GENE] mRNA.",
        "label": 2,
        "major": 4,
        "len": 9
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting [GENE]apoA-I[\\GENE] from catabolism through ABCA1 induction and lipidation of apoA-I.",
        "label": 2,
        "major": 4,
        "len": 42
    },
    {
        "text": "Effect of [CHEMICAL]pitavastatin[\\CHEMICAL] on [GENE]apolipoprotein A-I[\\GENE] production in HepG2 cell.",
        "label": 2,
        "major": 9,
        "len": 10
    },
    {
        "text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced [GENE]apoA-I[\\GENE] more efficiently than [CHEMICAL]simvastatin[\\CHEMICAL] and atorvastatin.",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced [GENE]apoA-I[\\GENE] more efficiently than simvastatin and [CHEMICAL]atorvastatin[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "Further study revealed that [CHEMICAL]pitavastatin[\\CHEMICAL] increased [GENE]ABCA1[\\GENE] mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and [CHEMICAL]Y27632[\\CHEMICAL]) increased [GENE]apoA-I[\\GENE] production in the HepG2 cells.",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases [GENE]apoA-I[\\GENE] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting [GENE]apoA-I[\\GENE] production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through [GENE]ABCA1[\\GENE] induction and lipidation of apoA-I.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of [GENE]apoA-I[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the [GENE]apoA-I[\\GENE] induction [CHEMICAL]pitavastatin[\\CHEMICAL] (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the [GENE]apoA-I[\\GENE] induction pitavastatin (3 microM)>[CHEMICAL]simvastatin[\\CHEMICAL] (10 microM)>atorvastatin (30 microM).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the [GENE]apoA-I[\\GENE] induction pitavastatin (3 microM)>simvastatin (10 microM)>[CHEMICAL]atorvastatin[\\CHEMICAL] (30 microM).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Based on HMG-CoA reductase inhibition, [CHEMICAL]pitavastatin[\\CHEMICAL]-induced [GENE]apoA-I[\\GENE] more efficiently than simvastatin and atorvastatin.",
        "label": 3,
        "major": 4,
        "len": 13
    },
    {
        "text": "The induction of [GENE]apoA-I[\\GENE] by statins disappeared with addition of [CHEMICAL]mevalonate[\\CHEMICAL], which indicates that the effect is HMG-CoA reductase inhibition-dependent.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that [GENE]Rho[\\GENE] and Rho kinase inhibitor (C3T and [CHEMICAL]Y27632[\\CHEMICAL]) increased apoA-I production in the HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and [GENE]Rho kinase[\\GENE] inhibitor (C3T and [CHEMICAL]Y27632[\\CHEMICAL]) increased apoA-I production in the HepG2 cells.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [GENE]HMG-CoA reductase[\\GENE] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "These results suggest that [CHEMICAL]pitavastatin[\\CHEMICAL] efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of [GENE]Rho[\\GENE] activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two [GENE]receptor tyrosine kinase[\\GENE] inhibitors, [CHEMICAL]imatinib[\\CHEMICAL] and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, [CHEMICAL]imatinib[\\CHEMICAL] and SU11248, were used to disrupt [GENE]PDGFR[\\GENE]-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, [CHEMICAL]imatinib[\\CHEMICAL] and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or [GENE]VEGFR[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two [GENE]receptor tyrosine kinase[\\GENE] inhibitors, imatinib and [CHEMICAL]SU11248[\\CHEMICAL], were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and [CHEMICAL]SU11248[\\CHEMICAL], were used to disrupt [GENE]PDGFR[\\GENE]-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and [CHEMICAL]SU11248[\\CHEMICAL], were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or [GENE]VEGFR[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "RESULTS: [CHEMICAL]Imatinib[\\CHEMICAL], despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or [GENE]VEGFR[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable [GENE]COX-1[\\GENE] prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not [CHEMICAL]etodolac[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 28
    },
    {
        "text": "In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable [GENE]COX-1[\\GENE] prostanoid TXB2 was significantly reduced by [CHEMICAL]phenylbutazone[\\CHEMICAL] (P<0.05), but not etodolac.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective [GENE]COX[\\GENE] inhibitor [CHEMICAL]phenylbutazone[\\CHEMICAL] in horses with lipopolysaccharide (LPS)-induced synovitis.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "However, MS A2756G was significantly associated with [CHEMICAL]cobalamin[\\CHEMICAL] levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR [GENE]A66G[\\GENE] (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).",
        "label": 2,
        "major": 10,
        "len": 46
    },
    {
        "text": "However, [GENE]MS[\\GENE] A2756G was significantly associated with [CHEMICAL]cobalamin[\\CHEMICAL] levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).",
        "label": 2,
        "major": 10,
        "len": 46
    },
    {
        "text": "However, MS [GENE]A2756G[\\GENE] was significantly associated with [CHEMICAL]cobalamin[\\CHEMICAL] levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).",
        "label": 2,
        "major": 10,
        "len": 46
    },
    {
        "text": "Differences in [CHEMICAL]cobalamin[\\CHEMICAL] and folate levels with the [GENE]MTRR[\\GENE] A66G and MS A2756G polymorphisms were noted.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "Differences in [CHEMICAL]cobalamin[\\CHEMICAL] and folate levels with the MTRR [GENE]A66G[\\GENE] and MS A2756G polymorphisms were noted.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "Differences in [CHEMICAL]cobalamin[\\CHEMICAL] and folate levels with the MTRR A66G and [GENE]MS[\\GENE] A2756G polymorphisms were noted.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "Differences in [CHEMICAL]cobalamin[\\CHEMICAL] and folate levels with the MTRR A66G and MS [GENE]A2756G[\\GENE] polymorphisms were noted.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [[GENE]methylenetetrahydrofolate reductase[\\GENE] (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase ([GENE]MTHFR[\\GENE]) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) [GENE]C677T[\\GENE] and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and [GENE]A1298C[\\GENE]; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; [GENE]methionine synthase[\\GENE] (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase ([GENE]MS[\\GENE]) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) [GENE]A2756G[\\GENE]; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; [GENE]methionine synthase reductase[\\GENE] (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase ([GENE]MTRR[\\GENE]) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "We studied several single nucleotide polymorphisms (SNP) in [CHEMICAL]Hcy[\\CHEMICAL]-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) [GENE]A66G[\\GENE]] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.",
        "label": 2,
        "major": 4,
        "len": 59
    },
    {
        "text": "However, MS A2756G was significantly associated with [CHEMICAL]cobalamin[\\CHEMICAL] levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was [GENE]MTRR[\\GENE] A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).",
        "label": 2,
        "major": 10,
        "len": 46
    },
    {
        "text": "[CHEMICAL]Bosentan[\\CHEMICAL] also decreased serum glucose level without any effect on [GENE]insulin[\\GENE] secretion in mild diabetic rats and potentiated the hypoglycemic action of insulin.",
        "label": 10,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Bosentan[\\CHEMICAL] partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in [GENE]insulin[\\GENE] level in normoglycemic stressed rats.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Bosentan[\\CHEMICAL] also decreased serum glucose level without any effect on insulin secretion in mild diabetic rats and potentiated the hypoglycemic action of [GENE]insulin[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "To test this, we studied the possible effect of the endothelin receptor antagonist, [CHEMICAL]bosentan[\\CHEMICAL] (50 and 100 mg kg(-1)) on serum glucose and [GENE]insulin[\\GENE] levels as well as on liver glycogen contents in normoglycemic stressed animals.",
        "label": 2,
        "major": 6,
        "len": 36
    },
    {
        "text": "Effect of [CHEMICAL]bosentan[\\CHEMICAL] ([GENE]ETA[\\GENE]/ETB receptor antagonist) on metabolic changes during stress and diabetes.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "Effect of [CHEMICAL]bosentan[\\CHEMICAL] (ETA/[GENE]ETB[\\GENE] receptor antagonist) on metabolic changes during stress and diabetes.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "To test this, we studied the possible effect of the [GENE]endothelin receptor[\\GENE] antagonist, [CHEMICAL]bosentan[\\CHEMICAL] (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.",
        "label": 6,
        "major": 6,
        "len": 36
    },
    {
        "text": "Pre-irradiation administration of RP-1 enhanced levels of [CHEMICAL]GSH[\\CHEMICAL] induced increase in [GENE]complex I[\\GENE] (upto 16 h), complex I/III (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "Pre-irradiation administration of RP-1 enhanced levels of [CHEMICAL]GSH[\\CHEMICAL] induced increase in complex I (upto 16 h), [GENE]complex I/III[\\GENE] (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "Pre-irradiation administration of RP-1 enhanced levels of [CHEMICAL]GSH[\\CHEMICAL] induced increase in complex I (upto 16 h), complex I/III (4 h) [GENE]complex II/III[\\GENE] activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "Jo2-induced activation of caspase-3 or -9 in liver tissues was inhibited by minocycline pretreatment, and yet the direct addition of [CHEMICAL]minocycline[\\CHEMICAL] to liver extracts from Jo2-challenged mice failed to block [GENE]caspase[\\GENE] activation in vitro.",
        "label": 10,
        "major": 3,
        "len": 34
    },
    {
        "text": "In contrast, [GENE]caspase-8[\\GENE] activation and Bid truncation triggered by Jo2 were not diminished by [CHEMICAL]minocycline[\\CHEMICAL] pretreatment in mouse livers.",
        "label": 10,
        "major": 3,
        "len": 19
    },
    {
        "text": "In contrast, caspase-8 activation and [GENE]Bid[\\GENE] truncation triggered by Jo2 were not diminished by [CHEMICAL]minocycline[\\CHEMICAL] pretreatment in mouse livers.",
        "label": 10,
        "major": 3,
        "len": 19
    },
    {
        "text": "Our results suggest that easing of [GENE]Fas[\\GENE]-triggered fulminant hepatitis by [CHEMICAL]minocycline[\\CHEMICAL] may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by [CHEMICAL]minocycline[\\CHEMICAL] may involve a mitochondrial apoptotic pathway, probably through preventing [GENE]cytochrome c[\\GENE] release and thereby blocking downstream caspase activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by [CHEMICAL]minocycline[\\CHEMICAL] may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream [GENE]caspase[\\GENE] activation.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma [GENE]amylase[\\GENE] (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; [CHEMICAL]PAG[\\CHEMICAL], 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.",
        "label": 2,
        "major": 4,
        "len": 49
    },
    {
        "text": "placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic [GENE]myeloperoxidase oxidase[\\GENE] (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; [CHEMICAL]PAG[\\CHEMICAL], 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase ([GENE]MPO[\\GENE]) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; [CHEMICAL]PAG[\\CHEMICAL], 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Also, prophylactic, as well as therapeutic, treatment with the [GENE]CSE[\\GENE] inhibitor, [CHEMICAL]DL-propargylglycine[\\CHEMICAL] (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.",
        "label": 4,
        "major": 4,
        "len": 49
    },
    {
        "text": "Also, prophylactic, as well as therapeutic, treatment with the [GENE]CSE[\\GENE] inhibitor, DL-propargylglycine ([CHEMICAL]PAG[\\CHEMICAL]), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.",
        "label": 4,
        "major": 4,
        "len": 49
    },
    {
        "text": "Cystathionine-gamma-lyase ([GENE]CSE[\\GENE]) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form [CHEMICAL]H2S[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Cystathionine-gamma-lyase (CSE) and [GENE]cystathionine-beta-synthase[\\GENE] (CBS) utilize L-cysteine as substrate to form [CHEMICAL]H2S[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ([GENE]CBS[\\GENE]) utilize L-cysteine as substrate to form [CHEMICAL]H2S[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "[GENE]Cystathionine-gamma-lyase[\\GENE] (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form [CHEMICAL]H2S[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Cystathionine-gamma-lyase ([GENE]CSE[\\GENE]) and cystathionine-beta-synthase (CBS) utilize [CHEMICAL]L-cysteine[\\CHEMICAL] as substrate to form H2S.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Cystathionine-gamma-lyase (CSE) and [GENE]cystathionine-beta-synthase[\\GENE] (CBS) utilize [CHEMICAL]L-cysteine[\\CHEMICAL] as substrate to form H2S.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ([GENE]CBS[\\GENE]) utilize [CHEMICAL]L-cysteine[\\CHEMICAL] as substrate to form H2S.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "[GENE]Cystathionine-gamma-lyase[\\GENE] (CSE) and cystathionine-beta-synthase (CBS) utilize [CHEMICAL]L-cysteine[\\CHEMICAL] as substrate to form H2S.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "[GENE]ABCG5[\\GENE] and ABCG8 themselves are regulated by [CHEMICAL]cholesterol[\\CHEMICAL] via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "ABCG5 and [GENE]ABCG8[\\GENE] themselves are regulated by [CHEMICAL]cholesterol[\\CHEMICAL] via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "ABCG5 and ABCG8 themselves are regulated by [CHEMICAL]cholesterol[\\CHEMICAL] via [GENE]liver X receptors[\\GENE] (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "ABCG5 and ABCG8 themselves are regulated by [CHEMICAL]cholesterol[\\CHEMICAL] via liver X receptors ([GENE]LXRs[\\GENE]), which are also activated by oxysterols and some derivatives of plant sterols.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "[GENE]Sterol transporters[\\GENE]: targets of natural [CHEMICAL]sterols[\\CHEMICAL] and new lipid lowering drugs.",
        "label": 2,
        "major": 9,
        "len": 11
    },
    {
        "text": "Studies in NPC1L1 knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that [GENE]NPC1L1[\\GENE] might also be involved in the mechanism of action of [CHEMICAL]ezetimibe[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors ([GENE]LXRs[\\GENE]), which are also activated by oxysterols and some derivatives of plant [CHEMICAL]sterols[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[GENE]NPC1L1[\\GENE] could recently be identified as a major sterol transporter for the intestinal uptake of [CHEMICAL]cholesterol[\\CHEMICAL] as well as plant sterols.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "NPC1L1 could recently be identified as a major [GENE]sterol transporter[\\GENE] for the intestinal uptake of [CHEMICAL]cholesterol[\\CHEMICAL] as well as plant sterols.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[GENE]NPC1L1[\\GENE] could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant [CHEMICAL]sterols[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "NPC1L1 could recently be identified as a major [GENE]sterol transporter[\\GENE] for the intestinal uptake of cholesterol as well as plant [CHEMICAL]sterols[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[Change of [GENE]dopamine transporter[\\GENE] activity (DAT) during the action of [CHEMICAL]bupropion[\\CHEMICAL] (in depression)].",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[Change of dopamine transporter activity ([GENE]DAT[\\GENE]) during the action of [CHEMICAL]bupropion[\\CHEMICAL] (in depression)].",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Bupropion[\\CHEMICAL] has an antidepressant effect through blocking the [GENE]dopamine transporter[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 10
    },
    {
        "text": "Modulation of [GENE]IL-2R[\\GENE] expression was observed at or above a [CHEMICAL]bexarotene[\\CHEMICAL] dose of 150 mg/day.",
        "label": 2,
        "major": 7,
        "len": 15
    },
    {
        "text": "In vitro studies demonstrated that the [GENE]retinoid X receptor[\\GENE] (RXR) retinoid, [CHEMICAL]bexarotene[\\CHEMICAL], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",
        "label": 2,
        "major": 3,
        "len": 46
    },
    {
        "text": "In vitro studies demonstrated that the retinoid X receptor ([GENE]RXR[\\GENE]) retinoid, [CHEMICAL]bexarotene[\\CHEMICAL], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",
        "label": 2,
        "major": 3,
        "len": 46
    },
    {
        "text": "Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of [CHEMICAL]bexarotene[\\CHEMICAL] are capable of in vivo upregulation of [GENE]CD25[\\GENE] expression on circulating leukemia cells.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, [CHEMICAL]bexarotene[\\CHEMICAL], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the [GENE]p55[\\GENE] and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, [CHEMICAL]bexarotene[\\CHEMICAL], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and [GENE]p75[\\GENE] subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, [CHEMICAL]bexarotene[\\CHEMICAL], at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the [GENE]IL-2R[\\GENE] and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.",
        "label": 3,
        "major": 3,
        "len": 46
    },
    {
        "text": "Unlike [GENE]transferrin receptor[\\GENE], the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [CHEMICAL]arginine[\\CHEMICAL] patch.",
        "label": 1,
        "major": 9,
        "len": 21
    },
    {
        "text": "Unlike transferrin receptor, the [GENE]protease domain[\\GENE] of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [CHEMICAL]arginine[\\CHEMICAL] patch.",
        "label": 1,
        "major": 9,
        "len": 21
    },
    {
        "text": "Unlike transferrin receptor, the protease domain of [GENE]PSMA[\\GENE] contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [CHEMICAL]arginine[\\CHEMICAL] patch.",
        "label": 1,
        "major": 2,
        "len": 21
    },
    {
        "text": "[GENE]PSMA[\\GENE] acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including [CHEMICAL]folate[\\CHEMICAL], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "PSMA acts as a [GENE]glutamate carboxypeptidase[\\GENE] (GCPII) on small molecule substrates, including [CHEMICAL]folate[\\CHEMICAL], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "PSMA acts as a glutamate carboxypeptidase ([GENE]GCPII[\\GENE]) on small molecule substrates, including [CHEMICAL]folate[\\CHEMICAL], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[GENE]PSMA[\\GENE] acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug [CHEMICAL]methotrexate[\\CHEMICAL], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "PSMA acts as a [GENE]glutamate carboxypeptidase[\\GENE] (GCPII) on small molecule substrates, including folate, the anticancer drug [CHEMICAL]methotrexate[\\CHEMICAL], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "PSMA acts as a glutamate carboxypeptidase ([GENE]GCPII[\\GENE]) on small molecule substrates, including folate, the anticancer drug [CHEMICAL]methotrexate[\\CHEMICAL], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[GENE]PSMA[\\GENE] acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide [CHEMICAL]N-acetyl-l-aspartyl-l-glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "PSMA acts as a [GENE]glutamate carboxypeptidase[\\GENE] (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide [CHEMICAL]N-acetyl-l-aspartyl-l-glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Elucidation of the [GENE]PSMA[\\GENE] structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate [CHEMICAL]N-acetyl-l-aspartyl-l-glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "The two active sites of dimeric [GENE]5-aminolevulinate synthase[\\GENE] (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential [CHEMICAL]amino acids[\\CHEMICAL] from each subunit.",
        "label": 1,
        "major": 1,
        "len": 29
    },
    {
        "text": "The two active sites of dimeric 5-aminolevulinate synthase ([GENE]ALAS[\\GENE]), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential [CHEMICAL]amino acids[\\CHEMICAL] from each subunit.",
        "label": 1,
        "major": 1,
        "len": 29
    },
    {
        "text": "We present our studies to demonstrate that HM74A, but not [GENE]HM74[\\GENE], binds [CHEMICAL]niacin[\\CHEMICAL] at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.",
        "label": 10,
        "major": 2,
        "len": 36
    },
    {
        "text": "Furthermore, HM74A, but not [GENE]HM74[\\GENE], expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by [CHEMICAL]niacin[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "Our results provided direct evidence indicating that HM74A, but not [GENE]HM74[\\GENE], was sufficient to mediate anti-lipolytic effect of [CHEMICAL]niacin[\\CHEMICAL] in adipose tissue.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "We present our studies to demonstrate that [GENE]HM74A[\\GENE], but not HM74, binds [CHEMICAL]niacin[\\CHEMICAL] at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "Furthermore, [GENE]HM74A[\\GENE], but not HM74, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by [CHEMICAL]niacin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 17
    },
    {
        "text": "Our results provided direct evidence indicating that [GENE]HM74A[\\GENE], but not HM74, was sufficient to mediate anti-lipolytic effect of [CHEMICAL]niacin[\\CHEMICAL] in adipose tissue.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "We present our studies to demonstrate that HM74A, but not HM74, binds [CHEMICAL]niacin[\\CHEMICAL] at high affinities and effectively mediates [GENE]Gi[\\GENE] signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.",
        "label": 3,
        "major": 2,
        "len": 36
    },
    {
        "text": "On the other hand, the [GENE]FUM1[\\GENE] (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form [CHEMICAL]malate[\\CHEMICAL] at all.",
        "label": 10,
        "major": 1,
        "len": 23
    },
    {
        "text": "On the other hand, the FUM1 ([GENE]fumarase[\\GENE]) gene disrupted mutant produced significantly higher levels of fumarate but did not form [CHEMICAL]malate[\\CHEMICAL] at all.",
        "label": 10,
        "major": 1,
        "len": 23
    },
    {
        "text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the [GENE]KGD1[\\GENE] (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of [CHEMICAL]succinate[\\CHEMICAL] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.",
        "label": 9,
        "major": 1,
        "len": 41
    },
    {
        "text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 ([GENE]alpha-ketoglutarate dehydrogenase[\\GENE]) gene disrupted mutant produced a lower level of [CHEMICAL]succinate[\\CHEMICAL] than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.",
        "label": 9,
        "major": 3,
        "len": 41
    },
    {
        "text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the [GENE]SDH1[\\GENE] (succinate dehydrogenase) gene-disrupted mutant produced an increased level of [CHEMICAL]succinate[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 41
    },
    {
        "text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 ([GENE]succinate dehydrogenase[\\GENE]) gene-disrupted mutant produced an increased level of [CHEMICAL]succinate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "On the other hand, the [GENE]FUM1[\\GENE] (fumarase) gene disrupted mutant produced significantly higher levels of [CHEMICAL]fumarate[\\CHEMICAL] but did not form malate at all.",
        "label": 9,
        "major": 10,
        "len": 23
    },
    {
        "text": "On the other hand, the FUM1 ([GENE]fumarase[\\GENE]) gene disrupted mutant produced significantly higher levels of [CHEMICAL]fumarate[\\CHEMICAL] but did not form malate at all.",
        "label": 9,
        "major": 1,
        "len": 23
    },
    {
        "text": "When the growth condition was shifted from aerobic to anaerobic, the increased level of [CHEMICAL]succinate[\\CHEMICAL] in [GENE]SDH1[\\GENE] disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.",
        "label": 9,
        "major": 3,
        "len": 35
    },
    {
        "text": "When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of [CHEMICAL]succinate[\\CHEMICAL] in the [GENE]KGD1[\\GENE] diruptant was still observed.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "A double mutant of the two [GENE]fumarate reductase[\\GENE] isozyme genes (OSM1 and FRDS) showed a [CHEMICAL]succinate[\\CHEMICAL] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.",
        "label": 9,
        "major": 1,
        "len": 31
    },
    {
        "text": "A double mutant of the two fumarate reductase isozyme genes ([GENE]OSM1[\\GENE] and FRDS) showed a [CHEMICAL]succinate[\\CHEMICAL] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "A double mutant of the two fumarate reductase isozyme genes (OSM1 and [GENE]FRDS[\\GENE]) showed a [CHEMICAL]succinate[\\CHEMICAL] productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.",
        "label": 9,
        "major": 4,
        "len": 31
    },
    {
        "text": "As examples, [CHEMICAL]ketorolac[\\CHEMICAL], flurbiprofen, ketoprofen and indomethacin have increased [GENE]COX-1[\\GENE] selectivity when compared with naproxen and ibuprofen.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "As examples, ketorolac, [CHEMICAL]flurbiprofen[\\CHEMICAL], ketoprofen and indomethacin have increased [GENE]COX-1[\\GENE] selectivity when compared with naproxen and ibuprofen.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "As examples, ketorolac, flurbiprofen, [CHEMICAL]ketoprofen[\\CHEMICAL] and indomethacin have increased [GENE]COX-1[\\GENE] selectivity when compared with naproxen and ibuprofen.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "As examples, ketorolac, flurbiprofen, ketoprofen and [CHEMICAL]indomethacin[\\CHEMICAL] have increased [GENE]COX-1[\\GENE] selectivity when compared with naproxen and ibuprofen.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased [GENE]COX-1[\\GENE] selectivity when compared with [CHEMICAL]naproxen[\\CHEMICAL] and ibuprofen.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased [GENE]COX-1[\\GENE] selectivity when compared with naproxen and [CHEMICAL]ibuprofen[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Vitamin E[\\CHEMICAL] supplementation was found to alter the plasma [GENE]HDL[\\GENE]-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while [GENE]HMG-CoA reductase[\\GENE] activity was the highest only in the [CHEMICAL]probucol[\\CHEMICAL] group.",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Vitamin E[\\CHEMICAL] and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and [GENE]low-density lipoprotein[\\GENE] cholesterol compared to HC-control group.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Vitamin E and [CHEMICAL]probucol[\\CHEMICAL] significantly suppressed an increase in plasma total-cholesterol (total-C) and [GENE]low-density lipoprotein[\\GENE] cholesterol compared to HC-control group.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, [CHEMICAL]probucol[\\CHEMICAL] supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma [GENE]HDL[\\GENE]-C concentration.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Hepatic [GENE]ACAT[\\GENE] activity was significantly lower in both [CHEMICAL]vitamin E[\\CHEMICAL] and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Hepatic [GENE]ACAT[\\GENE] activity was significantly lower in both vitamin E and [CHEMICAL]probucol[\\CHEMICAL] groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL][3H]-maraviroc[\\CHEMICAL] bound with high affinity to [GENE]CCR5[\\GENE] from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque CCR5.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "[CHEMICAL][3H]-maraviroc[\\CHEMICAL] bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from [GENE]macaque CCR5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [[CHEMICAL]125I[\\CHEMICAL]]-MIP-1beta and [3H]-maraviroc with [GENE]human recombinant CCR5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and [CHEMICAL][3H]-maraviroc[\\CHEMICAL] with [GENE]human recombinant CCR5[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "[[CHEMICAL]125I[\\CHEMICAL]]-MIP-1beta bound with similar high affinity to [GENE]CCR5[\\GENE] from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Maraviroc[\\CHEMICAL] inhibited binding of [125I]-MIP-1beta to [GENE]CCR5[\\GENE] from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).",
        "label": 2,
        "major": 2,
        "len": 54
    },
    {
        "text": "Maraviroc inhibited binding of [[CHEMICAL]125I[\\CHEMICAL]]-MIP-1beta to [GENE]CCR5[\\GENE] from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).",
        "label": 2,
        "major": 2,
        "len": 54
    },
    {
        "text": "However, as with the human receptor, [CHEMICAL]maraviroc[\\CHEMICAL] was shown to be a high affinity, potent functional antagonist of [GENE]macaque CCR5[\\GENE] thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.",
        "label": 6,
        "major": 6,
        "len": 45
    },
    {
        "text": "However, as with the human receptor, [CHEMICAL]maraviroc[\\CHEMICAL] was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel [GENE]CCR5[\\GENE] antagonists.",
        "label": 6,
        "major": 2,
        "len": 45
    },
    {
        "text": "The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel [GENE]CCR5[\\GENE] antagonists, such as [CHEMICAL]maraviroc[\\CHEMICAL] (UK-427,857).",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel [GENE]CCR5[\\GENE] antagonists, such as maraviroc ([CHEMICAL]UK-427,857[\\CHEMICAL]).",
        "label": 6,
        "major": 6,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Maraviroc[\\CHEMICAL] inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through [GENE]CCR5[\\GENE] from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).",
        "label": 6,
        "major": 4,
        "len": 54
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the [CHEMICAL]retinoids[\\CHEMICAL], all-trans retinoic acid and 9-cis retinoic acid, that bind [GENE]CRABPI[\\GENE], promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the retinoids, [CHEMICAL]all-trans retinoic acid[\\CHEMICAL] and 9-cis retinoic acid, that bind [GENE]CRABPI[\\GENE], promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and [CHEMICAL]9-cis retinoic acid[\\CHEMICAL], that bind [GENE]CRABPI[\\GENE], promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the [CHEMICAL]retinoids[\\CHEMICAL], all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in [GENE]p75NTR[\\GENE] PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the retinoids, [CHEMICAL]all-trans retinoic acid[\\CHEMICAL] and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in [GENE]p75NTR[\\GENE] PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and [CHEMICAL]9-cis retinoic acid[\\CHEMICAL], that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in [GENE]p75NTR[\\GENE] PC-3 cells, but not in neo control PC-3 cells.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "The mouse orthologue of GPR109A, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated [GENE]PUMA-G[\\GENE]-deficient mice restored the [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced flushing response.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "Our data clearly indicate that [GENE]GPR109A[\\GENE] mediates [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced flushing and that this effect involves release of PGE(2) and PGD(2), most likely from immune cells of the skin.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Recently, a [GENE]G-protein-coupled receptor[\\GENE], termed GPR109A (HM74A in humans, PUMA-G in mice), was described and shown to mediate the [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced antilipolytic effects in adipocytes.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Recently, a G-protein-coupled receptor, termed [GENE]GPR109A[\\GENE] (HM74A in humans, PUMA-G in mice), was described and shown to mediate the [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced antilipolytic effects in adipocytes.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Recently, a G-protein-coupled receptor, termed GPR109A ([GENE]HM74A[\\GENE] in humans, PUMA-G in mice), was described and shown to mediate the [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced antilipolytic effects in adipocytes.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Recently, a G-protein-coupled receptor, termed GPR109A (HM74A in humans, [GENE]PUMA-G[\\GENE] in mice), was described and shown to mediate the [CHEMICAL]nicotinic acid[\\CHEMICAL]-induced antilipolytic effects in adipocytes.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "Its special profile of actions, especially the rise in [GENE]HDL[\\GENE]-cholesterol levels induced by [CHEMICAL]nicotinic acid[\\CHEMICAL], is unique among the currently available pharmacological tools to treat lipid disorders.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Bisoprolol[\\CHEMICAL] reduced dobutamine-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Bisoprolol reduced [CHEMICAL]dobutamine[\\CHEMICAL]-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "RESULTS: With regard to PRA, [CHEMICAL]dobutamine[\\CHEMICAL] increased PRA more potently in Arg389-[GENE]beta1AR[\\GENE] versus Gly389-beta1AR subjects.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "RESULTS: With regard to PRA, [CHEMICAL]dobutamine[\\CHEMICAL] increased PRA more potently in Arg389-beta1AR versus Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Bisoprolol[\\CHEMICAL] markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "Bisoprolol markedly suppressed the [CHEMICAL]dobutamine[\\CHEMICAL]-induced PRA increase in Arg389- but only marginally in Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "With regard to hemodynamics, [CHEMICAL]dobutamine[\\CHEMICAL] caused larger heart rate and contractility increases and diastolic blood pressure decreases in Arg389- versus Gly389-[GENE]beta1AR[\\GENE] subjects.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "Although chronic [CHEMICAL]valproic acid[\\CHEMICAL] produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter [GENE]phospholipase A(2)[\\GENE] activity, suggesting that it targets a different enzyme in the turnover pathway.",
        "label": 10,
        "major": 10,
        "len": 33
    },
    {
        "text": "Furthermore, [GENE]brain microsomal Acsl[\\GENE] did not produce [CHEMICAL]valproyl-CoA[\\CHEMICAL].",
        "label": 10,
        "major": 9,
        "len": 8
    },
    {
        "text": "RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an [CHEMICAL]arachidonic acid[\\CHEMICAL]-selective [GENE]phospholipase A(2)[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 39
    },
    {
        "text": "RATIONALE: Several drugs used to treat bipolar disorder ([CHEMICAL]lithium[\\CHEMICAL] and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [GENE]phospholipase A(2)[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that [CHEMICAL]valproic acid[\\CHEMICAL] is a non-competitive inhibitor of [GENE]Acsl[\\GENE], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.",
        "label": 4,
        "major": 4,
        "len": 45
    },
    {
        "text": "RATIONALE: Several drugs used to treat bipolar disorder (lithium and [CHEMICAL]carbamazepine[\\CHEMICAL]), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [GENE]phospholipase A(2)[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Valproic acid[\\CHEMICAL] selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by [GENE]brain microsomal long-chain fatty acyl-CoA synthetases[\\GENE]: relevance to bipolar disorder.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "CONCLUSIONS: This study shows that [CHEMICAL]valproic acid[\\CHEMICAL] acts as a non-competitive inhibitor of [GENE]brain microsomal Acsl[\\GENE], and that inhibition is substrate-selective.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Valproic acid selectively inhibits conversion of arachidonic acid to [CHEMICAL]arachidonoyl-CoA[\\CHEMICAL] by [GENE]brain microsomal long-chain fatty acyl-CoA synthetases[\\GENE]: relevance to bipolar disorder.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Valproic acid selectively inhibits conversion of [CHEMICAL]arachidonic acid[\\CHEMICAL] to arachidonoyl-CoA by [GENE]brain microsomal long-chain fatty acyl-CoA synthetases[\\GENE]: relevance to bipolar disorder.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "On the other hand, holocarboxylase synthetase ([GENE]HCS[\\GENE]) mRNA levels were markedly low in the deficient animals, and increased upon [CHEMICAL]biotin[\\CHEMICAL] injection.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "On the other hand, [GENE]holocarboxylase synthetase[\\GENE] (HCS) mRNA levels were markedly low in the deficient animals, and increased upon [CHEMICAL]biotin[\\CHEMICAL] injection.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by [CHEMICAL]indomethacin[\\CHEMICAL], a preferential [GENE]COX-1[\\GENE] inhibitor, but not by NS-398, a selective COX-2 inhibitor.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by [CHEMICAL]NS-398[\\CHEMICAL], a selective [GENE]COX-2[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Involvement of [GENE]COX-1[\\GENE] and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced [CHEMICAL]prostaglandin E2[\\CHEMICAL] production by microglia.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "Involvement of COX-1 and up-regulated [GENE]prostaglandin E synthases[\\GENE] in phosphatidylserine liposome-induced [CHEMICAL]prostaglandin E2[\\CHEMICAL] production by microglia.",
        "label": 9,
        "major": 3,
        "len": 16
    },
    {
        "text": "These observations strongly suggest that the up-regulation of terminal [GENE]PGESs[\\GENE] that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced [CHEMICAL]PGE2[\\CHEMICAL] production by microglia.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with [GENE]COX-1[\\GENE], especially mPGES-2, plays the pivotal role in PS liposome-induced [CHEMICAL]PGE2[\\CHEMICAL] production by microglia.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially [GENE]mPGES-2[\\GENE], plays the pivotal role in PS liposome-induced [CHEMICAL]PGE2[\\CHEMICAL] production by microglia.",
        "label": 9,
        "major": 9,
        "len": 29
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-[GENE]kinase[\\GENE] inhibitors (MKIs) [CHEMICAL]sorafenib[\\CHEMICAL], sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) [CHEMICAL]sorafenib[\\CHEMICAL], sunitinib, and AG013736, which target multiple [GENE]VEGFRs[\\GENE] as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) [CHEMICAL]sorafenib[\\CHEMICAL], sunitinib, and AG013736, which target multiple VEGFRs as well as [GENE]PDGFR-beta[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-[GENE]kinase[\\GENE] inhibitors (MKIs) sorafenib, [CHEMICAL]sunitinib[\\CHEMICAL], and AG013736, which target multiple VEGFRs as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, [CHEMICAL]sunitinib[\\CHEMICAL], and AG013736, which target multiple [GENE]VEGFRs[\\GENE] as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, [CHEMICAL]sunitinib[\\CHEMICAL], and AG013736, which target multiple VEGFRs as well as [GENE]PDGFR-beta[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-[GENE]kinase[\\GENE] inhibitors (MKIs) sorafenib, sunitinib, and [CHEMICAL]AG013736[\\CHEMICAL], which target multiple VEGFRs as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and [CHEMICAL]AG013736[\\CHEMICAL], which target multiple [GENE]VEGFRs[\\GENE] as well as PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and [CHEMICAL]AG013736[\\CHEMICAL], which target multiple VEGFRs as well as [GENE]PDGFR-beta[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] has the added advantage of inhibiting multiple different [GENE]Raf[\\GENE] isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target [GENE]TGF-alpha[\\GENE]/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/[GENE]EGFR[\\GENE] signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of [GENE]VEGFR[\\GENE] and PDGFR-beta.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL] has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and [GENE]PDGFR-beta[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]DVS[\\CHEMICAL] showed weak binding affinity (62% inhibition at 100 microM) at the [GENE]human dopamine (DA) transporter[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Inhibition of [3H]5-HT or [3H]NE uptake by [CHEMICAL]DVS[\\CHEMICAL] for the [GENE]hSERT[\\GENE] or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Inhibition of [3H]5-HT or [3H]NE uptake by [CHEMICAL]DVS[\\CHEMICAL] for the hSERT or [GENE]hNET[\\GENE] produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",
        "label": 2,
        "major": 9,
        "len": 26
    },
    {
        "text": "Competitive radioligand binding assays were performed using cells expressing either the [GENE]human serotonin (5-HT) transporter[\\GENE] (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for [CHEMICAL]DVS[\\CHEMICAL] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter ([GENE]hSERT[\\GENE]) or norepinephrine (NE) transporter (hNET) with K(i) values for [CHEMICAL]DVS[\\CHEMICAL] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",
        "label": 4,
        "major": 9,
        "len": 36
    },
    {
        "text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or [GENE]norepinephrine (NE) transporter[\\GENE] (hNET) with K(i) values for [CHEMICAL]DVS[\\CHEMICAL] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",
        "label": 4,
        "major": 9,
        "len": 36
    },
    {
        "text": "Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter ([GENE]hNET[\\GENE]) with K(i) values for [CHEMICAL]DVS[\\CHEMICAL] of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a [GENE]5-HT(1A)[\\GENE] antagonist, [CHEMICAL]N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt[\\CHEMICAL] (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT(1A) autoreceptors, a [GENE]5-HT(1A)[\\GENE] antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt ([CHEMICAL]WAY-100635[\\CHEMICAL]) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "Inhibition of [CHEMICAL][3H]5-HT[\\CHEMICAL] or [3H]NE uptake by DVS for the [GENE]hSERT[\\GENE] or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Inhibition of [3H]5-HT or [CHEMICAL][3H]NE[\\CHEMICAL] uptake by DVS for the hSERT or [GENE]hNET[\\GENE] produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Further, [CHEMICAL]cholesterol[\\CHEMICAL] metabolites, predominantly the oxysterols, the natural ligands for [GENE]liver X receptor[\\GENE] (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, [CHEMICAL]cholesterol[\\CHEMICAL] metabolites, predominantly the oxysterols, the natural ligands for liver X receptor ([GENE]LXR[\\GENE]), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, cholesterol metabolites, predominantly the [CHEMICAL]oxysterols[\\CHEMICAL], the natural ligands for [GENE]liver X receptor[\\GENE] (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, cholesterol metabolites, predominantly the [CHEMICAL]oxysterols[\\CHEMICAL], the natural ligands for liver X receptor ([GENE]LXR[\\GENE]), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 2,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, [CHEMICAL]cholesterol[\\CHEMICAL] metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of [GENE]sterol regulatory element binding protein-1c[\\GENE] (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, [CHEMICAL]cholesterol[\\CHEMICAL] metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c ([GENE]SREBP-1c[\\GENE]) that bound to the regulatory regions of these genes.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, cholesterol metabolites, predominantly the [CHEMICAL]oxysterols[\\CHEMICAL], the natural ligands for liver X receptor (LXR), induced these genes via upregulation of [GENE]sterol regulatory element binding protein-1c[\\GENE] (SREBP-1c) that bound to the regulatory regions of these genes.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "Further, cholesterol metabolites, predominantly the [CHEMICAL]oxysterols[\\CHEMICAL], the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c ([GENE]SREBP-1c[\\GENE]) that bound to the regulatory regions of these genes.",
        "label": 3,
        "major": 3,
        "len": 35
    },
    {
        "text": "The tissue RA level is maintained through a cascade of metabolic reactions where [GENE]retinal dehydrogenases[\\GENE] (RALDHs) catalyze the terminal reaction of [CHEMICAL]RA[\\CHEMICAL] biosynthesis from retinal, a rate-limiting step.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases ([GENE]RALDHs[\\GENE]) catalyze the terminal reaction of [CHEMICAL]RA[\\CHEMICAL] biosynthesis from retinal, a rate-limiting step.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "The tissue RA level is maintained through a cascade of metabolic reactions where [GENE]retinal dehydrogenases[\\GENE] (RALDHs) catalyze the terminal reaction of RA biosynthesis from [CHEMICAL]retinal[\\CHEMICAL], a rate-limiting step.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "The tissue RA level is maintained through a cascade of metabolic reactions where retinal dehydrogenases ([GENE]RALDHs[\\GENE]) catalyze the terminal reaction of RA biosynthesis from [CHEMICAL]retinal[\\CHEMICAL], a rate-limiting step.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Hypermethlyation of [GENE]RELN and GAD67 promoters[\\GENE] can be induced by treating mice with [CHEMICAL]methionine[\\CHEMICAL], and these mice display brain and behavioral abnormalities similar to +/rl.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the [GENE]AT1[\\GENE] antagonist [CHEMICAL]olmesartan medoxomil[\\CHEMICAL].",
        "label": 6,
        "major": 10,
        "len": 18
    },
    {
        "text": "Functional and bioenergetic consequences of [GENE]AT1[\\GENE] antagonist [CHEMICAL]olmesartan medoxomil[\\CHEMICAL] in hearts with postinfarction LV remodeling.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Experiments with Schwann cell primary cultures revealed an effect of [CHEMICAL]retinoic acid[\\CHEMICAL] on the expression of the [GENE]neuregulin receptor[\\GENE] ErbB3, suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Experiments with Schwann cell primary cultures revealed an effect of [CHEMICAL]retinoic acid[\\CHEMICAL] on the expression of the neuregulin receptor [GENE]ErbB3[\\GENE], suggesting that one function of retinoic acid consists in the regulation of neuroglial interactions after peripheral nerve injury.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Since the effect of [CHEMICAL]retinoic acid[\\CHEMICAL] is mediated via [GENE]retinoic acid receptors[\\GENE] and retinoid X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Since the effect of [CHEMICAL]retinoic acid[\\CHEMICAL] is mediated via retinoic acid receptors and [GENE]retinoid X receptors[\\GENE], we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Imatinib[\\CHEMICAL] inhibits RET-mediated MTC cell growth affecting [GENE]RET[\\GENE] protein levels in vitro in a dose-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "RESULTS: [CHEMICAL]Imatinib[\\CHEMICAL] inhibited [GENE]RET[\\GENE] Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "RESULTS: [CHEMICAL]Imatinib[\\CHEMICAL] inhibited RET [GENE]Y1062[\\GENE] phosphorylation in a dose-dependent manner after 1.5 hours of exposure.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Imatinib[\\CHEMICAL] inhibits [GENE]RET[\\GENE]-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The concentration of [CHEMICAL]imatinib[\\CHEMICAL] necessary to inhibit [GENE]RET[\\GENE] in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.",
        "label": 4,
        "major": 10,
        "len": 29
    },
    {
        "text": "We evaluated [CHEMICAL]imatinib[\\CHEMICAL], a [GENE]tyrosine kinase[\\GENE] inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.",
        "label": 4,
        "major": 1,
        "len": 39
    },
    {
        "text": "In eukaryotes, the most prominent Mo-enzymes are (1) [GENE]sulfite oxidase[\\GENE], which catalyzes the final step in the degradation of [CHEMICAL]sulfur[\\CHEMICAL]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.",
        "label": 9,
        "major": 9,
        "len": 79
    },
    {
        "text": "Among them, [CHEMICAL]tamibarotene[\\CHEMICAL] (Am80) is an RARalpha- and RARbeta-specific (but [GENE]RARgamma[\\GENE]- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, [CHEMICAL]tamibarotene[\\CHEMICAL] (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and [GENE]RXRs[\\GENE]-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene ([CHEMICAL]Am80[\\CHEMICAL]) is an RARalpha- and RARbeta-specific (but [GENE]RARgamma[\\GENE]- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene ([CHEMICAL]Am80[\\CHEMICAL]) is an RARalpha- and RARbeta-specific (but RARgamma- and [GENE]RXRs[\\GENE]-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but [GENE]RARgamma[\\GENE]- and RXRs-nonbinding) synthetic [CHEMICAL]retinoid[\\CHEMICAL] that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and [GENE]RXRs[\\GENE]-nonbinding) synthetic [CHEMICAL]retinoid[\\CHEMICAL] that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 10,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Retinoid[\\CHEMICAL] is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of [GENE]nuclear hormone receptor[\\GENE] superfamily.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Retinoid[\\CHEMICAL] is a collective term for compounds which bind to and activate [GENE]retinoic acid receptors[\\GENE] (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Among them, [CHEMICAL]tamibarotene[\\CHEMICAL] (Am80) is an [GENE]RARalpha[\\GENE]- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, [CHEMICAL]tamibarotene[\\CHEMICAL] (Am80) is an RARalpha- and [GENE]RARbeta[\\GENE]-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene ([CHEMICAL]Am80[\\CHEMICAL]) is an [GENE]RARalpha[\\GENE]- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene ([CHEMICAL]Am80[\\CHEMICAL]) is an RARalpha- and [GENE]RARbeta[\\GENE]-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene (Am80) is an [GENE]RARalpha[\\GENE]- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic [CHEMICAL]retinoid[\\CHEMICAL] that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Among them, tamibarotene (Am80) is an RARalpha- and [GENE]RARbeta[\\GENE]-specific (but RARgamma- and RXRs-nonbinding) synthetic [CHEMICAL]retinoid[\\CHEMICAL] that is effective in the treatment of psoriasis patients and relapsed APL.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Retinoid[\\CHEMICAL] is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of [GENE]nuclear hormone receptor[\\GENE] superfamily.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Retinoid[\\CHEMICAL] is a collective term for compounds which bind to and activate [GENE]retinoic acid receptors[\\GENE] (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The cholesterol-lowering drug [CHEMICAL]simvastatin[\\CHEMICAL] inhibits LFA-1 signaling by binding to an allosteric site on [GENE]CD11a[\\GENE] (LFA-1 alpha chain), which leads to immunomodulation.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "The cholesterol-lowering drug [CHEMICAL]simvastatin[\\CHEMICAL] inhibits LFA-1 signaling by binding to an allosteric site on CD11a ([GENE]LFA-1 alpha chain[\\GENE]), which leads to immunomodulation.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL] abolished these anti-[GENE]CD11a[\\GENE] mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "The cholesterol-lowering drug [CHEMICAL]simvastatin[\\CHEMICAL] inhibits [GENE]LFA-1[\\GENE] signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.",
        "label": 4,
        "major": 7,
        "len": 22
    },
    {
        "text": "Similar to [CHEMICAL]menthol[\\CHEMICAL], both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other [GENE]thermoTRPs[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to menthol, both [CHEMICAL]camphor[\\CHEMICAL] and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other [GENE]thermoTRPs[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to menthol, both camphor and [CHEMICAL]cinnamaldehyde[\\CHEMICAL] (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other [GENE]thermoTRPs[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Menthol[\\CHEMICAL], popularly known for its cooling effect, activates [GENE]TRPM8[\\GENE]--a cold-activated thermoTRP ion channel.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Menthol[\\CHEMICAL], popularly known for its cooling effect, activates TRPM8--a cold-activated [GENE]thermoTRP ion channel[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that [CHEMICAL]menthol[\\CHEMICAL] also activates heat-activated [GENE]TRPV3[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Similar to [CHEMICAL]menthol[\\CHEMICAL], both camphor and cinnamaldehyde (initially reported to be specific activators of [GENE]TRPV3[\\GENE] and TRPA1, respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to [CHEMICAL]menthol[\\CHEMICAL], both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and [GENE]TRPA1[\\GENE], respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to menthol, both [CHEMICAL]camphor[\\CHEMICAL] and cinnamaldehyde (initially reported to be specific activators of [GENE]TRPV3[\\GENE] and TRPA1, respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 7,
        "len": 22
    },
    {
        "text": "Similar to menthol, both [CHEMICAL]camphor[\\CHEMICAL] and cinnamaldehyde (initially reported to be specific activators of TRPV3 and [GENE]TRPA1[\\GENE], respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to menthol, both camphor and [CHEMICAL]cinnamaldehyde[\\CHEMICAL] (initially reported to be specific activators of [GENE]TRPV3[\\GENE] and TRPA1, respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Similar to menthol, both camphor and [CHEMICAL]cinnamaldehyde[\\CHEMICAL] (initially reported to be specific activators of TRPV3 and [GENE]TRPA1[\\GENE], respectively) also modulate other thermoTRPs.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "We further show that [CHEMICAL]menthol[\\CHEMICAL] inhibits [GENE]TRPA1[\\GENE], potentially explaining the use of menthol as an analgesic.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "These currents were produced by [GENE]glutamate-aspartate transporters[\\GENE] (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [CHEMICAL]dihydrokainate[\\CHEMICAL], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "These currents were produced by glutamate-aspartate transporters ([GENE]GLAST[\\GENE]) (excitatory amino acid transporter 1) because they were weakly inhibited by [CHEMICAL]dihydrokainate[\\CHEMICAL], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "These currents were produced by glutamate-aspartate transporters (GLAST) ([GENE]excitatory amino acid transporter 1[\\GENE]) because they were weakly inhibited by [CHEMICAL]dihydrokainate[\\CHEMICAL], an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [CHEMICAL]dihydrokainate[\\CHEMICAL], an antagonist of [GENE]glutamate transporter-1[\\GENE] (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.",
        "label": 6,
        "major": 9,
        "len": 38
    },
    {
        "text": "These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by [CHEMICAL]dihydrokainate[\\CHEMICAL], an antagonist of glutamate transporter-1 ([GENE]excitatory amino acid transporter 2[\\GENE]) and were absent from IPCs in GLAST-/- cochleas.",
        "label": 6,
        "major": 9,
        "len": 38
    },
    {
        "text": "Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated [GENE]anion channel[\\GENE] and blocked by the transporter antagonist [CHEMICAL]D,L-threo-beta-benzyloxyaspartate[\\CHEMICAL].",
        "label": 6,
        "major": 9,
        "len": 33
    },
    {
        "text": "The glutamate-aspartate transporter [GENE]GLAST[\\GENE] mediates [CHEMICAL]glutamate[\\CHEMICAL] uptake at inner hair cell afferent synapses in the mammalian cochlea.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "The [GENE]glutamate-aspartate transporter[\\GENE] GLAST mediates [CHEMICAL]glutamate[\\CHEMICAL] uptake at inner hair cell afferent synapses in the mammalian cochlea.",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by [CHEMICAL]L-glutamate[\\CHEMICAL], a prominent feature of [GENE]GLAST[\\GENE], and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.",
        "label": 9,
        "major": 3,
        "len": 47
    },
    {
        "text": "[GENE]Proline oxidase[\\GENE] (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [CHEMICAL]pyrroline- 5-carboxylate[\\CHEMICAL] (P5C).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Proline oxidase ([GENE]POX[\\GENE]), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to [CHEMICAL]pyrroline- 5-carboxylate[\\CHEMICAL] (P5C).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "[GENE]Proline oxidase[\\GENE] (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate ([CHEMICAL]P5C[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Proline oxidase ([GENE]POX[\\GENE]), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate ([CHEMICAL]P5C[\\CHEMICAL]).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Overexpression of [GENE]proline oxidase[\\GENE] induces [CHEMICAL]proline[\\CHEMICAL]-dependent and mitochondria-mediated apoptosis.",
        "label": 9,
        "major": 3,
        "len": 9
    },
    {
        "text": "We conclude that in the presence of [CHEMICAL]proline[\\CHEMICAL], high [GENE]POX[\\GENE] activity is sufficient to induce mitochondria-mediated apoptosis.",
        "label": 9,
        "major": 3,
        "len": 17
    },
    {
        "text": "[GENE]Proline oxidase[\\GENE] (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of [CHEMICAL]proline[\\CHEMICAL] to pyrroline- 5-carboxylate (P5C).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "Proline oxidase ([GENE]POX[\\GENE]), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of [CHEMICAL]proline[\\CHEMICAL] to pyrroline- 5-carboxylate (P5C).",
        "label": 9,
        "major": 9,
        "len": 17
    },
    {
        "text": "To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing [GENE]POX[\\GENE] exhibit an [CHEMICAL]L-proline[\\CHEMICAL]-dependent apoptotic response.",
        "label": 9,
        "major": 9,
        "len": 25
    },
    {
        "text": "The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of [CHEMICAL]L-proline[\\CHEMICAL] to cells with maximally induced [GENE]POX[\\GENE].",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "The exception was [CHEMICAL]bupropion[\\CHEMICAL], a dual [GENE]norepinephrine transporter[\\GENE]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "The exception was [CHEMICAL]bupropion[\\CHEMICAL], a dual norepinephrine transporter/[GENE]dopamine transporter[\\GENE] blocker, which tended to increase spontaneous locomotor activity.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Coadministration of reboxetine and the [GENE]dopamine transporter[\\GENE] blocker [CHEMICAL]GBR 12909[\\CHEMICAL] also increased spontaneous locomotor activity.",
        "label": 4,
        "major": 9,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Tamoxifen[\\CHEMICAL] blocks the action of estrogen by binding to the [GENE]ER[\\GENE], and possesses both ER-agonist and antagonist properties.",
        "label": 2,
        "major": 6,
        "len": 18
    },
    {
        "text": "Tamoxifen blocks the action of [CHEMICAL]estrogen[\\CHEMICAL] by binding to the [GENE]ER[\\GENE], and possesses both ER-agonist and antagonist properties.",
        "label": 2,
        "major": 6,
        "len": 18
    },
    {
        "text": "The selective [GENE]ER[\\GENE] modulator (SERM) [CHEMICAL]tamoxifen[\\CHEMICAL] has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of ER-positive disease.",
        "label": 2,
        "major": 7,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Fulvestrant[\\CHEMICAL] is a novel ER antagonist that destroys the [GENE]ER[\\GENE] and its signaling pathway and is not associated with tamoxifen-like agonist effects.",
        "label": 4,
        "major": 5,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Tamoxifen[\\CHEMICAL] blocks the action of estrogen by binding to the ER, and possesses both [GENE]ER[\\GENE]-agonist and antagonist properties.",
        "label": 5,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Tamoxifen[\\CHEMICAL] blocks the action of estrogen by binding to the ER, and possesses both [GENE]ER[\\GENE]-agonist and antagonist properties.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Fulvestrant[\\CHEMICAL] is a novel [GENE]ER[\\GENE] antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.",
        "label": 6,
        "major": 10,
        "len": 22
    },
    {
        "text": "This indicated that the [CHEMICAL]N[\\CHEMICAL]-terminal 46 amino acids in [GENE]GAF-B[\\GENE] are required for high vardenafil potency.",
        "label": 1,
        "major": 1,
        "len": 16
    },
    {
        "text": "This indicated that the N-terminal 46 [CHEMICAL]amino acids[\\CHEMICAL] in [GENE]GAF-B[\\GENE] are required for high vardenafil potency.",
        "label": 1,
        "major": 1,
        "len": 16
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four [CHEMICAL]N[\\CHEMICAL]-terminal truncation mutants were generated: [GENE]PDE5Delta1-321[\\GENE] contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.",
        "label": 1,
        "major": 4,
        "len": 56
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four [CHEMICAL]N[\\CHEMICAL]-terminal truncation mutants were generated: PDE5Delta1-321 contained [GENE]GAF-B domain[\\GENE], C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.",
        "label": 1,
        "major": 1,
        "len": 56
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four [CHEMICAL]N[\\CHEMICAL]-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; [GENE]PDE5Delta1-419[\\GENE] contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.",
        "label": 1,
        "major": 4,
        "len": 56
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four [CHEMICAL]N[\\CHEMICAL]-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; [GENE]PDE5Delta1-465[\\GENE] contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.",
        "label": 1,
        "major": 1,
        "len": 56
    },
    {
        "text": "Truncated proteins with a complete GAF-B were dimers, but those lacking the [CHEMICAL]N[\\CHEMICAL]-terminal 46 amino acids of [GENE]GAF-B[\\GENE] were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the [CHEMICAL]C[\\CHEMICAL]-terminal portion of [GENE]GAF-B[\\GENE]; and PDE5Delta1-534 contained only C domain.",
        "label": 1,
        "major": 1,
        "len": 56
    },
    {
        "text": "To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the [CHEMICAL]C[\\CHEMICAL]-terminal portion of GAF-B; and [GENE]PDE5Delta1-534[\\GENE] contained only C domain.",
        "label": 1,
        "major": 1,
        "len": 56
    },
    {
        "text": "A 46-[CHEMICAL]amino acid[\\CHEMICAL] segment in [GENE]phosphodiesterase-5[\\GENE] GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 1,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-[CHEMICAL]amino acid[\\CHEMICAL] segment in phosphodiesterase-5 [GENE]GAF-B domain[\\GENE] provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 1,
        "major": 1,
        "len": 23
    },
    {
        "text": "Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 [CHEMICAL]amino acids[\\CHEMICAL] of [GENE]GAF-B[\\GENE] were monomers, indicating that these residues are vital for GAF-B-mediated PDE5 dimerization.",
        "label": 1,
        "major": 1,
        "len": 30
    },
    {
        "text": "Binding of [CHEMICAL]cGMP[\\CHEMICAL] to [GENE]GAF-A[\\GENE] increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Binding of cGMP to GAF-A increases cNPK phosphorylation of [GENE]PDE5[\\GENE] and improves catalytic site affinity for [CHEMICAL]cGMP[\\CHEMICAL] or inhibitors.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "GAF-B contributes to dimerization of PDE5, inhibition of [CHEMICAL]cGMP[\\CHEMICAL] binding to [GENE]GAF-A[\\GENE], and sequestration of the phosphorylation site.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "All [GENE]PDE5[\\GENE] constructs had similar affinities for [CHEMICAL]3-isobutyl-1-methylxanthine[\\CHEMICAL], sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "All PDE5 constructs had similar affinities for [CHEMICAL]3-isobutyl-1-methylxanthine[\\CHEMICAL], sildenafil, tadalafil, and UK-122764, but mutants containing a complete [GENE]GAF-B[\\GENE] had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "All [GENE]PDE5[\\GENE] constructs had similar affinities for 3-isobutyl-1-methylxanthine, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, [CHEMICAL]sildenafil[\\CHEMICAL], tadalafil, and UK-122764, but mutants containing a complete [GENE]GAF-B[\\GENE] had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "All [GENE]PDE5[\\GENE] constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, [CHEMICAL]tadalafil[\\CHEMICAL], and UK-122764, but mutants containing a complete [GENE]GAF-B[\\GENE] had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "All [GENE]PDE5[\\GENE] constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and [CHEMICAL]UK-122764[\\CHEMICAL], but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 1,
        "len": 34
    },
    {
        "text": "All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and [CHEMICAL]UK-122764[\\CHEMICAL], but mutants containing a complete [GENE]GAF-B[\\GENE] had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete [GENE]GAF-B[\\GENE] had 7- to 18-fold higher affinity for [CHEMICAL]vardenafil[\\CHEMICAL]-based compounds compared with those lacking a complete GAF-B.",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "This indicated that the N-terminal 46 amino acids in [GENE]GAF-B[\\GENE] are required for high [CHEMICAL]vardenafil[\\CHEMICAL] potency.",
        "label": 2,
        "major": 1,
        "len": 16
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over [CHEMICAL]sildenafil[\\CHEMICAL] and tadalafil and is involved in [GENE]phosphodiesterase-5[\\GENE] dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in [GENE]phosphodiesterase-5[\\GENE] GAF-B domain provides for high vardenafil potency over [CHEMICAL]sildenafil[\\CHEMICAL] and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 [GENE]GAF-B domain[\\GENE] provides for high vardenafil potency over [CHEMICAL]sildenafil[\\CHEMICAL] and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and [CHEMICAL]tadalafil[\\CHEMICAL] and is involved in [GENE]phosphodiesterase-5[\\GENE] dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in [GENE]phosphodiesterase-5[\\GENE] GAF-B domain provides for high vardenafil potency over sildenafil and [CHEMICAL]tadalafil[\\CHEMICAL] and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 [GENE]GAF-B domain[\\GENE] provides for high vardenafil potency over sildenafil and [CHEMICAL]tadalafil[\\CHEMICAL] and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high [CHEMICAL]vardenafil[\\CHEMICAL] potency over sildenafil and tadalafil and is involved in [GENE]phosphodiesterase-5[\\GENE] dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in [GENE]phosphodiesterase-5[\\GENE] GAF-B domain provides for high [CHEMICAL]vardenafil[\\CHEMICAL] potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "A 46-amino acid segment in phosphodiesterase-5 [GENE]GAF-B domain[\\GENE] provides for high [CHEMICAL]vardenafil[\\CHEMICAL] potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.",
        "label": 2,
        "major": 1,
        "len": 23
    },
    {
        "text": "Binding of [CHEMICAL]cGMP[\\CHEMICAL] to GAF-A increases [GENE]cNPK[\\GENE] phosphorylation of PDE5 and improves catalytic site affinity for cGMP or inhibitors.",
        "label": 3,
        "major": 2,
        "len": 19
    },
    {
        "text": "Binding of [CHEMICAL]cGMP[\\CHEMICAL] to GAF-A increases cNPK phosphorylation of [GENE]PDE5[\\GENE] and improves catalytic site affinity for cGMP or inhibitors.",
        "label": 3,
        "major": 2,
        "len": 19
    },
    {
        "text": "[GENE]Phosphodiesterase-5[\\GENE] (PDE5) contains a catalytic domain (C domain) that hydrolyzes [CHEMICAL]cGMP[\\CHEMICAL] and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).",
        "label": 9,
        "major": 2,
        "len": 43
    },
    {
        "text": "Phosphodiesterase-5 ([GENE]PDE5[\\GENE]) contains a catalytic domain (C domain) that hydrolyzes [CHEMICAL]cGMP[\\CHEMICAL] and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).",
        "label": 9,
        "major": 2,
        "len": 43
    },
    {
        "text": "K(m) values of the mutants for [CHEMICAL]cGMP[\\CHEMICAL] were similar to that of full-length [GENE]PDE5[\\GENE].",
        "label": 9,
        "major": 1,
        "len": 14
    },
    {
        "text": "However, the expression of [GENE]AT1R[\\GENE] was not suppressed by other AT1R antagonists such as [CHEMICAL]candesartan[\\CHEMICAL] or olmesartan.",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "However, the expression of [GENE]AT1R[\\GENE] was not suppressed by other AT1R antagonists such as candesartan or [CHEMICAL]olmesartan[\\CHEMICAL].",
        "label": 10,
        "major": 6,
        "len": 17
    },
    {
        "text": "Since previous studies have demonstrated that PPARgamma activators suppressed AT1R expression, we examined whether [CHEMICAL]telmisartan[\\CHEMICAL] affects [GENE]AT1R[\\GENE] expression in vascular smooth muscle cells.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Telmisartan[\\CHEMICAL] downregulates angiotensin II type 1 receptor through activation of [GENE]peroxisome proliferator-activated receptor gamma[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 14
    },
    {
        "text": "CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [CHEMICAL]telmisartan[\\CHEMICAL] inhibits AT1R gene expression through [GENE]PPARgamma[\\GENE] activation.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "Since the suppression of [GENE]AT1R[\\GENE] expression was prevented by pretreatment with [CHEMICAL]GW9662[\\CHEMICAL], a PPARgamma antagonist, PPARgamma should have participated in the process.",
        "label": 3,
        "major": 6,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Telmisartan[\\CHEMICAL] downregulates [GENE]angiotensin II type 1 receptor[\\GENE] through activation of peroxisome proliferator-activated receptor gamma.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Decreased AT1R promoter activity with unchanged mRNA stability suggested that [CHEMICAL]telmisartan[\\CHEMICAL] suppressed [GENE]AT1R[\\GENE] gene expression at the transcriptional level.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The deletion and mutation analysis of the [GENE]AT1R[\\GENE] gene promoter indicated that a GC box located in the proximal promoter region is responsible for the [CHEMICAL]telmisartan[\\CHEMICAL]-induced downregulation.",
        "label": 4,
        "major": 1,
        "len": 27
    },
    {
        "text": "The deletion and mutation analysis of the AT1R gene promoter indicated that a [GENE]GC box[\\GENE] located in the proximal promoter region is responsible for the [CHEMICAL]telmisartan[\\CHEMICAL]-induced downregulation.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "CONCLUSION: Our data provides a novel insight into an effect of telmisartan: [CHEMICAL]telmisartan[\\CHEMICAL] inhibits [GENE]AT1R[\\GENE] gene expression through PPARgamma activation.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "RESULTS: [CHEMICAL]Telmisartan[\\CHEMICAL] decreased the expression of [GENE]AT1R[\\GENE] at the mRNA and protein levels in a dose- and time-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Telmisartan[\\CHEMICAL], an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of [GENE]peroxisome proliferator-activated receptor gamma[\\GENE] (PPARgamma).",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Telmisartan[\\CHEMICAL], an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma ([GENE]PPARgamma[\\GENE]).",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "However, the expression of AT1R was not suppressed by other [GENE]AT1R[\\GENE] antagonists such as [CHEMICAL]candesartan[\\CHEMICAL] or olmesartan.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "However, the expression of AT1R was not suppressed by other [GENE]AT1R[\\GENE] antagonists such as candesartan or [CHEMICAL]olmesartan[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Telmisartan[\\CHEMICAL], an [GENE]angiotensin II type 1 receptor[\\GENE] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).",
        "label": 6,
        "major": 3,
        "len": 28
    },
    {
        "text": "OBJECTIVE: [CHEMICAL]Telmisartan[\\CHEMICAL], an angiotensin II type 1 receptor ([GENE]AT1R[\\GENE]) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Since the suppression of AT1R expression was prevented by pretreatment with [CHEMICAL]GW9662[\\CHEMICAL], a [GENE]PPARgamma[\\GENE] antagonist, PPARgamma should have participated in the process.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "Upon differentiation, osteoclasts express [GENE]vesicular glutamate transporter 1[\\GENE] (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of [CHEMICAL]glutamate[\\CHEMICAL] in neurons.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Upon differentiation, osteoclasts express vesicular glutamate transporter 1 ([GENE]VGLUT1[\\GENE]), which is essential for vesicular storage and subsequent exocytosis of [CHEMICAL]glutamate[\\CHEMICAL] in neurons.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble [CHEMICAL]methotrexate[\\CHEMICAL] (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [GENE]mammalian DHFR[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate ([CHEMICAL]MTX[\\CHEMICAL], 1) structure features and fitted with functional groups believed to enhance inhibition of [GENE]mammalian DHFR[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "In order to produce potent new leads for anticancer drugs, a new series of [CHEMICAL]quinazoline[\\CHEMICAL] analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [GENE]mammalian DHFR[\\GENE] activity.",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "Synthesis, [GENE]dihydrofolate reductase[\\GENE] inhibition, antitumor testing, and molecular modeling study of some new [CHEMICAL]4(3H)-quinazolinone[\\CHEMICAL] analogs.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Administration of [CHEMICAL]m-chlorophenylpiperazine[\\CHEMICAL] and fenfluramine, both of which induce anorexic effects via [GENE]5-HT2C[\\GENE] receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Administration of [CHEMICAL]m-chlorophenylpiperazine[\\CHEMICAL] and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or [GENE]5-HT1B[\\GENE] receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Administration of m-chlorophenylpiperazine and [CHEMICAL]fenfluramine[\\CHEMICAL], both of which induce anorexic effects via [GENE]5-HT2C[\\GENE] receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Administration of m-chlorophenylpiperazine and [CHEMICAL]fenfluramine[\\CHEMICAL], both of which induce anorexic effects via 5-HT2C receptors and/or [GENE]5-HT1B[\\GENE] receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "CONCLUSION: Intake of high [CHEMICAL]SFAs[\\CHEMICAL] and MUFAs appears to increase expression of PBMC [GENE]D6D[\\GENE] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "CONCLUSION: Intake of high [CHEMICAL]SFAs[\\CHEMICAL] and MUFAs appears to increase expression of PBMC D6D and [GENE]D5D[\\GENE] genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "CONCLUSION: Intake of high SFAs and [CHEMICAL]MUFAs[\\CHEMICAL] appears to increase expression of PBMC [GENE]D6D[\\GENE] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "CONCLUSION: Intake of high SFAs and [CHEMICAL]MUFAs[\\CHEMICAL] appears to increase expression of PBMC D6D and [GENE]D5D[\\GENE] genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high [CHEMICAL]EFAs[\\CHEMICAL] intake appears to decrease expression of PBMC [GENE]D6D[\\GENE] and D5D genes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high [CHEMICAL]EFAs[\\CHEMICAL] intake appears to decrease expression of PBMC D6D and [GENE]D5D[\\GENE] genes.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Because [CHEMICAL]progesterone[\\CHEMICAL] (1) affects both menstruation and gestation via the [GENE]progesterone receptor[\\GENE] (PR), research aimed at modulating its activity is usually surrounded by controversy.",
        "label": 2,
        "major": 7,
        "len": 24
    },
    {
        "text": "Because [CHEMICAL]progesterone[\\CHEMICAL] (1) affects both menstruation and gestation via the progesterone receptor ([GENE]PR[\\GENE]), research aimed at modulating its activity is usually surrounded by controversy.",
        "label": 2,
        "major": 7,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Decitabine[\\CHEMICAL] inhibits [GENE]DNA methyltransferase[\\GENE] and has shown therapeutic effects in patients with hematologic malignancies.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "KIEs were measured on the arsenolysis of [CHEMICAL]5'-methylthioadenosine[\\CHEMICAL] (MTA) catalyzed by [GENE]MTAP[\\GENE] and were corrected for the forward commitment to catalysis.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "KIEs were measured on the arsenolysis of 5'-methylthioadenosine ([CHEMICAL]MTA[\\CHEMICAL]) catalyzed by [GENE]MTAP[\\GENE] and were corrected for the forward commitment to catalysis.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Blocking [CHEMICAL]retinyl ester[\\CHEMICAL] formation by a targeted knock down of [GENE]Lratb[\\GENE] results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.",
        "label": 9,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]ADP[\\CHEMICAL] initiates platelet aggregation by 'simultaneous activation of two [GENE]G protein-coupled receptors[\\GENE], P2Y1 and P2Y12.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]ADP[\\CHEMICAL] initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, [GENE]P2Y1[\\GENE] and P2Y12.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]ADP[\\CHEMICAL] initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and [GENE]P2Y12[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Our results imply that [GENE]P2Y12[\\GENE] has the potential to be inhibited by [CHEMICAL]ADP[\\CHEMICAL]/ATP analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Our results imply that [GENE]P2Y12[\\GENE] has the potential to be inhibited by ADP/[CHEMICAL]ATP[\\CHEMICAL] analogs, and it suggests that P2Y12 acts as a target of new drugs that inhibit platelet aggregation.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] decreased ERalpha expression, but not [GENE]ERbeta[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 7
    },
    {
        "text": "[CHEMICAL]Estradiol[\\CHEMICAL] (E2) stimulates BC cells proliferation by binding the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Estradiol[\\CHEMICAL] (E2) stimulates BC cells proliferation by binding the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "Estradiol ([CHEMICAL]E2[\\CHEMICAL]) stimulates BC cells proliferation by binding the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "Estradiol ([CHEMICAL]E2[\\CHEMICAL]) stimulates BC cells proliferation by binding the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Cadmium[\\CHEMICAL] induces mitogenic signaling in breast cancer cell by an [GENE]ERalpha[\\GENE]-dependent mechanism.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an [GENE]ERalpha[\\GENE]-dependent mechanism.",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating [GENE]Akt[\\GENE], ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and [GENE]PDGFRalpha[\\GENE] kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha [GENE]kinases[\\GENE] activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating [GENE]c-fos[\\GENE], c-jun and PDGFA by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, [GENE]c-jun[\\GENE] and PDGFA by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "In conclusion, our results indicate that [CHEMICAL]Cd[\\CHEMICAL] increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and [GENE]PDGFA[\\GENE] by an ERalpha-dependent mechanism.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] also increased ERK1/2, [GENE]Akt[\\GENE] and PDGFRalpha phosphorylation while ICI blocked it.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] also increased ERK1/2, Akt and [GENE]PDGFRalpha[\\GENE] phosphorylation while ICI blocked it.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] rapidly increased [GENE]c-jun[\\GENE], c-fos and PDGFA expression.",
        "label": 3,
        "major": 3,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] rapidly increased c-jun, [GENE]c-fos[\\GENE] and PDGFA expression.",
        "label": 3,
        "major": 3,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] rapidly increased c-jun, c-fos and [GENE]PDGFA[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 8
    },
    {
        "text": "[CHEMICAL]Cd[\\CHEMICAL] decreased [GENE]ERalpha[\\GENE] expression, but not ERbeta.",
        "label": 4,
        "major": 10,
        "len": 7
    },
    {
        "text": "In contrast to testosterone, [CHEMICAL]GnRH[\\CHEMICAL]-induced nuclear translocation did not transcriptionally activate the [GENE]androgen receptor[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 14
    },
    {
        "text": "Since the GnRH receptor has been shown to affect sex steroid hormone receptor function, we considered that part of [CHEMICAL]GnRH[\\CHEMICAL] analog actions on prostate cells may be mediated through modulation of the [GENE]human androgen receptor[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Gonadotropin-releasing hormone[\\CHEMICAL] functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving [GENE]Hic-5[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 20
    },
    {
        "text": "In this setting there is a [CHEMICAL]GnRH[\\CHEMICAL]-induced association and nuclear translocation of the [GENE]androgen receptor[\\GENE] with Hic-5.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "In this setting there is a [CHEMICAL]GnRH[\\CHEMICAL]-induced association and nuclear translocation of the androgen receptor with [GENE]Hic-5[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "GnRH-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the [CHEMICAL]GnRH[\\CHEMICAL]-induced nuclear translocation of a green fluorescent protein-tagged [GENE]human androgen receptor[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced c-Src activation resulted in the phosphorylation of expressed [GENE]Hic-5[\\GENE] and promoted its association with the human androgen receptor.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the [GENE]human androgen receptor[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "We then demonstrated that [CHEMICAL]GnRH[\\CHEMICAL] can also stimulate [GENE]androgen receptor[\\GENE] mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Gonadotropin-releasing hormone functionally antagonizes [CHEMICAL]testosterone[\\CHEMICAL] activation of the [GENE]human androgen receptor[\\GENE] in prostate cells through focal adhesion complexes involving Hic-5.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced [GENE]Pyk2[\\GENE] activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced [GENE]c-Src[\\GENE] activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "In contrast to [CHEMICAL]testosterone[\\CHEMICAL], GnRH-induced nuclear translocation did not transcriptionally activate the [GENE]androgen receptor[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced Pyk2 activation opposed the association of [GENE]Hic-5[\\GENE] with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]GnRH[\\CHEMICAL]-induced Pyk2 activation opposed the association of Hic-5 with [GENE]androgen receptor[\\GENE] as overexpression of a dominant negative Pyk2 enhanced the GnRH-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Gonadotropin-releasing hormone[\\CHEMICAL] functionally antagonizes testosterone activation of the [GENE]human androgen receptor[\\GENE] in prostate cells through focal adhesion complexes involving Hic-5.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "Recently, it was reported that [CHEMICAL]METH[\\CHEMICAL], AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that [CHEMICAL]METH[\\CHEMICAL], AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, [CHEMICAL]AMPH[\\CHEMICAL], POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, [CHEMICAL]AMPH[\\CHEMICAL], POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, [CHEMICAL]POHA[\\CHEMICAL], and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, [CHEMICAL]POHA[\\CHEMICAL], and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs [CHEMICAL]para-tyramine[\\CHEMICAL] (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs [CHEMICAL]para-tyramine[\\CHEMICAL] (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine ([CHEMICAL]TYR[\\CHEMICAL]) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine ([CHEMICAL]TYR[\\CHEMICAL]) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and [CHEMICAL]beta-phenylethylamine[\\CHEMICAL] (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and [CHEMICAL]beta-phenylethylamine[\\CHEMICAL] (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine ([CHEMICAL]PEA[\\CHEMICAL]) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing [GENE]rat trace amine-associated receptor 1[\\GENE] (rTAAR1).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine ([CHEMICAL]PEA[\\CHEMICAL]) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 ([GENE]rTAAR1[\\GENE]).",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "The discovery that [CHEMICAL]METH[\\CHEMICAL] and AMPH activate the [GENE]rTAAR1[\\GENE] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The discovery that METH and [CHEMICAL]AMPH[\\CHEMICAL] activate the [GENE]rTAAR1[\\GENE] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PEA[\\CHEMICAL] was a potent and full agonist at each species of [GENE]TAAR1[\\GENE], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.",
        "label": 5,
        "major": 5,
        "len": 29
    },
    {
        "text": "PEA was a potent and full agonist at each species of TAAR1, whereas [CHEMICAL]TYR[\\CHEMICAL] was a full agonist for the [GENE]rodent TAAR1s[\\GENE] but was a partial agonist at h-rChTAAR1.",
        "label": 5,
        "major": 5,
        "len": 29
    },
    {
        "text": "Interestingly, both isomers of [CHEMICAL]METH[\\CHEMICAL] were full agonists at [GENE]mTAAR1[\\GENE] and h-rChTAAR1, whereas both were partial agonists at rTAAR1.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "Interestingly, both isomers of [CHEMICAL]METH[\\CHEMICAL] were full agonists at mTAAR1 and [GENE]h-rChTAAR1[\\GENE], whereas both were partial agonists at rTAAR1.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "PEA was a potent and full agonist at each species of TAAR1, whereas [CHEMICAL]TYR[\\CHEMICAL] was a full agonist for the rodent TAAR1s but was a partial agonist at [GENE]h-rChTAAR1[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 29
    },
    {
        "text": "Interestingly, both isomers of [CHEMICAL]METH[\\CHEMICAL] were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at [GENE]rTAAR1[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "Finally, we showed that [CHEMICAL]chlorate[\\CHEMICAL] activated endocrine cell development by inducing [GENE]neurogenin 3[\\GENE] (Neurog3) expression in early endocrine progenitor cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Finally, we showed that [CHEMICAL]chlorate[\\CHEMICAL] activated endocrine cell development by inducing neurogenin 3 ([GENE]Neurog3[\\GENE]) expression in early endocrine progenitor cells.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Simple [CHEMICAL]benzenesulfonamides[\\CHEMICAL] were rather ineffective [GENE]hCA VI[\\GENE] inhibitors, with inhibition constants in the range of 1090-6680 nM.",
        "label": 10,
        "major": 4,
        "len": 17
    },
    {
        "text": "The metallic taste reported as a side effect after the treatment with systemic [CHEMICAL]sulfonamides[\\CHEMICAL] may be due to the inhibition of the [GENE]salivary CA VI[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, [CHEMICAL]dichlorophenamide[\\CHEMICAL], dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as [CHEMICAL]acetazolamide[\\CHEMICAL], methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, [CHEMICAL]methazolamide[\\CHEMICAL], ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, [CHEMICAL]ethoxzolamide[\\CHEMICAL], dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "DNA cloning, characterization, and inhibition studies of the [GENE]human secretory isoform VI[\\GENE], a new target for [CHEMICAL]sulfonamide[\\CHEMICAL] and sulfamate inhibitors.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "DNA cloning, characterization, and inhibition studies of the [GENE]human secretory isoform VI[\\GENE], a new target for sulfonamide and [CHEMICAL]sulfamate[\\CHEMICAL] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, [CHEMICAL]dorzolamide[\\CHEMICAL], brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, [CHEMICAL]brinzolamide[\\CHEMICAL], topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, [CHEMICAL]topiramate[\\CHEMICAL], sulpiride, and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, [CHEMICAL]sulpiride[\\CHEMICAL], and indisulam, or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and [CHEMICAL]indisulam[\\CHEMICAL], or the orphan drug benzolamide, showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug [CHEMICAL]benzolamide[\\CHEMICAL], showed effective [GENE]hCA VI[\\GENE] inhibitory activity, with inhibition constants of 0.8-79 nM.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The best inhibitors were [CHEMICAL]brinzolamide[\\CHEMICAL] and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a [GENE]CA VI[\\GENE]-selective inhibitor.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The best inhibitors were brinzolamide and [CHEMICAL]sulpiride[\\CHEMICAL] (KI values of 0.8-0.9 nM), the latter compound being also a [GENE]CA VI[\\GENE]-selective inhibitor.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant [CHEMICAL]CO2[\\CHEMICAL] hydrase activity of enamel [GENE]CA VI[\\GENE], which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.",
        "label": 9,
        "major": 9,
        "len": 46
    },
    {
        "text": "Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel [GENE]CA VI[\\GENE], which leads to the formation of protons and [CHEMICAL]bicarbonate[\\CHEMICAL] and may have a role in cariogenesis.",
        "label": 9,
        "major": 4,
        "len": 46
    },
    {
        "text": "Transmembrane isoforms of [GENE]adenylate cyclases[\\GENE] (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate [CHEMICAL]cAMP[\\CHEMICAL] production in response to calcium entry.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Transmembrane isoforms of adenylate cyclases ([GENE]AC[\\GENE]) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate [CHEMICAL]cAMP[\\CHEMICAL] production in response to calcium entry.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "Here, we report that the antifibrotic drug [CHEMICAL]5-methyl-1-phenyl-2-(1H)-pyridone[\\CHEMICAL] (pirfenidone, PFD) elicits growth-inhibitory effects and reduces [GENE]TGF-beta2[\\GENE] protein levels in human glioma cell lines.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone ([CHEMICAL]pirfenidone[\\CHEMICAL], PFD) elicits growth-inhibitory effects and reduces [GENE]TGF-beta2[\\GENE] protein levels in human glioma cell lines.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, [CHEMICAL]PFD[\\CHEMICAL]) elicits growth-inhibitory effects and reduces [GENE]TGF-beta2[\\GENE] protein levels in human glioma cell lines.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "This reduction in [GENE]TGF-beta2[\\GENE] is biologically relevant since [CHEMICAL]PFD[\\CHEMICAL] treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "This reduction in TGF-beta2 is biologically relevant since [CHEMICAL]PFD[\\CHEMICAL] treatment reduces the growth inhibition of [GENE]TGF-beta[\\GENE]-sensitive CCL-64 cells mediated by conditioned media of glioma cells.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of [GENE]TGF-beta2[\\GENE] mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature [GENE]TGF-beta2[\\GENE] protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the [GENE]TGF-beta[\\GENE] pro-protein convertase furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta [GENE]pro-protein convertase[\\GENE] furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase [GENE]furin[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, [CHEMICAL]PFD[\\CHEMICAL] reduces the protein levels of the [GENE]matrix metalloproteinase (MMP)-11[\\GENE], a TGF-beta target gene and furin substrate involved in carcinogenesis.",
        "label": 4,
        "major": 9,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Pirfenidone[\\CHEMICAL] inhibits [GENE]TGF-beta[\\GENE] expression in malignant glioma cells.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the [GENE]TGF-beta[\\GENE] pro-protein convertase furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta [GENE]pro-protein convertase[\\GENE] furin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]PFD[\\CHEMICAL] leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase [GENE]furin[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, [CHEMICAL]PFD[\\CHEMICAL] reduces the protein levels of the matrix metalloproteinase (MMP)-11, a [GENE]TGF-beta[\\GENE] target gene and furin substrate involved in carcinogenesis.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "UNLABELLED: [GENE]Bile acid-coenzyme A:amino acid N-acyltransferase[\\GENE] (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [CHEMICAL]taurine[\\CHEMICAL] and glycine.",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ([GENE]BAAT[\\GENE]) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [CHEMICAL]taurine[\\CHEMICAL] and glycine.",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "UNLABELLED: [GENE]Bile acid-coenzyme A:amino acid N-acyltransferase[\\GENE] (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and [CHEMICAL]glycine[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ([GENE]BAAT[\\GENE]) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and [CHEMICAL]glycine[\\CHEMICAL].",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "UNLABELLED: [GENE]Bile acid-coenzyme A:amino acid N-acyltransferase[\\GENE] (BAAT) is the sole enzyme responsible for conjugation of primary and secondary [CHEMICAL]bile acids[\\CHEMICAL] to taurine and glycine.",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase ([GENE]BAAT[\\GENE]) is the sole enzyme responsible for conjugation of primary and secondary [CHEMICAL]bile acids[\\CHEMICAL] to taurine and glycine.",
        "label": 9,
        "major": 1,
        "len": 24
    },
    {
        "text": "The absence or presence of a cytosolic pool of [GENE]BAAT[\\GENE] has important implications for the intracellular transport of unconjugated/deconjugated [CHEMICAL]bile salts[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the [GENE]riboflavin kinase[\\GENE], enzyme that converts riboflavin to [CHEMICAL]flavinmononucleotide[\\CHEMICAL]) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.",
        "label": 9,
        "major": 9,
        "len": 43
    },
    {
        "text": "The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the [GENE]riboflavin kinase[\\GENE], enzyme that converts [CHEMICAL]riboflavin[\\CHEMICAL] to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.",
        "label": 9,
        "major": 9,
        "len": 43
    },
    {
        "text": "Pre-steady-state currents in [GENE]neutral amino acid transporters[\\GENE] induced by photolysis of a new caged [CHEMICAL]alanine[\\CHEMICAL] derivative.",
        "label": 2,
        "major": 9,
        "len": 16
    },
    {
        "text": "Here, we describe a new photolabile [CHEMICAL]alanine[\\CHEMICAL] derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [GENE]ASCT2[\\GENE], SNAT1, and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile [CHEMICAL]alanine[\\CHEMICAL] derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [GENE]SNAT1[\\GENE], and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile [CHEMICAL]alanine[\\CHEMICAL] derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [GENE]SNAT2[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of [CHEMICAL]alanine[\\CHEMICAL] with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [GENE]ASCT2[\\GENE], SNAT1, and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of [CHEMICAL]alanine[\\CHEMICAL] with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [GENE]SNAT1[\\GENE], and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of [CHEMICAL]alanine[\\CHEMICAL] with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [GENE]SNAT2[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the [CHEMICAL]4-methoxy-7-nitroindolinyl[\\CHEMICAL] (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [GENE]ASCT2[\\GENE], SNAT1, and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the [CHEMICAL]4-methoxy-7-nitroindolinyl[\\CHEMICAL] (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [GENE]SNAT1[\\GENE], and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the [CHEMICAL]4-methoxy-7-nitroindolinyl[\\CHEMICAL] (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [GENE]SNAT2[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the [GENE]neutral amino acid transporters[\\GENE] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the [GENE]solute carrier 1[\\GENE] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[GENE]SLC1[\\GENE], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [GENE]alanine serine cysteine transporter 1[\\GENE] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([GENE]ASCT1[\\GENE]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [GENE]ASCT2[\\GENE]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and [GENE]SLC38[\\GENE] families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[GENE]sodium-coupled neutral amino acid transporter 1[\\GENE] (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([GENE]SNAT1[\\GENE]), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [GENE]SNAT2[\\GENE], and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral [CHEMICAL]amino acids[\\CHEMICAL], such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [GENE]SNAT4[\\GENE]].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ([CHEMICAL]MNI[\\CHEMICAL]) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [GENE]ASCT2[\\GENE], SNAT1, and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ([CHEMICAL]MNI[\\CHEMICAL]) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [GENE]SNAT1[\\GENE], and SNAT2.",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl ([CHEMICAL]MNI[\\CHEMICAL]) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [GENE]SNAT2[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 34
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the [GENE]neutral amino acid transporters[\\GENE] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the [GENE]solute carrier 1[\\GENE] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[GENE]SLC1[\\GENE], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [GENE]alanine serine cysteine transporter 1[\\GENE] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([GENE]ASCT1[\\GENE]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [GENE]ASCT2[\\GENE]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and [GENE]SLC38[\\GENE] families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[GENE]sodium-coupled neutral amino acid transporter 1[\\GENE] (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([GENE]SNAT1[\\GENE]), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [GENE]SNAT2[\\GENE], and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as [CHEMICAL]glutamine[\\CHEMICAL] and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [GENE]SNAT4[\\GENE]].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the [GENE]neutral amino acid transporters[\\GENE] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the [GENE]solute carrier 1[\\GENE] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[GENE]SLC1[\\GENE], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [GENE]alanine serine cysteine transporter 1[\\GENE] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([GENE]ASCT1[\\GENE]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [GENE]ASCT2[\\GENE]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[GENE]sodium-coupled neutral amino acid transporter 1[\\GENE] (SNAT1), SNAT2, and SNAT4].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([GENE]SNAT1[\\GENE]), SNAT2, and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [GENE]SNAT2[\\GENE], and SNAT4].",
        "label": 9,
        "major": 9,
        "len": 50
    },
    {
        "text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and [CHEMICAL]alanine[\\CHEMICAL], is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [GENE]SNAT4[\\GENE]].",
        "label": 9,
        "major": 1,
        "len": 50
    },
    {
        "text": "Reticulated platelets and uninhibited [GENE]COX-1[\\GENE] and COX-2 decrease the antiplatelet effects of [CHEMICAL]aspirin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 13
    },
    {
        "text": "Reticulated platelets and uninhibited COX-1 and [GENE]COX-2[\\GENE] decrease the antiplatelet effects of [CHEMICAL]aspirin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 13
    },
    {
        "text": "Immature (reticulated) platelets may modulate the antiplatelet effects of [CHEMICAL]aspirin[\\CHEMICAL] through uninhibited [GENE]cyclooxygenase[\\GENE] (COX)-1 and COX-2.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "Immature (reticulated) platelets may modulate the antiplatelet effects of [CHEMICAL]aspirin[\\CHEMICAL] through uninhibited cyclooxygenase [GENE](COX)-1[\\GENE] and COX-2.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "Immature (reticulated) platelets may modulate the antiplatelet effects of [CHEMICAL]aspirin[\\CHEMICAL] through uninhibited cyclooxygenase (COX)-1 and [GENE]COX-2[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 16
    },
    {
        "text": "Stimulated [GENE]P-selectin[\\GENE] and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after [CHEMICAL]aspirin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Stimulated P-selectin and [GENE]integrin alpha(IIb)beta(3)[\\GENE] expression were also higher in the upper tertile both before and after [CHEMICAL]aspirin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "We also found that [CHEMICAL]17beta-estradiol[\\CHEMICAL] protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and [GENE]ER[\\GENE]-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Moreover, [GENE]ERalpha[\\GENE] mediated the protection afforded by [CHEMICAL]estrogen[\\CHEMICAL] since only the ERalpha agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "Neuroprotection by [CHEMICAL]estrogen[\\CHEMICAL] against MPP+-induced dopamine neuron death is mediated by [GENE]ERalpha[\\GENE] in primary cultures of mouse mesencephalon.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Since glial cells were shown to express significant levels of [GENE]ERalpha[\\GENE], we investigated a possible indirect mechanism of [CHEMICAL]estrogen[\\CHEMICAL]-mediated neuroprotection through glial cell interaction.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the [GENE]ERbeta[\\GENE] agonist, [CHEMICAL]DPN[\\CHEMICAL], protected against dopamine cell loss.",
        "label": 5,
        "major": 10,
        "len": 25
    },
    {
        "text": "At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the [GENE]ER[\\GENE] antagonist, [CHEMICAL]ICI 182,780[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "[GENE]CREB[\\GENE]-dependent gene transcription, which may underlie long-lasting drug-induced changes in behavior and the subjective effects of [CHEMICAL]cocaine[\\CHEMICAL], varies depending on the stage of drug exposure or withdrawal and the cell population involved.",
        "label": 2,
        "major": 3,
        "len": 32
    },
    {
        "text": "The temporal and anatomical determinants of cocaine-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of [GENE]CREB[\\GENE] in early and late [CHEMICAL]cocaine[\\CHEMICAL] effects.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "Differential activation of [GENE]cAMP response element binding protein[\\GENE] in discrete nucleus accumbens subregions during early and late [CHEMICAL]cocaine[\\CHEMICAL] sensitization.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The temporal and anatomical determinants of [CHEMICAL]cocaine[\\CHEMICAL]-induced [GENE]CREB[\\GENE] activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The present study examined the differential [CHEMICAL]cocaine[\\CHEMICAL]-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein ([GENE]CREB[\\GENE]) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "The present study examined the differential [CHEMICAL]cocaine[\\CHEMICAL]-induced activation of the [GENE]cyclic adenosine monophosphate (cAMP) response element binding protein[\\GENE] (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Repeated [CHEMICAL]cocaine[\\CHEMICAL] resulted in [GENE]CREB[\\GENE] phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated cocaine, but rats challenged after 2 drug-free days yielded a more localized activation of CREB in the 3 most dorsomedial zones of the shell.",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "Repeated cocaine resulted in CREB phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated [CHEMICAL]cocaine[\\CHEMICAL], but rats challenged after 2 drug-free days yielded a more localized activation of [GENE]CREB[\\GENE] in the 3 most dorsomedial zones of the shell.",
        "label": 3,
        "major": 3,
        "len": 51
    },
    {
        "text": "Furthermore, with respect to [GENE]GSTM1[\\GENE] and GSTT1 there were statistically significant differences in [CHEMICAL]TTCA[\\CHEMICAL]-levels between genotypes among exposed workers but not among controls.",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "Furthermore, with respect to GSTM1 and [GENE]GSTT1[\\GENE] there were statistically significant differences in [CHEMICAL]TTCA[\\CHEMICAL]-levels between genotypes among exposed workers but not among controls.",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, [GENE]H3R[\\GENE] and H4R).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and [GENE]H4R[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] regulates many functions by binding to four [GENE]histamine G-coupled receptor proteins[\\GENE] (H1R, H2R, H3R and H4R).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] regulates many functions by binding to four histamine G-coupled receptor proteins ([GENE]H1R[\\GENE], H2R, H3R and H4R).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, [GENE]H2R[\\GENE], H3R and H4R).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "[CHEMICAL]RAMH[\\CHEMICAL] inhibition of cholangiocyte growth was associated with decreased cAMP levels and [GENE]PKA[\\GENE]/ERK1/2/Elk-1 phosphorylation.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]RAMH[\\CHEMICAL] inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/[GENE]ERK1/2[\\GENE]/Elk-1 phosphorylation.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]RAMH[\\CHEMICAL] inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/[GENE]Elk-1[\\GENE] phosphorylation.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "(2) Does in vivo administration of [CHEMICAL](R)-(alpha)-(-)-methylhistamine dihydrobromide[\\CHEMICAL] (RAMH) ([GENE]H3R[\\GENE] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide ([CHEMICAL]RAMH[\\CHEMICAL]) ([GENE]H3R[\\GENE] agonist), thioperamide maleate (H3R antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (H3R agonist), [CHEMICAL]thioperamide maleate[\\CHEMICAL] ([GENE]H3R[\\GENE] antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?",
        "label": 6,
        "major": 5,
        "len": 32
    },
    {
        "text": "[GENE]Proline dehydrogenase[\\GENE] (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [CHEMICAL]glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase ([GENE]PRODH[\\GENE]) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [CHEMICAL]glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase (PRODH) and [GENE]Delta(1)-pyrroline-5-carboxylate dehydrogenase[\\GENE] (P5CDH) catalyze the two-step oxidation of proline to [CHEMICAL]glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase ([GENE]P5CDH[\\GENE]) catalyze the two-step oxidation of proline to [CHEMICAL]glutamate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Finally, we demonstrate that [GENE]T. thermophilus PRODH[\\GENE] reacts with O(2) producing [CHEMICAL]superoxide[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "This is significant because [CHEMICAL]superoxide[\\CHEMICAL] production underlies the role of [GENE]human PRODH[\\GENE] in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "[GENE]Proline dehydrogenase[\\GENE] (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of [CHEMICAL]proline[\\CHEMICAL] to glutamate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase ([GENE]PRODH[\\GENE]) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of [CHEMICAL]proline[\\CHEMICAL] to glutamate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase (PRODH) and [GENE]Delta(1)-pyrroline-5-carboxylate dehydrogenase[\\GENE] (P5CDH) catalyze the two-step oxidation of [CHEMICAL]proline[\\CHEMICAL] to glutamate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase ([GENE]P5CDH[\\GENE]) catalyze the two-step oxidation of [CHEMICAL]proline[\\CHEMICAL] to glutamate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Finally, we demonstrate that [GENE]T. thermophilus PRODH[\\GENE] reacts with [CHEMICAL]O(2)[\\CHEMICAL] producing superoxide.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Results of early clinical trials with both topically ([CHEMICAL]cipamfylline[\\CHEMICAL], CP80,633) and systemically (CC-10004) active [GENE]PDE4[\\GENE] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Results of early clinical trials with both topically (cipamfylline, [CHEMICAL]CP80,633[\\CHEMICAL]) and systemically (CC-10004) active [GENE]PDE4[\\GENE] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Consequently, [GENE]PDE4[\\GENE] inhibitors including [CHEMICAL]cilomilast[\\CHEMICAL] and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Consequently, [GENE]PDE4[\\GENE] inhibitors including cilomilast and [CHEMICAL]AWD 12-281[\\CHEMICAL] have been tested in several models of allergic and irritant skin inflammation.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The C2 domains studied here both utilize the TAMA mechanism, in which the [GENE]C2 domain[\\GENE] [CHEMICAL]Ca2+[\\CHEMICAL] affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Ca2+[\\CHEMICAL] activation targets the [GENE]PKCalpha C2 domain[\\GENE] to the plasma membrane and the cPLA2alpha C2 domain to the internal membranes, with no detectable spatial overlap.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Ca2+[\\CHEMICAL] activation targets the PKCalpha C2 domain to the plasma membrane and the [GENE]cPLA2alpha C2 domain[\\GENE] to the internal membranes, with no detectable spatial overlap.",
        "label": 2,
        "major": 3,
        "len": 25
    },
    {
        "text": "For the [GENE]cPLA2alpha C2 domain[\\GENE], the target lipid [CHEMICAL]phosphatidylcholine[\\CHEMICAL] (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.",
        "label": 2,
        "major": 10,
        "len": 39
    },
    {
        "text": "Although considerable functional diversity exists, most [GENE]C2 domains[\\GENE] are activated by [CHEMICAL]Ca2+[\\CHEMICAL] binding and then dock to a specific cellular membrane.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "These data support the novel finding that [CHEMICAL]clofibrate[\\CHEMICAL] treatment does not directly regulate [GENE]BAT[\\GENE] activity but does alter the subcellular localization of BAT.",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "These data support the novel finding that [CHEMICAL]clofibrate[\\CHEMICAL] treatment does not directly regulate BAT activity but does alter the subcellular localization of [GENE]BAT[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 23
    },
    {
        "text": "[GENE]Bile acid coenzyme A:amino acid N-acyltransferase[\\GENE] (BAT) is responsible for the amidation of [CHEMICAL]bile acids[\\CHEMICAL] with the amino acids glycine and taurine.",
        "label": 9,
        "major": 1,
        "len": 22
    },
    {
        "text": "Bile acid coenzyme A:amino acid N-acyltransferase ([GENE]BAT[\\GENE]) is responsible for the amidation of [CHEMICAL]bile acids[\\CHEMICAL] with the amino acids glycine and taurine.",
        "label": 9,
        "major": 1,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Asparagine[\\CHEMICAL] secretion by MSCs was directly related to their [GENE]ASNS[\\GENE] expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.",
        "label": 9,
        "major": 3,
        "len": 32
    },
    {
        "text": "Stimulation of [GENE]NR1[\\GENE]/NR2A receptors with [CHEMICAL]NMDA[\\CHEMICAL]/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Stimulation of NR1/[GENE]NR2A[\\GENE] receptors with [CHEMICAL]NMDA[\\CHEMICAL]/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Stimulation of NR1/NR2A receptors with [CHEMICAL]NMDA[\\CHEMICAL]/glycine revealed an increase in intracellular calcium in cells pre-exposed to [GENE]Abeta(1-40)[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Stimulation of [GENE]NR1[\\GENE]/NR2A receptors with NMDA/[CHEMICAL]glycine[\\CHEMICAL] revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Stimulation of NR1/[GENE]NR2A[\\GENE] receptors with NMDA/[CHEMICAL]glycine[\\CHEMICAL] revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Stimulation of NR1/NR2A receptors with NMDA/[CHEMICAL]glycine[\\CHEMICAL] revealed an increase in intracellular calcium in cells pre-exposed to [GENE]Abeta(1-40)[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]MK-801[\\CHEMICAL] ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive [GENE]NMDA receptor[\\GENE] antagonist, partially prevented the decrease in cell viability and the energy impairment.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "MK-801 ([CHEMICAL](+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate[\\CHEMICAL]), a noncompetitive [GENE]NMDA receptor[\\GENE] antagonist, partially prevented the decrease in cell viability and the energy impairment.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of [CHEMICAL]ALA[\\CHEMICAL] suggests that the competition between 24:5n-3 and ALA for [GENE]D6D[\\GENE] may contribute to the limited accumulation of DHA in cell membranes.",
        "label": 0,
        "major": 3,
        "len": 37
    },
    {
        "text": "The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for [GENE]D6D[\\GENE] may contribute to the limited accumulation of [CHEMICAL]DHA[\\CHEMICAL] in cell membranes.",
        "label": 9,
        "major": 3,
        "len": 37
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of [CHEMICAL]DHA[\\CHEMICAL] from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from [CHEMICAL]ALA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "The accumulation of the post-[GENE]D6D[\\GENE] products of 22:5n-3, 24:6n-3 and [CHEMICAL]DHA[\\CHEMICAL], in cell phospholipids was saturated at concentrations of >18 microM ALA. Supplementation of HepG2 cells with preformed DHA revealed that, although the accumulation of DHA in cell phospholipids approached saturation, the level of DHA in cell phospholipids was significantly greater compared with the accumulation of DHA from ALA, indicating that the accumulation of DHA from ALA was not limited by incorporation.",
        "label": 9,
        "major": 10,
        "len": 72
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to [CHEMICAL]docosahexaenoic acid[\\CHEMICAL] (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to [CHEMICAL]docosahexaenoic acid[\\CHEMICAL] (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ([CHEMICAL]DHA[\\CHEMICAL]; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid ([CHEMICAL]DHA[\\CHEMICAL]; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of [CHEMICAL]DHA[\\CHEMICAL] from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from [CHEMICAL]ALA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of [CHEMICAL]alpha-linolenic acid[\\CHEMICAL] (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of [CHEMICAL]alpha-linolenic acid[\\CHEMICAL] (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of [GENE]Delta 6 desaturase[\\GENE] (D6D) twice in the conversion of alpha-linolenic acid ([CHEMICAL]ALA[\\CHEMICAL]; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The use of Delta 6 desaturase ([GENE]D6D[\\GENE]) twice in the conversion of alpha-linolenic acid ([CHEMICAL]ALA[\\CHEMICAL]; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA. We examined this using an in vitro model of fatty acid metabolism to measure the accumulation of the long-chain metabolites of ALA in HepG2 cell phospholipids.",
        "label": 9,
        "major": 9,
        "len": 66
    },
    {
        "text": "The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and [CHEMICAL]ALA[\\CHEMICAL] for [GENE]D6D[\\GENE] may contribute to the limited accumulation of DHA in cell membranes.",
        "label": 9,
        "major": 3,
        "len": 37
    },
    {
        "text": "Potential binding conformations of D1 and D2 receptors were obtained, and the [GENE]D1[\\GENE]-[CHEMICAL]SPD[\\CHEMICAL] and D2-SPD complexes were generated, which are in good agreement with most of experimental data.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Potential binding conformations of D1 and D2 receptors were obtained, and the D1-SPD and [GENE]D2[\\GENE]-[CHEMICAL]SPD[\\CHEMICAL] complexes were generated, which are in good agreement with most of experimental data.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "The [GENE]D1[\\GENE]-[CHEMICAL]SPD[\\CHEMICAL] structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of SPD.",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with [CHEMICAL]SPD[\\CHEMICAL] are crucial in understanding the structural and functional characteristics of [GENE]dopamine receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[GENE]Dopamine D1 receptor[\\GENE] agonist and D2 receptor antagonist effects of the natural product [CHEMICAL](-)-stepholidine[\\CHEMICAL]: molecular modeling and dynamics simulations.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "[CHEMICAL](-)-Stepholidine[\\CHEMICAL] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a [GENE]dopamine receptor D1[\\GENE] agonist and D2 antagonist.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "(-)-Stepholidine ([CHEMICAL]SPD[\\CHEMICAL]), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a [GENE]dopamine receptor D1[\\GENE] agonist and D2 antagonist.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "Dopamine D1 receptor agonist and [GENE]D2 receptor[\\GENE] antagonist effects of the natural product [CHEMICAL](-)-stepholidine[\\CHEMICAL]: molecular modeling and dynamics simulations.",
        "label": 6,
        "major": 9,
        "len": 19
    },
    {
        "text": "[CHEMICAL](-)-Stepholidine[\\CHEMICAL] (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [GENE]D2[\\GENE] antagonist.",
        "label": 6,
        "major": 5,
        "len": 28
    },
    {
        "text": "(-)-Stepholidine ([CHEMICAL]SPD[\\CHEMICAL]), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and [GENE]D2[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "The Ki for mycophenolic acid inhibition of the [GENE]L263F[\\GENE] variant was comparable with the wild-type, and the variant Km for [CHEMICAL]inosine 5'-monophosphate[\\CHEMICAL] and nicotinamide adenine dinucleotide did not change significantly.",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "The Ki for mycophenolic acid inhibition of the [GENE]L263F[\\GENE] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and [CHEMICAL]nicotinamide adenine dinucleotide[\\CHEMICAL] did not change significantly.",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "The Ki for [CHEMICAL]mycophenolic acid[\\CHEMICAL] inhibition of the [GENE]L263F[\\GENE] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "Reducing GSH levels in female mice CNS by pretreatment with [CHEMICAL]diethyl maleate[\\CHEMICAL] or L-propargyl glycine did not result in inhibition of [GENE]complex I[\\GENE] activity, unlike male mice.",
        "label": 10,
        "major": 4,
        "len": 27
    },
    {
        "text": "Reducing GSH levels in female mice CNS by pretreatment with diethyl maleate or [CHEMICAL]L-propargyl glycine[\\CHEMICAL] did not result in inhibition of [GENE]complex I[\\GENE] activity, unlike male mice.",
        "label": 10,
        "major": 4,
        "len": 27
    },
    {
        "text": "Further, treatment of female mice depleted of GSH with [CHEMICAL]L-BOAA[\\CHEMICAL] did not induce inhibition of [GENE]complex I[\\GENE] indicating that GSH levels were not critical for maintaining complex I activity in female mice unlike their male counterpart.",
        "label": 10,
        "major": 4,
        "len": 36
    },
    {
        "text": "Further, treatment of female mice depleted of GSH with L-BOAA did not induce inhibition of complex I indicating that [CHEMICAL]GSH[\\CHEMICAL] levels were not critical for maintaining [GENE]complex I[\\GENE] activity in female mice unlike their male counterpart.",
        "label": 10,
        "major": 4,
        "len": 36
    },
    {
        "text": "Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of [GENE]glutaredoxin[\\GENE] using antisense oligonucleotides sensitizes them to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity seen as mitochondrial complex I loss.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Ovariectomy downregulates [GENE]glutaredoxin[\\GENE] and renders female mice vulnerable to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of [GENE]glutaredoxin[\\GENE] in neuroprotection.",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity as evidenced by activation of [GENE]AP1[\\GENE], loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity as evidenced by activation of AP1, loss of GSH and [GENE]complex I[\\GENE] activity indicating the important role of glutaredoxin in neuroprotection.",
        "label": 3,
        "major": 4,
        "len": 32
    },
    {
        "text": "Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to [CHEMICAL]L-BOAA[\\CHEMICAL] toxicity seen as [GENE]mitochondrial complex I[\\GENE] loss.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]L-BOAA[\\CHEMICAL] causes loss of GSH and inhibition of [GENE]mitochondrial complex I[\\GENE] in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We have expressed [GENE]VIAAT[\\GENE] and the plasmalemmal transporters for glycine and [CHEMICAL]GABA[\\CHEMICAL] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "We have expressed VIAAT and the [GENE]plasmalemmal transporters[\\GENE] for glycine and [CHEMICAL]GABA[\\CHEMICAL] in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "We found that [CHEMICAL]glycine[\\CHEMICAL] is released from vesicles when [GENE]VIAAT[\\GENE] is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when [CHEMICAL]GABA[\\CHEMICAL] is introduced into the secretory cell and competes for uptake by [GENE]VIAAT[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports [CHEMICAL]glycine[\\CHEMICAL] exocytosis in the presence of [GENE]GlyT2[\\GENE], and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.",
        "label": 9,
        "major": 1,
        "len": 38
    },
    {
        "text": "Together, these results suggest that an increased cytosolic availability of [CHEMICAL]glycine[\\CHEMICAL] in [GENE]VIAAT[\\GENE]-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.",
        "label": 9,
        "major": 3,
        "len": 24
    },
    {
        "text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, [CHEMICAL]glycine[\\CHEMICAL] and GABA, share the same [GENE]vesicular inhibitory amino acid transporter[\\GENE] (VIAAT) and are both present in neurons during postnatal development.",
        "label": 9,
        "major": 10,
        "len": 42
    },
    {
        "text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, [CHEMICAL]glycine[\\CHEMICAL] and GABA, share the same vesicular inhibitory amino acid transporter ([GENE]VIAAT[\\GENE]) and are both present in neurons during postnatal development.",
        "label": 9,
        "major": 4,
        "len": 42
    },
    {
        "text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and [CHEMICAL]GABA[\\CHEMICAL], share the same [GENE]vesicular inhibitory amino acid transporter[\\GENE] (VIAAT) and are both present in neurons during postnatal development.",
        "label": 9,
        "major": 10,
        "len": 42
    },
    {
        "text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and [CHEMICAL]GABA[\\CHEMICAL], share the same vesicular inhibitory amino acid transporter ([GENE]VIAAT[\\GENE]) and are both present in neurons during postnatal development.",
        "label": 9,
        "major": 1,
        "len": 42
    },
    {
        "text": "We have expressed [GENE]VIAAT[\\GENE] and the plasmalemmal transporters for [CHEMICAL]glycine[\\CHEMICAL] and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "We have expressed VIAAT and the [GENE]plasmalemmal transporters[\\GENE] for [CHEMICAL]glycine[\\CHEMICAL] and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.",
        "label": 9,
        "major": 9,
        "len": 32
    },
    {
        "text": "Additionally, [CHEMICAL]Na+[\\CHEMICAL] and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on [GENE]KARs[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "Additionally, Na+ and [CHEMICAL]Cl-[\\CHEMICAL] ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on [GENE]KARs[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Na+[\\CHEMICAL]/Cl- dipole couples agonist binding to [GENE]kainate receptor[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 9
    },
    {
        "text": "Na+/[CHEMICAL]Cl-[\\CHEMICAL] dipole couples agonist binding to [GENE]kainate receptor[\\GENE] activation.",
        "label": 3,
        "major": 5,
        "len": 9
    },
    {
        "text": "[GENE]Kainate-selective ionotropic glutamate receptors[\\GENE] (GluRs) require external Na+ and Cl- as well as the neurotransmitter [CHEMICAL]L-glutamate[\\CHEMICAL] for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "Kainate-selective ionotropic glutamate receptors ([GENE]GluRs[\\GENE]) require external Na+ and Cl- as well as the neurotransmitter [CHEMICAL]L-glutamate[\\CHEMICAL] for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "[GENE]Kainate-selective ionotropic glutamate receptors[\\GENE] (GluRs) require external [CHEMICAL]Na+[\\CHEMICAL] and Cl- as well as the neurotransmitter L-glutamate for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "Kainate-selective ionotropic glutamate receptors ([GENE]GluRs[\\GENE]) require external [CHEMICAL]Na+[\\CHEMICAL] and Cl- as well as the neurotransmitter L-glutamate for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "[GENE]Kainate-selective ionotropic glutamate receptors[\\GENE] (GluRs) require external Na+ and [CHEMICAL]Cl-[\\CHEMICAL] as well as the neurotransmitter L-glutamate for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "Kainate-selective ionotropic glutamate receptors ([GENE]GluRs[\\GENE]) require external Na+ and [CHEMICAL]Cl-[\\CHEMICAL] as well as the neurotransmitter L-glutamate for activation.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "Additionally, [CHEMICAL]Na+[\\CHEMICAL] and Cl- ions coactivate [GENE]GluR6[\\GENE] receptors by establishing a dipole, accounting for their common effect on KARs.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Additionally, Na+ and [CHEMICAL]Cl-[\\CHEMICAL] ions coactivate [GENE]GluR6[\\GENE] receptors by establishing a dipole, accounting for their common effect on KARs.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "This effect probably involves interaction of [CHEMICAL]phenserine[\\CHEMICAL] with a regulatory element in the 5'-untranslated region of the [GENE]APP[\\GENE] gene that controls APP expression.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL] deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of [GENE]beta-amyloid precursor protein[\\GENE] (APP) in neuronal cell culture by reducing APP translation.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL] deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein ([GENE]APP[\\GENE]) in neuronal cell culture by reducing APP translation.",
        "label": 2,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL] apparently reduces translational efficiency of [GENE]APP[\\GENE] mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.",
        "label": 4,
        "major": 2,
        "len": 23
    },
    {
        "text": "As a consequence, [CHEMICAL]phenserine[\\CHEMICAL] reduces [GENE]beta-amyloid[\\GENE] peptide (Abeta) formation in vitro and in vivo.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "As a consequence, [CHEMICAL]phenserine[\\CHEMICAL] reduces beta-amyloid peptide ([GENE]Abeta[\\GENE]) formation in vitro and in vivo.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL] deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing [GENE]APP[\\GENE] translation.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL], a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ([GENE]AChE[\\GENE]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL], a derivative of physostigmine, was first described as an inhibitor of [GENE]acetylcholinesterase[\\GENE] (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Phenserine is also unique because of differing actions of its enantiomers: [CHEMICAL](-)-phenserine[\\CHEMICAL] is the active enantiomer for inhibition of [GENE]AChE[\\GENE], whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas [CHEMICAL](+)-phenserine[\\CHEMICAL] ('posiphen') has weak activity as an [GENE]AChE[\\GENE] inhibitor and can be dosed much higher.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('[CHEMICAL]posiphen[\\CHEMICAL]') has weak activity as an [GENE]AChE[\\GENE] inhibitor and can be dosed much higher.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Phenserine, a derivative of [CHEMICAL]physostigmine[\\CHEMICAL], was first described as an inhibitor of acetylcholinesterase ([GENE]AChE[\\GENE]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Phenserine, a derivative of [CHEMICAL]physostigmine[\\CHEMICAL], was first described as an inhibitor of [GENE]acetylcholinesterase[\\GENE] (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Phenserine[\\CHEMICAL] deserves attention for an additional quality of action: in addition to inhibiting [GENE]AChE[\\GENE], it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The [GENE]AMPK[\\GENE] inhibitor Compound C prevented the action of [CHEMICAL]metformin[\\CHEMICAL] and AICAR but not phenformin.",
        "label": 10,
        "major": 4,
        "len": 15
    },
    {
        "text": "The [GENE]AMPK[\\GENE] inhibitor Compound C prevented the action of metformin and [CHEMICAL]AICAR[\\CHEMICAL] but not phenformin.",
        "label": 10,
        "major": 4,
        "len": 15
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Activation of [GENE]alpha1-AMPK[\\GENE] is associated with inhibition of apical amiloride-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of [CHEMICAL]metformin[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical [GENE]amiloride-sensitive Na(+) channels[\\GENE] (ENaC), which has important implications for the clinical use of [CHEMICAL]metformin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive Na(+) channels ([GENE]ENaC[\\GENE]), which has important implications for the clinical use of [CHEMICAL]metformin[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Additional pharmacological effects evoked by [CHEMICAL]AICAR[\\CHEMICAL] and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, [GENE]ENaC[\\GENE] activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by [CHEMICAL]AICAR[\\CHEMICAL] and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where [GENE]Na+K+ATPase[\\GENE] is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and [CHEMICAL]phenformin[\\CHEMICAL] on I(ouabain), with potential secondary effects on apical Na+ conductance, [GENE]ENaC[\\GENE] activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and [CHEMICAL]phenformin[\\CHEMICAL] on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where [GENE]Na+K+ATPase[\\GENE] is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and phenformin on I([CHEMICAL]ouabain[\\CHEMICAL]), with potential secondary effects on apical Na+ conductance, [GENE]ENaC[\\GENE] activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and phenformin on I([CHEMICAL]ouabain[\\CHEMICAL]), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where [GENE]Na+K+ATPase[\\GENE] is an important component.",
        "label": 2,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by [CHEMICAL]AICAR[\\CHEMICAL] and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [GENE]AMPK[\\GENE] in cell systems where Na+K+ATPase is an important component.",
        "label": 3,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and [CHEMICAL]phenformin[\\CHEMICAL] on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [GENE]AMPK[\\GENE] in cell systems where Na+K+ATPase is an important component.",
        "label": 3,
        "major": 3,
        "len": 43
    },
    {
        "text": "Additional pharmacological effects evoked by AICAR and phenformin on I([CHEMICAL]ouabain[\\CHEMICAL]), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of [GENE]AMPK[\\GENE] in cell systems where Na+K+ATPase is an important component.",
        "label": 3,
        "major": 3,
        "len": 43
    },
    {
        "text": "BACKGROUND AND PURPOSE: [GENE]AMP-activated protein kinase[\\GENE] (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([CHEMICAL]AICAR[\\CHEMICAL]).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ([GENE]AMPK[\\GENE]) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside ([CHEMICAL]AICAR[\\CHEMICAL]).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: [GENE]AMP-activated protein kinase[\\GENE] (AMPK) is activated by [CHEMICAL]metformin[\\CHEMICAL], phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ([GENE]AMPK[\\GENE]) is activated by [CHEMICAL]metformin[\\CHEMICAL], phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: [GENE]AMP-activated protein kinase[\\GENE] (AMPK) is activated by metformin, [CHEMICAL]phenformin[\\CHEMICAL], and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ([GENE]AMPK[\\GENE]) is activated by metformin, [CHEMICAL]phenformin[\\CHEMICAL], and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "KEY RESULTS: [CHEMICAL]Phenformin[\\CHEMICAL], AICAR and metformin increased [GENE]AMPK (alpha1)[\\GENE] activity and decreased I(amiloride).",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "KEY RESULTS: Phenformin, [CHEMICAL]AICAR[\\CHEMICAL] and metformin increased [GENE]AMPK (alpha1)[\\GENE] activity and decreased I(amiloride).",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "KEY RESULTS: Phenformin, AICAR and [CHEMICAL]metformin[\\CHEMICAL] increased [GENE]AMPK (alpha1)[\\GENE] activity and decreased I(amiloride).",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "The [GENE]AMPK[\\GENE] inhibitor Compound C prevented the action of metformin and AICAR but not [CHEMICAL]phenformin[\\CHEMICAL].",
        "label": 3,
        "major": 10,
        "len": 15
    },
    {
        "text": "BACKGROUND AND PURPOSE: [GENE]AMP-activated protein kinase[\\GENE] (AMPK) is activated by metformin, phenformin, and the AMP mimetic, [CHEMICAL]5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside[\\CHEMICAL] (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase ([GENE]AMPK[\\GENE]) is activated by metformin, phenformin, and the AMP mimetic, [CHEMICAL]5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside[\\CHEMICAL] (AICAR).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Compared with normal control group, [CHEMICAL]PTZ[\\CHEMICAL]-kindled mice had significantly higher levels of malondialdehyde, nitrite, [GENE]myeloperoxidase[\\GENE] but had lower levels of reduced glutathione in the whole brain homogenate.",
        "label": 3,
        "major": 4,
        "len": 27
    },
    {
        "text": "Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or [CHEMICAL]rofecoxib[\\CHEMICAL] (selective [GENE]COX-2[\\GENE] inhibitor) against chemical kindling in mice.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "With this background, the present study was designed to explore the possible effect of [CHEMICAL]nimesulide[\\CHEMICAL] (a preferential [GENE]COX-2[\\GENE] inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Neuroprotective effect of [CHEMICAL]nimesulide[\\CHEMICAL], a preferential [GENE]COX-2[\\GENE] inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "These results suggested that [CHEMICAL]nimesulide[\\CHEMICAL], a preferential [GENE]COX-2[\\GENE] inhibitor offered neuroprotection against PTZ-induced kindling in mice.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Previous studies have explored the protective effect of [CHEMICAL]naproxen[\\CHEMICAL] (non-selective [GENE]COX[\\GENE]-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Brain cyclooxygenases ([GENE]COX[\\GENE]), the rate-limiting enzyme in [CHEMICAL]prostaglandin[\\CHEMICAL] synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "Brain [GENE]cyclooxygenases[\\GENE] (COX), the rate-limiting enzyme in [CHEMICAL]prostaglandin[\\CHEMICAL] synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "While vitamin C is essential for [GENE]PHD[\\GENE] activity in vitro, [CHEMICAL]N-acetyl-L-cysteine[\\CHEMICAL] had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three PHDs, demonstrating different functions of these antioxidants.",
        "label": 10,
        "major": 4,
        "len": 34
    },
    {
        "text": "While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and [CHEMICAL]gallic acid[\\CHEMICAL] or n-propyl gallate efficiently inhibited the activity of all three [GENE]PHDs[\\GENE], demonstrating different functions of these antioxidants.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or [CHEMICAL]n-propyl gallate[\\CHEMICAL] efficiently inhibited the activity of all three [GENE]PHDs[\\GENE], demonstrating different functions of these antioxidants.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in [CHEMICAL]eicosanoid[\\CHEMICAL] and glutathione metabolism that includes 5-lipoxygenase-activating protein, [GENE]microsomal glutathione S-transferases[\\GENE] (MGSTs), and microsomal prostaglandin E synthase 1 (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in [CHEMICAL]eicosanoid[\\CHEMICAL] and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases ([GENE]MGSTs[\\GENE]), and microsomal prostaglandin E synthase 1 (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in [CHEMICAL]eicosanoid[\\CHEMICAL] and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and [GENE]microsomal prostaglandin E synthase 1[\\GENE] (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and [CHEMICAL]glutathione[\\CHEMICAL] metabolism that includes 5-lipoxygenase-activating protein, [GENE]microsomal glutathione S-transferases[\\GENE] (MGSTs), and microsomal prostaglandin E synthase 1 (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and [CHEMICAL]glutathione[\\CHEMICAL] metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases ([GENE]MGSTs[\\GENE]), and microsomal prostaglandin E synthase 1 (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and [CHEMICAL]glutathione[\\CHEMICAL] metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and [GENE]microsomal prostaglandin E synthase 1[\\GENE] (ref.",
        "label": 9,
        "major": 3,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([GENE]GABA-T[\\GENE]), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] (PLZ), a nonselective irreversible inhibitor of [GENE]monoamine oxidase[\\GENE] (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] (PLZ), a nonselective irreversible inhibitor of monoamine oxidase ([GENE]MAO[\\GENE]), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits [GENE]GABA-transaminase[\\GENE] (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the [GENE]MAO[\\GENE] inhibitor [CHEMICAL]tranylcypromine[\\CHEMICAL] (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the [GENE]MAO[\\GENE] inhibitor tranylcypromine ([CHEMICAL]TCP[\\CHEMICAL]) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "[CHEMICAL]Phenelzine[\\CHEMICAL] causes an increase in brain ornithine that is prevented by prior [GENE]monoamine oxidase[\\GENE] inhibition.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([GENE]GABA-T[\\GENE]), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), a nonselective irreversible inhibitor of [GENE]monoamine oxidase[\\GENE] (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), a nonselective irreversible inhibitor of monoamine oxidase ([GENE]MAO[\\GENE]), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Phenelzine ([CHEMICAL]PLZ[\\CHEMICAL]), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits [GENE]GABA-transaminase[\\GENE] (GABA-T), markedly increasing brain GABA levels.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of [CHEMICAL]PLZ[\\CHEMICAL] formed by the action of [GENE]MAO[\\GENE] is responsible for the elevation of brain ORN observed.",
        "label": 9,
        "major": 3,
        "len": 62
    },
    {
        "text": "[CHEMICAL]PLZ[\\CHEMICAL] is also a substrate for [GENE]MAO[\\GENE], and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "As further support, [CHEMICAL]alpha-methyl-DL-aspartate[\\CHEMICAL], an inhibitor of [GENE]argininosuccinate synthase[\\GENE] (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "As further support, [CHEMICAL]alpha-methyl-DL-aspartate[\\CHEMICAL], an inhibitor of argininosuccinate synthase ([GENE]AS[\\GENE]), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Nitric oxide ([CHEMICAL]NO[\\CHEMICAL]) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Nitric oxide[\\CHEMICAL] (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Nitric oxide[\\CHEMICAL] (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Nitric oxide (NO) is an important vasorelaxant produced along with [CHEMICAL]L-citrulline[\\CHEMICAL] from L-arginine in a reaction catalyzed by [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Nitric oxide (NO) is an important vasorelaxant produced along with [CHEMICAL]L-citrulline[\\CHEMICAL] from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from [CHEMICAL]L-arginine[\\CHEMICAL] in a reaction catalyzed by [GENE]endothelial nitric oxide synthase[\\GENE] (eNOS).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from [CHEMICAL]L-arginine[\\CHEMICAL] in a reaction catalyzed by endothelial nitric oxide synthase ([GENE]eNOS[\\GENE]).",
        "label": 9,
        "major": 9,
        "len": 23
    },
    {
        "text": "It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than [CHEMICAL]citalopram[\\CHEMICAL] in binding to the [GENE]histamine H1[\\GENE] and muscarinic receptors.",
        "label": 2,
        "major": 2,
        "len": 52
    },
    {
        "text": "It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than [CHEMICAL]citalopram[\\CHEMICAL] in binding to the histamine H1 and [GENE]muscarinic receptors[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 52
    },
    {
        "text": "[CHEMICAL]AZD6140[\\CHEMICAL] is a reversible oral [GENE]P2Y(12)[\\GENE] receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "AZD6140 is a reversible oral [GENE]P2Y(12)[\\GENE] receptor antagonist that has been studied in ACS patients in comparison with [CHEMICAL]clopidogrel[\\CHEMICAL] (DISPERSE-2 study).",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Inhibition of platelet aggregation by AZD6140, a reversible oral [GENE]P2Y12[\\GENE] receptor antagonist, compared with [CHEMICAL]clopidogrel[\\CHEMICAL] in patients with acute coronary syndromes.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of platelet aggregation by [CHEMICAL]AZD6140[\\CHEMICAL], a reversible oral [GENE]P2Y12[\\GENE] receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "Compounds 1 and 2 potently displaced [CHEMICAL](3)H-NMS[\\CHEMICAL] binding at m1, m3 and m4 receptors, but were less potent at the [GENE]m2[\\GENE] and m5 subtypes.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Compounds 1 and 2 potently displaced [CHEMICAL](3)H-NMS[\\CHEMICAL] binding at m1, m3 and m4 receptors, but were less potent at the m2 and [GENE]m5[\\GENE] subtypes.",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Oxybutynin[\\CHEMICAL] (1) is a non-selective [GENE]muscarinic receptor[\\GENE] antagonist that is used clinically for the treatment of urinary incontinence.",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not [CHEMICAL]pilocarpine[\\CHEMICAL] (0.3 mg/kg for 7 days po), recovered the [GENE]AQP5[\\GENE] protein level reduced by CTD and increased the AQP1 protein level above the control one.",
        "label": 10,
        "major": 3,
        "len": 42
    },
    {
        "text": "Administration of [CHEMICAL]cevimeline hydrochloride[\\CHEMICAL], an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the [GENE]AQP5[\\GENE] protein level reduced by CTD and increased the AQP1 protein level above the control one.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "Administration of [CHEMICAL]cevimeline hydrochloride[\\CHEMICAL], an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the [GENE]AQP1[\\GENE] protein level above the control one.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "Administration of [CHEMICAL]chloroquine[\\CHEMICAL] (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the [GENE]AQP5[\\GENE] protein level reduced by CTD.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Degradation of submandibular gland [GENE]AQP5[\\GENE] by parasympathetic denervation of chorda tympani and its recovery by [CHEMICAL]cevimeline[\\CHEMICAL], an M3 muscarinic receptor agonist.",
        "label": 3,
        "major": 5,
        "len": 21
    },
    {
        "text": "Administration of [CHEMICAL]cevimeline hydrochloride[\\CHEMICAL], an [GENE]M3 muscarinic receptor[\\GENE] agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.",
        "label": 5,
        "major": 4,
        "len": 42
    },
    {
        "text": "Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by [CHEMICAL]cevimeline[\\CHEMICAL], an [GENE]M3 muscarinic receptor[\\GENE] agonist.",
        "label": 5,
        "major": 5,
        "len": 21
    },
    {
        "text": "In both rodent and primate animal models, the binding of radiolabeled [CHEMICAL]d-MPH[\\CHEMICAL] to [GENE]dopamine transporter[\\GENE] was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "In both rodent and primate animal models, the binding of radiolabeled d-MPH to [GENE]dopamine transporter[\\GENE] was found to be selective, saturable, and reversible, whereas binding of [CHEMICAL]l-MPH[\\CHEMICAL] was diffuse and nonspecific.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "The importance of [CHEMICAL]MPH[\\CHEMICAL] chirality to central nervous system [GENE]MPH receptor[\\GENE] targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas l-MPH binding is nonspecific.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "[CHEMICAL]threo-methylphenidate[\\CHEMICAL] inhibits the [GENE]dopamine transporter[\\GENE] and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]threo-methylphenidate[\\CHEMICAL] inhibits the dopamine transporter and the [GENE]norepinephrine transporter[\\GENE], resulting in elevations of these monoamines after impulse release.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "threo-methylphenidate inhibits the [GENE]dopamine transporter[\\GENE] and the norepinephrine transporter, resulting in elevations of these [CHEMICAL]monoamines[\\CHEMICAL] after impulse release.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "threo-methylphenidate inhibits the dopamine transporter and the [GENE]norepinephrine transporter[\\GENE], resulting in elevations of these [CHEMICAL]monoamines[\\CHEMICAL] after impulse release.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "The direct inhibition of [GENE]stathmin[\\GENE] by [CHEMICAL]CCNU[\\CHEMICAL] is likely a contributing factor.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Pharmacological and in silico investigations concerning the interactions of these compounds with the [GENE]hERG[\\GENE] channel revealed that compounds carrying a basic [CHEMICAL]nitrogen[\\CHEMICAL] in the side chain display a much higher affinity than those lacking such a group.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Specifically, [CHEMICAL]B2-O-CH(2)-CH(2)-N-piperidine[\\CHEMICAL] and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards [GENE]hERG[\\GENE] channels than amiodarone.",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "Specifically, B2-O-CH(2)-CH(2)-N-piperidine and [CHEMICAL]B2-O-CH(2)-CH(2)-N-pyrrolidine[\\CHEMICAL] revealed a higher affinity towards [GENE]hERG[\\GENE] channels than amiodarone.",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "Specifically, B2-O-CH(2)-CH(2)-N-piperidine and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards [GENE]hERG[\\GENE] channels than [CHEMICAL]amiodarone[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "Interaction with the [GENE]hERG[\\GENE] channel and cytotoxicity of [CHEMICAL]amiodarone[\\CHEMICAL] and amiodarone analogues.",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "Interaction with the [GENE]hERG[\\GENE] channel and cytotoxicity of amiodarone and [CHEMICAL]amiodarone[\\CHEMICAL] analogues.",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "CONCLUSIONS AND IMPLICATIONS: [CHEMICAL]Amiodarone[\\CHEMICAL] analogues with better [GENE]hERG[\\GENE] channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The principal aim of the study was to find [CHEMICAL]amiodarone[\\CHEMICAL] analogues that retained [GENE]human ether-a-go-go-related protein (hERG) channel[\\GENE] inhibition but with reduced cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "However, [GENE]holo-alpha-lactalbumin[\\GENE] was unable to bind [CHEMICAL]fatty acids[\\CHEMICAL] as measured by this technique.",
        "label": 10,
        "major": 2,
        "len": 13
    },
    {
        "text": "[GENE]Apo-alpha-lactalbumin[\\GENE], obtained by treatment with EDTA, displays one binding site for [CHEMICAL]fatty acids[\\CHEMICAL], the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "[GENE]Apo-alpha-lactalbumin[\\GENE], obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for [CHEMICAL]oleic and palmitic acids[\\CHEMICAL] being 1.9.10(6) and 4.2.10(5) M(-1), respectively.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The interaction of holo- and apo-forms of [GENE]human alpha-lactalbumin[\\GENE] with [CHEMICAL]fatty acids[\\CHEMICAL] was studied by a partition equilibrium method.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Interaction of [GENE]human alpha-lactalbumin[\\GENE] with [CHEMICAL]fatty acids[\\CHEMICAL]: determination of binding parameters.",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as [CHEMICAL]carbetocin[\\CHEMICAL] ([GENE]OT[\\GENE] agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",
        "label": 5,
        "major": 6,
        "len": 43
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP ([CHEMICAL]desmopressin[\\CHEMICAL], [GENE]V(2)[\\GENE] agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",
        "label": 5,
        "major": 6,
        "len": 43
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), [CHEMICAL]terlipressin[\\CHEMICAL] ([GENE]V(1a)[\\GENE] agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), [CHEMICAL]felypressin[\\CHEMICAL] ([GENE]V(1a)[\\GENE] agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.",
        "label": 5,
        "major": 5,
        "len": 43
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and [CHEMICAL]atosiban[\\CHEMICAL] (Tractocile [GENE]OT[\\GENE] antagonist) are also in clinical use.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban ([CHEMICAL]Tractocile[\\CHEMICAL] [GENE]OT[\\GENE] antagonist) are also in clinical use.",
        "label": 6,
        "major": 5,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide [GENE]V(2)[\\GENE] antagonists (Vaptans); notably, [CHEMICAL]Tolvaptan[\\CHEMICAL], Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide [GENE]V(2)[\\GENE] antagonists (Vaptans); notably, Tolvaptan, [CHEMICAL]Lixivaptan[\\CHEMICAL] and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide [GENE]V(2)[\\GENE] antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and [CHEMICAL]Satavaptan[\\CHEMICAL], are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed [GENE]V(2)[\\GENE]/V(1a), antagonist [CHEMICAL]Conivaptan[\\CHEMICAL] (Vaprisol), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/[GENE]V(1a)[\\GENE], antagonist [CHEMICAL]Conivaptan[\\CHEMICAL] (Vaprisol), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed [GENE]V(2)[\\GENE]/V(1a), antagonist Conivaptan ([CHEMICAL]Vaprisol[\\CHEMICAL]), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/[GENE]V(1a)[\\GENE], antagonist Conivaptan ([CHEMICAL]Vaprisol[\\CHEMICAL]), has been approved by the US FDA for clinical use (by i.v.",
        "label": 6,
        "major": 10,
        "len": 43
    },
    {
        "text": "In a Phase III trial comparing lapatinib and [CHEMICAL]capecitabine[\\CHEMICAL] with capecitabine alone in women with [GENE]HER2[\\GENE]-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).",
        "label": 2,
        "major": 3,
        "len": 82
    },
    {
        "text": "In a Phase III trial comparing lapatinib and capecitabine with [CHEMICAL]capecitabine[\\CHEMICAL] alone in women with [GENE]HER2[\\GENE]-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).",
        "label": 2,
        "major": 3,
        "len": 82
    },
    {
        "text": "In a Phase III trial comparing [CHEMICAL]lapatinib[\\CHEMICAL] and capecitabine with capecitabine alone in women with [GENE]HER2[\\GENE]-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).",
        "label": 2,
        "major": 3,
        "len": 82
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Lapatinib[\\CHEMICAL] is a dual inhibitor of the [GENE]EGFR[\\GENE] and HER2 tyrosine kinases.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Lapatinib[\\CHEMICAL] is a dual inhibitor of the EGFR and [GENE]HER2[\\GENE] tyrosine kinases.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Lapatinib[\\CHEMICAL] is a dual inhibitor of the EGFR and HER2 [GENE]tyrosine kinases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Lapatinib[\\CHEMICAL]: a dual inhibitor of [GENE]human epidermal growth factor receptor[\\GENE] tyrosine kinases.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Lapatinib[\\CHEMICAL]: a dual inhibitor of human epidermal growth factor receptor [GENE]tyrosine kinases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Lapatinib[\\CHEMICAL], the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 ([GENE]HER2[\\GENE]) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Lapatinib[\\CHEMICAL], the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) [GENE]tyrosine kinases[\\GENE], was approved by the US Food and Drug Administration (FDA) in 2007.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Lapatinib[\\CHEMICAL], the first dual inhibitor of [GENE]epidermal growth factor receptor[\\GENE] (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Lapatinib[\\CHEMICAL], the first dual inhibitor of epidermal growth factor receptor ([GENE]EGFR[\\GENE]) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "BACKGROUND: [CHEMICAL]Lapatinib[\\CHEMICAL], the first dual inhibitor of epidermal growth factor receptor (EGFR) and [GENE]human epidermal growth factor receptor 2[\\GENE] (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Lapatinib[\\CHEMICAL] is metabolized primarily by the [GENE]cytochrome P450 3A4[\\GENE] isozyme, with 1 metabolite remaining active against EGFR but not HER2.",
        "label": 9,
        "major": 10,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Quinpirole[\\CHEMICAL] and 7-OH-DPAT also increased the phosphorylation of [GENE]extracellular signal-regulated kinase[\\GENE] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Quinpirole[\\CHEMICAL] and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) within minutes, an effect blocked by pretreatment with SB-277011-A.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Quinpirole and [CHEMICAL]7-OH-DPAT[\\CHEMICAL] also increased the phosphorylation of [GENE]extracellular signal-regulated kinase[\\GENE] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Quinpirole and [CHEMICAL]7-OH-DPAT[\\CHEMICAL] also increased the phosphorylation of extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) within minutes, an effect blocked by pretreatment with SB-277011-A.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of [GENE]extracellular signal-regulated kinase[\\GENE] (ERK) within minutes, an effect blocked by pretreatment with [CHEMICAL]SB-277011-A[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase ([GENE]ERK[\\GENE]) within minutes, an effect blocked by pretreatment with [CHEMICAL]SB-277011-A[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective [GENE]D3 receptor[\\GENE] antagonist [CHEMICAL]SB-277011-A[\\CHEMICAL] at a low dose (50 nm).",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "Triphosphate nucleotides (ATP, GTP, and [CHEMICAL]UTP[\\CHEMICAL]) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of [GENE]purine receptors[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triphosphate nucleotides[\\CHEMICAL] (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of [GENE]purine receptors[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triphosphate nucleotides ([CHEMICAL]ATP[\\CHEMICAL], GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of [GENE]purine receptors[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triphosphate nucleotides (ATP, [CHEMICAL]GTP[\\CHEMICAL], and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of [GENE]purine receptors[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triphosphate nucleotides (ATP, GTP, and [CHEMICAL]UTP[\\CHEMICAL]) rapidly and reversibly inhibited [GENE]Panx1[\\GENE] currents via mechanism(s) independent of purine receptors.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: [CHEMICAL]carbenoxolone[\\CHEMICAL] > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > [CHEMICAL]disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate[\\CHEMICAL] (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate ([CHEMICAL]DIDS[\\CHEMICAL]) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately [CHEMICAL]disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate[\\CHEMICAL] approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately [CHEMICAL]5-nitro-2-(3-phenylpropylamino)benzoic acid[\\CHEMICAL] > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > [CHEMICAL]indanyloxyacetic acid 94[\\CHEMICAL] >> probenecid >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> [CHEMICAL]probenecid[\\CHEMICAL] >> flufenamic acid = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> [CHEMICAL]flufenamic acid[\\CHEMICAL] = niflumic acid.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We found compounds that inhibited [GENE]Panx1[\\GENE] currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = [CHEMICAL]niflumic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Triphosphate nucleotides[\\CHEMICAL] (ATP, GTP, and UTP) rapidly and reversibly inhibited [GENE]Panx1[\\GENE] currents via mechanism(s) independent of purine receptors.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triphosphate nucleotides ([CHEMICAL]ATP[\\CHEMICAL], GTP, and UTP) rapidly and reversibly inhibited [GENE]Panx1[\\GENE] currents via mechanism(s) independent of purine receptors.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Triphosphate nucleotides (ATP, [CHEMICAL]GTP[\\CHEMICAL], and UTP) rapidly and reversibly inhibited [GENE]Panx1[\\GENE] currents via mechanism(s) independent of purine receptors.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), [CHEMICAL]DIDS[\\CHEMICAL] was found to act as a [GENE]P2X(7)R[\\GENE] antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.",
        "label": 6,
        "major": 6,
        "len": 31
    },
    {
        "text": "[GENE]MMP-2[\\GENE] and MMP-9 expressions and activities in right ventricles increased significantly in [CHEMICAL]monocrotaline[\\CHEMICAL]-injected rats and captopril inhibited them.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "MMP-2 and [GENE]MMP-9[\\GENE] expressions and activities in right ventricles increased significantly in [CHEMICAL]monocrotaline[\\CHEMICAL]-injected rats and captopril inhibited them.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These findings indicate that captopril attenuates the development of [CHEMICAL]monocrotaline[\\CHEMICAL]-induced right ventricular hypertrophy in association with inhibition of [GENE]MMP-2[\\GENE] and MMP-9 in rats.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "These findings indicate that captopril attenuates the development of [CHEMICAL]monocrotaline[\\CHEMICAL]-induced right ventricular hypertrophy in association with inhibition of MMP-2 and [GENE]MMP-9[\\GENE] in rats.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "[GENE]MMP-2[\\GENE] and MMP-9 expressions and activities in right ventricles increased significantly in [CHEMICAL]monocrotaline[\\CHEMICAL]-injected rats and captopril inhibited them.",
        "label": 3,
        "major": 4,
        "len": 18
    },
    {
        "text": "MMP-2 and [GENE]MMP-9[\\GENE] expressions and activities in right ventricles increased significantly in [CHEMICAL]monocrotaline[\\CHEMICAL]-injected rats and captopril inhibited them.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[GENE]MMP-2[\\GENE] and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [CHEMICAL]captopril[\\CHEMICAL] inhibited them.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "MMP-2 and [GENE]MMP-9[\\GENE] expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [CHEMICAL]captopril[\\CHEMICAL] inhibited them.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[GENE]MMP-2[\\GENE] and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [CHEMICAL]captopril[\\CHEMICAL] inhibited them.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "MMP-2 and [GENE]MMP-9[\\GENE] expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and [CHEMICAL]captopril[\\CHEMICAL] inhibited them.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "These findings indicate that [CHEMICAL]captopril[\\CHEMICAL] attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of [GENE]MMP-2[\\GENE] and MMP-9 in rats.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These findings indicate that [CHEMICAL]captopril[\\CHEMICAL] attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and [GENE]MMP-9[\\GENE] in rats.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "We investigated the effect of [CHEMICAL]captopril[\\CHEMICAL], an [GENE]ACE[\\GENE] inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Examining the four X-ray crystal structures of their [GENE]CA II[\\GENE] adducts, we observed several (2-3) active site water molecules interacting with the [CHEMICAL]chlorthalidone[\\CHEMICAL], trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Examining the four X-ray crystal structures of their [GENE]CA II[\\GENE] adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, [CHEMICAL]trichloromethiazide[\\CHEMICAL], and furosemide scaffolds which may be responsible for this important difference of activity.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Examining the four X-ray crystal structures of their [GENE]CA II[\\GENE] adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and [CHEMICAL]furosemide[\\CHEMICAL] scaffolds which may be responsible for this important difference of activity.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Indeed, [CHEMICAL]indapamide[\\CHEMICAL] bound to [GENE]CA II[\\GENE] has no interactions with active site water molecules.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with [CHEMICAL]chlorthalidone[\\CHEMICAL], trichloromethiazide, and furosemide being efficient inhibitors against [GENE]CA II[\\GENE] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, [CHEMICAL]trichloromethiazide[\\CHEMICAL], and furosemide being efficient inhibitors against [GENE]CA II[\\GENE] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and [CHEMICAL]furosemide[\\CHEMICAL] being efficient inhibitors against [GENE]CA II[\\GENE] (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against [GENE]CA II[\\GENE] (K(I)s of 65-138 nM), whereas [CHEMICAL]indapamide[\\CHEMICAL] is a much weaker one (K(I) of 2520 nM).",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "[CHEMICAL]Thiazide[\\CHEMICAL] and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Thiazide[\\CHEMICAL] and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Thiazide[\\CHEMICAL] and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as [CHEMICAL]acetazolamide[\\CHEMICAL], methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) with a very different profile as compared to classical inhibitors, such as [CHEMICAL]acetazolamide[\\CHEMICAL], methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as [CHEMICAL]acetazolamide[\\CHEMICAL], methazolamide, and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, [CHEMICAL]methazolamide[\\CHEMICAL], and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) with a very different profile as compared to classical inhibitors, such as acetazolamide, [CHEMICAL]methazolamide[\\CHEMICAL], and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, [CHEMICAL]methazolamide[\\CHEMICAL], and ethoxzolamide.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase ([GENE]CA[\\GENE], EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and [CHEMICAL]ethoxzolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, [GENE]EC 4.2.1.1[\\GENE]) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and [CHEMICAL]ethoxzolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of [GENE]carbonic anhydrase[\\GENE] (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and [CHEMICAL]ethoxzolamide[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Sergliflozin etabonate[\\CHEMICAL] increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of [GENE]insulin[\\GENE] secretion in normal rats.",
        "label": 10,
        "major": 3,
        "len": 27
    },
    {
        "text": "Chronic treatment with [CHEMICAL]sergliflozin etabonate[\\CHEMICAL] reduced the levels of [GENE]glycated hemoglobin[\\GENE] and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "We discovered [CHEMICAL]sergliflozin etabonate[\\CHEMICAL], a novel selective [GENE]SGLT2[\\GENE] inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "We discovered [CHEMICAL]sergliflozin etabonate[\\CHEMICAL], a novel selective SGLT2 inhibitor, and found that selective inhibition of [GENE]SGLT2[\\GENE] increased urinary glucose excretion and consequently decreased plasma glucose levels.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an [GENE]alpha-glucosidase[\\GENE] inhibitor ([CHEMICAL]voglibose[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Sergliflozin etabonate[\\CHEMICAL], a selective [GENE]SGLT2[\\GENE] inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "The low-affinity [GENE]sodium glucose cotransporter[\\GENE] (SGLT2) is responsible for most of the [CHEMICAL]glucose[\\CHEMICAL] reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "The low-affinity sodium glucose cotransporter ([GENE]SGLT2[\\GENE]) is responsible for most of the [CHEMICAL]glucose[\\CHEMICAL] reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "A PKC or MAP kinase inhibitor blocked the inhibitory effect of [CHEMICAL]fenoldopam[\\CHEMICAL] on insulin receptor expression, indicating that [GENE]PKC[\\GENE] and MAP kinase were involved in the signaling pathway.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "A PKC or MAP kinase inhibitor blocked the inhibitory effect of [CHEMICAL]fenoldopam[\\CHEMICAL] on insulin receptor expression, indicating that PKC and [GENE]MAP kinase[\\GENE] were involved in the signaling pathway.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [CHEMICAL]fenoldopam[\\CHEMICAL], a D1-like receptor agonist, inhibited the stimulatory effect of [GENE]insulin[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "The inhibitory effect of [CHEMICAL]fenoldopam[\\CHEMICAL] on [GENE]insulin[\\GENE]-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.",
        "label": 4,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Fenoldopam[\\CHEMICAL] also inhibited [GENE]insulin receptor[\\GENE] mRNA and protein expression, which was time dependent and concentration dependent.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "A PKC or MAP kinase inhibitor blocked the inhibitory effect of [CHEMICAL]fenoldopam[\\CHEMICAL] on [GENE]insulin receptor[\\GENE] expression, indicating that PKC and MAP kinase were involved in the signaling pathway.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with [CHEMICAL]fenoldopam[\\CHEMICAL], a [GENE]D1-like receptor[\\GENE] agonist, inhibited the stimulatory effect of insulin.",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by [CHEMICAL]SCH23390[\\CHEMICAL], a [GENE]D1-like receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "The progress of the enzymatic reaction of the hydrolysis of [CHEMICAL]acetylthiocholine[\\CHEMICAL] at pH 8 in the presence of [GENE]AChE[\\GENE] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).",
        "label": 9,
        "major": 4,
        "len": 39
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, [CHEMICAL]trimedoxime[\\CHEMICAL], obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, [CHEMICAL]obidoxime[\\CHEMICAL] and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and [CHEMICAL]HI-6[\\CHEMICAL]) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and [CHEMICAL]diazepam[\\CHEMICAL] are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]atropine[\\CHEMICAL], [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended [CHEMICAL]pyridinium oximes[\\CHEMICAL] (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes ([CHEMICAL]pralidoxime[\\CHEMICAL], trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "atropine, [GENE]AChE[\\GENE] reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of [CHEMICAL]OP[\\CHEMICAL] poisoning in humans.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "The mechanism of [CHEMICAL]OP[\\CHEMICAL] poisoning involves inhibition of [GENE]acetylcholinesterase[\\GENE] (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The mechanism of [CHEMICAL]OP[\\CHEMICAL] poisoning involves inhibition of acetylcholinesterase ([GENE]AChE[\\GENE]) leading to inactivation of the enzyme which has an important role in neurotransmission.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "They act by reactivation of [GENE]AChE[\\GENE] inhibited by [CHEMICAL]OP[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 9
    },
    {
        "text": "[CHEMICAL](18)F-AV-45[\\CHEMICAL] displayed excellent binding affinity to [GENE]Abeta[\\GENE] plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "RESULTS: [CHEMICAL](18)F-AV-45[\\CHEMICAL] displayed a high binding affinity and specificity to [GENE]Abeta[\\GENE] plaques (K(d), 3.72 +/- 0.30 nM).",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Oral [CHEMICAL]palonosetron[\\CHEMICAL] is likely to be a useful addition to oral formulations of other [GENE]5-HT3 recepto[\\GENE]r antagonists in preventing CINV in patients receiving MEC.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Palonosetron[\\CHEMICAL] is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation [GENE]5-HT3 receptor[\\GENE] antagonists.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Palonosetron[\\CHEMICAL] is a second-generation [GENE]serotonin 5-HT3 receptor[\\GENE] antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "Two pure GnRH antagonists have been developed, [CHEMICAL]abarelix[\\CHEMICAL] and degarelix, that are devoid of any agonist effect on the [GENE]GnRH receptor[\\GENE] and consequently do not result in testosterone flare.",
        "label": 2,
        "major": 6,
        "len": 29
    },
    {
        "text": "Two pure GnRH antagonists have been developed, abarelix and [CHEMICAL]degarelix[\\CHEMICAL], that are devoid of any agonist effect on the [GENE]GnRH receptor[\\GENE] and consequently do not result in testosterone flare.",
        "label": 2,
        "major": 5,
        "len": 29
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as [CHEMICAL]buserelin[\\CHEMICAL], goserelin, leuprorelin and triptorelin, stimulate the pituitary's [GENE]gonadotrophin-releasing hormone (GnRH) receptor[\\GENE], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 3,
        "major": 5,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, [CHEMICAL]goserelin[\\CHEMICAL], leuprorelin and triptorelin, stimulate the pituitary's [GENE]gonadotrophin-releasing hormone (GnRH) receptor[\\GENE], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, [CHEMICAL]leuprorelin[\\CHEMICAL] and triptorelin, stimulate the pituitary's [GENE]gonadotrophin-releasing hormone (GnRH) receptor[\\GENE], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 3,
        "major": 5,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and [CHEMICAL]triptorelin[\\CHEMICAL], stimulate the pituitary's [GENE]gonadotrophin-releasing hormone (GnRH) receptor[\\GENE], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 3,
        "major": 4,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as [CHEMICAL]buserelin[\\CHEMICAL], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [GENE]LH[\\GENE] and testosterone levels.",
        "label": 4,
        "major": 5,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, [CHEMICAL]goserelin[\\CHEMICAL], leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [GENE]LH[\\GENE] and testosterone levels.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, [CHEMICAL]leuprorelin[\\CHEMICAL] and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [GENE]LH[\\GENE] and testosterone levels.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and [CHEMICAL]triptorelin[\\CHEMICAL], stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [GENE]LH[\\GENE] and testosterone levels.",
        "label": 4,
        "major": 5,
        "len": 32
    },
    {
        "text": "[GENE]Luteinizing hormone-releasing hormone[\\GENE] (LHRH) agonists, such as [CHEMICAL]buserelin[\\CHEMICAL], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone ([GENE]LHRH[\\GENE]) agonists, such as [CHEMICAL]buserelin[\\CHEMICAL], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "[GENE]Luteinizing hormone-releasing hormone[\\GENE] (LHRH) agonists, such as buserelin, [CHEMICAL]goserelin[\\CHEMICAL], leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 4,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone ([GENE]LHRH[\\GENE]) agonists, such as buserelin, [CHEMICAL]goserelin[\\CHEMICAL], leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "[GENE]Luteinizing hormone-releasing hormone[\\GENE] (LHRH) agonists, such as buserelin, goserelin, [CHEMICAL]leuprorelin[\\CHEMICAL] and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone ([GENE]LHRH[\\GENE]) agonists, such as buserelin, goserelin, [CHEMICAL]leuprorelin[\\CHEMICAL] and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 5,
        "len": 32
    },
    {
        "text": "[GENE]Luteinizing hormone-releasing hormone[\\GENE] (LHRH) agonists, such as buserelin, goserelin, leuprorelin and [CHEMICAL]triptorelin[\\CHEMICAL], stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 4,
        "len": 32
    },
    {
        "text": "Luteinizing hormone-releasing hormone ([GENE]LHRH[\\GENE]) agonists, such as buserelin, goserelin, leuprorelin and [CHEMICAL]triptorelin[\\CHEMICAL], stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.",
        "label": 5,
        "major": 3,
        "len": 32
    },
    {
        "text": "Two pure [GENE]GnRH[\\GENE] antagonists have been developed, [CHEMICAL]abarelix[\\CHEMICAL] and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.",
        "label": 6,
        "major": 5,
        "len": 29
    },
    {
        "text": "Two pure [GENE]GnRH[\\GENE] antagonists have been developed, abarelix and [CHEMICAL]degarelix[\\CHEMICAL], that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.",
        "label": 6,
        "major": 5,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Abarelix[\\CHEMICAL] was the first [GENE]GnRH[\\GENE] antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.",
        "label": 6,
        "major": 6,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Fulvestrant[\\CHEMICAL], a pure [GENE]estrogen receptor[\\GENE] downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "PURPOSE: XL184 ([CHEMICAL]cabozantinib[\\CHEMICAL]) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([GENE]VEGFR2[\\GENE]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: XL184 ([CHEMICAL]cabozantinib[\\CHEMICAL]) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and [GENE]RET[\\GENE], with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: XL184 ([CHEMICAL]cabozantinib[\\CHEMICAL]) is a potent inhibitor of [GENE]MET[\\GENE], vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: XL184 ([CHEMICAL]cabozantinib[\\CHEMICAL]) is a potent inhibitor of MET, [GENE]vascular endothelial growth factor receptor 2[\\GENE] (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: [CHEMICAL]XL184[\\CHEMICAL] (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([GENE]VEGFR2[\\GENE]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: [CHEMICAL]XL184[\\CHEMICAL] (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and [GENE]RET[\\GENE], with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: [CHEMICAL]XL184[\\CHEMICAL] (cabozantinib) is a potent inhibitor of [GENE]MET[\\GENE], vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "PURPOSE: [CHEMICAL]XL184[\\CHEMICAL] (cabozantinib) is a potent inhibitor of MET, [GENE]vascular endothelial growth factor receptor 2[\\GENE] (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Activity of [CHEMICAL]XL184[\\CHEMICAL] (Cabozantinib), an oral [GENE]tyrosine kinase[\\GENE] inhibitor, in patients with medullary thyroid cancer.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Activity of XL184 ([CHEMICAL]Cabozantinib[\\CHEMICAL]), an oral [GENE]tyrosine kinase[\\GENE] inhibitor, in patients with medullary thyroid cancer.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Whole-exome analysis of the [GENE]Pik3ca[\\GENE](H1047R)-driven mammary tumors identified multiple mutations, including [CHEMICAL]Trp[\\CHEMICAL]53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "Whole-exome analysis of the Pik3ca([GENE]H1047R[\\GENE])-driven mammary tumors identified multiple mutations, including [CHEMICAL]Trp[\\CHEMICAL]53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "Further, we used this model to test the efficacy of [CHEMICAL]GDC-0941[\\CHEMICAL], a [GENE]PI3K[\\GENE] inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Further, we used this model to test the efficacy of [CHEMICAL]GDC-0941[\\CHEMICAL], a PI3K inhibitor, in clinical development, and showed that the tumors respond to [GENE]PI3K[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "By synthesizing and testing a series of alanine point-mutated [GENE]cyclic peptides[\\GENE], we identified which [CHEMICAL]amino acid[\\CHEMICAL] was important for the inhibition of the phospholamban function.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which [CHEMICAL]amino acid[\\CHEMICAL] was important for the inhibition of the [GENE]phospholamban[\\GENE] function.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "The structures of active and inactive [CHEMICAL]alanine[\\CHEMICAL]-mutated [GENE]cyclic peptides[\\GENE], and of phospholamban (1-36), were determined by NMR.",
        "label": 1,
        "major": 1,
        "len": 17
    },
    {
        "text": "By synthesizing and testing a series of [CHEMICAL]alanine[\\CHEMICAL] point-mutated [GENE]cyclic peptides[\\GENE], we identified which amino acid was important for the inhibition of the phospholamban function.",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "However, chronic treatment of cLH rats with [CHEMICAL]MPEP[\\CHEMICAL] did not reverse learned helplessness, indicating that the enhanced [GENE]mGlu5 receptor[\\GENE] function is not the only player in the behavioral phenotype of this genetic model of depression.",
        "label": 3,
        "major": 10,
        "len": 35
    },
    {
        "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while [CHEMICAL]MS-275[\\CHEMICAL] or PEPA ([GENE]AMPA receptor[\\GENE] potentiator) failed to affect extinction acquisition in S1 mice.",
        "label": 3,
        "major": 4,
        "len": 49
    },
    {
        "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or [CHEMICAL]PEPA[\\CHEMICAL] ([GENE]AMPA receptor[\\GENE] potentiator) failed to affect extinction acquisition in S1 mice.",
        "label": 3,
        "major": 5,
        "len": 49
    },
    {
        "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of [CHEMICAL]valproic acid[\\CHEMICAL] (a GABAergic enhancer and [GENE]HDAC[\\GENE] inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",
        "label": 4,
        "major": 4,
        "len": 49
    },
    {
        "text": "Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or [CHEMICAL]MS-275[\\CHEMICAL] ([GENE]histone deacetylase[\\GENE] (HDAC) inhibitor), applied after extinction training.",
        "label": 4,
        "major": 5,
        "len": 23
    },
    {
        "text": "Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or [CHEMICAL]MS-275[\\CHEMICAL] (histone deacetylase ([GENE]HDAC[\\GENE]) inhibitor), applied after extinction training.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or [CHEMICAL]AMN082[\\CHEMICAL] [[GENE]metabotropic glutamate receptor 7[\\GENE] (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",
        "label": 5,
        "major": 4,
        "len": 49
    },
    {
        "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or [CHEMICAL]AMN082[\\CHEMICAL] [metabotropic glutamate receptor 7 ([GENE]mGlu7[\\GENE]) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.",
        "label": 5,
        "major": 4,
        "len": 49
    },
    {
        "text": "Electroencephalographic recordings during substance consumption showed reduced alpha activity and [GENE]P300[\\GENE] latencies in the [CHEMICAL]nicotine[\\CHEMICAL] group compared to the control group.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Our study determined whether there was a significant dose-dependent correlation between increasing [CHEMICAL]Hg[\\CHEMICAL] exposure from dental amalgams and [GENE]GST-\u03b1[\\GENE] and GST-\u03c0 as biomarkers of kidney integrity.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "Our study determined whether there was a significant dose-dependent correlation between increasing [CHEMICAL]Hg[\\CHEMICAL] exposure from dental amalgams and GST-\u03b1 and [GENE]GST-\u03c0[\\GENE] as biomarkers of kidney integrity.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] induces NF-\u03baB transcriptional activity leading to expression of several [GENE]chemokines[\\GENE] and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] induces NF-\u03baB transcriptional activity leading to expression of several chemokines and [GENE]cytokines[\\GENE], of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which [GENE]tumor necrosis factor alpha[\\GENE] (TNF-\u03b1) is the most important for single-agent tumor activity.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] induces NF-\u03baB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha ([GENE]TNF-\u03b1[\\GENE]) is the most important for single-agent tumor activity.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Toxicity profile of small-molecule IAP antagonist [CHEMICAL]GDC-0152[\\CHEMICAL] is linked to [GENE]TNF-\u03b1[\\GENE] pharmacology.",
        "label": 2,
        "major": 6,
        "len": 12
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] induces [GENE]NF-\u03baB[\\GENE] transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-\u03b1) is the most important for single-agent tumor activity.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]GDC-0152[\\CHEMICAL] is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing [GENE]IAPs[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Toxicity profile of small-molecule [GENE]IAP[\\GENE] antagonist [CHEMICAL]GDC-0152[\\CHEMICAL] is linked to TNF-\u03b1 pharmacology.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced [GENE]Tub[\\GENE]-p-[CHEMICAL]tyr[\\CHEMICAL] and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.",
        "label": 1,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]Tub[\\GENE] [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation (Tub-p-tyr) is modulated by nutritional status.",
        "label": 1,
        "major": 7,
        "len": 9
    },
    {
        "text": "[GENE]Tub[\\GENE] tyrosine phosphorylation (Tub-p-[CHEMICAL]tyr[\\CHEMICAL]) is modulated by nutritional status.",
        "label": 1,
        "major": 7,
        "len": 9
    },
    {
        "text": "Accordingly, in transfection experiments performed in TPC1 cells, treatment with [CHEMICAL]PJ34[\\CHEMICAL] increased NIS promoter activity without affecting [GENE]PARP-1[\\GENE] binding to the promoter sequence.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The PARP inhibitor [CHEMICAL]PJ34[\\CHEMICAL] modifies proliferation, [GENE]NIS[\\GENE] expression and epigenetic marks in thyroid cancer cell lines.",
        "label": 2,
        "major": 4,
        "len": 16
    },
    {
        "text": "Accordingly, in transfection experiments performed in TPC1 cells, treatment with [CHEMICAL]PJ34[\\CHEMICAL] increased [GENE]NIS promoter[\\GENE] activity without affecting PARP-1 binding to the promoter sequence.",
        "label": 3,
        "major": 2,
        "len": 23
    },
    {
        "text": "In TPC1, BCPAP, FRO, WRO cell lines [CHEMICAL]PJ34[\\CHEMICAL] induced a strong increase in [GENE]NIS[\\GENE] mRNA levels.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "We also investigated the epigenetic status of NIS promoter after [CHEMICAL]PJ34[\\CHEMICAL] treatment in TPC1 cell line: in addition to an increase of [GENE]histone modification activation marks[\\GENE] (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We also investigated the epigenetic status of NIS promoter after [CHEMICAL]PJ34[\\CHEMICAL] treatment in TPC1 cell line: in addition to an increase of histone modification activation marks ([GENE]H3K9K14ac[\\GENE], H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "We also investigated the epigenetic status of NIS promoter after [CHEMICAL]PJ34[\\CHEMICAL] treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, [GENE]H3K4me3[\\GENE]), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the [GENE]PARP[\\GENE] inhibitor [CHEMICAL]PJ34[\\CHEMICAL] on several properties of thyroid cancer cell lines was investigated.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "The [GENE]PARP[\\GENE] inhibitor [CHEMICAL]PJ34[\\CHEMICAL] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Both [CHEMICAL]apo-lycopenoic acids[\\CHEMICAL] also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in [GENE]NOX-4[\\GENE] and COX-2 expressions caused by CSE.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Both [CHEMICAL]apo-lycopenoic acids[\\CHEMICAL] also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and [GENE]COX-2[\\GENE] expressions caused by CSE.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Here, in expressing [CHEMICAL]cocaine[\\CHEMICAL]-hydrolyzing mutants of [GENE]BChE[\\GENE] in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.",
        "label": 9,
        "major": 1,
        "len": 37
    },
    {
        "text": "Second, feeding increased both the expression of [GENE]COX[\\GENE] isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with [CHEMICAL]cimetidine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We examined in cats the 1) ulcerogenic effects of selective [GENE]COX-1[\\GENE] ([CHEMICAL]SC-560[\\CHEMICAL], ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "We examined in cats the 1) ulcerogenic effects of selective [GENE]COX-1[\\GENE] (SC-560, [CHEMICAL]ketorolac[\\CHEMICAL]) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and [GENE]COX-2[\\GENE] ([CHEMICAL]celecoxib[\\CHEMICAL], meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and [GENE]COX-2[\\GENE] (celecoxib, [CHEMICAL]meloxicam[\\CHEMICAL]) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "Reversal of inhibition by [GENE]D2[\\GENE] agonist quinpirole was produced by serotonin (50 \u00b5M) and by [CHEMICAL]neurotensin[\\CHEMICAL] (5-10 nM).",
        "label": 3,
        "major": 5,
        "len": 18
    },
    {
        "text": "Reversal of inhibition by [GENE]D2[\\GENE] agonist quinpirole was produced by [CHEMICAL]serotonin[\\CHEMICAL] (50 \u00b5M) and by neurotensin (5-10 nM).",
        "label": 3,
        "major": 5,
        "len": 18
    },
    {
        "text": "Reversal of inhibition by [GENE]D2[\\GENE] agonist [CHEMICAL]quinpirole[\\CHEMICAL] was produced by serotonin (50 \u00b5M) and by neurotensin (5-10 nM).",
        "label": 5,
        "major": 5,
        "len": 18
    },
    {
        "text": "Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or [GENE]cPKC[\\GENE] antagonist [CHEMICAL]5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile[\\CHEMICAL] (G\u00f66976).",
        "label": 6,
        "major": 3,
        "len": 15
    },
    {
        "text": "Serotonin-induced or neurotensin-induced reversal was blocked by \u03b2-ARK1 inhibitor, dynasore, or [GENE]cPKC[\\GENE] antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile ([CHEMICAL]G\u00f66976[\\CHEMICAL]).",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "However, 4'G-RSV, but not [CHEMICAL]3G-RSV[\\CHEMICAL], induced [GENE]SIRT1[\\GENE]-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "However, 4'G-RSV, but not [CHEMICAL]3G-RSV[\\CHEMICAL], induced SIRT1-dependent [GENE]histone H3[\\GENE] deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 10,
        "major": 10,
        "len": 26
    },
    {
        "text": "However, 4'G-RSV, but not [CHEMICAL]3G-RSV[\\CHEMICAL], induced SIRT1-dependent histone H3 deacetylation and [GENE]SOD2[\\GENE] expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "However, [CHEMICAL]4'G-RSV[\\CHEMICAL], but not 3G-RSV, induced SIRT1-dependent [GENE]histone H3[\\GENE] deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "However, [CHEMICAL]4'G-RSV[\\CHEMICAL], but not 3G-RSV, induced [GENE]SIRT1[\\GENE]-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 3,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]RSV[\\CHEMICAL] targets and activates the [GENE]NAD(+)-dependent protein deacetylase SIRT1[\\GENE]; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]RSV[\\CHEMICAL] targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, [GENE]SIRT1[\\GENE] induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "However, [CHEMICAL]4'G-RSV[\\CHEMICAL], but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and [GENE]SOD2[\\GENE] expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.",
        "label": 3,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]RSV[\\CHEMICAL] targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing [GENE]mitochondrial superoxide dismutase[\\GENE] (SOD2).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]RSV[\\CHEMICAL] targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase ([GENE]SOD2[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "Hydrophobic [CHEMICAL]amino acids[\\CHEMICAL] in the hinge region of the [GENE]5A apolipoprotein[\\GENE] mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.",
        "label": 1,
        "major": 1,
        "len": 23
    },
    {
        "text": "These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the [GENE]ABCA1[\\GENE] transporter during the [CHEMICAL]cholesterol[\\CHEMICAL] efflux process.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "The bihelical [GENE]apolipoprotein mimetic peptide 5A[\\GENE] effluxes [CHEMICAL]cholesterol[\\CHEMICAL] from cells and reduces inflammation and atherosclerosis in animal models.",
        "label": 9,
        "major": 4,
        "len": 18
    },
    {
        "text": "Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing [CHEMICAL]cholesterol[\\CHEMICAL] by the [GENE]ABCA1[\\GENE] transporter.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting [CHEMICAL]cholesterol[\\CHEMICAL] efflux by the [GENE]ABCA1[\\GENE] transporter.",
        "label": 9,
        "major": 1,
        "len": 23
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the [GENE]GluK1[\\GENE] (GluR5)/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [CHEMICAL](3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid[\\CHEMICAL] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 10,
        "len": 51
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 ([GENE]GluR5[\\GENE])/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [CHEMICAL](3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid[\\CHEMICAL] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 10,
        "len": 51
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/[GENE]\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor[\\GENE] antagonist [CHEMICAL](3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid[\\CHEMICAL] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the [GENE]GluK1[\\GENE] (GluR5)/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([CHEMICAL]LY293558[\\CHEMICAL]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 10,
        "len": 51
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 ([GENE]GluR5[\\GENE])/\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([CHEMICAL]LY293558[\\CHEMICAL]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 10,
        "len": 51
    },
    {
        "text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/[GENE]\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor[\\GENE] antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([CHEMICAL]LY293558[\\CHEMICAL]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.",
        "label": 6,
        "major": 6,
        "len": 51
    },
    {
        "text": "Efficacy of the [GENE]GluK1[\\GENE]/AMPA receptor antagonist [CHEMICAL]LY293558[\\CHEMICAL] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Efficacy of the GluK1/[GENE]AMPA receptor[\\GENE] antagonist [CHEMICAL]LY293558[\\CHEMICAL] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Cellular release of [GENE]AChE[\\GENE] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists [CHEMICAL]carbachol[\\CHEMICAL] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 3,
        "major": 5,
        "len": 30
    },
    {
        "text": "Cellular release of [GENE]AChE[\\GENE] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or [CHEMICAL]muscarine[\\CHEMICAL], with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 3,
        "major": 6,
        "len": 30
    },
    {
        "text": "Cellular release of [GENE]AChE[\\GENE] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of [CHEMICAL]carbachol[\\CHEMICAL] blocked by the mAChR antagonist atropine.",
        "label": 3,
        "major": 5,
        "len": 30
    },
    {
        "text": "Cellular release of [GENE]AChE[\\GENE] by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist [CHEMICAL]atropine[\\CHEMICAL].",
        "label": 4,
        "major": 6,
        "len": 30
    },
    {
        "text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the [GENE]muscarinic acetylcholine receptor[\\GENE] (mAChR) agonists [CHEMICAL]carbachol[\\CHEMICAL] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 5,
        "major": 5,
        "len": 30
    },
    {
        "text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor ([GENE]mAChR[\\GENE]) agonists [CHEMICAL]carbachol[\\CHEMICAL] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 5,
        "major": 5,
        "len": 30
    },
    {
        "text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the [GENE]muscarinic acetylcholine receptor[\\GENE] (mAChR) agonists carbachol or [CHEMICAL]muscarine[\\CHEMICAL], with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 5,
        "major": 6,
        "len": 30
    },
    {
        "text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor ([GENE]mAChR[\\GENE]) agonists carbachol or [CHEMICAL]muscarine[\\CHEMICAL], with the effect of carbachol blocked by the mAChR antagonist atropine.",
        "label": 5,
        "major": 5,
        "len": 30
    },
    {
        "text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the [GENE]mAChR[\\GENE] antagonist [CHEMICAL]atropine[\\CHEMICAL].",
        "label": 6,
        "major": 5,
        "len": 30
    },
    {
        "text": "Nevertheless, low [CHEMICAL]L-BMAA[\\CHEMICAL] concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, [GENE]20S proteasomal[\\GENE] and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "Nevertheless, low [CHEMICAL]L-BMAA[\\CHEMICAL] concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and [GENE]caspase 12[\\GENE] activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "Nevertheless, low [CHEMICAL]L-BMAA[\\CHEMICAL] concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of [GENE]elf2\u03b1[\\GENE] in SH-SY5Y cells.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "Nevertheless, low [CHEMICAL]L-BMAA[\\CHEMICAL] concentrations (\u2265 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker [GENE]CHOP[\\GENE], and enhanced phosphorylation of elf2\u03b1 in SH-SY5Y cells.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]L-BMAA[\\CHEMICAL] induced ER stress and enhanced [GENE]caspase 12[\\GENE] cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These data suggest that [CHEMICAL]ribavirin[\\CHEMICAL]-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates [GENE]FVII[\\GENE] mRNA transcription elongation.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as [CHEMICAL]mycophenolic acid[\\CHEMICAL] and 6-mercaptopurine, up-regulated [GENE]F7[\\GENE] expression.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and [CHEMICAL]6-mercaptopurine[\\CHEMICAL], up-regulated [GENE]F7[\\GENE] expression.",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "We observed that [CHEMICAL]ribavirin[\\CHEMICAL] enhanced [GENE]ELL3[\\GENE] recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "We observed that [CHEMICAL]ribavirin[\\CHEMICAL] enhanced ELL3 recruitment to [GENE]F7[\\GENE], whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Ribavirin[\\CHEMICAL]-induced intracellular GTP depletion activates transcription elongation in [GENE]coagulation factor VII[\\GENE] gene expression.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished [CHEMICAL]ribavirin[\\CHEMICAL]-induced [GENE]FVII[\\GENE] mRNA up-regulation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These data suggest that [CHEMICAL]ribavirin[\\CHEMICAL]-induced intracellular GTP depletion recruits a super elongation complex containing [GENE]P-TEFb[\\GENE], AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.",
        "label": 3,
        "major": 7,
        "len": 26
    },
    {
        "text": "These data suggest that [CHEMICAL]ribavirin[\\CHEMICAL]-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, [GENE]AFF4[\\GENE] and ELL3, to F7, and modulates FVII mRNA transcription elongation.",
        "label": 3,
        "major": 7,
        "len": 26
    },
    {
        "text": "These data suggest that [CHEMICAL]ribavirin[\\CHEMICAL]-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and [GENE]ELL3[\\GENE], to F7, and modulates FVII mRNA transcription elongation.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "These data suggest that [CHEMICAL]ribavirin[\\CHEMICAL]-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to [GENE]F7[\\GENE], and modulates FVII mRNA transcription elongation.",
        "label": 3,
        "major": 7,
        "len": 26
    },
    {
        "text": "Collectively, we have elucidated a basal mechanism for [CHEMICAL]ribavirin[\\CHEMICAL]-induced [GENE]FVII[\\GENE] mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in\u00a0vivo.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "In the present study, we investigated the molecular mechanism of [CHEMICAL]ribavirin[\\CHEMICAL]-induced up-regulation of [GENE]F7[\\GENE] expression in HepG2 (human hepatoma cell line).",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Neuropeptide Y Y1 receptor knockdown can modify [GENE]glutathione peroxidase[\\GENE] and c-AMP response element-binding protein in [CHEMICAL]phenylpropanolamine[\\CHEMICAL]-treated rats.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and [GENE]c-AMP response element-binding protein[\\GENE] in [CHEMICAL]phenylpropanolamine[\\CHEMICAL]-treated rats.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of [GENE]PKC[\\GENE] by [CHEMICAL]phorbol 12-myristate,13-acetate[\\CHEMICAL] potentiated GluK2/GluK5.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by [CHEMICAL]phorbol 12-myristate,13-acetate[\\CHEMICAL] potentiated [GENE]GluK2[\\GENE]/GluK5.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by [CHEMICAL]phorbol 12-myristate,13-acetate[\\CHEMICAL] potentiated GluK2/[GENE]GluK5[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "The potentiation of heteromeric [GENE]KARs[\\GENE] by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator [CHEMICAL]1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid[\\CHEMICAL] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by [GENE]mGlu1[\\GENE] activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator [CHEMICAL]1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid[\\CHEMICAL] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric [GENE]KARs[\\GENE] by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ([CHEMICAL]BAPTA[\\CHEMICAL]), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by [GENE]mGlu1[\\GENE] activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ([CHEMICAL]BAPTA[\\CHEMICAL]), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the [GENE]phosphatase[\\GENE] inhibitor [CHEMICAL]okadaic acid[\\CHEMICAL], but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric [GENE]KARs[\\GENE] by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor [CHEMICAL]okadaic acid[\\CHEMICAL], but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by [GENE]mGlu1[\\GENE] activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor [CHEMICAL]okadaic acid[\\CHEMICAL], but unaffected by the tyrosine kinase inhibitor lavendustin A.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the [GENE]tyrosine kinase[\\GENE] inhibitor [CHEMICAL]lavendustin A[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric [GENE]KARs[\\GENE] by mGlu1 activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor [CHEMICAL]lavendustin A[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "The potentiation of heteromeric KARs by [GENE]mGlu1[\\GENE] activation was attenuated by GDP\u03b2S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor [CHEMICAL]lavendustin A[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Fingolimod[\\CHEMICAL] (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different [GENE]sphingosine-1-phosphate receptor[\\GENE] (S1PR) subtypes.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Fingolimod[\\CHEMICAL] (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor ([GENE]S1PR[\\GENE]) subtypes.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Fingolimod ([CHEMICAL]FTY720[\\CHEMICAL]), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different [GENE]sphingosine-1-phosphate receptor[\\GENE] (S1PR) subtypes.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Fingolimod ([CHEMICAL]FTY720[\\CHEMICAL]), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor ([GENE]S1PR[\\GENE]) subtypes.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective [GENE]type-1 S1PR[\\GENE] (S1P1R) antagonist, [CHEMICAL]W146[\\CHEMICAL], and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.",
        "label": 6,
        "major": 4,
        "len": 31
    },
    {
        "text": "Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR ([GENE]S1P1R[\\GENE]) antagonist, [CHEMICAL]W146[\\CHEMICAL], and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.",
        "label": 6,
        "major": 4,
        "len": 31
    },
    {
        "text": "The disposition of [CHEMICAL]anagliptin[\\CHEMICAL], an orally active, highly selective [GENE]dipeptidyl peptidase-4[\\GENE] inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Pharmacokinetics and metabolism of [CHEMICAL][(14)C]anagliptin[\\CHEMICAL], a novel [GENE]dipeptidyl peptidase-4[\\GENE] inhibitor, in humans.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [CHEMICAL]anagliptin[\\CHEMICAL] may be a substrate of [GENE]OAT1[\\GENE], OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [CHEMICAL]anagliptin[\\CHEMICAL] may be a substrate of OAT1, [GENE]OAT3[\\GENE], MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [CHEMICAL]anagliptin[\\CHEMICAL] may be a substrate of OAT1, OAT3, [GENE]MDR1[\\GENE] and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that [CHEMICAL]anagliptin[\\CHEMICAL] may be a substrate of OAT1, OAT3, MDR1 and [GENE]MRP2[\\GENE], and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Antiretroviral [GENE]protease[\\GENE] inhibitors [CHEMICAL]lopinavir[\\CHEMICAL] (LPV) and ritonavir (RTV) are reported BSEP inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral protease inhibitors [CHEMICAL]lopinavir[\\CHEMICAL] (LPV) and ritonavir (RTV) are reported [GENE]BSEP[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral [GENE]protease[\\GENE] inhibitors lopinavir ([CHEMICAL]LPV[\\CHEMICAL]) and ritonavir (RTV) are reported BSEP inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral protease inhibitors lopinavir ([CHEMICAL]LPV[\\CHEMICAL]) and ritonavir (RTV) are reported [GENE]BSEP[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral [GENE]protease[\\GENE] inhibitors lopinavir (LPV) and [CHEMICAL]ritonavir[\\CHEMICAL] (RTV) are reported BSEP inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral protease inhibitors lopinavir (LPV) and [CHEMICAL]ritonavir[\\CHEMICAL] (RTV) are reported [GENE]BSEP[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral [GENE]protease[\\GENE] inhibitors lopinavir (LPV) and ritonavir ([CHEMICAL]RTV[\\CHEMICAL]) are reported BSEP inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir ([CHEMICAL]RTV[\\CHEMICAL]) are reported [GENE]BSEP[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "The altered activities of key enzymes such as [GENE]glucose-6-phosphatase[\\GENE] and fructose-1,6-bisphosphatase of [CHEMICAL]carbohydrate[\\CHEMICAL] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).",
        "label": 9,
        "major": 4,
        "len": 50
    },
    {
        "text": "The altered activities of key enzymes such as glucose-6-phosphatase and [GENE]fructose-1,6-bisphosphatase[\\GENE] of [CHEMICAL]carbohydrate[\\CHEMICAL] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).",
        "label": 9,
        "major": 3,
        "len": 50
    },
    {
        "text": "In contrast, [CHEMICAL]ibandronate[\\CHEMICAL] did not affect [GENE]FAS[\\GENE] and DNMT1 expression in MC3T3-E1 non-neoplastic cells.",
        "label": 10,
        "major": 10,
        "len": 14
    },
    {
        "text": "In contrast, [CHEMICAL]ibandronate[\\CHEMICAL] did not affect FAS and [GENE]DNMT1[\\GENE] expression in MC3T3-E1 non-neoplastic cells.",
        "label": 10,
        "major": 10,
        "len": 14
    },
    {
        "text": "Further we found stimulation of [GENE]FAS[\\GENE]-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both [CHEMICAL]geranylgeranyl-pyrophosphate[\\CHEMICAL] and farnesylpyrophosphate.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Further we found stimulation of [GENE]FAS[\\GENE]-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [CHEMICAL]farnesylpyrophosphate[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "Data suggest that [CHEMICAL]bisphosphonates[\\CHEMICAL] via modulation of the activity of small-[GENE]GTPases[\\GENE] induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Data suggest that [CHEMICAL]bisphosphonates[\\CHEMICAL] via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-[GENE]CpG[\\GENE]-demethylation and stimulation of FAS-expression.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Ibandronate[\\CHEMICAL] increases the expression of the pro-apoptotic gene [GENE]FAS[\\GENE] by epigenetic mechanisms in tumor cells.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Data suggest that [CHEMICAL]bisphosphonates[\\CHEMICAL] via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of [GENE]FAS[\\GENE]-expression.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [GENE]DNMT1[\\GENE], which was rescued by re-isoprenylation by both [CHEMICAL]geranylgeranyl-pyrophosphate[\\CHEMICAL] and farnesylpyrophosphate.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of [GENE]DNMT1[\\GENE], which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and [CHEMICAL]farnesylpyrophosphate[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] had no effect on [GENE]AR[\\GENE] activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells.",
        "label": 10,
        "major": 3,
        "len": 22
    },
    {
        "text": "In conclusion, the CAG length dependent effect of [CHEMICAL]TCDD[\\CHEMICAL] on [GENE]AR[\\GENE] activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of TCDD on AR activity.",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "In conclusion, the CAG length dependent effect of TCDD on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of [CHEMICAL]TCDD[\\CHEMICAL] on [GENE]AR[\\GENE] activity.",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] acts through the [GENE]aryl hydrocarbon receptor[\\GENE] (AhR), which interacts with the androgen receptor (AR).",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] acts through the aryl hydrocarbon receptor ([GENE]AhR[\\GENE]), which interacts with the androgen receptor (AR).",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "The [GENE]AhR[\\GENE] target gene CYP1A1 mRNA expression was induced by [CHEMICAL]TCDD[\\CHEMICAL], but was not affected by the AR CAG length.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "TCDD had no effect on AR activity in PC-3 cells, whereas the shortest [GENE]AR[\\GENE] variant was induced by [CHEMICAL]TCDD[\\CHEMICAL] in PNT1A cells.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "The AhR target gene [GENE]CYP1A1[\\GENE] mRNA expression was induced by [CHEMICAL]TCDD[\\CHEMICAL], but was not affected by the AR CAG length.",
        "label": 3,
        "major": 10,
        "len": 20
    },
    {
        "text": "Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several cytokines in mice and replacement of plasmid by [CHEMICAL]polyglutamate[\\CHEMICAL] reduced the elevation of all assayed [GENE]cytokines[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 33
    },
    {
        "text": "However, down-regulation of [GENE]ATF4[\\GENE] and/or CHOP expression by siRNA had no effect on [CHEMICAL]helenalin[\\CHEMICAL]-induced apoptosis in Caki and HCT116 cells.",
        "label": 10,
        "major": 4,
        "len": 20
    },
    {
        "text": "However, down-regulation of ATF4 and/or [GENE]CHOP[\\GENE] expression by siRNA had no effect on [CHEMICAL]helenalin[\\CHEMICAL]-induced apoptosis in Caki and HCT116 cells.",
        "label": 10,
        "major": 4,
        "len": 20
    },
    {
        "text": "We found that [CHEMICAL]helenalin[\\CHEMICAL] markedly induced endoplasmic reticulum (ER) stress-related genes, such as [GENE]regulated in development and DNA damage responses (REDD) 1[\\GENE], activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "We found that [CHEMICAL]helenalin[\\CHEMICAL] markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, [GENE]activating transcription factor-4[\\GENE] (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "We found that [CHEMICAL]helenalin[\\CHEMICAL] markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 ([GENE]ATF4[\\GENE]) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "We found that [CHEMICAL]helenalin[\\CHEMICAL] markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the [GENE]CCAAT enhancer-binding protein-homologous protein[\\GENE] (CHOP).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "We found that [CHEMICAL]helenalin[\\CHEMICAL] markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein ([GENE]CHOP[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "In conclusion, [GENE]rCtr1[\\GENE] can transport copper and [CHEMICAL]platinum[\\CHEMICAL] drugs, and sensitizes cells to their cytotoxicities.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "DRG neurons display substantial capacity for accumulating [CHEMICAL]copper[\\CHEMICAL] via a transport process mediated by [GENE]rCtr1[\\GENE], but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "DRG neurons display substantial capacity for accumulating copper via a transport process mediated by [GENE]rCtr1[\\GENE], but appear able to resist copper toxicity and use alternative mechanisms to take up [CHEMICAL]oxaliplatin[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 30
    },
    {
        "text": "Heterologous expression of [GENE]rCtr1[\\GENE] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of [CHEMICAL]copper[\\CHEMICAL], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/[GENE]rCtr1[\\GENE] cells) increased the uptake and cytotoxicity of [CHEMICAL]copper[\\CHEMICAL], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of [GENE]rCtr1[\\GENE] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, [CHEMICAL]oxaliplatin[\\CHEMICAL], cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/[GENE]rCtr1[\\GENE] cells) increased the uptake and cytotoxicity of copper, [CHEMICAL]oxaliplatin[\\CHEMICAL], cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of [GENE]rCtr1[\\GENE] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, [CHEMICAL]cisplatin[\\CHEMICAL] and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/[GENE]rCtr1[\\GENE] cells) increased the uptake and cytotoxicity of copper, oxaliplatin, [CHEMICAL]cisplatin[\\CHEMICAL] and carboplatin, in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of [GENE]rCtr1[\\GENE] in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and [CHEMICAL]carboplatin[\\CHEMICAL], in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/[GENE]rCtr1[\\GENE] cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and [CHEMICAL]carboplatin[\\CHEMICAL], in comparison to isogenic vector-transfected control cells.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "The uptake of [CHEMICAL]copper[\\CHEMICAL] by both cultured rat DRG neurons and HEK/[GENE]rCtr1[\\GENE] cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "In conclusion, [GENE]rCtr1[\\GENE] can transport [CHEMICAL]copper[\\CHEMICAL] and platinum drugs, and sensitizes cells to their cytotoxicities.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Altogether, our results suggest that a high dose of [CHEMICAL]glucosamine[\\CHEMICAL] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of [GENE]p21[\\GENE], p53 and HO-1 expression, and nuclear p21 accumulation.",
        "label": 2,
        "major": 4,
        "len": 54
    },
    {
        "text": "Altogether, our results suggest that a high dose of [CHEMICAL]glucosamine[\\CHEMICAL] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, [GENE]p53[\\GENE] and HO-1 expression, and nuclear p21 accumulation.",
        "label": 2,
        "major": 4,
        "len": 54
    },
    {
        "text": "Altogether, our results suggest that a high dose of [CHEMICAL]glucosamine[\\CHEMICAL] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and [GENE]HO-1[\\GENE] expression, and nuclear p21 accumulation.",
        "label": 2,
        "major": 4,
        "len": 54
    },
    {
        "text": "In addition, [CHEMICAL]glucosamine[\\CHEMICAL] attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing [GENE]p21[\\GENE] nuclear accumulation.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Altogether, our results suggest that a high dose of [CHEMICAL]glucosamine[\\CHEMICAL] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear [GENE]p21[\\GENE] accumulation.",
        "label": 3,
        "major": 4,
        "len": 54
    },
    {
        "text": "[CHEMICAL]Glucosamine[\\CHEMICAL] at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of [GENE]p53[\\GENE] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Glucosamine[\\CHEMICAL] at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and [GENE]heme oxygenase-1[\\GENE] (HO-1), but also caused a reduction in p21 protein expression.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, [CHEMICAL]glucosamine[\\CHEMICAL] attenuated [GENE]p21[\\GENE] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Glucosamine[\\CHEMICAL] at 50\u00a0mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in [GENE]p21[\\GENE] protein expression.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Altogether, our results suggest that a high dose of [CHEMICAL]glucosamine[\\CHEMICAL] may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [GENE]Rb[\\GENE] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.",
        "label": 4,
        "major": 4,
        "len": 54
    },
    {
        "text": "Examination of phosphorylation in [GENE]retinoblastoma (Rb) protein[\\GENE], we found an inhibitory effect by [CHEMICAL]glucosamine[\\CHEMICAL] at 20 and 50\u00a0mM.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a [CHEMICAL]benzyloxyl[\\CHEMICAL] substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased [GENE]MT(1)[\\GENE] potency.",
        "label": 10,
        "major": 4,
        "len": 38
    },
    {
        "text": "Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the [CHEMICAL]3-methoxyphenyl[\\CHEMICAL] ring dramatically enhanced the MT(2) potency and at the same time decreased [GENE]MT(1)[\\GENE] potency.",
        "label": 10,
        "major": 4,
        "len": 38
    },
    {
        "text": "Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a [CHEMICAL]benzyloxyl[\\CHEMICAL] substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the [GENE]MT(2)[\\GENE] potency and at the same time decreased MT(1) potency.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the [CHEMICAL]3-methoxyphenyl[\\CHEMICAL] ring dramatically enhanced the [GENE]MT(2)[\\GENE] potency and at the same time decreased MT(1) potency.",
        "label": 2,
        "major": 4,
        "len": 38
    },
    {
        "text": "Characterization of substituted [CHEMICAL]phenylpropylamides[\\CHEMICAL] as highly selective agonists at the [GENE]melatonin MT2 receptor[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 13
    },
    {
        "text": "We show that the expression of PIM-1 is induced in response to [CHEMICAL]estradiol[\\CHEMICAL] in MCF-7 cells and that the induction is mediated by [GENE]ER\u03b1[\\GENE]-regulated enhancers located distally upstream from the gene.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "We show that the expression of [GENE]PIM-1[\\GENE] is induced in response to [CHEMICAL]estradiol[\\CHEMICAL] in MCF-7 cells and that the induction is mediated by ER\u03b1-regulated enhancers located distally upstream from the gene.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Distinct roles of [CHEMICAL]methamphetamine[\\CHEMICAL] in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of [GENE]ERK[\\GENE] and CREB activation in hippocampus and prefrontal cortex.",
        "label": 3,
        "major": 7,
        "len": 25
    },
    {
        "text": "Distinct roles of [CHEMICAL]methamphetamine[\\CHEMICAL] in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and [GENE]CREB[\\GENE] activation in hippocampus and prefrontal cortex.",
        "label": 3,
        "major": 7,
        "len": 25
    },
    {
        "text": "In contrast, activation of both [GENE]ERK[\\GENE] and CREB in the PFC was found following memory retrieval but not other processes in [CHEMICAL]METH[\\CHEMICAL]-treated mouse groups.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "In contrast, activation of both ERK and [GENE]CREB[\\GENE] in the PFC was found following memory retrieval but not other processes in [CHEMICAL]METH[\\CHEMICAL]-treated mouse groups.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Moreover, activation of the [GENE]ERK[\\GENE] and CREB signaling pathway in the hippocampus might be involved in [CHEMICAL]METH[\\CHEMICAL]-induced spatial memory changes.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Moreover, activation of the ERK and [GENE]CREB[\\GENE] signaling pathway in the hippocampus might be involved in [CHEMICAL]METH[\\CHEMICAL]-induced spatial memory changes.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "A reporter construct driven by 4 kb of the [GENE]chicken ras-dva[\\GENE] 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by [CHEMICAL]corticosterone[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative [GENE]pituitary-specific transcription factor-1 (Pit-1) binding sites[\\GENE] and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by [CHEMICAL]corticosterone[\\CHEMICAL].",
        "label": 3,
        "major": 2,
        "len": 41
    },
    {
        "text": "A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential [GENE]glucocorticoid receptor (GR) binding sites[\\GENE], was highly activated in embryonic pituitary cells and up-regulated by [CHEMICAL]corticosterone[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "However, mutating putative [GENE]GR binding sites[\\GENE] did not substantially reduce induction of ras-dva promoter activity by [CHEMICAL]corticosterone[\\CHEMICAL], suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.",
        "label": 3,
        "major": 2,
        "len": 30
    },
    {
        "text": "However, mutating putative GR binding sites did not substantially reduce induction of [GENE]ras-dva promoter[\\GENE] activity by [CHEMICAL]corticosterone[\\CHEMICAL], suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the [GENE]mGluR8[\\GENE]-specific orthosteric agonist [CHEMICAL](S)-3,4-dicarboxyphenylglycine[\\CHEMICAL] (DCPG).",
        "label": 5,
        "major": 7,
        "len": 34
    },
    {
        "text": "To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the [GENE]mGluR8[\\GENE]-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine ([CHEMICAL]DCPG[\\CHEMICAL]).",
        "label": 5,
        "major": 7,
        "len": 34
    },
    {
        "text": "To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of [GENE]mGluR8[\\GENE], [CHEMICAL]AZ12216052[\\CHEMICAL] (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).",
        "label": 7,
        "major": 7,
        "len": 34
    },
    {
        "text": "Here, we compared the effects of a dimeric [GENE]PSD-95[\\GENE] inhibitor, [CHEMICAL]UCCB01-125[\\CHEMICAL], and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",
        "label": 4,
        "major": 6,
        "len": 29
    },
    {
        "text": "Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the [GENE]NMDAR[\\GENE] antagonist, [CHEMICAL]MK-801[\\CHEMICAL], on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.",
        "label": 6,
        "major": 4,
        "len": 29
    },
    {
        "text": "UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the [GENE]NMDA receptor[\\GENE] antagonist [CHEMICAL]MK-801[\\CHEMICAL].",
        "label": 6,
        "major": 4,
        "len": 22
    },
    {
        "text": "Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction [CHEMICAL]amino acid[\\CHEMICAL] sequence of the [GENE]translocator protein TSPO[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 17
    },
    {
        "text": "A domain in the [CHEMICAL]carboxy[\\CHEMICAL]-terminus of [GENE]TSPO[\\GENE] was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).",
        "label": 1,
        "major": 2,
        "len": 19
    },
    {
        "text": "A domain in the carboxy-terminus of [GENE]TSPO[\\GENE] was identified and characterized as the cholesterol recognition/interaction [CHEMICAL]amino acid[\\CHEMICAL] consensus (CRAC).",
        "label": 1,
        "major": 2,
        "len": 19
    },
    {
        "text": "A domain in the carboxy-terminus of [GENE]TSPO[\\GENE] was identified and characterized as the [CHEMICAL]cholesterol[\\CHEMICAL] recognition/interaction amino acid consensus (CRAC).",
        "label": 2,
        "major": 1,
        "len": 19
    },
    {
        "text": "The [GENE]translocator protein (18-kDa) TSPO[\\GENE] is an ubiquitous high affinity [CHEMICAL]cholesterol[\\CHEMICAL]-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "The treatment also prevented the high [CHEMICAL]cholesterol[\\CHEMICAL] diet-induced increase in serum [GENE]creatine kinase[\\GENE], total and isoforms, markers of neurological, cardiac and muscular damage.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "GIP potentiates [CHEMICAL]glucose[\\CHEMICAL]-stimulated [GENE]insulin[\\GENE] secretion and induces energy accumulation into adipose tissue, resulting in obesity.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "We concluded that in overweight and obese women with PCOS [CHEMICAL]Orlistat[\\CHEMICAL] administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and [GENE]insulin[\\GENE] sensitivity, and increased serum AMH levels.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "We concluded that in overweight and obese women with PCOS [CHEMICAL]Orlistat[\\CHEMICAL] administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum [GENE]AMH[\\GENE] levels.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Diet, physical exercise and [CHEMICAL]Orlistat[\\CHEMICAL] administration increase serum [GENE]Anti-M\u00fcllerian Hormone[\\GENE] (AMH) levels in women with polycystic ovary syndrome (PCOS).",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Diet, physical exercise and [CHEMICAL]Orlistat[\\CHEMICAL] administration increase serum Anti-M\u00fcllerian Hormone ([GENE]AMH[\\GENE]) levels in women with polycystic ovary syndrome (PCOS).",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of [GENE]organic anion transporter[\\GENE] (Oat)1 and Oat3 in rat kidney in response to [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter [GENE](Oat)1[\\GENE] and Oat3 in rat kidney in response to [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and [GENE]Oat3[\\GENE] in rat kidney in response to [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 9,
        "len": 34
    },
    {
        "text": "Inhibitory effect of [CHEMICAL]1\u03b1,25-dihydroxyvitamin D\u2083[\\CHEMICAL] on excretion of JBP485 via [GENE]organic anion transporters[\\GENE] in rats.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "Moreover, [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] decreased expression of [GENE]Oat1[\\GENE] and Oat3 in rat kidney.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Moreover, [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] decreased expression of Oat1 and [GENE]Oat3[\\GENE] in rat kidney.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of [CHEMICAL]1,25(OH)(2)D(3)[\\CHEMICAL] on expression of [GENE]Oats[\\GENE] in rat kidney.",
        "label": 4,
        "major": 2,
        "len": 27
    },
    {
        "text": "These results indicate that neonatal [CHEMICAL]diazinon[\\CHEMICAL] exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the [GENE]NMDA receptor[\\GENE] and neurotrophin in young adult and adult mice.",
        "label": 2,
        "major": 7,
        "len": 33
    },
    {
        "text": "Initiating event of the mitochondrial-mediated apoptosis induced by [CHEMICAL]ISO[\\CHEMICAL] is [GENE]MAPK[\\GENE] signals.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "Furthermore, [CHEMICAL]U0126[\\CHEMICAL] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of [GENE]cytochrome c[\\GENE] to the cytosol fraction, and the levels of cleaved caspase-3.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Furthermore, [CHEMICAL]U0126[\\CHEMICAL] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved [GENE]caspase-3[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "[GENE]MAPK[\\GENE] signaling pathways regulate mitochondrial-mediated apoptosis induced by [CHEMICAL]isoorientin[\\CHEMICAL] in human hepatoblastoma cancer cells.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "These results demonstrated for the first time that [CHEMICAL]ISO[\\CHEMICAL] induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating [GENE]JNK[\\GENE] and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results demonstrated for the first time that [CHEMICAL]ISO[\\CHEMICAL] induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and [GENE]p38[\\GENE] kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results demonstrated for the first time that [CHEMICAL]ISO[\\CHEMICAL] induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 [GENE]kinases[\\GENE], and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by [CHEMICAL]ISO[\\CHEMICAL] is able to activate the [GENE]MAPK[\\GENE] singaling pathway as the upstream signaling molecules.",
        "label": 3,
        "major": 3,
        "len": 42
    },
    {
        "text": "[CHEMICAL]ISO[\\CHEMICAL] significantly inhibited the levels of ERK1/2 kinase and increased the expression of [GENE]JNK[\\GENE] and p38 kinases.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]ISO[\\CHEMICAL] significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and [GENE]p38[\\GENE] kinases.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]ISO[\\CHEMICAL] significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 [GENE]kinases[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Furthermore, [CHEMICAL]U0126[\\CHEMICAL] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the [GENE]Bax[\\GENE]/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Furthermore, [CHEMICAL]U0126[\\CHEMICAL] (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/[GENE]Bcl-2[\\GENE] ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the [CHEMICAL]ISO[\\CHEMICAL]-induced the [GENE]Bax[\\GENE]/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the [CHEMICAL]ISO[\\CHEMICAL]-induced the Bax/[GENE]Bcl-2[\\GENE] ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.",
        "label": 3,
        "major": 4,
        "len": 27
    },
    {
        "text": "While SP600125 (a [GENE]JNK[\\GENE] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by [CHEMICAL]ISO[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "While SP600125 (a JNK inhibitor) and SB203580 (a [GENE]p38[\\GENE] inhibitor) markedly prevented the expression of these proteins induced by [CHEMICAL]ISO[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ISO[\\CHEMICAL] is able to induce apoptosis through mitochondrial dysfunction and inhibition of [GENE]PI3K[\\GENE]/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]ISO[\\CHEMICAL] is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/[GENE]Akt[\\GENE] signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "While [CHEMICAL]SP600125[\\CHEMICAL] (a [GENE]JNK[\\GENE] inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "While SP600125 (a JNK inhibitor) and [CHEMICAL]SB203580[\\CHEMICAL] (a [GENE]p38[\\GENE] inhibitor) markedly prevented the expression of these proteins induced by ISO.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [CHEMICAL]IMG[\\CHEMICAL] or hyperoside inhibited production of [GENE]thrombin[\\GENE] and FXa in HUVECs.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and [CHEMICAL]IMG[\\CHEMICAL] or hyperoside inhibited production of thrombin and [GENE]FXa[\\GENE] in HUVECs.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or [CHEMICAL]hyperoside[\\CHEMICAL] inhibited production of [GENE]thrombin[\\GENE] and FXa in HUVECs.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or [CHEMICAL]hyperoside[\\CHEMICAL] inhibited production of thrombin and [GENE]FXa[\\GENE] in HUVECs.",
        "label": 4,
        "major": 9,
        "len": 33
    },
    {
        "text": "In addition, treatment with [CHEMICAL]IMG[\\CHEMICAL] and hyperoside resulted in inhibition of TNF-\u03b1-induced production of [GENE]PAI-1[\\GENE], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In addition, treatment with IMG and [CHEMICAL]hyperoside[\\CHEMICAL] resulted in inhibition of TNF-\u03b1-induced production of [GENE]PAI-1[\\GENE], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with [CHEMICAL]IMG[\\CHEMICAL] resulted in significant reduction of the [GENE]PAI-1[\\GENE] to t-PA ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-\u03b1-induced production of PAI-1, and treatment with [CHEMICAL]IMG[\\CHEMICAL] resulted in significant reduction of the PAI-1 to [GENE]t-PA[\\GENE] ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Treatment with [CHEMICAL]IMG[\\CHEMICAL] and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of [GENE]thrombin[\\GENE] and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Treatment with [CHEMICAL]IMG[\\CHEMICAL] and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and [GENE]FXa[\\GENE], and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.",
        "label": 4,
        "major": 9,
        "len": 33
    },
    {
        "text": "Treatment with IMG and [CHEMICAL]hyperoside[\\CHEMICAL] resulted in significantly prolonged aPTT and PT and inhibition of the activities of [GENE]thrombin[\\GENE] and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.",
        "label": 4,
        "major": 9,
        "len": 33
    },
    {
        "text": "Treatment with IMG and [CHEMICAL]hyperoside[\\CHEMICAL] resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and [GENE]FXa[\\GENE], and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.",
        "label": 4,
        "major": 9,
        "len": 33
    },
    {
        "text": "In addition, treatment with [CHEMICAL]IMG[\\CHEMICAL] and hyperoside resulted in inhibition of [GENE]TNF-\u03b1[\\GENE]-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In addition, treatment with IMG and [CHEMICAL]hyperoside[\\CHEMICAL] resulted in inhibition of [GENE]TNF-\u03b1[\\GENE]-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([CHEMICAL]JMC08-4[\\CHEMICAL]) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and [GENE]human leukotriene A(4) hydrolase[\\GENE] (LTA(4)H-h) was found.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([CHEMICAL]JMC08-4[\\CHEMICAL]) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase ([GENE]LTA(4)H-h[\\GENE]) was found.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([CHEMICAL]JMC08-4[\\CHEMICAL]) for [GENE]human nonpancreatic secretory phospholipase A(2)[\\GENE] (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor ([CHEMICAL]JMC08-4[\\CHEMICAL]) for human nonpancreatic secretory phospholipase A(2) ([GENE]hnps-PLA(2)[\\GENE]) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Optimization of [CHEMICAL]5-hydroxytryptamines[\\CHEMICAL] as dual function inhibitors targeting [GENE]phospholipase A2[\\GENE] and leukotriene A4 hydrolase.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Optimization of [CHEMICAL]5-hydroxytryptamines[\\CHEMICAL] as dual function inhibitors targeting phospholipase A2 and [GENE]leukotriene A4 hydrolase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Dual function inhibitors targeting phospholipase A(2) ([GENE]PLA(2)[\\GENE]) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) metabolic network and be used as new anti-inflammatory drugs.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and [GENE]leukotriene A(4) hydrolase[\\GENE] (LTA(4)H) may balance the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) metabolic network and be used as new anti-inflammatory drugs.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase ([GENE]LTA(4)H[\\GENE]) may balance the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) metabolic network and be used as new anti-inflammatory drugs.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Dual function inhibitors targeting [GENE]phospholipase A(2)[\\GENE] (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [CHEMICAL]arachidonic acid[\\CHEMICAL] (AA) metabolic network and be used as new anti-inflammatory drugs.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "On the contrary, [GENE]human TRPA1[\\GENE] could be concentration-dependently modulated by [CHEMICAL]apomorphine[\\CHEMICAL].",
        "label": 2,
        "major": 7,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Apomorphine[\\CHEMICAL] is a bimodal modulator of [GENE]TRPA1[\\GENE] channels.",
        "label": 2,
        "major": 7,
        "len": 8
    },
    {
        "text": "In addition, we provide evidence that [CHEMICAL]apomorphine[\\CHEMICAL] also acts on endogenous [GENE]TRPA1[\\GENE] in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of TRPA1.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Our study shows that [GENE]human TRPA1[\\GENE] is a target for [CHEMICAL]apomorphine[\\CHEMICAL], suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "In addition, we provide evidence that [CHEMICAL]apomorphine[\\CHEMICAL] also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [GENE]TRPA1[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "Our study shows that human TRPA1 is a target for [CHEMICAL]apomorphine[\\CHEMICAL], suggesting that an activation of [GENE]TRPA1[\\GENE] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of [GENE]TRPA1[\\GENE] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [CHEMICAL]apomorphine[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "Whereas the addition of [CHEMICAL]apomorphine[\\CHEMICAL] in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [GENE]TRPA1[\\GENE] channels, resulting from a reduction of single-channel open times.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Dietary [CHEMICAL]carbohydrates[\\CHEMICAL] increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and [GENE]SREBP-1c[\\GENE] -independent pathways.",
        "label": 10,
        "major": 2,
        "len": 19
    },
    {
        "text": "Dietary [CHEMICAL]carbohydrates[\\CHEMICAL] increase SCD-1 gene expression in liver by [GENE]sterol response element binding protein (SREBP)-1c[\\GENE]-dependent and SREBP-1c -independent pathways.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Dietary [CHEMICAL]carbohydrates[\\CHEMICAL] increase [GENE]SCD-1[\\GENE] gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.",
        "label": 3,
        "major": 2,
        "len": 19
    },
    {
        "text": "[GENE]Human stearoyl-CoA desaturase 1[\\GENE] (SCD-1) gene expression is negatively regulated by [CHEMICAL]thyroid hormone[\\CHEMICAL] without direct binding of thyroid hormone receptor to the gene promoter.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Human stearoyl-CoA desaturase 1 ([GENE]SCD-1[\\GENE]) gene expression is negatively regulated by [CHEMICAL]thyroid hormone[\\CHEMICAL] without direct binding of thyroid hormone receptor to the gene promoter.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "Finally, chronic administration of [CHEMICAL]metformin[\\CHEMICAL] in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating Beclin1 and [GENE]Bcl-2[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Finally, chronic administration of [CHEMICAL]metformin[\\CHEMICAL] in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating [GENE]Beclin1[\\GENE] and Bcl-2.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted [GENE]Beclin1[\\GENE] binding to Bcl-2.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to [GENE]Bcl-2[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "Finally, chronic administration of [CHEMICAL]metformin[\\CHEMICAL] in diabetic mice restored cardiac autophagy by activating [GENE]JNK1[\\GENE]-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Finally, chronic administration of [CHEMICAL]metformin[\\CHEMICAL] in diabetic mice restored cardiac autophagy by activating JNK1-[GENE]Bcl-2[\\GENE] pathways and dissociating Beclin1 and Bcl-2.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited [GENE]Jun NH2-terminal kinase 1[\\GENE] (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 ([GENE]JNK1[\\GENE])-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-[GENE]B-cell lymphoma 2[\\GENE] (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 ([GENE]Bcl-2[\\GENE]) signaling, and promoted Beclin1 binding to Bcl-2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Exposure of H9c2 cells to high [CHEMICAL]glucose[\\CHEMICAL] reduced [GENE]AMPK[\\GENE] activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In this current study, [CHEMICAL]paclitaxel[\\CHEMICAL] was found to increase phosphorylation of [GENE]mitogen-activated protein kinase[\\GENE] (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "In this current study, [CHEMICAL]paclitaxel[\\CHEMICAL] was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-[GENE]p38[\\GENE] MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "In this current study, [CHEMICAL]paclitaxel[\\CHEMICAL] was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 [GENE]MAPK[\\GENE] as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Furthermore, metformin was able to not only decrease the [CHEMICAL]paclitaxel[\\CHEMICAL]-induced [GENE]p38[\\GENE] MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 3,
        "major": 10,
        "len": 23
    },
    {
        "text": "Furthermore, metformin was able to not only decrease the [CHEMICAL]paclitaxel[\\CHEMICAL]-induced p38 [GENE]MAPK[\\GENE]-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 3,
        "major": 10,
        "len": 23
    },
    {
        "text": "In this current study, [CHEMICAL]paclitaxel[\\CHEMICAL] was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of [GENE]ERCC1[\\GENE] in H1650 and H1703 cells.",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Moreover, [CHEMICAL]paclitaxel[\\CHEMICAL]-induced [GENE]ERCC1[\\GENE] protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Furthermore, metformin was able to not only decrease the [CHEMICAL]paclitaxel[\\CHEMICAL]-induced p38 MAPK-mediated [GENE]ERCC1[\\GENE] expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL]-mediated downregulation of [GENE]p38[\\GENE] mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL]-mediated downregulation of p38 [GENE]mitogen-activated protein kinase[\\GENE]-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Furthermore, [CHEMICAL]metformin[\\CHEMICAL] was able to not only decrease the paclitaxel-induced p38 MAPK-mediated [GENE]ERCC1[\\GENE] expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate [GENE]ERCC1[\\GENE] downregulation by [CHEMICAL]metformin[\\CHEMICAL] and paclitaxel as well as cell viability and DNA repair capacity.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate [GENE]ERCC1[\\GENE] downregulation by metformin and [CHEMICAL]paclitaxel[\\CHEMICAL] as well as cell viability and DNA repair capacity.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of [GENE]p38[\\GENE] activity by either a p38 MAPK inhibitor [CHEMICAL]SB202190[\\CHEMICAL] or p38 knockdown with specific small interfering RNA (siRNA).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a [GENE]p38[\\GENE] MAPK inhibitor [CHEMICAL]SB202190[\\CHEMICAL] or p38 knockdown with specific small interfering RNA (siRNA).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 [GENE]MAPK[\\GENE] inhibitor [CHEMICAL]SB202190[\\CHEMICAL] or p38 knockdown with specific small interfering RNA (siRNA).",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Furthermore, [CHEMICAL]metformin[\\CHEMICAL] was able to not only decrease the paclitaxel-induced [GENE]p38[\\GENE] MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Furthermore, [CHEMICAL]metformin[\\CHEMICAL] was able to not only decrease the paclitaxel-induced p38 [GENE]MAPK[\\GENE]-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Overall, our results suggest that inhibition of the [GENE]p38[\\GENE] MAPK signaling by [CHEMICAL]metformin[\\CHEMICAL] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Overall, our results suggest that inhibition of the p38 [GENE]MAPK[\\GENE] signaling by [CHEMICAL]metformin[\\CHEMICAL] coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on [GENE]CES1[\\GENE], placing CES2 one of the most sensitive targets of [CHEMICAL]orlistat[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 28
    },
    {
        "text": "[GENE]Carboxylesterase-2[\\GENE] is a highly sensitive target of the antiobesity agent [CHEMICAL]orlistat[\\CHEMICAL] with profound implications in the activation of anticancer prodrugs.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Contrary to the hypothesis, orlistat at 1 nM inhibited [GENE]CES2[\\GENE] activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of [CHEMICAL]orlistat[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing [GENE]CES2[\\GENE] one of the most sensitive targets of [CHEMICAL]orlistat[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Orlistat[\\CHEMICAL] has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [GENE]lipases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of this [GENE]carboxylesterase[\\GENE] probably presents a major source for altered therapeutic activity of these medicines if co-administered with [CHEMICAL]orlistat[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "This study was designed to test the hypothesis that [CHEMICAL]orlistat[\\CHEMICAL] inhibits [GENE]CESs[\\GENE] with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "This study was designed to test the hypothesis that [CHEMICAL]orlistat[\\CHEMICAL] inhibits CESs with higher potency toward [GENE]CES1[\\GENE] than CES2, a carboxylesterase with little lipase activity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "This study was designed to test the hypothesis that [CHEMICAL]orlistat[\\CHEMICAL] inhibits CESs with higher potency toward CES1 than [GENE]CES2[\\GENE], a carboxylesterase with little lipase activity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "This study was designed to test the hypothesis that [CHEMICAL]orlistat[\\CHEMICAL] inhibits CESs with higher potency toward CES1 than CES2, a [GENE]carboxylesterase[\\GENE] with little lipase activity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "This study was designed to test the hypothesis that [CHEMICAL]orlistat[\\CHEMICAL] inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little [GENE]lipase[\\GENE] activity.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "On stimulation by G(s), the activities of [GENE]ACs[\\GENE] can be further selectively modulated by other pathways to ensure precise control of intracellular [CHEMICAL]cAMP[\\CHEMICAL] responses to specific stimuli.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL]-mediated induction of senescence was not dependent on [GENE]p21[\\GENE] or p53; however, p21 conferred protection against the growth inhibitory effects of E235.",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL]-mediated induction of senescence was not dependent on p21 or [GENE]p53[\\GENE]; however, p21 conferred protection against the growth inhibitory effects of E235.",
        "label": 10,
        "major": 4,
        "len": 22
    },
    {
        "text": "E235 also activated DNA damage response signaling, resulting in increased levels of [CHEMICAL]Ser[\\CHEMICAL]15-[GENE]phosphorylated p53[\\GENE], \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.",
        "label": 1,
        "major": 3,
        "len": 31
    },
    {
        "text": "E235-mediated induction of senescence was not dependent on p21 or p53; however, [GENE]p21[\\GENE] conferred protection against the growth inhibitory effects of [CHEMICAL]E235[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "We identified one compound, [CHEMICAL]E235[\\CHEMICAL] (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of [GENE]ATF4[\\GENE] in transformed cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "We identified one compound, E235 [CHEMICAL](N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)[\\CHEMICAL], that activated the ISR and dose-dependently increased levels of [GENE]ATF4[\\GENE] in transformed cells.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL] also activated DNA damage response signaling, resulting in increased levels of Ser15-[GENE]phosphorylated p53[\\GENE], \u03b3-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL] also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, [GENE]\u03b3-H2AX[\\GENE], and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL] also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and [GENE]phosphorylated checkpoint kinase 2[\\GENE] (Chk2), although E235 does not appear to cause physical DNA damage.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]E235[\\CHEMICAL] also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, \u03b3-H2AX, and phosphorylated checkpoint kinase 2 ([GENE]Chk2[\\GENE]), although E235 does not appear to cause physical DNA damage.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "We aim to \"tilt\" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the [CHEMICAL]amino acid[\\CHEMICAL] sequence of the [GENE]H1[\\GENE], H2, and proximal residues.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "We aim to \"tilt\" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the [CHEMICAL]amino acid[\\CHEMICAL] sequence of the H1, [GENE]H2[\\GENE], and proximal residues.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "Cell culture studies demonstrated that [CHEMICAL]PKAA[\\CHEMICAL] is capable of delivering anti-TNF (tumor necrosis factor)-\u03b1 siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of [GENE]TNF-\u03b1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[CHEMICAL]PKAA[\\CHEMICAL]/anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the [GENE]ALT[\\GENE] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]PKAA[\\CHEMICAL]/anti-TNF-\u03b1 siRNA nanocomplexes significantly reduced the ALT ([GENE]alanine transaminase[\\GENE]) and the hepatic cellular damages in APAP-intoxicated mice.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "Moreover, wogonin repressed [CHEMICAL]anisomycin[\\CHEMICAL]-induced phosphorylation of [GENE]p38[\\GENE], cav-1 and vascular permeability.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "Moreover, wogonin repressed [CHEMICAL]anisomycin[\\CHEMICAL]-induced phosphorylation of p38, [GENE]cav-1[\\GENE] and vascular permeability.",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "These results suggested that wogonin could inhibit [CHEMICAL]H2O2[\\CHEMICAL]-induced vascular permeability by downregulating the phosphorylation of [GENE]cav-1[\\GENE], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",
        "label": 3,
        "major": 4,
        "len": 37
    },
    {
        "text": "Wogonin inhibits [CHEMICAL]H2O2[\\CHEMICAL]-induced vascular permeability through suppressing the phosphorylation of [GENE]caveolin-1[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 11
    },
    {
        "text": "The mechanism revealed that wogonin inhibited [CHEMICAL]H2O2[\\CHEMICAL]-induced phosphorylation of [GENE]caveolin-1[\\GENE] (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The mechanism revealed that wogonin inhibited [CHEMICAL]H2O2[\\CHEMICAL]-induced phosphorylation of caveolin-1 ([GENE]cav-1[\\GENE]) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "We found that wogonin can suppress the [CHEMICAL]H2O2[\\CHEMICAL]-stimulated [GENE]actin[\\GENE] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that wogonin can suppress the [CHEMICAL]H2O2[\\CHEMICAL]-stimulated actin remodeling and [GENE]albumin[\\GENE] uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that [CHEMICAL]wogonin[\\CHEMICAL] can suppress the H2O2-stimulated [GENE]actin[\\GENE] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "We found that [CHEMICAL]wogonin[\\CHEMICAL] can suppress the H2O2-stimulated actin remodeling and [GENE]albumin[\\GENE] uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "The mechanism revealed that [CHEMICAL]wogonin[\\CHEMICAL] inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [GENE]VE-cadherin[\\GENE] and \u03b2-catenin.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The mechanism revealed that [CHEMICAL]wogonin[\\CHEMICAL] inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and [GENE]\u03b2-catenin[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Moreover, [CHEMICAL]wogonin[\\CHEMICAL] repressed anisomycin-induced phosphorylation of [GENE]p38[\\GENE], cav-1 and vascular permeability.",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "Moreover, [CHEMICAL]wogonin[\\CHEMICAL] repressed anisomycin-induced phosphorylation of p38, [GENE]cav-1[\\GENE] and vascular permeability.",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "These results suggested that [CHEMICAL]wogonin[\\CHEMICAL] could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of [GENE]cav-1[\\GENE], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Wogonin[\\CHEMICAL] inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of [GENE]caveolin-1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "The mechanism revealed that [CHEMICAL]wogonin[\\CHEMICAL] inhibited H2O2-induced phosphorylation of [GENE]caveolin-1[\\GENE] (cav-1) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The mechanism revealed that [CHEMICAL]wogonin[\\CHEMICAL] inhibited H2O2-induced phosphorylation of caveolin-1 ([GENE]cav-1[\\GENE]) associating with the suppression of stabilization of VE-cadherin and \u03b2-catenin.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "In an attempt to further improve overall profiles of the [CHEMICAL]oxadiazine[\\CHEMICAL] series of GSMs, in particular the [GENE]hERG[\\GENE] activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved hERG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.",
        "label": 2,
        "major": 4,
        "len": 55
    },
    {
        "text": "The discovery of fused [CHEMICAL]oxadiazepines[\\CHEMICAL] as [GENE]gamma secretase[\\GENE] modulators for treatment of Alzheimer's disease.",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the hERG activity, conformational modifications of the core structure resulted in the identification of fused [CHEMICAL]oxadiazepines[\\CHEMICAL] such as 7i which had an improved [GENE]hERG[\\GENE] inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.",
        "label": 4,
        "major": 4,
        "len": 55
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors [GENE]survivin[\\GENE], Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, [GENE]Bcl-2[\\GENE], and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and [GENE]X-linked inhibitor of apoptosis protein[\\GENE], These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of [GENE]MAPK[\\GENE], Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, [GENE]Akt[\\GENE], and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and [GENE]p70S6K[\\GENE] and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by [CHEMICAL]BZA[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 39
    },
    {
        "text": "The reduction of BiFC signal mediated by [CHEMICAL]nutlin-3[\\CHEMICAL] was correlated with an increase in [GENE]Puma[\\GENE] transactivation, PARP cleavage, and cell death.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The reduction of BiFC signal mediated by [CHEMICAL]nutlin-3[\\CHEMICAL] was correlated with an increase in Puma transactivation, [GENE]PARP[\\GENE] cleavage, and cell death.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "We used [CHEMICAL]nutlin-3[\\CHEMICAL], a well-known disruptor of [GENE]p53[\\GENE]-Mdm2 interaction, to validate the specificity of the assay.",
        "label": 4,
        "major": 2,
        "len": 16
    },
    {
        "text": "We used [CHEMICAL]nutlin-3[\\CHEMICAL], a well-known disruptor of p53-[GENE]Mdm2[\\GENE] interaction, to validate the specificity of the assay.",
        "label": 4,
        "major": 2,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced [GENE]pAkt[\\GENE] level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: [GENE]pCREB[\\GENE], pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, [GENE]pGSK-3\u03b2[\\GENE], Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, [GENE]Bcl-2[\\GENE] and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and [GENE]neurotrophins[\\GENE] GDNF, BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins [GENE]GDNF[\\GENE], BDNF suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, [GENE]BDNF[\\GENE] suggesting repressed PI3K/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed [GENE]PI3K[\\GENE]/Akt signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sal[\\CHEMICAL] toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3\u03b2, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/[GENE]Akt[\\GENE] signaling.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "This was confirmed on adding [CHEMICAL]LY294002[\\CHEMICAL] the [GENE]PI3K[\\GENE] inhibitor which abolished the protection.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [GENE]glutathione peroxidase[\\GENE], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, [GENE]glutathione reductase[\\GENE], reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and [GENE]NADH-dehydrogenases[\\GENE], cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, [GENE]cytochrome-C-oxidase[\\GENE] and adenosine triphosphate.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [GENE]glutathione peroxidase[\\GENE], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, [GENE]glutathione reductase[\\GENE], reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and [GENE]NADH-dehydrogenases[\\GENE], cytochrome-C-oxidase and adenosine triphosphate.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "[CHEMICAL]Isoproterenol[\\CHEMICAL] induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, \u03b1-ketoglutarate and NADH-dehydrogenases, [GENE]cytochrome-C-oxidase[\\GENE] and adenosine triphosphate.",
        "label": 4,
        "major": 3,
        "len": 47
    },
    {
        "text": "Increased urinary excretion of [GENE]albumin[\\GENE], hemopexin, transferrin and VDBP correlates with chronic sensitization to [CHEMICAL]gentamicin[\\CHEMICAL] nephrotoxicity in rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Increased urinary excretion of albumin, [GENE]hemopexin[\\GENE], transferrin and VDBP correlates with chronic sensitization to [CHEMICAL]gentamicin[\\CHEMICAL] nephrotoxicity in rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Increased urinary excretion of albumin, hemopexin, [GENE]transferrin[\\GENE] and VDBP correlates with chronic sensitization to [CHEMICAL]gentamicin[\\CHEMICAL] nephrotoxicity in rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Increased urinary excretion of albumin, hemopexin, transferrin and [GENE]VDBP[\\GENE] correlates with chronic sensitization to [CHEMICAL]gentamicin[\\CHEMICAL] nephrotoxicity in rats.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Design and synthesis of novel [CHEMICAL]2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one[\\CHEMICAL] derivatives as [GENE]telomerase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] induced dose-dependent reduction of the protein levels of [GENE]inducible nitric oxide synthase[\\GENE] (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase ([GENE]iNOS[\\GENE]) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and [GENE]cyclooxygenase-2[\\GENE] (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 ([GENE]COX-2[\\GENE]) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).",
        "label": 4,
        "major": 9,
        "len": 29
    },
    {
        "text": "Additionally, [CHEMICAL]DPEP[\\CHEMICAL] suppressed the production of inflammatory [GENE]cytokines[\\GENE], including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Additionally, [CHEMICAL]DPEP[\\CHEMICAL] suppressed the production of inflammatory cytokines, including [GENE]tumor necrosis factor-\u03b1[\\GENE] (TNF-\u03b1), interleukin (IL)-1\u03b2, and IL-6.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Additionally, [CHEMICAL]DPEP[\\CHEMICAL] suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 ([GENE]TNF-\u03b1[\\GENE]), interleukin (IL)-1\u03b2, and IL-6.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Additionally, [CHEMICAL]DPEP[\\CHEMICAL] suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), [GENE]interleukin (IL)-1\u03b2[\\GENE], and IL-6.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Additionally, [CHEMICAL]DPEP[\\CHEMICAL] suppressed the production of inflammatory cytokines, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, and [GENE]IL-6[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] inhibited LPS-induced phosphorylation of [GENE]ERK[\\GENE], JNK, and p38.",
        "label": 4,
        "major": 3,
        "len": 9
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] inhibited LPS-induced phosphorylation of ERK, [GENE]JNK[\\GENE], and p38.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]DPEP[\\CHEMICAL] inhibited LPS-induced phosphorylation of ERK, JNK, and [GENE]p38[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 9
    },
    {
        "text": "Furthermore, [CHEMICAL]DPEP[\\CHEMICAL] inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and NF-\u03baB [GENE]p50[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 13
    },
    {
        "text": "Furthermore, [CHEMICAL]DPEP[\\CHEMICAL] inhibited the LPS-induced phosphorylation of [GENE]inhibitor \u03baB (I\u03baB)-\u03b1[\\GENE] and NF-\u03baB p50.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Furthermore, [CHEMICAL]DPEP[\\CHEMICAL] inhibited the LPS-induced phosphorylation of inhibitor \u03baB (I\u03baB)-\u03b1 and [GENE]NF-\u03baB[\\GENE] p50.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Taken together, the results of this study demonstrate that [CHEMICAL]DPEP[\\CHEMICAL] inhibits LPS-stimulated inflammation by blocking the [GENE]NF-\u03baB[\\GENE] and MAPK pathways in macrophages.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Taken together, the results of this study demonstrate that [CHEMICAL]DPEP[\\CHEMICAL] inhibits LPS-stimulated inflammation by blocking the NF-\u03baB and [GENE]MAPK[\\GENE] pathways in macrophages.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "To determine how [GENE]pol \u03b2[\\GENE] discriminates between [CHEMICAL]anti- and syn-8-oxoG[\\CHEMICAL], we introduced a point mutation (R283K) to alter insertion specificity.",
        "label": 2,
        "major": 1,
        "len": 20
    },
    {
        "text": "[GENE]DNA polymerase minor groove[\\GENE] interactions modulate mutagenic bypass of a templating [CHEMICAL]8-oxoguanine[\\CHEMICAL] lesion.",
        "label": 2,
        "major": 7,
        "len": 13
    },
    {
        "text": "In contrast to wild-type [GENE]pol \u03b2[\\GENE], the ternary complex of the R283K mutant with an incoming [CHEMICAL]dATP[\\CHEMICAL]-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "In contrast to wild-type pol \u03b2, the ternary complex of the [GENE]R283K[\\GENE] mutant with an incoming [CHEMICAL]dATP[\\CHEMICAL]-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "In contrast to wild-type pol \u03b2, the ternary complex of the [GENE]R283K[\\GENE] mutant with an incoming dATP-analogue and templating [CHEMICAL]8-oxoG[\\CHEMICAL] resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "In contrast to wild-type pol \u03b2, the ternary complex of the [GENE]R283K[\\GENE] mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with [CHEMICAL]8-oxoG[\\CHEMICAL] adopting an anti-conformation.",
        "label": 2,
        "major": 1,
        "len": 30
    },
    {
        "text": "These results demonstrate that the incoming [CHEMICAL]nucleotide[\\CHEMICAL] is unable to induce a syn-8-oxoG conformation without [GENE]minor groove[\\GENE] DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.",
        "label": 2,
        "major": 7,
        "len": 29
    },
    {
        "text": "These results demonstrate that the incoming [CHEMICAL]nucleotide[\\CHEMICAL] is unable to induce a syn-8-oxoG conformation without minor groove [GENE]DNA polymerase[\\GENE] interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.",
        "label": 2,
        "major": 7,
        "len": 29
    },
    {
        "text": "These results demonstrate that the incoming nucleotide is unable to induce a [CHEMICAL]syn-8-oxoG[\\CHEMICAL] conformation without [GENE]minor groove[\\GENE] DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "These results demonstrate that the incoming nucleotide is unable to induce a [CHEMICAL]syn-8-oxoG[\\CHEMICAL] conformation without minor groove [GENE]DNA polymerase[\\GENE] interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.",
        "label": 2,
        "major": 7,
        "len": 29
    },
    {
        "text": "This leads to decreased expression of [GENE]glutamate aspartate transporter[\\GENE], which in turn reduces [CHEMICAL]glutamate[\\CHEMICAL] transport.",
        "label": 9,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Tetrahydropyrroloquinolinone[\\CHEMICAL] type dual inhibitors of [GENE]aromatase[\\GENE]/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Tetrahydropyrroloquinolinone[\\CHEMICAL] type dual inhibitors of aromatase/[GENE]aldosterone synthase[\\GENE] as a novel strategy for breast cancer patients with elevated cardiovascular risks.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Furthermore, [CHEMICAL]MDZ[\\CHEMICAL] caused mechanism-based inactivation of [GENE]cytochrome P450 3A[\\GENE]-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Furthermore, MDZ caused mechanism-based inactivation of [GENE]cytochrome P450 3A[\\GENE]-dependent [CHEMICAL]TRZ[\\CHEMICAL] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.",
        "label": 9,
        "major": 3,
        "len": 21
    },
    {
        "text": "Although [CHEMICAL]tamoxifen[\\CHEMICAL] (TAM), a selective [GENE]estrogen receptor[\\GENE] modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.",
        "label": 2,
        "major": 3,
        "len": 28
    },
    {
        "text": "Although tamoxifen ([CHEMICAL]TAM[\\CHEMICAL]), a selective [GENE]estrogen receptor[\\GENE] modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as [GENE]Snail[\\GENE] and N-cadherin increased, whereas E-cadherin decreased in the [CHEMICAL]TAM[\\CHEMICAL]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",
        "label": 3,
        "major": 3,
        "len": 50
    },
    {
        "text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and [GENE]N-cadherin[\\GENE] increased, whereas E-cadherin decreased in the [CHEMICAL]TAM[\\CHEMICAL]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",
        "label": 3,
        "major": 3,
        "len": 50
    },
    {
        "text": "Collectively, our data suggest that [CHEMICAL]TAM[\\CHEMICAL] can repress the miR-200 family and induce EMT via the up-regulation of [GENE]c-Myc[\\GENE] in endometrial cancer cells.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[GENE]miR-200[\\GENE], a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to [CHEMICAL]TAM[\\CHEMICAL] treatment.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas [GENE]E-cadherin[\\GENE] decreased in the [CHEMICAL]TAM[\\CHEMICAL]-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.",
        "label": 4,
        "major": 3,
        "len": 50
    },
    {
        "text": "In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in [CHEMICAL]TAM[\\CHEMICAL]-treated endometrial cancer cells leads to the down-regulation of [GENE]miR-200[\\GENE] and eventually to EMT.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Collectively, our data suggest that [CHEMICAL]TAM[\\CHEMICAL] can repress the [GENE]miR-200[\\GENE] family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as [CHEMICAL]resveratrol[\\CHEMICAL], both of which down-regulated p300 protein levels but not [GENE]p300[\\GENE] mRNA levels.",
        "label": 10,
        "major": 4,
        "len": 33
    },
    {
        "text": "We found that SIRT1 induced p300 down-regulation via the [GENE]ubiquitin[\\GENE]-proteasome pathway by deacetylation of [CHEMICAL]lysine[\\CHEMICAL] residues for ubiquitination.",
        "label": 1,
        "major": 3,
        "len": 18
    },
    {
        "text": "We found that SIRT1 induced p300 down-regulation via the ubiquitin-[GENE]proteasome[\\GENE] pathway by deacetylation of [CHEMICAL]lysine[\\CHEMICAL] residues for ubiquitination.",
        "label": 1,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Resveratrol[\\CHEMICAL] improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of [GENE]p300[\\GENE] protein.",
        "label": 2,
        "major": 7,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Resveratrol[\\CHEMICAL] improves cardiomyopathy in dystrophin-deficient mice through [GENE]SIRT1[\\GENE] protein-mediated modulation of p300 protein.",
        "label": 2,
        "major": 7,
        "len": 13
    },
    {
        "text": "Here, we show that oral administration of [CHEMICAL]resveratrol[\\CHEMICAL], which leads to activation of an [GENE]NAD(+)-dependent protein deacetylase SIRT1[\\GENE], suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and [CHEMICAL]resveratrol[\\CHEMICAL] administration down-regulated the [GENE]p300[\\GENE] protein level.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the \u03b1(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as [CHEMICAL]resveratrol[\\CHEMICAL], both of which down-regulated [GENE]p300[\\GENE] protein levels but not p300 mRNA levels.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "We previously reported that caffeoyl-amino acidyl-hydroxamic acid ([CHEMICAL]CA-Xaa-NHOH[\\CHEMICAL]) acted as both a good antioxidant and [GENE]tyrosinase[\\GENE] inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "In addition, derivatives of [CHEMICAL]caffeic acid[\\CHEMICAL] and sinapic acid efficiently inhibited [GENE]tyrosinase[\\GENE] activity and reduced melanin content in melanocytes Mel-Ab cell.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "In addition, derivatives of caffeic acid and [CHEMICAL]sinapic acid[\\CHEMICAL] efficiently inhibited [GENE]tyrosinase[\\GENE] activity and reduced melanin content in melanocytes Mel-Ab cell.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Synthesis and dual biological effects of [CHEMICAL]hydroxycinnamoyl phenylalanyl[\\CHEMICAL]/prolyl hydroxamic acid derivatives as [GENE]tyrosinase[\\GENE] inhibitor and antioxidant.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/[CHEMICAL]prolyl hydroxamic acid[\\CHEMICAL] derivatives as [GENE]tyrosinase[\\GENE] inhibitor and antioxidant.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "We previously reported that [CHEMICAL]caffeoyl-amino acidyl-hydroxamic acid[\\CHEMICAL] (CA-Xaa-NHOH) acted as both a good antioxidant and [GENE]tyrosinase[\\GENE] inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.",
        "label": 4,
        "major": 1,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Ruxolitinib[\\CHEMICAL] is a small-molecule inhibitor\u00a0of [GENE]JAK1[\\GENE] and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Ruxolitinib[\\CHEMICAL] is a small-molecule inhibitor\u00a0of JAK1 and [GENE]JAK2[\\GENE] and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Stenesen and colleagues (2012) activate [GENE]AMPK[\\GENE] both directly and indirectly by altering [CHEMICAL]AMP[\\CHEMICAL] biosynthesis to slow aging in Drosophila, highlighting AMPK as a conserved life span modulator that links energy sensing to longevity.",
        "label": 2,
        "major": 7,
        "len": 33
    },
    {
        "text": "Stenesen and colleagues (2012) activate [GENE]AMPK[\\GENE] both directly and indirectly by altering [CHEMICAL]AMP[\\CHEMICAL] biosynthesis to slow aging in Drosophila, highlighting AMPK as a conserved life span modulator that links energy sensing to longevity.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Pb[\\CHEMICAL] and BaP treatments significantly increased active [GENE]caspase-3[\\GENE] levels in a time-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "Pb and [CHEMICAL]BaP[\\CHEMICAL] treatments significantly increased active [GENE]caspase-3[\\GENE] levels in a time-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]TAA[\\CHEMICAL] increased the number and area of [GENE]glutathione S-transferase placental form[\\GENE] (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]TAA[\\CHEMICAL] increased the number and area of glutathione S-transferase placental form ([GENE]GST-P[\\GENE])(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]TAA[\\CHEMICAL] also increased the numbers of ED2(+), [GENE]cyclooxygenase-2[\\GENE](+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]TAA[\\CHEMICAL] also increased the numbers of ED2(+), cyclooxygenase-2(+), and [GENE]heme oxygenase-1[\\GENE](+) liver cells, as well as the number of CD3(+) lymphocytes.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]TAA[\\CHEMICAL] also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of [GENE]CD3[\\GENE](+) lymphocytes.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "With the exception of three residues, the specific [CHEMICAL]amino acids[\\CHEMICAL] that form the putative binding pocket for ICA in [GENE]ERG[\\GENE] are conserved in EAG.",
        "label": 1,
        "major": 1,
        "len": 24
    },
    {
        "text": "With the exception of three residues, the specific [CHEMICAL]amino acids[\\CHEMICAL] that form the putative binding pocket for ICA in ERG are conserved in [GENE]EAG[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 24
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of [GENE]EAG[\\GENE] and ERG potassium channels.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and [GENE]ERG[\\GENE] potassium channels.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG [GENE]potassium channels[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "With the exception of three residues, the specific amino acids that form the putative binding pocket for [CHEMICAL]ICA[\\CHEMICAL] in [GENE]ERG[\\GENE] are conserved in EAG.",
        "label": 2,
        "major": 1,
        "len": 24
    },
    {
        "text": "With the exception of three residues, the specific amino acids that form the putative binding pocket for [CHEMICAL]ICA[\\CHEMICAL] in ERG are conserved in [GENE]EAG[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 24
    },
    {
        "text": "Mutations introduced into [GENE]EAG[\\GENE] to replicate the [CHEMICAL]ICA[\\CHEMICAL] binding site in ERG did not alter the functional response to ICA.",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Mutations introduced into EAG to replicate the [CHEMICAL]ICA[\\CHEMICAL] binding site in [GENE]ERG[\\GENE] did not alter the functional response to ICA.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Mutations introduced into [GENE]EAG[\\GENE] to replicate the ICA binding site in ERG did not alter the functional response to [CHEMICAL]ICA[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Mutations introduced into EAG to replicate the ICA binding site in [GENE]ERG[\\GENE] did not alter the functional response to [CHEMICAL]ICA[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Together these findings suggest that [CHEMICAL]ICA[\\CHEMICAL] binds to the same site in [GENE]EAG[\\GENE] and ERG channels to elicit opposite functional effects.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Together these findings suggest that [CHEMICAL]ICA[\\CHEMICAL] binds to the same site in EAG and [GENE]ERG[\\GENE] channels to elicit opposite functional effects.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Although [CHEMICAL]ICA[\\CHEMICAL] greatly attenuates [GENE]ERG[\\GENE] inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of [GENE]EAG[\\GENE] and ERG potassium channels.",
        "label": 3,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and [GENE]ERG[\\GENE] potassium channels.",
        "label": 3,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ICA-105574[\\CHEMICAL] interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG [GENE]potassium channels[\\GENE].",
        "label": 3,
        "major": 2,
        "len": 20
    },
    {
        "text": "Although [CHEMICAL]ICA[\\CHEMICAL] greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of [GENE]EAG[\\GENE] inactivation without altering its voltage dependence.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]ICA[\\CHEMICAL] is a mixed agonist of mutant [GENE]EAG[\\GENE] and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "[CHEMICAL]ICA[\\CHEMICAL] is a mixed agonist of mutant EAG and [GENE]EAG[\\GENE]/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "[CHEMICAL]ICA[\\CHEMICAL] is a mixed agonist of mutant EAG and EAG/[GENE]ERG[\\GENE] chimera channels that inactivate by a combination of slow and fast mechanisms.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10\u00a0mg/kg) that was significantly reduced by the [GENE]serotonin 5-HT1a receptor[\\GENE] antagonist [CHEMICAL]WAY-100135[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "However the [GENE]\u03b17 receptor[\\GENE] antagonist [CHEMICAL]methyllycaconitine[\\CHEMICAL] was unable to reverse these anxiety-like effects seen with PNU-282987.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "As a result of this study, [CHEMICAL]microgrewiapine A[\\CHEMICAL] (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit [GENE]nicotinic receptor[\\GENE] antagonistic activity for both the h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes.",
        "label": 6,
        "major": 6,
        "len": 40
    },
    {
        "text": "Thus, SN mDA neurons are represented by at least two distinct subpopulations including [CHEMICAL]MPTP[\\CHEMICAL]-resistant [GENE]Pitx3[\\GENE]-autonomous, calbindin-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.",
        "label": 10,
        "major": 2,
        "len": 38
    },
    {
        "text": "IKK phosphorylates [GENE]BAD[\\GENE] at [CHEMICAL]serine[\\CHEMICAL]-26 (Ser26) and primes it for inactivation.",
        "label": 1,
        "major": 3,
        "len": 11
    },
    {
        "text": "IKK phosphorylates [GENE]BAD[\\GENE] at serine-26 ([CHEMICAL]Ser[\\CHEMICAL]26) and primes it for inactivation.",
        "label": 1,
        "major": 3,
        "len": 11
    },
    {
        "text": "Elimination of [CHEMICAL]Ser[\\CHEMICAL]26 phosphorylation promotes [GENE]BAD[\\GENE] proapoptotic activity, thereby accelerating TNF\u03b1-induced apoptosis in cultured cells and increasing mortality in animals.",
        "label": 1,
        "major": 3,
        "len": 20
    },
    {
        "text": "PURPOSE: To characterise further the previously observed [GENE]cytochrome P450 3A4[\\GENE] (CYP3A4) interaction of the dual orexin receptor antagonist [CHEMICAL]almorexant[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "PURPOSE: To characterise further the previously observed cytochrome P450 3A4 ([GENE]CYP3A4[\\GENE]) interaction of the dual orexin receptor antagonist [CHEMICAL]almorexant[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual [GENE]orexin receptor[\\GENE] antagonist [CHEMICAL]almorexant[\\CHEMICAL].",
        "label": 6,
        "major": 2,
        "len": 19
    },
    {
        "text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)\u2193Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature [GENE]BMP-2[\\GENE] peptide ([CHEMICAL]Arg[\\CHEMICAL](289)\u2193Lys(290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)\u2193Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature [GENE]BMP-2[\\GENE] peptide (Arg(289)\u2193[CHEMICAL]Lys[\\CHEMICAL](290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "[CHEMICAL]N[\\CHEMICAL]-terminal sequencing indicated that [GENE]pro-BMP-2[\\GENE] was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)\u2193Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)\u2193Lys(290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature [GENE]BMP-2[\\GENE] ([CHEMICAL]Arg[\\CHEMICAL](282)\u2193Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)\u2193Lys(290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature [GENE]BMP-2[\\GENE] (Arg(282)\u2193[CHEMICAL]Gln[\\CHEMICAL](283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)\u2193Lys(290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)\u2193Gln(283)), as well as in the [CHEMICAL]N[\\CHEMICAL]-terminal heparin binding region of mature [GENE]BMP-2[\\GENE], generating a truncated mature BMP-2 peptide (Arg(289)\u2193Lys(290)).",
        "label": 1,
        "major": 2,
        "len": 40
    },
    {
        "text": "Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse [GENE]5-HT2C[\\GENE] ligands result in different 5-HT2C receptor signaling outcomes compared to [CHEMICAL]DOI[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 31
    },
    {
        "text": "In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of [CHEMICAL]DOI[\\CHEMICAL] to activate mouse 5-HT2C receptor-mediated [GENE]PLC[\\GENE] signaling in HEK cells.",
        "label": 2,
        "major": 5,
        "len": 29
    },
    {
        "text": "Results indicate that 5-HT2C receptor agonists and antagonists attenuate the DOI-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse 5-HT2C ligands result in different [GENE]5-HT2C[\\GENE] receptor signaling outcomes compared to [CHEMICAL]DOI[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 31
    },
    {
        "text": "In\u00a0vitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the DOI-elicited-HTR also reduced the efficacy of [CHEMICAL]DOI[\\CHEMICAL] to activate [GENE]mouse 5-HT2C[\\GENE] receptor-mediated PLC signaling in HEK cells.",
        "label": 3,
        "major": 5,
        "len": 29
    },
    {
        "text": "Commercially-available [GENE]5-HT2C[\\GENE] agonists ([CHEMICAL]CP 809101[\\CHEMICAL], Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 5,
        "len": 35
    },
    {
        "text": "Commercially-available [GENE]5-HT2C[\\GENE] agonists (CP 809101, [CHEMICAL]Ro 60-0175[\\CHEMICAL], WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 6,
        "len": 35
    },
    {
        "text": "Commercially-available [GENE]5-HT2C[\\GENE] agonists (CP 809101, Ro 60-0175, [CHEMICAL]WAY 161503[\\CHEMICAL], mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 5,
        "len": 35
    },
    {
        "text": "Commercially-available [GENE]5-HT2C[\\GENE] agonists (CP 809101, Ro 60-0175, WAY 161503, [CHEMICAL]mCPP[\\CHEMICAL], and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 6,
        "len": 35
    },
    {
        "text": "Commercially-available [GENE]5-HT2C[\\GENE] agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and [CHEMICAL]1-methylpsilocin[\\CHEMICAL]), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 6,
        "len": 35
    },
    {
        "text": "Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a0[CHEMICAL]4-phenyl-2-N,N-dimethyl-aminotetralin[\\CHEMICAL] (PAT)-type [GENE]5-HT2C[\\GENE] agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 6,
        "len": 35
    },
    {
        "text": "Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin ([CHEMICAL]PAT[\\CHEMICAL])-type [GENE]5-HT2C[\\GENE] agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 5,
        "major": 10,
        "len": 35
    },
    {
        "text": "Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for [GENE]5-HT2A[\\GENE] ([CHEMICAL]M100907[\\CHEMICAL]), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 6,
        "major": 10,
        "len": 35
    },
    {
        "text": "Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel\u00a04-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), [GENE]5-HT2C[\\GENE] ([CHEMICAL]SB-242084[\\CHEMICAL]), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.",
        "label": 6,
        "major": 10,
        "len": 35
    },
    {
        "text": "This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based [GENE]CYP2B6[\\GENE] inhibitor [CHEMICAL]ticlopidine[\\CHEMICAL], given orally for 4 days.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Methadone[\\CHEMICAL] N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [GENE]CYP3A4[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Methadone[\\CHEMICAL] N-demethylation in vitro is catalyzed by hepatic [GENE]cytochrome P4502B6[\\GENE] (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Methadone[\\CHEMICAL] N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 ([GENE]CYP2B6[\\GENE]) and CYP3A4, but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Methadone[\\CHEMICAL] N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and [GENE]CYP3A4[\\GENE], but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Methadone [CHEMICAL]N[\\CHEMICAL]-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to [GENE]CYP3A4[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Methadone [CHEMICAL]N[\\CHEMICAL]-demethylation in vitro is catalyzed by hepatic [GENE]cytochrome P4502B6[\\GENE] (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Methadone [CHEMICAL]N[\\CHEMICAL]-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 ([GENE]CYP2B6[\\GENE]) and CYP3A4, but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Methadone [CHEMICAL]N[\\CHEMICAL]-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and [GENE]CYP3A4[\\GENE], but clinical disposition is often attributed to CYP3A4.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "CYP2B6 inhibition reduces methadone N-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for [GENE]CYP2B6[\\GENE] in clinical [CHEMICAL]methadone[\\CHEMICAL] disposition.",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "This investigation tested the hypothesis that [GENE]CYP2B6[\\GENE] is a prominent CYP isoform responsible for clinical [CHEMICAL]methadone[\\CHEMICAL] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "This investigation tested the hypothesis that CYP2B6 is a prominent [GENE]CYP[\\GENE] isoform responsible for clinical [CHEMICAL]methadone[\\CHEMICAL] N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "This investigation tested the hypothesis that [GENE]CYP2B6[\\GENE] is a prominent CYP isoform responsible for clinical methadone [CHEMICAL]N[\\CHEMICAL]-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "This investigation tested the hypothesis that CYP2B6 is a prominent [GENE]CYP[\\GENE] isoform responsible for clinical methadone [CHEMICAL]N[\\CHEMICAL]-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, [CHEMICAL]quinpirole[\\CHEMICAL], triggered an increase in the expression of [GENE]GDNF[\\GENE] that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",
        "label": 3,
        "major": 2,
        "len": 54
    },
    {
        "text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, [CHEMICAL]quinpirole[\\CHEMICAL], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of [GENE]zinc-finger protein 268[\\GENE] (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, [CHEMICAL]quinpirole[\\CHEMICAL], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 ([GENE]Zif268[\\GENE]), a DNA-binding transcription factor encoded by an immediate-early gene.",
        "label": 3,
        "major": 2,
        "len": 54
    },
    {
        "text": "Moreover, the D2R inhibitor [CHEMICAL]raclopride[\\CHEMICAL] blocked the increase of both [GENE]GDNF[\\GENE] and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Moreover, the D2R inhibitor [CHEMICAL]raclopride[\\CHEMICAL] blocked the increase of both GDNF and [GENE]Zif268[\\GENE] expression following potassium-evoked dopamine release in SH-SY5Y cells.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Moreover, the [GENE]D2R[\\GENE] inhibitor [CHEMICAL]raclopride[\\CHEMICAL] blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the [GENE]dopamine D2 receptor[\\GENE] (D2R) agonist, [CHEMICAL]quinpirole[\\CHEMICAL], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",
        "label": 5,
        "major": 5,
        "len": 54
    },
    {
        "text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor ([GENE]D2R[\\GENE]) agonist, [CHEMICAL]quinpirole[\\CHEMICAL], triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.",
        "label": 5,
        "major": 5,
        "len": 54
    },
    {
        "text": "In this paper a series of new [CHEMICAL]1,3,4-thiadiazole[\\CHEMICAL] derivatives has been designed, synthesized and evaluated as the [GENE]acetyl- and butyrylcholinesterase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Synthesis and biological evaluation of [CHEMICAL]1,3,4-thiadiazole[\\CHEMICAL] analogues as novel [GENE]AChE[\\GENE] and BuChE inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Synthesis and biological evaluation of [CHEMICAL]1,3,4-thiadiazole[\\CHEMICAL] analogues as novel AChE and [GENE]BuChE[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate [GENE]JNK[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/AKT inhibitor, selectively activated the [GENE]p38[\\GENE] MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/AKT inhibitor, selectively activated the p38 [GENE]MAPK[\\GENE] kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK [GENE]kinase[\\GENE] pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced [GENE]c-Jun[\\GENE] phosphorylation, but did not activate JNK.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific [GENE]PI3K[\\GENE]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "[CHEMICAL]LY294002[\\CHEMICAL], a specific PI3K/[GENE]AKT[\\GENE] inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The pharmacological inhibitors [CHEMICAL]SB203580[\\CHEMICAL] ([GENE]p38[\\GENE] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The pharmacological inhibitors SB203580 (p38 inhibitor) and [CHEMICAL]SP600125[\\CHEMICAL] (a [GENE]JNK[\\GENE] inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Autophagy takes place in mutated [GENE]p53[\\GENE] neuroblastoma cells in response to hypoxia mimetic [CHEMICAL]CoCl(2)[\\CHEMICAL].",
        "label": 2,
        "major": 1,
        "len": 14
    },
    {
        "text": "Today, we used [CHEMICAL]cobalt chloride[\\CHEMICAL], a hypoxia mimetic that inhibits proteasomal [GENE]HIF-1[\\GENE] degradation and generates reactive oxygen species (ROS).",
        "label": 3,
        "major": 4,
        "len": 19
    },
    {
        "text": "An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the [GENE]p53[\\GENE](mut) presence decreased with [CHEMICAL]CoCl2[\\CHEMICAL] time exposure.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Both [GENE]myosin-18A[\\GENE] isoforms bound [CHEMICAL]N-methylanthraniloyl-nucleotides[\\CHEMICAL], but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "[GENE]Actin[\\GENE] binding was unchanged by presence of [CHEMICAL]nucleotide[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 8
    },
    {
        "text": "USP7 binds directly to the [GENE]supervillin[\\GENE] [CHEMICAL]N[\\CHEMICAL] terminus and can deubiquitinate and stabilize supervillin.",
        "label": 1,
        "major": 2,
        "len": 14
    },
    {
        "text": "Cellular responses to DNA damage induced by [CHEMICAL]etoposide[\\CHEMICAL] or doxorubicin include down-regulation of endogenous supervillin coincident with increases in [GENE]p53[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Cellular responses to DNA damage induced by etoposide or [CHEMICAL]doxorubicin[\\CHEMICAL] include down-regulation of endogenous supervillin coincident with increases in [GENE]p53[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Cellular responses to DNA damage induced by [CHEMICAL]etoposide[\\CHEMICAL] or doxorubicin include down-regulation of endogenous [GENE]supervillin[\\GENE] coincident with increases in p53.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Cellular responses to DNA damage induced by etoposide or [CHEMICAL]doxorubicin[\\CHEMICAL] include down-regulation of endogenous [GENE]supervillin[\\GENE] coincident with increases in p53.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Novel [CHEMICAL]acylethanolamide[\\CHEMICAL] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin ([GENE]POMC[\\GENE]) and/or decreased neuropeptide Y (NPY).",
        "label": 3,
        "major": 4,
        "len": 18
    },
    {
        "text": "Novel [CHEMICAL]acylethanolamide[\\CHEMICAL] derivatives that modulate body weight through enhancement of hypothalamic [GENE]pro-opiomelanocortin[\\GENE] (POMC) and/or decreased neuropeptide Y (NPY).",
        "label": 3,
        "major": 7,
        "len": 18
    },
    {
        "text": "Novel [CHEMICAL]acylethanolamide[\\CHEMICAL] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased [GENE]neuropeptide Y[\\GENE] (NPY).",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Novel [CHEMICAL]acylethanolamide[\\CHEMICAL] derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y ([GENE]NPY[\\GENE]).",
        "label": 4,
        "major": 7,
        "len": 18
    },
    {
        "text": "Despite the importance of [GENE]UDP-glucuronosyltransferase (UGT) 1A1[\\GENE]*28 in [CHEMICAL]irinotecan[\\CHEMICAL] pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.",
        "label": 2,
        "major": 10,
        "len": 19
    },
    {
        "text": "Refining the [GENE]UGT1A[\\GENE] haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with [CHEMICAL]5-fluorouracil[\\CHEMICAL]/irinotecan-based regimens.",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "Refining the [GENE]UGT1A[\\GENE] haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/[CHEMICAL]irinotecan[\\CHEMICAL]-based regimens.",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "Refining the [GENE]UGT1A[\\GENE] haplotype associated with [CHEMICAL]irinotecan[\\CHEMICAL]-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to [CHEMICAL]DON[\\CHEMICAL] lead to similar intestinal lesions and activation of [GENE]MAPK[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "The food contaminant [CHEMICAL]deoxynivalenol[\\CHEMICAL] activates the [GENE]mitogen activated protein kinases[\\GENE] in the intestine: interest of ex vivo models as an alternative to in vivo experiments.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Paeoniflorin[\\CHEMICAL] protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the [GENE]NF-E2-related factor 2[\\GENE]/heme oxygenase-1 pathway.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Paeoniflorin[\\CHEMICAL] protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/[GENE]heme oxygenase-1[\\GENE] pathway.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "Furthermore, inhibition of [GENE]HO-1[\\GENE] with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of [CHEMICAL]Paeoniflorin[\\CHEMICAL] against radiation-induced damage in EA.hy926 cells.",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "Our findings confirmed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] protected EA.hy926 cells against radiation-induced injury through the [GENE]Nrf2[\\GENE]/HO-1 pathway.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Our findings confirmed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] protected EA.hy926 cells against radiation-induced injury through the Nrf2/[GENE]HO-1[\\GENE] pathway.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "In particular, we showed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and [GENE]superoxide dismutase[\\GENE] (SOD) in EA.hy926 cells.",
        "label": 3,
        "major": 4,
        "len": 42
    },
    {
        "text": "In particular, we showed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase ([GENE]SOD[\\GENE]) in EA.hy926 cells.",
        "label": 3,
        "major": 9,
        "len": 42
    },
    {
        "text": "Treatment of these cells with [CHEMICAL]Paeoniflorin[\\CHEMICAL] significantly induced [GENE]HO-1[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "The [CHEMICAL]Paeoniflorin[\\CHEMICAL]-induced [GENE]HO-1[\\GENE] expression was abrogated by Nrf2 siRNA.",
        "label": 3,
        "major": 3,
        "len": 9
    },
    {
        "text": "In particular, we showed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and [GENE]lactate dehydrogenase[\\GENE] (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "In particular, we showed that [CHEMICAL]Paeoniflorin[\\CHEMICAL] significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase ([GENE]LDH[\\GENE]) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.",
        "label": 4,
        "major": 9,
        "len": 42
    },
    {
        "text": "Furthermore, inhibition of [GENE]HO-1[\\GENE] with [CHEMICAL]zinc protoporphyrin IX[\\CHEMICAL] (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Furthermore, inhibition of [GENE]HO-1[\\GENE] with zinc protoporphyrin IX ([CHEMICAL]ZNPP[\\CHEMICAL]) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Palonosetron[\\CHEMICAL], a second-generation [GENE]5-HT3[\\GENE] receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.",
        "label": 6,
        "major": 6,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Aprepitant[\\CHEMICAL], the first and only agent clinically available in the [GENE]NK1 receptor[\\GENE] antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Rolapitant[\\CHEMICAL] and netupitant are other [GENE]NK1 receptor[\\GENE] antagonists that are currently in phase III clinical trials.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "Rolapitant and [CHEMICAL]netupitant[\\CHEMICAL] are other [GENE]NK1 receptor[\\GENE] antagonists that are currently in phase III clinical trials.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "Moderate inhibitory effect of [GENE]LDL[\\GENE]-C oxidation by [CHEMICAL]phytosteryl phenolates[\\CHEMICAL] was observed.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "Aqueous [CHEMICAL]ethanol[\\CHEMICAL] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting [GENE]15-LOX[\\GENE] (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Aqueous [CHEMICAL]ethanol[\\CHEMICAL] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate [GENE]COX-1[\\GENE] (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Aqueous [CHEMICAL]ethanol[\\CHEMICAL] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and [GENE]COX-2[\\GENE] (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Aqueous [CHEMICAL]ethanol[\\CHEMICAL] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the [GENE]COX[\\GENE] pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "Aqueous [CHEMICAL]ethanol[\\CHEMICAL] (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 \u03bcg/ml), with moderate COX-1 (IC(50), 66 \u03bcg/ml) and COX-2 (IC(50), 119 \u03bcg/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild [GENE]LOX[\\GENE] inhibitory activity.",
        "label": 4,
        "major": 4,
        "len": 47
    },
    {
        "text": "We searched for inhibitors of [GENE]HDC[\\GENE] from the [CHEMICAL]ethyl acetate[\\CHEMICAL] extract of the petal of Filipendula ulmaria, also called meadowsweet.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[GENE]Histidine decarboxylase[\\GENE] (HDC) catalyses the formation of histamine, a bioactive [CHEMICAL]amine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "Histidine decarboxylase ([GENE]HDC[\\GENE]) catalyses the formation of histamine, a bioactive [CHEMICAL]amine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "[GENE]Histidine decarboxylase[\\GENE] (HDC) catalyses the formation of [CHEMICAL]histamine[\\CHEMICAL], a bioactive amine.",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "Histidine decarboxylase ([GENE]HDC[\\GENE]) catalyses the formation of [CHEMICAL]histamine[\\CHEMICAL], a bioactive amine.",
        "label": 9,
        "major": 9,
        "len": 11
    },
    {
        "text": "High throughput screening led to the identification of a novel series of [CHEMICAL]quinolone[\\CHEMICAL] \u03b17 nicotinic acetylcholine receptor ([GENE]nAChR[\\GENE]) agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "High throughput screening led to the identification of a novel series of [CHEMICAL]quinolone[\\CHEMICAL] [GENE]\u03b17 nicotinic acetylcholine receptor[\\GENE] (nAChR) agonists.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "Discovery of a novel series of [CHEMICAL]quinolone[\\CHEMICAL] [GENE]\u03b17 nicotinic acetylcholine receptor[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 12
    },
    {
        "text": "This is distinct from [GENE]Rock[\\GENE] inhibitors based on non-[CHEMICAL]amino acid[\\CHEMICAL] derived quinazolinones, where high selectivity against PKA could be obtained.",
        "label": 4,
        "major": 1,
        "len": 20
    },
    {
        "text": "This is distinct from Rock inhibitors based on non-[CHEMICAL]amino acid[\\CHEMICAL] derived quinazolinones, where high selectivity against [GENE]PKA[\\GENE] could be obtained.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "This is distinct from [GENE]Rock[\\GENE] inhibitors based on non-amino acid derived [CHEMICAL]quinazolinones[\\CHEMICAL], where high selectivity against PKA could be obtained.",
        "label": 4,
        "major": 1,
        "len": 20
    },
    {
        "text": "This is distinct from Rock inhibitors based on non-amino acid derived [CHEMICAL]quinazolinones[\\CHEMICAL], where high selectivity against [GENE]PKA[\\GENE] could be obtained.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "SAR and lead optimization studies for [GENE]Rock[\\GENE] inhibitors based on [CHEMICAL]amino acid[\\CHEMICAL]-derived quinazolines are described.",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "SAR and lead optimization studies for [GENE]Rock[\\GENE] inhibitors based on amino acid-derived [CHEMICAL]quinazolines[\\CHEMICAL] are described.",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Amino acid[\\CHEMICAL] derived quinazolines as [GENE]Rock[\\GENE]/PKA inhibitors.",
        "label": 4,
        "major": 1,
        "len": 7
    },
    {
        "text": "[CHEMICAL]Amino acid[\\CHEMICAL] derived quinazolines as Rock/[GENE]PKA[\\GENE] inhibitors.",
        "label": 4,
        "major": 1,
        "len": 7
    },
    {
        "text": "Amino acid derived [CHEMICAL]quinazolines[\\CHEMICAL] as [GENE]Rock[\\GENE]/PKA inhibitors.",
        "label": 4,
        "major": 1,
        "len": 7
    },
    {
        "text": "Amino acid derived [CHEMICAL]quinazolines[\\CHEMICAL] as Rock/[GENE]PKA[\\GENE] inhibitors.",
        "label": 4,
        "major": 1,
        "len": 7
    },
    {
        "text": "The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the [GENE]IIA subdomain[\\GENE] and that upon binding, it acetylates [CHEMICAL]lysine[\\CHEMICAL] 199.",
        "label": 1,
        "major": 2,
        "len": 27
    },
    {
        "text": "The [GENE]acetylated albumin[\\GENE] had twofold weaker binding affinity for [CHEMICAL]diflunisal[\\CHEMICAL] as demonstrated by fluorescence quenching.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "Reduced binding affinity means that [CHEMICAL]diflunisal[\\CHEMICAL] is more easily released from [GENE]acetylated albumin[\\GENE] into the circulation.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because [CHEMICAL]diflunisal[\\CHEMICAL] strongly binds to [GENE]human serum albumin[\\GENE] (HSA).",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because [CHEMICAL]diflunisal[\\CHEMICAL] strongly binds to human serum albumin ([GENE]HSA[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "To reduce the binding affinity of [CHEMICAL]diflunisal[\\CHEMICAL] to [GENE]albumin[\\GENE], we designed and synthesized the prodrug acetyldiflunisal.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "The crystal structure of [GENE]HSA[\\GENE] complexed with [CHEMICAL]fatty acid[\\CHEMICAL] and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The crystal structure of [GENE]HSA[\\GENE] complexed with fatty acid and [CHEMICAL]acetyldiflunisal[\\CHEMICAL] revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that [CHEMICAL]acetyldiflunisal[\\CHEMICAL] binds to the [GENE]IIA subdomain[\\GENE] and that upon binding, it acetylates lysine 199.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The [GENE]cyclooxygenase-2[\\GENE] inhibitor, [CHEMICAL]diflunisal[\\CHEMICAL], is used in the clinic for its anti-inflammatory activity.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Although there was no change in the levels of [GENE]insulin receptor[\\GENE] (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 4,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor ([GENE]IR[\\GENE]), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 9,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), [GENE]Akt[\\GENE] (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 9,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt ([GENE]protein kinase B[\\GENE]) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 4,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and [GENE]glucose transporter-4[\\GENE] (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 9,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 ([GENE]GLUT4[\\GENE]) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 10,
        "major": 4,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, [GENE]Akt[\\GENE] and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 4,
        "major": 9,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the IR, Akt and [GENE]GLUT4[\\GENE] protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 4,
        "major": 9,
        "len": 42
    },
    {
        "text": "Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, [CHEMICAL]BPA[\\CHEMICAL] significantly decreased the [GENE]IR[\\GENE], Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, [GENE]lactate dehydrogenase[\\GENE], acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 3,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, [GENE]acid phosphatase[\\GENE], alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, [GENE]alkaline phosphatase[\\GENE] and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and [GENE]testicular steroidogenic enzymes[\\GENE]: 3\u03b2-hydroxysteroid dehydrogenase (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: [GENE]3\u03b2-hydroxysteroid dehydrogenase[\\GENE] (HSD), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase ([GENE]HSD[\\GENE]), 17\u03b2-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 3,
        "len": 51
    },
    {
        "text": "The obtained results showed that [CHEMICAL]Cd[\\CHEMICAL] increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3\u03b2-hydroxysteroid dehydrogenase (HSD), [GENE]17\u03b2-HSD[\\GENE] activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase ([GENE]GST[\\GENE])).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system ([GENE]superoxide dismutase[\\GENE] (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase ([GENE]SOD[\\GENE]), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), [GENE]catalase[\\GENE] (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase ([GENE]CAT[\\GENE]), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), [GENE]glutathione peroxidase[\\GENE] (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase ([GENE]GSH-Px[\\GENE]), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), [GENE]glutathione reductase[\\GENE] (GR), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase ([GENE]GR[\\GENE]), glutathione (GSH), and glutathione-S-transferase (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Acute intoxication with [CHEMICAL]Cd[\\CHEMICAL] was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and [GENE]glutathione-S-transferase[\\GENE] (GST)).",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10\u00b5M), revealing that [CHEMICAL]MeHg[\\CHEMICAL] increases [GENE]tyrosine hydroxylase[\\GENE] activity.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The [GENE]tyrosine hydroxylase[\\GENE] inhibitor [CHEMICAL]\u03b1-methyltyrosine[\\CHEMICAL] (300\u00b5M, 24h) completely abolished MeHg-induced DA release.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of [CHEMICAL]benzoxazinyl-oxazolidinone[\\CHEMICAL] analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low [GENE]hERG[\\GENE] inhibition.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "Activity of ponatinib against clinically-relevant [CHEMICAL]AC220[\\CHEMICAL]-resistant [GENE]kinase domain[\\GENE] mutants of FLT3-ITD.",
        "label": 10,
        "major": 1,
        "len": 11
    },
    {
        "text": "Activity of ponatinib against clinically-relevant [CHEMICAL]AC220[\\CHEMICAL]-resistant kinase domain mutants of [GENE]FLT3[\\GENE]-ITD.",
        "label": 10,
        "major": 1,
        "len": 11
    },
    {
        "text": "The switch control inhibitor [CHEMICAL]DCC-2036[\\CHEMICAL] was similarly inactive against [GENE]FLT3[\\GENE] AL mutations.",
        "label": 10,
        "major": 4,
        "len": 12
    },
    {
        "text": "Substitution of the [GENE]FLT3[\\GENE] \"gatekeeper\" [CHEMICAL]phenylalanine[\\CHEMICAL] with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.",
        "label": 1,
        "major": 3,
        "len": 30
    },
    {
        "text": "Substitution of the [GENE]FLT3[\\GENE] \"gatekeeper\" phenylalanine with [CHEMICAL]leucine[\\CHEMICAL] (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.",
        "label": 1,
        "major": 3,
        "len": 30
    },
    {
        "text": "Activity of [CHEMICAL]ponatinib[\\CHEMICAL] against clinically-relevant AC220-resistant [GENE]kinase domain[\\GENE] mutants of FLT3-ITD.",
        "label": 2,
        "major": 1,
        "len": 11
    },
    {
        "text": "Activity of [CHEMICAL]ponatinib[\\CHEMICAL] against clinically-relevant AC220-resistant kinase domain mutants of [GENE]FLT3[\\GENE]-ITD.",
        "label": 2,
        "major": 1,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Ponatinib[\\CHEMICAL] has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in [GENE]FLT3[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 21
    },
    {
        "text": "Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the [GENE]FLT3[\\GENE] inhibitors [CHEMICAL]AC220[\\CHEMICAL] (quizartinib) and sorafenib.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the [GENE]FLT3[\\GENE] inhibitors AC220 ([CHEMICAL]quizartinib[\\CHEMICAL]) and sorafenib.",
        "label": 4,
        "major": 1,
        "len": 29
    },
    {
        "text": "Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the [GENE]FLT3[\\GENE] inhibitors AC220 (quizartinib) and [CHEMICAL]sorafenib[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Ponatinib[\\CHEMICAL] (AP24534) is a [GENE]multikinase[\\GENE] inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.",
        "label": 4,
        "major": 1,
        "len": 25
    },
    {
        "text": "Ponatinib ([CHEMICAL]AP24534[\\CHEMICAL]) is a [GENE]multikinase[\\GENE] inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in [GENE]p53[\\GENE] levels could be detected in MCF-7 cells after [CHEMICAL]BSC[\\CHEMICAL] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.",
        "label": 10,
        "major": 4,
        "len": 38
    },
    {
        "text": "However, the involvement of the [GENE]caspase[\\GENE]-dependent pathway in the process of cell death induced by either [CHEMICAL]BSC[\\CHEMICAL] 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pancaspase inhibitor z-VAD-fmk.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Bisacylimidoselenocarbamates[\\CHEMICAL] Cause G2/M Arrest Associated with the Modulation of [GENE]CDK1[\\GENE] and Chk2 in Human Breast Cancer MCF-7 Cells.",
        "label": 2,
        "major": 7,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Bisacylimidoselenocarbamates[\\CHEMICAL] Cause G2/M Arrest Associated with the Modulation of CDK1 and [GENE]Chk2[\\GENE] in Human Breast Cancer MCF-7 Cells.",
        "label": 2,
        "major": 7,
        "len": 18
    },
    {
        "text": "Moreover, since reduced levels of [GENE]p21CIP1[\\GENE] and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after [CHEMICAL]BSC[\\CHEMICAL] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Moreover, since reduced levels of p21CIP1 and [GENE]Chk2[\\GENE] proteins but no change in p53 levels could be detected in MCF-7 cells after [CHEMICAL]BSC[\\CHEMICAL] 3g or 3n treatment our results suggest that BSC treated cells die from lethal mitosis.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "However, the involvement of the caspase-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan[GENE]caspase[\\GENE] inhibitor [CHEMICAL]z-VAD-fmk[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "These compounds were evaluated for their acetylcholinesterase (AChE) inhibitory activity and [CHEMICAL]5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile[\\CHEMICAL] was found to be the most potent against [GENE]AChE[\\GENE] with IC50 4.16 \u03bcmol/L.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "A one-pot domino synthesis and discovery of highly functionalized [CHEMICAL]dihydrobenzo[b]thiophenes[\\CHEMICAL] as [GENE]AChE[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including [CHEMICAL]paclitaxel[\\CHEMICAL], doxorubicin, actinomycin-D, and rapamycin, which are also [GENE]P-gp[\\GENE] substrates.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, [CHEMICAL]doxorubicin[\\CHEMICAL], actinomycin-D, and rapamycin, which are also [GENE]P-gp[\\GENE] substrates.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, [CHEMICAL]actinomycin-D[\\CHEMICAL], and rapamycin, which are also [GENE]P-gp[\\GENE] substrates.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and [CHEMICAL]rapamycin[\\CHEMICAL], which are also [GENE]P-gp[\\GENE] substrates.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[CHEMICAL]MMC[\\CHEMICAL] rats showed higher [GENE]quinone reductase[\\GENE] and depleted xanthine oxidase activities.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-[CHEMICAL]MMC[\\CHEMICAL] rats showed higher quinone reductase and depleted [GENE]xanthine oxidase[\\GENE] activities.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Conclusively, protein malnutrition alters CP, FU and [CHEMICAL]MMC[\\CHEMICAL] metabolism in rat stomach by enhancing [GENE]CCBL[\\GENE] pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.",
        "label": 9,
        "major": 3,
        "len": 31
    },
    {
        "text": "N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase ([GENE]JNK[\\GENE]) inhibitor ([CHEMICAL]SP600125[\\CHEMICAL], 33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg/ml) and 3.3% FCS.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "N-acetylcysteine (NAC, 33 mM) and the [GENE]c-jun N-terminal kinase[\\GENE] (JNK) inhibitor ([CHEMICAL]SP600125[\\CHEMICAL], 33 \u03bcM) further decreased the viability in the presence of DEP (200 \u03bcg/ml) and 3.3% FCS.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a [GENE]BK \u03b21[\\GENE] site that includes [CHEMICAL]Thr[\\CHEMICAL]169.",
        "label": 1,
        "major": 3,
        "len": 24
    },
    {
        "text": "The endogenous steroid [CHEMICAL]lithocholic acid[\\CHEMICAL] (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a [GENE]BK \u03b21[\\GENE] site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The endogenous steroid lithocholic acid ([CHEMICAL]LCA[\\CHEMICAL]) dilates cerebral arteries via BK channel activation, which requires recognition by a [GENE]BK \u03b21[\\GENE] site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]HENA[\\CHEMICAL] failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets \u03b21-containing BK channels via the [GENE]BK \u03b21[\\GENE] steroid-sensing site.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "The endogenous [CHEMICAL]steroid[\\CHEMICAL] lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a [GENE]BK \u03b21[\\GENE] site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The endogenous steroid [CHEMICAL]lithocholic acid[\\CHEMICAL] (LCA) dilates cerebral arteries via [GENE]BK channel[\\GENE] activation, which requires recognition by a BK \u03b21 site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The endogenous steroid lithocholic acid ([CHEMICAL]LCA[\\CHEMICAL]) dilates cerebral arteries via [GENE]BK channel[\\GENE] activation, which requires recognition by a BK \u03b21 site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "The endogenous [CHEMICAL]steroid[\\CHEMICAL] lithocholic acid (LCA) dilates cerebral arteries via [GENE]BK channel[\\GENE] activation, which requires recognition by a BK \u03b21 site that includes Thr169.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]HENA[\\CHEMICAL] activated the [GENE]BK (cbv1 + \u03b21) channels[\\GENE] cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of LCA.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "HENA activated the [GENE]BK (cbv1 + \u03b21) channels[\\GENE] cloned from rat cerebral artery myocytes with a potency (EC50 = 53 \u03bcM) similar to and an efficacy (\u00d72.5 potentiation) significantly greater than that of [CHEMICAL]LCA[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]HENA[\\CHEMICAL] failed to activate the channels made of cbv1 + \u03b22, \u03b23, \u03b24, or \u03b21T169A, indicating that this drug selectively targets [GENE]\u03b21-containing BK channels[\\GENE] via the BK \u03b21 steroid-sensing site.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "RATIONALE: [GENE]Histamine H3 receptor[\\GENE] antagonists, such as [CHEMICAL]ABT-288[\\CHEMICAL], have been shown to possess cognitive-enhancing and wakefulness-promoting effects.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Assessment of the abuse liability of [CHEMICAL]ABT-288[\\CHEMICAL], a novel [GENE]histamine H3 receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that [CHEMICAL]ABT-288[\\CHEMICAL] is unlikely to possess a high potential for abuse in the human population and suggests that [GENE]H3[\\GENE] antagonists, as a class, are similar in this regard.",
        "label": 6,
        "major": 6,
        "len": 45
    },
    {
        "text": "Uptake of [CHEMICAL]estrone-3-sulfate[\\CHEMICAL] (5\u2009nM) by [GENE]OATP1B1[\\GENE] was reduced by 82%-95%.",
        "label": 9,
        "major": 4,
        "len": 10
    },
    {
        "text": "The docking data indicated that [CHEMICAL]l-glutamine[\\CHEMICAL] bind to the [GENE]GLP-1 receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "[CHEMICAL]l-glutamine[\\CHEMICAL] decreased plasma glucose, increased plasma and pancreatic [GENE]insulin[\\GENE], increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "[CHEMICAL]l-glutamine[\\CHEMICAL] decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active [GENE]GLP-1[\\GENE] (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The objective of the present investigation was to evaluate [CHEMICAL]l-glutamine[\\CHEMICAL] increases [GENE]glucagon like peptide-1[\\GENE] (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "The objective of the present investigation was to evaluate [CHEMICAL]l-glutamine[\\CHEMICAL] increases glucagon like peptide-1 ([GENE]GLP-1[\\GENE]) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Oral [CHEMICAL]l-glutamine[\\CHEMICAL] increases active [GENE]GLP-1[\\GENE] (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "While CRF increased spontaneous glutamate release in the CeAL, [GENE]CRF[\\GENE] caused no significant changes to optogenetically evoked [CHEMICAL]glutamate[\\CHEMICAL] release in this region.",
        "label": 10,
        "major": 3,
        "len": 22
    },
    {
        "text": "In the present study, [CHEMICAL]hinokitiol[\\CHEMICAL] (1 and 2\u03bcM) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including [GENE]thrombin[\\GENE], arachidonic acid, and ADP.",
        "label": 10,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] did not influence the binding of a fluorescent triflavin probe to the [GENE]\u03b1IIb\u03b23 integrin[\\GENE] on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.",
        "label": 10,
        "major": 10,
        "len": 31
    },
    {
        "text": "In the present study, [CHEMICAL]hinokitiol[\\CHEMICAL] (1 and 2\u03bcM) inhibited the [GENE]collagen[\\GENE]-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.",
        "label": 4,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of [GENE]phospholipase C (PLC)\u03b32[\\GENE], protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, [GENE]protein kinase C[\\GENE] (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C ([GENE]PKC[\\GENE]), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), [GENE]mitogen-activated protein kinases[\\GENE] (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases ([GENE]MAPKs[\\GENE]), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and [GENE]Akt[\\GENE] in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] inhibited the phosphorylation of phospholipase C (PLC)\u03b32, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in [GENE]collagen[\\GENE]-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Hinokitiol[\\CHEMICAL] also reduced the [GENE]PKC[\\GENE] activation and platelet aggregation stimulated by PDBu.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "In conclusion, [CHEMICAL]hinokitiol[\\CHEMICAL] may inhibit platelet activation by inhibiting the [GENE]PLC\u03b32[\\GENE]-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]hinokitiol[\\CHEMICAL] may inhibit platelet activation by inhibiting the PLC\u03b32-[GENE]PKC[\\GENE] cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]hinokitiol[\\CHEMICAL] may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of [GENE]MAPKs[\\GENE] and Akt.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]hinokitiol[\\CHEMICAL] may inhibit platelet activation by inhibiting the PLC\u03b32-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and [GENE]Akt[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Novel [CHEMICAL]5-(benzyloxy)pyridin-2(1H)-one[\\CHEMICAL] derivatives as potent [GENE]c-Met[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 7
    },
    {
        "text": "Of the new compounds, Dmt(1)-(R)-\u03b2Pro(2)-[CHEMICAL]Trp[\\CHEMICAL](3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [GENE]MOR[\\GENE], in the picomolar range (Ki(\u03bc) = 3.72 pM).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Of the new compounds, Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-[CHEMICAL](2-furyl)Map[\\CHEMICAL](4) (analogue 12) displayed the highest affinity toward [GENE]MOR[\\GENE], in the picomolar range (Ki(\u03bc) = 3.72 pM).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Of the new compounds, [CHEMICAL]Dmt[\\CHEMICAL](1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [GENE]MOR[\\GENE], in the picomolar range (Ki(\u03bc) = 3.72 pM).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Of the new compounds, Dmt(1)-[CHEMICAL](R)-\u03b2Pro[\\CHEMICAL](2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [GENE]MOR[\\GENE], in the picomolar range (Ki(\u03bc) = 3.72 pM).",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Design, Synthesis, and Pharmacological Characterization of Novel [CHEMICAL]Endomorphin-1[\\CHEMICAL] Analogues as Extremely Potent [GENE]\u03bc-Opioid[\\GENE] Agonists.",
        "label": 5,
        "major": 5,
        "len": 14
    },
    {
        "text": "We report that two common variants of [GENE]high-temperature requirement A1[\\GENE] (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for [CHEMICAL]Ala[\\CHEMICAL]34 and Gly36 to less frequently used codons.",
        "label": 1,
        "major": 3,
        "len": 43
    },
    {
        "text": "We report that two common variants of high-temperature requirement A1 ([GENE]HTRA1[\\GENE]) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for [CHEMICAL]Ala[\\CHEMICAL]34 and Gly36 to less frequently used codons.",
        "label": 1,
        "major": 3,
        "len": 43
    },
    {
        "text": "We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of [GENE]HTRA1[\\GENE] that convert common codons for [CHEMICAL]Ala[\\CHEMICAL]34 and Gly36 to less frequently used codons.",
        "label": 1,
        "major": 3,
        "len": 43
    },
    {
        "text": "We report that two common variants of [GENE]high-temperature requirement A1[\\GENE] (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and [CHEMICAL]Gly[\\CHEMICAL]36 to less frequently used codons.",
        "label": 1,
        "major": 3,
        "len": 43
    },
    {
        "text": "We report that two common variants of high-temperature requirement A1 ([GENE]HTRA1[\\GENE]) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and [CHEMICAL]Gly[\\CHEMICAL]36 to less frequently used codons.",
        "label": 1,
        "major": 3,
        "len": 43
    },
    {
        "text": "We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of [GENE]HTRA1[\\GENE] that convert common codons for Ala34 and [CHEMICAL]Gly[\\CHEMICAL]36 to less frequently used codons.",
        "label": 1,
        "major": 9,
        "len": 43
    },
    {
        "text": "Wild-type mice were more sensitive to [CHEMICAL]DEX[\\CHEMICAL]-dependent decreases in [GENE]insulin[\\GENE] sensitivity than GR(dim/dim) mice.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "Interestingly, insulin treatment of \u03b1XBPKD cells reduced [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation of [GENE]IRS-1[\\GENE] (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.",
        "label": 1,
        "major": 4,
        "len": 23
    },
    {
        "text": "Interestingly, insulin treatment of \u03b1XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing [CHEMICAL]serine[\\CHEMICAL] phosphorylation (pS(307)) of [GENE]IRS-1[\\GENE].",
        "label": 1,
        "major": 4,
        "len": 23
    },
    {
        "text": "Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; [CHEMICAL]tetrahydrocannabinol[\\CHEMICAL] was included as the classical non-endogenous [GENE]cannabinoid receptor[\\GENE] ligand.",
        "label": 2,
        "major": 10,
        "len": 48
    },
    {
        "text": "Toxicological profiles of selected synthetic [CHEMICAL]cannabinoids[\\CHEMICAL] showing high binding affinities to the [GENE]cannabinoid receptor subtype CB1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with [CHEMICAL]JWH-210[\\CHEMICAL] and JWH-122 which caused a decrease of [GENE]TNF\u03b1[\\GENE] and IL-12/23p40.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with [CHEMICAL]JWH-210[\\CHEMICAL] and JWH-122 which caused a decrease of TNF\u03b1 and [GENE]IL-12[\\GENE]/23p40.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with [CHEMICAL]JWH-210[\\CHEMICAL] and JWH-122 which caused a decrease of TNF\u03b1 and IL-12/[GENE]23p40[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and [CHEMICAL]JWH-122[\\CHEMICAL] which caused a decrease of [GENE]TNF\u03b1[\\GENE] and IL-12/23p40.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and [CHEMICAL]JWH-122[\\CHEMICAL] which caused a decrease of TNF\u03b1 and [GENE]IL-12[\\GENE]/23p40.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF\u03b1 levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and [CHEMICAL]JWH-122[\\CHEMICAL] which caused a decrease of TNF\u03b1 and IL-12/[GENE]23p40[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Curcuminoids[\\CHEMICAL] Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and [GENE]Oxidized LDL[\\GENE] in Obese Individuals.",
        "label": 10,
        "major": 10,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Curcuminoids[\\CHEMICAL] Modulate Pro-Oxidant-Antioxidant Balance but not the Immune Response to [GENE]Heat Shock Protein 27[\\GENE] and Oxidized LDL in Obese Individuals.",
        "label": 10,
        "major": 7,
        "len": 20
    },
    {
        "text": "[CHEMICAL]AlCl3[\\CHEMICAL] markedly reduced AA performance and activities of [GENE]cytochrome c oxidase[\\GENE] (COX) and acetylcholinesterase (AChE) in all regions.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]AlCl3[\\CHEMICAL] markedly reduced AA performance and activities of cytochrome c oxidase ([GENE]COX[\\GENE]) and acetylcholinesterase (AChE) in all regions.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]AlCl3[\\CHEMICAL] markedly reduced AA performance and activities of cytochrome c oxidase (COX) and [GENE]acetylcholinesterase[\\GENE] (AChE) in all regions.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]AlCl3[\\CHEMICAL] markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase ([GENE]AChE[\\GENE]) in all regions.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Furthermore, the [CHEMICAL](22R)-spirosolanol glycoside[\\CHEMICAL] (11) selectively induced apoptosis in A549 cells without affecting the [GENE]caspase-3[\\GENE] activity level.",
        "label": 10,
        "major": 3,
        "len": 17
    },
    {
        "text": "The present study aimed to determine the protective effects and the underlying mechanisms of [CHEMICAL]curcumin[\\CHEMICAL] on [GENE]ovalbumin[\\GENE] (OVA)-induced allergic inflammation in a mouse model of allergic asthma.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Our study demonstrated that [CHEMICAL]curcumin[\\CHEMICAL] inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased [GENE]IL-10[\\GENE] level in bronchoalveolar lavage fluid.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Histological studies demonstrated that [CHEMICAL]curcumin[\\CHEMICAL] substantially inhibited [GENE]OVA[\\GENE]-induced eosinophilia in lung tissue.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "The results in vivo show [GENE]ovalbumin[\\GENE]-induced significantly broke Treg/Th17 balance; [CHEMICAL]curcumin[\\CHEMICAL] treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Our study demonstrated that [CHEMICAL]curcumin[\\CHEMICAL] inhibited [GENE]OVA[\\GENE]-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "Our study demonstrated that [CHEMICAL]curcumin[\\CHEMICAL] inhibited OVA-induced increases in eosinophil count; [GENE]interleukin (IL)-17A[\\GENE] level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "By combining our structure with previously solved [GENE]KIF1A[\\GENE] structures complexed with two [CHEMICAL]ATP[\\CHEMICAL] analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "Structural Basis for the [CHEMICAL]ATP[\\CHEMICAL]-Induced Isomerization of [GENE]Kinesin[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 8
    },
    {
        "text": "Previous studies have revealed that the [CHEMICAL]ATP[\\CHEMICAL] binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of [GENE]ATPase[\\GENE] activity to guarantee the processive movement of dimeric KIFs.",
        "label": 2,
        "major": 9,
        "len": 35
    },
    {
        "text": "Previous studies have revealed that the [CHEMICAL]ATP[\\CHEMICAL] binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of ATPase activity to guarantee the processive movement of dimeric [GENE]KIFs[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "In addition, putative osteogenic actions of [GENE]PTHrP[\\GENE] might be ascribed not only to its [CHEMICAL]N[\\CHEMICAL]-terminal domain but also to its PTH-unrelated C-terminal region.",
        "label": 1,
        "major": 10,
        "len": 23
    },
    {
        "text": "In addition, putative osteogenic actions of PTHrP might be ascribed not only to its N-terminal domain but also to its [GENE]PTH[\\GENE]-unrelated [CHEMICAL]C[\\CHEMICAL]-terminal region.",
        "label": 1,
        "major": 10,
        "len": 23
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a [CHEMICAL]Gd[\\CHEMICAL]-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to [GENE]proton pumps[\\GENE] in the stomach and colon.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent ([CHEMICAL]DOTA[\\CHEMICAL]), with pantoprazole, which is a widely used proton pump inhibitor that binds to [GENE]proton pumps[\\GENE] in the stomach and colon.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with [CHEMICAL]pantoprazole[\\CHEMICAL], which is a widely used proton pump inhibitor that binds to [GENE]proton pumps[\\GENE] in the stomach and colon.",
        "label": 2,
        "major": 4,
        "len": 44
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a [CHEMICAL]Gd[\\CHEMICAL]-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used [GENE]proton pump[\\GENE] inhibitor that binds to proton pumps in the stomach and colon.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent ([CHEMICAL]DOTA[\\CHEMICAL]), with pantoprazole, which is a widely used [GENE]proton pump[\\GENE] inhibitor that binds to proton pumps in the stomach and colon.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with [CHEMICAL]pantoprazole[\\CHEMICAL], which is a widely used [GENE]proton pump[\\GENE] inhibitor that binds to proton pumps in the stomach and colon.",
        "label": 4,
        "major": 2,
        "len": 44
    },
    {
        "text": "Synthesis of a [CHEMICAL]DOTA[\\CHEMICAL] (Gd(3+))-conjugate of [GENE]proton-pump[\\GENE] inhibitor pantoprazole for gastric wall imaging studies.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Synthesis of a DOTA ([CHEMICAL]Gd(3+)[\\CHEMICAL])-conjugate of [GENE]proton-pump[\\GENE] inhibitor pantoprazole for gastric wall imaging studies.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Synthesis of a DOTA (Gd(3+))-conjugate of [GENE]proton-pump[\\GENE] inhibitor [CHEMICAL]pantoprazole[\\CHEMICAL] for gastric wall imaging studies.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible [GENE]AChE[\\GENE] inhibitor [CHEMICAL]donepezil[\\CHEMICAL] (100nM).",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[GENE]CYP3A5[\\GENE] carrier status had no influence on midazolam oral clearance or its inhibition by [CHEMICAL]ketoconazole[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "We then evaluated the interactions with the [GENE]CYP3A[\\GENE] inhibitor [CHEMICAL]ketoconazole[\\CHEMICAL] (400\u2009mg q.d.)",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "A Nanogram Dose of the [GENE]CYP3A[\\GENE] Probe Substrate [CHEMICAL]Midazolam[\\CHEMICAL] to Evaluate Drug Interactions.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "[GENE]CYP3A5[\\GENE] carrier status had no influence on [CHEMICAL]midazolam[\\CHEMICAL] oral clearance or its inhibition by ketoconazole.",
        "label": 9,
        "major": 4,
        "len": 15
    },
    {
        "text": "CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; [GENE]CYP3A7[\\GENE] did not metabolize [CHEMICAL]BDP[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "[GENE]CYP3A4[\\GENE] and CYP3A5 metabolized [CHEMICAL]BDP[\\CHEMICAL] via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.",
        "label": 9,
        "major": 10,
        "len": 21
    },
    {
        "text": "CYP3A4 and [GENE]CYP3A5[\\GENE] metabolized [CHEMICAL]BDP[\\CHEMICAL] via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.",
        "label": 9,
        "major": 10,
        "len": 21
    },
    {
        "text": "Effect of the Potent Antiviral [CHEMICAL]1-Cinnamoyl-3,11-Dihydroxymeliacarpin[\\CHEMICAL] on [GENE]Cytokine[\\GENE] Production by Murine Macrophages Stimulated with HSV-2.",
        "label": 2,
        "major": 9,
        "len": 15
    },
    {
        "text": "The antiherpetic action of [CHEMICAL]CDM[\\CHEMICAL] was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the [GENE]cytokine[\\GENE] production using a bioassay and ELISA method.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In macrophages, levels of [GENE]TNF-\u03b1[\\GENE], IFN-\u03b3, NO, IL-6 and IL-10 were increased by [CHEMICAL]CDM[\\CHEMICAL] used alone or in combination with HSV-2.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "In macrophages, levels of TNF-\u03b1, [GENE]IFN-\u03b3[\\GENE], NO, IL-6 and IL-10 were increased by [CHEMICAL]CDM[\\CHEMICAL] used alone or in combination with HSV-2.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, [GENE]IL-6[\\GENE] and IL-10 were increased by [CHEMICAL]CDM[\\CHEMICAL] used alone or in combination with HSV-2.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "In macrophages, levels of TNF-\u03b1, IFN-\u03b3, NO, IL-6 and [GENE]IL-10[\\GENE] were increased by [CHEMICAL]CDM[\\CHEMICAL] used alone or in combination with HSV-2.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Besides, [CHEMICAL]CDM[\\CHEMICAL] not only synergized [GENE]TNF-\u03b1[\\GENE] production combined with IFN-\u03b3, but also prolonged its expression in time.",
        "label": 3,
        "major": 9,
        "len": 17
    },
    {
        "text": "Besides, [CHEMICAL]CDM[\\CHEMICAL] not only synergized TNF-\u03b1 production combined with [GENE]IFN-\u03b3[\\GENE], but also prolonged its expression in time.",
        "label": 3,
        "major": 10,
        "len": 17
    },
    {
        "text": "Results indicate that [CHEMICAL]CDM[\\CHEMICAL] inhibits HSV-2 multiplication in epithelial cells and also increases [GENE]cytokine[\\GENE] production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.",
        "label": 3,
        "major": 9,
        "len": 30
    },
    {
        "text": "A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an [GENE]11\u03b2-HSD1[\\GENE] inhibitor, [CHEMICAL]AMG 221[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Intestinal and hepatic first-pass extraction of the [GENE]11\u03b2-HSD1[\\GENE] inhibitor [CHEMICAL]AMG 221[\\CHEMICAL] in rats with chronic vascular catheters.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to [CHEMICAL]elisidepsin[\\CHEMICAL], whereas the presence of [GENE]KRAS[\\GENE] activating mutations was associated with resistance.",
        "label": 10,
        "major": 1,
        "len": 24
    },
    {
        "text": "In addition, high [GENE]ErbB3[\\GENE] and Muc1 expression was correlated with sensitivity to [CHEMICAL]elisidepsin[\\CHEMICAL], whereas the presence of KRAS activating mutations was associated with resistance.",
        "label": 2,
        "major": 1,
        "len": 24
    },
    {
        "text": "In addition, high ErbB3 and [GENE]Muc1[\\GENE] expression was correlated with sensitivity to [CHEMICAL]elisidepsin[\\CHEMICAL], whereas the presence of KRAS activating mutations was associated with resistance.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "In DU-PM cells with acquired resistance to [CHEMICAL]elisidepsin[\\CHEMICAL], ErbB3 expression was decreased, while [GENE]Bcl2[\\GENE] was increased.",
        "label": 3,
        "major": 4,
        "len": 16
    },
    {
        "text": "In DU-PM cells with acquired resistance to [CHEMICAL]elisidepsin[\\CHEMICAL], [GENE]ErbB3[\\GENE] expression was decreased, while Bcl2 was increased.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "Administration of [CHEMICAL]bicuculline[\\CHEMICAL], a [GENE]GABAA[\\GENE] inhibitor, isolated a single response to \u03c9-agatoxin, which was characterized by a reduction in network activity.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Administration of [CHEMICAL]bicuculline[\\CHEMICAL], a GABAA inhibitor, isolated a single response to [GENE]\u03c9-agatoxin[\\GENE], which was characterized by a reduction in network activity.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Compounds 8\u2009b and 10\u2009c selectively inhibited HDAC6 at the nanomolar level, whereas the other [CHEMICAL]hydroxamates[\\CHEMICAL] effected an increase in [GENE]acetyl-\u03b1-tubulin[\\GENE] levels in human acute myeloid leukemia U937 cells.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the [CHEMICAL]tert-butylcarbamate[\\CHEMICAL] group at the CAP moiety as [GENE]histone deacetylase[\\GENE] (HDAC) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the [CHEMICAL]tert-butylcarbamate[\\CHEMICAL] group at the CAP moiety as histone deacetylase ([GENE]HDAC[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel [CHEMICAL]pyrrole[\\CHEMICAL]- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as [GENE]histone deacetylase[\\GENE] (HDAC) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel [CHEMICAL]pyrrole[\\CHEMICAL]- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ([GENE]HDAC[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and [CHEMICAL]benzene[\\CHEMICAL]-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as [GENE]histone deacetylase[\\GENE] (HDAC) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and [CHEMICAL]benzene[\\CHEMICAL]-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ([GENE]HDAC[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based [CHEMICAL]hydroxamates[\\CHEMICAL] (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as [GENE]histone deacetylase[\\GENE] (HDAC) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based [CHEMICAL]hydroxamates[\\CHEMICAL] (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ([GENE]HDAC[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and [CHEMICAL]2'-aminoanilides[\\CHEMICAL] (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as [GENE]histone deacetylase[\\GENE] (HDAC) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and [CHEMICAL]2'-aminoanilides[\\CHEMICAL] (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase ([GENE]HDAC[\\GENE]) inhibitors.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]tert-Butylcarbamate[\\CHEMICAL]-Containing [GENE]Histone Deacetylase[\\GENE] Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "As a potent synthetic [GENE]APN[\\GENE] inhibitor (IC50=850nM, versus [CHEMICAL]bestatin[\\CHEMICAL] of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "As a potent synthetic [GENE]APN[\\GENE] inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), [CHEMICAL]LB-4b[\\CHEMICAL] was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "As a potent synthetic [GENE]APN[\\GENE] inhibitor (IC50=850nM, versus bestatin of 8.1\u03bcM), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than [CHEMICAL]bestatin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]LB-4b[\\CHEMICAL] is the first synthetic [GENE]APN[\\GENE] inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Discovery of a synthetic [GENE]Aminopeptidase N[\\GENE] inhibitor [CHEMICAL]LB-4b[\\CHEMICAL] as a potential anticancer agent.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Both types of granules contain [GENE]catechol oxidase[\\GENE] that catalyzes oxidative cross-linking of [CHEMICAL]L-DOPA[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "Under [CHEMICAL]NaCl[\\CHEMICAL] and sorbitol stresses, [GENE]catalase[\\GENE] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",
        "label": 3,
        "major": 1,
        "len": 20
    },
    {
        "text": "Under [CHEMICAL]NaCl[\\CHEMICAL] and sorbitol stresses, catalase ([GENE]CAT[\\GENE]) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",
        "label": 3,
        "major": 1,
        "len": 20
    },
    {
        "text": "Under NaCl and [CHEMICAL]sorbitol[\\CHEMICAL] stresses, [GENE]catalase[\\GENE] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",
        "label": 3,
        "major": 1,
        "len": 20
    },
    {
        "text": "Under NaCl and [CHEMICAL]sorbitol[\\CHEMICAL] stresses, catalase ([GENE]CAT[\\GENE]) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.",
        "label": 3,
        "major": 1,
        "len": 20
    },
    {
        "text": "Immunofluorescence staining and western blotting demonstrated that [CHEMICAL]cilostazol[\\CHEMICAL] treatment reduced GFAP and [GENE]VEGF[\\GENE] expression in the retinas of OLETF rats.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Immunofluorescence staining and western blotting demonstrated that [CHEMICAL]cilostazol[\\CHEMICAL] treatment reduced [GENE]GFAP[\\GENE] and VEGF expression in the retinas of OLETF rats.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Other dams received 1.8ng/kg/day of a mixture of [GENE]aryl hydrocarbon receptor[\\GENE] (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and [CHEMICAL]PC-dibenzofurans[\\CHEMICAL]) without or with 0.5M (0.5MAhR).",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "Other dams received 1.8ng/kg/day of a mixture of [GENE]aryl hydrocarbon receptor[\\GENE] (AhR) agonists ([CHEMICAL]non-ortho PCB[\\CHEMICAL]s, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "Other dams received 1.8ng/kg/day of a mixture of [GENE]aryl hydrocarbon receptor[\\GENE] (AhR) agonists (non-ortho PCBs, [CHEMICAL]PC-dibenzodioxins[\\CHEMICAL] and PC-dibenzofurans) without or with 0.5M (0.5MAhR).",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "Phlebotomy and dietary [CHEMICAL]iron[\\CHEMICAL] restriction reduces [GENE]serum transaminase[\\GENE] in NAFLD/NASH patients.",
        "label": 2,
        "major": 4,
        "len": 11
    },
    {
        "text": "We report the discovery of a novel series of ATP-competitive [GENE]Janus kinase 3[\\GENE] (JAK3) inhibitors based on the [CHEMICAL]5H-pyrrolo[2,3-b]pyrazine[\\CHEMICAL] scaffold.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "We report the discovery of a novel series of ATP-competitive Janus kinase 3 ([GENE]JAK3[\\GENE]) inhibitors based on the [CHEMICAL]5H-pyrrolo[2,3-b]pyrazine[\\CHEMICAL] scaffold.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Discovery of a series of novel [CHEMICAL]5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers[\\CHEMICAL], as potent [GENE]JAK3[\\GENE] kinase inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Discovery of a series of novel [CHEMICAL]5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers[\\CHEMICAL], as potent JAK3 [GENE]kinase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]ATO[\\CHEMICAL] inhibited the phosphorylation and activation of AKT and STAT3 through [GENE]Notch[\\GENE] signaling blockade.",
        "label": 4,
        "major": 10,
        "len": 14
    },
    {
        "text": "[CHEMICAL]ATO[\\CHEMICAL] inhibited the phosphorylation and activation of AKT and [GENE]STAT3[\\GENE] through Notch signaling blockade.",
        "label": 4,
        "major": 10,
        "len": 14
    },
    {
        "text": "[CHEMICAL]ATO[\\CHEMICAL] inhibited the phosphorylation and activation of [GENE]AKT[\\GENE] and STAT3 through Notch signaling blockade.",
        "label": 4,
        "major": 10,
        "len": 14
    },
    {
        "text": "These data show that the [CHEMICAL]ATO[\\CHEMICAL] is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of [GENE]Notch[\\GENE] pathway.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Arsenic trioxide[\\CHEMICAL] depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of [GENE]Notch[\\GENE] pathway.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Finally, epididymal mRNA abundance of [GENE]GLUT4[\\GENE] was significantly increased by [CHEMICAL]fisetin[\\CHEMICAL] supplementation, compared to levels in the control and HF groups.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The high fat diet significantly increased hepatic mRNA expressions of [GENE]PPAR\u03b3[\\GENE], SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with [CHEMICAL]fisetin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, [GENE]SREBP1C[\\GENE] and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with [CHEMICAL]fisetin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "The high fat diet significantly increased hepatic mRNA expressions of PPAR\u03b3, SREBP1C and [GENE]SCD-1[\\GENE] genes in comparison to the control diet, which was subsequently reversed by supplementation with [CHEMICAL]fisetin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "In addition, [CHEMICAL]fisetin[\\CHEMICAL] supplementation significantly reduced hepatic mRNA abundance of [GENE]FAS[\\GENE], ATPCL and G6Pase compared to the control group.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In addition, [CHEMICAL]fisetin[\\CHEMICAL] supplementation significantly reduced hepatic mRNA abundance of FAS, [GENE]ATPCL[\\GENE] and G6Pase compared to the control group.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In addition, [CHEMICAL]fisetin[\\CHEMICAL] supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and [GENE]G6Pase[\\GENE] compared to the control group.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Western blot assay demonstrated that [CHEMICAL]DICO[\\CHEMICAL] decreased Bcl-2 level and induced [GENE]Bax[\\GENE] translocation to cause cytochrome c release.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Western blot assay demonstrated that [CHEMICAL]DICO[\\CHEMICAL] decreased Bcl-2 level and induced Bax translocation to cause [GENE]cytochrome c[\\GENE] release.",
        "label": 3,
        "major": 4,
        "len": 18
    },
    {
        "text": "Western blot assay demonstrated that [CHEMICAL]DICO[\\CHEMICAL] decreased [GENE]Bcl-2[\\GENE] level and induced Bax translocation to cause cytochrome c release.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Quercetin[\\CHEMICAL] and rutin also increased [GENE]alkaline phosphatase[\\GENE] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Quercetin and [CHEMICAL]rutin[\\CHEMICAL] also increased [GENE]alkaline phosphatase[\\GENE] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Further, both the [CHEMICAL]flavonoids[\\CHEMICAL] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like [GENE]osteopontin[\\GENE], osterix, RunX2, osteoprotegerin and osteocalcin.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Further, both the [CHEMICAL]flavonoids[\\CHEMICAL] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, [GENE]osterix[\\GENE], RunX2, osteoprotegerin and osteocalcin.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Further, both the [CHEMICAL]flavonoids[\\CHEMICAL] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, [GENE]RunX2[\\GENE], osteoprotegerin and osteocalcin.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Further, both the [CHEMICAL]flavonoids[\\CHEMICAL] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, [GENE]osteoprotegerin[\\GENE] and osteocalcin.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Further, both the [CHEMICAL]flavonoids[\\CHEMICAL] were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and [GENE]osteocalcin[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede [CHEMICAL]S[\\CHEMICAL]-nitrosation of [GENE]GSTP1-1[\\GENE].",
        "label": 1,
        "major": 10,
        "len": 34
    },
    {
        "text": "LPO was increased while as GSH, [GENE]CAT[\\GENE] and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [CHEMICAL]NAC[\\CHEMICAL] restored these liver markers to normal levels (p<0.001).",
        "label": 3,
        "major": 4,
        "len": 29
    },
    {
        "text": "LPO was increased while as GSH, CAT and [GENE]GPx[\\GENE] decreased by the administration of CCl4 and TAA (p<0.001); co-administration of [CHEMICAL]NAC[\\CHEMICAL] restored these liver markers to normal levels (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Serum markers of liver damage ([GENE]AST[\\GENE], ALT, ALP and Bilirubin) were increased by [CHEMICAL]CCl4[\\CHEMICAL] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, [GENE]ALT[\\GENE], ALP and Bilirubin) were increased by [CHEMICAL]CCl4[\\CHEMICAL] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, ALT, [GENE]ALP[\\GENE] and Bilirubin) were increased by [CHEMICAL]CCl4[\\CHEMICAL] and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage ([GENE]AST[\\GENE], ALT, ALP and Bilirubin) were increased by CCl4 and [CHEMICAL]TAA[\\CHEMICAL] intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, [GENE]ALT[\\GENE], ALP and Bilirubin) were increased by CCl4 and [CHEMICAL]TAA[\\CHEMICAL] intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, ALT, [GENE]ALP[\\GENE] and Bilirubin) were increased by CCl4 and [CHEMICAL]TAA[\\CHEMICAL] intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage ([GENE]AST[\\GENE], ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [CHEMICAL]NAC[\\CHEMICAL] reversed such changes (p<0.001).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, [GENE]ALT[\\GENE], ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [CHEMICAL]NAC[\\CHEMICAL] reversed such changes (p<0.001).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Serum markers of liver damage (AST, ALT, [GENE]ALP[\\GENE] and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with [CHEMICAL]NAC[\\CHEMICAL] reversed such changes (p<0.001).",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Oxysterol[\\CHEMICAL]-dependent [GENE]NOX1[\\GENE] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking [CHEMICAL]oxysterol[\\CHEMICAL]-related [GENE]NOX1[\\GENE] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",
        "label": 3,
        "major": 3,
        "len": 36
    },
    {
        "text": "[CHEMICAL]Oxysterol[\\CHEMICAL]-dependent NOX1 activation, as well as [GENE]interleukin[\\GENE] synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in [GENE]interleukin[\\GENE] synthesis induced by dietary [CHEMICAL]oxysterols[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial [GENE]NOX1[\\GENE] down-regulation and was ineffective in interleukin synthesis induced by dietary [CHEMICAL]oxysterols[\\CHEMICAL].",
        "label": 3,
        "major": 9,
        "len": 28
    },
    {
        "text": "Oxysterol-dependent NOX1 activation, as well as [GENE]interleukin[\\GENE] synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular [CHEMICAL]phenolic acids[\\CHEMICAL] and flavonoids.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Oxysterol-dependent NOX1 activation, as well as [GENE]interleukin[\\GENE] synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and [CHEMICAL]flavonoids[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Oxysterol-dependent [GENE]NOX1[\\GENE] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular [CHEMICAL]phenolic acids[\\CHEMICAL] and flavonoids.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Oxysterol-dependent [GENE]NOX1[\\GENE] activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and [CHEMICAL]flavonoids[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Besides this direct activity, an excess of [CHEMICAL]phenolic[\\CHEMICAL] compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related [GENE]NOX1[\\GENE] induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "In a different group of BMT patients treated with [CHEMICAL]cyclosporine[\\CHEMICAL], the magnitude of interaction with [GENE]IL-6[\\GENE] was under predicted ~3-fold.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "In contrast, activation of Nrf2 by [CHEMICAL]sulforaphane[\\CHEMICAL] and tert-butylhydroquinone depend upon Keap1-C151 and not [GENE]p62[\\GENE] (the canonical mechanism).",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "In contrast, activation of Nrf2 by sulforaphane and [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL] depend upon Keap1-C151 and not [GENE]p62[\\GENE] (the canonical mechanism).",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Arsenic[\\CHEMICAL] inhibits autophagic flux activating the Nrf2-Keap1 pathway in a [GENE]p62[\\GENE]-dependent manner.",
        "label": 2,
        "major": 4,
        "len": 12
    },
    {
        "text": "Thus, [CHEMICAL]arsenic[\\CHEMICAL] activates Nrf2 through a non-canonical mechanism ([GENE]p62[\\GENE]-dependent), leading to a chronic, sustained activation of Nrf2.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "In contrast, activation of Nrf2 by [CHEMICAL]sulforaphane[\\CHEMICAL] and tert-butylhydroquinone depend upon [GENE]Keap1[\\GENE]-C151 and not p62 (the canonical mechanism).",
        "label": 2,
        "major": 10,
        "len": 18
    },
    {
        "text": "In contrast, activation of Nrf2 by sulforaphane and [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL] depend upon [GENE]Keap1[\\GENE]-C151 and not p62 (the canonical mechanism).",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Arsenic[\\CHEMICAL] inhibits autophagic flux activating the [GENE]Nrf2[\\GENE]-Keap1 pathway in a p62-dependent manner.",
        "label": 3,
        "major": 3,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Arsenic[\\CHEMICAL] inhibits autophagic flux activating the Nrf2-[GENE]Keap1[\\GENE] pathway in a p62-dependent manner.",
        "label": 3,
        "major": 4,
        "len": 12
    },
    {
        "text": "Collectively, these findings provide evidence that [CHEMICAL]arsenic[\\CHEMICAL] causes prolonged activation of [GENE]Nrf2[\\GENE] through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of Nrf2 found in certain human cancers.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Collectively, these findings provide evidence that [CHEMICAL]arsenic[\\CHEMICAL] causes prolonged activation of Nrf2 through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of [GENE]Nrf2[\\GENE] found in certain human cancers.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Thus, [CHEMICAL]arsenic[\\CHEMICAL] activates [GENE]Nrf2[\\GENE] through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of Nrf2.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Thus, [CHEMICAL]arsenic[\\CHEMICAL] activates Nrf2 through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of [GENE]Nrf2[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "In contrast, activation of [GENE]Nrf2[\\GENE] by [CHEMICAL]sulforaphane[\\CHEMICAL] and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "In contrast, activation of [GENE]Nrf2[\\GENE] by sulforaphane and [CHEMICAL]tert-butylhydroquinone[\\CHEMICAL] depend upon Keap1-C151 and not p62 (the canonical mechanism).",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "Ovarian [GENE]AR[\\GENE] was not influenced by either treatment, and oviduct AR was reduced after [CHEMICAL]ethanol[\\CHEMICAL]-melatonin combination.",
        "label": 10,
        "major": 4,
        "len": 16
    },
    {
        "text": "Ovarian [GENE]AR[\\GENE] was not influenced by either treatment, and oviduct AR was reduced after ethanol-[CHEMICAL]melatonin[\\CHEMICAL] combination.",
        "label": 10,
        "major": 4,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Ethanol[\\CHEMICAL] and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of [GENE]sex steroid receptors[\\GENE] in female reproductive tissues.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "Ethanol and [CHEMICAL]melatonin[\\CHEMICAL] exert opposite effects on E2 and P4, and they differentially regulate the expression of [GENE]sex steroid receptors[\\GENE] in female reproductive tissues.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]MT1R[\\GENE] was increased in ovaries and uteri of [CHEMICAL]melatonin[\\CHEMICAL]-treated rats.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "Ovarian AR was not influenced by either treatment, and oviduct [GENE]AR[\\GENE] was reduced after [CHEMICAL]ethanol[\\CHEMICAL]-melatonin combination.",
        "label": 4,
        "major": 10,
        "len": 16
    },
    {
        "text": "Ovarian AR was not influenced by either treatment, and oviduct [GENE]AR[\\GENE] was reduced after ethanol-[CHEMICAL]melatonin[\\CHEMICAL] combination.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Oviduct [GENE]ER-\u03b1[\\GENE], ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either [CHEMICAL]ethanol[\\CHEMICAL] or melatonin.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Oviduct ER-\u03b1, [GENE]ER-\u03b2[\\GENE] and uterine ER-\u03b2 were down-regulated by either [CHEMICAL]ethanol[\\CHEMICAL] or melatonin.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Oviduct ER-\u03b1, ER-\u03b2 and uterine [GENE]ER-\u03b2[\\GENE] were down-regulated by either [CHEMICAL]ethanol[\\CHEMICAL] or melatonin.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Oviduct [GENE]ER-\u03b1[\\GENE], ER-\u03b2 and uterine ER-\u03b2 were down-regulated by either ethanol or [CHEMICAL]melatonin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Oviduct ER-\u03b1, [GENE]ER-\u03b2[\\GENE] and uterine ER-\u03b2 were down-regulated by either ethanol or [CHEMICAL]melatonin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Oviduct ER-\u03b1, ER-\u03b2 and uterine [GENE]ER-\u03b2[\\GENE] were down-regulated by either ethanol or [CHEMICAL]melatonin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Conversely, ovarian PRA and PRB were positively regulated by ethanol and ethanol-melatonin combination, whereas [GENE]PRA[\\GENE] was down-regulated in the uterus and oviduct after [CHEMICAL]ethanol[\\CHEMICAL] consumption.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "Conversely, ovarian [GENE]PRA[\\GENE] and PRB were positively regulated by [CHEMICAL]ethanol[\\CHEMICAL] and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 9,
        "len": 25
    },
    {
        "text": "Conversely, ovarian PRA and [GENE]PRB[\\GENE] were positively regulated by [CHEMICAL]ethanol[\\CHEMICAL] and ethanol-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 9,
        "len": 25
    },
    {
        "text": "Conversely, ovarian [GENE]PRA[\\GENE] and PRB were positively regulated by ethanol and [CHEMICAL]ethanol[\\CHEMICAL]-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 4,
        "len": 25
    },
    {
        "text": "Conversely, ovarian PRA and [GENE]PRB[\\GENE] were positively regulated by ethanol and [CHEMICAL]ethanol[\\CHEMICAL]-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 4,
        "len": 25
    },
    {
        "text": "Conversely, ovarian [GENE]PRA[\\GENE] and PRB were positively regulated by ethanol and ethanol-[CHEMICAL]melatonin[\\CHEMICAL] combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 9,
        "len": 25
    },
    {
        "text": "Conversely, ovarian PRA and [GENE]PRB[\\GENE] were positively regulated by ethanol and ethanol-[CHEMICAL]melatonin[\\CHEMICAL] combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.",
        "label": 7,
        "major": 9,
        "len": 25
    },
    {
        "text": "Intraplantar or intrathecal administered Ph\u03b11\u03b2 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with [CHEMICAL]SB366791[\\CHEMICAL], a specific [GENE]TRPV1[\\GENE] antagonist.",
        "label": 6,
        "major": 4,
        "len": 25
    },
    {
        "text": "While [CHEMICAL]imatinib[\\CHEMICAL] was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of [GENE]p53[\\GENE], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 10,
        "major": 4,
        "len": 41
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates [GENE]TAp63[\\GENE]-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of [GENE]TAp73[\\GENE] by c-Abl-induced BAX expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by [GENE]c-Abl[\\GENE]-induced BAX expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Our findings indicate that [CHEMICAL]imatinib[\\CHEMICAL] protects oocytes from cisplatin-induced cell death by inhibiting c-Abl [GENE]kinase[\\GENE], which would otherwise activate TAp73-BAX-mediated apoptosis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that imatinib protects oocytes from [CHEMICAL]cisplatin[\\CHEMICAL]-induced cell death by inhibiting [GENE]c-Abl[\\GENE] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that imatinib protects oocytes from [CHEMICAL]cisplatin[\\CHEMICAL]-induced cell death by inhibiting c-Abl [GENE]kinase[\\GENE], which would otherwise activate TAp73-BAX-mediated apoptosis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that imatinib protects oocytes from [CHEMICAL]cisplatin[\\CHEMICAL]-induced cell death by inhibiting c-Abl kinase, which would otherwise activate [GENE]TAp73[\\GENE]-BAX-mediated apoptosis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that imatinib protects oocytes from [CHEMICAL]cisplatin[\\CHEMICAL]-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-[GENE]BAX[\\GENE]-mediated apoptosis.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "We found that, before apoptosis, [CHEMICAL]cisplatin[\\CHEMICAL] induces [GENE]c-Abl[\\GENE] and TAp73 expression in the oocyte.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "We found that, before apoptosis, [CHEMICAL]cisplatin[\\CHEMICAL] induces c-Abl and [GENE]TAp73[\\GENE] expression in the oocyte.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "While imatinib was unable to block [CHEMICAL]cisplatin[\\CHEMICAL]-induced DNA damage and damage response, such as the upregulation of [GENE]p53[\\GENE], imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [CHEMICAL]imatinib[\\CHEMICAL] inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of [GENE]TAp63[\\GENE] and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 3,
        "major": 4,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the [CHEMICAL]cisplatin[\\CHEMICAL]-induced nuclear accumulation of [GENE]c-Abl[\\GENE]/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the [CHEMICAL]cisplatin[\\CHEMICAL]-induced nuclear accumulation of c-Abl/[GENE]TAp73[\\GENE] and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the [CHEMICAL]cisplatin[\\CHEMICAL]-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of [GENE]Bax[\\GENE], thereby abrogating oocyte cell death.",
        "label": 3,
        "major": 3,
        "len": 41
    },
    {
        "text": "Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of [GENE]c-Abl[\\GENE] and TAp73 caused by [CHEMICAL]cisplatin[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "Surprisingly, the conditional deletion of Trp63, but not \u0394Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and [GENE]TAp73[\\GENE] caused by [CHEMICAL]cisplatin[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates TAp63-dependent expression of [GENE]c-Abl[\\GENE] and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates TAp63-dependent expression of c-Abl and [GENE]TAp73[\\GENE] and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that [CHEMICAL]cisplatin[\\CHEMICAL] activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced [GENE]BAX[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [CHEMICAL]imatinib[\\CHEMICAL] inhibited the cisplatin-induced nuclear accumulation of [GENE]c-Abl[\\GENE]/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [CHEMICAL]imatinib[\\CHEMICAL] inhibited the cisplatin-induced nuclear accumulation of c-Abl/[GENE]TAp73[\\GENE] and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, [CHEMICAL]imatinib[\\CHEMICAL] inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of [GENE]Bax[\\GENE], thereby abrogating oocyte cell death.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the [CHEMICAL]cisplatin[\\CHEMICAL]-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of [GENE]TAp63[\\GENE] and upregulation of Bax, thereby abrogating oocyte cell death.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "Recently, the [GENE]c-Abl[\\GENE] kinase inhibitor [CHEMICAL]imatinib mesylate[\\CHEMICAL] (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Recently, the c-Abl [GENE]kinase[\\GENE] inhibitor [CHEMICAL]imatinib mesylate[\\CHEMICAL] (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Recently, the [GENE]c-Abl[\\GENE] kinase inhibitor imatinib mesylate ([CHEMICAL]imatinib[\\CHEMICAL]) has become the focus of research as a fertoprotective drug against cisplatin.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Recently, the c-Abl [GENE]kinase[\\GENE] inhibitor imatinib mesylate ([CHEMICAL]imatinib[\\CHEMICAL]) has become the focus of research as a fertoprotective drug against cisplatin.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Our findings indicate that [CHEMICAL]imatinib[\\CHEMICAL] protects oocytes from cisplatin-induced cell death by inhibiting [GENE]c-Abl[\\GENE] kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that [CHEMICAL]imatinib[\\CHEMICAL] protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate [GENE]TAp73[\\GENE]-BAX-mediated apoptosis.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Our findings indicate that [CHEMICAL]imatinib[\\CHEMICAL] protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-[GENE]BAX[\\GENE]-mediated apoptosis.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Thus, [CHEMICAL]imatinib[\\CHEMICAL] and other [GENE]c-Abl[\\GENE] kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "Thus, [CHEMICAL]imatinib[\\CHEMICAL] and other c-Abl [GENE]kinase[\\GENE] inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "These results suggest that [GENE]ZIP8[\\GENE] plays a pivotal role in the transport and toxicity of [CHEMICAL]Cd(2+)[\\CHEMICAL] and Mn(2+) in RBL-2H3 cells.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Among the possible transporters involved in the uptake of [CHEMICAL]Cd(2+)[\\CHEMICAL] and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [GENE]Slc39a8[\\GENE], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Among the possible transporters involved in the uptake of [CHEMICAL]Cd(2+)[\\CHEMICAL] and Mn(2+), the expression of [GENE]ZIP8[\\GENE] (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Among the possible transporters involved in the uptake of [CHEMICAL]Cd(2+)[\\CHEMICAL] and Mn(2+), the expression of ZIP8 ([GENE]Zrt-, Irt-related protein 8[\\GENE]), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Among the possible transporters involved in the uptake of Cd(2+) and [CHEMICAL]Mn(2+)[\\CHEMICAL], the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [GENE]Slc39a8[\\GENE], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Among the possible transporters involved in the uptake of Cd(2+) and [CHEMICAL]Mn(2+)[\\CHEMICAL], the expression of [GENE]ZIP8[\\GENE] (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Among the possible transporters involved in the uptake of Cd(2+) and [CHEMICAL]Mn(2+)[\\CHEMICAL], the expression of ZIP8 ([GENE]Zrt-, Irt-related protein 8[\\GENE]), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "These results suggest that [GENE]ZIP8[\\GENE] plays a pivotal role in the transport and toxicity of Cd(2+) and [CHEMICAL]Mn(2+)[\\CHEMICAL] in RBL-2H3 cells.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of [CHEMICAL]1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione[\\CHEMICAL] inhibitors of [GENE]HIV capsid[\\GENE] (CA) assembly are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of [CHEMICAL]1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione[\\CHEMICAL] inhibitors of HIV capsid ([GENE]CA[\\GENE]) assembly are described.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of [GENE]HIV capsid[\\GENE] assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[CHEMICAL]phenyl[\\CHEMICAL] moiety.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Optimization of a [CHEMICAL]1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione[\\CHEMICAL] series of [GENE]HIV capsid[\\GENE] assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Arsenic[\\CHEMICAL] upregulates the expression of [GENE]angiotensin II Type I receptor[\\GENE] in mouse aortic endothelial cells.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Taken together, our results indicate that [CHEMICAL]arsenic[\\CHEMICAL] indeed upregulates the [GENE]AT1R[\\GENE] expression, thus highlighting a role of arsenic-induced aberrant AT1R signaling in the pathogenesis of hypertension.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Taken together, our results indicate that arsenic indeed upregulates the AT1R expression, thus highlighting a role of [CHEMICAL]arsenic[\\CHEMICAL]-induced aberrant [GENE]AT1R[\\GENE] signaling in the pathogenesis of hypertension.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 [GENE]AT1R[\\GENE] subtypes, AT1AR and AT1BR following [CHEMICAL]sodium arsenite[\\CHEMICAL] (SA) treatment.",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, [GENE]AT1AR[\\GENE] and AT1BR following [CHEMICAL]sodium arsenite[\\CHEMICAL] (SA) treatment.",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "To delineate the pathogenesis, we examined changes in the mRNA levels of 2 angiotensin II Type I receptor (AT1R) subtypes, AT1AR and AT1BR, in a mouse aortic endothelial cell line, END-D. Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and [GENE]AT1BR[\\GENE] following [CHEMICAL]sodium arsenite[\\CHEMICAL] (SA) treatment.",
        "label": 3,
        "major": 3,
        "len": 54
    },
    {
        "text": "Finally, SA-induced [GENE]AT1R[\\GENE] expression was found to be prevented both by NAC and specific JNK inhibitor, [CHEMICAL]SP6001325[\\CHEMICAL], strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific [GENE]JNK[\\GENE] inhibitor, [CHEMICAL]SP6001325[\\CHEMICAL], strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "The expressions of [GENE]HSP70[\\GENE] and HO-1 were significantly (P<0.05) increased in the [CHEMICAL]NaAsO2[\\CHEMICAL] group and reduced in the combined treatment group.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The expressions of HSP70 and [GENE]HO-1[\\GENE] were significantly (P<0.05) increased in the [CHEMICAL]NaAsO2[\\CHEMICAL] group and reduced in the combined treatment group.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "The mRNA levels of [GENE]SOD1[\\GENE], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined [CHEMICAL]Na2SeO3[\\CHEMICAL]+NaAsO2 treatment group.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, [GENE]CAT[\\GENE], GPx and Txnrd1 were increased significantly (P<0.05) in the combined [CHEMICAL]Na2SeO3[\\CHEMICAL]+NaAsO2 treatment group.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, CAT, [GENE]GPx[\\GENE] and Txnrd1 were increased significantly (P<0.05) in the combined [CHEMICAL]Na2SeO3[\\CHEMICAL]+NaAsO2 treatment group.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of [GENE]SOD1[\\GENE], CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[CHEMICAL]NaAsO2[\\CHEMICAL] treatment group.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, [GENE]CAT[\\GENE], GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[CHEMICAL]NaAsO2[\\CHEMICAL] treatment group.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, CAT, [GENE]GPx[\\GENE] and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+[CHEMICAL]NaAsO2[\\CHEMICAL] treatment group.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, CAT, GPx and [GENE]Txnrd1[\\GENE] were increased significantly (P<0.05) in the combined Na2SeO3+[CHEMICAL]NaAsO2[\\CHEMICAL] treatment group.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "The mRNA levels of SOD1, CAT, GPx and [GENE]Txnrd1[\\GENE] were increased significantly (P<0.05) in the combined [CHEMICAL]Na2SeO3[\\CHEMICAL]+NaAsO2 treatment group.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, [CHEMICAL]methyl-3,5-di-O-caffeoylquinate[\\CHEMICAL] showed competitive inhibition of [GENE]rhAR[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "From the 10 isolated compounds, [CHEMICAL]methyl-3,5-di-O-caffeoylquinate[\\CHEMICAL] showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for [GENE]rAR[\\GENE] and rhAR, respectively.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "From the 10 isolated compounds, [CHEMICAL]methyl-3,5-di-O-caffeoylquinate[\\CHEMICAL] showed the most potent inhibition, with IC50 values of 0.30 and 0.67\u00a0\u03bcM for rAR and [GENE]rhAR[\\GENE], respectively.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "This preference is partial because [GENE]UGT2B10[\\GENE] did not conjugate the [CHEMICAL]tertiary cyclic amine[\\CHEMICAL] in trifluoperazine.",
        "label": 10,
        "major": 10,
        "len": 15
    },
    {
        "text": "This preference is partial because [GENE]UGT2B10[\\GENE] did not conjugate the tertiary cyclic amine in [CHEMICAL]trifluoperazine[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 15
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and [GENE]UGT1A3[\\GENE], although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and [GENE]UGT1A3[\\GENE], although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of [GENE]UGT2B10[\\GENE], highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of UGT1A4 and UGT1A3.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of [GENE]UGT1A4[\\GENE] and UGT1A3.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of UGT1A4 and [GENE]UGT1A3[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, [CHEMICAL]ketotifen[\\CHEMICAL], pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, [CHEMICAL]pizotifen[\\CHEMICAL], olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, [CHEMICAL]olanzapine[\\CHEMICAL], diphenhydramine, tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, [CHEMICAL]diphenhydramine[\\CHEMICAL], tamoxifen, ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, [CHEMICAL]tamoxifen[\\CHEMICAL], ketoconazole and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, [CHEMICAL]ketoconazole[\\CHEMICAL] and midazolam.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Using recombinant [GENE]UGT2B10[\\GENE], we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and [CHEMICAL]midazolam[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Recent observations revealed that [GENE]human UDP-glucuronosyltransferase (UGT) 2B10[\\GENE] catalyzes N-glucuronidation of [CHEMICAL]amine[\\CHEMICAL]-containing compounds.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for [CHEMICAL]amitriptyline[\\CHEMICAL], imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and [GENE]UGT1A3[\\GENE], although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, [CHEMICAL]imipramine[\\CHEMICAL], and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of [GENE]UGT2B10[\\GENE] for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of [GENE]UGT1A4[\\GENE] and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and [GENE]UGT1A3[\\GENE], although the Vmax values of UGT1A4 toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and [CHEMICAL]diphenhydramine[\\CHEMICAL] are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of [GENE]UGT1A4[\\GENE] toward these drugs are considerably higher.",
        "label": 9,
        "major": 2,
        "len": 38
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of [GENE]UGT2B10[\\GENE], highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of UGT1A4 and UGT1A3.",
        "label": 9,
        "major": 2,
        "len": 31
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of [GENE]UGT1A4[\\GENE] and UGT1A3.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for [CHEMICAL]tertiary amines[\\CHEMICAL] with higher affinities and clearance values than those of UGT1A4 and [GENE]UGT1A3[\\GENE].",
        "label": 9,
        "major": 2,
        "len": 31
    },
    {
        "text": "Molecular docking studies suggested that SB has a good affinity towards [CHEMICAL]vinblastine[\\CHEMICAL]-binding site on [GENE]\u03b2-tubulin[\\GENE] subunit.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit [GENE]IL-8[\\GENE]-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 4,
        "major": 6,
        "len": 29
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an [GENE]IL-8 receptor B[\\GENE] (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 6,
        "major": 4,
        "len": 29
    },
    {
        "text": "[CHEMICAL]SB225002[\\CHEMICAL] (SB) is an IL-8 receptor B ([GENE]IL-8RB[\\GENE]) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "Of note, [CHEMICAL]SB265610[\\CHEMICAL] which is a close structural analogue of SB225002 with a potent [GENE]IL-8RB[\\GENE] antagonistic activity did not exhibit a similar antimitotic activity.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Of note, SB265610 which is a close structural analogue of [CHEMICAL]SB225002[\\CHEMICAL] with a potent [GENE]IL-8RB[\\GENE] antagonistic activity did not exhibit a similar antimitotic activity.",
        "label": 6,
        "major": 10,
        "len": 24
    },
    {
        "text": "Furthermore, expression of a multivalent but not a monovalent GAG containing [GENE]syndecan-1[\\GENE] proteoglycan recapitulates the elongation phenotype observed with the bivalent [CHEMICAL]xylosides[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "In support of this observation, elongation can be reversed by the [GENE]tyrosine kinase[\\GENE] inhibitor [CHEMICAL]SU5402[\\CHEMICAL], mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Overexpression of [GENE]Akt1[\\GENE] or Akt2 in TW2.6 cells rescued growth inhibition caused by [CHEMICAL]CAPE[\\CHEMICAL] treatment.",
        "label": 10,
        "major": 4,
        "len": 15
    },
    {
        "text": "Overexpression of Akt1 or [GENE]Akt2[\\GENE] in TW2.6 cells rescued growth inhibition caused by [CHEMICAL]CAPE[\\CHEMICAL] treatment.",
        "label": 10,
        "major": 4,
        "len": 15
    },
    {
        "text": "Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, [GENE]phospho-Rb[\\GENE] [CHEMICAL]Ser[\\CHEMICAL]807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 1,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, [GENE]phospho-Akt[\\GENE] [CHEMICAL]Ser[\\CHEMICAL]473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 1,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor [GENE]p27Kip[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Caffeic Acid Phenethyl Ester[\\CHEMICAL] Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of [GENE]Akt[\\GENE] Signaling.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of [GENE]Akt[\\GENE], Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, [GENE]Akt1[\\GENE], Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, [GENE]Akt2[\\GENE], Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, [GENE]Akt3[\\GENE], phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, [GENE]phospho-Akt[\\GENE] Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, [GENE]phospho-Akt[\\GENE] Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, [GENE]GSK3\u03b2[\\GENE], FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, [GENE]FOXO1[\\GENE], FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, [GENE]FOXO3a[\\GENE], phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, [GENE]phospho-FOXO1[\\GENE] Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, [GENE]phospho-FoxO3a[\\GENE] Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, [GENE]NF-\u03baB[\\GENE], phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, [GENE]phospho-NF-\u03baB[\\GENE] Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, [GENE]Rb[\\GENE], phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, [GENE]phospho-Rb[\\GENE] Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, [GENE]Skp2[\\GENE], and cyclin D1, but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Treatment with [CHEMICAL]CAPE[\\CHEMICAL] decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3\u03b2, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-\u03baB, phospho-NF-\u03baB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and [GENE]cyclin D1[\\GENE], but increased cell cycle inhibitor p27Kip.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Using siRNA we found that ATF4, but not [GENE]Nrf2[\\GENE], is important for [CHEMICAL]fisetin[\\CHEMICAL]'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.",
        "label": 10,
        "major": 3,
        "len": 37
    },
    {
        "text": "Using siRNA we found that [GENE]ATF4[\\GENE], but not Nrf2, is important for [CHEMICAL]fisetin[\\CHEMICAL]'s ability to increase GSH levels under basal conditions whereas both ATF4 and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.",
        "label": 2,
        "major": 10,
        "len": 37
    },
    {
        "text": "Here we show that [CHEMICAL]fisetin[\\CHEMICAL] rapidly increases the levels of both [GENE]Nrf2[\\GENE] and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Here we show that [CHEMICAL]fisetin[\\CHEMICAL] rapidly increases the levels of both Nrf2 and [GENE]ATF4[\\GENE] as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Here we show that [CHEMICAL]fisetin[\\CHEMICAL] rapidly increases the levels of both Nrf2 and ATF4 as well as [GENE]Nrf2[\\GENE]- and ATF4-dependent gene transcription via distinct mechanisms.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Here we show that [CHEMICAL]fisetin[\\CHEMICAL] rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and [GENE]ATF4[\\GENE]-dependent gene transcription via distinct mechanisms.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Although [CHEMICAL]fisetin[\\CHEMICAL] greatly increases the stability of both [GENE]Nrf2[\\GENE] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Although [CHEMICAL]fisetin[\\CHEMICAL] greatly increases the stability of both Nrf2 and [GENE]ATF4[\\GENE], only the effect on ATF4 is dependent on protein kinase activity.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Amino acid[\\CHEMICAL] sequences of cynomolgus [GENE]FMO1-5[\\GENE], respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human FMO1-5.",
        "label": 1,
        "major": 1,
        "len": 23
    },
    {
        "text": "Rates of [CHEMICAL]benzydamine[\\CHEMICAL] N-oxygenation (catalyzed by [GENE]FMO3[\\GENE]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "Rates of benzydamine [CHEMICAL]N[\\CHEMICAL]-oxygenation (catalyzed by [GENE]FMO3[\\GENE]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in [CHEMICAL]benzydamine[\\CHEMICAL] N-oxygenation might be partly accounted for by the variable [GENE]FMO3[\\GENE] expression.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine [CHEMICAL]N[\\CHEMICAL]-oxygenation might be partly accounted for by the variable [GENE]FMO3[\\GENE] expression.",
        "label": 9,
        "major": 9,
        "len": 41
    },
    {
        "text": "Activation of AMPK using AICAR resulted in [GENE]STIM1[\\GENE] phosphorylation on [CHEMICAL]serine[\\CHEMICAL] residues and prevented PAR-1-induced Ca2+ entry.",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]Ca2+[\\CHEMICAL] sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and [GENE]Orai channels[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "The [CHEMICAL]Ca2+[\\CHEMICAL] sensor [GENE]STIM1[\\GENE] is crucial for activation of store-operated Ca2+ entry (SOCE) through TRPC and Orai channels.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "The [CHEMICAL]Ca2+[\\CHEMICAL] sensor STIM1 is crucial for activation of store-operated Ca2+ entry (SOCE) through [GENE]TRPC[\\GENE] and Orai channels.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Interestingly, [CHEMICAL]SB203580[\\CHEMICAL], a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained [GENE]STIM1[\\GENE]-puncta formation and Ca2+ entry.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Activation of [GENE]AMPK[\\GENE] using [CHEMICAL]AICAR[\\CHEMICAL] resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Activation of AMPK using [CHEMICAL]AICAR[\\CHEMICAL] resulted in [GENE]STIM1[\\GENE] phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Activation of AMPK using [CHEMICAL]AICAR[\\CHEMICAL] resulted in STIM1 phosphorylation on serine residues and prevented [GENE]PAR-1[\\GENE]-induced Ca2+ entry.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Further, [CHEMICAL]AICAR[\\CHEMICAL] pretreatment blocked [GENE]PAR-1[\\GENE]-induced increase in permeability of mouse-lung microvessels.",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "Interestingly, [CHEMICAL]SB203580[\\CHEMICAL], a selective inhibitor of [GENE]p38[\\GENE] MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Interestingly, [CHEMICAL]SB203580[\\CHEMICAL], a selective inhibitor of p38 [GENE]MAPK[\\GENE], blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Interestingly, [CHEMICAL]SB203580[\\CHEMICAL], a selective inhibitor of p38 MAPK, blocked [GENE]STIM1[\\GENE] phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The precise fashion in which these proteins interact and move [CHEMICAL]cholesterol[\\CHEMICAL] from the OMM to [GENE]P450scc[\\GENE], and the means by which cholesterol is loaded into the OMM, remain unclear.",
        "label": 9,
        "major": 2,
        "len": 29
    },
    {
        "text": "Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the [CHEMICAL]cholesterol[\\CHEMICAL] side-chain cleavage enzyme, [GENE]P450scc[\\GENE], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "New series of [CHEMICAL]pyrrolidine mercaptosulfide[\\CHEMICAL], 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine [GENE]matrix metalloproteinase[\\GENE] inhibitors (MMPIs) were designed, synthesized, and evaluated.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Exhibiting unique properties over other MMPIs (e.g., [CHEMICAL]hydroxamates[\\CHEMICAL]), these newly reported compounds are capable of modulating activities of several [GENE]MMPs[\\GENE] in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).",
        "label": 4,
        "major": 7,
        "len": 42
    },
    {
        "text": "Exhibiting unique properties over other MMPIs (e.g., [CHEMICAL]hydroxamates[\\CHEMICAL]), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including [GENE]MMP-2[\\GENE] (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).",
        "label": 4,
        "major": 7,
        "len": 42
    },
    {
        "text": "Exhibiting unique properties over other MMPIs (e.g., [CHEMICAL]hydroxamates[\\CHEMICAL]), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), [GENE]MMP-13[\\GENE] (~2 to 50 nM), and MMP-14 (~4 to 60 nM).",
        "label": 4,
        "major": 7,
        "len": 42
    },
    {
        "text": "Exhibiting unique properties over other MMPIs (e.g., [CHEMICAL]hydroxamates[\\CHEMICAL]), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and [GENE]MMP-14[\\GENE] (~4 to 60 nM).",
        "label": 4,
        "major": 7,
        "len": 42
    },
    {
        "text": "New series of pyrrolidine mercaptosulfide, [CHEMICAL]2-mercaptocyclopentane arylsulfonamide[\\CHEMICAL], and 3-mercapto-4-arylsulfonamido pyrrolidine [GENE]matrix metalloproteinase[\\GENE] inhibitors (MMPIs) were designed, synthesized, and evaluated.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and [CHEMICAL]3-mercapto-4-arylsulfonamido pyrrolidine[\\CHEMICAL] [GENE]matrix metalloproteinase[\\GENE] inhibitors (MMPIs) were designed, synthesized, and evaluated.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[GENE]Matrix Metalloproteinase[\\GENE] Inhibitors Based on the [CHEMICAL]3-Mercaptopyrrolidine[\\CHEMICAL] Core.",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "A Structural Snapshot of [GENE]Cytochrome P450 2B4[\\GENE] in Complex with [CHEMICAL]Paroxetine[\\CHEMICAL] Provides Insights into Ligand Binding and Clusters of Conformational States.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as [GENE]interleukin-1\u03b2[\\GENE] (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression).",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 ([GENE]IL-1\u03b2[\\GENE]), and apoptosis (Bax and caspase 3 expression).",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis ([GENE]Bax[\\GENE] and caspase 3 expression).",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and [GENE]caspase 3[\\GENE] expression).",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased [GENE]nuclear factor (NF)-kB[\\GENE] translocation, pro-inflammatory cytokine production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression).",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive [CHEMICAL]RS -GRA[\\CHEMICAL] significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory [GENE]cytokine[\\GENE] production such as interleukin-1\u03b2 (IL-1\u03b2), and apoptosis (Bax and caspase 3 expression).",
        "label": 4,
        "major": 9,
        "len": 38
    },
    {
        "text": "In the presence of [CHEMICAL]H2O2[\\CHEMICAL], calycopterin inhibited decrease in GSH level and [GENE]SOD[\\GENE] activity.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, [CHEMICAL]calycopterin[\\CHEMICAL], against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of [GENE]CREB[\\GENE] phosphorylation and Nrf2 pathway.",
        "label": 2,
        "major": 7,
        "len": 30
    },
    {
        "text": "CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, [CHEMICAL]calycopterin[\\CHEMICAL], against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and [GENE]Nrf2[\\GENE] pathway.",
        "label": 2,
        "major": 7,
        "len": 30
    },
    {
        "text": "CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against [CHEMICAL]H2O2[\\CHEMICAL]-induced oxidative stress in differentiated PC12 cells by modulating the level of [GENE]CREB[\\GENE] phosphorylation and Nrf2 pathway.",
        "label": 2,
        "major": 7,
        "len": 30
    },
    {
        "text": "CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against [CHEMICAL]H2O2[\\CHEMICAL]-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and [GENE]Nrf2[\\GENE] pathway.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the presence of H2O2, [CHEMICAL]calycopterin[\\CHEMICAL] inhibited decrease in GSH level and [GENE]SOD[\\GENE] activity.",
        "label": 3,
        "major": 4,
        "len": 14
    },
    {
        "text": "There was also an increase in [GENE]\u03b3-GCS[\\GENE] and HO-1 levels in [CHEMICAL]calycopterin[\\CHEMICAL] pretreated cells.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "There was also an increase in \u03b3-GCS and [GENE]HO-1[\\GENE] levels in [CHEMICAL]calycopterin[\\CHEMICAL] pretreated cells.",
        "label": 3,
        "major": 3,
        "len": 14
    },
    {
        "text": "Moreover, [CHEMICAL]calycopterin[\\CHEMICAL], in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, [GENE]CREB[\\GENE] and Nrf2, which play an important role in antioxidant capacity of the cell.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Moreover, [CHEMICAL]calycopterin[\\CHEMICAL], in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and [GENE]Nrf2[\\GENE], which play an important role in antioxidant capacity of the cell.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on [CHEMICAL]H2O2[\\CHEMICAL]-induced disruption of [GENE]phase II detoxifying enzyme[\\GENE] system and cAMP response element binding protein (CREB) phosphorylation.",
        "label": 4,
        "major": 2,
        "len": 28
    },
    {
        "text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on [CHEMICAL]H2O2[\\CHEMICAL]-induced disruption of phase II detoxifying enzyme system and [GENE]cAMP response element binding protein[\\GENE] (CREB) phosphorylation.",
        "label": 4,
        "major": 2,
        "len": 28
    },
    {
        "text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on [CHEMICAL]H2O2[\\CHEMICAL]-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein ([GENE]CREB[\\GENE]) phosphorylation.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "I3S increased expression of ROR\u03b3t, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as [CHEMICAL]2,3,7,8-tetrachlorodibenzo-p-dioxin[\\CHEMICAL] (TCDD), a prototypical [GENE]AhR[\\GENE] ligand.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "I3S increased expression of ROR\u03b3t, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin ([CHEMICAL]TCDD[\\CHEMICAL]), a prototypical [GENE]AhR[\\GENE] ligand.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by [GENE]AhR[\\GENE] ligands, was also increased by [CHEMICAL]I3S[\\CHEMICAL] and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 2,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by [GENE]AhR[\\GENE] ligands, was also increased by I3S and [CHEMICAL]TCDD[\\CHEMICAL], and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 2,
        "major": 3,
        "len": 62
    },
    {
        "text": "Activation of [GENE]STAT3[\\GENE], which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Activation of STAT3, which is phosphorylated by the [GENE]IL-6[\\GENE] signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Phosphorylation of [GENE]c-Src[\\GENE], which was shown to be activated by AhR ligands, was also increased by [CHEMICAL]I3S[\\CHEMICAL] and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of [GENE]c-Src[\\GENE], which was shown to be activated by AhR ligands, was also increased by I3S and [CHEMICAL]TCDD[\\CHEMICAL], and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "[CHEMICAL]Indoxyl 3-sulfate[\\CHEMICAL] stimulates Th17 differentiation enhancing phosphorylation of [GENE]c-Src[\\GENE] and STAT3 to worsen experimental autoimmune encephalomyelitis.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Indoxyl 3-sulfate[\\CHEMICAL] stimulates Th17 differentiation enhancing phosphorylation of c-Src and [GENE]STAT3[\\GENE] to worsen experimental autoimmune encephalomyelitis.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of [CHEMICAL]I3S[\\CHEMICAL] and TCDD on Th17 differentiation could be exerted via increased phosphorylation of [GENE]c-Src[\\GENE], which in turn stimulates STAT3 activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of [CHEMICAL]I3S[\\CHEMICAL] and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates [GENE]STAT3[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and [CHEMICAL]TCDD[\\CHEMICAL] on Th17 differentiation could be exerted via increased phosphorylation of [GENE]c-Src[\\GENE], which in turn stimulates STAT3 activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and [CHEMICAL]TCDD[\\CHEMICAL] on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates [GENE]STAT3[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 62
    },
    {
        "text": "In the present study, using in vitro Th17 differentiation model, we examined effects of [GENE]AhR[\\GENE] activation by [CHEMICAL]indoxyl 3-sulfate[\\CHEMICAL] (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "In the present study, using in vitro Th17 differentiation model, we examined effects of [GENE]AhR[\\GENE] activation by indoxyl 3-sulfate ([CHEMICAL]I3S[\\CHEMICAL]), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Activation of [GENE]STAT3[\\GENE], which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by [CHEMICAL]I3S[\\CHEMICAL] and TCDD.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Activation of STAT3, which is phosphorylated by the [GENE]IL-6[\\GENE] signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by [CHEMICAL]I3S[\\CHEMICAL] and TCDD.",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "Finally, we found that [CHEMICAL]I3S[\\CHEMICAL] worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of [GENE]IL-17[\\GENE]-producing cells in draining lymph nodes.",
        "label": 3,
        "major": 9,
        "len": 27
    },
    {
        "text": "[CHEMICAL]I3S[\\CHEMICAL] increased expression of [GENE]ROR\u03b3t[\\GENE], the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of [GENE]c-Src[\\GENE] activity by [CHEMICAL]4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine[\\CHEMICAL] (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 4,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by [CHEMICAL]4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine[\\CHEMICAL] (PP2) inhibited phosphorylation of both [GENE]c-Src[\\GENE] and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 4,
        "major": 3,
        "len": 62
    },
    {
        "text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by [CHEMICAL]4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine[\\CHEMICAL] (PP2) inhibited phosphorylation of both c-Src and [GENE]STAT3[\\GENE], raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.",
        "label": 4,
        "major": 3,
        "len": 62
    },
    {
        "text": "[GENE]IGFBP-4[\\GENE] was not induced by [CHEMICAL]TCDD[\\CHEMICAL] in the parental cell line of 5L cells, Fao, and in various closely related rat hepatoma cell lines as well as in other unrelated cell types.",
        "label": 10,
        "major": 10,
        "len": 32
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] treatment of the cells largely prevented the activation of [GENE]eukaryotic translation initiation factor 4E-binding protein 1[\\GENE], a regulator of translation initiation and substrate of the mammalian target of rapamycin (mTOR).",
        "label": 10,
        "major": 3,
        "len": 31
    },
    {
        "text": "The observations suggest that in 5L cells the [GENE]Igfbp-4[\\GENE] gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing [GENE]dioxin responsive element(s)[\\GENE] leading to the induction of IGFBP-4 by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the [GENE]mammalian target of rapamycin[\\GENE] (mTOR).",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of rapamycin ([GENE]mTOR[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "By \"working upwards\" from mTOR, we observed that [CHEMICAL]TCDD[\\CHEMICAL] inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of [GENE]insulin receptor substrate 1[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that [GENE]IGFBP-4[\\GENE] is a previously unknown transcriptional target of [CHEMICAL]TCDD[\\CHEMICAL] in 5L cells.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]TCDD[\\CHEMICAL] induces the expression of [GENE]insulin-like growth factor binding protein 4[\\GENE] in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.",
        "label": 3,
        "major": 2,
        "len": 31
    },
    {
        "text": "This inhibition was mediated by a [CHEMICAL]TCDD[\\CHEMICAL]-induced secreted factor which was identified as [GENE]insulin-like growth factor binding protein 4[\\GENE] (IGFBP-4).",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "This inhibition was mediated by a [CHEMICAL]TCDD[\\CHEMICAL]-induced secreted factor which was identified as insulin-like growth factor binding protein 4 ([GENE]IGFBP-4[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of [GENE]IGFBP-4[\\GENE] by [CHEMICAL]TCDD[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "By \"working upwards\" from mTOR, we observed that [CHEMICAL]TCDD[\\CHEMICAL] inhibited endogenous and IGF-I-induced [GENE]AKT[\\GENE] and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "By \"working upwards\" from mTOR, we observed that [CHEMICAL]TCDD[\\CHEMICAL] inhibited endogenous and IGF-I-induced AKT and [GENE]ERK[\\GENE] activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of [GENE]IGFBP-4[\\GENE] mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of [CHEMICAL]TCDD[\\CHEMICAL] in 5L cells.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "By \"working upwards\" from mTOR, we observed that [CHEMICAL]TCDD[\\CHEMICAL] inhibited endogenous and [GENE]IGF-I[\\GENE]-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "These effects were not mimicked by oral administration of the [GENE]beta 2-adrenoceptor[\\GENE] agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of [CHEMICAL]DL-propranolol[\\CHEMICAL] (200 mg/kg diet).",
        "label": 10,
        "major": 4,
        "len": 36
    },
    {
        "text": "The potent anabolic effects of the beta 2-adrenoceptor agonist [CHEMICAL]clenbuterol[\\CHEMICAL] on skeletal muscle have been reported to be independent of actions on [GENE]beta-adrenoceptors[\\GENE].",
        "label": 10,
        "major": 5,
        "len": 23
    },
    {
        "text": "These results indicate that the anabolic effects of [CHEMICAL]clenbuterol[\\CHEMICAL] are dependent on interaction with the [GENE]beta 2-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "Anabolic effects of [CHEMICAL]clenbuterol[\\CHEMICAL] on skeletal muscle are mediated by [GENE]beta 2-adrenoceptor[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "These effects were not mimicked by oral administration of the [GENE]beta 2-adrenoceptor[\\GENE] agonist [CHEMICAL]salbutamol[\\CHEMICAL] even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
        "label": 5,
        "major": 4,
        "len": 36
    },
    {
        "text": "These effects were not mimicked by oral administration of the [GENE]beta 2-adrenoceptor[\\GENE] agonist salbutamol even at high dose (52 mg/kg diet), and the effects of [CHEMICAL]clenbuterol[\\CHEMICAL] were not inhibited by addition of DL-propranolol (200 mg/kg diet).",
        "label": 5,
        "major": 4,
        "len": 36
    },
    {
        "text": "The potent anabolic effects of the [GENE]beta 2-adrenoceptor[\\GENE] agonist [CHEMICAL]clenbuterol[\\CHEMICAL] on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.",
        "label": 5,
        "major": 5,
        "len": 23
    },
    {
        "text": "In the hot-plate test in mice, the antinociceptive action of the [GENE]alpha 2-adrenoceptor[\\GENE] agonist, [CHEMICAL]UK 14,304[\\CHEMICAL], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
        "label": 5,
        "major": 5,
        "len": 39
    },
    {
        "text": "The preferential [GENE]alpha 2A-adrenoceptor[\\GENE] partial agonist, [CHEMICAL]guanfacine[\\CHEMICAL], partially inhibited UK 14,304-induced antinociception.",
        "label": 5,
        "major": 3,
        "len": 12
    },
    {
        "text": "The preferential [GENE]alpha 2A-adrenoceptor[\\GENE] partial agonist, guanfacine, partially inhibited [CHEMICAL]UK 14,304[\\CHEMICAL]-induced antinociception.",
        "label": 5,
        "major": 3,
        "len": 12
    },
    {
        "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the [GENE]alpha 2-adrenoceptor[\\GENE] antagonist, [CHEMICAL]idazoxan[\\CHEMICAL], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent [GENE]alpha 2A-adrenoceptor[\\GENE] antagonist, [CHEMICAL]RX 821002[\\CHEMICAL] and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.",
        "label": 6,
        "major": 5,
        "len": 39
    },
    {
        "text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential [GENE]alpha 2A-adrenoceptor[\\GENE] antagonist, [CHEMICAL]BRL 44408[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "The identity of the lung [GENE]beta-ADHs[\\GENE] was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [CHEMICAL]4-methylpyrazole[\\CHEMICAL] or 1,10-phenanthroline.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The identity of the lung [GENE]beta-ADHs[\\GENE] was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or [CHEMICAL]1,10-phenanthroline[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The identity of the lung [GENE]beta-ADHs[\\GENE] was further demonstrated by their characteristic pH-activity profiles for [CHEMICAL]ethanol[\\CHEMICAL] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "The identity of the lung [GENE]beta-ADHs[\\GENE] was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and [CHEMICAL]ethanol[\\CHEMICAL], and inhibition by 4-methylpyrazole or 1,10-phenanthroline.",
        "label": 9,
        "major": 4,
        "len": 29
    },
    {
        "text": "Abrupt removal of [CHEMICAL]amrinone[\\CHEMICAL] or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented [GENE]TNF[\\GENE] production.",
        "label": 3,
        "major": 9,
        "len": 20
    },
    {
        "text": "Abrupt removal of amrinone or [CHEMICAL]pentoxifylline[\\CHEMICAL] from the culture medium prior to LPS stimulation, however, caused significantly augmented [GENE]TNF[\\GENE] production.",
        "label": 3,
        "major": 9,
        "len": 20
    },
    {
        "text": "We now demonstrate that [CHEMICAL]amrinone[\\CHEMICAL], a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced [GENE]TNF[\\GENE] production at concentrations readily achieved in vivo.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Combined application of [CHEMICAL]dexamethasone[\\CHEMICAL] and amrinone caused additive inhibition of [GENE]TNF[\\GENE] biosynthesis in vitro.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Combined application of dexamethasone and [CHEMICAL]amrinone[\\CHEMICAL] caused additive inhibition of [GENE]TNF[\\GENE] biosynthesis in vitro.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Sedation and [GENE]histamine H1-receptor[\\GENE] antagonism: studies in man with the enantiomers of chlorpheniramine and [CHEMICAL]dimethindene[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Sedation and [GENE]histamine H1-receptor[\\GENE] antagonism: studies in man with the enantiomers of [CHEMICAL]chlorpheniramine[\\CHEMICAL] and dimethindene.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "Monoclonal antibody 25B1 generated against [CHEMICAL]diisopropyl phosphorofluoridate[\\CHEMICAL] inhibited fetal [GENE]bovine serum acetylcholinesterase[\\GENE] has been extensively characterized with respect to its anticholinesterase properties.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the [GENE]alpha 2 adrenoceptor[\\GENE] mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",
        "label": 10,
        "major": 4,
        "len": 46
    },
    {
        "text": "This same dose of carvedilol also inhibited, but to a lesser degree, the [GENE]beta 2 adrenoceptor[\\GENE] mediated vasodepressor response to [CHEMICAL]salbutamol[\\CHEMICAL] in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "Carvedilol produced significant inhibition of the [GENE]alpha 1 adrenoceptor[\\GENE] mediated pressor response to [CHEMICAL]cirazoline[\\CHEMICAL] in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",
        "label": 2,
        "major": 9,
        "len": 46
    },
    {
        "text": "Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the [GENE]alpha 2 adrenoceptor[\\GENE] mediated pressor response to [CHEMICAL]B-HT 933[\\CHEMICAL], suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",
        "label": 2,
        "major": 4,
        "len": 46
    },
    {
        "text": "Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the [GENE]beta 1 adrenoceptor[\\GENE] mediated positive chronotropic response to [CHEMICAL]isoproterenol[\\CHEMICAL].",
        "label": 3,
        "major": 10,
        "len": 19
    },
    {
        "text": "The vasopressor response to the [GENE]calcium channel[\\GENE] activator, [CHEMICAL]BAY-K-8644[\\CHEMICAL], which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
        "label": 3,
        "major": 6,
        "len": 51
    },
    {
        "text": "The vasopressor response to the calcium channel activator, [CHEMICAL]BAY-K-8644[\\CHEMICAL], which is mediated through the opening of [GENE]voltage dependent calcium channels[\\GENE] and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
        "label": 3,
        "major": 4,
        "len": 51
    },
    {
        "text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [GENE]voltage dependent calcium channels[\\GENE] and the subsequent translocation of extracellular calcium, was significantly inhibited by [CHEMICAL]carvedilol[\\CHEMICAL] (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
        "label": 4,
        "major": 4,
        "len": 51
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] (0.3 mg/kg, iv) produced a significant inhibition of the [GENE]beta 1 adrenoceptor[\\GENE] mediated positive chronotropic response to isoproterenol.",
        "label": 4,
        "major": 10,
        "len": 19
    },
    {
        "text": "This same dose of [CHEMICAL]carvedilol[\\CHEMICAL] also inhibited, but to a lesser degree, the [GENE]beta 2 adrenoceptor[\\GENE] mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] produced significant inhibition of the [GENE]alpha 1 adrenoceptor[\\GENE] mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.",
        "label": 4,
        "major": 9,
        "len": 46
    },
    {
        "text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that [CHEMICAL]carvedilol[\\CHEMICAL] is also a [GENE]calcium channel[\\GENE] antagonist, consistent with our previous in vitro studies.",
        "label": 6,
        "major": 4,
        "len": 51
    },
    {
        "text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the [GENE]alpha 1 adrenoceptor[\\GENE] antagonist, [CHEMICAL]prazosin[\\CHEMICAL] (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 65
    },
    {
        "text": "In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective [GENE]beta adrenoceptor[\\GENE] antagonist, [CHEMICAL]propranolol[\\CHEMICAL] (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.",
        "label": 6,
        "major": 9,
        "len": 65
    },
    {
        "text": "We therefore conclude that [CHEMICAL]carvedilol[\\CHEMICAL], at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of [GENE]calcium channels[\\GENE] in vascular smooth muscle.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "The mechanism(s) responsible for arterial vasodilation observed following acute administration of [CHEMICAL]racemic carvedilol[\\CHEMICAL], a novel vasodilator/[GENE]beta adrenoceptor[\\GENE] antagonist, has been investigated in rats.",
        "label": 6,
        "major": 6,
        "len": 23
    },
    {
        "text": "Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that [CHEMICAL]carvedilol[\\CHEMICAL] is also an [GENE]alpha 1 adrenoceptor[\\GENE] antagonist at antihypertensive doses.",
        "label": 6,
        "major": 6,
        "len": 46
    },
    {
        "text": "The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of [GENE]voltage dependent calcium channels[\\GENE] and the subsequent translocation of extracellular [CHEMICAL]calcium[\\CHEMICAL], was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.",
        "label": 9,
        "major": 3,
        "len": 51
    },
    {
        "text": "Characterization of [GENE]5-hydroxytryptamine1B[\\GENE] receptors in rat spinal cord via [CHEMICAL][125I]iodocyanopindolol[\\CHEMICAL] binding and inhibition of [3H]-5-hydroxytryptamine release.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "A positively charged derivative, [CHEMICAL]estramustine sarcosinate[\\CHEMICAL], did not inhibit microtubule assembly or alter the composition of the coassembled [GENE]MAPs[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic [CHEMICAL]amino acid[\\CHEMICAL] repeats of these [GENE]MAPs[\\GENE], considered to be the ultimate tubulin binding domains.",
        "label": 1,
        "major": 2,
        "len": 38
    },
    {
        "text": "Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic [CHEMICAL]amino acid[\\CHEMICAL] repeats of these MAPs, considered to be the ultimate [GENE]tubulin[\\GENE] binding domains.",
        "label": 1,
        "major": 2,
        "len": 38
    },
    {
        "text": "Both these [GENE]MAPs[\\GENE] were found to have two to three binding sites for [CHEMICAL]estramustine phosphate[\\CHEMICAL] which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.",
        "label": 2,
        "major": 1,
        "len": 38
    },
    {
        "text": "The Kd for the binding of [CHEMICAL]estramustine phosphate[\\CHEMICAL] to [GENE]MAP2[\\GENE] was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Our results suggest that only negatively charged [CHEMICAL]estramustine[\\CHEMICAL] derivatives have a [GENE]MAP[\\GENE]-dependent microtubule inhibitory effect.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "The negatively charged [CHEMICAL]estramustine phosphate[\\CHEMICAL] has been found previously to be a [GENE]microtubule-associated protein[\\GENE] (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "The negatively charged [CHEMICAL]estramustine phosphate[\\CHEMICAL] has been found previously to be a microtubule-associated protein ([GENE]MAP[\\GENE])-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Two new negatively charged [CHEMICAL]estramustine[\\CHEMICAL] derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar [GENE]MAP[\\GENE]-dependent microtubule inhibitors.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Two new negatively charged estramustine derivatives, [CHEMICAL]estramustine sulphate[\\CHEMICAL] and estramustine glucuronide, were found to be similar [GENE]MAP[\\GENE]-dependent microtubule inhibitors.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Two new negatively charged estramustine derivatives, estramustine sulphate and [CHEMICAL]estramustine glucuronide[\\CHEMICAL], were found to be similar [GENE]MAP[\\GENE]-dependent microtubule inhibitors.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Unlike bacterial [GENE]3-keto-5-ene-steroid isomerase[\\GENE], the human isomerase reaction is stimulated by [CHEMICAL]diphosphopyridine nucleotides[\\CHEMICAL] (NADH, NAD+).",
        "label": 10,
        "major": 3,
        "len": 15
    },
    {
        "text": "Unlike bacterial [GENE]3-keto-5-ene-steroid isomerase[\\GENE], the human isomerase reaction is stimulated by diphosphopyridine nucleotides ([CHEMICAL]NADH[\\CHEMICAL], NAD+).",
        "label": 10,
        "major": 3,
        "len": 15
    },
    {
        "text": "Unlike bacterial [GENE]3-keto-5-ene-steroid isomerase[\\GENE], the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, [CHEMICAL]NAD+[\\CHEMICAL]).",
        "label": 10,
        "major": 3,
        "len": 15
    },
    {
        "text": "The [CHEMICAL]3 beta-hydroxysteroid[\\CHEMICAL] substrate, pregnenolone, protects isomerase as well as [GENE]dehydrogenase[\\GENE] from inactivation by FSA.",
        "label": 10,
        "major": 3,
        "len": 15
    },
    {
        "text": "The 3 beta-hydroxysteroid substrate, [CHEMICAL]pregnenolone[\\CHEMICAL], protects isomerase as well as [GENE]dehydrogenase[\\GENE] from inactivation by FSA.",
        "label": 10,
        "major": 9,
        "len": 15
    },
    {
        "text": "Analysis of coenzyme binding by [GENE]human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase[\\GENE] and steroid 5----4-ene-isomerase using [CHEMICAL]5'-[p-(fluorosulfonyl)benzoyl]adenosine[\\CHEMICAL], an affinity labeling cofactor analog.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and [GENE]steroid 5----4-ene-isomerase[\\GENE] using [CHEMICAL]5'-[p-(fluorosulfonyl)benzoyl]adenosine[\\CHEMICAL], an affinity labeling cofactor analog.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "The affinity labeling [CHEMICAL]nucleotide[\\CHEMICAL] analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the [GENE]dehydrogenase[\\GENE] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The affinity labeling nucleotide analog, [CHEMICAL]5'-[p-(fluorosulfonyl)benzoyl]adenosine[\\CHEMICAL] (FSA), inactivates the [GENE]dehydrogenase[\\GENE] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine ([CHEMICAL]FSA[\\CHEMICAL]), inactivates the [GENE]dehydrogenase[\\GENE] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).",
        "label": 4,
        "major": 2,
        "len": 35
    },
    {
        "text": "The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as [GENE]dehydrogenase[\\GENE] from inactivation by [CHEMICAL]FSA[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 15
    },
    {
        "text": "Analysis of coenzyme binding by [GENE]human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase[\\GENE] and steroid 5----4-ene-isomerase using [CHEMICAL]5'-[p-(fluorosulfonyl)benzoyl]adenosine[\\CHEMICAL], an affinity labeling cofactor analog.",
        "label": 8,
        "major": 2,
        "len": 20
    },
    {
        "text": "Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and [GENE]steroid 5----4-ene-isomerase[\\GENE] using [CHEMICAL]5'-[p-(fluorosulfonyl)benzoyl]adenosine[\\CHEMICAL], an affinity labeling cofactor analog.",
        "label": 8,
        "major": 2,
        "len": 20
    },
    {
        "text": "FSA is a cofactor site-directed reagent that binds with similar affinity as a competitive inhibitor of [CHEMICAL]NAD+[\\CHEMICAL] reduction by [GENE]dehydrogenase[\\GENE] (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM).",
        "label": 8,
        "major": 2,
        "len": 34
    },
    {
        "text": "Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the [GENE]dehydrogenase[\\GENE] and isomerase substrate [CHEMICAL]steroids[\\CHEMICAL] bind at different sites on the same protein.",
        "label": 9,
        "major": 2,
        "len": 21
    },
    {
        "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [GENE]alpha 1-adrenoceptor[\\GENE] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both [CHEMICAL]WB4101[\\CHEMICAL] and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [GENE]alpha 1-adrenoceptor[\\GENE] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and [CHEMICAL]5-methyl-urapidil[\\CHEMICAL]), which was in good agreement with radioligand binding studies.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "Radioligand binding studies with the nonselective [GENE]alpha 1-adrenoceptor[\\GENE] antagonist radioligand [CHEMICAL]125I-BE2254[\\CHEMICAL] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Radioligand binding studies with the nonselective [GENE]alpha 1-adrenoceptor[\\GENE] antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are [CHEMICAL]CEC[\\CHEMICAL] sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Radioligand binding studies with the nonselective [GENE]alpha 1-adrenoceptor[\\GENE] antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for [CHEMICAL]WB4101[\\CHEMICAL] (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Radioligand binding studies with the nonselective [GENE]alpha 1-adrenoceptor[\\GENE] antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for [CHEMICAL]5-methylurapidil[\\CHEMICAL] (pKd = 7.1).",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [GENE]alpha 1a-adrenoceptor[\\GENE]-selective agonist [CHEMICAL]methoxamine[\\CHEMICAL]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
        "label": 5,
        "major": 3,
        "len": 47
    },
    {
        "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [GENE]alpha 1a-adrenoceptor[\\GENE]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [CHEMICAL]WB4101[\\CHEMICAL] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
        "label": 6,
        "major": 5,
        "len": 47
    },
    {
        "text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against [GENE]alpha 1a-adrenoceptor[\\GENE]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for [CHEMICAL]5-methyl-urapidil[\\CHEMICAL].",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [GENE]alpha 1-adrenoceptor[\\GENE] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for [CHEMICAL]WB4101[\\CHEMICAL] and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.",
        "label": 6,
        "major": 2,
        "len": 70
    },
    {
        "text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that [GENE]alpha 1-adrenoceptor[\\GENE] populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for [CHEMICAL]5-methyl-urapidil[\\CHEMICAL]) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.",
        "label": 6,
        "major": 2,
        "len": 70
    },
    {
        "text": "Using the [GENE]alpha 1-adrenoceptor[\\GENE] subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and [CHEMICAL]5-methyl-urapidil[\\CHEMICAL], we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Using the [GENE]alpha 1-adrenoceptor[\\GENE] subtype-selective antagonists [CHEMICAL]chlorethylclonidine[\\CHEMICAL] (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Radioligand binding studies with the nonselective [GENE]alpha 1-adrenoceptor[\\GENE] antagonist radioligand [CHEMICAL]125I-BE2254[\\CHEMICAL] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).",
        "label": 6,
        "major": 2,
        "len": 43
    },
    {
        "text": "Using the [GENE]alpha 1-adrenoceptor[\\GENE] subtype-selective antagonists chlorethylclonidine ([CHEMICAL]CEC[\\CHEMICAL]), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Using the [GENE]alpha 1-adrenoceptor[\\GENE] subtype-selective antagonists chlorethylclonidine (CEC), [CHEMICAL]WB4101[\\CHEMICAL], and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "The Schild plots for the competitive antagonists [CHEMICAL]WB4101[\\CHEMICAL] and 5-methyl-urapidil against [GENE]alpha 1a-adrenoceptor[\\GENE]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
        "label": 6,
        "major": 3,
        "len": 47
    },
    {
        "text": "The Schild plots for the competitive antagonists WB4101 and [CHEMICAL]5-methyl-urapidil[\\CHEMICAL] against [GENE]alpha 1a-adrenoceptor[\\GENE]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.",
        "label": 6,
        "major": 10,
        "len": 47
    },
    {
        "text": "Pretreatment with [CHEMICAL]ceruletide[\\CHEMICAL] (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by [GENE]arginine-vasopressin[\\GENE] (1 microgram/rat, ICV).",
        "label": 10,
        "major": 10,
        "len": 42
    },
    {
        "text": "Intracerebroventricular administration of [CHEMICAL]SMS 201-995[\\CHEMICAL] (5 micrograms/rat), a [GENE]somatostatin[\\GENE] analogue, induced barrel rotation in rats.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "The suppressive effect of [CHEMICAL]ceruletide[\\CHEMICAL] on barrel rotation could be partially countered by MK-329, a selective peripheral [GENE]CCK[\\GENE] (CCK-A) receptor antagonist.",
        "label": 4,
        "major": 6,
        "len": 21
    },
    {
        "text": "The suppressive effect of [CHEMICAL]ceruletide[\\CHEMICAL] on barrel rotation could be partially countered by MK-329, a selective peripheral CCK [GENE](CCK-A) receptor[\\GENE] antagonist.",
        "label": 4,
        "major": 6,
        "len": 21
    },
    {
        "text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by [CHEMICAL]MK-329[\\CHEMICAL], a selective peripheral [GENE]CCK[\\GENE] (CCK-A) receptor antagonist.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by [CHEMICAL]MK-329[\\CHEMICAL], a selective peripheral CCK [GENE](CCK-A) receptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the [CHEMICAL]Ca2(+)[\\CHEMICAL]-[GENE]calmodulin[\\GENE] interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "The smooth muscle relaxant, [CHEMICAL]W-7[\\CHEMICAL], which is believed relatively specific in inhibiting the Ca2(+)-[GENE]calmodulin[\\GENE] interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Role of extracellular [CHEMICAL]calcium[\\CHEMICAL] and calmodulin in [GENE]prolactin[\\GENE] secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "The smooth muscle relaxant, [CHEMICAL]W-7[\\CHEMICAL], which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced [GENE]PRL[\\GENE] secretion in a dose-dependent manner (r = -0.991, p less than 0.01).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Removing medium Ca2+, blocking [GENE]Ca2+ channels[\\GENE] with 50 mumol/l [CHEMICAL]verapamil[\\CHEMICAL], or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting [GENE]calmodulin[\\GENE] activation with 20 mumol/l [CHEMICAL]trifluoperazine[\\CHEMICAL], 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting [GENE]calmodulin[\\GENE] activation with 20 mumol/l trifluoperazine, 10 mumol/l [CHEMICAL]chlorpromazine[\\CHEMICAL] or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting [GENE]calmodulin[\\GENE] activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l [CHEMICAL]pimozide[\\CHEMICAL] almost completely blocked hyposmolarity-induced secretion.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "There was no escape of i.c.v.-administered [3H]R-PIA from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of [CHEMICAL]ethanol[\\CHEMICAL]-[GENE]adenosine[\\GENE] interaction.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "To clarify if the behavioral interaction between [CHEMICAL]ethanol[\\CHEMICAL] and [GENE]adenosine[\\GENE] reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of [GENE]adenosine[\\GENE] modulation of this effect of [CHEMICAL]ethanol[\\CHEMICAL] and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.",
        "label": 2,
        "major": 5,
        "len": 40
    },
    {
        "text": "Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in [CHEMICAL]ethanol[\\CHEMICAL]-[GENE]adenosine[\\GENE] interactions.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain [GENE]adenosine receptor[\\GENE] mechanism(s) in [CHEMICAL]ethanol[\\CHEMICAL]-adenosine interactions.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest [GENE]adenosine receptor[\\GENE] activation adequate to produce behavioral interaction with [CHEMICAL]ethanol[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Enprofylline[\\CHEMICAL], a weak adenosine antagonist but potent inhibitor of [GENE]cyclic AMP phosphodiesterase[\\GENE], did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, [CHEMICAL]N6-(R-phenylisopropyl)adenosine[\\CHEMICAL] (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine ([CHEMICAL]R-PIA[\\CHEMICAL]), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), [CHEMICAL]N6-(S-phenylisopropyl)adenosine[\\CHEMICAL], 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.",
        "label": 5,
        "major": 6,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, [CHEMICAL]5'-(N-cyclopropyl)-carboxamidoadenosine[\\CHEMICAL], antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, [CHEMICAL]theophylline[\\CHEMICAL] and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.",
        "label": 6,
        "major": 5,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and [CHEMICAL]8-p-(sulfophenyl)theophylline[\\CHEMICAL] as well as enprofylline on ethanol-(i.p.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "[GENE]adenosine[\\GENE] agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as [CHEMICAL]enprofylline[\\CHEMICAL] on ethanol-(i.p.",
        "label": 6,
        "major": 5,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Enprofylline[\\CHEMICAL], a weak [GENE]adenosine[\\GENE] antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.",
        "label": 6,
        "major": 2,
        "len": 29
    },
    {
        "text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant [CHEMICAL]BDZ[\\CHEMICAL] which does not bind to high affinity [GENE]BDZ receptors[\\GENE] (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.",
        "label": 10,
        "major": 2,
        "len": 52
    },
    {
        "text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity [GENE]BDZ receptors[\\GENE] ([CHEMICAL]Ro 5-4864[\\CHEMICAL]) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.",
        "label": 10,
        "major": 2,
        "len": 52
    },
    {
        "text": "These findings suggest that limitation of SRF was produced by binding of BDZs, but not [CHEMICAL]beta CCs[\\CHEMICAL], to [GENE]voltage-dependent sodium channels[\\GENE] and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.",
        "label": 10,
        "major": 2,
        "len": 42
    },
    {
        "text": "These findings suggest that limitation of SRF was produced by binding of BDZs, but not [CHEMICAL]beta CCs[\\CHEMICAL], to voltage-dependent sodium channels and not to high affinity central [GENE]BDZ receptors[\\GENE], and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.",
        "label": 10,
        "major": 2,
        "len": 42
    },
    {
        "text": "These findings suggest that limitation of SRF was produced by binding of [CHEMICAL]BDZs[\\CHEMICAL], but not beta CCs, to [GENE]voltage-dependent sodium channels[\\GENE] and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "These findings suggest that limitation of SRF was produced by binding of [CHEMICAL]BDZs[\\CHEMICAL], but not beta CCs, to voltage-dependent sodium channels and not to high affinity central [GENE]BDZ receptors[\\GENE], and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "The limitation of SRF by [CHEMICAL]diazepam[\\CHEMICAL] was not prevented by inverse or partial agonists at the [GENE]BDZ receptor[\\GENE], including Ro 15-1788 and the beta CCs.",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that [CHEMICAL]BDZs[\\CHEMICAL] limit SRF by slowing recovery of [GENE]sodium channels[\\GENE] from inactivation.",
        "label": 3,
        "major": 2,
        "len": 42
    },
    {
        "text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a [GENE]BDZ receptor[\\GENE] weak partial agonist ([CHEMICAL]Ro 15-1788[\\CHEMICAL]) at micromolar concentrations.",
        "label": 5,
        "major": 2,
        "len": 52
    },
    {
        "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [GENE]BDZ receptor[\\GENE], including [CHEMICAL]Ro 15-1788[\\CHEMICAL] and the beta CCs.",
        "label": 5,
        "major": 10,
        "len": 25
    },
    {
        "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [GENE]BDZ receptor[\\GENE], including Ro 15-1788 and the [CHEMICAL]beta CCs[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [GENE]BDZ receptor[\\GENE], including [CHEMICAL]Ro 15-1788[\\CHEMICAL] and the beta CCs.",
        "label": 5,
        "major": 10,
        "len": 25
    },
    {
        "text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the [GENE]BDZ receptor[\\GENE], including Ro 15-1788 and the [CHEMICAL]beta CCs[\\CHEMICAL].",
        "label": 5,
        "major": 10,
        "len": 25
    },
    {
        "text": "The mitogenic effect of [CHEMICAL]DHT[\\CHEMICAL] on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the [GENE]androgen receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "The mitogenic effect of DHT on bone cells was inhibited by antiandrogens ([CHEMICAL]hydroxyflutamide[\\CHEMICAL] and cyproterone acetate) which compete for binding to the [GENE]androgen receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and [CHEMICAL]cyproterone acetate[\\CHEMICAL]) which compete for binding to the [GENE]androgen receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "We conclude that [CHEMICAL]androgens[\\CHEMICAL] can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an [GENE]androgen receptor[\\GENE] mediated mechanism.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "In addition to effects on cell proliferation, [CHEMICAL]DHT[\\CHEMICAL] increased the percentage of [GENE]alkaline phosphatase[\\GENE] (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "In addition to effects on cell proliferation, [CHEMICAL]DHT[\\CHEMICAL] increased the percentage of alkaline phosphatase ([GENE]ALP[\\GENE]) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.",
        "label": 3,
        "major": 4,
        "len": 31
    },
    {
        "text": "We conclude that [CHEMICAL]androgens[\\CHEMICAL] can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the [GENE]osteoblast-line differentiation marker[\\GENE] ALP, presumably by an androgen receptor mediated mechanism.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "We conclude that [CHEMICAL]androgens[\\CHEMICAL] can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker [GENE]ALP[\\GENE], presumably by an androgen receptor mediated mechanism.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The effect of [GENE]histamine-H1 receptor[\\GENE] antagonism with [CHEMICAL]terfenadine[\\CHEMICAL] on concentration-related AMP-induced bronchoconstriction in asthma.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Alprenolol[\\CHEMICAL] treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect [GENE]beta 2-adrenoceptor[\\GENE] density.",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of [CHEMICAL]ICYP[\\CHEMICAL] to [GENE]beta 2-adrenoceptors[\\GENE] was not changed during or after treatment.",
        "label": 2,
        "major": 10,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Propranolol[\\CHEMICAL] treatment (4 X 40 mg/day) increased the density of [GENE]beta 2-adrenoceptors[\\GENE] by 25% after 2 days; concomitantly PRA and heart rate were reduced.",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Mepindolol[\\CHEMICAL] treatment (2 X 5 mg/day) caused a 30% decrease of [GENE]beta 2-adrenoceptor[\\GENE] density and PRA after 2 days; both parameters remained reduced during treatment.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective [GENE]beta-adrenoceptor[\\GENE] antagonists [CHEMICAL]propranolol[\\CHEMICAL] [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
        "label": 6,
        "major": 2,
        "len": 49
    },
    {
        "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective [GENE]beta-adrenoceptor[\\GENE] antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], [CHEMICAL]alprenolol[\\CHEMICAL] (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
        "label": 6,
        "major": 2,
        "len": 49
    },
    {
        "text": "To study the mechanism underlying this phenomenon, the effects of the nonselective [GENE]beta-adrenoceptor[\\GENE] antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and [CHEMICAL]mepindolol[\\CHEMICAL] (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.",
        "label": 6,
        "major": 2,
        "len": 49
    },
    {
        "text": "Inhibition of [GENE]5-lipoxygenase[\\GENE] pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and [CHEMICAL]5-aminosalicylic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Inhibition of [GENE]5-lipoxygenase[\\GENE] pathway of arachidonic acid metabolism in human neutrophils by [CHEMICAL]sulfasalazine[\\CHEMICAL] and 5-aminosalicylic acid.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Interference with [GENE]lipoxygenase[\\GENE] enzymes, rather than a [CHEMICAL]steroid[\\CHEMICAL]-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Inhibition of [GENE]5-lipoxygenase[\\GENE] pathway of [CHEMICAL]arachidonic acid[\\CHEMICAL] metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.",
        "label": 9,
        "major": 4,
        "len": 16
    },
    {
        "text": "Interference with [GENE]lipoxygenase[\\GENE] enzymes, rather than a steroid-like inhibition of [CHEMICAL]arachidonic acid[\\CHEMICAL] release from intracellular phospholipids, seems to be the mode of action.",
        "label": 9,
        "major": 4,
        "len": 23
    },
    {
        "text": "Evidence has been obtained in man for interaction with [GENE]alpha-adrenoceptors[\\GENE] in the brain; and in the peripheral circulation [CHEMICAL]bevantolol[\\CHEMICAL] does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it.",
        "label": 2,
        "major": 4,
        "len": 33
    },
    {
        "text": "It is suggested that all the additional actions of [CHEMICAL]bevantolol[\\CHEMICAL] can be attributed to a partial agonist action on [GENE]alpha-adrenoceptors[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "UNLABELLED: [CHEMICAL]Bevantolol[\\CHEMICAL] is a [GENE]beta-1 adrenoceptor[\\GENE] antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Bevantolol[\\CHEMICAL]: a [GENE]beta-1 adrenoceptor[\\GENE] antagonist with unique additional actions.",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "[GENE]Benzodiazepine receptor[\\GENE] binding of [CHEMICAL]triazolobenzodiazepines[\\CHEMICAL] in vivo: increased receptor number with low-dose alprazolam.",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "The apparent affinity of [GENE]benzodiazepine receptors[\\GENE] for [CHEMICAL]clonazepam[\\CHEMICAL] in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.",
        "label": 2,
        "major": 3,
        "len": 33
    },
    {
        "text": "[GENE]Benzodiazepine receptor[\\GENE] binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose [CHEMICAL]alprazolam[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 13
    },
    {
        "text": "The apparent affinity of [GENE]benzodiazepine receptors[\\GENE] for clonazepam in mice receiving [CHEMICAL]alprazolam[\\CHEMICAL] (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The apparent affinity of [GENE]benzodiazepine receptors[\\GENE] for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of [CHEMICAL]alprazolam[\\CHEMICAL] increased receptor number.",
        "label": 3,
        "major": 2,
        "len": 33
    },
    {
        "text": "In vitro binding affinities of chlorpromazine, [CHEMICAL]fluphenazine[\\CHEMICAL], levomepromazine, perphenazine and some of their metabolites for [GENE]dopamine D2 receptors[\\GENE], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Chlorpromazine, [CHEMICAL]levomepromazine[\\CHEMICAL], and their metabolites had 5-30 times higher binding affinities for [GENE]muscarinic cholinergic receptors[\\GENE] than fluphenazine, perphenazine and their metabolites.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for [GENE]muscarinic cholinergic receptors[\\GENE] than [CHEMICAL]fluphenazine[\\CHEMICAL], perphenazine and their metabolites.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "In vitro binding affinities of chlorpromazine, fluphenazine, [CHEMICAL]levomepromazine[\\CHEMICAL], perphenazine and some of their metabolites for [GENE]dopamine D2 receptors[\\GENE], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for [GENE]muscarinic cholinergic receptors[\\GENE] than fluphenazine, [CHEMICAL]perphenazine[\\CHEMICAL] and their metabolites.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Levomepromazine[\\CHEMICAL] was the most potent and fluphenazine the least potent of the four drugs in [GENE]histamine H1 receptor[\\GENE] binding.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Levomepromazine was the most potent and [CHEMICAL]fluphenazine[\\CHEMICAL] the least potent of the four drugs in [GENE]histamine H1 receptor[\\GENE] binding.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]7-Hydroxy levomepromazine[\\CHEMICAL], 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, [CHEMICAL]perphenazine[\\CHEMICAL] and some of their metabolites for [GENE]dopamine D2 receptors[\\GENE], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "7-Hydroxy levomepromazine, [CHEMICAL]3-hydroxy levomepromazine[\\CHEMICAL] and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and [CHEMICAL]7-hydroxy fluphenazine[\\CHEMICAL] had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the [CHEMICAL]7-hydroxy[\\CHEMICAL]-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the 7-hydroxy-metabolites of [CHEMICAL]chlorpromazine[\\CHEMICAL] and perphenazine had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [GENE]histamine H1 receptor[\\GENE] binding, while the 7-hydroxy-metabolites of chlorpromazine and [CHEMICAL]perphenazine[\\CHEMICAL] had about 75% of the potency of the parent drug in this binding system.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Muscarinic cholinergic and [GENE]histamine H1 receptor[\\GENE] binding of [CHEMICAL]phenothiazine[\\CHEMICAL] drug metabolites.",
        "label": 2,
        "major": 10,
        "len": 11
    },
    {
        "text": "Their [GENE]histamine H1 receptor[\\GENE] binding affinities indicate that metabolites may contribute to the sedative effects of [CHEMICAL]chlorpromazine[\\CHEMICAL] and levomepromazine.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Their [GENE]histamine H1 receptor[\\GENE] binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and [CHEMICAL]levomepromazine[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "In vitro binding affinities of [CHEMICAL]chlorpromazine[\\CHEMICAL], fluphenazine, levomepromazine, perphenazine and some of their metabolites for [GENE]dopamine D2 receptors[\\GENE], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The present study reports the in vitro binding affinities of the same compounds for [GENE]muscarinic cholinergic receptors[\\GENE] and for histamine H1 receptors in rat brain, using [CHEMICAL]3H-quinuclidinyl benzilate[\\CHEMICAL] and 3H-mepyramine as radioligands.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for [GENE]histamine H1 receptors[\\GENE] in rat brain, using [CHEMICAL]3H-quinuclidinyl benzilate[\\CHEMICAL] and 3H-mepyramine as radioligands.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The present study reports the in vitro binding affinities of the same compounds for [GENE]muscarinic cholinergic receptors[\\GENE] and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and [CHEMICAL]3H-mepyramine[\\CHEMICAL] as radioligands.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for [GENE]histamine H1 receptors[\\GENE] in rat brain, using 3H-quinuclidinyl benzilate and [CHEMICAL]3H-mepyramine[\\CHEMICAL] as radioligands.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Chlorpromazine[\\CHEMICAL], levomepromazine, and their metabolites had 5-30 times higher binding affinities for [GENE]muscarinic cholinergic receptors[\\GENE] than fluphenazine, perphenazine and their metabolites.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "In contrast, serum [GENE]alkaline phosphatase[\\GENE] was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with [CHEMICAL]ROAc[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 21
    },
    {
        "text": "Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The [CHEMICAL]retinoids[\\CHEMICAL] had no effect on [GENE]prothrombin[\\GENE] times of animals fed the supplemented diet.",
        "label": 10,
        "major": 10,
        "len": 88
    },
    {
        "text": "13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [GENE]osteocalcin[\\GENE], an effect that correlated with [CHEMICAL]retinoid[\\CHEMICAL]-induced bone effects.",
        "label": 2,
        "major": 10,
        "len": 21
    },
    {
        "text": "Hence, plasma [GENE]osteocalcin[\\GENE] is a better predictor of [CHEMICAL]retinoid[\\CHEMICAL]-induced bone effects than serum alkaline phosphatase.",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "Hence, plasma osteocalcin is a better predictor of [CHEMICAL]retinoid[\\CHEMICAL]-induced bone effects than serum [GENE]alkaline phosphatase[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 15
    },
    {
        "text": "In contrast, serum [GENE]alkaline phosphatase[\\GENE] was elevated in animals dosed with [CHEMICAL]13cisRA[\\CHEMICAL] or 4HPR but not in those dose with ROAc.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "In contrast, serum [GENE]alkaline phosphatase[\\GENE] was elevated in animals dosed with 13cisRA or [CHEMICAL]4HPR[\\CHEMICAL] but not in those dose with ROAc.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "In the high-dose [CHEMICAL]ROAc[\\CHEMICAL] group, there was a twofold increase in [GENE]prothrombin[\\GENE] times but only after prolonged dosing.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "The order of effect was [CHEMICAL]4HPR[\\CHEMICAL] greater than ROAc greater than 13cisRA, with increases in [GENE]prothrombin[\\GENE] times correlating with increases in hemorrhagic deaths.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The order of effect was 4HPR greater than [CHEMICAL]ROAc[\\CHEMICAL] greater than 13cisRA, with increases in [GENE]prothrombin[\\GENE] times correlating with increases in hemorrhagic deaths.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The order of effect was 4HPR greater than ROAc greater than [CHEMICAL]13cisRA[\\CHEMICAL], with increases in [GENE]prothrombin[\\GENE] times correlating with increases in hemorrhagic deaths.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "[CHEMICAL]13cisRA[\\CHEMICAL] and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma [GENE]osteocalcin[\\GENE], an effect that correlated with retinoid-induced bone effects.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "13cisRA and [CHEMICAL]ROAc[\\CHEMICAL], but not 4HPR, caused a dose-dependent reduction in plasma [GENE]osteocalcin[\\GENE], an effect that correlated with retinoid-induced bone effects.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "13cisRA and ROAc, but not [CHEMICAL]4HPR[\\CHEMICAL], caused a dose-dependent reduction in plasma [GENE]osteocalcin[\\GENE], an effect that correlated with retinoid-induced bone effects.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Multiple affinity states of [GENE]opiate receptor[\\GENE] can be demonstrated further by Scatchard analysis of saturation binding studies with [CHEMICAL][3H]DADLE[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "These multiple affinity states of receptor in the hybrid cells are agonist-specific, and the percentage of total [GENE]opiate receptor[\\GENE] in high affinity state is relatively constant in various concentrations of [CHEMICAL]Na+[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 31
    },
    {
        "text": "However, in the presence of 100 mM [CHEMICAL]Na+[\\CHEMICAL], which is required for opiate inhibition of [GENE]adenylate cyclase[\\GENE] activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.",
        "label": 4,
        "major": 4,
        "len": 72
    },
    {
        "text": "In contrast to diethylcarbamazine, [CHEMICAL]piriprost[\\CHEMICAL] (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the [GENE]leukotriene synthetase[\\GENE] of these cells.",
        "label": 10,
        "major": 4,
        "len": 35
    },
    {
        "text": "In contrast to diethylcarbamazine, piriprost ([CHEMICAL]U-60,257[\\CHEMICAL]; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the [GENE]leukotriene synthetase[\\GENE] of these cells.",
        "label": 10,
        "major": 4,
        "len": 35
    },
    {
        "text": "In contrast to diethylcarbamazine, piriprost (U-60,257; [CHEMICAL]6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1[\\CHEMICAL]), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the [GENE]leukotriene synthetase[\\GENE] of these cells.",
        "label": 10,
        "major": 4,
        "len": 35
    },
    {
        "text": "Kinetic analysis revealed that the inhibition of the [GENE]leukotriene C synthetase[\\GENE] reaction by diethylcarbamazine was competitive with respect to [CHEMICAL]LTA4[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Kinetic analysis revealed that the inhibition of the [GENE]leukotriene C synthetase[\\GENE] reaction by [CHEMICAL]diethylcarbamazine[\\CHEMICAL] was competitive with respect to LTA4.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In contrast to [CHEMICAL]diethylcarbamazine[\\CHEMICAL], piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [GENE]5-lipoxygenase[\\GENE] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "In contrast to [CHEMICAL]diethylcarbamazine[\\CHEMICAL], piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the [GENE]leukotriene synthetase[\\GENE] of these cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "In contrast to diethylcarbamazine, [CHEMICAL]piriprost[\\CHEMICAL] (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [GENE]5-lipoxygenase[\\GENE] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",
        "label": 4,
        "major": 10,
        "len": 35
    },
    {
        "text": "In contrast to diethylcarbamazine, piriprost ([CHEMICAL]U-60,257[\\CHEMICAL]; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [GENE]5-lipoxygenase[\\GENE] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",
        "label": 4,
        "major": 10,
        "len": 35
    },
    {
        "text": "In contrast to diethylcarbamazine, piriprost (U-60,257; [CHEMICAL]6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1[\\CHEMICAL]), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the [GENE]5-lipoxygenase[\\GENE] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between [CHEMICAL]diethylcarbamazine[\\CHEMICAL] and piriprost, a [GENE]5-lipoxygenase[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and [CHEMICAL]piriprost[\\CHEMICAL], a [GENE]5-lipoxygenase[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of the [GENE]leukotriene synthetase[\\GENE] of rat basophil leukemia cells by [CHEMICAL]diethylcarbamazine[\\CHEMICAL], and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Similar concentrations also inhibited the formation of [CHEMICAL]leukotriene C4[\\CHEMICAL] (LTC4) by [GENE]LTC synthetase[\\GENE], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Similar concentrations also inhibited the formation of leukotriene C4 ([CHEMICAL]LTC4[\\CHEMICAL]) by [GENE]LTC synthetase[\\GENE], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of [CHEMICAL]sulfidopeptide leuktrienes[\\CHEMICAL] in RBL cells at the [GENE]5-lipoxygenase[\\GENE] step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of [CHEMICAL]LTA4[\\CHEMICAL] in the [GENE]leukotriene C synthetase[\\GENE] reaction.",
        "label": 9,
        "major": 4,
        "len": 47
    },
    {
        "text": "Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by [GENE]LTC synthetase[\\GENE], a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling [CHEMICAL]LTA4[\\CHEMICAL] to glutathione.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "The EC50 for inhibition of the [GENE]leukotriene C synthetase[\\GENE] of RBL cells was directly proportional to the [CHEMICAL]LTA4[\\CHEMICAL] concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.",
        "label": 9,
        "major": 4,
        "len": 38
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as [CHEMICAL]prazosin[\\CHEMICAL], yohimbine and clonidine failed to bind to [GENE]calmodulin[\\GENE] when examined under the same experimental conditions.",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, [CHEMICAL]yohimbine[\\CHEMICAL] and clonidine failed to bind to [GENE]calmodulin[\\GENE] when examined under the same experimental conditions.",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and [CHEMICAL]clonidine[\\CHEMICAL] failed to bind to [GENE]calmodulin[\\GENE] when examined under the same experimental conditions.",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "In addition, [CHEMICAL]phenoxybenzamine[\\CHEMICAL] showed little or no calcium-dependent binding to the [GENE]S-100 protein[\\GENE], bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 10,
        "major": 2,
        "len": 43
    },
    {
        "text": "In addition, [CHEMICAL]phenoxybenzamine[\\CHEMICAL] showed little or no calcium-dependent binding to the S-100 protein, [GENE]bovine serum albumin[\\GENE] or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 10,
        "major": 2,
        "len": 43
    },
    {
        "text": "In addition, [CHEMICAL]phenoxybenzamine[\\CHEMICAL] showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or [GENE]cytochrome c[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 19
    },
    {
        "text": "The site at which [CHEMICAL]phenoxybenzamine[\\CHEMICAL] bound to [GENE]calmodulin[\\GENE] appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "To determine the factors that influence the interaction between [CHEMICAL]phenoxybenzamine[\\CHEMICAL] and [GENE]calmodulin[\\GENE], the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including [CHEMICAL]penfluridol[\\CHEMICAL], pimozide and spiroperidol, prevented the binding of phenoxybenzamine to [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, [CHEMICAL]pimozide[\\CHEMICAL] and spiroperidol, prevented the binding of phenoxybenzamine to [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and [CHEMICAL]spiroperidol[\\CHEMICAL], prevented the binding of phenoxybenzamine to [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] to [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 36
    },
    {
        "text": "However, in contrast to the reversible binding of most [CHEMICAL]phenothiazines[\\CHEMICAL] to [GENE]calmodulin[\\GENE], phenoxybenzamine bound to calmodulin irreversibly.",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "However, in contrast to the reversible binding of most phenothiazines to calmodulin, [CHEMICAL]phenoxybenzamine[\\CHEMICAL] bound to [GENE]calmodulin[\\GENE] irreversibly.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "The binding of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] to [GENE]calmodulin[\\GENE] was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Characteristics of the binding of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] to [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 8
    },
    {
        "text": "To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] to [GENE]calmodulin[\\GENE] was determined by equilibrium dialysis under a variety of experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "In addition, phenoxybenzamine showed little or no [CHEMICAL]calcium[\\CHEMICAL]-dependent binding to the S-100 protein, bovine serum albumin or [GENE]cytochrome c[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between [CHEMICAL]phenoxybenzamine[\\CHEMICAL] and [GENE]calmodulin[\\GENE] may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "This interaction was found to be similar in some respects to the interaction between [CHEMICAL]phenothiazines[\\CHEMICAL] and [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other [GENE]alpha-adrenergic[\\GENE] agents such as [CHEMICAL]prazosin[\\CHEMICAL], yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other [GENE]alpha-adrenergic[\\GENE] agents such as prazosin, [CHEMICAL]yohimbine[\\CHEMICAL] and clonidine failed to bind to calmodulin when examined under the same experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The binding of phenoxybenzamine to calmodulin was fairly selective in that other [GENE]alpha-adrenergic[\\GENE] agents such as prazosin, yohimbine and [CHEMICAL]clonidine[\\CHEMICAL] failed to bind to calmodulin when examined under the same experimental conditions.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "In addition, phenoxybenzamine showed little or no [CHEMICAL]calcium[\\CHEMICAL]-dependent binding to the [GENE]S-100 protein[\\GENE], bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "In addition, phenoxybenzamine showed little or no [CHEMICAL]calcium[\\CHEMICAL]-dependent binding to the S-100 protein, [GENE]bovine serum albumin[\\GENE] or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 2,
        "major": 4,
        "len": 43
    },
    {
        "text": "In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between [CHEMICAL]phenoxybenzamine[\\CHEMICAL] and calmodulin may be useful for inhibiting certain [GENE]calmodulin[\\GENE]-dependent reactions and for studying the various biological functions of calmodulin.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "The following was demonstrated in the rat and confirmed in man: interaction of [CHEMICAL]Anandron[\\CHEMICAL] with the [GENE]prostatic androgen receptor[\\GENE], antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.",
        "label": 2,
        "major": 3,
        "len": 37
    },
    {
        "text": "Replacement of the methyl groups of theophylline with [CHEMICAL]n-propyl[\\CHEMICAL] or larger alkyl groups yields xanthines with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an 8-phenyl moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Replacement of the methyl groups of theophylline with n-propyl or larger [CHEMICAL]alkyl[\\CHEMICAL] groups yields xanthines with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an 8-phenyl moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields [CHEMICAL]xanthines[\\CHEMICAL] with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an 8-phenyl moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an [CHEMICAL]8-phenyl[\\CHEMICAL] moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Certain analogs of [CHEMICAL]caffeine[\\CHEMICAL] in which the methyl group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for [GENE]A2 receptors[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Certain analogs of caffeine in which the [CHEMICAL]methyl[\\CHEMICAL] group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for [GENE]A2 receptors[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl or [CHEMICAL]propyl[\\CHEMICAL] group display selectivity for [GENE]A2 receptors[\\GENE].",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "The profile of a series of [CHEMICAL]adenosine[\\CHEMICAL] analogs or of xanthine antagonists can be used to define the nature of [GENE]adenosine receptors[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "The profile of a series of adenosine analogs or of [CHEMICAL]xanthine[\\CHEMICAL] antagonists can be used to define the nature of [GENE]adenosine receptors[\\GENE].",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "The subregion of the [GENE]adenosine receptor[\\GENE] that interacts with the [CHEMICAL]N6[\\CHEMICAL]-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "The subregion of the [GENE]adenosine receptor[\\GENE] that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to [CHEMICAL]phenyl[\\CHEMICAL] interactions, bulk tolerance and stereoselectivity.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Replacement of the [CHEMICAL]methyl[\\CHEMICAL] groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an 8-phenyl moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "Replacement of the methyl groups of [CHEMICAL]theophylline[\\CHEMICAL] with n-propyl or larger alkyl groups yields xanthines with selectivity for [GENE]A1 receptors[\\GENE], particularly when combined with an 8-phenyl moiety.",
        "label": 2,
        "major": 1,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Xanthines[\\CHEMICAL] are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of [GENE]adenosine receptors[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Xanthines[\\CHEMICAL] are classical antagonists for [GENE]adenosine receptors[\\GENE] for many of their pharmacological actions may be due to blockade of adenosine receptors.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Co-incubation with human serum albumin or poly-L-lysine but not lysine protected [GENE]human and hamster LDH-X[\\GENE] from [CHEMICAL]gossypol[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "Co-incubation with human serum albumin or poly-L-lysine but not [CHEMICAL]lysine[\\CHEMICAL] protected [GENE]human and hamster LDH-X[\\GENE] from gossypol.",
        "label": 10,
        "major": 10,
        "len": 17
    },
    {
        "text": "Co-incubation with human serum albumin or [CHEMICAL]poly-L-lysine[\\CHEMICAL] but not lysine protected [GENE]human and hamster LDH-X[\\GENE] from gossypol.",
        "label": 2,
        "major": 10,
        "len": 17
    },
    {
        "text": "Inhibition of testicular [GENE]LDH-X[\\GENE] from laboratory animals and man by [CHEMICAL]gossypol[\\CHEMICAL] and its isomers.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Gossypol acetic acid[\\CHEMICAL] (0-100 mumol/l) inhibited [GENE]LDH-X[\\GENE] prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "The inhibitory effect of [CHEMICAL](+)-, (-)-, (+/-)-gossypol[\\CHEMICAL] and (+/-)-gossypol acetic acid upon testicular cytosolic [GENE]LDH-X[\\GENE] was measured in vitro.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Gossypol[\\CHEMICAL] and its isomers were non-competitive inhibitors of [GENE]human and hamster LDH-X[\\GENE] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and [CHEMICAL](+/-)-gossypol acetic acid[\\CHEMICAL] upon testicular cytosolic [GENE]LDH-X[\\GENE] was measured in vitro.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme [CHEMICAL]NADH[\\CHEMICAL], competitive inhibitors of [GENE]human LDH-X[\\GENE] and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.",
        "label": 4,
        "major": 9,
        "len": 35
    },
    {
        "text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of [GENE]hamster LDH-X[\\GENE] with respect to the substrate [CHEMICAL]alpha-ketobutyrate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Most reducing cofactors for the peroxidase protect [GENE]PHS[\\GENE] and prostacyclin synthase from inactivation by [CHEMICAL]hydroperoxides[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Most reducing cofactors for the peroxidase protect PHS and [GENE]prostacyclin synthase[\\GENE] from inactivation by [CHEMICAL]hydroperoxides[\\CHEMICAL].",
        "label": 4,
        "major": 8,
        "len": 15
    },
    {
        "text": "Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of [GENE]PHS[\\GENE] is markedly increased in the presence of 100 microM [CHEMICAL]H2O2[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "Inactivation of [GENE]prostaglandin H synthase[\\GENE] and prostacyclin synthase by [CHEMICAL]phenylbutazone[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 10
    },
    {
        "text": "Inactivation of prostaglandin H synthase and [GENE]prostacyclin synthase[\\GENE] by [CHEMICAL]phenylbutazone[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 10
    },
    {
        "text": "Phenylbutazone ([CHEMICAL]PB[\\CHEMICAL]), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of [GENE]prostaglandin H synthase[\\GENE] (PHS).",
        "label": 8,
        "major": 4,
        "len": 20
    },
    {
        "text": "Phenylbutazone ([CHEMICAL]PB[\\CHEMICAL]), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ([GENE]PHS[\\GENE]).",
        "label": 8,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Phenylbutazone[\\CHEMICAL] (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of [GENE]prostaglandin H synthase[\\GENE] (PHS).",
        "label": 8,
        "major": 8,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Phenylbutazone[\\CHEMICAL] (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase ([GENE]PHS[\\GENE]).",
        "label": 8,
        "major": 4,
        "len": 20
    },
    {
        "text": "Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that [CHEMICAL]PB[\\CHEMICAL]-dependent inactivation of [GENE]PHS[\\GENE] is markedly increased in the presence of 100 microM H2O2.",
        "label": 8,
        "major": 3,
        "len": 28
    },
    {
        "text": "Chromatographic analysis of the metabolism of [CHEMICAL]14C-labeled arachidonic acid[\\CHEMICAL] in this system revealed that PB-dependent inactivation of [GENE]PHS[\\GENE] is markedly increased in the presence of 100 microM H2O2.",
        "label": 9,
        "major": 3,
        "len": 28
    },
    {
        "text": "Drug-protein interactions: isolation and characterization of covalent adducts of [CHEMICAL]phenoxybenzamine[\\CHEMICAL] and [GENE]calmodulin[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Phenoxybenzamine[\\CHEMICAL], an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels [GENE]calmodulin[\\GENE] in the presence of calcium.",
        "label": 2,
        "major": 6,
        "len": 15
    },
    {
        "text": "Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the [CHEMICAL]chlorpromazine[\\CHEMICAL] binding capacities of the phenoxybenzamine-[GENE]calmodulin[\\GENE] adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Phenoxybenzamine, an alpha-adrenergic antagonist containing a [CHEMICAL](chloroethyl)amine[\\CHEMICAL] group, labels [GENE]calmodulin[\\GENE] in the presence of calcium.",
        "label": 2,
        "major": 6,
        "len": 15
    },
    {
        "text": "Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the [CHEMICAL]phenoxybenzamine[\\CHEMICAL]-[GENE]calmodulin[\\GENE] adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Staining was largely absent when substrate was omitted or after pretreatment with the irreversible [GENE]SSAO[\\GENE] inhibitor, [CHEMICAL]hydralazine[\\CHEMICAL] and the slowly reversible inhibitor, semicarbazide.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Staining was largely absent when substrate was omitted or after pretreatment with the irreversible [GENE]SSAO[\\GENE] inhibitor, hydralazine and the slowly reversible inhibitor, [CHEMICAL]semicarbazide[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 23
    },
    {
        "text": "Positive staining of mitochondria was achieved in the presence of the [GENE]MAO[\\GENE] substrate, [CHEMICAL]tryptamine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 14
    },
    {
        "text": "Staining around the edges of the brown fat cells was observed with the [GENE]SSAO[\\GENE] substrates, [CHEMICAL]tyramine[\\CHEMICAL] and benzylamine.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Staining around the edges of the brown fat cells was observed with the [GENE]SSAO[\\GENE] substrates, tyramine and [CHEMICAL]benzylamine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Binding of [CHEMICAL]penicillins[\\CHEMICAL] to penicillin-binding protein 1Bs produces lysis, binding to [GENE]penicillin-binding protein 2[\\GENE] produces round cells, and binding to penicillin-binding protein 3 produces long filaments.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Binding of [CHEMICAL]penicillins[\\CHEMICAL] to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to [GENE]penicillin-binding protein 3[\\GENE] produces long filaments.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Binding of [CHEMICAL]penicillins[\\CHEMICAL] to [GENE]penicillin-binding protein 1Bs[\\GENE] produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments.",
        "label": 2,
        "major": 9,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Amdinocillin[\\CHEMICAL] is a beta-amidino penicillanic acid derivative that binds specifically to [GENE]penicillin-binding protein 2[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Amdinocillin is a [CHEMICAL]beta-amidino penicillanic acid[\\CHEMICAL] derivative that binds specifically to [GENE]penicillin-binding protein 2[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "[GENE]Penicillin-binding proteins[\\GENE] and role of [CHEMICAL]amdinocillin[\\CHEMICAL] in causing bacterial cell death.",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "This agent acts synergistically with many [CHEMICAL]penicillins[\\CHEMICAL], such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 9,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as [CHEMICAL]ampicillin[\\CHEMICAL], carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 2,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as ampicillin, [CHEMICAL]carbenicillin[\\CHEMICAL], and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 9,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with [CHEMICAL]cephalosporins[\\CHEMICAL], cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, [CHEMICAL]cefazolin[\\CHEMICAL], cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 4,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, [CHEMICAL]cefamandole[\\CHEMICAL], or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 9,
        "len": 46
    },
    {
        "text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or [CHEMICAL]cefoxitin[\\CHEMICAL] to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the [GENE]peptidoglycan[\\GENE] of the bacterial cell wall.",
        "label": 3,
        "major": 9,
        "len": 46
    },
    {
        "text": "[CHEMICAL]W-7[\\CHEMICAL] did not induce a loss of cell surface [GENE]beta 2-microglobulin[\\GENE], a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane.",
        "label": 10,
        "major": 10,
        "len": 46
    },
    {
        "text": "We have found that certain [CHEMICAL]naphthalenesulfonamides[\\CHEMICAL] [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain [CHEMICAL]naphthalenesulfonamides[\\CHEMICAL] [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain [CHEMICAL]naphthalenesulfonamides[\\CHEMICAL] [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "The extent of [GENE]EGF receptor[\\GENE] loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when [CHEMICAL]W-7[\\CHEMICAL] is removed.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., [CHEMICAL]N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide[\\CHEMICAL] (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., [CHEMICAL]N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide[\\CHEMICAL] (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., [CHEMICAL]N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide[\\CHEMICAL] (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "Loss of alpha 2-macroglobulin and [GENE]epidermal growth factor[\\GENE] surface binding induced by phenothiazines and [CHEMICAL]naphthalene sulfonamides[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Loss of [GENE]alpha 2-macroglobulin[\\GENE] and epidermal growth factor surface binding induced by phenothiazines and [CHEMICAL]naphthalene sulfonamides[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ([CHEMICAL]W-7[\\CHEMICAL])] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ([CHEMICAL]W-7[\\CHEMICAL])] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide ([CHEMICAL]W-7[\\CHEMICAL])] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "Loss of alpha 2-macroglobulin and [GENE]epidermal growth factor[\\GENE] surface binding induced by [CHEMICAL]phenothiazines[\\CHEMICAL] and naphthalene sulfonamides.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Loss of [GENE]alpha 2-macroglobulin[\\GENE] and epidermal growth factor surface binding induced by [CHEMICAL]phenothiazines[\\CHEMICAL] and naphthalene sulfonamides.",
        "label": 2,
        "major": 10,
        "len": 16
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and [CHEMICAL]phenothiazines[\\CHEMICAL] [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and [CHEMICAL]phenothiazines[\\CHEMICAL] [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and [CHEMICAL]phenothiazines[\\CHEMICAL] [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., [CHEMICAL]trifluoperazine[\\CHEMICAL] (TFP)] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., [CHEMICAL]trifluoperazine[\\CHEMICAL] (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., [CHEMICAL]trifluoperazine[\\CHEMICAL] (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ([CHEMICAL]TFP[\\CHEMICAL])] induce a loss of cell-surface receptors for [GENE]alpha 2-macroglobulin[\\GENE], and epidermal growth factor (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ([CHEMICAL]TFP[\\CHEMICAL])] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and [GENE]epidermal growth factor[\\GENE] (EGF) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine ([CHEMICAL]TFP[\\CHEMICAL])] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor ([GENE]EGF[\\GENE]) in fibroblasts.",
        "label": 2,
        "major": 10,
        "len": 30
    },
    {
        "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using [CHEMICAL]rhodamine[\\CHEMICAL]-labeled [GENE]alpha 2-macroglobulin[\\GENE], we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",
        "label": 2,
        "major": 3,
        "len": 132
    },
    {
        "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of [CHEMICAL]rhodamine[\\CHEMICAL]-labeled [GENE]alpha 2-macroglobulin[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 132
    },
    {
        "text": "Since both [CHEMICAL]TFP[\\CHEMICAL] and W-7 are potent inhibitors of [GENE]calmodulin[\\GENE], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Since both TFP and [CHEMICAL]W-7[\\CHEMICAL] are potent inhibitors of [GENE]calmodulin[\\GENE], we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) [CHEMICAL]Promethazine[\\CHEMICAL], a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [GENE]calmodulin[\\GENE] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",
        "label": 4,
        "major": 2,
        "len": 132
    },
    {
        "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a [CHEMICAL]phenothiazine[\\CHEMICAL] that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [GENE]calmodulin[\\GENE] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",
        "label": 4,
        "major": 3,
        "len": 132
    },
    {
        "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as [CHEMICAL]TFP[\\CHEMICAL] at inhibiting endocytosis; calmidazolium, a potent inhibitor of several [GENE]calmodulin[\\GENE] functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.",
        "label": 4,
        "major": 10,
        "len": 132
    },
    {
        "text": "The binding of [GENE]FHA[\\GENE]-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists [CHEMICAL]diphenhydramine[\\CHEMICAL] and clemastine.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "The binding of [GENE]FHA[\\GENE]-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and [CHEMICAL]clemastine[\\CHEMICAL].",
        "label": 4,
        "major": 6,
        "len": 20
    },
    {
        "text": "The histamine H2 receptor antagonist [CHEMICAL]cimetidine[\\CHEMICAL] blocked the [GENE]FHA[\\GENE]-HIS binding on 14-37% of the platelets.",
        "label": 4,
        "major": 2,
        "len": 15
    },
    {
        "text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the [GENE]histamine H1 receptor[\\GENE] antagonists [CHEMICAL]diphenhydramine[\\CHEMICAL] and clemastine.",
        "label": 6,
        "major": 4,
        "len": 20
    },
    {
        "text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the [GENE]histamine H1 receptor[\\GENE] antagonists diphenhydramine and [CHEMICAL]clemastine[\\CHEMICAL].",
        "label": 6,
        "major": 2,
        "len": 20
    },
    {
        "text": "The [GENE]histamine H2 receptor[\\GENE] antagonist [CHEMICAL]cimetidine[\\CHEMICAL] blocked the FHA-HIS binding on 14-37% of the platelets.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "[GENE]Alanine:glyoxylate aminotransferase[\\GENE] (AGT) in the liver catalyzes most of the [CHEMICAL]glyoxylate[\\CHEMICAL] transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.",
        "label": 9,
        "major": 10,
        "len": 21
    },
    {
        "text": "Alanine:glyoxylate aminotransferase ([GENE]AGT[\\GENE]) in the liver catalyzes most of the [CHEMICAL]glyoxylate[\\CHEMICAL] transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.",
        "label": 9,
        "major": 10,
        "len": 21
    },
    {
        "text": "The holo activity of combined peroxisomal and mitochondrial [GENE]AGT 1[\\GENE] with a low Km for [CHEMICAL]L-alanine[\\CHEMICAL] rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).",
        "label": 9,
        "major": 4,
        "len": 43
    },
    {
        "text": "The holo activity of AGT 2 with a high Km for [CHEMICAL]L-alanine[\\CHEMICAL] decreased more slowly than [GENE]AGT 1[\\GENE] (by 33% in 14 days, by 60% in 28 days).",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "The holo activity of [GENE]AGT 2[\\GENE] with a high Km for [CHEMICAL]L-alanine[\\CHEMICAL] decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Triclosan[\\CHEMICAL] inhibited both [GENE]cyclooxygenase 1[\\GENE] and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triclosan[\\CHEMICAL] inhibited both cyclooxygenase 1 and [GENE]cyclo-oxygenase 2[\\GENE] with IC-50 values of 43 microM and 227 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Triclosan[\\CHEMICAL] also inhibited [GENE]5-lipoxygenase[\\GENE] with an IC-50 of 43 microM.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "The [GENE]15-lipoxygenase[\\GENE] was similarly inhibited by [CHEMICAL]triclosan[\\CHEMICAL] with an IC-50 of 61 microM.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Hence, [CHEMICAL]triclosan[\\CHEMICAL] has the ability to inhibit both the [GENE]cyclo-oxygenase[\\GENE] and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Hence, [CHEMICAL]triclosan[\\CHEMICAL] has the ability to inhibit both the cyclo-oxygenase and [GENE]lipoxygenase[\\GENE] pathways of arachidonic acid metabolism with similar efficacy.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "In cell culture experiments, it was found that [CHEMICAL]triclosan[\\CHEMICAL] inhibited [GENE]IL-1 beta[\\GENE] induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "In cell culture experiments, it was found that triclosan inhibited [GENE]IL-1 beta[\\GENE] induced [CHEMICAL]prostaglandin E2[\\CHEMICAL] production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Hence, triclosan has the ability to inhibit both the [GENE]cyclo-oxygenase[\\GENE] and lipoxygenase pathways of [CHEMICAL]arachidonic acid[\\CHEMICAL] metabolism with similar efficacy.",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and [GENE]lipoxygenase[\\GENE] pathways of [CHEMICAL]arachidonic acid[\\CHEMICAL] metabolism with similar efficacy.",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "Cells propagated in medium containing [CHEMICAL]N5-methyltetrahydrofolate[\\CHEMICAL] and homocysteine showed a substantial increase in [GENE]MS[\\GENE] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Cells propagated in medium containing N5-methyltetrahydrofolate and [CHEMICAL]homocysteine[\\CHEMICAL] showed a substantial increase in [GENE]MS[\\GENE] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Ergovaline[\\CHEMICAL] inhibition of radioligand binding to the [GENE]D2 dopamine receptor[\\GENE] and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",
        "label": 2,
        "major": 9,
        "len": 35
    },
    {
        "text": "Our results indicate that ergot compounds, especially [CHEMICAL]ergovaline[\\CHEMICAL], bind to [GENE]D2 dopamine receptors[\\GENE] and elicit second messenger responses similar to that of dopamine.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Our results indicate that ergot compounds, especially ergovaline, bind to [GENE]D2 dopamine receptors[\\GENE] and elicit second messenger responses similar to that of [CHEMICAL]dopamine[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Ergovaline[\\CHEMICAL] binding and activation of [GENE]D2 dopamine receptors[\\GENE] in GH4ZR7 cells.",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Ergovaline[\\CHEMICAL] inhibition of the binding of the [GENE]D2[\\GENE]-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "Ergovaline inhibition of the binding of the [GENE]D2[\\GENE]-specific radioligand, [CHEMICAL][3H]YM-09151-2[\\CHEMICAL], exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Ergovaline inhibition of the binding of the [GENE]D2[\\GENE]-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas [CHEMICAL]dopamine[\\CHEMICAL] was much less potent (370 +/- 160 nM).",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Ergovaline[\\CHEMICAL] binding and activation of [GENE]D2 dopamine receptors[\\GENE] in GH4ZR7 cells.",
        "label": 3,
        "major": 2,
        "len": 11
    },
    {
        "text": "These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several [CHEMICAL]ergot alkaloids[\\CHEMICAL] including ergovaline, may be due to [GENE]D2 dopamine receptor[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including [CHEMICAL]ergovaline[\\CHEMICAL], may be due to [GENE]D2 dopamine receptor[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Ergot alkaloids[\\CHEMICAL] were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 9,
        "len": 40
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for [CHEMICAL]ergovaline[\\CHEMICAL], ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for ergovaline, [CHEMICAL]ergonovine[\\CHEMICAL], alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, [CHEMICAL]alpha-ergocryptine[\\CHEMICAL], ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 9,
        "len": 40
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, [CHEMICAL]ergotamine[\\CHEMICAL], and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 9,
        "len": 40
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and [CHEMICAL]dopamine[\\CHEMICAL] of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 4,
        "major": 3,
        "len": 40
    },
    {
        "text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and [CHEMICAL]ergot alkaloid[\\CHEMICAL] inhibition of [GENE]vasoactive intestinal peptide[\\GENE] (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",
        "label": 4,
        "major": 2,
        "len": 35
    },
    {
        "text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and [CHEMICAL]ergot alkaloid[\\CHEMICAL] inhibition of vasoactive intestinal peptide ([GENE]VIP[\\GENE])-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",
        "label": 4,
        "major": 9,
        "len": 35
    },
    {
        "text": "Inhibition of cyclic AMP production by ergovaline was blocked by the [GENE]dopamine receptor[\\GENE] antagonist, [CHEMICAL](-)-sulpiride[\\CHEMICAL] (IC50, 300 +/- 150 nM).",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "Ergot alkaloids were also effective in inhibiting [GENE]VIP[\\GENE]-stimulated [CHEMICAL]cyclic AMP[\\CHEMICAL] production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.",
        "label": 9,
        "major": 9,
        "len": 40
    },
    {
        "text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of [GENE]vasoactive intestinal peptide[\\GENE] (VIP)-stimulated [CHEMICAL]cyclic AMP[\\CHEMICAL] production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide ([GENE]VIP[\\GENE])-stimulated [CHEMICAL]cyclic AMP[\\CHEMICAL] production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.",
        "label": 9,
        "major": 9,
        "len": 35
    },
    {
        "text": "Saturation experiments showed that [CHEMICAL][3H]prazosin[\\CHEMICAL] labelled a single population of binding sites in the spleen ([GENE]alpha 1B[\\GENE]) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Saturation experiments showed that [CHEMICAL][3H]prazosin[\\CHEMICAL] labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus ([GENE]alpha 1A[\\GENE] and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Saturation experiments showed that [CHEMICAL][3H]prazosin[\\CHEMICAL] labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (alpha 1A and [GENE]alpha 1B[\\GENE]) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, (+)-butaclamol, [CHEMICAL]clozapine[\\CHEMICAL], haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, [CHEMICAL]haloperidol[\\CHEMICAL], spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, [CHEMICAL]spiperone[\\CHEMICAL], thioridazine and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: [CHEMICAL]risperidone[\\CHEMICAL] is selective for the [GENE]alpha 1B-adrenoceptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 17
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, [CHEMICAL]thioridazine[\\CHEMICAL] and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and [CHEMICAL]YM-09151-2[\\CHEMICAL] was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The binding of the antipsychotic drugs [CHEMICAL]risperidone[\\CHEMICAL], (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "The binding of the antipsychotic drugs risperidone, [CHEMICAL](+)-butaclamol[\\CHEMICAL], clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the [GENE]alpha 1-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Incubation of rat aortic membranes with the irreversible [GENE]alpha 1B-adrenoceptor[\\GENE] antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [CHEMICAL][3H]-prazosin[\\CHEMICAL] binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "Mediation of [CHEMICAL]noradrenaline[\\CHEMICAL]-induced contractions of rat aorta by the [GENE]alpha 1B-adrenoceptor[\\GENE] subtype.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "Incubation of rat aortic membranes with the irreversible [GENE]alpha 1B-adrenoceptor[\\GENE] antagonist, [CHEMICAL]chloroethylclonidine[\\CHEMICAL] (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
        "label": 6,
        "major": 4,
        "len": 39
    },
    {
        "text": "Incubation of rat aortic membranes with the irreversible [GENE]alpha 1B-adrenoceptor[\\GENE] antagonist, chloroethylclonidine ([CHEMICAL]CEC[\\CHEMICAL]: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).",
        "label": 6,
        "major": 10,
        "len": 39
    },
    {
        "text": "Beta 2- but not [GENE]beta 1-adrenoceptors[\\GENE] are involved in [CHEMICAL]desipramine[\\CHEMICAL] enhancement of aggressive behavior in long-term isolated mice.",
        "label": 10,
        "major": 10,
        "len": 18
    },
    {
        "text": "Taken together with our previous finding that the [CHEMICAL]desipramine[\\CHEMICAL]-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also [GENE]beta 2-adrenoceptor[\\GENE] stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",
        "label": 2,
        "major": 3,
        "len": 48
    },
    {
        "text": "Moreover, [CHEMICAL]clenbuterol HCl[\\CHEMICAL] (0.1-0.5 mg/kg, IP), a lipophilic [GENE]beta 2-adrenoceptor[\\GENE] agonist, significantly increased the duration of basal aggressive behavior.",
        "label": 5,
        "major": 3,
        "len": 19
    },
    {
        "text": "Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by [CHEMICAL]yohimbine[\\CHEMICAL], an [GENE]alpha 2-adrenoceptor[\\GENE] antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.",
        "label": 6,
        "major": 3,
        "len": 48
    },
    {
        "text": "Intraperitoneal administration of [CHEMICAL](+/- )propranolol HCl[\\CHEMICAL] (2.5-10 mg/kg), a nonselective [GENE]beta-adrenoceptor[\\GENE] antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "[CHEMICAL]ICI118,551 HCl[\\CHEMICAL] (1.25-5 mg/kg, IP), a selective [GENE]beta 2-adrenoceptor[\\GENE] antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.",
        "label": 6,
        "major": 6,
        "len": 37
    },
    {
        "text": "ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas [CHEMICAL]metoprolol tartrate[\\CHEMICAL] (5-20 mg/kg, IP), a selective [GENE]beta 1-adrenoceptor[\\GENE] antagonist, did not affect it.",
        "label": 6,
        "major": 10,
        "len": 37
    },
    {
        "text": "Furthermore, the phosphorylation of [GENE]myosin light chain[\\GENE] produced by [CHEMICAL]norepinephrine[\\CHEMICAL] was greater than that produced by clonidine.",
        "label": 3,
        "major": 9,
        "len": 17
    },
    {
        "text": "Furthermore, the phosphorylation of [GENE]myosin light chain[\\GENE] produced by norepinephrine was greater than that produced by [CHEMICAL]clonidine[\\CHEMICAL].",
        "label": 3,
        "major": 9,
        "len": 17
    },
    {
        "text": "In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective [GENE]alpha 1A-adrenoceptor[\\GENE] antagonist [CHEMICAL]WB 4101[\\CHEMICAL] (100 nM).",
        "label": 6,
        "major": 4,
        "len": 45
    },
    {
        "text": "We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by [CHEMICAL]STZ[\\CHEMICAL], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not [GENE]GLUT1[\\GENE].",
        "label": 10,
        "major": 9,
        "len": 36
    },
    {
        "text": "Consistent with these data, only [GENE]GLUT2[\\GENE]-expressing RIN or AtT-20ins cells transported [CHEMICAL]STZ[\\CHEMICAL] efficiently.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "We conclude that expression of [GENE]GLUT2[\\GENE] is required for efficient killing of neuroendocrine cells by [CHEMICAL]STZ[\\CHEMICAL], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by [CHEMICAL]STZ[\\CHEMICAL], and this effect is related to specific recognition of the drug as a transported substrate by [GENE]GLUT2[\\GENE] but not GLUT1.",
        "label": 9,
        "major": 9,
        "len": 36
    },
    {
        "text": "The present study utilized blood from normal volunteers and [CHEMICAL]125I[\\CHEMICAL]-[GENE]fibrinogen[\\GENE] in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.",
        "label": 2,
        "major": 4,
        "len": 83
    },
    {
        "text": "The data suggest that [CHEMICAL]lysine[\\CHEMICAL] analogues, even at low concentrations, reduce the rate of [GENE]t-PA[\\GENE] induced whole blood clot lysis by several mechanisms.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. [CHEMICAL]AMCA[\\CHEMICAL] (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous [GENE]t-PA[\\GENE] or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.",
        "label": 4,
        "major": 3,
        "len": 83
    },
    {
        "text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. [CHEMICAL]AMCA[\\CHEMICAL] (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous [GENE]t-PA[\\GENE] and a lysine analogue.",
        "label": 4,
        "major": 3,
        "len": 83
    },
    {
        "text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and [CHEMICAL]EACA[\\CHEMICAL] (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous [GENE]t-PA[\\GENE] or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.",
        "label": 4,
        "major": 3,
        "len": 83
    },
    {
        "text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and [CHEMICAL]EACA[\\CHEMICAL] (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous [GENE]t-PA[\\GENE] and a lysine analogue.",
        "label": 4,
        "major": 4,
        "len": 83
    },
    {
        "text": "Inhibitory effects of [CHEMICAL]lysine[\\CHEMICAL] analogues on [GENE]t-PA[\\GENE] induced whole blood clot lysis.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "However, their inhibitory effect was markedly reduced if clots were formed in the presence of [GENE]t-PA[\\GENE] and then exposed to either of the [CHEMICAL]lysine[\\CHEMICAL] analogues.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of [CHEMICAL]lysine[\\CHEMICAL] analogues required for inhibition of clot lysis induced by exogenous [GENE]t-PA[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Histamine[\\CHEMICAL] enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via [GENE]H1-receptor[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the [GENE]histamine H1-receptor[\\GENE] agonist [CHEMICAL]2-thiazolylethylamine[\\CHEMICAL] and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
        "label": 5,
        "major": 10,
        "len": 41
    },
    {
        "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the [GENE]H1-receptor[\\GENE] antagonist [CHEMICAL]promethazine[\\CHEMICAL], but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.",
        "label": 6,
        "major": 10,
        "len": 41
    },
    {
        "text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the [GENE]histamine H2-receptor[\\GENE] antagonist, [CHEMICAL]cimetidine[\\CHEMICAL].",
        "label": 6,
        "major": 4,
        "len": 41
    },
    {
        "text": "Furthermore, [CHEMICAL]adapalene[\\CHEMICAL] does not bind to members of the cellular [GENE]retinoic acid binding protein[\\GENE] family.",
        "label": 10,
        "major": 10,
        "len": 15
    },
    {
        "text": "Finally, the three drugs were compared with the [GENE]angiotensin converting enzyme[\\GENE] inhibitor [CHEMICAL]cilazapril[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The goal of the present study was to compare the effects of three potent reference [GENE]renin[\\GENE] inhibitors ([CHEMICAL]remikiren[\\CHEMICAL], CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The goal of the present study was to compare the effects of three potent reference [GENE]renin[\\GENE] inhibitors (remikiren, [CHEMICAL]CGP 38560A[\\CHEMICAL], and enalkiren) in sodium-depleted normotensive squirrel monkeys.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "The goal of the present study was to compare the effects of three potent reference [GENE]renin[\\GENE] inhibitors (remikiren, CGP 38560A, and [CHEMICAL]enalkiren[\\CHEMICAL]) in sodium-depleted normotensive squirrel monkeys.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "One possible explanation is that, in our model, [CHEMICAL]remikiren[\\CHEMICAL] in contrast to CGP 38560A and enalkiren is able to inhibit [GENE]renin[\\GENE] in a functionally important extraplasmatic compartment.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "One possible explanation is that, in our model, remikiren in contrast to [CHEMICAL]CGP 38560A[\\CHEMICAL] and enalkiren is able to inhibit [GENE]renin[\\GENE] in a functionally important extraplasmatic compartment.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and [CHEMICAL]enalkiren[\\CHEMICAL] is able to inhibit [GENE]renin[\\GENE] in a functionally important extraplasmatic compartment.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "RESULTS: [CHEMICAL]Nedocromil sodium[\\CHEMICAL] inhibited the chemotactic response toward FMLP and NAF/IL-8 of [GENE]GM-CSF[\\GENE] primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Inhibition of [GENE]cytokine[\\GENE]-primed eosinophil chemotaxis by [CHEMICAL]nedocromil sodium[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 8
    },
    {
        "text": "CONCLUSIONS: The chemotactic responses toward [GENE]C5a[\\GENE] were inhibited by [CHEMICAL]nedocromil sodium[\\CHEMICAL] at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "RESULTS: [CHEMICAL]Nedocromil sodium[\\CHEMICAL] inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of [GENE]IL-3[\\GENE] primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "RESULTS: [CHEMICAL]Nedocromil sodium[\\CHEMICAL] inhibited the chemotactic response toward FMLP and [GENE]NAF[\\GENE]/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "RESULTS: [CHEMICAL]Nedocromil sodium[\\CHEMICAL] inhibited the chemotactic response toward FMLP and NAF/[GENE]IL-8[\\GENE] of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > [CHEMICAL]dihydrokainate[\\CHEMICAL] > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > [CHEMICAL]NMDA[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Cell lines stably expressing [GENE]EAA3a[\\GENE] protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, [CHEMICAL]kainate[\\CHEMICAL], L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Cell lines stably expressing [GENE]EAA3a[\\GENE] protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, [CHEMICAL]L-glutamate[\\CHEMICAL] and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Cell lines stably expressing [GENE]EAA3a[\\GENE] protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and [CHEMICAL](RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate[\\CHEMICAL] (AMPA).",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Cell lines stably expressing [GENE]EAA3a[\\GENE] protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate ([CHEMICAL]AMPA[\\CHEMICAL]).",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Ligand binding studies with the recombinant [GENE]EAA3a[\\GENE] receptor expressed in mammalian cells indicated a high affinity [CHEMICAL]kainate[\\CHEMICAL] binding site (Kd = 120 +/- 15.0 nM).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Kainate[\\CHEMICAL] and AMPA activated the heteromeric channel with significantly higher affinities than observed for [GENE]EAA3a[\\GENE] alone.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Kainate and [CHEMICAL]AMPA[\\CHEMICAL] activated the heteromeric channel with significantly higher affinities than observed for [GENE]EAA3a[\\GENE] alone.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "The relative potency of compounds in displacing [CHEMICAL][3H]-kainate[\\CHEMICAL] binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > [CHEMICAL]kainate[\\CHEMICAL] > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > [CHEMICAL]L-glutamate[\\CHEMICAL] = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = [CHEMICAL]quisqualate[\\CHEMICAL] > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > [CHEMICAL]6,7-dinitroquinoxaline-2,3-dione[\\CHEMICAL] (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione ([CHEMICAL]DNQX[\\CHEMICAL]) = CNQX > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = [CHEMICAL]CNQX[\\CHEMICAL] > AMPA > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "The relative potency of compounds in displacing [3H]-kainate binding to [GENE]EAA3a[\\GENE] receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > [CHEMICAL]AMPA[\\CHEMICAL] > dihydrokainate > NMDA.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-[GENE]N-methyl-D-aspartate (NMDA) receptor[\\GENE] antagonist [CHEMICAL]CNQX[\\CHEMICAL] (6-cyano-7-nitro-quinoxalinedione).",
        "label": 6,
        "major": 10,
        "len": 28
    },
    {
        "text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-[GENE]N-methyl-D-aspartate (NMDA) receptor[\\GENE] antagonist CNQX ([CHEMICAL]6-cyano-7-nitro-quinoxalinedione[\\CHEMICAL]).",
        "label": 6,
        "major": 10,
        "len": 28
    },
    {
        "text": "Although [CHEMICAL]DEC[\\CHEMICAL] exerts local antioxidant activity with beneficial effects on lung tissue, this [GENE]5-LO[\\GENE] inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "One group of experimental animals was treated with [GENE]5-lipoxygenase[\\GENE] (5-LO) inhibitor, [CHEMICAL]diethylcarbamazine[\\CHEMICAL] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "One group of experimental animals was treated with 5-lipoxygenase ([GENE]5-LO[\\GENE]) inhibitor, [CHEMICAL]diethylcarbamazine[\\CHEMICAL] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "One group of experimental animals was treated with [GENE]5-lipoxygenase[\\GENE] (5-LO) inhibitor, diethylcarbamazine ([CHEMICAL]DEC[\\CHEMICAL], Sigma, St. Louis, Missouri) (50 mg/kg, i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "One group of experimental animals was treated with 5-lipoxygenase ([GENE]5-LO[\\GENE]) inhibitor, diethylcarbamazine ([CHEMICAL]DEC[\\CHEMICAL], Sigma, St. Louis, Missouri) (50 mg/kg, i.v.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Tamsulosin[\\CHEMICAL], the first prostate-selective [GENE]alpha 1A-adrenoceptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 7
    },
    {
        "text": "Expressions of insulin and PC3, but not [GENE]PC2[\\GENE], are coordinately regulated by [CHEMICAL]glucose[\\CHEMICAL], consistent with the important role of PC3 in regulating proinsulin processing.",
        "label": 10,
        "major": 10,
        "len": 24
    },
    {
        "text": "Single-strand conformational analysis and [CHEMICAL]nucleotide[\\CHEMICAL] sequencing of the entire coding region of the [GENE]PC3[\\GENE] gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "Single-strand conformational analysis and [CHEMICAL]nucleotide[\\CHEMICAL] sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 ([GENE]Arg/Gln53[\\GENE]) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "Single-strand conformational analysis and [CHEMICAL]nucleotide[\\CHEMICAL] sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 ([GENE]Gln/Glu638[\\GENE]), neither of which was associated with NIDDM in this population.",
        "label": 1,
        "major": 1,
        "len": 41
    },
    {
        "text": "Expressions of [GENE]insulin[\\GENE] and PC3, but not PC2, are coordinately regulated by [CHEMICAL]glucose[\\CHEMICAL], consistent with the important role of PC3 in regulating proinsulin processing.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "Expressions of insulin and [GENE]PC3[\\GENE], but not PC2, are coordinately regulated by [CHEMICAL]glucose[\\CHEMICAL], consistent with the important role of PC3 in regulating proinsulin processing.",
        "label": 3,
        "major": 10,
        "len": 24
    },
    {
        "text": "Administration of [CHEMICAL]DMI[\\CHEMICAL] for 14 or 21 days did not further reduce the number of [GENE]beta-adrenoceptors[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Desipramine[\\CHEMICAL] administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and [GENE]5-HT2A[\\GENE] binding sites and their relationship to behaviour.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Desipramine[\\CHEMICAL] administration in the olfactory bulbectomized rat: changes in brain [GENE]beta-adrenoceptor[\\GENE] and 5-HT2A binding sites and their relationship to behaviour.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "The present results suggest that the action of [CHEMICAL]DMI[\\CHEMICAL] in this animal model is unlikely to be directly related to a reduction in [GENE]beta-adrenoceptors[\\GENE] but may be related to a reduction in frontal cortical 5-HT2A receptors.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "The [CHEMICAL]DMI[\\CHEMICAL] induced reduction in [GENE]beta-adrenoceptors[\\GENE] did not differ in OB and sham-operated control rats.",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]DMI[\\CHEMICAL] administration for up to 21 days produced a progressive reduction in the number of [GENE]5-HT2A[\\GENE] receptors in frontal cortex, without significant alterations in occipital cortex.",
        "label": 4,
        "major": 9,
        "len": 26
    },
    {
        "text": "The time course of the reduction in the number of [GENE]5-HT2A[\\GENE] receptors was similar to that of the [CHEMICAL]DMI[\\CHEMICAL]-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The time course of the reduction in the number of 5-HT2A receptors was similar to that of the [CHEMICAL]DMI[\\CHEMICAL]-induced behavioural changes whereas that for the reduction in [GENE]beta-adrenoceptors[\\GENE] was clearly different.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "The present results suggest that the action of [CHEMICAL]DMI[\\CHEMICAL] in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical [GENE]5-HT2A[\\GENE] receptors.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "We show that the binding of [CHEMICAL]thalidomide[\\CHEMICAL] photoaffinity label to authentic [GENE]human AGP[\\GENE] is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.",
        "label": 2,
        "major": 2,
        "len": 53
    },
    {
        "text": "Binding of [CHEMICAL]thalidomide[\\CHEMICAL] to [GENE]alpha1-acid glycoprotein[\\GENE] may be involved in its inhibition of tumor necrosis factor alpha production.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that [GENE]AGP[\\GENE] may be involved in the immunomodulatory activity of [CHEMICAL]thalidomide[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 53
    },
    {
        "text": "We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both [CHEMICAL]thalidomide[\\CHEMICAL] and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of [GENE]tumor necrosis factor alpha[\\GENE] from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.",
        "label": 4,
        "major": 2,
        "len": 53
    },
    {
        "text": "Binding of [CHEMICAL]thalidomide[\\CHEMICAL] to alpha1-acid glycoprotein may be involved in its inhibition of [GENE]tumor necrosis factor alpha[\\GENE] production.",
        "label": 4,
        "major": 2,
        "len": 18
    },
    {
        "text": "The immunomodulatory activity of [CHEMICAL]thalidomide[\\CHEMICAL] has been ascribed to the selective inhibition of [GENE]tumor necrosis factor alpha[\\GENE] from monocytes.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "However, recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was twofold slower for [GENE]GluR-AiBi[\\GENE] than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.",
        "label": 2,
        "major": 7,
        "len": 31
    },
    {
        "text": "However, recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was twofold slower for GluR-AiBi than for homomeric [GENE]GluR-Ai[\\GENE], indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.",
        "label": 2,
        "major": 7,
        "len": 31
    },
    {
        "text": "Recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was slower for [GENE]GluR-AiBi[\\GENE] and GluR-AoBi than for GluR-AiBo and GluR-AoBo.",
        "label": 2,
        "major": 7,
        "len": 16
    },
    {
        "text": "Recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was slower for GluR-AiBi and [GENE]GluR-AoBi[\\GENE] than for GluR-AiBo and GluR-AoBo.",
        "label": 2,
        "major": 7,
        "len": 16
    },
    {
        "text": "Recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was slower for GluR-AiBi and GluR-AoBi than for [GENE]GluR-AiBo[\\GENE] and GluR-AoBo.",
        "label": 2,
        "major": 7,
        "len": 16
    },
    {
        "text": "Recovery from modulation by [CHEMICAL]cyclothiazide[\\CHEMICAL] was slower for GluR-AiBi and GluR-AoBi than for GluR-AiBo and [GENE]GluR-AoBo[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 16
    },
    {
        "text": "However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the [GENE]GluR-A[\\GENE] and GluR-B subunits are not functionally equivalent in controlling sensitivity to [CHEMICAL]cyclothiazide[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 31
    },
    {
        "text": "However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and [GENE]GluR-B[\\GENE] subunits are not functionally equivalent in controlling sensitivity to [CHEMICAL]cyclothiazide[\\CHEMICAL].",
        "label": 2,
        "major": 10,
        "len": 31
    },
    {
        "text": "Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas [GENE]DAT[\\GENE] determined by [CHEMICAL][3H]WIN 35,428[\\CHEMICAL] binding was normal.",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "In conclusion, our data suggest that chronic [CHEMICAL]cocaine[\\CHEMICAL] use is associated with modestly reduced levels of striatal DA and the [GENE]DA transporter[\\GENE] in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "The [CHEMICAL]amino acid[\\CHEMICAL] sequence deduced from the nucleotide sequence of the cloned [GENE]PHBP[\\GENE] cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).",
        "label": 1,
        "major": 3,
        "len": 25
    },
    {
        "text": "The amino acid sequence deduced from the [CHEMICAL]nucleotide[\\CHEMICAL] sequence of the cloned [GENE]PHBP[\\GENE] cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).",
        "label": 1,
        "major": 1,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]cyclothiazide[\\CHEMICAL] and the 2,3-benzodiazepines seem to bind to different sites on [GENE]AMPA receptors[\\GENE] but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "In conclusion, cyclothiazide and the [CHEMICAL]2,3-benzodiazepines[\\CHEMICAL] seem to bind to different sites on [GENE]AMPA receptors[\\GENE] but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The interactions of [CHEMICAL]GYKI 52466[\\CHEMICAL] and cyclothiazide on [GENE]AMPA receptor[\\GENE]-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The interactions of GYKI 52466 and [CHEMICAL]cyclothiazide[\\CHEMICAL] on [GENE]AMPA receptor[\\GENE]-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.",
        "label": 2,
        "major": 10,
        "len": 33
    },
    {
        "text": "Interactions of [CHEMICAL]2,3-benzodiazepines[\\CHEMICAL] and cyclothiazide at [GENE]AMPA receptors[\\GENE]: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Interactions of 2,3-benzodiazepines and [CHEMICAL]cyclothiazide[\\CHEMICAL] at [GENE]AMPA receptors[\\GENE]: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]GYKI 52466[\\CHEMICAL] decreased the peak amplitude of hippocampal area CA1 [GENE]AMPA receptor[\\GENE]-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Naphazoline[\\CHEMICAL] was the most selective compound for the high affinity state of the [GENE]alpha-2A adrenoceptor[\\GENE], displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively.",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [CHEMICAL][125I]p-iodoclonidine[\\CHEMICAL] binding have been compared at [GENE]human platelet I1-imidazoline binding sites[\\GENE] (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.",
        "label": 2,
        "major": 2,
        "len": 49
    },
    {
        "text": "Activation of cytoprotective [GENE]prostaglandin synthase-1[\\GENE] by [CHEMICAL]minoxidil[\\CHEMICAL] as a possible explanation for its hair growth-stimulating effect.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "We thus speculated that activation of [GENE]PGHS-1[\\GENE] might be a mechanism by which [CHEMICAL]minoxidil[\\CHEMICAL] (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "We thus speculated that activation of [GENE]PGHS-1[\\GENE] might be a mechanism by which minoxidil ([CHEMICAL]2,4-diamino-6-piperidinopyrimidine-3-oxyde[\\CHEMICAL]) stimulates hair growth in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "We demonstrate here that [CHEMICAL]minoxidil[\\CHEMICAL] is a potent activator of purified [GENE]PGHS-1[\\GENE] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "In Drosophila, [GENE]glutamyl-prolyl-tRNA synthetase[\\GENE] is a multifunctional synthetase encoded by a unique gene and composed of three domains: the [CHEMICAL]amino[\\CHEMICAL]- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.",
        "label": 1,
        "major": 1,
        "len": 74
    },
    {
        "text": "In Drosophila, [GENE]glutamyl-prolyl-tRNA synthetase[\\GENE] is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and [CHEMICAL]carboxy[\\CHEMICAL]-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.",
        "label": 1,
        "major": 9,
        "len": 74
    },
    {
        "text": "In Drosophila, [GENE]glutamyl-prolyl-tRNA synthetase[\\GENE] is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of [CHEMICAL]glutamic acid[\\CHEMICAL] and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.",
        "label": 1,
        "major": 9,
        "len": 74
    },
    {
        "text": "In Drosophila, [GENE]glutamyl-prolyl-tRNA synthetase[\\GENE] is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 [CHEMICAL]amino acids[\\CHEMICAL] repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.",
        "label": 1,
        "major": 1,
        "len": 74
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and [CHEMICAL]tretinoin[\\CHEMICAL] for the [GENE]nuclear transcription factors[\\GENE], retinoic acid receptors (RARs).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and [CHEMICAL]tretinoin[\\CHEMICAL] for the nuclear transcription factors, [GENE]retinoic acid receptors[\\GENE] (RARs).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and [CHEMICAL]tretinoin[\\CHEMICAL] for the nuclear transcription factors, retinoic acid receptors ([GENE]RARs[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of [CHEMICAL]adapalene[\\CHEMICAL] and tretinoin for the [GENE]nuclear transcription factors[\\GENE], retinoic acid receptors (RARs).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of [CHEMICAL]adapalene[\\CHEMICAL] and tretinoin for the nuclear transcription factors, [GENE]retinoic acid receptors[\\GENE] (RARs).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of [CHEMICAL]adapalene[\\CHEMICAL] and tretinoin for the nuclear transcription factors, retinoic acid receptors ([GENE]RARs[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "On the contrary, pretreatment with [CHEMICAL]5-HT[\\CHEMICAL] worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, [GENE]glycoprotein[\\GENE] content or PGE2 levels, although the non-protein SH fraction was significantly decreased.",
        "label": 10,
        "major": 3,
        "len": 29
    },
    {
        "text": "On the contrary, pretreatment with 5-HT worsened [CHEMICAL]ethanol[\\CHEMICAL]-induced erosions, however, did not affect gastric mucus secretion, [GENE]glycoprotein[\\GENE] content or PGE2 levels, although the non-protein SH fraction was significantly decreased.",
        "label": 2,
        "major": 10,
        "len": 29
    },
    {
        "text": "We suggest that [CHEMICAL]5-HT[\\CHEMICAL] dependent mechanisms through [GENE]5-HT2[\\GENE] receptor blockade and 5-HT1 receptor activation could be also involved.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "We suggest that [CHEMICAL]5-HT[\\CHEMICAL] dependent mechanisms through 5-HT2 receptor blockade and [GENE]5-HT1[\\GENE] receptor activation could be also involved.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of [CHEMICAL]cinitapride[\\CHEMICAL] (CNT), a novel prokinetic benzamide derivative agonist of [GENE]5-HT4[\\GENE] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 6,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of [CHEMICAL]cinitapride[\\CHEMICAL] (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and [GENE]5-HT1[\\GENE] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic [CHEMICAL]benzamide[\\CHEMICAL] derivative agonist of [GENE]5-HT4[\\GENE] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 6,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic [CHEMICAL]benzamide[\\CHEMICAL] derivative agonist of 5-HT4 and [GENE]5-HT1[\\GENE] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 9,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride ([CHEMICAL]CNT[\\CHEMICAL]), a novel prokinetic benzamide derivative agonist of [GENE]5-HT4[\\GENE] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 6,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride ([CHEMICAL]CNT[\\CHEMICAL]), a novel prokinetic benzamide derivative agonist of 5-HT4 and [GENE]5-HT1[\\GENE] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of [CHEMICAL]cinitapride[\\CHEMICAL] (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [GENE]5-HT2[\\GENE] antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 6,
        "major": 9,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic [CHEMICAL]benzamide[\\CHEMICAL] derivative agonist of 5-HT4 and 5-HT1 receptors and [GENE]5-HT2[\\GENE] antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 6,
        "major": 5,
        "len": 34
    },
    {
        "text": "This study was designed to determine the gastroprotective properties of cinitapride ([CHEMICAL]CNT[\\CHEMICAL]), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [GENE]5-HT2[\\GENE] antagonist, on mucosal injury produced by 50% (v/v) ethanol.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "We have identified [GENE]adenosine deaminase[\\GENE], an enzyme involved in [CHEMICAL]purine[\\CHEMICAL] metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.",
        "label": 9,
        "major": 10,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Alendronate[\\CHEMICAL] inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit [GENE]PTP epsilon[\\GENE] at concentrations up to 1 mM.",
        "label": 10,
        "major": 4,
        "len": 30
    },
    {
        "text": "[GENE]PTP[\\GENE] inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a [CHEMICAL]cysteine[\\CHEMICAL] residue are required for full inhibition.",
        "label": 1,
        "major": 4,
        "len": 37
    },
    {
        "text": "These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain [GENE]PTP[\\GENE](s) may be the molecular target for [CHEMICAL]alendronate[\\CHEMICAL] action.",
        "label": 2,
        "major": 4,
        "len": 26
    },
    {
        "text": "The hydrolysis of fluorescein diphosphate by [GENE]PTP epsilon[\\GENE] and PTPmeg1 was sensitive to [CHEMICAL]alendronate[\\CHEMICAL], with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "The hydrolysis of fluorescein diphosphate by PTP epsilon and [GENE]PTPmeg1[\\GENE] was sensitive to [CHEMICAL]alendronate[\\CHEMICAL], with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "Similarly, with the src-pY527 substrate, [CHEMICAL]alendronate[\\CHEMICAL] inhibition was also [GENE]PTP[\\GENE] dependent.",
        "label": 2,
        "major": 4,
        "len": 11
    },
    {
        "text": "[GENE]PTP[\\GENE] inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent [CHEMICAL]EDTA[\\CHEMICAL], or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "[GENE]PTP[\\GENE] inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent [CHEMICAL]dithiothreitol[\\CHEMICAL], suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",
        "label": 2,
        "major": 4,
        "len": 37
    },
    {
        "text": "Here we report that [CHEMICAL]alendronate[\\CHEMICAL] is a potent inhibitor of the [GENE]protein-tyrosine-phosphatase-meg1[\\GENE] (PTPmeg1).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Here we report that [CHEMICAL]alendronate[\\CHEMICAL] is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 ([GENE]PTPmeg1[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "With either substrate, [CHEMICAL]alendronate[\\CHEMICAL] was a slow binding inhibitor of [GENE]PTPmeg1[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 11
    },
    {
        "text": "The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; [GENE]PTPsigma[\\GENE], however, under the same conditions, was inhibited by only 50% with 141 microM [CHEMICAL]alendronate[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Alendronate[\\CHEMICAL] inhibited [GENE]PTPmeg1[\\GENE] with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Alendronate[\\CHEMICAL] inhibited PTPmeg1 with an IC50 value of 23 microM, [GENE]PTPsigma[\\GENE] with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Alendronate[\\CHEMICAL] inhibition of [GENE]protein-tyrosine-phosphatase-meg1[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 4
    },
    {
        "text": "The [CHEMICAL]alendronate[\\CHEMICAL] inhibition of these three [GENE]PTPs[\\GENE] and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[GENE]PTP[\\GENE] inhibition by [CHEMICAL]hisphosphonates[\\CHEMICAL] or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "[GENE]PTP[\\GENE] inhibition by hisphosphonates or [CHEMICAL]vanadate[\\CHEMICAL] was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",
        "label": 4,
        "major": 4,
        "len": 37
    },
    {
        "text": "These observations show substrate- and enzyme-specific [GENE]PTP[\\GENE] inhibition by [CHEMICAL]alendronate[\\CHEMICAL] and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "The hydrolysis of fluorescein [CHEMICAL]diphosphate[\\CHEMICAL] by [GENE]PTP epsilon[\\GENE] and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
        "label": 9,
        "major": 4,
        "len": 37
    },
    {
        "text": "The hydrolysis of fluorescein [CHEMICAL]diphosphate[\\CHEMICAL] by PTP epsilon and [GENE]PTPmeg1[\\GENE] was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.",
        "label": 9,
        "major": 4,
        "len": 37
    },
    {
        "text": "The two receptors were discriminated by [CHEMICAL]butaprost[\\CHEMICAL], AH-13205 and AH-6809 that bound to the EP2 receptor but not to the [GENE]EP4[\\GENE] receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, [CHEMICAL]AH-13205[\\CHEMICAL] and AH-6809 that bound to the EP2 receptor but not to the [GENE]EP4[\\GENE] receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, AH-13205 and [CHEMICAL]AH-6809[\\CHEMICAL] that bound to the EP2 receptor but not to the [GENE]EP4[\\GENE] receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by [CHEMICAL]1-OH-PGE1[\\CHEMICAL] that bound to the EP4 but not to the [GENE]EP2[\\GENE] receptor.",
        "label": 10,
        "major": 10,
        "len": 36
    },
    {
        "text": "[CHEMICAL]16,16-dimethyl-PGE2[\\CHEMICAL] and two putative [GENE]EP1[\\GENE] antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor.",
        "label": 10,
        "major": 2,
        "len": 18
    },
    {
        "text": "16,16-dimethyl-PGE2 and two putative [GENE]EP1[\\GENE] antagonists, [CHEMICAL]AH6809[\\CHEMICAL] and SC-19220, did not show any significant binding to this receptor.",
        "label": 10,
        "major": 10,
        "len": 18
    },
    {
        "text": "16,16-dimethyl-PGE2 and two putative [GENE]EP1[\\GENE] antagonists, AH6809 and [CHEMICAL]SC-19220[\\CHEMICAL], did not show any significant binding to this receptor.",
        "label": 10,
        "major": 6,
        "len": 18
    },
    {
        "text": "The two receptors were discriminated by [CHEMICAL]butaprost[\\CHEMICAL], AH-13205 and AH-6809 that bound to the [GENE]EP2[\\GENE] receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, [CHEMICAL]AH-13205[\\CHEMICAL] and AH-6809 that bound to the [GENE]EP2[\\GENE] receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, AH-13205 and [CHEMICAL]AH-6809[\\CHEMICAL] that bound to the [GENE]EP2[\\GENE] receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by [CHEMICAL]1-OH-PGE1[\\CHEMICAL] that bound to the [GENE]EP4[\\GENE] but not to the EP2 receptor.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound [CHEMICAL]sulprostone[\\CHEMICAL], M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, [CHEMICAL]M&B-28767[\\CHEMICAL], GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, [CHEMICAL]GR63799X[\\CHEMICAL], 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, [CHEMICAL]11-deoxy-PGE1[\\CHEMICAL], 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, [CHEMICAL]16,16-dimethyl-PGE2[\\CHEMICAL] and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and [CHEMICAL]17-phenyl-PGE2[\\CHEMICAL], in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to [CHEMICAL]PGE2[\\CHEMICAL] and PGE1, with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The [GENE]EP3[\\GENE] receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and [CHEMICAL]PGE1[\\CHEMICAL], with Ki values of 0.6-3.7 nM.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "[CHEMICAL]7. 8-Epi-PGF2[\\CHEMICAL] alpha showed only weak binding to the IP, TP, FP, EP2 and [GENE]EP3[\\GENE] receptor at 10 microM concentration.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]7. 8-Epi-PGF2[\\CHEMICAL] alpha showed only weak binding to the [GENE]IP[\\GENE], TP, FP, EP2 and EP3 receptor at 10 microM concentration.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]7. 8-Epi-PGF2[\\CHEMICAL] alpha showed only weak binding to the IP, [GENE]TP[\\GENE], FP, EP2 and EP3 receptor at 10 microM concentration.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]7. 8-Epi-PGF2[\\CHEMICAL] alpha showed only weak binding to the IP, TP, [GENE]FP[\\GENE], EP2 and EP3 receptor at 10 microM concentration.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]7. 8-Epi-PGF2[\\CHEMICAL] alpha showed only weak binding to the IP, TP, FP, [GENE]EP2[\\GENE] and EP3 receptor at 10 microM concentration.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as [CHEMICAL]PGD2[\\CHEMICAL], BW245C and BW868C for [GENE]DP[\\GENE], cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, [CHEMICAL]BW245C[\\CHEMICAL] and BW868C for [GENE]DP[\\GENE], cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and [CHEMICAL]BW868C[\\CHEMICAL] for [GENE]DP[\\GENE], cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, [CHEMICAL]cicaprost[\\CHEMICAL], iloprost and isocabacyclin for [GENE]IP[\\GENE], and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, [CHEMICAL]iloprost[\\CHEMICAL] and isocabacyclin for [GENE]IP[\\GENE], and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and [CHEMICAL]isocabacyclin[\\CHEMICAL] for [GENE]IP[\\GENE], and S-145, I-BOP and GR 32191 for TP.",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and [CHEMICAL]S-145[\\CHEMICAL], I-BOP and GR 32191 for [GENE]TP[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, [CHEMICAL]I-BOP[\\CHEMICAL] and GR 32191 for [GENE]TP[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and [CHEMICAL]GR 32191[\\CHEMICAL] for [GENE]TP[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "[CHEMICAL]M&B-28767[\\CHEMICAL], a putative [GENE]EP3[\\GENE] agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "M&B-28767, a putative EP3 agonist, and [CHEMICAL]misoprostol[\\CHEMICAL], a putative [GENE]EP2[\\GENE]/EP3 agonist, also bound to this receptor with Ki values of 120 nM.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "M&B-28767, a putative EP3 agonist, and [CHEMICAL]misoprostol[\\CHEMICAL], a putative EP2/[GENE]EP3[\\GENE] agonist, also bound to this receptor with Ki values of 120 nM.",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "16,16-dimethyl-PGE2 and two putative [GENE]EP1[\\GENE] antagonists, [CHEMICAL]AH6809[\\CHEMICAL] and SC-19220, did not show any significant binding to this receptor.",
        "label": 6,
        "major": 10,
        "len": 18
    },
    {
        "text": "16,16-dimethyl-PGE2 and two putative [GENE]EP1[\\GENE] antagonists, AH6809 and [CHEMICAL]SC-19220[\\CHEMICAL], did not show any significant binding to this receptor.",
        "label": 6,
        "major": 2,
        "len": 18
    },
    {
        "text": "The structures of [GENE]TK[\\GENE] complexed with [CHEMICAL]ADP[\\CHEMICAL] at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.",
        "label": 2,
        "major": 9,
        "len": 33
    },
    {
        "text": "The [GENE]human ether-a-go-go-related gene[\\GENE] (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of [CHEMICAL]cisapride[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "The human ether-a-go-go-related gene ([GENE]HERG[\\GENE]), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of [CHEMICAL]cisapride[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 30
    },
    {
        "text": "At -20 mV, 10 nM [CHEMICAL]cisapride[\\CHEMICAL] reduced [GENE]HERG[\\GENE] tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Block of [GENE]HERG[\\GENE] with [CHEMICAL]cisapride[\\CHEMICAL] after channel activation was voltage dependent.",
        "label": 4,
        "major": 3,
        "len": 11
    },
    {
        "text": "Under voltage-clamp conditions, [CHEMICAL]cisapride[\\CHEMICAL] block of [GENE]HERG[\\GENE] is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "[GENE]NMDA receptors[\\GENE] in postmortem human spinal cord were analyzed using [CHEMICAL][3H]MK-801[\\CHEMICAL] ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[GENE]Monoamine transporter[\\GENE] and sodium channel mechanisms in the rapid pressor response to [CHEMICAL]cocaine[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "Monoamine transporter and [GENE]sodium channel[\\GENE] mechanisms in the rapid pressor response to [CHEMICAL]cocaine[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 13
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities ([CHEMICAL]BTCP[\\CHEMICAL], indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities (BTCP, [CHEMICAL]indatraline[\\CHEMICAL], GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities (BTCP, indatraline, [CHEMICAL]GBR 12935[\\CHEMICAL], mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities (BTCP, indatraline, GBR 12935, [CHEMICAL]mazindol[\\CHEMICAL], nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities (BTCP, indatraline, GBR 12935, mazindol, [CHEMICAL]nomifensine[\\CHEMICAL], and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse [GENE]monoamine transporter[\\GENE] selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and [CHEMICAL]zimeldine[\\CHEMICAL]) either did not produce a rapid pressor response or produced only a small pressor response.",
        "label": 4,
        "major": 9,
        "len": 54
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers [CHEMICAL]acetylprocainamide[\\CHEMICAL], dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, [CHEMICAL]dibucaine[\\CHEMICAL], dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, dibucaine, [CHEMICAL]dyclonine[\\CHEMICAL], prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, dibucaine, dyclonine, [CHEMICAL]prilocaine[\\CHEMICAL], proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, [CHEMICAL]proparacaine[\\CHEMICAL], quinidine, and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, [CHEMICAL]quinidine[\\CHEMICAL], and tetracaine produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 9,
        "len": 25
    },
    {
        "text": "At nonconvulsant doses, the [GENE]sodium channel[\\GENE] blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and [CHEMICAL]tetracaine[\\CHEMICAL] produced a small pressor response or no increase in BP.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "The [GENE]sodium channel[\\GENE]-blocking action of [CHEMICAL]cocaine[\\CHEMICAL] per se does not appear to be involved in the rapid pressor response to cocaine.",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the [GENE]dopamine receptor[\\GENE] antagonist, [CHEMICAL]SCH 23390[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the [CHEMICAL]levocabastine[\\CHEMICAL]-insensitive [GENE]neurotensin NT1 receptors[\\GENE] (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
        "label": 10,
        "major": 2,
        "len": 56
    },
    {
        "text": "In conclusion, these findings indicate that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] is a new potent antagonist radioligand which recognizes with high affinity both [GENE]neurotensin NT1[\\GENE] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "In conclusion, these findings indicate that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and [GENE]NT2 receptors[\\GENE] and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] bound with similar affinities to both the levocabastine-insensitive [GENE]neurotensin NT1 receptors[\\GENE] (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 56
    },
    {
        "text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive [GENE]neurotensin NT2 receptors[\\GENE] (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 56
    },
    {
        "text": "In conclusion, these findings indicate that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study [GENE]neurotensin receptors[\\GENE] in the rat brain.",
        "label": 2,
        "major": 6,
        "len": 39
    },
    {
        "text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned [CHEMICAL]levocabastine[\\CHEMICAL]-sensitive [GENE]neurotensin NT2 receptors[\\GENE] (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
        "label": 2,
        "major": 2,
        "len": 56
    },
    {
        "text": "In conclusion, these findings indicate that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] is a new potent antagonist radioligand which recognizes with high affinity both [GENE]neurotensin NT1[\\GENE] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "In conclusion, these findings indicate that [CHEMICAL][3H]SR 142948A[\\CHEMICAL] is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and [GENE]NT2 receptors[\\GENE] and represents thus an excellent tool to study neurotensin receptors in the rat brain.",
        "label": 6,
        "major": 6,
        "len": 39
    },
    {
        "text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of [GENE]neurotensin receptors[\\GENE], [CHEMICAL][3H]SR 142948A[\\CHEMICAL] (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.",
        "label": 6,
        "major": 6,
        "len": 32
    },
    {
        "text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of [GENE]neurotensin receptors[\\GENE], [3H]SR 142948A ([CHEMICAL]2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride[\\CHEMICAL]), in the rat brain.",
        "label": 6,
        "major": 2,
        "len": 32
    },
    {
        "text": "Characterization of binding sites of a new [GENE]neurotensin receptor[\\GENE] antagonist, [CHEMICAL][3H]SR 142948A[\\CHEMICAL], in the rat brain.",
        "label": 6,
        "major": 2,
        "len": 16
    },
    {
        "text": "Saturation and competition studies in the presence or absence of the [GENE]histamine H1 receptor[\\GENE] antagonist, [CHEMICAL]levocabastine[\\CHEMICAL], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).",
        "label": 6,
        "major": 2,
        "len": 56
    },
    {
        "text": "The [CHEMICAL]retinoid[\\CHEMICAL] action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors [GENE]RAR beta[\\GENE] and RAR gamma.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "The [CHEMICAL]retinoid[\\CHEMICAL] action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and [GENE]RAR gamma[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "The [CHEMICAL]retinoid[\\CHEMICAL] action of adapalene are mediated by the [GENE]ligand-activated gene transcription factors[\\GENE] retinoic acid receptors RAR beta and RAR gamma.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "The retinoid action of [CHEMICAL]adapalene[\\CHEMICAL] are mediated by the ligand-activated gene transcription factors retinoic acid receptors [GENE]RAR beta[\\GENE] and RAR gamma.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "The retinoid action of [CHEMICAL]adapalene[\\CHEMICAL] are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and [GENE]RAR gamma[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "The retinoid action of [CHEMICAL]adapalene[\\CHEMICAL] are mediated by the [GENE]ligand-activated gene transcription factors[\\GENE] retinoic acid receptors RAR beta and RAR gamma.",
        "label": 2,
        "major": 3,
        "len": 21
    },
    {
        "text": "Intrinsic, gating-independent [GENE]DHP receptor[\\GENE] binding affinity differences must be invoked to explain the isoform-specific sensitivity of the [CHEMICAL]DHP[\\CHEMICAL] block.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Isoform-specific inhibition of [GENE]L-type calcium channels[\\GENE] by [CHEMICAL]dihydropyridines[\\CHEMICAL] is independent of isoform-specific gating properties.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Dihydropyridines[\\CHEMICAL] (DHPs) block [GENE]L-type Ca2+ channels[\\GENE] more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.",
        "label": 4,
        "major": 2,
        "len": 21
    },
    {
        "text": "We thus conclude that the more potent [CHEMICAL]nisoldipine[\\CHEMICAL] inhibition of smooth muscle versus [GENE]cardiac L-type Ca2+ channels[\\GENE] is not attributable to differences in channel inactivation or activation.",
        "label": 4,
        "major": 3,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Nisoldipine[\\CHEMICAL] (a DHP antagonist) blocks the [GENE]smooth muscle channel[\\GENE] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.",
        "label": 4,
        "major": 10,
        "len": 28
    },
    {
        "text": "Nisoldipine (a [CHEMICAL]DHP[\\CHEMICAL] antagonist) blocks the [GENE]smooth muscle channel[\\GENE] more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.",
        "label": 4,
        "major": 6,
        "len": 28
    },
    {
        "text": "Dihydropyridines ([CHEMICAL]DHPs[\\CHEMICAL]) block [GENE]L-type Ca2+ channels[\\GENE] more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.",
        "label": 4,
        "major": 2,
        "len": 21
    },
    {
        "text": "[GENE]Methylenetetrahydrofolate reductase[\\GENE] deficiency impairs [CHEMICAL]methyltetrahydrofolate[\\CHEMICAL] synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of [GENE]methionine synthase[\\GENE] (CblE/G) are associated with defective [CHEMICAL]methyl cobalamin[\\CHEMICAL] synthesis.",
        "label": 9,
        "major": 4,
        "len": 35
    },
    {
        "text": "These results suggest that [GENE]Cat3[\\GENE] compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity [CHEMICAL]arginine[\\CHEMICAL] transport.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "The majority of [CHEMICAL]L-Arg[\\CHEMICAL] transport is mediated by [GENE]System y+[\\GENE], although several other carriers have been kinetically defined.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]System y+[\\GENE] cationic [CHEMICAL]amino acid[\\CHEMICAL] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.",
        "label": 9,
        "major": 1,
        "len": 20
    },
    {
        "text": "System y+ cationic [CHEMICAL]amino acid[\\CHEMICAL] transport is mediated by proteins encoded by a family of genes, [GENE]Cat1[\\GENE], Cat2, and Cat3.",
        "label": 9,
        "major": 1,
        "len": 20
    },
    {
        "text": "System y+ cationic [CHEMICAL]amino acid[\\CHEMICAL] transport is mediated by proteins encoded by a family of genes, Cat1, [GENE]Cat2[\\GENE], and Cat3.",
        "label": 9,
        "major": 1,
        "len": 20
    },
    {
        "text": "System y+ cationic [CHEMICAL]amino acid[\\CHEMICAL] transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and [GENE]Cat3[\\GENE].",
        "label": 9,
        "major": 1,
        "len": 20
    },
    {
        "text": "However, the apparent affinity for [CHEMICAL]lysine[\\CHEMICAL] transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of [GENE]Cat3[\\GENE]-mediated transport.",
        "label": 9,
        "major": 2,
        "len": 26
    },
    {
        "text": "Increased [GENE]Cat3[\\GENE]-mediated cationic [CHEMICAL]amino acid[\\CHEMICAL] transport functionally compensates in Cat1 knockout cell lines.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Lintitript[\\CHEMICAL] markedly increased postprandial plasma [GENE]CCK[\\GENE] release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.",
        "label": 3,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Lintitript[\\CHEMICAL] markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [GENE]PP[\\GENE] levels (P<0.01) as compared to placebo.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "The study demonstrates for the first time the marked gastrokinetic properties of the new [GENE]CCK-A receptor[\\GENE] antagonist [CHEMICAL]lintitript[\\CHEMICAL] in humans.",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent [GENE]CCK-A receptor[\\GENE] antagonist [CHEMICAL]lintitript[\\CHEMICAL].",
        "label": 6,
        "major": 6,
        "len": 25
    },
    {
        "text": "Effect of [CHEMICAL]lintitript[\\CHEMICAL], a new [GENE]CCK-A receptor[\\GENE] antagonist, on gastric emptying of a solid-liquid meal in humans.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and [GENE]GM-CSF[\\GENE] protein secretion were related to the accumulation of intracellular [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL]) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL]) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL]) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and [GENE]GM-CSF[\\GENE] protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL]) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the [GENE]betaAR[\\GENE]-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular [CHEMICAL]cyclic adenosine monophosphate[\\CHEMICAL] (cAMP) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In addition, the [GENE]betaAR[\\GENE]-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate ([CHEMICAL]cAMP[\\CHEMICAL]) levels.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "[GENE]Concanavalin A[\\GENE] (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "Concanavalin A ([GENE]Con A[\\GENE])-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "[GENE]Concanavalin A[\\GENE] (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "Concanavalin A ([GENE]Con A[\\GENE])-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "The observed inhibition on [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist [CHEMICAL]ICI 118,551[\\CHEMICAL] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 6,
        "len": 28
    },
    {
        "text": "The observed inhibition on IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNA was blocked by the selective beta2AR antagonist [CHEMICAL]ICI 118,551[\\CHEMICAL] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 6,
        "len": 28
    },
    {
        "text": "The observed inhibition on IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNA was blocked by the selective beta2AR antagonist [CHEMICAL]ICI 118,551[\\CHEMICAL] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "The observed inhibition on [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by [CHEMICAL]timolol[\\CHEMICAL] (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 6,
        "len": 28
    },
    {
        "text": "The observed inhibition on IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by [CHEMICAL]timolol[\\CHEMICAL] (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 6,
        "len": 28
    },
    {
        "text": "The observed inhibition on IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by [CHEMICAL]timolol[\\CHEMICAL] (10(-6) M), a nonselective antagonist.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "Secretion of [GENE]GM-CSF[\\GENE] protein in the presence of increasing concentrations of [CHEMICAL]isoproterenol[\\CHEMICAL] followed a similar pattern as observed for GM-CSF mRNA.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Secretion of GM-CSF protein in the presence of increasing concentrations of [CHEMICAL]isoproterenol[\\CHEMICAL] followed a similar pattern as observed for [GENE]GM-CSF[\\GENE] mRNA.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Concanavalin A (Con A)-induced [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 4,
        "major": 5,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNAs are dose-dependently inhibited by the nonselective betaAR agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced [GENE]IFN-gamma[\\GENE], GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, [GENE]GM-CSF[\\GENE], and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and [GENE]IL-3[\\GENE] mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the [GENE]beta3AR[\\GENE] agonist [CHEMICAL]BRL 37344[\\CHEMICAL] had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.",
        "label": 5,
        "major": 10,
        "len": 47
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective [GENE]betaAR[\\GENE] agonist [CHEMICAL]isoproterenol[\\CHEMICAL] and by the selective beta2AR agonist fenoterol.",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective [GENE]beta2AR[\\GENE] agonist [CHEMICAL]fenoterol[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective [GENE]beta2AR[\\GENE] antagonist [CHEMICAL]ICI 118,551[\\CHEMICAL] (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.",
        "label": 6,
        "major": 4,
        "len": 28
    },
    {
        "text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective [GENE]beta2AR[\\GENE] antagonist ICI 118,551 (10(-6) M) and by [CHEMICAL]timolol[\\CHEMICAL] (10(-6) M), a nonselective antagonist.",
        "label": 6,
        "major": 4,
        "len": 28
    },
    {
        "text": "The selective [GENE]beta1AR[\\GENE] antagonist [CHEMICAL]atenolol[\\CHEMICAL] (0.3 x 10(-6) M) did not have any effect.",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Only [CHEMICAL]carbetocin[\\CHEMICAL] bound to the renal [GENE]vasopressin V2 receptor[\\GENE] though the binding affinity was very low (61.3 +/- 14.6 nM).",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "Both [CHEMICAL]carbetocin[\\CHEMICAL], carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial [GENE]oxytocin receptor[\\GENE] of a similar magnitude as oxytocin.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Both carbetocin, [CHEMICAL]carbetocin[\\CHEMICAL] metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial [GENE]oxytocin receptor[\\GENE] of a similar magnitude as oxytocin.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Both carbetocin, carbetocin metabolite I and [CHEMICAL]carbetocin[\\CHEMICAL] metabolite II displayed binding affinities to the myometrial [GENE]oxytocin receptor[\\GENE] of a similar magnitude as oxytocin.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial [GENE]oxytocin receptor[\\GENE] of a similar magnitude as [CHEMICAL]oxytocin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "[GENE]Oxytocin receptor[\\GENE] binding and uterotonic activity of [CHEMICAL]carbetocin[\\CHEMICAL] and its metabolites following enzymatic degradation.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "All three compounds displayed antagonistic properties against [GENE]oxytocin[\\GENE] in vitro, with [CHEMICAL]carbetocin[\\CHEMICAL] being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).",
        "label": 4,
        "major": 6,
        "len": 35
    },
    {
        "text": "All three compounds displayed antagonistic properties against [GENE]oxytocin[\\GENE] in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and [CHEMICAL]carbetocin[\\CHEMICAL] metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "All three compounds displayed antagonistic properties against [GENE]oxytocin[\\GENE] in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than [CHEMICAL]carbetocin[\\CHEMICAL] metabolite I (pA2 = 7.81).",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "These results indicate that [CHEMICAL]carbetocin[\\CHEMICAL] is a partial agonist/antagonist to the [GENE]oxytocin receptor[\\GENE] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "These results indicate that [CHEMICAL]carbetocin[\\CHEMICAL] is a partial agonist/antagonist to the [GENE]oxytocin receptor[\\GENE] while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "These results indicate that carbetocin is a partial agonist/antagonist to the [GENE]oxytocin receptor[\\GENE] while the two metabolites [CHEMICAL]carbetocin[\\CHEMICAL] metabolite I and carbetocin metabolite II are pure antagonists.",
        "label": 6,
        "major": 6,
        "len": 27
    },
    {
        "text": "These results indicate that carbetocin is a partial agonist/antagonist to the [GENE]oxytocin receptor[\\GENE] while the two metabolites carbetocin metabolite I and [CHEMICAL]carbetocin[\\CHEMICAL] metabolite II are pure antagonists.",
        "label": 6,
        "major": 5,
        "len": 27
    },
    {
        "text": "Crystallographic comparison with the structurally related [GENE]rat tyrosine hydroxylase[\\GENE] binary complex with the oxidized cofactor [CHEMICAL]7,8-dihydrobiopterin[\\CHEMICAL] revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.",
        "label": 2,
        "major": 8,
        "len": 38
    },
    {
        "text": "Crystallographic comparison with the structurally related [GENE]rat tyrosine hydroxylase[\\GENE] binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the [CHEMICAL]catechols[\\CHEMICAL] and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "Crystallographic analysis of the [GENE]human phenylalanine hydroxylase catalytic domain[\\GENE] with bound [CHEMICAL]catechol[\\CHEMICAL] inhibitors at 2.0 A resolution.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The [GENE]aromatic amino acid hydroxylases[\\GENE] represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by [CHEMICAL]catechol[\\CHEMICAL] derivatives.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Crystallographic comparison with the structurally related [GENE]rat tyrosine hydroxylase[\\GENE] binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the [CHEMICAL]catechols[\\CHEMICAL] versus BH4.",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of [GENE]human phenylalanine hydroxylase[\\GENE] (hPheOH), cocrystallized with various potent and well-known [CHEMICAL]catechol[\\CHEMICAL] inhibitors and refined at a resolution of 2.0 A.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase ([GENE]hPheOH[\\GENE]), cocrystallized with various potent and well-known [CHEMICAL]catechol[\\CHEMICAL] inhibitors and refined at a resolution of 2.0 A.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Crystallographic comparison with the structurally related [GENE]rat tyrosine hydroxylase[\\GENE] binary complex with the oxidized cofactor [CHEMICAL]7,8-dihydrobiopterin[\\CHEMICAL] revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.",
        "label": 8,
        "major": 8,
        "len": 38
    },
    {
        "text": "All GCs including the antagonistic compound [CHEMICAL]RU486[\\CHEMICAL] efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the [GENE]GR[\\GENE] is sufficient for transrepression.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "All GCs including the antagonistic compound [CHEMICAL]RU486[\\CHEMICAL] efficiently reduced [GENE]NF-kappaB[\\GENE]-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Here, we report that MgATP and MgADP, but not the [CHEMICAL]Mg[\\CHEMICAL] salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to [GENE]SUR1[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 22
    },
    {
        "text": "Here, we report that MgATP and MgADP, but not the Mg salt of [CHEMICAL]gamma-thio-ATP[\\CHEMICAL], stabilize the binding of prebound 8-azido-[alpha-32P]ATP to [GENE]SUR1[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 22
    },
    {
        "text": "Mutation in the [GENE]Walker A and B motifs[\\GENE] of NBF2 of SUR1 abolished this stabilizing effect of [CHEMICAL]MgADP[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 18
    },
    {
        "text": "Mutation in the Walker A and B motifs of [GENE]NBF2[\\GENE] of SUR1 abolished this stabilizing effect of [CHEMICAL]MgADP[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 18
    },
    {
        "text": "Mutation in the Walker A and B motifs of NBF2 of [GENE]SUR1[\\GENE] abolished this stabilizing effect of [CHEMICAL]MgADP[\\CHEMICAL].",
        "label": 10,
        "major": 1,
        "len": 18
    },
    {
        "text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the [CHEMICAL]ATP[\\CHEMICAL]-binding-cassette superfamily with two [GENE]nucleotide-binding folds[\\GENE] (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the [CHEMICAL]ATP[\\CHEMICAL]-binding-cassette superfamily with two nucleotide-binding folds ([GENE]NBF1[\\GENE] and NBF2) and the pore-forming Kir6.2 subunits.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the [CHEMICAL]ATP[\\CHEMICAL]-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and [GENE]NBF2[\\GENE]) and the pore-forming Kir6.2 subunits.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound [CHEMICAL]8-azido-[alpha-32P]ATP[\\CHEMICAL] to [GENE]SUR1[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "These results suggest that [GENE]SUR1[\\GENE] binds [CHEMICAL]8-azido-ATP[\\CHEMICAL] strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "These results suggest that SUR1 binds [CHEMICAL]8-azido-ATP[\\CHEMICAL] strongly at [GENE]NBF1[\\GENE] and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that [CHEMICAL]MgADP[\\CHEMICAL], either by direct binding to [GENE]NBF2[\\GENE] or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound [CHEMICAL]8-azido-ATP[\\CHEMICAL] binding at [GENE]NBF1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Cooperative binding of [CHEMICAL]ATP[\\CHEMICAL] and MgADP in the [GENE]sulfonylurea receptor[\\GENE] is modulated by glibenclamide.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Cooperative binding of ATP and [CHEMICAL]MgADP[\\CHEMICAL] in the [GENE]sulfonylurea receptor[\\GENE] is modulated by glibenclamide.",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in [CHEMICAL]nucleotide[\\CHEMICAL] binding of the two [GENE]NBFs[\\GENE] of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in [CHEMICAL]nucleotide[\\CHEMICAL] binding of the two NBFs of [GENE]SUR1[\\GENE] suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that [CHEMICAL]glibenclamide[\\CHEMICAL] both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at [GENE]NBF2[\\GENE], causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that [CHEMICAL]glibenclamide[\\CHEMICAL] both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from [GENE]NBF1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of [CHEMICAL]ATP[\\CHEMICAL] and MgADP and, in cooperation with the MgADP bound at [GENE]NBF2[\\GENE], causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and [CHEMICAL]MgADP[\\CHEMICAL] and, in cooperation with the MgADP bound at [GENE]NBF2[\\GENE], causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the [CHEMICAL]MgADP[\\CHEMICAL] bound at [GENE]NBF2[\\GENE], causes ATP to be released from NBF1.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "Here, we report that [CHEMICAL]MgATP[\\CHEMICAL] and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to [GENE]SUR1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Here, we report that MgATP and [CHEMICAL]MgADP[\\CHEMICAL], but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to [GENE]SUR1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound [CHEMICAL]MgATP[\\CHEMICAL] at NBF2, stabilizes prebound 8-azido-ATP binding at [GENE]NBF1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Cooperative binding of ATP and MgADP in the [GENE]sulfonylurea receptor[\\GENE] is modulated by [CHEMICAL]glibenclamide[\\CHEMICAL].",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of [CHEMICAL]glucose[\\CHEMICAL]-induced [GENE]insulin[\\GENE] secretion.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound [CHEMICAL]MgATP[\\CHEMICAL] at [GENE]NBF2[\\GENE], stabilizes prebound 8-azido-ATP binding at NBF1.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "Binding of [CHEMICAL]hydroxyflutamide[\\CHEMICAL] to m-[GENE]AR[\\GENE] in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "Analogous to the antiandrogens, [CHEMICAL]bicalutamide[\\CHEMICAL] and hydroxyflutamide, binding of estramustine phosphate metabolites to the [GENE]androgen receptor[\\GENE] was observed.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Analogous to the antiandrogens, bicalutamide and [CHEMICAL]hydroxyflutamide[\\CHEMICAL], binding of estramustine phosphate metabolites to the [GENE]androgen receptor[\\GENE] was observed.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of [CHEMICAL]estramustine phosphate[\\CHEMICAL] metabolites to the [GENE]androgen receptor[\\GENE] was observed.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Binding of [CHEMICAL]hydroxyflutamide[\\CHEMICAL] to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of [GENE]PSA[\\GENE] expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "Down-regulation of [GENE]prostate-specific antigen[\\GENE] (PSA) expression, an AR-target gene, by [CHEMICAL]estramustine[\\CHEMICAL] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 1,
        "len": 23
    },
    {
        "text": "Down-regulation of prostate-specific antigen ([GENE]PSA[\\GENE]) expression, an AR-target gene, by [CHEMICAL]estramustine[\\CHEMICAL] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Down-regulation of prostate-specific antigen (PSA) expression, an [GENE]AR[\\GENE]-target gene, by [CHEMICAL]estramustine[\\CHEMICAL] and bicalutamide was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 1,
        "len": 23
    },
    {
        "text": "Down-regulation of [GENE]prostate-specific antigen[\\GENE] (PSA) expression, an AR-target gene, by estramustine and [CHEMICAL]bicalutamide[\\CHEMICAL] was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Down-regulation of prostate-specific antigen ([GENE]PSA[\\GENE]) expression, an AR-target gene, by estramustine and [CHEMICAL]bicalutamide[\\CHEMICAL] was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 1,
        "len": 23
    },
    {
        "text": "Down-regulation of prostate-specific antigen (PSA) expression, an [GENE]AR[\\GENE]-target gene, by estramustine and [CHEMICAL]bicalutamide[\\CHEMICAL] was accompanied by the blockade of the mutated androgen receptor.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The levels of [GENE]PSA[\\GENE] mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of [CHEMICAL]estramustine[\\CHEMICAL], respectively (IC50 = 10.97 +/- 1.68 microM).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by [CHEMICAL]estramustine[\\CHEMICAL] and bicalutamide was accompanied by the blockade of the mutated [GENE]androgen receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and [CHEMICAL]bicalutamide[\\CHEMICAL] was accompanied by the blockade of the mutated [GENE]androgen receptor[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Exposure of LNCaP cells to [CHEMICAL]estramustine[\\CHEMICAL] for 24 hr caused transcriptional inhibition of [GENE]PSA[\\GENE] in a concentration-dependent manner.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that [CHEMICAL]hydroxyflutamide[\\CHEMICAL] acted as an agonist of the m-[GENE]AR[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "Our data indicate that [CHEMICAL]estramustine phosphate[\\CHEMICAL] metabolites perform as androgen antagonists of [GENE]AR[\\GENE], an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "Our data indicate that estramustine phosphate metabolites perform as [CHEMICAL]androgen[\\CHEMICAL] antagonists of [GENE]AR[\\GENE], an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Androgen[\\CHEMICAL] antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated [GENE]androgen receptor[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 14
    },
    {
        "text": "Androgen antagonistic effect of [CHEMICAL]estramustine phosphate[\\CHEMICAL] (EMP) metabolites on wild-type and mutated [GENE]androgen receptor[\\GENE].",
        "label": 6,
        "major": 1,
        "len": 14
    },
    {
        "text": "Androgen antagonistic effect of estramustine phosphate ([CHEMICAL]EMP[\\CHEMICAL]) metabolites on wild-type and mutated [GENE]androgen receptor[\\GENE].",
        "label": 6,
        "major": 1,
        "len": 14
    },
    {
        "text": "In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of [GENE]Torpedo californica AChE[\\GENE] soaked with the reversible inhibitor [CHEMICAL]edrophonium[\\CHEMICAL], using a total X-ray exposure time of 24 ms. Electron-density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.",
        "label": 4,
        "major": 4,
        "len": 73
    },
    {
        "text": "The current study evaluates the effects of a selective [GENE]COX-2[\\GENE] inhibitor ([CHEMICAL]SC-236[\\CHEMICAL]) on renal function in cirrhotic rats with ascites.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [GENE]COX-1[\\GENE]/COX-2 inhibitor, [CHEMICAL]ketorolac[\\CHEMICAL], resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/[GENE]COX-2[\\GENE] inhibitor, [CHEMICAL]ketorolac[\\CHEMICAL], resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "Selective inhibition of [GENE]cyclooxygenase 2[\\GENE] spares renal function and [CHEMICAL]prostaglandin[\\CHEMICAL] synthesis in cirrhotic rats with ascites.",
        "label": 9,
        "major": 4,
        "len": 16
    },
    {
        "text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective [GENE]COX-1[\\GENE]/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of [CHEMICAL]prostaglandins[\\CHEMICAL], and glomerular filtration rate and in a significant impairment in renal water metabolism.",
        "label": 9,
        "major": 4,
        "len": 46
    },
    {
        "text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/[GENE]COX-2[\\GENE] inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of [CHEMICAL]prostaglandins[\\CHEMICAL], and glomerular filtration rate and in a significant impairment in renal water metabolism.",
        "label": 9,
        "major": 4,
        "len": 46
    },
    {
        "text": "By contrast, membrane expression of [GENE]annexin-1[\\GENE], which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M [CHEMICAL]FP[\\CHEMICAL], and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA).",
        "label": 2,
        "major": 10,
        "len": 38
    },
    {
        "text": "[CHEMICAL]FMLP[\\CHEMICAL]/CB-stimulated translocation of [GENE]cPLA2[\\GENE] to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "FMLP/[CHEMICAL]CB[\\CHEMICAL]-stimulated translocation of [GENE]cPLA2[\\GENE] to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M [CHEMICAL]FP[\\CHEMICAL] in the presence of 10 pg/ml [GENE]human recombinant interleukin-5[\\GENE] (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M [CHEMICAL]FP[\\CHEMICAL] in the presence of 10 pg/ml human recombinant interleukin-5 ([GENE]rhIL-5[\\GENE]) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml [GENE]human recombinant interleukin-5[\\GENE] (rhIL-5) and activated with [CHEMICAL]formyl-met-leu-phe[\\CHEMICAL] (FMLP) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ([GENE]rhIL-5[\\GENE]) and activated with [CHEMICAL]formyl-met-leu-phe[\\CHEMICAL] (FMLP) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml [GENE]human recombinant interleukin-5[\\GENE] (rhIL-5) and activated with formyl-met-leu-phe ([CHEMICAL]FMLP[\\CHEMICAL]) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ([GENE]rhIL-5[\\GENE]) and activated with formyl-met-leu-phe ([CHEMICAL]FMLP[\\CHEMICAL]) + cytochalasin B (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml [GENE]human recombinant interleukin-5[\\GENE] (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + [CHEMICAL]cytochalasin B[\\CHEMICAL] (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ([GENE]rhIL-5[\\GENE]) and activated with formyl-met-leu-phe (FMLP) + [CHEMICAL]cytochalasin B[\\CHEMICAL] (CB).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml [GENE]human recombinant interleukin-5[\\GENE] (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B ([CHEMICAL]CB[\\CHEMICAL]).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 ([GENE]rhIL-5[\\GENE]) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B ([CHEMICAL]CB[\\CHEMICAL]).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Inhibition of LTC4 synthesis precedes the global cytotoxic effects of [CHEMICAL]FP[\\CHEMICAL] as indicated by the simultaneous upregulation of [GENE]annexin-1[\\GENE] expression.",
        "label": 3,
        "major": 4,
        "len": 20
    },
    {
        "text": "FMLP/CB-stimulated translocation of [GENE]cPLA2[\\GENE] to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by [CHEMICAL]FP[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Inhibition of [GENE]cPLA2[\\GENE] translocation and leukotriene C4 secretion by [CHEMICAL]fluticasone propionate[\\CHEMICAL] in exogenously activated human eosinophils.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "We find that [CHEMICAL]FP[\\CHEMICAL] causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by [GENE]phospholipase A2[\\GENE] (PLA2).",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "We find that FP causes a decrease in stimulated eosinophil secretion of [CHEMICAL]LTC4[\\CHEMICAL] that is regulated by [GENE]phospholipase A2[\\GENE] (PLA2).",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "We find that FP causes a decrease in stimulated eosinophil secretion of [CHEMICAL]LTC4[\\CHEMICAL] that is regulated by phospholipase A2 ([GENE]PLA2[\\GENE]).",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "Desipramine treatment decreases [CHEMICAL]3H-nisoxetine[\\CHEMICAL] binding and [GENE]norepinephrine transporter[\\GENE] mRNA in SK-N-SHSY5Y cells.",
        "label": 2,
        "major": 9,
        "len": 12
    },
    {
        "text": "We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of [CHEMICAL]desipramine[\\CHEMICAL] to downregulate the [GENE]NET[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The antidepressant [CHEMICAL]desipramine[\\CHEMICAL] has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ([GENE]NET[\\GENE]) in vivo and in vitro, on both an acute and a chronic basis.",
        "label": 4,
        "major": 9,
        "len": 30
    },
    {
        "text": "The antidepressant [CHEMICAL]desipramine[\\CHEMICAL] has been shown to decrease synaptic membrane concentrations of the [GENE]norepinephrine re-uptake transporter[\\GENE] (NET) in vivo and in vitro, on both an acute and a chronic basis.",
        "label": 4,
        "major": 9,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Desipramine[\\CHEMICAL] treatment decreases 3H-nisoxetine binding and [GENE]norepinephrine transporter[\\GENE] mRNA in SK-N-SHSY5Y cells.",
        "label": 4,
        "major": 9,
        "len": 12
    },
    {
        "text": "6 In conclusion, [GENE]HERG[\\GENE] channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external [CHEMICAL]potassium[\\CHEMICAL] concentration.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "Inhibition of the [GENE]human ether-a-go-go-related gene (HERG) potassium channel[\\GENE] by [CHEMICAL]cisapride[\\CHEMICAL]: affinity for open and inactivated states.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "6 In conclusion, [GENE]HERG[\\GENE] channel inhibition by [CHEMICAL]cisapride[\\CHEMICAL] exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "2 In a chronic transfection model using CHO-K1 cells, [CHEMICAL]cisapride[\\CHEMICAL] inhibited [GENE]HERG[\\GENE] tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Ziprasidone[\\CHEMICAL] is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to [GENE]5-HT1D[\\GENE], 5-HT2, and D2 sites.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Ziprasidone[\\CHEMICAL] is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, [GENE]5-HT2[\\GENE], and D2 sites.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Ziprasidone[\\CHEMICAL] is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and [GENE]D2[\\GENE] sites.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Ziprasidone[\\CHEMICAL] is a novel antipsychotic agent which binds with high affinity to [GENE]5-HT1A receptors[\\GENE] (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites.",
        "label": 2,
        "major": 2,
        "len": 26
    },
    {
        "text": "The goal of the present study was to examine the [GENE]5-HT1A[\\GENE] properties of [CHEMICAL]ziprasidone[\\CHEMICAL] in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus.",
        "label": 2,
        "major": 4,
        "len": 36
    },
    {
        "text": "Pretreatment with the [GENE]5-HT1A[\\GENE] antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the [CHEMICAL]ziprasidone[\\CHEMICAL]-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.",
        "label": 2,
        "major": 9,
        "len": 29
    },
    {
        "text": "Pretreatment with the [GENE]5-HT1A[\\GENE] antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by [CHEMICAL]clozapine[\\CHEMICAL] and olanzapine.",
        "label": 2,
        "major": 6,
        "len": 29
    },
    {
        "text": "Pretreatment with the [GENE]5-HT1A[\\GENE] antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and [CHEMICAL]olanzapine[\\CHEMICAL].",
        "label": 2,
        "major": 6,
        "len": 29
    },
    {
        "text": "Comparison of the novel antipsychotic [CHEMICAL]ziprasidone[\\CHEMICAL] with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of [GENE]5-HT1A receptor[\\GENE] activation.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "Comparison of the novel antipsychotic ziprasidone with [CHEMICAL]clozapine[\\CHEMICAL] and olanzapine: inhibition of dorsal raphe cell firing and the role of [GENE]5-HT1A receptor[\\GENE] activation.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "Comparison of the novel antipsychotic ziprasidone with clozapine and [CHEMICAL]olanzapine[\\CHEMICAL]: inhibition of dorsal raphe cell firing and the role of [GENE]5-HT1A receptor[\\GENE] activation.",
        "label": 2,
        "major": 4,
        "len": 23
    },
    {
        "text": "These profiles suggest a mechanism of action for each agent, [GENE]5-HT1A[\\GENE] agonism for [CHEMICAL]ziprasidone[\\CHEMICAL] and alpha 1 antagonism for clozapine and olanzapine.",
        "label": 5,
        "major": 6,
        "len": 22
    },
    {
        "text": "The [GENE]5-HT1A[\\GENE] agonist activity reported here clearly distinguishes [CHEMICAL]ziprasidone[\\CHEMICAL] from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.",
        "label": 5,
        "major": 5,
        "len": 28
    },
    {
        "text": "While it is an antagonist at these latter receptors, [CHEMICAL]ziprasidone[\\CHEMICAL] behaves as a [GENE]5-HT1A[\\GENE] agonist in vitro in adenylate cyclase measurements.",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "Pretreatment with the [GENE]5-HT1A[\\GENE] antagonist [CHEMICAL]WAY-100,635[\\CHEMICAL] (10 micrograms/kg i.v.)",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "Pretreatment with the [GENE]5-HT1A[\\GENE] antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of [CHEMICAL]WAY-100,635[\\CHEMICAL] had little effect on the inhibition produced by clozapine and olanzapine.",
        "label": 6,
        "major": 3,
        "len": 29
    },
    {
        "text": "The nonselective and irreversible [GENE]MAO[\\GENE] inhibitors, [CHEMICAL]phenelzine[\\CHEMICAL] (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The nonselective and irreversible [GENE]MAO[\\GENE] inhibitors, phenelzine (3-10 mg/kg), [CHEMICAL]tranylcypromine[\\CHEMICAL] (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The nonselective and irreversible [GENE]MAO[\\GENE] inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and [CHEMICAL]nialamide[\\CHEMICAL] (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "The irreversible [GENE]MAO-B[\\GENE] inhibitors, [CHEMICAL]pargyline[\\CHEMICAL] (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The reversible [GENE]MAO-A[\\GENE] inhibitor, [CHEMICAL]befloxatone[\\CHEMICAL] (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible [GENE]MAO-A[\\GENE] inhibitor, [CHEMICAL]clorgyline[\\CHEMICAL] (10-30 mg/kg), also reduced ethanol self-administration.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The irreversible [GENE]MAO-B[\\GENE] inhibitors, pargyline (30 mg/kg) and [CHEMICAL]l-deprenyl[\\CHEMICAL] (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Dicumarol[\\CHEMICAL], a potent inhibitor of [GENE]quinone oxidoreductase[\\GENE], at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "A novel missense mutation, [GENE]G663A[\\GENE], in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with [CHEMICAL]pyridoxine[\\CHEMICAL]-responsive sideroblastic anemia.",
        "label": 2,
        "major": 1,
        "len": 25
    },
    {
        "text": "A novel missense mutation, G663A, in exon 5 of the [GENE]erythroid-specific delta-aminolevulinate synthase[\\GENE] gene (ALAS2) was identified in a Japanese male with [CHEMICAL]pyridoxine[\\CHEMICAL]-responsive sideroblastic anemia.",
        "label": 2,
        "major": 1,
        "len": 25
    },
    {
        "text": "A novel missense mutation, G663A, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene ([GENE]ALAS2[\\GENE]) was identified in a Japanese male with [CHEMICAL]pyridoxine[\\CHEMICAL]-responsive sideroblastic anemia.",
        "label": 2,
        "major": 1,
        "len": 25
    },
    {
        "text": "Activity of the mutant [GENE]delta-aminolevulinate synthase[\\GENE] protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to [CHEMICAL]pyridoxine[\\CHEMICAL] treatment.",
        "label": 2,
        "major": 3,
        "len": 40
    },
    {
        "text": "A novel mutation of the [GENE]erythroid-specific gamma-Aminolevulinate synthase[\\GENE] gene in a patient with non-inherited [CHEMICAL]pyridoxine[\\CHEMICAL]-responsive sideroblastic anemia.",
        "label": 2,
        "major": 1,
        "len": 17
    },
    {
        "text": "Activity of the mutant [GENE]delta-aminolevulinate synthase[\\GENE] protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL], consistent with the clinical response of the patient to pyridoxine treatment.",
        "label": 3,
        "major": 1,
        "len": 40
    },
    {
        "text": "Preferential cerebrospinal fluid [GENE]acetylcholinesterase[\\GENE] inhibition by [CHEMICAL]rivastigmine[\\CHEMICAL] in humans.",
        "label": 4,
        "major": 4,
        "len": 9
    },
    {
        "text": "Inhibition of [GENE]AChE[\\GENE] in the CSF after [CHEMICAL]rivastigmine[\\CHEMICAL] administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Plasma [GENE]BuChE[\\GENE] activity was significantly lower after [CHEMICAL]rivastigmine[\\CHEMICAL] than after placebo, but this was not clinically relevant.",
        "label": 4,
        "major": 10,
        "len": 17
    },
    {
        "text": "[GENE]BuChE[\\GENE] activity in CSF was significantly lower after [CHEMICAL]rivastigmine[\\CHEMICAL] than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [CHEMICAL]rivastigmine[\\CHEMICAL] markedly inhibits CSF [GENE]AChE[\\GENE] after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [CHEMICAL]rivastigmine[\\CHEMICAL] markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central [GENE]AChE[\\GENE] is substantially greater than that of peripheral AChE or BuChE.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [CHEMICAL]rivastigmine[\\CHEMICAL] markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral [GENE]AChE[\\GENE] or BuChE.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that [CHEMICAL]rivastigmine[\\CHEMICAL] markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or [GENE]BuChE[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "[CHEMICAL]Amino acids[\\CHEMICAL] between Ile(183) and Val(191) are necessary for proper [GENE]factor IX[\\GENE] activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.",
        "label": 1,
        "major": 3,
        "len": 32
    },
    {
        "text": "To identify key [CHEMICAL]amino acids[\\CHEMICAL] involved in [GENE]factor IX[\\GENE] activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.",
        "label": 1,
        "major": 1,
        "len": 32
    },
    {
        "text": "To identify key amino acids involved in factor IX activation, recombinant [GENE]factor XIa[\\GENE] proteins containing [CHEMICAL]alanine[\\CHEMICAL] substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.",
        "label": 1,
        "major": 3,
        "len": 32
    },
    {
        "text": "Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the [CHEMICAL]N[\\CHEMICAL] terminus and for Ser(258)-Ser(264) at the C terminus of the [GENE]A3 domain[\\GENE] markedly decreased factor XI coagulant activity.",
        "label": 1,
        "major": 4,
        "len": 26
    },
    {
        "text": "Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the [CHEMICAL]C[\\CHEMICAL] terminus of the [GENE]A3 domain[\\GENE] markedly decreased factor XI coagulant activity.",
        "label": 1,
        "major": 4,
        "len": 26
    },
    {
        "text": "Identification of [CHEMICAL]amino acids[\\CHEMICAL] in the [GENE]factor XI apple 3 domain[\\GENE] required for activation of factor IX.",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "Identification of [CHEMICAL]amino acids[\\CHEMICAL] in the factor XI apple 3 domain required for activation of [GENE]factor IX[\\GENE].",
        "label": 1,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for [GENE]h5-HT(1A)[\\GENE], h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), [GENE]h5-HT(1B)[\\GENE], h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), [GENE]h5-HT(1D)[\\GENE], and hD(2) receptors and weak affinity for hD(3) receptors.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and [GENE]hD(2) receptors[\\GENE] and weak affinity for hD(3) receptors.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for [GENE]hD(3) receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "In [[CHEMICAL](35)S[\\CHEMICAL]]GTPgammaS binding protocols, yohimbine exerts antagonist actions at [GENE]halpha(2A)-AR[\\GENE], h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 2,
        "major": 6,
        "len": 22
    },
    {
        "text": "In [[CHEMICAL](35)S[\\CHEMICAL]]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, [GENE]h5-HT(1B)[\\GENE], h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "In [[CHEMICAL](35)S[\\CHEMICAL]]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), [GENE]h5-HT(1D)[\\GENE], and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 2,
        "major": 5,
        "len": 22
    },
    {
        "text": "In [[CHEMICAL](35)S[\\CHEMICAL]]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and [GENE]hD(2)[\\GENE] sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "In [[CHEMICAL](35)S[\\CHEMICAL]]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at [GENE]h5-HT(1A)[\\GENE] sites.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Herein, we evaluate the interaction of the alpha(2)-AR antagonist, [CHEMICAL]yohimbine[\\CHEMICAL], as compared to fluparoxan, at multiple [GENE]monoaminergic receptors[\\GENE] and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
        "label": 2,
        "major": 7,
        "len": 34
    },
    {
        "text": "Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to [CHEMICAL]fluparoxan[\\CHEMICAL], at multiple [GENE]monoaminergic receptors[\\GENE] and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
        "label": 2,
        "major": 7,
        "len": 34
    },
    {
        "text": "However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the [GENE]5-HT(1A)[\\GENE] agonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
        "label": 5,
        "major": 6,
        "len": 32
    },
    {
        "text": "In [(35)S]GTPgammaS binding protocols, [CHEMICAL]yohimbine[\\CHEMICAL] exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at [GENE]h5-HT(1A)[\\GENE] sites.",
        "label": 5,
        "major": 6,
        "len": 22
    },
    {
        "text": "In vivo, agonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] at [GENE]5-HT(1A)[\\GENE] sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.",
        "label": 5,
        "major": 5,
        "len": 19
    },
    {
        "text": "In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the [GENE]5-HT(1B)[\\GENE] agonist, [CHEMICAL]GR46,611[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 22
    },
    {
        "text": "In distinction to [CHEMICAL]yohimbine[\\CHEMICAL], fluparoxan shows only modest partial agonist actions at [GENE]h5-HT(1A)[\\GENE] sites versus marked antagonist actions at halpha(2)-ARs.",
        "label": 5,
        "major": 6,
        "len": 20
    },
    {
        "text": "In distinction to yohimbine, [CHEMICAL]fluparoxan[\\CHEMICAL] shows only modest partial agonist actions at [GENE]h5-HT(1A)[\\GENE] sites versus marked antagonist actions at halpha(2)-ARs.",
        "label": 5,
        "major": 6,
        "len": 20
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors [GENE](AR)s[\\GENE], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin [GENE](5-HT)(1A)[\\GENE], 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), [GENE]5-HT(1B)[\\GENE], 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), [GENE]5-HT(1D)[\\GENE] and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of yohimbine as compared to [CHEMICAL]fluparoxan[\\CHEMICAL] at alpha(2)-adrenergic receptors [GENE](AR)s[\\GENE], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of yohimbine as compared to [CHEMICAL]fluparoxan[\\CHEMICAL] at [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 5,
        "major": 6,
        "len": 24
    },
    {
        "text": "In conclusion, the [GENE]alpha(2)-AR[\\GENE] antagonist properties of [CHEMICAL]yohimbine[\\CHEMICAL] increase DA and NAD levels both alone and in association with fluoxetine.",
        "label": 6,
        "major": 3,
        "len": 20
    },
    {
        "text": "However, in contrast to the selective [GENE]alpha(2)-AR[\\GENE] antagonist, [CHEMICAL]fluparoxan[\\CHEMICAL], the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.",
        "label": 6,
        "major": 5,
        "len": 32
    },
    {
        "text": "In [(35)S]GTPgammaS binding protocols, [CHEMICAL]yohimbine[\\CHEMICAL] exerts antagonist actions at [GENE]halpha(2A)-AR[\\GENE], h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "In [(35)S]GTPgammaS binding protocols, [CHEMICAL]yohimbine[\\CHEMICAL] exerts antagonist actions at halpha(2A)-AR, [GENE]h5-HT(1B)[\\GENE], h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "In [(35)S]GTPgammaS binding protocols, [CHEMICAL]yohimbine[\\CHEMICAL] exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), [GENE]h5-HT(1D)[\\GENE], and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 6,
        "major": 2,
        "len": 22
    },
    {
        "text": "In [(35)S]GTPgammaS binding protocols, [CHEMICAL]yohimbine[\\CHEMICAL] exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and [GENE]hD(2)[\\GENE] sites, yet partial agonist actions at h5-HT(1A) sites.",
        "label": 6,
        "major": 2,
        "len": 22
    },
    {
        "text": "Herein, we evaluate the interaction of the [GENE]alpha(2)-AR antagonist[\\GENE], [CHEMICAL]yohimbine[\\CHEMICAL], as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
        "label": 6,
        "major": 7,
        "len": 34
    },
    {
        "text": "In vivo, agonist actions of yohimbine at [GENE]5-HT(1A)[\\GENE] sites are revealed by [CHEMICAL]WAY100,635[\\CHEMICAL]-reversible induction of hypothermia in the rat.",
        "label": 6,
        "major": 5,
        "len": 19
    },
    {
        "text": "In guinea pigs, antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] at [GENE]5-HT(1B)[\\GENE] receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.",
        "label": 6,
        "major": 6,
        "len": 22
    },
    {
        "text": "Herein, we evaluate the interaction of the [GENE]alpha(2)-AR antagonist[\\GENE], yohimbine, as compared to [CHEMICAL]fluparoxan[\\CHEMICAL], at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.",
        "label": 6,
        "major": 6,
        "len": 34
    },
    {
        "text": "In distinction to [CHEMICAL]yohimbine[\\CHEMICAL], fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at [GENE]halpha(2)-ARs[\\GENE].",
        "label": 6,
        "major": 6,
        "len": 20
    },
    {
        "text": "In distinction to yohimbine, [CHEMICAL]fluparoxan[\\CHEMICAL] shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at [GENE]halpha(2)-ARs[\\GENE].",
        "label": 6,
        "major": 5,
        "len": 20
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors [GENE](AR)s[\\GENE], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin [GENE](5-HT)(1A)[\\GENE], 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), [GENE]5-HT(1B)[\\GENE], 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), [GENE]5-HT(1D)[\\GENE] and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of [CHEMICAL]yohimbine[\\CHEMICAL] as compared to fluparoxan at [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of yohimbine as compared to [CHEMICAL]fluparoxan[\\CHEMICAL] at alpha(2)-adrenergic receptors [GENE](AR)s[\\GENE], serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Agonist and antagonist actions of yohimbine as compared to [CHEMICAL]fluparoxan[\\CHEMICAL] at [GENE]alpha(2)-adrenergic receptors[\\GENE] (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and [GENE]kappa-opioid receptor[\\GENE] ([CHEMICAL]BRL 52974[\\CHEMICAL]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
        "label": 5,
        "major": 9,
        "len": 39
    },
    {
        "text": "The nonselective [GENE]opioid receptor[\\GENE] antagonist, naloxone (3 mg/kg, i.m. ), attenuated the antitussive effects of [CHEMICAL]codeine[\\CHEMICAL] or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
        "label": 5,
        "major": 6,
        "len": 30
    },
    {
        "text": "The nonselective [GENE]opioid receptor[\\GENE] antagonist, naloxone (3 mg/kg, i.m. ), attenuated the antitussive effects of codeine or [CHEMICAL]SB 227122[\\CHEMICAL], indicating that the antitussive activity of both compounds is opioid receptor-mediated.",
        "label": 5,
        "major": 6,
        "len": 30
    },
    {
        "text": "The [GENE]delta-receptor[\\GENE] antagonist, SB 244525 (10 mg/kg, i.p. ), inhibited the antitussive effect of [CHEMICAL]SB 227122[\\CHEMICAL] (20 mg/kg, i.p.).",
        "label": 5,
        "major": 6,
        "len": 19
    },
    {
        "text": "In this study, the activity of the [GENE]delta-opioid receptor[\\GENE] subtype-selective agonist, [CHEMICAL]SB 227122[\\CHEMICAL], was investigated in a guinea pig model of citric acid-induced cough.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "The [GENE]sigma-receptor[\\GENE] antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [CHEMICAL]dextromethorphan[\\CHEMICAL] (30 mg/kg, i.p.",
        "label": 5,
        "major": 4,
        "len": 16
    },
    {
        "text": "These studies provide compelling evidence that the antitussive effects of [CHEMICAL]SB 227122[\\CHEMICAL] in this guinea pig cough model are mediated by agonist activity at the [GENE]delta-opioid receptor[\\GENE].",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "Parenteral administration of selective agonists of the [GENE]delta-opioid receptor[\\GENE] ([CHEMICAL]SB 227122[\\CHEMICAL]), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
        "label": 5,
        "major": 4,
        "len": 39
    },
    {
        "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), [GENE]mu-opioid receptor[\\GENE] ([CHEMICAL]codeine[\\CHEMICAL] and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
        "label": 5,
        "major": 3,
        "len": 39
    },
    {
        "text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), [GENE]mu-opioid receptor[\\GENE] (codeine and [CHEMICAL]hydrocodone[\\CHEMICAL]), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.",
        "label": 5,
        "major": 3,
        "len": 39
    },
    {
        "text": "The nonselective [GENE]opioid receptor[\\GENE] antagonist, [CHEMICAL]naloxone[\\CHEMICAL] (3 mg/kg, i.m.",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "The [GENE]delta-receptor[\\GENE] antagonist, [CHEMICAL]SB 244525[\\CHEMICAL] (10 mg/kg, i.p.",
        "label": 6,
        "major": 6,
        "len": 8
    },
    {
        "text": "In contrast, combined pretreatment with [CHEMICAL]beta-funaltrexamine[\\CHEMICAL] ([GENE]mu-receptor[\\GENE] antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
        "label": 6,
        "major": 5,
        "len": 44
    },
    {
        "text": "In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and [CHEMICAL]norbinaltorphimine[\\CHEMICAL] ([GENE]kappa-receptor[\\GENE] antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).",
        "label": 6,
        "major": 6,
        "len": 44
    },
    {
        "text": "The [GENE]sigma-receptor[\\GENE] antagonist [CHEMICAL]rimcazole[\\CHEMICAL] (3 mg/kg, i.p.)",
        "label": 6,
        "major": 6,
        "len": 7
    },
    {
        "text": "New modes of therapy have recently been introduced, and data on the [GENE]cyclooxygenase-2[\\GENE] (COX-2)-specific inhibitors [CHEMICAL]celecoxib[\\CHEMICAL] and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ([GENE]COX-2[\\GENE])-specific inhibitors [CHEMICAL]celecoxib[\\CHEMICAL] and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "New modes of therapy have recently been introduced, and data on the [GENE]cyclooxygenase-2[\\GENE] (COX-2)-specific inhibitors celecoxib and [CHEMICAL]rofecoxib[\\CHEMICAL] suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 ([GENE]COX-2[\\GENE])-specific inhibitors celecoxib and [CHEMICAL]rofecoxib[\\CHEMICAL] suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "[CHEMICAL]Dichloroally]-lawsone[\\CHEMICAL] was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for [GENE]mammalian dihydroorotate dehydrogenases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "Another inhibitor, [CHEMICAL]brequinar[\\CHEMICAL] was previously reported to be a slow-binding inhibitor of the [GENE]human dihydroorotate dehydrogenase[\\GENE] [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of [GENE]human and rat dihyroorotate dehydrogenase[\\GENE] by immunosuppressive [CHEMICAL]isoxazol[\\CHEMICAL] and cinchoninic acid derivatives, Biochem.",
        "label": 4,
        "major": 2,
        "len": 36
    },
    {
        "text": "Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of [GENE]human and rat dihyroorotate dehydrogenase[\\GENE] by immunosuppressive isoxazol and [CHEMICAL]cinchoninic acid[\\CHEMICAL] derivatives, Biochem.",
        "label": 4,
        "major": 10,
        "len": 36
    },
    {
        "text": "With respect to the substrate [CHEMICAL]dihydroorotate[\\CHEMICAL], atovaquone was an uncompetitive inhibitor of [GENE]human dihydroorotate dehydrogenase[\\GENE] (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).",
        "label": 4,
        "major": 9,
        "len": 34
    },
    {
        "text": "With respect to the substrate dihydroorotate, [CHEMICAL]atovaquone[\\CHEMICAL] was an uncompetitive inhibitor of [GENE]human dihydroorotate dehydrogenase[\\GENE] (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Kinetics of inhibition of [GENE]human and rat dihydroorotate dehydrogenase[\\GENE] by atovaquone, lawsone derivatives, [CHEMICAL]brequinar sodium[\\CHEMICAL] and polyporic acid.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Kinetics of inhibition of [GENE]human and rat dihydroorotate dehydrogenase[\\GENE] by atovaquone, lawsone derivatives, brequinar sodium and [CHEMICAL]polyporic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Kinetics of inhibition of [GENE]human and rat dihydroorotate dehydrogenase[\\GENE] by [CHEMICAL]atovaquone[\\CHEMICAL], lawsone derivatives, brequinar sodium and polyporic acid.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Kinetics of inhibition of [GENE]human and rat dihydroorotate dehydrogenase[\\GENE] by atovaquone, [CHEMICAL]lawsone[\\CHEMICAL] derivatives, brequinar sodium and polyporic acid.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, [CHEMICAL]atovaquone[\\CHEMICAL] (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of [GENE]human dihydroorotate dehydrogenase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and [CHEMICAL]dichloroally-lawsone[\\CHEMICAL] (Kic = 9.8 nM) were shown to be competitive inhibitors of [GENE]human dihydroorotate dehydrogenase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Mitochondrially-bound [GENE]dihydroorotate dehydrogenase[\\GENE] (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of [CHEMICAL]uridine monophosphate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Mitochondrially-bound dihydroorotate dehydrogenase ([GENE]EC 1.3.99.11[\\GENE]) catalyzes the fourth sequential step in the de novo synthesis of [CHEMICAL]uridine monophosphate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "With respect to the [CHEMICAL]quinone[\\CHEMICAL] co-substrate of the [GENE]dihydroorotate dehydrogenase[\\GENE], atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.",
        "label": 9,
        "major": 4,
        "len": 31
    },
    {
        "text": "METHODS AND RESULTS: The effect of intravenous [CHEMICAL]ajmaline[\\CHEMICAL] (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a [GENE]SCN5A[\\GENE] mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).",
        "label": 2,
        "major": 10,
        "len": 67
    },
    {
        "text": "METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), [CHEMICAL]procainamide[\\CHEMICAL] (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a [GENE]SCN5A[\\GENE] mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).",
        "label": 2,
        "major": 10,
        "len": 67
    },
    {
        "text": "METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or [CHEMICAL]flecainide[\\CHEMICAL] (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a [GENE]SCN5A[\\GENE] mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).",
        "label": 2,
        "major": 10,
        "len": 67
    },
    {
        "text": "To further analyze the mechanism governing the [GENE]Ca2+ channel[\\GENE]-[CHEMICAL]Mibefradil[\\CHEMICAL] interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.",
        "label": 2,
        "major": 2,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] blocked alpha1A and alpha1E with a Kd comparable to that reported for [GENE]T-type channels[\\GENE], but had a lower affinity (approximately 30-fold) for alpha1C.",
        "label": 4,
        "major": 2,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Mibefradil[\\CHEMICAL] (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block [GENE]T-type Ca2+ channels[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "Determinants of voltage-dependent inactivation affect [CHEMICAL]Mibefradil[\\CHEMICAL] block of [GENE]calcium channels[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 10
    },
    {
        "text": "Mibefradil ([CHEMICAL]Ro 40-5967[\\CHEMICAL]) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block [GENE]T-type Ca2+ channels[\\GENE].",
        "label": 4,
        "major": 6,
        "len": 27
    },
    {
        "text": "Postoperative concentrations of [GENE]plasminogen[\\GENE] were decreased significantly in the [CHEMICAL]tranexamic acid[\\CHEMICAL] group (P < 0.001).",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "Iontophoresis of [CHEMICAL]+/- propranolol[\\CHEMICAL], whose serotonergic actions include antagonism and partial agonism at [GENE]5-HT1[\\GENE] receptors, also increased serotonin and decreased firing (n=4).",
        "label": 5,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Methiothepin[\\CHEMICAL] (intravenous, 1 mg/kg), whose serotonergic actions include [GENE]5-HT1[\\GENE] and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "[CHEMICAL]Methiothepin[\\CHEMICAL] (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and [GENE]5-HT2[\\GENE] antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).",
        "label": 6,
        "major": 6,
        "len": 29
    },
    {
        "text": "Iontophoresis of [CHEMICAL]+/- propranolol[\\CHEMICAL], whose serotonergic actions include antagonism and partial agonism at [GENE]5-HT1[\\GENE] receptors, also increased serotonin and decreased firing (n=4).",
        "label": 6,
        "major": 3,
        "len": 22
    },
    {
        "text": "Treatment with [CHEMICAL]geldanamycin[\\CHEMICAL], however, does not affect the activation of [GENE]lysophosphatide acyltransferase[\\GENE], which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation.",
        "label": 10,
        "major": 3,
        "len": 26
    },
    {
        "text": "In this study, we demonstrate that [CHEMICAL]geldanamycin[\\CHEMICAL] treatment blocks [GENE]interleukin (IL)-2[\\GENE] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "In this study, we demonstrate that [CHEMICAL]geldanamycin[\\CHEMICAL] treatment blocks interleukin (IL)-2 secretion, [GENE]IL-2 receptor[\\GENE] expression, and proliferation of stimulated T-lymphocytes.",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of [GENE]Lck[\\GENE] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and [GENE]Raf-1[\\GENE] kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and Raf-1 [GENE]kinases[\\GENE] and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Through demonstrating the selective inhibition of [GENE]kinase[\\GENE]-related T-lymphocyte responses by [CHEMICAL]geldanamycin[\\CHEMICAL], our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Improper function of these proteins can be induced by selective disruption of their complexes with [GENE]Hsp90[\\GENE] using the [CHEMICAL]benzoquinonoid ansamycin[\\CHEMICAL] geldanamycin.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Improper function of these proteins can be induced by selective disruption of their complexes with [GENE]Hsp90[\\GENE] using the benzoquinonoid ansamycin [CHEMICAL]geldanamycin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of [GENE]Lck[\\GENE] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and [GENE]Raf-1[\\GENE] kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and Raf-1 [GENE]kinases[\\GENE] and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the [GENE]extracellular signal regulated kinase (ERK)-2[\\GENE] kinase.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Moreover, [CHEMICAL]geldanamycin[\\CHEMICAL] decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 [GENE]kinase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Geldanamycin[\\CHEMICAL] also disrupts the [GENE]T-cell receptor[\\GENE]-mediated activation of nuclear factor of activated T-cells (NF-AT).",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Geldanamycin[\\CHEMICAL] also disrupts the T-cell receptor-mediated activation of [GENE]nuclear factor of activated T-cells[\\GENE] (NF-AT).",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Geldanamycin[\\CHEMICAL] also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells ([GENE]NF-AT[\\GENE]).",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "The [GENE]Hsp90[\\GENE]-specific inhibitor [CHEMICAL]geldanamycin[\\CHEMICAL] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "The Hsp90-specific inhibitor [CHEMICAL]geldanamycin[\\CHEMICAL] selectively disrupts [GENE]kinase[\\GENE]-mediated signaling events of T-lymphocyte activation.",
        "label": 4,
        "major": 3,
        "len": 12
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on [CHEMICAL]Fe2+[\\CHEMICAL], alpha-ketoglutarate, ascorbate and oxygen.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, [CHEMICAL]alpha-ketoglutarate[\\CHEMICAL], ascorbate and oxygen.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, [CHEMICAL]ascorbate[\\CHEMICAL] and oxygen.",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and [CHEMICAL]oxygen[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in [CHEMICAL]carnitine[\\CHEMICAL] biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of [CHEMICAL]L-carnitine[\\CHEMICAL] from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "[GENE]gamma-Butyrobetaine hydroxylase[\\GENE] catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from [CHEMICAL]gamma-butyrobetaine[\\CHEMICAL], a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] do not promote dissociation of (125)I-[GENE]ET-1[\\GENE] ETB receptor complexes.",
        "label": 10,
        "major": 10,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] do not promote dissociation of (125)I-ET-1 [GENE]ETB receptor[\\GENE] complexes.",
        "label": 10,
        "major": 10,
        "len": 10
    },
    {
        "text": "Salicylates do not promote dissociation of [CHEMICAL](125)I[\\CHEMICAL]-[GENE]ET-1[\\GENE] ETB receptor complexes.",
        "label": 2,
        "major": 10,
        "len": 10
    },
    {
        "text": "Salicylates do not promote dissociation of [CHEMICAL](125)I[\\CHEMICAL]-ET-1 [GENE]ETB receptor[\\GENE] complexes.",
        "label": 2,
        "major": 10,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] inhibit (125)I-[GENE]ET-1[\\GENE] binding to recombinant rat ETA receptors.",
        "label": 2,
        "major": 4,
        "len": 9
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] inhibit (125)I-ET-1 binding to recombinant [GENE]rat ETA receptors[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 9
    },
    {
        "text": "Salicylates inhibit [CHEMICAL](125)I[\\CHEMICAL]-[GENE]ET-1[\\GENE] binding to recombinant rat ETA receptors.",
        "label": 2,
        "major": 2,
        "len": 9
    },
    {
        "text": "The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of [CHEMICAL]salicylates[\\CHEMICAL] and ETA receptor antagonists should be used to evaluate the physiopathological role of [GENE]ET-1[\\GENE] and may be of therapeutic interest in the treatment of ischemic heart disease.",
        "label": 2,
        "major": 2,
        "len": 50
    },
    {
        "text": "Inhibition of the actions of [GENE]ET-1[\\GENE] by [CHEMICAL]salicylates[\\CHEMICAL] is apparently competitive.",
        "label": 4,
        "major": 4,
        "len": 11
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and sodium salicylate inhibit endothelin [GENE]ETA receptors[\\GENE] by an allosteric type of mechanism.",
        "label": 7,
        "major": 4,
        "len": 14
    },
    {
        "text": "Aspirin and [CHEMICAL]sodium salicylate[\\CHEMICAL] inhibit endothelin [GENE]ETA receptors[\\GENE] by an allosteric type of mechanism.",
        "label": 7,
        "major": 7,
        "len": 14
    },
    {
        "text": "It is concluded that [CHEMICAL]salicylates[\\CHEMICAL] are allosteric inhibitors of [GENE]ETA receptors[\\GENE].",
        "label": 7,
        "major": 4,
        "len": 11
    },
    {
        "text": "Among the various enzymes, [CHEMICAL]dicoumarol[\\CHEMICAL] inhibitable cytosolic [GENE]NAD(P)H:quinone oxidoreductase1[\\GENE] (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Among the various enzymes, [CHEMICAL]dicoumarol[\\CHEMICAL] inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ([GENE]NQO1[\\GENE]) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "This activity, like [GENE]NQO1[\\GENE], was inhibited by [CHEMICAL]dicoumarol[\\CHEMICAL] and immunologically related to NQO1.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "Among the various enzymes, dicoumarol inhibitable cytosolic [GENE]NAD(P)H:quinone oxidoreductase1[\\GENE] (NQO1) was shown to catalyse bioreductive activation of [CHEMICAL]MMC[\\CHEMICAL] leading to cross-linking of the DNA and cytotoxicity.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 ([GENE]NQO1[\\GENE]) was shown to catalyse bioreductive activation of [CHEMICAL]MMC[\\CHEMICAL] leading to cross-linking of the DNA and cytotoxicity.",
        "label": 9,
        "major": 4,
        "len": 26
    },
    {
        "text": "However, the role of [GENE]NQO1[\\GENE] in metabolic activation of [CHEMICAL]MMC[\\CHEMICAL] has been disputed.",
        "label": 9,
        "major": 3,
        "len": 13
    },
    {
        "text": "In this report, we present cellular and animal models to demonstrate that [GENE]NQO1[\\GENE] may play only a minor role in metabolic activation of [CHEMICAL]MMC[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 24
    },
    {
        "text": "A unique cytosolic activity related but distinct from [GENE]NQO1[\\GENE] catalyses metabolic activation of [CHEMICAL]mitomycin C[\\CHEMICAL].",
        "label": 9,
        "major": 3,
        "len": 15
    },
    {
        "text": "In this study, we investigated the effect of [CHEMICAL]troglitazone[\\CHEMICAL], a ligand of the [GENE]nuclear receptor[\\GENE] peroxisome proliferator activated receptor-gamma, on PAI-1 expression and secretion in human adipocytes.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In this study, we investigated the effect of [CHEMICAL]troglitazone[\\CHEMICAL], a ligand of the nuclear receptor [GENE]peroxisome proliferator activated receptor-gamma[\\GENE], on PAI-1 expression and secretion in human adipocytes.",
        "label": 2,
        "major": 3,
        "len": 27
    },
    {
        "text": "In cultures from severely obese subjects, [CHEMICAL]troglitazone[\\CHEMICAL] induced a decrease of [GENE]PAI-1[\\GENE] antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05).",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to [CHEMICAL]troglitazone[\\CHEMICAL] induced a similar reduction of [GENE]PAI-1[\\GENE] concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively).",
        "label": 4,
        "major": 3,
        "len": 42
    },
    {
        "text": "CONCLUSION/INTERPRETATION: This study provides evidence that [CHEMICAL]troglitazone[\\CHEMICAL] reduces [GENE]PAI-1[\\GENE] production in human adipocytes, probably at the transcriptional level.",
        "label": 4,
        "major": 9,
        "len": 18
    },
    {
        "text": "RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml [CHEMICAL]troglitazone[\\CHEMICAL] for 72 h caused a reduction of both [GENE]PAI-1[\\GENE] secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml [CHEMICAL]troglitazone[\\CHEMICAL] for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and [GENE]PAI-1[\\GENE] mRNA expression (by 26 +/- 3%; p < 0.05).",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Troglitazone[\\CHEMICAL] reduces [GENE]plasminogen activator inhibitor-1[\\GENE] expression and secretion in cultured human adipocytes.",
        "label": 4,
        "major": 4,
        "len": 12
    },
    {
        "text": "In these tissues, [CHEMICAL]JTH-601[\\CHEMICAL], prazosin (a non-selective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "In these tissues, JTH-601, [CHEMICAL]prazosin[\\CHEMICAL] (a non-selective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and [CHEMICAL]tamsulosin[\\CHEMICAL] (an [GENE]alpha(1A)-adrenoceptor[\\GENE] antagonist) competitively antagonized contraction in a concentration-dependent manner.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "We examined the effect of JTH-601 (3- inverted question mark[CHEMICAL]N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom[\\CHEMICAL] ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [GENE]alpha(1L)-adrenoceptor[\\GENE] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom [CHEMICAL]ethyl[\\CHEMICAL] inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [GENE]alpha(1L)-adrenoceptor[\\GENE] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "[CHEMICAL]JTH-601[\\CHEMICAL] is expected to be an effective [GENE]alpha(1)-adrenoceptor[\\GENE] antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-[CHEMICAL]4-methoxy-2,5,6-trimethylphenol hemifumarate[\\CHEMICAL]), a new [GENE]alpha(1L)-adrenoceptor[\\GENE] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "We examined the effect of [CHEMICAL]JTH-601[\\CHEMICAL] (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [GENE]alpha(1L)-adrenoceptor[\\GENE] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "The salivary fluid secretory mechanism is thought to require [GENE]Na(+)/K(+)/2Cl(-) cotransporter[\\GENE]-mediated [CHEMICAL]Cl(-)[\\CHEMICAL] uptake.",
        "label": 9,
        "major": 9,
        "len": 13
    },
    {
        "text": "UNLABELLED: Apparent [GENE]muscarinic acetylcholine (mAch) receptor[\\GENE] occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate ([CHEMICAL]3H-NMPB[\\CHEMICAL]) and 3H-quinuclidinyl benzilate (3H-QNB).",
        "label": 2,
        "major": 6,
        "len": 43
    },
    {
        "text": "UNLABELLED: Apparent [GENE]muscarinic acetylcholine (mAch) receptor[\\GENE] occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and [CHEMICAL]3H-quinuclidinyl benzilate[\\CHEMICAL] (3H-QNB).",
        "label": 2,
        "major": 6,
        "len": 43
    },
    {
        "text": "UNLABELLED: Apparent [GENE]muscarinic acetylcholine (mAch) receptor[\\GENE] occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate ([CHEMICAL]3H-QNB[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 43
    },
    {
        "text": "Both radioligands labeled [GENE]mAch receptors[\\GENE] in these brain regions, and the relative regional distributions of the specific binding of [CHEMICAL]3H-NMPB[\\CHEMICAL] in vivo paralleled the distribution of mAch receptors.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of [CHEMICAL]3H-NMPB[\\CHEMICAL] in vivo paralleled the distribution of [GENE]mAch receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "A similar discrepancy in sensitivity to competitors between [CHEMICAL]3H-NMPB[\\CHEMICAL] and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the [GENE]mAch receptor[\\GENE] could not account for the observed differences in sensitivity to competition.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "A similar discrepancy in sensitivity to competitors between 3H-NMPB and [CHEMICAL]3H-QNB[\\CHEMICAL] was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the [GENE]mAch receptor[\\GENE] could not account for the observed differences in sensitivity to competition.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when [CHEMICAL]biperiden[\\CHEMICAL] was used as a competitor, indicating that binding to different subtypes of the [GENE]mAch receptor[\\GENE] could not account for the observed differences in sensitivity to competition.",
        "label": 2,
        "major": 10,
        "len": 42
    },
    {
        "text": "UNLABELLED: Apparent [GENE]muscarinic acetylcholine (mAch) receptor[\\GENE] occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: [CHEMICAL]3H-N-methyl piperidyl benzilate[\\CHEMICAL] (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
        "label": 2,
        "major": 6,
        "len": 43
    },
    {
        "text": "UNLABELLED: Apparent [GENE]muscarinic acetylcholine (mAch) receptor[\\GENE] occupancy in mouse cerebral cortex, hippocampus, and striatum by [CHEMICAL]scopolamine[\\CHEMICAL], an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and [CHEMICAL]biperiden[\\CHEMICAL], a relatively selective [GENE]M1[\\GENE] antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).",
        "label": 6,
        "major": 6,
        "len": 43
    },
    {
        "text": "However, in virgin mice, [CHEMICAL]bezafibrate[\\CHEMICAL] and WY-14,643 do not significantly affect [GENE]UCP-3[\\GENE] mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams.",
        "label": 10,
        "major": 10,
        "len": 27
    },
    {
        "text": "However, in virgin mice, bezafibrate and [CHEMICAL]WY-14,643[\\CHEMICAL] do not significantly affect [GENE]UCP-3[\\GENE] mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams.",
        "label": 10,
        "major": 10,
        "len": 27
    },
    {
        "text": "[CHEMICAL]4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid[\\CHEMICAL] (WY-14,643), a specific ligand of the [GENE]PPAR-alpha[\\GENE] subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",
        "label": 2,
        "major": 3,
        "len": 38
    },
    {
        "text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ([CHEMICAL]WY-14,643[\\CHEMICAL]), a specific ligand of the [GENE]PPAR-alpha[\\GENE] subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",
        "label": 2,
        "major": 3,
        "len": 38
    },
    {
        "text": "Changes in [GENE]UCP-3[\\GENE] mRNA occur in parallel with modifications in the levels of free [CHEMICAL]fatty acids[\\CHEMICAL], which are reduced in lactation and are upregulated due to weaning or fasting.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Conversely, when mice are fed a high-fat diet after parturition, the downregulation of [GENE]UCP-3[\\GENE] mRNA and UCP-3 protein levels due to lactation is partially reversed, as is the reduction in serum free [CHEMICAL]fatty acid[\\CHEMICAL] levels.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "Conversely, when mice are fed a high-fat diet after parturition, the downregulation of UCP-3 mRNA and [GENE]UCP-3[\\GENE] protein levels due to lactation is partially reversed, as is the reduction in serum free [CHEMICAL]fatty acid[\\CHEMICAL] levels.",
        "label": 2,
        "major": 4,
        "len": 35
    },
    {
        "text": "However, in virgin mice, bezafibrate and WY-14,643 do not significantly affect [GENE]UCP-3[\\GENE] mRNA expression, whereas [CHEMICAL]troglitazone[\\CHEMICAL] is at least as effective as it is in lactating dams.",
        "label": 2,
        "major": 10,
        "len": 27
    },
    {
        "text": "It is proposed that the [GENE]UCP-3[\\GENE] gene is regulated in skeletal muscle during lactation in response to changes in circulating free [CHEMICAL]fatty acids[\\CHEMICAL] by mechanisms involving activation of PPARs.",
        "label": 2,
        "major": 3,
        "len": 29
    },
    {
        "text": "The impaired expression of the [GENE]UCP-3[\\GENE] gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of [CHEMICAL]fatty acids[\\CHEMICAL] as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.",
        "label": 2,
        "major": 4,
        "len": 47
    },
    {
        "text": "The impaired expression of the UCP-3 gene is consistent with the involvement of [GENE]UCP-3[\\GENE] gene regulation in the reduction of the use of [CHEMICAL]fatty acids[\\CHEMICAL] as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.",
        "label": 2,
        "major": 4,
        "len": 47
    },
    {
        "text": "Treatment of lactating mice with a single injection of [CHEMICAL]bezafibrate[\\CHEMICAL], an activator of the [GENE]peroxisome proliferator-activated receptor[\\GENE] (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "Treatment of lactating mice with a single injection of [CHEMICAL]bezafibrate[\\CHEMICAL], an activator of the peroxisome proliferator-activated receptor ([GENE]PPAR[\\GENE]), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas [CHEMICAL]troglitazone[\\CHEMICAL], a specific activator of [GENE]PPAR-gamma[\\GENE], also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",
        "label": 3,
        "major": 3,
        "len": 38
    },
    {
        "text": "It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free [CHEMICAL]fatty acids[\\CHEMICAL] by mechanisms involving activation of [GENE]PPARs[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 29
    },
    {
        "text": "Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and [CHEMICAL]troglitazone[\\CHEMICAL] reverse lactation-induced downregulation of the [GENE]uncoupling protein-3[\\GENE] gene.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Treatment of lactating mice with a single injection of [CHEMICAL]bezafibrate[\\CHEMICAL], an activator of the peroxisome proliferator-activated receptor (PPAR), raises [GENE]UCP-3[\\GENE] mRNA in skeletal muscle to levels similar to those in virgin mice.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid[\\CHEMICAL] (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in [GENE]UCP-3[\\GENE] mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",
        "label": 3,
        "major": 3,
        "len": 38
    },
    {
        "text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ([CHEMICAL]WY-14,643[\\CHEMICAL]), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in [GENE]UCP-3[\\GENE] mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.",
        "label": 3,
        "major": 3,
        "len": 38
    },
    {
        "text": "4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas [CHEMICAL]troglitazone[\\CHEMICAL], a specific activator of PPAR-gamma, also significantly increases [GENE]UCP-3[\\GENE] mRNA abundance in skeletal muscle of lactating mice.",
        "label": 3,
        "major": 3,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Retigabine[\\CHEMICAL], a novel anti-convulsant, enhances activation of KCNQ2/Q3 [GENE]potassium channels[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "This was the first study to investigate platelet [CHEMICAL][3H]paroxetine[\\CHEMICAL] binding in alcohol-dependent and age-matched control subjects in relation to the [GENE]5-HTTLPR[\\GENE] genotype.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "These results do not support previous results of altered [CHEMICAL][3H]paroxetine[\\CHEMICAL] binding sites in alcohol-dependent subjects or [GENE]5-HTTLPR[\\GENE] S-allele carriers.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Blood samples were taken from both alcohol-dependent and control subjects to determine [GENE]5-HTTLPR[\\GENE] genotypes using PCR of lymphocyte DNA, and to perform platelet [CHEMICAL][3H]paroxetine[\\CHEMICAL] binding (binding capacity: B(max); and dissociation constant: K(D)).",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "[GENE]Serotonin transporter[\\GENE] gene regulatory region polymorphism (5-HTTLPR), [CHEMICAL][3H]paroxetine[\\CHEMICAL] binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.",
        "label": 2,
        "major": 9,
        "len": 21
    },
    {
        "text": "Serotonin transporter gene regulatory region polymorphism ([GENE]5-HTTLPR[\\GENE]), [CHEMICAL][3H]paroxetine[\\CHEMICAL] binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of [CHEMICAL]arachidonic acid[\\CHEMICAL] and nonsteroidal anti-inflammatory drugs induces conformational changes in the [GENE]human prostaglandin endoperoxide H(2) synthase enzyme[\\GENE] (PGHS-2).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of [CHEMICAL]arachidonic acid[\\CHEMICAL] and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme ([GENE]PGHS-2[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-[CHEMICAL]steroidal[\\CHEMICAL] anti-inflammatory drugs alters the conformation of [GENE]PGHS[\\GENE], but the present experiments are the first to directly measure such changes.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The finding that [CHEMICAL]arachidonate[\\CHEMICAL] can also induce a conformational change in [GENE]PGHS-2[\\GENE] was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "The finding that [CHEMICAL]arachidonate[\\CHEMICAL] can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the [GENE]cyclooxygenase[\\GENE] catalytic mechanism.",
        "label": 2,
        "major": 3,
        "len": 31
    },
    {
        "text": "Line shape broadening resulting from spin-spin coupling of [CHEMICAL]nitroxide[\\CHEMICAL] pairs introduced into the membrane-binding helices of [GENE]PGHS-2[\\GENE] was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands.",
        "label": 2,
        "major": 2,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Arachidonic acid[\\CHEMICAL] and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 ([GENE]cyclooxygenase-2[\\GENE]).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Arachidonic acid[\\CHEMICAL] and nonsteroidal anti-inflammatory drugs induce conformational changes in the [GENE]human prostaglandin endoperoxide H2 synthase-2[\\GENE] (cyclooxygenase-2).",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Activation of extracellular signal-related kinase (ERK) 1 and 2, [GENE]c-Jun-N-terminal kinase (JNK) 1[\\GENE], and p38 was unaffected by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 19
    },
    {
        "text": "Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and [GENE]p38[\\GENE] was unaffected by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 19
    },
    {
        "text": "RESULTS: [GENE]NF-kappaB[\\GENE]/Rel activity induced by tumor necrosis factor alpha, [CHEMICAL]12-O-tetradecanoylphorbol-13-acetate[\\CHEMICAL], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/[GENE]Rel[\\GENE] activity induced by tumor necrosis factor alpha, [CHEMICAL]12-O-tetradecanoylphorbol-13-acetate[\\CHEMICAL], or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.",
        "label": 3,
        "major": 1,
        "len": 30
    },
    {
        "text": "The suppression of [GENE]NF-kappaB[\\GENE] activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "The suppression of NF-kappaB activation by inhibition of the [GENE]IKKs[\\GENE] contributes to the well-known anti-inflammatory and immunosuppressive effects of [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 20
    },
    {
        "text": "The aim of this study was to define the molecular mechanism by which [CHEMICAL]sulfasalazine[\\CHEMICAL] inhibits [GENE]NF-kappaB[\\GENE] activation.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "RESULTS: [GENE]NF-kappaB[\\GENE]/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/[GENE]Rel[\\GENE] activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of [GENE]NF-kappaB-inducing kinase[\\GENE], IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, [GENE]IKK-alpha[\\GENE], IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, [GENE]IKK-beta[\\GENE], or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active [GENE]IKK-alpha[\\GENE] and IKK-beta mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 1,
        "len": 30
    },
    {
        "text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and [GENE]IKK-beta[\\GENE] mutants was inhibited dose dependently by [CHEMICAL]sulfasalazine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] inhibited [GENE]tumor necrosis factor alpha[\\GENE]-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] inhibited tumor necrosis factor alpha-induced activation of endogenous [GENE]IKK[\\GENE] in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified [GENE]IKK-alpha[\\GENE] and IKK-beta in vitro.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and [GENE]IKK-beta[\\GENE] in vitro.",
        "label": 4,
        "major": 3,
        "len": 31
    },
    {
        "text": "Suppression of [GENE]NF-kappaB[\\GENE] activity by [CHEMICAL]sulfasalazine[\\CHEMICAL] is mediated by direct inhibition of IkappaB kinases alpha and beta.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of [GENE]IKKs[\\GENE] and can be antagonized by excess [CHEMICAL]adenosine triphosphate[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 26
    },
    {
        "text": "Selective COX-2 inhibitors, such as [CHEMICAL]meloxicam[\\CHEMICAL], celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, [CHEMICAL]celecoxib[\\CHEMICAL] (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib ([CHEMICAL]SC-58635[\\CHEMICAL]), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and [CHEMICAL]rofecoxib[\\CHEMICAL] (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ([CHEMICAL]MK-0966[\\CHEMICAL]), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not [GENE]COX-1[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 25
    },
    {
        "text": "For instance, [CHEMICAL]meloxicam[\\CHEMICAL] inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express [GENE]COX-2[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 30
    },
    {
        "text": "This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of [GENE]Bcl-2[\\GENE], as has been demonstrated for some nonselective NSAIDs, for instance, [CHEMICAL]flurbiprofen[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "In contrast, aspirin-like nonselective NSAIDs such as sulindac and [CHEMICAL]indomethacin[\\CHEMICAL] inhibit not only the enzymatic action of the highly inducible, proinflammatory [GENE]COX-2[\\GENE] but the constitutively expressed, cytoprotective COX-1 as well.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "In contrast, aspirin-like nonselective NSAIDs such as sulindac and [CHEMICAL]indomethacin[\\CHEMICAL] inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective [GENE]COX-1[\\GENE] as well.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Selective COX-2 inhibitors, such as [CHEMICAL]meloxicam[\\CHEMICAL], celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [GENE]COX-2[\\GENE] but not COX-1.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective [GENE]COX-2[\\GENE] inhibitors, such as [CHEMICAL]meloxicam[\\CHEMICAL], celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, [CHEMICAL]celecoxib[\\CHEMICAL] (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [GENE]COX-2[\\GENE] but not COX-1.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective [GENE]COX-2[\\GENE] inhibitors, such as meloxicam, [CHEMICAL]celecoxib[\\CHEMICAL] (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib ([CHEMICAL]SC-58635[\\CHEMICAL]), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [GENE]COX-2[\\GENE] but not COX-1.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective [GENE]COX-2[\\GENE] inhibitors, such as meloxicam, celecoxib ([CHEMICAL]SC-58635[\\CHEMICAL]), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and [CHEMICAL]rofecoxib[\\CHEMICAL] (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit [GENE]COX-2[\\GENE] but not COX-1.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective [GENE]COX-2[\\GENE] inhibitors, such as meloxicam, celecoxib (SC-58635), and [CHEMICAL]rofecoxib[\\CHEMICAL] (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ([CHEMICAL]MK-0966[\\CHEMICAL]), are NSAIDs that have been modified chemically to preferentially inhibit [GENE]COX-2[\\GENE] but not COX-1.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "Selective [GENE]COX-2[\\GENE] inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib ([CHEMICAL]MK-0966[\\CHEMICAL]), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.",
        "label": 4,
        "major": 10,
        "len": 25
    },
    {
        "text": "For instance, [CHEMICAL]meloxicam[\\CHEMICAL] inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express [GENE]COX-2[\\GENE] but has no effect on HCT-116 tumor cells that do not express COX-2.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "In contrast, [CHEMICAL]aspirin[\\CHEMICAL]-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory [GENE]COX-2[\\GENE] but the constitutively expressed, cytoprotective COX-1 as well.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "In contrast, [CHEMICAL]aspirin[\\CHEMICAL]-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective [GENE]COX-1[\\GENE] as well.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In contrast, aspirin-like nonselective NSAIDs such as [CHEMICAL]sulindac[\\CHEMICAL] and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory [GENE]COX-2[\\GENE] but the constitutively expressed, cytoprotective COX-1 as well.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "In contrast, aspirin-like nonselective NSAIDs such as [CHEMICAL]sulindac[\\CHEMICAL] and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective [GENE]COX-1[\\GENE] as well.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[GENE]COX-2[\\GENE] produces [CHEMICAL]prostaglandins[\\CHEMICAL] that inhibit apoptosis and stimulate angiogenesis and invasiveness.",
        "label": 9,
        "major": 4,
        "len": 11
    },
    {
        "text": "For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), [GENE]AAAD[\\GENE] activity was correlated with the potency of [CHEMICAL]carbidopa[\\CHEMICAL]-induced cytotoxicity.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors [CHEMICAL]carbidopa[\\CHEMICAL] (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors carbidopa ([CHEMICAL]alpha-methyl-dopahydrazine[\\CHEMICAL]), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors carbidopa (alpha-methyl-dopahydrazine), [CHEMICAL]alpha-monofluoromethyldopa[\\CHEMICAL] (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa ([CHEMICAL]MFMD[\\CHEMICAL]), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and [CHEMICAL]3-hydroxybenzylhydrazine[\\CHEMICAL] (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, [GENE]AAAD[\\GENE] inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine ([CHEMICAL]NSD-1015[\\CHEMICAL]) were incubated (72 h) with NCI-H727 human lung carcinoid cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "In a search for less flexible analogues of caproctamine (1), a diamine [CHEMICAL]diamide[\\CHEMICAL] endowed with an interesting [GENE]AChE[\\GENE] affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "In a search for less flexible analogues of [CHEMICAL]caproctamine[\\CHEMICAL] (1), a diamine diamide endowed with an interesting [GENE]AChE[\\GENE] affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "In a search for less flexible analogues of caproctamine (1), a [CHEMICAL]diamine[\\CHEMICAL] diamide endowed with an interesting [GENE]AChE[\\GENE] affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.",
        "label": 2,
        "major": 2,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Hexahydrochromeno[4,3-b]pyrrole[\\CHEMICAL] derivatives as [GENE]acetylcholinesterase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 5
    },
    {
        "text": "Since this compound retains good [GENE]AChE[\\GENE] inhibitory activity and its [CHEMICAL]hexahydrochromeno[4,3-b]pyrrole[\\CHEMICAL] moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Since this compound retains good [GENE]AChE[\\GENE] inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the [CHEMICAL]hexahydropyrrolo[2,3-b]indole of physostigmine[\\CHEMICAL] (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Moreover, it was suggested that promotion of [GENE]CYP11A1[\\GENE] mRNA expression in Th2 cells was partially involved due to an increase in level of [CHEMICAL]corticosterone[\\CHEMICAL] in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor-bearing mice.",
        "label": 2,
        "major": 3,
        "len": 54
    },
    {
        "text": "When the anti-corticosterone drug [CHEMICAL]aminoglutethimide[\\CHEMICAL] (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and [GENE]CYP11A1[\\GENE] mRNA expression were decreased at 14 days after tumor inoculation.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "When the anti-corticosterone drug [CHEMICAL]aminoglutethimide[\\CHEMICAL] ([GENE]CYP11A1[\\GENE] inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive [GENE]NADH-->UQ oxidoreductase[\\GENE] activity of complex I, which was insensitive to [CHEMICAL]cAMP[\\CHEMICAL] stimulation.",
        "label": 10,
        "major": 3,
        "len": 23
    },
    {
        "text": "Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive NADH-->UQ oxidoreductase activity of [GENE]complex I[\\GENE], which was insensitive to [CHEMICAL]cAMP[\\CHEMICAL] stimulation.",
        "label": 10,
        "major": 3,
        "len": 23
    },
    {
        "text": "Furthermore, h[[CHEMICAL]Gly2[\\CHEMICAL]]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the [GENE]GLP-2 receptor[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "We report here that a human degradation-resistant [GENE]GLP-2[\\GENE] analogue, h[[CHEMICAL]Gly2[\\CHEMICAL]]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil.",
        "label": 2,
        "major": 4,
        "len": 39
    },
    {
        "text": "Furthermore, h[[CHEMICAL]Gly2[\\CHEMICAL]]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited [GENE]poly(ADP-ribose) polymerase[\\GENE] cleavage in heterologous cells transfected with the GLP-2 receptor.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of [GENE]topoisomerase I[\\GENE] inhibitor [CHEMICAL]irinotecan hydrochloride[\\CHEMICAL] or the antimetabolite 5-fluorouracil.",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "OBJECTIVES: The hypothesis of the present study was that differences among [GENE]dopamine transporter[\\GENE] (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [CHEMICAL]DA[\\CHEMICAL] uptake inhibitors.",
        "label": 9,
        "major": 4,
        "len": 33
    },
    {
        "text": "OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter ([GENE]DAT[\\GENE]) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [CHEMICAL]DA[\\CHEMICAL] uptake inhibitors.",
        "label": 9,
        "major": 4,
        "len": 33
    },
    {
        "text": "Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of [GENE]NKCC1[\\GENE]-mediated [CHEMICAL]Cl-[\\CHEMICAL] transport.",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Contribution of the [GENE]Na+-K+-2Cl- cotransporter[\\GENE] NKCC1 to [CHEMICAL]Cl-[\\CHEMICAL] secretion in rat OMCD.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "Contribution of the Na+-K+-2Cl- cotransporter [GENE]NKCC1[\\GENE] to [CHEMICAL]Cl-[\\CHEMICAL] secretion in rat OMCD.",
        "label": 9,
        "major": 9,
        "len": 12
    },
    {
        "text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through [CHEMICAL]Cl-[\\CHEMICAL] uptake across the basolateral membrane mediated by [GENE]NKCC1[\\GENE] in series with Cl- efflux across the apical membrane.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by [GENE]NKCC1[\\GENE] in series with [CHEMICAL]Cl-[\\CHEMICAL] efflux across the apical membrane.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "This mutation is the first described in exon 9 and impairs the last 27 [CHEMICAL]amino acids[\\CHEMICAL] of the [GENE]hormone-binding domain[\\GENE].",
        "label": 1,
        "major": 1,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Domperidone[\\CHEMICAL] and haloperidol, which have affinity for [GENE]dopamine D3 receptor[\\GENE], also inhibited R(+)-7-OH-DPAT-induced hypothermia.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Domperidone and [CHEMICAL]haloperidol[\\CHEMICAL], which have affinity for [GENE]dopamine D3 receptor[\\GENE], also inhibited R(+)-7-OH-DPAT-induced hypothermia.",
        "label": 2,
        "major": 3,
        "len": 14
    },
    {
        "text": "Domperidone and haloperidol, which have affinity for [GENE]dopamine D3 receptor[\\GENE], also inhibited [CHEMICAL]R(+)-7-OH-DPAT[\\CHEMICAL]-induced hypothermia.",
        "label": 2,
        "major": 4,
        "len": 14
    },
    {
        "text": "In mice, [CHEMICAL]AS-8112[\\CHEMICAL] (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [GENE]dopamine D3 receptor[\\GENE] agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",
        "label": 4,
        "major": 3,
        "len": 25
    },
    {
        "text": "In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of [CHEMICAL]2-methyl-5HT[\\CHEMICAL], a [GENE]5-HT3 receptor[\\GENE] agonist (pA2 value of 7.04).",
        "label": 5,
        "major": 9,
        "len": 23
    },
    {
        "text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [GENE]dopamine D3 receptor[\\GENE] agonist; [CHEMICAL]R(+)-7-OH-DPAT[\\CHEMICAL] (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).",
        "label": 5,
        "major": 3,
        "len": 25
    },
    {
        "text": "In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the [GENE]dopamine D3 receptor[\\GENE] agonist; R(+)-7-OH-DPAT ([CHEMICAL]R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline[\\CHEMICAL]) (0.3 mg kg(-1) s.c.).",
        "label": 5,
        "major": 4,
        "len": 25
    },
    {
        "text": "In guinea-pig isolated colon, [CHEMICAL]AS-8112[\\CHEMICAL] produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a [GENE]5-HT3 receptor[\\GENE] agonist (pA2 value of 7.04).",
        "label": 6,
        "major": 9,
        "len": 23
    },
    {
        "text": "Other [GENE]5-HT3 receptor[\\GENE] antagonists also produced such a shift in the following antagonistic-potency order: [CHEMICAL]granisetron[\\CHEMICAL]> ondansetron=AS-8112>>metoclopramide.",
        "label": 6,
        "major": 9,
        "len": 16
    },
    {
        "text": "Other [GENE]5-HT3 receptor[\\GENE] antagonists also produced such a shift in the following antagonistic-potency order: granisetron> [CHEMICAL]ondansetron[\\CHEMICAL]=AS-8112>>metoclopramide.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "Other [GENE]5-HT3 receptor[\\GENE] antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=[CHEMICAL]AS-8112[\\CHEMICAL]>>metoclopramide.",
        "label": 6,
        "major": 9,
        "len": 16
    },
    {
        "text": "Other [GENE]5-HT3 receptor[\\GENE] antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>>[CHEMICAL]metoclopramide[\\CHEMICAL].",
        "label": 6,
        "major": 9,
        "len": 16
    },
    {
        "text": "The broad-spectrum anti-emetic activity of [CHEMICAL]AS-8112[\\CHEMICAL], a novel dopamine D2, D3 and [GENE]5-HT3 receptors[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 15
    },
    {
        "text": "In conclusion, [CHEMICAL]AS-8112[\\CHEMICAL] is a potent dopamine D2, D3 and [GENE]5-HT3 receptors[\\GENE] antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.",
        "label": 6,
        "major": 6,
        "len": 24
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), [CHEMICAL]Arg[\\CHEMICAL](125), Arg(165), Lys(169), Lys(236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), [CHEMICAL]Arg[\\CHEMICAL](125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), [CHEMICAL]Arg[\\CHEMICAL](165), Lys(169), Lys(236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), [CHEMICAL]Arg[\\CHEMICAL](165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), [CHEMICAL]Lys[\\CHEMICAL](169), Lys(236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), [CHEMICAL]Lys[\\CHEMICAL](169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), [CHEMICAL]Lys[\\CHEMICAL](236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), [CHEMICAL]Lys[\\CHEMICAL](236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and [CHEMICAL]Arg[\\CHEMICAL](240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and [CHEMICAL]Arg[\\CHEMICAL](240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues [CHEMICAL]Arg[\\CHEMICAL](93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues [CHEMICAL]Arg[\\CHEMICAL](93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), [CHEMICAL]Lys[\\CHEMICAL](96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) ([GENE]chymotrypsin[\\GENE] numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "Recent studies have indicated that the basic residues Arg(93), [CHEMICAL]Lys[\\CHEMICAL](96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of [GENE]factor Xa[\\GENE] that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.",
        "label": 1,
        "major": 2,
        "len": 50
    },
    {
        "text": "[CHEMICAL]Rofecoxib[\\CHEMICAL] is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the [GENE]COX-1[\\GENE] isoenzyme at doses up to 1000 mg/day.",
        "label": 10,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Rofecoxib[\\CHEMICAL] is a selective [GENE]cyclo-oxygenase (COX)-2[\\GENE] inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "[CHEMICAL]Fibrates[\\CHEMICAL] bind to the [GENE]peroxisome proliferator-activated receptor (PPAR)-alpha[\\GENE], and thiazolidinediones are ligands of PPAR-gamma.",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and [CHEMICAL]thiazolidinediones[\\CHEMICAL] are ligands of [GENE]PPAR-gamma[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Fenofibrate[\\CHEMICAL] and GW2331 induced expression of [GENE]acyl-coenzyme A (CoA) oxidase[\\GENE] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Fenofibrate[\\CHEMICAL] and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and [GENE]enoyl-CoA hydratase[\\GENE] and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Fenofibrate and [CHEMICAL]GW2331[\\CHEMICAL] induced expression of [GENE]acyl-coenzyme A (CoA) oxidase[\\GENE] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Fenofibrate and [CHEMICAL]GW2331[\\CHEMICAL] induced expression of acyl-coenzyme A (CoA) oxidase and [GENE]enoyl-CoA hydratase[\\GENE] and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rosiglitazone[\\CHEMICAL] modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of [GENE]glucose transporter 4[\\GENE] and phosphoenolpyruvate carboxykinase in adipose tissue.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Rosiglitazone[\\CHEMICAL] modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and [GENE]phosphoenolpyruvate carboxykinase[\\GENE] in adipose tissue.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Rosiglitazone[\\CHEMICAL] modestly increased [GENE]apolipoprotein C-III[\\GENE] mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.",
        "label": 3,
        "major": 3,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Fenofibrate[\\CHEMICAL] and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [GENE]apolipoprotein C-III[\\GENE] and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Fenofibrate[\\CHEMICAL] and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and [GENE]phosphoenolpyruvate carboxykinase[\\GENE] mRNAs.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Fenofibrate and [CHEMICAL]GW2331[\\CHEMICAL] induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [GENE]apolipoprotein C-III[\\GENE] and phosphoenolpyruvate carboxykinase mRNAs.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Fenofibrate and [CHEMICAL]GW2331[\\CHEMICAL] induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and [GENE]phosphoenolpyruvate carboxykinase[\\GENE] mRNAs.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "We have previously isolated from human hemofiltrate an [CHEMICAL]N[\\CHEMICAL]-terminally truncated form of the [GENE]hemofiltrate CC chemokine 1[\\GENE] (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.",
        "label": 1,
        "major": 5,
        "len": 34
    },
    {
        "text": "We have previously isolated from human hemofiltrate an [CHEMICAL]N[\\CHEMICAL]-terminally truncated form of the hemofiltrate CC chemokine 1 ([GENE]HCC-1[\\GENE]), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.",
        "label": 1,
        "major": 5,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Long-chain alkanols[\\CHEMICAL] are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the [GENE]AChR[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Cembranoid[\\CHEMICAL] and long-chain alkanol sites on the [GENE]nicotinic acetylcholine receptor[\\GENE] and their allosteric interaction.",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "Cembranoid and [CHEMICAL]long-chain alkanol[\\CHEMICAL] sites on the [GENE]nicotinic acetylcholine receptor[\\GENE] and their allosteric interaction.",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Long-chain alkanols[\\CHEMICAL] are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [GENE]nicotinic acetylcholine receptor[\\GENE] (AChR) by binding to one or more specific sites on the AChR.",
        "label": 4,
        "major": 2,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Cembranoids[\\CHEMICAL] are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal [GENE]AChRs[\\GENE], which have no demonstrable general anesthetic activity in vivo.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "The [GENE]x(c)- cystine transporter[\\GENE] represents a novel target for [CHEMICAL]sulfasalazine[\\CHEMICAL]-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL] was fortuitously found to be a novel, potent inhibitor of the [GENE]x(c)- transporter[\\GENE].",
        "label": 4,
        "major": 9,
        "len": 14
    },
    {
        "text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [GENE]x(c)[\\GENE]--mediated cystine uptake, in contrast to its colonic metabolites, [CHEMICAL]sulfapyridine[\\CHEMICAL] and 5-aminosalicylic acid.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [GENE]x(c)[\\GENE]--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and [CHEMICAL]5-aminosalicylic acid[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Sulfasalazine[\\CHEMICAL], a potent suppressor of lymphoma growth by inhibition of the [GENE]x(c)- cystine transporter[\\GENE]: a new action for an old drug.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of [GENE]x(c)[\\GENE]--mediated [CHEMICAL]cystine[\\CHEMICAL] uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.",
        "label": 9,
        "major": 4,
        "len": 33
    },
    {
        "text": "The [GENE]x(c)- cystine transporter[\\GENE] represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular [CHEMICAL]cyst(e)ine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "Like conventional ACE inhibitors, [CHEMICAL]omapatrilat[\\CHEMICAL] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of [GENE]atrial and brain natriuretic peptides[\\GENE] and bradykinin.",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Like conventional ACE inhibitors, [CHEMICAL]omapatrilat[\\CHEMICAL] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and [GENE]bradykinin[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 23
    },
    {
        "text": "Like conventional [GENE]ACE[\\GENE] inhibitors, [CHEMICAL]omapatrilat[\\CHEMICAL] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with [CHEMICAL]omapatrilat[\\CHEMICAL], a [GENE]vasopeptidase[\\GENE] inhibitor.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Omapatrilat[\\CHEMICAL], the prototypical [GENE]vasopeptidase[\\GENE] inhibitor, inhibits not only ACE but also neutral endopeptidase.",
        "label": 4,
        "major": 10,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Omapatrilat[\\CHEMICAL], the prototypical vasopeptidase inhibitor, inhibits not only [GENE]ACE[\\GENE] but also neutral endopeptidase.",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Omapatrilat[\\CHEMICAL], the prototypical vasopeptidase inhibitor, inhibits not only ACE but also [GENE]neutral endopeptidase[\\GENE].",
        "label": 4,
        "major": 10,
        "len": 13
    },
    {
        "text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to [CHEMICAL]Na+[\\CHEMICAL]-H+ exchange ([GENE]NHE1[\\GENE] isoform).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-[CHEMICAL]H+[\\CHEMICAL] exchange ([GENE]NHE1[\\GENE] isoform).",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce [GENE]BiP[\\GENE] expression.",
        "label": 10,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and salicylate bind to [GENE]immunoglobulin heavy chain binding protein[\\GENE] (BiP) and inhibit its ATPase activity in human fibroblasts.",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Aspirin and [CHEMICAL]salicylate[\\CHEMICAL] bind to [GENE]immunoglobulin heavy chain binding protein[\\GENE] (BiP) and inhibit its ATPase activity in human fibroblasts.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "Salicylates inhibited [GENE]ATPase[\\GENE] activity stimulated by this specific heptapeptide but did not block [CHEMICAL]ATP[\\CHEMICAL] binding or induce BiP expression.",
        "label": 2,
        "major": 3,
        "len": 19
    },
    {
        "text": "These results indicate that [CHEMICAL]salicylates[\\CHEMICAL] bind specifically to the polypeptide binding site of [GENE]BiP[\\GENE] in human cells that may interfere with folding and transport of proteins important in inflammation.",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The Kd values of [CHEMICAL]SA[\\CHEMICAL] binding to crude extract and to recombinant [GENE]BiP[\\GENE] were 45.2 and 54.6 microM, respectively.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Salicylates[\\CHEMICAL] inhibited [GENE]ATPase[\\GENE] activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Aspirin[\\CHEMICAL] and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [GENE]ATPase[\\GENE] activity in human fibroblasts.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Aspirin and [CHEMICAL]salicylate[\\CHEMICAL] bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its [GENE]ATPase[\\GENE] activity in human fibroblasts.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "The specific activity of only [GENE]ornithine aminotransferase[\\GENE] (OAT), the rate-limiting enzyme in the conversion of ornithine to [CHEMICAL]proline[\\CHEMICAL], increased in 2 weeks of hypertrophy.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "The specific activity of only ornithine aminotransferase ([GENE]OAT[\\GENE]), the rate-limiting enzyme in the conversion of ornithine to [CHEMICAL]proline[\\CHEMICAL], increased in 2 weeks of hypertrophy.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "The specific activity of only [GENE]ornithine aminotransferase[\\GENE] (OAT), the rate-limiting enzyme in the conversion of [CHEMICAL]ornithine[\\CHEMICAL] to proline, increased in 2 weeks of hypertrophy.",
        "label": 9,
        "major": 3,
        "len": 24
    },
    {
        "text": "The specific activity of only ornithine aminotransferase ([GENE]OAT[\\GENE]), the rate-limiting enzyme in the conversion of [CHEMICAL]ornithine[\\CHEMICAL] to proline, increased in 2 weeks of hypertrophy.",
        "label": 9,
        "major": 3,
        "len": 24
    },
    {
        "text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and [CHEMICAL]thromboxane B2[\\CHEMICAL] (as a biomarker for [GENE]COX-1[\\GENE] activity) with parallel assessments of pain.",
        "label": 2,
        "major": 9,
        "len": 44
    },
    {
        "text": "Celecoxib selectively suppressed PGE2 but not [CHEMICAL]TxB2[\\CHEMICAL] at time points consistent with [GENE]COX-2[\\GENE] activity, while producing analgesia.",
        "label": 2,
        "major": 9,
        "len": 17
    },
    {
        "text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective [GENE]cyclooxygenase (COX)-2[\\GENE] inhibitor ([CHEMICAL]celecoxib[\\CHEMICAL]) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual [GENE]COX-1[\\GENE]/COX-2 inhibitor ([CHEMICAL]ketorolac[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/[GENE]COX-2[\\GENE] inhibitor ([CHEMICAL]ketorolac[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 42
    },
    {
        "text": "[CHEMICAL]Celecoxib[\\CHEMICAL] selectively suppressed PGE2 but not TxB2 at time points consistent with [GENE]COX-2[\\GENE] activity, while producing analgesia.",
        "label": 4,
        "major": 10,
        "len": 17
    },
    {
        "text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of [CHEMICAL]prostaglandin E2[\\CHEMICAL] (PGE2; a product of both [GENE]COX-1[\\GENE] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of [CHEMICAL]prostaglandin E2[\\CHEMICAL] (PGE2; a product of both COX-1 and [GENE]COX-2[\\GENE]) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ([CHEMICAL]PGE2[\\CHEMICAL]; a product of both [GENE]COX-1[\\GENE] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ([CHEMICAL]PGE2[\\CHEMICAL]; a product of both COX-1 and [GENE]COX-2[\\GENE]) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.",
        "label": 9,
        "major": 9,
        "len": 44
    },
    {
        "text": "The time course of [CHEMICAL]PGE2[\\CHEMICAL] production was consistent with early release due to [GENE]COX-1[\\GENE] activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "The time course of [CHEMICAL]PGE2[\\CHEMICAL] production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with [GENE]COX-2[\\GENE] expression.",
        "label": 9,
        "major": 3,
        "len": 27
    },
    {
        "text": "Celecoxib selectively suppressed [CHEMICAL]PGE2[\\CHEMICAL] but not TxB2 at time points consistent with [GENE]COX-2[\\GENE] activity, while producing analgesia.",
        "label": 9,
        "major": 10,
        "len": 17
    },
    {
        "text": "These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of [GENE]COX-2[\\GENE] mediated [CHEMICAL]PGE2[\\CHEMICAL] is temporally related to NSAID analgesia.",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "These data indicate that a [CHEMICAL][3H]dofetilide[\\CHEMICAL] binding assay using [GENE]HERG[\\GENE] membranes may help identify compounds that prolong the QT interval.",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL][3H]dofetilide[\\CHEMICAL] binding to [GENE]HERG[\\GENE] transfected membranes: a potential high throughput preclinical screen.",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "Acute and chronic [CHEMICAL]PLZ[\\CHEMICAL] administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, [GENE]GABA transaminase[\\GENE] (GABA-T).",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Acute and chronic [CHEMICAL]PLZ[\\CHEMICAL] administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase ([GENE]GABA-T[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of [CHEMICAL]PLZ[\\CHEMICAL] on [GENE]alanine transaminase[\\GENE] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
        "label": 4,
        "major": 9,
        "len": 43
    },
    {
        "text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of [CHEMICAL]PLZ[\\CHEMICAL] on alanine transaminase ([GENE]ALA-T[\\GENE]), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
        "label": 4,
        "major": 3,
        "len": 43
    },
    {
        "text": "In addition, we also showed that the elevation in alanine levels and the inhibition of [GENE]alanine transaminase[\\GENE] in the brain are retained after 14 days of [CHEMICAL]PLZ[\\CHEMICAL] treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "In the study reported here, the effects of acute PLZ treatment on the levels of various [CHEMICAL]amino acids[\\CHEMICAL], some of which are also metabolized by [GENE]pyridoxal phosphate-dependent transaminases[\\GENE] were compared in rat whole brain.",
        "label": 9,
        "major": 1,
        "len": 34
    },
    {
        "text": "In addition, we also showed that the elevation in [CHEMICAL]alanine[\\CHEMICAL] levels and the inhibition of [GENE]alanine transaminase[\\GENE] in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.",
        "label": 9,
        "major": 3,
        "len": 40
    },
    {
        "text": "The elevation in brain [CHEMICAL]alanine[\\CHEMICAL] levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [GENE]alanine transaminase[\\GENE] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
        "label": 9,
        "major": 9,
        "len": 43
    },
    {
        "text": "The elevation in brain [CHEMICAL]alanine[\\CHEMICAL] levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ([GENE]ALA-T[\\GENE]), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.",
        "label": 9,
        "major": 3,
        "len": 43
    },
    {
        "text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the [CHEMICAL]GABA[\\CHEMICAL] metabolizing enzyme, [GENE]GABA transaminase[\\GENE] (GABA-T).",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the [CHEMICAL]GABA[\\CHEMICAL] metabolizing enzyme, GABA transaminase ([GENE]GABA-T[\\GENE]).",
        "label": 9,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]Cyclooxygenase-1[\\GENE] (COX-1) inhibitors ([CHEMICAL]flurbiprofen[\\CHEMICAL], ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 ([GENE]COX-1[\\GENE]) inhibitors ([CHEMICAL]flurbiprofen[\\CHEMICAL], ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Cyclooxygenase-1[\\GENE] (COX-1) inhibitors (flurbiprofen, [CHEMICAL]ketoprofen[\\CHEMICAL] and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 ([GENE]COX-1[\\GENE]) inhibitors (flurbiprofen, [CHEMICAL]ketoprofen[\\CHEMICAL] and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "[GENE]Cyclooxygenase-1[\\GENE] (COX-1) inhibitors (flurbiprofen, ketoprofen and [CHEMICAL]ketrolack[\\CHEMICAL]) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 ([GENE]COX-1[\\GENE]) inhibitors (flurbiprofen, ketoprofen and [CHEMICAL]ketrolack[\\CHEMICAL]) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitors at high concentrations ([CHEMICAL]nimesulide[\\CHEMICAL] and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitors at high concentrations ([CHEMICAL]nimesulide[\\CHEMICAL] and NS-389) slightly attenuated the contraction.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and [GENE]cyclooxygenase-2[\\GENE] (COX-2) inhibitors at high concentrations (nimesulide and [CHEMICAL]NS-389[\\CHEMICAL]) slightly attenuated the contraction.",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 ([GENE]COX-2[\\GENE]) inhibitors at high concentrations (nimesulide and [CHEMICAL]NS-389[\\CHEMICAL]) slightly attenuated the contraction.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "A [GENE]TXA2 synthetase[\\GENE] inhibitor ([CHEMICAL]OKY-046[\\CHEMICAL]) attenuated the contraction to a small extent only at high concentrations.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "A [GENE]TXA2 receptor[\\GENE] antagonist ([CHEMICAL]S-1452[\\CHEMICAL]) attenuated the contraction in a concentration-dependent manner.",
        "label": 6,
        "major": 6,
        "len": 12
    },
    {
        "text": "A [GENE]nicotinic receptor[\\GENE] antagonist ([CHEMICAL]hexamethonium[\\CHEMICAL]) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an [GENE]alpha-adrenoceptor[\\GENE] antagonist ([CHEMICAL]prazosin[\\CHEMICAL]) nearly abolished the contraction.",
        "label": 6,
        "major": 6,
        "len": 19
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, [CHEMICAL]zomepirac[\\CHEMICAL], indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, [CHEMICAL]indomethacin[\\CHEMICAL], diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, [CHEMICAL]diclofenac[\\CHEMICAL] and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and [CHEMICAL]meclofenamic acid[\\CHEMICAL] were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: [CHEMICAL]rofecoxib[\\CHEMICAL], ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, [CHEMICAL]ketoprofen[\\CHEMICAL], suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, [CHEMICAL]suprofen[\\CHEMICAL], carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, [CHEMICAL]carprofen[\\CHEMICAL], zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 2,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, [CHEMICAL]zomepirac[\\CHEMICAL], indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, [CHEMICAL]indomethacin[\\CHEMICAL], diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, [CHEMICAL]diclofenac[\\CHEMICAL] and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and [CHEMICAL]meclofenamic acid[\\CHEMICAL] were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Non-[CHEMICAL]steroidal[\\CHEMICAL] anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [GENE]cyclooxygenase[\\GENE] (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-[CHEMICAL]steroidal[\\CHEMICAL] anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ([GENE]COX[\\GENE]), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: [CHEMICAL]rofecoxib[\\CHEMICAL], ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, [CHEMICAL]ketoprofen[\\CHEMICAL], suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, [CHEMICAL]suprofen[\\CHEMICAL], carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Accordingly, docking of different [GENE]COX[\\GENE] inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, [CHEMICAL]carprofen[\\CHEMICAL], zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [GENE]cyclooxygenase[\\GENE] (COX), the enzyme that mediates biosynthesis of [CHEMICAL]prostaglandins[\\CHEMICAL] and thromboxanes from arachidonic acid.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ([GENE]COX[\\GENE]), the enzyme that mediates biosynthesis of [CHEMICAL]prostaglandins[\\CHEMICAL] and thromboxanes from arachidonic acid.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [GENE]cyclooxygenase[\\GENE] (COX), the enzyme that mediates biosynthesis of prostaglandins and [CHEMICAL]thromboxanes[\\CHEMICAL] from arachidonic acid.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ([GENE]COX[\\GENE]), the enzyme that mediates biosynthesis of prostaglandins and [CHEMICAL]thromboxanes[\\CHEMICAL] from arachidonic acid.",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of [GENE]cyclooxygenase[\\GENE] (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from [CHEMICAL]arachidonic acid[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase ([GENE]COX[\\GENE]), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from [CHEMICAL]arachidonic acid[\\CHEMICAL].",
        "label": 9,
        "major": 4,
        "len": 22
    },
    {
        "text": "ICI 182,780 (fulvestrant) (Faslodex) and [CHEMICAL]ICI 164,384[\\CHEMICAL] are competitive inhibitors of estrogen by binding to the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "ICI 182,780 (fulvestrant) (Faslodex) and [CHEMICAL]ICI 164,384[\\CHEMICAL] are competitive inhibitors of estrogen by binding to the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of [CHEMICAL]estrogen[\\CHEMICAL] by binding to the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of [CHEMICAL]estrogen[\\CHEMICAL] by binding to the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "[CHEMICAL]EM-800[\\CHEMICAL] and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to [GENE]ER[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "EM-800 and [CHEMICAL]EM-652[\\CHEMICAL] are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to [GENE]ER[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "EM-800 and EM-652 are the most potent pure antiestrogens and [CHEMICAL]EM-652[\\CHEMICAL] has the highest affinity of all antiestrogens to [GENE]ER[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 20
    },
    {
        "text": "[CHEMICAL]ICI 182,780[\\CHEMICAL] (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]ICI 182,780[\\CHEMICAL] (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "ICI 182,780 ([CHEMICAL]fulvestrant[\\CHEMICAL]) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "ICI 182,780 ([CHEMICAL]fulvestrant[\\CHEMICAL]) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "ICI 182,780 (fulvestrant) ([CHEMICAL]Faslodex[\\CHEMICAL]) and ICI 164,384 are competitive inhibitors of estrogen by binding to the [GENE]estrogen receptor[\\GENE] (ER).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "ICI 182,780 (fulvestrant) ([CHEMICAL]Faslodex[\\CHEMICAL]) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor ([GENE]ER[\\GENE]).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "Olopatadine hydrochloride ([CHEMICAL]olopatadine[\\CHEMICAL], 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[GENE]histamine H1-receptor[\\GENE] antagonistic drug that was synthesized and evaluated in our laboratories.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Olopatadine hydrochloride (olopatadine, [CHEMICAL]11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride[\\CHEMICAL]) is a novel antiallergic/[GENE]histamine H1-receptor[\\GENE] antagonistic drug that was synthesized and evaluated in our laboratories.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Olopatadine[\\CHEMICAL] is a selective [GENE]histamine H1-receptor[\\GENE] antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Olopatadine hydrochloride[\\CHEMICAL] (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[GENE]histamine H1-receptor[\\GENE] antagonistic drug that was synthesized and evaluated in our laboratories.",
        "label": 6,
        "major": 6,
        "len": 21
    },
    {
        "text": "Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter ([GENE]5HTT[\\GENE]), may mediate central effects of [CHEMICAL]cocaine[\\CHEMICAL] and may also be involved in impulsive and aggressive behavior.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "Considerable evidence indicates that serotonergic mechanisms, particularly the [GENE]serotonin transporter[\\GENE] (5HTT), may mediate central effects of [CHEMICAL]cocaine[\\CHEMICAL] and may also be involved in impulsive and aggressive behavior.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of [GENE]HDAC[\\GENE] which is subsequently recruited by [CHEMICAL]corticosteroids[\\CHEMICAL] to suppress inflammatory genes.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "This increased [GENE]HDAC[\\GENE] activity is then available for [CHEMICAL]corticosteroid[\\CHEMICAL] recruitment and predicts a cooperative interaction between corticosteroids and theophylline.",
        "label": 2,
        "major": 2,
        "len": 19
    },
    {
        "text": "A molecular mechanism of action of [CHEMICAL]theophylline[\\CHEMICAL]: Induction of [GENE]histone deacetylase[\\GENE] activity to decrease inflammatory gene expression.",
        "label": 3,
        "major": 4,
        "len": 17
    },
    {
        "text": "Thus we have shown that low-dose [CHEMICAL]theophylline[\\CHEMICAL] exerts an anti-asthma effect through increasing activation of [GENE]HDAC[\\GENE] which is subsequently recruited by corticosteroids to suppress inflammatory genes.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "In conclusion, these results show that [CHEMICAL]rifamycin SV[\\CHEMICAL] and rifampicin interact with [GENE]OATP[\\GENE]-mediated substrate transport to different extents.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "In conclusion, these results show that rifamycin SV and [CHEMICAL]rifampicin[\\CHEMICAL] interact with [GENE]OATP[\\GENE]-mediated substrate transport to different extents.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "Inhibition of [GENE]human liver OATPs[\\GENE] can explain the previously observed effects of [CHEMICAL]rifamycin SV[\\CHEMICAL] and rifampicin on hepatic organic anion elimination.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Inhibition of [GENE]human liver OATPs[\\GENE] can explain the previously observed effects of rifamycin SV and [CHEMICAL]rifampicin[\\CHEMICAL] on hepatic organic anion elimination.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited [GENE]human organic anion transporting polypeptide C[\\GENE] (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C ([GENE]SLC21A6[\\GENE]) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) ([GENE]OATP-C[\\GENE]), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), [GENE]human organic anion transporting polypeptide 8[\\GENE] (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 ([GENE]SLC21A8[\\GENE]) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) ([GENE]OATP8[\\GENE]), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), [GENE]human organic anion transporting polypeptide B[\\GENE] (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B ([GENE]SLC21A9[\\GENE]) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) ([GENE]OATP-B[\\GENE]), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and [GENE]human organic anion transporting polypeptide A[\\GENE] (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A ([GENE]SLC21A3[\\GENE]) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 9,
        "len": 62
    },
    {
        "text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, [CHEMICAL]rifamycin SV[\\CHEMICAL] (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) ([GENE]OATP-A[\\GENE]) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.",
        "label": 4,
        "major": 4,
        "len": 62
    },
    {
        "text": "[CHEMICAL]Rifampicin[\\CHEMICAL] (10 micromol/L) inhibited [GENE]OATP8[\\GENE]-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rifampicin[\\CHEMICAL] (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of [GENE]OATP-C[\\GENE]-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",
        "label": 4,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rifampicin[\\CHEMICAL] (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, [GENE]OATP-B[\\GENE]-, and OATP-A-mediated BSP transport was below 15%.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Rifampicin[\\CHEMICAL] (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and [GENE]OATP-A[\\GENE]-mediated BSP transport was below 15%.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "In rats, [CHEMICAL]rifamycin SV[\\CHEMICAL] and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the [GENE]organic anion transporting polypeptides[\\GENE] Oatp1 and Oatp2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In rats, [CHEMICAL]rifamycin SV[\\CHEMICAL] and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides [GENE]Oatp1[\\GENE] and Oatp2.",
        "label": 4,
        "major": 9,
        "len": 26
    },
    {
        "text": "In rats, [CHEMICAL]rifamycin SV[\\CHEMICAL] and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and [GENE]Oatp2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "100 micromol/L [CHEMICAL]rifampicin[\\CHEMICAL] inhibited [GENE]OATP-C[\\GENE]- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L [CHEMICAL]rifampicin[\\CHEMICAL] inhibited OATP-C- and [GENE]OATP8[\\GENE]-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L [CHEMICAL]rifampicin[\\CHEMICAL] inhibited OATP-C- and OATP8-, [GENE]OATP-B[\\GENE]- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L [CHEMICAL]rifampicin[\\CHEMICAL] inhibited OATP-C- and OATP8-, OATP-B- and [GENE]OATP-A[\\GENE]-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "In rats, rifamycin SV and [CHEMICAL]rifampicin[\\CHEMICAL] were shown to interfere with hepatic organic anion uptake by inhibition of the [GENE]organic anion transporting polypeptides[\\GENE] Oatp1 and Oatp2.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "In rats, rifamycin SV and [CHEMICAL]rifampicin[\\CHEMICAL] were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides [GENE]Oatp1[\\GENE] and Oatp2.",
        "label": 4,
        "major": 9,
        "len": 26
    },
    {
        "text": "In rats, rifamycin SV and [CHEMICAL]rifampicin[\\CHEMICAL] were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and [GENE]Oatp2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Rifampicin (10 micromol/L) inhibited [GENE]OATP8[\\GENE]-mediated [CHEMICAL]BSP[\\CHEMICAL] uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of [GENE]OATP-C[\\GENE]-, OATP-B-, and OATP-A-mediated [CHEMICAL]BSP[\\CHEMICAL] transport was below 15%.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, [GENE]OATP-B[\\GENE]-, and OATP-A-mediated [CHEMICAL]BSP[\\CHEMICAL] transport was below 15%.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and [GENE]OATP-A[\\GENE]-mediated [CHEMICAL]BSP[\\CHEMICAL] transport was below 15%.",
        "label": 9,
        "major": 9,
        "len": 21
    },
    {
        "text": "100 micromol/L rifampicin inhibited [GENE]OATP-C[\\GENE]- and OATP8-, OATP-B- and OATP-A-mediated [CHEMICAL]BSP[\\CHEMICAL] uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L rifampicin inhibited OATP-C- and [GENE]OATP8[\\GENE]-, OATP-B- and OATP-A-mediated [CHEMICAL]BSP[\\CHEMICAL] uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, [GENE]OATP-B[\\GENE]- and OATP-A-mediated [CHEMICAL]BSP[\\CHEMICAL] uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and [GENE]OATP-A[\\GENE]-mediated [CHEMICAL]BSP[\\CHEMICAL] uptake by 66%, 96%, 25%, and 49%, respectively.",
        "label": 9,
        "major": 4,
        "len": 19
    },
    {
        "text": "Direct transport of [CHEMICAL]rifampicin[\\CHEMICAL] could be shown for [GENE]OATP-C[\\GENE] (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Direct transport of [CHEMICAL]rifampicin[\\CHEMICAL] could be shown for OATP-C (apparent K(m) value 13 micromol/L) and [GENE]OATP8[\\GENE] (2.3 micromol/L).",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "The increase in [GENE]AMPK alpha2[\\GENE] activity was likely due to a change in muscle energy status because [CHEMICAL]ATP[\\CHEMICAL] and phosphocreatine concentrations were lower after metformin treatment.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "The increase in [GENE]AMPK alpha2[\\GENE] activity was likely due to a change in muscle energy status because ATP and [CHEMICAL]phosphocreatine[\\CHEMICAL] concentrations were lower after metformin treatment.",
        "label": 2,
        "major": 3,
        "len": 26
    },
    {
        "text": "We recently reported that [GENE]AMPK[\\GENE] is activated by [CHEMICAL]metformin[\\CHEMICAL] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.",
        "label": 3,
        "major": 9,
        "len": 24
    },
    {
        "text": "In the present study, we evaluated whether therapeutic doses of [CHEMICAL]metformin[\\CHEMICAL] increase [GENE]AMPK[\\GENE] activity in vivo in subjects with type 2 diabetes.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] treatment for 10 weeks significantly increased [GENE]AMPK alpha2[\\GENE] activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of [GENE]AMPK[\\GENE] on Thr172 and decreased acetyl-CoA carboxylase-2 activity.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] increases [GENE]AMP-activated protein kinase[\\GENE] activity in skeletal muscle of subjects with type 2 diabetes.",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "The increase in [GENE]AMPK alpha2[\\GENE] activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after [CHEMICAL]metformin[\\CHEMICAL] treatment.",
        "label": 3,
        "major": 3,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL]-induced increases in [GENE]AMPK[\\GENE] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL] treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased [GENE]acetyl-CoA carboxylase-2[\\GENE] activity.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "[GENE]AMP-activated protein kinase[\\GENE] (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [CHEMICAL]glucose[\\CHEMICAL] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
        "label": 9,
        "major": 3,
        "len": 35
    },
    {
        "text": "AMP-activated protein kinase ([GENE]AMPK[\\GENE]) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [CHEMICAL]glucose[\\CHEMICAL] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.",
        "label": 9,
        "major": 3,
        "len": 35
    },
    {
        "text": "BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of [GENE]tumor necrosis factor (TNF) alpha[\\GENE] are critical for progression of [CHEMICAL]alcoholic[\\CHEMICAL] liver injury.",
        "label": 2,
        "major": 9,
        "len": 27
    },
    {
        "text": "CONCLUSIONS: These results collectively indicate that [CHEMICAL]thalidomide[\\CHEMICAL] prevents alcoholic liver injury through suppression of [GENE]TNF-alpha[\\GENE] production and abolishment of KC sensitization.",
        "label": 4,
        "major": 9,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] has been shown to suppress [GENE]TNF-alpha[\\GENE] production from macrophages.",
        "label": 4,
        "major": 9,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Thalidomide[\\CHEMICAL] prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and [GENE]TNF-alpha[\\GENE] production.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "Furthermore, [CHEMICAL]thalidomide[\\CHEMICAL] abolished the LPS-induced increase in [GENE]CD14[\\GENE] expression and [Ca2+]i elevation in KCs.",
        "label": 4,
        "major": 3,
        "len": 14
    },
    {
        "text": "Moreover, [CHEMICAL]thalidomide[\\CHEMICAL] reduced the LPS-induced [GENE]TNF-alpha[\\GENE] production by KCs by decreasing TNF-alpha messenger RNA.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Moreover, [CHEMICAL]thalidomide[\\CHEMICAL] reduced the LPS-induced TNF-alpha production by KCs by decreasing [GENE]TNF-alpha[\\GENE] messenger RNA.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [GENE]oxidase[\\GENE] strongly favoured spermine over N (1)-acetylspermine and that it failed to act on [CHEMICAL]N (1)-acetylspermidine[\\CHEMICAL], spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
        "label": 10,
        "major": 9,
        "len": 39
    },
    {
        "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [GENE]oxidase[\\GENE] strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, [CHEMICAL]spermidine[\\CHEMICAL] or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
        "label": 10,
        "major": 9,
        "len": 39
    },
    {
        "text": "A BLAST search using [GENE]maize PAO[\\GENE] sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 [CHEMICAL]amino acids[\\CHEMICAL].",
        "label": 1,
        "major": 1,
        "len": 27
    },
    {
        "text": "The [GENE]PAO[\\GENE] inhibitor, [CHEMICAL]MDL-72,527[\\CHEMICAL], only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by [GENE]polyamine oxidase[\\GENE] (PAO) to produce [CHEMICAL]spermidine[\\CHEMICAL] and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ([GENE]PAO[\\GENE]) to produce [CHEMICAL]spermidine[\\CHEMICAL] and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by [GENE]polyamine oxidase[\\GENE] (PAO) to produce spermidine and [CHEMICAL]putrescine[\\CHEMICAL], respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ([GENE]PAO[\\GENE]) to produce spermidine and [CHEMICAL]putrescine[\\CHEMICAL], respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, [CHEMICAL]spermine[\\CHEMICAL] and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ([GENE]SSAT[\\GENE]) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, [CHEMICAL]spermine[\\CHEMICAL] and spermidine are first acetylated by [GENE]spermidine/spermine N(1)-acetyltransferase[\\GENE] (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves [CHEMICAL]spermine[\\CHEMICAL] in the absence of prior acetylation by [GENE]SSAT[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 27
    },
    {
        "text": "During polyamine catabolism, spermine and [CHEMICAL]spermidine[\\CHEMICAL] are first acetylated by spermidine/spermine N(1)-acetyltransferase ([GENE]SSAT[\\GENE]) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During polyamine catabolism, spermine and [CHEMICAL]spermidine[\\CHEMICAL] are first acetylated by [GENE]spermidine/spermine N(1)-acetyltransferase[\\GENE] (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During [CHEMICAL]polyamine[\\CHEMICAL] catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase ([GENE]SSAT[\\GENE]) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "During [CHEMICAL]polyamine[\\CHEMICAL] catabolism, spermine and spermidine are first acetylated by [GENE]spermidine/spermine N(1)-acetyltransferase[\\GENE] (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.",
        "label": 9,
        "major": 9,
        "len": 26
    },
    {
        "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [GENE]oxidase[\\GENE] strongly favoured [CHEMICAL]spermine[\\CHEMICAL] over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified [GENE]oxidase[\\GENE] strongly favoured spermine over [CHEMICAL]N (1)-acetylspermine[\\CHEMICAL] and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred [GENE]PAO[\\GENE] substrate, [CHEMICAL]N (1), N (12)-diacetylspermine[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported [GENE]PAO[\\GENE] substrate, [CHEMICAL]N (1)-( n -octanesulphonyl)spermine[\\CHEMICAL], potently inhibited the reaction.",
        "label": 9,
        "major": 4,
        "len": 24
    },
    {
        "text": "A moderate (twofold) stimulation of [GENE]CD62P[\\GENE] expression by abciximab but not by [CHEMICAL]tirofiban[\\CHEMICAL] or eptifibatide was observed in one patient.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "A moderate (twofold) stimulation of [GENE]CD62P[\\GENE] expression by abciximab but not by tirofiban or [CHEMICAL]eptifibatide[\\CHEMICAL] was observed in one patient.",
        "label": 10,
        "major": 3,
        "len": 20
    },
    {
        "text": "In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or [CHEMICAL]ADP[\\CHEMICAL]-stimulated [GENE]CD62P[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 39
    },
    {
        "text": "Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or [CHEMICAL]ADP[\\CHEMICAL]-induced [GENE]CD62P[\\GENE] expression.",
        "label": 3,
        "major": 10,
        "len": 21
    },
    {
        "text": "The juvenile visceral steatosis (jvs) mouse, having a mutation in the [CHEMICAL]carnitine[\\CHEMICAL] transporter gene [GENE]Octn2[\\GENE], is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).",
        "label": 9,
        "major": 1,
        "len": 28
    },
    {
        "text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of [CHEMICAL]MPP+[\\CHEMICAL], indicating the NAT and not an [GENE]OCT[\\GENE] as their primary site of action.",
        "label": 10,
        "major": 3,
        "len": 35
    },
    {
        "text": "No trans-stimulation of [CHEMICAL][3H]-MPP+[\\CHEMICAL] outflow was observed by the [GENE]OCTN1[\\GENE] and OCTN2 substrate carnitine at 100 microM.",
        "label": 10,
        "major": 9,
        "len": 17
    },
    {
        "text": "No trans-stimulation of [CHEMICAL][3H]-MPP+[\\CHEMICAL] outflow was observed by the OCTN1 and [GENE]OCTN2[\\GENE] substrate carnitine at 100 microM.",
        "label": 10,
        "major": 9,
        "len": 17
    },
    {
        "text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the [GENE]OCT3[\\GENE] inhibitors cyanine 863, [CHEMICAL]oestradiol[\\CHEMICAL] and corticosterone.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the [GENE]OCT3[\\GENE] inhibitors cyanine 863, oestradiol and [CHEMICAL]corticosterone[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of [CHEMICAL]MPP+[\\CHEMICAL], indicating the [GENE]NAT[\\GENE] and not an OCT as their primary site of action.",
        "label": 9,
        "major": 10,
        "len": 35
    },
    {
        "text": "Our observations indicate an [GENE]OCT[\\GENE]-mediated transmembrane transport of [CHEMICAL][3H]-MPP+[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 9
    },
    {
        "text": "Amongst the three [GENE]OCTs[\\GENE] expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [CHEMICAL][3H]-MPP+[\\CHEMICAL] release.",
        "label": 9,
        "major": 3,
        "len": 26
    },
    {
        "text": "Amongst the three OCTs expressed in the SCG, [GENE]OCT3[\\GENE] best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [CHEMICAL][3H]-MPP+[\\CHEMICAL] release.",
        "label": 9,
        "major": 3,
        "len": 26
    },
    {
        "text": "Reuptake of extracellular [CHEMICAL]noradrenaline[\\CHEMICAL] (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the [GENE]noradrenaline transporter[\\GENE] (NAT, uptake 1).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Reuptake of extracellular [CHEMICAL]noradrenaline[\\CHEMICAL] (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ([GENE]NAT[\\GENE], uptake 1).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Reuptake of extracellular noradrenaline ([CHEMICAL]NA[\\CHEMICAL]) into superior cervical ganglion (SCG) neurones is mediated by means of the [GENE]noradrenaline transporter[\\GENE] (NAT, uptake 1).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "Reuptake of extracellular noradrenaline ([CHEMICAL]NA[\\CHEMICAL]) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ([GENE]NAT[\\GENE], uptake 1).",
        "label": 9,
        "major": 9,
        "len": 22
    },
    {
        "text": "The outflow of [CHEMICAL][3H]-MPP+[\\CHEMICAL] was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [GENE]OCT[\\GENE]-related transmembrane transporters.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [CHEMICAL][3H]-MPP+[\\CHEMICAL] was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related [GENE]transmembrane transporters[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by [CHEMICAL]MPP+[\\CHEMICAL], guanidine, choline and amantadine as potential substrates for [GENE]OCT[\\GENE]-related transmembrane transporters.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by [CHEMICAL]MPP+[\\CHEMICAL], guanidine, choline and amantadine as potential substrates for OCT-related [GENE]transmembrane transporters[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, [CHEMICAL]guanidine[\\CHEMICAL], choline and amantadine as potential substrates for [GENE]OCT[\\GENE]-related transmembrane transporters.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, [CHEMICAL]guanidine[\\CHEMICAL], choline and amantadine as potential substrates for OCT-related [GENE]transmembrane transporters[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, [CHEMICAL]choline[\\CHEMICAL] and amantadine as potential substrates for [GENE]OCT[\\GENE]-related transmembrane transporters.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, [CHEMICAL]choline[\\CHEMICAL] and amantadine as potential substrates for OCT-related [GENE]transmembrane transporters[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and [CHEMICAL]amantadine[\\CHEMICAL] as potential substrates for [GENE]OCT[\\GENE]-related transmembrane transporters.",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and [CHEMICAL]amantadine[\\CHEMICAL] as potential substrates for OCT-related [GENE]transmembrane transporters[\\GENE].",
        "label": 9,
        "major": 9,
        "len": 20
    },
    {
        "text": "Long-term administration of [CHEMICAL]propargylamines[\\CHEMICAL] to rats increased the activities of antioxidative enzymes [GENE]superoxide dismutase[\\GENE] (SOD) and catalase in the brain regions containing dopamine neurons.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Long-term administration of [CHEMICAL]propargylamines[\\CHEMICAL] to rats increased the activities of antioxidative enzymes superoxide dismutase ([GENE]SOD[\\GENE]) and catalase in the brain regions containing dopamine neurons.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "Long-term administration of [CHEMICAL]propargylamines[\\CHEMICAL] to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and [GENE]catalase[\\GENE] in the brain regions containing dopamine neurons.",
        "label": 3,
        "major": 3,
        "len": 24
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic [GENE]Bcl-2[\\GENE] and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a [GENE]neurotrophic factor[\\GENE], glial cell line-derived neurotrophic factor (GDNF).",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, [GENE]glial cell line-derived neurotrophic factor[\\GENE] (GDNF).",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Rasagiline[\\CHEMICAL] prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor ([GENE]GDNF[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 25
    },
    {
        "text": "An inhibitor of [GENE]type B monoamine oxidase[\\GENE] (MAO-B), [CHEMICAL](-)deprenyl[\\CHEMICAL] (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "An inhibitor of type B monoamine oxidase ([GENE]MAO-B[\\GENE]), [CHEMICAL](-)deprenyl[\\CHEMICAL] (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "An inhibitor of [GENE]type B monoamine oxidase[\\GENE] (MAO-B), (-)deprenyl ([CHEMICAL]selegiline[\\CHEMICAL]), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "An inhibitor of type B monoamine oxidase ([GENE]MAO-B[\\GENE]), (-)deprenyl ([CHEMICAL]selegiline[\\CHEMICAL]), was reported to have neuroprotective activity, but clinical trials failed to confirm it.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to [CHEMICAL]PBZ[\\CHEMICAL] of the [GENE]cyclo-oxygenase[\\GENE] (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.",
        "label": 2,
        "major": 2,
        "len": 65
    },
    {
        "text": "These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to [CHEMICAL]PBZ[\\CHEMICAL] of the cyclo-oxygenase ([GENE]COX[\\GENE]) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.",
        "label": 2,
        "major": 2,
        "len": 65
    },
    {
        "text": "These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to [CHEMICAL]PBZ[\\CHEMICAL] of the cyclo-oxygenase (COX) isoenzymes, [GENE]COX-1[\\GENE] and COX-2 or; (d) a combination of these factors.",
        "label": 2,
        "major": 2,
        "len": 65
    },
    {
        "text": "These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to [CHEMICAL]PBZ[\\CHEMICAL] of the cyclo-oxygenase (COX) isoenzymes, COX-1 and [GENE]COX-2[\\GENE] or; (d) a combination of these factors.",
        "label": 2,
        "major": 2,
        "len": 65
    },
    {
        "text": "A streamlined and high-yielding synthesis of [CHEMICAL]aprepitant[\\CHEMICAL] (1), a potent [GENE]substance P (SP) receptor[\\GENE] antagonist, is described.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "Practical asymmetric synthesis of [CHEMICAL]aprepitant[\\CHEMICAL], a potent human [GENE]NK-1 receptor[\\GENE] antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.",
        "label": 6,
        "major": 9,
        "len": 19
    },
    {
        "text": "Pentosan polysulfate [CHEMICAL]sodium[\\CHEMICAL] (PPS) has been shown to exert antitumor activity by antagonizing the binding of [GENE]bFGF[\\GENE] to cell surface receptors.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Pentosan polysulfate [CHEMICAL]sodium[\\CHEMICAL] (PPS) has been shown to exert antitumor activity by antagonizing the binding of [GENE]bFGF[\\GENE] to cell surface receptors.",
        "label": 6,
        "major": 2,
        "len": 21
    },
    {
        "text": "Colocalization of [GENE]RhBG[\\GENE] with carbonic anhydrase II, the [CHEMICAL]thiazide[\\CHEMICAL]-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.",
        "label": 2,
        "major": 9,
        "len": 31
    },
    {
        "text": "These findings suggest that [GENE]RhBG[\\GENE] and RhCG may play important and cell-specific roles in [CHEMICAL]ammonium[\\CHEMICAL] transport and signaling in these regions of the kidney.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "These findings suggest that RhBG and [GENE]RhCG[\\GENE] may play important and cell-specific roles in [CHEMICAL]ammonium[\\CHEMICAL] transport and signaling in these regions of the kidney.",
        "label": 9,
        "major": 9,
        "len": 24
    },
    {
        "text": "This approach is validated by the clinical efficacy and safety of [CHEMICAL]sildenafil[\\CHEMICAL], the pioneering drug for selective [GENE]PDE5[\\GENE] inhibitor therapy for ED.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant [GENE]PDE[\\GENE] in the phototransduction cascade in rods.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] exhibits inhibitory potency against [GENE]PDE5[\\GENE] and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Sildenafil[\\CHEMICAL] exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment [GENE]PDE6[\\GENE], the predominant PDE in the phototransduction cascade in rods.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "As free [CHEMICAL]sildenafil[\\CHEMICAL] plasma concentrations approach concentrations sufficient to inhibit retinal [GENE]PDE6[\\GENE], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Selective inhibition of [GENE]PDE5[\\GENE] is a rational therapeutic approach in ED, as proved by the clinical success of [CHEMICAL]sildenafil[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of [CHEMICAL]cGMP[\\CHEMICAL]-specific [GENE]PDE5[\\GENE] is a means of improving erectile function at minimal risk of adverse events.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[GENE]PDE5[\\GENE] is the predominant PDE in the corpus cavernosum, and [CHEMICAL]cGMP[\\CHEMICAL] is its primary substrate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "PDE5 is the predominant [GENE]PDE[\\GENE] in the corpus cavernosum, and [CHEMICAL]cGMP[\\CHEMICAL] is its primary substrate.",
        "label": 9,
        "major": 9,
        "len": 15
    },
    {
        "text": "Study of the nematode putative [GENE]GABA type-A receptor[\\GENE] subunits: evidence for modulation by [CHEMICAL]ivermectin[\\CHEMICAL].",
        "label": 2,
        "major": 7,
        "len": 14
    },
    {
        "text": "Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and [CHEMICAL]yohimbine[\\CHEMICAL] dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the [GENE]alpha2C-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "The [CHEMICAL]yohimbine[\\CHEMICAL] dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. respectively) for the [GENE]alpha2C-adrenoceptor[\\GENE] in receptor binding and in functional studies (42- and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Yohimbine[\\CHEMICAL] is a potent and selective [GENE]alpha2- versus alpha1-adrenoceptor[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 10
    },
    {
        "text": "These results demonstrate that [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules directly induce pDC maturation as determined by cytokine induction, [GENE]CCR7[\\GENE] and co-stimulatory marker expression and prolonging viability.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Plasmacytoid dendritic cells produce [GENE]cytokines[\\GENE] and mature in response to the TLR7 agonists, imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 16
    },
    {
        "text": "Plasmacytoid dendritic cells produce [GENE]cytokines[\\GENE] and mature in response to the TLR7 agonists, [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod.",
        "label": 2,
        "major": 5,
        "len": 16
    },
    {
        "text": "Results indicate that [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle [GENE]IFN[\\GENE]-producing cells in the blood.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Results indicate that imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL] induce [GENE]IFN-alpha[\\GENE] and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Results indicate that imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL] induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle [GENE]IFN[\\GENE]-producing cells in the blood.",
        "label": 2,
        "major": 9,
        "len": 23
    },
    {
        "text": "These results demonstrate that [CHEMICAL]imidazoquinoline[\\CHEMICAL] molecules directly induce pDC maturation as determined by [GENE]cytokine[\\GENE] induction, CCR7 and co-stimulatory marker expression and prolonging viability.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The immune response modifiers, [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod, are TLR7 agonists that induce [GENE]type I interferon[\\GENE] in numerous species, including humans.",
        "label": 3,
        "major": 5,
        "len": 20
    },
    {
        "text": "Results indicate that [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod induce [GENE]IFN-alpha[\\GENE] and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.",
        "label": 3,
        "major": 9,
        "len": 23
    },
    {
        "text": "Results indicate that [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod induce IFN-alpha and [GENE]IFN-omega[\\GENE] from purified pDC, and pDC are the principle IFN-producing cells in the blood.",
        "label": 3,
        "major": 3,
        "len": 23
    },
    {
        "text": "The immune response modifiers, imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL], are TLR7 agonists that induce [GENE]type I interferon[\\GENE] in numerous species, including humans.",
        "label": 3,
        "major": 5,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Resiquimod[\\CHEMICAL]-stimulated pDC also produce a number of other [GENE]cytokines[\\GENE] including TNF-alpha and IP-10.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Resiquimod[\\CHEMICAL]-stimulated pDC also produce a number of other cytokines including [GENE]TNF-alpha[\\GENE] and IP-10.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Resiquimod[\\CHEMICAL]-stimulated pDC also produce a number of other cytokines including TNF-alpha and [GENE]IP-10[\\GENE].",
        "label": 3,
        "major": 9,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Resiquimod[\\CHEMICAL] enhances co-stimulatory marker expression, [GENE]CCR7[\\GENE] expression, and pDC viability.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the [GENE]TLR7[\\GENE] agonists, imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL].",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the [GENE]TLR7[\\GENE] agonists, [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "The immune response modifiers, [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod, are [GENE]TLR7[\\GENE] agonists that induce type I interferon in numerous species, including humans.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Here, we characterize the activation of human pDC with the [GENE]TLR7[\\GENE] agonists [CHEMICAL]imiquimod[\\CHEMICAL] and resiquimod.",
        "label": 5,
        "major": 5,
        "len": 15
    },
    {
        "text": "Here, we characterize the activation of human pDC with the [GENE]TLR7[\\GENE] agonists imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL].",
        "label": 5,
        "major": 3,
        "len": 15
    },
    {
        "text": "The immune response modifiers, imiquimod and [CHEMICAL]resiquimod[\\CHEMICAL], are [GENE]TLR7[\\GENE] agonists that induce type I interferon in numerous species, including humans.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "[CHEMICAL]H2O2[\\CHEMICAL] caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and [GENE]caspase-3[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Pre-treatment with arsenite increased [GENE]protein kinase B[\\GENE] (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after [CHEMICAL]H2O2[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "Pre-treatment with arsenite increased protein kinase B ([GENE]Akt[\\GENE]) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after [CHEMICAL]H2O2[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "The results show that transient [CHEMICAL]arsenite[\\CHEMICAL] pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of [GENE]Akt[\\GENE] following H2O2.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of [GENE]Akt[\\GENE] following [CHEMICAL]H2O2[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Induction of [GENE]heat shock proteins[\\GENE] (HSPs) by [CHEMICAL]sodium arsenite[\\CHEMICAL] in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
        "label": 3,
        "major": 4,
        "len": 19
    },
    {
        "text": "Induction of heat shock proteins ([GENE]HSPs[\\GENE]) by [CHEMICAL]sodium arsenite[\\CHEMICAL] in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.",
        "label": 3,
        "major": 4,
        "len": 19
    },
    {
        "text": "The results show that transient [CHEMICAL]arsenite[\\CHEMICAL] pre-treatment induces [GENE]Hsp72[\\GENE], HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The results show that transient [CHEMICAL]arsenite[\\CHEMICAL] pre-treatment induces Hsp72, [GENE]HO-1[\\GENE] and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "The results show that transient [CHEMICAL]arsenite[\\CHEMICAL] pre-treatment induces Hsp72, HO-1 and, to a lesser extent, [GENE]Hsp27[\\GENE]; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Arsenite[\\CHEMICAL] triggered strong induction of [GENE]HSPs[\\GENE], which was prevented by 1 micro g/mL cycloheximide (CXH).",
        "label": 3,
        "major": 3,
        "len": 15
    },
    {
        "text": "Arsenite triggered strong induction of [GENE]HSPs[\\GENE], which was prevented by 1 micro g/mL [CHEMICAL]cycloheximide[\\CHEMICAL] (CXH).",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "Arsenite triggered strong induction of [GENE]HSPs[\\GENE], which was prevented by 1 micro g/mL cycloheximide ([CHEMICAL]CXH[\\CHEMICAL]).",
        "label": 4,
        "major": 3,
        "len": 15
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of [GENE]BrBK4-8[\\GENE] and BrBK2-8.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and [GENE]BrBK2-8[\\GENE].",
        "label": 10,
        "major": 9,
        "len": 18
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] increased the production of both BrBK1-8 and Br-Phe5 but not that of [GENE]BrBK4-8[\\GENE] and BrBK2-8.",
        "label": 10,
        "major": 3,
        "len": 18
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and [GENE]BrBK2-8[\\GENE].",
        "label": 10,
        "major": 9,
        "len": 18
    },
    {
        "text": "Unlike [CHEMICAL]GW660511X[\\CHEMICAL], omapatrilat abolished the production of [GENE]BrBK1-5[\\GENE] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "Unlike [CHEMICAL]GW660511X[\\CHEMICAL], omapatrilat abolished the production of BrBK1-5 and [GENE]BrBK1-7[\\GENE], suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over [CHEMICAL]GW660511X[\\CHEMICAL] as no [GENE]NEP[\\GENE] activity was found.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "The production of [GENE]Br-Phe5[\\GENE] was reduced with GW660511X while no significant change was observed with [CHEMICAL]omapatrilat[\\CHEMICAL] after 4 h of incubation.",
        "label": 10,
        "major": 9,
        "len": 21
    },
    {
        "text": "Investigation of [GENE]bradykinin[\\GENE] metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors [CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat.",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "Investigation of [GENE]bradykinin[\\GENE] metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 20
    },
    {
        "text": "In rat plasma the [GENE]BrBK[\\GENE] half-life values in the absence or in the presence of [CHEMICAL]GW660511X[\\CHEMICAL] (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "In rat plasma the [GENE]BrBK[\\GENE] half-life values in the absence or in the presence of GW660511X (530 nM) or [CHEMICAL]omapatrilat[\\CHEMICAL] (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.",
        "label": 2,
        "major": 10,
        "len": 56
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat increased the production of both [GENE]BrBK1-8[\\GENE] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.",
        "label": 3,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat increased the production of both BrBK1-8 and [GENE]Br-Phe5[\\GENE] but not that of BrBK4-8 and BrBK2-8.",
        "label": 3,
        "major": 3,
        "len": 18
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] increased the production of both [GENE]BrBK1-8[\\GENE] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.",
        "label": 3,
        "major": 9,
        "len": 18
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] increased the production of both BrBK1-8 and [GENE]Br-Phe5[\\GENE] but not that of BrBK4-8 and BrBK2-8.",
        "label": 3,
        "major": 10,
        "len": 18
    },
    {
        "text": "In addition the production of [GENE]BrBK1-8[\\GENE] was enhanced in the presence of these inhibitors with a greater accumulation being observed with [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 3,
        "major": 9,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat reduced the production of [GENE]BrBK1-5[\\GENE] and BrBK1-7 with more effect being observed with omapatrilat.",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "[CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat reduced the production of BrBK1-5 and [GENE]BrBK1-7[\\GENE] with more effect being observed with omapatrilat.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] reduced the production of [GENE]BrBK1-5[\\GENE] and BrBK1-7 with more effect being observed with omapatrilat.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL] reduced the production of BrBK1-5 and [GENE]BrBK1-7[\\GENE] with more effect being observed with omapatrilat.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "GW660511X and omapatrilat reduced the production of [GENE]BrBK1-5[\\GENE] and BrBK1-7 with more effect being observed with [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "GW660511X and omapatrilat reduced the production of BrBK1-5 and [GENE]BrBK1-7[\\GENE] with more effect being observed with [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 4,
        "major": 9,
        "len": 17
    },
    {
        "text": "Unlike GW660511X, [CHEMICAL]omapatrilat[\\CHEMICAL] abolished the production of [GENE]BrBK1-5[\\GENE] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Unlike GW660511X, [CHEMICAL]omapatrilat[\\CHEMICAL] abolished the production of BrBK1-5 and [GENE]BrBK1-7[\\GENE], suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "The production of [GENE]Br-Phe5[\\GENE] was reduced with [CHEMICAL]GW660511X[\\CHEMICAL] while no significant change was observed with omapatrilat after 4 h of incubation.",
        "label": 4,
        "major": 9,
        "len": 21
    },
    {
        "text": "This study shows that the potency of [CHEMICAL]GW660511X[\\CHEMICAL] in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [GENE]ACE[\\GENE]/NEP inhibition in relation to effects in humans.",
        "label": 4,
        "major": 10,
        "len": 50
    },
    {
        "text": "This study shows that the potency of [CHEMICAL]GW660511X[\\CHEMICAL] in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/[GENE]NEP[\\GENE] inhibition in relation to effects in humans.",
        "label": 4,
        "major": 4,
        "len": 50
    },
    {
        "text": "This study shows that the potency of GW660511X in comparison with [CHEMICAL]omapatrilat[\\CHEMICAL] is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/[GENE]NEP[\\GENE] inhibition in relation to effects in humans.",
        "label": 4,
        "major": 4,
        "len": 50
    },
    {
        "text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual [GENE]ACE[\\GENE]/NEP inhibitors ([CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat) currently under clinical trial.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/[GENE]NEP[\\GENE] inhibitors ([CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat) currently under clinical trial.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual [GENE]ACE[\\GENE]/NEP inhibitors (GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL]) currently under clinical trial.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/[GENE]NEP[\\GENE] inhibitors (GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL]) currently under clinical trial.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "Unlike GW660511X, [CHEMICAL]omapatrilat[\\CHEMICAL] abolished the production of BrBK1-5 and BrBK1-7, suggesting a better [GENE]ACE[\\GENE] inhibition effect over GW660511X as no NEP activity was found.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better [GENE]ACE[\\GENE] inhibition effect over [CHEMICAL]GW660511X[\\CHEMICAL] as no NEP activity was found.",
        "label": 4,
        "major": 9,
        "len": 24
    },
    {
        "text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual [GENE]ACE[\\GENE]/NEP inhibitors [CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/[GENE]NEP[\\GENE] inhibitors [CHEMICAL]GW660511X[\\CHEMICAL] and omapatrilat.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual [GENE]ACE[\\GENE]/NEP inhibitors GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/[GENE]NEP[\\GENE] inhibitors GW660511X and [CHEMICAL]omapatrilat[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for [GENE]BuChE[\\GENE] ([CHEMICAL]cymserine[\\CHEMICAL] analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for [GENE]BuChE[\\GENE] (cymserine analogues, [CHEMICAL]MF-8622[\\CHEMICAL]) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",
        "label": 2,
        "major": 4,
        "len": 40
    },
    {
        "text": "The development of specific [GENE]BuChE[\\GENE] inhibitors and further experience with the dual enzyme inhibitor [CHEMICAL]rivastigmine[\\CHEMICAL] will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both [GENE]AChE[\\GENE] and BuChE, [CHEMICAL]rivastigmine[\\CHEMICAL], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and [GENE]BuChE[\\GENE], [CHEMICAL]rivastigmine[\\CHEMICAL], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, [CHEMICAL]rivastigmine[\\CHEMICAL], indicates potential therapeutic benefits of inhibiting both [GENE]AChE[\\GENE] and BuChE in AD and related dementias.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, [CHEMICAL]rivastigmine[\\CHEMICAL], indicates potential therapeutic benefits of inhibiting both AChE and [GENE]BuChE[\\GENE] in AD and related dementias.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Angiotensin II[\\CHEMICAL] acting on [GENE]angiotensin AT1 receptors[\\GENE] at the central nervous system appears to have an important role in these modulatory processes.",
        "label": 2,
        "major": 7,
        "len": 22
    },
    {
        "text": "We investigated the effect of [GENE]AT1 receptor[\\GENE] blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent [CHEMICAL]pancuronium bromide[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 29
    },
    {
        "text": "[GENE]Angiotensin AT1 receptor[\\GENE] antagonist [CHEMICAL]losartan[\\CHEMICAL] and the defence reaction in the anaesthetised rat.",
        "label": 6,
        "major": 6,
        "len": 13
    },
    {
        "text": "Defective processing of the [GENE]transforming growth factor-beta1[\\GENE] in [CHEMICAL]azoxymethane[\\CHEMICAL]-induced mouse colon tumors.",
        "label": 2,
        "major": 3,
        "len": 12
    },
    {
        "text": "Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) [GENE]OFQ II(1-28)[\\GENE] does not bind or stimulate [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in cells expressing the mu opioid receptor.",
        "label": 10,
        "major": 3,
        "len": 41
    },
    {
        "text": "Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in cells expressing the [GENE]mu opioid receptor[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 41
    },
    {
        "text": "Unlike OFQ II(1-17), high concentrations of its [CHEMICAL]C[\\CHEMICAL]-terminal extension, [GENE]OFQ II(1-28)[\\GENE], stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.",
        "label": 1,
        "major": 3,
        "len": 28
    },
    {
        "text": "Taken together, these findings support the view that (1) [GENE]OFQ[\\GENE] is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in cells expressing the mu opioid receptor.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "Taken together, these findings support the view that (1) OFQ is the only [GENE]ppOFQ[\\GENE] peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in cells expressing the mu opioid receptor.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the [GENE]ORL1[\\GENE] receptor and (2) OFQ II(1-28) does not bind or stimulate [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in cells expressing the mu opioid receptor.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "[GENE]Orphanin FQ[\\GENE] (OFQ) stimulated [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Orphanin FQ ([GENE]OFQ[\\GENE]) stimulated [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [[CHEMICAL]125I[\\CHEMICAL]]-[GENE]OFQ[\\GENE] at the endogenous opioid receptor-like (ORL1) receptor.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Unlike [GENE]OFQ II(1-17)[\\GENE], high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in a [GENE]mu (mu) opioid receptor[\\GENE]-like distribution and the effect was blocked by naloxone.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a [GENE]mu (mu) opioid receptor[\\GENE]-like distribution and the effect was blocked by [CHEMICAL]naloxone[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Binding and [CHEMICAL]GTPgammaS[\\CHEMICAL] autoradiographic analysis of preproorphanin precursor peptide products at the [GENE]ORL1[\\GENE] and opioid receptors.",
        "label": 2,
        "major": 2,
        "len": 16
    },
    {
        "text": "Binding and [CHEMICAL]GTPgammaS[\\CHEMICAL] autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and [GENE]opioid receptors[\\GENE].",
        "label": 2,
        "major": 9,
        "len": 16
    },
    {
        "text": "Binding and [CHEMICAL]GTPgammaS[\\CHEMICAL] autoradiographic analysis of [GENE]preproorphanin precursor peptide[\\GENE] products at the ORL1 and opioid receptors.",
        "label": 2,
        "major": 9,
        "len": 16
    },
    {
        "text": "Unlike OFQ II(1-17), high concentrations of its C-terminal extension, [GENE]OFQ II(1-28)[\\GENE], stimulated [CHEMICAL][35S]-GTPgammaS[\\CHEMICAL] binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "RESULTS: [CHEMICAL]Rolipram[\\CHEMICAL] unmasked the inhibitory effect of [GENE]beta(2)-adrenoceptor[\\GENE] stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4).",
        "label": 2,
        "major": 4,
        "len": 22
    },
    {
        "text": "CONCLUSIONS: Inhibition of PDE4 by [CHEMICAL]rolipram[\\CHEMICAL] unmasks [GENE]beta(2)-adrenergic[\\GENE] blockade of LTC(4) synthesis caused by FMLP/B.",
        "label": 2,
        "major": 4,
        "len": 15
    },
    {
        "text": "RESULTS: Rolipram unmasked the inhibitory effect of [GENE]beta(2)-adrenoceptor[\\GENE] stimulation with [CHEMICAL]salmeterol[\\CHEMICAL] and significantly attenuated the stimulated release of AA and subsequent LTC(4).",
        "label": 3,
        "major": 4,
        "len": 22
    },
    {
        "text": "Inhibition corresponded to increased cAMP production caused by rolipram alone or [CHEMICAL]rolipram[\\CHEMICAL] plus salmeterol and blocked proportionately the phosphorylation and activation of [GENE]gIV-PLA(2)[\\GENE] in FMLP/B-activated eosinophils.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus [CHEMICAL]salmeterol[\\CHEMICAL] and blocked proportionately the phosphorylation and activation of [GENE]gIV-PLA(2)[\\GENE] in FMLP/B-activated eosinophils.",
        "label": 4,
        "major": 3,
        "len": 26
    },
    {
        "text": "CONCLUSIONS: Inhibition of [GENE]PDE4[\\GENE] by [CHEMICAL]rolipram[\\CHEMICAL] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "OBJECTIVE: To determine (a) whether [GENE]PDE4[\\GENE] inhibition alone with [CHEMICAL]rolipram[\\CHEMICAL] blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.",
        "label": 4,
        "major": 4,
        "len": 66
    },
    {
        "text": "Blockade of [CHEMICAL]LTC4[\\CHEMICAL] synthesis caused by additive inhibition of [GENE]gIV-PLA2[\\GENE] phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.",
        "label": 9,
        "major": 4,
        "len": 20
    },
    {
        "text": "Tazarotene is an acetylenic retinoid which is metabolised to [CHEMICAL]tazarotenic acid[\\CHEMICAL] and which binds selectively to the [GENE]retinoid receptors[\\GENE] RARbeta and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Tazarotene is an acetylenic retinoid which is metabolised to [CHEMICAL]tazarotenic acid[\\CHEMICAL] and which binds selectively to the retinoid receptors [GENE]RARbeta[\\GENE] and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Tazarotene is an acetylenic retinoid which is metabolised to [CHEMICAL]tazarotenic acid[\\CHEMICAL] and which binds selectively to the retinoid receptors RARbeta and [GENE]RARgamma[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Tazarotene[\\CHEMICAL] is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the [GENE]retinoid receptors[\\GENE] RARbeta and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Tazarotene[\\CHEMICAL] is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors [GENE]RARbeta[\\GENE] and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Tazarotene[\\CHEMICAL] is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and [GENE]RARgamma[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Tazarotene is an [CHEMICAL]acetylenic retinoid[\\CHEMICAL] which is metabolised to tazarotenic acid and which binds selectively to the [GENE]retinoid receptors[\\GENE] RARbeta and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Tazarotene is an [CHEMICAL]acetylenic retinoid[\\CHEMICAL] which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors [GENE]RARbeta[\\GENE] and RARgamma.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Tazarotene is an [CHEMICAL]acetylenic retinoid[\\CHEMICAL] which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and [GENE]RARgamma[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "These characteristics of the bound PLP suggest that [GENE]SDH[\\GENE] catalysis is not facilitated by forming the resonance-stabilized structure of the [CHEMICAL]PLP-Ser aldimine[\\CHEMICAL] as seen in aminotransferases.",
        "label": 10,
        "major": 9,
        "len": 26
    },
    {
        "text": "Formation of pyruvate by [GENE]SDH[\\GENE] is a two-step reaction in which the [CHEMICAL]hydroxyl[\\CHEMICAL] group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
        "label": 1,
        "major": 9,
        "len": 33
    },
    {
        "text": "Formation of pyruvate by [GENE]SDH[\\GENE] is a two-step reaction in which the hydroxyl group of [CHEMICAL]serine[\\CHEMICAL] is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
        "label": 1,
        "major": 9,
        "len": 33
    },
    {
        "text": "The phosphate group of [CHEMICAL]PLP[\\CHEMICAL] is surrounded by a characteristic [GENE]G-rich sequence[\\GENE] ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.",
        "label": 1,
        "major": 1,
        "len": 34
    },
    {
        "text": "The phosphate group of PLP is surrounded by a characteristic [GENE]G-rich sequence[\\GENE] ((168)[CHEMICAL]GGGGL[\\CHEMICAL](172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.",
        "label": 1,
        "major": 1,
        "len": 34
    },
    {
        "text": "These characteristics of the bound [CHEMICAL]PLP[\\CHEMICAL] suggest that [GENE]SDH[\\GENE] catalysis is not facilitated by forming the resonance-stabilized structure of the PLP-Ser aldimine as seen in aminotransferases.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "The [GENE]holo-SDH[\\GENE] crystallized with [CHEMICAL]O-methylserine[\\CHEMICAL] (OMS) was also determined at 2.6 A resolution by molecular replacement.",
        "label": 2,
        "major": 1,
        "len": 16
    },
    {
        "text": "The [GENE]holo-SDH[\\GENE] crystallized with O-methylserine ([CHEMICAL]OMS[\\CHEMICAL]) was also determined at 2.6 A resolution by molecular replacement.",
        "label": 2,
        "major": 1,
        "len": 16
    },
    {
        "text": "The [GENE]holo-SDH[\\GENE] contained PLP-OMS [CHEMICAL]aldimine[\\CHEMICAL] in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.",
        "label": 2,
        "major": 10,
        "len": 27
    },
    {
        "text": "The [GENE]holo-SDH[\\GENE] contained PLP-OMS aldimine in the active site, indicating that [CHEMICAL]OMS[\\CHEMICAL] can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.",
        "label": 2,
        "major": 10,
        "len": 27
    },
    {
        "text": "These characteristics of the bound PLP suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the [CHEMICAL]PLP-Ser aldimine[\\CHEMICAL] as seen in [GENE]aminotransferases[\\GENE].",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "[GENE]SDH[\\GENE] (L-serine dehydratase, EC 4.3.1.17) catalyzes the [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH (L-serine dehydratase, [GENE]EC 4.3.1.17[\\GENE]) catalyzes the [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH [GENE](L-serine dehydratase[\\GENE], EC 4.3.1.17) catalyzes the [CHEMICAL]pyridoxal 5'-phosphate[\\CHEMICAL] (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]SDH[\\GENE] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate ([CHEMICAL]PLP[\\CHEMICAL])-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH (L-serine dehydratase, [GENE]EC 4.3.1.17[\\GENE]) catalyzes the pyridoxal 5'-phosphate ([CHEMICAL]PLP[\\CHEMICAL])-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH [GENE](L-serine dehydratase[\\GENE], EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate ([CHEMICAL]PLP[\\CHEMICAL])-dependent dehydration of L-serine to yield pyruvate and ammonia.",
        "label": 8,
        "major": 9,
        "len": 18
    },
    {
        "text": "The [GENE]holo-SDH[\\GENE] contained PLP-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with [CHEMICAL]PLP[\\CHEMICAL], but the subsequent dehydration did not occur.",
        "label": 8,
        "major": 10,
        "len": 27
    },
    {
        "text": "Formation of [CHEMICAL]pyruvate[\\CHEMICAL] by [GENE]SDH[\\GENE] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Formation of pyruvate by [GENE]SDH[\\GENE] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce [CHEMICAL]pyruvate[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "[GENE]SDH[\\GENE] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [CHEMICAL]pyruvate[\\CHEMICAL] and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH (L-serine dehydratase, [GENE]EC 4.3.1.17[\\GENE]) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [CHEMICAL]pyruvate[\\CHEMICAL] and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH [GENE](L-serine dehydratase[\\GENE], EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield [CHEMICAL]pyruvate[\\CHEMICAL] and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]SDH[\\GENE] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and [CHEMICAL]ammonia[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH (L-serine dehydratase, [GENE]EC 4.3.1.17[\\GENE]) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and [CHEMICAL]ammonia[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH [GENE](L-serine dehydratase[\\GENE], EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and [CHEMICAL]ammonia[\\CHEMICAL].",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]SDH[\\GENE] (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of [CHEMICAL]L-serine[\\CHEMICAL] to yield pyruvate and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH (L-serine dehydratase, [GENE]EC 4.3.1.17[\\GENE]) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of [CHEMICAL]L-serine[\\CHEMICAL] to yield pyruvate and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "SDH [GENE](L-serine dehydratase[\\GENE], EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of [CHEMICAL]L-serine[\\CHEMICAL] to yield pyruvate and ammonia.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Formation of pyruvate by [GENE]SDH[\\GENE] is a two-step reaction in which the hydroxyl group of serine is cleaved to produce [CHEMICAL]aminoacrylate[\\CHEMICAL], and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) [CHEMICAL]GW572016[\\CHEMICAL] decreased the postradiation survival of irradiated [GENE]Ras[\\GENE]-transformed cells and normal cells but had no effect on the survival of unirradiated cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Blocking [GENE]EGFR[\\GENE] signaling with the EGFR/HER-2 kinase inhibitor (KI) [CHEMICAL]GW572016[\\CHEMICAL] decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Thus, [GENE]Ras[\\GENE] utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI [CHEMICAL]GW572016[\\CHEMICAL] acts as a radiosensitizer.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Blocking EGFR signaling with the [GENE]EGFR[\\GENE]/HER-2 kinase inhibitor (KI) [CHEMICAL]GW572016[\\CHEMICAL] decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Blocking EGFR signaling with the EGFR/[GENE]HER-2[\\GENE] kinase inhibitor (KI) [CHEMICAL]GW572016[\\CHEMICAL] decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "Ras-CM and TGF-alpha also increase [GENE]PI3-K[\\GENE] activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Ras-CM and TGF-alpha also increase PI3-K activity downstream of the [GENE]EGFR[\\GENE] and increase postradiation survival, both of which are abrogated by [CHEMICAL]GW572016[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the [GENE]EGFR[\\GENE] KI [CHEMICAL]GW572016[\\CHEMICAL] acts as a radiosensitizer.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "(-)-Isoprenaline and a nonconventional [GENE]beta(3)-adrenoceptor[\\GENE] agonist, [CHEMICAL](+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride[\\CHEMICAL] ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
        "label": 5,
        "major": 3,
        "len": 20
    },
    {
        "text": "(-)-Isoprenaline and a nonconventional [GENE]beta(3)-adrenoceptor[\\GENE] agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ([CHEMICAL](+/-)-CGP12177A[\\CHEMICAL]), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "Pretreatment with a combination of [CHEMICAL](+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate[\\CHEMICAL] (CGP20712A, a selective [GENE]beta(1)-adrenoceptor[\\GENE] antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 53
    },
    {
        "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ([CHEMICAL]CGP20712A[\\CHEMICAL], a selective [GENE]beta(1)-adrenoceptor[\\GENE] antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
        "label": 6,
        "major": 9,
        "len": 53
    },
    {
        "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and [CHEMICAL](+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride[\\CHEMICAL] (ICI-118,5511, a selective [GENE]beta(2)-adrenoceptor[\\GENE] antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 53
    },
    {
        "text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ([CHEMICAL]ICI-118,5511[\\CHEMICAL], a selective [GENE]beta(2)-adrenoceptor[\\GENE] antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.",
        "label": 6,
        "major": 6,
        "len": 53
    },
    {
        "text": "BACKGROUND: The [GENE]norepinephrine transporter[\\GENE] (NET) is a high-affinity transporter for [CHEMICAL]catecholamines[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "BACKGROUND: The norepinephrine transporter ([GENE]NET[\\GENE]) is a high-affinity transporter for [CHEMICAL]catecholamines[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "The specificity of tracer uptake was determined by adding the [GENE]NET[\\GENE] inhibitor [CHEMICAL]imipramine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 13
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, [CHEMICAL]formoterol[\\CHEMICAL], broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 2,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, [CHEMICAL]broxaterol[\\CHEMICAL]) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists ([CHEMICAL]epinephrine[\\CHEMICAL], norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 5,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, [CHEMICAL]norepinephrine[\\CHEMICAL], isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, [CHEMICAL]isoproterenol[\\CHEMICAL], fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 6,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, [CHEMICAL]fenoterol[\\CHEMICAL], salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 2,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, [CHEMICAL]salbutamol[\\CHEMICAL], salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, [CHEMICAL]salmeterol[\\CHEMICAL], terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 5,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, [CHEMICAL]terbutalin[\\CHEMICAL], formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 5,
        "major": 2,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists ([CHEMICAL]propranolol[\\CHEMICAL], alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, [CHEMICAL]alprenolol[\\CHEMICAL], atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 2,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, [CHEMICAL]atenolol[\\CHEMICAL], metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 5,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, [CHEMICAL]metoprolol[\\CHEMICAL], bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 2,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, [CHEMICAL]bisoprolol[\\CHEMICAL], carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, [CHEMICAL]carvedilol[\\CHEMICAL], pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 6,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, [CHEMICAL]pindolol[\\CHEMICAL], BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 6,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, [CHEMICAL]BRL 37344[\\CHEMICAL], CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 5,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, [CHEMICAL]CGP 20712[\\CHEMICAL], SR 59230A, CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 5,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, [CHEMICAL]SR 59230A[\\CHEMICAL], CGP 12177, ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 10,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, [CHEMICAL]CGP 12177[\\CHEMICAL], ICI 118551) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 6,
        "len": 55
    },
    {
        "text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, [CHEMICAL]ICI 118551[\\CHEMICAL]) at all three subtypes of [GENE]human beta-adrenergic receptors[\\GENE] in an identical cellular background.",
        "label": 6,
        "major": 6,
        "len": 55
    },
    {
        "text": "Responses to [CHEMICAL]isoproterenol[\\CHEMICAL] could be restored to normal by beta2AR blockade, suggesting a beta2AR-mediated inhibition of [GENE]beta1AR[\\GENE] signalling.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "Adenovirally-mediated overexpression of [GENE]NCX[\\GENE], at levels, which did not alter basal contraction of myocytes, markedly depressed the [CHEMICAL]isoproterenol[\\CHEMICAL] concentration-response curve.",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Responses to [CHEMICAL]isoproterenol[\\CHEMICAL] could be restored to normal by [GENE]beta2AR[\\GENE] blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "Responses to [CHEMICAL]isoproterenol[\\CHEMICAL] could be restored to normal by beta2AR blockade, suggesting a [GENE]beta2AR[\\GENE]-mediated inhibition of beta1AR signalling.",
        "label": 2,
        "major": 4,
        "len": 18
    },
    {
        "text": "The nonsteroidal anti-inflammatory drugs [CHEMICAL]flurbiprofen[\\CHEMICAL] and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by [GENE]COX-1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "The nonsteroidal anti-inflammatory drugs flurbiprofen and [CHEMICAL]ibuprofen[\\CHEMICAL] were modified in an attempt to alter the kinetics of inhibitor binding by [GENE]COX-1[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "Manipulation of kinetic profiles in [CHEMICAL]2-aryl propionic acid[\\CHEMICAL] [GENE]cyclooxygenase[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of [CHEMICAL]GW572016[\\CHEMICAL] to inhibit downstream [GENE]ERK[\\GENE] and Akt activation, despite inhibition of HER2 phosphorylation.",
        "label": 10,
        "major": 3,
        "len": 25
    },
    {
        "text": "Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of [CHEMICAL]GW572016[\\CHEMICAL] to inhibit downstream ERK and [GENE]Akt[\\GENE] activation, despite inhibition of HER2 phosphorylation.",
        "label": 10,
        "major": 3,
        "len": 25
    },
    {
        "text": "Resistance to [CHEMICAL]GW572016[\\CHEMICAL] was not due to a lack of receptor inhibition, but rather with a lack of inhibition of [GENE]ERK[\\GENE] and Akt, suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.",
        "label": 10,
        "major": 4,
        "len": 41
    },
    {
        "text": "Resistance to [CHEMICAL]GW572016[\\CHEMICAL] was not due to a lack of receptor inhibition, but rather with a lack of inhibition of ERK and [GENE]Akt[\\GENE], suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.",
        "label": 10,
        "major": 4,
        "len": 41
    },
    {
        "text": "RESULTS: GW572016 inhibited constitutive and/or ligand-induced [GENE]EGFR[\\GENE] or HER2 [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",
        "label": 1,
        "major": 4,
        "len": 28
    },
    {
        "text": "RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or [GENE]HER2[\\GENE] [CHEMICAL]tyrosine[\\CHEMICAL] phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",
        "label": 1,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]GW572016[\\CHEMICAL] radiosensitized [GENE]EGFR[\\GENE]-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization.",
        "label": 2,
        "major": 10,
        "len": 32
    },
    {
        "text": "GW572016 radiosensitized EGFR-overexpressing cell lines, but [GENE]HER2[\\GENE]-overexpressing cells were unable to form colonies after brief exposure to [CHEMICAL]GW572016[\\CHEMICAL] even in the absence of radiation, and thus could not be evaluated for radiosensitization.",
        "label": 2,
        "major": 10,
        "len": 32
    },
    {
        "text": "Effects of the [GENE]EGFR[\\GENE]/HER2 kinase inhibitor [CHEMICAL]GW572016[\\CHEMICAL] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Effects of the EGFR/[GENE]HER2[\\GENE] kinase inhibitor [CHEMICAL]GW572016[\\CHEMICAL] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Effects of the EGFR/HER2 [GENE]kinase[\\GENE] inhibitor [CHEMICAL]GW572016[\\CHEMICAL] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of [CHEMICAL]GW572016[\\CHEMICAL] to inhibit downstream ERK and Akt activation, despite inhibition of [GENE]HER2[\\GENE] phosphorylation.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "CONCLUSION: [CHEMICAL]GW572016[\\CHEMICAL] potently inhibits receptor phosphorylation in either [GENE]EGFR[\\GENE]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "CONCLUSION: [CHEMICAL]GW572016[\\CHEMICAL] potently inhibits receptor phosphorylation in either EGFR- or [GENE]HER2[\\GENE]-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.",
        "label": 4,
        "major": 4,
        "len": 20
    },
    {
        "text": "To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual [GENE]EGFR[\\GENE]/HER2 inhibitor, [CHEMICAL]GW572016[\\CHEMICAL], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/[GENE]HER2[\\GENE] inhibitor, [CHEMICAL]GW572016[\\CHEMICAL], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.",
        "label": 4,
        "major": 4,
        "len": 46
    },
    {
        "text": "RESULTS: [CHEMICAL]GW572016[\\CHEMICAL] inhibited constitutive and/or ligand-induced [GENE]EGFR[\\GENE] or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "RESULTS: [CHEMICAL]GW572016[\\CHEMICAL] inhibited constitutive and/or ligand-induced EGFR or [GENE]HER2[\\GENE] tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL], but not leptin, regulates [GENE]AMP-activated protein kinase[\\GENE] in pancreatic islets: impact on glucose-stimulated insulin secretion.",
        "label": 2,
        "major": 3,
        "len": 16
    },
    {
        "text": "Incubation with [CHEMICAL]metformin[\\CHEMICAL] (0.2-1 mM) activated [GENE]AMPK[\\GENE] in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",
        "label": 3,
        "major": 3,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL], a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of [GENE]AMP-activated protein kinase[\\GENE] (AMPK).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Metformin[\\CHEMICAL], a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase ([GENE]AMPK[\\GENE]).",
        "label": 3,
        "major": 3,
        "len": 33
    },
    {
        "text": "Whether [CHEMICAL]metformin[\\CHEMICAL] or the satiety factor leptin, which also stimulates [GENE]AMPK[\\GENE] in muscle, regulates this enzyme in pancreatic islets is unknown.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on [CHEMICAL]glucose[\\CHEMICAL]-stimulated [GENE]insulin[\\GENE] secretion.",
        "label": 3,
        "major": 3,
        "len": 16
    },
    {
        "text": "Incubation with [CHEMICAL]metformin[\\CHEMICAL] (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of [GENE]insulin[\\GENE] secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "The inhibitory effects of [CHEMICAL]metformin[\\CHEMICAL] on [GENE]insulin[\\GENE] secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "Increases in [CHEMICAL]glucose[\\CHEMICAL] concentration from 0 to 3 and from 3 to 17 mM inhibited [GENE]AMPK[\\GENE] activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "The ability of this cis-acting [GENE]RAR-RXR binding element[\\GENE] to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an [GENE]octamer transcription factor 1[\\GENE] (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a [GENE]nuclear factor of activated T cells[\\GENE] (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 3,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells ([GENE]NFATc[\\GENE]) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 3,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a [GENE]cyclic AMP response element binding factor[\\GENE] (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 3,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor ([GENE]CREB[\\GENE]) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the [GENE]blr1[\\GENE] gene, were necessary.",
        "label": 2,
        "major": 2,
        "len": 70
    },
    {
        "text": "A transcription factor-transcription factor binding array analysis of nuclear lysate from [CHEMICAL]RA[\\CHEMICAL]-treated cells indicated several prominent RARalpha binding partners; among these, [GENE]Oct1[\\GENE], NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "A transcription factor-transcription factor binding array analysis of nuclear lysate from [CHEMICAL]RA[\\CHEMICAL]-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, [GENE]NFATc3[\\GENE], and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "A transcription factor-transcription factor binding array analysis of nuclear lysate from [CHEMICAL]RA[\\CHEMICAL]-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and [GENE]CREB2[\\GENE] were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "In sum the results of the present study indicate that [CHEMICAL]RA[\\CHEMICAL]-induced expression of blr1 expression depends on a novel [GENE]RA response element[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Within this sequence DNase I footprinting revealed that [CHEMICAL]RA[\\CHEMICAL] induced binding of a nuclear protein complex to an element containing two [GENE]GT boxes[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 23
    },
    {
        "text": "Within this sequence DNase I footprinting revealed that [CHEMICAL]RA[\\CHEMICAL] induced binding of a [GENE]nuclear protein complex[\\GENE] to an element containing two GT boxes.",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "Both [GENE]GT boxes[\\GENE] were needed for binding the complex, and mutation of either GT box caused the loss of transcriptional activation by [CHEMICAL]RA[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 23
    },
    {
        "text": "A transcription factor-transcription factor binding array analysis of nuclear lysate from [CHEMICAL]RA[\\CHEMICAL]-treated cells indicated several prominent [GENE]RARalpha[\\GENE] binding partners; among these, Oct1, NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.",
        "label": 2,
        "major": 2,
        "len": 41
    },
    {
        "text": "A 5'-flanking region capable of supporting [CHEMICAL]RA[\\CHEMICAL]-induced [GENE]blr1[\\GENE] activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of [GENE]blr1[\\GENE] expression by [CHEMICAL]RA[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "A novel retinoic acid-responsive element regulates [CHEMICAL]retinoic acid[\\CHEMICAL]-induced [GENE]BLR1[\\GENE] expression.",
        "label": 3,
        "major": 3,
        "len": 10
    },
    {
        "text": "[CHEMICAL]RA[\\CHEMICAL] is known to induce expression of the [GENE]Burkitt's lymphoma receptor 1[\\GENE] (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "[CHEMICAL]RA[\\CHEMICAL] is known to induce expression of the Burkitt's lymphoma receptor 1 ([GENE]BLR1[\\GENE]) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.",
        "label": 3,
        "major": 3,
        "len": 40
    },
    {
        "text": "In sum the results of the present study indicate that [CHEMICAL]RA[\\CHEMICAL]-induced expression of [GENE]blr1[\\GENE] expression depends on a novel RA response element.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to [CHEMICAL]RA[\\CHEMICAL] also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a [GENE]nuclear factor of activated T cells[\\GENE] (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.",
        "label": 4,
        "major": 2,
        "len": 70
    },
    {
        "text": "[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [CHEMICAL][3H]DMI[\\CHEMICAL] with the [GENE]NET[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "The retention and slow diffusion of [CHEMICAL]DMI[\\CHEMICAL] and nisoxetine from membranes may contribute to their pharmacological and modulatory action on [GENE]NET[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "The retention and slow diffusion of DMI and [CHEMICAL]nisoxetine[\\CHEMICAL] from membranes may contribute to their pharmacological and modulatory action on [GENE]NET[\\GENE].",
        "label": 2,
        "major": 7,
        "len": 21
    },
    {
        "text": "[CHEMICAL][3H]DMI[\\CHEMICAL] trapped in membranes was displaceable by the structurally unrelated [GENE]NET[\\GENE] inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.",
        "label": 2,
        "major": 4,
        "len": 25
    },
    {
        "text": "The persistent membrane retention of [CHEMICAL]desipramine[\\CHEMICAL] causes lasting inhibition of [GENE]norepinephrine transporter[\\GENE] function.",
        "label": 4,
        "major": 9,
        "len": 13
    },
    {
        "text": "[3H]DMI trapped in membranes was displaceable by the structurally unrelated [GENE]NET[\\GENE] inhibitor, [CHEMICAL]nisoxetine[\\CHEMICAL], in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.",
        "label": 4,
        "major": 2,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Irbesartan[\\CHEMICAL] is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype ([GENE]AT1[\\GENE]-receptor).",
        "label": 2,
        "major": 6,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Irbesartan[\\CHEMICAL] may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of [GENE]angiotensin II[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Irbesartan[\\CHEMICAL] may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this [GENE]AT1[\\GENE]-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II.",
        "label": 4,
        "major": 4,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Irbesartan[\\CHEMICAL] is a long-acting [GENE]angiotensin II[\\GENE] antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).",
        "label": 6,
        "major": 6,
        "len": 18
    },
    {
        "text": "We conclude that [CHEMICAL](-)-[(3)H]-CGP12177[\\CHEMICAL] binds at two sites in the recombinant [GENE]beta(1)-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, [GENE]human beta(1)-adrenoceptors[\\GENE], expressed in CHO cells, were labelled with [CHEMICAL](-)-[(3)H]-CGP12177[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two [GENE]beta(1)-adrenoceptor[\\GENE] sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with [CHEMICAL](-)-[(3)H]-CGP12177[\\CHEMICAL].",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist [CHEMICAL](-)-CGP12177[\\CHEMICAL] binds at two beta(1)-adrenoceptor sites, [GENE]human beta(1)-adrenoceptors[\\GENE], expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist [CHEMICAL](-)-CGP12177[\\CHEMICAL] binds at two [GENE]beta(1)-adrenoceptor[\\GENE] sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
        "label": 2,
        "major": 5,
        "len": 25
    },
    {
        "text": "Binding of [CHEMICAL](-)-[3H]-CGP12177[\\CHEMICAL] at two sites in recombinant [GENE]human beta 1-adrenoceptors[\\GENE] and interaction with beta-blockers.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist [CHEMICAL](-)-CGP12177[\\CHEMICAL] binds at two beta(1)-adrenoceptor sites, [GENE]human beta(1)-adrenoceptors[\\GENE], expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
        "label": 5,
        "major": 2,
        "len": 25
    },
    {
        "text": "To verify the hypothesis that the non-conventional partial agonist [CHEMICAL](-)-CGP12177[\\CHEMICAL] binds at two [GENE]beta(1)-adrenoceptor[\\GENE] sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.",
        "label": 5,
        "major": 5,
        "len": 25
    },
    {
        "text": "[GENE]Perforin[\\GENE] release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by [CHEMICAL]IMQ[\\CHEMICAL].",
        "label": 10,
        "major": 3,
        "len": 14
    },
    {
        "text": "[CHEMICAL]Imiquimod[\\CHEMICAL] (IMQ), an activator of [GENE]Toll-like receptor-7[\\GENE] (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "[CHEMICAL]Imiquimod[\\CHEMICAL] (IMQ), an activator of Toll-like receptor-7 ([GENE]TLR-7[\\GENE]), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Imiquimod ([CHEMICAL]IMQ[\\CHEMICAL]), an activator of [GENE]Toll-like receptor-7[\\GENE] (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "Imiquimod ([CHEMICAL]IMQ[\\CHEMICAL]), an activator of Toll-like receptor-7 ([GENE]TLR-7[\\GENE]), induces by several routes a profound anti-viral and anti-tumor effect in vivo.",
        "label": 3,
        "major": 3,
        "len": 20
    },
    {
        "text": "In peripheral lymphocytes of healthy and diseased subjects, [CHEMICAL]IMQ[\\CHEMICAL] induced a significant increase of [GENE]perforin[\\GENE](+) CTLs within 12h in all experiments performed.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of [GENE]perforin[\\GENE](+) CTLs were induced by 2.5 microg/ml [corrected] [CHEMICAL]IMQ[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Imiquimod[\\CHEMICAL], a Toll-like receptor-7 agonist, induces [GENE]perforin[\\GENE] in cytotoxic T lymphocytes in vitro.",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "[CHEMICAL]Imiquimod[\\CHEMICAL], a [GENE]Toll-like receptor-7[\\GENE] agonist, induces perforin in cytotoxic T lymphocytes in vitro.",
        "label": 5,
        "major": 3,
        "len": 13
    },
    {
        "text": "CONCLUSION: [CHEMICAL]Imidapril[\\CHEMICAL] and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [GENE]TGF-beta1[\\GENE], c-Jun in SHR.",
        "label": 4,
        "major": 10,
        "len": 24
    },
    {
        "text": "CONCLUSION: [CHEMICAL]Imidapril[\\CHEMICAL] and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, [GENE]c-Jun[\\GENE] in SHR.",
        "label": 4,
        "major": 10,
        "len": 24
    },
    {
        "text": "CONCLUSION: Imidapril and [CHEMICAL]irbesartan[\\CHEMICAL] can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of [GENE]TGF-beta1[\\GENE], c-Jun in SHR.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "CONCLUSION: Imidapril and [CHEMICAL]irbesartan[\\CHEMICAL] can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, [GENE]c-Jun[\\GENE] in SHR.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Plasma from [CHEMICAL]duloxetine[\\CHEMICAL]-treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to [GENE]human NET[\\GENE] (maximum inhibition was 60%) (P=0.02).",
        "label": 2,
        "major": 4,
        "len": 19
    },
    {
        "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [GENE]NET[\\GENE] by a range of doses of [CHEMICAL]duloxetine[\\CHEMICAL] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.",
        "label": 6,
        "major": 9,
        "len": 37
    },
    {
        "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [GENE]NET[\\GENE] by a range of doses of duloxetine [[CHEMICAL](+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine[\\CHEMICAL]], which blocks the NE reuptake process.",
        "label": 6,
        "major": 6,
        "len": 37
    },
    {
        "text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized [GENE]NET[\\GENE] by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the [CHEMICAL]NE[\\CHEMICAL] reuptake process.",
        "label": 9,
        "major": 9,
        "len": 37
    },
    {
        "text": "[CHEMICAL]Auranofin[\\CHEMICAL], an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [GENE]glutathione peroxidase[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Auranofin[\\CHEMICAL], an antirheumatic gold compound, is an inhibitor of [GENE]selenocysteine enzymes[\\GENE], such as thioredoxin reductase and glutathione peroxidase.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Auranofin[\\CHEMICAL], an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as [GENE]thioredoxin reductase[\\GENE] and glutathione peroxidase.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "There was significantly less [GENE]thioredoxin reductase[\\GENE] activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of [CHEMICAL]auranofin[\\CHEMICAL] used was able to selectively inhibit one of these enzyme systems.",
        "label": 4,
        "major": 4,
        "len": 36
    },
    {
        "text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that [CHEMICAL]gallium[\\CHEMICAL] behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with [GENE]transferrin[\\GENE] and transferrin receptor-mediated endocytosis.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that [CHEMICAL]gallium[\\CHEMICAL] behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and [GENE]transferrin receptor[\\GENE]-mediated endocytosis.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an [CHEMICAL]iron[\\CHEMICAL] analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with [GENE]transferrin[\\GENE] and transferrin receptor-mediated endocytosis.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an [CHEMICAL]iron[\\CHEMICAL] analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and [GENE]transferrin receptor[\\GENE]-mediated endocytosis.",
        "label": 2,
        "major": 2,
        "len": 44
    },
    {
        "text": "Apart from the consequences of iron deprivation, [CHEMICAL]gallium[\\CHEMICAL] exerts cytotoxic effects by direct interaction with the iron-dependent enzyme [GENE]ribonucleotide reductase[\\GENE], resulting in reduced dNTP pools and inhibition of DNA synthesis.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the [CHEMICAL]iron[\\CHEMICAL]-dependent enzyme [GENE]ribonucleotide reductase[\\GENE], resulting in reduced dNTP pools and inhibition of DNA synthesis.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Both the abundance of [GENE]transferrin receptors[\\GENE] and upregulation of ribonucleotide reductase render tumors susceptible to [CHEMICAL]gallium[\\CHEMICAL]-induced cytotoxicity.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Both the abundance of transferrin receptors and upregulation of [GENE]ribonucleotide reductase[\\GENE] render tumors susceptible to [CHEMICAL]gallium[\\CHEMICAL]-induced cytotoxicity.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Furthermore, [CHEMICAL]gallium[\\CHEMICAL] also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on [GENE]vacuolar-type H(+)-ATPases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "However, some experimental findings raise the question whether these effects resulting from the [CHEMICAL]iron[\\CHEMICAL]-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting [GENE]tubulin[\\GENE] polymerization.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of [CHEMICAL]gallium[\\CHEMICAL] are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting [GENE]tubulin[\\GENE] polymerization.",
        "label": 4,
        "major": 4,
        "len": 43
    },
    {
        "text": "Here, we show that the [GENE]synaptic vesicle protein SV2A[\\GENE] is the brain binding site of [CHEMICAL]levetiracetam[\\CHEMICAL] (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "Here, we show that the [GENE]synaptic vesicle protein SV2A[\\GENE] is the brain binding site of levetiracetam ([CHEMICAL]LEV[\\CHEMICAL]), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "The [GENE]synaptic vesicle protein SV2A[\\GENE] is the binding site for the antiepileptic drug [CHEMICAL]levetiracetam[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 14
    },
    {
        "text": "These experimental results suggest that [GENE]SV2A[\\GENE] is the binding site of [CHEMICAL]LEV[\\CHEMICAL] in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "These experimental results suggest that SV2A is the binding site of LEV in the brain and that [CHEMICAL]LEV[\\CHEMICAL] acts by modulating the function of [GENE]SV2A[\\GENE], supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that [GENE]SV2A[\\GENE] is necessary for [CHEMICAL]LEV[\\CHEMICAL] binding.",
        "label": 2,
        "major": 10,
        "len": 25
    },
    {
        "text": "[CHEMICAL]LEV[\\CHEMICAL] and related compounds bind to [GENE]SV2A[\\GENE] expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that [GENE]SV2A[\\GENE] is sufficient for [CHEMICAL]LEV[\\CHEMICAL] binding.",
        "label": 2,
        "major": 2,
        "len": 18
    },
    {
        "text": "Furthermore, there is a high degree of correlation between binding affinities of a series of [CHEMICAL]LEV[\\CHEMICAL] derivatives to [GENE]SV2A[\\GENE] in fibroblasts and to the LEV-binding site in brain.",
        "label": 2,
        "major": 2,
        "len": 28
    },
    {
        "text": "Their affinity for [CHEMICAL]GABA[\\CHEMICAL] was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two [GENE]GABA binding sites[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "[CHEMICAL]GABA[\\CHEMICAL]-evoked currents were completely and reversibly blocked by the competitive [GENE]GABAA receptor[\\GENE] antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "Furthermore, [GENE]GABA receptors[\\GENE] of horizontal cells were modulated by extracellular application of [CHEMICAL]diazepam[\\CHEMICAL], zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Furthermore, [GENE]GABA receptors[\\GENE] of horizontal cells were modulated by extracellular application of diazepam, [CHEMICAL]zolpidem[\\CHEMICAL], methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Furthermore, [GENE]GABA receptors[\\GENE] of horizontal cells were modulated by extracellular application of diazepam, zolpidem, [CHEMICAL]methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate[\\CHEMICAL], pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Furthermore, [GENE]GABA receptors[\\GENE] of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, [CHEMICAL]pentobarbital[\\CHEMICAL], and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "Furthermore, [GENE]GABA receptors[\\GENE] of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and [CHEMICAL]alphaxalone[\\CHEMICAL], thus showing typical pharmacological properties of CNS GABAA receptors.",
        "label": 2,
        "major": 7,
        "len": 28
    },
    {
        "text": "GABA-evoked currents were completely and reversibly blocked by the competitive [GENE]GABAA receptor[\\GENE] antagonist [CHEMICAL]bicuculline[\\CHEMICAL] (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.",
        "label": 6,
        "major": 10,
        "len": 26
    },
    {
        "text": "Cerebral [GENE]histamine H1 receptor[\\GENE] (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [CHEMICAL][(11)C]-doxepin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "Cerebral histamine H1 receptor ([GENE]H(1)R[\\GENE]) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [CHEMICAL][(11)C]-doxepin[\\CHEMICAL].",
        "label": 2,
        "major": 2,
        "len": 24
    },
    {
        "text": "[GENE]Histamine H1-receptor[\\GENE] (H1R) antagonists, or [CHEMICAL]antihistamines[\\CHEMICAL], often induce sedative side effects when used for the treatment of allergic disorders.",
        "label": 6,
        "major": 3,
        "len": 19
    },
    {
        "text": "Histamine H1-receptor ([GENE]H1R[\\GENE]) antagonists, or [CHEMICAL]antihistamines[\\CHEMICAL], often induce sedative side effects when used for the treatment of allergic disorders.",
        "label": 6,
        "major": 3,
        "len": 19
    },
    {
        "text": "A novel membrane sensor for [GENE]histamine H1-receptor[\\GENE] antagonist \"[CHEMICAL]fexofenadine[\\CHEMICAL]\".",
        "label": 6,
        "major": 6,
        "len": 9
    },
    {
        "text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates [CHEMICAL]ZD1694[\\CHEMICAL] (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent [GENE]TS[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 ([CHEMICAL]raltitrexed[\\CHEMICAL], Tomudex) and AG337 (Thymitag) are more specific and potent [GENE]TS[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, [CHEMICAL]Tomudex[\\CHEMICAL]) and AG337 (Thymitag) are more specific and potent [GENE]TS[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and [CHEMICAL]AG337[\\CHEMICAL] (Thymitag) are more specific and potent [GENE]TS[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 ([CHEMICAL]Thymitag[\\CHEMICAL]) are more specific and potent [GENE]TS[\\GENE] inhibitors.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that [GENE]thymidine phosphorylase[\\GENE], the activating enzyme for [CHEMICAL]5-FU[\\CHEMICAL], is expressed at a higher level in tumor tissue compared with normal tissue counterparts.",
        "label": 9,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Orlistat[\\CHEMICAL] is an inhibitor of [GENE]pancreatic lipase[\\GENE] which is able to block the absorption of 30% of ingested fat.",
        "label": 4,
        "major": 4,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Bosentan[\\CHEMICAL] also decreased viability as measured by the [GENE]LDH[\\GENE], MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.",
        "label": 2,
        "major": 10,
        "len": 34
    },
    {
        "text": "[CHEMICAL]Troglitazone[\\CHEMICAL], bosentan and glibenclamide inhibit the [GENE]bile salt export pump[\\GENE] (Bsep) which transports taurocholate into bile.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Troglitazone[\\CHEMICAL], bosentan and glibenclamide inhibit the bile salt export pump ([GENE]Bsep[\\GENE]) which transports taurocholate into bile.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "Troglitazone, [CHEMICAL]bosentan[\\CHEMICAL] and glibenclamide inhibit the [GENE]bile salt export pump[\\GENE] (Bsep) which transports taurocholate into bile.",
        "label": 4,
        "major": 9,
        "len": 16
    },
    {
        "text": "Troglitazone, [CHEMICAL]bosentan[\\CHEMICAL] and glibenclamide inhibit the bile salt export pump ([GENE]Bsep[\\GENE]) which transports taurocholate into bile.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Troglitazone, bosentan and [CHEMICAL]glibenclamide[\\CHEMICAL] inhibit the [GENE]bile salt export pump[\\GENE] (Bsep) which transports taurocholate into bile.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Troglitazone, bosentan and [CHEMICAL]glibenclamide[\\CHEMICAL] inhibit the bile salt export pump ([GENE]Bsep[\\GENE]) which transports taurocholate into bile.",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "Troglitazone, bosentan and glibenclamide inhibit the [GENE]bile salt export pump[\\GENE] (Bsep) which transports [CHEMICAL]taurocholate[\\CHEMICAL] into bile.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump ([GENE]Bsep[\\GENE]) which transports [CHEMICAL]taurocholate[\\CHEMICAL] into bile.",
        "label": 9,
        "major": 9,
        "len": 16
    },
    {
        "text": "Unique binding interactions of [CHEMICAL]valdecoxib[\\CHEMICAL] with [GENE]COX-2[\\GENE] translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "The overall saturation binding affinity for [GENE]COX-2[\\GENE] of [CHEMICAL]valdecoxib[\\CHEMICAL] is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "The overall saturation binding affinity for [GENE]COX-2[\\GENE] of valdecoxib is 2.6 nM (compared with 1.6 nM for [CHEMICAL]celecoxib[\\CHEMICAL], 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "The overall saturation binding affinity for [GENE]COX-2[\\GENE] of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for [CHEMICAL]rofecoxib[\\CHEMICAL], and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "The overall saturation binding affinity for [GENE]COX-2[\\GENE] of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for [CHEMICAL]etoricoxib[\\CHEMICAL]), with a slow off-rate (t(1/2) approximately 98 min).",
        "label": 2,
        "major": 2,
        "len": 35
    },
    {
        "text": "Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of [GENE]COX-2[\\GENE] (110,000 M/s compared with 7000 M/s for [CHEMICAL]rofecoxib[\\CHEMICAL] and 80 M/s for etoricoxib).",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of [GENE]COX-2[\\GENE] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for [CHEMICAL]etoricoxib[\\CHEMICAL]).",
        "label": 2,
        "major": 2,
        "len": 29
    },
    {
        "text": "Unique binding interactions of [CHEMICAL]valdecoxib[\\CHEMICAL] with COX-2 translate into a fast rate of inactivation of [GENE]COX-2[\\GENE] (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "We report here the pharmacological properties of a third selective [GENE]COX-2[\\GENE] inhibitor, [CHEMICAL]valdecoxib[\\CHEMICAL], which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "We report here the pharmacological properties of a third selective COX-2 inhibitor, [CHEMICAL]valdecoxib[\\CHEMICAL], which is the most potent and in vitro selective of the marketed [GENE]COX-2[\\GENE] inhibitors that we have studied.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Valdecoxib[\\CHEMICAL] potently inhibits recombinant [GENE]COX-2[\\GENE], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Valdecoxib potently inhibits recombinant [GENE]COX-2[\\GENE], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for [CHEMICAL]celecoxib[\\CHEMICAL], 0.5 microM for rofecoxib, and 5 microM for etoricoxib.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Valdecoxib potently inhibits recombinant [GENE]COX-2[\\GENE], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for [CHEMICAL]rofecoxib[\\CHEMICAL], and 5 microM for etoricoxib.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Valdecoxib potently inhibits recombinant [GENE]COX-2[\\GENE], with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for [CHEMICAL]etoricoxib[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Valdecoxib[\\CHEMICAL] inhibits [GENE]COX-1[\\GENE] in a competitive fashion only at very high concentrations (IC(50) = 150 microM).",
        "label": 4,
        "major": 4,
        "len": 16
    },
    {
        "text": "The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing [CHEMICAL]prostaglandin[\\CHEMICAL] formation from [GENE]COX-1[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 28
    },
    {
        "text": "An angiotensin II AT1 receptor antagonist, [CHEMICAL]telmisartan[\\CHEMICAL] augments glucose uptake and [GENE]GLUT4[\\GENE] protein expression in 3T3-L1 adipocytes.",
        "label": 3,
        "major": 6,
        "len": 17
    },
    {
        "text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with [CHEMICAL]telmisartan[\\CHEMICAL] caused a dose-dependent increase in mRNA levels for [GENE]PPARgamma[\\GENE] target genes such as aP2 and adiponectin.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with [CHEMICAL]telmisartan[\\CHEMICAL] caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as [GENE]aP2[\\GENE] and adiponectin.",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with [CHEMICAL]telmisartan[\\CHEMICAL] caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and [GENE]adiponectin[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 27
    },
    {
        "text": "Of note, we demonstrated for the first time that [CHEMICAL]telmisartan[\\CHEMICAL] augmented [GENE]GLUT4[\\GENE] protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",
        "label": 3,
        "major": 10,
        "len": 36
    },
    {
        "text": "An [GENE]angiotensin II AT1 receptor[\\GENE] antagonist, [CHEMICAL]telmisartan[\\CHEMICAL] augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.",
        "label": 6,
        "major": 6,
        "len": 17
    },
    {
        "text": "An angiotensin II AT1 receptor antagonist, telmisartan augments [CHEMICAL]glucose[\\CHEMICAL] uptake and [GENE]GLUT4[\\GENE] protein expression in 3T3-L1 adipocytes.",
        "label": 9,
        "major": 6,
        "len": 17
    },
    {
        "text": "Of note, we demonstrated for the first time that telmisartan augmented [GENE]GLUT4[\\GENE] protein expression and [CHEMICAL]2-deoxy glucose[\\CHEMICAL] uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.",
        "label": 9,
        "major": 10,
        "len": 36
    },
    {
        "text": "We found a strong interaction of baseline FEV(1) with the [GENE]Arg16Glycine[\\GENE] ([CHEMICAL]Gly[\\CHEMICAL]) polymorphism in predicting bronchodilator response.",
        "label": 1,
        "major": 2,
        "len": 17
    },
    {
        "text": "We tested the association of [GENE]beta(2)AR[\\GENE] genotypes with asthma severity and bronchodilator response to [CHEMICAL]albuterol[\\CHEMICAL] in Puerto Ricans and Mexicans with asthma.",
        "label": 2,
        "major": 10,
        "len": 22
    },
    {
        "text": "Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme [GENE]tyrosinase[\\GENE], as compared to the standard tyrosinase inhibitors [CHEMICAL]kojic acid[\\CHEMICAL] (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.",
        "label": 4,
        "major": 9,
        "len": 44
    },
    {
        "text": "Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme [GENE]tyrosinase[\\GENE], as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and [CHEMICAL]L-mimosine[\\CHEMICAL] (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.",
        "label": 4,
        "major": 9,
        "len": 44
    },
    {
        "text": "[CHEMICAL]Antag I[\\CHEMICAL] and Antag II did not alter [GENE]oxytocin receptor[\\GENE] number or binding affinity significantly at each time point studied compared with controls.",
        "label": 10,
        "major": 2,
        "len": 23
    },
    {
        "text": "Antag I and [CHEMICAL]Antag II[\\CHEMICAL] did not alter [GENE]oxytocin receptor[\\GENE] number or binding affinity significantly at each time point studied compared with controls.",
        "label": 10,
        "major": 2,
        "len": 23
    },
    {
        "text": "In Experiment 2, [CHEMICAL]TT-235[\\CHEMICAL] induced a significant decrease (p<0.05) in [GENE]oxytocin receptor[\\GENE] number and binding affinity at both 0.5 and 4 hours compared with controls.",
        "label": 2,
        "major": 2,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]TT-235[\\CHEMICAL] may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and [GENE]oxytocin[\\GENE] binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "In Experiment 2, [CHEMICAL]TT-235[\\CHEMICAL] induced a significant decrease (p<0.05) in [GENE]oxytocin receptor[\\GENE] number and binding affinity at both 0.5 and 4 hours compared with controls.",
        "label": 4,
        "major": 2,
        "len": 25
    },
    {
        "text": "In conclusion, [CHEMICAL]TT-235[\\CHEMICAL] may inhibit the uterine response to oxytocin by decreasing [GENE]oxytocin receptor[\\GENE] numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In conclusion, [CHEMICAL]TT-235[\\CHEMICAL] may inhibit the uterine response to [GENE]oxytocin[\\GENE] by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.",
        "label": 4,
        "major": 2,
        "len": 29
    },
    {
        "text": "The purpose of the present study was to confirm the duration of [CHEMICAL]TT-235[\\CHEMICAL] to block [GENE]oxytocin[\\GENE]-induced uterine contractions in estrous rats.",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "Oxytocin antagonist (OTA), [CHEMICAL]TT-235[\\CHEMICAL], was developed by our group and shown to inhibit either spontaneous or [GENE]oxytocin[\\GENE]-induced uterine contractions in primates.",
        "label": 4,
        "major": 6,
        "len": 21
    },
    {
        "text": "In Experiment 1, [CHEMICAL]Antag I[\\CHEMICAL], Antag II and TT-235 inhibited the integrated uterine response to [GENE]oxytocin[\\GENE] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In Experiment 1, Antag I, [CHEMICAL]Antag II[\\CHEMICAL] and TT-235 inhibited the integrated uterine response to [GENE]oxytocin[\\GENE] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In Experiment 1, Antag I, Antag II and [CHEMICAL]TT-235[\\CHEMICAL] inhibited the integrated uterine response to [GENE]oxytocin[\\GENE] at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).",
        "label": 4,
        "major": 4,
        "len": 29
    },
    {
        "text": "In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged [GENE]oxytocin[\\GENE] antagonist activity of [CHEMICAL]TT-235[\\CHEMICAL].",
        "label": 6,
        "major": 2,
        "len": 29
    },
    {
        "text": "[GENE]Oxytocin[\\GENE] antagonist (OTA), [CHEMICAL]TT-235[\\CHEMICAL], was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.",
        "label": 6,
        "major": 4,
        "len": 21
    },
    {
        "text": "In cellular assays, [CHEMICAL]lumiracoxib[\\CHEMICAL] had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of [GENE]COX-1[\\GENE] at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",
        "label": 10,
        "major": 4,
        "len": 33
    },
    {
        "text": "This manuscript presents the preclinical profile of [CHEMICAL]lumiracoxib[\\CHEMICAL], a novel [GENE]cyclooxygenase-2[\\GENE] (COX-2) selective inhibitor.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "This manuscript presents the preclinical profile of [CHEMICAL]lumiracoxib[\\CHEMICAL], a novel cyclooxygenase-2 ([GENE]COX-2[\\GENE]) selective inhibitor.",
        "label": 4,
        "major": 4,
        "len": 14
    },
    {
        "text": "Ex vivo, [CHEMICAL]lumiracoxib[\\CHEMICAL] inhibited [GENE]COX-1[\\GENE]-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",
        "label": 4,
        "major": 4,
        "len": 39
    },
    {
        "text": "Preclinical pharmacology of [CHEMICAL]lumiracoxib[\\CHEMICAL]: a novel selective inhibitor of [GENE]cyclooxygenase-2[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 10
    },
    {
        "text": "However, consistent with its low [GENE]COX-1[\\GENE] inhibitory activity, [CHEMICAL]lumiracoxib[\\CHEMICAL] at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Lumiracoxib[\\CHEMICAL] inhibited purified [GENE]COX-1[\\GENE] and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Lumiracoxib[\\CHEMICAL] inhibited purified COX-1 and [GENE]COX-2[\\GENE] with K(i) values of 3 and 0.06 microM, respectively.",
        "label": 4,
        "major": 4,
        "len": 15
    },
    {
        "text": "However, consistent with its low [GENE]COX-1[\\GENE] inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than [CHEMICAL]diclofenac[\\CHEMICAL] (P<0.05).",
        "label": 4,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Lumiracoxib[\\CHEMICAL] is a highly selective [GENE]COX-2[\\GENE] inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Lumiracoxib is a highly selective [GENE]COX-2[\\GENE] inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with [CHEMICAL]diclofenac[\\CHEMICAL], the reference NSAID, but with much improved gastrointestinal safety.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "In cellular assays, [CHEMICAL]lumiracoxib[\\CHEMICAL] had an IC(50) of 0.14 microM in [GENE]COX-2[\\GENE]-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Ex vivo, lumiracoxib inhibited [GENE]COX-1[\\GENE]-derived [CHEMICAL]thromboxane B(2)[\\CHEMICAL] (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "Ex vivo, lumiracoxib inhibited [GENE]COX-1[\\GENE]-derived thromboxane B(2) ([CHEMICAL]TxB(2)[\\CHEMICAL]) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas [GENE]COX-2[\\GENE]-derived production of [CHEMICAL]prostaglandin E(2)[\\CHEMICAL] (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",
        "label": 9,
        "major": 9,
        "len": 39
    },
    {
        "text": "Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas [GENE]COX-2[\\GENE]-derived production of prostaglandin E(2) ([CHEMICAL]PGE(2)[\\CHEMICAL]) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",
        "label": 9,
        "major": 3,
        "len": 39
    },
    {
        "text": "[CHEMICAL]Denufosol[\\CHEMICAL] is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated [GENE]P2Y(2)[\\GENE] agonists.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "Safety and tolerability of [CHEMICAL]denufosol tetrasodium[\\CHEMICAL] inhalation solution, a novel [GENE]P2Y2 receptor[\\GENE] agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.",
        "label": 5,
        "major": 5,
        "len": 27
    },
    {
        "text": "[CHEMICAL]Denufosol tetrasodium[\\CHEMICAL] (INS37217) is a selective [GENE]P2Y(2)[\\GENE] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
        "label": 5,
        "major": 3,
        "len": 34
    },
    {
        "text": "Denufosol tetrasodium ([CHEMICAL]INS37217[\\CHEMICAL]) is a selective [GENE]P2Y(2)[\\GENE] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.",
        "label": 5,
        "major": 5,
        "len": 34
    },
    {
        "text": "The [CHEMICAL]Cl(-)[\\CHEMICAL] secretory response is mediated via a non-[GENE]CFTR[\\GENE] pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.",
        "label": 9,
        "major": 9,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Dextromethorphan[\\CHEMICAL] and dimemorfan are high-affinity ligands at [GENE]sigma1 receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 9
    },
    {
        "text": "Dextromethorphan and [CHEMICAL]dimemorfan[\\CHEMICAL] are high-affinity ligands at [GENE]sigma1 receptors[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 9
    },
    {
        "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of [CHEMICAL]dextromethorphan[\\CHEMICAL] or dimemorfan is, at least in part, related to [GENE]sigma1 receptor[\\GENE]-activated modulation of AP-1 transcription factors.",
        "label": 2,
        "major": 7,
        "len": 41
    },
    {
        "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of [CHEMICAL]dextromethorphan[\\CHEMICAL] or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of [GENE]AP-1[\\GENE] transcription factors.",
        "label": 2,
        "major": 3,
        "len": 41
    },
    {
        "text": "The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via [GENE]sigma1 receptor[\\GENE] activation: comparison with the effects of [CHEMICAL]dextromethorphan[\\CHEMICAL].",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or [CHEMICAL]dimemorfan[\\CHEMICAL] is, at least in part, related to [GENE]sigma1 receptor[\\GENE]-activated modulation of AP-1 transcription factors.",
        "label": 2,
        "major": 7,
        "len": 41
    },
    {
        "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or [CHEMICAL]dimemorfan[\\CHEMICAL] is, at least in part, related to sigma1 receptor-activated modulation of [GENE]AP-1[\\GENE] transcription factors.",
        "label": 2,
        "major": 7,
        "len": 41
    },
    {
        "text": "Dimemorfan pre-treatment also attenuated the [CHEMICAL]KA[\\CHEMICAL]-induced increases in c-fos/c-jun expression, [GENE]activator protein (AP)-1[\\GENE] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "The dextromethorphan analog [CHEMICAL]dimemorfan[\\CHEMICAL] attenuates kainate-induced seizures via [GENE]sigma1 receptor[\\GENE] activation: comparison with the effects of dextromethorphan.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "The [CHEMICAL]dextromethorphan[\\CHEMICAL] analog dimemorfan attenuates kainate-induced seizures via [GENE]sigma1 receptor[\\GENE] activation: comparison with the effects of dextromethorphan.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Dimemorfan pre-treatment also attenuated the [CHEMICAL]KA[\\CHEMICAL]-induced increases in [GENE]c-fos[\\GENE]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "Dimemorfan pre-treatment also attenuated the [CHEMICAL]KA[\\CHEMICAL]-induced increases in c-fos/[GENE]c-jun[\\GENE] expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 3,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Dimemorfan[\\CHEMICAL] pre-treatment also attenuated the KA-induced increases in [GENE]c-fos[\\GENE]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Dimemorfan[\\CHEMICAL] pre-treatment also attenuated the KA-induced increases in c-fos/[GENE]c-jun[\\GENE] expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Dimemorfan[\\CHEMICAL] pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, [GENE]activator protein (AP)-1[\\GENE] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.",
        "label": 4,
        "major": 3,
        "len": 28
    },
    {
        "text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective [GENE]sigma1 receptor[\\GENE] antagonist [CHEMICAL]BD 1047[\\CHEMICAL], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.",
        "label": 6,
        "major": 6,
        "len": 41
    },
    {
        "text": "For both agonists, important binding domains were the extracellular [CHEMICAL]N[\\CHEMICAL]-terminus (=E1) and the extracellular loops E2 and E3 from the [GENE]oxytocin receptor[\\GENE].",
        "label": 1,
        "major": 2,
        "len": 22
    },
    {
        "text": "In contrast, the binding of [CHEMICAL]barusiban[\\CHEMICAL] was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the [GENE]vasopressin V2 receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The binding domain of [CHEMICAL]barusiban[\\CHEMICAL] differs from the binding domain of the agonists and the nonselective [GENE]oxytocin receptor[\\GENE] antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies.",
        "label": 2,
        "major": 6,
        "len": 27
    },
    {
        "text": "We have analyzed binding domains of the [GENE]oxytocin receptor[\\GENE] for [CHEMICAL]barusiban[\\CHEMICAL], a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.",
        "label": 2,
        "major": 5,
        "len": 33
    },
    {
        "text": "Binding domains of the [GENE]oxytocin receptor[\\GENE] for the selective oxytocin receptor antagonist [CHEMICAL]barusiban[\\CHEMICAL] in comparison to the agonists oxytocin and carbetocin.",
        "label": 2,
        "major": 2,
        "len": 21
    },
    {
        "text": "For the vasopressin V1A/oxytocin receptor antagonist [CHEMICAL]atosiban[\\CHEMICAL], none of the receptor constructs were able to provide a binding with higher affinity than the starting [GENE]vasopressin V2 receptor[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [GENE]vasopressin V1A/oxytocin receptor[\\GENE] antagonist atosiban and the agonists [CHEMICAL]oxytocin[\\CHEMICAL] and carbetocin.",
        "label": 5,
        "major": 6,
        "len": 33
    },
    {
        "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [GENE]vasopressin V1A/oxytocin receptor[\\GENE] antagonist atosiban and the agonists oxytocin and [CHEMICAL]carbetocin[\\CHEMICAL].",
        "label": 5,
        "major": 2,
        "len": 33
    },
    {
        "text": "Binding domains of the oxytocin receptor for the selective [GENE]oxytocin receptor[\\GENE] antagonist barusiban in comparison to the agonists [CHEMICAL]oxytocin[\\CHEMICAL] and carbetocin.",
        "label": 5,
        "major": 2,
        "len": 21
    },
    {
        "text": "Binding domains of the oxytocin receptor for the selective [GENE]oxytocin receptor[\\GENE] antagonist barusiban in comparison to the agonists oxytocin and [CHEMICAL]carbetocin[\\CHEMICAL].",
        "label": 5,
        "major": 6,
        "len": 21
    },
    {
        "text": "The binding domain of barusiban differs from the binding domain of the agonists and the nonselective [GENE]oxytocin receptor[\\GENE] antagonist [CHEMICAL]d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin[\\CHEMICAL] that has been used in previous studies.",
        "label": 6,
        "major": 2,
        "len": 27
    },
    {
        "text": "We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined [GENE]vasopressin V1A/oxytocin receptor[\\GENE] antagonist [CHEMICAL]atosiban[\\CHEMICAL] and the agonists oxytocin and carbetocin.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "We have analyzed binding domains of the oxytocin receptor for [CHEMICAL]barusiban[\\CHEMICAL], a highly selective [GENE]oxytocin receptor[\\GENE] antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.",
        "label": 6,
        "major": 6,
        "len": 33
    },
    {
        "text": "Binding domains of the oxytocin receptor for the selective [GENE]oxytocin receptor[\\GENE] antagonist [CHEMICAL]barusiban[\\CHEMICAL] in comparison to the agonists oxytocin and carbetocin.",
        "label": 6,
        "major": 5,
        "len": 21
    },
    {
        "text": "For the [GENE]vasopressin V1A/oxytocin receptor[\\GENE] antagonist [CHEMICAL]atosiban[\\CHEMICAL], none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.",
        "label": 6,
        "major": 2,
        "len": 27
    },
    {
        "text": "Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that [CHEMICAL]AZC[\\CHEMICAL] and PCA did not profoundly affect on [GENE]CD3-zeta chain[\\GENE] transcription in Jurkat T leukemia cells clone E6-1.",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and [CHEMICAL]PCA[\\CHEMICAL] did not profoundly affect on [GENE]CD3-zeta chain[\\GENE] transcription in Jurkat T leukemia cells clone E6-1.",
        "label": 10,
        "major": 10,
        "len": 30
    },
    {
        "text": "However, the flowcytometric analysis revealed that [CHEMICAL]AZC[\\CHEMICAL] and PCA decreased intracellular contents of [GENE]CD3-zeta chain[\\GENE] in these cells in dose dependent manner.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "However, the flowcytometric analysis revealed that AZC and [CHEMICAL]PCA[\\CHEMICAL] decreased intracellular contents of [GENE]CD3-zeta chain[\\GENE] in these cells in dose dependent manner.",
        "label": 4,
        "major": 4,
        "len": 22
    },
    {
        "text": "The compounds [CHEMICAL]5'-azacytidine[\\CHEMICAL] (AZC) and procainamide (PCA) belong to inhibitors of [GENE]DNMT1[\\GENE], whose low activity correlates with increase in transcription of various genes.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The compounds 5'-azacytidine ([CHEMICAL]AZC[\\CHEMICAL]) and procainamide (PCA) belong to inhibitors of [GENE]DNMT1[\\GENE], whose low activity correlates with increase in transcription of various genes.",
        "label": 4,
        "major": 3,
        "len": 23
    },
    {
        "text": "The compounds 5'-azacytidine (AZC) and [CHEMICAL]procainamide[\\CHEMICAL] (PCA) belong to inhibitors of [GENE]DNMT1[\\GENE], whose low activity correlates with increase in transcription of various genes.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "The compounds 5'-azacytidine (AZC) and procainamide ([CHEMICAL]PCA[\\CHEMICAL]) belong to inhibitors of [GENE]DNMT1[\\GENE], whose low activity correlates with increase in transcription of various genes.",
        "label": 4,
        "major": 4,
        "len": 23
    },
    {
        "text": "These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to [GENE]TS[\\GENE] inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate ([CHEMICAL]FdUMP[\\CHEMICAL]).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "Clinical studies in cancer patients treated with the new [CHEMICAL]fluoropyrimidine[\\CHEMICAL] analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new [CHEMICAL]fluoropyrimidine[\\CHEMICAL] analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue [CHEMICAL]capecitabine[\\CHEMICAL] (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue [CHEMICAL]capecitabine[\\CHEMICAL] (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ([CHEMICAL]N4-pentoxycarbonyl-5'-5-fluorocytidine[\\CHEMICAL]) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine ([CHEMICAL]N4-pentoxycarbonyl-5'-5-fluorocytidine[\\CHEMICAL]) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma [CHEMICAL]2'-deoxyuridine[\\CHEMICAL] was significantly elevated after 1 week of treatment, consistent with inhibition of [GENE]thymidylate synthase[\\GENE] (TS).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma [CHEMICAL]2'-deoxyuridine[\\CHEMICAL] was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase ([GENE]TS[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "These findings suggest that the mechanism of antiproliferative toxicity of [CHEMICAL]capecitabine[\\CHEMICAL] is at least partly due to [GENE]TS[\\GENE] inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to [GENE]TS[\\GENE] inhibitory activity of its active metabolite [CHEMICAL]5-fluoro-2'-deoxyuridine monophosphate[\\CHEMICAL] (FdUMP).",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "An in vitro kinase assay showed that [CHEMICAL]imatinib[\\CHEMICAL] did not directly affect EGFR [GENE]kinase[\\GENE] activity, suggesting involvement of EGFR-activating molecules.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "An in vitro kinase assay showed that [CHEMICAL]imatinib[\\CHEMICAL] did not directly affect EGFR kinase activity, suggesting involvement of [GENE]EGFR[\\GENE]-activating molecules.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "An in vitro kinase assay showed that [CHEMICAL]imatinib[\\CHEMICAL] did not directly affect [GENE]EGFR[\\GENE] kinase activity, suggesting involvement of EGFR-activating molecules.",
        "label": 2,
        "major": 10,
        "len": 20
    },
    {
        "text": "Together, these results suggested that [CHEMICAL]imatinib[\\CHEMICAL] affects [GENE]EGFR[\\GENE] activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "Induction of [GENE]heparin-binding EGF-like growth factor[\\GENE] and activation of EGF receptor in [CHEMICAL]imatinib mesylate[\\CHEMICAL]-treated squamous carcinoma cells.",
        "label": 2,
        "major": 3,
        "len": 17
    },
    {
        "text": "Together, these results suggested that [CHEMICAL]imatinib[\\CHEMICAL] affects [GENE]EGFR[\\GENE] activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands.",
        "label": 2,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL]-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of [GENE]EGFR[\\GENE] in this process.",
        "label": 3,
        "major": 6,
        "len": 18
    },
    {
        "text": "Western blot analysis of cells incubated with [CHEMICAL]imatinib[\\CHEMICAL] demonstrated activation of [GENE]EGFR[\\GENE] and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "Induction of heparin-binding EGF-like growth factor and activation of [GENE]EGF receptor[\\GENE] in [CHEMICAL]imatinib mesylate[\\CHEMICAL]-treated squamous carcinoma cells.",
        "label": 3,
        "major": 3,
        "len": 17
    },
    {
        "text": "Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced [CHEMICAL]imatinib[\\CHEMICAL]-mediated [GENE]mitogen activated protein kinase[\\GENE] (MAPK) activation.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced [CHEMICAL]imatinib[\\CHEMICAL]-mediated mitogen activated protein kinase ([GENE]MAPK[\\GENE]) activation.",
        "label": 3,
        "major": 4,
        "len": 28
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic [GENE]MAPK[\\GENE] activation.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Although, [CHEMICAL]imatinib[\\CHEMICAL] primarily inhibits tyrosine kinases, it also stimulates the activity of [GENE]EGFR[\\GENE] tyrosine kinase in head and neck squamous tumors.",
        "label": 3,
        "major": 4,
        "len": 21
    },
    {
        "text": "Although, [CHEMICAL]imatinib[\\CHEMICAL] primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR [GENE]tyrosine kinase[\\GENE] in head and neck squamous tumors.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of [CHEMICAL]imatinib[\\CHEMICAL]-induced changes in cell morphology and growth similar to changes associated with [GENE]epidermal growth factor receptor[\\GENE] (EGFR) activation.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of [CHEMICAL]imatinib[\\CHEMICAL]-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor ([GENE]EGFR[\\GENE]) activation.",
        "label": 3,
        "major": 3,
        "len": 31
    },
    {
        "text": "Western blot analysis of cells incubated with [CHEMICAL]imatinib[\\CHEMICAL] demonstrated activation of [GENE]EGFR[\\GENE] and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.",
        "label": 3,
        "major": 4,
        "len": 33
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] stimulated the rapid release of soluble [GENE]HB-EGF[\\GENE] and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound [GENE]HB-EGF[\\GENE], which correlated with biphasic MAPK activation.",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Together, these results suggested that [CHEMICAL]imatinib[\\CHEMICAL] affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous [GENE]EGFR[\\GENE]-activating ligands.",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor ([GENE]PDGFR[\\GENE]), and c-kit kinases.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and [GENE]c-kit[\\GENE] kinases.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit [GENE]kinases[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a [GENE]tyrosine kinase[\\GENE] inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a tyrosine kinase inhibitor of the [GENE]ABL[\\GENE], platelet-derived growth factor receptor (PDGFR), and c-kit kinases.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Imatinib mesylate[\\CHEMICAL] is a tyrosine kinase inhibitor of the ABL, [GENE]platelet-derived growth factor receptor[\\GENE] (PDGFR), and c-kit kinases.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Although, [CHEMICAL]imatinib[\\CHEMICAL] primarily inhibits [GENE]tyrosine kinases[\\GENE], it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "In the presence of [GENE]IL-18[\\GENE], [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 2,
        "major": 9,
        "len": 32
    },
    {
        "text": "The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of [GENE]HMG-CoA reductase[\\GENE] in the action of [CHEMICAL]simvastatin[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 28
    },
    {
        "text": "The IL-18 production is located upstream of the [GENE]cytokine[\\GENE] cascade activated by [CHEMICAL]simvastatin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 13
    },
    {
        "text": "In the presence of IL-18, [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of ICAM-1 and CD40 as well as the production of [GENE]IL-12[\\GENE], TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 3,
        "major": 9,
        "len": 32
    },
    {
        "text": "In the presence of IL-18, [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, [GENE]TNF-alpha[\\GENE] and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 3,
        "major": 9,
        "len": 32
    },
    {
        "text": "In the presence of IL-18, [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and [GENE]IFN-gamma[\\GENE] in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 3,
        "major": 9,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL] induces [GENE]interleukin-18[\\GENE] production in human peripheral blood mononuclear cells.",
        "label": 3,
        "major": 9,
        "len": 10
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL], an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of [GENE]interleukin (IL)-18[\\GENE], tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL], an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, [GENE]tumor necrosis factor (TNF)-alpha[\\GENE] and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL], an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and [GENE]interferon (IFN)-gamma[\\GENE] in human peripheral blood mononuclear cells (PBMC).",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "The [GENE]IL-18[\\GENE] production is located upstream of the cytokine cascade activated by [CHEMICAL]simvastatin[\\CHEMICAL].",
        "label": 3,
        "major": 9,
        "len": 13
    },
    {
        "text": "Moreover, [CHEMICAL]simvastatin[\\CHEMICAL] concentration-dependently inhibited the expression of ICAM-1 and induced the expression of [GENE]CD40[\\GENE] on monocytes.",
        "label": 3,
        "major": 4,
        "len": 16
    },
    {
        "text": "In the presence of IL-18, [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of [GENE]ICAM-1[\\GENE] and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 4,
        "major": 9,
        "len": 32
    },
    {
        "text": "In the presence of IL-18, [CHEMICAL]simvastatin[\\CHEMICAL] suppressed the expression of ICAM-1 and [GENE]CD40[\\GENE] as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.",
        "label": 4,
        "major": 9,
        "len": 32
    },
    {
        "text": "Moreover, [CHEMICAL]simvastatin[\\CHEMICAL] concentration-dependently inhibited the expression of [GENE]ICAM-1[\\GENE] and induced the expression of CD40 on monocytes.",
        "label": 4,
        "major": 3,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL], an [GENE]HMG-CoA reductase[\\GENE] inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "[CHEMICAL]Simvastatin[\\CHEMICAL], an HMG-CoA reductase inhibitor with mild inhibition of [GENE]LFA-1[\\GENE], induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The effects of simvastatin were abolished by the addition of the product of the [GENE]HMG-CoA reductase[\\GENE], [CHEMICAL]mevalonate[\\CHEMICAL], indicating the involvement of HMG-CoA reductase in the action of simvastatin.",
        "label": 9,
        "major": 9,
        "len": 28
    },
    {
        "text": "We report on the inhibitory activity of the NSAIDs meloxicam, [CHEMICAL]carprofen[\\CHEMICAL], phenylbutazone and flunixin, on blood [GENE]cyclooxygenases[\\GENE] in the horse using in vitro enzyme-linked assays.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, [CHEMICAL]phenylbutazone[\\CHEMICAL] and flunixin, on blood [GENE]cyclooxygenases[\\GENE] in the horse using in vitro enzyme-linked assays.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and [CHEMICAL]flunixin[\\CHEMICAL], on blood [GENE]cyclooxygenases[\\GENE] in the horse using in vitro enzyme-linked assays.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[GENE]COX-1[\\GENE] and COX-2 inhibition in horse blood by [CHEMICAL]phenylbutazone[\\CHEMICAL], flunixin, carprofen and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "COX-1 and [GENE]COX-2[\\GENE] inhibition in horse blood by [CHEMICAL]phenylbutazone[\\CHEMICAL], flunixin, carprofen and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[GENE]COX-1[\\GENE] and COX-2 inhibition in horse blood by phenylbutazone, [CHEMICAL]flunixin[\\CHEMICAL], carprofen and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "COX-1 and [GENE]COX-2[\\GENE] inhibition in horse blood by phenylbutazone, [CHEMICAL]flunixin[\\CHEMICAL], carprofen and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[GENE]COX-1[\\GENE] and COX-2 inhibition in horse blood by phenylbutazone, flunixin, [CHEMICAL]carprofen[\\CHEMICAL] and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "COX-1 and [GENE]COX-2[\\GENE] inhibition in horse blood by phenylbutazone, flunixin, [CHEMICAL]carprofen[\\CHEMICAL] and meloxicam: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "[GENE]COX-1[\\GENE] and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and [CHEMICAL]meloxicam[\\CHEMICAL]: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "COX-1 and [GENE]COX-2[\\GENE] inhibition in horse blood by phenylbutazone, flunixin, carprofen and [CHEMICAL]meloxicam[\\CHEMICAL]: an in vitro analysis.",
        "label": 4,
        "major": 4,
        "len": 17
    },
    {
        "text": "As expected, comparison of IC50 indicated that [CHEMICAL]meloxicam[\\CHEMICAL] and carprofen are more selective inhibitors of [GENE]COX-2[\\GENE] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "As expected, comparison of IC50 indicated that meloxicam and [CHEMICAL]carprofen[\\CHEMICAL] are more selective inhibitors of [GENE]COX-2[\\GENE] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of [GENE]COX-2[\\GENE] than [CHEMICAL]phenylbutazone[\\CHEMICAL] and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of [GENE]COX-2[\\GENE] than phenylbutazone and [CHEMICAL]flunixin[\\CHEMICAL]; meloxicam was the most advantageous for horses of four NSAIDs examined.",
        "label": 4,
        "major": 4,
        "len": 31
    },
    {
        "text": "We report on the inhibitory activity of the NSAIDs [CHEMICAL]meloxicam[\\CHEMICAL], carprofen, phenylbutazone and flunixin, on blood [GENE]cyclooxygenases[\\GENE] in the horse using in vitro enzyme-linked assays.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Treatment with [CHEMICAL]valsartan[\\CHEMICAL], doxazosin, or N-acetylcysteine did not significantly affect [GENE]HIF-1alpha[\\GENE] and VEGF proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Treatment with [CHEMICAL]valsartan[\\CHEMICAL], doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and [GENE]VEGF[\\GENE] proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Treatment with valsartan, [CHEMICAL]doxazosin[\\CHEMICAL], or N-acetylcysteine did not significantly affect [GENE]HIF-1alpha[\\GENE] and VEGF proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Treatment with valsartan, [CHEMICAL]doxazosin[\\CHEMICAL], or N-acetylcysteine did not significantly affect HIF-1alpha and [GENE]VEGF[\\GENE] proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Treatment with valsartan, doxazosin, or [CHEMICAL]N-acetylcysteine[\\CHEMICAL] did not significantly affect [GENE]HIF-1alpha[\\GENE] and VEGF proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "Treatment with valsartan, doxazosin, or [CHEMICAL]N-acetylcysteine[\\CHEMICAL] did not significantly affect HIF-1alpha and [GENE]VEGF[\\GENE] proteins expression in the banding groups.",
        "label": 10,
        "major": 10,
        "len": 19
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] prevents cardiac hypertrophy and overexpression of [GENE]hypoxia-inducible factor-1alpha[\\GENE] and vascular endothelial growth factor in pressure-overloaded rat heart.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "[CHEMICAL]Carvedilol[\\CHEMICAL] prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and [GENE]vascular endothelial growth factor[\\GENE] in pressure-overloaded rat heart.",
        "label": 4,
        "major": 3,
        "len": 18
    },
    {
        "text": "Increased immunohistochemical labeling of [GENE]HIF-1alpha[\\GENE], VEGF, and BNP in the ventricular myocardium was observed in the banding group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Increased immunohistochemical labeling of HIF-1alpha, [GENE]VEGF[\\GENE], and BNP in the ventricular myocardium was observed in the banding group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "Increased immunohistochemical labeling of HIF-1alpha, VEGF, and [GENE]BNP[\\GENE] in the ventricular myocardium was observed in the banding group and [CHEMICAL]carvedilol[\\CHEMICAL] again normalized the labeling.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "The reported mechanism of [CHEMICAL]imatinib[\\CHEMICAL] resistance in GISTs involves missense mutation in the [GENE]kinase domain[\\GENE] of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala.",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "The reported mechanism of [CHEMICAL]imatinib[\\CHEMICAL] resistance in GISTs involves missense mutation in the kinase domain of [GENE]KIT,[\\GENE] including Thr670Ile, Tyr823Asp, and Val654Ala.",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "The reported mechanism of [CHEMICAL]imatinib[\\CHEMICAL] resistance in GISTs involves missense mutation in the kinase domain of KIT, including [GENE]Thr670Ile[\\GENE], Tyr823Asp, and Val654Ala.",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "The reported mechanism of [CHEMICAL]imatinib[\\CHEMICAL] resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, [GENE]Tyr823Asp[\\GENE], and Val654Ala.",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "The reported mechanism of [CHEMICAL]imatinib[\\CHEMICAL] resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and [GENE]Val654Ala[\\GENE].",
        "label": 10,
        "major": 1,
        "len": 22
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [GENE]KIT[\\GENE], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [GENE]ABL[\\GENE], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [GENE]BCR[\\GENE]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[GENE]ABL[\\GENE], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [GENE]PDGFRA[\\GENE], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "[CHEMICAL]Imatinib[\\CHEMICAL] (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [GENE]PDGFRB,[\\GENE] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [GENE]KIT[\\GENE], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [GENE]ABL[\\GENE], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [GENE]BCR[\\GENE]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[GENE]ABL[\\GENE], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [GENE]PDGFRA[\\GENE], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib ([CHEMICAL]STI571[\\CHEMICAL], Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [GENE]PDGFRB,[\\GENE] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [GENE]KIT[\\GENE], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [GENE]ABL[\\GENE], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [GENE]BCR[\\GENE]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[GENE]ABL[\\GENE], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [GENE]PDGFRA[\\GENE], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, [CHEMICAL]Gleevec[\\CHEMICAL], Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [GENE]PDGFRB,[\\GENE] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [GENE]KIT[\\GENE], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [GENE]ABL[\\GENE], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [GENE]BCR[\\GENE]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[GENE]ABL[\\GENE], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [GENE]PDGFRA[\\GENE], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Imatinib (STI571, Gleevec, [CHEMICAL]Glivec[\\CHEMICAL]; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [GENE]PDGFRB,[\\GENE] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.",
        "label": 4,
        "major": 4,
        "len": 40
    },
    {
        "text": "Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific [CHEMICAL][(3)H]histamine[\\CHEMICAL] binding to the [GENE]hH(4)R[\\GENE] at concentrations up to 10 microM.",
        "label": 2,
        "major": 6,
        "len": 30
    },
    {
        "text": "Most of the tested H(2)R agonists and [CHEMICAL]imidazole[\\CHEMICAL]-based [GENE]H(3)R[\\GENE] ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.",
        "label": 2,
        "major": 5,
        "len": 30
    },
    {
        "text": "Most of the tested H(2)R agonists and [CHEMICAL]imidazole[\\CHEMICAL]-based H(3)R ligands show micromolar-to-nanomolar range [GENE]hH(4)R[\\GENE] affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.",
        "label": 2,
        "major": 5,
        "len": 30
    },
    {
        "text": "Interestingly, we identified [CHEMICAL]4-methylhistamine[\\CHEMICAL] as a high-affinity [GENE]H(4)R[\\GENE] ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Interestingly, we identified [CHEMICAL]4-methylhistamine[\\CHEMICAL] as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the [GENE]hH(4)R[\\GENE] over the other histamine receptor subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "Interestingly, we identified [CHEMICAL]4-methylhistamine[\\CHEMICAL] as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other [GENE]histamine receptor[\\GENE] subtypes.",
        "label": 2,
        "major": 2,
        "len": 27
    },
    {
        "text": "The identification of [CHEMICAL]4-methylhistamine[\\CHEMICAL] as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the [GENE]H(4)R[\\GENE].",
        "label": 2,
        "major": 5,
        "len": 24
    },
    {
        "text": "Moreover, [CHEMICAL]4-methylhistamine[\\CHEMICAL] potently activated the [GENE]hH(4)R[\\GENE] (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",
        "label": 3,
        "major": 6,
        "len": 31
    },
    {
        "text": "Most of the tested H(2)R agonists and [CHEMICAL]imidazole[\\CHEMICAL]-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [GENE]hH(4)R[\\GENE] activities, ranging from full agonists to inverse agonists.",
        "label": 5,
        "major": 2,
        "len": 30
    },
    {
        "text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of [CHEMICAL]4-methylhistamine[\\CHEMICAL] as the first potent and selective [GENE]H4 receptor[\\GENE] agonist.",
        "label": 5,
        "major": 5,
        "len": 26
    },
    {
        "text": "The identification of [CHEMICAL]4-methylhistamine[\\CHEMICAL] as a potent [GENE]H(4)R[\\GENE] agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.",
        "label": 5,
        "major": 5,
        "len": 24
    },
    {
        "text": "Most of the tested H(2)R agonists and [CHEMICAL]imidazole[\\CHEMICAL]-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic [GENE]hH(4)R[\\GENE] activities, ranging from full agonists to inverse agonists.",
        "label": 5,
        "major": 2,
        "len": 30
    },
    {
        "text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective [GENE]H(4)R[\\GENE] antagonist [CHEMICAL]JNJ 7777120[\\CHEMICAL] [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).",
        "label": 6,
        "major": 3,
        "len": 31
    },
    {
        "text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective [GENE]H(4)R[\\GENE] antagonist JNJ 7777120 [[CHEMICAL]1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine[\\CHEMICAL]] (pA(2) = 7.8).",
        "label": 6,
        "major": 6,
        "len": 31
    },
    {
        "text": "Late-onset diarrhea appears to be associated with intestinal exposure to [CHEMICAL]SN-38[\\CHEMICAL] (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to [GENE]Topo I[\\GENE] and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.",
        "label": 2,
        "major": 3,
        "len": 42
    },
    {
        "text": "Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 ([CHEMICAL]7-ethyl-10-hydroxycamptothecin[\\CHEMICAL]), the major active metabolite of CPT-11, which may bind to [GENE]Topo I[\\GENE] and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.",
        "label": 2,
        "major": 3,
        "len": 42
    },
    {
        "text": "Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of [CHEMICAL]CPT-11[\\CHEMICAL], which may bind to [GENE]Topo I[\\GENE] and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.",
        "label": 2,
        "major": 2,
        "len": 42
    },
    {
        "text": "Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of [GENE]acetylcholinesterase[\\GENE] activity, which can be eliminated by administration of [CHEMICAL]atropine[\\CHEMICAL].",
        "label": 3,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]CPT-11[\\CHEMICAL] and SN-38 may also stimulate the production of pro-inflammatory [GENE]cytokines[\\GENE] and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "CPT-11 and [CHEMICAL]SN-38[\\CHEMICAL] may also stimulate the production of pro-inflammatory [GENE]cytokines[\\GENE] and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).",
        "label": 3,
        "major": 3,
        "len": 22
    },
    {
        "text": "Irinotecan (CPT-11, [CHEMICAL]7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin[\\CHEMICAL]) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [GENE]DNA topoisomerase I[\\GENE] (Topo I).",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "Irinotecan (CPT-11, [CHEMICAL]7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin[\\CHEMICAL]) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ([GENE]Topo I[\\GENE]).",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "Early-onset diarrhea is observed immediately after [CHEMICAL]CPT-11[\\CHEMICAL] infusion and probably due to the inhibition of [GENE]acetylcholinesterase[\\GENE] activity, which can be eliminated by administration of atropine.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "[CHEMICAL]Irinotecan[\\CHEMICAL] (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [GENE]DNA topoisomerase I[\\GENE] (Topo I).",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Irinotecan[\\CHEMICAL] (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ([GENE]Topo I[\\GENE]).",
        "label": 4,
        "major": 4,
        "len": 21
    },
    {
        "text": "Irinotecan ([CHEMICAL]CPT-11[\\CHEMICAL], 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting [GENE]DNA topoisomerase I[\\GENE] (Topo I).",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "Irinotecan ([CHEMICAL]CPT-11[\\CHEMICAL], 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I ([GENE]Topo I[\\GENE]).",
        "label": 4,
        "major": 10,
        "len": 21
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, [CHEMICAL]N6-methyl-(R)-roscovitine[\\CHEMICAL], and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to [GENE]CDKs[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and [CHEMICAL]O6-(R)-roscovitine[\\CHEMICAL], the two latter derivatives being designed to bind to PDXK but not to [GENE]CDKs[\\GENE].",
        "label": 10,
        "major": 2,
        "len": 32
    },
    {
        "text": "Affinity chromatography investigations have shown that [CHEMICAL](R)-roscovitine[\\CHEMICAL] also interacts with [GENE]PDXK[\\GENE].",
        "label": 2,
        "major": 2,
        "len": 11
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of [GENE]PDXK[\\GENE] in complex with [CHEMICAL](R)-roscovitine[\\CHEMICAL], N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of [GENE]PDXK[\\GENE] in complex with (R)-roscovitine, [CHEMICAL]N6-methyl-(R)-roscovitine[\\CHEMICAL], and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, [CHEMICAL]N6-methyl-(R)-roscovitine[\\CHEMICAL], and O6-(R)-roscovitine, the two latter derivatives being designed to bind to [GENE]PDXK[\\GENE] but not to CDKs.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of [GENE]PDXK[\\GENE] in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and [CHEMICAL]O6-(R)-roscovitine[\\CHEMICAL], the two latter derivatives being designed to bind to PDXK but not to CDKs.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and [CHEMICAL]O6-(R)-roscovitine[\\CHEMICAL], the two latter derivatives being designed to bind to [GENE]PDXK[\\GENE] but not to CDKs.",
        "label": 2,
        "major": 2,
        "len": 32
    },
    {
        "text": "Structural analysis revealed that these three [CHEMICAL]roscovitines[\\CHEMICAL] bind similarly in the pyridoxal-binding site of [GENE]PDXK[\\GENE] rather than in the anticipated ATP-binding site.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Structural analysis revealed that these three roscovitines bind similarly in the [CHEMICAL]pyridoxal[\\CHEMICAL]-binding site of [GENE]PDXK[\\GENE] rather than in the anticipated ATP-binding site.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of [GENE]PDXK[\\GENE] rather than in the anticipated [CHEMICAL]ATP[\\CHEMICAL]-binding site.",
        "label": 2,
        "major": 2,
        "len": 22
    },
    {
        "text": "This work provides detailed structural information on the interactions between [GENE]PDXK[\\GENE] and [CHEMICAL]roscovitine[\\CHEMICAL] and analogs.",
        "label": 2,
        "major": 2,
        "len": 15
    },
    {
        "text": "[GENE]Pyridoxal kinase[\\GENE] (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of [CHEMICAL]ATP[\\CHEMICAL] and Zn2+.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "Pyridoxal kinase ([GENE]PDXK[\\GENE]) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of [CHEMICAL]ATP[\\CHEMICAL] and Zn2+.",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Pyridoxal kinase[\\GENE] (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and [CHEMICAL]Zn2+[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "Pyridoxal kinase ([GENE]PDXK[\\GENE]) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and [CHEMICAL]Zn2+[\\CHEMICAL].",
        "label": 2,
        "major": 9,
        "len": 18
    },
    {
        "text": "[CHEMICAL](R)-Roscovitine[\\CHEMICAL] (CYC202, Seliciclib) is a relatively selective inhibitor of [GENE]cyclin-dependent kinases[\\GENE] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[CHEMICAL](R)-Roscovitine[\\CHEMICAL] (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ([GENE]CDKs[\\GENE]), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "(R)-Roscovitine ([CHEMICAL]CYC202[\\CHEMICAL], Seliciclib) is a relatively selective inhibitor of [GENE]cyclin-dependent kinases[\\GENE] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "(R)-Roscovitine ([CHEMICAL]CYC202[\\CHEMICAL], Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ([GENE]CDKs[\\GENE]), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "(R)-Roscovitine (CYC202, [CHEMICAL]Seliciclib[\\CHEMICAL]) is a relatively selective inhibitor of [GENE]cyclin-dependent kinases[\\GENE] (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "(R)-Roscovitine (CYC202, [CHEMICAL]Seliciclib[\\CHEMICAL]) is a relatively selective inhibitor of cyclin-dependent kinases ([GENE]CDKs[\\GENE]), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.",
        "label": 4,
        "major": 4,
        "len": 27
    },
    {
        "text": "[GENE]Pyridoxal kinase[\\GENE] (PDXK) catalyzes the phosphorylation of [CHEMICAL]pyridoxal[\\CHEMICAL], pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Pyridoxal kinase ([GENE]PDXK[\\GENE]) catalyzes the phosphorylation of [CHEMICAL]pyridoxal[\\CHEMICAL], pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Pyridoxal kinase[\\GENE] (PDXK) catalyzes the phosphorylation of pyridoxal, [CHEMICAL]pyridoxamine[\\CHEMICAL], and pyridoxine in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Pyridoxal kinase ([GENE]PDXK[\\GENE]) catalyzes the phosphorylation of pyridoxal, [CHEMICAL]pyridoxamine[\\CHEMICAL], and pyridoxine in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "[GENE]Pyridoxal kinase[\\GENE] (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and [CHEMICAL]pyridoxine[\\CHEMICAL] in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "Pyridoxal kinase ([GENE]PDXK[\\GENE]) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and [CHEMICAL]pyridoxine[\\CHEMICAL] in the presence of ATP and Zn2+.",
        "label": 9,
        "major": 9,
        "len": 18
    },
    {
        "text": "The [GENE]gastric mucin[\\GENE] secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, [CHEMICAL]PD98059[\\CHEMICAL].",
        "label": 10,
        "major": 4,
        "len": 30
    },
    {
        "text": "The inhibition of ERK, moreover, did not cause attenuation in [GENE]mucin[\\GENE] secretion in response to [CHEMICAL]cAMP[\\CHEMICAL] and forskolin.",
        "label": 10,
        "major": 4,
        "len": 18
    },
    {
        "text": "The inhibition of ERK, moreover, did not cause attenuation in [GENE]mucin[\\GENE] secretion in response to cAMP and [CHEMICAL]forskolin[\\CHEMICAL].",
        "label": 10,
        "major": 10,
        "len": 18
    },
    {
        "text": "The [GENE]gastric mucin[\\GENE] secretory responses to [CHEMICAL]isoproterenol[\\CHEMICAL], furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",
        "label": 2,
        "major": 4,
        "len": 30
    },
    {
        "text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as [GENE]adenylate cyclase[\\GENE] activator, [CHEMICAL]forskolin[\\CHEMICAL].",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by [CHEMICAL]PP2[\\CHEMICAL], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent [GENE]EGFR[\\GENE] autophosphorylation, but not by ERK inhibitor, PD98059.",
        "label": 3,
        "major": 4,
        "len": 30
    },
    {
        "text": "Both inhibitors, moreover, blunted the [GENE]mucin[\\GENE] secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, [CHEMICAL]forskolin[\\CHEMICAL].",
        "label": 4,
        "major": 3,
        "len": 21
    },
    {
        "text": "The [GENE]gastric mucin[\\GENE] secretory responses to isoproterenol, furthermore, were inhibited by [CHEMICAL]PP2[\\CHEMICAL], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on [GENE]mucin[\\GENE] secretion was inhibited by EGFR kinase inhibitor, [CHEMICAL]PD153035[\\CHEMICAL], as well as wortmannin, a specific inhibitor of PI3K.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on [GENE]mucin[\\GENE] secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as [CHEMICAL]wortmannin[\\CHEMICAL], a specific inhibitor of PI3K.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by [CHEMICAL]PP2[\\CHEMICAL], a selective inhibitor of [GENE]tyrosine kinase[\\GENE] Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by [CHEMICAL]PP2[\\CHEMICAL], a selective inhibitor of tyrosine kinase [GENE]Src[\\GENE] responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by [GENE]ERK[\\GENE] inhibitor, [CHEMICAL]PD98059[\\CHEMICAL].",
        "label": 4,
        "major": 10,
        "len": 30
    },
    {
        "text": "The inhibition of [GENE]ERK[\\GENE], moreover, did not cause attenuation in mucin secretion in response to [CHEMICAL]cAMP[\\CHEMICAL] and forskolin.",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "The inhibition of [GENE]ERK[\\GENE], moreover, did not cause attenuation in mucin secretion in response to cAMP and [CHEMICAL]forskolin[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 18
    },
    {
        "text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by [GENE]EGFR[\\GENE] kinase inhibitor, [CHEMICAL]PD153035[\\CHEMICAL], as well as wortmannin, a specific inhibitor of PI3K.",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR [GENE]kinase[\\GENE] inhibitor, [CHEMICAL]PD153035[\\CHEMICAL], as well as wortmannin, a specific inhibitor of PI3K.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as [CHEMICAL]wortmannin[\\CHEMICAL], a specific inhibitor of [GENE]PI3K[\\GENE].",
        "label": 4,
        "major": 4,
        "len": 33
    },
    {
        "text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, [CHEMICAL]cAMP[\\CHEMICAL] as well as [GENE]adenylate cyclase[\\GENE] activator, forskolin.",
        "label": 9,
        "major": 4,
        "len": 21
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL] (parent compound), has moderate affinity for the [GENE]AT(1) receptor[\\GENE] (competitive inhibition).",
        "label": 2,
        "major": 2,
        "len": 12
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL] is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [GENE]AT(1) receptor[\\GENE] (non-competitive inhibition).",
        "label": 2,
        "major": 9,
        "len": 38
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL] is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [GENE]AT(1) receptor[\\GENE] (non-competitive inhibition).",
        "label": 4,
        "major": 4,
        "len": 38
    },
    {
        "text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with [CHEMICAL]losartan[\\CHEMICAL] versus captopril, a drug from the [GENE]angiotensin-converting-enzyme[\\GENE] inhibitor class with proven benefit in this population.",
        "label": 4,
        "major": 9,
        "len": 31
    },
    {
        "text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus [CHEMICAL]captopril[\\CHEMICAL], a drug from the [GENE]angiotensin-converting-enzyme[\\GENE] inhibitor class with proven benefit in this population.",
        "label": 4,
        "major": 9,
        "len": 31
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL]: a selective [GENE]angiotensin II type 1 (AT1) receptor[\\GENE] antagonist for the treatment of heart failure.",
        "label": 6,
        "major": 6,
        "len": 16
    },
    {
        "text": "[CHEMICAL]Losartan[\\CHEMICAL] (COZAAR) is the prototype of a new class of potent and selective [GENE]angiotensin II (AII) type 1 (AT(1)) receptor[\\GENE] antagonists with the largest published preclinical and clinical data base.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "Losartan ([CHEMICAL]COZAAR[\\CHEMICAL]) is the prototype of a new class of potent and selective [GENE]angiotensin II (AII) type 1 (AT(1)) receptor[\\GENE] antagonists with the largest published preclinical and clinical data base.",
        "label": 6,
        "major": 6,
        "len": 30
    },
    {
        "text": "Therefore, decreases of [GENE]PLK[\\GENE] and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] (GABA) function.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Therefore, decreases of PLK and [GENE]PNPO[\\GENE] in the hippocampal CA1 region of aged brains may be involved in aging processes related with [CHEMICAL]gamma-aminobutyric acid[\\CHEMICAL] (GABA) function.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Therefore, decreases of [GENE]PLK[\\GENE] and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ([CHEMICAL]GABA[\\CHEMICAL]) function.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "Therefore, decreases of PLK and [GENE]PNPO[\\GENE] in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid ([CHEMICAL]GABA[\\CHEMICAL]) function.",
        "label": 4,
        "major": 4,
        "len": 26
    },
    {
        "text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by [CHEMICAL]H(+)[\\CHEMICAL]-coupled [GENE]monocarboxylate transport system[\\GENE].",
        "label": 2,
        "major": 4,
        "len": 32
    },
    {
        "text": "These results provide biochemical evidence of a [CHEMICAL]H(+)[\\CHEMICAL]-coupled and saturable transport system, presumed to be a [GENE]low-affinity monocarboxylate transporter[\\GENE] MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "These results provide biochemical evidence of a [CHEMICAL]H(+)[\\CHEMICAL]-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter [GENE]MCT4[\\GENE] or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown [CHEMICAL]H(+)[\\CHEMICAL][GENE]H(+)-coupled monocarboxylate transport system[\\GENE], for nicotinate in rat cerebrocortical astrocytes.",
        "label": 2,
        "major": 2,
        "len": 33
    },
    {
        "text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical [GENE]monocarboxylate transporter[\\GENE] (MCT) inhibitor, [CHEMICAL]alpha-cyano-4-hydroxycinnamic acid[\\CHEMICAL], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter ([GENE]MCT[\\GENE]) inhibitor, [CHEMICAL]alpha-cyano-4-hydroxycinnamic acid[\\CHEMICAL], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that [CHEMICAL]nicotinate[\\CHEMICAL] uptake by rat astrocytes is mediated by H(+)-coupled [GENE]monocarboxylate transport system[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 32
    },
    {
        "text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that [CHEMICAL]nicotinate[\\CHEMICAL] uptake in rat astrocytes is mediated by [GENE]MCT1[\\GENE] and/or MCT2.",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that [CHEMICAL]nicotinate[\\CHEMICAL] uptake in rat astrocytes is mediated by MCT1 and/or [GENE]MCT2[\\GENE].",
        "label": 9,
        "major": 4,
        "len": 27
    },
    {
        "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a [GENE]low-affinity monocarboxylate transporter[\\GENE] MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for [CHEMICAL]nicotinate[\\CHEMICAL] in rat cerebrocortical astrocytes.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter [GENE]MCT4[\\GENE] or other unknown H(+)-coupled monocarboxylate transport system, for [CHEMICAL]nicotinate[\\CHEMICAL] in rat cerebrocortical astrocytes.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown [GENE]H(+)-coupled monocarboxylate transport system[\\GENE], for [CHEMICAL]nicotinate[\\CHEMICAL] in rat cerebrocortical astrocytes.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "The marked antihypertensive efficacy of [CHEMICAL]olmesartan medoxomil[\\CHEMICAL] may result from a unique pharmacological interaction of the drug with the [GENE]AT1[\\GENE] receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II.",
        "label": 2,
        "major": 2,
        "len": 30
    },
    {
        "text": "The marked antihypertensive efficacy of [CHEMICAL]olmesartan medoxomil[\\CHEMICAL] may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of [GENE]A-II[\\GENE].",
        "label": 4,
        "major": 2,
        "len": 30
    },
    {
        "text": "We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific [GENE]neutrophil elastase[\\GENE] inhibitor ([CHEMICAL]ONO-5046[\\CHEMICAL]) on acid lung injury in rats.",
        "label": 4,
        "major": 3,
        "len": 33
    },
    {
        "text": "Effects of [GENE]granulocyte colony-stimulating factor[\\GENE] (G-CSF) and neutrophil elastase inhibitor ([CHEMICAL]ONO-5046[\\CHEMICAL]) on acid-induced lung injury in rats.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Effects of granulocyte colony-stimulating factor ([GENE]G-CSF[\\GENE]) and neutrophil elastase inhibitor ([CHEMICAL]ONO-5046[\\CHEMICAL]) on acid-induced lung injury in rats.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "Effects of granulocyte colony-stimulating factor (G-CSF) and [GENE]neutrophil elastase[\\GENE] inhibitor ([CHEMICAL]ONO-5046[\\CHEMICAL]) on acid-induced lung injury in rats.",
        "label": 4,
        "major": 3,
        "len": 17
    },
    {
        "text": "[CHEMICAL]Miglustat[\\CHEMICAL], an imino sugar that reversibly inhibits [GENE]glucosylceramide synthase[\\GENE] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "Miglustat, an [CHEMICAL]imino sugar[\\CHEMICAL] that reversibly inhibits [GENE]glucosylceramide synthase[\\GENE] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.",
        "label": 4,
        "major": 4,
        "len": 48
    },
    {
        "text": "Nicotinic-receptor potentiator drugs, huprine X and [CHEMICAL]galantamine[\\CHEMICAL], increase ACh release by blocking AChE activity but not acting on [GENE]nicotinic receptors[\\GENE].",
        "label": 10,
        "major": 10,
        "len": 20
    },
    {
        "text": "[GENE]Nicotinic-receptor[\\GENE] potentiator drugs, huprine X and [CHEMICAL]galantamine[\\CHEMICAL], increase ACh release by blocking AChE activity but not acting on nicotinic receptors.",
        "label": 2,
        "major": 3,
        "len": 20
    },
    {
        "text": "Nicotinic-receptor potentiator drugs, huprine X and [CHEMICAL]galantamine[\\CHEMICAL], increase ACh release by blocking [GENE]AChE[\\GENE] activity but not acting on nicotinic receptors.",
        "label": 4,
        "major": 10,
        "len": 20
    },
    {
        "text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of [CHEMICAL]haloperidol[\\CHEMICAL] (HAL; 0.01 microM), a [GENE]dopamine D2[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol ([CHEMICAL]HAL[\\CHEMICAL]; 0.01 microM), a [GENE]dopamine D2[\\GENE] antagonist.",
        "label": 6,
        "major": 6,
        "len": 28
    },
    {
        "text": "mRNA levels for [GENE]RAR-alpha[\\GENE], RAR-beta and RAR-gamma, the nuclear receptors for [CHEMICAL]retinoic acid[\\CHEMICAL], decreased during activation of freshly isolated HSC even with retinoid supplementation.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, [GENE]RAR-beta[\\GENE] and RAR-gamma, the nuclear receptors for [CHEMICAL]retinoic acid[\\CHEMICAL], decreased during activation of freshly isolated HSC even with retinoid supplementation.",
        "label": 2,
        "major": 3,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, RAR-beta and [GENE]RAR-gamma[\\GENE], the nuclear receptors for [CHEMICAL]retinoic acid[\\CHEMICAL], decreased during activation of freshly isolated HSC even with retinoid supplementation.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the [GENE]nuclear receptors[\\GENE] for [CHEMICAL]retinoic acid[\\CHEMICAL], decreased during activation of freshly isolated HSC even with retinoid supplementation.",
        "label": 2,
        "major": 4,
        "len": 24
    },
    {
        "text": "mRNA levels for [GENE]RAR-alpha[\\GENE], RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [CHEMICAL]retinoid[\\CHEMICAL] supplementation.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, [GENE]RAR-beta[\\GENE] and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [CHEMICAL]retinoid[\\CHEMICAL] supplementation.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, RAR-beta and [GENE]RAR-gamma[\\GENE], the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with [CHEMICAL]retinoid[\\CHEMICAL] supplementation.",
        "label": 4,
        "major": 3,
        "len": 24
    },
    {
        "text": "mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the [GENE]nuclear receptors[\\GENE] for retinoic acid, decreased during activation of freshly isolated HSC even with [CHEMICAL]retinoid[\\CHEMICAL] supplementation.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of [CHEMICAL]methacholine[\\CHEMICAL]-contracted preparations in a concentration dependent fashion, indicating desensitization of the [GENE]beta(2)-adrenoceptor[\\GENE].",
        "label": 2,
        "major": 3,
        "len": 36
    },
    {
        "text": "Preincubation with 1 microM of the [GENE]protein kinase C[\\GENE] (PKC) activator phorbol 12-myristate 13-acetate ([CHEMICAL]PMA[\\CHEMICAL]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C ([GENE]PKC[\\GENE]) activator phorbol 12-myristate 13-acetate ([CHEMICAL]PMA[\\CHEMICAL]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ([CHEMICAL]PMA[\\CHEMICAL]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated [GENE]PKC[\\GENE]-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the [GENE]protein kinase C[\\GENE] (PKC) activator [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C ([GENE]PKC[\\GENE]) activator [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated [GENE]PKC[\\GENE]-mediated heterologous beta(2)-adrenoceptor desensitization.",
        "label": 3,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate ([CHEMICAL]PMA[\\CHEMICAL]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous [GENE]beta(2)-adrenoceptor[\\GENE] desensitization.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of [CHEMICAL]fenoterol[\\CHEMICAL] decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [GENE]beta(2)-adrenoceptor[\\GENE].",
        "label": 4,
        "major": 3,
        "len": 36
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator [CHEMICAL]phorbol 12-myristate 13-acetate[\\CHEMICAL] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous [GENE]beta(2)-adrenoceptor[\\GENE] desensitization.",
        "label": 4,
        "major": 3,
        "len": 30
    },
    {
        "text": "Moreover, the specific [GENE]PKC[\\GENE]-inhibitor [CHEMICAL]2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide[\\CHEMICAL] (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Moreover, the specific [GENE]PKC[\\GENE]-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ([CHEMICAL]GF 109203X[\\CHEMICAL]) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.",
        "label": 4,
        "major": 3,
        "len": 34
    },
    {
        "text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in [CHEMICAL]isoprenaline[\\CHEMICAL]-induced E(max), indicating activated PKC-mediated heterologous [GENE]beta(2)-adrenoceptor[\\GENE] desensitization.",
        "label": 5,
        "major": 3,
        "len": 30
    },
    {
        "text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased [CHEMICAL]isoprenaline[\\CHEMICAL]-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [GENE]beta(2)-adrenoceptor[\\GENE].",
        "label": 5,
        "major": 3,
        "len": 36
    },
    {
        "text": "Tyrosine kinase inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of [GENE]EGFR[\\GENE] signaling.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "[GENE]Tyrosine kinase[\\GENE] inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "Tyrosine kinase inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular [GENE]tyrosine kinase domain[\\GENE] of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "Tyrosine kinase inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including [GENE]EGFR[\\GENE], Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "Tyrosine kinase inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, [GENE]Erb2[\\GENE], and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.",
        "label": 4,
        "major": 3,
        "len": 44
    },
    {
        "text": "Tyrosine kinase inhibitors are [CHEMICAL]quinazoline[\\CHEMICAL]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and [GENE]vascular endothelial growth factor receptor[\\GENE], and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.",
        "label": 4,
        "major": 4,
        "len": 44
    },
    {
        "text": "The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 [CHEMICAL]amino acids[\\CHEMICAL] (92% identity to [GENE]human PAT1[\\GENE]).",
        "label": 1,
        "major": 1,
        "len": 35
    },
    {
        "text": "In the presence of Na+ and under conditions in which [GENE]PAT1[\\GENE] transport function was suppressed, a second [CHEMICAL]proline[\\CHEMICAL] uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that [GENE]PAT1[\\GENE] is the low-affinity transporter of [CHEMICAL]proline[\\CHEMICAL], glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.",
        "label": 9,
        "major": 2,
        "len": 33
    },
    {
        "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that [GENE]PAT1[\\GENE] is the low-affinity transporter of proline, [CHEMICAL]glycine[\\CHEMICAL] and hydroxyproline believed to be defective in patients with iminoglycinuria.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that [GENE]PAT1[\\GENE] is the low-affinity transporter of proline, glycine and [CHEMICAL]hydroxyproline[\\CHEMICAL] believed to be defective in patients with iminoglycinuria.",
        "label": 9,
        "major": 9,
        "len": 33
    },
    {
        "text": "Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived [GENE]IL-10[\\GENE] production, with significant effects elicited by the noradrenaline reuptake inhibitors [CHEMICAL]reboxetine[\\CHEMICAL] and desipramine.",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived [GENE]IL-10[\\GENE] production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and [CHEMICAL]desipramine[\\CHEMICAL].",
        "label": 2,
        "major": 4,
        "len": 29
    },
    {
        "text": "In this study, antidepressants with selectivity for the [GENE]noradrenaline transporter[\\GENE] ([CHEMICAL]reboxetine[\\CHEMICAL] and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "In this study, antidepressants with selectivity for the [GENE]noradrenaline transporter[\\GENE] (reboxetine and [CHEMICAL]desipramine[\\CHEMICAL]), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the [GENE]serotonin transporter[\\GENE] ([CHEMICAL]fluoxetine[\\CHEMICAL] and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.",
        "label": 2,
        "major": 9,
        "len": 36
    },
    {
        "text": "In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the [GENE]serotonin transporter[\\GENE] (fluoxetine and [CHEMICAL]clomipramine[\\CHEMICAL]) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.",
        "label": 2,
        "major": 10,
        "len": 36
    },
    {
        "text": "The fact that [CHEMICAL]trimipramine[\\CHEMICAL] also suppressed [GENE]IFN-gamma[\\GENE] production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.",
        "label": 4,
        "major": 9,
        "len": 27
    },
    {
        "text": "[GENE]Leptin[\\GENE] is a 167 [CHEMICAL]amino acid[\\CHEMICAL] protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.",
        "label": 1,
        "major": 2,
        "len": 33
    },
    {
        "text": "This increase may suggest that both [GENE]leptin[\\GENE] and [CHEMICAL]cyproheptadine[\\CHEMICAL] may affect appetite via similar receptors and that cyproheptadine does not impair leptin activity through these receptors.",
        "label": 2,
        "major": 10,
        "len": 26
    },
    {
        "text": "[CHEMICAL]Cyproheptadine[\\CHEMICAL] is a piperidine antihistamine that increases appetite through its antiserotonergic effect on [GENE]5-HT2[\\GENE] receptors in the brain.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Cyproheptadine is a [CHEMICAL]piperidine[\\CHEMICAL] antihistamine that increases appetite through its antiserotonergic effect on [GENE]5-HT2[\\GENE] receptors in the brain.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "Cyproheptadine is a piperidine [CHEMICAL]antihistamine[\\CHEMICAL] that increases appetite through its antiserotonergic effect on [GENE]5-HT2[\\GENE] receptors in the brain.",
        "label": 2,
        "major": 3,
        "len": 18
    },
    {
        "text": "The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean [GENE]leptin[\\GENE] level after 1 week of treatment with [CHEMICAL]cyproheptadine[\\CHEMICAL] (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).",
        "label": 3,
        "major": 10,
        "len": 50
    },
    {
        "text": "We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), [CHEMICAL]N-acetylcysteine[\\CHEMICAL] (only -SH group not [GENE]ACE[\\GENE] inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",
        "label": 10,
        "major": 3,
        "len": 35
    },
    {
        "text": "It was found that a single intragastric gavage by [CHEMICAL]L-methionine[\\CHEMICAL] resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and [GENE]angiotensin-converting enzyme[\\GENE] activity compared with the control group.",
        "label": 10,
        "major": 4,
        "len": 56
    },
    {
        "text": "Given the treatment with three doses of [CHEMICAL]Captopril[\\CHEMICAL] (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of [GENE]PON1[\\GENE] and SOD in serum by single intragastric gavaged L-methionine.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "Given the treatment with three doses of [CHEMICAL]Captopril[\\CHEMICAL] (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and [GENE]SOD[\\GENE] in serum by single intragastric gavaged L-methionine.",
        "label": 3,
        "major": 4,
        "len": 44
    },
    {
        "text": "These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of [CHEMICAL]Captopril[\\CHEMICAL] may be related to attenuating the decrease in [GENE]PON1[\\GENE] activity and NO levels.",
        "label": 3,
        "major": 3,
        "len": 37
    },
    {
        "text": "These results suggested that Captopril can protect the vascular endothelium against the damages induced by [CHEMICAL]L-methionine[\\CHEMICAL] in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in [GENE]PON1[\\GENE] activity and NO levels.",
        "label": 4,
        "major": 3,
        "len": 37
    },
    {
        "text": "We compared the effects of [CHEMICAL]Captopril[\\CHEMICAL] (an [GENE]ACE[\\GENE] inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",
        "label": 4,
        "major": 4,
        "len": 35
    },
    {
        "text": "We compared the effects of Captopril (an [GENE]ACE[\\GENE] inhibitor with -[CHEMICAL]SH[\\CHEMICAL] group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "We compared the effects of Captopril (an ACE inhibitor with -SH group), [CHEMICAL]enalapril[\\CHEMICAL] (an [GENE]ACE[\\GENE]-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.",
        "label": 4,
        "major": 3,
        "len": 35
    },
    {
        "text": "Comparison of [CHEMICAL]captopril[\\CHEMICAL] and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [GENE]ACE[\\GENE] inhibitors in high dieted methionine mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Comparison of captopril and [CHEMICAL]enalapril[\\CHEMICAL] to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [GENE]ACE[\\GENE] inhibitors in high dieted methionine mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "Comparison of captopril and enalapril to study the role of the [CHEMICAL]sulfhydryl[\\CHEMICAL]-group in improvement of endothelial dysfunction with [GENE]ACE[\\GENE] inhibitors in high dieted methionine mice.",
        "label": 4,
        "major": 4,
        "len": 25
    },
    {
        "text": "It was found that a single intragastric gavage by [CHEMICAL]L-methionine[\\CHEMICAL] resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [GENE]PON1[\\GENE] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.",
        "label": 4,
        "major": 4,
        "len": 56
    },
    {
        "text": "It was found that a single intragastric gavage by [CHEMICAL]L-methionine[\\CHEMICAL] resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and [GENE]SOD[\\GENE], similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.",
        "label": 4,
        "major": 4,
        "len": 56
    },
    {
        "text": "Further characterization showed that [CHEMICAL]sorafenib[\\CHEMICAL] suppresses both wild-type and [GENE]V599E[\\GENE] mutant B-Raf activity in vitro.",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "Further characterization showed that [CHEMICAL]sorafenib[\\CHEMICAL] suppresses both wild-type and V599E mutant [GENE]B-Raf[\\GENE] activity in vitro.",
        "label": 4,
        "major": 1,
        "len": 15
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL], which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of [GENE]Raf-1[\\GENE] and its favorable kinase selectivity profile.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "[CHEMICAL]Sorafenib[\\CHEMICAL], which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable [GENE]kinase[\\GENE] selectivity profile.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Sorafenib, which belongs chemically to a class that can be described as [CHEMICAL]bis-aryl ureas[\\CHEMICAL], was selected for further pharmacologic characterization based on potent inhibition of [GENE]Raf-1[\\GENE] and its favorable kinase selectivity profile.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "Sorafenib, which belongs chemically to a class that can be described as [CHEMICAL]bis-aryl ureas[\\CHEMICAL], was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable [GENE]kinase[\\GENE] selectivity profile.",
        "label": 4,
        "major": 4,
        "len": 32
    },
    {
        "text": "In vivo angiogenesis assay utilising gelfoam sponges, [CHEMICAL]bexarotene[\\CHEMICAL] reduced angiogenesis in sponges containing [GENE]vascular endothelial growth factor[\\GENE], epidermal growth factor and basic fibroblast growth factor to various extent.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In vivo angiogenesis assay utilising gelfoam sponges, [CHEMICAL]bexarotene[\\CHEMICAL] reduced angiogenesis in sponges containing vascular endothelial growth factor, [GENE]epidermal growth factor[\\GENE] and basic fibroblast growth factor to various extent.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "In vivo angiogenesis assay utilising gelfoam sponges, [CHEMICAL]bexarotene[\\CHEMICAL] reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic [GENE]fibroblast growth factor[\\GENE] to various extent.",
        "label": 2,
        "major": 4,
        "len": 28
    },
    {
        "text": "The ability of [CHEMICAL]bexarotene[\\CHEMICAL] to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner [GENE]peroxisome proliferator-activated receptor gamma[\\GENE].",
        "label": 3,
        "major": 3,
        "len": 21
    },
    {
        "text": "Analysis of tumour-conditioned medium indicated that [CHEMICAL]bexarotene[\\CHEMICAL] decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of [GENE]matrix metalloproteinases[\\GENE].",
        "label": 3,
        "major": 4,
        "len": 24
    },
    {
        "text": "Analysis of tumour-conditioned medium indicated that [CHEMICAL]bexarotene[\\CHEMICAL] decreased the secretion of angiogenic factors and [GENE]matrix metalloproteinases[\\GENE] and increased the tissue inhibitor of matrix metalloproteinases.",
        "label": 4,
        "major": 4,
        "len": 24
    },
    {
        "text": "A selective [GENE]retinoid X receptor[\\GENE] agonist [CHEMICAL]bexarotene[\\CHEMICAL] (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "A selective [GENE]retinoid X receptor[\\GENE] agonist bexarotene ([CHEMICAL]LGD1069[\\CHEMICAL], targretin) inhibits angiogenesis and metastasis in solid tumours.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "A selective [GENE]retinoid X receptor[\\GENE] agonist bexarotene (LGD1069, [CHEMICAL]targretin[\\CHEMICAL]) inhibits angiogenesis and metastasis in solid tumours.",
        "label": 5,
        "major": 5,
        "len": 16
    },
    {
        "text": "The present study determined the influence of a [GENE]retinoid X receptor[\\GENE] agonist [CHEMICAL]bexarotene[\\CHEMICAL] on angiogenesis and metastasis in solid tumours.",
        "label": 5,
        "major": 5,
        "len": 20
    },
    {
        "text": "In subjects with dysmenorrhea the increase in pain following the administration of [GENE]vasopressin[\\GENE] was significantly lower during [CHEMICAL]atosiban[\\CHEMICAL] than during placebo infusion.",
        "label": 4,
        "major": 3,
        "len": 22
    },
    {
        "text": "CONCLUSIONS: [CHEMICAL]Atosiban[\\CHEMICAL] reduces [GENE]vasopressin[\\GENE]-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.",
        "label": 4,
        "major": 3,
        "len": 19
    },
    {
        "text": "Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the [GENE]acetylcholinesterase[\\GENE] inhibitor [CHEMICAL]tacrine[\\CHEMICAL].",
        "label": 4,
        "major": 4,
        "len": 30
    },
    {
        "text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of [GENE]acetylcholinesterase[\\GENE] and of butyrylcholinesterase which is another catalytic enzyme hydrolysing [CHEMICAL]acetylcholine[\\CHEMICAL].",
        "label": 9,
        "major": 10,
        "len": 29
    },
    {
        "text": "Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of [GENE]butyrylcholinesterase[\\GENE] which is another catalytic enzyme hydrolysing [CHEMICAL]acetylcholine[\\CHEMICAL].",
        "label": 9,
        "major": 10,
        "len": 29
    },
    {
        "text": "Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main [CHEMICAL]histamine[\\CHEMICAL] metabolizing enzyme in the brain, [GENE]N-methyltransferase[\\GENE], chemically show structural elements of the acetylcholinesterase inhibitor tacrine.",
        "label": 9,
        "major": 4,
        "len": 30
    },
    {
        "text": "For some, pharmacologic inhibitors are available, including [CHEMICAL]sorafenib[\\CHEMICAL] for [GENE]BRAF[\\GENE], farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, [CHEMICAL]PD-0325901[\\CHEMICAL] for [GENE]mitogen-activated protein kinase[\\GENE]/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, [CHEMICAL]PD-0325901[\\CHEMICAL] for mitogen-activated protein kinase/[GENE]extracellular signal-regulated kinase kinase[\\GENE], rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.",
        "label": 4,
        "major": 3,
        "len": 41
    },
    {
        "text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, [CHEMICAL]rapamycin[\\CHEMICAL] analogues for [GENE]mammalian target of rapamycin[\\GENE], and agents that inhibit either vascular endothelial growth factor or its receptors.",
        "label": 4,
        "major": 4,
        "len": 41
    },
    {
        "text": "Similar to the [GENE]plasma membrane PS transporter[\\GENE], Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the [CHEMICAL]sn-2,3-glycerol[\\CHEMICAL] stereoisomer.",
        "label": 10,
        "major": 3,
        "len": 24
    },
    {
        "text": "Similar to the plasma membrane PS transporter, [GENE]Atp8a1[\\GENE] is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the [CHEMICAL]sn-2,3-glycerol[\\CHEMICAL] stereoisomer.",
        "label": 10,
        "major": 9,
        "len": 24
    },
    {
        "text": "Activation of Atp8a1 is also reduced by these modifications; [CHEMICAL]phosphatidylserine-O-methyl ester[\\CHEMICAL], lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate [GENE]Atp8a1[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 28
    },
    {
        "text": "Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, [CHEMICAL]lysophosphatidylserine[\\CHEMICAL], glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate [GENE]Atp8a1[\\GENE].",
        "label": 10,
        "major": 4,
        "len": 28
    },
    {
        "text": "Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, [CHEMICAL]glycerophosphoserine[\\CHEMICAL], and phosphoserine, which are not transported by the plasma membrane flippase, do not activate [GENE]Atp8a1[\\GENE].",
        "label": 10,
        "major": 3,
        "len": 28
    }
]